PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Baranovic, J; Ramanujan, CS; Kasai, N; Midgett, CR; Madden, DR; Torimitsu, K; Ryan, JF				Baranovic, Jelena; Ramanujan, Chandra S.; Kasai, Nahoko; Midgett, Charles R.; Madden, Dean R.; Torimitsu, Keiichi; Ryan, John F.			Reconstitution of Homomeric GluA2(flop) Receptors in Supported Lipid Membranes FUNCTIONAL AND STRUCTURAL PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; IONOTROPIC GLUTAMATE RECEPTORS; PERMEABLE AMPA RECEPTOR; ACETYLCHOLINE-RECEPTOR; PROTEIN RECONSTITUTION; POTASSIUM CHANNEL; SINGLE; SOLUBILIZATION; VISUALIZATION; ARCHITECTURE	AMPA receptors (AMPARs) are glutamate-gated ion channels ubiquitous in the vertebrate central nervous system, where they mediate fast excitatory neurotransmission and act as molecular determinants of memory formation and learning. Together with detailed analyses of individual AMPAR domains, structural studies of full-length AMPARs by electron microscopy and x-ray crystallography have provided important insights into channel assembly and function. However, the correlation between the structure and functional states of the channel remains ambiguous particularly because these functional states can be assessed only with the receptor bound within an intact lipid bilayer. To provide a basis for investigating AMPAR structure in a membrane environment, we developed an optimized reconstitution protocol using a receptor whose structure has previously been characterized by electron microscopy. Single-channel recordings of reconstituted homomeric GluA2(flop) receptors recapitulate key electrophysiological parameters of the channels expressed in native cellular membranes. Atomic force microscopy studies of the reconstituted samples provide high-resolution images of membrane-embedded full-length AMPARs at densities comparable to those in postsynaptic membranes. The data demonstrate the effect of protein density on conformational flexibility and dimensions of the receptors and provide the first structural characterization of functional membrane-embedded AMPARs, thus laying the foundation for correlated structure-function analyses of the predominant mediators of excitatory synaptic signals in the brain.	[Ryan, John F.] Univ Oxford, Dept Phys, Oxford OX1 3PU, England; [Kasai, Nahoko; Torimitsu, Keiichi] NTT Basic Res Labs, Atsugi, Kanagawa 2430198, Japan; [Midgett, Charles R.; Madden, Dean R.] Geisel Sch Med Dartmouth, Dept Biochem, Hanover, NH 03755 USA	University of Oxford; Nippon Telegraph & Telephone Corporation; Dartmouth College	Baranovic, J (corresponding author), Leibniz Inst Mol Pharmacol FMP, Campus Berlin Buch,Robert Rossle Str 10, D-13125 Berlin, Germany.	baranovic@fmp-berlin.de	TORIMITSU, KEIICHI/GQR-2299-2022; Torimitsu, Keiichi/AAE-4333-2019; Torimitsu, Keiichi/A-3078-2011	Baranovic, Jelena/0000-0003-2310-960X	Hitchcock Foundation; Medical Research Council, United Kingdom	Hitchcock Foundation; Medical Research Council, United Kingdom(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported in part by the Hitchcock Foundation (to D. R. M.) and the Medical Research Council, United Kingdom (to J. B.).	BAHR BA, 1992, J NEUROCHEM, V59, P1979, DOI 10.1111/j.1471-4159.1992.tb11038.x; Bowie D, 2008, CNS NEUROL DISORD-DR, V7, P129, DOI 10.2174/187152708784083821; Buzhynskyy N, 2007, EMBO REP, V8, P51, DOI 10.1038/sj.embor.7400858; Cladera J, 1997, EUR J BIOCHEM, V243, P798, DOI 10.1111/j.1432-1033.1997.00798.x; CORONADO R, 1983, BIOPHYS J, V43, P231, DOI 10.1016/S0006-3495(83)84343-4; Cull-Candy S, 2006, CURR OPIN NEUROBIOL, V16, P288, DOI 10.1016/j.conb.2006.05.012; Derkach VA, 2007, NAT REV NEUROSCI, V8, P101, DOI 10.1038/nrn2055; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; Jaroslawski S, 2007, J MOL BIOL, V374, P500, DOI 10.1016/j.jmb.2007.09.043; Jespersen LK, 2000, EUR J BIOCHEM, V267, P1382, DOI 10.1046/j.1432-1327.2000.01137.x; Jin RS, 2003, NAT NEUROSCI, V6, P803, DOI 10.1038/nn1091; Kasai N, 2010, BBA-GEN SUBJECTS, V1800, P655, DOI 10.1016/j.bbagen.2010.03.002; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Madden Dean R, 2007, Methods Mol Biol, V363, P39, DOI 10.1007/978-1-59745-209-0_3; Mari SA, 2011, P NATL ACAD SCI USA, V108, P20802, DOI 10.1073/pnas.1111149108; Masugi-Tokita M, 2007, J NEUROSCI, V27, P2135, DOI 10.1523/JNEUROSCI.2861-06.2007; Midgett CR, 2008, J MOL BIOL, V382, P578, DOI 10.1016/j.jmb.2008.07.021; Midgett CR, 2012, FRONT MOL NEUROSCI, V4, DOI [10.3389/fnmol.2011.00056, 10.3389/fnmo1.2011.00056]; Momiyama A, 2003, J PHYSIOL-LONDON, V549, P75, DOI 10.1113/jphysiol.2002.033472; Muller DJ, 2007, NAT PROTOC, V2, P2191, DOI 10.1038/nprot.2007.309; MULLER DJ, 1995, J MOL BIOL, V249, P239, DOI 10.1006/jmbi.1995.0292; Muller DJ, 1997, J STRUCT BIOL, V119, P149, DOI 10.1006/jsbi.1997.3878; Nakagawa T, 2006, BIOL CHEM, V387, P179, DOI 10.1515/BC.2006.024; Nakagawa T, 2005, NATURE, V433, P545, DOI 10.1038/nature03328; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Plested AJR, 2009, J NEUROSCI, V29, P11912, DOI 10.1523/JNEUROSCI.2971-09.2009; Prieto ML, 2010, J NEUROSCI, V30, P4449, DOI 10.1523/JNEUROSCI.5613-09.2010; Rasband W.S., 2018, IMAGEJ; Rigaud JL, 1998, EUR BIOPHYS J BIOPHY, V27, P305, DOI 10.1007/s002490050138; Rigaud JL, 2003, METHOD ENZYMOL, V372, P65; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; Scheuring S, 2005, BBA-BIOMEMBRANES, V1712, P109, DOI 10.1016/j.bbamem.2005.04.005; Schurholz T, 1996, BIOPHYS CHEM, V58, P87, DOI 10.1016/0301-4622(95)00088-7; Shinozaki Y, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000103; Smith TC, 2000, J NEUROSCI, V20, P2073; Sobolevsky AI, 2009, NATURE, V462, P745, DOI 10.1038/nature08624; Soderling TR, 2000, TRENDS NEUROSCI, V23, P75, DOI 10.1016/S0166-2236(99)01490-3; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; Suhara W, 2006, NEUROSCI LETT, V391, P102, DOI 10.1016/j.neulet.2005.08.066; Sukumaran M, 2011, EMBO J, V30, P972, DOI 10.1038/emboj.2011.17; Swanson GT, 1997, J NEUROSCI, V17, P58, DOI 10.1523/JNEUROSCI.17-01-00058.1997; Vaithianathan H, 2005, CELL BIOCHEM BIOPHYS, V42, P75, DOI 10.1385/CBB:42:1:075; VODYANOY V, 1993, NEUROSCI LETT, V150, P80, DOI 10.1016/0304-3940(93)90113-Y; Vuong N, 2010, CHEM PHYS LIPIDS, V163, P117, DOI 10.1016/j.chemphyslip.2009.09.003; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; WO ZG, 1995, TRENDS NEUROSCI, V18, P161; Wollmuth LP, 2004, TRENDS NEUROSCI, V27, P321, DOI 10.1016/j.tins.2004.04.005; Zhang W, 2008, J NEUROSCI, V28, P932, DOI 10.1523/JNEUROSCI.3309-07.2008	48	4	4	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2013	288	12					8647	8657		10.1074/jbc.M112.422105	http://dx.doi.org/10.1074/jbc.M112.422105			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112AS	23382380	hybrid, Green Published			2023-01-03	WOS:000316564500065
J	Rather, MA; Sharma, R; Gupta, S; Ferosekhan, S; Ramya, VL; Jadhao, SB				Rather, Mohd Ashraf; Sharma, Rupam; Gupta, Subodh; Ferosekhan, S.; Ramya, V. L.; Jadhao, Sanjay B.			Chitosan-Nanoconjugated Hormone Nanoparticles for Sustained Surge of Gonadotropins and Enhanced Reproductive Output in Female Fish	PLOS ONE			English	Article							OXIDE NANOPARTICLES; DELIVERY SYSTEMS; COMMON CARP; ABSORPTION; CARRIERS; MATURATION; TELEOST; WATER	A controlled release delivery system helps to overcome the problem of short life of the leutinizing hormone releasing hormone (LHRH) in blood and avoids use of multiple injections to enhance reproductive efficacy. Chitosan- and chitosan-gold nanoconjugates of salmon LHRH of desired size, dispersity and zeta potential were synthesized and evaluated at half the dose rate against full dose of bare LHRH for their reproductive efficacy in the female fish, Cyprinus carpio. Whereas injections of both the nanoconjugates induced controlled and sustained surge of the hormones with peak (P<0.01) at 24 hrs, surge due to bare LHRH reached its peak at 7 hrs and either remained at plateau or sharply declined thereafter. While the percentage of relative total eggs produced by fish were 130 and 67 per cent higher, that of fertilised eggs were 171 and 88 per cent higher on chitosan- and chitosan-gold nanoconjugates than bare LHRH. Chitosan nanoconjugates had a 13 per cent higher and chitosan gold preparation had a 9 per cent higher fertilization rate than bare LHRH. Histology of the ovaries also attested the pronounced effect of nanoparticles on reproductive output. This is the first report on use of chitosan-conjugated nanodelivery of gonadotropic hormone in fish.	[Rather, Mohd Ashraf; Sharma, Rupam; Gupta, Subodh; Ferosekhan, S.; Ramya, V. L.; Jadhao, Sanjay B.] Cent Inst Fisheries Educ, Mumbai, Maharashtra, India	Indian Council of Agricultural Research (ICAR); ICAR - Central Institute of Fisheries Education	Jadhao, SB (corresponding author), Cent Inst Fisheries Educ, Mumbai, Maharashtra, India.	sbjadhao@hotmail.com	Ferosekhan, Shajahan/E-5051-2010	Ferosekhan, Shajahan/0000-0003-4662-8306; Gupta, Subodh/0000-0002-9420-480X; Rather, Mohd Ashraf/0000-0001-5710-8176; Jadhao, Sanjay/0000-0003-2859-8529				Bhattarai N, 2006, INT J NANOMED, V1, P181, DOI 10.2147/nano.2006.1.2.181; Bhumkar DR, 2007, PHARM RES-DORDR, V24, P1415, DOI 10.1007/s11095-007-9257-9; Calvo P, 1997, J APPL POLYM SCI, V63, P125, DOI 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4; Chae SY, 2005, J CONTROL RELEASE, V102, P383, DOI 10.1016/j.jconrel.2004.10.012; Chen Y, 2008, BIOPOLYMERS, V90, P663, DOI 10.1002/bip.21055; Chondar S, 1994, INDUCED CAR BREEDING, P64; Crim L.W., 1997, RECENT ADV MARINE BI, P369; Dounighi NM, 2012, J VENOM ANIM TOXINS, V18, P44, DOI 10.1590/S1678-91992012000100006; DRORI S, 1994, AQUACULTURE, V119, P393, DOI 10.1016/0044-8486(94)90303-4; Eaton A.D, 1998, STANDARD METHODS EXA; GOETZ FW, 1983, FISH PHYSIOL, V9, P117; Goren A, 1987, GEN COMP ENDOCR, V79, P291; Hall S.J., 2011, BLUE FRONTIERS MANAG; Hallaj-Nezhadi S, 2011, J PHARM PHARM SCI, V14, P181, DOI 10.18433/J3TP4T; Hughes GA, 2005, NANOMED-NANOTECHNOL, V1, P22, DOI 10.1016/j.nano.2004.11.009; Janes KA, 2001, ADV DRUG DELIVER REV, V47, P83, DOI 10.1016/S0169-409X(00)00123-X; Joshi H, 2004, J PHYS CHEM B, V108, P11535, DOI 10.1021/jp048766z; Joshi HM, 2006, LANGMUIR, V22, P300, DOI 10.1021/la051982u; Kabanov AV, 2002, ADV DRUG DELIVER REV, V54, P223, DOI 10.1016/S0169-409X(02)00018-2; Kim TH, 2004, BIOMATERIALS, V25, P3783, DOI 10.1016/j.biomaterials.2003.10.063; KOBAYASHI M, 1989, FISH PHYSIOL BIOCHEM, V7, P141, DOI 10.1007/BF00004700; Larsson DGJ, 1997, CAN J FISH AQUAT SCI, V54, P1957, DOI 10.1139/cjfas-54-9-1957; Lasagna-Reeves C, 2010, BIOCHEM BIOPH RES CO, V393, P649, DOI 10.1016/j.bbrc.2010.02.046; Leuschner C, 2006, BREAST CANCER RES TR, V99, P163, DOI 10.1007/s10549-006-9199-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luna L. G., 1968, MANUAL HISTOLOGICAL, P38; Mananos E, 2002, J FISH BIOL, V60, P328, DOI 10.1006/jfbi.2001.1839; Marino G, 2003, AQUACULTURE, V219, P841, DOI 10.1016/S0044-8486(03)00036-X; Marte C, 1989, ADV TROP AQUAC; Mikolajczyk T, 2002, AQUACULTURE, V203, P375, DOI 10.1016/S0044-8486(01)00637-8; Mittal G, 2007, J CONTROL RELEASE, V119, P77, DOI 10.1016/j.jconrel.2007.01.016; NAGAHAMA Y, 1983, FISH PHYSIOL, V9, P223; PANKHURST NW, 1991, PROCEEDINGS OF THE FOURTH INTERNATIONAL SYMPOSIUM ON THE REPRODUCTIVE PHYSIOLOGY OF FISH, P131; Pulavendran S, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-15; Sadeghi AMM, 2008, EUR J PHARM BIOPHARM, V70, P270, DOI 10.1016/j.ejpb.2008.03.004; Salehizadeh H, 2012, J NANOBIOTECHNOL, V10, DOI 10.1186/1477-3155-10-3; Thanou M, 2001, ADV DRUG DELIVER REV, V50, pS91, DOI 10.1016/S0169-409X(01)00180-6; Turkevich J., 1985, GOLD BULL, V18, P125, DOI [10.1007/BF03214694, DOI 10.1007/BF03214690]; Wang C, 2007, CHINESE SCI BULL, V52, P883, DOI 10.1007/s11434-007-0127-y; Wang XM, 2008, EUR J PHARM BIOPHARM, V70, P735, DOI 10.1016/j.ejpb.2008.07.005; Yu JM, 2008, EUR POLYM J, V44, P555, DOI 10.1016/j.eurpolymj.2008.01.013; Zohar J, 1994, US Patent, Patent No. 5288705; Zohar Y, 2001, AQUACULTURE, V197, P99, DOI 10.1016/S0044-8486(01)00584-1; Zohar Y., 1988, Colloques de l'INRA, V44, P47	44	56	57	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2013	8	2							e57094	10.1371/journal.pone.0057094	http://dx.doi.org/10.1371/journal.pone.0057094			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	098BN	23468918	gold, Green Published, Green Submitted			2023-01-03	WOS:000315519000061
J	Li, GC; Zhang, Z; Ma, XJ; Zhu, J; Cai, G				Li, Guichao; Zhang, Zhen; Ma, Xuejun; Zhu, Ji; Cai, Gang			Postoperative Chemoradiotherapy Combined with Epirubicin-Based Triplet Chemotherapy for Locally Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction	PLOS ONE			English	Article							PHASE-III TRIAL; RESECTABLE GASTRIC-CANCER; ADJUVANT CHEMOTHERAPY; CURATIVE RESECTION; PERIOPERATIVE CHEMOTHERAPY; COMPARING CAPECITABINE; D2 GASTRECTOMY; ASIAN PATIENTS; UNITED-STATES; SURGERY	Background: Due to low tolerance to chemotherapy, the maximum number of cycles of postoperative adjuvant chemotherapy is 4 in adjuvant gastric clinical trials. The aim of this study is to retrospectively evaluate the safety and efficacy of adjuvant epirubicin-based triplet chemotherapy and radiotherapy in the treatment of resected locally advanced stomach or gastroesophageal junction adenocarcinoma. Methodology/Principal Findings: From January 2004 to July 2008, ninety-seven consecutive gastric or gastroesophageal junction adenocarcinoma patients in stages T3-4/N+ were treated with postoperative radiotherapy and chemotherapy. The recommended treatment plan was radical resection followed by 1-2 cycles of adjuvant chemotherapy (ACT), postoperative chemoradiotherapy (CRT), and, finally, 4-5 cycles of ACT. The patients were classified into two groups depending on the number of cycles of ACT: group 1 received 4-6 cycles (n = 59), and group 2 received 0-3 cycles (n = 38). The detailed grouping is as follows: RT alone, 2; RT and CT, 18; concurrent RTCT and CT, 41; and CRT, 36. Of the 97 patients, 77 patients received concurrent therapy (CRT, (5-fluorouracil or capecitabine), and 20 received radiotherapy alone because of patient refusal (n = 15) or treatment toxicity (n = 5). After a median follow-up of 44 months, the 3-year disease free survival(DFS) and overall survival (OS) were 66.5% and 69.5% for group 1 and 45.5% and 50% for group 2, respectively (p = 0.005 and p = 0.024). Multivariate analysis revealed that 4-6 cycles of ACT, lymphovascular invasion, or peritoneal metastasis were independent prognostic factors for disease-free survival or overall survival (p < 0.05). Conclusions/Significance: This study demonstrates that concurrent chemoradiation with adjuvant epirubicin-based triplet chemotherapy is feasible and tolerable for gastric or gastroesophageal junction carcinoma patients. Patients can benefit from more cycles of ACT.	[Zhang, Zhen] Fudan Univ, Shanghai Canc Ctr, Shanghai Med Coll, Dept Radiat Oncol, Shanghai 200433, Peoples R China; Fudan Univ, Shanghai Med Coll, Shanghai Canc Ctr, Dept Oncol, Shanghai 200433, Peoples R China	Fudan University; Fudan University	Zhang, Z (corresponding author), Fudan Univ, Shanghai Canc Ctr, Shanghai Med Coll, Dept Radiat Oncol, Shanghai 200433, Peoples R China.	zhenzhang6@163.com	zhu, ji/HDM-1538-2022	Zhu, Ji/0000-0001-7134-9419				Bang YJ, 2012, LANCET, V379, P315, DOI 10.1016/S0140-6736(11)61873-4; COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; Earle CC, 1999, EUR J CANCER, V35, P1059, DOI 10.1016/S0959-8049(99)00076-3; Forman D, 2006, BEST PRACT RES CL GA, V20, P633, DOI 10.1016/j.bpg.2006.04.008; Gill R D, 1992, Math Popul Stud, V3, P259; Greene FL, 2002, AJCC CANC STAGING MA, DOI DOI 10.1007/978-1-4757-3656-4; HALLISSEY MT, 1994, LANCET, V343, P1309, DOI 10.1016/S0140-6736(94)92464-3; HERMANS J, 1993, J CLIN ONCOL, V11, P1441, DOI 10.1200/JCO.1993.11.8.1441; Janunger KG, 2001, ACTA ONCOL, V40, P309, DOI 10.1080/02841860151116385; Japanese Gastric Cancer Association, 1998, Gastric Cancer, V1, P10; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kim S, 2005, INT J RADIAT ONCOL, V63, P1279, DOI 10.1016/j.ijrobp.2005.05.005; Lee J, 2012, J CLIN ONCOL, V30, P268, DOI 10.1200/JCO.2011.39.1953; Leong T, 2011, INT J RADIAT ONCOL, V79, P690, DOI 10.1016/j.ijrobp.2009.11.042; Lim DH, 2004, BRIT J CANCER, V91, P11, DOI 10.1038/sj.bjc.6601896; Macdonald JS, 2001, NEW ENGL J MED, V345, P725, DOI 10.1056/NEJMoa010187; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Mari E, 2000, ANN ONCOL, V11, P837, DOI 10.1023/A:1008377101672; Noguchi Y, 2000, CANCER-AM CANCER SOC, V89, P2237, DOI 10.1002/1097-0142(20001201)89:11<2237::AID-CNCR12>3.3.CO;2-0; Paoletti X, 2010, JAMA-J AM MED ASSOC, V303, P1729, DOI 10.1001/jama.2010.534; Quero L, 2012, INT J RADIAT ONCOL, V83, P574, DOI 10.1016/j.ijrobp.2011.07.031; Sasako M, 2011, J CLIN ONCOL, V29, P4387, DOI 10.1200/JCO.2011.36.5908; Smalley SR, 2012, J CLIN ONCOL, V30, P2327, DOI 10.1200/JCO.2011.36.7136; Sumpter K, 2005, BRIT J CANCER, V92, P1976, DOI 10.1038/sj.bjc.6602572; Tepper JE, 2002, SEMIN RADIAT ONCOL, V12, P187, DOI 10.1053/srao.2002.30827; Theuer CP, 2000, CANCER, V89, P1883, DOI 10.1002/1097-0142(20001101)89:9<1883::AID-CNCR3>3.3.CO;2-8; Trotti A, 2003, SEMIN RADIAT ONCOL, V13, P176, DOI 10.1016/S1053-4296(03)00031-6; van de Velde CJH, 1998, ANN CHIR GYNAECOL FE, V87, P89; Ychou M, 2011, J CLIN ONCOL, V29, P1715, DOI 10.1200/JCO.2010.33.0597	31	10	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2013	8	1							e54233	10.1371/journal.pone.0054233	http://dx.doi.org/10.1371/journal.pone.0054233			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	093RV	23372688	Green Published, gold, Green Submitted			2023-01-03	WOS:000315210400009
J	Neal, ML; Trister, AD; Cloke, T; Sodt, R; Ahn, S; Baldock, AL; Bridge, CA; Lai, A; Cloughesy, TF; Mrugala, MM; Rockhill, JK; Rockne, RC; Swanson, KR				Neal, Maxwell Lewis; Trister, Andrew D.; Cloke, Tyler; Sodt, Rita; Ahn, Sunyoung; Baldock, Anne L.; Bridge, Carly A.; Lai, Albert; Cloughesy, Timothy F.; Mrugala, Maciej M.; Rockhill, Jason K.; Rockne, Russell C.; Swanson, Kristin R.			Discriminating Survival Outcomes in Patients with Glioblastoma Using a Simulation-Based, Patient-Specific Response Metric	PLOS ONE			English	Article							INDIVIDUAL PATIENTS; GLIOMA GROWTH; CRITERIA; PSEUDOPROGRESSION; PSEUDORESPONSE; PROLIFERATION; RADIOTHERAPY; INVASION; QUANTIFY; TUMORS	Accurate clinical assessment of a patient's response to treatment for glioblastoma multiforme (GBM), the most malignant type of primary brain tumor, is undermined by the wide patient-to-patient variability in GBM dynamics and responsiveness to therapy. Using computational models that account for the unique geometry and kinetics of individual patients' tumors, we developed a method for assessing treatment response that discriminates progression-free and overall survival following therapy for GBM. Applying these models as untreated virtual controls, we generate a patient-specific "Days Gained'' response metric that estimates the number of days a therapy delayed imageable tumor progression. We assessed treatment response in terms of Days Gained scores for 33 patients at the time of their first MRI scan following first-line radiation therapy. Based on Kaplan-Meier analyses, patients with Days Gained scores of 100 or more had improved progression-free survival, and patients with scores of 117 or more had improved overall survival. Our results demonstrate that the Days Gained response metric calculated at the routinely acquired first post-radiation treatment time point provides prognostic information regarding progression and survival outcomes. Applied prospectively, our model-based approach has the potential to improve GBM treatment by accounting for patient-to-patient heterogeneity in GBM dynamics and responses to therapy.	[Neal, Maxwell Lewis; Cloke, Tyler; Sodt, Rita; Ahn, Sunyoung; Baldock, Anne L.; Bridge, Carly A.; Rockne, Russell C.; Swanson, Kristin R.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA; [Trister, Andrew D.; Rockhill, Jason K.] Univ Washington, Dept Radiat Oncol, Seattle, WA 98195 USA; [Baldock, Anne L.; Bridge, Carly A.; Rockne, Russell C.; Swanson, Kristin R.] Northwestern Univ, Dept Neurol Surg, Chicago, IL 60611 USA; [Baldock, Anne L.; Bridge, Carly A.; Rockne, Russell C.; Swanson, Kristin R.] NW Brain Tumor Inst, Chicago, IL USA; [Lai, Albert; Cloughesy, Timothy F.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; [Mrugala, Maciej M.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [Swanson, Kristin R.] Univ Washington, Dept Appl Math, Seattle, WA 98195 USA; [Swanson, Kristin R.] Univ Washington, Nancy & Buster Alvord Brain Tumor Ctr, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Northwestern University; University of California System; University of California Los Angeles; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Neal, ML (corresponding author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA.	mneal@uw.edu; Kristin.swanson@northwestern.edu	Cloughesy, Timothy Francis/AGV-1013-2022; Rockne, Russell/T-1549-2017	Rockne, Russell/0000-0002-1557-159X; Trister, Andrew/0000-0002-7070-0139; Neal, Maxwell/0000-0002-2390-6572	McDonnell Foundation; Brain Tumor Funders Collaborative; National Institutes of Health [R01 CA164371, R01 NS 060752, U54 CA143970]; James D. Murray Endowed Chair; University of Washington Academic Pathology Fund; NATIONAL CANCER INSTITUTE [R01CA164371, U54CA143970] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS060752] Funding Source: NIH RePORTER	McDonnell Foundation; Brain Tumor Funders Collaborative; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); James D. Murray Endowed Chair; University of Washington Academic Pathology Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was funded by the McDonnell Foundation, the Brain Tumor Funders Collaborative, the National Institutes of Health (R01 CA164371, R01 NS 060752, U54 CA143970), the James D. Murray Endowed Chair and the University of Washington Academic Pathology Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALVORD EC, 1995, AM J NEURORADIOL, V16, P1013; Alvord Jr E.C., 1991, PATHOLOGY AGING HUMA, P210; BJ Karnofsky DA., 1949, EVALUATION CHEMOTHER, P191; Brandsma D, 2009, CURR OPIN NEUROL, V22, P633, DOI 10.1097/WCO.0b013e328332363e; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Friston K, 2007, STATISTICAL PARAMETRIC MAPPING: THE ANALYSIS OF FUNCTIONAL BRAIN IMAGES, P1; Gu SL, 2012, MATH MED BIOL, V29, P31, DOI 10.1093/imammb/dqr002; Harpold HLP, 2007, J NEUROPATH EXP NEUR, V66, P1, DOI 10.1097/nen.0b013e31802d9000; da Cruz LCH, 2011, AM J NEURORADIOL, V32, P1978, DOI 10.3174/ajnr.A2397; MACDONALD DR, 1990, J CLIN ONCOL, V8, P1277, DOI 10.1200/JCO.1990.8.7.1277; Mandonnet E, 2003, ANN NEUROL, V53, P524, DOI 10.1002/ana.10528; Neal ML, 2011, NEURO-ONCOLOGY, V13, P83; Neal ML, 2010, BRIEF BIOINFORM, V11, P111, DOI 10.1093/bib/bbp049; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Rockne R, 2010, PHYS MED BIOL, V55, P3271, DOI 10.1088/0031-9155/55/12/001; Rockne Russell, 2008, Biophysical Reviews and Letters, V3, P111, DOI 10.1142/S1793048008000642; Shaw E. G., 2003, International Journal of Radiation Oncology Biology Physics, V57, pS135, DOI 10.1016/S0360-3016(03)00843-5; Sodt R, COMPUTATION IN PRESS, V2; Stupp R, 2002, J CLIN ONCOL, V20, P1375, DOI 10.1200/JCO.20.5.1375; Swanson K., 1999, THESIS U WASHINGTON; Swanson KR, 2008, CLIN ONCOL-UK, V20, P301, DOI 10.1016/j.clon.2008.01.006; Swanson KR, 2008, BRIT J CANCER, V98, P113, DOI 10.1038/sj.bjc.6604125; Swanson K R, 2002, NEURO-ONCOLOGY, P4340, DOI DOI 10.1093/NEUONC/4.4.308; Swanson KR, 2000, CELL PROLIFERAT, V33, P317, DOI 10.1046/j.1365-2184.2000.00177.x; Swanson KR, 2003, J NEUROL SCI, V216, P1, DOI 10.1016/j.jns.2003.06.001; Swanson K, 2007, NEURO-ONCOLOGY, V9, P575; Szeto MD, 2009, CANCER RES, V69, P4502, DOI 10.1158/0008-5472.CAN-08-3884; Wang CH, 2009, CANCER RES, V69, P9133, DOI 10.1158/0008-5472.CAN-08-3863; Wen PY, 2010, J CLIN ONCOL, V28, P1963, DOI 10.1200/JCO.2009.26.3541	29	61	61	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2013	8	1							e51951	10.1371/journal.pone.0051951	http://dx.doi.org/10.1371/journal.pone.0051951			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	077IQ	23372647	Green Submitted, Green Published, gold			2023-01-03	WOS:000314021500007
J	Balbus, JM; Barouki, R; Birnbaum, LS; Etzel, RA; Gluckman, PD; Grandjean, P; Hancock, C; Hanson, MA; Heindel, JJ; Hoffman, K; Jensen, GK; Keeling, A; Neira, M; Rabadan-Diehl, C; Ralston, J; Tang, KC				Balbus, John M.; Barouki, Robert; Birnbaum, Linda S.; Etzel, Ruth A.; Gluckman, Peter D.; Grandjean, Philippe; Hancock, Christine; Hanson, Mark A.; Heindel, Jerrold J.; Hoffman, Kate; Jensen, Genon K.; Keeling, Ann; Neira, Maria; Rabadan-Diehl, Cristina; Ralston, Johanna; Tang, Kwok-Cho			Early-life prevention of non-communicable diseases	LANCET			English	Editorial Material							CHILDHOOD; HEALTH		[Balbus, John M.] NIEHS, NIH, Bethesda, MD 20892 USA; [Barouki, Robert] Univ Paris 05, Paris, France; [Birnbaum, Linda S.] NIEHS, Natl Technol Program, Res Triangle Pk, NC 27709 USA; [Heindel, Jerrold J.] NIEHS, Div Extramural Res & Training, Res Triangle Pk, NC 27709 USA; [Etzel, Ruth A.] Univ Wisconsin, Joseph J Zilber Sch Publ Hlth, Madison, WI 53706 USA; [Gluckman, Peter D.] Univ Auckland, Auckland 1, New Zealand; [Grandjean, Philippe] Univ So Denmark, Odense, Denmark; [Hancock, Christine] C3 Collaborating Hlth, London, England; [Hanson, Mark A.] Univ Southampton, Southampton Gen Hosp, Southampton, Hants, England; [Hoffman, Kate] Social & Sci Syst, Durham, NC USA; [Hoffman, Kate] Univ N Carolina, Chapel Hill, NC USA; [Jensen, Genon K.] Hlth & Environm Alliance, Brussels, Belgium; [Keeling, Ann] Int Diabet Federat, Brussels, Belgium; [Neira, Maria; Tang, Kwok-Cho] WHO, CH-1211 Geneva, Switzerland; [Rabadan-Diehl, Cristina] NHLBI, NIH, Bethesda, MD 20892 USA; [Ralston, Johanna] World Heart Federat, Geneva, Switzerland	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); UDICE-French Research Universities; Universite Paris Cite; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Wisconsin System; University of Wisconsin Madison; University of Auckland; University of Southern Denmark; University of Southampton; Social & Scientific Systems; University of North Carolina; University of North Carolina Chapel Hill; World Health Organization; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Balbus, JM (corresponding author), NIEHS, NIH, 31 Ctr Dr,Room B1CO2, Bethesda, MD 20892 USA.	john.balbus@nih.gov	Hanson, Mark/AAE-8236-2019; Etzel, Ruth A./N-5700-2019; Grandjean, Philippe/I-2962-2014	Hanson, Mark/0000-0002-6907-613X; Etzel, Ruth A./0000-0002-5236-3976; Grandjean, Philippe/0000-0003-4046-9658; Birnbaum, Linda/0000-0001-5429-5658; hoffman, kate/0000-0001-8029-7710	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012199, T32ES007018] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES012199, T32 ES007018] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barouki R, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-42; Boney CM, 2005, PEDIATRICS, V115, pE290, DOI 10.1542/peds.2004-1808; Gale CR, 2006, ARTERIOSCL THROM VAS, V26, P1877, DOI 10.1161/01.ATV.0000228819.13039.b8; Godfrey KM, 1998, EUR J OBSTET GYN R B, V78, P141, DOI 10.1016/S0301-2115(98)00060-8; Hou LF, 2012, INT J EPIDEMIOL, V41, P79, DOI 10.1093/ije/dyr154; Perera F, 2011, REPROD TOXICOL, V31, P363, DOI 10.1016/j.reprotox.2010.12.055; Perera F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004488; Skinner MK, 2011, REPROD TOXICOL, V31, P337, DOI 10.1016/j.reprotox.2010.10.012; UN,, 2012, ARES66288 UN; United Nations, 2011, MILL DEV GOALS REP 2; United Nations, 2011, NCDS MDGS SUCC SYN; WHO, 2010, GLOB STAT REP NONC D	12	108	110	0	34	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 5	2013	381	9860					3	4		10.1016/S0140-6736(12)61609-2	http://dx.doi.org/10.1016/S0140-6736(12)61609-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	064AW	23290956	Green Accepted, Green Submitted			2023-01-03	WOS:000313044300004
J	Relman, DA				Relman, David A.			Restoration of the gut microbial habitat as a disease therapy	NATURE BIOTECHNOLOGY			English	Editorial Material							INFECTION; MICE		[Relman, David A.] Stanford Univ, Dept Med, Stanford, CA 94305 USA; [Relman, David A.] Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA; [Relman, David A.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA	Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Relman, DA (corresponding author), Stanford Univ, Dept Med, Stanford, CA 94305 USA.	relman@stanford.edu		Relman, David A./0000-0001-8331-1354	OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD000964] Funding Source: NIH RePORTER; NIH HHS [DP1 OD000964] Funding Source: Medline	OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BOHNHOFF M, 1962, J INFECT DIS, V111, P117, DOI 10.1093/infdis/111.2.117; Brandt LJ, 2012, AM J GASTROENTEROL, V107, P1079, DOI 10.1038/ajg.2012.60; Costello EK, 2012, SCIENCE, V336, P1255, DOI 10.1126/science.1224203; Dethlefsen L, 2007, NATURE, V449, P811, DOI 10.1038/nature06245; Goodman AL, 2011, P NATL ACAD SCI USA, V108, P6252, DOI 10.1073/pnas.1102938108; Guarner F, 2012, J CLIN GASTROENTEROL, V46, P468, DOI 10.1097/MCG.0b013e3182549092; Holling C.S., 1973, Annual Rev Ecol Syst, V4, P1, DOI 10.1146/annurev.es.04.110173.000245; Lawley TD, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002995; Lemon KP, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004183; Pray L, 2012, HUMAN MICROBIOME DIE, P99	10	8	8	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2013	31	1					35	37		10.1038/nbt.2475	http://dx.doi.org/10.1038/nbt.2475			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	071CP	23302933				2023-01-03	WOS:000313563600019
J	Tucker, ME				Tucker, Miriam E.			US drug shortages: a disappearing problem?	BRITISH MEDICAL JOURNAL			English	Editorial Material												miriametucker@aol.com						American Society of Anesthesiologists, 2012, 2012 ASA DRUG SHORT; FDA, IMP AM SHUTD REC DRU; Generic Pharmaceutical Association, DRUG SHORT; Government Accountability Office, 2011, DRUG SHORT FDAS AB R; Silverman E, 2012, PHARMALOT       1211	5	1	1	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	DEC 21	2012	345								e8551	10.1136/bmj.e8551	http://dx.doi.org/10.1136/bmj.e8551			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	059JR	23261759				2023-01-03	WOS:000312701700024
J	Flavel, SC; Koch, JD; White, JM; Todd, G				Flavel, Stanley C.; Koch, Jenna D.; White, Jason M.; Todd, Gabrielle			Illicit Stimulant Use in Humans Is Associated with a Long-Term Increase in Tremor	PLOS ONE			English	Article							MDMA ECSTASY; RAT-BRAIN; (+/-)3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; 3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; CLINICAL-PHARMACOLOGY; DOPAMINE TRANSPORTER; PARKINSONS-DISEASE; MOVEMENT-DISORDERS; COCAINE; NEURONS	Use of illicit stimulants such as methamphetamine, cocaine, and ecstasy is a significant health problem. The United Nations Office on Drugs and Crime estimates that 14-57 million people use stimulants each year. Chronic use of illicit stimulants can cause neurotoxicity in animals and humans but the long-term functional consequences are not well understood. Stimulant users self-report problems with tremor whilst abstinent. Thus, the aim of the current study was to investigate the long-term effect of stimulant use on human tremor during rest and movement. We hypothesized that individuals with a history of stimulant use would exhibit abnormally large tremor during rest and movement. Tremor was assessed in abstinent ecstasy users (n = 9; 22 +/- 3 yrs) and abstinent users of amphetamine-like drugs (n = 7; 33 +/- 9 yrs) and in two control groups: non-drug users (n = 23; 27 +/- 8 yrs) and cannabis users (n = 12; 24 +/- 7 yrs). Tremor was measured with an accelerometer attached to the index finger at rest (30 s) and during flexion and extension of the index finger (30 s). Acceleration traces were analyzed with fast-Fourier transform. During movement, tremor amplitude was significantly greater in ecstasy users than in non-drug users (frequency range 3.9-13.3 Hz; P<0.05), but was unaffected in cannabis users or users of amphetamine-like drugs. The peak frequency of tremor did not significantly differ between groups nor did resting tremor. In conclusion, abstinent ecstasy users exhibit an abnormally large tremor during movement. Further work is required to determine if the abnormality translates to increased risk of movement disorders in this population.	[Flavel, Stanley C.; Koch, Jenna D.; White, Jason M.; Todd, Gabrielle] Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia; [White, Jason M.; Todd, Gabrielle] Univ S Australia, Sansom Inst, Adelaide, SA 5001, Australia	University of South Australia; University of South Australia	Todd, G (corresponding author), Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia.	gabrielle.todd@unisa.edu.au	Todd, Gabrielle/K-7122-2012; White, Jason M/A-2795-2011	Todd, Gabrielle/0000-0002-2465-6026; White, Jason M/0000-0001-6750-1078	Clive and Vera Ramaciotti Foundation [2974/2010]; National Health and Medical Research Council of Australia [627003]; University of South Australia	Clive and Vera Ramaciotti Foundation; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); University of South Australia	This work was supported by the Clive and Vera Ramaciotti Foundation (Establishment Grant, ID 2974/2010), National Health and Medical Research Council of Australia (GT holds a Career Development Award; ID 627003), and University of South Australia (GT holds a RsearchSA Fellowship, SF held an Australian Postgraduate Award, and JK held a South Australia Rural Health Scholarship). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AIHW, 2005, STAT DRUG US AUSTR 2, V62, P1; AIHW, 2011, 2010 NAT DRUG STRAT, P1; Baker SN, 2007, CURR OPIN NEUROBIOL, V17, P649, DOI 10.1016/j.conb.2008.01.007; BAUER LO, 1993, PSYCHIAT RES, V47, P69, DOI 10.1016/0165-1781(93)90056-M; Beck A.T., 1996, PSYCHOL CORP; BENOWITZ NL, 1993, PHARMACOL TOXICOL, V72, P3, DOI 10.1111/j.1600-0773.1993.tb01331.x; Benton AL, 1983, MULTILINGUAL APHASIA; Bousman CA, 2010, J INT NEUROPSYCH SOC, V16, P1047, DOI 10.1017/S1355617710000846; Buchert R, 2003, J NUCL MED, V44, P375; Callaghan RC, 2010, MOVEMENT DISORD, V25, P2333, DOI 10.1002/mds.23263; CARDOSO F, 1993, NEUROL CLIN, V11, P625, DOI 10.1016/S0733-8619(18)30143-9; CARDOSO FEC, 1993, MOVEMENT DISORD, V8, P175, DOI 10.1002/mds.870080210; Catalano G, 1997, SOUTH MED J, V90, P1050, DOI 10.1097/00007611-199710000-00017; COMMINS DL, 1987, J PHARMACOL EXP THER, V241, P338; Cosentino C, 2004, MOVEMENT DISORD, V19, P1386, DOI 10.1002/mds.20306; Dafters RI, 1999, PSYCHOPHARMACOLOGY, V145, P82, DOI 10.1007/s002130051035; Demirkiran M, 1996, CLIN NEUROPHARMACOL, V19, P157, DOI 10.1097/00002826-199619020-00004; Diaz-Martinez A, 1998, CLIN THER, V20, P467, DOI 10.1016/S0149-2918(98)80056-8; Downes Michael A, 2005, Emerg Med Australas, V17, P277; Esteban B, 2001, PSYCHOPHARMACOLOGY, V154, P251, DOI 10.1007/s002130000645; FACTOR SA, 1988, ANN NEUROL, V23, P423, DOI 10.1002/ana.410230431; Farmer SF, 1998, J PHYSIOL-LONDON, V509, P3, DOI 10.1111/j.1469-7793.1998.003bo.x; FISCHER C, 1995, J NEUROSCI, V15, P5476; FREEMAN JS, 1993, J NEUROL NEUROSUR PS, V56, P1078, DOI 10.1136/jnnp.56.10.1078; Frei E, 2001, HUM BRAIN MAPP, V14, P152, DOI 10.1002/hbm.1049; Greco PG, 2003, EUR J PHARMACOL, V479, P117, DOI 10.1016/j.ejphar.2003.08.062; Green AR, 2003, PHARMACOL REV, V55, P463, DOI 10.1124/pr.55.3.3; GRIGSBY J, 1995, PERCEPT MOTOR SKILL, V80, P732, DOI 10.2466/pms.1995.80.3.732; Hallett M, 1998, MOVEMENT DISORD, V13, P43; Hatzidimitriou G, 1999, J NEUROSCI, V19, P5096; Jones DC, 2005, J PHARMACOL EXP THER, V313, P422, DOI 10.1124/jpet.104.077628; KEARCOLWELL JJ, 1978, J CLIN PSYCHOL, V34, P437, DOI 10.1002/1097-4679(197804)34:2<437::AID-JCLP2270340239>3.0.CO;2-K; Kish SJ, 2010, J PSYCHOPHARMACOL, V24, P281, DOI 10.1177/0269881108097724; Lew R, 1996, J PHARMACOL EXP THER, V276, P855; LUNDH H, 1981, J NEUROL NEUROSUR PS, V44, P728, DOI 10.1136/jnnp.44.8.728; Lyons KE, 2008, CNS DRUGS, V22, P1037, DOI 10.2165/0023210-200822120-00006; McAuley JH, 2000, BRAIN, V123, P1545, DOI 10.1093/brain/123.8.1545; McCann UD, 1998, LANCET, V352, P1433, DOI 10.1016/S0140-6736(98)04329-3; MCCANN UD, 1994, NEUROPSYCHOPHARMACOL, V10, P129, DOI 10.1038/npp.1994.15; Morefield KM, 2011, ADDICTION, V106, P1293, DOI 10.1111/j.1360-0443.2011.03399.x; Mrazik M, 2010, ARCH CLIN NEUROPSYCH, V25, P236, DOI 10.1093/arclin/acq006; Mueller M, 2011, SYNAPSE, V65, P983, DOI 10.1002/syn.20925; Parrott AC, 2002, HUM PSYCHOPHARM CLIN, V17, P309, DOI 10.1002/hup.415; PASCUALLEONE A, 1990, NEUROLOGY, V40, P999, DOI 10.1212/WNL.40.6.999; PRIORI A, 1995, MOVEMENT DISORD, V10, P353, DOI 10.1002/mds.870100323; Raethjen J, 2001, J NEUROL NEUROSUR PS, V70, P78, DOI 10.1136/jnnp.70.1.78; Reneman L, 2002, NEUROPSYCHOPHARMACOL, V26, P387, DOI 10.1016/S0893-133X(01)00366-9; RICAURTE GA, 1992, J PHARMACOL EXP THER, V261, P616; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Rothwell JC, 1998, MOVEMENT DISORD, V13, P24; SCHMIDT CJ, 1987, BIOCHEM PHARMACOL, V36, P4095, DOI 10.1016/0006-2952(87)90566-1; Scholey AB, 2004, ADDICT BEHAV, V29, P743, DOI 10.1016/j.addbeh.2004.02.022; Selvaraj S, 2009, BRIT J PSYCHIAT, V194, P355, DOI 10.1192/bjp.bp.108.050344; Sulzer D, 2005, PROG NEUROBIOL, V75, P406, DOI 10.1016/j.pneurobio.2005.04.003; Thompson G.B., 1992, PSYCHOL ASSESSMENT, V4, P363; Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4; Toomey R, 2003, ARCH GEN PSYCHIAT, V60, P303, DOI 10.1001/archpsyc.60.3.303; VALLBO AB, 1993, J PHYSIOL-LONDON, V469, P673, DOI 10.1113/jphysiol.1993.sp019837; Vickers D, 1972, Perception, V1, P263, DOI 10.1068/p010263; Volkow ND, 2001, AM J PSYCHIAT, V158, P377, DOI 10.1176/appi.ajp.158.3.377; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL; Yamamoto Bryan K., 2005, Critical Reviews in Neurobiology, V17, P87	63	19	21	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 18	2012	7	12							e52025	10.1371/journal.pone.0052025	http://dx.doi.org/10.1371/journal.pone.0052025			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	056JC	23272201	Green Submitted, Green Accepted, Green Published, gold			2023-01-03	WOS:000312483300049
J	Broxmeyer, HE; Hoggatt, J; O'Leary, HA; Mantel, C; Chitteti, BR; Cooper, S; Messina-Graham, S; Hangoc, G; Farag, S; Rohrabaugh, SL; Ou, X; Speth, J; Pelus, LM; Srour, EF; Campbell, TB				Broxmeyer, Hal E.; Hoggatt, Jonathan; O'Leary, Heather A.; Mantel, Charlie; Chitteti, Brahmananda R.; Cooper, Scott; Messina-Graham, Steven; Hangoc, Giao; Farag, Sherif; Rohrabaugh, Sara L.; Ou, Xuan; Speth, Jennifer; Pelus, Louis M.; Srour, Edward F.; Campbell, Timothy B.			Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis	NATURE MEDICINE			English	Article							RECOMBINANT MURINE INTERLEUKIN-3; PROGENITOR CELLS; STEM-CELLS; CD26 INHIBITION; GM-CSF; ENHANCES ENGRAFTMENT; REPLATING CAPACITY; CD34(+) CELLS; IN-VITRO; MICE	Enhancement of hematopoietic recovery after radiation, chemotherapy, or hematopoietic stem cell (HSC) transplantation is clinically relevant. Dipeptidylpeptidase (DPP4) cleaves a wide variety of substrates, including the chemokine stromal cell-derived factor-1 (SDF-1). In the course of experiments showing that inhibition of DPP4 enhances SDF-1-mediated progenitor cell survival, ex vivo cytokine expansion and replating frequency, we unexpectedly found that DPP4 has a more general role in regulating colony-stimulating factor (CSF) activity. DPP4 cleaved within the N-termini of the CSFs granulocyte-macrophage (GM)-CSF, G-CSF, interleukin-3 (IL-3) and erythropoietin and decreased their activity. Dpp4 knockout or DPP4 inhibition enhanced CSF activities both in vitro and in vivo. The reduced activity of DPP4-truncated versus full-length human GM-CSF was mechanistically linked to effects on receptor-binding affinity, induction of GM-CSF receptor oligomerization and signaling capacity. Hematopoiesis in mice after radiation or chemotherapy was enhanced in Dpp4(-/-) mice or mice receiving an orally active DPP4 inhibitor. DPP4 inhibition enhanced engraftment in mice without compromising HSC function, suggesting the potential clinical utility of this approach.	[Broxmeyer, Hal E.; Hoggatt, Jonathan; O'Leary, Heather A.; Mantel, Charlie; Cooper, Scott; Messina-Graham, Steven; Hangoc, Giao; Rohrabaugh, Sara L.; Ou, Xuan; Speth, Jennifer; Pelus, Louis M.; Srour, Edward F.; Campbell, Timothy B.] Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; [Chitteti, Brahmananda R.; Farag, Sherif; Srour, Edward F.] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN USA; [Srour, Edward F.] Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Broxmeyer, HE (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA.	hbroxmey@iupui.edu		O'Leary, Heather/0000-0003-1321-1520; Speth, Jennifer/0000-0002-7724-6995	US Health Service National Institutes of Health (NIH) [R01 HL056416, R01 HL067284, R01 HL112669]; Center of Excellence in Hematology [P01 DK090948, HL69669, HL96305]; NIH [T32 DK07519, T32 HL07910, R25 GM079657, T32 CA111198]; NATIONAL CANCER INSTITUTE [T32CA111198] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067384, R01HL112669, R01HL067284, R01HL069669, R01HL056416, R01HL096305, T32HL007910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007519, P30DK090948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM079657] Funding Source: NIH RePORTER	US Health Service National Institutes of Health (NIH); Center of Excellence in Hematology; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	These studies were supported by US Health Service National Institutes of Health (NIH) grants R01 HL056416, R01 HL067284 and R01 HL112669 and a Center of Excellence in Hematology grant P01 DK090948 to H.E.B., and HL69669 and HL96305 to L.M.P.J.H. was supported as a doctoral candidate on NIH T32 DK07519 (to H.E.B.) and as a postdoc on NIH T32 HL07910 (to H.E.B.); H.A.O. was supported as a postdoc on NIH T32 DK07519; S.M.-G. was supported as a doctoral candidate on NIH R25 GM079657 (to H.E.B.); and T.B.C. was supported as a doctoral candidate on NIH T32 DK07519. S.L.R. was supported by NIH T32 CA111198 for parts of this study. We thank Y.-R. Zhou, The Feinstein Insitute for Medical Research, for the Cre<SUP>+</SUP> Cxcr4<SUP>F1/F1</SUP> mice.	Adolfsson J, 2005, CELL, V121, P295, DOI 10.1016/j.cell.2005.02.013; Broxmeyer H.E., 2009, THOMAS HEMATOPOIETIC, P559; Broxmeyer HE, 2007, STEM CELLS DEV, V16, P589, DOI 10.1089/scd.2007.0044; Broxmeyer HE, 2011, BLOOD, V117, P4773, DOI 10.1182/blood-2011-01-330514; BROXMEYER HE, 1978, BLOOD, V51, P889; Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385; BROXMEYER HE, 1987, J CLIN INVEST, V79, P721, DOI 10.1172/JCI112877; BROXMEYER HE, 1987, P NATL ACAD SCI USA, V84, P3871, DOI 10.1073/pnas.84.11.3871; Broxmeyer HE, 2003, J LEUKOCYTE BIOL, V73, P630, DOI 10.1189/jlb.1002495; BROXMEYER HE, 1991, INT J HEMATOL, V54, P447; Broxmeyer HE, 2003, J IMMUNOL, V170, P421, DOI 10.4049/jimmunol.170.1.421; Bryder D, 2006, AM J PATHOL, V169, P338, DOI 10.2353/ajpath.2006.060312; Campbell TB, 2008, FRONT BIOSCI-LANDMRK, V13, P1795, DOI 10.2741/2800; Campbell TB, 2007, STEM CELLS DEV, V16, P347, DOI 10.1089/scd.2007.9995; CAROW CE, 1993, BLOOD, V81, P942; Chitteti B. R., 2011, CORD BLOOD BIOL TRAN, P75; Chitteti BR, 2010, BLOOD, V115, P3239, DOI 10.1182/blood-2009-09-246173; Cho SY, 2010, CANCER RES, V70, P3402, DOI 10.1158/0008-5472.CAN-09-3977; Christensen JL, 2001, P NATL ACAD SCI USA, V98, P14541, DOI 10.1073/pnas.261562798; Christopherson KW, 2007, STEM CELLS DEV, V16, P355, DOI 10.1089/scd.2007.9996; Christopherson KW, 2006, EXP HEMATOL, V34, P1060, DOI 10.1016/j.exphem.2006.03.012; Christopherson KW, 2004, SCIENCE, V305, P1000, DOI 10.1126/science.1097071; Christopherson KW, 2002, J IMMUNOL, V169, P7000, DOI 10.4049/jimmunol.169.12.7000; Gotoh A, 1996, BLOOD, V88, P138; Guthridge MA, 2004, BLOOD, V103, P820, DOI 10.1182/blood-2003-06-1999; Haman A, 1999, J BIOL CHEM, V274, P34155, DOI 10.1074/jbc.274.48.34155; Hansen G, 2008, CELL, V134, P496, DOI 10.1016/j.cell.2008.05.053; Hercus TR, 2009, BLOOD, V114, P1289, DOI 10.1182/blood-2008-12-164004; Kajiyama H, 2002, CANCER RES, V62, P2753; Kawai T, 2007, STEM CELLS DEV, V16, P361, DOI 10.1089/scd.2007.9997; Kidd S, 2011, EXP HEMATOL, V39, P580, DOI 10.1016/j.exphem.2011.01.012; Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007; Lataillade JJ, 2002, BLOOD, V99, P1117, DOI 10.1182/blood.V99.4.1117; Lee Y, 2002, BLOOD, V99, P4307, DOI 10.1182/blood.V99.12.4307; Lopez AF, 2010, IUBMB LIFE, V62, P509, DOI 10.1002/iub.350; Mantel C, 2008, CELL CYCLE, V7, P484, DOI 10.4161/cc.7.4.5316; Nie YC, 2008, J EXP MED, V205, P777, DOI 10.1084/jem.20072513; Niu LH, 1999, BLOOD, V94, P3748, DOI 10.1182/blood.V94.11.3748.423k16_3748_3753; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Pang R, 2010, CELL STEM CELL, V6, P603, DOI 10.1016/j.stem.2010.04.001; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Peranteau WH, 2006, BLOOD, V108, P4268, DOI 10.1182/blood-2006-04-018986; Piacibello W, 2002, BLOOD, V100, P4391, DOI 10.1182/blood.V100.13.4391; Rasmussen HB, 2003, NAT STRUCT BIOL, V10, P19, DOI 10.1038/nsb882; Shaheen MA, 2009, HEMATOLOGY BASIC PRI, P253; Sitnicka E, 2002, IMMUNITY, V17, P463, DOI 10.1016/S1074-7613(02)00419-3; Tian C, 2006, GENE THER, V13, P652, DOI 10.1038/sj.gt.3302695; Waterstrat A, 2010, BLOOD, V115, P408, DOI 10.1182/blood-2008-03-143370; Woodcock JM, 1999, INT J BIOCHEM CELL B, V31, P1017, DOI 10.1016/S1357-2725(99)00084-9; Woodcock JM, 1996, J BIOL CHEM, V271, P25999, DOI 10.1074/jbc.271.42.25999; Woodcock JM, 1997, BAILLIERE CLIN HAEM, V10, P507, DOI 10.1016/S0950-3536(97)80023-6; Wyss BK, 2009, EXP HEMATOL, V37, P814, DOI 10.1016/j.exphem.2009.03.005; Zaruba MM, 2009, CELL STEM CELL, V4, P313, DOI 10.1016/j.stem.2009.02.013	55	165	169	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2012	18	12					1786	+		10.1038/nm.2991	http://dx.doi.org/10.1038/nm.2991			13	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	049QZ	23160239	Green Accepted			2023-01-03	WOS:000311999800026
J	Xu, R; Han, QF; Zhu, TY; Ren, YP; Chen, JH; Zhao, HP; Chen, MH; Dong, J; Wang, Y; Hao, CM; Zhang, R; Zhang, XH; Wang, M; Tian, N; Wang, HY				Xu, Rong; Han, Qing-Feng; Zhu, Tong-Ying; Ren, Ye-Ping; Chen, Jiang-Hua; Zhao, Hui-Ping; Chen, Meng-Hua; Dong, Jie; Wang, Yue; Hao, Chuan-Ming; Zhang, Rui; Zhang, Xiao-Hui; Wang, Mei; Tian, Na; Wang, Hai-Yan			Impact of Individual and Environmental Socioeconomic Status on Peritoneal Dialysis Outcomes: A Retrospective Multicenter Cohort Study	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; TECHNIQUE FAILURE; SURVIVAL; HEMODIALYSIS; PATIENT; RISK; POPULATION; PREDICTORS; MORTALITY; CARE	Objectives: We aimed to explore the impacts of individual and environmental socioeconomic status (SES) on the outcome of peritoneal dialysis (PD) in regions with significant SES disparity, through a retrospective multicenter cohort in China. Methods: Overall, 2,171 incident patients from seven PD centers were included. Individual SES was evaluated from yearly household income per person and education level. Environmental SES was represented by regional gross domestic product (GDP) per capita and medical resources. Undeveloped regions were defined as those with regional GDP lower than the median. All-cause and cardiovascular death and initial peritonitis were recorded as outcome events. Results: Poorer PD patients or those who lived in undeveloped areas were younger and less-educated and bore a heavier burden of medical expenses. They had lower hemoglobin and serum albumin at baseline. Low income independently predicted the highest risks for all-cause or cardiovascular death and initial peritonitis compared with medium and high income. The interaction effect between individual education and regional GDP was determined. In undeveloped regions, patients with an elementary school education or lower were at significantly higher risk for all-cause death but not cardiovascular death or initial peritonitis compared with those who attended high school or had a higher diploma. Regional GDP was not associated with any outcome events. Conclusion: Low personal income independently influenced all-cause and cardiovascular death, and initial peritonitis in PD patients. Education level predicted all-cause death only for patients in undeveloped regions. For PD patients in these high risk situations, integrated care before dialysis and well-constructed PD training programs might be helpful.	[Xu, Rong; Dong, Jie; Wang, Hai-Yan] Peking Univ, Key Lab Renal Dis, Minist Educ,Hosp 1, Renal Div,Dept Med,Inst Nephrol,Minist Hlth, Beijing 100871, Peoples R China; [Han, Qing-Feng; Wang, Yue] Peking Univ, Dept Nephrol, Hosp 3, Beijing 100871, Peoples R China; [Zhu, Tong-Ying; Hao, Chuan-Ming] Fudan Univ, Dept Nephrol, Huashan Hosp, Shanghai 200433, Peoples R China; [Ren, Ye-Ping; Zhang, Rui] Harbin Med Univ, Affiliated Hosp 2, Dept Nephrol, Harbin, Heilongjiang, Peoples R China; [Chen, Jiang-Hua; Zhang, Xiao-Hui] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Kidney Dis Ctr, Hangzhou 310003, Zhejiang, Peoples R China; [Zhao, Hui-Ping; Wang, Mei] Peking Univ, Dept Nephrol, Peoples Hosp, Beijing 100871, Peoples R China; [Chen, Meng-Hua; Tian, Na] Ningxia Med Univ, Gen Hosp, Dept Nephrol, Ningxia, Peoples R China	Peking University; Peking University; Fudan University; Harbin Medical University; Zhejiang University; Peking University; Ningxia Medical University	Dong, J (corresponding author), Peking Univ, Key Lab Renal Dis, Minist Educ,Hosp 1, Renal Div,Dept Med,Inst Nephrol,Minist Hlth, Beijing 100871, Peoples R China.	dongjie@medmail.com.cn	Dong, Jie/AFM-0048-2022; tian, na/GVR-9226-2022		Baxter Corp, China; ISN GO RP Committee; Baxter Corp	Baxter Corp, China; ISN GO RP Committee; Baxter Corp	This study is supported by Baxer Clinical Research Award from Baxter Corp, China and ISN Research Award from ISN GO R&P Committee. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors have the following interests. This work was supported in part by the Baxer Clinical Research Award of Baxter Corp. There are no patents, products in development or marketed products to declare. This does not alter authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.	Adams AS, 2003, BMC HEALTH SERV RES, V3, DOI 10.1186/1472-6963-3-6; Afolalu B, 2009, PERITON DIALYSIS INT, V29, P292; ANZDATA website, 2007, 30 ANZDATA; AVRAM MM, 1994, AM J KIDNEY DIS, V23, P91, DOI 10.1016/S0272-6386(12)80817-1; Bastos KD, 2011, CLIN J AM SOC NEPHRO, V6, P1676, DOI 10.2215/CJN.09041010; Batlle D, 2006, KIDNEY INT, V70, pS40, DOI 10.1038/sj.ki.5001976; BLAKE PG, 1993, J AM SOC NEPHROL, V3, P1501; Blake PG, 2000, AM J KIDNEY DIS, V35, P506, DOI 10.1016/S0272-6386(00)70205-8; Brown EA, 2010, NEPHROL DIAL TRANSPL, V25, P3755, DOI 10.1093/ndt/gfq212; Carruthers D M, 1996, Perit Dial Int, V16 Suppl 1, pS452; Carruthers Dale, 2004, Nephrology (Carlton), V9 Suppl 4, pS129, DOI 10.1111/j.1440-1797.2004.00348.x; Caskey FJ, 2006, KIDNEY INT, V70, P2134, DOI 10.1038/sj.ki.5001999; Chichlowska KL, 2008, PSYCHOSOM MED, V70, P986, DOI 10.1097/PSY.0b013e318183a491; Chidambaram M, 2011, PERITON DIALYSIS INT, V31, P565, DOI 10.3747/pdi.2010.00096; FARIAS MG, 1994, KIDNEY INT, V46, P1392, DOI 10.1038/ki.1994.410; Goldfarb-Rumyantzev AS, 2010, NEPHROL DIAL TRANSPL, V25, P3672, DOI 10.1093/ndt/gfq177; Goldman DP, 2002, P NATL ACAD SCI USA, V99, P10929, DOI 10.1073/pnas.162086599; Jager KJ, 2004, AM J KIDNEY DIS, V43, P891, DOI 10.1053/j.ajkd.2003.12.051; Juergensen E, 2006, CLIN J AM SOC NEPHRO, V1, P1191, DOI 10.2215/CJN.01220406; Kennedy BP, 1998, BRIT MED J, V317, P917; Klarenbach S, 2009, SEMIN NEPHROL, V29, P524, DOI 10.1016/j.semnephrol.2009.06.009; Leinig CE, 2011, J RENAL NUTR, V21, P176, DOI 10.1053/j.jrn.2010.06.026; Li PKT, 2010, PERITON DIALYSIS INT, V30, P393, DOI 10.3747/pdi.2010.00049; Lim WH, 2011, NEPHROL DIAL TRANSPL, V26, P3366, DOI 10.1093/ndt/gfr070; Martin LC, 2011, CLIN J AM SOC NEPHRO, V6, P1944, DOI 10.2215/CJN.11431210; Mehrotra R, 2011, PERIT DIAL INT; Merkin SS, 2007, SOC SCI MED, V65, P809, DOI 10.1016/j.socscimed.2007.04.011; Mujais S, 2006, KIDNEY INT, V70, pS21, DOI 10.1038/sj.ki.5001912; Oliver MJ, 2007, KIDNEY INT, V71, P673, DOI 10.1038/sj.ki.5002107; Oliver MJ, 2010, NEPHROL DIAL TRANSPL, V25, P2737, DOI 10.1093/ndt/gfq085; Pereira BJG, 2000, KIDNEY INT, V57, P351, DOI 10.1046/j.1523-1755.2000.00840.x; Raaijmakers R, 2010, PEDIATR NEPHROL, V25, P2149, DOI 10.1007/s00467-010-1592-0; RUBIN J, 1985, ARCH INTERN MED, V145, P1041, DOI 10.1001/archinte.145.6.1041; RUBIN J, 1983, AM J KIDNEY DIS, V2, P602, DOI 10.1016/S0272-6386(83)80039-0; Sanabria M, 2008, KIDNEY INT, V73, pS165, DOI 10.1038/sj.ki.5002619; Schaubel DE, 2001, KIDNEY INT, V60, P1517, DOI 10.1046/j.1523-1755.2001.00969.x; Smith SC, 2004, CIRCULATION, V109, P3112, DOI 10.1161/01.CIR.0000133427.35111.67; Taira DA, 2007, ETHNIC HEALTH, V12, P265, DOI 10.1080/13557850701234955; Tonelli M, 2007, KIDNEY INT, V72, P1023, DOI 10.1038/sj.ki.5002443; Volkova N, 2008, J AM SOC NEPHROL, V19, P356, DOI 10.1681/ASN.2006080934; Wee LE, 2012, HYPERTENS RES, V35, P295, DOI 10.1038/hr.2011.187; Weinhandl ED, 2010, J AM SOC NEPHROL, V21, P499, DOI 10.1681/ASN.2009060635; Xu R, 2012, PERITON DIALYSIS INT, V32, P94, DOI 10.3747/pdi.2010.00213; Yang X, 2011, CHINESE MED J-PEKING, V124, P2696, DOI 10.3760/cma.j.issn.0366-6999.2011.17.024; Zhang LX, 2012, LANCET, V379, P815, DOI 10.1016/S0140-6736(12)60033-6; Zuo L, 2006, ETHNIC DIS, V16	46	41	44	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2012	7	11							e50766	10.1371/journal.pone.0050766	http://dx.doi.org/10.1371/journal.pone.0050766			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	054WM	23226378	Green Published, gold, Green Submitted			2023-01-03	WOS:000312376100189
J	Lindh, J; Magnusson, M; Grunewald, M; Hulth, A				Lindh, Johan; Magnusson, Mans; Grunewald, Maria; Hulth, Anette			Head Lice Surveillance on a Deregulated OTC-Sales Market: A Study Using Web Query Data	PLOS ONE			English	Article							BARTONELLA-QUINTANA; BODY LICE	The head louse, Pediculus humanus capitis, is an obligate ectoparasite that causes infestations of humans. Studies have demonstrated a correlation between sales figures for over-the-counter (OTC) treatment products and the number of humans with head lice. The deregulation of the Swedish pharmacy market on July 1, 2009, decreased the possibility to obtain complete sale figures and thereby the possibility to obtain yearly trends of head lice infestations. In the presented study we wanted to investigate whether web queries on head lice can be used as substitute for OTC sales figures. Via Google Insights for Search and Vardguiden medical web site, the number of queries on "huvudloss" (head lice) and "harloss" (lice in hair) were obtained. The analysis showed that both the Vardguiden series and the Google series were statistically significant (p<0.001) when added separately, but if the Google series were already included in the model, the Vardguiden series were not statistically significant (p=0.5689). In conclusion, web queries can detect if there is an increase or decrease of head lice infested humans in Sweden over a period of years, and be as reliable a proxy as the OTC-sales figures.	[Lindh, Johan; Magnusson, Mans; Grunewald, Maria; Hulth, Anette] Swedish Inst Communicable Dis Control, Solna, Sweden; [Lindh, Johan] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden	Swedish Institute for Infectious Disease Control; Karolinska Institutet	Lindh, J (corresponding author), Swedish Inst Communicable Dis Control, Solna, Sweden.	johan.lindh@smi.se	Hulth, Anette/E-2162-2017	Hulth, Anette/0000-0002-3132-808X				Angelakis E, 2011, FEMS IMMUNOL MED MIC, V62, P244, DOI 10.1111/j.1574-695X.2011.00804.x; Bauer E, 2009, PARASITOL RES, V104, P677, DOI 10.1007/s00436-008-1245-4; Bonilla DL, 2009, EMERG INFECT DIS, V15, P912, DOI 10.3201/eid1506.090054; Brownstein JS, 2009, NEW ENGL J MED, V360, P2153, DOI [10.1056/NEJMp0900702, 10.1056/NEJMp0904012]; Buczek A, 2004, EUR J EPIDEMIOL, V19, P491, DOI 10.1023/B:EJEP.0000027347.76908.61; Carneiro HA, 2009, CLIN INFECT DIS, V49, P1557, DOI 10.1086/630200; CLORE ER, 1990, J SCHOOL HEALTH, V60, P212, DOI 10.1111/j.1746-1561.1990.tb05917.x; Dukic VM, 2011, EMERG INFECT DIS, V17, P1068, DOI [10.3201/eid1706.101451, 10.3201/eid/1706.101451]; Eysenbach Gunther, 2006, AMIA Annu Symp Proc, P244; Fox J., 2010, TIME SERIES REGRESSI; Ginsberg J, 2009, NATURE, V457, P1012, DOI 10.1038/nature07634; Goel S, 2010, P NATL ACAD SCI USA, V107, P17486, DOI 10.1073/pnas.1005962107; Google, 2012, GOOGL INS SEARCH; Hulth A, 2011, EURO SURVEILL, V16; Hulth A, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-252; Hulth A, 2010, EMERG INFECT DIS, V16, P1319, DOI 10.3201/eid1608.100093; Hulth A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004378; Lebwohl M, 2007, PEDIATRICS, V119, P965, DOI 10.1542/peds.2006-3087; Leo NP, 2005, PARASITOL RES, V98, P44, DOI 10.1007/s00436-005-0013-y; Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074; Rukke BA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032686; Speare R, 1999, INT J DERMATOL, V38, P285, DOI 10.1046/j.1365-4362.1999.00680.x; Wilson K, 2009, CAN MED ASSOC J, V180, P829, DOI [10.1503/cmaj.1090215, 10.1503/cmaj.090215]	23	8	9	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2012	7	11							e48666	10.1371/journal.pone.0048666	http://dx.doi.org/10.1371/journal.pone.0048666			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	048TK	23144923	Green Submitted, gold, Green Published			2023-01-03	WOS:000311935800093
J	Beck, EJ; Mandalia, S; Sangha, R; Youle, M; Brettle, R; Gompels, M; Johnson, M; Pozniak, A; Schwenk, A; Taylor, S; Walsh, J; Wilkins, E; Williams, I; Gazzard, B				Beck, Eduard J.; Mandalia, Sundhiya; Sangha, Roshni; Youle, Mike; Brettle, Ray; Gompels, Mark; Johnson, Margaret; Pozniak, Anton; Schwenk, Achim; Taylor, Stephen; Walsh, John; Wilkins, Ed; Williams, Ian; Gazzard, Brian		NPMS-HHC Steering Grp	Lower Healthcare Costs Associated with the Use of a Single-Pill ARV Regimen in the UK, 2004-2008	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; TABLET REGIMEN; ADHERENCE; SIMPLIFICATION; AIDS	Aim: Investigate the cost and effects of a single-pill versus two- or three pill first-line antiretroviral combinations in reducing viral load, increasing CD4 counts, and first-line failure rate associated with respective regimens at 6 and 12 months. Methods: Patients on first-line TDF+3TC+EFV, TDF+FTC+EFV, Truvada (R)+EFV or Atripla (R) between 1996-2008 were identified and viral load and CD4 counts measured at baseline, six and twelve months respectively. Factors that independently predicted treatment failure at six and twelve months were derived using multivariate Cox's proportional hazard regression analyses. Use and cost of hospital services were calculated at six and twelve months respectively. Results: All regimens reduced viral load to below the limit of detection and CD4 counts increased to similar levels at six and twelve months for all treatment regimens. No statistically significant differences were observed for rate of treatment failure at six and twelve months. People on Atripla (R) generated lower healthcare costs for non-AIDS patients at 5,340 pound (5,254 pound to 5,426) pound per patient-semester and 9,821 pound (9,719 pound to 9,924) pound per patient-year that was 1,344 pound (95%CI 1,222 pound to 1,465) pound less per patient-semester and 1,954 pound (95%CI 1,801 pound to 2,107) pound less per patient-year compared with Truvada (R)+EFV; healthcare costs for AIDS patients were similar across all regimens. Conclusion: The single pill regimen is as effective as the two- and three-pill regimens of the same drugs, but if started as first-line induction therapy there would be a 20% savings on healthcare costs at six and 17% of costs at twelve months compared with Truvada (R)+EFV, that generated the next lowest costs.	[Beck, Eduard J.; Mandalia, Sundhiya; Sangha, Roshni; Youle, Mike; Gazzard, Brian] NPMS HHC CIC, Coordinating & Analyt Ctr, London, England; [Beck, Eduard J.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; [Mandalia, Sundhiya; Gazzard, Brian] Univ London Imperial Coll Sci Technol & Med, London, England; [Youle, Mike; Johnson, Margaret] Royal Free Hosp, London NW3 2QG, England; [Brettle, Ray] Edinburgh Gen Hosp, Edinburgh, Midlothian, Scotland; [Gompels, Mark] Southmead Hosp, Bristol, Avon, England; [Beck, Eduard J.; Mandalia, Sundhiya; Pozniak, Anton; Gazzard, Brian] Chelsea & Westminster Hosp, London, England; [Schwenk, Achim] N Middlesex Hosp, London N18 1QX, England; [Taylor, Stephen] Birmingham Heartland Hosp, Birmingham, W Midlands, England; [Walsh, John] St Marys Hosp, London, England; [Wilkins, Ed] N Manchester Grp Hosp, Manchester, Lancs, England; [Williams, Ian] Mortimer Market Ctr, London, England	University of London; London School of Hygiene & Tropical Medicine; Imperial College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Southmead Hospital; Imperial College London; Heart of England NHS Foundation Trust; Imperial College London	Beck, EJ (corresponding author), NPMS HHC CIC, Coordinating & Analyt Ctr, London, England.	becke@unaids.org			Gilead	Gilead(Gilead Sciences)	This study was financially supported through a non-restrictive grant from Gilead, with no influence on the independence of the Steering Group and its editorial policy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors have read the journal's policy and have the following conflicts: This study was financially supported through a non-restrictive grant from Gilead. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.	Airoldi M, 2010, PATIENT PREFER ADHER, V4, P115; Badri M, 2006, PLOS MED, V3, P48, DOI 10.1371/journal.pmed.0030004; Bangsberg DR, 2010, AIDS, V24, P2835, DOI 10.1097/QAD.0b013e328340a209; Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015; Beck E.J., 2001, EFFECTIVE MANAGEMENT, P113; Beck EJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027830; Beck EJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020200; Beck Eduard J., 2006, HIV PANDEMIC LOCAL G; Beck EJ, 2004, AIDS, V18, P2411; Beck EJ, 2012, PHARMACOECONOMICS, V30, P1; Beck EJ, 2003, BRIT J SEX MED, V27, P21; BECK EJ, 2010, USE COST HIV SERVICE; Calmy A, 2006, AIDS, V20, P1163, DOI 10.1097/01.aids.0000226957.79847.d6; Cohen C, 2011, 13 EUR AIDS C EACS O; Colombo GL, 2011, CLINICOECONOMIC OUTC, V3, P197, DOI 10.2147/CEOR.S24130; DeJesus E, 2009, JAIDS-J ACQ IMM DEF, V51, P163, DOI 10.1097/QAI.0b013e3181a572cf; Duse AG, 2008, S AFR J HIV MED, P53; Gupta AK, 2010, HYPERTENSION, V55, P399, DOI 10.1161/HYPERTENSIONAHA.109.139816; Hodder SL, 2010, AIDS PATIENT CARE ST, V24, P87, DOI 10.1089/apc.2009.0259; Maggiolo F, 2008, J INT AIDS SOC S1, V11, pP167; Mandalia S, 2002, HIV Med, V3, P254, DOI 10.1046/j.1468-1293.2002.00110.x; Mandalia S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015677; Mills EJ, 2006, JAMA-J AM MED ASSOC, V296, P679, DOI 10.1001/jama.296.6.679; Panel on Antiretroviral Guidelines for Adults and Adolescents, GUID US ANT AG HIV 1; Postma MJ, 1997, HEALTH POLICY, V41, P157, DOI 10.1016/S0168-8510(97)00019-5; Rossi V, 2012, WHOS 2010 RECOMMENDA; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Sax PE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031591; Schafer J.L., 1997, ANAL INCOMPLETE MULT; Scourfield A, 2012, 17 INT AIDS C MEX CI, V26, P1399; Thakkar B, 1998, 23 SUGI; TOLLEY K, 1993, HEALTH POLICY, V24, P55, DOI 10.1016/0168-8510(93)90088-7; Tolley K, 1995, EC SOCIAL IMPACT AID, P54; UNAIDS/PEPFAR, 2007, INT GUID PROT CONF S; Wood E, 2003, ANN INTERN MED, V139, P810, DOI 10.7326/0003-4819-139-10-200311180-00008; World Health Organization, 2003, M HELD 16 18 DEC 200; World Health Organization, 2011, TREATM 2 0 FRAM ACT; World Health Organization, 2010, UN ACC SCAL PRIOR HI	38	16	16	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2012	7	10							e47376	10.1371/journal.pone.0047376	http://dx.doi.org/10.1371/journal.pone.0047376			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	032HJ	23118869	Green Published, gold, Green Submitted			2023-01-03	WOS:000310705600011
J	Fuller, C; Michie, S; Savage, J; McAteer, J; Besser, S; Charlett, A; Hayward, A; Cookson, BD; Cooper, BS; Duckworth, G; Jeanes, A; Roberts, J; Teare, L; Stone, S				Fuller, Christopher; Michie, Susan; Savage, Joanne; McAteer, John; Besser, Sarah; Charlett, Andre; Hayward, Andrew; Cookson, Barry D.; Cooper, Ben S.; Duckworth, Georgia; Jeanes, Annette; Roberts, Jenny; Teare, Louise; Stone, Sheldon			The Feedback Intervention Trial (FIT)-Improving Hand-Hygiene Compliance in UK Healthcare Workers: A Stepped Wedge Cluster Randomised Controlled Trial	PLOS ONE			English	Article							BEHAVIOR; STAFF; RISK	Introduction: Achieving a sustained improvement in hand-hygiene compliance is the WHO's first global patient safety challenge. There is no RCT evidence showing how to do this. Systematic reviews suggest feedback is most effective and call for long term well designed RCTs, applying behavioural theory to intervention design to optimise effectiveness. Methods: Three year stepped wedge cluster RCT of a feedback intervention testing hypothesis that the intervention was more effective than routine practice in 16 English/Welsh Hospitals (16 Intensive Therapy Units [ITU]; 44 Acute Care of the Elderly [ACE] wards) routinely implementing a national cleanyourhands campaign). Intervention-based on Goal & Control theories. Repeating 4 week cycle (20 mins/week) of observation, feedback and personalised action planning, recorded on forms. Computer-generated stepwise entry of all hospitals to intervention. Hospitals aware only of own allocation. Primary outcome: direct blinded hand hygiene compliance (%). Results: All 16 trusts (60 wards) randomised, 33 wards implemented intervention (11 ITU, 22 ACE). Mixed effects regression analysis (all wards) accounting for confounders, temporal trends, ward type and fidelity to intervention (forms/month used). Intention to Treat Analysis: Estimated odds ratio (OR) for hand hygiene compliance rose post randomisation (1.44; 95% CI 1.18, 1.76; p<0.001) in ITUs but not ACE wards, equivalent to 7-9% absolute increase in compliance. Per-Protocol Analysis for Implementing Wards: OR for compliance rose for both ACE (1.67 [1.28-2.22]; p<0.001) & ITUs (2.09 [1.55-2.81]; p<0.001) equating to absolute increases of 10-13% and 13-18% respectively. Fidelity to intervention closely related to compliance on ITUs (OR 1.12 [1.04, 1.20];p = 0.003 per completed form) but not ACE wards. Conclusion: Despite difficulties in implementation, intention-to-treat, per-protocol and fidelity to intervention, analyses showed an intervention coupling feedback to personalised action planning produced moderate but significant sustained improvements in hand-hygiene compliance, in wards implementing a national hand-hygiene campaign. Further implementation studies are needed to maximise the intervention's effect in different settings.	[Fuller, Christopher; Savage, Joanne; Besser, Sarah; Hayward, Andrew; Stone, Sheldon] UCL, Sch Med, London, England; [Charlett, Andre; Cookson, Barry D.; Cooper, Ben S.; Duckworth, Georgia] Hlth Protect Agcy, London, England; [Jeanes, Annette] Univ Coll London Hosp, London, England; [Roberts, Jenny] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; [Teare, Louise] Mid Essex NHS Trust, Chelmsford, Essex, England	University of London; University College London; UCL Medical School; Health Protection Agency; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; London School of Hygiene & Tropical Medicine	Stone, S (corresponding author), UCL, Sch Med, Royal Free Campus, London, England.	s.stone@medsch.ucl.ac.uk	Cooper, Ben/HGC-7082-2022; Jeanes, Annette/L-6927-2019; Hayward, Andrew C/C-3268-2013; Michie, Susan/A-1745-2010	Hayward, Andrew C/0000-0002-3549-6232; Besser, Sarah Jane/0000-0003-3252-9665; Cooper, Ben/0000-0002-9445-7217; Michie, Susan/0000-0003-0063-6378	Patient Safety Research Programme [PS/029]; Trustees of the Royal Free; GOJO industries	Patient Safety Research Programme; Trustees of the Royal Free; GOJO industries	This work was supported by the Patient Safety Research Programme (PS/029), http://www.publichealth.bham.ac.uk/psrp; Trustees of the Royal Free, http://royalfreecharity.org; and GOJO industries, www.gojo.com (who provided an educational grant). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Brown C.A., 2006, BMC MED RES METHODOL, V6, P54, DOI DOI 10.1186/1471-2288-6-54; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; Carver CS, 2000, HDB SELF REGULATION; Curtis V, 2003, LANCET INFECT DIS, V3, P275, DOI 10.1016/S1473-3099(03)00606-6; DUBBERT PM, 1990, INFECT CONT HOSP EP, V11, P191; Erasmus V, 2010, INFECT CONT HOSP EP, V31, P283, DOI 10.1086/650451; Feiveson AH, 2002, STATA J, V2, P107, DOI 10.1177/1536867X0200200201; Fuller C, 2010, AM J INFECT CONTROL, V38, P332, DOI 10.1016/j.ajic.2009.10.005; Gardner B, 2010, SOC SCI MED, V70, P1618, DOI 10.1016/j.socscimed.2010.01.039; Glanz K, 2010, ANNU REV PUBL HEALTH, V31, P399, DOI 10.1146/annurev.publhealth.012809.103604; Gould DJ, 2008, J HOSP INFECT, V68, P193, DOI 10.1016/j.jhin.2007.11.013; Grimshaw JM, 2004, HEALTH TECHNOL ASSES, V8, P1, DOI 10.3310/hta8060; Hugonnet S, 2002, ARCH INTERN MED, V162, P1037, DOI 10.1001/archinte.162.9.1037; Hussain M, 1996, J HOSP INFECT, V32, P117, DOI 10.1016/S0195-6701(96)90053-5; Jamtvedt G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000259.pub2; Locke E.A., 1990, THEORY GOAL; Magiorakos AP, 2010, EUROSURVEILLANCE, V15; MAYER JA, 1986, INFECT CONT HOSP EP, V7, P259, DOI 10.1017/S0195941700064171; McAteer J, 2008, J HOSP INFECT, V68, P222, DOI 10.1016/j.jhin.2007.12.009; MCATEER J, 2006, J HOSP INFECT S1, V64, pS53; McAteer J, 2010, THESIS U COLL LONDON; Michie S, 2005, QUAL SAF HEALTH CARE, V14, P26, DOI 10.1136/qshc.2004.011155; Michie S, 2008, APPL PSYCHOL-INT REV, V57, P660, DOI 10.1111/j.1464-0597.2008.00341.x; Naikoba S, 2001, J HOSP INFECT, V47, P173, DOI 10.1053/jhin.2000.0882; National Patient Safety Agency, 2004, ACH OUR AIMS EV RES; National Patient Safety Agency, 2004, READ STEAD GO FULL G; Nosocomial Infection National Surveillance Service, 2002, SURV HOSP ACQ BACT E; Pittet D, 2000, LANCET, V356, P1307, DOI 10.1016/S0140-6736(00)02814-2; Pratt R. J., 2001, Journal of Hospital Infection, V47, pS1; RAJU TNK, 1991, AM J MED SCI, V302, P355, DOI 10.1097/00000441-199112000-00006; Salemi C, 2002, INFECT CONT HOSP EP, V23, P32, DOI 10.1086/501965; Skinner B. F., 1953, SCI HUMAN BEHAV; Stone S, 2001, LANCET, V357, P479, DOI 10.1016/S0140-6736(05)71288-5; Stone S, 2012, REPORT PATIENT SAFET; Stone SP, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3005; The Joint commission, 2009, MEAS HAND HYG ADH OV; Tibballs J, 1996, MED J AUSTRALIA, V164, P395, DOI 10.5694/j.1326-5377.1996.tb122084.x; van de Mortel T, 2000, Aust Crit Care, V13, P91, DOI 10.1016/S1036-7314(00)70630-8; WHO, 2009, PAT SAF WORLD ALL SA; World Health Organisation, 2010, INCR ACH	41	106	110	1	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2012	7	10							e41617	10.1371/journal.pone.0041617	http://dx.doi.org/10.1371/journal.pone.0041617			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	025MO	23110040	Green Published, gold			2023-01-03	WOS:000310193600001
J	Kashima, S; Matsumoto, M; Ogawa, T; Eboshida, A; Takeuchi, K				Kashima, Saori; Matsumoto, Masatoshi; Ogawa, Takahiko; Eboshida, Akira; Takeuchi, Keisuke			The Impact of Travel Time on Geographic Distribution of Dialysis Patients	PLOS ONE			English	Article							STAGE RENAL-DISEASE; QUALITY-OF-LIFE; PRACTICE PATTERNS; MORTALITY; OUTCOMES; CARE	Backgrounds: The geographic disparity of prevalence rates among dialysis patients is unclear. We evaluate the association between travel time to dialysis facilities and prevalence rates of dialysis patients living in 1,867 census areas of Hiroshima, Japan. Furthermore, we study the effects of geographic features (mainland or island) on the prevalence rates and assess if these effects modify the association between travel time and prevalence. Methods: The study subjects were all 7,374 people that were certified as the "renal disabled'' by local governments in 2011. The travel time from each patient to the nearest available dialysis facility was calculated by incorporating both travel time and the capacity of all 98 facilities. The effect of travel time on the age-and sex-adjusted standard prevalence rate (SPR) and 95% confidence intervals (CIs) at each census area was evaluated in two-level Poisson regression models with 1,867 census areas (level 1) nested within 35 towns or cities (level 2). The results were adjusted for area-based parameters of socioeconomic status, urbanity, and land type. Furthermore, the SPR of dialysis patients was calculated in each specific subgroup of population for travel time, land type, and combination of land type and travel time. Results: In the regression analysis, SPR decreased by 5.2% (95% CI: -27.9-22.3) per 10-min increase in travel time even after adjusting for potential confounders. The effect of travel time on prevalence was different in the mainland and island groups. There was no travel time-dependent SPR disparity on the islands. The SPR among remote residents (>30 min from facilities) in the mainland was lower (0.77, 95% CI: 0.71-0.85) than that of closer residents (<= 30 min; 0.95, 95% CI: 0.92-0.97). Conclusions: The prevalence of dialysis patients was lower among remote residents. Geographic difficulties for commuting seem to decrease the prevalence rate.	[Kashima, Saori; Eboshida, Akira] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Publ Hlth & Hlth Policy, Hiroshima, Japan; [Matsumoto, Masatoshi; Takeuchi, Keisuke] Hiroshima Univ, Fac Med, Dept Community Based Med Syst, Hiroshima, Japan; [Ogawa, Takahiko] Hiroshima Prefectural Hosp, Ctr Kidney Dis, Hiroshima, Japan	Hiroshima University; Hiroshima University	Kashima, S (corresponding author), Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Publ Hlth & Hlth Policy, Hiroshima, Japan.	saori_ksm@ybb.ne.jp	Kashima, Saori/B-4524-2010	Kashima, Saori/0000-0002-3401-8191; Matsumoto, Masatoshi/0000-0002-8341-9303	Hiroshima Dialysis Association; Hiroshima Association of Kidney Patients; Higher Education Grant Program of ESRI Japan Corp.	Hiroshima Dialysis Association; Hiroshima Association of Kidney Patients; Higher Education Grant Program of ESRI Japan Corp.	The authors thank the Hiroshima Dialysis Association and the Hiroshima Association of Kidney Patients, for their support of this study. The software used in this study was supported by the Higher Education Grant Program of ESRI Japan Corp.	[Anonymous], 2011, OV REG DIAL TREATM J; [Anonymous], 2007, MIN INT AFF COMM JAP; Disability and Welfare Section Hiroshima City, 2004, PHYS GUID DIS CERT; Fukuhara Shunichi, 2007, Int J Health Care Finance Econ, V7, P217, DOI 10.1007/s10754-007-9017-8; Greenland S, 2008, MODERN EPIDEMIOLOGY, P258; Ikegami N, 2011, LANCET, V378, P1106, DOI 10.1016/S0140-6736(11)60828-3; Imasawa T, 2010, JAPANESE J NEPHROLOG, V52, P1015; Japanese Society for Dialysis Therapy, 2012, OV REG DIAL TREATM J; Judge A, 2011, NEPHROL DIAL TRANSPL; Klag MJ, 1997, JAMA-J AM MED ASSOC, V277, P1293, DOI 10.1001/jama.277.16.1293; Lawson A, 2003, DIS MAPPING WINBUGS, Vxiii; Lawson A.B., 2006, STAT METHODS SPATIAL, P41; Maheswaran R, 2003, J EPIDEMIOL COMMUN H, V57, P523, DOI 10.1136/jech.57.7.523; Matsumoto M, 2012, INT J HEALTH GEOGR, V11, DOI 10.1186/1476-072X-11-28; Matsumoto M, 2010, HEALTH PLACE, V16, P164, DOI 10.1016/j.healthplace.2009.07.005; Moist LM, 2008, AM J KIDNEY DIS, V51, P641, DOI 10.1053/j.ajkd.2007.12.021; Nakai S, 2012, NIHON TOSEKI IGAKKAI, V45, P1; OECD, 2011, HLTH GLANC 2011 OECD; R DEVELOPMENT CORE TEAM, 2011, R LANG ENV STAT COMP; Rasbash J, 2010, MLWIN VERSION  2 22; Roderick P, 1999, J Health Serv Res Policy, V4, P139; Rucker D, 2011, KIDNEY INT, V79, P210, DOI 10.1038/ki.2010.376; Smyth GK., 2004, STAT APPL GENET MOL, V3, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Sugisawa H, 2010, J JAPANESE ASS DIAL, V25, P135; Tonelli M, 2007, CAN MED ASSOC J, V177, P1039, DOI 10.1503/cmaj.070343; Udayaraj UP, 2010, J EPIDEMIOL COMMUN H, V64, P535, DOI 10.1136/jech.2009.093518; Untas A, 2011, CLIN J AM SOC NEPHRO, V6, P142, DOI 10.2215/CJN.02340310; White P, 2006, QJM-INT J MED, V99, P445, DOI 10.1093/qjmed/hcl054; WHITTLE JC, 1991, ARCH INTERN MED, V151, P1359, DOI 10.1001/archinte.151.7.1359	29	5	5	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2012	7	10							e47753	10.1371/journal.pone.0047753	http://dx.doi.org/10.1371/journal.pone.0047753			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	038AF	23082209	Green Submitted, Green Published, gold			2023-01-03	WOS:000311146900106
J	Rigotti, NA				Rigotti, Nancy A.			Strategies to Help a Smoker Who Is Struggling to Quit	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUSTAINED-RELEASE BUPROPION; RECEPTOR PARTIAL AGONIST; SMOKING-CESSATION; TOBACCO DEPENDENCE; ADVERSE EVENTS; DOUBLE-BLIND; VARENICLINE; PLACEBO; THERAPY; SAFETY	Tobacco use is the leading preventable cause of death worldwide. Stopping tobacco use benefits virtually every smoker. Most of the 19% of US residents who smoke want to quit and have tried to do so. Most individual quit attempts fail, but two-thirds of smokers use no treatment when trying to quit. Treating tobacco dependence is one of the most cost-effective actions in health care. With a brief intervention, physicians can prompt smokers to attempt to quit and connect them to evidence-based treatment that includes pharmacotherapy and behavioral support (ie, counseling). Physicians can link smokers to effective counseling support offered by a free national network of telephone quit lines. Smokers who use nicotine replacement therapy (NRT), bupropion, or varenicline when trying to quit double their odds of success. The most effective way to use NRT is to combine the long-acting nicotine patch with a shorter-acting product (lozenge, gum, inhaler, or nasal spray) and extend treatment beyond 12 weeks. Observational studies have not confirmed case reports of behavior changes associated with varenicline and bupropion, and these drugs' benefits outweigh potential risks. A chronic disease management model is effective for treating tobacco dependence, which deserves as high a priority in health care systems as treating other chronic diseases like diabetes and hypertension. JAMA. 2012;308(15):1573-1580 www.jama.com	[Rigotti, Nancy A.] Harvard Univ, Massachusetts Gen Hosp, Div Gen Med, Dept Med,Med Sch, Boston, MA 02114 USA; [Rigotti, Nancy A.] Harvard Univ, Sch Med, Tobacco Res & Treatment Ctr, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School	Rigotti, NA (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Div Gen Med, Dept Med,Med Sch, 50 Staniford St,9th Floor, Boston, MA 02114 USA.	nrigotti@partners.org			Nabi Biopharmaceuticals Inc; Pfizer Inc.; National Institutes of Health, National Heart, Lung, and Blood Institute [5K24HL4440-10]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL004440] Funding Source: NIH RePORTER	Nabi Biopharmaceuticals Inc; Pfizer Inc.(Pfizer); National Institutes of Health, National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and reported that she has received royalties from UpToDate Inc and research grants to her institution from Nabi Biopharmaceuticals Inc, and Pfizer Inc. She also reported that she has served as an unpaid consultant for Pfizer Inc and Alere Wellbeing Inc.; This was supported by grant 5K24HL4440-10, a Mid-Career Investigator Award in Patient-Oriented Research from the National Institutes of Health, National Heart, Lung, and Blood Institute.	Abroms LC, 2011, AM J PREV MED, V40, P279, DOI 10.1016/j.amepre.2010.10.032; [Anonymous], COCHR SUMM; Aubin HJ, 2008, THORAX, V63, P717, DOI 10.1136/thx.2007.090647; Aveyard P, 2012, TOB CONTROL, V21, P252, DOI 10.1136/tobaccocontrol-2011-050348; Barry MB, US QUITLINES CROSS R; Benowitz NL, 2011, CLIN PHARMACOL THER, V90, P491, DOI 10.1038/clpt.2011.191; Benowitz NL, 2010, NEW ENGL J MED, V362, P2295, DOI 10.1056/NEJMra0809890; Blumenthal D, 2010, NEW ENGL J MED, V363, P501, DOI 10.1056/NEJMp1006114; Cahill K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006103.pub5; Centers for Disease Control and Prevention, GUID COMM PREV SERV; Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P1227; Cobb NK, 2011, NEW ENGL J MED, V365, P193, DOI 10.1056/NEJMp1105249; Cochrane Tobacco Addiction Group, COCHRANE LIB; Critchley JA, 2003, JAMA-J AM MED ASSOC, V290, P86, DOI 10.1001/jama.290.1.86; Doll R, 2004, BMJ-BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE; Ebbert JO, 2009, NICOTINE TOB RES, V11, P572, DOI 10.1093/ntr/ntp042; Ebbert JO, 2009, NICOTINE TOB RES, V11, P234, DOI 10.1093/ntr/ntn031; Ferguson SG, 2012, ADDICTION, V107, P1349, DOI 10.1111/j.1360-0443.2012.03801.x; Fiore M. C., 2008, TREATING TOBACCO USE; Fiore MC, 2011, NEW ENGL J MED, V365, P1222, DOI 10.1056/NEJMcp1101512; Food and Drug Administration, FDA DRUG SAF COMM CH; Food and Drug Administration, FDA DRUG SAF COMM SA; Food and Drug Administration, PUBL HLTH ADV FDA RE; Free C, 2011, LANCET, V378, P49, DOI 10.1016/S0140-6736(11)60701-0; Gonzales D, 2006, JAMA-J AM MED ASSOC, V296, P47, DOI 10.1001/jama.296.1.47; Gourlay S G, 2004, Cochrane Database Syst Rev, pCD000058, DOI 10.1002/14651858.CD000058.pub2; Gunnell D, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b3805; Hays JT, 2011, CAN MED ASSOC J, V183, P1346, DOI 10.1503/cmaj.110804; Hughes JR, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000031.pub3, 10.1002/14651858.CD000031.pub4]; Hughes JR, 2004, ADDICTION, V99, P29, DOI 10.1111/j.1360-0443.2004.00540.x; Jorenby DE, 2006, JAMA-J AM MED ASSOC, V296, P56, DOI 10.1001/jama.296.1.56; Joseph AM, 2011, ARCH INTERN MED, V171, P1894, DOI 10.1001/archinternmed.2011.500; King Brian, 2011, Morbidity and Mortality Weekly Report, V60, P1207; Lai DTC, 2010, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006936.pub2, 10.1002/14651858.CD006936.pub3]; Lindson N, 2011, PSYCHOPHARMACOLOGY, V214, P579, DOI 10.1007/s00213-010-2069-3; Lindson N, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008033.pub2; Lumley J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001055.pub3; Maarcher Ann, 2011, Morbidity and Mortality Weekly Report, V60, P1513; Meyer TE, 2011, PHARMACOEPIDEM DR S, V20, pS245; Mills Edward J, 2010, Tob Induc Dis, V8, P8, DOI 10.1186/1617-9625-8-8; Moore David, 2009, BMJ, V338, pb1024, DOI 10.1136/bmj.b1024; North American Quitline Consortium, FREE DISC MED; Pachas GN, 2012, J DUAL DIAGN, V8, P117, DOI 10.1080/15504263.2012.663675; Piper ME, 2009, ARCH GEN PSYCHIAT, V66, P1253, DOI 10.1001/archgenpsychiatry.2009.142; Primack BA, 2008, ANN BEHAV MED, V36, P81, DOI 10.1007/s12160-008-9047-6; Prochaska JJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2856; Rigotti NA, 2011, AM J PREV MED, V41, P498, DOI 10.1016/j.amepre.2011.07.022; Rigotti NA, 2011, ARCH INTERN MED, V171, P53, DOI 10.1001/archinternmed.2010.491; Schnoll RA, 2010, ANN INTERN MED, V152, P144, DOI 10.7326/0003-4819-152-3-201002020-00005; Schroeder SA, 2009, JAMA-J AM MED ASSOC, V301, P522, DOI 10.1001/jama.2008.982; Shahab L, 2009, ADDICTION, V104, P1792, DOI 10.1111/j.1360-0443.2009.02710.x; Shiffman S, 2008, ADDICTION, V103, P1371, DOI 10.1111/j.1360-0443.2008.02268.x; Singh S, 2011, CAN MED ASSOC J, V183, P1359, DOI 10.1503/cmaj.110218; Smith SS, 2009, ARCH INTERN MED, V169, P2148, DOI 10.1001/archinternmed.2009.426; Stead LF, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002850.pub2; Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub3; Stead LF, 2008, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD000165.PUB3; Steinberg MB, 2008, ANN INTERN MED, V148, P554, DOI 10.7326/0003-4819-148-7-200804010-00012; Steinberg MB, 2009, ANN INTERN MED, V150, P447, DOI 10.7326/0003-4819-150-7-200904070-00004; Tonstad S, 2010, DRUG SAFETY, V33, P289, DOI 10.2165/11319180-000000000-00000; Tynan M., 2010, Morbidity and Mortality Weekly Report, V59, P487; U.S. Department of Health and Human Services, 2010, END TOB EP TOB CONTR; US Food and Drug Administration, CHANT VAR DRUG LABL; Whittaker R, 2009, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006611.pub2, 10.1002/14651858.CD006611.pub3]; Williams JM, 2012, J CLIN PSYCHIAT, V73, P654, DOI 10.4088/JCP.11m07522	65	69	69	0	32	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 17	2012	308	15					1573	1580		10.1001/jama.2012.13043	http://dx.doi.org/10.1001/jama.2012.13043			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	021AQ	23073954	Green Accepted			2023-01-03	WOS:000309858100024
J	Graw, JA; Spies, CD; Wernecke, KD; Braun, JP				Graw, Jan A.; Spies, Claudia D.; Wernecke, Klaus-D.; Braun, Jan-Peter			Managing End-Of-Life Decision Making in Intensive Care Medicine - A Perspective from Charite Hospital, Germany	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; ADVANCE DIRECTIVES; SUSTAINING TREATMENT; SUPPORT; WITHDRAWAL; UNITS; COMMUNICATION; PREFERENCES; STATEMENT; HEALTH	Introduction: End-of-life-decisions (EOLD) have become an important part of modern intensive care medicine. With increasing therapeutic possibilities on the one hand and many ICU-patients lacking decision making capacity or an advance directive on the other the decision making process is a major challenge on the intensive care unit (ICU). Currently, data are poor on factors associated with EOLD in Germany. In 2009, a new law on advance directives binding physicians and the patients surrogate decision makers was enacted in Germany. So far it is unknown if this law influenced proceedings of EOLD making on the ICU. Methods: A retrospective analysis was conducted on all deceased patients (n = 224) in a 22-bed surgical ICU of a German university medical center from 08/2008 to 09/2010. Patient characteristics were compared between patients with an EOLD and those without an EOLD. Patients with an EOLD admitted before and after change of legislation were compared with respect to frequencies of EOLD performance as well as advance directive rates. Results: In total, 166 (74.1%) of deaths occurred after an EOLD. Compared to patients without an EOLD, comorbidities, ICU severity scores, and organ replacement technology did not differ significantly. EOLDs were shared within the caregiverteam and with the patients surrogate decision makers. After law enacting, no differences in EOLD performance or frequency of advance directives (8.9% vs. 9.9%; p = 0.807) were observed except an increase of documentation efforts associated with EOLDs (18.7% vs. 43.6%; p<0.001). Conclusions: In our ICU EOLD proceedings were performed patient-individually. But EOLDs follow a standard of shared decision making within the caregiverteam and the patients surrogate decision makers. Enacting a law on advance directives has not affected the decision making-process in EOLDs nor has it affected populations advance care planning habits. However, it has led to increased EOLD-associated documentation on the ICU.	[Graw, Jan A.; Spies, Claudia D.; Braun, Jan-Peter] Charite, Dept Anesthesiol & Intens Care Med, D-13353 Berlin, Germany; [Graw, Jan A.; Spies, Claudia D.; Braun, Jan-Peter] Charite, Campus Virchow Klinikum, D-13353 Berlin, Germany; [Wernecke, Klaus-D.] Charite, Inst Med Biometry, D-13353 Berlin, Germany; [Wernecke, Klaus-D.] SOSTANA GmbH, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Sostana GmbH	Graw, JA (corresponding author), Charite, Dept Anesthesiol & Intens Care Med, Campus Charite Mitte, D-13353 Berlin, Germany.	jan.graw@charite.de		Spies, Claudia/0000-0002-1062-0495				Braun JP, 2010, ANASTH INTENSIVMED, V51, pS809, DOI 10.3205/000111; Cohen S, 2005, INTENS CARE MED, V31, P1215, DOI 10.1007/s00134-005-2742-x; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; Esteban A, 2001, INTENS CARE MED, V27, P1744, DOI 10.1007/s00134-001-1111-7; Ferrand E, 2001, LANCET, V357, P9, DOI 10.1016/S0140-6736(00)03564-9; Floer B, 2004, DEUT MED WOCHENSCHR, V129, P2343, DOI 10.1055/s-2004-835265; Gerstel E, 2008, AM J RESP CRIT CARE, V178, P798, DOI 10.1164/rccm.200711-1617OC; Goodman MD, 1998, CRIT CARE MED, V26, P701, DOI 10.1097/00003246-199804000-00018; Jox RJ, 2010, J CRIT CARE, V25, P413, DOI 10.1016/j.jcrc.2009.06.012; Kompanje EJO, 2008, INTENS CARE MED, V34, P1593, DOI 10.1007/s00134-008-1172-y; Kon AA, 2010, JAMA-J AM MED ASSOC, V304, P903, DOI 10.1001/jama.2010.1208; Lang FR, 2007, DEUT MED WOCHENSCHR, V132, P2558, DOI 10.1055/s-2007-993097; Levy MM, 2006, CRIT CARE MED, V34, pS306, DOI 10.1097/01.CCM.0000246096.18214.79; Lustbader DR, 2012, CHEST, V141, P787, DOI 10.1378/chest.11-2012; Meissner A, 2010, CRIT CARE MED, V38, P1060, DOI 10.1097/CCM.0b013e3181cd1110; Morrison RS, 1998, J CLIN ETHIC, V9, P118; Murray E, 2007, PATIENT EDUC COUNS, V65, P189, DOI 10.1016/j.pec.2006.07.007; Palker N B, 1995, Nurse Pract, V20, P7; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; Prendergast TJ, 2001, CRIT CARE MED, V29, pN34, DOI 10.1097/00003246-200102001-00007; Schaden E, 2010, BMC MED ETHICS, V11, DOI 10.1186/1472-6939-11-19; Scheunemann LP, 2011, CHEST, V139, P543, DOI 10.1378/chest.10-0595; Schimmer C, 2012, INTERACT CARDIOV TH, V14, P294, DOI 10.1093/icvts/ivr119; Silveira MJ, 2010, NEW ENGL J MED, V362, P1211, DOI 10.1056/NEJMsa0907901; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; Spies CD, 2006, ACTA ANAESTH SCAND, V50, P1019, DOI 10.1111/j.1399-6576.2006.01097.x; Spronk PE, 2009, ANESTH ANALG, V109, P841, DOI 10.1213/ane.0b013e3181acc64a; Sprung CL, 2003, JAMA-J AM MED ASSOC, V290, P790, DOI 10.1001/jama.290.6.790; Thompson BT, 2004, CRIT CARE MED, V32, P1781, DOI 10.1097/01.CCM.0000126895.66850.14; Thorevska N, 2005, J CRIT CARE, V20, P26, DOI 10.1016/j.jcrc.2004.11.002; Truog RD, 2008, CRIT CARE MED, V36, P953, DOI 10.1097/CCM.0B013E3181659096; van Oorschot Birgitt, 2008, Bull Soc Sci Med Grand Duche Luxemb, P443; White DB, 2006, CRIT CARE MED, V34, P2053, DOI 10.1097/01.CCM.0000227654.38708.C1; Wiesing U, 2010, J MED ETHICS, V36, P779, DOI 10.1136/jme.2010.036376; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665; Zamperetti N, 2010, MINERVA ANESTESIOL, V76, P541	36	22	22	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2012	7	10							e46446	10.1371/journal.pone.0046446	http://dx.doi.org/10.1371/journal.pone.0046446			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	014PQ	23049701	Green Published, Green Submitted, gold			2023-01-03	WOS:000309388500028
J	Schultke, E; Trippel, M; Brauer-Krisch, E; Renier, M; Bartzsch, S; Requardt, H; Dobrossy, MD; Nikkhah, G				Schueltke, Elisabeth; Trippel, Michael; Braeuer-Krisch, Elke; Renier, Michel; Bartzsch, Stefan; Requardt, Herwig; Doebroessy, Mate D.; Nikkhah, Guido			Pencilbeam Irradiation Technique for Whole Brain Radiotherapy: Technical and Biological Challenges in a Small Animal Model	PLOS ONE			English	Article							MICROBEAM RADIATION-THERAPY; X-RAY-BEAMS; 9L GLIOSARCOMA; SYNCHROTRON	We have conducted the first in-vivo experiments in pencilbeam irradiation, a new synchrotron radiation technique based on the principle of microbeam irradiation, a concept of spatially fractionated high-dose irradiation. In an animal model of adult C57 BL/6J mice we have determined technical and physiological limitations with the present technical setup of the technique. Fifty-eight animals were distributed in eleven experimental groups, ten groups receiving whole brain radiotherapy with arrays of 50 mu m wide beams. We have tested peak doses ranging between 172 Gy and 2,298 Gy at 3 mm depth. Animals in five groups received whole brain radiotherapy with a center-to-center (ctc) distance of 200 mu m and a peak-to-valley ratio (PVDR) of similar to 100, in the other five groups the ctc was 400 mm (PVDR similar to 400). Motor and memory abilities were assessed during a six months observation period following irradiation. The lower dose limit, determined by the technical equipment, was at 172 Gy. The LD50 was about 1,164 Gy for a ctc of 200 mu m and higher than 2,298 Gy for a ctc of 400 mu m. Age-dependent loss in motor and memory performance was seen in all groups. Better overall performance (close to that of healthy controls) was seen in the groups irradiated with a ctc of 400 mu m.	[Schueltke, Elisabeth; Trippel, Michael; Doebroessy, Mate D.; Nikkhah, Guido] Univ Freiburg, Med Ctr, Div Stereotact & Funct Neurosurg, Hugstetter Str 55, D-79106 Freiburg, Germany; [Braeuer-Krisch, Elke; Renier, Michel; Requardt, Herwig] ESRF, Grenoble, France; [Bartzsch, Stefan] Deutsch Krebsforschungszentrum DKFZ, Heidelberg, Germany	University of Freiburg; European Synchrotron Radiation Facility (ESRF); Helmholtz Association; German Cancer Research Center (DKFZ)	Schultke, E (corresponding author), Univ Freiburg, Med Ctr, Div Stereotact & Funct Neurosurg, Hugstetter Str 55, D-79106 Freiburg, Germany.	elisabeth.schueltke@uniklinik-freiburg.de	Dobrossy, Mate/AAL-7897-2021; Schultke, Elisabeth/M-3959-2013; Brauer-Krisch, Elke/O-6026-2017	Dobrossy, Mate/0000-0002-0187-2252; Brauer-Krisch, Elke/0000-0003-4587-1160; Bartzsch, Stefan/0000-0001-9550-9122	FP 7 Programme of the European Union [PIRG07-GA-2010]; Research Commission of the Faculty of Medicine at the Albert-Ludwigs-University Freiburg	FP 7 Programme of the European Union; Research Commission of the Faculty of Medicine at the Albert-Ludwigs-University Freiburg	Dr. Schultke holds a Marie-Curie-Reintegration Grant from the FP 7 Programme of the European Union (PIRG07-GA-2010; http://cordis.europa.eu/fp7/dc/index.cfm?fuseaction = UserSite.peopleDetailsCallPage&call_id = 168). Drs. Schultke and Trippel received funding from the Research Commission of the Faculty of Medicine at the Albert-Ludwigs-University Freiburg (no grant number). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2007, ISP EBT PRODUCT BRIE; [Anonymous], GAFCHR HD 810 RAD DO; Bouchet A, 2010, INT J RADIAT ONCOL, V78, P1503, DOI 10.1016/j.ijrobp.2010.06.021; Brauer-Krisch E, 2010, MUTAT RES-REV MUTAT, V704, P160, DOI 10.1016/j.mrrev.2009.12.003; Brauer-Krisch E, 2009, REV SCI INSTRUM, V80, DOI 10.1063/1.3170035; Brauer-Krisch E, 2009, IFMBE P, V25, P174, DOI [10.1007/978-3-642-03902-7-49, DOI 10.1007/978-3-642-03902-7-49]; D'Ambrosio DJ, 2007, J NEURO-ONCOL, V85, P77, DOI 10.1007/s11060-007-9384-5; Dilmanian FA, 2002, NEURO-ONCOLOGY, V4, P26, DOI 10.1093/neuonc/4.1.26; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Kerklaan JP, 2011, J NEUROL, V258, P1098, DOI 10.1007/s00415-010-5892-x; Laissue JA, 2001, P SOC PHOTO-OPT INS, V4508, P65, DOI 10.1117/12.450774; Laissue JA, 1998, INT J CANCER, V78, P654, DOI 10.1002/(SICI)1097-0215(19981123)78:5<654::AID-IJC21>3.0.CO;2-L; Martinez-Rovira I, 2012, MED PHYS, V39, P119, DOI 10.1118/1.3665768; Monje ML, 2003, CURR OPIN NEUROL, V16, P129, DOI 10.1097/00019052-200304000-00002; Qiu D, 2007, INT J RADIAT ONCOL, V69, P846, DOI 10.1016/j.ijrobp.2007.04.041; Regnard P, 2008, PHYS MED BIOL, V53, P861, DOI 10.1088/0031-9155/53/4/003; Schultke E, 2008, EUR J RADIOL, V68, pS142, DOI 10.1016/j.ejrad.2008.04.051; Serduc R, 2009, PHYS MED BIOL, V54, P6711, DOI 10.1088/0031-9155/54/21/017; Shi L, 2009, J NEUROL SCI, V285, P178, DOI 10.1016/j.jns.2009.06.031; Szerlip N, 2011, J NEURO-ONCOL, V103, P111, DOI 10.1007/s11060-010-0358-7; Uyama A, 2011, J SYNCHROTRON RADIAT, V18, P1	21	18	18	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2013	8	1							e54960	10.1371/journal.pone.0054960	http://dx.doi.org/10.1371/journal.pone.0054960			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	093SF	23383014	Green Published, gold, Green Submitted			2023-01-03	WOS:000315211500040
J	Wang, YB; Liu, YF; Lu, XT; Yan, FF; Wang, B; Bai, WW; Zhao, YX				Wang, Ying-Bin; Liu, Yun-Fang; Lu, Xiao-Ting; Yan, Fang-Fang; Wang, Bo; Bai, Wen-Wu; Zhao, Yu-Xia			Rehmannia Glutinosa Extract Activates Endothelial Progenitor Cells in a Rat Model of Myocardial Infarction through a SDF-1 alpha/CXCR4 Cascade	PLOS ONE			English	Article							CORONARY-ARTERY DISEASE; STEM-CELLS; BONE-MARROW; CXCR4 RECEPTOR; TRANSPLANTATION; EXPRESSION; BINDING; REPAIR; HEART; DIFFERENTIATION	Objectives: Endothelial progenitor cells (EPCs) can be used to repair tissues after myocardial infarction (MI) but EPC activators have adverse reactions. Rehmannia glutinosa is a herb used in traditional Chinese medicine, which can promote bone-marrow proliferation and protect the ischemic myocardium. We investigated the effects of Rehmannia glutinosa extract (RGE) on EPCs in a rat model of MI. Methods: A total of 120 male Wistar rats were randomized to 2 groups (n = 60 each) for treatment: high-dose RGE (1.5 g.kg(-1).day(-1) orally) for 8 weeks, then left anterior descending coronary artery ligation, mock surgery or no treatment, then RGE orally for 4 weeks; or normal saline (NS) as the above protocol. The infarct region of the left ventricle was assessed by serial sectioning and morphology. EPCs were evaluated by number and function. Protein and mRNA levels of CD133, vascular endothelial growth factor receptor 2 (VEGFR2), chemokine C-X-C motif receptor 4 (CXCR4), stromal cell-derived factor-1 alpha (SDF-1 alpha) were measured by immunohistochemistry, Western blot and quantitative PCR analysis. Results: RGE significantly improved left ventricular function, decreased the ischemic area and the apoptotic index in the infarct myocardium, also decreased the concentration of serum cardiac troponin T and brain natriuretic peptide at the chronic stage after MI (from week 2 to week 4). RGE increased EPC number, proliferation, migration and tube-formation capacity. It was able to up-regulate the expression of angiogenesis-associated ligand/receptor, including CD133, VEGFR2 and SDF-1 alpha/CXCR4. In vitro, the effect of RGE on SDF-1 alpha/CXCR4 cascade was reversed by the CXCR4 specific antagonist AMD3100. Conclusion: RGE may enhance the mobilization, migration and therapeutic angiogenesis of EPCs after MI by activating the SDF-1 alpha/CXCR4 cascade.	[Wang, Ying-Bin; Lu, Xiao-Ting; Bai, Wen-Wu] Shandong Univ, Key Lab Cardiovasc Remodeling & Funct Res, Jinan, Shandong, Peoples R China; [Wang, Ying-Bin; Yan, Fang-Fang; Wang, Bo; Zhao, Yu-Xia] Shandong Univ, Dept Tradit Chinese Med, Qilu Hosp, Jinan, Shandong, Peoples R China; [Liu, Yun-Fang] Shandong Univ, Dept Diag, Coll Med, Jinan, Shandong, Peoples R China	Shandong University; Shandong University; Shandong University	Zhao, YX (corresponding author), Shandong Univ, Dept Tradit Chinese Med, Qilu Hosp, Jinan, Shandong, Peoples R China.	yuxia_zhao@126.com			National 973 Basic Research Program of China [2012CB518603]; National Natural Science Foundation of China [30873325, 81100103, 81173251]; Natural Science Foundation of Shandong Province [ZR2011HQ020, ZR2009CM049]; postdoctoral special foundation for innovative projects of Shandong Province [201103049]	National 973 Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); postdoctoral special foundation for innovative projects of Shandong Province	This study was partially supported by grants from the National 973 Basic Research Program of China (No. 2012CB518603), National Natural Science Foundation of China (Nos. 30873325, 81100103, 81173251), Natural Science Foundation of Shandong Province (Nos. ZR2011HQ020, ZR2009CM049), and postdoctoral special foundation for innovative projects of Shandong Province (No. 201103049). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbott JD, 2004, CIRCULATION, V110, P3300, DOI 10.1161/01.CIR.0000147780.30124.CF; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Caplice NM, 2003, CIRC RES, V92, P6, DOI 10.1161/01.RES.0000052826.35667.40; Chae HJ, 2005, LIFE SCI, V76, P2027, DOI 10.1016/j.lfs.2004.07.032; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Davani S, 2003, CIRCULATION, V108, P253, DOI 10.1161/01.cir.0000089186.09692.fa; de Lemos JA, 2002, CIRCULATION, V106, P2868, DOI 10.1161/01.CIR.0000042763.07757.C0; Frederick JR, 2010, CIRCULATION, V122, pS107, DOI 10.1161/CIRCULATIONAHA.109.930404; Gehling UM, 2000, BLOOD, V95, P3106; Haider HK, 2008, CIRC RES, V103, P1300, DOI 10.1161/CIRCRESAHA.108.186742; Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287; Huang XQ, 2003, BIOPHYS J, V84, P171, DOI 10.1016/S0006-3495(03)74840-1; Iwami Y, 2004, J CELL MOL MED, V8, P488, DOI 10.1111/j.1582-4934.2004.tb00473.x; Jiang L, 2008, BIOCHEM BIOPH RES CO, V371, P185, DOI 10.1016/j.bbrc.2008.03.129; Kang HJ, 2004, LANCET, V363, P751, DOI 10.1016/S0140-6736(04)15689-4; Kawamoto A, 2001, CIRCULATION, V103, P634; Kucia M, 2005, LEUKEMIA, V19, P1118, DOI 10.1038/sj.leu.2403796; LIU FJ, 1994, CHIN J PHAM TOXICOL, V8, P118; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mendez-Ferrer S, 2008, NATURE, V452, P442, DOI 10.1038/nature06685; Orlic D, 2002, CIRC RES, V91, P1092, DOI 10.1161/01.RES.0000046045.00846.B0; OSHIO H, 1981, Shoyakugaku Zasshi, V35, P291; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Rae PC, 2011, VASC CELL, V3, DOI 10.1186/2045-824X-3-11; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Rosenkilde MM, J BIOL CHEM, V279, P3033; Shi AW, 2009, ACTA PHARMACOL SIN, V30, P299, DOI 10.1038/aps.2009.6; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Tang YL, 2009, CIRC RES, V104, P1209, DOI 10.1161/CIRCRESAHA.109.197723; Tepper OM, 2002, CIRCULATION, V106, P2781, DOI 10.1161/01.CIR.0000039526.42991.93; Torzewski M, 1998, ARTERIOSCL THROM VAS, V18, P369, DOI 10.1161/01.ATV.18.3.369; Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78; Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953; Vasa M, 2001, CIRCULATION, V103, P2885, DOI 10.1161/hc2401.092816; Werner N, 2003, CIRC RES, V93, pE17, DOI 10.1161/01.RES.0000083812.30141.74; Wojciech W, 2005, FOLIA HISTOCHEM CYTO, V43, P229; Yu Z, 2001, J TRANDIT CHIN MED, V28, P240; Zhang L, 2006, EUR J HAEMATOL, V76, P1, DOI 10.1111/j.1600-0609.2005.00579.x; Zhang RX, 2008, J ETHNOPHARMACOL, V117, P199, DOI 10.1016/j.jep.2008.02.018	40	19	29	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 18	2013	8	1							e54303	10.1371/journal.pone.0054303	http://dx.doi.org/10.1371/journal.pone.0054303			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	075GQ	23349848	gold, Green Submitted, Green Published			2023-01-03	WOS:000313872800038
J	De Lima, YV; Evans, D; Page-Shipp, L; Barnard, A; Sanne, I; Menezes, CN; Van Rie, A				De Lima, Yara Voss; Evans, Denise; Page-Shipp, Liesl; Barnard, Antonia; Sanne, Ian; Menezes, Colin N.; Van Rie, Annelies			Linkage to Care and Treatment for TB and HIV among People Newly Diagnosed with TB or HIV-Associated TB at a Large, Inner City South African Hospital	PLOS ONE			English	Article							POTENT ANTIRETROVIRAL THERAPY; TUBERCULOSIS TREATMENT; TREATMENT INITIATION; INFECTED PATIENTS; RISK-FACTORS; DEFAULT; MORTALITY; PREVENTION; REFERRALS; PATIENT	Objective: To assess the outcomes of linkage to TB and HIV care and identify risk factors for poor referral outcomes. Design: Cohort study of TB patients diagnosed at an urban hospital. Methods: Linkage to care was determined by review of clinic files, national death register, and telephone contact, and classified as linked to care, delayed linkage to care (>7 days for TB treatment, >30 days for HIV care), or failed linkage to care. We performed log-binomial regression to identify patient and referral characteristics associated with poor referral outcomes. Results: Among 593 TB patients, 23% failed linkage to TB treatment and 30.3% of the 77.0% who linked to care arrived late. Among 486 (86.9%) HIV-infected TB patients, 38.3% failed linkage to HIV care, and 32% of the 61.7% who linked to care presented late. One in six HIV-infected patients failed linkage to both TB and HIV care. Only 20.2% of HIV-infected patients were referred to a single clinic for integrated care. A referral letter was present in 90.3%, but only 23.7% included HIV status and 18.8% CD4 cell count. Lack of education (RR 1.85) and low CD4 count (CD4 <= 50 vs. >250cells/mm(3); RR 1.66) were associated with failed linkage to TB care. Risk factors for failed linkage to HIV care were antiretroviral-naive status (RR 1.29), and absence of referral letter with HIV or CD4 cell count (RR1.23). Conclusions: Linkage to TB/HIV care should be strengthened by communication of HIV and CD4 results, ART initiation during hospitalization and TB/HIV integration at primary care.	[De Lima, Yara Voss; Sanne, Ian] Univ Witwatersrand, Clin HIV Res Unit, Fac Hlth Sci, Johannesburg, South Africa; [Evans, Denise] Univ Witwatersrand, Hlth Econ & Epidemiol Res Off, Johannesburg, South Africa; [Page-Shipp, Liesl] Right To Care, Johannesburg, South Africa; [Barnard, Antonia] Gauteng Dept Hlth & Social Dev, Johannesburg, South Africa; [Menezes, Colin N.] Univ Witwatersrand, Fac Hlth Sci, Dept Med, Infect Dis Unit, Johannesburg, South Africa; [Van Rie, Annelies] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA	University of Witwatersrand; University of Witwatersrand; University of Witwatersrand; University of North Carolina; University of North Carolina Chapel Hill	Van Rie, A (corresponding author), Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA.	vanrie@email.unc.edu	Sanne, Ian/ABH-2231-2020; Van Rie, Annelies/C-2082-2017	Van Rie, Annelies/0000-0001-7666-3263; Menezes, Colin/0000-0003-3838-5359	United States Agency for International Development (PEPFAR) [674-A-00-08-00007-00]; National Institutes of Health [ICOHRTA AIDS/TB U2RTW007370]	United States Agency for International Development (PEPFAR)(United States Agency for International Development (USAID)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by United States Agency for International Development (PEPFAR in a grant to Right to Care 674-A-00-08-00007-00) and the National Institutes of Health (ICOHRTA AIDS/TB U2RTW007370). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Babu BS, 2008, INT J TUBERC LUNG D, V12, P1055; Bassett IV, 2009, JAIDS-J ACQ IMM DEF, V51, P135, DOI 10.1097/QAI.0b013e3181a44ef2; Blanc FX, 2011, NEW ENGL J MED, V365, P1471, DOI 10.1056/NEJMoa1013911; Botha E, 2008, INT J TUBERC LUNG D, V12, P936; Botha E, 2008, INT J TUBERC LUNG D, V12, P820; Brinkhof MWG, 2008, B WORLD HEALTH ORGAN, V86, P559, DOI 10.2471/BLT.07.044248; Buu TN, 2003, INT J TUBERC LUNG D, V7, P735; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Creek TL, 2000, INT J TUBERC LUNG D, V4, P956; Daniel OJ, 2006, NIGERIAN J MED, V15, P64; Department of Health, 2009, NAT TUB MAN GUID; Edginton ME, 2006, INT J TUBERC LUNG D, V10, P1018; Edginton ME, 2005, INT J TUBERC LUNG D, V9, P398; Elbireer S, 2011, TROP MED INT HEALTH, V16, P981, DOI 10.1111/j.1365-3156.2011.02800.x; Franke MF, 2008, CLIN INFECT DIS, V46, P1844, DOI 10.1086/588292; Havlir DV, 2011, NEW ENGL J MED, V365, P1482, DOI 10.1056/NEJMoa1013607; Holtz TH, 2006, INT J TUBERC LUNG D, V10, P649; Kapella BK, 2009, INT J TUBERC LUNG D, V13, P232; Karim SSA, 2010, NEW ENGL J MED, V362, P697, DOI 10.1056/NEJMoa0905848; Losina E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009538; Micek MA, 2009, JAIDS-J ACQ IMM DEF, V52, P397, DOI 10.1097/QAI.0b013e3181ab73e2; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; Nuwaha F, 1999, INT J TUBERC LUNG D, V3, P224; de Albuquerque MDPM, 2007, CAD SAUDE PUBLICA, V23, P1573, DOI 10.1590/S0102-311X2007000700008; Powers KA, 2011, LANCET, V378, P256, DOI 10.1016/S0140-6736(11)60842-8; Rao VK, 1998, CHEST, V114, P1244, DOI 10.1378/chest.114.5.1244; SANS 5999, 2004, TIN DET TIMB; Squire SB, 2005, INT J TUBERC LUNG D, V9, P25; Terris-Prestholt Fern, 2008, Cost Eff Resour Alloc, V6, P2, DOI 10.1186/1478-7547-6-2; Tsiouris SJ, 2005, TUBERCULOSIS HIV OPE; Tuboi SH, 2009, JAIDS-J ACQ IMM DEF, V51, P615, DOI 10.1097/QAI.0b013e3181a44f0a; Walensky RP, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001101; Wanyenze RK, 2011, AIDS BEHAV, V15, P751, DOI 10.1007/s10461-010-9704-1; World Health Organization, 2010, GLOB TUB CONTR SURV; World Health Organization, 2009, GLOB TUB CONTR EP ST	35	12	13	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2013	8	1							e49140	10.1371/journal.pone.0049140	http://dx.doi.org/10.1371/journal.pone.0049140			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072OV	23341869	gold, Green Published, Green Submitted			2023-01-03	WOS:000313682700002
J	Loi, S; Michiels, S; Baselga, J; Bartlett, JMS; Singhal, SK; Sabine, VS; Sims, AH; Sahmoud, T; Dixon, JM; Piccart, MJ; Sotiriou, C				Loi, Sherene; Michiels, Stefan; Baselga, Jose; Bartlett, John M. S.; Singhal, Sandeep K.; Sabine, Vicky S.; Sims, Andrew H.; Sahmoud, Tarek; Dixon, J. Michael; Piccart, Martine J.; Sotiriou, Christos			PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer	PLOS ONE			English	Article							ENDOCRINE THERAPY; EXPRESSION; CELLS; PI3K; SENSITIVITY; APOPTOSIS; MODELS; MTOR; AKT	The phosphatidylinositol 39 kinase (PI3K) pathway is commonly activated in breast cancer and aberrations such as PI3K mutations are common. Recent exciting clinical trial results in advanced estrogen receptor-positive (ER) breast cancer support mTOR activation is a major means of estrogen-independent tumor growth. Hence the means to identify a responsive breast cancer population that would most benefit from these compounds in the adjuvant or earlier stage setting is of high interest. Here we study PIK3CA genotype as well as a previously reported PI3K/mTOR-pathway gene signature (PIK3CA-GS) and their ability to estimate the level of PI3K pathway activation in two clinical trials of newly diagnosed ER-positive breast cancer patients- a total of 81 patients- one of which was randomized between letrozole and placebo vs letrozole and everolimus. The main objectives were to correlate the baseline PIK3CA genotype and GS with the relative change from baseline to day 15 in Ki67 (which has been shown to be prognostic in breast cancer) and phosphorylated S6 (S240) immunohistochemistry (a substrate of mTOR). In the randomized dataset, the PIK3CA-GS could identify those patients with the largest relative decreases in Ki67 to letrozole/everolimus (R = -0.43, p = 0.008) compared with letrozole/ placebo (R = 0.07, p = 0.58; interaction test p = 0.02). In a second dataset of pre-surgical everolimus alone, the PIK3CA-GS was not significantly correlated with relative change in Ki67 (R = -0.11, p = 0.37) but with relative change in phosphorlyated S6 (S240) (R = -0.46, p = 0.028). PIK3CA genotype was not significantly associated with any endpoint in either datasets. Our results suggest that the PIK3CA-GS has potential to identify those ER-positive BCs who may benefit from the addition of everolimus to letrozole. Further evaluation of the PIK3CA-GS as a predictive biomarker is warranted as it may facilitate better selection of responsive patient populations for mTOR inhibition in combination with letrozole.	[Loi, Sherene; Michiels, Stefan; Singhal, Sandeep K.; Sotiriou, Christos] Inst Jules Bordet, Breast Canc Translat Res Lab BCTL, B-1000 Brussels, Belgium; [Baselga, Jose] Massachusetts Gen Hosp, Ctr Canc, Div Hematol & Oncol, Boston, MA USA; [Bartlett, John M. S.; Sabine, Vicky S.] Univ Edinburgh, Western Gen Hosp, Canc Res Ctr, Endocrine Canc Grp, Edinburgh, Midlothian, Scotland; [Bartlett, John M. S.] Ontario Inst Canc Res, Toronto, ON, Canada; [Sims, Andrew H.] Univ Edinburgh, Western Gen Hosp, Inst Genet & Mol Med, Edinburgh Breast Unit, Edinburgh, Midlothian, Scotland; [Sahmoud, Tarek] Novartis Pharmaceut, E Hanover, NJ USA; [Dixon, J. Michael] Univ Edinburgh, Western Gen Hosp, Appl Bioinformat Canc Grp, Canc Res Ctr,Inst Genet & Mol Med,Edinburgh Break, Edinburgh, Midlothian, Scotland; [Piccart, Martine J.] Inst Jules Bordet, Dept Med, B-1000 Brussels, Belgium	Institut Jules Bordet; Harvard University; Massachusetts General Hospital; University of Edinburgh; Ontario Institute for Cancer Research; University of Toronto; University Toronto Affiliates; University of Edinburgh; Novartis; University of Edinburgh; Institut Jules Bordet	Loi, S (corresponding author), Inst Jules Bordet, Breast Canc Translat Res Lab BCTL, B-1000 Brussels, Belgium.	sherene.loi@bordet.be	Michiels, Stefan/L-1516-2013; Loi, Sherene/H-1979-2016; Sims, Andrew/E-4819-2012	Michiels, Stefan/0000-0002-6963-2968; Loi, Sherene/0000-0001-6137-9171; Sims, Andrew/0000-0001-9082-3665	JC Fonds Heuson, Belgium; Estee Lauder Breast Cancer Research Foundation, NY	JC Fonds Heuson, Belgium; Estee Lauder Breast Cancer Research Foundation, NY	SL and CS are supported by the JC Fonds Heuson, Belgium and the Estee Lauder Breast Cancer Research Foundation, NY. The authors acknowledge the Edinburgh Cancer Medicine Centre and Cancer Research UK for tissue banking support for dataset B. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Novartis Pharma did not provide any financial support for research reported in this manuscript.	Bachelot T, 2012, J CLIN ONCOL, V30, P2718, DOI 10.1200/JCO.2011.39.0708; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Baselga J, 2009, J CLIN ONCOL, V27, P2630, DOI 10.1200/JCO.2008.18.8391; Boulay A, 2005, CLIN CANCER RES, V11, P5319, DOI 10.1158/1078-0432.CCR-04-2402; Brachmann SM, 2009, P NATL ACAD SCI USA, V106, P22299, DOI 10.1073/pnas.0905152106; Chow LWC, 2006, BREAST CANC RES T S1, P6091; Cizkova M, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3113; Di Nicolantonio F, 2010, J CLIN INVEST, V120, P2858, DOI 10.1172/JCI37539; Dowsett M, 2006, CLIN CANCER RES, V12, p1024S, DOI 10.1158/1078-0432.CCR-05-2127; Dowsett M, 2007, JNCI-J NATL CANCER I, V99, P167, DOI 10.1093/jnci/djk020; Ellis MJ, 2008, J NATL CANCER I, V100, P1380, DOI 10.1093/jnci/djn309; Ellis MJ, 2010, BREAST CANCER RES TR, V119, P379, DOI 10.1007/s10549-009-0575-y; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Kalinsky K, 2009, CLIN CANCER RES, V15, P5049, DOI 10.1158/1078-0432.CCR-09-0632; Loi S, 2010, P NATL ACAD SCI USA, V107, P10208, DOI 10.1073/pnas.0907011107; Macaskill EJ, 2010, BREAST CANC RES TREA; McShane LM, 2005, JNCI-J NATL CANCER I, V97, P1180, DOI 10.1093/jnci/dji237; O'Brien C, 2010, CLIN CANCER RES, V16, P3670, DOI 10.1158/1078-0432.CCR-09-2828; Pinhel IF, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2719; Sabine VS, 2010, BREAST CANCER RES TR, V122, P419, DOI 10.1007/s10549-010-0928-6; She QB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003065; Whyte DB, 2006, BIOCHEM BIOPH RES CO, V340, P469, DOI 10.1016/j.bbrc.2005.12.025	23	60	60	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 2	2013	8	1							e53292	10.1371/journal.pone.0053292	http://dx.doi.org/10.1371/journal.pone.0053292			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	067UP	23301057	Green Published, gold			2023-01-03	WOS:000313320900073
J	Ose, D; Rochon, J; Campbell, SM; Wensing, M; van Lieshout, J; Uhlmann, L; Freund, T; Szecsenyi, J; Ludt, S				Ose, Dominik; Rochon, Justine; Campbell, Stephen M.; Wensing, Michel; van Lieshout, Jan; Uhlmann, Lorenz; Freund, Tobias; Szecsenyi, Joachim; Ludt, Sabine			Secondary Prevention in Patients with Coronary Heart Diseases: What Factors Are Associated with Health Status in Usual Primary Care?	PLOS ONE			English	Article							QUALITY-OF-LIFE; CARDIOVASCULAR-DISEASE; STRUCTURAL CAPABILITIES; CLINICAL-PRACTICE; GUIDED CARE; MANAGEMENT; RISK; BURDEN; TRIAL; INDICATORS	Background: For patients with coronary heart diseases a substantial part of secondary prevention is delivered in primary care. Along with the growing importance of prevention, health-related quality of life (HRQoL) is an indicator of patient-centered care that has gained increased attention. Different approaches for reorganization in primary care have been associated with improvements in HRQoL. However, these are often results of complex interventions. Evidence on aspects concerning usual primary care that actually have an impact on HRQoL remains scarce. Therefore, this observational study aimed to identify factors which are associated with HRQoL in usual primary care at practice and patient-level. Methods: This observational study was conducted in eight European countries. We were able to match data from survey instruments for 3505 patients with coronary heart disease (CHD) in 228 practices. A multilevel analysis was performed to identify associations of EQ-5D scores at patient and practice-level. Results: After dropping patients with missing information, our cohort consisted of 2656 patients. In this sample, 30.5% were female and the mean age was 67.5 years (SD 10.1). The final model included a total set of 14 potential explanatory variables. At practice-level no variable was associated with EQ-5D. At patient-level, lower education (r = -0.0381, p < 0.0001), female gender (r = -0.0543, p < 0.0001) and a higher number of other conditions (r = -0.0340, p < 0.0001), had a strong negative effect on HRQoL. Strong positive associations with HRQoL were found for a good medication adherence (Morisky) (r = 0.0195, p < 0.0001) and more positive evaluations of physicians' clinical behavior (r = 0.0282, p = 0.002). In terms of HRQoL no differences between single-handed and group practices exist. Conclusion: The results of our study suggest that a better patient-physician relationship rather than organization of CHD care is associated with higher HRQOL in the primary care setting. The results may imply that interventions to improve HRQoL require a strong patient-centered approach.	[Ose, Dominik; Campbell, Stephen M.; Wensing, Michel; Freund, Tobias; Szecsenyi, Joachim; Ludt, Sabine] Univ Heidelberg Hosp, Dept Gen Practice & Hlth Serv, Heidelberg, Germany; [Wensing, Michel; van Lieshout, Jan] Radboud Univ Nijmegen, Med Ctr, Sci Inst Qual Healthcare, Nijmegen, Netherlands; [Rochon, Justine; Uhlmann, Lorenz] Heidelberg Univ, Inst Med Biometry & Informat, Heidelberg, Germany; [Campbell, Stephen M.] Univ Manchester, Hlth Sci Primary Care Grp, Manchester, Lancs, England	Ruprecht Karls University Heidelberg; Radboud University Nijmegen; Ruprecht Karls University Heidelberg; University of Manchester	Ose, D (corresponding author), Univ Heidelberg Hosp, Dept Gen Practice & Hlth Serv, Heidelberg, Germany.	dominik.ose@med.uni-heidelberg.de	Uhlmann, Lorenz/AAL-9839-2020; Ose, Dominik J/F-7691-2013; Wensing, Michel/H-8113-2014; Ose, Dominik/L-4250-2019; Van Lieshout, J./L-4490-2015	Ose, Dominik J/0000-0002-5079-2152; Wensing, Michel/0000-0001-6569-8137; Ose, Dominik/0000-0002-5079-2152; Campbell, Stephen/0000-0002-2328-4136	Bertelsmann Foundation (Gutersloh, Germany); IQ Healthcare of the Radboud University Nijmegen (The Netherlands)	Bertelsmann Foundation (Gutersloh, Germany); IQ Healthcare of the Radboud University Nijmegen (The Netherlands)	The Bertelsmann Foundation (Gutersloh, Germany) initiated, coordinated, and funded the EPA Cardio project, in collaboration with IQ Healthcare of the Radboud University Nijmegen (The Netherlands). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bell RJ, 2007, CLIN ENDOCRINOL, V66, P548, DOI 10.1111/j.1365-2265.2007.02771.x; Bielaszka-DuVernay C, 2011, HEALTH AFFAIR, V30, P431, DOI 10.1377/hlthaff.2011.0043; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Boyd CM, 2007, GERONTOLOGIST, V47, P697, DOI 10.1093/geront/47.5.697; Boyd CM, 2010, J GEN INTERN MED, V25, P235, DOI 10.1007/s11606-009-1192-5; Brown JR, 2010, NEW ENGL J MED, V362, P2150, DOI 10.1056/NEJMp1003880; Byrne M, 2005, J PSYCHOSOM RES, V58, P403, DOI 10.1016/j.jpsychores.2004.11.010; Campbell SM, 2008, EUR J CARDIOV PREV R, V15, P509, DOI 10.1097/HJR.0b013e328302f44d; Counsell SR, 2007, JAMA-J AM MED ASSOC, V298, P2623, DOI 10.1001/jama.298.22.2623; Davis PD, 1995, SURV METHODOL, V21, P99; Dyer MTD, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-13; Engels Y, 2006, FAM PRACT, V23, P137, DOI 10.1093/fampra/cmi091; Eriksson MK, 2010, ARCH INTERN MED, V170, P1470, DOI 10.1001/archinternmed.2010.301; Ford ES, 2008, J WOMENS HEALTH, V17, P757, DOI 10.1089/jwh.2007.0468; Friedberg MW, 2009, ANN INTERN MED, V151, P456, DOI 10.7326/0003-4819-151-7-200910060-00006; Friedberg MW, 2009, J GEN INTERN MED, V24, P162, DOI 10.1007/s11606-008-0856-x; Frieden TR, 2011, NEW ENGL J MED, V365, DOI [10.1056/NEJMp1110421, 10.1056/NEJMP1110421]; Friedman SM, 2005, GERONTOLOGIST, V45, P157, DOI 10.1093/geront/45.2.157; Garster NC, 2009, QUAL LIFE RES, V18, P1239, DOI 10.1007/s11136-009-9533-8; Graham I, 2007, EUR HEART J, V28, P2375, DOI 10.1093/eurheartj/ehm316; Greiner Wolfgang, 2003, Eur J Health Econ, V4, P222, DOI 10.1007/s10198-003-0182-5; Koertge J, 2003, AM J CARDIOL, V91, P1316, DOI 10.1016/S0002-9149(03)00320-5; Leal J, 2006, EUR HEART J, V27, P1610, DOI 10.1093/eurheartj/ehi733; Lloyd-Jones DM, 2010, CIRCULATION, V121, P586, DOI 10.1161/CIRCULATIONAHA.109.192703; Ludt S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029334; Mensah GA, 2007, HEALTH AFFAIR, V26, P38, DOI 10.1377/hlthaff.26.1.38; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; Nadash P, 2004, GERONTOLOGIST, V44, P644, DOI 10.1093/geront/44.5.644; Ose D, 2009, DIABETES CARE, V32, P1594, DOI 10.2337/dc08-2223; Parker RM, 1999, JAMA-J AM MED ASSOC, V281, P552; Piette JD, 2005, ARCH INTERN MED, V165, P1749, DOI 10.1001/archinte.165.15.1749; Rasbash J, 2011, MLWIN VERSION 2 24; Raudenbusch S. W., 2002, HIERARCHICAL LINEAR; REDELMEIER DA, 1993, JAMA-J AM MED ASSOC, V270, P72, DOI 10.1001/jama.270.1.72; Rosamond W, 2008, CIRCULATION, V117, pE25, DOI 10.1161/CIRCULATIONAHA.107.187998; Rumsfeld JS, 2002, CIRCULATION, V106, P5, DOI 10.1161/01.CIR.0000020805.31531.48; Simons-Morton DG, 2001, JAMA-J AM MED ASSOC, V286, P677; Street RL, 2009, PATIENT EDUC COUNS, V74, P295, DOI 10.1016/j.pec.2008.11.015; Takach M, 2010, STRENGTHENING PRIMAR; Tsai AC, 2005, AM J MANAG CARE, V11, P478; van Dam RM, 2009, CIRCULATION, V120, P1171, DOI 10.1161/CIRCULATIONAHA.109.891507; van Lieshout J, 2009, AM J MANAG CARE, V15, P255; Vargas RB, 2007, J GEN INTERN MED, V22, P215, DOI 10.1007/s11606-006-0072-5; Wadden TA, 2011, NEW ENGL J MED, V365, P1969, DOI 10.1056/NEJMoa1109220; Wang WR, 2012, HEART LUNG, V41, P15, DOI 10.1016/j.hrtlng.2011.05.005; Wensing M, 2000, EUROPEAN J GEN PRACT, V6, P82, DOI DOI 10.3109/13814780009069953; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wroth TH, 2006, J AM BOARD FAM MED, V19, P478, DOI 10.3122/jabfm.19.5.478; Xie JP, 2008, CIRCULATION, V118, P491, DOI 10.1161/CIRCULATIONAHA.107.752006; Yusuf S, 2001, CIRCULATION, V104, P2855, DOI 10.1161/hc4701.099488	50	12	13	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 26	2012	7	12							e51726	10.1371/journal.pone.0051726	http://dx.doi.org/10.1371/journal.pone.0051726			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	071TV	23300560	gold, Green Published, Green Submitted			2023-01-03	WOS:000313618800024
J	Koo, HJ; Gang, DR				Koo, Hyun Jo; Gang, David R.			Suites of Terpene Synthases Explain Differential Terpenoid Production in Ginger and Turmeric Tissues	PLOS ONE			English	Article							ZINGIBER-ZERUMBET SMITH; CURCUMA-LONGA; FUNCTIONAL-CHARACTERIZATION; GLANDULAR TRICHOMES; SESQUITERPENE SYNTHASES; BY-PRODUCT; BIOSYNTHESIS; OFFICINALE; CLONING; OIL	The essential oils of ginger (Zingiber officinale) and turmeric (Curcuma longa) contain a large variety of terpenoids, some of which possess anticancer, antiulcer, and antioxidant properties. Despite their importance, only four terpene synthases have been identified from the Zingiberaceae family: (+)-germacrene D synthase and (S)-beta-bisabolene synthase from ginger rhizome, and alpha-humulene synthase and beta-eudesmol synthase from shampoo ginger (Zingiber zerumbet) rhizome. We report the identification of 25 mono-and 18 sesquiterpene synthases from ginger and turmeric, with 13 and 11, respectively, being functionally characterized. Novel terpene synthases, (-)-caryolan-1-ol synthase and alpha-zingiberene/beta-sesquiphellandrene synthase, which is responsible for formation of the major sesquiterpenoids in ginger and turmeric rhizomes, were also discovered. These suites of enzymes are responsible for formation of the majority of the terpenoids present in these two plants. Structures of several were modeled, and a comparison of sets of paralogs suggests how the terpene synthases in ginger and turmeric evolved. The most abundant and most important sesquiterpenoids in turmeric rhizomes, (+)-alpha-turmerone and (+)-beta-turmerone, are produced from (-)-alpha-zingiberene and (-)-beta-sesquiphellandrene, respectively, via alpha-zingiberene/beta-sesquiphellandrene oxidase and a still unidentified dehydrogenase.	Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA; Univ Arizona, Inst Bio5, Tucson, AZ USA	University of Arizona; University of Arizona	Gang, DR (corresponding author), Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA.	gangd@wsu.edu			US National Science Foundation [DBI-0227618]	US National Science Foundation(National Science Foundation (NSF))	This research was funded by a grant from the US National Science Foundation to DRG (grant #DBI-0227618; www.nsf.gov). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams R. P, 1995, IDENTIFICATION ESSEN; Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770; de Kraker JW, 1998, PLANT PHYSIOL, V117, P1381, DOI 10.1104/pp.117.4.1381; Ficker CE, 2003, MYCOSES, V46, P29, DOI 10.1046/j.1439-0507.2003.00838.x; Fischer MJC, 2011, BIOTECHNOL BIOENG, V108, P1883, DOI 10.1002/bit.23129; Fujisawa M, 2010, PLANTA, V232, P121, DOI 10.1007/s00425-010-1137-6; Garms S, 2012, PHYTOCHEMISTRY, V75, P6, DOI 10.1016/j.phytochem.2011.12.009; Gennadios HA, 2009, BIOCHEMISTRY-US, V48, P6175, DOI 10.1021/bi900483b; Gopfert JC, 2009, BMC PLANT BIOL, V9, DOI 10.1186/1471-2229-9-86; Golding BT, 1992, J CHEM SOC P1, V1, P1519; Habib SHM, 2008, CLINICS, V63, P807, DOI 10.1590/S1807-59322008000600017; Hiserodt R, 1996, J CHROMATOGR A, V740, P51, DOI 10.1016/0021-9673(96)00103-3; Hyatt DC, 2007, P NATL ACAD SCI USA, V104, P5360, DOI 10.1073/pnas.0700915104; Jayaprakasha GK, 2002, Z NATURFORSCH C, V57, P828; Jeong CH, 2009, CANCER RES, V69, P5584, DOI 10.1158/0008-5472.CAN-09-0491; Jiang HL, 2006, PHYTOCHEMISTRY, V67, P1673, DOI 10.1016/j.phytochem.2005.08.001; Jianjun Q, 2008, THORAC CARDIOV SURG, V56, P103, DOI 10.1055/s-2007-965708; Jurenka JS, 2009, ALTERN MED REV, V14, P141; KISO Y, 1983, PHYTOCHEMISTRY, V22, P596, DOI 10.1016/0031-9422(83)83057-X; Kreiser W, 1999, HELV CHIM ACTA, V82, P1427, DOI 10.1002/(SICI)1522-2675(19990908)82:9<1427::AID-HLCA1427>3.0.CO;2-S; Kundu JK, 2009, FORUM NUTR, V61, P182, DOI 10.1159/000212750; Lee HS, 2006, BIORESOURCE TECHNOL, V97, P1372, DOI 10.1016/j.biortech.2005.07.006; Lee Y, 2009, BMB REP, V42, P96, DOI 10.5483/BMBRep.2009.42.2.096; Leong-Skornickova J, 2007, ANN BOT-LONDON, V100, P505, DOI 10.1093/aob/mcm144; Lopez P, 2005, J AGR FOOD CHEM, V53, P6939, DOI 10.1021/jf050709v; Martin DM, 2010, BMC PLANT BIOL, V10, DOI 10.1186/1471-2229-10-226; Martin VJJ, 2003, NAT BIOTECHNOL, V21, P796, DOI 10.1038/nbt833; Nakano C, 2011, J BIOL CHEM, P21; Negi PS, 1999, J AGR FOOD CHEM, V47, P4297, DOI 10.1021/jf990308d; Nigam N, 2009, CANCER CHEMOTH PHARM, V24, P24; Nishiyama T, 2005, J AGR FOOD CHEM, V53, P959, DOI 10.1021/jf0483873; Oswald M, 2007, FEMS YEAST RES, V7, P413, DOI 10.1111/j.1567-1364.2006.00172.x; Picaud S, 2006, ARCH BIOCHEM BIOPHYS, V452, P17, DOI 10.1016/j.abb.2006.06.007; Ponnamperuma K, 1996, ARCH BIOCHEM BIOPHYS, V329, P9, DOI 10.1006/abbi.1996.0185; Ravindran J, 2009, AAPS J, V11, P495, DOI 10.1208/s12248-009-9128-x; Ro DK, 2006, NATURE, V440, P940, DOI 10.1038/nature04640; Shukla Y, 2007, FOOD CHEM TOXICOL, V45, P683, DOI 10.1016/j.fct.2006.11.002; Wang G, 2005, CELL MOL LIFE SCI, V62, P881, DOI 10.1007/s00018-005-5017-3; Wang GD, 2008, PLANT PHYSIOL, V148, P1254, DOI 10.1104/pp.108.125187; YAMAHARA J, 1992, YAKUGAKU ZASSHI, V112, P645, DOI 10.1248/yakushi1947.112.9_645; YAMAHARA J, 1988, J ETHNOPHARMACOL, V23, P299, DOI 10.1016/0378-8741(88)90009-8; Yu F, 2008, FEBS LETT, V582, P565, DOI 10.1016/j.febslet.2008.01.020; Yu FN, 2008, PLANTA, V227, P1291, DOI 10.1007/s00425-008-0700-x; Zhuang XF, 2012, PLANT J, V69, P70, DOI 10.1111/j.1365-313X.2011.04771.x	44	30	33	2	59	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 18	2012	7	12							e51481	10.1371/journal.pone.0051481	http://dx.doi.org/10.1371/journal.pone.0051481			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	056JC	23272109	Green Published, gold, Green Submitted			2023-01-03	WOS:000312483300017
J	Bretler, DM; Hansen, PR; Lindhardsen, J; Ahlehoff, O; Andersson, C; Jensen, TB; Raunso, J; Torp-Pedersen, C; Gislason, GH				Bretler, Ditte-Marie; Hansen, Peter Riis; Lindhardsen, Jesper; Ahlehoff, Ole; Andersson, Charlotte; Jensen, Thomas Bo; Raunso, Jakob; Torp-Pedersen, Christian; Gislason, Gunnar Hilmar			Hormone Replacement Therapy and Risk of New-Onset Atrial Fibrillation after Myocardial Infarction - A Nationwide Cohort Study	PLOS ONE			English	Article							ESTROGEN PLUS PROGESTIN; CARDIOVASCULAR EVENTS; POSTMENOPAUSAL WOMEN; MORTALITY; POPULATION; FLUTTER; PREVALENCE; VALIDATION; PREVENTION; DIAGNOSIS	Objectives: Our aim was to assess the association between use of hormone replacement therapy (HRT) and risk of new-onset atrial fibrillation (AF) after myocardial infarction. Design, Setting and Participants: We used Danish nationwide registers of hospitalizations and prescriptions to identify all women admitted with myocardial infarction in the period 1997 to 2009 and with no known diagnosis of AF. Their use of overall HRT and HRT categories was assessed. Multivariable Cox proportional hazards analysis was used to calculate the risk of new-onset AF first year after discharge, comparing use of HRT to no use. Main Outcome Measures: New-onset atrial fibrillation. Results: In the period 1997 to 2009, 32 925 women were discharged alive after MI. In the first year after MI, new-onset AF was diagnosed in 1381 women (4.2%). Unadjusted incidence rates of AF decreased with use of HRT (incidence rate 37.4 for use of overall HRT and 53.7 for no use). Overall HRT was associated with a decreased risk of AF (HR 0.82, 95% confidence interval [CI] 0.68-1.00). The lowest risk of AF was found in women >= 80 years old for use of overall HRT and vaginal estrogen (HR 0.63, CI 0.42-0.94, and HR 0.58, CI 0.34-0.99, respectively). Decreased risk of AF with use of overall HRT and HRT categories was also found in other age groups. Conclusions: Use of HRT is associated with a decreased risk of new-onset AF in women with myocardial infarction first year after discharge. The underlying mechanisms remain to be determined. Unmeasured confounding might be one of them.	[Bretler, Ditte-Marie; Hansen, Peter Riis; Lindhardsen, Jesper; Ahlehoff, Ole; Andersson, Charlotte; Jensen, Thomas Bo; Raunso, Jakob; Torp-Pedersen, Christian; Gislason, Gunnar Hilmar] Univ Copenhagen, Gentofte Hosp, Dept Cardiol, Hellerup, Denmark; [Torp-Pedersen, Christian] Univ Copenhagen, Panum Inst, Fac Hlth Sci, DK-2200 Copenhagen, Denmark; [Raunso, Jakob] Univ Copenhagen, Hosp Holbaek, Dept Internal Med, Holbaek, Denmark	University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Holbaek Hospital; University of Copenhagen	Bretler, DM (corresponding author), Univ Copenhagen, Gentofte Hosp, Dept Cardiol, Hellerup, Denmark.	dimabr01@geh.regionh.dk	Torp-Pedersen, Christian/E-5931-2013; Gislason, Gunnar/B-7561-2009; Andersson, Charlotte/P-4849-2014; Hansen, Peter Riis/AAR-7659-2020; Jensen, Thomas Bo/H-9518-2019	Gislason, Gunnar/0000-0002-0548-402X; Jensen, Thomas Bo/0000-0002-8920-9374; Hansen, Peter Riis/0000-0002-9056-535X	Danish Heart Foundation [08-4-R65-A1904-B844-22440F]; Lundbeck Foundation [R31-A2566]; Novo Nordisk Foundation	Danish Heart Foundation; Lundbeck Foundation(Lundbeckfonden); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited)	DMB was supported by the Danish Heart Foundation [grant 08-4-R65-A1904-B844-22440F], and the Lundbeck Foundation [grant R31-A2566]. Dr. Gislason has received a research grant from the Novo Nordisk Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Khalili F, 1998, AM J CARDIOL, V82, P215, DOI 10.1016/S0002-9149(98)00314-2; Andersson P, 2012, J INTERN MED, V272, P170, DOI 10.1111/j.1365-2796.2012.02519.x; Aronson D, 2011, AM J CARDIOL, V107, P1738, DOI 10.1016/j.amjcard.2011.02.334; Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946; BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840; Berry JD, 2010, AM J CARDIOL, V105, P844, DOI 10.1016/j.amjcard.2009.11.039; Boos CJ, 2006, EUR HEART J, V27, P136, DOI 10.1093/eurheartj/ehi645; Bretler DM, 2011, BRIT J CLIN PHARMACO, V71, P105, DOI 10.1111/j.1365-2125.2010.03790.x; Cavasin MA, 2003, AM J PHYSIOL-HEART C, V284, pH1560, DOI 10.1152/ajpheart.01087.2002; Christiansen CF, 2009, ARCH INTERN MED, V169, P1677, DOI 10.1001/archinternmed.2009.297; Cirillo DJ, 2005, JAMA-J AM MED ASSOC, V293, P330, DOI 10.1001/jama.293.3.330; Conen D, 2011, JAMA-J AM MED ASSOC, V305, P2080, DOI 10.1001/jama.2011.659; Ekholm O, 2009, SCAND J PUBLIC HEALT, V37, P758, DOI 10.1177/1403494809341095; Ettinger B, 2011, MENOPAUSE; Frost L, 2004, ARCH INTERN MED, V164, P1993, DOI 10.1001/archinte.164.18.1993; Frost L, 2007, AM J MED, V120, P47, DOI 10.1016/j.amjmed.2005.12.027; Gaist D, 1997, DAN MED BULL, V44, P445; Gislason GH, 2006, EUR HEART J, V27, P1153, DOI 10.1093/eurheartj/ehi705; Gorodeski EZ, 2010, MENOPAUSE, V17, P443, DOI 10.1097/gme.0b013e3181d0edaa; Guazzi M, 2009, HEART, V95, P102, DOI 10.1136/hrt.2007.135277; Heeringa J, 2006, EUR HEART J, V27, P949, DOI 10.1093/eurheartj/ehi825; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Humphries KH, 2001, CIRCULATION, V103, P2365; Iwakura A, 2006, CIRCULATION, V113, P1605, DOI 10.1161/CIRCULATIONAHA.105.553925; Jabre P, 2011, CIRCULATION, V123, P2094, DOI 10.1161/CIRCULATIONAHA.110.990192; Jons C, 2010, EUR J ECHOCARDIOGR, V11, P602, DOI 10.1093/ejechocard/jeq024; Karim R, 2010, MENOPAUSE, V17, P785, DOI 10.1097/gme.0b013e3181cc50b2; Kumler T, 2008, EUR J HEART FAIL, V10, P658, DOI 10.1016/j.ejheart.2008.05.006; Lokkegaard EL, 2004, ACTA OBSTET GYN SCAN, V83, P476, DOI 10.1111/j.0001-6349.2004.00376.x; Lokkegaard E, 2007, ACTA OBSTET GYN SCAN, V86, P1342, DOI 10.1080/00016340701505523; Maalouf NM, 2010, ARCH INTERN MED, V170, P1678, DOI 10.1001/archinternmed.2010.342; Macchia A, 2008, EUR J CLIN PHARMACOL, V64, P627, DOI 10.1007/s00228-008-0464-z; Madsen M, 2003, J CLIN EPIDEMIOL, V56, P124, DOI 10.1016/S0895-4356(02)00591-7; Magnani JW, 2012, AM HEART J, V163, P729, DOI 10.1016/j.ahj.2012.01.010; Margolis DJ, 2002, LANCET, V359, P675, DOI 10.1016/S0140-6736(02)07806-6; Mitchell GF, 2007, JAMA-J AM MED ASSOC, V297, P709, DOI 10.1001/jama.297.7.709; Mukamal KJ, 2005, CIRCULATION, V112, P1736, DOI 10.1161/CIRCULATIONAHA.105.547844; Olesen Jonas Bjerring, 2011, BMJ, V342, pd124, DOI 10.1136/bmj.d124; Olesen JB, 2011, PHARMACOEPIDEM DR S, V20, P146, DOI 10.1002/pds.2073; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Schmidt M, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3450; Shinmura K, 2008, CARDIOVASC RES, V79, P387, DOI 10.1093/cvr/cvn086; Smith PJW, 2000, CIRCULATION, V102, P2983; Tang JY, 2011, J NATL CANCER I, V103, P1469, DOI 10.1093/jnci/djr333; Tu JV, 2001, J AM COLL CARDIOL, V37, P992, DOI 10.1016/S0735-1097(01)01109-3; van Eickels M, 2003, J AM COLL CARDIOL, V41, P2084, DOI 10.1016/S0735-1097(03)00423-6; Vermeulen MJ, 2007, J CLIN EPIDEMIOL, V60, P971, DOI 10.1016/j.jclinepi.2006.12.009; Vestergaard P, 2010, CALCIFIED TISSUE INT, V86, P335, DOI 10.1007/s00223-010-9349-0; Zanger D, 2000, J AM COLL CARDIOL, V36, P1797, DOI 10.1016/S0735-1097(00)00952-9	49	22	23	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 17	2012	7	12							e51580	10.1371/journal.pone.0051580	http://dx.doi.org/10.1371/journal.pone.0051580			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	055RZ	23284717	Green Published, Green Submitted, gold			2023-01-03	WOS:000312435900029
J	Kapczynski, A; Park, C; Sampat, B				Kapczynski, Amy; Park, Chan; Sampat, Bhaven			Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis of "Secondary'' Pharmaceutical Patents	PLOS ONE			English	Article							LIFE	Background: While there has been much discussion by policymakers and stakeholders about the effects of "secondary patents'' on the pharmaceutical industry, there is no empirical evidence on their prevalence or determinants. Characterizing the landscape of secondary patents is important in light of recent court decisions in the U.S. that may make them more difficult to obtain, and for developing countries considering restrictions on secondary patents. Methodology/Principal Findings: We read the claims of the 1304 Orange Book listed patents on all new molecular entities approved in the U.S. between 1988 and 2005, and coded the patents as including chemical compound claims (claims covering the active molecule itself) and/or one of several types of secondary claims. We distinguish between patents with any secondary claims, and those with only secondary claims and no chemical compound claims ("independent'' secondary patents). We find that secondary claims are common in the pharmaceutical industry. We also show that independent secondary patents tend to be filed and issued later than chemical compound patents, and are also more likely to be filed after the drug is approved. When present, independent formulation patents add an average of 6.5 years of patent life (95% C.I.: 5.9 to 7.3 years), independent method of use patents add 7.4 years (95% C.I.: 6.4 to 8.4 years), and independent patents on polymorphs, isomers, prodrug, ester, and/or salt claims add 6.3 years (95% C.I.: 5.3 to 7.3 years). We also provide evidence that late-filed independent secondary patents are more common for higher sales drugs. Conclusions/Significance: Policies and court decisions affecting secondary patenting are likely to have a significant impact on the pharmaceutical industry. Secondary patents provide substantial additional patent life in the pharmaceutical industry, at least nominally. Evidence that they are also more common for best-selling drugs is consistent with accounts of active "life cycle management'' or "evergreening'' of patent portfolios in the industry.	[Sampat, Bhaven] Columbia Univ, Mailman Sch Publ Hlth, Dept Hlth Policy & Management, New York, NY 10027 USA; [Kapczynski, Amy] Yale Univ, Yale Law Sch, New Haven, CT USA; [Park, Chan] Med Patent Pool, Geneva, Switzerland	Columbia University; Yale University	Sampat, B (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Dept Hlth Policy & Management, New York, NY 10027 USA.	bns3@columbia.edu						Agency for Healthcare Research and Quality, 1996, MEDICAL EXPENDITURE; Amin T, 2012, HEALTH AFFAIR, V31, P2286, DOI 10.1377/hlthaff.2012.0107; Burdon M., 2003, J MED MARK, V3, P226, DOI DOI 10.1057/PALGRAVE.JMM.5040125; CAVES RE, 1991, BROOKINGS PAP ECO AC, P1; Cheng J, 2008, COLUMBIA LAW REV, V108, P1471; Cohen Wesley M., 2000, WORKING PAPER NO 755; Correa C. M., 2007, GUIDELINES FOR THE E; Eisenberg Rebecca S., 2008, LEWIS CLARK L REV, V12, P375; European Commission, 2009, PHARMACEUTICAL SECTO; Federal Trade Commission, 2002, GENERIC DRUG ENTRY P; Furrow ME, 2008, FOOD DRUG LAW J, V63, P275; Gorlin DL, 2008, FOOD DRUG LAW J, V63, P823; Grabowski HG, 2000, INT J TECHNOL MANAGE, V19, P98, DOI 10.1504/IJTM.2000.002803; Grubb PW, 2010, PATENTS FOR CHEMICAL; Hemphill CS, 2012, J HEALTH ECON, V31, P327, DOI 10.1016/j.jhealeco.2012.01.004; Hemphill CS, 2011, J EMPIR LEGAL STUD, V8, P613, DOI 10.1111/j.1740-1461.2011.01235.x; Jaffe A, 2006, INNOVATION AND ITS D; Kapczynski A, 2009, CALIF LAW REV, V97, P1571; LEVIN RC, 1987, BROOKINGS PAP ECO AC, P783; MANSFIELD E, 1986, MANAGE SCI, V32, P173, DOI 10.1287/mnsc.32.2.173; OECD, 2004, PATENTS INNOVATION A; Pammolli F, 2011, NAT REV DRUG DISCOV, V10, P428, DOI 10.1038/nrd3405; Park C, 2008, DEFINING THE CONCEPT; Park C, 2010, THE IMPLEMENTATION O; Rathod S, 2010, EVER GREENING A STAT, V7, P227; Scherer F.M., 2009, J TELECOMM HIGH TECH, V7, P167; US Food and Drug Administration, ORANGE BOOK APPROVED; USPTO, CASSIS BIB DVD	28	67	69	2	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2012	7	12							e49470	10.1371/journal.pone.0049470	http://dx.doi.org/10.1371/journal.pone.0049470			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	057TZ	23227141	Green Submitted, Green Published, gold			2023-01-03	WOS:000312588200004
J	Zhou, SW; Huang, YY; Wei, Y; Jiang, ZM; Zhang, YD; Yang, Q; Xie, DR				Zhou, Si-wei; Huang, Yuan-yuan; Wei, Ying; Jiang, Zhi-min; Zhang, Yuan-dong; Yang, Qiong; Xie, De-rong			No Survival Benefit from Adding Cetuximab or Panitumumab to Oxaliplatin-Based Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer in KRAS Wild Type Patients: A Meta-Analysis	PLOS ONE			English	Article							FLUOROURACIL; BEVACIZUMAB; LEUCOVORIN; EFFICACY; TRIAL	Background: The efficacy of combined therapies of oxaliplatin-based chemotherapy and anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies (MAbs) remains controversial in colorectal cancer (CRC). The aim of this study is to estimate the efficacy and safety of adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first line treatment in KRAS wild type patients with metastatic colorectal cancer (mCRC) through meta-analysis. Methods: Medline, EMBASE, and Cochrane library, American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) were searched. Eligible studies were randomized controlled trials (RCTs) which evaluated oxaliplatin-based chemotherapy with or without anti-EGFR drugs (cetuximab or panitumumab) in untreated KRAS wild type patients with mCRC. The outcomes included overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and toxicities. Hazard ratios (HR) and risk ratio (RR) were used for the meta-analysis and were expressed with 95% confidence intervals. Results: This meta-analysis included four RCTs with 1270 patients, and all of the patients were administered oxaliplatin-based chemotherapy regimens with or without anti-EGFR MAbs. The result of heterogeneity of OS was not significant. Compared with chemotherapy alone, the addition of cetuximab or panitumumab didn't result in significant improvement in OS (HR = 1.00, 95% CI [0.88, 1.13], P = 0.95) or PFS (HR = 0.86, 95% CI [0.71, 1.04], P = 0.13). The subgroup analysis of cetuximab also revealed no significant benefit in OS (HR = 1.02, 95% CI [0.89, 1.18], P = 0.75) or in PFS (HR = 0.87, 95% CI [0.65, 1.17], P = 0.36). Patients who received combined therapy didn't have a higher ORR (Risk Ratio = 1.08, 95% CI [0.86, 1.36]). Toxicities slightly increased in anti-EGFR drugs group. Conclusions: The addition of cetuximab or panitumumab to oxaliplatin-based chemotherapy in first-line treatment of mCRC in wild type KRAS population did not improve efficacy in survival benefit and response rate. More RCTs are warranted to evaluate the combination of chemotherapy and targeted therapy.	[Zhou, Si-wei; Wei, Ying; Jiang, Zhi-min; Yang, Qiong; Xie, De-rong] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Key Lab Malignant Tumor Gene Regulat & Target The, Guangdong Higher Educ Inst,Dept Oncol, Guangzhou 510275, Guangdong, Peoples R China; [Huang, Yuan-yuan] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, Guangzhou 510275, Guangdong, Peoples R China; [Zhang, Yuan-dong] Guangdong Acad Med Sci, Guangdong Gen Hosp, Ctr Canc, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Guangdong Academy of Medical Sciences & Guangdong General Hospital	Xie, DR (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Key Lab Malignant Tumor Gene Regulat & Target The, Guangdong Higher Educ Inst,Dept Oncol, Guangzhou 510275, Guangdong, Peoples R China.	xiederong@21cn.com						Adelstein BA, 2011, EUR J CANCER, V47, P1343, DOI 10.1016/j.ejca.2011.03.031; Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Bokemeyer C, 2011, ANN ONCOL, V22, P1535, DOI 10.1093/annonc/mdq632; Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397; Bria E GR, 2007, J CLIN ONCOL, V25; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860; Hecht JR, 2009, J CLIN ONCOL, V27, P672, DOI 10.1200/JCO.2008.19.8135; Ibrahim EM, 2010, INT J COLORECTAL DIS, V25, P713, DOI 10.1007/s00384-010-0927-4; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JEMAL A, 2011, CA CANCER J CLIN, V61, P134; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kopetz S, 2009, CANCER RES, V69, P3842, DOI 10.1158/0008-5472.CAN-08-2246; Lara PN, 2011, J CLIN ONCOL, V29, P2965, DOI 10.1200/JCO.2011.35.0660; Lu Y, 2007, CANCER RES, V67, P8240, DOI 10.1158/0008-5472.CAN-07-0589; Maughan TS, 2011, LANCET, V377, P2103, DOI 10.1016/S0140-6736(11)60613-2; O'Neil BH, 2008, ONCOLOGIST, V13, P1074, DOI 10.1634/theoncologist.2008-0083; Sterne JAC, 2001, BMJ-BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101; Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268; Tveit K. M., 2012, J CLIN ONCOL, P4; US Department of Health and Human Services, GUID IND CLIN TRIAL; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Wolpin BM, 2008, GASTROENTEROLOGY, V134, P1296, DOI 10.1053/j.gastro.2008.02.098; Wong SL, 2010, J CLIN ONCOL, V28, P493, DOI 10.1200/JCO.2009.23.4450	24	26	27	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2012	7	11							e50925	10.1371/journal.pone.0050925	http://dx.doi.org/10.1371/journal.pone.0050925			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	054WM	23226426	gold, Green Published, Green Submitted			2023-01-03	WOS:000312376100237
J	Brown, EM; McDougall, GJ; Stewart, D; Pereira-Caro, G; Gonzalez-Barrio, R; Allsopp, P; Magee, P; Crozier, A; Rowland, I; Gill, CIR				Brown, Emma M.; McDougall, Gordon J.; Stewart, Derek; Pereira-Caro, Gema; Gonzalez-Barrio, Rocio; Allsopp, Philip; Magee, Pamela; Crozier, Alan; Rowland, Ian; Gill, Chris I. R.			Persistence of Anticancer Activity in Berry Extracts after Simulated Gastrointestinal Digestion and Colonic Fermentation	PLOS ONE			English	Article							ANTHOCYANIN-RICH EXTRACTS; PHENOLIC-COMPOUNDS; ELLAGIC ACID; FECAL WATER; CANCER; POLYPHENOLS; BIOAVAILABILITY; PHYTOCHEMICALS; INVASION; CELLS	Fruit and vegetable consumption is associated at the population level with a protective effect against colorectal cancer. Phenolic compounds, especially abundant in berries, are of interest due to their putative anticancer activity. After consumption, however, phenolic compounds are subject to digestive conditions within the gastrointestinal tract that alter their structures and potentially their function. However, the majority of phenolic compounds are not efficiently absorbed in the small intestine and a substantial portion pass into the colon. We characterized berry extracts (raspberries, strawberries, blackcurrants) produced by in vitro-simulated upper intestinal tract digestion and subsequent fecal fermentation. These extracts and selected individual colonic metabolites were then evaluated for their putative anticancer activities using in vitro models of colorectal cancer, representing the key stages of initiation, promotion and invasion. Over a physiologically-relevant dose range (0-50 mg/ml gallic acid equivalents), the digested and fermented extracts demonstrated significant anti-genotoxic, anti-mutagenic and anti-invasive activity on colonocytes. This work indicates that phenolic compounds from berries undergo considerable structural modifications during their passage through the gastrointestinal tract but their breakdown products and metabolites retain biological activity and can modulate cellular processes associated with colon cancer.	[Brown, Emma M.; Allsopp, Philip; Magee, Pamela; Gill, Chris I. R.] Univ Ulster, Ctr Mol Biosci, No Ireland Ctr Food & Hlth, Coleraine BT52 1SA, Londonderry, North Ireland; [McDougall, Gordon J.; Stewart, Derek] James Hutton Inst, Environm & Biochem Sci Grp, Dundee, Scotland; [Pereira-Caro, Gema; Gonzalez-Barrio, Rocio; Crozier, Alan] Univ Glasgow, Sch Med, Plant Prod & Human Nutr Grp, Glasgow, Lanark, Scotland; [Rowland, Ian] Univ Reading, Hugh Sinclair Unit Human Nutr, Dept Food & Nutr Sci, Reading, Berks, England; [Stewart, Derek] Heriot Watt Univ, Sch Life Sci, Edinburgh, Midlothian, Scotland	Ulster University; James Hutton Institute; University of Glasgow; University of Reading; Heriot Watt University	Gill, CIR (corresponding author), Univ Ulster, Ctr Mol Biosci, No Ireland Ctr Food & Hlth, Coleraine BT52 1SA, Londonderry, North Ireland.	C.Gill@ulster.ac.uk	Gonzalez-Barrio, Rocío/F-2180-2018; Crozier, Alan/H-6642-2017	Gonzalez-Barrio, Rocío/0000-0002-6648-5229; Crozier, Alan/0000-0001-7581-6782; Pereira Caro, Gema/0000-0003-3162-0432; Brown, Emma/0000-0002-2762-2489; Magee, Pamela/0000-0002-0479-3314	University of Ulster; N. Ireland Department of Education and Learning; James Hutton Institute; Washington Red Raspberry Commission	University of Ulster; N. Ireland Department of Education and Learning; James Hutton Institute; Washington Red Raspberry Commission	EB was in receipt of a joint PhD studentship scheme between the University of Ulster (an award from the N. Ireland Department of Education and Learning), and the James Hutton Institute. The study was part funded by the Washington Red Raspberry Commission. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams LS, 2010, CANCER RES, V70, P3594, DOI 10.1158/0008-5472.CAN-09-3565; Aura Anna-Marja, 2008, Phytochemistry Reviews, V7, P407, DOI 10.1007/s11101-008-9095-3; Bermudez-Soto MJ, 2007, FOOD CHEM, V102, P865, DOI 10.1016/j.foodchem.2006.06.025; Borges G, 2010, J AGR FOOD CHEM, V58, P3901, DOI 10.1021/jf902263n; Boyd LA, 2006, NUTR CANCER, V55, P232, DOI 10.1207/s15327914nc5502_15; Brown EM, 2012, CURR PHARM BIOTECHNO, V13, P200; Chen PN, 2006, CANCER LETT, V235, P248, DOI 10.1016/j.canlet.2005.04.033; Coates Emma M, 2007, J Carcinog, V6, P4, DOI 10.1186/1477-3163-6-4; Duthie SJ, 2007, MOL NUTR FOOD RES, V51, P665, DOI 10.1002/mnfr.200600257; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gil-Izquierdo A, 2002, EUR FOOD RES TECHNOL, V214, P155, DOI 10.1007/s00217-001-0428-3; Gonzalez-Barrio R, 2010, J AGR FOOD CHEM, V58, P3933, DOI 10.1021/jf100315d; Gonzalez-Sarrias A, 2010, BRIT J NUTR, V104, P503, DOI 10.1017/S0007114510000826; Hashim YZHY, 2008, INT J CANCER, V122, P495, DOI 10.1002/ijc.23148; Holst B, 2008, CURR OPIN BIOTECH, V19, P73, DOI 10.1016/j.copbio.2008.03.003; Jenner AM, 2005, FREE RADICAL BIO MED, V38, P763, DOI 10.1016/j.freeradbiomed.2004.11.020; Johnson IT, 2004, MUTAT RES-FUND MOL M, V551, P9, DOI 10.1016/j.mrfmmm.2004.02.017; Lala G, 2006, NUTR CANCER, V54, P84, DOI 10.1207/s15327914nc5401_10; Macheix JJ, 1990, FRUIT PHENOLICS; Makena PS, 2007, FOOD CHEM TOXICOL, V45, P1899, DOI 10.1016/j.fct.2007.04.007; Manach C, 2004, AM J CLIN NUTR, V79, P727, DOI 10.1093/ajcn/79.5.727; McCann MJ, 2008, MOL NUTR FOOD RES, V52, P567, DOI 10.1002/mnfr.200700052; McDougall G, 2007, ACTA HORTIC, P135, DOI 10.17660/ActaHortic.2007.744.13; McDougall GJ, 2005, J AGR FOOD CHEM, V53, P5896, DOI 10.1021/jf050131p; Parr C, 2000, INT J CANCER, V85, P563, DOI 10.1002/(SICI)1097-0215(20000215)85:4<563::AID-IJC19>3.3.CO;2-4; Pearson JR, 2009, NUTR REV, V67, P509, DOI 10.1111/j.1753-4887.2009.00224.x; Perez-Vicente A, 2002, J AGR FOOD CHEM, V50, P2308, DOI 10.1021/jf0113833; Petermann A, 2009, MOL NUTR FOOD RES, V53, P1245, DOI 10.1002/mnfr.200900110; Ramnani P, 2012, ANAEROBE, V18, P1, DOI 10.1016/j.anaerobe.2011.08.003; Ramos S, 2008, MOL NUTR FOOD RES, V52, P507, DOI 10.1002/mnfr.200700326; Reyes-Zurita FJ, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-154; Roowi S, 2010, J AGR FOOD CHEM, V58, P1296, DOI 10.1021/jf9032975; SAHASRABUDHE SR, 1991, GENETICS, V129, P981; Seeram NP, 2008, J AGR FOOD CHEM, V56, P630, DOI 10.1021/jf072504n; Sharma M, 2010, J AGR FOOD CHEM, V58, P3965, DOI 10.1021/jf902857v; Shin DY, 2011, ONCOL REP, V25, P567, DOI 10.3892/or.2010.1104; Singh BN, 2009, FOOD CHEM TOXICOL, V47, P1161, DOI 10.1016/j.fct.2009.02.004; Spada PDS, 2008, J MED FOOD, V11, P144, DOI 10.1089/jmf.2007.598; Thomasset S, 2009, CANCER PREV RES, V2, P625, DOI 10.1158/1940-6207.CAPR-08-0201; van Duijnhoven FJB, 2009, AM J CLIN NUTR, V89, P1441, DOI 10.3945/ajcn.2008.27120; van Duynhoven J, 2011, P NATL ACAD SCI USA, V108, P4531, DOI 10.1073/pnas.1000098107; Williamson G, 2010, BRIT J NUTR, V104, pS48, DOI 10.1017/S0007114510003946; Yun JW, 2010, FOOD CHEM TOXICOL, V48, P903, DOI 10.1016/j.fct.2009.12.031; Zhao C, 2004, J AGR FOOD CHEM, V52, P6122, DOI 10.1021/jf049517a	45	54	55	1	74	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2012	7	11							e49740	10.1371/journal.pone.0049740	http://dx.doi.org/10.1371/journal.pone.0049740			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	047ER	23185422	Green Accepted, gold, Green Published			2023-01-03	WOS:000311821000098
J	Jack, A				Jack, Andrew			Faking it	BRITISH MEDICAL JOURNAL			English	Editorial Material									Financial Times, London, England		Jack, A (corresponding author), Financial Times, London, England.	andrew.jack@ft.com		Jack, Andrew/0000-0001-9679-2898				[Anonymous], IPHARMACIST ME; Bate R, 2012, RES REP TROP MED, V3, P57, DOI 10.2147/RRTM.S33108; Bate R, 2012, RES REP TROP MED, V3, P63, DOI 10.2147/RRTM.S33690; Efpia, 2012, EUR STAK MOD; European Commission, 2011, REP EU CUST ENF INT; Gathigah M, 2011, KEN CIV SOC DEF ACC; Jack A., 2012, FINANCIAL TIMES; Jack Andrew, 2011, FINANC TIMES; Jack Andrew., 2008, FINANCIAL TIMES; Organization W. H., 2012, MED SPUR FALS LAB FA; Pharmaceutical Security Institute, COUNT SIT; Tanne JH, 2008, BRIT MED J, V336, P412, DOI 10.1136/bmj.39496.419248.DB; WHO, 2006, COUNT MED FACTSH REV	13	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	NOV 20	2012	345								e7836	10.1136/bmj.e7836	http://dx.doi.org/10.1136/bmj.e7836			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	044GT	23169809				2023-01-03	WOS:000311608200012
J	Eickholt, C; Siekiera, M; Kirmanoglou, K; Rodenbeck, A; Heussen, N; Schauerte, P; Lichtenberg, A; Balzer, J; Rassaf, T; Perings, S; Kelm, M; Shin, DI; Meyer, C				Eickholt, Christian; Siekiera, Marcus; Kirmanoglou, Kiriakos; Rodenbeck, Astrid; Heussen, Nicole; Schauerte, Patrick; Lichtenberg, Artur; Balzer, Jan; Rassaf, Tienush; Perings, Stefan; Kelm, Malte; Shin, Dong-In; Meyer, Christian			Improvement of Left Ventricular Function under Cardiac Resynchronization Therapy Goes along with a Reduced Incidence of Ventricular Arrhythmia	PLOS ONE			English	Article							IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; CONGESTIVE-HEART-FAILURE; SOCIETY-OF-CARDIOLOGY; EUROPEAN-SOCIETY; RESYNCHRONISATION THERAPY; DILATED CARDIOMYOPATHY; FOLLOW-UP; ASSOCIATION; TRIAL; CRT	Objectives: The beneficial effects of cardiac resynchronization therapy (CRT) are thought to result from favorable left ventricular (LV) reverse remodeling, however CRT is only successful in about 70% of patients. Whether response to CRT is associated with a decrease in ventricular arrhythmias (VA) is still discussed controversially. Therefore, we investigated the incidence of VA in CRT responders in comparison with non-responders. Methods: In this nonrandomized, two-center, observational study patients with moderate-to-severe heart failure, LV ejection fraction (LVEF) <= 35%, and QRS duration >120 ms undergoing CRT were included. After 6 months patients were classified as CRT responders or non-responders. Incidence of VA was compared between both groups by Kaplan-Meier analysis and Cox regression analysis. ROC analysis was performed to determine the aptitude of LVEF cut-off values to predict VA. Results: In total 126 consecutive patients (64 +/- 11years; 67% male) were included, 74 were classified as responders and 52 as non-responders. While the mean LVEF at baseline was comparable in both groups (25 +/- 7% vs. 24 +/- 8%; P = 0.4583) only the responder group showed an improvement of LVEF (36 +/- 6% vs. 24 +/- 7; p<0.0001) under CRT. In total in 56 patients VA were observed during a mean follow-up of 28 +/- 14 months, with CRT responders experiencing fewer VA than non-responders (35% vs. 58%, p<0.0061). Secondary preventive CRT implantation was associated with a higher likelihood of VA. As determined by ROC analysis an increase of LVEF by >7% was found to be a predictor of a significantly lower incidence of VA (AUC = 0.606). Conclusions: Improvement of left ventricular function under cardiac resynchronization therapy goes along with a reduced incidence of ventricular arrhythmia.	[Eickholt, Christian; Siekiera, Marcus; Kirmanoglou, Kiriakos; Balzer, Jan; Rassaf, Tienush; Perings, Stefan; Kelm, Malte; Shin, Dong-In; Meyer, Christian] Univ Dusseldorf, Fac Med, Dept Cardiol Pulmol & Angiol, D-40225 Dusseldorf, Germany; [Rodenbeck, Astrid; Schauerte, Patrick] Univ Hosp RWTH Aachen, Div Cardiol Pulmol & Angiol, Aachen, Germany; [Heussen, Nicole] Univ Hosp RWTH Aachen, Dept Med Stat, Aachen, Germany; [Lichtenberg, Artur] Univ Dusseldorf, Dept Cardiovasc Surg, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; Heinrich Heine University Dusseldorf	Meyer, C (corresponding author), Univ Dusseldorf, Fac Med, Dept Cardiol Pulmol & Angiol, D-40225 Dusseldorf, Germany.	christian.meyer@med.uni-duesseldorf.de	Heussen, Nicole/Q-5309-2019; Eickholt, Christian/G-1466-2013; Heussen, Nicole/C-7006-2013; Meyer, Christian/G-2440-2013	Heussen, Nicole/0000-0002-6134-7206; Eickholt, Christian/0000-0002-5458-9688; Kelm, Malte/0000-0003-0060-1052; Meyer, Christian/0000-0002-9877-1393; Meyer, Christian/0000-0003-0217-3960	European Heart Rhythm Association; Hans-und-Gertie-Fischer Stiftung	European Heart Rhythm Association; Hans-und-Gertie-Fischer Stiftung	CM received support as a fellow of the European Heart Rhythm Association for the 1-year fellowship (advanced program) in interventional electrophysiology (mentor: Prof Helmut Purerfellner). CM is also the recipient of a research grant from the Hans-und-Gertie-Fischer Stiftung. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aiba T, 2012, J CARDIOVASC TRANSL, V5, P170, DOI 10.1007/s12265-012-9348-9; Aiba T, 2010, CURR OPIN CARDIOL, V25, P29, DOI 10.1097/HCO.0b013e328333d3d6; Anand IS, 2009, CIRCULATION, V119, P969, DOI 10.1161/CIRCULATIONAHA.108.793273; Arya A, 2005, HEART RHYTHM, V2, P1094, DOI 10.1016/j.hrthm.2005.07.007; Barsheshet A, 2011, J AM COLL CARDIOL, V57, P2416, DOI 10.1016/j.jacc.2010.12.041; Bax JJ, 2005, J AM COLL CARDIOL, V46, P2168, DOI 10.1016/j.jacc.2005.09.020; Boriani G, 2006, INT J CARDIOL, V108, P165, DOI 10.1016/j.ijcard.2005.04.029; Boriani G, 2010, FUND CLIN PHARMACOL, V24, P575, DOI 10.1111/j.1472-8206.2010.00853.x; Bradley DJ, 2003, JAMA-J AM MED ASSOC, V289, P730, DOI 10.1001/jama.289.6.730; Butter C, 2006, AM HEART J, V151, P115, DOI 10.1016/j.ahj.2005.02.047; Chakir K, 2009, CIRCULATION, V119, P1231, DOI 10.1161/CIRCULATIONAHA.108.774752; Chan CP, 2008, AM J CARDIOL, V102, P602, DOI 10.1016/j.amjcard.2008.04.032; Cleland JGF, 2006, EUR HEART J, V27, P1928, DOI 10.1093/eurheartj/ehl099; Daubert JC, 2012, HEART RHYTHM, V9, P1524, DOI 10.1016/j.hrthm.2012.07.025; Di Biase L, 2008, J AM COLL CARDIOL, V52, P1442, DOI 10.1016/j.jacc.2008.07.043; Di Cori A, 2005, J INTERV CARD ELECTR, V12, P231, DOI 10.1007/s10840-005-0338-6; Fish JM, 2005, J AM COLL CARDIOL, V46, P2340, DOI 10.1016/j.jacc.2005.08.035; Gehi AK, 2006, JAMA-J AM MED ASSOC, V296, P2839, DOI 10.1001/jama.296.23.2839; Guerra JM, 2003, J CARDIOVASC ELECTR, V14, P1245, DOI 10.1046/j.1540-8167.2003.03303.x; Higgins SL, 2000, J AM COLL CARDIOL, V36, P824, DOI 10.1016/S0735-1097(00)00795-6; Higgins SL, 2003, J AM COLL CARDIOL, V42, P1454, DOI 10.1016/S0735-1097(03)01042-8; Jenkins C, 2009, EUR HEART J, V30, P98, DOI 10.1093/eurheartj/ehn484; Kass DA, 2009, HEART RHYTHM, V6, P1660, DOI 10.1016/j.hrthm.2009.08.017; Kies P, 2005, AM J CARDIOL, V95, P1111, DOI 10.1016/j.amjcard.2005.01.029; Knappe D, 2011, CIRC-HEART FAIL, V4, P433, DOI 10.1161/CIRCHEARTFAILURE.111.962902; Koneru JN, 2011, CIRC-ARRHYTHMIA ELEC, V4, P778, DOI 10.1161/CIRCEP.110.961243; Kronborg MB, 2010, EUROPACE, V12, P216, DOI 10.1093/europace/eup364; Kurita T, 2011, J ELECTROCARDIOL, V44, P736, DOI 10.1016/j.jelectrocard.2011.09.002; Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005; Lellouche N, 2011, EUROPACE, V13, P1180, DOI 10.1093/europace/eur106; Leon AR, 2005, J CARDIOVASC ELECTR, V16, P100, DOI 10.1046/j.1540-8167.2005.04600.x; Lin G, 2008, HEART, V94, P186, DOI 10.1136/hrt.2007.118372; Linde C, 2002, J AM COLL CARDIOL, V40, P111, DOI 10.1016/S0735-1097(02)01932-0; Linde C, 2012, HEART RHYTHM, V9, pS3, DOI 10.1016/j.hrthm.2012.04.026; McMurray JJV, 2012, EUR HEART J, V33, P1787, DOI 10.1093/eurheartj/ehs104; Metra M, 2007, EUR J HEART FAIL, V9, P684, DOI 10.1016/j.ejheart.2007.04.003; Meyer C, 2009, INT HEART J, V50, P741, DOI 10.1536/ihj.50.741; Penicka M, 2004, CIRCULATION, V109, P978, DOI 10.1161/01.CIR.0000116765.43251.D7; Pouleur AC, 2011, EUR HEART J, V32, P1720, DOI 10.1093/eurheartj/ehr185; Sachse FB, 2012, CIRC RES, V110, P588, DOI 10.1161/CIRCRESAHA.111.257428; Singh JP, 2012, EUR HEART J, V33, P305, DOI 10.1093/eurheartj/ehr366; Steffel J, 2011, HEART, V97, P1668, DOI 10.1136/heartjnl-2011-300222; Sutton MSJ, 2009, CIRCULATION, V120, P1858, DOI 10.1161/CIRCULATIONAHA.108.818724; Ukkonen H, 2008, EUROPACE, V10, P114, DOI 10.1093/europace/eun228; Ypenburg C, 2006, J AM COLL CARDIOL, V48, P464, DOI 10.1016/j.jacc.2006.04.072; Ypenburg C, 2009, J AM COLL CARDIOL, V53, P483, DOI 10.1016/j.jacc.2008.10.032	46	12	14	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2012	7	11							e48926	10.1371/journal.pone.0048926	http://dx.doi.org/10.1371/journal.pone.0048926			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	039HA	23152822	Green Published, Green Submitted, gold			2023-01-03	WOS:000311234000035
J	Liu, SF; Chang, SY; Lee, TC; Chuang, LY; Guh, JY; Hung, CY; Hung, TJ; Hung, YJ; Chen, PY; Hsieh, PF; Yang, YL				Liu, Shu-Fen; Chang, Shan-Yu; Lee, Tao-Chen; Chuang, Lea-Yea; Guh, Jinn-Yuh; Hung, Chien-Ya; Hung, Tsung-Jen; Hung, Yu-Ju; Chen, Po-Yi; Hsieh, Pei-fang; Yang, Yu-Lin			Dioscorea alata Attenuates Renal Interstitial Cellular Fibrosis by Regulating Smad- and Epithelial-Mesenchymal Transition Signaling Pathways	PLOS ONE			English	Article							GROWTH-FACTOR-BETA; ANGIOTENSIN-II; TGF-BETA; TISSUE FIBROSIS; DISEASE; TRANSDIFFERENTIATION; CELLS	Renal interstitial fibrosis is characterized by increased extracellular matrix (ECM) synthesis. Epithelial-mesenchymal transition (EMT) in kidneys is driven by regulated expression of fibrogenic cytokines such as transforming growth factor-beta (TGF-beta). Yam, or Dioscorea alata (DA) is an important herb in Chinese medicine widely used for the treatment of clinical diabetes mellitus. However, the fibrosis regulatory effect of DA is unclear. Thus, we examined TGF-beta signaling mechanisms against EMT in rat fibroblast cells (NRK-49F). The characterization of DA water-extracts used various methods; after inducing cellular fibrosis in NRK-49F cells by treatment with beta-hydroxybutyrate (beta-HB) (10 mM), we used Western blotting to examine the protein expression in the TGF-beta-related signal protein type I and type II TGF-beta receptors, Smads2 and Smad3 (Smad2/3), pSmad2 and Smad3 (pSmad2/3), Smads4, Smads7, and EMT markers. These markers included E-cadherin, alpha-smooth muscle actin (alpha-MA), and matrix metalloproteinase-2 (MMP-2). Bioactive TGF-beta and fibronectin levels in the culture media were determined using ELISA. Expressions of fibronectin and Snail transcription factor, an EMT-regulatory transcription factor, were assessed by immunofluorescence staining. DA extract dose-dependently (50-200 mu g/mL) suppressed beta-HB-induced expression of fibronectin in NRK-49F cells concomitantly with the inhibition of Smad2/3, pSmad2/3, and Smad4. By contrast, Smad7 expression was significantly increased. DA extract caused a decrease in alpha-SMA (alpha-smooth muscle actin) and MMP-2 levels, and an increase in E-cadherin expression. We propose that DA extract might act as a novel fibrosis antagonist, which acts partly by down regulating the TGF-beta/smad signaling pathway and modulating EMT expression. Citation: Liu S-F, Chang S-Y, Lee T-C, Chuang L-Y, Guh J-Y, et al. (2012) Dioscorea alata Attenuates Renal Interstitial Cellular Fibrosis by Regulating Smad- and Epithelial-Mesenchymal Transition Signaling Pathways. PLoS ONE 7(11): e47482. doi:10.1371/journal.pone.0047482	[Chang, Shan-Yu; Hung, Tsung-Jen; Hsieh, Pei-fang; Yang, Yu-Lin] Chung Hwa Univ Med Technol, Dept Grad Inst Biomed Sci, Tainan, Taiwan; [Liu, Shu-Fen; Guh, Jinn-Yuh] Kaohsiung Med Univ, Dept Internal Med, Kaohsiung, Taiwan; [Lee, Tao-Chen] Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Kaohsiung, Taiwan; [Chuang, Lea-Yea] Kaohsiung Med Univ, Dept Biochem, Kaohsiung, Taiwan; [Hung, Chien-Ya] Chung Hwa Univ Med Technol, Dept Food Nutr, Tainan, Taiwan; [Hung, Yu-Ju] Natl Taiwan Univ, Dept Publ Hlth, Taipei 10764, Taiwan; [Chen, Po-Yi] Chung Hwa Univ Med Technol, Dept Optometry, Tainan, Taiwan; [Yang, Yu-Lin] Chung Hwa Univ Med Technol, Dept Med Lab Sci & Biotechnol, Tainan, Taiwan	Chung Hua University; Kaohsiung Medical University; Chang Gung Memorial Hospital; Chang Gung University; Kaohsiung Medical University; Chung Hua University; National Taiwan University; Chung Hua University; Chung Hua University	Yang, YL (corresponding author), Chung Hwa Univ Med Technol, Dept Grad Inst Biomed Sci, Tainan, Taiwan.	call0955443221@gmail.com		Hung, Yu-Ju/0000-0003-4568-9983	National Science Council, Taiwan [NSC 99-2628-B-273-001 -MY3]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by research grants from the National Science Council, Taiwan (NSC 99-2628-B-273-001 -MY3). http://web1.nsc.gov.tw/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; BOHLE A, 1994, EXP NEPHROL, V2, P205; Border WA, 1998, HYPERTENSION, V31, P181, DOI 10.1161/01.HYP.31.1.181; Border WA, 1997, KIDNEY INT, V51, P1388, DOI 10.1038/ki.1997.190; Bottinger EP, 2002, J AM SOC NEPHROL, V13, P2600, DOI 10.1097/01.ASN.0000033611.79556.AE; Chang HY, 2011, J AGR FOOD CHEM, V59, P5357, DOI 10.1021/jf200598w; Chang SJ, 2004, J AGR FOOD CHEM, V52, P1720, DOI 10.1021/jf0345954; Cook HT, 2010, AM J PATHOL, V176, P22, DOI 10.2353/ajpath.2010.090898; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Eddy AA, 1996, J AM SOC NEPHROL, V7, P2495; Fan JM, 1999, KIDNEY INT, V56, P1455, DOI 10.1046/j.1523-1755.1999.00656.x; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; Liu YH, 2004, J AM SOC NEPHROL, V15, P1, DOI 10.1097/01.ASN.0000106015.29070.E7; Luft FC, 1999, J MOL MED, V77, P517, DOI 10.1007/s001099900033; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Olayemi J, 2010, AFRICAN J BIOTECHNOL, V6; ONG ACM, 1994, KIDNEY INT, V45, P345, DOI 10.1038/ki.1994.44; Peters H, 1997, KIDNEY INT, V51, P1481, DOI 10.1038/ki.1997.203; Remuzzi G, 1998, NEW ENGL J MED, V339, P1448, DOI 10.1056/NEJM199811123392007; Stahl PJ, 2001, AM J PATHOL, V159, P1187, DOI 10.1016/S0002-9440(10)62503-5; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Yanez-Mo M, 2003, NEW ENGL J MED, V348, P403, DOI 10.1056/NEJMoa020809; Yang JW, 2001, AM J PATHOL, V159, P1465, DOI 10.1016/S0002-9440(10)62533-3; Zeisberg M, 2002, AM J PATHOL, V160, P2001, DOI 10.1016/S0002-9440(10)61150-9	24	22	24	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2012	7	11							e47482	10.1371/journal.pone.0047482	http://dx.doi.org/10.1371/journal.pone.0047482			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	053KE	23144821	Green Published, gold, Green Submitted			2023-01-03	WOS:000312269500009
J	Sobhakumari, A; Love-Homan, L; Fletcher, EVM; Martin, SM; Parsons, AD; Spitz, DR; Knudson, CM; Simons, AL				Sobhakumari, Arya; Love-Homan, Laurie; Fletcher, Elise V. M.; Martin, Sean M.; Parsons, Arlene D.; Spitz, Douglas R.; Knudson, C. Michael; Simons, Andrean L.			Susceptibility of Human Head and Neck Cancer Cells to Combined Inhibition of Glutathione and Thioredoxin Metabolism	PLOS ONE			English	Article							BUTHIONINE SULFOXIMINE; OXIDATIVE STRESS; PHASE-I; CARCINOMA CELLS; MESSENGER-RNA; REDUCTASE; RESISTANCE; APOPTOSIS; DEPLETION; MODULATION	Increased glutathione (GSH) and thioredoxin (Trx) metabolism are mechanisms that are widely implicated in resistance of cancer cells to chemotherapy. The current study determined if simultaneous inhibition of GSH and Trx metabolism enhanced cell killing of human head and neck squamous cell carcinoma (HNSCC) cells by a mechanism involving oxidative stress. Inhibition of GSH and Trx metabolism with buthionine sulfoximine (BSO) and auranofin (AUR), respectively, induced significant decreases in clonogenic survival compared to either drug alone in FaDu, Cal-27 and SCC-25 HNSCC cells in vitro and in vivo in Cal-27 xenografts. BSO+AUR significantly increased glutathione and thioredoxin oxidation and suppressed peroxiredoxin activity in vitro. Pre-treatment with N-acetylcysteine completely reversed BSO+AUR-induced cell killing in FaDu and Cal-27 cells, while catalase and selenium supplementation only inhibited BSO+AUR-induced cell killing in FaDu cells. BSO+AUR decreased caspase 3/7 activity in HNSCC cells and significantly reduced the viability of both Bax/Bak double knockout (DKO) and DKO-Bax reconstituted hematopoietic cells suggesting that necrosis was involved. BSO+AUR also significantly sensitized FaDu, Cal-27, SCC-25 and SQ20B cells to cell killing induced by the EGFR inhibitor Erlotinib in vitro. These results support the conclusion that simultaneous inhibition of GSH and Trx metabolism pathways induces oxidative stress and clonogenic killing in HNSCCs and this strategy may be useful in sensitizing HNSCCs to EGFR inhibitors.	[Sobhakumari, Arya; Love-Homan, Laurie; Fletcher, Elise V. M.; Martin, Sean M.; Knudson, C. Michael; Simons, Andrean L.] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; [Sobhakumari, Arya; Fletcher, Elise V. M.; Spitz, Douglas R.; Simons, Andrean L.] Univ Iowa, Interdisciplinary Human Toxicol Program, Iowa City, IA USA; [Parsons, Arlene D.; Spitz, Douglas R.; Knudson, C. Michael; Simons, Andrean L.] Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA USA; [Spitz, Douglas R.; Knudson, C. Michael; Simons, Andrean L.] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa	Simons, AL (corresponding author), Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA.	andrean-simons@uiowa.edu		Burnett, Andrean/0000-0002-6685-0353; Spitz, Douglas/0000-0002-1254-8765; Knudson, Charles Michael/0000-0003-3964-5466	National Institutes of Health [K01CA134941, R01CA133114, P30CA086862]; Departments of Pathology and Radiation Oncology at The University of Iowa; NATIONAL CANCER INSTITUTE [P30CA086862, K01CA134941, T32CA078586, R01CA133114] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Departments of Pathology and Radiation Oncology at The University of Iowa; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by National Institutes of Health Grants K01CA134941 (ALS), R01CA133114 and P30CA086862 (DRS), as well as the Departments of Pathology and Radiation Oncology at The University of Iowa. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aebi H, 1984, Methods Enzymol, V105, P121; Ang KK, 2002, CANCER RES, V62, P7350; Armstrong JS, 2002, CELL DEATH DIFFER, V9, P252, DOI 10.1038/sj.cdd.4400959; BAILEY HH, 1994, J CLIN ONCOL, V12, P194, DOI 10.1200/JCO.1994.12.1.194; Bailey HH, 1997, J NATL CANCER I, V89, P1789, DOI 10.1093/jnci/89.23.1789; Bailey HH, 1998, CHEM-BIOL INTERACT, V112, P239, DOI 10.1016/S0009-2797(97)00164-6; BENN HP, 1990, J RHEUMATOL, V17, P466; BLOCKA K, 1983, AM J MED, V75, P114, DOI 10.1016/0002-9343(83)90483-7; Bozonet SM, 2005, J BIOL CHEM, V280, P23319, DOI 10.1074/jbc.M502757200; Brown KK, 2010, FEBS LETT, V584, P1257, DOI 10.1016/j.febslet.2010.02.042; Corti A, 2010, ANTICANCER RES, V30, P1169; Cox AG, 2008, BIOCHEM PHARMACOL, V76, P1097, DOI 10.1016/j.bcp.2008.08.021; Eriksson SE, 2009, FREE RADICAL BIO MED, V47, P1661, DOI 10.1016/j.freeradbiomed.2009.09.016; Fath MA, 2011, CLIN CANCER RES, V17, P6206, DOI 10.1158/1078-0432.CCR-11-0736; GALLO JM, 1995, CANCER RES, V55, P4507; GRANDIS JR, 1993, CANCER RES, V53, P3579; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kandasamy K, 2003, CANCER RES, V63, P1712; Kim JA, 2005, ANAL BIOCHEM, V338, P216, DOI 10.1016/j.ab.2004.12.008; LAI SL, 1995, ONCOL RES, V7, P31; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Mandal PK, 2010, CANCER RES, V70, P9505, DOI 10.1158/0008-5472.CAN-10-1509; Mao L, 2004, CANCER CELL, V5, P311, DOI 10.1016/S1535-6108(04)00090-X; Marty L, 2009, P NATL ACAD SCI USA, V106, P9109, DOI 10.1073/pnas.0900206106; MAVIS RD, 1968, J BIOL CHEM, V243, P809; McKeage MJ, 2002, COORDIN CHEM REV, V232, P127, DOI 10.1016/S0010-8545(02)00048-6; Mitchell J B, 1987, Br J Cancer Suppl, V8, P96; Mustacich D, 2007, BIOCHEM J, V346, P1; ODWYER PJ, 1992, J NATL CANCER I, V84, P264, DOI 10.1093/jnci/84.4.264; Rabik CA, 2007, CANCER TREAT REV, V33, P9, DOI 10.1016/j.ctrv.2006.09.006; Rackham O, 2011, FREE RADICAL BIO MED, V50, P689, DOI 10.1016/j.freeradbiomed.2010.12.015; Reichheld JP, 2007, PLANT CELL, V19, P1851, DOI 10.1105/tpc.107.050849; Rigobello MP, 2005, FREE RADICAL RES, V39, P687, DOI 10.1080/10715760500135391; Scarbrough PM, 2012, FREE RADICAL BIO MED, V52, P436, DOI 10.1016/j.freeradbiomed.2011.10.493; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; SCHNIER C, 1990, BIOL TRACE ELEM RES, V26-7, P471, DOI 10.1007/BF02992702; SHAH JP, 1995, CA-CANCER J CLIN, V45, P352, DOI 10.3322/canjclin.45.6.352; Shaw CF, 1999, CHEM REV, V99, P2589, DOI 10.1021/cr980431o; Siegsmund MJ, 1999, UROL RES, V27, P157, DOI 10.1007/s002400050103; Simons AL, 2009, J ONCOL, V2009, DOI 10.1155/2009/519563; Song JJ, 2003, BIOCHEM J, V373, P845, DOI 10.1042/BJ20030275; SPITZ DR, 1990, BIOCHEM J, V267, P453, DOI 10.1042/bj2670453; SPITZ DR, 1993, J CELL PHYSIOL, V156, P72, DOI 10.1002/jcp.1041560111; SPITZ DR, 1995, J CELL PHYSIOL, V165, P600, DOI 10.1002/jcp.1041650318; Tan SX, 2010, J BIOL CHEM, V285, P6118, DOI 10.1074/jbc.M109.062844; Troyano A, 2001, J BIOL CHEM, V276, P47107, DOI 10.1074/jbc.M104516200; Watson WH, 2003, J BIOL CHEM, V278, P33408, DOI 10.1074/jbc.M211107200; Weber CN, 2007, CANCER BIOL THER, V6, P156, DOI 10.4161/cbt.6.2.3556; WEICHSELBAUM RR, 1986, P NATL ACAD SCI USA, V83, P2684, DOI 10.1073/pnas.83.8.2684; YAO KS, 1993, CANCER RES, V53, P3662; Zimmermann M, 2006, RADIAT ONCOL, V1, DOI 10.1186/1748-717X-1-11	53	55	57	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2012	7	10							e48175	10.1371/journal.pone.0048175	http://dx.doi.org/10.1371/journal.pone.0048175			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	030WJ	23118946	Green Submitted, Green Published, gold			2023-01-03	WOS:000310600500077
J	Bernards, R				Bernards, Rene			A Missing Link in Genotype-Directed Cancer Therapy	CELL			English	Editorial Material							INHIBITION; VEMURAFENIB; EGFR	Genotype-directed therapy holds great promise for the treatment of cancer, but crosstalk between signaling pathways often confounds simple genotype-drug response relationships. To deliver on the promise of precision medicine, a coordinated effort is needed to make a comprehensive inventory of the many signaling feedback circuits that exist in cancer cells.	[Bernards, Rene] Netherlands Canc Inst, Div Mol Carcinogenesis, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; [Bernards, Rene] Netherlands Canc Inst, Canc Genom Ctr, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Ctr Biomed Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.bernards@nki.nl		Bernards, Rene/0000-0001-8677-3423				Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Committee on a Framework for Developing a New Taxonomy of Disease; National Research Council, 2011, PREC MED BUILD KNOWL; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Spear BB, 2001, TRENDS MOL MED, V7, P201, DOI 10.1016/S1471-4914(01)01986-4; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096	9	76	79	0	18	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 26	2012	151	3					465	468		10.1016/j.cell.2012.10.014	http://dx.doi.org/10.1016/j.cell.2012.10.014			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	029WY	23101617	Bronze			2023-01-03	WOS:000310529300002
J	Han, HJ; Kass, PH; Wilsey, BL; Li, CS				Han, Huijun; Kass, Philip H.; Wilsey, Barth L.; Li, Chin-Shang			Individual and County-Level Factors Associated with Use of Multiple Prescribers and Multiple Pharmacies to Obtain Opioid Prescriptions in California	PLOS ONE			English	Article							NEIGHBORHOOD SOCIOECONOMIC-STATUS; CORONARY-HEART-DISEASE; ILLICIT DRUG-USE; INJECTION CESSATION; ADOLESCENT ALCOHOL; MARIJUANA USE; CHRONIC PAIN; RISK; DISADVANTAGE; ENVIRONMENT	Use of multiple prescribers and pharmacies is a means by which some individuals misuse opioids. Community characteristics may be important determinants of the likelihood of this phenomenon independent of individual-level factors. This was a retrospective cohort study with individual-level data derived from California's statewide prescription drug monitoring program (PDMP) and county-level socioeconomic status (SES) data derived from the United States Census. Zero-truncated negative binomial (ZTNB) regression was used to model the association of individual factors (age, gender, drug schedule and drug dose type) and county SES factors (ethnicity, adult educational attainment, median household income, and physician availability) with the number of prescribers and the number of pharmacies that an individual used during a single year (2006). The incidence rates of new prescriber use and new pharmacy use for opioid prescriptions declined across increasing age groups. Males had a lower incidence rate of new prescriber use and new pharmacy use than females. The total number of licensed physicians and surgeons in a county was positively, linearly, and independently associated with the number of prescribers and pharmacies that individuals used for prescription opioids. In summary, younger age, female gender, and living in counties with more licensed physicians and surgeons were associated with use of more prescribers and/or more pharmacies for obtaining prescription opioids.	[Kass, Philip H.; Li, Chin-Shang] Univ Calif Davis, Dept Populat Hlth & Reprod, Davis, CA 95616 USA; [Han, Huijun] Univ Calif Davis, Dept Publ Hlth Sci, Davis, CA 95616 USA; [Wilsey, Barth L.] Univ Calif Davis, Med Ctr, Dept Phys Med & Rehabil, Davis, CA 95616 USA; [Wilsey, Barth L.] Univ Calif Davis, Med Ctr, VA No Calif Hlth Care Syst, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Kass, PH (corresponding author), Univ Calif Davis, Dept Populat Hlth & Reprod, Davis, CA 95616 USA.	phkass@ucdavis.edu			Robert Wood Johnson Foundation; National Center for Research Resources, a component of the National Institutes of Health (NIH) [UL1 RR024146]; NIH; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024146] Funding Source: NIH RePORTER	Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); National Center for Research Resources, a component of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Funding for this project was provided by the Robert Wood Johnson Foundation. Database architect support was derived through Grant Number UL1 RR024146 from the National Center for Research Resources, a component of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research. This research and its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson T.L., 2001, ENCY CRIMINOLOGY DEV, V4, P286; Boardman JD, 2001, J HEALTH SOC BEHAV, V42, P151, DOI 10.2307/3090175; Braveman PA, 2005, JAMA-J AM MED ASSOC, V294, P2879, DOI 10.1001/jama.294.22.2879; Chichlowska KL, 2008, PSYCHOSOM MED, V70, P986, DOI 10.1097/PSY.0b013e318183a491; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Crum RM, 1996, DRUG ALCOHOL DEPEN, V43, P155, DOI 10.1016/S0376-8716(96)01298-7; Curtis LH, 2006, HEALTH SERV RES, V41, P837, DOI 10.1111/j.1475-6773.2006.00511.x; Davis WR, 2008, DRUG ALCOHOL DEPEN, V92, P267, DOI 10.1016/j.drugalcdep.2007.08.008; EPA, 1999, FED REG, V74; Food and Drug Administration, 2009, JOINT M DRUG SAF RIS; Franks P, 2010, ANN FAM MED, V8, P447, DOI 10.1370/afm.1167; Furr-Holden CDM, 2011, J STUD ALCOHOL DRUGS, V72, P371, DOI 10.15288/jsad.2011.72.371; Galea S, 2003, J URBAN HEALTH, V80, P50; Genberg BL, 2011, ADDICTION, V106, P1966, DOI 10.1111/j.1360-0443.2011.03501.x; Green TC, 2009, DRUG ALCOHOL DEPEN, V103, P65, DOI 10.1016/j.drugalcdep.2009.03.014; Grow HMG, 2010, SOC SCI MED, V71, P584, DOI 10.1016/j.socscimed.2010.04.018; Hall AJ, 2008, JAMA-J AM MED ASSOC, V300, P2613, DOI 10.1001/jama.2008.802; Institute of Medicine, 2011, REL PAIN AM BLUEPR T; Ives TJ, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-46; Kim D, 2010, CANCER-AM CANCER SOC, V116, P4187, DOI 10.1002/cncr.25195; Lineberry TW, 2004, MAYO CLIN PROC, V79, P1031, DOI 10.4065/79.8.1031; Mallinckrodt C H, 2001, J Biopharm Stat, V11, P9, DOI 10.1081/BIP-100104194; Manchikanti Laxmaiah, 2007, J Opioid Manag, V3, P89; Nandi A, 2010, AM J EPIDEMIOL, V171, P391, DOI 10.1093/aje/kwp416; National Center for Health Statistics, 2006, HLTH US 2006 CHARTB, P68; Pradel V, 2009, PHARMACOEPIDEM DR S, V18, P36, DOI 10.1002/pds.1681; RAND California, 2006, PHYS SURG CAL; Roux AVD, 2001, NEW ENGL J MED, V345, P99, DOI 10.1056/NEJM200107123450205; Rustoen T, 2005, CLIN J PAIN, V21, P513, DOI 10.1097/01.ajp.0000146217.31780.ef; SAMHSA, 2009, NSDUH SER; Schroeder JR, 2001, ANN EPIDEMIOL, V11, P389, DOI 10.1016/S1047-2797(01)00225-3; Sellstrom E, 2011, HEALTH PLACE, V17, P551, DOI 10.1016/j.healthplace.2010.12.013; Simoni-Wastila L, 2004, AM J PUBLIC HEALTH, V94, P266, DOI 10.2105/AJPH.94.2.266; Simoni-Wastila L, 2004, SUBST USE MISUSE, V39, P1, DOI 10.1081/JA-120027764; Streiner DL, 2002, CAN J PSYCHIAT, V47, P68; Substance Abuse and Mental Health Services Administration, 2007, NSDUH SER H; Substance Abuse and Mental Health Services Administration, 2007, NSDUH REP ILL DRUG U; Substance Abuse and Mental Health Services Administration, 2010, NSDUH SER H A, VH-38A; Sunder PK, 2007, AM J COMMUN PSYCHOL, V40, P167, DOI 10.1007/s10464-007-9135-y; Sundquist K, 2004, AM J EPIDEMIOL, V159, P655, DOI 10.1093/aje/kwh096; *US CENS BUR, 2006, AM COMM SURV; Von Korff M, 2008, CLIN J PAIN, V24, P521, DOI 10.1097/AJP.0b013e318169d03b; Weisner CM, 2009, PAIN, V145, P287, DOI 10.1016/j.pain.2009.05.006; White Alan G, 2005, J Manag Care Pharm, V11, P469; White AG, 2009, AM J MANAG CARE, V15, P897; Wilsey BL, 2010, DRUG ALCOHOL DEPEN, V112, P99, DOI 10.1016/j.drugalcdep.2010.05.007; Wilson N, 2005, AM J HEALTH PROMOT, V20, P11, DOI 10.4278/0890-1171-20.1.11; Winstanley EL, 2008, DRUG ALCOHOL DEPEN, V92, P173, DOI 10.1016/j.drugalcdep.2007.07.012	48	11	11	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2012	7	9							e46246	10.1371/journal.pone.0046246	http://dx.doi.org/10.1371/journal.pone.0046246			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	016YP	23049992	Green Published, gold, Green Submitted			2023-01-03	WOS:000309556100164
J	Tanser, F; Barnighausen, T; Grapsa, E; Zaidi, J; Newell, ML				Tanser, Frank; Baernighausen, Till; Grapsa, Erofili; Zaidi, Jaffer; Newell, Marie-Louise			High Coverage of ART Associated with Decline in Risk of HIV Acquisition in Rural KwaZulu-Natal, South Africa	SCIENCE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; COHORT PROFILE; PREVENTION; POPULATION; INFECTIONS; IMPACT; EPIDEMIOLOGY; PREVALENCE; COMMUNITY; PROGRAM	The landmark HIV Prevention Trials Network (HPTN) 052 trial in HIV-discordant couples demonstrated unequivocally that treatment with antiretroviral therapy (ART) substantially lowers the probability of HIV transmission to the HIV-uninfected partner. However, it has been vigorously debated whether substantial population-level reductions in the rate of new HIV infections could be achieved in "real-world" sub-Saharan African settings where stable, cohabiting couples are often not the norm and where considerable operational challenges exist to the successful and sustainable delivery of treatment and care to large numbers of patients. We used data from one of Africa's largest population-based prospective cohort studies (in rural KwaZulu-Natal, South Africa) to follow up a total of 16,667 individuals who were HIV-uninfected at baseline, observing individual HIV seroconversions over the period 2004 to 2011. Holding other key HIV risk factors constant, individual HIV acquisition risk declined significantly with increasing ART coverage in the surrounding local community. For example, an HIV-uninfected individual living in a community with high ART coverage (30 to 40% of all HIV-infected individuals on ART) was 38% less likely to acquire HIV than someone living in a community where ART coverage was low (<10% of all HIV-infected individuals on ART).	[Tanser, Frank; Baernighausen, Till; Grapsa, Erofili; Zaidi, Jaffer; Newell, Marie-Louise] Univ KwaZulu Natal, Africa Ctr Hlth & Populat Studies, Durban, South Africa; [Baernighausen, Till] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA; [Newell, Marie-Louise] UCL, Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London, England	University of Kwazulu Natal; Harvard University; Harvard T.H. Chan School of Public Health; University of London; University College London	Tanser, F (corresponding author), Univ KwaZulu Natal, Africa Ctr Hlth & Populat Studies, Durban, South Africa.	tanserf@africacentre.ac.za	Tanser, Frank/ABE-8326-2021; Newell, Marie-Louise/AAE-8222-2019; Bärnighausen, Till/Y-2388-2019	Newell, Marie-Louise/0000-0002-1074-7699; Tanser, Frank/0000-0001-9797-0000	National Institute of Child Health and Human Development [1R01-HD058482-01]; Wellcome Trust, UK [082384/Z/07/Z]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD058482] Funding Source: NIH RePORTER	National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Wellcome Trust, UK(Wellcome Trust); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	Supported by grant 1R01-HD058482-01 from the National Institute of Child Health and Human Development. Funding for the Africa Centre's Demographic Surveillance Information System and Population-Based HIV Survey was received from the Wellcome Trust, UK (grant 082384/Z/07/Z).	Anglemyer A, 2011, COCHRANE DB SYST REV, V2011; [Anonymous], 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003255, DOI 10.1002/14651858.CD003255]; Barnighausen T, 2008, AIDS, V22, P139, DOI 10.1097/QAD.0b013e3282f2ef43; Bor J, 2013, SCIENCE, V339, P961, DOI 10.1126/science.1230413; Budtz-Jorgensen E, 2003, STAT MED, V22, P3089, DOI 10.1002/sim.1541; Castel A., 2011, 18 ANN C RETR OPP IN; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Das M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011068; Eaton JW, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001245; Fang CT, 2004, J INFECT DIS, V190, P879, DOI 10.1086/422601; Granich R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030216; Granich R, 2011, CURR HIV RES, V9, P446, DOI 10.2174/157016211798038597; Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9; Herbst AJ, 2009, B WORLD HEALTH ORGAN, V87, P754, DOI 10.2471/BLT.08.058982; Hontelez JAC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021919; Houlihan CF, 2011, INT J EPIDEMIOL, V40, P318, DOI 10.1093/ije/dyp402; Katz MH, 2002, AM J PUBLIC HEALTH, V92, P388, DOI 10.2105/AJPH.92.3.388; Law MG, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-10; McGrath N, 2012, 19 INT AIDS C WASH D; Montaner JSG, 2010, LANCET, V376, P532, DOI 10.1016/S0140-6736(10)60936-1; Mutevedzi PC, 2010, B WORLD HEALTH ORGAN, V88, P593, DOI 10.2471/BLT.09.069419; Porco TC, 2004, AIDS, V18, P81, DOI 10.1097/00002030-200401020-00010; Shelton JD, 2011, SCIENCE, V334, P1645, DOI 10.1126/science.1212353; Smith K, 2011, CURR OPIN HIV AIDS, V6, P315, DOI 10.1097/COH.0b013e32834788e7; South African National Department of Health, 2010, NAT ANT TREATM GUID; SUSSER M, 1991, AM J EPIDEMIOL, V133, P635, DOI 10.1093/oxfordjournals.aje.a115939; Tanser F, 2008, INT J EPIDEMIOL, V37, P956, DOI 10.1093/ije/dym211; Tanser F, 2011, LANCET, V378, P247, DOI 10.1016/S0140-6736(11)60779-4; Tanser F, 2009, INT J EPIDEMIOL, V38, P1008, DOI 10.1093/ije/dyp148; UNAIDS, 2012, TOG WE WILL END AIDS; United Nations General Assembly, 2011, POL DECL HIV AIDS IN; Venkatesh KK, 2011, AIDS, V25, P1939, DOI 10.1097/QAD.0b013e32834b4ced; Wood E, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1649	33	585	591	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 22	2013	339	6122					966	971		10.1126/science.1228160	http://dx.doi.org/10.1126/science.1228160			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	092UX	23430656	Green Accepted			2023-01-03	WOS:000315149600052
J	Lim, SG; Venkatraman, SS; Burnett, JC; Chen, HH				Lim, Soo Ghim; Venkatraman, Subbu S.; Burnett, John C., Jr.; Chen, Horng H.			In-Vivo Evaluation of an In Situ Polymer Precipitation Delivery System for a Novel Natriuretic Peptide	PLOS ONE			English	Article							PHASE INVERSION DYNAMICS; DRUG-DELIVERY; ATRIAL; NESIRITIDE; LEUPROLIDE; EFFICACY; IMPLANT	This study reports on the release of a novel natriuretic peptide, CD-NP, from an in situ polymer precipitation delivery system. Following extensive screening of in-vitro release profiles, an in-vivo evaluation of the efficacy of the delivery system was carried out in Wistar rats. Gel injection was performed subcutaneously on the back of the rats. A secondary messenger, cyclic Guanosine 3'5' Monophosphate (cGMP), was tested for verification of CD-NP bioactivity, in addition to direct measurements of CD-NP levels in plasma and urine using a radio-immuno assay. Plasma evaluation showed an elevated level of CD-NP over 3 weeks' duration. Unexpectedly, plasma cGMP level followed a decreasing trend over the same duration despite high CD-NP level. Loss of drug bioactivity was ruled out as a high level of CD-NP and cGMP excretion was observed in the treatment group as compared to baseline readings. This unexpected low-plasma cGMP levels and high-urinary cGMP excretion suggest that there might be other compensatory responses to regulation of the CDNP bioactivity as a result of the high drug dosing. The results stress the importance of assessing the overall bioactivity of released drug (in-vivo) concurrently in addition to measuring its concentrations, to determine the correct release profile.	[Lim, Soo Ghim; Venkatraman, Subbu S.] Nanyang Technol Univ, Sch Mat Sci & Engn, Singapore 639798, Singapore; [Burnett, John C., Jr.; Chen, Horng H.] Mayo Clin, Div Cardiovasc Dis, Cardiorenal Res Lab, Rochester, MN 55905 USA	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Mayo Clinic	Chen, HH (corresponding author), Mayo Clin, Div Cardiovasc Dis, Cardiorenal Res Lab, Rochester, MN 55905 USA.	chen.horng@mayo.edu	Venkatraman, Subramanian/A-2228-2011	Venkatraman, Subramanian/0000-0002-8693-1070	National Institute of Health [RO1 HL36634, R01 HL83231, HL101439, PO1 HL76611]; Mayo Foundation; National Research Foundation - Competitive Research Programme; Singapore Economic Development Board - The Strategic Attachment and Training Programme; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P20HL101439, P01HL076611, R01HL036634, R01HL083231] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mayo Foundation; National Research Foundation - Competitive Research Programme; Singapore Economic Development Board - The Strategic Attachment and Training Programme; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the following grants: The National Institute of Health, http://www.nih.gov/(RO1 HL36634, R01 HL83231, HL101439-and PO1 HL76611); The Mayo Foundation, http://www.mayoclinic.com/; The National Research Foundation - Competitive Research Programme, http://www.nrf.gov.sg/; Singapore Economic Development Board - The Strategic Attachment and Training Programme, www.edb.gov.sg/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akesson B, 1994, ARBETE OCH HALSA, P1; Andersen F, 2003, INT J TOXICOLOGY; Arora RR, 2006, AM HEART J, V152, P1084, DOI 10.1016/j.ahj.2006.07.002; Brodbeck KJ, 1999, J CONTROL RELEASE, V62, P333, DOI 10.1016/S0168-3659(99)00159-5; BROWN RE, 1989, ANAL BIOCHEM, V180, P136, DOI 10.1016/0003-2697(89)90101-2; CLAVELL AL, 1993, AM J PHYSIOL, V264, pR290, DOI 10.1152/ajpregu.1993.264.2.R290; Del Ry S, 2005, CLIN CHEM LAB MED, V43, P641, DOI 10.1515/CCLM.2005.110; Dickey DM, 2008, J BIOL CHEM, V283, P35003, DOI 10.1074/jbc.M804538200; Dunn R.L., 1990, US Patent, Patent No. [4 938 763, 4938763, US patent no. 4,938,763]; Evans D, 2012, US Patent, Patent No. [us 20120178689, 20120178689]; Graham PD, 1999, J CONTROL RELEASE, V58, P233, DOI 10.1016/S0168-3659(98)00158-8; Horio T, 2003, ENDOCRINOLOGY, V144, P2279, DOI 10.1210/en.2003-0128; HUNT PJ, 1994, J CLIN ENDOCR METAB, V78, P1428, DOI 10.1210/jc.78.6.1428; Igaki T, 1998, HYPERTENS RES-CLIN E, V21, P7, DOI 10.1291/hypres.21.7; Kim TK, 2002, J PHARM PHARMACOL, V54, P897, DOI 10.1211/002235702760089009; Kohzu H, 2007, J CARD FAIL, V13, pS40; La Villa G, 1998, CLIN SCI, V95, P595; Lee CYW, 2007, HEART FAIL REV, V12, P131, DOI 10.1007/s10741-007-9016-3; LEE KP, 1987, FUND APPL TOXICOL, V9, P222, DOI 10.1016/0272-0590(87)90045-5; Lisy O, 2003, J AM COLL CARDIOL, V41, p312A; Lisy O, 2008, J AM COLL CARDIOL, V52, P60, DOI 10.1016/j.jacc.2008.02.077; Lloyd-Jones D, 2010, CIRCULATION, V121, pE46, DOI 10.1161/CIRCULATIONAHA.109.192667; McKie Paul M, 2010, Curr Heart Fail Rep, V7, P93, DOI 10.1007/s11897-010-0016-6; MISONO KS, 1984, BIOCHEM BIOPH RES CO, V123, P444, DOI 10.1016/0006-291X(84)90250-X; Packhaeuser CB, 2004, EUR J PHARM BIOPHARM, V58, P445, DOI 10.1016/j.ejpb.2004.03.003; Peacock WF, 2004, J CARD FAIL, V10, P120, DOI 10.1016/j.cardfail.2003.08.012; Ravivarapu HB, 2000, INT J PHARM, V194, P181, DOI 10.1016/S0378-5173(99)00371-3; Royals MA, 1999, J BIOMED MATER RES, V45, P231, DOI 10.1002/(SICI)1097-4636(19990605)45:3<231::AID-JBM11>3.0.CO;2-H; Sartor O, 2003, UROLOGY, V61, P25, DOI 10.1016/S0090-4295(02)02396-8; Sartor O, 2006, EUR UROL SUPPL, V5, P905, DOI 10.1016/j.eursup.2006.08.006; Shah SJ, 2010, J CARD FAIL, V16, P720, DOI 10.1016/j.cardfail.2010.04.008; Socki T, 2005, J AM COLL CARDIOL, V45, P608, DOI 10.1016/j.jacc.2004.10.067; Wei CM, 1993, AM J PHYSL HEART CIR, P264	33	1	1	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2013	8	2							e52484	10.1371/journal.pone.0052484	http://dx.doi.org/10.1371/journal.pone.0052484			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	092YP	23441143	gold, Green Published			2023-01-03	WOS:000315159200001
J	Shroff, RC; Price, KL; Kolatsi-Joannou, M; Todd, AF; Wells, D; Deanfield, J; Johnson, RJ; Rees, L; Woolf, AS; Long, DA				Shroff, Rukshana C.; Price, Karen L.; Kolatsi-Joannou, Maria; Todd, Alexandra F.; Wells, David; Deanfield, John; Johnson, Richard J.; Rees, Lesley; Woolf, Adrian S.; Long, David A.			Circulating Angiopoietin-2 Is a Marker for Early Cardiovascular Disease in Children on Chronic Dialysis	PLOS ONE			English	Article							PULSE-WAVE VELOCITY; ENDOTHELIAL FUNCTION; ARTERIAL STIFFNESS; YOUNG-ADULTS; URIC-ACID; EXPRESSION; RELEASE; TIE-2; CALCIFICATION; ANGIOGENESIS	Cardiovascular disease (CVD) is increasingly recognised as a complication of childhood chronic kidney disease (CKD) even in the absence of diabetes and hypertension. We hypothesized that an alteration in angiopoietin-1 and -2, growth factors which regulate endothelial and vascular function could be involved. We report that the endothelial survival factor, angiopoietin-1 is low in children with pre-dialysis CKD whereas the pro-inflammatory angiopoietin-2 is elevated in children on dialysis. In dialysis patients, angiopoietin-2 positively correlated with time on dialysis, systolic blood pressure, and carotid artery intima media thickness. Elevated angiopoietin-2 levels in dialysis versus pre-dialysis CKD patients were also associated with an anti-angiogenic (high soluble VEGFR-1 and low VEGF-A) and pro-inflammatory (high urate, E-selectin, P-selectin and VCAM-1) milieu. Ang-2 was immunodetected in arterial biopsy samples whilst the expression of VEGF-A was significantly downregulated in dialysis patients. Serum urate correlated with angiopoietin-2 levels in dialysis patients and addition of uric acid was able to induce rapid release of angiopoietin-2 from cultured endothelial cells. Thus, angiopoietin-2 is a marker for cardiovascular disease in children on chronic dialysis and may act as an anti-angiogenic and pro-inflammatory effector in this context. The possibility that the release of angiopoietin-2 from endothelia is mediated by urate should be explored further.	[Shroff, Rukshana C.; Price, Karen L.; Kolatsi-Joannou, Maria; Todd, Alexandra F.; Rees, Lesley; Long, David A.] UCL Inst Child Hlth, Nephrourol Unit, London, England; [Shroff, Rukshana C.; Price, Karen L.; Kolatsi-Joannou, Maria; Todd, Alexandra F.; Rees, Lesley; Long, David A.] Great Ormond St Hosp Sick Children, London WC1N 3JH, England; [Wells, David] Great Ormond St Hosp Sick Children, Dept Chem Pathol, London WC1N 3JH, England; [Deanfield, John] UCL, Natl Ctr Cardiovasc Dis Prevent & Outcomes, London, England; [Johnson, Richard J.] Univ Colorado, Div Renal Dis & Hypertens, Denver, CO 80202 USA; [Woolf, Adrian S.] Univ Manchester, Inst Human Dev, Manchester, Lancs, England; [Woolf, Adrian S.] Royal Manchester Childrens Hosp, Manchester M27 1HA, Lancs, England	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; University of Colorado System; University of Colorado Denver; University of Manchester; Royal Manchester Children's Hospital	Long, DA (corresponding author), UCL Inst Child Hlth, Nephrourol Unit, London, England.	d.long@ucl.ac.uk	Price, Karen L/A-5323-2009; Long, David/I-3254-2019; Shroff, Rukshana C/C-7347-2008; Rees, Lesley/C-5027-2008; Shroff, Rukshana/AAG-5383-2019; Woolf, Adrian S./AAZ-1075-2020	Long, David/0000-0001-6580-3435; Shroff, Rukshana C/0000-0001-8501-1072; Shroff, Rukshana/0000-0001-8501-1072; Woolf, Adrian S./0000-0001-5541-1358; Deanfield, John/0000-0001-8806-6052; Price, Karen/0000-0002-8113-1461; Todd, Angelique/0000-0002-9207-4925	Great Ormond Street Hospital; UCL Institute of Child Health Biomedical Research Centre; Kids Kidney Research; Kidney Research UK Senior Non-Clinical Fellowship; Medical Research Council New Investigator Award; Manchester Biomedical Research Centre; MRC [MR/J003638/1] Funding Source: UKRI; Kidney Research UK [RP18/2011, SF1/2008] Funding Source: researchfish; Medical Research Council [MR/J003638/1] Funding Source: researchfish	Great Ormond Street Hospital; UCL Institute of Child Health Biomedical Research Centre; Kids Kidney Research(Kidney Research UK (KRUK)); Kidney Research UK Senior Non-Clinical Fellowship(Kidney Research UK (KRUK)); Medical Research Council New Investigator Award(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Manchester Biomedical Research Centre(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Kidney Research UK(Kidney Research UK (KRUK)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by a project grant from the Great Ormond Street Hospital and UCL Institute of Child Health Biomedical Research Centre (to D. A. L., R. C. S. and L. R.) and a studentship from Kids Kidney Research (to L. R., D. A. L. and R. C. S.). D. A. L. is supported by a Kidney Research UK Senior Non-Clinical Fellowship and a Medical Research Council New Investigator Award. A. S. W. acknowledges grant support from the Manchester Biomedical Research Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	COLE TJ, 1992, STAT MED, V11, P1305, DOI 10.1002/sim.4780111005; Covic A, 2006, NEPHROL DIAL TRANSPL, V21, P729, DOI 10.1093/ndt/gfi196; David S, 2012, NEPHROL DIAL TRANSPL, V27, P1867, DOI 10.1093/ndt/gfr551; David S, 2010, NEPHROL DIAL TRANSPL, V25, P2571, DOI 10.1093/ndt/gfq060; David S, 2009, AM J KIDNEY DIS, V53, P770, DOI 10.1053/j.ajkd.2008.11.030; Davis S, 2003, NAT STRUCT BIOL, V10, P38, DOI 10.1038/nsb880; Di Marco GS, 2009, J AM SOC NEPHROL, V20, P2235, DOI 10.1681/ASN.2009010061; Dursun I, 2009, NEPHROL DIAL TRANSPL, V24, P2511, DOI 10.1093/ndt/gfp066; Feig DI, 2008, NEW ENGL J MED, V359, P1811, DOI 10.1056/NEJMra0800885; Felcht M, 2012, J CLIN INVEST, V122, P1991, DOI 10.1172/JCI58832; Fiedler U, 2004, BLOOD, V103, P4150, DOI 10.1182/blood-2003-10-3685; Fiedler U, 2006, NAT MED, V12, P235, DOI 10.1038/nm1351; Futrakul N, 2008, RENAL FAILURE, V30, P215, DOI 10.1080/08860220701813335; Goldstein SL, 2006, CLIN J AM SOC NEPHRO, V1, P979, DOI 10.2215/CJN.02291205; Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003; Hubbard NE, 2005, CELL IMMUNOL, V234, P102, DOI 10.1016/j.cellimm.2005.06.001; Jourdan C, 2005, J HYPERTENS, V23, P1707, DOI 10.1097/01.hjh.0000178834.26353.d5; Kari JA, 1997, KIDNEY INT, V52, P468, DOI 10.1038/ki.1997.354; Kim KT, 2005, J BIOL CHEM, V280, P20126, DOI 10.1074/jbc.M500292200; Korff T, 2012, CARDIOVASC RES, V94, P510, DOI 10.1093/cvr/cvs124; Kracht D, 2011, AM J HYPERTENS, V24, P1294, DOI 10.1038/ajh.2011.147; Krausz S, 2012, ANN RHEUM DIS, V71, P1402, DOI 10.1136/annrheumdis-2011-200718; Kuo MC, 2008, J AM SOC NEPHROL, V19, P2321, DOI 10.1681/ASN.2007111200; Lee SW, 2007, INT J MOL MED, V19, P445; Li JJ, 2001, THROMB HAEMOSTASIS, V85, P204, DOI 10.1055/s-0037-1615677; Lieb W, 2010, CIRC-CARDIOVASC GENE, V3, P300, DOI 10.1161/CIRCGENETICS.109.914556; Lilien MR, 2009, NAT REV NEPHROL, V5, P229, DOI 10.1038/nrneph.2009.10; Lilien MR, 2005, PEDIATR NEPHROL, V20, P200, DOI 10.1007/s00467-004-1718-3; Lim HS, 2005, ATHEROSCLEROSIS, V180, P113, DOI 10.1016/j.atherosclerosis.2004.11.004; Litwin M, 2005, J AM SOC NEPHROL, V16, P1494, DOI 10.1681/ASN.2004110932; London GM, 2002, NEPHROL DIAL TRANSPL, V17, P1713, DOI 10.1093/ndt/17.10.1713; Long DA, 2001, J AM SOC NEPHROL, V12, P2721, DOI 10.1681/ASN.V12122721; Long DA, 2008, KIDNEY INT, V74, P300, DOI 10.1038/ki.2008.179; Long DA, 2012, NAT REV NEPHROL, V8, P244, DOI 10.1038/nrneph.2011.219; Lukasz A, 2008, CRIT CARE, V12, DOI 10.1186/cc6966; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Matsunaga N, 2011, MOL PHARMACOL, V79, P34, DOI 10.1124/mol.110.068064; McDonald SP, 2004, NEW ENGL J MED, V350, P2654, DOI 10.1056/NEJMoa031643; Mestas J, 2008, TRENDS CARDIOVAS MED, V18, P228, DOI 10.1016/j.tcm.2008.11.004; Mitsnefes MM, 2006, PEDIATR NEPHROL, V21, P1167, DOI 10.1007/s00467-006-0180-9; Murdoch C, 2007, J IMMUNOL, V178, P7405, DOI 10.4049/jimmunol.178.11.7405; Nakayama T, 2010, AM J PATHOL, V176, P2198, DOI 10.2353/ajpath.2010.090316; Oh J, 2002, CIRCULATION, V106, P100, DOI 10.1161/01.CIR.0000020222.63035.C0; Otani A, 2001, DIABETES, V50, P867, DOI 10.2337/diabetes.50.4.867; Phelps ED, 2006, AM J PHYSIOL-CELL PH, V290, pC352, DOI 10.1152/ajpcell.00050.2005; Price KL, 2006, J AM SOC NEPHROL, V17, P1791, DOI 10.1681/ASN.2006030264; Reusz GS, 2010, HYPERTENSION, V56, P217, DOI 10.1161/HYPERTENSIONAHA.110.152686; Scholz A, 2011, BLOOD, V118, P5050, DOI 10.1182/blood-2011-03-343293; Shroff RC, 2008, CIRCULATION, V118, P1748, DOI 10.1161/CIRCULATIONAHA.108.783738; Shroff RC, 2007, J AM SOC NEPHROL, V18, P2996, DOI 10.1681/ASN.2006121397; Silverstein DM, 2011, PEDIATR NEPHROL, V26, P1123, DOI 10.1007/s00467-011-1875-0; Yu MA, 2010, J HYPERTENS, V28, P1234, DOI 10.1097/HJH.0b013e328337da1d; Yuan HT, 2000, J AM SOC NEPHROL, V11, P1055, DOI 10.1681/ASN.V1161055	53	33	34	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2013	8	2							e56273	10.1371/journal.pone.0056273	http://dx.doi.org/10.1371/journal.pone.0056273			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	086CJ	23409162	Green Submitted, gold, Green Published			2023-01-03	WOS:000314660300069
J	Kouwer, PHJ; Koepf, M; Le Sage, VAA; Jaspers, M; van Buul, AM; Eksteen-Akeroyd, ZH; Woltinge, T; Schwartz, E; Kitto, HJ; Hoogenboom, R; Picken, SJ; Nolte, RJM; Mendes, E; Rowan, AE				Kouwer, Paul H. J.; Koepf, Matthieu; Le Sage, Vincent A. A.; Jaspers, Maarten; van Buul, Arend M.; Eksteen-Akeroyd, Zaskia H.; Woltinge, Tim; Schwartz, Erik; Kitto, Heather J.; Hoogenboom, Richard; Picken, Stephen J.; Nolte, Roeland J. M.; Mendes, Eduardo; Rowan, Alan E.			Responsive biomimetic networks from polyisocyanopeptide hydrogels	NATURE			English	Article							ELASTICITY; MEDICINE; ACTIN	Mechanical responsiveness is essential to all biological systems down to the level of tissues and cells(1,2). The intra- and extracellular mechanics of such systems are governed by a series of proteins, such as microtubules, actin, intermediate filaments and collagen(3,4). As a general design motif, these proteins self-assemble into helical structures and superstructures that differ in diameter and persistence length to cover the full mechanical spectrum(1). Gels of cytoskeletal proteins display particular mechanical responses (stress stiffening) that until now have been absent in synthetic polymeric and low-molar-mass gels. Here we present synthetic gels that mimic in nearly all aspects gels prepared from intermediate filaments. They are prepared from polyisocyanopeptides(5-7) grafted with oligo(ethylene glycol) side chains. These responsive polymers possess a stiff and helical architecture, and show a tunable thermal transition where the chains bundle together to generate transparent gels at extremely low concentrations. Using characterization techniques operating at different length scales (for example, macroscopic rheology, atomic force microscopy and molecular force spectroscopy) combined with an appropriate theoretical network model(8-10), we establish the hierarchical relationship between the bulk mechanical properties and the single-molecule parameters. Our results show that to develop artificial cytoskeletal or extracellular matrix mimics, the essential design parameters are not only the molecular stiffness, but also the extent of bundling. In contrast to the peptidic materials, our polyisocyanide polymers are readily modified, giving a starting point for functional biomimetic hydrogels with potentially a wide variety of applications(11-14), in particular in the biomedical field.	[Kouwer, Paul H. J.; Koepf, Matthieu; Le Sage, Vincent A. A.; Jaspers, Maarten; van Buul, Arend M.; Eksteen-Akeroyd, Zaskia H.; Woltinge, Tim; Schwartz, Erik; Kitto, Heather J.; Hoogenboom, Richard; Nolte, Roeland J. M.; Rowan, Alan E.] Radboud Univ Nijmegen, Inst Mol & Mat, Dept Mol Mat, NL-6525 AJ Nijmegen, Netherlands; [Picken, Stephen J.; Mendes, Eduardo] Delft Univ Technol, Dept NanoStruct Mat, NL-2628 BL Delft, Netherlands	Radboud University Nijmegen; Delft University of Technology	Kouwer, PHJ (corresponding author), Radboud Univ Nijmegen, Inst Mol & Mat, Dept Mol Mat, Heyendaalseweg 135, NL-6525 AJ Nijmegen, Netherlands.	p.kouwer@science.ru.nl; a.rowan@science.ru.nl	Schwartz, Erik/AAS-9329-2021; Mendes, Eduardo/K-7280-2012; Schwartz, Erik/C-7346-2011; Nolte, Roeland/C-9930-2013; Eksteen-Akeroyd, Zaskia H/F-2179-2015; Kouwer, Paul H. J./B-4847-2008; Rowan, Alan E/F-9702-2015; Hoogenboom, Richard/B-8977-2008	Mendes, Eduardo/0000-0002-7519-0668; Nolte, Roeland/0000-0002-5612-7815; Eksteen-Akeroyd, Zaskia H/0000-0002-5999-3110; Kouwer, Paul H. J./0000-0002-2760-191X; Rowan, Alan E/0000-0003-0728-3851; Hoogenboom, Richard/0000-0001-7398-2058; Picken, Stephen/0000-0002-6003-518X	Technology Foundation STW; Council for the Chemical Sciences of the Netherlands Organisation for Scientific Research [NWO-CW-7005644]; NRSCC; Royal Academy for Arts and Sciences; EU [PITN-CT-2007-215851, PITN-CT-2009-238177]	Technology Foundation STW(Technologiestichting STW); Council for the Chemical Sciences of the Netherlands Organisation for Scientific Research; NRSCC; Royal Academy for Arts and Sciences; EU(European Commission)	We thank B. Norder for assistance with rheological experiments, C. Broersz for support with nonlinear rheology, F. MacKintosh for discussions on the interpretation of the semi-flexible polymer network theory and E. Cator for work on the statistical analysis of the AFM images. We acknowledge financial support from Technology Foundation STW, the Council for the Chemical Sciences of the Netherlands Organisation for Scientific Research (NWO-CW-7005644), NRSCC, the Royal Academy for Arts and Sciences and EU projects Hierarchy (PITN-CT-2007-215851) and Superior (PITN-CT-2009-238177).	Bathe M, 2008, BIOPHYS J, V94, P2955, DOI 10.1529/biophysj.107.119743; Broedersz CP, 2011, SOFT MATTER, V7, P3186, DOI 10.1039/c0sm01004a; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; Cornelissen JJLM, 2001, SCIENCE, V293, P676, DOI 10.1126/science.1062224; Fernandez P, 2006, BIOPHYS J, V90, P3796, DOI 10.1529/biophysj.105.072215; Fernandez-Gonzalez R, 2012, CELL, V149, P965, DOI 10.1016/j.cell.2012.05.006; Gardel ML, 2004, SCIENCE, V304, P1301, DOI 10.1126/science.1095087; Grason GM, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.098101; Han S, 2003, MACROMOLECULES, V36, P8312, DOI 10.1021/ma0347971; Hirst AR, 2008, ANGEW CHEM INT EDIT, V47, P8002, DOI 10.1002/anie.200800022; Huisman EM, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.208103; Kamm R. D., 2006, CYTOSKELETAL MECH MO, P1; Keereweer B, 2011, FUNCTIONAL SUPRAMOLE, V1, P135; Leterrier JF, 1996, J BIOL CHEM, V271, P15687, DOI 10.1074/jbc.271.26.15687; Lin YC, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.058101; Lutz JF, 2006, MACROMOLECULES, V39, P893, DOI 10.1021/ma0517042; MACKINTOSH FC, 1995, PHYS REV LETT, V75, P4425, DOI 10.1103/PhysRevLett.75.4425; Mason TG, 1998, MACROMOLECULES, V31, P3600, DOI 10.1021/ma970564w; Onck PR, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.178102; Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612; Place ES, 2009, NAT MATER, V8, P457, DOI [10.1038/nmat2441, 10.1038/NMAT2441]; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Rowan A. E, 2011, European Patent, Patent No. [2,287,221, 2287221]; Schwartz E, 2010, CHEM SOC REV, V39, P1576, DOI 10.1039/b922160c; Storm C, 2005, NATURE, V435, P191, DOI 10.1038/nature03521; Tiller JC, 2003, ANGEW CHEM INT EDIT, V42, P3072, DOI 10.1002/anie.200301647; Van Buul A. M, CHEM SCI UNPUB; Wang HM, 2011, SOFT MATTER, V7, P3897, DOI 10.1039/c0sm01405b	28	350	359	30	857	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 31	2013	493	7434					651	655		10.1038/nature11839	http://dx.doi.org/10.1038/nature11839			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	080CU	23354048	Green Published			2023-01-03	WOS:000314219600052
J	Brown, J; Machen, H; Kawaza, K; Mwanza, Z; Iniguez, S; Lang, H; Gest, A; Kennedy, N; Miros, R; Richards-Kortum, R; Molyneux, E; Oden, M				Brown, Jocelyn; Machen, Heather; Kawaza, Kondwani; Mwanza, Zondiwe; Iniguez, Suzanne; Lang, Hans; Gest, Alfred; Kennedy, Neil; Miros, Robert; Richards-Kortum, Rebecca; Molyneux, Elizabeth; Oden, Maria			A High-Value, Low-Cost Bubble Continuous Positive Airway Pressure System for Low-Resource Settings: Technical Assessment and Initial Case Reports	PLOS ONE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; SUPPORT; CPAP	Acute respiratory infections are the leading cause of global child mortality. In the developing world, nasal oxygen therapy is often the only treatment option for babies who are suffering from respiratory distress. Without the added pressure of bubble Continuous Positive Airway Pressure (bCPAP) which helps maintain alveoli open, babies struggle to breathe and can suffer serious complications, and frequently death. A stand-alone bCPAP device can cost $6,000, too expensive for most developing world hospitals. Here, we describe the design and technical evaluation of a new, rugged bCPAP system that can be made in small volume for a cost-of-goods of approximately $350. Moreover, because of its simple design-consumer-grade pumps, medical tubing, and regulators-it requires only the simple replacement of a <$1 diaphragm approximately every 2 years for maintenance. The low-cost bCPAP device delivers pressure and flow equivalent to those of a reference bCPAP system used in the developed world. We describe the initial clinical cases of a child with bronchiolitis and a neonate with respiratory distress who were treated successfully with the new bCPAP device.	[Brown, Jocelyn; Richards-Kortum, Rebecca; Oden, Maria] Rice Univ, Dept Bioengn, Houston, TX 77251 USA; [Machen, Heather] Baylor Coll Med, Dept Pediat Emergency Med, Houston, TX 77030 USA; [Kawaza, Kondwani; Mwanza, Zondiwe; Kennedy, Neil; Molyneux, Elizabeth] Coll Med, Dept Pediat, Blantyre, Malawi; [Kawaza, Kondwani; Mwanza, Zondiwe; Kennedy, Neil; Molyneux, Elizabeth] Queen Elizabeth Cent Hosp, Blantyre, Malawi; [Iniguez, Suzanne] Texas Childrens Hosp, Dept Resp Care, Houston, TX 77030 USA; [Lang, Hans] Coll Med, Dept Pediat, Lilongwe, Malawi; [Lang, Hans] Kamuzu Cent Hosp, Lilongwe, Malawi; [Gest, Alfred] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Miros, Robert] 3rd Stone Design, San Rafael, CA USA	Rice University; Baylor College of Medicine; University of Malawi; University of Malawi; Baylor College of Medicine; University of Malawi; Baylor College of Medicine	Richards-Kortum, R (corresponding author), Rice Univ, Dept Bioengn, Houston, TX 77251 USA.	rkortum@rice.edu	Richards-Kortum, Rebecca R/P-4074-2014	Richards-Kortum, Rebecca R/0000-0003-2347-9467; Kennedy, Neil/0000-0002-6262-2679				Bonner Krista M, 2008, Adv Neonatal Care, V8, P78, DOI 10.1097/01.ANC.0000317256.76201.72; Diblasi RM, 2010, PEDIATR RES, V68, P526, DOI 10.1203/PDR.0b013e3181f985f0; Duke T, 2005, ARCH DIS CHILD-FETAL, V90, P211, DOI 10.1136/adc.2003.048108; Enarson P, 2008, B WORLD HEALTH ORGAN, V86, P344, DOI 10.2471/BLT.07.048017; Howson CP, 2012, BORN TOO SOON GLOBAL, P2; Kamath BD, 2011, PEDIATRICS, V127, P1139, DOI 10.1542/peds.2010-3212; Kaur C, 2008, INDIAN PEDIATR, V45, P312; Koyamaibole L, 2006, J TROP PEDIATRICS, V52, P249, DOI 10.1093/tropej/fmi109; Lawn JE, 2010, SEMIN PERINATOL, V34, P371, DOI 10.1053/j.semperi.2010.09.011; Madhi SA, 2006, DISEASE AND MORTALITY IN SUB-SAHARAN AFRICA, 2ND EDITION, P149; Nowadzky T, 2009, PEDIATRICS, V123, P1534, DOI 10.1542/peds.2008-1279; Urs PS, 2009, INDIAN PEDIATR, V46, P409; Van den Heuvel M, 2011, ANN TROP PAEDIATR, V31, P59, DOI 10.1179/1465328110Y.0000000001; Watson AD., 2010, PREMARKET NOTIFICATI; World Health Organization, 2006, NEON PER MORT COUNTR, P22	15	48	49	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2013	8	1							e53622	10.1371/journal.pone.0053622	http://dx.doi.org/10.1371/journal.pone.0053622			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	077IQ	23372661	Green Published, gold			2023-01-03	WOS:000314021500017
J	Pan, D; Marcato, P; Ahn, DG; Gujar, S; Pan, LZ; Shmulevitz, M; Lee, PWK				Pan, Da; Marcato, Paola; Ahn, Dae-Gyun; Gujar, Shashi; Pan, Lu-Zhe; Shmulevitz, Maya; Lee, Patrick W. K.			Activation of p53 by Chemotherapeutic Agents Enhances Reovirus Oncolysis	PLOS ONE			English	Article							NF-KAPPA-B; APOPTOTIC RESPONSE; PHASE-I; CANCER; THERAPY; CYTOTOXICITY; PROMOTES; ARREST; SPREAD; TRIAL	Mammalian reovirus is a benign virus that possesses the natural ability to preferentially infect and kill cancer cells (reovirus oncolysis). Reovirus exploits aberrant Ras signalling in many human cancers to promote its own replication and spread. In vitro and in vivo studies using reovirus either singly or in combination with anti-cancer drugs have shown very encouraging results. Presently, a number of reovirus combination therapies are undergoing clinical trials for a variety of cancers. Previously we showed that accumulation of the tumor suppressor protein p53 by Nutlin-3a (a specific p53 stabilizer) enhanced reovirus-induced apoptosis, and resulted in significantly higher levels of reovirus dissemination. In this study, we examined the role of p53 in combination therapies involving reovirus and chemotherapeutic drugs. We showed that sublethal concentrations of traditional chemotherapy drugs actinomycin D or etoposide, but not doxorubicin, enhanced reovirus-induced apoptosis in a p53-dependent manner. Furthermore, NF-kappa B activation and expression of p53-target genes (p21 and bax) were important for the p53-dependent enhancement of cell death. Our results show that p53 status affects the efficacy of combination therapy involving reovirus. Choosing the right combination partner for reovirus and a low dosage of the drug may help to both enhance reovirus-induced cancer elimination and reduce drug toxicity.	[Pan, Da; Ahn, Dae-Gyun; Gujar, Shashi; Pan, Lu-Zhe; Lee, Patrick W. K.] Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS, Canada; [Marcato, Paola; Lee, Patrick W. K.] Dalhousie Univ, Dept Pathol, Halifax, NS, Canada; [Shmulevitz, Maya] Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB, Canada	Dalhousie University; Dalhousie University; University of Alberta	Lee, PWK (corresponding author), Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS, Canada.	patrick.lee@dal.ca	; Ahn, Dae-Gyun/L-7106-2015	Shmulevitz, Maya/0000-0002-8627-068X; Marcato, Paola/0000-0001-8619-283X; Gujar, Shashi/0000-0002-5427-0829; Ahn, Dae-Gyun/0000-0001-8251-8820	Canadian Institutes for Health Research (CIHR); Cancer Research Training Program (CRTP) through Dalhousie University; Alberta Heritage Foundation for Medical Research; CRTP	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Cancer Research Training Program (CRTP) through Dalhousie University; Alberta Heritage Foundation for Medical Research(Alberta Heritage Foundation for Medical ResearchGeneral Electric); CRTP	This work was supported by an operating grant from the Canadian Institutes for Health Research (CIHR) (P.W.K Lee), doctoral scholarships from the Cancer Research Training Program (CRTP) through Dalhousie University (D. Pan), and postdoctoral fellowships from the Alberta Heritage Foundation for Medical Research (P. Marcato) and CRTP (P. Marcato and S. Gujar). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alain T, 2002, BLOOD, V100, P4146, DOI 10.1182/blood-2002-02-0503; Bagnyukova T, 2010, CANCER BIOL THER, V10, P843, DOI 10.4161/cbt.10.9.13738; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Berard Alicia, 2009, Curr Protoc Microbiol, VChapter 15, DOI 10.1002/9780471729259.mc15c01s14; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chang PY, 2006, MOL CANCER RES, V4, P101, DOI 10.1158/1541-7786.MCR-05-0259; Chaturvedi MM, 2011, ONCOGENE, V30, P1615, DOI 10.1038/onc.2010.566; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Dey A, 2008, BRIT J CANCER, V98, P4, DOI 10.1038/sj.bjc.6604098; DUNCAN MR, 1978, J VIROL, V28, P444, DOI 10.1128/JVI.28.2.444-449.1978; Forsyth P, 2008, MOL THER, V16, P627, DOI 10.1038/sj.mt.6300403; Gollamudi R, 2010, INVEST NEW DRUG, V28, P641, DOI 10.1007/s10637-009-9279-8; Harrington KJ, 2010, CYTOKINE GROWTH F R, V21, P91, DOI 10.1016/j.cytogfr.2010.02.006; Harrington KJ, 2010, CLIN CANCER RES, V16, P3067, DOI 10.1158/1078-0432.CCR-10-0054; Harrison C, 2012, NAT REV DRUG DISCOV, V11, DOI 10.1038/nrd3782; HASHIRO G, 1977, ARCH VIROL, V54, P307, DOI 10.1007/BF01314776; Hingorani P, 2011, CANCER-AM CANCER SOC, V117, P1764, DOI 10.1002/cncr.25741; Hirasawa K, 2002, CANCER RES, V62, P1696; Karapanagiotou EM, 2012, CLIN CANCER RES, V18, P2080, DOI 10.1158/1078-0432.CCR-11-2181; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Lolkema MP, 2011, CLIN CANCER RES, V17, P581, DOI 10.1158/1078-0432.CCR-10-2159; Marcato P, 2007, MOL THER, V15, P1522, DOI 10.1038/sj.mt.6300179; Marcato P, 2009, MOL THER, V17, P972, DOI 10.1038/mt.2009.58; Mendez II, 2000, J VIROL METHODS, V90, P59, DOI 10.1016/S0166-0934(00)00217-2; Norman KL, 2002, HUM GENE THER, V13, P641, DOI 10.1089/10430340252837233; Pan D, 2011, BRIT J CANCER, V105, P1012, DOI 10.1038/bjc.2011.325; Pandha HS, 2009, CLIN CANCER RES, V15, P6158, DOI 10.1158/1078-0432.CCR-09-0796; Shmulevitz M, 2010, CANCER RES, V70, P4912, DOI 10.1158/0008-5472.CAN-09-4676; SMITH RE, 1969, VIROLOGY, V39, P791, DOI 10.1016/0042-6822(69)90017-8; SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Thirukkumaran CM, 2010, CANCER RES, V70, P2435, DOI 10.1158/0008-5472.CAN-09-2408; Twigger K, 2008, CLIN CANCER RES, V14, P912, DOI 10.1158/1078-0432.CCR-07-1400; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Vidal L, 2008, CLIN CANCER RES, V14, P7127, DOI 10.1158/1078-0432.CCR-08-0524; Wuerzberger-Davis SM, 2005, MOL CANCER RES, V3, P345, DOI 10.1158/1541-7786.MCR-05-0028; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Yu X, 2012, CANCER CELL, V21, P614, DOI 10.1016/j.ccr.2012.03.042; Zhang GH, 1997, BIOTECHNIQUES, V23, P525, DOI 10.2144/97233pf01; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	40	16	16	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2013	8	1							Citation: e54006	10.1371/journal.pone.0054006	http://dx.doi.org/10.1371/journal.pone.0054006			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072OV	23342061	Green Published, gold, Green Submitted			2023-01-03	WOS:000313682700075
J	Elul, B; Basinga, P; Nuwagaba-Biribonwoha, H; Saito, S; Horowitz, D; Nash, D; Mugabo, J; Mugisha, V; Rugigana, E; Nkunda, R; Asiimwe, A				Elul, Batya; Basinga, Paulin; Nuwagaba-Biribonwoha, Harriet; Saito, Suzue; Horowitz, Deborah; Nash, Denis; Mugabo, Jules; Mugisha, Veronicah; Rugigana, Etienne; Nkunda, Richard; Asiimwe, Anita			High Levels of Adherence and Viral Suppression in a Nationally Representative Sample of HIV-Infected Adults on Antiretroviral Therapy for 6, 12 and 18 Months in Rwanda	PLOS ONE			English	Article							SELF-REPORTED ADHERENCE; SUB-SAHARAN AFRICA; IMMUNOLOGICAL OUTCOMES; PREDICTORS; PROGRAM; HAART; TRIAL	Background: Generalizable data are needed on the magnitude and determinants of adherence and virological suppression among patients on antiretroviral therapy (ART) in Africa. Methods: We conducted a cross-sectional survey with chart abstraction, patient interviews and site assessments in a nationally representative sample of adults on ART for 6, 12 and 18 months at 20 sites in Rwanda. Adherence was assessed using 3- and 30-day patient recall. A systematically selected sub-sample had viral load (VL) measurements. Multivariable logistic regression examined predictors of non-perfect (<100%) 30-day adherence and detectable VL (>40 copies/ml). Results: Overall, 1,417 adults were interviewed and 837 had VL measures. Ninety-four percent and 78% reported perfect adherence for the last 3 and 30 days, respectively. Eighty-three percent had undetectable VL. In adjusted models, characteristics independently associated with higher odds of non-perfect 30-day adherence were: being on ART for 18 months (vs. 6 months); younger age; reporting severe (vs. no or few) side effects in the prior 30 days; having no documentation of CD4 cell count at ART initiation (vs. having a CD4 cell count of <200 cells/mu L); alcohol use; and attending sites which initiated ART services in 2003-2004 and 2005 (vs. 2006-2007); sites with >= 600 (vs. <600 patients) on ART; or sites with peer educators. Participation in an association for people living with HIV/AIDS; and receiving care at sites which regularly conduct home-visits were independently associated with lower odds of non-adherence. Higher odds of having a detectable VL were observed among patients at sites with peer educators. Being female; participating in an association for PLWHA; and using a reminder tool were independently associated with lower odds of having detectable VL. Conclusions: High levels of adherence and viral suppression were observed in the Rwandan national ART program, and associated with potentially modifiable factors.	[Elul, Batya; Nuwagaba-Biribonwoha, Harriet; Saito, Suzue; Horowitz, Deborah; Mugisha, Veronicah] Columbia Univ, ICAP, Mailman Sch Publ Hlth, New York, NY 10027 USA; [Elul, Batya; Saito, Suzue; Nash, Denis] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA; [Basinga, Paulin; Rugigana, Etienne] Natl Univ Rwanda, Sch Publ Hlth, Dept Community Hlth, Kigali, Rwanda; [Basinga, Paulin] Bill & Melinda Gates Fdn, Seattle, WA USA; [Nash, Denis] CUNY Hunter Coll, Epidemiol & Biostat Program, Sch Publ Hlth, New York, NY 10021 USA; [Mugabo, Jules; Asiimwe, Anita] Minist Hlth, RBC, Kigali, Rwanda; [Nkunda, Richard] NRL, Kigali, Rwanda	Columbia University; Columbia University; University of Rwanda; Bill & Melinda Gates Foundation; City University of New York (CUNY) System; Hunter College (CUNY)	Elul, B (corresponding author), Columbia Univ, ICAP, Mailman Sch Publ Hlth, New York, NY 10027 USA.	be2124@columbia.edu	Nash, Denis/AFI-7485-2022	Nash, Denis/0000-0002-3280-5386	Global Fund to Fight AIDS, TB and Malaria; Centers for Disease Control and Prevention [5U62PS222407]	Global Fund to Fight AIDS, TB and Malaria(United States Agency for International Development (USAID)); Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This article was supported by the Global Fund to Fight AIDS, TB and Malaria, and cooperative agreement number 5U62PS222407 from the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abaasa AM, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-241; Amberbir A, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-265; Barth RE, 2010, LANCET INFECT DIS, V10, P155, DOI 10.1016/S1473-3099(09)70328-7; Bhat VG, 2010, EUR J CLIN MICROBIOL, V29, P947, DOI 10.1007/s10096-010-0949-4; Brambatti LP, 2007, PSYCHOL PROGRAM PROC; Brinkhof MWG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005790; Bussmann H, 2008, AIDS, V22, P2303, DOI 10.1097/QAD.0b013e3283129db0; Chang LW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010923; Chesney MA, 2000, AIDS CARE, V12, P255, DOI 10.1080/09540120050042891; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Dahab M, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-63; Demeester R, 2005, JAIDS-J ACQ IMM DEF, V40, P113, DOI 10.1097/01.qai.0000176590.68430.59; El-Khatib Ziad, 2011, J AIDS Clin Res, V2; Etienne Martine, 2010, J Int Assoc Physicians AIDS Care (Chic), V9, P98, DOI 10.1177/1545109710361383; Graham SM, 2010, J INFECT DIS, V202, P1538, DOI 10.1086/656790; Hendershot CS, 2009, JAIDS-J ACQ IMM DEF, V52, P180, DOI 10.1097/QAI.0b013e3181b18b6e; Kalichman Seth C, 2008, J Int Assoc Physicians AIDS Care (Chic), V7, P317, DOI 10.1177/1545109708328130; Kashuba AD, 2011, LANCET; Kip E, 2009, J NURS SCHOLARSHIP, V41, P149, DOI 10.1111/j.1547-5069.2009.01266.x; Kipp W, 2010, AIDS CARE, V22, P271, DOI 10.1080/09540120903193625; Lowrance DW, 2009, JAIDS-J ACQ IMM DEF, V52, P49, DOI 10.1097/QAI.0b013e3181b03316; Mascolini Mark, 2008, J Int Assoc Physicians AIDS Care (Chic), V7, P160, DOI 10.1177/1545109708322728; Mills EJ, 2006, JAMA-J AM MED ASSOC, V296, P679, DOI 10.1001/jama.296.6.679; Ministry of Health GoR, 2011, ANN REP JUL 2010 JUN; Musiime S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027832; Nachega JB, 2009, JAIDS-J ACQ IMM DEF, V51, P65, DOI 10.1097/QAI.0b013e318199072e; National Institute of Statistics of Rwanda (NISR) MoHMR ICF International, 2012, RWAND DEM HLTH SURV; Osborn CY, 2010, AIDS BEHAV, V14, P181, DOI 10.1007/s10461-008-9484-z; Oyugi JH, 2004, JAIDS-J ACQ IMM DEF, V36, P1100, DOI 10.1097/00126334-200408150-00014; Pearson CR, 2007, JAIDS-J ACQ IMM DEF, V46, P238, DOI 10.1097/QAI.0b013e318153f7ba; Peltzer K, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-111; Perrine R, 2011, JAIDS-J ACQ IMM DEF, V57, pS40, DOI 10.1097/QAI.0b013e318222b5c2; Pop-Eleches C, 2011, AIDS, V25, P825, DOI 10.1097/QAD.0b013e32834380c1; Rwanda Go, 2010, UN GEN ASS SPEC SESS; Shumbusho F, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000163; Simoni JM, 2011, AIDS BEHAV, V15, P919, DOI 10.1007/s10461-010-9828-3; Somi G, 2009, Tanzan J Health Res, V11, P136; UNAIDS, 2011, GLOB HIV AIDS RESP E; Unge C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013613; Uzochukwu BSC, 2009, HEALTH POLICY PLANN, V24, P189, DOI 10.1093/heapol/czp006; Walsh JC, 2002, AIDS, V16, P269, DOI 10.1097/00002030-200201250-00017; Watt MH, 2010, AIDS CARE, V22, P381, DOI 10.1080/09540120903193708; Wise J, 2008, AIDS PATIENT CARE ST, V22, P495, DOI 10.1089/apc.2007.0180; World Health Organization, 2007, ESSENTIAL PREVENTION	44	54	54	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2013	8	1							e53586	10.1371/journal.pone.0053586	http://dx.doi.org/10.1371/journal.pone.0053586			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	070YR	23326462	gold, Green Published			2023-01-03	WOS:000313551500086
J	Moyer, VA				Moyer, Virginia A.		US Preventive Serv Task Force	Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: US Preventive Services Task Force Recommendation Statement	ANNALS OF INTERNAL MEDICINE			English	Article							CONJUGATED EQUINE ESTROGENS; POSTMENOPAUSAL WOMEN; LIFETIME RISK; STROKE; HYSTERECTOMY; DEMENTIA; CANCER; UPDATE	Description: Update of the 2005 U. S. Preventive Services Task Force (USPSTF) recommendation statement on hormone therapy for the prevention of chronic conditions in postmenopausal women. Methods: The USPSTF commissioned a review of the literature to update evidence about the benefits and harms of using menopausal hormone therapy to prevent chronic conditions, as well as whether the benefits and harms of hormone therapy differ by population subgroups defined by age; the presence of comorbid medical conditions; and the type, dose, and method of hormonal delivery. Population: This recommendation applies to postmenopausal women who are considering hormone therapy for the primary prevention of chronic medical conditions. It does not apply to women who are considering hormone therapy for the management of menopausal symptoms, such as hot flashes or vaginal dryness. It also does not apply to women younger than 50 years who have had surgical menopause. Recommendation: The USPSTF recommends against the use of combined estrogen and progestin for the prevention of chronic conditions in postmenopausal women. (Grade D recommendation). The USPSTF recommends against the use of estrogen for the prevention of chronic conditions in postmenopausal women who have had a hysterectomy. (Grade D recommendation). Ann Intern Med. 2013;158:47-54. www.annals.org For author affiliation, see end of text.	[Moyer, Virginia A.; US Preventive Serv Task Force] US Preventive Serv Task Force, Rockville, MD USA		Moyer, VA (corresponding author), US Preventive Serv Task Force, Rockville, MD USA.				Agency for Healthcare Research and Quality	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	The USPSTF is an independent, voluntary body. The U.S. Congress mandates that the Agency for Healthcare Research and Quality support the operations of the USPSTF.	Alzheimer's Association, 2011, 2011 ALZH DIS FACTS; American Academy of Family Physicians, 2005, HORM REPL THER; American College of Obstetricians and Gynecologists Committee on Gynecologic Practice, 2008, Obstet Gynecol, V112, P1189, DOI 10.1097/AOG.0b013e31818e8782; Anderson GL, 2012, LANCET ONCOL, V13, P476, DOI 10.1016/S1470-2045(12)70075-X; [Anonymous], 2012, MENOPAUSE, V19, P257, DOI 10.1097/gme.0b013e31824b970a; Berg AO, 2002, ANN INTERN MED, V137, P56, DOI 10.7326/0003-4819-137-1-200207020-00016; Calonge N, 2011, ANN INTERN MED, V154, P356, DOI 10.7326/0003-4819-154-5-201103010-00307; Chlebowski RT, 2012, JNCI-J NATL CANCER I, V104, P517, DOI 10.1093/jnci/djs014; Chlebowski RT, 2010, JNCI-J NATL CANCER I, V102, P1413, DOI 10.1093/jnci/djq285; Heiss G, 2008, JAMA-J AM MED ASSOC, V299, P1036, DOI 10.1001/jama.299.9.1036; Hendrix SL, 2005, JAMA-J AM MED ASSOC, V293, P935, DOI 10.1001/jama.293.8.935; Howlader N, 2011, SEER CANC STAT REV 1; LaCroix AZ, 2011, JAMA-J AM MED ASSOC, V305, P1305, DOI 10.1001/jama.2011.382; Lloyd-Jones DM, 1999, LANCET, V353, P89, DOI 10.1016/S0140-6736(98)10279-9; Minino Arialdi M, 2011, Natl Vital Stat Rep, V59, P1; Mosca, 2011, CIRCULATION, V123, pE624, DOI 10.1161/CIR.0b013e318222b330; Nelson HD, 2012, AHRQ PUBLICATION, V12-05167-EF-1; Nelson HD, 2012, ANN INTERN MED, V157, P104, DOI 10.7326/0003-4819-157-2-201207170-00466; Office of the Surgeon General (US), 2004, BON HLTH OST REP SUR; Pfizer Pharmaceuticals, 2011, PREM PACK INS; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Seshadri S, 2006, STROKE, V37, P345, DOI 10.1161/01.STR.0000199613.38911.b2; Seshadri S, 2007, LANCET NEUROL, V6, P1106, DOI 10.1016/S1474-4422(07)70291-0; Shamliyan T, 2012, COMP EFFECTIVENESS R; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; U.S. Food and Drug Administration, 2008, BIOID SORT MYTHS FAC; Wathen CN, 2004, CAN MED ASSOC J, V170, P1535, DOI 10.1503/cmaj.1030756; Yang XP, 2011, CURR OPIN NEPHROL HY, V20, P133, DOI 10.1097/MNH.0b013e3283431921	28	78	80	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	2013	158	1					47	U123		10.7326/0003-4819-158-1-201301010-00553	http://dx.doi.org/10.7326/0003-4819-158-1-201301010-00553			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	065AV	23090711				2023-01-03	WOS:000313119900007
J	Kanzaki, S; Fujioka, M; Yasuda, A; Shibata, S; Nakamura, M; Okano, HJ; Ogawa, K; Okano, H				Kanzaki, Sho; Fujioka, Masato; Yasuda, Akimasa; Shibata, Shinsuke; Nakamura, Masaya; Okano, Hirotaka James; Ogawa, Kaoru; Okano, Hideyuki			Novel In Vivo Imaging Analysis of an Inner Ear Drug Delivery System in Mice: Comparison of Inner Ear Drug Concentrations over Time after Transtympanic and Systemic Injections	PLOS ONE			English	Article							DEXAMETHASONE PHARMACOKINETICS	Objective: Systemic steroid injections are used to treat idiopathic sudden-onset sensorineural hearing loss (ISSHL) and some inner ear disorders. Recent studies show that transtympanic (TT) steroid injections are effective for treating ISSHL. As in vivo monitoring of drug delivery dynamics for inner ear is lacking, its time course and dispersion of drugs is unknown. Here, we used a new in vivo imaging system to monitor drug delivery in live mice and to compare drug concentrations over time after TT and systemic injections. Methods: Luciferin delivered into the inner ears of GFAP-Luc transgenic mice reacted with luciferase in GFAP-expressing cells in the cochlear spiral ganglion, resulting in photon bioluminescence. We used the Xenogen IVISH imaging system to measure how long photons continued to be emitted in the inner ear after TT or systemic injections of luciferin, and then compared the associated drug dynamics. Results: The response to TT and IP injections differed significantly. Photons were detected five minutes after TT injection, peaking at,20 minutes. By contrast, photons were first detected 30 minutes after i.p. injection. TT and i.p. drug delivery time differed considerably. With TT injections, photons were detected earlier than with IP injections. Photon bioluminescence also disappeared sooner. Delivery time varied with TT injections. Conclusions: We speculate that the drug might enter the Eustachian tube from the middle ear. We conclude that inner-ear drug concentration can be maintained longer if the two injection routes are combined. As the size of luciferin differs from that of therapeutics like dexamethasone, combining drugs with luciferin may advance our understanding of in vivo drug delivery dynamics in the inner ear.	[Kanzaki, Sho; Fujioka, Masato; Ogawa, Kaoru] Keio Univ, Dept Otolaryngol Head & Neck Surg, Shinjuku Ku, Tokyo, Japan; [Yasuda, Akimasa; Nakamura, Masaya] Keio Univ, Sch Med, Dept Orthoped, Shinjuku Ku, Tokyo, Japan; [Shibata, Shinsuke; Okano, Hirotaka James; Okano, Hideyuki] Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 160, Japan	Keio University; Keio University; Keio University	Kanzaki, S (corresponding author), Keio Univ, Dept Otolaryngol Head & Neck Surg, Shinjuku Ku, Tokyo, Japan.	skan@a7.keio.jp	Okano, Hideyuki/I-7584-2019; Shibata, Shinsuke/AAM-6620-2020; Nakamura, Masaya/K-4111-2013; Kanzaki, Sho/B-3100-2014	Kanzaki, Sho/0000-0001-9056-0850; Okano, Hirotaka James/0000-0003-4611-7098; Fujioka, Masato/0000-0002-5317-0885	Ministry of Health, Labor and Welfare [KO 2011]; Ministry of Education, Culture, Sports, Science and Technology [KO 2012]	Ministry of Health, Labor and Welfare(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by a grant from the Ministry of Health, Labor and Welfare (KO 2011) and by a grant from the Ministry of Education, Culture, Sports, Science and Technology (KO 2012). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chandrasekhar SS, 2000, OTOLARYNG HEAD NECK, V122, P521, DOI 10.1016/S0194-5998(00)70094-5; Hahn H, 2006, HEARING RES, V212, P236, DOI 10.1016/j.heares.2005.12.001; Iizuka T, 2008, HUM GENE THER, V19, P384, DOI 10.1089/hum.2007.167; Kanzaki S, 2012, AURIS NASUS LARYNX, V39, P208, DOI 10.1016/j.anl.2011.04.006; Liu HJ, 2006, ORL-J OTO-RHIN-LARYN, V68, P93, DOI 10.1159/000091210; Parnes LS, 1999, LARYNGOSCOPE, V109, P1, DOI 10.1097/00005537-199907001-00001; Rauch SD, 2011, JAMA-J AM MED ASSOC, V305, P2071, DOI 10.1001/jama.2011.679; Silverstein H, 1997, AM J OTOL, V18, P586; Thorne M, 1999, LARYNGOSCOPE, V109, P1661, DOI 10.1097/00005537-199910000-00021; Zhu LY, 2004, NEUROSCI LETT, V367, P210, DOI 10.1016/j.neulet.2004.06.020	10	18	27	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2012	7	12							e48480	10.1371/journal.pone.0048480	http://dx.doi.org/10.1371/journal.pone.0048480			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	066QV	23251331	Green Published, gold, Green Submitted			2023-01-03	WOS:000313236200005
J	Medina-Franco, JL; Martinez-Mayorga, K; Peppard, TL; Del Rio, A				Medina-Franco, Jose L.; Martinez-Mayorga, Karina; Peppard, Terry L.; Del Rio, Alberto			Chemoinformatic Analysis of GRAS (Generally Recognized as Safe) Flavor Chemicals and Natural Products	PLOS ONE			English	Article							DRUG DISCOVERY; SPACE; DATABASES; FOOD; INHIBITORS; DIVERSITY; MOLECULES	Food materials designated as "Generally Recognized as Safe'' (GRAS) are attracting the attention of researchers in their attempts to systematically identify compounds with putative health-related benefits. In particular, there is currently a great deal of interest in exploring possible secondary benefits of flavor ingredients, such as those relating to health and wellness. One step in this direction is the comprehensive characterization of the chemical structures contained in databases of flavoring substances. Herein, we report a comprehensive analysis of the recently updated FEMA GRAS list of flavoring substances (discrete chemical entities only). Databases of natural products, approved drugs and a large set of commercial molecules were used as references. Remarkably, natural products continue to be an important source of bioactive compounds for drug discovery and nutraceutical purposes. The comparison of five collections of compounds of interest was performed using molecular properties, rings, atom counts and structural fingerprints. It was found that the molecular size of the GRAS flavoring substances is, in general, smaller cf. members of the other databases analyzed. The lipophilicity profile of the GRAS database, a key property to predict human bioavailability, is similar to approved drugs. Several GRAS chemicals overlap to a broad region of the property space occupied by drugs. The GRAS list analyzed in this work has high structural diversity, comparable to approved drugs, natural products and libraries of screening compounds. This study represents one step towards the use of the distinctive features of the flavoring chemicals contained in the GRAS list and natural products to systematically search for compounds with potential health-related benefits.	[Medina-Franco, Jose L.; Martinez-Mayorga, Karina] Torrey Pines Inst Mol Studies, Port St Lucie, FL USA; [Peppard, Terry L.] Robertet Flavors Inc, Piscataway, NJ USA; [Del Rio, Alberto] Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy	Torrey Pines Institute for Molecular Studies, Florida; University of Bologna	Medina-Franco, JL (corresponding author), Torrey Pines Inst Mol Studies, Port St Lucie, FL USA.	jmedina@tpims.org	Medina-Franco, Jose/AAJ-1633-2020; Del Rio, Alberto/F-5230-2010	Medina-Franco, Jose/0000-0003-4940-1107; Del Rio, Alberto/0000-0002-1890-6797	State of Florida, Executive Office of the Governor's Office of Tourism, Trade, and Economic Development	State of Florida, Executive Office of the Governor's Office of Tourism, Trade, and Economic Development	This work was supported by the State of Florida, Executive Office of the Governor's Office of Tourism, Trade, and Economic Development. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrafiotis DK, 2001, J CHEM INF COMP SCI, V41, P159, DOI 10.1021/ci000091j; Andreoli F, 2013, CURR PHARM IN PRESS; [Anonymous], 2011, MOL OP ENV MOE VERS; [Anonymous], 2012, CANV VERS 1 5; Barbosa AJM, 2012, CURR TOP MED CHEM, V12, P866; Bickerton GR, 2012, NAT CHEM, V4, P90, DOI [10.1038/NCHEM.1243, 10.1038/nchem.1243]; Bonachera F, 2012, BIOORGAN MED CHEM, V20, P5396, DOI 10.1016/j.bmc.2012.04.024; Burdock GA, 2006, TOXICOLOGY, V221, P17, DOI 10.1016/j.tox.2006.01.012; Burdock GA, 2004, TOXICOL LETT, V150, P3, DOI 10.1016/j.toxlet.2003.07.004; Burdock GA, 2003, FOOD TECHNOL-CHICAGO, V57, P17; Caporuscio F, 2011, J MED CHEM, V54, P4006, DOI 10.1021/jm2000689; Clemons PA, 2011, P NATL ACAD SCI USA, V108, P6817, DOI 10.1073/pnas.1015024108; Dandapani S, 2010, NAT CHEM BIOL, V6, P861, DOI 10.1038/nchembio.479; Del Rio A, 2010, MOL BIOSYST, V6, P2122, DOI 10.1039/c0mb00039f; Duan JX, 2010, J MOL GRAPH MODEL, V29, P157, DOI 10.1016/j.jmgm.2010.05.008; Ertl P, 2008, J CHEM INF MODEL, V48, P68, DOI 10.1021/ci700286x; Feher M, 2003, J CHEM INF COMP SCI, V43, P218, DOI 10.1021/ci0200467; Ganesan A, 2008, CURR OPIN CHEM BIOL, V12, P306, DOI 10.1016/j.cbpa.2008.03.016; Harvey AL, 2008, DRUG DISCOV TODAY, V13, P894, DOI 10.1016/j.drudis.2008.07.004; Harvey AL, 2010, EXPERT OPIN DRUG DIS, V5, P559, DOI 10.1517/17460441.2010.488263; Henkel T, 1999, ANGEW CHEM INT EDIT, V38, P643, DOI 10.1002/(SICI)1521-3773(19990301)38:5<643::AID-ANIE643>3.0.CO;2-G; Lachance H, 2012, J MED CHEM, V55, P5989, DOI 10.1021/jm300288g; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; Lopez-Vallejo F, 2012, DRUG DISCOV TODAY, V17, P718, DOI 10.1016/j.drudis.2012.04.001; Lopez-Vallejo F, 2011, EXPERT OPIN DRUG DIS, V6, P1227, DOI 10.1517/17460441.2011.637106; Lopez-Vallejo F, 2011, COMB CHEM HIGH T SCR, V14, P475, DOI 10.2174/138620711795767866; Lopez-Vallejo F, 2011, CHEM BIOL DRUG DES, V77, P328, DOI 10.1111/j.1747-0285.2011.01100.x; Martinez-Mayorga K, 2013, 245 ACS NAT M NEW OR; Martinez-Mayorga K, 2011, J CHEMOMETR, V25, P550, DOI 10.1002/cem.1399; Medina-Franco JL, 2012, DRUG DEVELOP RES, V73, P430, DOI 10.1002/ddr.21034; Medina-Franco JL, 2011, MOL DIVERS, V15, P293, DOI 10.1007/s11030-010-9262-5; Medina-Franco JL, 2008, CURR COMPUT-AID DRUG, V4, P322, DOI 10.2174/157340908786786010; Paul J., 1901, B SOC VAUD SCI NAT, V37, P547, DOI 10.5169/seals-266450; Peppard TL, 2008, PREDICTION TOOL MODE, P374; Perez-Villanueva J, 2010, BIOORGAN MED CHEM, V18, P7380, DOI 10.1016/j.bmc.2010.09.019; Ritchie TJ, 2011, DRUG DISCOV TODAY, V16, P164, DOI 10.1016/j.drudis.2010.11.014; Ritchie TJ, 2009, DRUG DISCOV TODAY, V14, P1011, DOI 10.1016/j.drudis.2009.07.014; Rogers D, 2010, J CHEM INF MODEL, V50, P742, DOI 10.1021/ci100050t; Rognan D, 2010, MOL INFORM, V29, P176, DOI 10.1002/minf.200900081; Sanders MPA, 2012, J CHEM INF MODEL, V52, P1607, DOI 10.1021/ci2005274; Scalbert A, 2011, J AGR FOOD CHEM, V59, P4331, DOI 10.1021/jf200591d; Singh N, 2009, J CHEM INF MODEL, V49, P1010, DOI 10.1021/ci800426u; Smith RL, 2011, FOOD TECHNOL-CHICAGO, V65, P44; Sprous DG, 2007, FOOD CHEM TOXICOL, V45, P1419, DOI 10.1016/j.fct.2007.02.004; Willett P, 1998, J CHEM INF COMP SCI, V38, P983, DOI 10.1021/ci9800211; Yongye AB, 2012, CHEM BIOL DRUG DES, V80, P717, DOI 10.1111/cbdd.12011; Yongye AB, 2011, J CHEM INF MODEL, V51, P1259, DOI 10.1021/ci200081k; Yoo J, 2011, COMPUT MOL BIOSCI, V1, P7	49	27	27	0	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2012	7	11							e50798	10.1371/journal.pone.0050798	http://dx.doi.org/10.1371/journal.pone.0050798			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	054WM	23226386	Green Published, gold, Green Submitted			2023-01-03	WOS:000312376100197
J	Land, R; Engler, G; Kral, A; Engel, AK				Land, Ruediger; Engler, Gerhard; Kral, Andrej; Engel, Andreas K.			Auditory Evoked Bursts in Mouse Visual Cortex during Isoflurane Anesthesia	PLOS ONE			English	Article							FUNCTIONAL CONNECTIVITY; GENERAL-ANESTHETICS; IN-VIVO; SUPPRESSION ANESTHESIA; NETWORK MECHANISMS; SLOW OSCILLATION; CEREBRAL-CORTEX; LESS-THAN-1 HZ; RAT; HIPPOCAMPAL	General anesthesia is not a uniform state of the brain. Ongoing activity differs between light and deep anesthesia and cortical response properties are modulated in dependence of anesthetic dosage. We investigated how anesthesia level affects cross-modal interactions in primary sensory cortex. To examine this, we continuously measured the effects of visual and auditory stimulation during increasing and decreasing isoflurane level in the mouse visual cortex and the subiculum (from baseline at 0.7 to 2.5 vol % and reverse). Auditory evoked burst activity occurred in visual cortex after a transition during increase of anesthesia level. At the same time, auditory and visual evoked bursts occurred in the subiculum, even though the subiculum was unresponsive to both stimuli previous to the transition. This altered sensory excitability was linked to the presence of burst suppression activity in cortex, and to a regular slow burst suppression rhythm (similar to 0.2 Hz) in the subiculum. The effect disappeared during return to light anesthesia. The results show that pseudo-heteromodal sensory burst responses can appear in brain structures as an effect of an anesthesia induced state change.	[Land, Ruediger; Engler, Gerhard; Kral, Andrej; Engel, Andreas K.] Univ Med Ctr Hamburg Eppendorf, Dept Neurophysiol & Pathophysiol, Hamburg, Germany; [Land, Ruediger; Kral, Andrej] Hannover Med Sch, Inst Audioneurotechnol, Dept Expt Otol, D-3000 Hannover, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; Hannover Medical School	Land, R (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Neurophysiol & Pathophysiol, Hamburg, Germany.	land.ruediger@mh-hannover.de	Land, Rüdiger/N-3512-2018; Engel, Andreas K./AAH-6384-2019; Engel, Andreas K/C-7781-2012	Land, Rüdiger/0000-0003-0264-585X; Engel, Andreas K./0000-0003-4899-8466; Engel, Andreas K/0000-0003-4899-8466; Kral, Andrej/0000-0002-7762-4642	German Research Foundation (DFG) [SFB 444/3]; European Union [IST-2000-28127, IST-2005-27268, NEST-Path-043457]; German Research Foundation [SPP 1608 Kr 3370/2-1]	German Research Foundation (DFG)(German Research Foundation (DFG)); European Union(European Commission); German Research Foundation(German Research Foundation (DFG))	This study was supported by grants from the German Research Foundation (DFG) (SFB 444/3, A. K. E.) and the European Union (IST-2000-28127, IST-2005-27268, NEST-Path-043457, A. K. E.) and supported in part by the German Research Foundation (SPP 1608 Kr 3370/2-1, AK).	Akrawi WP, 1996, J NEUROSURG ANESTH, V8, P40, DOI 10.1097/00008506-199601000-00010; Bokil H, 2010, J NEUROSCI METH, V192, P146, DOI 10.1016/j.jneumeth.2010.06.020; Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357; Butovas S, 2010, ANESTHESIOLOGY, V113, P48, DOI 10.1097/ALN.0b013e3181dc1db7; Campagna JA, 2003, NEW ENGL J MED, V348, P2110, DOI 10.1056/NEJMra021261; CLARK DL, 1973, ANESTHESIOLOGY, V38, P564, DOI 10.1097/00000542-197306000-00011; Compte A, 2003, J NEUROPHYSIOL, V89, P2707, DOI 10.1152/jn.00845.2002; de Sousa SLM, 2000, ANESTHESIOLOGY, V92, P1055, DOI 10.1097/00000542-200004000-00024; Doi A, 2007, EUR J NEUROSCI, V26, P2565, DOI 10.1111/j.1460-9568.2007.05885.x; Erchova IA, 2002, EUR J NEUROSCI, V15, P744, DOI 10.1046/j.0953-816x.2002.01898.x; Franks NP, 2008, NAT REV NEUROSCI, V9, P370, DOI 10.1038/nrn2372; Friedberg MH, 1999, J NEUROPHYSIOL, V81, P2243, DOI 10.1152/jn.1999.81.5.2243; Friedman EB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011903; Gao EQ, 2010, J NEUROSCI, V30, P5912, DOI 10.1523/JNEUROSCI.6456-09.2010; Garcia PS, 2010, CURR NEUROPHARMACOL, V8, P2, DOI 10.2174/157015910790909502; Greenberg DS, 2008, NAT NEUROSCI, V11, P749, DOI 10.1038/nn.2140; Hahn TTG, 2006, NAT NEUROSCI, V9, P1359, DOI 10.1038/nn1788; Hartikainen K, 1999, ANAESTHESIA, V54, P210, DOI 10.1046/j.1365-2044.1999.00300.x; HARTIKAINEN KM, 1995, ANESTH ANALG, V81, P1223, DOI 10.1097/00000539-199512000-00018; HENRY CE, 1952, ELECTROEN CLIN NEURO, V4, P1, DOI 10.1016/0013-4694(52)90027-8; HIRSCH JA, 1991, J NEUROSCI, V11, P1800; Hudetz AG, 2007, ANESTHESIOLOGY, V107, P983, DOI 10.1097/01.anes.0000291471.80659.55; Huotari AM, 2004, BRIT J ANAESTH, V92, P18, DOI 10.1093/bja/aeh022; Imas OA, 2005, ANESTHESIOLOGY, V102, P937, DOI 10.1097/00000542-200505000-00012; Isomura Y, 2006, NEURON, V52, P871, DOI 10.1016/j.neuron.2006.10.023; Jackson J, 2011, J NEUROSCI, V31, P12104, DOI 10.1523/JNEUROSCI.1370-11.2011; KELLAWAY P, 1966, EXP NEUROL, V14, P281, DOI 10.1016/0014-4886(66)90115-4; Kisley MA, 1999, J NEUROSCI, V19, P10451; Kroeger D, 2007, J NEUROSCI, V27, P10597, DOI 10.1523/JNEUROSCI.3440-07.2007; Laramee ME, 2011, EUR J NEUROSCI, V34, P65, DOI 10.1111/j.1460-9568.2011.07732.x; Larsen DD, 2009, FRONT NEUROANAT, V3, DOI 10.3389/neuro.05.030.2009; Lukatch HS, 2005, CEREB CORTEX, V15, P1322, DOI 10.1093/cercor/bhi015; MacIver MB, 1996, ANESTHESIOLOGY, V84, P1411, DOI 10.1097/00000542-199606000-00018; Magill PJ, 2006, J NEUROSCI, V26, P6318, DOI 10.1523/jneurosci.0620-06.2006; Naber PA, 1998, J COMP NEUROL, V393, P284; Niedermeyer Ernst, 2009, Am J Electroneurodiagnostic Technol, V49, P333; Niell CM, 2008, J NEUROSCI, V28, P7520, DOI 10.1523/JNEUROSCI.0623-08.2008; O'Mara SM, 2001, PROG NEUROBIOL, V64, P129, DOI 10.1016/S0301-0082(00)00054-X; Paxinos G., 2004, MOUSE BRAIN STEREOTA, V2nd; Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366; Petersen CCH, 2003, P NATL ACAD SCI USA, V100, P13638, DOI 10.1073/pnas.2235811100; Porciatti V, 1999, VISION RES, V39, P3071, DOI 10.1016/S0042-6989(99)00022-X; RAMPIL IJ, 1988, ANESTHESIOLOGY, V69, P298, DOI 10.1097/00000542-198809000-00002; Rudolph U, 2004, NAT REV NEUROSCI, V5, P709, DOI 10.1038/nrn1496; Ruiz-Mejias M, 2011, J NEUROPHYSIOL, V106, P2910, DOI 10.1152/jn.00440.2011; Sanchez-Vives MV, 2000, NAT NEUROSCI, V3, P1027, DOI 10.1038/79848; STERIADE M, 1994, ELECTROEN CLIN NEURO, V90, P1, DOI 10.1016/0013-4694(94)90108-2; STERIADE M, 1993, J NEUROSCI, V13, P3252, DOI 10.1523/jneurosci.13-08-03252.1993; SWANK RL, 1949, J NEUROPHYSIOL, V12, P137, DOI 10.1152/jn.1949.12.2.137; Takagaki K, 2008, NEUROSCI LETT, V431, P191, DOI 10.1016/j.neulet.2007.11.069; Taxidis J, 2010, BIOL CYBERN, V102, P327, DOI 10.1007/s00422-010-0370-1; TOMODA K, 1993, BRIT J ANAESTH, V71, P383, DOI 10.1093/bja/71.3.383; Wilson DA, 2010, J NEUROPHYSIOL, V104, P3231, DOI 10.1152/jn.00711.2010; Wolansky T, 2006, J NEUROSCI, V26, P6213, DOI 10.1523/JNEUROSCI.5594-05.2006; Worgotter F, 1998, NATURE, V396, P165, DOI 10.1038/24157; Xu WF, 2007, NEURON, V55, P119, DOI 10.1016/j.neuron.2007.06.016; YLIHANKALA A, 1993, ELECTROEN CLIN NEURO, V87, P215, DOI 10.1016/0013-4694(93)90021-M	57	31	31	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2012	7	11							e49855	10.1371/journal.pone.0049855	http://dx.doi.org/10.1371/journal.pone.0049855			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	047ER	23185462	Green Published, Green Submitted, gold			2023-01-03	WOS:000311821000125
J	Souza, PM; Elias, ST; Simeoni, LA; de Paula, JE; Gomes, SM; Guerra, ENS; Fonseca, YM; Silva, EC; Silveira, D; Magalhaes, PO				Souza, Paula Monteiro; Elias, Silvia Taveira; Simeoni, Luiz Alberto; de Paula, Jose Elias; Gomes, Sueli Maria; Silva Guerra, Eliete Neves; Fonseca, Yris Maria; Silva, Elton Clementino; Silveira, Damaris; Magalhaes, Perola Oliveira			Plants from Brazilian Cerrado with Potent Tyrosinase Inhibitory Activity	PLOS ONE			English	Article							MUSHROOM TYROSINASE; CONSTITUENTS; MECHANISM; EXTRACTS	The increased amount of melanin leads to skin disorders such as age spots, freckles, melasma and malignant melanoma. Tyrosinase is known to be the key enzyme in melanin production. Plants and their extracts are inexpensive and rich resources of active compounds that can be utilized to inhibit tyrosinase as well as can be used for the treatment of dermatological disorders associated with melanin hyperpigmentation. Using in vitro tyrosinase inhibitory activity assay, extracts from 13 plant species from Brazilian Cerrado were evaluated. The results showed that Pouteria torta and Eugenia dysenterica extracts presented potent in vitro tyrosinase inhibition compared to positive control kojic acid. Ethanol extract of Eugenia dysenterica leaves showed significant (p<0.05) tyrosinase inhibitory activity exhibiting the IC50 value of 11.88 mu g/mL, compared to kojic acid (IC50 value of 13.14 mu g/mL). Pouteria torta aqueous extract leaves also showed significant inhibitory activity with IC50 value of 30.01 mu g/mL. These results indicate that Pouteria torta and Eugenia dysenterica extracts and their isolated constituents are promising agents for skin-whitening or antimelanogenesis formulations.	[Souza, Paula Monteiro; Simeoni, Luiz Alberto; Fonseca, Yris Maria; Silva, Elton Clementino; Silveira, Damaris; Magalhaes, Perola Oliveira] Univ Brasilia, Sch Hlth Sci, Dept Pharmaceut Sci, Brasilia, DF, Brazil; [Elias, Silvia Taveira; Silva Guerra, Eliete Neves] Univ Brasilia, Sch Hlth Sci, Dept Odontol, Brasilia, DF, Brazil; [de Paula, Jose Elias; Gomes, Sueli Maria] Univ Brasilia, Inst Biol Sci, Dept Bot, Brasilia, DF, Brazil	Universidade de Brasilia; Universidade de Brasilia; Universidade de Brasilia	Magalhaes, PO (corresponding author), Univ Brasilia, Sch Hlth Sci, Dept Pharmaceut Sci, Campus Darcy Ribeiro, Brasilia, DF, Brazil.	perolamagalhaes@unb.br	Fonseca, Yris M/A-9893-2016; Guerra, Eliete Neves Silva/E-1021-2016; Souza, Paula/AAE-5731-2021; Gomes, Sueli M./J-7147-2012; MAGALHÃES, PÉROLA/P-3378-2018; Simeoni, Luiz Alberto/A-9088-2008; Silveira, Damaris/J-5165-2019; MAGALHÃES, PÉROLA O/P-2521-2017; Silveira, Damaris/A-1942-2008	Fonseca, Yris M/0000-0002-1230-3207; Guerra, Eliete Neves Silva/0000-0002-7622-1550; Gomes, Sueli M./0000-0002-6234-7777; MAGALHÃES, PÉROLA/0000-0001-8011-6940; Simeoni, Luiz Alberto/0000-0003-3401-290X; Silveira, Damaris/0000-0003-1851-5224; MAGALHÃES, PÉROLA O/0000-0001-8011-6940; Silveira, Damaris/0000-0003-1851-5224; Souza, Paula/0000-0003-1824-2211; Elias, Silvia/0000-0001-7309-0877	Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF); Fundacao de Empreendimentos Cientificos e Tecnologicos (FINATEC); Conselho Nacional de Pesquisa (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF)); Fundacao de Empreendimentos Cientificos e Tecnologicos (FINATEC); Conselho Nacional de Pesquisa (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This research was supported by Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF), Fundacao de Empreendimentos Cientificos e Tecnologicos (FINATEC), Conselho Nacional de Pesquisa (CNPq) and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES). The authors are grateful to Universidade de Brasilia (UnB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baurin N, 2002, J ETHNOPHARMACOL, V82, P155, DOI 10.1016/S0378-8741(02)00174-5; Boonclarm D, 2006, ACTA BIOCH BIOPH SIN, V38, P563, DOI 10.1111/j.1745-7270.2006.00196.x; Caramori SS, 2004, BRAZ ARCH BIOL TECHN, V47, P253, DOI 10.1590/S1516-89132004000200013; Chang TS, 2009, INT J MOL SCI, V10, P2440, DOI 10.3390/ijms10062440; Costa TR, 2000, J ETHNOPHARMACOL, V72, P111, DOI 10.1016/S0378-8741(00)00214-2; de Faria RO, 2007, FOOD TECHNOL BIOTECH, V45, P287; Chiari ME, 2011, BIOORGAN MED CHEM, V19, P3474, DOI 10.1016/j.bmc.2011.04.025; Falguera V, 2010, FOOD RES INT, V43, P66, DOI 10.1016/j.foodres.2009.08.013; Karioti A, 2007, BIOORGAN MED CHEM, V15, P2708, DOI 10.1016/j.bmc.2007.01.035; Khan SB, 2005, CHEM PHARM BULL, V53, P86, DOI 10.1248/cpb.53.86; Khatib S, 2005, BIOORGAN MED CHEM, V13, P433, DOI 10.1016/j.bmc.2004.10.010; Kim D, 2006, J AGR FOOD CHEM, V54, P935, DOI 10.1021/jf0521855; Kim YJ, 2005, CELL MOL LIFE SCI, V62, P1707, DOI 10.1007/s00018-005-5054-y; Kim YJ, 2004, BIOMACROMOLECULES, V5, P474, DOI 10.1021/bm034320x; Kubo I, 1999, J AGR FOOD CHEM, V47, P4121, DOI 10.1021/jf990201q; Kubo I, 2007, MOLECULES, V12, P1045, DOI 10.3390/12051045; Lee K. T., 1997, International Journal of Cosmetic Science, V19, P291, DOI 10.1046/j.1467-2494.1997.171725.x; Lin JW, 2008, J FOOD DRUG ANAL, V16, P1, DOI 10.1097/01.JNR.0000387284.45935.c7; Lin JY, 2007, NATURE, V445, P843, DOI 10.1038/nature05660; MATSUDA H, 1995, BIOL PHARM BULL, V18, P1148, DOI 10.1248/bpb.18.1148; Momtaz S, 2008, J ETHNOPHARMACOL, V119, P507, DOI 10.1016/j.jep.2008.06.006; Momtaz S, 2008, S AFR J BOT, V74, P577, DOI 10.1016/j.sajb.2008.02.005; Nakatsu T, 2000, STUD NAT PROD CHEM, V21, P571; Napolitano DR, 2005, J ETHNOPHARMACOL, V99, P37, DOI 10.1016/j.jep.2005.01.059; No JK, 1999, LIFE SCI, V65, pPL241, DOI 10.1016/S0024-3205(99)00492-0; Ortonne JP, 2005, DERMATOL CLIN, V23, P209, DOI 10.1016/j.det.2005.01.001; Parvez S, 2007, PHYTOTHER RES, V21, P805, DOI 10.1002/ptr.2184; Petit L., 2003, International Journal of Cosmetic Science, V25, P169, DOI 10.1046/j.1467-2494.2003.00182.x; Rebecca MA, 2002, J ETHNOPHARMACOL, V83, P101, DOI 10.1016/S0378-8741(02)00219-2; SANCHEZFERRER A, 1995, BBA-PROTEIN STRUCT M, V1247, P1; Si YX, 2012, J BIOMOL STRUCT DYN, V29, P999, DOI 10.1080/073911012010525028; Silva CAM, 2009, REV BRAS FARMACOGN, V19, P501, DOI 10.1590/S0102-695X2009000300025; Wang H, 2010, J TAIWAN I CHEM ENG	33	54	58	2	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2012	7	11							e48589	10.1371/journal.pone.0048589	http://dx.doi.org/10.1371/journal.pone.0048589			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	048BN	23173036	Green Published, Green Submitted, gold			2023-01-03	WOS:000311885300006
J	Weinstock, JV				Weinstock, Joel V.			The worm returns	NATURE			English	Editorial Material							INFLAMMATORY-BOWEL-DISEASE; TRICHURIS-SUIS THERAPY; CROHNS-DISEASE; COLITIS		[Weinstock, Joel V.] Tufts Univ, Boston, MA 02111 USA; [Weinstock, Joel V.] Tufts Med Ctr, Div Gastroenterol & Hepatol, Boston, MA 02111 USA	Tufts University; Tufts Medical Center	Weinstock, JV (corresponding author), Tufts Univ, Boston, MA 02111 USA.	jweinstock2@tuftsmedicalcenter.org			NIDDK NIH HHS [R01 DK091987] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK091987] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEER RJS, 1976, RES VET SCI, V20, P47, DOI 10.1016/S0034-5288(18)33478-7; Blum AM, 2012, J IMMUNOL, V189, P2512, DOI 10.4049/jimmunol.1102892; Elliott DE, 2003, AM J PHYSIOL-GASTR L, V284, pG385, DOI 10.1152/ajpgi.00049.2002; Elliott DE, 2000, FASEB J, V14, P1848, DOI 10.1096/fj.99-0885hyp; Shivananda S, 1996, GUT, V39, P690, DOI 10.1136/gut.39.5.690; SONNENBERG A, 1991, GASTROENTEROLOGY, V100, P143, DOI 10.1016/0016-5085(91)90594-B; Summers RW, 2005, GASTROENTEROLOGY, V128, P825, DOI 10.1053/j.gastro.2005.01.005; Summers RW, 2005, GUT, V54, P87, DOI 10.1136/gut.2004.041749; Weinstock JV, 2004, GUT, V53, P7, DOI 10.1136/gut.53.1.7; World Health Organization, 2007, ACT WORMS	10	60	69	1	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 8	2012	491	7423					183	185		10.1038/491183a	http://dx.doi.org/10.1038/491183a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	033DP	23135449	Green Accepted, Bronze			2023-01-03	WOS:000310774300014
J	Sasson, C; Magid, DJ; Chan, P; Root, ED; McNally, BF; Kellermann, AL; Haukoos, JS				Sasson, Comilla; Magid, David J.; Chan, Paul; Root, Elisabeth D.; McNally, Bryan F.; Kellermann, Arthur L.; Haukoos, Jason S.		CARES Surveillance Grp	Association of Neighborhood Characteristics with Bystander-Initiated CPR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITAL CARDIAC-ARREST; AMERICAN-HEART-ASSOCIATION; EUROPEAN-RESUSCITATION-COUNCIL; CARDIOPULMONARY-RESUSCITATION; SOCIOECONOMIC-STATUS; MULTILEVEL ANALYSIS; RACIAL-DIFFERENCES; STROKE-FOUNDATION; TASK-FORCE; SURVIVAL	BACKGROUND For persons who have an out-of-hospital cardiac arrest, the probability of receiving bystander-initiated cardiopulmonary resuscitation (CPR) may be influenced by neighborhood characteristics. METHODS We analyzed surveillance data prospectively submitted from 29 U. S. sites to the Cardiac Arrest Registry to Enhance Survival between October 1, 2005, and December 31, 2009. The neighborhood in which each cardiac arrest occurred was determined from census-tract data. We classified neighborhoods as high-income or low-income on the basis of a median household income threshold of $40,000 and as white or black if more than 80% of the census tract was predominantly of one race. Neighborhoods without a predominant racial composition were classified as integrated. We analyzed the relationship between the median income and racial composition of a neighborhood and the performance of bystander-initiated CPR. RESULTS Among 14,225 patients with cardiac arrest, bystander-initiated CPR was provided to 4068 (28.6%). As compared with patients who had a cardiac arrest in high-income white neighborhoods, those in low-income black neighborhoods were less likely to receive bystander-initiated CPR (odds ratio, 0.49; 95% confidence interval [CI], 0.41 to 0.58). The same was true of patients with cardiac arrest in neighborhoods characterized as low-income white (odds ratio, 0.65; 95% CI, 0.51 to 0.82), low-income integrated (odds ratio, 0.62; 95% CI, 0.56 to 0.70), and high-income black (odds ratio, 0.77; 95% CI, 0.68 to 0.86). The odds ratio for bystander-initiated CPR in high-income integrated neighborhoods (1.03; 95% CI, 0.64 to 1.65) was similar to that for high-income white neighborhoods. CONCLUSIONS In a large cohort study, we found that patients who had an out-of-hospital cardiac arrest in low-income black neighborhoods were less likely to receive bystander-initiated CPR than those in high-income white neighborhoods. (Funded by the Centers for Disease Control and Prevention and others.)	[Sasson, Comilla; Haukoos, Jason S.] Univ Colorado, Sch Med, Dept Emergency Med, Leprino Off Bldg,12401 E 17th Ave,B215, Aurora, CO 80045 USA; [Magid, David J.] Kaiser Permanente, Inst Healthcare Res, Denver, CO USA; [Haukoos, Jason S.] Colorado Sch Publ Hlth, Dept Epidemiol, Denver, CO USA; [Chan, Paul] St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA; [Root, Elisabeth D.] Univ Colorado, Dept Geog, Boulder, CO 80309 USA; [McNally, Bryan F.] Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA; [Kellermann, Arthur L.] RAND Corp, Washington, DC USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Kaiser Permanente; Colorado School of Public Health; Saint Luke's Hospital - Missouri; Saint Luke's Mid America Heart Institute; University of Colorado System; University of Colorado Boulder; Emory University; RAND Corporation	Sasson, C (corresponding author), Univ Colorado, Sch Med, Dept Emergency Med, Leprino Off Bldg,12401 E 17th Ave,B215, Aurora, CO 80045 USA.	comilla.sasson@ucdenver.edu	Root, Elisabeth/A-7429-2016; McNally, Bryan/AAE-9332-2020	Root, Elisabeth/0000-0002-9566-4031; McMullan, Jason/0000-0002-7656-7447	Cardiac Arrest Registry to Enhance Survival [U18 PS000314]; Centers for Disease Control and Prevention [U18 PS000314]; Emergency Medicine Foundation; American Heart Association; Agency for Healthcare Research and Quality [K02 HS017526]; National Heart, Lung, and Blood Institute [K23HL102224]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K02HS017526] Funding Source: NIH RePORTER; NATIONAL CENTER FOR HIV, VIRAL HEPATITIS, STDS AND TB PREVENTION [U18PS000314] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL102224] Funding Source: NIH RePORTER	Cardiac Arrest Registry to Enhance Survival; Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Emergency Medicine Foundation; American Heart Association(American Heart Association); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR HIV, VIRAL HEPATITIS, STDS AND TB PREVENTION(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by a cooperative agreement between the Cardiac Arrest Registry to Enhance Survival and the Centers for Disease Control and Prevention (U18 PS000314); grants from the Emergency Medicine Foundation and the American Heart Association (to Dr. Sasson); an Independent Scientist Award from the Agency for Healthcare Research and Quality (K02 HS017526, to Dr. Haukoos); and a grant from the National Heart, Lung, and Blood Institute (K23HL102224, to Dr. Chan).	Abella BS, 2008, CIRCULATION, V117, P704, DOI 10.1161/CIRCULATIONAHA.107.188486; [Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; BECKER LB, 1993, NEW ENGL J MED, V329, P600, DOI 10.1056/NEJM199308263290902; BROOKOFF D, 1994, ANN EMERG MED, V24, P1147, DOI 10.1016/S0196-0644(94)70246-2; Chan PS, 2009, JAMA-J AM MED ASSOC, V302, P1195, DOI 10.1001/jama.2009.1340; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; CUMMINS RO, 1993, ANNU REV PUBL HEALTH, V14, P313; Diez-Roux AV, 2000, SOC SCI MED, V50, P673, DOI 10.1016/S0277-9536(99)00320-2; Diez-Roux AV, 2000, ANNU REV PUBL HEALTH, V21, P171, DOI 10.1146/annurev.publhealth.21.1.171; Ding JZ, 2003, AM HEART J, V146, P459, DOI 10.1016/S0002-8703(03)00228-X; Dunne RB, 2007, RESUSCITATION, V72, P59, DOI 10.1016/j.resuscitation.2006.04.017; Galea S, 2007, AM J EPIDEMIOL, V166, P534, DOI 10.1093/aje/kwm102; Govindarajan P, 2012, RESUSCITATION, V83, P76, DOI 10.1016/j.resuscitation.2011.06.026; Grenvik ASP., 1981, BRAIN FAILURE RESUSC, P155; Iwashyna TJ, 1999, ANN EMERG MED, V34, P459, DOI 10.1016/S0196-0644(99)80047-X; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; Krieger N, 2002, AM J EPIDEMIOL, V156, P471, DOI 10.1093/aje/kwf068; Lisabeth LD, 2007, AM J EPIDEMIOL, V165, P279, DOI 10.1093/aje/kwk005; McNally Bryan, 2011, Morbidity and Mortality Weekly Report, V60, P1; McNally B, 2009, ANN EMERG MED, V54, P674, DOI 10.1016/j.annemergmed.2009.03.018; Mitchell MJ, 2009, PREHOSP EMERG CARE, V13, P478, DOI 10.1080/10903120903144833; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Petersen LA, 2002, MED CARE, V40, P86; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Sasson C, 2008, JAMA-J AM MED ASSOC, V300, P1432, DOI 10.1001/jama.300.12.1432; Sasson C, 2011, RESUSCITATION, V82, P674, DOI 10.1016/j.resuscitation.2011.02.002; Sasson C, 2010, ANN INTERN MED, V153, P19, DOI 10.7326/0003-4819-153-1-201007060-00255; Sasson C, 2010, CIRC-CARDIOVASC QUAL, V3, P63, DOI 10.1161/CIRCOUTCOMES.109.889576; U.S. Census Bureau, TOP INT GEOGR ENC RE; Vadeboncoeur TF, 2008, AM J EMERG MED, V26, P655, DOI 10.1016/j.ajem.2007.10.002; Vaillancourt C, 2008, RESUSCITATION, V79, P417, DOI 10.1016/j.resuscitation.2008.07.012	32	183	189	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 25	2012	367	17					1607	1615		10.1056/NEJMoa1110700	http://dx.doi.org/10.1056/NEJMoa1110700			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	024TO	23094722	Green Accepted			2023-01-03	WOS:000310131700007
J	Niederman, MS; Krilov, LR				Niederman, Michael S.; Krilov, Leonard R.			Acute lower respiratory infections in developing countries	LANCET			English	Editorial Material							PNEUMONIA ETIOLOGY RESEARCH; CHILDHOOD PNEUMONIA; CHILDREN		[Niederman, Michael S.] SUNY Stony Brook, Winthrop Univ Hosp, Dept Med, Mineola, NY 11501 USA; [Krilov, Leonard R.] SUNY Stony Brook, Winthrop Univ Hosp, Dept Pediat, Mineola, NY 11501 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Winthrop University Hospital	Niederman, MS (corresponding author), SUNY Stony Brook, Winthrop Univ Hosp, Dept Med, Mineola, NY 11501 USA.	mniederman@winthrop.org						Adegbola RA, 2012, CLIN INFECT DIS, V54, pS89, DOI 10.1093/cid/cir1051; Bradley JS, 2011, CLIN INFECT DIS, V53, pE25, DOI [10.1093/cid/cir531, 10.1093/cid/cir625]; Gilani Z, 2012, CLIN INFECT DIS, V54, pS102, DOI 10.1093/cid/cir1053; Johnston IDA, 1998, NEW ENGL J MED, V338, P581, DOI 10.1056/NEJM199802263380904; Kyaw MH, 2006, NEW ENGL J MED, V354, P1455, DOI 10.1056/NEJMoa051642; Levine OS, 2012, CLIN INFECT DIS, V54, pS93, DOI 10.1093/cid/cir1052; Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1; Madhi SA, 2013, PEDIATR INFECT DIS J, V32, pE119, DOI 10.1097/INF.0b013e3182784b26; Nair H, 2012, LANCET; Rudan I, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001099; Wonodi CB, 2012, CLIN INFECT DIS, V54, pS124, DOI 10.1093/cid/cir1067	11	15	16	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 20	2013	381	9875					1341	1342		10.1016/S0140-6736(12)62178-3	http://dx.doi.org/10.1016/S0140-6736(12)62178-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	130EF	23369798				2023-01-03	WOS:000317894800009
J	You, H; Chen, JH; Bogg, L; Wu, Y; Duan, SN; Ye, CY; Liu, XF; Yu, H; Diwan, V; Dong, HJ				You, Hua; Chen, Jianhua; Bogg, Lennart; Wu, Yuan; Duan, Shengnan; Ye, Chiyu; Liu, Xiaofang; Yu, Hai; Diwan, Vinod; Dong, Hengjin			Study on the Factors Associated with Postpartum Visits in Rural China	PLOS ONE			English	Article							HOME VISIT; POSTNATAL CARE; PREDICTORS; BANGLADESH; MOTHERS; TRIAL	Background: Postpartum visits (PPVs) have been advocated as a way to improve health outcomes for mothers and their infants, but the rate of PPVs is still low in rural China. This study aims to investigate the utilization of PPVs and to explore the factors associated with PPVs in rural China. Parity is the most concerned factor in this study. Methods: A cross-sectional household survey was performed in two counties of Zhejiang province. Questions include socioeconomic, health services and women's delivery data. Chi-square tests and multivariate logistic regression analyses were performed to identify factors associated with PPVs. Results: 223 women who had a delivery history in the recent five years were enrolled in analyses. 173 (78%) of them were primiparous. Among the primiparous women, 43 (25%) had not received any PPVs. The majority, 27 (55%) of the 49 multiparous women, had not received any PPVs. Multiparous women were less likely to receive PPVs than primiparous women. Among 223 puerperal women, 47 (21%) had been compensated for delivery fee expenses. Women who received compensation were found to be more likely to receive standard (at least 3) PPVs. Conclusions: It was found that women with "second babies" were less likely to use PPVs. This could be an unintended consequence of the "one-child policy", due to fear that contact with public health facilities could result in sanctions. This phenomenon should be taken seriously by government in order to improve the health of babies and their mothers. Financial compensation for delivery fee charges can improve the use of PPVs, thus free-of-charge delivery should be promoted.	[You, Hua; Chen, Jianhua; Wu, Yuan; Duan, Shengnan; Ye, Chiyu; Liu, Xiaofang; Yu, Hai; Dong, Hengjin] Zhejiang Univ, Sch Med, Ctr Hlth Policy Studies, Hangzhou 310003, Zhejiang, Peoples R China; [Bogg, Lennart; Diwan, Vinod] Karolinska Inst, Inst Global Hlth, Stockholm, Sweden; [Bogg, Lennart] Malardalen Univ, Sch Hlth Care & Welf, Vasteras, Sweden; [Dong, Hengjin] Heidelberg Univ, Inst Publ Hlth, Heidelberg, Germany	Zhejiang University; Karolinska Institutet; Malardalen University; Ruprecht Karls University Heidelberg	Dong, HJ (corresponding author), Zhejiang Univ, Sch Med, Ctr Hlth Policy Studies, Hangzhou 310003, Zhejiang, Peoples R China.	donghj@zju.edu.cn		Bogg, Lennart/0000-0003-0368-050X	China Medical Board [09-989]; European Union [261304]	China Medical Board; European Union(European Commission)	Funded by China Medical Board: 09-989 (http://www.chinamedicalboard.org/); and European Union: 261304 (http://europa.eu/index_en.htm). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albers LL, 2000, J MIDWIFERY WOM HEAL, V45, P55, DOI 10.1016/S1526-9523(99)00003-3; Apgar BS, 2005, AM FAM PHYSICIAN, V72, P2443; Baqui AH, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2826; Bogg L, 1998, AM J PUBLIC HEALTH, V88, P649, DOI 10.2105/AJPH.88.4.649; Brown MS, 1984, NURSE PRACT, V9, P46; Brown MS, 1984, NURSE PRACT, V9, P42; Bryant AS, 2006, MATERN CHILD HLTH J, V10, P511, DOI 10.1007/s10995-006-0128-5; Bryce J, 2008, LANCET, V371, P1247, DOI 10.1016/S0140-6736(08)60559-0; Chakraborty N, 2002, HEALTH SOC CARE COMM, V10, P492, DOI 10.1046/j.1365-2524.2002.00389.x; Christie J, 2011, INT J NURS STUD, V48, P689, DOI 10.1016/j.ijnurstu.2010.10.011; Dhakal Sulochana, 2007, BMC Pregnancy Childbirth, V7, P19, DOI 10.1186/1471-2393-7-19; Gorlin R, 1979, Female Patient, V4, P89; Hamburg M V, 1981, SIECUS Rep, V10, P3; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Jing Y, 2012, ZHONG GUO FU YOU BAO, V27, P170; Kabakian-Khasholian Tamar, 2006, Health Care Women Int, V27, P839, DOI 10.1080/07399330600880392; Li WJ, 2009, ZHONG GUO FU YOU BAO, V33, P4645; Lu MC, 2002, AM J OBSTET GYNECOL, V187, P1329, DOI 10.1067/mob.2002.126848; Ministry of Health of China, 1989, MAN MEAS SYST MAT HE; Ministry of Health of China, 2004, REP 3 NAT HLTH SERV; Ministry of Health of China UNICEF WHO UNFPA, 2006, JOINT REV MAT CHILD; Quinlivan JA, 2003, LANCET, V361, P893, DOI 10.1016/S0140-6736(03)12770-5; Sword WA, 2006, CAN J PUBLIC HEALTH, V97, P191, DOI 10.1007/BF03405582; Tao FB, 2011, MIDWIFERY, V27, P707, DOI 10.1016/j.midw.2009.10.001; Tian DZ, 2012, 7 MONTH PREGNANT WOM; Wager KA, 2004, PUBLIC HEALTH NURS, V21, P541, DOI 10.1111/j.0737-1209.2004.21606.x; World Health Organization, 1998, BAS NEWB RES PRACT G	27	11	11	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2013	8	2							e55955	10.1371/journal.pone.0055955	http://dx.doi.org/10.1371/journal.pone.0055955			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	098BN	23460789	Green Submitted, Green Published, gold			2023-01-03	WOS:000315519000012
J	Jones, CM; Mack, KA; Paulozzi, LJ				Jones, Christopher M.; Mack, Karin A.; Paulozzi, Leonard J.			Pharmaceutical Overdose Deaths, United States, 2010	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Jones, Christopher M.; Mack, Karin A.; Paulozzi, Leonard J.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30329 USA	Centers for Disease Control & Prevention - USA	Jones, CM (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30329 USA.	fjr0@cdc.gov	Mack, Karin A/A-3263-2012; MACK, KARIN/P-9227-2019	Mack, Karin A/0000-0001-9274-3001; 				Becker WC, 2008, DRUG ALCOHOL DEPEN, V94, P38, DOI 10.1016/j.drugalcdep.2007.09.018; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Centers for Disease Control and Prevention. National Vital Statistics System, 2010, NAT VIT STAT SYST 20; Edlund MJ, 2010, J PAIN SYMPTOM MANAG, V40, P279, DOI 10.1016/j.jpainsymman.2010.01.012; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Wysowski DK, 2007, DRUG SAFETY, V30, P533, DOI 10.2165/00002018-200730060-00007	6	506	513	0	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	2013	309	7					657	659		10.1001/jama.2013.272	http://dx.doi.org/10.1001/jama.2013.272			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	091EK	23423407	Bronze			2023-01-03	WOS:000315032000016
J	Lamb, SE; Gates, S; Williams, MA; Williamson, EM; Mt-Isa, S; Withers, EJ; Castelnuovo, E; Smith, J; Ashby, D; Cooke, MW; Petrou, S; Underwood, MR				Lamb, Sarah E.; Gates, Simon; Williams, Mark A.; Williamson, Esther M.; Mt-Isa, Shahrul; Withers, Emma J.; Castelnuovo, Emanuela; Smith, Jessica; Ashby, Deborah; Cooke, Matthew W.; Petrou, Stavros; Underwood, Martin R.		Managing Injuries Neck Trial MINT	Emergency department treatments and physiotherapy for acute whiplash: a pragmatic, two-step, randomised controlled trial	LANCET			English	Article							2000-2010 TASK-FORCE; MANAGING INJURIES; EARLY MANAGEMENT; NECK PAIN; DISORDERS; INTERVENTION; GUIDELINES; MINT; RECOVERY; IMPROVE	Background Little is known about the effectiveness of treatments for acute whiplash injury. We aimed to estimate whether training of staff in emergency departments to provide active management consultations was more effective than usual consultations (Step 1) and to estimate whether a physiotherapy package was more effective than one additional physiotherapy advice session in patients with persisting symptoms (Step 2). Methods Step 1 was a pragmatic, cluster randomised trial of 12 NHS Trust hospitals including 15 emergency departments who treated patients with acute whiplash associated disorder of grades I-III. The hospitals were randomised by clusters to either active management or usual care consultations. In Step 2, we used a nested individually randomised trial. Patients were randomly assigned to receive either a package of up to six physiotherapy sessions or a single advice session. Randomisation in Step 2 was stratified by centre. Investigator-masked outcomes were obtained at 4, 8, and 12 months. Masking of clinicians and patients was not possible in all steps of the trial. The primary outcome was the Neck Disability Index (NDI). Analysis was intention to treat, and included an economic evaluation. The study is registered ISRCTN33302125. Findings Recruitment ran from Dec 5, 2005 to Nov 30, 2007. Follow-up was completed on Dec 19, 2008. In Step 1, 12 NHS Trusts were randomised, and 3851 of 6952 eligible patients agreed to participate (1598 patients were assigned to usual care and 2253 patients were assigned to active management). 2704 (70%) of 3851 patients provided data at 12 months. NDI score did not differ between active management and usual care consultations (difference at 12 months 0.5, 95% CI -1.5 to 2.5). In Step 2, 599 patients were randomly assigned to receive either advice (299 patients) or a physiotherapy package (300 patients). 479 (80%) patients provided data at 12 months. The physiotherapy package at 4 months showed a modest benefit compared to advice (NDI difference -3.7, -6.1 to -1.3), but not at 8 or 12 months. Active management consultations and the physiotherapy package were more expensive than usual care and single advice session. No treatment-related serious adverse events or deaths were noted. Interpretation Provision of active management consultation did not show additional benefit. A package of physiotherapy gave a modest acceleration to early recovery of persisting symptoms but was not cost effective from a UK NHS perspective. Usual consultations in emergency departments and a single physiotherapy advice session for persistent symptoms are recommended.	[Lamb, Sarah E.; Gates, Simon; Williams, Mark A.; Williamson, Esther M.; Withers, Emma J.; Castelnuovo, Emanuela; Smith, Jessica; Cooke, Matthew W.; Petrou, Stavros; Underwood, Martin R.] Univ Warwick, Warwick Med Sch, Warwick Clin Trials Unit, Coventry CV4 7AL, W Midlands, England; [Lamb, Sarah E.] John Radcliff Hosp, Kadoorie Crit Care Res Ctr, Oxford, England; [Mt-Isa, Shahrul; Ashby, Deborah] Univ London Imperial Coll Sci Technol & Med, London, England	University of Warwick; Imperial College London	Lamb, SE (corresponding author), Univ Warwick, Warwick Med Sch, Warwick Clin Trials Unit, Coventry CV4 7AL, W Midlands, England.	s.lamb@warwick.ac.uk	Petrou, Stavros/ABD-8323-2021; Mt-Isa, Shahrul/F-1275-2010; Williams, Mark/J-5347-2013; Sterling, Michele/F-1679-2010; Underwood, Martin/D-6364-2015	Petrou, Stavros/0000-0003-3121-6050; Mt-Isa, Shahrul/0000-0002-7163-8402; Williams, Mark/0000-0002-3488-847X; Sterling, Michele/0000-0003-1772-2248; Underwood, Martin/0000-0002-0309-1708; Lamb, Sarah/0000-0003-4349-7195; Williamson, Esther/0000-0003-0638-0406	NIHR Health Technology Assessment programme [02/35/02]; Birmingham Science; Advantage West Midlands; National Institute for Health Research [NF-SI-0512-10103, 02/35/02] Funding Source: researchfish	NIHR Health Technology Assessment programme(National Institute for Health Research (NIHR)); Birmingham Science; Advantage West Midlands(General Electric); National Institute for Health Research(National Institute for Health Research (NIHR))	MINT was funded by the NIHR Health Technology Assessment Programme, project number 02/35/02. This project benefitted from facilities funded through Birmingham Science. City Translational Medicine Clinical Research and Infrastructure Trials Platform, with support from Advantage West Midlands.	[Anonymous], 2002, BC MED J; Carroll LJ, 2008, SPINE, V33, pS83, DOI 10.1097/BRS.0b013e3181643eb8; Ferrari R, 2005, ACAD EMERG MED, V12, P699, DOI 10.1197/j.aem.2005.03.531; Gargan M, 1997, J BONE JOINT SURG BR, V79B, P523, DOI 10.1302/0301-620X.79B4.6940; Gates S, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-44; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Hurwitz EL, 2008, SPINE, V33, pS123, DOI 10.1097/BRS.0b013e3181644b1d; Kongsted A, 2008, SPINE, V33, pE843, DOI 10.1097/BRS.0b013e318182bee2; Lamb SE, 2009, EMERG MED J, V26, P644, DOI 10.1136/emj.2008.065276; Lamb SE, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471-2474-8-7; Mayou R, 1996, INJURY, V27, P617, DOI 10.1016/S0020-1383(96)00114-3; McClune T, 2003, EMERG MED J, V20, P514, DOI 10.1136/emj.20.6.514; National Centre for Social Research and University of College London. Department of Epidemiology and Public Health HSfE, 1991, HLTH SURV ENGL 2006; National Institute for Health and Clinical Excellence (NICE), 2008, GUID METH TECHN APPR; PENNIE B, 1991, INJURY, V22, P57, DOI 10.1016/0020-1383(91)90166-C; Pietrobon B, 2002, SPINE, V27, P515, DOI 10.1097/00007632-200203010-00012; Provinciali L, 1996, SCAND J REHABIL MED, V28, P105; Rasbash J., 2009, MLWIN VERSION 2 1; Rosenfeld M, 2003, SPINE, V28, P2491, DOI 10.1097/01.BRS.0000090822.96814.13; Rushton A, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000265; Savigny P, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1805; SPITZER WO, 1995, SPINE, V20, pS1; Torgerson DJ, 2001, BMJ-BRIT MED J, V322, P355, DOI 10.1136/bmj.322.7282.355; Underwood M, 2002, FAM PRACT, V19, P511, DOI 10.1093/fampra/19.5.511; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.3.CO;2-I; Verhagen A, 2007, COCHRANE DB SYST REV, V2; VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409; Waddell G, 2005, WHIPLASH BOOK; WILLIAMS A., 1995, MEASUREMENT VALUATIO; Williamson E, 2009, PHYSIOTHERAPY, V95, P15, DOI 10.1016/j.physio.2008.11.001	30	84	86	0	44	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 16	2013	381	9866					546	556		10.1016/S0140-6736(12)61304-X	http://dx.doi.org/10.1016/S0140-6736(12)61304-X			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	089RK	23260167				2023-01-03	WOS:000314927500029
J	Kamerow, D				Kamerow, Douglas			Reassessing hospital readmission penalties	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							30-DAY READMISSIONS		RTI Int, Res Triangle Pk, NC 27709 USA	Research Triangle Institute	Kamerow, D (corresponding author), RTI Int, Res Triangle Pk, NC 27709 USA.	dkamerow@rti.org		Kamerow, Douglas/0000-0001-7000-9957				Dharmarajan K, 2013, JAMA-J AM MED ASSOC, V309, P355, DOI 10.1001/jama.2012.216476; Joynt KE, 2013, JAMA-J AM MED ASSOC, V309, P342, DOI 10.1001/jama.2012.94856; Joynt KE, 2012, NEW ENGL J MED, V366, P1366, DOI 10.1056/NEJMp1201598; Rau J, 2012, KAISER HLTH NEW 1126; Williams MV, 2013, JAMA-J AM MED ASSOC, V309, P394, DOI 10.1001/jama.2012.233964	5	2	2	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 14	2013	346								f1043	10.1136/bmj.f1043	http://dx.doi.org/10.1136/bmj.f1043			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	091ZR	23412742				2023-01-03	WOS:000315088800006
J	Luque-Fernandez, MA; Van Cutsem, G; Goemaere, E; Hilderbrand, K; Schomaker, M; Mantangana, N; Mathee, S; Dubula, V; Ford, N; Hernan, MA; Boulle, A				Luque-Fernandez, Miguel Angel; Van Cutsem, Gilles; Goemaere, Eric; Hilderbrand, Katherine; Schomaker, Michael; Mantangana, Nompumelelo; Mathee, Shaheed; Dubula, Vuyiseka; Ford, Nathan; Hernan, Miguel A.; Boulle, Andrew			Effectiveness of Patient Adherence Groups as a Model of Care for Stable Patients on Antiretroviral Therapy in Khayelitsha, Cape Town, South Africa	PLOS ONE			English	Article							TREATMENT PROGRAM; HIV TREATMENT; HEALTH-CARE; OUTCOMES; ZIDOVUDINE; EXPERIENCE; RATES	Background: Innovative models of care are required to cope with the ever-increasing number of patients on antiretroviral therapy in the most affected countries. This study, in Khayelitsha, South Africa, evaluates the effectiveness of a group-based model of care run predominantly by non-clinical staff in retaining patients in care and maintaining adherence. Methods and Findings: Participation in "adherence clubs'' was offered to adults who had been on ART for at least 18 months, had a current CD4 count > 200 cells/ml and were virologically suppressed. Embedded in an ongoing cohort study, we compared loss to care and virologic rebound in patients receiving the intervention with patients attending routine nurse-led care from November 2007 to February 2011. We used inverse probability weighting to estimate the intention-to-treat effect of adherence club participation, adjusted for measured baseline and time-varying confounders. The principal outcome was the combination of death or loss to follow-up. The secondary outcome was virologic rebound in patients who were virologically suppressed at study entry. Of 2829 patients on ART for > 18 months with a CD4 count above 200 cells/mu l, 502 accepted club participation. At the end of the study, 97% of club patients remained in care compared with 85% of other patients. In adjusted analyses club participation reduced loss-to-care by 57% (hazard ratio [HR] 0.43, 95% CI = 0.21-0.91) and virologic rebound in patients who were initially suppressed by 67% (HR 0.33, 95% CI = 0.16-0.67). Discussion: Patient adherence groups were found to be an effective model for improving retention and documented virologic suppression for stable patients in long term ART care. Out-of-clinic group-based models facilitated by non-clinical staff are a promising approach to assist in the long-term management of people on ART in high burden low or middle-income settings.	[Luque-Fernandez, Miguel Angel; Van Cutsem, Gilles; Goemaere, Eric; Hilderbrand, Katherine; Schomaker, Michael; Ford, Nathan; Boulle, Andrew] Univ Cape Town, Ctr Infect Dis Epidemiol & Res, Sch Publ Hlth & Family Med, ZA-7925 Cape Town, South Africa; [Van Cutsem, Gilles; Goemaere, Eric; Hilderbrand, Katherine] Medecins Sans Frontieres, Cape Town, South Africa; [Mantangana, Nompumelelo; Mathee, Shaheed] Prov Govt Western Cape, Dept Hlth, Khayelitsha Community Hlth Ctr, Cape Town, South Africa; [Dubula, Vuyiseka] Treatment Act Campaign, Cape Town, South Africa; [Ford, Nathan] Medecins Sans Frontieres, Geneva, Switzerland; [Hernan, Miguel A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Hernan, Miguel A.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Hernan, Miguel A.] Harvard Massachusetts Inst Technol, Div Hlth Sci & Technol, Boston, MA USA	University of Cape Town; Doctors Without Borders; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	Luque-Fernandez, MA (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.	miguel.luquefernandez@uct.ac.za	FERNANDEZ, MIGUEL ANGEL LUQUE/AAK-7183-2021; Boulle, Andrew/C-1413-2008; Van Cutsem, Gilles/ABB-1171-2021; Dubula-Majola, Vuyiseka/AAV-2562-2021; FERNANDEZ, MIGUEL ANGEL LUQUE/AAZ-5017-2020; Schomaker, Michael/K-3840-2019; FERNANDEZ, MIGUEL ANGEL LUQUE/L-4053-2015	FERNANDEZ, MIGUEL ANGEL LUQUE/0000-0001-6683-5164; Boulle, Andrew/0000-0002-7713-8062; Van Cutsem, Gilles/0000-0002-8972-4480; FERNANDEZ, MIGUEL ANGEL LUQUE/0000-0001-6683-5164; Schomaker, Michael/0000-0002-8475-0591; FERNANDEZ, MIGUEL ANGEL LUQUE/0000-0001-6683-5164; Dubula-Majola, Vuyiseka/0000-0003-0559-5974; Hernan, Miguel/0000-0003-1619-8456	University of Cape Town [LQFMIG001]; National Institute of Allergy and Infectious Diseases [U01AI069924-01]; NIH [R01 AI102634]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI069924, R01AI102634] Funding Source: NIH RePORTER	University of Cape Town; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	MALF was supported by the University of Cape Town with a postdoctoral fellowship (LQFMIG001). AB was partially supported by the National Institute of Allergy and Infectious Diseases (U01AI069924-01). MAH was partly funded by NIH grant R01 AI102634. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barnighausen T, 2011, LANCET INFECT DIS, V11, P942, DOI 10.1016/S1473-3099(11)70181-5; Bedelu M, 2007, J INFECT DIS, V196, pS464, DOI 10.1086/521114; Bemelmans M, 2010, TROP MED INT HEALTH, V15, P1413, DOI 10.1111/j.1365-3156.2010.02649.x; Boulle A, 2010, AIDS, V24, P563, DOI 10.1097/QAD.0b013e328333bfb7; Callaghan M, 2010, HUM RESOUR HEALTH, V8, DOI 10.1186/1478-4491-8-8; Choi HK, 2002, LANCET, V359, P1173, DOI 10.1016/S0140-6736(02)08213-2; Coetzee D, 2004, AIDS, V18, P887, DOI 10.1097/00002030-200404090-00006; Cohen R, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-23; Cole SR, 2008, AM J EPIDEMIOL, V168, P656, DOI 10.1093/aje/kwn164; Cornell M, 2010, AIDS, V24, P2263, DOI 10.1097/QAD.0b013e32833d45c5; Decroo T, 2010, J ACQ IMMUN DEF SYND; Fewell Z, 2004, STATA J, V4, P402, DOI 10.1177/1536867X0400400403; Ford N, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001060; Granich R, 2010, CURR OPIN HIV AIDS, V5, P298, DOI 10.1097/COH.0b013e32833a6c32; Hernan MA, 2000, EPIDEMIOLOGY, V11, P561, DOI 10.1097/00001648-200009000-00012; Hernan MA, 2002, STAT MED, V21, P1689, DOI 10.1002/sim.1144; Jaffar S, 2009, LANCET, V374, P2080, DOI 10.1016/S0140-6736(09)61674-3; Massaquoi M, 2009, T ROY SOC TROP MED H, V103, P594, DOI 10.1016/j.trstmh.2009.02.012; Nabudere H, 2011, INT J TECHNOL ASSESS, V27, P173, DOI 10.1017/S0266462311000055; Nachega JB, 2009, JAIDS-J ACQ IMM DEF, V51, P65, DOI 10.1097/QAI.0b013e318199072e; [National Department of Health SA Health Do], 2008, S AFR ANT TREATM GUI; National Department of Health SA, 2010, S AFR ANT TREATM GUI; Organization WH, 2011, WORLD HLTH STAT; ROSENBERG PS, 1995, BIOMETRICS, V51, P874, DOI 10.2307/2532989; Roura M, 2009, AIDS PATIENT CARE ST, V23, P203, DOI 10.1089/apc.2008.0129; Sanne I, 2010, LANCET, V376, P33, DOI 10.1016/S0140-6736(10)60894-X; Selke HM, 2010, JAIDS-J ACQ IMM DEF, V55, P483, DOI 10.1097/QAI.0b013e3181eb5edb; Van Cutsem G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014684; Wringe A, 2009, AIDS CARE, V21, P632, DOI 10.1080/09540120802385629; Zachariah R, 2010, T ROY SOC TROP MED H, V104, P387, DOI 10.1016/j.trstmh.2010.01.004	30	152	154	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2013	8	2							e56088	10.1371/journal.pone.0056088	http://dx.doi.org/10.1371/journal.pone.0056088			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104DM	23418518	Green Published, gold, Green Accepted, Green Submitted			2023-01-03	WOS:000315970300110
J	Kesselheim, AS; Mello, MM; Avorn, J				Kesselheim, Aaron S.; Mello, Michelle M.; Avorn, Jerry			FDA Regulation of Off-label Drug Promotion Under Attack	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PHARMACEUTICAL PROMOTION		[Kesselheim, Aaron S.; Avorn, Jerry] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon,Dept Med, Boston, MA 02120 USA; [Mello, Michelle M.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Kesselheim, AS (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon,Dept Med, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA.	akesselheim@partners.org	Kesselheim, Aaron/R-6793-2017	Kesselheim, Aaron/0000-0002-8867-2666; Mello, Michelle/0000-0003-2877-4270	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS018465] Funding Source: NIH RePORTER; AHRQ HHS [K08HS18465-01] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Gagnon MA, 2008, PLOS MED, V5, P29, DOI 10.1371/journal.pmed.0050001; Jazz Pharmaceuticals Inc, 2007, AGR PAY 20 MILL RES; Kesselheim AS, 2008, NEW ENGL J MED, V358, P1727, DOI 10.1056/NEJMsb0708920; Mello MM, 2011, NEW ENGL J MED, V365, P1248, DOI 10.1056/NEJMhle1107678; Orphan Medical, 2002, XYR DRUG LAB	5	9	10	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 6	2013	309	5					445	446		10.1001/jama.2012.207972	http://dx.doi.org/10.1001/jama.2012.207972			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	083LY	23385267				2023-01-03	WOS:000314466900022
J	Coussens, LM; Zitvogel, L; Palucka, AK				Coussens, Lisa M.; Zitvogel, Laurence; Palucka, A. Karolina			Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?	SCIENCE			English	Review							CD4(+) T-CELLS; RHEUMATOID-ARTHRITIS; DENDRITIC CELLS; CANCER; IMMUNITY; MACROPHAGES; STROMA; RISK; CLASSIFICATION; IMMUNOTHERAPY	There have been substantial advances in cancer diagnostics and therapies in the past decade. Besides chemotherapeutic agents and radiation therapy, approaches now include targeting cancer cell-intrinsic mediators linked to genetic aberrations in cancer cells, in addition to cancer cell-extrinsic pathways, especially those regulating vascular programming of solid tumors. More recently, immunotherapeutics have entered the clinic largely on the basis of the recognition that several immune cell subsets, when chronically activated, foster tumor development. Here, we discuss clinical and experimental studies delineating protumorigenic roles for immune cell subsets that are players in cancer-associated inflammation. Some of these cells can be targeted to reprogram their function, leading to resolution, or at least neutralization, of cancer-promoting chronic inflammation, thereby facilitating cancer rejection.	[Coussens, Lisa M.] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Cell & Dev Biol, Portland, OR 97239 USA; [Zitvogel, Laurence] Univ Paris 11, Inst Gustave Roussy, CICBT507, INSERM,U1015, F-94805 Paris, France; [Palucka, A. Karolina] BIIR, Dallas, TX 75204 USA; [Palucka, A. Karolina] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA	Oregon Health & Science University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Icahn School of Medicine at Mount Sinai	Coussens, LM (corresponding author), Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Cell & Dev Biol, 3181 SW Sam Jackson Pk Rd,Mail Code L215,Room 550, Portland, OR 97239 USA.	coussenl@ohsu.edu	Coussens, Lisa/ABH-9834-2020	ZITVOGEL, laurence/0000-0003-1596-0998	NIH/National Cancer Institute (NCI); Department of Defense; Susan B. Komen Foundation; Breast Cancer Research Foundation; LIGUE Francaise Contre le Cancer; Fondation pour la Recherche Medicale; Institut National du Cancer (SIRIC); Fondation Gustave Roussy; BIIR; Baylor University Medical Center foundations; Cancer Prevention Research Institute of Texas; NIH/NCI; NATIONAL CANCER INSTITUTE [R01CA155331, U54CA163123] Funding Source: NIH RePORTER	NIH/National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)National Research Council of Science & Technology (NST), Republic of Korea); Department of Defense(United States Department of Defense); Susan B. Komen Foundation(Susan G. Komen Breast Cancer Foundation); Breast Cancer Research Foundation; LIGUE Francaise Contre le Cancer; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Institut National du Cancer (SIRIC); Fondation Gustave Roussy; BIIR; Baylor University Medical Center foundations; Cancer Prevention Research Institute of Texas; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank members of their laboratories for critical discussions on content and specifically A. Gunderson and B. Ruffell for critical reading of the manuscript. L. M. C. acknowledges support from the NIH/National Cancer Institute (NCI), a Department of Defense Breast Cancer Research Program Era of Hope Scholar Scholar Expansion Award, Susan B. Komen Foundation, and the Breast Cancer Research Foundation. L.Z. is supported by LIGUE Francaise Contre le Cancer, Fondation pour la Recherche Medicale, Institut National du Cancer (SIRIC), and Fondation Gustave Roussy. A.K.P. acknowledges the support from the BIIR and Baylor University Medical Center foundations, Susan B. Komen Foundation, Cancer Prevention Research Institute of Texas, and NIH/NCI.	Adams S, 2012, CLIN CANCER RES, V18, P6748, DOI 10.1158/1078-0432.CCR-12-1149; Ammirante M, 2010, NATURE, V464, P302, DOI 10.1038/nature08782; Andreu P, 2010, CANCER CELL, V17, P121, DOI 10.1016/j.ccr.2009.12.019; Anglesio MS, 2011, CLIN CANCER RES, V17, P2538, DOI 10.1158/1078-0432.CCR-10-3314; Aspord C, 2007, J EXP MED, V204, P1037, DOI 10.1084/jem.20061120; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Balkwill FR, 2012, SEMIN CANCER BIOL, V22, P33, DOI 10.1016/j.semcancer.2011.12.005; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Beatty GL, 2011, SCIENCE, V331, P1612, DOI 10.1126/science.1198443; Beck AH, 2009, CLIN CANCER RES, V15, P778, DOI 10.1158/1078-0432.CCR-08-1283; Bickels J, 2002, ISRAEL MED ASSOC J, V4, P471; Bluestone JA, 2009, NAT REV IMMUNOL, V9, P811, DOI 10.1038/nri2654; Bongartz T, 2006, JAMA-J AM MED ASSOC, V295, P2275, DOI 10.1001/jama.295.19.2275; Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609; Campbell MJ, 2011, BREAST CANCER RES TR, V128, P703, DOI 10.1007/s10549-010-1154-y; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; De Monte L, 2011, J EXP MED, V208, P469, DOI 10.1084/jem.20101876; de Visser KE, 2005, CANCER CELL, V7, P411, DOI 10.1016/j.ccr.2005.04.014; Demehri S, 2012, CANCER CELL, V22, P494, DOI 10.1016/j.ccr.2012.08.017; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; DeNardo DG, 2009, CANCER CELL, V16, P91, DOI 10.1016/j.ccr.2009.06.018; Di Piazza M, 2012, CANCER CELL, V22, P479, DOI 10.1016/j.ccr.2012.08.016; Dinarello CA, 2010, CANCER METAST REV, V29, P317, DOI 10.1007/s10555-010-9229-0; Doedens AL, 2010, CANCER RES, V70, P7465, DOI 10.1158/0008-5472.CAN-10-1439; Dong C, 2008, NAT REV IMMUNOL, V8, P337, DOI 10.1038/nri2295; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Freund A, 2010, TRENDS MOL MED, V16, P238, DOI 10.1016/j.molmed.2010.03.003; Galon J, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-205; Galon J, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-1; Geborek P, 2005, ANN RHEUM DIS, V64, P699, DOI 10.1136/ard.2004.030528; Gocheva V, 2010, GENE DEV, V24, P241, DOI 10.1101/gad.1874010; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Haas KM, 2005, IMMUNITY, V23, P7, DOI 10.1016/j.immuni.2005.04.011; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hasan A, 2011, EXPERT OPIN THER TAR, V15, P1211, DOI 10.1517/14728222.2011.613826; Heber G, 2009, J DTSCH DERMATOL GES, V7, P534, DOI 10.1111/j.1610-0387.2009.07038.x; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Horikawa M, 2011, J CLIN INVEST, V121, P4268, DOI 10.1172/JCI59266; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kessel A, 2008, CLIN REV ALLERG IMMU, V34, P74, DOI 10.1007/s12016-008-8074-1; Kido M, 2010, INFECT IMMUN, V78, P108, DOI 10.1128/IAI.00762-09; Kozin SV, 2010, CANCER RES, V70, P5679, DOI 10.1158/0008-5472.CAN-09-4446; Kristensen VN, 2012, P NATL ACAD SCI USA, V109, P2802, DOI 10.1073/pnas.1108781108; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Lu PF, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005058; Matsushita H, 2012, NATURE, V482, P400, DOI 10.1038/nature10755; Pedroza-Gonzalez A, 2011, J EXP MED, V208, P479, DOI 10.1084/jem.20102131; Pillai S, 2011, CURR OPIN IMMUNOL, V23, P721, DOI 10.1016/j.coi.2011.10.007; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Qian DZ, 2010, PROSTATE, V70, P433, DOI 10.1002/pros.21077; Ruffell B, 2012, TRENDS IMMUNOL, V33, P119, DOI 10.1016/j.it.2011.12.001; Sakthivel P, 2012, REV RECENT CLIN TRIA, V7, P10, DOI 10.2174/157488712799363262; Schioppa T, 2011, P NATL ACAD SCI USA, V108, P10662, DOI 10.1073/pnas.1100994108; Sharpe AH, 2007, NAT IMMUNOL, V8, P239, DOI 10.1038/ni1443; Shree T, 2011, GENE DEV, V25, P2465, DOI 10.1101/gad.180331.111; Skinnider BF, 2002, BLOOD, V99, P4283, DOI 10.1182/blood-2002-01-0099; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Tan TT, 2007, CURR OPIN IMMUNOL, V19, P209, DOI 10.1016/j.coi.2007.01.001; Tanchot C, 2013, CANCER MICROENVIRON, V6, P147, DOI 10.1007/s12307-012-0122-y; Terabe M, 2004, CANCER IMMUNOL IMMUN, V53, P79, DOI 10.1007/s00262-003-0445-0; Thun Michael J, 2004, Novartis Found Symp, V256, P6; Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224; Wang SDA, 2011, CURR TOP MICROBIOL, V344, P245, DOI 10.1007/82_2010_81; Wei EK, 2010, J CLIN ONCOL, V28, P4052, DOI 10.1200/JCO.2009.26.9324; Wei S, 2012, ONCOIMMUNOLOGY, V1, DOI 10.4161/onci.19440; Welford AF, 2011, J CLIN INVEST, V121, P1969, DOI 10.1172/JCI44562; Wooster R, 2010, CURR OPIN GENET DEV, V20, P336, DOI 10.1016/j.gde.2010.03.007; ZBAR B, 1971, SCIENCE, V172, P271, DOI 10.1126/science.172.3980.271; Zhang WJ, 2008, CYTOKINE, V42, P39, DOI 10.1016/j.cyto.2008.01.016	73	744	781	5	232	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 18	2013	339	6117					286	291		10.1126/science.1232227	http://dx.doi.org/10.1126/science.1232227			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	071UW	23329041	Green Accepted			2023-01-03	WOS:000313622000035
J	Costa-da-Silva, AL; Navarrete, FR; Salvador, FS; Karina-Costa, M; Ioshino, RS; Azevedo, DS; Rocha, DR; Romano, CM; Capurro, ML				Costa-da-Silva, Andre Luis; Navarrete, Flavia Rosa; Salvador, Felipe Scassi; Karina-Costa, Maria; Ioshino, Rafaella Sayuri; Azevedo, Diego Soares; Rocha, Desiree Rafaela; Romano, Camila Malta; Capurro, Margareth Lara			Glytube: A Conical Tube and Parafilm M-Based Method as a Simplified Device to Artificially Blood-Feed the Dengue Vector Mosquito, Aedes aegypti	PLOS ONE			English	Article							RHODNIUS-PROLIXUS; SYSTEM; INSECT	Aedes aegypti, the main vector of dengue virus, requires a blood meal to produce eggs. Although live animals are still the main blood source for laboratory colonies, many artificial feeders are available. These feeders are also the best method for experimental oral infection of Ae. aegypti with Dengue viruses. However, most of them are expensive or laborious to construct. Based on principle of Rutledge-type feeder, a conventional conical tube, glycerol and Parafilm-M were used to develop a simple in-house feeder device. The blood feeding efficiency of this apparatus was compared to a live blood source, mice, and no significant differences (p = 0.1189) were observed between artificial-fed (51.3% of engorgement) and mice-fed groups (40.6%). Thus, an easy to assemble and cost-effective artificial feeder, designated "Glytube" was developed in this report. This simple and efficient feeding device can be built with common laboratory materials for research on Ae. aegypti.	[Costa-da-Silva, Andre Luis; Navarrete, Flavia Rosa; Karina-Costa, Maria; Ioshino, Rafaella Sayuri; Azevedo, Diego Soares; Rocha, Desiree Rafaela; Capurro, Margareth Lara] Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, BR-05508 Sao Paulo, Brazil; [Salvador, Felipe Scassi; Romano, Camila Malta] Univ Sao Paulo, Virol Lab, Inst Trop Med, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo	Costa-da-Silva, AL (corresponding author), Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, BR-05508 Sao Paulo, Brazil.	alcosta@icb.usp.br	Capurro, Margareth L/F-8679-2012; Ioshino, Rafaella Sayuri/P-9814-2016; Romano, Camila/ABC-2883-2020; Silva, Andre/N-8654-2013; Costa-da-Silva, Andre Luis/F-7874-2012; Capurro, Margareth/M-5286-2019; Salvador, Felipe Scassi/AAU-8431-2021; Costa-Da-Silva, André Luis/J-8913-2019; Romano, Camila M/C-8185-2013	Capurro, Margareth L/0000-0002-7480-2116; Ioshino, Rafaella Sayuri/0000-0002-9225-0140; Romano, Camila/0000-0003-4550-1987; Costa-da-Silva, Andre Luis/0000-0002-7615-7376; Costa-Da-Silva, André Luis/0000-0002-7615-7376; 	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESP [2008/10254-1, 2009/53637-0]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq/Departamento de Ciencia e Tecnologia - DECIT [555648/2009-5]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - CAPES; Instituto Nacional de Ciencia e Tecnologia em Entomologia Molecular - INCT-EM	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq/Departamento de Ciencia e Tecnologia - DECIT; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Instituto Nacional de Ciencia e Tecnologia em Entomologia Molecular - INCT-EM	This work was supported by grants from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESP (#2008/10254-1; #2009/53637-0) - www.fapesp.br, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq/Departamento de Ciencia e Tecnologia - DECIT (#555648/2009-5) - www.cnpq.br, Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - CAPES - www.capes.gov.br, Instituto Nacional de Ciencia e Tecnologia em Entomologia Molecular - INCT-EM - www.inctem.bioqmed.ufrj.br. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Benedict M. Q., 2009, METHODS ANOPHELES RE, P288; BENZON GL, 1987, J AM MOSQUITO CONTR, V3, P322; Chiang RG, 2010, ARCH INSECT BIOCHEM, V74, P103, DOI 10.1002/arch.20365; Clements AN., 1992, BIOL MOSQUITOES DEV; COSGROVE JB, 1995, J AM MOSQUITO CONTR, V11, P339; COSGROVE JB, 1994, J AM MOSQUITO CONTR, V10, P434; Das Suchismita, 2007, J Vis Exp, P220, DOI 10.3791/220; Deng L, 2012, TROP BIOMED, V29, P169; Ferdowsian HR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024059; Filipecki Ana Tereza Pinto, 2011, ILAR J, V52, pE8; Gauthier C, 2008, I ANIMAL CARE COMMIT, V14, P157; Ghaninia M, 2008, J EXP BIOL, V211, P3020, DOI 10.1242/jeb.016360; HUEBNER E, 1994, CAN J ZOOL, V72, P2244, DOI 10.1139/z94-299; Jagjiwanram, 2004, INDIAN J ENG MATER S, V11, P125; Pothikasikorn J, 2010, J VECTOR ECOL, V35, P149, DOI 10.1111/j.1948-7134.2010.00041.x; Rampersad J, 2007, J AM MOSQUITO CONTR, V23, P149, DOI 10.2987/8756-971X(2007)23[149:VBBFLF]2.0.CO;2; RUTLEDGE L. C., 1964, MOSQUITO NEWS, V24, P407; Salazar MI, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-9; Tseng M, 2003, J MED ENTOMOL, V40, P588, DOI 10.1603/0022-2585-40.4.588; Waladde SM, 1996, PARASITOL TODAY, V12, P272, DOI 10.1016/0169-4758(96)10027-2	20	36	36	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2013	8	1							e53816	10.1371/journal.pone.0053816	http://dx.doi.org/10.1371/journal.pone.0053816			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	087KE	23342010	Green Submitted, Green Published, gold			2023-01-03	WOS:000314759400088
J	Amieva, H; Meillon, C; Helmer, C; Barberger-Gateau, P; Dartigues, JF				Amieva, Helene; Meillon, Celine; Helmer, Catherine; Barberger-Gateau, Pascale; Dartigues, Jean Francois			Ginkgo Biloba Extract and Long-Term Cognitive Decline: A 20-Year Follow-Up Population-Based Study	PLOS ONE			English	Article							PRECLINICAL ALZHEIMERS-DISEASE; PLACEBO-CONTROLLED TRIAL; EGB 761(R); BENZODIAZEPINE USE; RANDOMIZED-TRIAL; VITAMIN-E; DEMENTIA; PREVENTION; SUPPLEMENTATION; IMPAIRMENT	Background: Numerous studies have looked at the potential benefits of various nootropic drugs such as Ginkgo biloba extract (EGb761 (R); Tanakan (R)) and piracetam (Nootropyl (R)) on age-related cognitive decline often leading to inconclusive results due to small sample sizes or insufficient follow-up duration. The present study assesses the association between intake of EGb761 (R) and cognitive function of elderly adults over a 20-year period. Methods and Findings: The data were gathered from the prospective community-based cohort study 'Paquid'. Within the study sample of 3612 non-demented participants aged 65 and over at baseline, three groups were compared: 589 subjects reporting use of EGb761 (R) at at least one of the ten assessment visits, 149 subjects reporting use of piracetam at one of the assessment visits and 2874 subjects not reporting use of either EGb761 (R) or piracetam. Decline on MMSE, verbal fluency and visual memory over the 20-year follow-up was analysed with a multivariate mixed linear effects model. A significant difference in MMSE decline over the 20-year follow-up was observed in the EGb761 (R) and piracetam treatment groups compared to the 'neither treatment' group. These effects were in opposite directions: the EGb761 (R) group declined less rapidly than the 'neither treatment' group, whereas the piracetam group declined more rapidly (beta = -0.6). Regarding verbal fluency and visual memory, no difference was observed between the EGb761 (R) group and the 'neither treatment' group (respectively, beta = 0.21 and beta = -0.03), whereas the piracetam group declined more rapidly (respectively, beta = -1.40 and beta = -0.44). When comparing the EGb761 (R) and piracetam groups directly, a different decline was observed for the three tests (respectively beta = -1.07, beta = -1.61 and beta = -0.41). Conclusion: Cognitive decline in a non-demented elderly population was lower in subjects who reported using EGb761 (R) than in those who did not. This effect may be a specific medication effect of EGb761 (R), since it was not observed for another nootropic medication, piracetam.	[Amieva, Helene; Meillon, Celine; Helmer, Catherine; Barberger-Gateau, Pascale; Dartigues, Jean Francois] Univ Bordeaux, ISPED, Ctr INSERM Epidemiol Biostat U897, Bordeaux, France; [Amieva, Helene] Univ Bordeaux, Dept Psychol, Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux	Amieva, H (corresponding author), Univ Bordeaux, ISPED, Ctr INSERM Epidemiol Biostat U897, Bordeaux, France.	helene.amieva@isped.u-bordeaux2.fr	DARTIGUES, Jean François/T-4513-2019; HELMER, Catherine/AAG-5126-2021; HELMER, Catherine/I-6581-2015; Amieva, Helene/T-4170-2019; Meillon, Céline/T-4487-2019; Amieva, Helene/E-4850-2014	HELMER, Catherine/0000-0002-5169-7421; Amieva, Helene/0000-0002-0119-7242; 	ARMA (Bordeaux); Caisse Nationale d'Assurance Maladie des Travailleurs Salaries (CNAMTS); Conseil General de la Dordogne; Conseil General de la Gironde; Conseil Regional d'Aquitaine; Fondation de France; France Alzheimer (Paris); GIS Longevite; Institut National de la Sante et de la Recherche Medicale (INSERM); Mutuelle Generale de l'Education Nationale (MGEN); Mutualite Sociale Agricole (MSA); NOVARTIS Pharma (France); SCOR Insurance (France)	ARMA (Bordeaux); Caisse Nationale d'Assurance Maladie des Travailleurs Salaries (CNAMTS); Conseil General de la Dordogne(Region Nouvelle-Aquitaine); Conseil General de la Gironde(Region Nouvelle-Aquitaine); Conseil Regional d'Aquitaine(Region Nouvelle-Aquitaine); Fondation de France(Fondation de France); France Alzheimer (Paris); GIS Longevite; Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Mutuelle Generale de l'Education Nationale (MGEN); Mutualite Sociale Agricole (MSA); NOVARTIS Pharma (France); SCOR Insurance (France)	Funding: The PAQUID study was supported by ARMA (Bordeaux); Caisse Nationale d'Assurance Maladie des Travailleurs Salaries (CNAMTS); Conseil General de la Dordogne; Conseil General de la Gironde; Conseil Regional d'Aquitaine; Fondation de France; France Alzheimer (Paris); GIS Longevite; Institut National de la Sante et de la Recherche Medicale (INSERM); Mutuelle Generale de l'Education Nationale (MGEN); Mutualite Sociale Agricole (MSA); NOVARTIS Pharma (France); SCOR Insurance (France). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdel-Kader R, 2007, PHARMACOL RES, V56, P493, DOI 10.1016/j.phrs.2007.09.011; American Psychiatric Association, 1987, DIAGNOSTIC STAT MANU, VThird; Amieva H, 2008, ANN NEUROL, V64, P492, DOI 10.1002/ana.21509; Andrieu S, 2003, J GERONTOL A-BIOL, V58, P372; Backman L, 2005, NEUROPSYCHOLOGY, V19, P520, DOI 10.1037/0894-4105.19.4.520; Benton A, 1965, MANUEL APPL TEST RET; Bierman EJM, 2007, INT J GERIATR PSYCH, V22, P1194, DOI 10.1002/gps.1811; Bjelakovic G, 2007, JAMA-J AM MED ASSOC, V297, P842, DOI 10.1001/jama.297.8.842; Chen PJ, 2001, ARCH GEN PSYCHIAT, V58, P853, DOI 10.1001/archpsyc.58.9.853; Cramer C, 2008, NEUROLOGY, V71, P344, DOI 10.1212/01.wnl.0000319647.15752.7b; Dartigues JF, 2007, J AM GERIATR SOC, V55, P395, DOI 10.1111/j.1532-5415.2007.01084.x; Dartigues JF, 1997, THERAPIE, V52, P503; DARTIGUES JF, 1992, NEUROEPIDEMIOLOGY, V11, P14, DOI 10.1159/000110955; DeKosky ST, 2008, JAMA-J AM MED ASSOC, V300, P2253, DOI 10.1001/jama.2008.683; Dodge HH, 2008, NEUROLOGY, V70, P1809, DOI 10.1212/01.wnl.0000303814.13509.db; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Galasko DR, 2012, ARCH NEUROL; Grodstein F, 2007, ARCH INTERN MED, V167, P2184, DOI 10.1001/archinte.167.20.2184; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; Herrschaft H, 2012, J PSYCHIATR RES, V46, P716, DOI 10.1016/j.jpsychires.2012.03.003; Howieson DB, 2008, J INT NEUROPSYCH SOC, V14, P192, DOI 10.1017/S1355617708080375; Ihl R, 2010, J NEUROL SCI, V299, P184, DOI 10.1016/j.jns.2010.08.033; ISAACS B, 1973, BRIT J PSYCHIAT, V123, P467, DOI 10.1192/bjp.123.4.467; Janssen IM, 2010, WIEN MED WOCHENSCHR, V160, P539, DOI 10.1007/s10354-010-0844-8; Jia X, 2008, J HUM NUTR DIET, V21, P317, DOI 10.1111/j.1365-277X.2008.00887.x; Kang JH, 2006, ARCH INTERN MED, V166, P2462, DOI 10.1001/archinte.166.22.2462; Kehr J, 2012, INT PSYCHOGERIATR, V24, pS25, DOI 10.1017/S1041610212000567; Kesse-Guyot E, 2011, AM J CLIN NUTR, V94, P892, DOI 10.3945/ajcn.110.007815; KOLTRINGER P, 1995, CLIN HEMORHEOL, V15, P649; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Leoutsakos JMS, 2012, INT J GERIATR PSYCH, V27, P364, DOI 10.1002/gps.2723; Luo Y, 2002, P NATL ACAD SCI USA, V99, P12197, DOI 10.1073/pnas.182425199; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Meinert CL, 2008, ALZHEIMERS DEMENT, V4, pS7, DOI 10.1016/j.jalz.2007.10.007; Paterniti S, 2002, J CLIN PSYCHOPHARM, V22, P285, DOI 10.1097/00004714-200206000-00009; Petersen RC, 2005, NEW ENGL J MED, V352, P2379, DOI 10.1056/NEJMoa050151; Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rockwood K, 2002, ARCH NEUROL-CHICAGO, V59, P223, DOI 10.1001/archneur.59.2.223; Rosler M, 1998, J NEURAL TRANSM-SUPP, P211; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Schneider Lon S., 2005, Current Alzheimer Research, V2, P541, DOI 10.2174/156720505774932287; Schneider LS, 2012, LANCET NEUROL, V11, P836, DOI 10.1016/S1474-4422(12)70212-0; Small BJ, 2007, CORTEX, V43, P826, DOI 10.1016/S0010-9452(08)70682-8; Tchantchou F, 2007, FASEB J, V21, P2400, DOI 10.1096/fj.06-7649com; Trompet S, 2010, J NEUROL, V257, P85, DOI 10.1007/s00415-009-5271-7; van Vliet P, 2009, EXP GERONTOL, V44, P112, DOI 10.1016/j.exger.2008.05.004; Vellas B, 2012, LANCET NEUROL, V11, P851, DOI 10.1016/S1474-4422(12)70206-5; Weinmann S, 2010, BMC GERIATR, V10, DOI 10.1186/1471-2318-10-14; Williams B, 2004, NEUROBIOL AGING, V25, P955, DOI 10.1016/j.neurobiolaging.2003.10.008; Wolozin B, 2007, BMC MED, V5, DOI 10.1186/1741-7015-5-20; Wu YJ, 2006, J NEUROSCI, V26, P13102, DOI 10.1523/JNEUROSCI.3448-06.2006; Yaffe K, 2004, NEUROLOGY, V63, P1705, DOI 10.1212/01.WNL.0000142969.19465.8F; Yoshitake T, 2010, BRIT J PHARMACOL, V159, P659, DOI 10.1111/j.1476-5381.2009.00580.x; Zandi PP, 2005, ARCH GEN PSYCHIAT, V62, P217, DOI 10.1001/archpsyc.62.2.217	55	48	59	1	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2013	8	1							e52755	10.1371/journal.pone.0052755	http://dx.doi.org/10.1371/journal.pone.0052755			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	086RY	23326356	Green Published, gold, Green Submitted			2023-01-03	WOS:000314705800024
J	Villanueva, C; Colomo, A; Bosch, A; Concepcion, M; Hernandez-Gea, V; Aracil, C; Graupera, I; Poca, M; Alvarez-Urturi, C; Gordillo, J; Guarner-Argente, C; Santalo, M; Muniz, E; Guarner, C				Villanueva, Candid; Colomo, Alan; Bosch, Alba; Concepcion, Mar; Hernandez-Gea, Virginia; Aracil, Carles; Graupera, Isabel; Poca, Maria; Alvarez-Urturi, Cristina; Gordillo, Jordi; Guarner-Argente, Carlos; Santalo, Miquel; Muniz, Eduardo; Guarner, Carlos			Transfusion Strategies for Acute Upper Gastrointestinal Bleeding	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLOOD-CELL TRANSFUSION; CONSENSUS RECOMMENDATIONS; PORTAL-HYPERTENSION; HEMORRHAGE; METHODOLOGY; MANAGEMENT; MORTALITY; PRESSURE; WORKSHOP; OUTCOMES	BACKGROUND The hemoglobin threshold for transfusion of red cells in patients with acute gastrointestinal bleeding is controversial. We compared the efficacy and safety of a restrictive transfusion strategy with those of a liberal transfusion strategy. METHODS We enrolled 921 patients with severe acute upper gastrointestinal bleeding and randomly assigned 461 of them to a restrictive strategy (transfusion when the hemoglobin level fell below 7 g per deciliter) and 460 to a liberal strategy (transfusion when the hemoglobin fell below 9 g per deciliter). Randomization was stratified according to the presence or absence of liver cirrhosis. RESULTS A total of 225 patients assigned to the restrictive strategy (51%), as compared with 65 assigned to the liberal strategy (15%), did not receive transfusions (P<0.001). The probability of survival at 6 weeks was higher in the restrictive-strategy group than in the liberal-strategy group (95% vs. 91%; hazard ratio for death with restrictive strategy, 0.55; 95% confidence interval [CI], 0.33 to 0.92; P = 0.02). Further bleeding occurred in 10% of the patients in the restrictive-strategy group as compared with 16% of the patients in the liberal-strategy group (P = 0.01), and adverse events occurred in 40% as compared with 48% (P = 0.02). The probability of survival was slightly higher with the restrictive strategy than with the liberal strategy in the subgroup of patients who had bleeding associated with a peptic ulcer (hazard ratio, 0.70; 95% CI, 0.26 to 1.25) and was significantly higher in the subgroup of patients with cirrhosis and Child-Pugh class A or B disease (hazard ratio, 0.30; 95% CI, 0.11 to 0.85), but not in those with cirrhosis and Child-Pugh class C disease (hazard ratio, 1.04; 95% CI, 0.45 to 2.37). Within the first 5 days, the portal-pressure gradient increased significantly in patients assigned to the liberal strategy (P = 0.03) but not in those assigned to the restrictive strategy. CONCLUSIONS As compared with a liberal transfusion strategy, a restrictive strategy significantly improved outcomes in patients with acute upper gastrointestinal bleeding. (Funded by Fundacio Investigacio Sant Pau; ClinicalTrials.govnumber, NCT00414713.)	[Villanueva, Candid; Colomo, Alan; Concepcion, Mar; Hernandez-Gea, Virginia; Aracil, Carles; Graupera, Isabel; Poca, Maria; Alvarez-Urturi, Cristina; Gordillo, Jordi; Guarner-Argente, Carlos; Guarner, Carlos] Autonomous Univ Barcelona, Hosp St Pau, Gastrointestinal Bleeding Unit, Dept Gastroenterol, Barcelona, Spain; [Bosch, Alba; Muniz, Eduardo] Autonomous Univ Barcelona, Hosp St Pau, Blood & Tissue Bank, Barcelona, Spain; [Santalo, Miquel] Autonomous Univ Barcelona, Hosp St Pau, Semicrit Unit, Barcelona, Spain; [Villanueva, Candid; Colomo, Alan; Graupera, Isabel; Guarner, Carlos] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain	Autonomous University of Barcelona; Autonomous University of Barcelona; Fundacio Banc Sang Teixits de les Illes Balears; Autonomous University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD	Villanueva, C (corresponding author), Hosp Santa Creu & Sant Pau, Serv Patol Digest, Mas Casanovas 90, Barcelona 08025, Spain.	cvillanueva@santpau.cat	Guarner-Argente, Carlos/M-7616-2019; Hernandez-Gea, Virginia/E-9485-2017; Callahan, Charles D/L-1641-2013	Guarner-Argente, Carlos/0000-0002-8180-1488; Hernandez-Gea, Virginia/0000-0001-7937-984X; Poca Sans, Maria/0000-0002-0235-1395; Guarner, Carlos/0000-0001-5957-9481; Graupera, Isabel/0000-0001-9170-9784	Fundacio Investigacio Sant Pau; Sequana Medical	Fundacio Investigacio Sant Pau; Sequana Medical	Supported in part by the Fundacio Investigacio Sant Pau.; Dr. Guarner reports receiving consulting fees from Sequana Medical. No other potential conflict of interest relevant to this article was reported.	Barkun A, 2003, ANN INTERN MED, V139, P843, DOI 10.7326/0003-4819-139-10-200311180-00012; Barkun AN, 2010, ANN INTERN MED, V152, P101, DOI 10.7326/0003-4819-152-2-201001190-00009; BLAIR SD, 1986, BRIT J SURG, V73, P783, DOI 10.1002/bjs.1800731007; British Society of Gastroenterology, UK UPP GI BLEED AUD; Carson JL, 2011, NEW ENGL J MED, V365, P2453, DOI 10.1056/NEJMoa1012452; Castaneda B, 2001, HEPATOLOGY, V33, P821, DOI 10.1053/jhep.2001.23437; Crooks C, 2011, GASTROENTEROLOGY, V141, P62, DOI 10.1053/j.gastro.2011.03.048; de Franchis R, 2000, J HEPATOL, V33, P846; de Franchis R, 2010, J HEPATOL, V53, P762, DOI 10.1016/j.jhep.2010.06.004; Duggan JM, 2001, ALIMENT PHARM THERAP, V15, P1109, DOI 10.1046/j.1365-2036.2001.01013.x; Gralnek IM, 2008, NEW ENGL J MED, V359, P928, DOI 10.1056/NEJMra0706113; Halland M, 2010, DIGEST DIS SCI, V55, P3430, DOI 10.1007/s10620-010-1223-4; Hearnshaw SA, 2010, ALIMENT PHARM THER, V32, P215, DOI 10.1111/j.1365-2036.2010.04348.x; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hebert PC, 1999, NEW ENGL J MED, V340, P1056; Jairath V, 2010, COCHRANE DB SYST REV, V9; Kanias T, 2012, TRANSFUSION, V52, P1388, DOI 10.1111/j.1537-2995.2012.03748.x; Koch CG, 2008, NEW ENGL J MED, V358, P1229, DOI 10.1056/NEJMoa070403; KRAVETZ D, 1986, GASTROENTEROLOGY, V90, P1232, DOI 10.1016/0016-5085(86)90390-2; Lacroix J, 2007, NEW ENGL J MED, V356, P1609, DOI 10.1056/NEJMoa066240; Malone DL, 2003, J TRAUMA, V54, P898, DOI 10.1097/01.TA.0000060261.10597.5C; Marik PE, 2008, CRIT CARE MED, V36, P2667, DOI 10.1097/CCM.0b013e3181844677; MCCORMICK PA, 1995, GUT, V36, P100, DOI 10.1136/gut.36.1.100; Palmer KR, 2002, GUT, V51, P1; Roberts I, 2001, LANCET, V357, P385, DOI 10.1016/S0140-6736(00)03653-9; Robinson WP, 2005, J TRAUMA, V58, P437, DOI 10.1097/01.TA.0000153935.18997.14; Vamvakas EC, 2007, BLOOD REV, V21, P327, DOI 10.1016/j.blre.2007.07.003; Villanueva C, 2001, GASTROENTEROLOGY, V121, P110, DOI 10.1053/gast.2001.25536; Villarejo F., 1999, Acta Gastroenterologica Latinoamericana, V29, P261	29	942	986	7	81	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 3	2013	368	1					11	21		10.1056/NEJMoa1211801	http://dx.doi.org/10.1056/NEJMoa1211801			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	062PA	23281973				2023-01-03	WOS:000312930600001
J	Mittal, N				Mittal, Nikhil			Cell Surface Concentrations and Concentration Ranges for Testing In Vitro Autocrine Loops and Small Molecules	PLOS ONE			English	Article							EMBRYONIC STEM-CELLS; TRANSPORT; BIOMARKER; SURVIVAL; ASSAYS; LIGAND; SERUM; MODEL	A common assumption made when performing in vitro cellular assays is that the concentration of substances in the culture system is uniform. However, since the cells that internalize and secrete substances reside at the bottom of the well, it is conceivable that a concentration gradient could arise across the fluid layer. Importantly, the concentration of a substance in the vicinity of a cell, which is the concentration of interest, cannot be measured via existing methods. In this work a simple strategy for estimating the concentration of a chemical species at the surface of a cell is presented. Finally, this result is used to outline a method for determining the appropriate concentration ranges for testing in vitro autocrine loops and small molecules.	Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Mittal, N (corresponding author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.	nvmittal@partners.org		Mittal, Nikhil/0000-0002-2360-7134				Aziz N, 1999, CLIN DIAGN LAB IMMUN, V6, P89, DOI 10.1128/CDLI.6.1.89-95.1999; Batsilas L, 2003, BIOPHYS J, V85, P3659, DOI 10.1016/S0006-3495(03)74783-3; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Chaigneau C, 2007, CLIN CHEM LAB MED, V45, P1390, DOI 10.1515/CCLM.2007.160; Ellison D, 2009, MOL BIOSYST, V5, P1004, DOI 10.1039/b905602e; Guo Y, 2005, STEM CELLS, V23, P1324, DOI 10.1634/stemcells.2005-0085; He L, 2003, BIOTECHNOL PROGR, V19, P544; KNAUER DJ, 1984, J BIOL CHEM, V259, P5623; Lengelle J, 2008, CYTOKINE, V44, P275, DOI 10.1016/j.cyto.2008.08.010; Li F, 2006, INT FREQ CONTR S EXP, P538; Monine MI, 2005, BIOPHYS J, V88, P2384, DOI 10.1529/biophysj.104.051425; Netti PA, 2000, CANCER RES, V60, P2497; Ramanujan S, 2002, BIOPHYS J, V83, P1650, DOI 10.1016/S0006-3495(02)73933-7; Shvartsman SY, 2001, BIOPHYS J, V81, P1854, DOI 10.1016/S0006-3495(01)75837-7; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; THAVASU PW, 1992, J IMMUNOL METHODS, V153, P115, DOI 10.1016/0022-1759(92)90313-I; Vander AJ, 2001, HUMAN PHYSL MECH BOD, Vxviii; Wilder PJ, 1997, DEV BIOL, V192, P614, DOI 10.1006/dbio.1997.8777	18	2	2	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 28	2012	7	12							e51796	10.1371/journal.pone.0051796	http://dx.doi.org/10.1371/journal.pone.0051796			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	064DQ	23284769	gold, Green Published			2023-01-03	WOS:000313051500014
J	Metzger, ML; Billett, A; Link, MP				Metzger, Monika L.; Billett, Amy; Link, Michael P.			The Impact of Drug Shortages on Children with Cancer - The Example of Mechlorethamine	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							UNITED-STATES		[Metzger, Monika L.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA; [Metzger, Monika L.] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA; [Billett, Amy] Dana Farber Canc Inst, Boston, MA 02115 USA; [Billett, Amy] Boston Childrens Hosp, Boston, MA USA; [Link, Michael P.] Stanford Univ, Sch Med, Stanford, CA 94305 USA; [Link, Michael P.] Lucile Packard Childrens Hosp, Stanford, CA USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Stanford University; Lucile Packard Children's Hospital (LPCH)	Metzger, ML (corresponding author), St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA.							Chabner BA, 2011, NEW ENGL J MED, V365, P2147, DOI 10.1056/NEJMp1112633; Gatesman ML, 2011, NEW ENGL J MED, V365, P1653, DOI 10.1056/NEJMp1109772; Link MP, 2012, J CLIN ONCOL, V30, P692, DOI 10.1200/JCO.2011.41.0936	3	61	61	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 27	2012	367	26					2461	2463		10.1056/NEJMp1212468	http://dx.doi.org/10.1056/NEJMp1212468			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	059OG	23268661				2023-01-03	WOS:000312714200001
J	Glombiewski, JA; Nestoriuc, Y; Rief, W; Glaesmer, H; Braehler, E				Glombiewski, Julia A.; Nestoriuc, Yvonne; Rief, Winfried; Glaesmer, Heide; Braehler, Elmar			Medication Adherence in the General Population	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; DRUG-THERAPY; NONADHERENCE; MEDICINES; BELIEFS; PERSISTENCE; PREDICTORS	Background: Adherence to medication is low in specific populations who need chronic medication. However, adherence to medication is also of interest in a more general fashion, independent of specific populations or side effects of particular drugs. If clinicians and researchers expect patients to show close to full adherence, it is relevant to know how likely the achievement of this goal is. Population based rates can provide an estimate of efforts needed to achieve near complete adherence in patient populations. The objective of the study was to collect normative data for medication nonadherence in the general population. Methods and Findings: We assessed 2,512 persons (a representative sample of German population). Adherence was measured by Rief Adherence Index. We also assessed current medication intake and side effects. We found that at least 33% of Germans repeatedly fail to follow their doctor's recommendations regarding pharmacological treatments and only 25% of Germans describe themselves as fully adherent. Nonadherence to medication occurs more often in younger patients with higher socioeconomic status taking short-term medications than in older patients with chronic conditions. Experience with medication side effects was the most prominent predictor of nonadherence. Conclusions: The major strengths of our study are a representative sample and a novel approach to assess adherence. Nonadherece seems to be commonplace in the general population. Therefore adherence cannot be expected per se but needs special efforts on behalf of prescribers and public health initiatives. Nonadherence to medication should not only be considered as a drug-specific behaviour problem, but as a behaviour pattern that is independent of the prescribed medication.	[Glombiewski, Julia A.; Nestoriuc, Yvonne; Rief, Winfried] Univ Marburg, Dept Clin Psychol & Psychotherapy, Marburg, Germany; [Glaesmer, Heide; Braehler, Elmar] Univ Leipzig, Dept Med Psychol & Med Sociol, Leipzig, Germany; [Nestoriuc, Yvonne] Univ Hamburg, Dept Clin Psychol & Psychotherapy, Hamburg, Germany	Philipps University Marburg; Leipzig University; University of Hamburg	Glombiewski, JA (corresponding author), Univ Marburg, Dept Clin Psychol & Psychotherapy, Marburg, Germany.	glombiew@staff.uni-marburg.de	Rief, Winfried/ABD-4994-2021; Braehler, Elmar/C-6535-2009	Rief, Winfried/0000-0002-7019-2250; Braehler, Elmar/0000-0002-2648-2728; Nestoriuc, Yvonne/0000-0003-2191-0495				Bardel A, 2007, EUR J CLIN PHARMACOL, V63, P307, DOI 10.1007/s00228-006-0246-4; BARSKY AJ, 1990, J PSYCHIAT RES, V24, P323, DOI 10.1016/0022-3956(90)90004-A; Bates TR, 2009, EXPERT OPIN PHARMACO, V10, P2973, DOI 10.1517/14656560903376186; Briesacher BA, 2008, PHARMACOTHERAPY, V28, P437, DOI 10.1592/phco.28.4.437; Chan DC, 2010, MED CARE, V48, P196, DOI 10.1097/MLR.0b013e3181c132ad; Cooper V, 2009, AIDS CARE, V21, P520, DOI 10.1080/09540120802301824; Cramer JA, 2008, VALUE HEALTH, V11, P44, DOI 10.1111/j.1524-4733.2007.00213.x; Curkendall S, 2005, VALUE HEALTH, V8, P360, DOI 10.1016/S1098-3015(10)62959-2; Cutler DM, 2010, NEW ENGL J MED, V362, P1553, DOI 10.1056/NEJMp1002305; Frankenfield DL, 2010, J HEALTH CARE POOR U, V21, P518, DOI 10.1353/hpu.0.0314; Horne R, 1999, J PSYCHOSOM RES, V47, P555, DOI 10.1016/S0022-3999(99)00057-4; Horne R, 1999, PSYCHOL HEALTH, V14, P1, DOI 10.1080/08870449908407311; Horne R, 2007, JAIDS-J ACQ IMM DEF, V45, P334; Ingersoll KS, 2008, J BEHAV MED, V31, P213, DOI 10.1007/s10865-007-9147-y; Jackson C, 2006, PATIENT EDUC COUNS, V61, P212, DOI 10.1016/j.pec.2005.03.010; Malta M, 2008, ADDICTION, V103, P1242, DOI 10.1111/j.1360-0443.2008.02269.x; Malta M, 2010, AIDS BEHAV, V14, P731, DOI 10.1007/s10461-008-9489-7; Nestoriuc Y, 2010, ARTHRIT CARE RES, V62, P791, DOI 10.1002/acr.20160; Organization WH, 2003, ADHERENCE LONG TERM; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Rief W, 2011, PHARMACOEPIDEM DR S, V20, P405, DOI 10.1002/pds.2067; Sandelowski M, 2009, AIDS CARE, V21, P953, DOI 10.1080/09540120802626212; Simoni Jane M, 2008, Curr Infect Dis Rep, V10, P515, DOI 10.1007/s11908-008-0083-y; Steiner JF, 2010, MED CARE, V48, P193, DOI 10.1097/MLR.0b013e3181d51ddf; van Bruggen R, 2009, PHARMACOEPIDEM DR S, V18, P983, DOI 10.1002/pds.1810; Yeaw J, 2009, J MANAGE CARE PHARM, V15, P728, DOI 10.18553/jmcp.2009.15.9.728; Ziller V, 2009, ANN ONCOL, V20, P431, DOI 10.1093/annonc/mdn646	27	34	35	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 18	2012	7	12							e50537	10.1371/journal.pone.0050537	http://dx.doi.org/10.1371/journal.pone.0050537			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	056JC	23272064	Green Published, gold, Green Submitted			2023-01-03	WOS:000312483300009
J	Ofri, D				Ofri, Danielle			The Storm and the Aftermath	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Ofri, Danielle] NYU, Sch Med, New York, NY 10003 USA; [Ofri, Danielle] Bellevue Hosp, New York, NY USA	New York University; Bellevue Hospital Center	Ofri, D (corresponding author), NYU, Sch Med, New York, NY 10003 USA.			Ofri, Danielle/0000-0001-9865-7104					0	16	17	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 13	2012	367	24					2265	2267		10.1056/NEJMp1213843	http://dx.doi.org/10.1056/NEJMp1213843			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	052HF	23151281				2023-01-03	WOS:000312187700014
J	Zha, BB; Wang, LM; Liu, XM; Liu, J; Chen, ZP; Xu, J; Sheng, L; Li, YM; Chu, YW				Zha, Bingbing; Wang, Luman; Liu, Xiaoming; Liu, Jun; Chen, Zaoping; Xu, Jiong; Sheng, Li; Li, Yiming; Chu, Yiwei			Decrease in Proportion of CD19(+)CD24(hi)CD27(+) B Cells and Impairment of Their Suppressive Function in Graves' Disease	PLOS ONE			English	Article							REGULATORY T-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; B10 CELLS; LYMPHOCYTE DEPLETION; THYROID-DISEASE; IN-VITRO; ANTIBODY; THERAPY; MICE; OPHTHALMOPATHY	IL-10-producing B cells (B10 cells) have been shown to play a suppressive role in the peripheral blood of humans, with their numbers and function altered in several autoimmune diseases. However, the role of B10 cells in Graves' disease (GD) remains unknown. In this study, we demonstrated that B10 cells in human peripheral blood belonged to a CD24(hi)CD27(+)B cell subpopulation. The proportion of B10 cells along with the CD19(+)CD24(hi)CD27(+) B cell subset was significantly lower in new-onset patients compared with healthy individuals. In recovered patients, these proportions were restored to levels similar to those seen in healthy individuals. Additionally, we found that CD19(+)CD24(hi)CD27(+) B cells from healthy individuals inhibited proliferation and TNF-alpha production of CD4(+) T cells via an IL-10-independent pathway. They also inhibited IFN-gamma production by CD4(+) T cells, through an IL-10-dependent pathway. In contrast, their suppressive function on CD4(+) T cell proliferation and cytokine production was impaired in new-onset and recovered patients compared with healthy individuals. Our study provides evidence that CD19(+)CD24(hi)CD27(+) B cells may possess the capacity to downregulate immune responses, partially by production of IL-10 in human peripheral blood. Impairment of their immunosuppressive function may contribute to GD pathogenesis and relapse.	[Zha, Bingbing; Li, Yiming] Fudan Univ, Dept Endocrinol & Metab, Huashan Hosp, Shanghai 200433, Peoples R China; [Wang, Luman; Liu, Xiaoming; Chu, Yiwei] Fudan Univ, Dept Immunol, Shanghai Med Coll, Shanghai 200433, Peoples R China; [Wang, Luman; Liu, Xiaoming; Chu, Yiwei] Fudan Univ, Biotherapy Res Ctr, Shanghai Med Coll, Shanghai 200433, Peoples R China; [Zha, Bingbing; Liu, Jun; Chen, Zaoping; Xu, Jiong; Sheng, Li] Fudan Univ, Dept Endocrinol & Metab, Shanghai Peoples Hosp 5, Shanghai 200433, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University	Li, YM (corresponding author), Fudan Univ, Dept Endocrinol & Metab, Huashan Hosp, Shanghai 200433, Peoples R China.	yimingli@fudan.edu.cn; yiwei_chu@126.com			National Science Foundation in China [81072408]; Science and Technology Commission of Shanghai Municipality in China [10JC1401100]; National 973 project in China [2011CB910404]	National Science Foundation in China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality in China(Science & Technology Commission of Shanghai Municipality (STCSM)); National 973 project in China(National Basic Research Program of China)	This work was supported by: 1) National Science Foundation in China (81072408) (http://www.nsfc.gov.cn/); 2) The Science and Technology Commission of Shanghai Municipality in China (10JC1401100) (http://www.stcsm.gov.cn/structure/index.htm); 3) The National 973 project in China (2011CB910404) (http://www.973.gov.cn/English/Index.aspx). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agematsu K, 1997, EUR J IMMUNOL, V27, P2073, DOI 10.1002/eji.1830270835; Amu S, 2010, J ALLERGY CLIN IMMUN, V125, P1114, DOI 10.1016/j.jaci.2010.01.018; Banga JP, 2008, THYROID, V18, P973, DOI 10.1089/thy.2007.0406; Bayry J, 2005, J IMMUNOL, V175, P15, DOI 10.4049/jimmunol.175.1.15; Blair PA, 2010, IMMUNITY, V32, P129, DOI 10.1016/j.immuni.2009.11.009; Bouaziz JD, 2010, EUR J IMMUNOL, V40, P2686, DOI 10.1002/eji.201040673; Brent GA, 2008, NEW ENGL J MED, V358, P2594, DOI 10.1056/NEJMcp0801880; Chen XJ, 2007, J IMMUNOL, V179, P2046, DOI 10.4049/jimmunol.179.4.2046; Cooper DS, 2003, LANCET, V362, P459, DOI 10.1016/S0140-6736(03)14073-1; El Fassi D, 2007, J CLIN ENDOCR METAB, V92, P1769, DOI 10.1210/jc.2006-2388; El Fassi D, 2006, EUR J ENDOCRINOL, V154, P623, DOI 10.1530/eje.1.02140; Goetz M, 2007, INFLAMM BOWEL DIS, V13, P1365, DOI 10.1002/ibd.20215; Gonnella PA, 2001, J IMMUNOL, V166, P4456, DOI 10.4049/jimmunol.166.7.4456; Hussain S, 2007, J IMMUNOL, V179, P7225, DOI 10.4049/jimmunol.179.11.7225; Iwata Y, 2011, BLOOD, V117, P530, DOI 10.1182/blood-2010-07-294249; Kalergis AM, 2002, J EXP MED, V195, P1653, DOI 10.1084/jem.20020338; Kirkland D, 2012, IMMUNITY, V36, P228, DOI 10.1016/j.immuni.2011.11.019; Lehmann-Horn K, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-146; Lemoine S, 2011, J AUTOIMMUN, V36, P228, DOI 10.1016/j.jaut.2011.01.005; Marazuela M, 2006, J CLIN ENDOCR METAB, V91, P3639, DOI 10.1210/jc.2005-2337; Maseda D, 2012, J IMMUNOL, V188, P1036, DOI 10.4049/jimmunol.1102500; Matsushita T, 2008, J CLIN INVEST, V118, P3420, DOI 10.1172/JCI36030; Matsushita T, 2010, J IMMUNOL, V185, P2240, DOI 10.4049/jimmunol.1001307; Mauri C, 2003, J EXP MED, V197, P489, DOI 10.1084/jem.20021293; Mizoguchi E, 2000, INT IMMUNOL, V12, P597, DOI 10.1093/intimm/12.5.597; Nielsen CH, 2007, EXPERT OPIN BIOL TH, V7, P1061, DOI 10.1517/14712598.7.7.1061; Palanichamy A, 2009, J IMMUNOL, V182, P5982, DOI 10.4049/jimmunol.0801859; Pan DS, 2009, CLIN ENDOCRINOL, V71, P587, DOI 10.1111/j.1365-2265.2009.03544.x; Parekh VV, 2003, J IMMUNOL, V170, P5897, DOI 10.4049/jimmunol.170.12.5897; Prabhakar BS, 2003, ENDOCR REV, V24, P802, DOI 10.1210/er.2002-0020; Rapoport B, 2007, THYROID, V17, P911, DOI 10.1089/thy.2007.0170; Ray A, 2012, J IMMUNOL, V188, P3188, DOI 10.4049/jimmunol.1103354; Rehnberg M, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2789; Ren XF, 2011, J NEUROSCI, V31, P8556, DOI 10.1523/JNEUROSCI.1623-11.2011; Sfikakis PP, 2005, ARTHRITIS RHEUM-US, V52, P501, DOI 10.1002/art.20858; Sims GP, 2005, BLOOD, V105, P4390, DOI 10.1182/blood-2004-11-4284; Sun JB, 2012, J IMMUNOL, V188, P1686, DOI 10.4049/jimmunol.1101771; Tedder TF, 2010, J ALLERGY CLIN IMMUN, V125, P1125, DOI 10.1016/j.jaci.2010.03.024; Weetman AP, 2004, AUTOIMMUNITY, V37, P337, DOI 10.1080/08916930410001705394; WEETMAN AP, 1990, J CLIN INVEST, V86, P723, DOI 10.1172/JCI114768; Wilson MS, 2010, EUR J IMMUNOL, V40, P1682, DOI 10.1002/eji.200939721; Xiu Y, 2008, J IMMUNOL, V180, P2863, DOI 10.4049/jimmunol.180.5.2863; Yanaba K, 2008, IMMUNITY, V28, P639, DOI 10.1016/j.immuni.2008.03.017; Yanaba K, 2011, AM J PATHOL, V178, P735, DOI 10.1016/j.ajpath.2010.10.022	44	55	63	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 26	2012	7	11							e49835	10.1371/journal.pone.0049835	http://dx.doi.org/10.1371/journal.pone.0049835			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	048RI	23189166	Green Published, gold, Green Submitted			2023-01-03	WOS:000311929800043
J	Ferreyra, C; Yun, O; Eisenberg, N; Alonso, E; Khamadi, AS; Mwau, M; Mugendi, MK; Alvarez, A; Velilla, E; Flevaud, L; Arnedo, M; Dalmau, D; Roddy, P; Bernasconi, A; Palma, PP				Ferreyra, Cecilia; Yun, Oliver; Eisenberg, Nell; Alonso, Elena; Khamadi, Ashimosi S.; Mwau, Matilu; Kihara Mugendi, Martha; Alvarez, Ana; Velilla, Elena; Flevaud, Laurence; Arnedo, Mireia; Dalmau, David; Roddy, Paul; Bernasconi, Andrea; Pablo Palma, Pedro			Evaluation of Clinical and Immunological Markers for Predicting Virological Failure in a HIV/AIDS Treatment Cohort in Busia, Kenya	PLOS ONE			English	Article							RESOURCE-LIMITED SETTINGS; ANTIRETROVIRAL TREATMENT FAILURE; INCOME COUNTRIES; THERAPY; PROGRAMS; CRITERIA; MONITOR; AFRICA	Background: In resource-limited settings where viral load (VL) monitoring is scarce or unavailable, clinicians must use immunological and clinical criteria to define HIV virological treatment failure. This study examined the performance of World Health Organization (WHO) clinical and immunological failure criteria in predicting virological failure in HIV patients receiving antiretroviral therapy (ART). Methods: In a HIV/AIDS program in Busia District Hospital, Kenya, a retrospective, cross-sectional cohort analysis was performed in April 2008 for all adult patients (>18 years old) on ART for >= 12 months, treatment-naive at ART start, attending the clinic at least once in last 6 months, and who had given informed consent. Treatment failure was assessed per WHO clinical (disease stage 3 or 4) and immunological (CD4 cell count) criteria, and compared with virological failure (VL >5,000 copies/mL). Results: Of 926 patients, 123 (13.3%) had clinically defined treatment failure, 53 (5.7%) immunologically defined failure, and 55 (6.0%) virological failure. Sensitivity, specificity, positive predictive value, and negative predictive value of both clinical and immunological criteria (combined) in predicting virological failure were 36.4%, 83.5%, 12.3%, and 95.4%, respectively. Conclusions: In this analysis, clinical and immunological criteria were found to perform relatively poorly in predicting virological failure of ART. VL monitoring and new algorithms for assessing clinical or immunological treatment failure, as well as improved adherence strategies, are required in ART programs in resource-limited settings.	[Ferreyra, Cecilia; Yun, Oliver; Eisenberg, Nell; Alonso, Elena; Kihara Mugendi, Martha; Alvarez, Ana; Velilla, Elena; Flevaud, Laurence; Roddy, Paul; Bernasconi, Andrea; Pablo Palma, Pedro] Med Sans Frontieres, Operat Ctr Barcelona Athens, Barcelona, Spain; [Khamadi, Ashimosi S.; Mwau, Matilu] Kenya Med Res Inst KEMRI, Nairobi, Kenya; [Arnedo, Mireia] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain; [Dalmau, David] Hosp Univ Mutua Terrassa, Terrassa, Spain	Doctors Without Borders; Kenya Medical Research Institute; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Hospital Universitario Mutua Terrassa	Ferreyra, C (corresponding author), Med Sans Frontieres, Operat Ctr Barcelona Athens, Barcelona, Spain.	cecilia.ferreyra@barcelona.msf.org		FERREYRA, CECILIA/0000-0001-5480-7940	Medecins sans Frontieres	Medecins sans Frontieres	The entire study has been funded by Medecins sans Frontieres. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], UN ACC SCAL PRIOR HI; Bagchi S, 2007, CLIN INFECT DIS, V44, P135, DOI 10.1086/510072; Barth RE, 2010, LANCET INFECT DIS, V10, P155, DOI 10.1016/S1473-3099(09)70328-7; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Calmy A, 2007, CLIN INFECT DIS, V44, P128, DOI 10.1086/510073; Colebunders R, 2006, LANCET INFECT DIS, V6, P53, DOI 10.1016/S1473-3099(05)70327-3; Elliott JH, 2008, AIDS, V22, P2053, DOI 10.1097/QAD.0b013e328309520d; Keiser O, 2009, AIDS, V23, P1867, DOI 10.1097/QAD.0b013e32832e05b2; Keiser O, 2009, TROP MED INT HEALTH, V14, P1220, DOI 10.1111/j.1365-3156.2009.02338.x; Mee P, 2008, AIDS, V22, P1971, DOI 10.1097/QAD.0b013e32830e4cd8; Mermin J, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6792; Moore DM, 2006, JAIDS-J ACQ IMM DEF, V43, P436, DOI 10.1097/01.qai.0000243105.80393.42; Reynolds SJ, 2009, AIDS, V23, P697, DOI 10.1097/QAD.0b013e3283262a78; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Tassie JM, 2003, AIDS, V17, P1995, DOI 10.1097/00002030-200309050-00023; UNAIDS, 2010, REP GLOB AIDS EP 201; WHO, HIV AIDS PROGR HIGHL; WHO, ANT THER HIV INF AD; *WHO, 2005, WHO CONS TECHN OP RE; World Health Organization, 2009, RAP ADV ANT THER HIV	20	21	22	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2012	7	11							e49834	10.1371/journal.pone.0049834	http://dx.doi.org/10.1371/journal.pone.0049834			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	047ER	23185450	Green Submitted, Green Published, gold			2023-01-03	WOS:000311821000116
J	Gurski, LA; Xu, X; Labrada, LN; Nguyen, NT; Xiao, LX; van Golen, KL; Jia, XQ; Farach-Carson, MC				Gurski, Lisa A.; Xu, Xian; Labrada, Lyana N.; Nguyen, Ngoc T.; Xiao, Longxi; van Golen, Kenneth L.; Jia, Xinqiao; Farach-Carson, Mary C.			Hyaluronan (HA) Interacting Proteins RHAMM and Hyaluronidase Impact Prostate Cancer Cell Behavior and Invadopodia Formation in 3D HA-Based Hydrogels	PLOS ONE			English	Article							BONE-MARROW; IN-VITRO; ACID; PROGRESSION; ACTIVATION; MIGRATION; INVASION; METASTASIS; MATRIX; ASSAYS	To study the individual functions of hyaluronan interacting proteins in prostate cancer (PCa) motility through connective tissues, we developed a novel three-dimensional (3D) hyaluronic acid (HA) hydrogel assay that provides a flexible, quantifiable, and physiologically relevant alternative to current methods. Invasion in this system reflects the prevalence of HA in connective tissues and its role in the promotion of cancer cell motility and tissue invasion, making the system ideal to study invasion through bone marrow or other HA-rich connective tissues. The bio-compatible cross-linking process we used allows for direct encapsulation of cancer cells within the gel where they adopt a distinct, cluster-like morphology. Metastatic PCa cells in these hydrogels develop fingerlike structures, "invadopodia", consistent with their invasive properties. The number of invadopodia, as well as cluster size, shape, and convergence, can provide a quantifiable measure of invasive potential. Among candidate hyaluronan interacting proteins that could be responsible for the behavior we observed, we found that culture in the HA hydrogel triggers invasive PCa cells to differentially express and localize receptor for hyaluronan mediated motility (RHAMM)/CD168 which, in the absence of CD44, appears to contribute to PCa motility and invasion by interacting with the HA hydrogel components. PCa cell invasion through the HA hydrogel also was found to depend on the activity of hyaluronidases. Studies shown here reveal that while hyaluronidase activity is necessary for invadopodia and inter-connecting cluster formation, activity alone is not sufficient for acquisition of invasiveness to occur. We therefore suggest that development of invasive behavior in 3D HA-based systems requires development of additional cellular features, such as activation of motility associated pathways that regulate formation of invadopodia. Thus, we report development of a 3D system amenable to dissection of biological processes associated with cancer cell motility through HA-rich connective tissues.	[Gurski, Lisa A.; Labrada, Lyana N.; Nguyen, Ngoc T.; van Golen, Kenneth L.; Farach-Carson, Mary C.] Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA; [Xu, Xian; Xiao, Longxi; Jia, Xinqiao] Univ Delaware, Dept Mat Sci & Engn, Newark, DE USA; [Gurski, Lisa A.; Xu, Xian; Labrada, Lyana N.; Nguyen, Ngoc T.; Xiao, Longxi; van Golen, Kenneth L.; Jia, Xinqiao] Univ Delaware, Ctr Translat Canc Res, Newark, DE USA; [Farach-Carson, Mary C.] Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77251 USA; [Farach-Carson, Mary C.] Rice Univ, Dept Bioengn, Houston, TX USA	University of Delaware; University of Delaware; University of Delaware; Rice University; Rice University	Farach-Carson, MC (corresponding author), Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA.	farachca@rice.edu	Xu, Xian/L-2448-2014	Farach-Carson, Mary/0000-0002-4526-3088	National Institutes of Health [P01CA098912, P20RR016458, P20RR017716, R01DC008965]; National Science Foundation [DMR 0643226, IGERT 0221651]; Delaware Health Science Alliance (DHSA); Department of Defense [PCRP W81XWH-05-1-0005, W81XWH-08-1-0356, PCRP W81XWH-11-1-0564]; Center for Translational Cancer Research; NATIONAL CANCER INSTITUTE [P01CA098912] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016458, P20RR017716] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC008965] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); Delaware Health Science Alliance (DHSA); Department of Defense(United States Department of Defense); Center for Translational Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This work was supported in part by the National Institutes of Health (www.nih.gov) P01CA098912 (MCFC) and P20RR016458, P20RR017716, R01DC008965 (XJ), the National Science Foundation (www.nsf.gov) DMR 0643226 (XJ) and IGERT 0221651 (LG) and Delaware Health Science Alliance (DHSA) (www.delawarehsa.org) (XJ), the Department of Defense (www.defense.gov) PCRP W81XWH-05-1-0005 and W81XWH-08-1-0356 (KLVG) and PCRP W81XWH-11-1-0564 (LG), and the Center for Translational Cancer Research (www.udel.edu/ctcr). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Maxwell CA, 2008, J CELL SCI, V121, P925, DOI 10.1242/jcs.022038; Barla F, 2009, BIOSCI BIOTECH BIOCH, V73, P2335, DOI 10.1271/bbb.90365; Bharadwaj AG, 2009, AM J PATHOL, V174, P1027, DOI 10.2353/ajpath.2009.080501; Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; Busco G, 2010, FASEB J, V24, P3903, DOI 10.1096/fj.09-149518; CHEN JL, 1969, J ALLERGY, V43, P89, DOI 10.1016/0021-8707(69)90129-4; Clark BR, 1995, ANN NY ACAD SCI, V770, P70, DOI 10.1111/j.1749-6632.1995.tb31044.x; Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078-0432.CCR-06-0931; Csoka AB, 2001, MATRIX BIOL, V20, P499, DOI 10.1016/S0945-053X(01)00172-X; Decaestecker C, 2007, MED RES REV, V27, P149, DOI 10.1002/med.20078; Edwards AM, 2000, CLIN EXP ALLERGY, V30, P756; Ekici S, 2004, INT J CANCER, V112, P121, DOI 10.1002/ijc.20368; Gomez CS, 2009, J UROLOGY, V182, P1350, DOI 10.1016/j.juro.2009.06.070; Goueffic Y, 2006, CARDIOVASC RES, V72, P339, DOI 10.1016/j.cardiores.2006.07.017; GUNTENHONER MW, 1992, MATRIX, V12, P388, DOI 10.1016/S0934-8832(11)80035-1; Gurski LA, 2009, BIOMATERIALS, V30, P6076, DOI 10.1016/j.biomaterials.2009.07.054; Gust KM, 2009, NEOPLASIA, V11, P956, DOI 10.1593/neo.09694; Hamilton SR, 2007, J BIOL CHEM, V282, P16667, DOI 10.1074/jbc.M702078200; Harada H, 2007, J BIOL CHEM, V282, P5597, DOI 10.1074/jbc.M608358200; Harper K, 2010, CANCER RES, V70, P4634, DOI 10.1158/0008-5472.CAN-09-3813; Harrison GM, 2006, ONCOL REP, V15, P199; HE XY, 1994, PHOTOCHEM PHOTOBIOL, V59, P468, DOI 10.1111/j.1751-1097.1994.tb05066.x; Hofinger ESA, 2008, GLYCOCONJUGATE J, V25, P101, DOI 10.1007/s10719-007-9058-8; Hurt EM, 2008, BRIT J CANCER, V98, P756, DOI 10.1038/sj.bjc.6604242; Huxley-Jones J, 2008, DRUG DISCOV TODAY, V13, P685, DOI 10.1016/j.drudis.2008.05.005; Jia XQ, 2004, BIOMATERIALS, V25, P4797, DOI 10.1016/j.biomaterials.2003.12.012; KAKEGAWA H, 1985, CHEM PHARM BULL, V33, P642; Kobayashi T, 2010, MOL ENDOCRINOL, V24, P722, DOI 10.1210/me.2009-0326; Lokeshwar VB, 2001, J BIOL CHEM, V276, P11922, DOI 10.1074/jbc.M008432200; Lokeshwar VB, 1996, CANCER RES, V56, P651; Marshall J, 2011, METHODS MOL BIOL, V769, P97, DOI 10.1007/978-1-61779-207-6_8; MEYER K, 1958, FED PROC, V17, P1075; Mio K, 2002, MATRIX BIOL, V21, P31, DOI 10.1016/S0945-053X(01)00185-8; MIURA RO, 1995, ANAL BIOCHEM, V225, P333, DOI 10.1006/abio.1995.1163; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Reiman T, 2003, BLOOD, V102, p680A; Ricciardelli C, 2007, J BIOL CHEM, V282, P10814, DOI 10.1074/jbc.M606991200; Russ AP, 2005, DRUG DISCOV TODAY, V10, P1607, DOI 10.1016/S1359-6446(05)03666-4; Sahiner N, 2008, J BIOMAT SCI-POLYM E, V19, P223, DOI 10.1163/156856208783432462; Schade UM, 2006, ACTA HISTOCHEM, V108, P141, DOI 10.1016/j.acthis.2006.03.018; Sequeira L, 2008, CLIN EXP METASTAS, V25, P569, DOI 10.1007/s10585-008-9173-3; Shaw MT, 2005, INTRODUCTION TO POLYMER VISCOELASTICITY, 3RD EDITION, P1, DOI 10.1002/0471741833; Society AC, 2012, CANC FACTS FIG 2012; Stern R, 2008, SEMIN CANCER BIOL, V18, P275, DOI 10.1016/j.semcancer.2008.03.017; THALMANN GN, 1994, CANCER RES, V54, P2577; Thalmann GN, 2000, PROSTATE, V44, P91; Thalmann GN, 1999, CLIN CANCER RES, V5, P2271; TURLEY EA, 1991, J CELL BIOL, V112, P1041, DOI 10.1083/jcb.112.5.1041; van Horssen R, 2011, J CELL PHYSIOL, V226, P288, DOI 10.1002/jcp.22330; Wu TT, 1998, INT J CANCER, V77, P887, DOI 10.1002/(SICI)1097-0215(19980911)77:6<887::AID-IJC15>3.0.CO;2-Z; Xiao WW, 2012, CLIN EXP METASTAS, V29, P1, DOI 10.1007/s10585-011-9423-7; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Zhang C, 2011, PROSTATE, V71, P157, DOI 10.1002/pros.21231; Zhang SW, 1998, J BIOL CHEM, V273, P11342, DOI 10.1074/jbc.273.18.11342	54	42	42	0	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2012	7	11							e50075	10.1371/journal.pone.0050075	http://dx.doi.org/10.1371/journal.pone.0050075			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	048BN	23166824	Green Published, gold, Green Submitted			2023-01-03	WOS:000311885300084
J	El Majdoub, F; Elawady, M; Blau, T; Buhrle, C; Hoevels, M; Runge, M; Muller, RP; Deckert, M; Sturm, V; Maarouf, M				El Majdoub, Faycal; Elawady, Moataz; Blau, Tobias; Buehrle, Christian; Hoevels, Mauritius; Runge, Matthias; Mueller, Rolf-Peter; Deckert, Martina; Sturm, Volker; Maarouf, Mohammad			Intracranial Ependymoma: Long-Term Results in a Series of 21 Patients Treated with Stereotactic (125)Iodine Brachytherapy	PLOS ONE			English	Article							PROGNOSTIC-FACTORS; I-125 SEEDS; CHILDREN; CHEMOTHERAPY; THERAPY; IRRADIATION; CHILDHOOD; CANCER; TUMORS; GRADE	Background: We evaluated the long-term outcome in patients harboring intracranial ependymomas treated with interstitial brachytherapy (IBT). Methods: Twenty-one patients (M/F = 9/12; median age: 29 years; range: 8-70 years), diagnosed with intracranial ependymoma (1 WHO I, 11 WHO II, 9 WHO III) were treated with IBT using stereotactically implanted 125 Iodine seeds between 1987 and 2010, either primarily, as adjuvant therapy following incomplete resection, or as salvage treatment upon tumor recurrence. Sixteen of 21 patients underwent microsurgical resection prior to IBT; in 5 patients, IBT was performed primarily after stereotactic biopsy for histological diagnosis. The cumulative tumor surface dose ranged from 50-65 Gy treating a median tumor volume of 3.6 ml (range, 0.3-11.6 ml). A median follow-up period of 105.3 months (range, 12.7-286.2 months) was evaluated. Results: Actuarial 2-, 5- and 10-years overall-and disease-specific survival rates after IBT were each 90% and 100% at all times for ependymomas WHO I/II, for anaplastic ependymomas WHO III 100%, 100%, 70% and 100%, 100%, 86%, respectively. The neurological status of seven patients improved, while there was no change in 12 and deterioration in 2 patients, respectively. Follow-up MR images disclosed a complete tumor remission in 3, a partial remission in 12 and a stable disease in 6 patients. Treatment-associated morbidity only occurred in a single patient. Conclusions: This study shows that stereotactic IBT for intracranial ependymomas is safe and can provide a high degree of local tumor control. Due to the low rate of side effects, IBT may evolve into an attractive alternative to microsurgery in ependymomas located in eloquent areas or as a salvage treatment.	[El Majdoub, Faycal; Elawady, Moataz; Buehrle, Christian; Hoevels, Mauritius; Runge, Matthias; Sturm, Volker; Maarouf, Mohammad] Univ Hosp, Dept Stereotaxy & Funct Neurosurg, Cologne, Germany; [Blau, Tobias; Deckert, Martina] Univ Hosp, Dept Neuropathol, Cologne, Germany; [Mueller, Rolf-Peter] Univ Hosp, Dept Radiat Oncol, Cologne, Germany	University of Cologne; University of Cologne; University of Cologne	El Majdoub, F (corresponding author), Univ Hosp, Dept Stereotaxy & Funct Neurosurg, Cologne, Germany.	faycal.el-majdoub@uk-koeln.de	Deckert, Martina/P-2842-2016					CHAMBERLAIN MC, 1995, ARCH NEUROL-CHICAGO, V52, P162, DOI 10.1001/archneur.1995.00540260066018; Combs SE, 2008, INT J RADIAT ONCOL, V71, P972, DOI 10.1016/j.ijrobp.2007.12.036; Costa FF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025114; Duffner PK, 1998, PEDIATR NEUROSURG, V28, P215, DOI 10.1159/000028654; El Majdoub F, 2009, STRAHLENTHER ONKOL, V185, P109, DOI 10.1007/s00066-009-1911-1; Grill J, 2001, J CLIN ONCOL, V19, P1288, DOI 10.1200/JCO.2001.19.5.1288; Kilday JP, 2009, MOL CANCER RES, V7, P765, DOI 10.1158/1541-7786.MCR-08-0584; Koot RW, 2000, CANCER-AM CANCER SOC, V88, P2796; Korinthenberg R, 2010, INT J RAD ONCOL BIOL; Korshunov A, 2004, CANCER, V100, P1230, DOI 10.1002/cncr.20075; Korshunov A, 2010, J CLIN ONCOL, V28, P3182, DOI 10.1200/JCO.2009.27.3359; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Maarouf M, 2010, STRAHLENTHER ONKOL; MACDONALD DR, 1990, J CLIN ONCOL, V8, P1277, DOI 10.1200/JCO.1990.8.7.1277; Massimino M, 2009, FUTURE ONCOL, V5, P207, DOI 10.2217/14796694.5.2.207; Moon K, 2006, CANCER-AM CANCER SOC, V107, P991, DOI 10.1002/cncr.22083; Needle MN, 1997, CANCER-AM CANCER SOC, V80, P341, DOI 10.1002/(SICI)1097-0142(19970715)80:2<341::AID-CNCR23>3.3.CO;2-N; Paulino AC, 2002, AM J CLIN ONCOL-CANC, V25, P117, DOI 10.1097/00000421-200204000-00003; Perilongo G, 1997, MED PEDIATR ONCOL, V29, P79; Peyre M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012932; POLLACK IF, 1995, NEUROSURGERY, V37, P655, DOI 10.1227/00006123-199510000-00008; Robertson PL, 1998, J NEUROSURG, V88, P695, DOI 10.3171/jns.1998.88.4.0695; ROUSSEAU P, 1994, INT J RADIAT ONCOL, V28, P381, DOI 10.1016/0360-3016(94)90061-2; Ruda R, 2008, CURR OPIN NEUROL, V21, P754, DOI 10.1097/WCO.0b013e328317efe8; Shim KW, 2009, CHILD NERV SYST, V25, P1167, DOI 10.1007/s00381-009-0900-0; STURM V, 1983, ACTA NEUROCHIR, V68, P11, DOI 10.1007/BF01406197; SUTTON LN, 1991, PEDIATR NEUROSURG, V16, P57, DOI 10.1159/000120509; Timmermann B, 2000, INT J RADIAT ONCOL, V46, P287, DOI 10.1016/S0360-3016(99)00414-9; Treuer H, 2005, RADIOTHER ONCOL, V77, P202, DOI 10.1016/j.radonc.2005.08.006; VOGES J, 1993, ACTA NEUROCHIR, V122, P127, DOI 10.1007/BF01446999	30	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2012	7	11							e47266	10.1371/journal.pone.0047266	http://dx.doi.org/10.1371/journal.pone.0047266			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	032TG	23144811	Green Submitted, Green Published, gold			2023-01-03	WOS:000310741400019
J	Kawabe, Y; Hayashida, Y; Numata, K; Harada, S; Hayashida, Y; Ito, A; Kamihira, M				Kawabe, Yoshinori; Hayashida, Yuuki; Numata, Kensaku; Harada, Shota; Hayashida, Yoshifumi; Ito, Akira; Kamihira, Masamichi			Oral Immunotherapy for Pollen Allergy Using T-Cell Epitope-Containing Egg White Derived from Genetically Manipulated Chickens	PLOS ONE			English	Article							2ND MAJOR ALLERGEN; FC FUSION PROTEIN; CRY-J-II; CEDAR POLLINOSIS; EXPRESSION; TOLERANCE; RHINITIS; VACCINE; DETERMINANTS; CRY-J-1	Peptide immunotherapy using T-cell epitopes is expected to be an effective treatment for allergic diseases such as Japanese cedar (Cryptomeria japonica; Cj) pollinosis. To develop a treatment for pollen allergy by inducing oral tolerance, we generated genetically manipulated (GM) chickens by retroviral gene transduction, to produce a fusion protein of chicken egg white lysozyme and a peptide derived from seven dominant human T-cell epitopes of Japanese cedar pollen allergens (cLys-7crp). The transgene sequence was detected in all chickens transduced with the retroviral vector. Transduction efficiency in blood cells correlated to transgene expression. Western blot analysis revealed that cLys-7crp was expressed in the egg white of GM hens. Mice induced to develop allergic rhinitis by Cj pollinosis were fed with cLys-7crp-containing egg white produced by GM chickens. Total and Cj allergen (Cry j 1)-specific IgE levels were significantly decreased in allergic mice fed with cLys-7crp-containing egg white compared with allergic mice fed with normal egg white. These results suggest that oral administration of T-cell epitope-containing egg white derived from GM chickens is effective for the induction of immune tolerance as an allergy therapy.	[Kawabe, Yoshinori; Hayashida, Yuuki; Numata, Kensaku; Harada, Shota; Hayashida, Yoshifumi; Ito, Akira; Kamihira, Masamichi] Kyushu Univ, Fac Engn, Dept Chem Engn, Fukuoka 812, Japan	Kyushu University	Kamihira, M (corresponding author), Kyushu Univ, Fac Engn, Dept Chem Engn, 6-10-1 Hakozaki, Fukuoka 812, Japan.	kamihira@chem-eng.kyushu-u.ac.jp	Kamihira, Masamichi/Q-7438-2019; Ito, Akira/S-8099-2017	Kamihira, Masamichi/0000-0003-2570-5712; Ito, Akira/0000-0001-8393-0518	Japan Society for the Promotion of Science [18656245, 20360376, 23360372, 23760753]; Kieikai Research Foundation	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Kieikai Research Foundation(Kieikai Research Foundation)	This work was supported in part by Grants-in-Aid for Scientific Research (nos. 18656245, 20360376, 23360372 and 23760753) from the Japan Society for the Promotion of Science and the Kieikai Research Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.	Akdis CA, 2012, NAT MED, V18, P736, DOI 10.1038/nm.2754; du Pre MF, 2011, ALLERGY, V66, P478, DOI 10.1111/j.1398-9995.2010.02519.x; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HASHIMOTO M, 1995, CLIN EXP ALLERGY, V25, P848, DOI 10.1111/j.1365-2222.1995.tb00027.x; Hirahara K, 2001, J ALLERGY CLIN IMMUN, V108, P94, DOI 10.1067/mai.2001.115481; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Hotta A, 2006, J BIOSCI BIOENG, V101, P361, DOI 10.1263/jbb.101.361; Houdebine LM, 2009, COMP IMMUNOL MICROB, V32, P107, DOI 10.1016/j.cimid.2007.11.005; Ishii M, 2010, INT IMMUNOPHARMACOL, V10, P1041, DOI 10.1016/j.intimp.2010.06.003; Ito A, 2009, J BIOSCI BIOENG, V108, P244, DOI 10.1016/j.jbiosc.2009.04.004; Kamihira M, 2005, J VIROL, V79, P10864, DOI 10.1128/JVI.79.17.10864-10874.2005; Kamihira M, 2009, J BIOTECHNOL, V141, P18, DOI 10.1016/j.jbiotec.2009.02.022; Kawabe Y, 2006, J BIOSCI BIOENG, V102, P297, DOI 10.1263/jbb.102.297; Kodama D, 2008, BIOCHEM BIOPH RES CO, V367, P834, DOI 10.1016/j.bbrc.2008.01.020; KOMIYAMA N, 1994, BIOCHEM BIOPH RES CO, V201, P1021, DOI 10.1006/bbrc.1994.1804; Kues WA, 2011, PREV VET MED, V102, P146, DOI 10.1016/j.prevetmed.2011.04.009; Lillico SG, 2007, P NATL ACAD SCI USA, V104, P1771, DOI 10.1073/pnas.0610401104; Moldaver D, 2011, ALLERGY, V66, P784, DOI 10.1111/j.1398-9995.2011.02610.x; Ohno N, 2000, IMMUNOLOGY, V99, P630, DOI 10.1046/j.1365-2567.2000.00021.x; Okamoto Yoshitaka, 2009, Allergology International, V58, P155, DOI 10.2332/allergolint.08-RAI-0074; Okuda M, 2003, ANN ALLERG ASTHMA IM, V91, P288, DOI 10.1016/S1081-1206(10)63532-6; Penno CA, 2010, TRANSGENIC RES, V19, P187, DOI 10.1007/s11248-009-9310-z; Platts-Mills TAE, 2011, IMMUNOL REV, V242, P51, DOI 10.1111/j.1600-065X.2011.01021.x; Prickett SR, 2011, J ALLERGY CLIN IMMUN, V127, P608, DOI 10.1016/j.jaci.2010.09.027; Rosenwasser LJ, 2011, CURR ALLERGY ASTHM R, V11, P178, DOI 10.1007/s11882-011-0179-6; Saito S., 2000, ANN REP SANKYO RES L, V52, P49; SAKAGUCHI M, 1990, ALLERGY, V45, P309, DOI 10.1111/j.1398-9995.1990.tb00501.x; Sakaguchi M, 2011, AURIS NASUS LARYNX, V38, P431, DOI 10.1016/j.anl.2010.12.002; Shin JH, 2010, OTOLARYNG HEAD NECK, V142, P370, DOI 10.1016/j.otohns.2009.11.025; SONE T, 1994, BIOCHEM BIOPH RES CO, V199, P619, DOI 10.1006/bbrc.1994.1273; Song G, 2011, ANN NY ACAD SCI, V1229, P69, DOI 10.1111/j.1749-6632.2011.06087.x; Stebbins KJ, 2010, EUR J PHARMACOL, V638, P142, DOI 10.1016/j.ejphar.2010.04.031; Takagi H, 2005, P NATL ACAD SCI USA, V102, P17525, DOI 10.1073/pnas.0503428102; Takagi H, 2005, PLANT BIOTECHNOL J, V3, P521, DOI 10.1111/j.1467-7652.2005.00143.x; Takagi H, 2008, VACCINE, V26, P6027, DOI 10.1016/j.vaccine.2008.09.019; Toda M, 2002, EUR J IMMUNOL, V32, P1631, DOI 10.1002/1521-4141(200206)32:6<1631::AID-IMMU1631>3.0.CO;2-O; Tsuji NM, 2008, TRENDS IMMUNOL, V29, P532, DOI 10.1016/j.it.2008.09.002; Tsunematsu M, 2008, BIOMED RES-TOKYO, V29, P119, DOI 10.2220/biomedres.29.119; Tsunematsu M, 2007, LIFE SCI, V80, P1388, DOI 10.1016/j.lfs.2006.12.038; Weiner HL, 2011, IMMUNOL REV, V241, P241, DOI 10.1111/j.1600-065X.2011.01017.x; Worm M, 2011, J ALLERGY CLIN IMMUN, V127, P89, DOI 10.1016/j.jaci.2010.11.029; Zhu DC, 2005, NAT MED, V11, P446, DOI 10.1038/nm1219; Zhu L, 2005, NAT BIOTECHNOL, V23, P1159, DOI 10.1038/nbt1132	44	13	14	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2012	7	10							e48512	10.1371/journal.pone.0048512	http://dx.doi.org/10.1371/journal.pone.0048512			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	032HH	23144766	Green Published, Green Submitted, gold			2023-01-03	WOS:000310705300076
J	Isanaka, S; Mugusi, F; Hawkins, C; Spiegelman, D; Okuma, J; Aboud, S; Guerino, C; Fawzi, WW				Isanaka, Sheila; Mugusi, Ferdinand; Hawkins, Claudia; Spiegelman, Donna; Okuma, James; Aboud, Said; Guerino, Chalamilla; Fawzi, Wafaie W.			Effect of High-Dose vs Standard-Dose Multivitamin Supplementation at the Initiation of HAART on HIV Disease Progression and Mortality in Tanzania A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; MICRONUTRIENT SUPPLEMENTATION; HIV-1-INFECTED PATIENTS; IMMUNE RECONSTITUTION; INFECTED INDIVIDUALS; TREATMENT PROGRAM; ALPHA-TOCOPHEROL; DIETARY-INTAKE; VITAMIN-E	Context Large randomized trials have previously shown that high-dose micronutrient supplementation can increase CD4 counts and reduce human immunodeficiency virus (HIV) disease progression and mortality among individuals not receiving highly active antiretroviral therapy (HAART); however, the safety and efficacy of such supplementation has not been established in the context of HAART. Objective To test the hypothesis that high-dose multivitamin supplementation vs standard-dose multivitamin supplementation decreases the risk of HIV disease progression or death and improves immunological, virological, and nutritional parameters in patients with HIV initiating HAART. Design, Setting, and Participants A randomized, double-blind, controlled trial of high-dose vs standard-dose multivitamin supplementation for 24 months in 3418 patients with HIV initiating HAART between November 2006 and November 2008 in 7 clinics in Dar es Salaam, Tanzania. Intervention The provision of daily oral supplements of vitamin B complex, vitamin C, and vitamin E at high levels or standard levels of the recommended dietary allowance. Main Outcome Measure The composite of HIV disease progression or death from any cause. Results The study was stopped early in March 2009 because of evidence of increased levels of alanine transaminase (ALT) in patients receiving the high-dose multivitamin supplement. At the time of stopping, 3418 patients were enrolled (median follow-up, 15 months), and there were 2374 HIV disease progression events and 453 observed deaths (2460 total combined events). Compared with standard-dose multivitamin supplementation, high-dose supplementation did not reduce the risk of HIV disease progression or death. The absolute risk of HIV progression or death was 72% in the high-dose group vs 72% in the standard-dose group (risk ratio [RR], 1.00; 95% CI, 0.96-1.04). High-dose supplementation had no effect on CD4 count, plasma viral load, body mass index, or hemoglobin level concentration, but increased the risk of ALT elevations (1239 events per 1215 person-years vs 879 events per 1236 person-years; RR, 1.44; 95% CI, 1.11-1.87) vs standard-dose supplementation. Conclusion In adults receiving HAART, use of high-dose multivitamin supplements compared with standard-dose multivitamin supplements did not result in a decrease in HIV disease progression or death but may have resulted in an increase in ALT levels.	[Isanaka, Sheila; Okuma, James; Guerino, Chalamilla; Fawzi, Wafaie W.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; [Spiegelman, Donna; Fawzi, Wafaie W.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Spiegelman, Donna] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Fawzi, Wafaie W.] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA; [Aboud, Said] Muhimbili Univ Hlth & Allied Sci, Dept Microbiol & Immunol, Dar Es Salaam, Tanzania; [Mugusi, Ferdinand] Muhimbili Univ Hlth & Allied Sci, Dept Internal Med, Dar Es Salaam, Tanzania; [Hawkins, Claudia] Northwestern Univ, Ctr Global Hlth, Feinberg Sch Med, Chicago, IL 60611 USA; [Guerino, Chalamilla] Management & Dev Hlth, Dar Es Salaam, Tanzania	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Muhimbili University of Health & Allied Sciences; Muhimbili University of Health & Allied Sciences; Northwestern University; Feinberg School of Medicine	Isanaka, S (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	sisanaka@hsph.harvard.edu	Isanaka, Sheila/AAQ-9056-2020		National Institute of Child Health and Human Development [R01 HD32257]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032257] Funding Source: NIH RePORTER	National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported by grant R01 HD32257 from the National Institute of Child Health and Human Development.	ABRAMS B, 1993, J ACQ IMMUN DEF SYND, V6, P949; Allard JP, 1998, AIDS, V12, P1653, DOI 10.1097/00002030-199813000-00013; [Anonymous], POL GUID US EM PLAN; [Anonymous], 1998, REP STAND COMM SCI E; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BAUM M, 1994, NUTRITION, V10, P16; BAUM MK, 1992, ANN NY ACAD SCI, V669, P165; Blanc FX, 2011, NEW ENGL J MED, V365, P1471, DOI 10.1056/NEJMoa1013911; Cantrell RA, 2008, JAIDS-J ACQ IMM DEF, V49, P190, DOI 10.1097/QAI.0b013e31818455d2; Carr A, 2000, LANCET, V356, P1423, DOI 10.1016/S0140-6736(00)02854-3; Chandra RK, 1988, NUTR IMMUNOLOGY; Coyne-Meyers Kristen, 2004, Nutr Clin Pract, V19, P340, DOI 10.1177/0115426504019004340; de Requena DG, 2002, AIDS, V16, P290, DOI 10.1097/00002030-200201250-00020; de Souza O, 2005, CLIN CHEM LAB MED, V43, P376, DOI 10.1515/CCLM.2005.068; Fairall LR, 2008, ARCH INTERN MED, V168, P86, DOI 10.1001/archinternmed.2007.10; Fawzi WW, 1998, LANCET, V351, P1477, DOI 10.1016/S0140-6736(98)04197-X; Fawzi WW, 2004, NEW ENGL J MED, V351, P23, DOI 10.1056/NEJMoa040541; Fitzmaurice GM, 2004, APPL LONGITUDINAL AN; Institute of Medicine (US) Panel on Dietary Antioxidants and Related Compounds, 2000, DIET REF INT VIT C V; Jaruga P, 2002, FREE RADICAL BIO MED, V32, P414, DOI 10.1016/S0891-5849(01)00821-8; Jiamton S, 2003, AIDS, V17, P2461, DOI 10.1097/00002030-200311210-00008; Johannessen A, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-52; Kaiser JD, 2006, JAIDS-J ACQ IMM DEF, V42, P523, DOI 10.1097/01.qai.0000230529.25083.42; Kamali A, 1996, INT J EPIDEMIOL, V25, P679, DOI 10.1093/ije/25.3.679; Karim SSA, 2010, NEW ENGL J MED, V362, P697, DOI 10.1056/NEJMoa0905848; Koethe JR, 2010, AM J CLIN NUTR, V91, p1138S, DOI 10.3945/ajcn.2010.28608D; Koethe JR, 2009, CLIN INFECT DIS, V49, P787, DOI 10.1086/605285; Laurent C, 2005, JAIDS-J ACQ IMM DEF, V38, P14, DOI 10.1097/00126334-200501010-00003; Lederman HM, 2003, J INFECT DIS, V188, P1794, DOI 10.1086/379900; Mahlungulu S, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004536.pub2; Mamlin J, 2009, AM J PUBLIC HEALTH, V99, P215, DOI 10.2105/AJPH.2008.137174; Martinez E, 2001, AIDS, V15, P1261, DOI 10.1097/00002030-200107060-00007; May MT, 2006, LANCET, V368, P451, DOI 10.1016/S0140-6736(06)69152-6; Mehandru S, 2006, PLOS MED, V3, P2335, DOI 10.1371/journal.pmed.0030484; Ministry of Health of the United Republic of Tanzania, 2005, NAT GUID CLIN MAN HI; Ndekha MJ, 2005, ACTA PAEDIATR, V94, P222, DOI 10.1080/08035250410022503; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PrayGod G, 2011, J NUTR, V141, P685, DOI 10.3945/jn.110.131672; Slain D, 2005, PHARMACOTHERAPY, V25, P165, DOI 10.1592/phco.25.2.165.56945; Spada C, 2002, CLIN CHEM LAB MED, V40, P456, DOI 10.1515/CCLM.2002.078; Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782; Sulkowski MS, 2000, JAMA-J AM MED ASSOC, V283, P74, DOI 10.1001/jama.283.1.74; Tang AM, 1997, AIDS, V11, P613, DOI 10.1097/00002030-199705000-00009; Tang AM, 1996, AM J EPIDEMIOL, V143, P1244, DOI 10.1093/oxfordjournals.aje.a008712; TRABER MG, 1987, NEW ENGL J MED, V317, P262, DOI 10.1056/NEJM198707303170502; van Oosterhout JJ, 2010, AIDS CARE, V22, P737, DOI 10.1080/09540120903373581; Webb AL, 2007, NUTR REV, V65, P181, DOI 10.1111/j.1753-4887.2007.tb00298.x; Wester CW, 2005, JAIDS-J ACQ IMM DEF, V40, P336, DOI 10.1097/01.qai.0000159668.80207.5b; WHO, 2010, ANT THER HIV INF AD; World Health Organization, 2004, SCAL ANT THER RES LT; World Health Organization, 2007, VERB AUT STAND ASC A; World Health Organization, 1999, MAN SEV MALN MAN PHY; World Health Organization, 2006, ANT THER HIV INF AD; Zachariah R, 2006, AIDS, V20, P2355, DOI 10.1097/QAD.0b013e32801086b0	54	35	35	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 17	2012	308	15					1535	1544		10.1001/jama.2012.13083	http://dx.doi.org/10.1001/jama.2012.13083			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	021AQ	23073950	Green Accepted, Bronze, Green Published			2023-01-03	WOS:000309858100020
J	Belderok, SM; van den Hoek, A; Roeffen, W; Sauerwein, R; Sonder, GJB				Belderok, Sanne-Meike; van den Hoek, Anneke; Roeffen, Will; Sauerwein, Robert; Sonder, Gerard J. B.			Adherence to Chemoprophylaxis and Plasmodium falciparum Anti-Circumsporozoite Seroconversion in a Prospective Cohort Study of Dutch Short-Term Travelers	PLOS ONE			English	Article							MALARIA CHEMOPROPHYLAXIS; ATOVAQUONE-PROGUANIL; NONIMMUNE TRAVELERS; IMPORTED MALARIA; DECLINING INCIDENCE; NORTH-AMERICAN; RISK; PROPHYLAXIS; DETERMINANTS; TRANSMISSION	Background: We conducted a prospective study in a cohort of short-term travelers assessing the incidence rate of anti-circumsporozoite seroconversion, adherence to chemoprophylaxis, symptoms of malaria during travel, and malaria treatment abroad. Methods: Adults were recruited from the travel clinic of the Public Health Service Amsterdam. They kept a structured daily travel diary and donated blood samples before and after travel. Blood samples were serologically tested for the presence of Plasmodium falciparum anti-circumsporozoite antibodies. Results: Overall, the incidence rate (IR) of anti-circumsporozoite seroconversion was 0.8 per 100 person-months. Of 945 travelers, 620 (66%) visited high-endemic areas and were advised about both chemoprophylaxis and preventive measures against mosquito bites. Most subjects (520/620 = 84%) took at least 75% of recommended prophylaxis during travel. Travel to Africa, use of mefloquine, travel duration of 14-29 days in endemic areas, and concurrent use of DEET (N,N-diethyl-metatoluamide) were associated with good adherence practices. Four travelers without fever seroconverted, becoming anti-circumsporozoite antibody-positive. All four had been adherent to chemoprophylaxis; two visited Africa, one Suriname, one India. Ten subjects with fever were tested for malaria while abroad and of these, three received treatment. All three were adherent to chemoprophylaxis and tested negative for anti-circumsporozoite antibodies. Conclusion: Travel to Africa, using mefloquine, travel duration of 14-29 days in endemic areas, and use of DEET were associated with good adherence to chemoprophylaxis. The combination of chemoprophylaxis and other preventive measures were sufficient to protect seroconverting travelers from clinical malaria. Travelers who were treated for malaria abroad did not seroconvert.	[Belderok, Sanne-Meike; van den Hoek, Anneke; Sonder, Gerard J. B.] Publ Hlth Serv GGD, Dept Infect Dis, Amsterdam, Netherlands; [Belderok, Sanne-Meike; van den Hoek, Anneke; Sonder, Gerard J. B.] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands; [Roeffen, Will; Sauerwein, Robert] Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, NL-6525 ED Nijmegen, Netherlands; [Sonder, Gerard J. B.] Natl Coordinat Ctr Travellers Hlth Advice LCR, Amsterdam, Netherlands	Public Health Service Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Radboud University Nijmegen	Belderok, SM (corresponding author), Publ Hlth Serv GGD, Dept Infect Dis, Amsterdam, Netherlands.	sbelderok@ggd.amsterdam.nl	Sauerwein, Robert/C-8519-2013; Roeffen, W.F.G./L-4607-2015		the Netherlands Organization for Health Research and Development (ZonMw) [7115 0001]	the Netherlands Organization for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development)	This study was conducted within the Amsterdam Academic Collaborative Center on Public Health: a collaboration between the Public Health Service of Amsterdam & the Academic Medical Center of the University of Amsterdam, the Netherlands. The Amsterdam Academic Collaborative Center on Public Health is financially supported by the Netherlands Organization for Health Research and Development (ZonMw; grant number 7115 0001, http://www.zonmw.nl/nl/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Behrens RH, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-114; Behrens RH, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-266; Behrens RH, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-235; Chen LH, 2005, INFECT DIS CLIN N AM, V19, P185, DOI 10.1016/j.idc.2004.10.006; Cobelens FGJ, 1998, AM J TROP MED HYG, V58, P75, DOI 10.4269/ajtmh.1998.58.75; Cobelens FGJ, 1997, TROP MED INT HEALTH, V2, P705, DOI 10.1046/j.1365-3156.1997.d01-357.x; DePetrillo JC, 2010, J TRAVEL MED, V17, P217, DOI 10.1111/j.1708-8305.2010.00426.x; DRUILHE P, 1986, INFECT IMMUN, V53, P393, DOI 10.1128/IAI.53.2.393-397.1986; Goodyer L, 2011, J TRAVEL MED, V18, P245, DOI 10.1111/j.1708-8305.2011.00534.x; GYORKOS TW, 1995, AM J TROP MED HYG, V53, P511, DOI 10.4269/ajtmh.1995.53.511; Hay SI, 2004, LANCET INFECT DIS, V4, P327, DOI 10.1016/S1473-3099(04)01043-6; Hogh B, 2000, LANCET, V356, P1888, DOI 10.1016/S0140-6736(00)03260-8; Huzly, 1996, J Travel Med, V3, P148, DOI 10.1111/j.1708-8305.1996.tb00729.x; Jelinek T, 1998, AM J TROP MED HYG, V59, P35, DOI 10.4269/ajtmh.1998.59.35; Jelinek T., 2008, Eurosurveillance, V13, P19077; Kain KC, 1998, CLIN INFECT DIS, V27, P142, DOI 10.1086/514616; Knappik M, 2002, TROP MED INT HEALTH, V7, P652, DOI 10.1046/j.1365-3156.2002.00906.x; Lalloo DG, 2008, BMJ-BRIT MED J, V336, P1362, DOI 10.1136/bmj.a153; [Landelijk Cordinatiecentrum Reizigersadvisering National Coordination Centre for Traveller's Health Advice], 2007, NAT COORD CTR TRAV H; Leder K, 2008, J TRAVEL MED, V15, P263, DOI 10.1111/j.1708-8305.2008.00218.x; LOBEL HO, 1990, B WORLD HEALTH ORGAN, V68, P209; Lobel HO, 2001, J TRAVEL MED, V8, P167, DOI 10.2310/7060.2001.22206; Neave PE, 2010, J TRAVEL MED, V17, P346, DOI 10.1111/j.1708-8305.2010.00440.x; Nothdurft HD, 1999, CLIN INFECT DIS, V28, P641, DOI 10.1086/515155; Orlandi-Pradines E, 2006, AM J TROP MED HYG, V74, P979; Overbosch D, 2001, CLIN INFECT DIS, V33, P1015, DOI 10.1086/322694; Petersen E, 2000, J TRAVEL MED, V7, P79; Resseguier N, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-41; Robert V, 2000, PARASITE IMMUNOL, V22, P589, DOI 10.1046/j.1365-3024.2000.00340.x; Roestenberg M, 2009, NEW ENGL J MED, V361, P468, DOI 10.1056/NEJMoa0805832; Ropers G, 2008, J TRAVEL MED, V15, P162, DOI 10.1111/j.1708-8305.2008.00188.x; Sagui E, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-232; Sauerwein RW, 2011, NAT REV IMMUNOL, V11, P57, DOI 10.1038/nri2902; Schlagenhauf P, 2008, CLIN MICROBIOL REV, V21, P466, DOI 10.1128/CMR.00059-07; United Nations Statistics Division, 2011, COMP MACR CONT REG G; van Rijckevorsel GGC, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-300; WEBSTER HK, 1987, J CLIN MICROBIOL, V25, P1002, DOI 10.1128/JCM.25.6.1002-1008.1987; Williams Christopher J, 2007, Travel Med Infect Dis, V5, P295, DOI 10.1016/j.tmaid.2007.05.001; World Health Organization, 2012, MAL FACTSH	39	12	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2013	8	2							e56863	10.1371/journal.pone.0056863	http://dx.doi.org/10.1371/journal.pone.0056863			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115ZB	23451100	Green Submitted, Green Published, gold			2023-01-03	WOS:000316849500036
J	Farnie, G; Willan, PM; Clarke, RB; Bundred, NJ				Farnie, Gillian; Willan, Pamela M.; Clarke, Robert B.; Bundred, Nigel J.			Combined Inhibition of ErbB1/2 and Notch Receptors Effectively Targets Breast Ductal Carcinoma In Situ (DCIS) Stem/Progenitor Cell Activity Regardless of ErbB2 Status	PLOS ONE			English	Article							CANCER CELLS; INITIATING CELLS; STEM-CELLS; RADIOTHERAPY; POPULATION	Pathways involved in DCIS stem and progenitor signalling are poorly understood yet are critical to understand DCIS biology and to develop new therapies. Notch and ErbB1/2 receptor signalling cross talk has been demonstrated in invasive breast cancer, but their role in DCIS stem and progenitor cells has not been investigated. We have utilised 2 DCIS cell lines, MCF10DCIS.com (ErbB2-normal) and SUM225 (ErbB2-overexpressing) and 7 human primary DCIS samples were cultured in 3D matrigel and as mammospheres in the presence, absence or combination of the Notch inhibitor, DAPT, and ErbB1/2 inhibitors, lapatinib or gefitinib. Western blotting was applied to assess downstream signalling. In this study we demonstrate that DAPT reduced acini size and mammosphere formation in MCF10DCIS.com whereas there was no effect in SUM225. Lapatinb reduced acini size and mammosphere formation in SUM225, whereas mammosphere formation and Notch1 activity were increased in MCF10DCIS.com. Combined DAPT/lapatinib treatment was more effective at reducing acini size in both DCIS cell lines. Mammosphere formation in cell lines and human primary DCIS was reduced further by DAPT/lapatinib or DAPT/gefitinib regardless of ErbB2 receptor status. Our pre-clinical human models of DCIS demonstrate that Notch and ErbB1/2 both play a role in DCIS acini growth and stem cell activity. We report for the first time that cross talk between the two pathways in DCIS occurs regardless of ErbB2 receptor status and inhibition of Notch and ErbB1/2 was more efficacious than either alone. These data provide further understanding of DCIS biology and suggest treatment strategies combining Notch and ErbB1/2 inhibitors should be investigated regardless of ErbB2 receptor status.	[Farnie, Gillian; Willan, Pamela M.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Paterson Inst Canc Res, Inst Canc Sci,Christie NHS Fdn Trust, Manchester, Lancs, England; [Clarke, Robert B.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Paterson Inst Canc Res,Inst Canc Sci, Breast Biol Grp,Christie NHS Fdn Trust, Manchester, Lancs, England; [Bundred, Nigel J.] Wythenshawe Hosp, Acad Dept Surg, Univ Hosp South Manchester NHS Fdn Trust, Educ & Res Ctr, Manchester M23 9LT, Lancs, England	Christie NHS Foundation Trust; Paterson Institute for Cancer Research; University of Manchester; Christie NHS Foundation Trust; Paterson Institute for Cancer Research; University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Farnie, G (corresponding author), Univ Manchester, Manchester Acad Hlth Sci Ctr, Paterson Inst Canc Res, Inst Canc Sci,Christie NHS Fdn Trust, Manchester, Lancs, England.	gfarnie@picr.man.ac.uk	Clarke, Robert/AAA-3442-2021; farnie, gillian/GLT-8777-2022	Clarke, Robert/0000-0001-5407-3123; Farnie, Gillian/0000-0002-1407-2529	Breast Cancer Campaign; Breast Cancer Now [MAN-Q1] Funding Source: researchfish	Breast Cancer Campaign; Breast Cancer Now	The authors would like to acknowledge the Breast Cancer Campaign for funding this project. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bijker N, 2006, J CLIN ONCOL, V24, P3381, DOI 10.1200/JCO.2006.06.1366; Diehn M, 2006, J NATL CANCER I, V98, P1755, DOI 10.1093/jnci/djj505; Dong YY, 2010, CANCER RES, V70, P5465, DOI 10.1158/0008-5472.CAN-10-0173; Farnie G, 2007, JNCI-J NATL CANCER I, V99, P616, DOI 10.1093/jnci/djk133; Grudzien P, 2010, ANTICANCER RES, V30, P3853; Harrison H, 2010, CANCER RES, V70, P709, DOI 10.1158/0008-5472.CAN-09-1681; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Leonard GD, 2004, JNCI-J NATL CANCER I, V96, P906, DOI 10.1093/jnci/djh164; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Magnifico A, 2009, CLIN CANCER RES, V15, P2010, DOI 10.1158/1078-0432.CCR-08-1327; Meurette O, 2009, CANCER RES, V69, P5015, DOI 10.1158/0008-5472.CAN-08-3478; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Osipo C, 2008, ONCOGENE, V27, P5019, DOI 10.1038/onc.2008.149; PAGE DL, 1995, CANCER, V76, P1197, DOI 10.1002/1097-0142(19951001)76:7<1197::AID-CNCR2820760715>3.0.CO;2-0; Pandya K, 2011, BRIT J CANCER, V105, P796, DOI 10.1038/bjc.2011.321; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Pradeep CR, 2012, ONCOGENE, V31, P907, DOI 10.1038/onc.2011.279; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sakorafas GH, 2008, CANCER TREAT REV, V34, P483, DOI 10.1016/j.ctrv.2008.03.001	20	29	29	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2013	8	2							e56840	10.1371/journal.pone.0056840	http://dx.doi.org/10.1371/journal.pone.0056840			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	099EJ	23457626	gold, Green Submitted, Green Published			2023-01-03	WOS:000315602700098
J	Pan, SC; Tien, KL; Hung, IC; Lin, YJ; Sheng, WH; Wang, MJ; Chang, SC; Kunin, CM; Chen, YC				Pan, Sung-Ching; Tien, Kuei-Lien; Hung, I-Chen; Lin, Yu-Jiun; Sheng, Wang-Huei; Wang, Ming-Jiuh; Chang, Shan-Chwen; Kunin, Calvin M.; Chen, Yee-Chun			Compliance of Health Care Workers with Hand Hygiene Practices: Independent Advantages of Overt and Covert Observers	PLOS ONE			English	Article							IMPROVE COMPLIANCE	Background: Evaluation and feedback of hand hygiene (HH) compliance are important elements of the WHO multimodal strategy for hospital infection control. Overt observation is recommended, but it may be confounded by Hawthorne effect. Covert observation offers the opportunity to decrease observer bias. In this study we conducted a one year hospital-wide HH promotion program that included medical students (MS) as covert observers. Methods: HH compliance for the five WHO indications was determined by trained and validated observers. The overt observers consisted of eleven infection control nurses (ICNs) and two unit HH ambassadors (UAs) in each of 83 wards. The covert observers consisted of nine MS during their rotating clinical clerkships. Feedback was provided to department heads and staff each quarter. Results: Of the 23,333 HH observations 76.0% were by MS, 5.3% by ICNs and 18.7% by UAs. The annual compliance rates were MS 44.1%, ICNs 74.4% and UAs 94.1%; P<0.001. The MS found significantly lower annual compliance rates for 4/5 HH indications compared to ICNs and UAs; P<0.05. The ICNs reported significantly improvement from the first to the fourth quarter; P<0.001. This was associated with feedback from the MS of very poor compliance by nurses during the first quarter. Conclusions: Based on these findings we recommend a two-pronged approach to HH programs. The role of ICNs and UAs is to educate, serve as role models, establish, sustain good HH practices and provide direct feedback. The role of the covert observers is to measure compliance and provide independent feedback.	[Pan, Sung-Ching; Tien, Kuei-Lien; Hung, I-Chen; Lin, Yu-Jiun; Sheng, Wang-Huei; Chang, Shan-Chwen; Chen, Yee-Chun] Natl Taiwan Univ Hosp, Ctr Infect Control, Taipei, Taiwan; [Pan, Sung-Ching; Sheng, Wang-Huei; Chen, Yee-Chun] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; [Wang, Ming-Jiuh] Natl Taiwan Univ Hosp, Dept Anesthesiol, Taipei, Taiwan; [Wang, Ming-Jiuh] Natl Taiwan Univ Hosp, Dept Hosp Planning, Taipei, Taiwan; [Chang, Shan-Chwen; Chen, Yee-Chun] Natl Taiwan Univ, Dept Med, Coll Med, Taipei 10764, Taiwan; [Kunin, Calvin M.] Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; [Kunin, Calvin M.] Univ Arizona, Tucson, AZ USA	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; University System of Ohio; Ohio State University; University of Arizona	Chen, YC (corresponding author), Natl Taiwan Univ Hosp, Ctr Infect Control, Taipei, Taiwan.	yeechunchen@gmail.com	Chen, Yee-Chun/AGW-7535-2022	Chen, Yee-Chun/0000-0002-1816-9010; PAN, SUNG-CHING/0000-0003-3154-6690; CHANG, SHAN-CHWEN/0000-0001-6505-4139; SHENG, WANG-HUEI/0000-0002-5605-7853	Center for Diseases Control, Department of Health, Taiwan [EU098040]; Department of Health, Taiwan [DOH100-TD-B-111-001]	Center for Diseases Control, Department of Health, Taiwan; Department of Health, Taiwan	The authors are grateful to members of the NTUH Center for Infection Control and Center for Quality Control for their sustained support of the hand hygiene program and the hospital staff for their commitment to improve patient safety and reduce healthcare-associated infections. The authors are indebted to the Center for Diseases Control, Department of Health, Taiwan, for providing financial support for the Center for Excellence for Hand Hygiene (EU098040). Y. C. Chen also received a grant from Department of Health, Taiwan (DOH100-TD-B-111-001). The funding organizations were not involved in designing or conducting the study, the data collection, management, analysis, and interpretation, nor the preparation, and approval of the manuscript.	Boyce JM, 2002, INFECT CONT HOSP EP, V23, pS3, DOI 10.1086/503164; Chen YT, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0017844, 10.1371/journal.pone.0017876, 10.1371/journal.pone.0027333, 10.1371/journal.pone.0021428, 10.1371/journal.pone.0027163, 10.1371/journal.pone.0024144]; Chuang YC, 2010, J HOSP INFECT, V76, P143, DOI 10.1016/j.jhin.2010.05.001; Daniels TL, 2012, J INFECT DIS, V206, P1488, DOI 10.1093/infdis/jis549; Eckmanns T, 2006, INFECT CONT HOSP EP, V27, P931, DOI 10.1086/507294; Haas JP, 2007, J HOSP INFECT, V66, P6, DOI 10.1016/j.jhin.2006.11.013; Hornbeck T, 2012, J INFECT DIS, V206, P1549, DOI 10.1093/infdis/jis542; Lin HC, 2010, INFECT CONTROL J, V20, P146; McAteer J, 2008, J HOSP INFECT, V68, P222, DOI 10.1016/j.jhin.2007.12.009; Miyachi H, 2007, AM J INFECT CONTROL, V35, P115, DOI 10.1016/j.ajic.2006.09.003; Pittet D, 2000, LANCET, V356, P1307, DOI 10.1016/S0140-6736(00)02814-2; Pittet D, 1999, ANN INTERN MED, V130, P126, DOI 10.7326/0003-4819-130-2-199901190-00006; Rosenthal T, 2009, ACAD MED, V84, P1705, DOI 10.1097/ACM.0b013e3181bf6988; SETO WH, 1991, AM J INFECT CONTROL, V19, P86, DOI 10.1016/0196-6553(91)90044-D; Son C, 2011, AM J INFECT CONTROL, V39, P716, DOI 10.1016/j.ajic.2010.12.008; van de Mortel T, 2006, AM J INFECT CONTROL, V34, P95, DOI 10.1016/j.ajic.2005.07.006; WHO Training Film, IMPL TOOLK; World Health Organization, 2009, WHO GUID HAND HYG HL	18	99	100	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2013	8	1							e53746	10.1371/journal.pone.0053746	http://dx.doi.org/10.1371/journal.pone.0053746			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	087KE	23341991	Green Published, gold, Green Submitted			2023-01-03	WOS:000314759400076
J	Formoso, G; Taraborrelli, M; Guagnano, MT; D'Adamo, M; Di Pietro, N; Tartaro, A; Consoli, A				Formoso, Gloria; Taraborrelli, Merilda; Guagnano, Maria T.; D'Adamo, Monica; Di Pietro, Natalia; Tartaro, Armando; Consoli, Agostino			Magnetic Resonance Imaging Determined Visceral Fat Reduction Associates with Enhanced IL-10 Plasma Levels in Calorie Restricted Obese Subjects	PLOS ONE			English	Article							ADIPOSE-TISSUE; INSULIN-RESISTANCE; WEIGHT-LOSS; GLUCOSE-INTOLERANCE; WAIST CIRCUMFERENCE; METABOLIC SYNDROME; INFLAMMATION; INTERLEUKIN-10; MARKERS; HUMANS	Background: Obesity is characterized by a low grade chronic inflammation state. Indeed circulating pro-inflammatory cytokines, such as TNF-alpha and IL-6, are elevated in obese subjects, while anti-inflammatory cytokines, such as IL-10, appear to be reduced. Cytokines profile improves after weight loss, but how visceral or subcutaneous fat loss respectively affect pro- or anti-inflammatory cytokines plasma levels has not been precisely assessed. Therefore in the present study we correlated changes in circulating cytokine profile with quantitative changes in visceral and subcutaneous adipose tissue depots measured by an ad hoc Magnetic Resonance Imaging (MRI) protocol before and after weight loss. Materials and Methods: In 14 obese subjects, MRI determination of visceral and subcutaneous fat and plasma glucose, insulin, TNF-alpha IL-6, and IL-10 measurements were performed before and after a caloric restriction induced weight loss of at least 5% of the original body weight. Results: Weight loss improved insulin sensitivity (QUICKI Index: 0.35 +/- 0.03 vs 0.37 +/- 0.04; P<0.05), increased IL-10 (3.4 +/- 1.9 vs 4.6 +/- 1.0 pg/mL; P<0.03), and reduced TNF-alpha and IL-6 plasma levels (2.5 +/- 1.3 vs 1.6 +/- 1.5 pg/mL, P<0.0015, 2.3 +/- 0.4 vs 1.6 +/- 0.6 pg/mL, P<0.02 respectively). A significant correlation was observed between the amount of visceral fat loss and the percentage reduction in both TNF-alpha (r = 0.56, p<0.05) and IL-6 (r = 0.19 p<0.05) plasma levels. In a multiple regression analysis, the amount of visceral fat loss independently correlated with the increase in IL-10 plasma levels. Conclusion: The reduction in visceral adipose tissue is the main driver of the improved inflammatory profile induced by weight loss.	[Formoso, Gloria; Taraborrelli, Merilda; Guagnano, Maria T.; Consoli, Agostino] Univ G DAnnunzio, Dept Med & Aging, Chieti, Italy; [Formoso, Gloria; Consoli, Agostino] Univ Roma Tor Vergata, Dept Internal Med, Rome, Italy; [Formoso, Gloria; Di Pietro, Natalia; Consoli, Agostino] Univ G DAnnunzio, Dept Expt & Clin Sci, Chieti, Italy; [Formoso, Gloria; Di Pietro, Natalia; Tartaro, Armando; Consoli, Agostino] Univ G DAnnunzio, Dept Neurosci & Imaging, Chieti, Italy; [Formoso, Gloria; Di Pietro, Natalia; Consoli, Agostino] Univ G dAnnunzio, CeSI, Aging Res Ctr, Chieti, Italy	G d'Annunzio University of Chieti-Pescara; University of Rome Tor Vergata; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara	Consoli, A (corresponding author), Univ G DAnnunzio, Dept Med & Aging, Chieti, Italy.	consoli@unich.it	tartaro, armando at/K-2184-2016; Guagnano, Maria Teresa/AAT-1701-2021; Consoli, Agostino/J-8027-2018; D'Adamo, Monica/AAL-4676-2020; Di Pietro, Natalia/K-1604-2016	tartaro, armando at/0000-0003-0095-2792; Consoli, Agostino/0000-0002-1885-451X; D'Adamo, Monica/0000-0002-1673-1591; Di Pietro, Natalia/0000-0001-9720-2116	Government Italian Research Grant [2009FATXW3]	Government Italian Research Grant	A Government Italian Research Grant, Protocol #2009FATXW3, supported the work. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Busetto L, 2000, INT J OBESITY, V24, P60, DOI 10.1038/sj.ijo.0801086; Camhi SM, 2011, OBESITY, V19, P402, DOI 10.1038/oby.2010.248; Cartier A, 2009, METABOLISM, V58, P1452, DOI 10.1016/j.metabol.2009.04.025; Chen H, 2005, DIABETES, V54, P1914, DOI 10.2337/diabetes.54.7.1914; Cornier MA, 2011, CIRCULATION, V124, P840, DOI 10.1161/CIRCULATIONAHA.110.968461; Despres JP, 2006, NATURE, V444, P881, DOI 10.1038/nature05488; Fain JN, 2004, ENDOCRINOLOGY, V145, P2273, DOI 10.1210/en.2003-1336; Fisher G, 2012, OBESITY, V20, P715, DOI 10.1038/oby.2011.85; Fisman EZ, 2003, CARDIOVASC DIABETOL, V2, DOI 10.1186/1475-2840-2-11; Fontana L, 2007, DIABETES, V56, P1010, DOI 10.2337/db06-1656; Gabriely I, 2002, DIABETES, V51, P2951, DOI 10.2337/diabetes.51.10.2951; Hajer GR, 2008, EUR HEART J, V29, P2959, DOI 10.1093/eurheartj/ehn387; Heeschen C, 2003, CIRCULATION, V107, P2109, DOI 10.1161/01.CIR.0000065232.57371.25; Indulekha K, 2011, CLIN BIOCHEM, V44, P281, DOI 10.1016/j.clinbiochem.2010.12.015; Jung SH, 2008, J NUTR BIOCHEM, V19, P371, DOI 10.1016/j.jnutbio.2007.05.007; Kern PA, 2001, AM J PHYSIOL-ENDOC M, V280, pE745; Klein S, 2004, NEW ENGL J MED, V350, P2549, DOI 10.1056/NEJMoa033179; Kuk JL, 2005, AM J CLIN NUTR, V81, P1330; Manigrasso MR, 2005, J CLIN ENDOCR METAB, V90, P5876, DOI 10.1210/jc.2005-0281; Mathieu P, 2010, CLIN PHARMACOL THER, V87, P407, DOI 10.1038/clpt.2009.311; Organization WH, 1997, WHONUTNCD981; ROSS R, 1992, J APPL PHYSIOL, V72, P787, DOI 10.1152/jappl.1992.72.2.787; Thorne A, 2002, INT J OBESITY, V26, P193, DOI 10.1038/sj.ijo.0801871; van Exel E, 2002, DIABETES, V51, P1088, DOI 10.2337/diabetes.51.4.1088; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Zhang HR, 2011, ARTERIOSCL THROM VAS, V31, P2063, DOI 10.1161/ATVBAHA.111.225870	26	17	18	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 26	2012	7	12							e52774	10.1371/journal.pone.0052774	http://dx.doi.org/10.1371/journal.pone.0052774			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	071TV	23300769	Green Published, Green Submitted, gold			2023-01-03	WOS:000313618800144
J	Miwa, S; Nishida, H; Tanzawa, Y; Takata, M; Takeuchi, A; Yamamoto, N; Shirai, T; Hayashi, K; Kimura, H; Igarashi, K; Mizukoshi, E; Nakamoto, Y; Kaneko, S; Tsuchiya, H				Miwa, Shinji; Nishida, Hideji; Tanzawa, Yoshikazu; Takata, Munetomo; Takeuchi, Akihiko; Yamamoto, Norio; Shirai, Toshiharu; Hayashi, Katsuhiro; Kimura, Hiroaki; Igarashi, Kentaro; Mizukoshi, Eishiro; Nakamoto, Yasunari; Kaneko, Shuichi; Tsuchiya, Hiroyuki			TNF-alpha and Tumor Lysate Promote the Maturation of Dendritic Cells for Immunotherapy for Advanced Malignant Bone and Soft Tissue Tumors	PLOS ONE			English	Article							CANCER; THERAPY; LYMPHOCYTES; MELANOMA; IMMUNITY; BLOOD; OSTEOSARCOMA; VACCINATION; ANTICANCER; ACTIVATION	Background: Dendritic cells (DCs) play a pivotal role in the immune system. There are many reports concerning DC-based immunotherapy. The differentiation and maturation of DCs is a critical part of DC-based immunotherapy. We investigated the differentiation and maturation of DCs in response to various stimuli. Methods: Thirty-one patients with malignant bone and soft tissue tumors were enrolled in this study. All the patients had metastatic tumors and/or recurrent tumors. Peripheral blood mononuclear cells (PBMCs) were suspended in media containing interleukin-4 (IL-4) and granulocyte-macrophage colony stimulating factor (GM-CSF). These cells were then treated with or without 1) tumor lysate (TL), 2) TL + TNF-alpha, 3) OK-432. The generated DCs were mixed and injected in the inguinal or axillary region. Treatment courses were performed every week and repeated 6 times. A portion of the cells were analyzed by flow cytometry to determine the degree of differentiation and maturation of the DCs. Serum IFN-gamma and serum IL-12 were measured in order to determine the immune response following the DC-based immunotherapy. Results: Approximately 50% of PBMCs differentiated into DCs. Maturation of the lysate-pulsed DCs was slightly increased. Maturation of the TL/TNF-alpha-pulsed DCs was increased, commensurate with OK-432-pulsed DCs. Serum IFN-gamma and serum IL-12 showed significant elevation at one and three months after DC-based immunotherapy. Conclusions: Although TL-pulsed DCs exhibit tumor specific immunity, TL-pulsed cells showed low levels of maturation. Conversely, the TL/TNF-alpha-pulsed DCs showed remarkable maturation. The combination of IL-4/GM-CSF/TL/TNF-alpha resulted in the greatest differentiation and maturation for DC-based immunotherapy for patients with bone and soft tissue tumors.	[Miwa, Shinji; Nishida, Hideji; Tanzawa, Yoshikazu; Takata, Munetomo; Takeuchi, Akihiko; Yamamoto, Norio; Shirai, Toshiharu; Hayashi, Katsuhiro; Kimura, Hiroaki; Igarashi, Kentaro; Tsuchiya, Hiroyuki] Kanazawa Univ, Sch Med, Dept Orthopaed Surg, Kanazawa, Ishikawa 920, Japan; [Mizukoshi, Eishiro; Nakamoto, Yasunari; Kaneko, Shuichi] Kanazawa Univ, Sch Med, Dept Dis Control & Homeostasis, Kanazawa, Ishikawa 920, Japan	Kanazawa University; Kanazawa University	Tsuchiya, H (corresponding author), Kanazawa Univ, Sch Med, Dept Orthopaed Surg, Kanazawa, Ishikawa 920, Japan.	tsuchi@med.kanazawa-u.ac.jp	Hayashi, K/C-4685-2015; Miwa, Shinji/AAI-9309-2020; Takeuchi, Akihiko/AAJ-1563-2020	Hayashi, K/0000-0001-8665-2154; Miwa, Shinji/0000-0002-5962-8287; Takeuchi, Akihiko/0000-0002-4071-5620; Igarashi, Kentaro/0000-0003-2278-1736	Grants-in-Aid for Scientific Research [23791630] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Agarwal A, 2010, IMMUNOPHARM IMMUNOT, V32, P348, DOI 10.3109/08923970903300151; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Bayry J, 2005, J IMMUNOL, V175, P15, DOI 10.4049/jimmunol.175.1.15; Crittenden MR, 2005, IMMUNOLOGY, V114, P11, DOI 10.1111/j.1365-2567.2004.02001.x; Dauer M, 2003, J IMMUNOL, V170, P4069, DOI 10.4049/jimmunol.170.8.4069; Dhodapkar MV, 1999, J CLIN INVEST, V104, P173, DOI 10.1172/JCI6909; Dougan M, 2009, ANNU REV IMMUNOL, V27, P83, DOI 10.1146/annurev.immunol.021908.132544; Figdor CG, 2004, NAT MED, V10, P475, DOI 10.1038/nm1039; Gregoire M, 2003, VACCINE, V21, P791, DOI 10.1016/S0264-410X(02)00600-X; Grimer RJ, 2005, LANCET ONCOL, V6, P85, DOI 10.1016/S1470-2045(05)01734-1; Hawiger D, 2001, J EXP MED, V194, P769, DOI 10.1084/jem.194.6.769; Hovden AO, 2011, BMC IMMUNOL, V12, DOI 10.1186/1471-2172-12-2; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; Iwamoto M, 2003, INT J CANCER, V104, P92, DOI 10.1002/ijc.10915; Joyama S, 2006, CLIN ORTHOP RELAT R, P318, DOI 10.1097/01.blo.0000229347.02834.5e; Kawano M, 2010, CLIN ORTHOP RELAT R, V468, P1373, DOI 10.1007/s11999-010-1302-z; Ladanyi A, 2007, CANCER IMMUNOL IMMUN, V56, P1459, DOI 10.1007/s00262-007-0286-3; Li YP, 2008, J IMMUNOL, V180, P1598, DOI 10.4049/jimmunol.180.3.1598; Matsumoto M, 2001, INT IMMUNOPHARMACOL, V1, P1559, DOI 10.1016/S1567-5769(01)00071-6; Menard C, 2009, CANCER RES, V69, P3563, DOI 10.1158/0008-5472.CAN-08-3807; Moretti S, 2001, MELANOMA RES, V11, P395, DOI 10.1097/00008390-200108000-00010; Nakamoto Y, 2007, CLIN EXP IMMUNOL, V147, P296, DOI 10.1111/j.1365-2249.2006.03290.x; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Okada H, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-67; OKAMOTO H, 1967, JPN J MICROBIOL, V11, P323, DOI 10.1111/j.1348-0421.1967.tb00350.x; Palucka K, 1999, J CLIN IMMUNOL, V19, P12, DOI 10.1023/A:1020558317162; Pulendran B, 2001, TRENDS IMMUNOL, V22, P41, DOI 10.1016/S1471-4906(00)01794-4; Reddy A, 1997, BLOOD, V90, P3640, DOI 10.1182/blood.V90.9.3640; Ribas A, 2003, J CLIN ONCOL, V21, P2415, DOI 10.1200/JCO.2003.06.041; Sabel MS, 2005, BREAST CANCER RES TR, V90, P97, DOI 10.1007/s10549-004-3289-1; Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x; Sanchez-Sanchez N, 2006, J IMMUNOL, V176, P5153, DOI 10.4049/jimmunol.176.9.5153; Small EJ, 2006, J CLIN ONCOL, V24, P3089, DOI 10.1200/JCO.2005.04.5252; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Tsuboi K, 2004, CANCER LETT, V205, P207, DOI 10.1016/j.canlet.2003.10.010; Villadangos JA, 2005, IMMUNOL REV, V207, P191, DOI 10.1111/j.0105-2896.2005.00317.x; Wertel I, 2008, CYTOM PART B-CLIN CY, V74B, P251, DOI 10.1002/cyto.b.20410	38	12	16	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 21	2012	7	12							e52926	10.1371/journal.pone.0052926	http://dx.doi.org/10.1371/journal.pone.0052926			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	065OW	23300824	Green Published, gold, Green Submitted			2023-01-03	WOS:000313158800108
J	Ritz, R; Scheidle, C; Noell, S; Roser, F; Schenk, M; Dietz, K; Strauss, WSL				Ritz, Rainer; Scheidle, Christian; Noell, Susan; Roser, Florian; Schenk, Martin; Dietz, Klaus; Strauss, Wolfgang S. L.			In Vitro Comparison of Hypericin and 5-Aminolevulinic Acid-Derived Protoporphyrin IX for Photodynamic Inactivation of Medulloblastoma Cells	PLOS ONE			English	Article							PROTEIN-KINASE-C; GLIOMA-CELLS; GLIOBLASTOMA-MULTIFORME; MOLECULAR EFFECTORS; MALIGNANT GLIOMA; SINGLET OXYGEN; FLUORESCENCE; THERAPY; ACCUMULATION; PORPHYRIN	Background: Hypericin (HYP) is a naturally occurring photosensitizer. Cellular uptake and photodynamic inactivation after incubation with this photosensitizer have neither been examined in medulloblastoma cells in vitro, nor compared with 5-aminolevulinic acid-derived protoporphyrin IX (5-ALA-derived PpIX). Methods: In 3 medulloblastoma cell lines (D283 Med, Daoy, and D341 Med) the time-and concentration-dependent intracellular accumulation of HYP and 5-ALA-derived PpIX was analyzed by fluorescence microscopy (FM) and FACS. Photocytotoxicity was measured after illumination at 595 nm (HYP) and 635 nm (5-ALA-derived PpIX) in D283 Med cells and compared to U373 MG glioma cells. Results: All medulloblastoma cell lines exhibited concentration-and time-dependent uptake of HYP. Incubation with HYP up to 10 mu M resulted in a rapid increase in fluorescence intensity, which peaked between 2 and 4 hours. 5-ALA-derived PpIX accumulation increased in D283 Med cells by 22% over baseline after 5-ALA incubation up to 1.2 mM. Photocytotoxicity of 5-ALA-derived PpIX was higher in D283 Med medulloblastoma compared to U373MG glioma. The LD50 [lethal dose (light dose that is required to reduce cell survival to 50% of control)] of 5-ALA-derived PpIX was 3.8 J/cm(2) in D283 Med cells versus 5.7 J/cm(2) in U373MG glioma cells. Photocytotoxicity of HYP in D283 Med cells was determined at 2.5 mu M after an incubation time of 2 h and an illumination wavelength of 595 nm. The LD50 value was 0.47 J/cm(2). Conclusion: By its 5-fold increase in fluorescence over autofluorescence levels HYP has excellent properties for tumor visualization in medulloblastomas. The high photocytotoxicity of HYP, compared to 5-ALA-derived PpIX, is convincingly demonstrated by its 8- to 13-fold lower LD50. Therefore HYP might be a promising molecule for intraoperative visualization and photodynamic treatment of medulloblastomas.	[Ritz, Rainer; Scheidle, Christian; Noell, Susan; Roser, Florian] Univ Tubingen, Dept Neurosurg, Tubingen, Germany; [Schenk, Martin] Univ Tubingen, Dept Gen Visceral & Transplant Surg, Tubingen, Germany; [Dietz, Klaus] Univ Tubingen, Dept Med Biometry, Tubingen, Germany; [Strauss, Wolfgang S. L.] Univ Ulm, Inst Lasertechnol Med & Messtech, Ulm, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Ulm University	Ritz, R (corresponding author), Univ Hosp Giessen & Marburg, Dept Neurosurg, Marburg, Germany.	rainer_ritz@hotmail.com	Dietz, Klaus/R-9268-2016	Dietz, Klaus/0000-0001-8503-9737; Roser, Florian/0000-0002-7854-6789				Ali SM, 2002, INT J ONCOL, V21, P531; Amo T, 2009, CELL BIOCHEM FUNCT, V27, P503, DOI 10.1002/cbf.1603; Bhuvaneswari R, 2007, INT J MOL MED, V20, P421; Blank M, 2004, INT J CANCER, V111, P596, DOI 10.1002/ijc.20285; Blank M, 2001, ONCOL RES, V12, P409; Blank M, 2001, PHOTOCHEM PHOTOBIOL, V74, P120, DOI 10.1562/0031-8655(2001)074&lt;0120:ACAOHI&gt;2.0.CO;2; Boiy A, 2011, J PHOTOCH PHOTOBIO B, V102, P123, DOI 10.1016/j.jphotobiol.2010.09.012; Buytaert E, 2008, ONCOGENE, V27, P1916, DOI 10.1038/sj.onc.1210825; Buytaert E, 2007, BBA-REV CANCER, V1776, P86, DOI 10.1016/j.bbcan.2007.07.001; Carre J, 1999, CELL MOL BIOL, V45, P433; Chen B, 2000, CANCER LETT, V150, P111, DOI 10.1016/S0304-3835(99)00381-X; COULDWELL WT, 1991, NEUROSURGERY, V29, P880, DOI 10.1227/00006123-199112000-00013; Crawford JR, 2007, LANCET NEUROL, V6, P1073, DOI 10.1016/S1474-4422(07)70289-2; DIWU Z, 1995, PHOTOCHEM PHOTOBIOL, V61, P529, DOI 10.1111/j.1751-1097.1995.tb09903.x; DIWU ZJ, 1993, FREE RADICAL BIO MED, V14, P209, DOI 10.1016/0891-5849(93)90012-J; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Ehrenberg B, 1998, PHOTOCHEM PHOTOBIOL, V68, P135, DOI 10.1111/j.1751-1097.1998.tb02479.x; Eleouet S, 2000, NEUROL RES, V22, P361, DOI 10.1080/01616412.2000.11740685; Eljamel MS, 2008, LASER MED SCI, V23, P361, DOI 10.1007/s10103-007-0494-2; FAUTREL A, 1991, TOXICOL IN VITRO, V5, P543, DOI 10.1016/0887-2333(91)90090-Z; Hadjur C, 1996, PHOTOCHEM PHOTOBIOL, V64, P375, DOI 10.1111/j.1751-1097.1996.tb02474.x; Hendrickx N, 2005, BIOCHEM BIOPH RES CO, V337, P928, DOI 10.1016/j.bbrc.2005.09.135; Huntosova V, 2012, PHOTOCH PHOTOBIO SCI, V11, P1428, DOI 10.1039/c2pp05409d; Jacquez John A., 1985, COMPARTMENTAL ANAL B; Karioti A, 2010, INT J MOL SCI, V11, P562, DOI 10.3390/ijms11020562; Kemmner W, 2008, FASEB J, V22, P500, DOI 10.1096/fj.07-8888com; Kubin A, 2005, CURR PHARM DESIGN, V11, P233, DOI 10.2174/1381612053382287; Luksiene Zivile, 2003, Medicina (Kaunas), V39, P677; Martinez-Poveda B, 2005, EUR J PHARMACOL, V516, P97, DOI 10.1016/j.ejphar.2005.03.047; Moan J, 1997, INT J CANCER, V70, P90, DOI 10.1002/(SICI)1097-0215(19970106)70:1<90::AID-IJC14>3.0.CO;2-H; Olivo M, 2006, CURR CLIN PHARMACOL, V1, P217, DOI 10.2174/157488406778249370; Packer RJ, 2008, ARCH NEUROL-CHICAGO, V65, P1419, DOI 10.1001/archneur.65.11.1419; Riesenberg R, 1996, EUR J CANCER, V32A, P328, DOI 10.1016/0959-8049(95)00548-X; Ritz R, 2005, INT J ONCOL, V27, P1543; Ritz R, 2007, INT J ONCOL, V30, P659; Sailer R, 2007, PHOTOCH PHOTOBIO SCI, V6, P145, DOI 10.1039/b611715e; Sattler S, 1997, J PHARM SCI, V86, P1120, DOI 10.1021/js970004a; SCHNECKENBURGER H, 1988, J PHOTOCH PHOTOBIO B, V2, P355, DOI 10.1016/1011-1344(88)85054-1; Stummer W, 2006, LANCET ONCOL, V7, P392, DOI 10.1016/S1470-2045(06)70665-9; Stummer W, 1998, J PHOTOCH PHOTOBIO B, V45, P160, DOI 10.1016/S1011-1344(98)00176-6; Stummer W, 2008, NEUROSURGERY, V62, P564, DOI [10.1227/01.NEU.0000297118.47076.5F, 10.1227/01.NEU.0000346230.80425.3A, 10.1227/01.neu.0000317304.31579.17]; Stylli SS, 2004, J CLIN NEUROSCI, V11, P584, DOI 10.1016/j.jocn.2004.02.001; TAKAHASHI I, 1989, BIOCHEM BIOPH RES CO, V165, P1207, DOI 10.1016/0006-291X(89)92730-7; Theodossiou T, 2004, PHOTOCHEM PHOTOBIOL, V80, P438, DOI 10.1562/2004-06-30-RA-220.1; Theodossiou TA, 2009, MOL PHARMACEUT, V6, P1775, DOI 10.1021/mp900166q; THOMAS C, 1992, PHOTOCHEM PHOTOBIOL, V55, P831, DOI 10.1111/j.1751-1097.1992.tb08531.x; THOMAS C, 1992, PHOTOCHEM PHOTOBIOL, V55, P47, DOI 10.1111/j.1751-1097.1992.tb04208.x; Uberriegler KP, 1995, PHOTOCHEM PHOTOBIOL, V62, P1052; UTSUMI T, 1995, ARCH BIOCHEM BIOPHYS, V316, P493, DOI 10.1006/abbi.1995.1065; Uzdensky AB, 2001, LASER MED SCI, V16, P276, DOI 10.1007/PL00011364; Van de Putte M, 2006, INT J ONCOL, V28, P655; Vandenbogaerde AL, 1998, J PHOTOCH PHOTOBIO B, V45, P87, DOI 10.1016/S1011-1344(98)00163-8; Vandenbogaerde AL, 1997, J PHOTOCH PHOTOBIO B, V38, P136, DOI 10.1016/S1011-1344(96)07446-5; WyssDesserich MT, 1996, BIOCHEM BIOPH RES CO, V224, P819, DOI 10.1006/bbrc.1996.1106	54	27	27	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2012	7	12							e51974	10.1371/journal.pone.0051974	http://dx.doi.org/10.1371/journal.pone.0051974			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	055AJ	23251668	Green Submitted, Green Published, gold			2023-01-03	WOS:000312386800123
J	Bourzac, K				Bourzac, Katherine			ANTI-AGEING Live long and prosper	NATURE			English	Editorial Material							CALORIC RESTRICTION											BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Fontana L, 2004, P NATL ACAD SCI USA, V101, P6659, DOI 10.1073/pnas.0308291101; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Mattison JA, 2012, NATURE, V489, P318, DOI 10.1038/nature11432; Stein PK, 2012, AGING CELL, V11, P644, DOI 10.1111/j.1474-9726.2012.00825.x	6	6	6	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 6	2012	492	7427					S18	S20		10.1038/492S18a	http://dx.doi.org/10.1038/492S18a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	048EQ	23222670	Bronze			2023-01-03	WOS:000311893400010
J	Feldacker, C; Johnson, D; Hosseinipour, M; Phiri, S; Tweya, H				Feldacker, Caryl; Johnson, Derek; Hosseinipour, Mina; Phiri, Sam; Tweya, Hannock			Who Starts? Factors Associated with Starting Antiretroviral Therapy among Eligible Patients in Two, Public HIV Clinics in Lilongwe, Malawi	PLOS ONE			English	Article							SUB-SAHARAN AFRICA; FOLLOW-UP; TREATMENT PROGRAMS; EARLY MORTALITY; PATIENTS LOST; PRE-ART; CARE; RETENTION; INITIATION; OUTCOMES	Background: Lighthouse Trust operates two, public, integrated HIV clinics, Lighthouse (LH) and Martin Preuss Center (MPC), in Lilongwe, Malawi. Approximately 20% of patients eligible for antiretroviral therapy (ART) do not start ART. We explore individual and geographic factors that influence whether ART-eligible patients initiate ART. Methods: Adult patients eligible for ART between 2008-2011 were included. Analysis was stratified by clinic. Using logistic regression, we evaluated factors associated with initiating ART including gender, age, body mass index (BMI), employment, tuberculosis (TB), eligible at initial registration, WHO stage, CD4, months in pre-ART care (from initial registration to eligibility date), and patient neighborhood distance to clinic. Results: Of 14,216 study patients, 4841 were from LH; 9285 were from MPC. At LH and MPC, respectively, median age was 34.2 and 33.8 years; median BMI was 22.0 and 20.6; and median distance was 5.6 and 4.9 Km. In multivariate models, odds of starting ART was highest among those older than 35 years and those eligible for ART based on WHO stages 3-4 vs. those in WHO stages 1-2 with CD4<250. Patients with 1-12 months in pre-ART were at least 11 times more likely to start ART than peers with less pre-ART time. At LH, living 2.5-5 Km from the clinic increased the likelihood of starting ART over patients living closer. Conclusions: Length of the pre-ART period is the most significant predictor of starting ART among eligible patients. Better understanding of motivation for retention in pre-ART care may reduce attrition along the treatment cascade.	[Feldacker, Caryl; Phiri, Sam; Tweya, Hannock] Lighthouse Trust, Lilongwe, Malawi; [Feldacker, Caryl] Univ Washington, I TECH, Seattle, WA 98195 USA; [Johnson, Derek; Hosseinipour, Mina] Univ N Carolina Project, Lilongwe, Malawi; [Hosseinipour, Mina] Univ N Carolina, Sch Med, Chapel Hill, NC USA	University of Washington; University of Washington Seattle; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Feldacker, C (corresponding author), Lighthouse Trust, Lilongwe, Malawi.	cfeldacker@gmail.com		Feldacker, Caryl/0000-0002-8152-6754	National Institutes of Health; University of Washington; I-TECH; U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA) [U91HA06801]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Washington(University of Washington); I-TECH; U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA)(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA))	Derek Johnson was funded by a Fogarty Fellowship of the National Institutes of Health and worked on this project in partial fulfillment of the requirements of the funding (http://www.fic.nih.gov/Programs/Pages/fulbright-fellowships.aspx). Funding for other authors was not associated with any grants. The development of this paper was supported by the University of Washington and I-TECH with funding from Cooperative Agreement U91HA06801 from the U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA). The funders played no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amuron B, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-290; Bassett IV, 2009, JAIDS-J ACQ IMM DEF, V51, P135, DOI 10.1097/QAI.0b013e3181a44ef2; Brinkhof MWG, 2008, B WORLD HEALTH ORGAN, V86, P559, DOI 10.2471/BLT.07.044248; Brinkhof MWG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005790; Douglas GP, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000319; Faal M, 2011, JAIDS-J ACQ IMM DEF, V58, pE54, DOI 10.1097/QAI.0b013e3182303921; Fox MP, 2010, TROP MED INT HEALTH, V15, P1, DOI 10.1111/j.1365-3156.2010.02508.x; Geng Elvin H, 2010, Curr HIV/AIDS Rep, V7, P234, DOI 10.1007/s11904-010-0061-5; Geng EH, 2010, JAIDS-J ACQ IMM DEF, V53, P405, DOI 10.1097/QAI.0b013e3181b843f0; Google Inc, 2011, GOOGL EARTH SOFTW; Government of Malawi Ministry of Health, 2011, Q HIV PROGR REP; Harries AD, 2010, TROP MED INT HEALTH, V15, P70, DOI 10.1111/j.1365-3156.2010.02506.x; Jani IV, 2011, LANCET, V378, P1572, DOI 10.1016/S0140-6736(11)61052-0; Jarvis JN, 2010, AIDS, V24, P1233, DOI 10.1097/QAD.0b013e3283383aeb; Katz IT, 2011, AIDS, V25, P2177, DOI 10.1097/QAD.0b013e32834b6464; Keiser O, 2008, TROP MED INT HEALTH, V13, P870, DOI 10.1111/j.1365-3156.2008.02078.x; Kitahata MM, 2009, NEW ENGL J MED, V360, P1815, DOI 10.1056/NEJMoa0807252; Kohler PK, 2011, AIDS, V25, P1657, DOI 10.1097/QAD.0b013e32834957fd; Kranzer K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013801; Lahuerta M, 2011, JAIDS-J ACQ IMM DEF, V58, pE75, DOI 10.1097/QAI.0b013e31822ac0a9; Larson BA, 2010, TROP MED INT HEALTH, V15, P43, DOI 10.1111/j.1365-3156.2010.02511.x; Lawn SD, 2008, AIDS, V22, P1897, DOI 10.1097/QAD.0b013e32830007cd; Lessells RJ, 2011, JAIDS-J ACQ IMM DEF, V56, pE79, DOI 10.1097/QAI.0b013e3182075ae2; Losina E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009538; Maskew M, 2007, SAMJ S AFR MED J, V97, P853; McGrath N, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-601; McGuire M, 2010, TROP MED INT HEALTH, V15, P55, DOI 10.1111/j.1365-3156.2010.02504.x; Ministry of Health and National AIDS Commission, 2011, MAL INT GUID CLIN MA; Ministry of Health Malawi, 2008, TREATM AIDS GUID US; Pepper DJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019484; Phiri S, 2011, TROP MED INT HEALTH, V16, P1397, DOI 10.1111/j.1365-3156.2011.02848.x; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Rosen S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001056; Scott V, 2011, TROP MED INT HEALTH, V16, P1384, DOI 10.1111/j.1365-3156.2011.02842.x; STATA, 2010, STATA 11 0 STAT STAT; Tayler-Smith K, 2010, T ROY SOC TROP MED H, V104, P313, DOI 10.1016/j.trstmh.2010.01.007; Tweya H, 2010, TROP MED INT HEALTH, V15, P82, DOI 10.1111/j.1365-3156.2010.02509.x; Weigel R, 2012, TROP MED INT HEALTH, V17, P751, DOI 10.1111/j.1365-3156.2012.02980.x; World Health Organization, 2004, PERSP PRACT ANT TREA; Yu JKL, 2007, B WORLD HEALTH ORGAN, V85, P550, DOI 10.2471/BLT.06.037739; Zachariah R, 2011, T ROY SOC TROP MED H, V105, P421, DOI 10.1016/j.trstmh.2011.04.014; Zachariah R, 2009, TROP MED INT HEALTH, V14, P713, DOI 10.1111/j.1365-3156.2009.02291.x	42	16	17	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2012	7	11							e50871	10.1371/journal.pone.0050871	http://dx.doi.org/10.1371/journal.pone.0050871			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	054WM	23226413	gold, Green Submitted, Green Published			2023-01-03	WOS:000312376100224
J	Gehlert, S; Bungartz, G; Willkomm, L; Korkmaz, Y; Pfannkuche, K; Schiffer, T; Bloch, W; Suhr, F				Gehlert, Sebastian; Bungartz, Gerd; Willkomm, Lena; Korkmaz, Yueksel; Pfannkuche, Kurt; Schiffer, Thorsten; Bloch, Wilhelm; Suhr, Frank			Intense Resistance Exercise Induces Early and Transient Increases in Ryanodine Receptor 1 Phosphorylation in Human Skeletal Muscle	PLOS ONE			English	Article							CALCIUM-RELEASE; FATIGUE; FIBERS; RECRUITMENT; ACTIVATION; EXPRESSION; PLASTICITY; VOLUNTARY; RESPONSES; CHANNELS	Background: While ryanodine receptor 1 (RyR1) critically contributes to skeletal muscle contraction abilities by mediating Ca(2+)ion oscillation between sarcoplasmatic and myofibrillar compartments, AMP-activated protein kinase (AMPK) senses contraction-induced energetic stress by phosphorylation at Thr(172). Phosphorylation of RyR1 at serine(2843) (pRyR1Ser(2843)) results in leaky RyR1 channels and impaired Ca2+ homeostasis. Because acute resistance exercise exerts decreased contraction performance in skeletal muscle, preceded by high rates of Ca2+-oscillation and energetic stress, intense myofiber contractions may induce increased RyR1 and AMPK phosphorylation. However, no data are available regarding the time-course and magnitude of early RyR1 and AMPK phosphorylation in human myofibers in response to acute resistance exercise. Purpose: Determine the effects and early time-course of resistance exercise on pRyR1Ser(2843) and pAMPKThr(172) in type I and II myofibers. Methods: 7 male subjects (age 23 +/- 2 years, height: 185 +/- 7 cm, weight: 82 +/- 5 kg) performed 3 sets of 8 repetitions of maximum eccentric knee extensions. Muscle biopsies were taken at rest, 15, 30 and 60 min post exercise. pRyR1Ser(2843) and pAMPKThr(172) levels were determined by western blot and semi-quantitative immunohistochemistry techniques. Results: While total RyR1 and total AMPK levels remained unchanged, RyR1 was significantly more abundant in type II than type I myofibers. pRyR1Ser(2843) increased 15 min and peaked 30 min (p<0.01) post exercise in both myofiber types. Type I fibers showed relatively higher increases in pRyR1Ser(2843) levels than type II myofibers and remained elevated up to 60 min post resistance exercise (p<0.05). pAMPKThr(172) also increased 15 to 30 min post exercise (p<0.01) in type I and II myofibers and in whole skeletal muscle. Conclusion: Resistance exercise induces acutely increased pRyR1Ser(2843) and concomitantly pAMPKThr(172) levels for up to 30 min in resistance exercised myofibers. This provides a time-course by which pRyR1Ser(2843) can mechanistically impact Ca2+ handling properties and consequently induce reduced myofiber contractility beyond immediate fatiguing mechanisms.	[Gehlert, Sebastian; Bungartz, Gerd; Willkomm, Lena; Bloch, Wilhelm; Suhr, Frank] German Sport Univ Cologne, Inst Cardiovasc Res & Sport Med, Dept Mol & Cellular Sport Med, Cologne, Germany; [Korkmaz, Yueksel] Univ Dusseldorf, Dept Operat Dent Periodont & Endodont, D-40225 Dusseldorf, Germany; [Pfannkuche, Kurt] Univ Cologne, Inst Neurophysiol, D-50931 Cologne, Germany; [Schiffer, Thorsten] German Sport Univ Cologne, Outpatient Clin Sportstraumatol, Cologne, Germany; [Gehlert, Sebastian; Willkomm, Lena; Bloch, Wilhelm; Suhr, Frank] German Sport Univ Cologne, German Res Ctr Elite Sport, Cologne, Germany	German Sport University Cologne; Heinrich Heine University Dusseldorf; University of Cologne; German Sport University Cologne; German Sport University Cologne	Gehlert, S (corresponding author), German Sport Univ Cologne, Inst Cardiovasc Res & Sport Med, Dept Mol & Cellular Sport Med, Cologne, Germany.	Gehlert@dshs-koeln.de	Gehlert, Sebastian/AAU-7086-2021; Suhr, Frank/AAU-5080-2021; Gehlert, Sebastian/P-7687-2016	Gehlert, Sebastian/0000-0001-6940-3084; Pfannkuche, Kurt Paul/0000-0002-4284-774X; Suhr, Frank/0000-0002-9013-3944	Federal Institute of Sports Science (BISp) [IIA1-507 070103/09-10]	Federal Institute of Sports Science (BISp)	This investigation was funded by the Federal Institute of Sports Science (BISp) IIA1-507 070103/09-10. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen DG, 2008, PHYSIOL REV, V88, P287, DOI 10.1152/physrev.00015.2007; Allen DG, 2008, J APPL PHYSIOL, V104, P296, DOI 10.1152/japplphysiol.00908.2007; Altenburg TM, 2007, J APPL PHYSIOL, V103, P1752, DOI 10.1152/japplphysiol.00496.2007; Atherton PJ, 2005, FASEB J, V19, P786, DOI 10.1096/fj.04-2179fje; Baker JS, 2010, J NUTR METAB, V2010, DOI 10.1155/2010/905612; Bellinger AM, 2008, P NATL ACAD SCI USA, V105, P2198, DOI 10.1073/pnas.0711074105; Bellinger AM, 2008, J CLIN INVEST, V118, P445, DOI 10.1172/JCI34006; Bellinger AM, 2009, NAT MED, V15, P325, DOI 10.1038/nm.1916; Beltman JGM, 2004, EUR J APPL PHYSIOL, V92, P485, DOI 10.1007/s00421-004-1105-6; Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215; BERGSTROM J, 1975, SCAND J CLIN LAB INV, V35, P606, DOI 10.3109/00365517509095787; Betzenhauser MJ, 2010, PFLUG ARCH EUR J PHY, V460, P467, DOI 10.1007/s00424-010-0794-4; BIGLANDRITCHIE B, 1984, MUSCLE NERVE, V7, P691, DOI 10.1002/mus.880070902; BIGLANDRITCHIE B, 1979, EXP NEUROL, V64, P414, DOI 10.1016/0014-4886(79)90280-2; BIGLANDRITCHIE B, 1983, J PHYSIOL-LONDON, V340, P335, DOI 10.1113/jphysiol.1983.sp014765; BIGLANDRITCHIE B, 1986, ACTA PHYSIOL SCAND, V128, P137; Bruton JD, 1998, ACTA PHYSIOL SCAND, V162, P285, DOI 10.1046/j.1365-201X.1998.0292f.x; CHASIOTIS D, 1983, ACTA PHYSIOL SCAND, P1; Chin ER, 2004, P NUTR SOC, V63, P279, DOI 10.1079/PNS2004335; Choi SJ, 2009, J APPL PHYSIOL, V107, P1156, DOI 10.1152/japplphysiol.00403.2009; Dreyer HC, 2006, J PHYSIOL-LONDON, V576, P613, DOI 10.1113/jphysiol.2006.113175; EDWARDS RHT, 1977, J PHYSIOL-LONDON, V272, P769, DOI 10.1113/jphysiol.1977.sp012072; Gehlert S, 2010, LYMPHAT RES BIOL, V8, P165, DOI 10.1089/lrb.2009.0035; Girard O, 2011, SPORTS MED, V41, P673, DOI 10.2165/11590550-000000000-00000; Godin R, 2010, J PHYSIOL-LONDON, V588, P4073, DOI 10.1113/jphysiol.2010.195925; Hardie DG, 2011, AM J CLIN NUTR, V93, p891S, DOI 10.3945/ajcn.110.001925; Lee-Young RS, 2009, J APPL PHYSIOL, V107, P283, DOI 10.1152/japplphysiol.91208.2008; Munch G, 2001, CIRCULATION, V103, P2739; PLAUGHER G, 1991, J MANIP PHYSIOL THER, V14, P503; Rose AJ, 2006, J PHYSIOL-LONDON, V574, P889, DOI 10.1113/jphysiol.2006.111757; Sahlin K, 1997, AM J PHYSIOL-CELL PH, V273, pC172, DOI 10.1152/ajpcell.1997.273.1.C172; Salanova M, 2008, HISTOCHEM CELL BIOL, V130, P105, DOI 10.1007/s00418-008-0399-6; Serrano AL, 2001, P NATL ACAD SCI USA, V98, P13108, DOI 10.1073/pnas.231148598; Westerblad H, 1997, J GEN PHYSIOL, V109, P385, DOI 10.1085/jgp.109.3.385; WESTERBLAD H, 1991, J GEN PHYSIOL, V98, P615, DOI 10.1085/jgp.98.3.615; Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163	36	31	31	2	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2012	7	11							e49326	10.1371/journal.pone.0049326	http://dx.doi.org/10.1371/journal.pone.0049326			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	048BN	23173055	Green Published, Green Submitted, gold			2023-01-03	WOS:000311885300029
J	Fejerskov, B; Zelikin, AN				Fejerskov, Betina; Zelikin, Alexander N.			Substrate Mediated Enzyme Prodrug Therapy	PLOS ONE			English	Article							ALCOHOL) PHYSICAL HYDROGELS; BETA-GLUCURONIDASE; DRUG-DELIVERY; BIOMEDICAL APPLICATIONS; CONTROLLED-RELEASE; FUSION PROTEIN; CELLS; ACTIVATION; ANTIBODY; DESIGN	In this report, we detail Substrate Mediated Enzyme Prodrug Therapy (SMEPT) as a novel approach in drug delivery which relies on enzyme-functionalized cell culture substrates to achieve a localized conversion of benign prodrug(s) into active therapeutics with subsequent delivery to adhering cells or adjacent tissues. For proof-of-concept SMEPT, we use surface adhered micro-structured physical hydrogels based on poly(vinyl alcohol), beta-glucuronidase enzyme and glucuronide prodrugs. We demonstrate enzymatic activity mediated by the assembled hydrogel samples and illustrate arms of control over rate of release of model fluorescent cargo. SMEPT was not impaired by adhering cells and afforded facile time - and dose - dependent uptake of the in situ generated fluorescent cargo by hepatic cells, HepG2. With the use of a glucuronide derivative of an anticancer drug, SN-38, SMEPT afforded a decrease in cell viability to a level similar to that achieved using parent drug. Finally, dose response was achieved using SMEPT and administration of judiciously chosen concentration of SN-38 glucuronide prodrug thus revealing external control over drug delivery using drug eluting surface. We believe that this highly adaptable concept will find use in diverse biomedical applications, specifically surface mediated drug delivery and tissue engineering.	[Fejerskov, Betina; Zelikin, Alexander N.] Aarhus Univ, Dept Chem, DK-8000 Aarhus, Denmark; [Zelikin, Alexander N.] Aarhus Univ, iNano Interdisciplinary Nanosci Ctr, Aarhus, Denmark	Aarhus University; Aarhus University	Zelikin, AN (corresponding author), Aarhus Univ, Dept Chem, Langelandsgade 140, DK-8000 Aarhus, Denmark.	zelikin@chem.au.dk	Zelikin, Alexander/J-3659-2012	Zelikin, Alexander/0000-0002-9864-321X	Lundbeck Foundation; Danish Council for Independent Research, Technology and Production Sciences, Denmark (ANZ)	Lundbeck Foundation(Lundbeckfonden); Danish Council for Independent Research, Technology and Production Sciences, Denmark (ANZ)	This work was supported by grant from the Lundbeck Foundation and Sapere Aude Starting Grant from the Danish Council for Independent Research, Technology and Production Sciences, Denmark (ANZ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen JW, 2003, BIOTECHNOL BIOENG, V82, P253, DOI 10.1002/bit.10569; Alves MH, 2011, MACROMOL BIOSCI, V11, P1293, DOI 10.1002/mabi.201100145; Bakina E, 1997, J MED CHEM, V40, P4013, DOI 10.1021/jm970066d; Bhatia SN, 1999, FASEB J, V13, P1883, DOI 10.1096/fasebj.13.14.1883; Bichara DA, 2010, J SURG RES, V163, P331, DOI 10.1016/j.jss.2010.03.070; BOSSLET K, 1994, CANCER RES, V54, P2151; Cao L, 2007, ADV DRUG DELIVER REV, V59, P1340, DOI 10.1016/j.addr.2007.08.012; Chen KC, 2007, CANCER GENE THER, V14, P187, DOI 10.1038/sj.cgt.7700999; Czichocki G, 2001, BIOTECHNOL LETT, V23, P1303, DOI 10.1023/A:1010569322537; de Graaf M, 2002, CURR PHARM DESIGN, V8, P1391; DEAN RT, 1974, BIOCHEM J, V138, P395, DOI 10.1042/bj1380395; Fejerskov B, 2012, ACS APPL MATER INTER, V4, P4981, DOI 10.1021/am3013467; Fukuda J, 2006, BIOMATERIALS, V27, P1479, DOI 10.1016/j.biomaterials.2005.09.015; Groger H, 2001, ORG LETT, V3, P1969, DOI 10.1021/ol015920g; Gulsen D, 2005, CURR EYE RES, V30, P1071, DOI 10.1080/02713680500346633; Haisma HJ, 1998, BLOOD, V92, P184, DOI 10.1182/blood.V92.1.184.413k26_184_190; Hassan CM, 2000, ADV POLYM SCI, V153, P37; Hoare TR, 2008, POLYMER, V49, P1993, DOI 10.1016/j.polymer.2008.01.027; Hosta-Rigau L, 2012, ADV HEALTHC MATER, V1, P791, DOI 10.1002/adhm.201200092; Jensen BEB, 2012, SOFT MATTER, V8, P4625, DOI 10.1039/c2sm07075h; Jensen BEB, 2011, LANGMUIR, V27, P10216, DOI 10.1021/la201595e; Khademhosseini A, 2007, BIOMATERIALS, V28, P5087, DOI 10.1016/j.biomaterials.2007.07.021; Khetani SR, 2008, NAT BIOTECHNOL, V26, P120, DOI 10.1038/nbt1361; Koutsopoulos S, 2009, P NATL ACAD SCI USA, V106, P4623, DOI 10.1073/pnas.0807506106; Kratz F, 2008, CHEMMEDCHEM, V3, P20, DOI 10.1002/cmdc.200700159; Ladewig K, 2011, EXPERT OPIN DRUG DEL, V8, P1175, DOI 10.1517/17425247.2011.588698; Levental I, 2007, SOFT MATTER, V3, P299, DOI 10.1039/b610522j; Li YL, 2012, CHEM SOC REV, V41, P2193, DOI 10.1039/c1cs15203c; Lin CC, 2006, ADV DRUG DELIVER REV, V58, P1379, DOI 10.1016/j.addr.2006.09.004; Lin CC, 2009, PHARM RES-DORDR, V26, P631, DOI 10.1007/s11095-008-9801-2; Liu SQ, 2010, SOFT MATTER, V6, P67, DOI 10.1039/b916705f; Lo CM, 2000, BIOPHYS J, V79, P144, DOI 10.1016/S0006-3495(00)76279-5; Lozinsky VI, 2003, TRENDS BIOTECHNOL, V21, P445, DOI 10.1016/j.tibtech.2003.08.002; Lozinsky VI, 1997, ENZYME MICROB TECH, V20, P182, DOI 10.1016/S0141-0229(96)00110-X; Mertz D, 2009, NAT MATER, V8, P731, DOI [10.1038/NMAT2504, 10.1038/nmat2504]; NiculescuDuvaz I, 1997, ADV DRUG DELIVER REV, V26, P151, DOI 10.1016/S0169-409X(97)00032-X; Saltzman WM, 2002, NAT REV DRUG DISCOV, V1, P177, DOI 10.1038/nrd744; Seliktar D, 2012, SCIENCE, V336, P1124, DOI 10.1126/science.1214804; Slaughter BV, 2009, ADV MATER, V21, P3307, DOI 10.1002/adma.200802106; Smith AAA, 2012, POLYM CHEM-UK, V3, P85, DOI 10.1039/c1py00429h; Starkey DE, 2001, J CHROMATOGR B, V762, P33, DOI 10.1016/S0378-4347(01)00313-9; Tietze LF, 2009, CHEM BIOL DRUG DES, V74, P205, DOI 10.1111/j.1747-0285.2009.00856.x; Uhrich KE, 1999, CHEM REV, V99, P3181, DOI 10.1021/cr940351u; Vogt C, 2012, ACS MACRO LETT, V1, P797, DOI 10.1021/mz3000896; Wang NX, 2011, MACROMOL BIOSCI, V11, P321, DOI 10.1002/mabi.201000206; Zelikin AN, 2010, ACS NANO, V4, P2494, DOI 10.1021/nn100634r; Zinchenko YS, 2006, TISSUE ENG, V12, P751, DOI 10.1089/ten.2006.12.751; Zustiak SP, 2011, BIOTECHNOL BIOENG, V108, P197, DOI 10.1002/bit.22911	48	20	21	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2012	7	11							e49619	10.1371/journal.pone.0049619	http://dx.doi.org/10.1371/journal.pone.0049619			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	039HF	23152927	Green Published, Green Submitted, gold			2023-01-03	WOS:000311234600050
J	Burkhardt, W; Kraft, S; Ochs, M; Proquitte, H; Mense, L; Rudiger, M				Burkhardt, Wolfram; Kraft, Stephan; Ochs, Matthias; Proquitte, Hans; Mense, Lars; Ruediger, Mario			Persurf, a New Method to Improve Surfactant Delivery: A Study in Surfactant Depleted Rats	PLOS ONE			English	Article							PARTIAL LIQUID VENTILATION; RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; EXOGENOUS SURFACTANT; GAS-EXCHANGE; II CELLS; MECHANICAL VENTILATION; NATURAL SURFACTANT; BOVINE SURFACTANT; HEALTHY PIGLETS	Purpose: Exogenous surfactant is not very effective in adults with ARDS, since surfactant does not reach atelectatic alveoli. Perfluorocarbons (PFC) can recruit atelectatic areas but do not replace impaired endogenous surfactant. A surfactant-PFC-mixture could combine benefits of both therapies. The aim of the proof-of-principal-study was to produce a PFC-in-surfactant emulsion (Persurf) and to test in surfactant depleted Wistar rats whether Persurf achieves I.) a more homogenous pulmonary distribution and II.) a more homogenous recruitment of alveoli when compared with surfactant or PFC alone. Methods: Three different PFC were mixed with surfactant and phospholipid concentration in the emulsion was measured. After surfactant depletion, animals either received 30 ml/kg of PF5080, 100 mg/kg of stained (green dye) Curosurf (TM) or 30 ml/kg of Persurf. Lungs were fixated after 1 hour of ventilation and alveolar aeration and surfactant distribution was estimated by a stereological approach. Results: Persurf contained 3 mg/ml phospholipids and was stable for more than 48 hours. Persurf-administration improved oxygenation. Histological evaluation revealed a more homogenous surfactant distribution and alveolar inflation when compared with surfactant treated animals. Conclusions: In surfactant depleted rats administration of PFC-in-surfactant emulsion leads to a more homogenous distribution and aeration of the lung than surfactant alone.	[Burkhardt, Wolfram; Mense, Lars; Ruediger, Mario] Tech Univ Dresden, Dept Neonatol & Pediat Intens Care Med, Klin Kinderheilkunde, Univ Klinikum Carl Gustav Carus,Med Fak, D-01062 Dresden, Germany; [Kraft, Stephan] Klinikum Mutterhaus Borromaerinnen, Dept Pediat Surg, Trier, Germany; [Ochs, Matthias] Hannover Med Sch, Inst Funct & Appl Anat, D-3000 Hannover, Germany; [Proquitte, Hans] Univ Med Berlin, Charite, Clin Neonatol, Berlin, Germany	Technische Universitat Dresden; Carl Gustav Carus University Hospital; Hannover Medical School; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Rudiger, M (corresponding author), Tech Univ Dresden, Dept Neonatol & Pediat Intens Care Med, Klin Kinderheilkunde, Univ Klinikum Carl Gustav Carus,Med Fak, D-01062 Dresden, Germany.	mario.ruediger@uniklinikum-dresden.de	Mense, Lars/ABB-7080-2021		Deutsche Forschungsgemeinschaft (DFG) [SI 785/3-1, RU 1233/1-2]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	The study was supported by grants from the Deutsche Forschungsgemeinschaft (DFG SI 785/3-1 and RU 1233/1-2). No additional fundings received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bendel-Stenzel Ellen M., 2000, Pediatr Crit Care Med, V1, P72, DOI 10.1097/00130478-200007000-00014; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Burkhardt W, 2004, INTENS CARE MED, V30, P315, DOI 10.1007/s00134-003-2090-7; Burkhardt W, 2002, BIOL NEONATE, V82, P250, DOI 10.1159/000065886; Chappell SE, 2001, RESP MED, V95, P612, DOI 10.1053/rmed.2001.1114; Cox PN, 2003, INTENS CARE MED, V29, P2297, DOI 10.1007/s00134-003-1881-1; Diemel RV, 2002, CRIT CARE MED, V30, P1083, DOI 10.1097/00003246-200205000-00020; Doctor A, 2003, J APPL PHYSIOL, V95, P1248, DOI 10.1152/japplphysiol.00598.2002; EDWARDS AD, 1992, PEDIATR RES, V32, P532, DOI 10.1203/00006450-199211000-00007; Espinosa FF, 1999, J APPL PHYSIOL, V86, P391, DOI 10.1152/jappl.1999.86.1.391; Gregory TJ, 1997, AM J RESP CRIT CARE, V155, P1309, DOI 10.1164/ajrccm.155.4.9105072; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Guthmann F, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-10; Hartog A, 1999, BRIT J ANAESTH, V82, P81, DOI 10.1093/bja/82.1.81; Jeng MJ, 2003, CRIT CARE MED, V31, P1166, DOI 10.1097/01.CCM.0000059312.90697.32; Krause MF, 2000, EUR RESPIR J, V15, P949, DOI 10.1034/j.1399-3003.2000.15e23.x; Krause MF, 2001, PEDIATR RES, V50, P34, DOI 10.1203/00006450-200107000-00009; LACHMANN B, 1980, ACTA ANAESTH SCAND, V24, P231, DOI 10.1111/j.1399-6576.1980.tb01541.x; Lachmann B, 1989, Eur Respir J Suppl, V3, p98s; LEACH CL, 1995, J PEDIATR-US, V126, P412, DOI 10.1016/S0022-3476(95)70461-2; Lewis JE, 2003, ANNU REV PHYSIOL, V65, P613, DOI 10.1146/annurev.physiol.65.092101.142434; Meister JC, 2000, PEDIATR RES, V47, P240, DOI 10.1203/00006450-200002000-00015; MODELL J H, 1970, Chest, V57, P263, DOI 10.1378/chest.57.3.263; Moller JC, 2003, INTENS CARE MED, V29, P437, DOI 10.1007/s00134-003-1650-1; Mrozek JD, 1999, CRIT CARE MED, V27, P1916, DOI 10.1097/00003246-199909000-00033; Ochs M, 2006, J MICROSC-OXFORD, V222, P188, DOI 10.1111/j.1365-2818.2006.01587.x; PETTY TL, 1979, CHEST, V75, P571, DOI 10.1378/chest.75.5.571; PETTY TL, 1977, AM REV RESPIR DIS, V115, P531; ROYALL JA, 1988, J PEDIATR-US, V112, P169, DOI 10.1016/S0022-3476(88)80053-2; Rudiger M, 1998, AM J PHYSIOL-LUNG C, V274, pL143, DOI 10.1152/ajplung.1998.274.1.L143; Rudiger M, 2003, PEDIATR RES, V54, P808, DOI 10.1203/01.PDR.000088070.62177.3A; Rudiger M, 2003, CRIT CARE MED, V31, P1190, DOI 10.1097/01.CCM.0000060008.96029.7D; Rudiger M, 2001, CRIT CARE MED, V29, P1786; Rudiger M, 2001, BIOL NEONATE, V79, P73, DOI 10.1159/000047070; Rudiger M, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-40; Skinner J, 1997, ARCH DIS CHILD-FETAL, V76, pF67, DOI 10.1136/fn.76.2.F67; Walmrath D, 2002, EUR RESPIR J, V19, P805, DOI 10.1183/09031936.02.00243402; Weibel ER, 2007, J APPL PHYSIOL, V102, P459, DOI 10.1152/japplphysiol.00808.2006; Wemhoner A, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-52; Wolf S, 2001, BRIT J ANAESTH, V87, P593, DOI 10.1093/bja/87.4.593; Wolfson MR, 1998, J APPL PHYSIOL, V84, P624, DOI 10.1152/jappl.1998.84.2.624	41	6	7	2	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2012	7	10							e47923	10.1371/journal.pone.0047923	http://dx.doi.org/10.1371/journal.pone.0047923			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	038AF	23082229	Green Submitted, gold, Green Published			2023-01-03	WOS:000311146900126
J	Hanggi, D; Perrin, J; Eicker, S; Beseoglu, K; Etminan, N; Kamp, MA; Heiroth, HJ; Bege, N; Macht, S; Frauenknecht, K; Sommer, C; Kissel, T; Steiger, HJ				Haenggi, Daniel; Perrin, Jason; Eicker, Sven; Beseoglu, Kerim; Etminan, Nima; Kamp, Marcel Alexander; Heiroth, Hi-Jae; Bege, Nadia; Macht, Stephan; Frauenknecht, Katrin; Sommer, Clemens; Kissel, Thomas; Steiger, Hans-Jakob			Local Delivery of Nimodipine by Prolonged-Release Microparticles-Feasibility, Effectiveness and Dose-Finding in Experimental Subarachnoid Hemorrhage	PLOS ONE			English	Article							CHRONIC CEREBRAL VASOSPASM; INTRATHECAL NIMODIPINE; IN-VIVO; MODEL; RAT; ANGIOGRAPHY; ARTERIES; THERAPY; NANOPARTICLES; PREVENTION	Background and Purpose: To investigate the effect of locally applied nimodipine prolonged-release microparticles on angiographic vasospasm and secondary brain injury after experimental subarachnoid hemorrhage (SAH). Methods: 70 male Wistar rats were categorized into three groups: 1) sham operated animals (control), 2) animals with SAH only (control) and the 3) treatment group. SAH was induced using the double hemorrhage model. The treatment group received different concentrations (20%, 30% or 40%) of nimodipine microparticles. Angiographic vasospasm was assessed 5 days later using digital subtraction angiography (DSA). Histological analysis of frozen sections was performed using H&E-staining as well as Iba1 and MAP2 immunohistochemistry. Results: DSA images were sufficient for assessment in 42 animals. Severe angiographic vasospasm was present in group 2 (SAH only), as compared to the sham operated group (p<0.001). Only animals within group 3 and the highest nimodipine microparticles concentration (40%) as well as group 1 (sham) demonstrated the largest intracranial artery diameters. Variation in vessel calibers, however, did not result in differences in Iba-1 or MAP2 expression, i.e. in histological findings for secondary brain injury. Conclusions: Local delivery of high-dose nimodipine prolonged-release microparticles at high concentration resulted in significant reduction in angiographic vasospasm after experimental SAH and with no histological signs for matrix toxicity.	[Haenggi, Daniel; Perrin, Jason; Eicker, Sven; Beseoglu, Kerim; Etminan, Nima; Kamp, Marcel Alexander; Heiroth, Hi-Jae; Steiger, Hans-Jakob] Univ Dusseldorf, Dept Neurosurg, D-40225 Dusseldorf, Germany; [Macht, Stephan] Univ Dusseldorf, Inst Neuroradiol, D-40225 Dusseldorf, Germany; [Bege, Nadia; Kissel, Thomas] Univ Marburg, Dept Pharmaceut & Biopharm, Marburg, Germany; [Frauenknecht, Katrin; Sommer, Clemens] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Neuropathol, Mainz, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Philipps University Marburg; Johannes Gutenberg University of Mainz	Hanggi, D (corresponding author), Univ Dusseldorf, Dept Neurosurg, D-40225 Dusseldorf, Germany.	daniel.haenggi@uni-duesseldorf.de	Frauenknecht, Katrin/AAF-1638-2020; Eicker, Sven/B-3341-2015; Steiger, Hans-Jakob/AAN-8307-2021	Frauenknecht, Katrin/0000-0002-1372-3297; Steiger, Hans-Jakob/0000-0002-8249-2998; Kamp, Marcel/0000-0002-1252-2944	Kluh Foundation, Dusseldorf, Germany	Kluh Foundation, Dusseldorf, Germany	The study was supported by a grant of the Kluh Foundation, Dusseldorf, Germany. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aladag MA, 2003, ACTA NEUROCHIR, V145, P673, DOI 10.1007/s00701-003-0052-z; AUER LM, 1982, ACTA NEUROCHIR, V63, P297, DOI 10.1007/BF01728885; Barth M, 2007, STROKE, V38, P330, DOI 10.1161/01.STR.0000254601.74596.0f; Bederson JB, 1998, NEUROSURGERY, V42, P352, DOI 10.1097/00006123-199802000-00091; BOULLIN DJ, 1981, NEURORADIOLOGY, V21, P245, DOI 10.1007/BF02100154; DELGADO TJ, 1985, STROKE, V16, P595, DOI 10.1161/01.STR.16.4.595; Frauenknecht K, 2010, J NEUROIMMUNOL, V227, P1, DOI 10.1016/j.jneuroim.2010.05.043; GIOIA AE, 1985, J NEUROSURG, V62, P721, DOI 10.3171/jns.1985.62.5.0721; Grasso G, 2004, BRAIN RES REV, V44, P49, DOI 10.1016/j.brainresrev.2003.10.003; Hanggi D, 2008, CLIN NEUROL NEUROSUR, V110, P784, DOI 10.1016/j.clineuro.2008.05.001; Hanggi D, 2009, NEUROSURGERY, V64, P1155, DOI 10.1227/01.NEU.0000340685.06407.FD; Hop JW, 1997, STROKE, V28, P660, DOI 10.1161/01.STR.28.3.660; Kasuya H, 2005, NEUROSURGERY, V56, P895; Lee SH, 2011, INT J PHARMACEUT, V403, P192, DOI 10.1016/j.ijpharm.2010.10.012; LEWIS PJ, 1988, NEUROSURGERY, V22, P492; Li XA, 2010, J CONTROL RELEASE, V147, P304, DOI 10.1016/j.jconrel.2010.07.113; Longo M, 2002, NEURORADIOLOGY, V44, P689, DOI 10.1007/s00234-002-0781-3; Lovelock CE, 2010, NEUROLOGY, V74, P1494, DOI 10.1212/WNL.0b013e3181dd42b3; Marbacher S, 2008, INTENS CARE MED, V34, P932, DOI 10.1007/s00134-008-0995-x; Megyesi JF, 2000, NEUROSURGERY, V46, P448, DOI 10.1097/00006123-200002000-00035; Ono S, 1997, STROKE, V28, P1631, DOI 10.1161/01.STR.28.8.1631; Paxinos G., 2007, RAT BRAIN STEREOTAXI; Prunell GF, 2004, NEUROSURGERY, V54, P426, DOI 10.1227/01.NEU.0000103670.09687.7A; Satoh M, 2002, STROKE, V33, P775, DOI 10.1161/hs0302.103734; Suarez JI, 2006, NEW ENGL J MED, V354, P387, DOI 10.1056/NEJMra052732; Tanay E, 2006, BRAIN RES, V1112, P222, DOI 10.1016/j.brainres.2006.07.004; Turowski B, 2007, NEURORADIOLOGY, V49, P129, DOI 10.1007/s00234-006-0168-y; Vatter H, 2006, NEUROSURGERY, V58, P1190, DOI 10.1227/01.NEU.0000199346.74649.66; VERLOOY J, 1992, ACTA NEUROCHIR, V117, P48, DOI 10.1007/BF01400635; VOLDBY B, 1984, ACTA NEUROCHIR, V70, P243, DOI 10.1007/BF01406653; ZABRAMSKI JM, 1986, NEUROSURGERY, V18, P1	31	14	14	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2012	7	9							e42597	10.1371/journal.pone.0042597	http://dx.doi.org/10.1371/journal.pone.0042597			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	016YP	23049732	Green Published, Green Submitted, gold			2023-01-03	WOS:000309556100004
J	Dreifuss, AA; Bastos-Pereira, AL; Fabossi, IA; Livero, FAD; Stolf, AM; de Souza, CEA; Gomes, LD; Constantin, RP; Furman, AEF; Strapasson, RLB; Teixeira, S; Zampronio, AR; Muscara, MN; Stefanello, MEA; Acco, A				Dreifuss, Arturo Alejandro; Bastos-Pereira, Amanda Leite; Fabossi, Isabella Aviles; dos Reis Livero, Francislaine Aparecida; Stolf, Aline Maria; Alves de Souza, Carlos Eduardo; Gomes, Liana de Oliveira; Constantin, Rodrigo Polimeni; Ferreira Furman, Aline Emmer; Batista Strapasson, Regiane Lauriano; Teixeira, Simone; Zampronio, Aleksander Roberto; Muscara, Marcelo Nicolas; Alves Stefanello, Maria Elida; Acco, Alexandra			Uncaria tomentosa Exerts Extensive Anti-Neoplastic Effects against the Walker-256 Tumour by Modulating Oxidative Stress and Not by Alkaloid Activity	PLOS ONE			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; QUINOVIC ACID GLYCOSIDES; UNA-DE-GATO; NF-KAPPA-B; OXINDOLE ALKALOIDS; CATS CLAW; ANTIINFLAMMATORY ACTIVITY; BEARING RATS; CANCER CACHEXIA; LEUKEMIA-CELLS	This study aimed to compare the anti-neoplastic effects of an Uncaria tomentosa (UT) brute hydroethanolic (BHE) extract with those of two fractions derived from it. These fractions are choroformic (CHCl3) and n-butanolic (BuOH), rich in pentacyclic oxindole alkaloids (POA) and antioxidant substances, respectively. The cancer model was the subcutaneous inoculation of Walker-256 tumour cells in the pelvic limb of male Wistar rat. Subsequently to the inoculation, gavage with BHE extract (50 mg.kg(-1)) or its fractions (as per the yield of the fractioning process) or vehicle (Control) was performed during 14 days. Baseline values, corresponding to individuals without tumour or treatment with UT, were also included. After treatment, tumour volume and mass, plasma biochemistry, oxidative stress in liver and tumour, TNF-alpha level in liver and tumour homogenates, and survival rates were analysed. Both the BHE extract and its BuOH fraction successfully reduced tumour weight and volume, and modulated anti-oxidant systems. The hepatic TNF-alpha level indicated a greater effect from the BHE extract as compared to its BuOH fraction. Importantly, both the BHE extract and its BuOH fraction increased the survival time of the tumour-bearing animals. Inversely, the CHCl3 fraction was ineffective. These data represent an in vivo demonstration of the importance of the modulation of oxidative stress as part of the anti-neoplastic activity of UT, as well as constitute evidence of the lack of activity of isolated POAs in the primary tumour of this tumour lineage. These effects are possibly resulting from a synergic combination of substances, most of them with antioxidant properties.	[Dreifuss, Arturo Alejandro; Bastos-Pereira, Amanda Leite; Fabossi, Isabella Aviles; dos Reis Livero, Francislaine Aparecida; Stolf, Aline Maria; Alves de Souza, Carlos Eduardo; Gomes, Liana de Oliveira; Zampronio, Aleksander Roberto; Acco, Alexandra] Univ Fed Parana, Dept Pharmacol, BR-80060000 Curitiba, Parana, Brazil; [Constantin, Rodrigo Polimeni] Univ Maringa, Dept Biochem, Maringa, Parana, Brazil; [Ferreira Furman, Aline Emmer] Univ Fed Parana, Training Lab, Dept Pharm, BR-80060000 Curitiba, Parana, Brazil; [Batista Strapasson, Regiane Lauriano; Alves Stefanello, Maria Elida] Univ Fed Parana, Dept Chem, BR-80060000 Curitiba, Parana, Brazil; [Teixeira, Simone; Muscara, Marcelo Nicolas] Univ Sao Paulo, Dept Pharmacol, BR-05508 Sao Paulo, Brazil	Universidade Federal do Parana; Universidade Federal do Parana; Universidade Federal do Parana; Universidade de Sao Paulo	Acco, A (corresponding author), Univ Fed Parana, Dept Pharmacol, BR-80060000 Curitiba, Parana, Brazil.	aleacco@ufpr.br	Muscará, Marcelo N/F-3250-2012; Acco, Alexandra/AAF-8826-2020; Bastos-Pereira, Amanda/AAQ-1375-2020; Constantin, Rodrigo P/A-4727-2016; Acco, Alexandra/K-1265-2014; Zampronio, Aleksander R/B-3915-2013; Lívero, Francislaine/AAG-6083-2019; Teixeira, Simone/K-3991-2016	Muscará, Marcelo N/0000-0002-8342-5586; Acco, Alexandra/0000-0003-3977-687X; Bastos-Pereira, Amanda/0000-0001-9416-1208; Acco, Alexandra/0000-0003-3977-687X; Lívero, Francislaine/0000-0001-6533-0850; Teixeira, Simone/0000-0002-8515-5030; Zampronio, Aleksander/0000-0002-8354-7081	REUNI/CAPES	REUNI/CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	The authors would like to express their gratitude to Dr. Jose Luis Aguilar, from the Cayetano Heredia Peruvian University, Lima, Peru; Dr. Armando Rivero, from the National University of San Marcos, Lima, Peru; and Peruvian Heritage, S. A. C., for their generous contribution of all botanic material employed in this work. Also, all our appreciation goes to Prof. Dr. Luiz Claudio Fernandes, Federal University of Parana, for his kindness in providing us with the Walker-256 tumour cells. Finally, many thankful regards go to Jorgete Constantin, Aparecida Pinto Munhos Hermoso and Renato Polimeni Constantin, from the University of Maringa, Parana, Brazil, for their invaluable help during some experimental procedures. The authors acknowledge REUNI/CAPES for the Master degree fellowship supported to the first author. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acco A, 2007, BASIC CLIN PHARMACOL, V101, P294, DOI 10.1111/j.1742-7843.2007.00124.x; Aebi H, 1984, CATALASE IN VITRO; Aguilar JL, 2002, J ETHNOPHARMACOL, V81, P271, DOI 10.1016/S0378-8741(02)00093-4; Dreifuss AA, 2010, J ETHNOPHARMACOL, V130, P127, DOI 10.1016/j.jep.2010.04.029; Allen-Hall L, 2010, J ETHNOPHARMACOL, V127, P685, DOI 10.1016/j.jep.2009.12.004; Aquino R, 1997, PHYTOCHEMISTRY, V45, P1035, DOI 10.1016/S0031-9422(96)00716-9; AQUINO R, 1991, J NAT PROD, V54, P453, DOI 10.1021/np50074a016; AQUINO R, 1990, J NAT PROD, V53, P559, DOI 10.1021/np50069a004; Bacher N, 2006, BRIT J HAEMATOL, V132, P615, DOI 10.1111/j.1365-2141.2005.05907.x; Bastos-Pereira AL, 2010, CANCER CHEMOTH PHARM, V65, P267, DOI 10.1007/s00280-009-1031-8; Bechtel W, 2009, ANTICANCER RES, V29, P4541; Bechtel W, 2009, ANTICANCER RES, V29, P4559; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Calabrese V, 2010, METHODS MOL BIOL, V610, P285, DOI 10.1007/978-1-60327-029-8_17; CERRI R, 1988, J NAT PROD, V51, P257, DOI 10.1021/np50056a010; Chen Y, 1999, J AGR FOOD CHEM, V47, P2226, DOI 10.1021/jf990092f; Coelho I, 2012, LIPIDS, V47, P1031, DOI 10.1007/s11745-012-3715-9; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; De Martino L, 2006, J ETHNOPHARMACOL, V107, P91, DOI 10.1016/j.jep.2006.02.013; Jumes FMD, 2010, CAN J PHYSIOL PHARM, V88, P21, DOI 10.1139/Y09-111; Earle WR, 1934, AM J CANC, V24, P566; Folador A, 2009, NUTR CANCER, V61, P670, DOI 10.1080/01635580902825548; Ganzera M, 2001, PLANTA MED, V67, P447, DOI 10.1055/s-2001-15824; Gao RM, 1998, BIOELECTROCH BIOENER, V45, P41, DOI 10.1016/S0302-4598(98)00072-5; Prado EG, 2007, PHYTOMEDICINE, V14, P280, DOI 10.1016/j.phymed.2006.12.023; Gate L, 1999, BIOMED PHARMACOTHER, V53, P169, DOI 10.1016/S0753-3322(99)80086-9; Giboney PT, 2005, AM FAM PHYSICIAN, V71, P1105; Goncalves C, 2005, PHYTOCHEMISTRY, V66, P89, DOI 10.1016/j.phytochem.2004.10.025; Green RM, 2002, GASTROENTEROLOGY, V123, P1367, DOI 10.1053/gast.2002.36061; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Heitzman ME, 2005, PHYTOCHEMISTRY, V66, P5, DOI 10.1016/j.phytochem.2004.10.022; JIANG ZY, 1991, LIPIDS, V26, P853, DOI 10.1007/BF02536169; Kitajima Mariko, 2004, Chemical & Pharmaceutical Bulletin (Tokyo), V52, P1258, DOI 10.1248/cpb.52.1258; LAUS G, 1994, J CHROMATOGR A, V662, P243, DOI 10.1016/0021-9673(94)80511-3; Laus G, 1997, PHYTOCHEMISTRY, V45, P855, DOI 10.1016/S0031-9422(97)00061-7; Gurrola-Diaz CM, 2011, PHYTOMEDICINE, V18, P683, DOI 10.1016/j.phymed.2010.11.002; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Miller M J, 2001, BMC Complement Altern Med, V1, P11, DOI 10.1186/1472-6882-1-11; Mizuno M, 1999, BIOCHEM MOL BIOL INT, V47, P707; Muhammad I, 2001, PHYTOCHEMISTRY, V57, P781, DOI 10.1016/S0031-9422(01)00043-7; Paniagua-Perez R, 2009, BASIC CLIN PHARMACOL, V104, P222, DOI 10.1111/j.1742-7843.2008.00366.x; Piffar PM, 2003, CANCER LETT, V201, P139, DOI 10.1016/S0304-3835(03)00472-5; Pilarski R, 2007, PHARMACOL REP, V59, P565; Pilarski R, 2010, PHYTOMEDICINE, V17, P1133, DOI 10.1016/j.phymed.2010.04.013; Portugal J, 2009, TUMORI J, V95, P409; Reinhard KH, 1999, J ALTERN COMPLEM MED, V5, P143, DOI 10.1089/acm.1999.5.143; Riva L, 2001, ANTICANCER RES, V21, P2457; RIZZI R, 1993, J ETHNOPHARMACOL, V38, P63, DOI 10.1016/0378-8741(93)90080-O; Sandoval M, 2000, FREE RADICAL BIO MED, V29, P71, DOI 10.1016/S0891-5849(00)00327-0; Sandoval-Chacon M, 1998, ALIMENT PHARM THER, V12, P1279, DOI 10.1046/j.1365-2036.1998.00424.x; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; SEKI H, 1993, CHEM PHARM BULL, V41, P2077, DOI 10.1248/cpb.41.2077; Sheng YZ, 1998, ANTICANCER RES, V18, P3363; Sheng YZ, 2000, J ETHNOPHARMACOL, V69, P115, DOI 10.1016/S0378-8741(99)00070-7; Takayama H, 2005, CURR ORG CHEM, V9, P1445, DOI 10.2174/138527205774370559; Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009; Vicentino C, 2002, LIVER, V22, P342, DOI 10.1034/j.1600-0676.2002.01656.x; WAGNER H, 1985, PLANTA MED, V51, P419, DOI 10.1055/s-2007-969537; YAMAGUCHI Y, 1992, BIOCHEM BIOPH RES CO, V189, P1084, DOI 10.1016/0006-291X(92)92315-O; YASMINEH WG, 1991, CANCER RES, V51, P3990	61	18	20	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2013	8	2							e54618	10.1371/journal.pone.0054618	http://dx.doi.org/10.1371/journal.pone.0054618			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	092XV	23408945	Green Submitted, Green Published, gold			2023-01-03	WOS:000315157200011
J	Teno, JM; Gozalo, PL; Bynum, JPW; Leland, NE; Miller, SC; Morden, NE; Scupp, T; Goodman, DC; Mor, V				Teno, Joan M.; Gozalo, Pedro L.; Bynum, Julie P. W.; Leland, Natalie E.; Miller, Susan C.; Morden, Nancy E.; Scupp, Thomas; Goodman, David C.; Mor, Vincent			Change in End-of-Life Care for Medicare Beneficiaries Site of Death, Place of Care, and Health Care Transitions in 2000, 2005, and 2009	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NURSING-HOME RESIDENTS; PALLIATIVE CARE; DECISION-MAKING; HOSPICE; OUTCOMES; CANCER; COST	Importance A recent Centers for Disease Control and Prevention report found that more persons die at home. This has been cited as evidence that persons dying in the United States are using more supportive care. Objective To describe changes in site of death, place of care, and health care transitions between 2000, 2005, and 2009. Design, Setting, and Patients Retrospective cohort study of a random 20% sample of fee-for-service Medicare beneficiaries, aged 66 years and older, who died in 2000 (n=270 202), 2005 (n=291 819), or 2009 (n=286 282). A multivariable regression model examined outcomes in 2000 and 2009 after adjustment for sociodemographic characteristics. Based on billing data, patients were classified as having a medical diagnosis of cancer, chronic obstructive pulmonary disease, or dementia in the last 180 days of life. Main Outcome Measures Site of death, place of care, rates of health care transitions, and potentially burdensome transitions (eg, health care transitions in the last 3 days of life). Results Comparing 2000, 2005, and 2009 shows a decrease in deaths in acute care hospitals and increases in intensive care unit (ICU) use in the last 30 days, hospice use at the time of death, and health care transitions at the end of the life (test of trend P < .001 for each). [GRAPHICS] In 2009, 28.4% (95% CI, 27.9%-28.5%) of hospice use at the time of death was for 3 days or less. Of these late hospice referrals, 40.3% (95% CI, 39.7%-40.8%) were preceded by hospitalization with an ICU stay. Conclusion and Relevance Among Medicare beneficiaries who died in 2009 and 2005 compared with 2000, a lower proportion died in an acute care hospital, although both ICU use and the rate of health care transitions increased in the last month of life. JAMA. 2013; 309(5): 470-477 www.jama.	[Teno, Joan M.; Gozalo, Pedro L.; Miller, Susan C.; Scupp, Thomas; Mor, Vincent] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA; [Bynum, Julie P. W.; Morden, Nancy E.; Goodman, David C.] Dartmouth Med Sch, Lebanon, NH USA; [Leland, Natalie E.] Univ So Calif, Los Angeles, CA USA; [Mor, Vincent] Providence VA Med Ctr, Hlth Serv Res & Dev, Providence, RI USA	Brown University; Dartmouth College; University of Southern California; US Department of Veterans Affairs; Veterans Health Administration (VHA); Providence VA Medical Center	Teno, JM (corresponding author), Brown Univ, Warren Alpert Med Sch, 121 S Main St, Providence, RI 02912 USA.	joan_teno@brown.edu	Leland, Natalie/F-7223-2012; Goodman, David/AAG-7497-2020; Miller, Susan/J-5450-2014	Leland, Natalie/0000-0002-0329-3772; Miller, Susan/0000-0003-2008-6385	National Institutes of Health; Center for Gerontology and Healthcare Research of Brown University; AmericanOccupational Therapy Association; Robert Wood Johnson Foundation; World Congress; Illinois Hospital Association; National Hospice Workgroup; National Association of Health Data Organizations; St Peters University Hospital; Massachusetts Hospital Association; Cooper Health System; Organizzato dal Laboratoria Management e Sanit a Scuola Superiore Sant'Anna di Pisa; Kentucky Academy of Family Physicians; Southern Illinois University Health Policy Institute; Ohio University College of Osteopathic Medicine; Institute for Clinical Quality and Value; Marwood Group; American Society of Clinical Oncologists; Delta Health Alliance; SUNY Upstate University; Intermountain Healthcare; Canadian Health Services Research Foundation; Massachusetts Health Data Consortium; Organisation for Economic Cooperation and Development; NATIONAL INSTITUTE ON AGING [P01AG027296] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for Gerontology and Healthcare Research of Brown University; AmericanOccupational Therapy Association; Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); World Congress; Illinois Hospital Association; National Hospice Workgroup; National Association of Health Data Organizations; St Peters University Hospital; Massachusetts Hospital Association; Cooper Health System; Organizzato dal Laboratoria Management e Sanit a Scuola Superiore Sant'Anna di Pisa; Kentucky Academy of Family Physicians; Southern Illinois University Health Policy Institute; Ohio University College of Osteopathic Medicine; Institute for Clinical Quality and Value; Marwood Group; American Society of Clinical Oncologists; Delta Health Alliance; SUNY Upstate University; Intermountain Healthcare; Canadian Health Services Research Foundation; Massachusetts Health Data Consortium; Organisation for Economic Cooperation and Development; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Teno reported having received honoraria for speeches and lectures from nonprofit organizations. Dr Bynum reported having received a grant from the National Institutes of Health. Dr Leland reported having received grants from the National Institutes of Health; having received a fellowship from the Center for Gerontology and Healthcare Research of Brown University; and having received a stipend for collaboratively writing practice guidelines for productive aging from the AmericanOccupational Therapy Association. Dr Miller reported having received funding as a co-investigator to design and simulate modification to the Medicare hospice benefit payment system from the National Hospice and Palliative CareOrganization. Dr Morden reported having received a grant from the Robert Wood Johnson Foundation. Dr Goodman reported having received grants from the Robert Wood Johnson Foundation and National Institutes of Health; having served as a consultant for HealthDialog; and having received speakers' fees from the World Congress, Illinois Hospital Association, National Hospice Workgroup, National Association of Health Data Organizations, St Peters University Hospital, Massachusetts Hospital Association, Cooper Health System, Organizzato dal Laboratoria Management e Sanit a Scuola Superiore Sant'Anna di Pisa, Kentucky Academy of Family Physicians, Southern Illinois University Health Policy Institute, Ohio University College of Osteopathic Medicine, Institute for Clinical Quality and Value, Marwood Group, American Society of Clinical Oncologists, OR Manager, Delta Health Alliance, SUNY Upstate University, Intermountain Healthcare, Canadian Health Services Research Foundation, Massachusetts Health Data Consortium, and Organisation for Economic Cooperation and Development. Dr Mor reported having received grants or having grants pending from the National Institutes of Health, Agency for Healthcare Research and Quality, National Institute on Aging, Commonwealth Fund, American Health Care Association, and Kidney Care Partners; having received travel support from the National Institutes of Health and Agency for Healthcare Research and Quality; having received speakers' fees from the Alliance for Long Term Care Quality; having served on a board for PointRight and HCR Manor Care; having consulted for Abt Associates, Research Triangle Institute, and Welsh Carson Investment; and owning stock in PointRight. No other disclosures were reported.	[Anonymous], HOSP SERV; Bakitas Marie, 2009, Palliat Support Care, V7, P75, DOI 10.1017/S1478951509000108; Barnato AE, 2012, INTENS CARE MED, V38, P1886, DOI 10.1007/s00134-012-2661-6; Berke EM, 2009, J PALLIAT MED, V12, P128, DOI 10.1089/jpm.2008.0239; Brody AA, 2010, J PALLIAT MED, V13, P541, DOI 10.1089/jpm.2009.0300; Gallup GH, 1997, SPIRITUAL BELIEFS DY; Gozalo P, 2011, NEW ENGL J MED, V365, P1212, DOI 10.1056/NEJMsa1100347; GREER DS, 1986, J CHRON DIS, V39, P5, DOI 10.1016/0021-9681(86)90102-5; Higginson I J, 2000, J Palliat Med, V3, P287, DOI 10.1089/jpm.2000.3.287; Higginson IJ, 2002, J PAIN SYMPTOM MANAG, V23, P96, DOI 10.1016/S0885-3924(01)00406-7; Intrator O, 2011, HEALTH SERV RES, V46, P120, DOI 10.1111/j.1475-6773.2010.01194.x; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Meier DE, 2011, MILBANK Q, V89, P343, DOI 10.1111/j.1468-0009.2011.00632.x; Morrison RS, 2008, ARCH INTERN MED, V168, P1783, DOI 10.1001/archinte.168.16.1783; Morrison RS, 2005, J PALLIAT MED, V8, P1127, DOI 10.1089/jpm.2005.8.1127; National Center for Health Statistics, HLTH US 2010 SPEC FE; National Hospice and Palliative Care Organization, 2019, NHPCO FACTS FIG HOSP; Smith TJ, 2009, J PAIN SYMPTOM MANAG, V38, P32, DOI 10.1016/j.jpainsymman.2009.05.001; Taylor DH, 2007, SOC SCI MED, V65, P1466, DOI 10.1016/j.socscimed.2007.05.028; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; Teno JM., FACTS DYING BROWN AT; Teno JM, 2012, J PAIN SYMPTOM MANAG, V43, P732, DOI 10.1016/j.jpainsymman.2011.05.012; Teno JM, 2011, J AM GERIATR SOC, V59, P881, DOI 10.1111/j.1532-5415.2011.03385.x; Unroe KT, 2011, ARCH INTERN MED, V171, P196, DOI 10.1001/archinternmed.2010.371; Waldrop DP, 2005, J PALLIAT CARE, V21, P88, DOI 10.1177/082585970502100204; Wright AA, 2010, J CLIN ONCOL, V28, P4457, DOI 10.1200/JCO.2009.26.3863	27	717	719	6	120	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 6	2013	309	5					470	477		10.1001/jama.2012.207624	http://dx.doi.org/10.1001/jama.2012.207624			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	083LY	23385273	Green Accepted, Bronze			2023-01-03	WOS:000314466900028
J	Li, BD; Zaveri, T; Ziegler, GR; Hayes, JE				Li, Bangde; Zaveri, Toral; Ziegler, Gregory R.; Hayes, John E.			User Preferences in a Carrageenan-Based Vaginal Drug Delivery System	PLOS ONE			English	Article							MICROBICIDE ACCEPTABILITY; WOMEN; HIV; CHALLENGES; CARRAGUARD; ATTITUDES; TRIALS; CONDOM	Topical microbicides are a promising solution to address the global threat of HIV and other sexually transmitted infections. To be successful, a microbicide not only needs to be biologically functional but also highly acceptable to users. User acceptability of microbicides can be incorporated early in the product formulation and design process. Previous qualitative research revealed women had strong preferences regarding product shape, while preferences related to size and firmness were less clear. Here, we explored the effect of size and firmness on the acceptability of semisolid ovoid microbicide prototypes intended for vaginal use. Sexually active women (n = 74) were randomized to one of two conditions: with and without applicator. Nine different prototypes were evaluated; they were formulated to low, medium and high firmness using mixtures of kappa and iota carrageenan and potassium chloride. Three sizes were produced at each firmness level. Women manipulated all nine prototypes, rating them for perceived effectiveness, imagined ease-of-insertion and willingness-to-try on visual analog scales. The influence of size and firmness on these three outcome measures were assessed using ANOVA and response surface models. Results indicated size and firmness both influenced the outcome measures, but firmess was more influential than size. Also, the specific effects of size and firmness depended strongly on presence or absence of an applicator. Generally, women in the without applicator condition wanted a larger, firmer product. Collectively, these data suggest efforts to rationally design of microbicides for enhanced user acceptability must consider factors like size and firmness. Also, the decision to include or forego an applicator should be addressed early in the design process, as it strongly influences other design decisions.	[Li, Bangde; Zaveri, Toral; Hayes, John E.] Penn State Univ, Coll Agr Sci, Sensory Evaluat Ctr, University Pk, PA 16802 USA; [Li, Bangde; Zaveri, Toral; Ziegler, Gregory R.; Hayes, John E.] Penn State Univ, Coll Agr Sci, Dept Food Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Hayes, JE (corresponding author), Penn State Univ, Coll Agr Sci, Sensory Evaluat Ctr, University Pk, PA 16802 USA.	jeh40@psu.edu	Hayes, John E/A-5893-2008	Hayes, John E/0000-0001-9065-6326; Ziegler, Gregory/0000-0002-3881-649X; Zaveri, Toral/0000-0003-0059-9212	National Institutes of Health from the National Institute Of Allergy And Infectious Diseases [R21AI094514]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI094514, R33AI094514] Funding Source: NIH RePORTER	National Institutes of Health from the National Institute Of Allergy And Infectious Diseases; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was funded by National Institutes of Health grant number R21AI094514 from the National Institute Of Allergy And Infectious Diseases to JEH and GRZ. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AMD, 2009, MICR PIP SUMM REP; Beksinska ME, 2001, S AFR MED J, V91, P672; Bentley ME, 2004, AM J PUBLIC HEALTH, V94, P1159, DOI 10.2105/AJPH.94.7.1159; CDC, 1993, SEXUALLY TRANSMITTED; Centers for Disease Control, 2012, HIV US GLANC; Coggins C, 2000, REPROD HEALTH MATTER, V8, P132, DOI 10.1016/S0968-8080(00)90015-6; Darroch JE, 1999, FAM PLANN PERSPECT, V31, P16, DOI 10.2307/2991552; Elias C, 2001, J WOMEN HEALTH GEN-B, V10, P163, DOI 10.1089/152460901300039502; FRANK ML, 1995, WOMEN HEALTH, V23, P31, DOI 10.1300/J013v23n02_03; Garg S, 2010, ANTIVIR RES, V88, pS19, DOI 10.1016/j.antiviral.2010.09.010; Giguere R, 2012, CULT HEALTH SEX, V14, P151, DOI 10.1080/13691058.2011.630099; Hammett TM, 2000, SEX TRANSM DIS, V27, P119, DOI 10.1097/00007435-200002000-00011; Han L, 2009, J WOMENS HEALTH, V18, P1377, DOI 10.1089/jwh.2008.1239; Hardy E, 2003, CONTRACEPTION, V67, P391, DOI 10.1016/S0010-7824(03)00026-X; HIRA SK, 1995, AM J PUBLIC HEALTH, V85, P1098, DOI 10.2105/AJPH.85.8_Pt_1.1098; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; Kilmarx PH, 2006, JAIDS-J ACQ IMM DEF, V43, P327, DOI 10.1097/01.qai.0000243056.59860.c1; Mahan ED, 2011, CONTRACEPTION, V84, P184, DOI 10.1016/j.contraception.2010.11.012; Mantell JE, 2005, SOC SCI MED, V60, P319, DOI 10.1016/j.socscimed.2004.05.011; Mason TH, 2003, AIDS BEHAV, V7, P339, DOI 10.1023/B:AIBE.0000004726.61630.96; Menon S, 2007, J WOMENS HEALTH, V16, P703, DOI 10.1089/jwh.2006.0163; Morrow KM, 2008, AIDS BEHAV, V12, P272, DOI 10.1007/s10461-007-9266-z; Morrow KM, 2007, HEALTH PSYCHOL, V26, P777, DOI 10.1037/0278-6133.26.6.777; Morrow KM, 2010, ANTIVIR RES, V88, pS40, DOI 10.1016/j.antiviral.2010.09.008; Nel AM, 2011, J WOMENS HEALTH, V20, P1207, DOI 10.1089/jwh.2010.2476; Nnorom J, 2008, W AFRICA HIV AIDS EP; Padian NS, 2010, AIDS, V24, P621, DOI 10.1097/QAD.0b013e328337798a; Piot P, 2001, J Am Med Womens Assoc (1972), V56, P90; Severy LJ, 2005, AIDS BEHAV, V9, P121, DOI 10.1007/s10461-005-1687-y; Stone A, 2002, NAT REV DRUG DISCOV, V1, P977, DOI 10.1038/nrd959; Tasoglu S, 2011, J NON-NEWTON FLUID, V166, P1116, DOI 10.1016/j.jnnfm.2011.06.007; Tolley EE, 2006, AM J PUBLIC HEALTH, V96, P79, DOI 10.2105/AJPH.2004.043471; UNAIDS, 2011, EP UPD HLTH SECT PRO; UNAIDS, 2007, JOINT ASS HIV AIDS P; van de Wijgert Janneke, 2002, BETA, V15, P23; Verguet S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015501; Whitehead SJ, 2006, AIDS, V20, P2141, DOI 10.1097/QAD.0b013e32801086c9; Whitehead SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014831; Zaveri T, 2012, 19 INT AIDS C JUL 22	39	15	16	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2013	8	1							e54975	10.1371/journal.pone.0054975	http://dx.doi.org/10.1371/journal.pone.0054975			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	077JK	23358688	gold, Green Submitted, Green Published			2023-01-03	WOS:000314023600140
J	Johansson, J; Manneras-Holm, L; Shao, RJ; Olsson, A; Lonn, M; Billig, H; Stener-Victorin, E				Johansson, Julia; Manneras-Holm, Louise; Shao, Ruijin; Olsson, AnneLiese; Lonn, Malin; Billig, Hakan; Stener-Victorin, Elisabet			Electrical vs Manual Acupuncture Stimulation in a Rat Model of Polycystic Ovary Syndrome: Different Effects on Muscle and Fat Tissue Insulin Signaling	PLOS ONE			English	Article							LOW-FREQUENCY ELECTROACUPUNCTURE; MESSENGER-RNA EXPRESSION; BLOOD-FLOW RESPONSES; PHYSICAL-EXERCISE; ADIPOSE-TISSUE; GLUCOSE-TRANSPORT; SKELETAL-MUSCLE; GENE-EXPRESSION; GROUP-III; WOMEN	In rats with dihydrotestosterone (DHT)-induced polycystic ovary syndrome (PCOS), repeated low-frequency electrical stimulation of acupuncture needles restores whole-body insulin sensitivity measured by euglycemic hyperinsulinemic clamp. We hypothesized that electrical stimulation causing muscle contractions and manual stimulation causing needle sensation have different effects on insulin sensitivity and related signaling pathways in skeletal muscle and adipose tissue, with electrical stimulation being more effective in DHT-induced PCOS rats. From age 70 days, rats received manual or low-frequency electrical stimulation of needles in abdominal and hind limb muscle five times/wk for 4-5 wks; controls were handled but untreated rats. Low-frequency electrical stimulation modified gene expression (decreased Tbc1d1 in soleus, increased Nr4a3 in mesenteric fat) and protein expression (increased pAS160/AS160, Nr4a3 and decreased GLUT4) by western blot and increased GLUT4 expression by immunohistochemistry in soleus muscle; glucose clearance during oral glucose tolerance tests was unaffected. Manual stimulation led to faster glucose clearance and modified mainly gene expression in mesenteric adipose tissue (increased Nr4a3, Mapk3/Erk, Adcy3, Gsk3b), but not protein expression to the same extent; however, Nr4a3 was reduced in soleus muscle. The novel finding is that electrical and manual muscle stimulation affect glucose homeostasis in DHT-induced PCOS rats through different mechanisms. Repeated electrical stimulation regulated key functional molecular pathways important for insulin sensitivity in soleus muscle and mesenteric adipose tissue to a larger extent than manual stimulation. Manual stimulation improved whole-body glucose tolerance, an effect not observed after electrical stimulation, but did not affect molecular signaling pathways to the same extent as electrical stimulation. Although more functional signaling pathways related to insulin sensitivity were affected by electrical stimulation, our findings suggest that manual stimulation of acupuncture needles has a greater effect on glucose tolerance. The underlying mechanism of the differential effects of the intermittent manual and the continuous electrical stimulation remains to be elucidated.	[Johansson, Julia; Manneras-Holm, Louise; Shao, Ruijin; Olsson, AnneLiese; Billig, Hakan; Stener-Victorin, Elisabet] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Physiol, Gothenburg, Sweden; [Lonn, Malin] Univ Gothenburg, Sahlgrenska Acad, Inst Biomed, Dept Clin Chem & Transfus Med, Gothenburg, Sweden; [Stener-Victorin, Elisabet] Heilongjiang Univ Chinese Med, Dept Obstet & Gynecol, Affiliated Hosp 1, Harbin, Peoples R China	University of Gothenburg; University of Gothenburg; Heilongjiang University of Chinese Medicine	Stener-Victorin, E (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Physiol, Gothenburg, Sweden.	elisabet.stener-victorin@neuro.gu.se	Billig, Hakan/E-8891-2011; Shao, Linus R/M-3134-2019; Stener-Victorin, Elisabet/W-6322-2018; Shao, Linus R/M-3059-2019	Billig, Hakan/0000-0001-6140-9182; Shao, Linus R/0000-0002-1339-9570; Stener-Victorin, Elisabet/0000-0002-3424-1502; Shao, Linus R/0000-0002-1339-9570	Genomics Core Facility at the Sahlgrenska Academy, University of Gothenburg; Knut and Alice Wallenberg Foundation	Genomics Core Facility at the Sahlgrenska Academy, University of Gothenburg; Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation)	For the use of technical equipment and support we thank the Genomics Core Facility at the Sahlgrenska Academy, University of Gothenburg, which was funded by a grant from the Knut and Alice Wallenberg Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed MI, 2008, HUM REPROD, V23, P2564, DOI 10.1093/humrep/den273; Atherton PJ, 2005, FASEB J, V19, P786, DOI 10.1096/fj.04-2179fje; Bruss MD, 2005, DIABETES, V54, P41, DOI 10.2337/diabetes.54.1.41; CEDERHOLM J, 1990, DIABETES RES CLIN PR, V10, P167, DOI 10.1016/0168-8227(90)90040-Z; Chadt A, 2008, NAT GENET, V40, P1354, DOI 10.1038/ng.244; Chang SL, 2006, LIFE SCI, V79, P967, DOI 10.1016/j.lfs.2006.05.005; Ciaraldi TP, 2009, J CLIN ENDOCR METAB, V94, P157, DOI 10.1210/jc.2008-1492; CIARALDI TP, 1992, J CLIN ENDOCR METAB, V75, P577, DOI 10.1210/jc.75.2.577; Deshmukh AS, 2008, INT J OBESITY, V32, pS18, DOI 10.1038/ijo.2008.118; DUNAIF A, 1992, DIABETES, V41, P1257, DOI 10.2337/diabetes.41.10.1257; Dunaif A, 2001, AM J PHYSIOL-ENDOC M, V281, pE392, DOI 10.1152/ajpendo.2001.281.2.E392; Feng Y, 2012, EXP PHYSL; Feng Y, 2012, EXP PHYSIOL, V97, P651, DOI 10.1113/expphysiol.2011.063131; Feng Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006638; Frosig C, 2009, OBESITY, V17, pS15, DOI 10.1038/oby.2009.383; Fu YC, 2007, J BIOL CHEM, V282, P31525, DOI 10.1074/jbc.M701132200; Goodyear LJ, 1998, ANNU REV MED, V49, P235, DOI 10.1146/annurev.med.49.1.235; Han J. S., 1997, J ALTERN COMPLEME S1, V3, P101; Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1; Higashimura Y, 2009, AUTON NEUROSCI-BASIC, V150, P100, DOI 10.1016/j.autneu.2009.06.003; Ishizaki N, 2009, METABOLISM, V58, P1372, DOI 10.1016/j.metabol.2009.05.001; Jedel E, 2011, AM J PHYSIOL-ENDOC M, V300, pE37, DOI 10.1152/ajpendo.00495.2010; Jensterle M, 2008, EUR J ENDOCRINOL, V158, P793, DOI 10.1530/EJE-07-0857; Johansson J, 2010, AM J PHYSIOL-ENDOC M, pE; Kagitani F, 2005, JPN J PHYSIOL, V55, P149, DOI 10.2170/jjphysiol.R2120; KAUFMAN MP, 1984, CARDIOVASC RES, V18, P663, DOI 10.1093/cvr/18.11.663; Kawasaki E, 2009, J APPL PHYSIOL, V106, P1826, DOI 10.1152/japplphysiol.90923.2008; Krook A, 2004, MED SCI SPORT EXER, V36, P1212, DOI 10.1249/01.MSS.0000132387.25853.3B; Lai Mao-Hua, 2010, Zhen Ci Yan Jiu, V35, P298; Liang FX, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/735297; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mahoney DJ, 2005, FASEB J, V19, P1498, DOI 10.1096/fj.04-3149fje; Manneras L, 2008, ENDOCRINOLOGY, V149, P3559, DOI 10.1210/en.2008-0053; Manneras L, 2007, ENDOCRINOLOGY, V148, P3781, DOI 10.1210/en.2007-0168; Manneras L, 2009, AM J PHYSIOL-REG I, V296, pR1124, DOI 10.1152/ajpregu.90947.2008; MARCONDES F. K., 2002, Braz. J. Biol., V62, P609, DOI 10.1590/S1519-69842002000400008; Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462; Ohkura N, 1996, BBA-GENE STRUCT EXPR, V1308, P205, DOI 10.1016/0167-4781(96)00101-7; Padmanabhan V, 2011, SEMIN REPROD MED, V29, P173, DOI 10.1055/s-0031-1275519; Pastore LM, 2011, J CLIN ENDOCR METAB, V96, P3143, DOI 10.1210/jc.2011-1126; Rizza RA, 2010, DIABETES, V59, P2697, DOI 10.2337/db10-1032; ROSENBAUM D, 1993, AM J PHYSIOL, V264, pE197, DOI 10.1152/ajpendo.1993.264.2.E197; Sakamoto K, 2008, AM J PHYSIOL-ENDOC M, V295, pE29, DOI 10.1152/ajpendo.90331.2008; Sato A, 2002, INT CONGR SER, V1238, P111, DOI 10.1016/S0531-5131(02)00418-1; Seow KM, 2007, HUM REPROD, V22, P1003, DOI 10.1093/humrep/del466; Shao RJ, 2007, AM J PHYSIOL-ENDOC M, V293, pE147, DOI 10.1152/ajpendo.00101.2007; Stener-Victorin E, 2003, AUTON NEUROSCI-BASIC, V108, P50, DOI 10.1016/j.autneu.2003.08.006; Stener-Victorin E, 2006, J APPL PHYSIOL, V101, P84, DOI 10.1152/japplphysiol.01593.2005; Stener-Victorin E, 2012, FERTIL STERIL, V97, P501, DOI 10.1016/j.fertnstert.2011.11.010; Stener-Victorin E, 2009, AM J PHYSIOL-REG I, V297, pR387, DOI 10.1152/ajpregu.00197.2009; Suwa M, 2008, METABOLISM, V57, P986, DOI 10.1016/j.metabol.2008.02.017; Taylor EB, 2008, J BIOL CHEM, V283, P9787, DOI 10.1074/jbc.M708839200; Teede HJ, 2006, ENDOCRINE, V30, P45, DOI 10.1385/ENDO:30:1:45; Zierath JR, 2000, DIABETOLOGIA, V43, P821, DOI 10.1007/s001250051457	54	25	26	2	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 18	2013	8	1							e54357	10.1371/journal.pone.0054357	http://dx.doi.org/10.1371/journal.pone.0054357			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	075GQ	23349861	Green Published, Green Submitted, gold			2023-01-03	WOS:000313872800042
J	Krug, U; Koschmieder, A; Schwammbach, D; Gerss, J; Tidow, N; Steffen, B; Bug, G; Brandts, CH; Schaich, M; Rollig, C; Thiede, C; Noppeney, R; Stelljes, M; Buchner, T; Koschmieder, S; Duhrsen, U; Serve, H; Ehninger, G; Berdel, WE; Muller-Tidow, C				Krug, Utz; Koschmieder, Anja; Schwammbach, Daniela; Gerss, Joachim; Tidow, Nicola; Steffen, Bjoern; Bug, Gesine; Brandts, Christian H.; Schaich, Markus; Roellig, Christoph; Thiede, Christian; Noppeney, Richard; Stelljes, Matthias; Buechner, Thomas; Koschmieder, Steffen; Duehrsen, Ulrich; Serve, Hubert; Ehninger, Gerhard; Berdel, Wolfgang E.; Mueller-Tidow, Carsten			Feasibility of Azacitidine Added to Standard Chemotherapy in Older Patients with Acute Myeloid Leukemia - A Randomised SAL Pilot Study	PLOS ONE			English	Article							CHRONIC MYELOMONOCYTIC LEUKEMIA; RISK MYELODYSPLASTIC SYNDROMES; CONVENTIONAL CARE REGIMENS; PROGNOSTIC IMPACT; DNMT3A MUTATIONS; IDH2 MUTATIONS; TET2; 5-AZACYTIDINE; RECOMMENDATIONS; INDUCTION	Introduction: Older patients with acute myeloid leukemia (AML) experience short survival despite intensive chemotherapy. Azacitidine has promising activity in patients with low proliferating AML. The aim of this dose-finding part of this trial was to evaluate feasibility and safety of azacitidine combined with a cytarabine-and daunorubicin-based chemotherapy in older patients with AML. Trial Design: Prospective, randomised, open, phase II trial with parallel group design and fixed sample size. Patients and Methods: Patients aged 61 years or older, with untreated acute myeloid leukemia with a leukocyte count of <20,000/mu l at the time of study entry and adequate organ function were eligible. Patients were randomised to receive azacitidine either 37.5 (dose level 1) or 75 mg/sqm (dose level 2) for five days before each cycle of induction (7+3 cytarabine plus daunorubicine) and consolidation (intermediate-dose cytarabine) therapy. Dose-limiting toxicity was the primary endpoint. Results: Six patients each were randomised into each dose level and evaluable for analysis. No dose-limiting toxicity occurred in either dose level. Nine serious adverse events occurred in five patients (three in the 37.5 mg, two in the 75 mg arm) with two fatal outcomes. Two patients at the 37.5 mg/sqm dose level and four patients at the 75 mg/sqm level achieved a complete remission after induction therapy. Median overall survival was 266 days and median event-free survival 215 days after a median follow up of 616 days. Conclusions: The combination of azacitidine 75 mg/sqm with standard induction therapy is feasible in older patients with AML and was selected as an investigational arm in the randomised controlled part of this phase-II study, which is currently halted due to an increased cardiac toxicity observed in the experimental arm.	[Krug, Utz; Koschmieder, Anja; Schwammbach, Daniela; Tidow, Nicola; Stelljes, Matthias; Buechner, Thomas; Koschmieder, Steffen; Berdel, Wolfgang E.; Mueller-Tidow, Carsten] Univ Hosp, Dept Med A, Munster, Germany; [Gerss, Joachim] Univ Hosp, Inst Biostat & Clin Res, Munster, Germany; [Steffen, Bjoern; Bug, Gesine; Brandts, Christian H.; Serve, Hubert] Goethe Univ Frankfurt, Dept Med, D-60054 Frankfurt, Germany; [Schaich, Markus; Roellig, Christoph; Thiede, Christian; Ehninger, Gerhard] Tech Univ Dresden, Dept Med 1, D-01062 Dresden, Germany; [Noppeney, Richard; Duehrsen, Ulrich] Univ Hosp, Dept Hematol, Essen, Germany	University of Munster; University of Munster; Goethe University Frankfurt; Technische Universitat Dresden; University of Duisburg Essen	Muller-Tidow, C (corresponding author), Univ Hosp, Dept Med A, Munster, Germany.	muellerc@uni-muenster.de	Bug, Gesine/H-8827-2013; Gerß, Joachim WO/B-5702-2013; Thiede, Christian/AAS-7595-2020; Müller-Tidow, Carsten/O-7207-2018	Thiede, Christian/0000-0003-1241-2048; Müller-Tidow, Carsten/0000-0002-7166-5232; Brandts, Christian H./0000-0003-1732-2535; Serve, Hubert/0000-0001-8472-5516; Koschmieder, Steffen/0000-0002-1011-8171	Celgene Inc.; Amgen Inc.	Celgene Inc.(Bristol-Myers SquibbCelgene Corporation); Amgen Inc.(Amgen)	This trial receives financial support from Celgene Inc. (http://www.celgene.com) and Amgen Inc. (http://www.amgen.com). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AVRAMIS VI, 1989, CANCER CHEMOTH PHARM, V24, P203; Buchner T, 2009, J CLIN ONCOL, V27, P61, DOI 10.1200/JCO.2007.15.4245; Cheson BD, 2003, J CLIN ONCOL, V21, P4642, DOI 10.1200/JCO.2003.04.036; COMINGS DE, 1973, EXP CELL RES, V77, P469, DOI 10.1016/0014-4827(73)90601-0; Cros E, 2004, LEUKEMIA LYMPHOMA, V45, P1123, DOI 10.1080/1042819032000159861; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Dohner H, 2010, BLOOD, V115, P453, DOI 10.1182/blood-2009-07-235358; Estey EH, 2006, SEMIN HEMATOL, V43, P89, DOI 10.1053/j.seminhematol.2006.01.002; Fenaux P, 2010, BRIT J HAEMATOL, V149, P244, DOI 10.1111/j.1365-2141.2010.08082.x; Fenaux P, 2010, J CLIN ONCOL, V28, P562, DOI 10.1200/JCO.2009.23.8329; Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Figueroa ME, 2009, BLOOD, V114, P3448, DOI 10.1182/blood-2009-01-200519; Gelsi-Boyer V, 2009, BRIT J HAEMATOL, V145, P788, DOI 10.1111/j.1365-2141.2009.07697.x; Itzykson R, 2011, LEUKEMIA, V25, P1147, DOI 10.1038/leu.2011.71; Kohlmann A, 2010, J CLIN ONCOL, V28, P3858, DOI 10.1200/JCO.2009.27.1361; KONG XB, 1991, MOL PHARMACOL, V39, P250; Krug Utz, 2007, V176, P243; Krug U, 2010, LANCET, V376, P2000, DOI 10.1016/S0140-6736(10)62105-8; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; MAYER RJ, 1994, NEW ENGL J MED, V331, P896, DOI 10.1056/NEJM199410063311402; NEIL GL, 1976, CANCER RES, V36, P1114; Scandura JM, 2011, BLOOD, V118, P1472, DOI 10.1182/blood-2010-11-320093; Thiede C, 2006, BLOOD, V107, P4011, DOI 10.1182/blood-2005-08-3167; Thiede C, 2002, BLOOD, V99, P4326, DOI 10.1182/blood.V99.12.4326; Thol F, 2011, J CLIN ONCOL, V29, P2889, DOI 10.1200/JCO.2011.35.4894; Thol F, 2010, BLOOD, V116, P614, DOI 10.1182/blood-2010-03-272146; Traina F, 2011, ASH ANN M, V118, pA461; Wagner K, 2010, J CLIN ONCOL, V28, P2356, DOI 10.1200/JCO.2009.27.6899; Walker AR, 2011, ASH ANN M, V118, pA944	30	24	25	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2012	7	12							e52695	10.1371/journal.pone.0052695	http://dx.doi.org/10.1371/journal.pone.0052695			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	075GO	23300745	gold, Green Published, Green Submitted			2023-01-03	WOS:000313872600022
J	Marseille, E; Giganti, MJ; Mwango, A; Chisembele-Taylor, A; Mulenga, L; Over, M; Kahn, JG; Stringer, JSA				Marseille, Elliot; Giganti, Mark J.; Mwango, Albert; Chisembele-Taylor, Angela; Mulenga, Lloyd; Over, Mead; Kahn, James G.; Stringer, Jeffrey S. A.			Taking ART to Scale: Determinants of the Cost and Cost-Effectiveness of Antiretroviral Therapy in 45 Clinical Sites in Zambia	PLOS ONE			English	Article							SOUTH-AFRICA; CARE; HIV; MORTALITY; COUNTRIES; CHILDREN; OUTCOMES; HEALTH; UGANDA	Background: We estimated the unit costs and cost-effectiveness of a government ART program in 45 sites in Zambia supported by the Centre for Infectious Disease Research Zambia (CIDRZ). Methods: We estimated per person-year costs at the facility level, and support costs incurred above the facility level and used multiple regression to estimate variation in these costs. To estimate ART effectiveness, we compared mortality in this Zambian population to that of a cohort of rural Ugandan HIV patients receiving co-trimoxazole (CTX) prophylaxis. We used micro-costing techniques to estimate incremental unit costs, and calculated cost-effectiveness ratios with a computer model which projected results to 10 years. Results: The program cost $69.7 million for 125,436 person-years of ART, or $556 per ART-year. Compared to CTX prophylaxis alone, the program averted 33.3 deaths or 244.5 disability adjusted life-years (DALYs) per 100 person-years of ART. In the base-case analysis, the net cost per DALY averted was $833 compared to CTX alone. More than two-thirds of the variation in average incremental total and on-site cost per patient-year of treatment is explained by eight determinants, including the complexity of the patient-case load, the degree of adherence among the patients, and institutional characteristics including, experience, scale, scope, setting and sector. Conclusions and Significance: The 45 sites exhibited substantial variation in unit costs and cost-effectiveness and are in the mid-range of cost-effectiveness when compared to other ART programs studied in southern Africa. Early treatment initiation, large scale, and hospital setting, are associated with statistically significantly lower costs, while others (rural location, private sector) are associated with shifting cost from on- to off-site. This study shows that ART programs can be significantly less costly or more cost-effective when they exploit economies of scale and scope, and initiate patients at higher CD4 counts.	[Marseille, Elliot] Hlth Strategies Int, Oakland, CA 94609 USA; [Giganti, Mark J.; Chisembele-Taylor, Angela; Mulenga, Lloyd; Stringer, Jeffrey S. A.] Ctr Infect Dis Res Zambia, Lusaka, Zambia; [Over, Mead] Ctr Global Dev, Washington, DC USA; [Mwango, Albert] Zambian Minist Hlth, Lusaka, Zambia; [Kahn, James G.] Super Models Global Hlth, Oakland, CA USA; [Kahn, James G.] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Marseille, E (corresponding author), Hlth Strategies Int, Oakland, CA 94609 USA.	emarseille@comcast.net	Stringer, Jeffrey S. A./AAU-2342-2021	Stringer, Jeffrey/0000-0002-9590-7216	U.S. Centers for Disease Control and Prevention [U62/CCU12354]	U.S. Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	The program that this work describes is supported through a multi-country grant from the U.S. Centers for Disease Control and Prevention (U62/CCU12354). The corresponding author had full access to all data in the study and takes final responsibility for the decision to submit the paper for publication. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the funding agencies.	[AVERTing HIV AIDS], 2011, PRESIDENTS EMERGENCY; Babigumira JB, 2009, PHARMACOECONOMICS, V27, P963, DOI 10.2165/11318230-000000000-00000; Badri M, 2006, PLOS MED, V3, P48, DOI 10.1371/journal.pmed.0030004; Bikilla AD, 2009, COST EFF RESOUR ALLO, V7, P6, DOI DOI 10.1186/1478-7547-7-6; Bolton-Moore C, 2007, JAMA-J AM MED ASSOC, V298, P1888, DOI 10.1001/jama.298.16.1888; Boulle A, 2002, SAMJ S AFR MED J, V92, P811; Cleary S, 2004, COST EFFECTIVENESS O; Cleary S, 2004, RESOURCE REQUIREMENT; Dezii C M, 2001, Manag Care, V10, P42; Donald PR, 2009, NEW ENGL J MED, V360, P2393, DOI 10.1056/NEJMp0903806; Drummond M.F., 1997, METHODS FOR THE ECON; Galarraga O, 2011, PHARMACOECONOMICS, V29, P579, DOI 10.2165/11586120-000000000-00000; Galaty D, 2004, SCALING UP ANTIRETRO; Geffen N, 2003, REPORT ISSUED BY CEN; Goldie SJ, 2006, NEW ENGL J MED, V355, P1141, DOI 10.1056/NEJMsa060247; Govender V, 2000, REPORT FROM PHR AND; Government of the Republic of Zambia, 2010, ZAMBIA COUNTRY REPOR; Hogan DR, 2005, BRIT MED J, V331, P1431, DOI 10.1136/bmj.38643.368692.68; Hounton SH, 2008, AIDS CARE, V20, P582, DOI 10.1080/09540120701868303; Jamison DT, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P1; Kevany S, 2009, SAMJ S AFR MED J, V99, P320; Kombe G, 2003, APPLICATION OF THE A; Kombe G, 2005, THE HUMAN AND FINANC; Kremer JM, 2009, ARTHRITIS RHEUM-US, V60, P1895, DOI 10.1002/art.24567; Marseille E, 2009, APPL HEALTH ECON HEA, V7, P229, DOI 10.2165/11318740-000000000-00000; Mermin J, 2005, AIDS, V19, P1035, DOI 10.1097/01.aids.0000174449.32756.c7; Mermin J, 2008, LANCET, V371, P752, DOI 10.1016/S0140-6736(08)60345-1; Morgan MG, 1990, UNCERTAINTY A GUIDE; Sikka R, 2005, AM J MANAG CARE, V11, P453; Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782; The U.S. President's Emergency Plan for AIDS Relief (PEPFAR), 2011, PEPFAR OPERATIONAL P; The World Bank, 1993, WORLD DEVELOPMENT RE; UNAIDS, 2008, 2008 REPORT ON THE G; UNAIDS/World Health Organization, 2008, EPIDEMIOLOGICAL FACT; World Health Organization, 2007, MATERNAL MORTALITY I; World Health Organization, 2009, RAPID ADVICE ANTIRET; Zwillich T, 2009, LANCET, V373, P1325, DOI 10.1016/S0140-6736(09)60755-8	37	38	38	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2012	7	12							e51993	10.1371/journal.pone.0051993	http://dx.doi.org/10.1371/journal.pone.0051993			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	060RA	23284843	Green Published, gold			2023-01-03	WOS:000312794500073
J	Jangi, S				Jangi, Sushrut			Facing Uncertainty - Dispatch from Beth Israel Medical Center, Manhattan	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Jangi, S (corresponding author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.								0	16	16	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 13	2012	367	24					2267	2269		10.1056/NEJMp1213844	http://dx.doi.org/10.1056/NEJMp1213844			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	052HF	23151280				2023-01-03	WOS:000312187700015
J	Ibler, KS; Jemec, GBE; Diepgen, TL; Gluud, C; Hansen, JL; Winkel, P; Thomsen, SF; Agner, T				Ibler, Kristina Sophie; Jemec, Gregor B. E.; Diepgen, Thomas L.; Gluud, Christian; Hansen, Jane Lindschou; Winkel, Per; Thomsen, Simon Francis; Agner, Tove			Skin care education and individual counselling versus treatment as usual in healthcare workers with hand eczema: randomised clinical trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; KITCHEN EMPLOYEES; PREVENTION; INTERVENTION; SEVERITY; INDEX; DISEASES; DERMATITIS; CLASSIFICATION; MULTICENTER	Objective To evaluate the effect of a secondary prevention programme with education on skin care and individual counselling versus treatment as usual in healthcare workers with hand eczema. Design Randomised, observer blinded parallel group superiority clinical trial. Setting Three hospitals in Denmark. Participants 255 healthcare workers with self reported hand eczema within the past year randomised centrally and stratified by profession, severity of eczema, and hospital. 123 were allocated to the intervention group and 132 to the control group. Interventions Education in skin care and individual counselling based on patch and prick testing and assessment of work and domestic related exposures. The control was treatment as usual. Main outcome measures The primary outcome was clinical severity of disease at five month follow-up measured by scores on the hand eczema severity index. The secondary outcomes were scores on the dermatology life quality index, self evaluated severity of hand eczema, skin protective behaviours, and knowledge of hand eczema from onset to follow-up. Results Follow-up data were available for 247 of 255 participants (97%). At follow-up, the mean score on the hand eczema severity index was significantly lower (improved) in the intervention group than control group: difference of means, unadjusted -3.56 (95% confidence interval -4.92 to -2.14); adjusted -3.47 (-4.80 to -2.14), both P<0.001 for difference. The mean score on the dermatology life quality index was also significantly lower (improved) in the intervention group at follow-up: difference of means: unadjusted -0.78, non-parametric test P=0.003; adjusted -0.92, -1.48 to -0.37). Self evaluated severity and skin protective behaviour by hand washings and wearing of protective gloves were also statistically significantly better in the intervention group, whereas this was not the case for knowledge of hand eczema. Conclusion A secondary prevention programme for hand eczema improved severity and quality of life and had a positive effect on self evaluated severity and skin protective behaviour by hand washings and wearing of protective gloves.	[Ibler, Kristina Sophie; Jemec, Gregor B. E.] Roskilde Hosp, Fac Hlth Sci, Dept Dermatol, DK-4000 Roskilde, Denmark; [Ibler, Kristina Sophie; Thomsen, Simon Francis; Agner, Tove] Bispebjerg Hosp, Fac Hlth Sci, Dept Dermatol, DK-2400 Copenhagen, Denmark; [Diepgen, Thomas L.] Heidelberg Univ, Dept Social Med Occupat & Environm Dermatol, D-6900 Heidelberg, Germany; [Gluud, Christian; Hansen, Jane Lindschou; Winkel, Per] Copenhagen Univ Hosp, Rigshosp, Ctr Clin Intervent Res, Copenhagen Trial Unit, Copenhagen, Denmark	University of Copenhagen; Bispebjerg Hospital; Ruprecht Karls University Heidelberg; Rigshospitalet; University of Copenhagen	Ibler, KS (corresponding author), Roskilde Hosp, Fac Hlth Sci, Dept Dermatol, Kogevej 7-13, DK-4000 Roskilde, Denmark.	kristinaibler@hotmail.com	Gluud, Christian/HGB-3191-2022; Jemec, Gregor/H-6702-2019; Gluud, Christian/AAY-1027-2021	Jemec, Gregor/0000-0002-0712-2540; Gluud, Christian/0000-0002-8861-0799; agner, tove/0000-0002-7543-8299; ibler, kristina/0000-0002-5324-1591	Region Zealand's Research Fund; Danish Working Environment Research Fund	Region Zealand's Research Fund; Danish Working Environment Research Fund	This study was funded by Region Zealand's Research Fund and the Danish Working Environment Research Fund.	Agner T, 2002, CONTACT DERMATITIS, V47, P253, DOI 10.1034/j.1600-0536.2002.470501.x; Agner T, 1997, UGESKR LAEGER S6, V159, P1; Agner T, 2008, CONTACT DERMATITIS, V59, P43, DOI 10.1111/j.1600-0536.2008.01362.x; ALK, 2012, ALL DIAGN; [Anonymous], 2001, 24512RET1 DS; Apfelbacher CJ, 2009, CONTACT DERMATITIS, V60, P144, DOI 10.1111/j.1600-0536.2008.01505.x; Basra MKA, 2012, DERMATOL CLIN, V30, P237, DOI 10.1016/j.det.2011.11.002; Coenraads PJ, 2005, BRIT J DERMATOL, V152, P296, DOI 10.1111/J.1365-2133.2004.06270.X; Cvetkovski RS, 2006, ARCH DERMATOL, V142, P305, DOI 10.1001/archderm.142.3.305; DailyMed, 2012, DAILYMED; Dickel H, 2002, BRIT MED J, V324, P1422, DOI 10.1136/bmj.324.7351.1422; Diepgen TL, 2009, BRIT J DERMATOL, V160, P353, DOI 10.1111/j.1365-2133.2008.08907.x; Dulon M, 2009, BRIT J DERMATOL, V161, P337, DOI 10.1111/j.1365-2133.2009.09226.x; FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x; Flyvholm MA, 2005, OCCUP ENVIRON MED, V62, P642, DOI 10.1136/oem.2004.016576; Flyvholm MA, 2007, CONTACT DERMATITIS, V57, P110, DOI 10.1111/j.1600-0536.2007.01134.x; Gluud C, 2006, J HEPATOL, V44, P607, DOI 10.1016/j.jhep.2005.12.006; Gluud LL, 2006, AM J EPIDEMIOL, V163, P493, DOI 10.1093/aje/kwj069; Hald M, 2009, BRIT J DERMATOL, V161, P1294, DOI 10.1111/j.1365-2133.2009.09402.x; Hald M, 2009, BRIT J DERMATOL, V160, P1229, DOI 10.1111/j.1365-2133.2009.09139.x; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; Held E, 2005, BRIT J DERMATOL, V152, P302, DOI 10.1111/J.1365-2133.2004.06305.X; Held E, 2002, OCCUP ENVIRON MED, V59, P556, DOI 10.1136/oem.59.8.556; Held E, 2001, CONTACT DERMATITIS, V44, P297, DOI 10.1034/j.1600-0536.2001.440509.x; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; HOLM S, 1979, SCAND J STAT, V6, P65; Hongbo Y, 2005, J INVEST DERMATOL, V125, P659, DOI 10.1111/j.0022-202X.2005.23621.x; Ibler K, 2011, DERMATOL REP, V3; Ibler KS, 2012, CONTACT DERMATITIS, V66, P247, DOI 10.1111/j.1600-0536.2011.02027.x; Ibler KS, 2011, ACTA DERMATOVENER CR, V19, P161; Ibler KS, 2010, BMC DERMATOL, V10, DOI 10.1186/1471-5945-10-8; Kowalski J, 2007, J AM ACAD DERMATOL, V56, P546; Loffler H, 2006, CONTACT DERMATITIS, V54, P202, DOI 10.1111/j.0105-1873.2006.00825.x; Meding B, 2001, CONTACT DERMATITIS, V45, P99, DOI 10.1034/j.1600-0536.2001.045002099.x; Melilli L, 2006, J AM ACAD DERMATOL, V54, P2894; Schurer N, 2005, INT ARCH OCC ENV HEA, V78, P149, DOI 10.1007/s00420-004-0588-0; Schwanitz HJ, 2003, INT ARCH OCC ENV HEA, V76, P374, DOI 10.1007/s00420-002-0428-z; Sell L, 2005, CONTACT DERMATITIS, V53, P155, DOI 10.1111/j.0105-1873.2005.00674.x; Shikiar Richard, 2005, Health Qual Life Outcomes, V3, P36, DOI 10.1186/1477-7525-3-36; Smedley J, 2012, OCCUP ENVIRON MED, V69, P276, DOI 10.1136/oemed-2011-100315; Soder Stefanie, 2007, J Dtsch Dermatol Ges, V5, P670, DOI 10.1111/j.1610-0387.2007.06419.x; Thomson KF, 2002, BRIT J DERMATOL, V146, P627, DOI 10.1046/j.1365-2133.2002.04692.x; Wallenhammar LM, 2004, J INVEST DERMATOL, V122, P1381, DOI 10.1111/j.0022-202X.2004.22604.x; Weisshaar E, 2007, INT ARCH OCC ENV HEA, V80, P477, DOI 10.1007/s00420-006-0154-z; Weisshaar E, 2006, CONTACT DERMATITIS, V54, P254, DOI 10.1111/j.0105-1873.2006.00811.x; Weisshaar Elke, 2005, J Dtsch Dermatol Ges, V3, P33, DOI 10.1046/j.1439-0353.2005.04798.x; Williams C, 2011, BRIT J DERMATOL, V164, P1311, DOI 10.1111/j.1365-2133.2011.10246.x; Williams C, 2010, BRIT J DERMATOL, V162, P1088, DOI 10.1111/j.1365-2133.2010.09643.x; Wood L, 2008, BMJ-BRIT MED J, V336, P601, DOI 10.1136/bmj.39465.451748.AD	49	84	83	1	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 12	2012	345								e7822	10.1136/bmj.e7822	http://dx.doi.org/10.1136/bmj.e7822			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	056MU	23236031	hybrid, Green Submitted, Green Published			2023-01-03	WOS:000312495100007
J	Hooper, L; Abdelhamid, A; Moore, HJ; Douthwaite, W; Skeaff, CM; Summerbell, CD				Hooper, Lee; Abdelhamid, Asmaa; Moore, Helen J.; Douthwaite, Wayne; Skeaff, C. Murray; Summerbell, Carolyn D.			Effect of reducing total fat intake on body weight: systematic review and meta-analysis of randomised controlled trials and cohort studies	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HIGH-CARBOHYDRATE DIET; BREAST-CANCER PATIENTS; DISEASE RISK-FACTORS; LIBITUM LOW-FAT; STEP II DIET; LONG-TERM; CARDIOVASCULAR-DISEASE; POSTMENOPAUSAL WOMEN; HDL CHOLESTEROL; BLOOD-PRESSURE	Objective To investigate the relation between total fat intake and body weight in adults and children. Design Systematic review and meta-analysis of randomised controlled trials and cohort studies. Data sources Medline, Embase, CINAHL, and the Cochrane Central Register of Controlled Trials to June 2010. Inclusion criteria Randomised controlled trials and cohort studies of adults or children that compared lower versus usual total fat intake and assessed the effects on measures of body fatness (body weight, body mass index, or waist circumference) after at least six months (randomised controlled trials) or one year (in cohorts). Randomised controlled trials with any intention to reduce weight in participants or confounded by additional medical or lifestyle interventions were excluded. Data extraction Data were extracted and validity was assessed independently and in duplicate. Random effects meta-analyses, subgroups, sensitivity analyses, and metaregression were done. Results 33 randomised controlled trials (73 589 participants) and 10 cohort studies were included, all from developed countries. Meta-analysis of data from the trials suggested that diets lower in total fat were associated with lower relative body weight (by 1.6 kg, 95% confidence interval -2.0 to -1.2 kg, I-2=75%, 57 735 participants). Lower weight gain in the low fat arm compared with the control arm was consistent across trials, but the size of the effect varied. Metaregression suggested that greater reduction in total fat intake and lower baseline fat intake were associated with greater relative weight loss, explaining most of the heterogeneity. The significant effect of a low fat diet on weight was not lost in sensitivity analyses (including removing trials that expended greater time and attention on low fat groups). Lower total fat intake also led to lower body mass index (-0.51 kg/m(2), 95% confidence interval -0.76 to -0.26, nine trials, I-2=77%) and waist circumference (by 0.3 cm, 95% confidence interval -0.58 to -0.02, 15 671 women, one trial). There was no suggestion of negative effects on other cardiovascular risk factors (lipid levels or blood pressure). GRADE assessment suggested high quality evidence for the relation between total fat intake and body weight in adults. Only one randomised controlled trial and three cohort studies were found in children and young people, but these confirmed a positive relation between total fat intake and weight gain. Conclusions There is high quality, consistent evidence that reduction of total fat intake has been achieved in large numbers of both healthy and at risk trial participants over many years. Lower total fat intake leads to small but statistically significant and clinically meaningful, sustained reductions in body weight in adults in studies with baseline fat intakes of 28-43% of energy intake and durations from six months to over eight years. Evidence supports a similar effect in children and young people.	[Hooper, Lee; Abdelhamid, Asmaa] Univ E Anglia, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England; [Moore, Helen J.; Douthwaite, Wayne; Summerbell, Carolyn D.] Univ Durham, Wolfson Res Inst, Sch Med & Hlth, Obes Related Behav Grp, Stockton On Tees, England; [Skeaff, C. Murray] Univ Otago, Dept Human Nutr, Dunedin, New Zealand	University of East Anglia; Durham University; University of Otago	Hooper, L (corresponding author), Univ E Anglia, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England.	L.hooper@uea.ac.uk	Summerbell, Carolyn/AAC-3159-2019; Hooper, Lee/D-2795-2009; Summerbell, Carolyn D/O-3001-2015; Summerbell, Carolyn D/O-3759-2015	Summerbell, Carolyn/0000-0003-1910-9383; Hooper, Lee/0000-0002-7904-3331; Summerbell, Carolyn D/0000-0003-1910-9383; Summerbell, Carolyn D/0000-0003-1910-9383; Abdelhamid, Asmaa/0000-0002-9897-5433; Moore, Helen J/0000-0002-0165-7552	WHO; Norwich Medical School, University of East Anglia	WHO(World Health Organization); Norwich Medical School, University of East Anglia	WHO provided funding to Durham University towards the cost of carrying out this systematic review. No funding was received for the searching, analysis, or writing up of the data from randomised controlled trials in adults, but it was supported by the Norwich Medical School, University of East Anglia. The funders did not have any vested interests in the findings of this research.	ANDERSON JW, 1990, ARTERIOSCLEROSIS, V10, pA882; ANDERSON JW, 1992, AM J CLIN NUTR, V56, P887, DOI 10.1093/ajcn/56.5.887; [Anonymous], 1965, LANCET, V2, P501; [Anonymous], 1968, LANCET, V2, P693; Appel LJ, 2003, JAMA-J AM MED ASSOC, V289, P2083, DOI 10.1001/jama.289.16.2083; Astrup A, 2000, BRIT J NUTR, V83, pS25; Azadbakht L, 2007, BRIT J NUTR, V97, P399, DOI 10.1017/S0007114507328602; BAKER BM, 1968, CIRCULATION, V37, P1; BLACK HS, 1994, NEW ENGL J MED, V330, P1272, DOI 10.1056/NEJM199405053301804; BLOEMBERG BPM, 1991, AM J EPIDEMIOL, V134, P39, DOI 10.1093/oxfordjournals.aje.a115991; Boyd NF, 1997, BRIT J CANCER, V76, P127, DOI 10.1038/bjc.1997.348; Boyd NF, 1996, CANCER EPIDEM BIOMAR, V5, P217; BOYD NF, 1988, LANCET, V2, P128, DOI 10.1016/S0140-6736(88)90684-8; Bray GA, 1998, AM J CLIN NUTR, V68, P1157, DOI 10.1093/ajcn/68.6.1157; Bray GA, 2002, AM J CLIN NUTR, V76, P928, DOI 10.1093/ajcn/76.5.928; BURR ML, 1989, LANCET, V2, P757; Butte NF, 2007, AM J CLIN NUTR, V85, P1478, DOI 10.1093/ajcn/85.6.1478; Castagnetta L, 2002, ANN NY ACAD SCI, V963, P282; CHLEBOWSKI RT, 1993, J CLIN ONCOL, V11, P2072, DOI 10.1200/JCO.1993.11.11.2072; CURZIO JL, 1989, J HYPERTENS, V7, pS254, DOI 10.1097/00004872-198900076-00123; Davison KK, 2001, INT J OBESITY, V25, P1834, DOI 10.1038/sj.ijo.0801835; DAYTON S, 1969, CIRCULATION, V40, pIII6; DEBONT AJ, 1981, DIABETOLOGIA, V21, P529, DOI 10.1007/BF00281543; Djuric Z, 2002, NUTR CANCER, V43, P141, DOI 10.1207/S15327914NC432_4; Due A, 2008, AM J CLIN NUTR, V88, P1232, DOI 10.3945/ajcn.2007.25695; DULLAART RPF, 1992, DIABETOLOGIA, V35, P165, DOI 10.1007/BF00402550; EDERER F, 1971, LANCET, V2, P203; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; FRENKIEL PG, 1986, AM J CLIN NUTR, V43, P239, DOI 10.1093/ajcn/43.2.239; Furukawa TA, 2007, JAMA-J AM MED ASSOC, V297, P468, DOI 10.1001/jama.297.5.468-b; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Hall WD, 2003, ETHNIC DIS, V13, P337; Hebert JR, 2001, J AM DIET ASSOC, V101, P421, DOI 10.1016/S0002-8223(01)00109-2; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, COCHRANE HDB SYSTEMA, P4; Hjerkinn EM, 2005, AM J CLIN NUTR, V81, P583; HOCKADAY TDR, 1978, BRIT J NUTR, V39, P357, DOI 10.1079/BJN19780045; HOLM LE, 1990, BREAST CANCER RES TR, V16, P103, DOI 10.1007/BF01809294; Hooper L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002137.pub3; HOUTSMULLER AJ, 1980, DOC OPHTHALMOL, V48, P363, DOI 10.1007/BF00141465; Howard BV, 2006, JAMA-J AM MED ASSOC, V295, P39, DOI 10.1001/jama.295.1.39; Kelly S, 2006, ASS FOOD NUTR PHYS A; KLESGES RC, 1995, PEDIATRICS, V95, P126; Lanza E, 1996, CANCER EPIDEM BIOMAR, V5, P385; Lean MEJ, 1997, EUR J CLIN NUTR, V51, P243, DOI 10.1038/sj.ejcn.1600391; Leren P, 1966, Acta Med Scand Suppl, V466, P1; Ley SJ, 2004, DIABETES RES CLIN PR, V63, P103, DOI 10.1016/j.diabres.2003.09.001; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; McAuley KA, 2005, DIABETOLOGIA, V48, P8, DOI 10.1007/s00125-004-1603-4; MCKEOWNEYSSEN GE, 1994, J CLIN EPIDEMIOL, V47, P525, DOI 10.1016/0895-4356(94)90299-2; Mihas C, 2010, PUBLIC HEALTH NUTR, V13, P712, DOI 10.1017/S1368980009991625; Moy T F, 2001, Prev Cardiol, V4, P158, DOI 10.1111/j.1520-037X.2001.00543.x; NORDEVANG E, 1990, EUR J CLIN NUTR, V44, P681; NORDEVANG E, 1992, EUR J CLIN NUTR, V46, P387; OConnell D, 2019, NEWCASTLE OTTAWA SCA; Pierce JP, 2007, JAMA-J AM MED ASSOC, V298, P289, DOI 10.1001/jama.298.3.289; PILKINGTON TRE, 1960, BRIT MED J, V1, P23, DOI 10.1136/bmj.1.5165.23; Poppitt SD, 2002, AM J CLIN NUTR, V75, P11, DOI 10.1093/ajcn/75.1.11; Prospective Studies Collaboration, 2009, LANCET, V373; Retzlaff BM, 1997, J AM COLL NUTR, V16, P52, DOI 10.1080/07315724.1997.10718649; RIVELLESE AA, 1994, BRIT MED J, V308, P227, DOI 10.1136/bmj.308.6923.227; ROSE GA, 1965, BMJ-BRIT MED J, V1, P1531, DOI 10.1136/bmj.1.5449.1531; Sacks FM, 2009, NEW ENGL J MED, V360, P859, DOI 10.1056/NEJMoa0804748; Saris WHM, 2000, INT J OBESITY, V24, P1310, DOI 10.1038/sj.ijo.0801451; Sarkkinen E, 1995, THESIS U KUOPIO; Schatzkin A, 1996, CANCER EPIDEM BIOMAR, V5, P375; Seppelt B, 1996, Z ERNAHRUNGSWISS, V35, P369, DOI 10.1007/BF01610555; Simon MS, 1997, NUTR CANCER, V27, P136, DOI 10.1080/01635589709514515; Sondergaard E, 2003, AM HEART J, V145, DOI 10.1016/S0002-8703(03)00078-4; Song YM, 2004, STROKE, V35, P831, DOI 10.1161/01.STR.0000119386.22691.1C; Stefanick ML, 1998, NEW ENGL J MED, V339, P12, DOI 10.1056/NEJM199807023390103; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; Strychar I, 2009, DIABETES CARE, V32, P1597, DOI 10.2337/dc08-2322; Summerbell CD, 2009, INT J OBESITY, V33, pS1, DOI 10.1038/ijo.2009.80; Tuttle KR, 2008, AM J CARDIOL, V101, P1523, DOI 10.1016/j.amjcard.2008.01.038; vanhetHof KH, 1997, INT J FOOD SCI NUTR, V48, P19, DOI 10.3109/09637489709006960; Walden CE, 1997, ARTERIOSCL THROM VAS, V17, P375, DOI 10.1161/01.ATV.17.2.375; Walden CE, 2000, ARTERIOSCL THROM VAS, V20, P1580, DOI 10.1161/01.ATV.20.6.1580; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; WHO, 2010, WHO HDB GUID DEV; Willett W C, 2002, Obes Rev, V3, P59, DOI 10.1046/j.1467-789X.2002.00060.x; Woodhill J M, 1978, Adv Exp Med Biol, V109, P317; World Cancer Research Fund/American Institute for Cancer Research, 2009, PREV CANC FOOD NUTR; Yu-Poth S, 1999, AM J CLIN NUTR, V69, P632	85	169	177	0	64	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 6	2012	345								e7666	10.1136/bmj.e7666	http://dx.doi.org/10.1136/bmj.e7666			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	052IG	23220130	Green Published, Green Accepted, hybrid			2023-01-03	WOS:000312190500001
J	McConville, JF; Kress, JP				McConville, John F.; Kress, John P.			Weaning Patients from the Ventilator	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PROLONGED MECHANICAL VENTILATION; POSITIVE-PRESSURE VENTILATION; CRITICALLY-ILL PATIENTS; NONINVASIVE VENTILATION; CONTROLLED-TRIAL; RESPIRATORY-DISTRESS; EXTUBATION FAILURE; CARDIAC-SURGERY; TRACHEOSTOMY; TRACHEOTOMY		[McConville, John F.; Kress, John P.] Univ Chicago, Dept Med, Sect Pulm & Crit Care, Chicago, IL 60637 USA	University of Chicago	Kress, JP (corresponding author), Univ Chicago, Dept Med, Sect Pulm & Crit Care, 5841 S Maryland Ave,MC 6026, Chicago, IL 60637 USA.	jkress@medicine.bsd.uchicago.edu			Hospira; France Foundation	Hospira; France Foundation	Dr. Kress reports receiving lecture fees from Hospira and the France Foundation. No other potential conflict of interest relevant to this article was reported.	Arabi Y, 2004, CRIT CARE, V8, pR347, DOI 10.1186/cc2924; Bendixin HH, 1965, RESPIRATORY CARE, P149; Blackwood B, 2010, COCHRANE DB SYST REV, V5, DOI DOI 10.1002/14651858; Boles JM, 2007, EUR RESPIR J, V29, P1033, DOI 10.1183/09031936.00010206; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Carson Shannon S, 2006, J Intensive Care Med, V21, P173, DOI 10.1177/0885066605282784; Coplin WM, 2000, AM J RESP CRIT CARE, V161, P1530, DOI 10.1164/ajrccm.161.5.9905102; Cox CE, 2004, CRIT CARE MED, V32, P2219, DOI 10.1097/01.CCM.0000145232.46143.40; Dezfulian C, 2005, AM J MED, V118, P11, DOI 10.1016/j.amjmed.2004.07.051; Epstein SK, 2009, RESP CARE, V54, P198; Epstein SK, 1998, AM J RESP CRIT CARE, V158, P489, DOI 10.1164/ajrccm.158.2.9711045; Epstein SK, 1997, CHEST, V112, P186, DOI 10.1378/chest.112.1.186; Esteban A, 1999, AM J RESP CRIT CARE, V159, P512, DOI 10.1164/ajrccm.159.2.9803106; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Esteban A, 1997, AM J RESP CRIT CARE, V156, P459, DOI 10.1164/ajrccm.156.2.9610109; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Esteban A, 2004, NEW ENGL J MED, V350, P2452, DOI 10.1056/NEJMoa032736; ESTEBAN A, 1994, CHEST, V106, P1188, DOI 10.1378/chest.106.4.1188; Esteban A, 2008, AM J RESP CRIT CARE, V177, P170, DOI 10.1164/rccm.200706-893OC; Ferrer M, 2006, AM J RESP CRIT CARE, V173, P164, DOI 10.1164/rccm.200505-718OC; Frutos-Vivar F, 2006, CHEST, V130, P1664, DOI 10.1378/chest.130.6.1664; Funk GC, 2010, EUR RESPIR J, V35, P88, DOI 10.1183/09031936.00056909; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Silva BNG, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007271.pub2; Gray A, 2008, NEW ENGL J MED, V359, P142, DOI 10.1056/NEJMoa0707992; Jubran A, 1997, AM J RESP CRIT CARE, V155, P906, DOI 10.1164/ajrccm.155.3.9117025; Keenan SP, 2002, JAMA-J AM MED ASSOC, V287, P3238, DOI 10.1001/jama.287.24.3238; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Krishnan JA, 2004, AM J RESP CRIT CARE, V169, P673, DOI 10.1164/rccm.200306-761OC; Kurek CJ, 1997, CRIT CARE MED, V25, P983, DOI 10.1097/00003246-199706000-00015; LEMAIRE F, 1988, ANESTHESIOLOGY, V69, P171, DOI 10.1097/00000542-198808000-00004; MacIntyre NR, 2001, CHEST, V120, p375S, DOI 10.1378/chest.120.6_suppl.375S; Masip J, 2005, JAMA-J AM MED ASSOC, V294, P3124, DOI 10.1001/jama.294.24.3124; Namen AM, 2001, AM J RESP CRIT CARE, V163, P658, DOI 10.1164/ajrccm.163.3.2003060; Nava S, 2005, CRIT CARE MED, V33, P2465, DOI 10.1097/01.CCM.0000186416.44752.72; Needham DM, 2005, CRIT CARE MED, V33, P574, DOI [10.1097/01.CCM.0000155992.21174.31, 10.1097/01.ccm.0000155992.21174.31]; Patel SB, 2011, ANN INTERN MED, V154, P434, DOI 10.7326/0003-4819-154-6-201103150-00011; Picot J, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004104.PUB3; Randolph AG, 2002, JAMA-J AM MED ASSOC, V288, P2561, DOI 10.1001/jama.288.20.2561; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Rose L, 2008, INTENS CARE MED, V34, P1788, DOI 10.1007/s00134-008-1179-4; Rumbak MJ, 2004, CRIT CARE MED, V32, P1689, DOI 10.1097/01.CCM.0000134835.05161.B6; Salam A, 2004, INTENS CARE MED, V30, P1334, DOI 10.1007/s00134-004-2231-7; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Seneff MG, 1996, CHEST, V110, P469, DOI 10.1378/chest.110.2.469; Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9; Trouillet JL, 2011, ANN INTERN MED, V154, P373, DOI 10.7326/0003-4819-154-6-201103150-00002; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564; Wunsch H, 2010, CRIT CARE MED, V38, P1947, DOI 10.1097/CCM.0b013e3181ef4460; YANG KL, 1991, NEW ENGL J MED, V324, P1445, DOI 10.1056/NEJM199105233242101	52	130	144	0	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 6	2012	367	23					2233	2239		10.1056/NEJMra1203367	http://dx.doi.org/10.1056/NEJMra1203367			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	048DO	23215559				2023-01-03	WOS:000311890600010
J	Prilipko, O; Huynh, N; Schwartz, S; Tantrakul, V; Kushida, C; Paiva, T; Guilleminault, C				Prilipko, Olga; Huynh, Nelly; Schwartz, Sophie; Tantrakul, Visasiri; Kushida, Clete; Paiva, Teresa; Guilleminault, Christian			The Effects of CPAP Treatment on Task Positive and Default Mode Networks in Obstructive Sleep Apnea Patients: An fMRI Study	PLOS ONE			English	Article							MAGNETIC-RESONANCE-SPECTROSCOPY; BODY-MASS INDEX; WORKING-MEMORY; COGNITIVE FUNCTION; BRAIN ACTIVATION; ATTENTIONAL NETWORKS; SUSTAINED ATTENTION; AIRWAY PRESSURE; DYSFUNCTION; DEPRIVATION	Introduction: Functional magnetic resonance imaging studies enable the investigation of neural correlates underlying behavioral performance. We investigate the effect of active and sham Continuous Positive Airway Pressure (CPAP) treatment on working memory function of patients with Obstructive Sleep Apnea Syndrome (OSAS) considering Task Positive and Default Mode networks (TPN and DMN). Methods: An experiment with 4 levels of visuospatial n-back task was used to investigate the pattern of cortical activation in 17 men with moderate or severe OSAS before and after 2 months of therapeutic (active) or sub-therapeutic (sham) CPAP treatment. Results: Patients with untreated OSAS had significantly less deactivation in the temporal regions of the DMN as compared to healthy controls, but activation within TPN regions was comparatively relatively preserved. After 2 months of treatment, active and sham CPAP groups exhibited opposite trends of cerebral activation and deactivation. After treatment, the active CPAP group demonstrated an increase of cerebral activation in the TPN at all task levels and of task-related cerebral deactivation in the anterior midline and medial temporal regions of the DMN at the 3-back level, associated with a significant improvement of behavioral performance, whereas the sham CPAP group exhibited less deactivation in the temporal regions of Default Mode Network and less Task Positive Network activation associated to longer response times at the 3-back. Conclusion: OSAS has a significant negative impact primarily on task-related DMN deactivation, particularly in the medial temporal regions, possibly due to nocturnal hypoxemia, as well as TPN activation, particularly in the right ventral frontoparietal network. After 2 months of active nasal CPAP treatment a positive response was noted in both TPN and DMN but without compete recovery of existing behavioral and neuronal deficits. Initiation of CPAP treatment early in the course of the disease may prevent or slow down the occurrence of irreversible impairment.	[Prilipko, Olga; Huynh, Nelly; Tantrakul, Visasiri; Kushida, Clete; Guilleminault, Christian] Stanford Univ, Sleep Clin, Redwood City, CA USA; [Prilipko, Olga; Huynh, Nelly; Tantrakul, Visasiri; Kushida, Clete; Guilleminault, Christian] Stanford Univ, Ctr Human Sleep Res, Redwood City, CA USA; [Schwartz, Sophie] Univ Geneva, Med Ctr, CH-1211 Geneva, Switzerland; [Paiva, Teresa] CENC, Dept Neurol, Lisbon, Portugal	Stanford University; Stanford University; University of Geneva	Guilleminault, C (corresponding author), Stanford Univ, Sleep Clin, Redwood City, CA USA.	cguil@stanford.edu		Paiva, Maria Teresa Aguiar dos Santos/0000-0002-7937-7841	Swiss National Foundation for Scientific Research; Swiss Foundation for Grants in Medicine and Biology (FSBMB)	Swiss National Foundation for Scientific Research(Swiss National Science Foundation (SNSF)); Swiss Foundation for Grants in Medicine and Biology (FSBMB)	This study was supported by research grants from Swiss National Foundation for Scientific Research and Swiss Foundation for Grants in Medicine and Biology (FSBMB), as well as Respironics, Resmed, and Covidien. The publication is supported by an unrestrictive educational grant from Kai sensor Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aloia MS, 2004, J INT NEUROPSYCH SOC, V10, P772, DOI 10.1017/S1355617704105134; Archbold KH, 2009, J CLIN SLEEP MED, V5, P21; Ayalon L, 2009, J SLEEP RES; Ayalon L, 2006, NEUROIMAGE, V31, P1817, DOI 10.1016/j.neuroimage.2006.02.042; Ayalon L, 2009, SLEEP, V32, P373, DOI 10.1093/sleep/32.3.373; Bartlett DJ, 2004, SLEEP MED, V5, P593, DOI 10.1016/j.sleep.2004.08.004; Beebe DW, 2002, J SLEEP RES, V11, P1, DOI 10.1046/j.1365-2869.2002.00289.x; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Canessa N, 2011, AM J RESP CRIT CARE, V183, P1419, DOI 10.1164/rccm.201005-0693OC; Castellanos FX, 2008, BIOL PSYCHIAT, V63, P332, DOI 10.1016/j.biopsych.2007.06.025; Castronovo V, 2009, SLEEP, V32, P1161, DOI 10.1093/sleep/32.9.1161; Chee MWL, 2008, CURR OPIN NEUROL, V21, P417, DOI 10.1097/WCO.0b013e3283052cf7; Choo WC, 2005, NEUROIMAGE, V25, P579, DOI 10.1016/j.neuroimage.2004.11.029; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Cournot M, 2006, NEUROLOGY, V67, P1208, DOI 10.1212/01.wnl.0000238082.13860.50; Demeter E, 2011, NEUROIMAGE, V54, P1518, DOI 10.1016/j.neuroimage.2010.09.026; Drummond SPA, 2005, SLEEP, V28, P1059; Fan J, 2005, NEUROIMAGE, V26, P471, DOI 10.1016/j.neuroimage.2005.02.004; Farre R, 1999, LANCET, V353, P1154, DOI 10.1016/S0140-6736(99)01056-9; Felver-Gant JC, 2007, J CLIN SLEEP MED, V3, P589; Ferini-Strambi L, 2003, BRAIN RES BULL, V61, P87, DOI 10.1016/S0361-9230(03)00068-6; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Garrity AG, 2007, AM J PSYCHIAT, V164, P450, DOI 10.1176/appi.ajp.164.3.450; Gazdzinski S, 2010, OBESITY, V18, P743, DOI 10.1038/oby.2009.325; Glover GH, 2001, MAGNET RESON MED, V46, P515, DOI 10.1002/mrm.1222; Goel N, 2009, SEMIN NEUROL, V29, P320, DOI 10.1055/s-0029-1237117; Grady CL, 2009, CEREB CORTEX; Gujar N, 2009, J COGN NEUROSCI; Gunstad J, 2007, COMPR PSYCHIAT, V48, P57, DOI 10.1016/j.comppsych.2006.05.001; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Kim DH, 2002, MAGNET RESON MED, V48, P715, DOI 10.1002/mrm.10267; Lau EYY, 2010, J INT NEUROPSYCH SOC, V16, P1077, DOI 10.1017/S1355617710000901; Ledberg A, 1998, NEUROIMAGE, V8, P113, DOI 10.1006/nimg.1998.0336; Morrell MJ, 2003, SLEEP MED, V4, P451, DOI 10.1016/S1389-9457(03)00159-X; O'Donoghue FJ, 2012, SLEEP, V35, P41, DOI 10.5665/sleep.1582; Prilipko O, 2011, SLEEP, V34, P293, DOI 10.1093/sleep/34.3.293; Quan SF, 2011, SLEEP, V34, P303, DOI 10.1093/sleep/34.3.303; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Saunamaki T, 2007, ACTA NEUROL SCAND, V115, P1, DOI 10.1111/j.1600-0404.2006.00744.x; Song XW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025031; Thomas RJ, 2005, J APPL PHYSIOL, V98, P2226, DOI 10.1152/japplphysiol.01225.2004; Tomasi D, 2009, CEREB CORTEX, V19, P233, DOI 10.1093/cercor/bhn073; Torelli F, 2011, NEUROIMAGE, V54, P787, DOI 10.1016/j.neuroimage.2010.09.065; Toro R, 2008, CEREB CORTEX, V18, P2553, DOI 10.1093/cercor/bhn014; van Eimeren T, 2009, ARCH NEUROL-CHICAGO, V66, P877, DOI 10.1001/archneurol.2009.97; Wolf PA, 2007, CURR ALZHEIMER RES, V4, P111, DOI 10.2174/156720507780362263; Worsley KJ, 2002, NEUROIMAGE, V15, P1, DOI 10.1006/nimg.2001.0933	47	23	24	2	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2012	7	12							e47433	10.1371/journal.pone.0047433	http://dx.doi.org/10.1371/journal.pone.0047433			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	057TZ	23227139	Green Submitted, Green Published, gold			2023-01-03	WOS:000312588200002
J	Stellmann, JP; Neuhaus, A; Herich, L; Schippling, S; Roeckel, M; Daumer, M; Martin, R; Heesen, C				Stellmann, Jan-Patrick; Neuhaus, Anneke; Herich, Lena; Schippling, Sven; Roeckel, Matthias; Daumer, Martin; Martin, Roland; Heesen, Christoph			Placebo Cohorts in Phase-3 MS Treatment Trials - Predictors for On-Trial Disease Activity 1990-2010 Based on a Meta-Analysis and Individual Case Data	PLOS ONE			English	Article							REMITTING MULTIPLE-SCLEROSIS; DIAGNOSTIC-CRITERIA; RELAPSE RATES	Background: Annualized relapse rates (ARR) in the placebo cohorts of phase-3 randomized controlled trials (RCT) of new treatments for relapsing remitting multiple sclerosis (RRMS) have decreased substantially during the last two decades. The causes of these changes are not clear. We consider a better understanding of this phenomenon essential for valuing the effects of new drugs and by designing new trials. Objectives: To identify predictive factors of on-study ARR in early and recent MS trials. Methods: ARR, rate of relapse-free patients, trial start dates, baseline demographics, relapse definitions and the use of McDonald criteria were retrieved by literature research of the placebo cohorts from RRMS phase-3 trials. Predictors were estimated by univariate and multivariate regression analyses and random-effects meta-regression. In addition, regression models were calculated by the Sylvia Lawry Centre's (SLC), including individual case data from clinical trials performed until 2000. The most reliable meta-analytic results can be gained from pooled individual case data. In lack of this, random-effects meta-analyses are recommended. Results: Data from 12 published and one unpublished trial show a decrease of ARR from 1988 to 2012 (adjR(2) = 0.807, p<0.0001). Regression models identified McDonald criteria followed by baseline mean age and the pre-study relapse rate as predictors of the ARR. The pooled individual case data (n = 505) confirmed a decrease of ARR over time. The pre-study relapse rate was the best predictor for on-study relapses. Lacking individual case data after implementation of the McDonald criteria excludes a direct comparison concerning McDonald criteria. Conclusion: Pre-study relapse rate was the best predictor for on-study relapse rate but failed to explain the decrease of the ARR over time alone. Higher age at baseline and the implementation of McDonald criteria were associated as well with a lowered relapse rate in the random-effects meta-regression. These findings need further clarification based on individual case data.	[Stellmann, Jan-Patrick; Heesen, Christoph] Univ Med Ctr Hamburg Eppendorf, Inst Neuroimmunol & Clin MS Res Inims, Hamburg, Germany; [Stellmann, Jan-Patrick; Heesen, Christoph] Univ Med Ctr Hamburg Eppendorf, Dept Neurol, Hamburg, Germany; [Neuhaus, Anneke; Daumer, Martin] Sylvia Lawry Ctr Multiple Sclerosis Res, Munich, Germany; [Herich, Lena] Univ Med Ctr Hamburg Eppendorf, Dept Med Biometry & Epidemiol, Hamburg, Germany; [Roeckel, Matthias] Teva Pharma GmbH, Ulm, Germany; [Schippling, Sven; Martin, Roland] Univ Med Ctr Zurich, Dept Clin Neuroimmunol & Multiple Sclerosis Res, Neurol Clin, Zurich, Switzerland	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf	Stellmann, JP (corresponding author), Univ Med Ctr Hamburg Eppendorf, Inst Neuroimmunol & Clin MS Res Inims, Hamburg, Germany.	j.stellmann@uke.uni-hamburg.de	Stellmann, Jan-Patrick/ABA-7132-2020	Stellmann, Jan-Patrick/0000-0003-2565-2833; Martin, Roland/0000-0002-0982-1329	NEU<SUP>2</SUP> consortium; Federal Ministry of Education and Research (BMBF) (Forderkennzeichen) [0315610-0315620]; Federal Ministry of Education and Research [01GI0904, 01GI0920]; Mayo Clinic Rochester, European Union [215820]; European Union [223865, LSHM-CT-2006-03759]; Federal Ministry of Economics and Technology [KF0564001KF7]; University of Oxford; Technical University of Munich; Hertie Foundation [1.01.1/07/015]; Bavarian Research Foundation; National Multiple Sclerosis Society (NMSS); Porticus Foundation [900.50578]; University of Rochester, European Union [LSHM-CT-2004-503485]; Sylvia Lawry Centre for Multiple Sclerosis Research	NEU<SUP>2</SUP> consortium; Federal Ministry of Education and Research (BMBF) (Forderkennzeichen)(Federal Ministry of Education & Research (BMBF)); Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Mayo Clinic Rochester, European Union; European Union(European Commission); Federal Ministry of Economics and Technology(Federal Ministry for Economic Affairs and Energy (BMWi)); University of Oxford; Technical University of Munich; Hertie Foundation; Bavarian Research Foundation; National Multiple Sclerosis Society (NMSS)(National Multiple Sclerosis Society); Porticus Foundation; University of Rochester, European Union; Sylvia Lawry Centre for Multiple Sclerosis Research	The work was funded by the NEU<SUP>2</SUP> consortium, which is supported by the Federal Ministry of Education and Research (BMBF) (Forderkennzeichen 0315610-0315620). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; J-PS, Christoph Heesen, SS and RM have received payment for lectures including service on speakers bureaus as well as travel/ accomodation/meeting expenses (unrelated to the activities listed) from GlaxoSmithKline, Merck, Novartis, Biogen Idec, Teva. MD, Scientific Director of the Sylvia Lawry Centre for Multiple Sclerosis Research e. V. (SLC) and one of the two Managing Directors of Trium Analysis Online GmbH, serves on the Editorial Board of MedNous and holds Patent 10 2007 044 705.3-35, German patent and trademark office 307 19 449.3/09. The Sylvia Lawry Centre received honoraria for interviews of MD with Propagate Pharma Limited and Deerfield Research LLC; is Medical Advisor of the German Multiple Sclerosis Society; received honoraria for consultancy, statistical analysis and use of actibeltH technology from the following entities: Bayer Schering, Biopartners, Biogen Idec, Biogenerix, Bohringer-Ingelheim, EISAI Limited, Heron Evidence Development Ltd, Hoffmann-La Roche, Johnson & Johnson Pharmaceutical Research & Development LLC, Sanofi-Aventis U.S. INC., Novartis Pharma GmbH, University of Oxford, Imperial College London, University of Southampton, Charite Berlin, University of Vienna, Greencoat Ltd, University Medical Center Hamburg-Eppendorf; serves on the advisory board for EPOSA study and received research grants from the following governmental entities: Federal Ministry of Education and Research Grant No 01GI0904, 01GI0920, Mayo Clinic Rochester, European Union (for SLC and Trium) Grant No 215820, European Union (for SLC) Grant No 223865, Federal Ministry of Economics and Technology Grant No KF0564001KF7, University of Oxford, Technical University of Munich, Hertie Foundation Grant No 1.01.1/07/015, Bavarian Research Foundation, National Multiple Sclerosis Society (NMSS), Porticus Foundation Grant No 900.50578, European Union Grant No LSHM-CT-2006-03759, University of Rochester, European Union Grant No LSHM-CT-2004-503485. AN is employee of the Sylvia Lawry Centre for Multiple Sclerosis Research. MR is employee of Teva Pharma. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.	Achiron A, 1998, NEUROLOGY, V50, P398, DOI 10.1212/WNL.50.2.398; Barkhof F, 2005, NEUROLOGY, V65, P1447, DOI 10.1212/01.wnl.0000183149.87975.32; Comi G, 2012, NEW ENGL J MED, V366, P1000, DOI 10.1056/NEJMoa1104318; Daumer M, 2009, NEUROLOGY, V72, P705, DOI 10.1212/01.wnl.0000336916.38629.43; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Ebers GC, 1998, LANCET, V352, P1498, DOI 10.1016/S0140-6736(98)03334-0; Fahrmeir L., 2001, MULTIVARIATE STAT MO, P69; Fazekas F, 1997, LANCET, V349, P589, DOI 10.1016/S0140-6736(96)09377-4; Gelman A, 2009, DATA ANAL USING REGR; Giovannoni G, 2010, NEW ENGL J MED, V362, P416, DOI 10.1056/NEJMoa0902533; Gold R, 2011, ECTRIMS AMST; Harrell, 2010, HMISC HARRELL MISCEL; Held U, 2005, NEUROLOGY, V65, P1769, DOI 10.1212/01.wnl.0000187122.71735.1f; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Inusah S, 2010, MULT SCLER J, V16, P1414, DOI 10.1177/1352458510379246; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494; Lambert PC, 2002, J CLIN EPIDEMIOL, V55, P86, DOI 10.1016/S0895-4356(01)00414-0; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Nicholas R, 2011, MULT SCLER J, V17, P1211, DOI 10.1177/1352458511406309; O'Connor P, 2011, NEW ENGL J MED, V365, P1293, DOI 10.1056/NEJMoa1014656; Okuda DT, 2009, NEUROLOGY, V72, P800, DOI 10.1212/01.wnl.0000335764.14513.1a; Polman CH, 2005, ANN NEUROL, V58, P840, DOI 10.1002/ana.20703; Polman Chris H, 2006, N Engl J Med, V354, P899; Polman Chris H, 2011, Ann Neurol, V69, P292, DOI 10.1002/ana.22366; R Core Team, 2021, R LANG ENV STAT COMP; Selmaj K, 2011, MULT SCLER, P994; Sormani MP, 2008, ANN NEUROL, V64, P428, DOI 10.1002/ana.21464; van Houwelingen HC, 2002, STAT MED, V21, P589, DOI 10.1002/sim.1040; Viechtbauer W, 2010, J 36, P36	33	19	19	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2012	7	11							e50347	10.1371/journal.pone.0050347	http://dx.doi.org/10.1371/journal.pone.0050347			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	051DI	23209717	Green Published, Green Accepted, gold, Green Submitted			2023-01-03	WOS:000312104900042
J	Bourzac, K				Bourzac, Katherine			NANOTECHNOLOGY Carrying drugs	NATURE			English	Editorial Material																		Douglas SM, 2012, SCIENCE, V335, P831, DOI 10.1126/science.1214081; Hrkach J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003651; Jain RK, 2010, NAT REV CLIN ONCOL, V7, P653, DOI 10.1038/nrclinonc.2010.139; von Maltzahn G, 2011, NAT MATER, V10, P545, DOI [10.1038/nmat3049, 10.1038/NMAT3049]	4	153	157	2	120	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 22	2012	491	7425					S58	S60		10.1038/491S58a	http://dx.doi.org/10.1038/491S58a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	040RE	23320289	Bronze			2023-01-03	WOS:000311339800006
J	den Heijer, CDJ; Beerepoot, MAJ; Prins, JM; Geerlings, SE; Stobberingh, EE				den Heijer, Casper D. J.; Beerepoot, Marielle A. J.; Prins, Jan M.; Geerlings, Suzanne E.; Stobberingh, Ellen E.			Determinants of Antimicrobial Resistance in Escherichia coli Strains Isolated from Faeces and Urine of Women with Recurrent Urinary Tract Infections	PLOS ONE			English	Article							DOUBLE-BLIND; SUSCEPTIBILITY; ANTIBIOTICS; FLORA	For women with recurrent urinary tract infections (rUTI), the contribution of antibiotic use versus patient-related factors in determining the presence of antimicrobial resistance in faecal and urinary Escherichia coli, obtained from the same patient population, has not been assessed yet. Within the context of the 'Non-antibiotic prophylaxis for recurrent urinary tract infections' (NAPRUTI) study, the present study assessed determinants of antimicrobial resistance in E. coli isolated from urinary and faecal samples of women with rUTIs collected at baseline. Potential determinants of resistance were retrieved from self-administered questionnaires. From 434 asymptomatic women, 433 urinary and 424 faecal samples were obtained. E. coli was isolated from 146 (34%) urinary samples and from 336 (79%) faecal samples, and subsequently tested for antimicrobial susceptibility. Multivariable analysis showed trimethoprim/sulfamethoxazole (SXT) use three months prior to inclusion to be associated with urine E. coli resistance to amoxicillin (OR 3.6, 95% confidence interval: 1.3-9.9), amoxicillin-clavulanic acid (OR 4.4, 1.5-13.3), trimethoprim (OR 3.9, 1.4-10.5) and SXT (OR 3.2, 1.2-8.5), and with faecal E. coli resistance to trimethoprim (OR 2.0, 1.0-3.7). The number of UTIs in the preceding year was correlated with urine E. coli resistance to amoxicillin-clavulanic acid (OR 1.11, 1.01-1.22), trimethoprim (OR 1.13, 1.03-1.23) and SXT (OR 1.10, 1.01-1.19). Age was predictive for faecal E. coli resistance to amoxicillin (OR 1.02, 1.00-1.03), norfloxacin and ciprofloxacin (both OR 1.03, 1.01-1.06). In conclusion, in women with rUTI different determinants were found for urinary and faecal E. coli resistance. Previous antibiotic use and UTI history were associated with urine E. coli resistance and age was a predictor of faecal E. coli resistance. These associations could best be explained by cumulative antibiotic use.	[den Heijer, Casper D. J.; Stobberingh, Ellen E.] Maastricht Univ, Med Ctr, Care & Publ Hlth Res Inst CAPHRI, Dept Med Microbiol, Maastricht, Netherlands; [Beerepoot, Marielle A. J.; Prins, Jan M.; Geerlings, Suzanne E.] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Div Infect Dis,Ctr Infect & Immun Amsterdam CINIM, NL-1105 AZ Amsterdam, Netherlands	Maastricht University; University of Amsterdam; Academic Medical Center Amsterdam	Stobberingh, EE (corresponding author), Maastricht Univ, Med Ctr, Care & Publ Hlth Res Inst CAPHRI, Dept Med Microbiol, Maastricht, Netherlands.	e.stobberingh@mumc.nl	Prins, Jan M./AAF-4945-2020	Prins, Jan/0000-0002-5415-8933	Netherlands Organization for Health, Research and Development [62000017]	Netherlands Organization for Health, Research and Development(Netherlands Organization for Health Research and Development)	This work was supported by grant 62000017 from the Netherlands Organization for Health, Research and Development. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beerepoot MAJ, 2012, CLIN MICROBIOL INFEC, V18, pE84, DOI 10.1111/j.1469-0691.2012.03773.x; Beerepoot MAJ, 2012, ARCH INTERN MED, V172, P704, DOI 10.1001/archinternmed.2012.777; Beerepoot MAJ, 2011, ARCH INTERN MED, V171, P1270, DOI 10.1001/archinternmed.2011.306; Blango MG, 2010, ANTIMICROB AGENTS CH, V54, P1855, DOI 10.1128/AAC.00014-10; Costelloe C, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2096; de Lastours V, 2010, ANTIMICROB AGENTS CH, V54, P5193, DOI 10.1128/AAC.00823-10; Dromigny JA, 2005, J ANTIMICROB CHEMOTH, V56, P236, DOI 10.1093/jac/dki158; EUCAST, 2000, CLIN MICROBIOL INFEC, V6, P570; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; Kahlmeter G, 2003, J ANTIMICROB CHEMOTH, V52, P128, DOI 10.1093/jac/dkg280; Lichtenberger P, 2011, INT J ANTIMICROB AG, V38, P36, DOI 10.1016/j.ijantimicag.2011.09.005; Moreno E, 2006, EPIDEMIOL INFECT, V134, P1015, DOI 10.1017/S0950268806005917; Raum E, 2008, CLIN MICROBIOL INFEC, V14, P41, DOI 10.1111/j.1469-0691.2007.01841.x; van den Bogaard AE, 2001, J ANTIMICROB CHEMOTH, V47, P763, DOI 10.1093/jac/47.6.763; van Pinxteren B, 2006, Ned Tijdschr Geneeskd, V150, P718	15	13	13	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2012	7	11							e49909	10.1371/journal.pone.0049909	http://dx.doi.org/10.1371/journal.pone.0049909			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	048BN	23166796	gold, Green Published, Green Submitted			2023-01-03	WOS:000311885300074
J	Dixon, CI; Walker, SE; King, SL; Stephens, DN				Dixon, Claire I.; Walker, Sophie E.; King, Sarah L.; Stephens, David N.			Deletion of the gabra2 Gene Results in Hypersensitivity to the Acute Effects of Ethanol but Does Not Alter Ethanol Self Administration	PLOS ONE			English	Article							CONDITIONED EMOTIONAL RESPONSE; GABA(A) RECEPTORS; ALCOHOL DEPENDENCE; ALPHA-2 SUBUNIT; SPINAL-CORD; ADULT-RAT; ASSOCIATION; MICE; SUBTYPES; BRAIN	Human genetic studies have suggested that polymorphisms of the GABRA2 gene encoding the GABA(A) alpha 2-subunit are associated with ethanol dependence. Variations in this gene also convey sensitivity to the subjective effects of ethanol, indicating a role in mediating ethanol-related behaviours. We therefore investigated the consequences of deleting the alpha 2-subunit on the ataxic and rewarding properties of ethanol in mice. Ataxic and sedative effects of ethanol were explored in GABAA alpha 2-subunit wildtype (WT) and knockout (KO) mice using a Rotarod apparatus, wire hang and the duration of loss of righting reflex. Following training, KO mice showed shorter latencies to fall than WT littermates under ethanol (2 g/kg i.p.) in both Rotarod and wire hang tests. After administration of ethanol (3.5 g/kg i.p.), KO mice took longer to regain the righting reflex than WT mice. To ensure the acute effects are not due to the gabra2 deletion affecting pharmacokinetics, blood ethanol concentrations were measured at 20 minute intervals after acute administration (2 g/kg i.p.), and did not differ between genotypes. To investigate ethanol's rewarding properties, WT and KO mice were trained to lever press to receive increasing concentrations of ethanol on an FR4 schedule of reinforcement. Both WT and KO mice self-administered ethanol at similar rates, with no differences in the numbers of reinforcers earned. These data indicate a protective role for alpha 2-subunits, against the acute sedative and ataxic effects of ethanol. However, no change was observed in ethanol self administration, suggesting the rewarding effects of ethanol remain unchanged.	[Dixon, Claire I.; Walker, Sophie E.; King, Sarah L.; Stephens, David N.] Univ Sussex, Sch Psychol, Brighton, E Sussex, England	University of Sussex	Stephens, DN (corresponding author), Univ Sussex, Sch Psychol, Brighton, E Sussex, England.	d.stephens@sussex.ac.uk		Walker, Sophie/0000-0001-8120-7000; King, Sarah/0000-0002-7412-9558	Medical Research Council [G0600874, G0802715, G1000008]; MRC [G1000008, G0802715, G0600874] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Funding was provided by Medical Research Council grants G0600874, G0802715 and G1000008.	Agrawal A, 2008, ADDICTION, V103, P1027, DOI 10.1111/j.1360-0443.2008.02236.x; Barbaccia ML, 1999, EUR J PHARMACOL, V384, pR1, DOI 10.1016/S0014-2999(99)00678-0; Belelli D, 2002, NEUROPHARMACOLOGY, V43, P651, DOI 10.1016/S0028-3908(02)00172-7; Blednov YA, 2011, J PHARMACOL EXP THER, V336, P145, DOI 10.1124/jpet.110.171645; Boehm SL, 2004, BIOCHEM PHARMACOL, V68, P1581, DOI 10.1016/j.bcp.2004.07.023; Bohlhalter S, 1996, J NEUROSCI, V16, P283, DOI 10.1523/jneurosci.16-01-00283.1996; Covault J, 2004, AM J MED GENET B, V129B, P104, DOI 10.1002/ajmg.b.30091; Dick DM, 2006, BEHAV GENET, V36, P577, DOI 10.1007/s10519-005-9041-8; Dixon CI, 2008, PHARMACOL BIOCHEM BE, V90, P1, DOI 10.1016/j.pbb.2008.01.015; Dixon CI, 2010, P NATL ACAD SCI USA, V107, P2289, DOI 10.1073/pnas.0910117107; Edenberg HJ, 2004, AM J HUM GENET, V74, P705, DOI 10.1086/383283; Enoch MA, 2006, AM J MED GENET B, V141B, P599, DOI 10.1002/ajmg.b.30336; Enoch MA, 2010, BIOL PSYCHIAT, V67, P20, DOI 10.1016/j.biopsych.2009.08.019; FAHLKE C, 1994, PHARMACOL BIOCHEM BE, V47, P345, DOI 10.1016/0091-3057(94)90020-5; HANSEN S, 1995, ALCOHOL, V12, P397, DOI 10.1016/0741-8329(95)00008-F; Haughey HM, 2008, GENES BRAIN BEHAV, V7, P447, DOI 10.1111/j.1601-183X.2007.00369.x; June HL, 2003, NEUROPSYCHOPHARMACOL, V28, P2124, DOI 10.1038/sj.npp.1300239; Khisti RT, 2004, ALCOHOL CLIN EXP RES, V28, P1249, DOI 10.1097/01.ALC.0000134232.44210.06; Kralic JE, 2006, J COMP NEUROL, V495, P408, DOI 10.1002/cne.20866; Kralic JE, 2002, NEUROPHARMACOLOGY, V43, P685, DOI 10.1016/S0028-3908(02)00174-0; Lappalainen J, 2005, ALCOHOL CLIN EXP RES, V29, P493, DOI 10.1097/01.ALC.0000158938.97464.90; Lind PA, 2008, ALCOHOL CLIN EXP RES, V32, P1721, DOI 10.1111/j.1530-0277.2008.00768.x; Low K, 2000, SCIENCE, V290, P131, DOI 10.1126/science.290.5489.131; Lydall GJ, 2011, NEUROSCI LETT, V500, P162, DOI 10.1016/j.neulet.2011.05.240; Morris HV, 2008, PHARMACOL BIOCHEM BE, V90, P9, DOI 10.1016/j.pbb.2008.02.010; Morris HV, 2006, EUR J NEUROSCI, V23, P2495, DOI 10.1111/j.1460-9568.2006.04775.x; Onori N, 2010, ALCOHOL CLIN EXP RES, V34, P659, DOI 10.1111/j.1530-0277.2009.01135.x; PERSOHN E, 1991, NEUROSCIENCE, V42, P497, DOI 10.1016/0306-4522(91)90392-2; Pierucci-Lagha A, 2005, NEUROPSYCHOPHARMACOL, V30, P1193, DOI 10.1038/sj.npp.1300688; Pirker S, 2000, NEUROSCIENCE, V101, P815, DOI 10.1016/S0306-4522(00)00442-5; Ponomarev I, 2006, J NEUROSCI, V26, P5673, DOI 10.1523/JNEUROSCI.0860-06.2006; Roberto M, 2004, J NEUROSCI, V24, P10159, DOI 10.1523/JNEUROSCI.3004-04.2004; Roh S, 2010, ALCOHOL CLIN EXP RES; Ruiz A, 2003, NEURON, V39, P961, DOI 10.1016/S0896-6273(03)00559-2; Sakai JT, 2010, DRUG ALCOHOL DEPEN, V106, P199, DOI 10.1016/j.drugalcdep.2009.08.015; SAMSON HH, 1986, ALCOHOL CLIN EXP RES, V10, P436, DOI 10.1111/j.1530-0277.1986.tb05120.x; Schwarzer C, 2001, J COMP NEUROL, V433, P526, DOI 10.1002/cne.1158; Tauber M, 2003, EUR J NEUROSCI, V18, P2599, DOI 10.1046/j.1460-9568.2003.02988.x; Ueno S, 1999, BRIT J PHARMACOL, V127, P377, DOI 10.1038/sj.bjp.0702563; Villafuerte S, 2011, MOL PSYCHIAT; Wafford KA, 2004, BIOCHEM SOC T, V32, P553, DOI 10.1042/BST0320553; Wakita M, 2012, J PHARMACOL EXP THER, V341, P809, DOI 10.1124/jpet.111.189126; Weiner JL, 2006, PHARMACOL THERAPEUT, V111, P533, DOI 10.1016/j.pharmthera.2005.11.002; Yang ARST, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00123; Zhu PJ, 2006, J NEUROPHYSIOL, V96, P433, DOI 10.1152/jn.01380.2005	45	15	15	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2012	7	10							e47135	10.1371/journal.pone.0047135	http://dx.doi.org/10.1371/journal.pone.0047135			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	026VC	23115637	Green Submitted, Green Accepted, gold, Green Published			2023-01-03	WOS:000310310200026
J	Talbert, J; Blumenschein, K; Burke, A; Stromberg, A; Freeman, P				Talbert, Jeffery; Blumenschein, Karen; Burke, Amy; Stromberg, Arnold; Freeman, Patricia			Pseudoephedrine Sales and Seizures of Clandestine Methamphetamine Laboratories in Kentucky	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Talbert, Jeffery; Blumenschein, Karen; Burke, Amy; Stromberg, Arnold; Freeman, Patricia] Univ Kentucky, Coll Pharm, Inst Pharmaceut Outcomes & Policy, Lexington, KY 40506 USA	University of Kentucky	Talbert, J (corresponding author), Univ Kentucky, Coll Pharm, Inst Pharmaceut Outcomes & Policy, Lexington, KY 40506 USA.	jtalb1@uky.edu	Talbert, Jeffery C/F-3929-2011; Freeman, Patricia/W-2473-2019; Freeman, Patricia R./L-3752-2019	Talbert, Jeffery C/0000-0002-4304-5167; Freeman, Patricia/0000-0002-4749-6563	NCATS NIH HHS [UL1 TR000117, UL1TR000117, UL1 TR001998] Funding Source: Medline; NCRR NIH HHS [UL1RR033173, UL1 RR033173] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001998, UL1TR000117] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR033173] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Kentucky State Police, 2010, METH MAN KENT; McKetin R, 2011, ADDICTION, V106, P1911, DOI 10.1111/j.1360-0443.2011.03582.x; Nonnemaker J, 2011, HEALTH ECON, V20, P519, DOI 10.1002/hec.1610; Prah PM, 2005, CQ RES, P589; US Department of Justice National Drug Intelligence Center, 2011, NAT DRUG THREAT ASS	5	2	2	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 17	2012	308	15					1524	1526		10.1001/jama.2012.12992	http://dx.doi.org/10.1001/jama.2012.12992			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	021AQ	23073945	Bronze, Green Accepted			2023-01-03	WOS:000309858100014
J	Das, S; Dey, KK; Dey, G; Pal, I; Majumder, A; MaitiChoudhury, S; Kundu, SC; Mandal, M				Das, Subhasis; Dey, Kaushik Kumar; Dey, Goutam; Pal, Ipsita; Majumder, Abhijit; MaitiChoudhury, Sujata; Kundu, Subhas C.; Mandal, Mahitosh			Antineoplastic and Apoptotic Potential of Traditional Medicines Thymoquinone and Diosgenin in Squamous Cell Carcinoma	PLOS ONE			English	Article							BREAST-CANCER CELLS; COLON-CANCER; IN-VITRO; ANTITUMOR-ACTIVITY; GENE-EXPRESSION; ACTIVATION; PATHWAY; VIVO; BEVACIZUMAB; GROWTH	Thymoquinone (TQ) and diosgenin (DG), the active ingredients obtained from black cumin (Nigella sativa) and fenugreek (Trigonella foenum graecum), respectively, exert potent bioactivity, including anticancer effects. This study investigated the antineoplastic activity of these agents against squamous cell carcinoma in vitro and sarcoma 180-induced tumors in vivo. TQ and DG inhibited cell proliferation and induced cytotoxicity in A431 and Hep2 cells. These agents induced apoptosis by increasing the sub-G1 population, LIVE/DEAD cytotoxicity, chromatin condensation, DNA laddering and TUNEL-positive cells significantly (P < 0.05). Increased Bax/Bcl-2 ratio, activation of caspases and cleavage of poly ADP ribose polymerase were observed in treated cells. These drugs inhibited Akt and JNK phosphorylations, thus inhibiting cell proliferation while inducing apoptosis. In combination, TQ and DG had synergistic effects, resulting in cell viability as low as 10%. In a mouse xenograft model, a combination of TQ and DG significantly (P<0.05) reduced tumor volume, mass and increased apoptosis. TQ and DG, alone and in combination, inhibit cell proliferation and induce apoptosis in squamous cell carcinoma. The combination of TQ and DG is a potential antineoplastic therapy in this common skin cancer.	[Das, Subhasis; Dey, Kaushik Kumar; Dey, Goutam; Pal, Ipsita; Mandal, Mahitosh] Indian Inst Technol Kharagpur, Sch Med Sci & Technol, Kharagpur, W Bengal, India; [Majumder, Abhijit] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; [MaitiChoudhury, Sujata] Vidyasagar Univ, Dept Human Physiol Community Hlth, W Midnapur, W Bengal, India; [Kundu, Subhas C.] Indian Inst Technol Kharagpur, Dept Biotechnol, Kharagpur, W Bengal, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Kharagpur; University of Texas System; UTMD Anderson Cancer Center; Vidyasagar University; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Kharagpur	Mandal, M (corresponding author), Indian Inst Technol Kharagpur, Sch Med Sci & Technol, Kharagpur, W Bengal, India.	mahitosh@smst.iitkgp.ernet.in	Dey, Kaushik Kumar/H-5997-2018; DAS, SUBHASIS/O-8421-2017; Pal, Ipsita/AAX-4410-2020; Kundu, Subhas C/AAC-1317-2020; Mandal, Mahitosh/GMW-6195-2022	Dey, Kaushik Kumar/0000-0002-9594-6362; DAS, SUBHASIS/0000-0003-1032-4407; Kundu, Subhas C/0000-0002-7170-2291; Mandal, Mahitosh/0000-0003-3861-3323; Dey, Goutam/0000-0002-8210-3219	Department of Science and Technolgy; Department of Biotechnology, Government of India	Department of Science and Technolgy; Department of Biotechnology, Government of India(Department of Biotechnology (DBT) India)	The authors are very thankful to the Department of Science and Technolgy, and the Department of Biotechnology, Government of India for financial support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Shabanah OA, 1998, J EXP CLIN CANC RES, V17, P193; Badary OA, 2003, DRUG CHEM TOXICOL, V26, P87, DOI 10.1081/DCT-120020404; Chen Pin-Shern, 2011, PLoS One, V6, pe20164, DOI 10.1371/journal.pone.0020164; Chiang CT, 2007, FEBS LETT, V581, P5735, DOI 10.1016/j.febslet.2007.11.021; Chien CS, 2010, MOL CELL BIOCHEM, V333, P169, DOI 10.1007/s11010-009-0217-z; Chou TC, 1984, ADV ENZYME REGUL, V22, P22; Corbiere C, 2004, CELL RES, V14, P188, DOI 10.1038/sj.cr.7290219; Effenberger-Neidnicht K, 2011, CANCER CHEMOTH PHARM, V67, P867, DOI 10.1007/s00280-010-1386-x; El-Mahdy MA, 2005, INT J CANCER, V117, P409, DOI 10.1002/ijc.21205; El-Najjar N, 2010, APOPTOSIS, V15, P183, DOI 10.1007/s10495-009-0421-z; Gali-Muhtasib HU, 2004, ANTI-CANCER DRUG, V15, P389, DOI 10.1097/00001813-200404000-00012; Gasparini G, 2005, NAT CLIN PRACT ONCOL, V2, P562, DOI 10.1038/ncponc0342; Ito H, 1997, ANTICANCER RES, V17, P277; Ivankovic S., 2006, Experimental Oncology, V28, P220; Jafri SH, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-87; Jaganathan SK, 2011, CELL BIOL INT, V35, P607, DOI 10.1042/CBI20100118; JOHNSON TM, 1992, J AM ACAD DERMATOL, V26, P467, DOI 10.1016/0190-9622(92)70074-P; Kaseb AO, 2007, CANCER RES, V67, P7782, DOI 10.1158/0008-5472.CAN-07-1483; Kerr DJ, 2004, NAT CLIN PRACT ONCOL, V1, P39, DOI 10.1038/ncponc0026; Lee J, 2007, LIFE SCI, V81, P249, DOI 10.1016/j.lfs.2007.05.009; Lee YL, 2003, EXP ANIM TOKYO, V52, P371, DOI 10.1538/expanim.52.371; Lei XF, 2012, BIOCHEM BIOPH RES CO, V417, P864, DOI 10.1016/j.bbrc.2011.12.063; Li F, 2010, CANCER LETT, V292, P197, DOI 10.1016/j.canlet.2009.12.003; Mandal M, 2001, GASTROENTEROLOGY, V120, P71, DOI 10.1053/gast.2001.20897; McAnuff MA, 2005, FOOD CHEM TOXICOL, V43, P1667, DOI 10.1016/j.fct.2005.05.008; Roepke M, 2007, CANCER BIOL THER, V6, P160, DOI 10.4161/cbt.6.2.3575; Salehi Z, 2007, CELL BIOL INT, V31, P1400, DOI 10.1016/j.cellbi.2007.06.006; Sarkar S, 2011, J CELL PHYSIOL, V226, P375, DOI 10.1002/jcp.22343; Sarkar S, 2010, CANCER BIOL THER, V9, P592, DOI 10.4161/cbt.9.8.11103; Sethi G, 2008, MOL CANCER RES, V6, P1059, DOI 10.1158/1541-7786.MCR-07-2088; Shishodia S, 2006, ONCOGENE, V25, P1463, DOI 10.1038/sj.onc.1209194; Tornita K, 1979, CANCER RES, V39, P4407; VanDeWater B, 1996, AM J PHYSIOL-RENAL, V270, pF593, DOI 10.1152/ajprenal.1996.270.4.F593; Velho-Pereira R, 2011, CELL BIOL INT, V35, P1025, DOI 10.1042/CBI20100701; Venkatesan P, 2011, BIOMATERIALS, V32, P3794, DOI 10.1016/j.biomaterials.2011.01.027; Woo CC, 2011, BIOCHEM PHARMACOL, V82, P464, DOI 10.1016/j.bcp.2011.05.030; Yang SX, 2008, CLIN CANCER RES, V14, P5893, DOI 10.1158/1078-0432.CCR-07-4762	37	100	105	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2012	7	10							e46641	10.1371/journal.pone.0046641	http://dx.doi.org/10.1371/journal.pone.0046641			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022WO	23077516	Green Published, gold, Green Submitted			2023-01-03	WOS:000309995100034
J	Gill, SS; Gupta, N; Bell, CM; Rochon, PA; Austin, PC; Laupacis, A				Gill, Sudeep S.; Gupta, Neeraj; Bell, Chaim M.; Rochon, Paula A.; Austin, Peter C.; Laupacis, Andreas			The Timing of Drug Funding Announcements Relative to Elections: A Case Study Involving Dementia Medications	PLOS ONE			English	Article							ALZHEIMERS-DISEASE; DOUBLE-BLIND; CHOLINESTERASE-INHIBITORS; SCIENTIFIC EVIDENCE; COST-EFFECTIVENESS; CANCER DRUGS; DONEPEZIL; POLICY; COVERAGE; MEMANTINE	Background: Following initial regulatory approval of prescription drugs, many factors may influence insurers and health systems when they decide whether to add these drugs to their formularies. The role of political pressures on drug funding announcements has received relatively little attention, and elections represent an especially powerful form of political pressure. We examined the temporal relationship between decisions to add one class of drugs to publicly funded formularies in Canada's ten provinces and elections in these jurisdictions. Methods: Dates of provincial formulary listings for cholinesterase inhibitors, which are drugs used to treat Alzheimer's disease and related dementias, were compared to the dates of provincial elections. Medical journal articles, media reports, and proceedings from provincial legislatures were reviewed to assemble information on the chronology of events. We tested whether there was a statistically significant increase in the probability of drug funding announcements within the 60-day intervals preceding provincial elections. Results: Decisions to fund the cholinesterase inhibitors were made over a nine-year span from 1999 to 2007 in the ten provinces. In four of ten provinces, the drugs were added to formularies in a time period closely preceding a provincial election (P = 0.032); funding announcements in these provinces were made between 2 and 47 days prior to elections. Statements made in provincial legislatures highlight the key role of political pressures in these funding announcements. Conclusions: Impending elections appeared to affect the timing of drug funding announcements in this case study. Despite an established structure for evidence-based decision-making, drug funding remains a complex process open to influence from many sources. Awareness of such influences is critical to maintain effective drug policy and public health decision-making.	[Gill, Sudeep S.; Gupta, Neeraj] Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada; [Gill, Sudeep S.; Bell, Chaim M.; Rochon, Paula A.; Austin, Peter C.; Laupacis, Andreas] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Bell, Chaim M.; Rochon, Paula A.; Austin, Peter C.; Laupacis, Andreas] Univ Toronto, Dept Med, Toronto, ON, Canada; [Bell, Chaim M.; Rochon, Paula A.; Austin, Peter C.; Laupacis, Andreas] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Bell, Chaim M.] Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; [Rochon, Paula A.] Womens Coll Hosp, Womens Coll Res Inst, Toronto, ON M5S 1B2, Canada; [Laupacis, Andreas] St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada	Queens University - Canada; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto	Gill, SS (corresponding author), Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada.	sudeep.gill@ices.on.ca	Rochon, Paula A/J-2918-2016; Bell, Chaim/C-4611-2015	Rochon, Paula A/0000-0002-5973-4151; Bell, Chaim/0000-0002-3778-9469; Austin, Peter/0000-0003-3337-233X	Canadian Institutes of Health Research (CIHR); CIHR; Canadian Patient Safety Institute Chair in Patient Safety and Continuity of Care; Heart and Stroke Foundation	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CIHR(Canadian Institutes of Health Research (CIHR)); Canadian Patient Safety Institute Chair in Patient Safety and Continuity of Care; Heart and Stroke Foundation(Heart & Stroke Foundation of Canada)	SSG is supported by a Canadian Institutes of Health Research (CIHR) New Investigator Award. CMB is supported by a CIHR and Canadian Patient Safety Institute Chair in Patient Safety and Continuity of Care. PCA is supported by a Career Investigator award from the Heart and Stroke Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The opinions, results and conclusions are those of the authors. No endorsement by the Ontario Ministry of Health and Long-Term Care, the Institute for Clinical Evaluative Sciences (ICES), ICES@Queen's or the funding sources is intended or should be inferred.	Ames D, 2008, INT PSYCHOGERIATR, V20, P259, DOI 10.1017/S1041610207006680; Andrews E, 2004, PHARMACOEPIDEM DR S, V13, P599, DOI 10.1002/pds.899; Anis AH, 2001, MED CARE, V39, P315, DOI 10.1097/00005650-200104000-00003; [Anonymous], 1998, GLOBE MAIL A    0813, P9; [Anonymous], 1999, CBC NEWS; [Anonymous], 2009, CBS NEWS 60 MIN; Bach PB, 2009, NEW ENGL J MED, V360, P626, DOI 10.1056/NEJMhpr0807774; BC Therapeutics Initiative, 2005, THERAPEUTICS LET APR; Bentham P, 2004, LANCET, V363, P2105; Booth CM, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-110; Carpenter D, 2008, NEW ENGL J MED, V358, P1354, DOI 10.1056/NEJMsa0706341; Chambers JD, 2011, NEW ENGL J MED, V364, P1687, DOI 10.1056/NEJMp1103057; Choi BCK, 2005, J EPIDEMIOL COMMUN H, V59, P632, DOI 10.1136/jech.2004.031765; Clement FM, 2009, JAMA-J AM MED ASSOC, V302, P1437, DOI 10.1001/jama.2009.1409; Detsky AS, 2007, JAMA-J AM MED ASSOC, V298, P221, DOI 10.1001/jama.298.2.221; Dhalla I, 2008, CAN MED ASSOC J, V178, P428, DOI 10.1503/cmaj.070799; Doyle Y, 2001, BRIT MED J, V323, P222, DOI 10.1136/bmj.323.7306.222; Elie LM, 1998, CAN MED ASSOC J, V158, P1014; Foy R, 1999, BRIT MED J, V318, P456, DOI 10.1136/bmj.318.7181.456; Gellad WF, 2008, J GEN INTERN MED, V23, P1435, DOI 10.1007/s11606-008-0689-7; Goldberg DS, 2012, AM J PUBLIC HEALTH, V102, P44, DOI 10.2105/AJPH.2011.300325; Gostin LO, 2012, JAMA-J AM MED ASSOC, V308, P571, DOI 10.1001/jama.2012.9061; Government of Newfoundland and Labrador Department of Health and Community Services, 2003, GOV CREAT NEW SEN DR; Government of Nova Scotia Department of Health, 2003, PLAN ALZH DRUG COV R; Haas M, 2009, HEALTH POLICY, V92, P288, DOI 10.1016/j.healthpol.2009.05.002; Howard R, 2012, NEW ENGL J MED, V366, P893, DOI 10.1056/NEJMoa1106668; Huang YD, 2012, CELL, V148, P1204, DOI 10.1016/j.cell.2012.02.040; Humphreys K, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1316; IMS Healthlink Incorporated, 2011, TOP 20 GLOB PROD 201; Jewell CJ, 2008, MILBANK Q, V86, P177, DOI 10.1111/j.1468-0009.2008.00519.x; Mah CL, 2011, AM J PUBLIC HEALTH, V101, P1850, DOI 10.2105/AJPH.2011.300205; Martin DK, 2001, LANCET, V358, P1676, DOI 10.1016/S0140-6736(01)06714-9; Menon D, 2005, CAN J PUBLIC HEALTH, V96, P454, DOI 10.1007/BF03405189; Morden NE, 2007, J AM GERIATR SOC, V55, P622, DOI 10.1111/j.1532-5415.2007.01106.x; Morrison S, 1998, HAMILTON SPECTA 0718; Neuman P, 2009, NEW ENGL J MED, V361, P406, DOI 10.1056/NEJMhpr0809949; Neumann PJ, 2012, NEW ENGL J MED, V366, P585, DOI 10.1056/NEJMp1200390; Okie S, 2011, NEW ENGL J MED, V365, P1069, DOI 10.1056/NEJMp1107288; Oliver TR, 2006, ANNU REV PUBL HEALTH, V27, P195, DOI 10.1146/annurev.publhealth.25.101802.123126; Ontario Ministry of Health and Long-Term Care, 1999, ONT STRAT ALZH DIS R; Province of Newfoundland and Labrador, 2000, NEWF LABR HOUS ASS P, VXLIV; Province of Newfoundland and Labrador, 2005, NEWF LABR HOUS ASS P, VXLV; Province of Newfoundland and Labrador, 1999, NEWF LABR HOUS ASS P, VXLIV; Province of Newfoundland and Labrador, 2006, NEWF LABR HOUS ASS P, VXLV; Province of Nova Scotia, 2002, NOV SCOT HOUS ASS DE; Raina P, 2008, ANN INTERN MED, V148, P379, DOI 10.7326/0003-4819-148-5-200803040-00009; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; Rogers SL, 1998, ARCH INTERN MED, V158, P1021, DOI 10.1001/archinte.158.9.1021; Rogers SL, 1996, DEMENTIA, V7, P293, DOI 10.1159/000106895; Schiff GD, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001220; Schwartz LM, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e1086; Simon GE, 2005, J GEN INTERN MED, V20, P964, DOI 10.1111/j.1525-1497.2005.0232.x; Voelker R, 2008, JAMA-J AM MED ASSOC, V299, P1763, DOI 10.1001/jama.299.15.1763	53	4	4	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2013	8	2							e56921	10.1371/journal.pone.0056921	http://dx.doi.org/10.1371/journal.pone.0056921			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	098BN	23460820	Green Submitted, gold, Green Published			2023-01-03	WOS:000315519000045
J	Missirlis, D; Teesalu, T; Black, M; Tirrell, M				Missirlis, Dimitris; Teesalu, Tambet; Black, Matthew; Tirrell, Matthew			The Non-Peptidic Part Determines the Internalization Mechanism and Intracellular Trafficking of Peptide Amphiphiles	PLOS ONE			English	Article							ANCHORED PROTEINS; PLASMA-MEMBRANE; CHOLERA-TOXIN; MICELLES; CELL; NANOPARTICLES; TUMORS; ENDOCYTOSIS; STABILITY; ALBUMIN	Background: Peptide amphiphiles (PAs) are a class of amphiphilic molecules able to self-assemble into nanomaterials that have shown efficient in vivo targeted delivery. Understanding the interactions of PAs with cells and the mechanisms of their internalization and intracellular trafficking is critical in their further development for therapeutic delivery applications. Methodology/Principal Findings: PAs of a novel, cell- and tissue-penetrating peptide were synthesized possessing two different lipophilic tail architectures and their interactions with prostate cancer cells were studied in vitro. Cell uptake of peptides was greatly enhanced post-modification. Internalization occurred via lipid-raft mediated endocytosis and was common for the two analogs studied. On the contrary, we identified the non-peptidic part as the determining factor of differences between intracellular trafficking and retention of PAs. PAs composed of di-stearyl lipid tails linked through poly(ethylene glycol) to the peptide exhibited higher exocytosis rates and employed different recycling pathways compared to ones consisting of di-palmitic-coupled peptides. As a result, cell association of the former PAs decreased with time. Conclusions/Significance: Control over peptide intracellular localization and retention is possible by appropriate modification with synthetic hydrophobic tails. We propose this as a strategy to design improved peptide-based delivery systems.	[Missirlis, Dimitris; Black, Matthew; Tirrell, Matthew] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA; [Missirlis, Dimitris] Heidelberg Univ, Inst Phys Chem, Dept Biophys Chem, Heidelberg, Germany; [Missirlis, Dimitris] Max Planck Inst Intelligent Syst, Dept New Mat & Biosyst, Stuttgart, Germany; [Teesalu, Tambet] Univ Tartu, Canc Biol Lab, Inst Biomed, Ctr Excellence Translat Med, EE-50090 Tartu, Estonia; [Teesalu, Tambet] Sanford Burnham Med Res Inst, Ctr Canc, La Jolla, CA USA; [Tirrell, Matthew] Univ Chicago, Inst Mol Engn, Chicago, IL 60637 USA	University of California System; University of California Berkeley; Ruprecht Karls University Heidelberg; Max Planck Society; University of Tartu; Sanford Burnham Prebys Medical Discovery Institute; University of Chicago	Missirlis, D (corresponding author), Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA.	missirlis@uni-heidelberg.de	Missirlis, Dimitris/S-3798-2019; Teesalu, Tambet/J-1802-2015	Missirlis, Dimitris/0000-0003-1874-676X; 	College of Engineering at the University of California, Berkeley; Marie Curie International Incoming Fellowship; CellNetworks Postdoctoral fellowship; S. Komen for Cure Career Development Award; European Regional Development Fund; European Research Council	College of Engineering at the University of California, Berkeley; Marie Curie International Incoming Fellowship(European Commission); CellNetworks Postdoctoral fellowship; S. Komen for Cure Career Development Award; European Regional Development Fund(European Commission); European Research Council(European Research Council (ERC)European Commission)	This work was funded by the College of Engineering at the University of California, Berkeley (DM, MT), a Marie Curie International Incoming Fellowship to DM, a CellNetworks Postdoctoral fellowship to DM, the S. Komen for Cure Career Development Award to TT, the European Regional Development Fund grant to TT, the European Research Council starting grant to TT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BERNDT P, 1995, J AM CHEM SOC, V117, P9515, DOI 10.1021/ja00142a019; Bhagatji P, 2009, J CELL BIOL, V186, P615, DOI 10.1083/jcb.200903102; Braun GB, 2009, ACS NANO, V3, P2007, DOI 10.1021/nn900469q; Chatterjee S, 2001, CELL MOL LIFE SCI, V58, P1969, DOI 10.1007/PL00000831; Chinnapen DJF, 2007, FEMS MICROBIOL LETT, V266, P129, DOI 10.1111/j.1574-6968.2006.00545.x; Cui HG, 2010, BIOPOLYMERS, V94, P1, DOI 10.1002/bip.21328; Foerg C, 2008, J PHARM SCI-US, V97, P144, DOI 10.1002/jps.21117; Hansen CG, 2009, J CELL SCI, V122, P1713, DOI 10.1242/jcs.033951; Karmali PP, 2009, NANOMED-NANOTECHNOL, V5, P73, DOI 10.1016/j.nano.2008.07.007; Kastantin M, 2010, J PHYS CHEM B, V114, P12632, DOI 10.1021/jp1001786; Kastantin M, 2009, LANGMUIR, V25, P7279, DOI 10.1021/la900310k; Lin BF, 2011, NANO LETT, V11, P3946, DOI 10.1021/nl202220q; Missirlis D, 2010, MOL PHARMACEUT, V7, P2173, DOI 10.1021/mp100193h; Missirlis D, 2009, BIOCHEMISTRY-US, V48, P3304, DOI 10.1021/bi802356k; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; Peters D, 2009, P NATL ACAD SCI USA, V106, P9815, DOI 10.1073/pnas.0903369106; Ramprasad OG, 2007, CELL MOTIL CYTOSKEL, V64, P199, DOI 10.1002/cm.20176; Roth L, 2012, ONCOGENE, V31, P3754, DOI 10.1038/onc.2011.537; Ruoslahti E, 2010, J CELL BIOL, V188, P759, DOI 10.1083/jcb.200910104; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; Schmidt N, 2010, FEBS LETT, V584, P1806, DOI 10.1016/j.febslet.2009.11.046; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; SILVIUS JR, 1993, BIOCHEMISTRY-US, V32, P3153, DOI 10.1021/bi00063a030; Stenmark H, 2009, NAT REV MOL CELL BIO, V10, P513, DOI 10.1038/nrm2728; Sugahara KN, 2009, CANCER CELL, V16, P510, DOI 10.1016/j.ccr.2009.10.013; Teesalu T, 2012, METHOD ENZYMOL, V503, P35, DOI 10.1016/B978-0-12-396962-0.00002-1; Teesalu T, 2009, P NATL ACAD SCI USA, V106, P16157, DOI 10.1073/pnas.0908201106; Torgersen ML, 2001, J CELL SCI, V114, P3737; Trent A, 2011, SOFT MATTER, V7, P9572, DOI 10.1039/c1sm05862b; Wang TY, 2005, J BIOL CHEM, V280, P22839, DOI 10.1074/jbc.M502920200; WEST MA, 1989, J CELL BIOL, V109, P2731, DOI 10.1083/jcb.109.6.2731; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	33	20	20	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2013	8	1							e54611	10.1371/journal.pone.0054611	http://dx.doi.org/10.1371/journal.pone.0054611			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	073JI	23349939	gold, Green Published, Green Submitted			2023-01-03	WOS:000313738900081
J	Reigada, R				Reigada, Ramon			Atomistic Study of Lipid Membranes Containing Chloroform: Looking for a Lipid-Mediated Mechanism of Anesthesia	PLOS ONE			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; LATERAL PRESSURE PROFILES; GENERAL-ANESTHETICS; FATTY-ACIDS; CHOLESTEROL; BILAYER; CHANNEL; CONFORMATION; PROTEINS; ALCOHOLS	The molecular mechanism of general anesthesia is still a controversial issue. Direct effect by linking of anesthetics to proteins and indirect action on the lipid membrane properties are the two hypotheses in conflict. Atomistic simulations of different lipid membranes subjected to the effect of small volatile organohalogen compounds are used to explore plausible lipid-mediated mechanisms. Simulations of homogeneous membranes reveal that electrostatic potential and lateral pressure transversal profiles are affected differently by chloroform (anesthetic) and carbon tetrachloride (non-anesthetic). Simulations of structured membranes that combine ordered and disordered regions show that chloroform molecules accumulate preferentially in highly disordered lipid domains, suggesting that the combination of both lateral and transversal partitioning of chloroform in the cell membrane could be responsible of its anesthetic action.	[Reigada, Ramon] Univ Barcelona, Dept Quim Fis, E-08028 Barcelona, Spain; [Reigada, Ramon] Univ Barcelona, Inst Quim Teor & Computac IQTCUB, Barcelona, Spain	University of Barcelona; University of Barcelona	Reigada, R (corresponding author), Univ Barcelona, Dept Quim Fis, E-08028 Barcelona, Spain.	reigada@ub.edu		Reigada, Ramon/0000-0003-2177-7014	Secretaria de Estado de Investigacion y Desarrollo [BFU2010-21847-C02-02]; Departament d'Universitats, Recerca i Sistemes de la Informacio [2009-SGR-1055]	Secretaria de Estado de Investigacion y Desarrollo; Departament d'Universitats, Recerca i Sistemes de la Informacio	Financial support is provided by Secretaria de Estado de Investigacion y Desarrollo through project BFU2010-21847-C02-02 and by Departament d'Universitats, Recerca i Sistemes de la Informacio through project 2009-SGR-1055. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aimon S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025529; Bachar M, 2004, J PHYS CHEM B, V108, P7170, DOI 10.1021/jp036981u; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Berendsen HJC, 1981, INTERMOLECULAR FORCE, P331, DOI 10.1007/978-94-015-7658-1_21; Berger O, 1997, BIOPHYS J, V72, P2002, DOI 10.1016/S0006-3495(97)78845-3; Bezanilla F, 2008, NAT REV MOL CELL BIO, V9, P323, DOI 10.1038/nrm2376; Bondarenko V, 2008, BIOPHYS J, V94, P1681, DOI 10.1529/biophysj.107.116772; Cantor RS, 1997, BIOCHEMISTRY-US, V36, P2339, DOI 10.1021/bi9627323; Cantor RS, 1999, CHEM PHYS LIPIDS, V101, P45, DOI 10.1016/S0009-3084(99)00054-7; Daura X, 1998, J COMPUT CHEM, V19, P535, DOI 10.1002/(SICI)1096-987X(19980415)19:5<535::AID-JCC6>3.0.CO;2-N; DAVIS JH, 1983, BIOCHIM BIOPHYS ACTA, V737, P117, DOI 10.1016/0304-4157(83)90015-1; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Franks NP, 1997, NAT MED, V3, P377, DOI 10.1038/nm0497-377; Gullingsrud J, 2004, BIOPHYS J, V86, P3496, DOI 10.1529/biophysj.103.034322; Gurtovenko AA, 2009, J CHEM PHYS, V130, DOI 10.1063/1.3148885; Heimburg T, 2007, BIOPHYS J, V92, P3159, DOI 10.1529/biophysj.106.099754; Holtje M, 2001, BBA-BIOMEMBRANES, V1511, P156, DOI 10.1016/S0005-2736(01)00270-X; Hu MY, 2012, BIOPHYS J, V102, P1403, DOI 10.1016/j.bpj.2012.02.013; Jerabek H, 2010, J AM CHEM SOC, V132, P7990, DOI 10.1021/ja910843d; Koubi L, 2001, BIOPHYS J, V81, P3339, DOI 10.1016/S0006-3495(01)75967-X; LIEB WR, 1982, BIOCHIM BIOPHYS ACTA, V688, P388, DOI 10.1016/0005-2736(82)90350-9; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Marsh D, 2007, BIOPHYS J, V93, P3884, DOI 10.1529/biophysj.107.107938; Marsh D, 2006, CHEM PHYS LIPIDS, V144, P146, DOI 10.1016/j.chemphyslip.2006.08.004; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; Martinez-Seara H, 2008, BIOPHYS J, V95, P3295, DOI 10.1529/biophysj.108.138123; Martinez-Seara H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011162; Martinez-Seara H, 2008, J CHEM PHYS, V129, DOI 10.1063/1.2976443; MILLER KW, 1989, P NATL ACAD SCI USA, V86, P1084, DOI 10.1073/pnas.86.3.1084; MILLER KW, 1976, NATURE, V263, P253, DOI 10.1038/263253a0; Nishizawa M, 2008, BIOPHYS J, V95, P1729, DOI 10.1529/biophysj.108.130658; Ollila OHS, 2007, J STRUCT BIOL, V159, P311, DOI 10.1016/j.jsb.2007.01.012; Ollila OHS, 2010, RSC BIOMOL SCI, P26, DOI 10.1039/9781849732154-00026; Ollila OHS, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.078101; Ollila S, 2007, J PHYS CHEM B, V111, P3139, DOI 10.1021/jp065424f; Pandit SA, 2004, BIOPHYS J, V87, P1092, DOI 10.1529/biophysj.104.041939; PANG KYY, 1978, BIOCHIM BIOPHYS ACTA, V511, P1, DOI 10.1016/0005-2736(78)90060-3; Patra M, 2005, EUR BIOPHYS J BIOPHY, V35, P79, DOI 10.1007/s00249-005-0011-0; Reigada R, 2011, J PHYS CHEM B, V115, P2527, DOI 10.1021/jp110699h; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Swartz KJ, 2008, NATURE, V456, P891, DOI 10.1038/nature07620; Tang P, 2002, P NATL ACAD SCI USA, V99, P16035, DOI 10.1073/pnas.252522299; Turkyilmaz S, 2010, LANGMUIR, V26, P5309, DOI 10.1021/la100712y; Turkyilmaz S, 2009, J AM CHEM SOC, V131, P5068, DOI 10.1021/ja9011468; Ueda I, 1998, BIOPHYS J, V75, P1052, DOI 10.1016/S0006-3495(98)77594-0; Ueda Issaku, 2001, Keio Journal of Medicine, V50, P20; Watts P, 2004, 58 WHO IPCS; Xu Y, 1997, BBA-BIOMEMBRANES, V1323, P154, DOI 10.1016/S0005-2736(96)00184-8	49	19	20	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 2	2013	8	1							e52631	10.1371/journal.pone.0052631	http://dx.doi.org/10.1371/journal.pone.0052631			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	067UP	23300982	Green Submitted, Green Published, gold			2023-01-03	WOS:000313320900034
J	Tamura, Y; Nakajima, Y; Ozeki, Y; Ono, T; Takei, M; Yamamoto, T; Fukuda, K				Tamura, Yuichi; Nakajima, Yasuo; Ozeki, Yasushi; Ono, Tomohiko; Takei, Makoto; Yamamoto, Tsunehisa; Fukuda, Keiichi			Temperature Variations around Medication Cassette and Carry Bag in Routine Use of Epoprostenol Administration in Healthy Volunteers	PLOS ONE			English	Article							PULMONARY ARTERIAL-HYPERTENSION; PROSTACYCLIN; DIAGNOSIS; THERAPY; TIME	Background: According to several treatment guidelines, epoprostenol is an important treatment option for pulmonary arterial hypertension. However, the pharmacokinetic characteristics and poor stability of epoprostenol at room temperature make its administration challenging. We therefore studied temperature fluctuations between the drug administration cassette and atmosphere to promote the safe use of epoprostenol. Methods and Findings: Five healthy volunteers carried a portable intravenous infusion pump attached to a medication cassette containing saline in a bag during their ordinary activities over 16 days during which the mean atmospheric temperature was 29.6 +/- 1.5 degrees C. The temperature around the medication cassette was not less than 25 degrees C on any occasion, and the mean period over 24 h during which the temperature around the cassette exceeded 35 degrees C and 40 degrees C was 96.9 +/- 156.4 min and 24.4 +/- 77.3 min, respectively. Significant correlations were observed between the temperatures outside the bag and around the cassette, as well as between temperatures around the cassette and of the saline solution in the cassette (r = 0.9258 and 0.8276, respectively). There were no differences in the temperatures outside the bag or around the cassette with respect to the bag material. Conclusions: Temperatures around a medication cassette and outside the bag containing the medication increase with sunlight exposure. The temperature around cassettes used for administering epoprostenol must therefore be kept low for as long as possible during hot summer conditions to maintain the drug stability.	[Tamura, Yuichi; Ono, Tomohiko; Takei, Makoto; Yamamoto, Tsunehisa; Fukuda, Keiichi] Keio Univ, Sch Med, Dept Cardiol, Shinjuku Ku, Tokyo, Japan; [Nakajima, Yasuo; Ozeki, Yasushi] GlaxoSmithKline KK, Dev & Med Affairs Div, Shibuya Ku, Tokyo, Japan	Keio University; GlaxoSmithKline	Tamura, Y (corresponding author), Keio Univ, Sch Med, Dept Cardiol, Shinjuku Ku, Tokyo, Japan.	u1@ta-mu.net	Fukuda, Keiichi/L-3777-2013; Yamamoto, Tsunehisa/O-2014-2013; Tamura, Yuichi/B-5991-2014	Tamura, Yuichi/0000-0002-4437-8019; Yamamoto, Tsunehisa/0000-0002-5241-9482	GlaxoSmithKline KK	GlaxoSmithKline KK(GlaxoSmithKline)	This study was sponsored by GlaxoSmithKline KK. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akagi S, 2010, CIRC J, V74, P2200, DOI 10.1253/circj.CJ-10-0190; Al-Qudah AA, 2007, J DENT, V35, P238, DOI 10.1016/j.jdent.2006.07.012; Barst RJ, 1986, NEW ENGL J MED, V334, P296; Benza RL, 2012, CHEST, V142, P448, DOI 10.1378/chest.11-1460; Flolan [package insert], 2011, FLOL PACK INS; Galie N, 2009, EUR HEART J, V30, P2493, DOI 10.1093/eurheartj/ehp297; Marty W, 2001, AM J FOREN MED PATH, V22, P215, DOI 10.1097/00000433-200109000-00001; RUBIN LJ, 1982, CIRCULATION, V66, P334, DOI 10.1161/01.CIR.66.2.334	8	1	2	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2012	7	12							e52216	10.1371/journal.pone.0052216	http://dx.doi.org/10.1371/journal.pone.0052216			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	061EA	23300618	Green Published, gold, Green Submitted			2023-01-03	WOS:000312829100030
J	Ruas, JL; White, JP; Rao, RR; Kleiner, S; Brannan, KT; Harrison, BC; Greene, NP; Wu, J; Estall, JL; Irving, BA; Lanza, IR; Rasbach, KA; Okutsu, M; Nair, KS; Yan, Z; Leinwand, LA; Spiegelman, BM				Ruas, Jorge L.; White, James P.; Rao, Rajesh R.; Kleiner, Sandra; Brannan, Kevin T.; Harrison, Brooke C.; Greene, Nicholas P.; Wu, Jun; Estall, Jennifer L.; Irving, Brian A.; Lanza, Ian R.; Rasbach, Kyle A.; Okutsu, Mitsuharu; Nair, K. Sreekumaran; Yan, Zhen; Leinwand, Leslie A.; Spiegelman, Bruce M.			A PGC-1 alpha Isoform Induced by Resistance Training Regulates Skeletal Muscle Hypertrophy	CELL			English	Article							TRANSCRIPTIONAL COACTIVATOR PGC-1-ALPHA; MICE; GROWTH; MASS; HOMEOSTASIS; EXPRESSION; PROTECTS; ATROPHY; FIBERS; DRIVES	PGC-1 alpha is a transcriptional coactivator induced by exercise that gives muscle many of the best known adaptations to endurance-type exercise but has no effects on muscle strength or hypertrophy. We have identified a form of PGC-1 alpha (PGC-1 alpha 4) that results from alternative promoter usage and splicing of the primary transcript. PGC-1 alpha 4 is highly expressed in exercised muscle but does not regulate most known PGC-1 alpha targets such as the mitochondrial OXPHOS genes. Rather, it specifically induces IGF1 and represses myostatin, and expression of PGC-1 alpha 4 in vitro and in vivo induces robust skeletal muscle hypertrophy. Importantly, mice with skeletal muscle-specific transgenic expression of PGC-1 alpha 4 show increased muscle mass and strength and dramatic resistance to the muscle wasting of cancer cachexia. Expression of PGC-1 alpha 4 is preferentially induced in mouse and human muscle during resistance exercise. These studies identify a PGC-1 alpha protein that regulates and coordinates factors involved in skeletal muscle hypertrophy.	[Ruas, Jorge L.; White, James P.; Rao, Rajesh R.; Kleiner, Sandra; Brannan, Kevin T.; Wu, Jun; Estall, Jennifer L.; Rasbach, Kyle A.; Spiegelman, Bruce M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Cell Biol, Boston, MA 02115 USA; [Harrison, Brooke C.; Leinwand, Leslie A.] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA; [Greene, Nicholas P.; Okutsu, Mitsuharu; Yan, Zhen] Univ Virginia, Dept Med, Charlottesville, VA 22908 USA; [Irving, Brian A.; Lanza, Ian R.; Nair, K. Sreekumaran] Mayo Clin, Div Endocrinol, Endocrine Res Unit, Rochester, MN 55905 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Colorado System; University of Colorado Boulder; University of Virginia; Mayo Clinic	Ruas, JL (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden.	jorge.ruas@ki.se; bruce_spiegelman@dfci.harvard.edu	Ruas, Jorge/AAE-6094-2019; Irving, Brian/B-9683-2016; Greene, Nicholas/G-7399-2015; Greene, Nicholas/A-6076-2013	Ruas, Jorge/0000-0002-1110-2606; Irving, Brian/0000-0002-4131-9523; Greene, Nicholas/0000-0002-9504-9362; Yan, Zhen/0000-0002-4826-9813; LEINWAND, LESLIE/0000-0003-1470-4810; Lanza, Ian/0000-0002-9858-3384; Estall, Jennifer/0000-0002-9838-1440; Greene, Nicholas/0000-0001-9621-2005	NIH [DK061562, 5K01AR55676-2, T32HL07284, AR050429, GM29090]; Novartis; Wenner-Gren Foundations, Sweden; AHA [09POST2010078, 12SDG8070003]; Novartis, Inc.;  [RR024151];  [AG09531]; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024151] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL119937, T32HL007284] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050429, K01AR055676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK054477, K01DK094824, R01DK061562] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029090] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009531] Funding Source: NIH RePORTER; Novo Nordisk Fonden [NNF12OC1016062] Funding Source: researchfish	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Novartis(Novartis); Wenner-Gren Foundations, Sweden; AHA(American Heart Association); Novartis, Inc.; ; ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Novo Nordisk Fonden(Novo Nordisk Foundation)	We thank Drs. Srikripa Devarakonda and Sibylle Jager for valuable discussions. ERR alpha and ERR gamma KO myoblasts were a kind gift from Dr. Zhidan Wu (Novartis Institutes for Biomedical Research). The MEF2C/Myogenin promoter cassette was kindly provided by Dr. Eric Olson (University of Texas Southwestern Medical Center). LLC cells were kindly donated by Dr. Jose M. Garcia (Baylor College of Medicine). This project was supported by grants (DK061562) from the NIH and from Novartis to B.M.S. J.L.R. was supported in part by a grant from the Wenner-Gren Foundations, Sweden. This research was supported in part by grants to B. C. H. (NIH, 5K01AR55676-2), N.P.G. (NIH, T32HL07284), J.W. (AHA, 09POST2010078 and 12SDG8070003), B.A.I. (RR024151 and AG09531), Z.Y. (NIH, AR050429), and L. A. L. (NIH, GM29090). B. M. S. is a shareholder and consultant to Ember Therapeutics and has received funding in the form of sponsored research from Novartis, Inc.	Adams GR, 2002, J APPL PHYSIOL, V93, P1159, DOI 10.1152/japplphysiol.01264.2001; Arany Z, 2008, CURR OPIN GENET DEV, V18, P426, DOI 10.1016/j.gde.2008.07.018; Arany Z, 2007, CELL METAB, V5, P35, DOI 10.1016/j.cmet.2006.12.003; Axell AM, 2006, AM J PHYSIOL-ENDOC M, V291, pE506, DOI 10.1152/ajpendo.00058.2006; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Busquets S, 2012, J CACHEXIA SARCOPENI, V3, P37, DOI 10.1007/s13539-011-0049-z; Chakkalakal JV, 2010, DEVELOPMENT, V137, P3489, DOI 10.1242/dev.053348; Chinsomboon J, 2009, P NATL ACAD SCI USA, V106, P21401, DOI 10.1073/pnas.0909131106; Choi CS, 2008, P NATL ACAD SCI USA, V105, P19926, DOI 10.1073/pnas.0810339105; Das SK, 2011, SCIENCE, V333, P233, DOI 10.1126/science.1198973; Dinchuk JE, 2010, ENDOCRINOLOGY, V151, P4123, DOI 10.1210/en.2010-0032; Fearon KCH, 2012, CELL METAB, V16, P153, DOI 10.1016/j.cmet.2012.06.011; FLORINI JR, 1987, MUSCLE NERVE, V10, P577, DOI 10.1002/mus.880100702; Gentry B, 2011, MUSCLE NERVE, V43, P49, DOI 10.1002/mus.21796; Giguere V, 2008, ENDOCR REV, V29, P677, DOI 10.1210/er.2008-0017; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Handschin C, 2007, J CLIN INVEST, V117, P3463, DOI 10.1172/JCI31785; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Iezzi S, 2004, DEV CELL, V6, P673, DOI 10.1016/S1534-5807(04)00107-8; Lee SJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000789; Lee SJ, 2004, ANNU REV CELL DEV BI, V20, P61, DOI 10.1146/annurev.cellbio.20.012103.135836; Li SJ, 2005, P NATL ACAD SCI USA, V102, P1082, DOI 10.1073/pnas.0409103102; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; MCMILLAN DN, 1992, J ANIM SCI, V70, P3014, DOI 10.2527/1992.70103014x; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Megeney LA, 1996, DEV GENET, V19, P139, DOI 10.1002/(SICI)1520-6408(1996)19:2<139::AID-DVG5>3.0.CO;2-A; Mendias CL, 2006, J APPL PHYSIOL, V101, P898, DOI 10.1152/japplphysiol.00126.2006; Mir LM, 1999, P NATL ACAD SCI USA, V96, P4262, DOI 10.1073/pnas.96.8.4262; Nair KS, 2005, AM J CLIN NUTR, V81, P953; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Sandri M, 2006, P NATL ACAD SCI USA, V103, P16260, DOI 10.1073/pnas.0607795103; Schiaffino S, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-4; Short KR, 2003, DIABETES, V52, P1888, DOI 10.2337/diabetes.52.8.1888; Tadaishi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028290; Wende AR, 2007, J BIOL CHEM, V282, P36642, DOI 10.1074/jbc.M707006200; Wenz T, 2009, P NATL ACAD SCI USA, V106, P20405, DOI 10.1073/pnas.0911570106; White JP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024650; Yoshioka T, 2009, J MATER CYCLES WASTE, V11, P1, DOI 10.1007/s10163-008-0223-3; Zhang YB, 2009, J BIOL CHEM, V284, P32813, DOI 10.1074/jbc.M109.037556	40	435	455	3	74	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 7	2012	151	6					1319	1331		10.1016/j.cell.2012.10.050	http://dx.doi.org/10.1016/j.cell.2012.10.050			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	049RA	23217713	Bronze, Green Accepted			2023-01-03	WOS:000311999900020
J	Spence, D				Spence, Des			How the Liverpool care pathway has transformed end of life care	BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk						Bowater D., 2012, TELEGRAPH; Doughty, 2012, DAILY MAIL	2	4	4	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	OCT 31	2012	345								e7308	10.1136/bmj.e7308	http://dx.doi.org/10.1136/bmj.e7308			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	033FF	23114070				2023-01-03	WOS:000310778900012
J	Yang, WY; Zhao, WH; Xiao, JZ; Li, R; Zhang, P; Kissimova-Skarbek, K; Schneider, E; Jia, WP; Ji, LN; Guo, XH; Shan, ZY; Liu, J; Tian, HM; Chen, L; Zhou, ZG; Ji, QH; Ge, JP; Chen, G; Brown, J				Yang, Wenying; Zhao, Wenhui; Xiao, Jianzhong; Li, Rui; Zhang, Ping; Kissimova-Skarbek, Katarzyna; Schneider, Erin; Jia, Weiping; Ji, Linong; Guo, Xiaohui; Shan, Zhongyan; Liu, Jie; Tian, Haoming; Chen, Li; Zhou, Zhiguang; Ji, Qiuhe; Ge, Jiapu; Chen, Gang; Brown, Jonathan			Medical Care and Payment for Diabetes in China: Enormous Threat and Great Opportunity	PLOS ONE			English	Article							PRESSURE-LOWERING DRUGS; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; COST-EFFECTIVENESS; LOW-INCOME; FOLLOW-UP; PREVENTION; MELLITUS; PREVALENCE; BURDEN	Background: The Diabetes Impact Study followed up a large national population-based screening study to estimate the use of and expenditures for medical care caused by diabetes in China and to ascertain the use and cost of essential basic medicines and care. Methods: In 2009-10, the study team interviewed 1482 adults with diabetes and 1553 adults with glucose tolerance in the normal range from population-based random samples at 12 sites in China. The response rate was 67%. Findings: After adjusting for age, sex, and urban/rural location, people with diabetes received 1.93 times more days of inpatient treatment, 2.40 times more outpatient visits, and 3.35 times more medications than people with normal glucose tolerance (all p<0.05). Adjusted expenditures for medical care were 3.38 times higher among people with diabetes than among people with normal glucose tolerance (p<0.01, unadjusted 3.97). Persons who were diagnosed with >= 10 years prior to the survey paid 3.75 times as much for medical care as those with <= 5 years of diagnosed diabetes. Among persons with diabetes, 45.2% took medication to control blood sugar, 21.1% took an antihypertensive medicine, 22.4% took daily aspirin, and 1.8% took a statin. Over the three months before the interview, 46.1% of persons with diabetes recalled seeing a doctor, 48.9% recalled a blood pressure measurement, and 54.5% recalled a blood sugar test. Over the year preceding the interview, 32.1% recalled a retinal screening and 17.9% recalled a foot examination. Conclusions: In China, health care use and costs were dramatically higher for people with diabetes than for people with normal glucose tolerance and, in relative terms, much higher than in industrialized countries. Low-cost generic medicines that would reduce diabetes expenditures were not fully used.	[Kissimova-Skarbek, Katarzyna; Schneider, Erin; Brown, Jonathan] Int Diabet Federat, Brussels, Belgium; [Yang, Wenying; Zhao, Wenhui; Xiao, Jianzhong] Chinese Japanese Friendship Hosp, Beijing, Peoples R China; [Zhao, Wenhui] Peking Union Med Coll, Grad Sch, Beijing 100021, Peoples R China; [Zhao, Wenhui] Chinese Acad Med Sci, Beijing 100730, Peoples R China; [Li, Rui; Zhang, Ping] Ctr Dis Control & Prevent, Atlanta, GA USA; [Kissimova-Skarbek, Katarzyna] Jagiellonian Univ, Coll Med, Inst Publ Hlth, Krakow, Poland; [Schneider, Erin] Natl Bur Asian Res, Seattle, WA USA; [Jia, Weiping] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Shanghai 200030, Peoples R China; [Ji, Linong] Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China; [Guo, Xiaohui] Peking Univ, Hosp 1, Beijing 100871, Peoples R China; [Shan, Zhongyan] Chinese Med Univ, Affiliated Hosp 1, Shenyang, Liaoling, Peoples R China; [Liu, Jie] Shanxi Prov Peoples Hosp, Taiyuan, Shaanxi, Peoples R China; [Tian, Haoming] Sichuan Univ, W China Hosp, Chengdu 610064, Sichuan, Peoples R China; [Chen, Li] Shandong Univ, Qilu Hosp, Jinan 250100, Shandong, Peoples R China; [Zhou, Zhiguang] Xiangya Second Hosp, Changsha, Hunan, Peoples R China; [Ji, Qiuhe] Fourth Mil Med Univ, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China; [Ge, Jiapu] Xinjiang Uygur Autonomous Reg Hosp, Urumqi, Xinjiang, Peoples R China; [Chen, Gang] Fujian Prov Hosp, Fuzhou, Fujiang, Peoples R China	China-Japan Friendship Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Centers for Disease Control & Prevention - USA; Jagiellonian University; Collegium Medicum Jagiellonian University; Shanghai Jiao Tong University; Peking University; Peking University; China Medical University; Shanxi People's Hospital; Sichuan University; Shandong University; Central South University; Air Force Military Medical University; Fujian Provincial Hospital	Brown, J (corresponding author), Int Diabet Federat, Brussels, Belgium.	jonabrown@gmail.com	Linong, Ji/AAB-6543-2020	Zhou, Zhiguang/0000-0002-0374-1838; Kissimova-Skarbek, Katarzyna/0000-0003-4624-0918	Economic Study Fund of the International Diabetes Federation (IDF); Chinese Diabetes Society; Merck and Co.; Novo Nordisk; Eli Lilly and Co.; Takeda Pharmaceuticals North America; GSK, Inc.; GSK; Eli Lilly; Merck; Roche and Co.	Economic Study Fund of the International Diabetes Federation (IDF); Chinese Diabetes Society; Merck and Co.(Merck & Company); Novo Nordisk(Novo Nordisk); Eli Lilly and Co.(Eli Lilly); Takeda Pharmaceuticals North America(Takeda Pharmaceutical Company Ltd); GSK, Inc.; GSK(GlaxoSmithKline); Eli Lilly(Eli Lilly); Merck(Merck & Company); Roche and Co.	This study was funded by allocations from the Economic Study Fund of the International Diabetes Federation (IDF), a not-for-profit NGO headquartered in Brussels, Belgium, and from the Chinese Diabetes Society. The IDF's Economic Studies Fund was created from contributions that IDF solicited from Merck and Co., Novo Nordisk, Eli Lilly and Co., Takeda Pharmaceuticals North America, and GSK, Inc. These funders had no role in study design, data collection and analysis, decision to publish, preparation of the manuscript, or selection of countries in which economic impact studies were conducted. Additional resources, in the form of volunteer time, logistical support, and expertise were provided by the 12 study sites in China, by the Chinese Diabetes Society, by the Chinese-Japanese Friendship Hospital, by the Kaiser Permanente Center for Health Research, by the United States Centers for Disease Control and Prevention, by the International Diabetes Federation, and by the authors.; Before retirement in 11/09 J. Brown led or could have led studies funded by research contracts with Novo Nordisk, GSK, Takeda Pharmaceuticals North America, Eli Lilly, and Merck. J. Brown had no consulting or other paid or unpaid arrangements with these or other actual or potential commercial funders. Starting in 2002 J. Brown led the creation of the IDF Economic Studies Fund with funds from Novo Nordisk, GSK, Takeda, Eli Lilly, and Merck. As per the rules of the Fund established before solicitation, the funders did not participate in decisions regarding countries to be studied or in doing, analyzing or writing up any study. Since election in Oct 2009 as unpaid IDF VP, J. Brown has accepted no grants or contracts or gifts or employment from any drug or device firms and has not accepted any positions on their editorial or advisory groups. In 2010, J. Brown accepted travel reimbursement from Novo Nordisk to speak at the 6th International Symposium on Diabetes and Pregnancy. In 2009, at the request of IDF, J. Brown accepted reimbursement from IDF to speak at a satellite meeting of ADA sponsored by Roche and Co. Drs. Ping Zhang and Rui Li worked on this project on their own time while in the employ of the United States Center for Disease Control. Drs. Zhang and Li declare that no potential competing interests exist. During most of this study Dr. Skarbek was an employee of the IDF. IDF is supported financially by many commercial entities. She declares that no competing interests exist. All other authors have no potentially competing interests. The authors declare that none of the competing interests described above will alter the authors' adherence to all the PLOS One policies on sharing data and materials.	Abegunde DO, 2007, LANCET, V370, P1929, DOI 10.1016/S0140-6736(07)61696-1; Banister J, 2010, 53 HARV PROGR GLOB D; Beaglehole R, 2011, LANCET, V378, P449, DOI 10.1016/S0140-6736(11)60879-9; Brown JB, 1999, DIABETES CARE, V22, P1116, DOI 10.2337/diacare.22.7.1116; Chen XB, 2003, CHIN J DIABETES, V11, P238; Gaziano TA, 2006, LANCET, V368, P679, DOI 10.1016/S0140-6736(06)69252-0; Gong Q, 2011, DIABETOLOGIA, V54, P300, DOI 10.1007/s00125-010-1948-9; Harbage B, 1999, AM J PREV MED, V16, P314, DOI 10.1016/S0749-3797(98)00101-9; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470; Holman RR, 2008, NEW ENGL J MED, V359, P1565, DOI 10.1056/NEJMoa0806359; Hu J-P, 2007, CHIN J PREV CHRONIC, V15, P4; Human Development Unit East Asia and Pacific Region World Bank, 2011, 62318CN WORLD BANK; IDF Clinical Guidelines Task Force, 2005, GLOB GUID TYP 2 DIAB; International Diabetes Federation, 2011, IDF DIAB ATL; Jonsson B, 1998, DIABETES CARE, V21, pC7, DOI 10.2337/diacare.21.3.C7; Koster I, 2006, DIABETOLOGIA, V49, P1498, DOI 10.1007/s00125-006-0277-5; Law MR, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1665; Law MR, 2003, BRIT MED J, V326, P1427, DOI 10.1136/bmj.326.7404.1427; Leeder S, 2004, RACE TIME CHALLENGE; Li R, 2010, DIABETES CARE, V33, P1872, DOI 10.2337/dc10-0843; Lim SS, 2007, LANCET, V370, P2054, DOI 10.1016/S0140-6736(07)61699-7; Mohan V, 2006, DIABETOLOGIA, V49, P1175, DOI 10.1007/s00125-006-0219-2; Narayan KMV, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P591; Nichols G, 2006, INT DIAB FED TRIENN; Nolan CJ, 2011, LANCET, V378, P169, DOI 10.1016/S0140-6736(11)60614-4; Petersen M, 2008, DIABETES CARE, V31, P1271, DOI 10.2337/dc08-9017; Petrou S, 2002, INT J TECHNOL ASSESS, V18, P705, DOI 10.1017/S026646230200051X; Rodgers A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019857; Roseboom TJ, 2011, MATURITAS, V70, P141, DOI 10.1016/j.maturitas.2011.06.017; Selby JV, 1997, DIABETES CARE, V20, P1396, DOI 10.2337/diacare.20.9.1396; Taylor F, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004816.pub4; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; Wang J, 2008, CHIL HLTH QUAL MANAG, V15, P65; Wang WB., 2008, CHIN HLTH RESOUR, V11, P127, DOI DOI 10.3969/J.ISSN.1007-953X.2008.03.013; Wang WB, 2009, AM J MANAG CARE, V15, P593; World Health Organization, 2010, GLOBAL RECOMMENDATIO, P18; Yang WY, 2010, NEW ENGL J MED, V362, P1090, DOI 10.1056/NEJMoa0908292; Yusuf S, 2009, LANCET, V373, P1341, DOI 10.1016/S0140-6736(09)60611-5; Zeileis A, 2008, J STAT SOFTW, V27, P1, DOI 10.18637/jss.v027.i08; Zhang P, 2010, DIABETES RES CLIN PR, V87, P293, DOI 10.1016/j.diabres.2010.01.026; Zhang Z, 2007, CHINESE HLTH RESOURC, V10, P162	41	57	61	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2012	7	9							e39513	10.1371/journal.pone.0039513	http://dx.doi.org/10.1371/journal.pone.0039513			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	016KP	23049727	Green Published, gold, Green Submitted			2023-01-03	WOS:000309517300002
J	Aomatsu, N; Yashiro, M; Kashiwagi, S; Takashima, T; Ishikawa, T; Ohsawa, M; Wakasa, K; Hirakawa, K				Aomatsu, Naoki; Yashiro, Masakazu; Kashiwagi, Shinichiro; Takashima, Tsutomu; Ishikawa, Tetsuro; Ohsawa, Masahiko; Wakasa, Kenichi; Hirakawa, Kosei			CD133 Is a Useful Surrogate Marker for Predicting Chemosensitivity to Neoadjuvant Chemotherapy in Breast Cancer	PLOS ONE			English	Article							SURGICAL ADJUVANT BREAST; STEM-CELLS; PROSPECTIVE IDENTIFICATION; PREOPERATIVE DOXORUBICIN; PATHOLOGICAL RESPONSE; GENE-EXPRESSION; PHASE-II; DOCETAXEL; CYCLOPHOSPHAMIDE; THERAPY	Background: Neoadjuvant chemotherapy (NAC) is a standard care regimen for patients with breast cancer. However, the pathologic complete response (pCR) rate remains at 30%. We hypothesized that a cancer stem cell marker may identify NAC-resistant patients, and evaluated CD133 and ALDH1 as a potential surrogate marker for breast cancer. The aim of this study was to find a surrogate maker to predict chemosensitivity of NAC for breast cancer. Methodology/Findings: A total of 102 patients with breast cancer were treated with NAC consisting of epirubicin followed by paclitaxel. Core needle biopsy (CNB) specimens and resected tumors were obtained from all patients before and after NAC, respectively. Chemosensitivity and prognostic potential of CD133 or ALDH1 expression was evaluated by immunohistochemistry. Clinical CR (cCR) and pCR rates were 18% (18/102) and 29% (30/102), respectively. Forty-seven (46%) patients had CD133-positive tumors before NAC, and CD133 expression was significantly associated with a low pCR rate (p = 0.035) and clinical non-responders. Multivariate analysis revealed that CD133 expression was significantly (p = 0.03) related to pCR. Recurrence was more frequent in patients with CD133-positive tumors (21/47, 45%) than that in patients with CD133-negative tumors (7/55, 13%). The number of patients with CD133-positive tumors (62%) after NAC was higher than that (46%) before NAC. Furthermore, most patients with CD133-positive tumors before NAC maintained the same status after NAC. Conclusion/Significance: CD133 before NAC might be a useful marker for predicting the effectiveness of NAC and recurrence of breast cancer after NAC.	[Aomatsu, Naoki; Yashiro, Masakazu; Kashiwagi, Shinichiro; Takashima, Tsutomu; Ishikawa, Tetsuro; Hirakawa, Kosei] Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Osaka 558, Japan; [Yashiro, Masakazu] Osaka City Univ, Grad Sch Med, Oncol Inst Geriatr & Med Sci, Osaka 558, Japan; [Ohsawa, Masahiko; Wakasa, Kenichi] Osaka City Univ, Dept Diagnost Pathol, Grad Sch Med, Abeno Ku, Osaka 558, Japan	Osaka Metropolitan University; Osaka Metropolitan University; Osaka Metropolitan University	Yashiro, M (corresponding author), Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Osaka 558, Japan.	m9312510@med.osaka-cu.ac.jp	Kashiwagi, Shinichiro/AAE-5243-2020; Kashiwagi, Shinichiro/AAC-7070-2019	Kashiwagi, Shinichiro/0000-0002-0460-9599; Kashiwagi, Shinichiro/0000-0002-0460-9599	Ministry of Education, Science, Sports, Culture and Technology of Japan [20591573, 22390262, 23390329]	Ministry of Education, Science, Sports, Culture and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was supported in part by Grants-in Aid for Scientific Research (KAKENHI, nos. 20591573, 22390262, and 23390329) from the Ministry of Education, Science, Sports, Culture and Technology of Japan. No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bear HD, 2006, J CLIN ONCOL, V24, P2019, DOI 10.1200/JCO.2005.04.1665; Bear HD, 2003, J CLIN ONCOL, V21, P4165, DOI 10.1200/JCO.2003.12.005; Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Chollet P, 2002, BRIT J CANCER, V86, P1041, DOI 10.1038/sj/bjc/6600210; Chuthapisith S, 2006, SURG-J R COLL SURG E, V4, P211, DOI 10.1016/S1479-666X(06)80062-4; Colleoni M, 2004, CLIN CANCER RES, V10, P6622, DOI 10.1158/1078-0432.CCR-04-0380; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Deng S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010277; Estevez LG, 2003, CLIN CANCER RES, V9, P686; Evans TRJ, 2005, J CLIN ONCOL, V23, P2988, DOI 10.1200/JCO.2005.06.156; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Fisher B, 1997, J CLIN ONCOL, V15, P2483, DOI 10.1200/JCO.1997.15.7.2483; Fisher CS, 2012, ANN SURG ONCOL, V19, P253, DOI 10.1245/s10434-011-1877-y; Ghods AJ, 2007, STEM CELLS, V25, P1645, DOI 10.1634/stemcells.2006-0624; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Goldhirsch A, 2007, ANN ONCOL, V18, P1133, DOI 10.1093/annonc/mdm271; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108; Horiguchi Kazumi, 2010, Journal of Medical and Dental Sciences, V57, P165; Jones RL, 2006, LANCET ONCOL, V7, P869, DOI 10.1016/S1470-2045(06)70906-8; Kai K, 2010, BREAST CANCER-TOKYO, V17, P80, DOI 10.1007/s12282-009-0176-y; Kurosumi M, 2008, BREAST CANCER-TOKYO, V15, P5, DOI 10.1007/s12282-007-0016-x; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Liu Q, 2009, CHINESE MED J-PEKING, V122, P2763, DOI 10.3760/cma.j.issn.0366-6999.2009.22.017; Lorico A, 2011, J ONCOL, V2011, DOI 10.1155/2011/135039; Mayer EL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1755; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; Neuzil J, 2007, BIOCHEM BIOPH RES CO, V355, P855, DOI 10.1016/j.bbrc.2007.01.159; Nishimura R, 2010, BREAST CANCER-TOKYO, V17, P269, DOI 10.1007/s12282-009-0161-5; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Resetkova E, 2010, BREAST CANCER RES TR, V123, P97, DOI 10.1007/s10549-009-0619-3; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Rody A, 2007, BREAST, V16, P86, DOI 10.1016/j.breast.2006.06.008; Ross JS, 2005, ADV CLIN CHEM, V40, P99, DOI 10.1016/S0065-2423(05)40003-7; Sachelarie I, 2006, ONCOLOGIST, V11, P574, DOI 10.1634/theoncologist.11-6-574; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Singletary S Eva, 2003, Semin Surg Oncol, V21, P53, DOI 10.1002/ssu.10021; Smith IC, 2002, J CLIN ONCOL, V20, P1456, DOI 10.1200/JCO.20.6.1456; Smith LM, 2008, BRIT J CANCER, V99, P100, DOI 10.1038/sj.bjc.6604437; Storci G, 2008, J PATHOL, V214, P25, DOI 10.1002/path.2254; Tanei T, 2009, CLIN CANCER RES, V15, P4234, DOI 10.1158/1078-0432.CCR-08-1479; Tang C, 2007, FASEB J, V21, P3777, DOI 10.1096/fj.07-8560rev; Toi M, 2008, BREAST CANCER RES TR, V110, P531, DOI 10.1007/s10549-007-9744-z; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Wolmark N, 2001, J Natl Cancer Inst Monogr, P96; Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855; Xiao Y, 2008, AM J PATHOL, V173, P561, DOI 10.2353/ajpath.2008.071214; Zhao P, 2011, CANCER SCI, V102, P1107, DOI 10.1111/j.1349-7006.2011.01894.x	52	43	46	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2012	7	9							e45865	10.1371/journal.pone.0045865	http://dx.doi.org/10.1371/journal.pone.0045865			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	016YP	23049880	Green Published, gold, Green Submitted			2023-01-03	WOS:000309556100093
J	Rummel, MJ; Niederle, N; Maschmeyer, G; Banat, GA; von Grunhagen, U; Losem, C; Kofahl-Krause, D; Heil, G; Welslau, M; Balser, C; Kaiser, U; Weidmann, E; Durk, H; Ballo, H; Stauch, M; Roller, F; Barth, J; Hoelzer, D; Hinke, A; Brugger, W				Rummel, Mathias J.; Niederle, Norbert; Maschmeyer, Georg; Banat, G. Andre; von Gruenhagen, Ulrich; Losem, Christoph; Kofahl-Krause, Dorothea; Heil, Gerhard; Welslau, Manfred; Balser, Christina; Kaiser, Ulrich; Weidmann, Eckhart; Duerk, Heinz; Ballo, Harald; Stauch, Martina; Roller, Fritz; Barth, Juergen; Hoelzer, Dieter; Hinke, Axel; Brugger, Wolfram		Study Grp Indolent Lymphomas StiL	Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial	LANCET			English	Article							ADVANCED FOLLICULAR LYMPHOMA; NON-HODGKINS-LYMPHOMA; B-CELL; II MULTICENTER; CHEMOTHERAPY; SURVIVAL; CYCLOPHOSPHAMIDE; MAINTENANCE; VINCRISTINE; COMBINATION	Background Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is the first-line standard of care for patients with advanced indolent lymphoma, and for elderly patients with mantle-cell lymphoma. Bendamustine plus rituximab is effective for relapsed or refractory disease. We compared bendamustine plus rituximab with CHOP plus rituximab (R-CHOP) as first-line treatment for patients with indolent and mantle-cell lymphomas. Methods We did a prospective, multicentre, randomised, open-label, non-inferiority trial at 81 centres in Germany between Sept 1, 2003, and Aug 31, 2008. Patients aged 18 years or older with a WHO performance status of 2 or less were eligible if they had newly diagnosed stage III or IV indolent or mantle-cell lymphoma. Patients were stratified by histological lymphoma subtype, then randomly assigned according to a prespecified randomisation list to receive either intravenous bendamustine (90 mg/m(2) on days 1 and 2 of a 4-week cycle) or CHOP (cycles every 3 weeks of cyclophosphamide 750 mg/m(2), doxorubicin 50 mg/m(2), and vincristine 1.4 mg/m(2) on day 1, and prednisone 100 mg/day for 5 days) for a maximum of six cycles. Patients in both groups received rituximab 375 mg/m(2) on day 1 of each cycle. Patients and treating physicians were not masked to treatment allocation. The primary endpoint was progression-free survival, with a non-inferiority margin of 10%. Analysis was per protocol. This study is registered with ClinicalTrials.gov, number NCT00991211, and the Federal Institute for Drugs and Medical Devices of Germany, BfArM 4021335. Findings 274 patients were assigned to bendamustine plus rituximab (261 assessed) and 275 to R-CHOP (253 assessed). At median follow-up of 45 months (IQR 25-57), median progression-free survival was significantly longer in the bendamustine plus rituximab group than in the R-CHOP group (69.5 months [26.1 to not yet reached] vs 31.2 months [15.2-65.7]; hazard ratio 0.58, 95% CI 0.44-0.74; p<0.0001). Bendamustine plus rituximab was better tolerated than R-CHOP, with lower rates of alopecia (0 patients vs 245 (100%) of 245 patients who recieved >= 3 cycles; p<0.0001), haematological toxicity (77 [30%] vs 173 [68%]; p<0.0001), infections (96 [37%] vs 127 [50%]); p=0.0025), peripheral neuropathy (18 [7%] vs 73 [29%]; p<0.0001), and stomatitis (16 [6%] vs 47 [19%]; p<0.0001). Erythematous skin reactions were more common in patients in the bendamustine plus rituximab group than in those in the R-CHOP group (42 [16%] vs 23 [9%]; p=0.024). Interpretation In patients with previously untreated indolent lymphoma, bendamustine plus rituximab can be considered as a preferred first-line treatment approach to R-CHOP because of increased progression-free survival and fewer toxic effects.	[Rummel, Mathias J.; Banat, G. Andre; Barth, Juergen] Hosp Justus Liebig Univ, Med Klin 4, Giessen, Germany; [Roller, Fritz] Hosp Justus Liebig Univ, Dept Radiol, Giessen, Germany; [Niederle, Norbert] Klinikum Leverkusen, Leverkusen, Germany; [Maschmeyer, Georg] Klinikum Ernst Von Bergmann, Potsdam, Germany; [Kofahl-Krause, Dorothea] Hannover Med Sch, Hannover, Germany; [Heil, Gerhard] Klinikum Ludenscheid, Ludenscheid, Germany; [Kaiser, Ulrich] St Bernward Krankenhaus, Hildesheim, Germany; [Weidmann, Eckhart] Krankenhaus NW Frankfurt, Frankfurt, Germany; [Duerk, Heinz] St Marien Hosp, Hamm, Germany; [Hoelzer, Dieter] Hosp Johann Wolfgang Goethe Univ, Frankfurt, Germany; [Hinke, Axel] Wissenschaftlicher Serv Pharma GmbH, Langenfeld, Germany; [Brugger, Wolfram] Univ Freiburg, Acad Teaching Hosp, Schwarzwald Baar Klinikum Villingen Schwenningen, D-79106 Freiburg, Germany	Klinikum Ernst von Bergmann; Hannover Medical School; Krankenhaus Nordwest; St. Marien Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Freiburg	Rummel, MJ (corresponding author), Univ Hosp, Med Klin 4, D-35392 Giessen, Germany.	mathias.rummel@innere.med.uni-giessen.de			Roche Pharma AG; Ribosepharm/Mundipharma GmbH; Roche; Mundipharma	Roche Pharma AG(Roche Holding); Ribosepharm/Mundipharma GmbH; Roche(Roche Holding); Mundipharma	Roche Pharma AG, Ribosepharm/Mundipharma GmbH.; MJR has received honoraria and research grants from Roche and Mundipharma. WB has received honoraria from Roche and Mundipharma. All other authors declare that they have no conflicts of interest.; Roche Pharma AG and Ribosepharm/Mundipharma GmbH provided financial support for this study. We thank the study investigators, coordinators, nurses, and patients and their families for their contributions; the team of the StiL study group office, including Caroline Zorb, Elke Metzler, and Helene Weikum, and in particular Ingeborg Dietz for her long-term support; and Mark Smith of Gardiner-Caldwell Communications (Stockport, UK) for editorial assistance.	[Anonymous], 2010, STAT FACT SHEETS NON; Cheson BD, 2009, J CLIN ONCOL, V27, P1492, DOI 10.1200/JCO.2008.18.7252; Czuczman MS, 1999, J CLIN ONCOL, V17, P268, DOI 10.1200/JCO.1999.17.1.268; Dreyling M, 2008, ANN ONCOL, V19, P41, DOI 10.1093/annonc/mdn193; Dreyling M, 2009, ANN ONCOL, V20, P119, DOI 10.1093/annonc/mdp148; Friedberg JW, 2008, J CLIN ONCOL, V26, P204, DOI 10.1200/JCO.2007.12.5070; Friedberg JW, 2009, J CLIN ONCOL, V27, P1202, DOI 10.1200/JCO.2008.18.1495; Ghielmini M, 2013, ANN ONCOL, V24, P561, DOI [10.1093/annonc/mds517, 10.1093/annonc/mdr388]; Harris NL, 1999, ANN ONCOL, V10, P1419, DOI 10.1023/A:1008375931236; Herold M, 2007, J CLIN ONCOL, V25, P1986, DOI 10.1200/JCO.2006.06.4618; Hesketh PJ, 2004, SUPPORT CARE CANCER, V12, P543, DOI 10.1007/s00520-003-0562-5; Hiddemann W, 2005, BLOOD, V106, P3725, DOI 10.1182/blood-2005-01-0016; Horning SJ, 2008, J CLIN ONCOL, V26, P4537, DOI 10.1200/JCO.2008.16.1398; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kahl BS, 2010, CANCER-AM CANCER SOC, V116, P106, DOI 10.1002/cncr.24714; Marcus R, 2005, BLOOD, V105, P1417, DOI 10.1182/blood-2004-08-3175; Marcus R, 2008, J CLIN ONCOL, V26, P4579, DOI 10.1200/JCO.2007.13.5376; Robinson KS, 2008, J CLIN ONCOL, V26, P4473, DOI 10.1200/JCO.2008.17.0001; Rummel MJ, 2005, J CLIN ONCOL, V23, P3383, DOI 10.1200/JCO.2005.08.100; Salles G, 2011, LANCET, V377, P42, DOI 10.1016/S0140-6736(10)62175-7; Salles G, 2008, BLOOD, V112, P4824, DOI 10.1182/blood-2008-04-153189; Schulz H, 2007, JNCI-J NATL CANCER I, V99, P706, DOI 10.1093/jnci/djk152; Solal-Celigny P, 2004, BLOOD, V104, P1258, DOI 10.1182/blood-2003-12-4434; Weiner GJ, 2010, SEMIN HEMATOL, V47, P115, DOI 10.1053/j.seminhematol.2010.01.011; Zelenetz AD, 2010, J NATL COMPR CANC NE, V8, P288, DOI 10.6004/jnccn.2010.0021	25	956	993	3	60	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 6	2013	381	9873					1203	1210		10.1016/S0140-6736(12)61763-2	http://dx.doi.org/10.1016/S0140-6736(12)61763-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122WU	23433739				2023-01-03	WOS:000317350100030
J	Ji, LN; Tong, XL; Wang, HY; Tian, HM; Zhou, HM; Zhang, LL; Li, QF; Wang, YZ; Li, HM; Liu, M; Yang, HJ; Gao, YB; Li, Y; Li, QM; Guo, XH; Yang, GY; Zhang, ZG; Zhou, ZG; Ning, G; Chen, YL; Paul, S				Ji, Linong; Tong, Xiaolin; Wang, Hongyuan; Tian, Haoming; Zhou, Huimin; Zhang, Lili; Li, Qifu; Wang, Yizhong; Li, Hongmei; Liu, Min; Yang, Hongjie; Gao, Yanbin; Li, Yan; Li, Quanmin; Guo, Xiaohui; Yang, Gangyi; Zhang, Zhongai; Zhou, Zhiguang; Ning, Guang; Chen, Yingli; Paul, Sanjoy		Evidence-Based Med Res Xiaoke Pill	Efficacy and Safety of Traditional Chinese Medicine for Diabetes: A Double-Blind, Randomised, Controlled Trial	PLOS ONE			English	Article							THERAPY	Background: Treatment of diabetes mellitus with Traditional Chinese Medicine has a long history. The aim of this study is to establish the safety and efficacy of traditional Chinese medicine combined with glibenclamide to treat type 2 diabetes mellitus. Methods: In a controlled, double blind, multicentre non-inferiority trial, 800 patients with unsatisfactory glycemic control (fasting glucose 7-13 mmol/L and HbA1c 7-11%) were randomly assigned to receive Xiaoke Pill, a compound of Chinese herbs combined with glibenclamide, or Glibenclamide in two study groups - drug naive group, and patients previously treated with metformin monotherapy (metformin group). Outcome measures at 48 weeks were the incidence and rate of hypoglycemia, mean difference in HbA1c, and proportion of patients with HbA1c<6.5%. Findings: In drug naive group, the total hypoglycemia rate and the mild hypoglycemic episode in the Xiaoke Pill arm were 38% (p = 0.024) and 41% (p = 0.002) less compared to Glibenclamide arm; in Metformin group, the average annual rate of hypoglycemia was 62% lower in Xiaoke Pill arm (p = 0.003). Respective mean changes in HbA1c from baseline were -0.70% and -0.66% for Xiaoke Pill and Glibenclamide, with a between-group difference (95% CI) of -0.04% (-0.20, 0.12) in the drug naive group, and those in metformin group were -0.45% and -0.59%, 0.14% (-0.12, 0.39) respectively. The respective proportions of patients with a HbA1c level <6.5% were 26.6% and 23.4% in the drug naive group and 20.1% and 18.9% in the metformin group. Interpretation: In patients with type 2 diabetes and inadequate glycaemic control, treatment with Xiaoke Pill led to significant reduction in risk of hypoglycemia and similar improvements in glycemic control after 48 weeks compared to Glibenclamide. Trial Registration: Chinese Clinical Trial Register number, ChiCTR-TRC-08000074	[Ji, Linong; Chen, Yingli] Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China; [Tong, Xiaolin] China Acad Chinese Medicial Sci, Guanganmen Hosp, Beijing, Peoples R China; [Wang, Hongyuan] Peking Univ, Sch Publ Hlth, Beijing 100871, Peoples R China; [Tian, Haoming] Sichuan Univ, West China Hosp, Chengdu 610064, Peoples R China; [Zhou, Huimin] Hebei Med Univ, Hosp 1, Shijiazhuang, Peoples R China; [Zhang, Lili] Peking Univ Tradit Chinese & Western Med, Affiliated Hosp 3, Beijing, Peoples R China; [Li, Qifu] Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China; [Wang, Yizhong] China Aerosp Corp, Cent Hosp, Beijing, Peoples R China; [Li, Hongmei] China Meitan Gen Hosp, Beijing, Peoples R China; [Liu, Min] Guangzhou Univ Tradit Chinese Med, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China; [Yang, Hongjie] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Shanghai, Peoples R China; [Gao, Yanbin] Beijing Univ Tradit Chinese Med, Dongfang Hosp, Beijing, Peoples R China; [Li, Yan] Zhongshan Univ, Sun Yai Sen Mem Hosp, Zhongshan, Peoples R China; [Li, Quanmin] PLA Second Artillery, Gen Hosp, Beijing, Peoples R China; [Guo, Xiaohui] Peking Univ, Hosp 1, Beijing 100871, Peoples R China; [Yang, Gangyi] Chongqing Med Univ, Affiliated Hosp 2, Chongqing, Peoples R China; [Zhang, Zhongai] Nanjing Hosp Tradit Chinese Med, Nanjing, Jiangsu, Peoples R China; [Zhou, Zhiguang] Cent S Univ, Xiangya Hosp 2, Changsha, Hunan, Peoples R China; [Ning, Guang] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai 200030, Peoples R China; [Paul, Sanjoy] Univ Queensland, Queensland Clin Trials & Biostat Ctr, Sch Populat Hlth, Brisbane, Qld 4072, Australia	Peking University; China Academy of Chinese Medical Sciences; Guang'anmen Hospital, CACMS; Peking University; Sichuan University; Hebei Medical University; Chongqing Medical University; Guangzhou University of Chinese Medicine; Shanghai University of Traditional Chinese Medicine; Beijing University of Chinese Medicine; Sun Yat Sen University; Peking University; Chongqing Medical University; Central South University; Shanghai Jiao Tong University; University of Queensland	Ji, LN (corresponding author), Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China.	jiln@bjmu.edu.cn; s.paul@sph.uq.edu.au	Paul, Sanjoy K/F-8199-2010; Linong, Ji/AAB-6543-2020	Paul, Sanjoy K/0000-0003-0848-7194; Li, Qifu/0000-0003-3904-410X; Zhou, Zhiguang/0000-0002-0374-1838; Hongjie, Yang/0000-0002-8054-9313	National Basic Research Program of China (973 program) [2011CB504001]; National High Technology Research and Development Program (863 program) [2006AA02A409]; Guangzhou Zhongyi Pharmaceutical; Eli Lilly; Bristol-Myers Squibb; Novartis; Novo Nordisk; Merck; Bayer; Takeda; Sanofi-Aventis; GlaxoSmithKline; Roche; Johnson Johnson; boehingeringelheim	National Basic Research Program of China (973 program)(National Basic Research Program of China); National High Technology Research and Development Program (863 program)(National High Technology Research and Development Program of China); Guangzhou Zhongyi Pharmaceutical; Eli Lilly(Eli Lilly); Bristol-Myers Squibb(Bristol-Myers Squibb); Novartis(Novartis); Novo Nordisk(Novo Nordisk); Merck(Merck & Company); Bayer(Bayer AG); Takeda(Takeda Pharmaceutical Company Ltd); Sanofi-Aventis(Sanofi-Aventis); GlaxoSmithKline(GlaxoSmithKline); Roche(Roche Holding); Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); boehingeringelheim	This work was supported by grants from National Basic Research Program of China (973 program, No. 2011CB504001), National High Technology Research and Development Program (863 program, No. 2006AA02A409), and Guangzhou Zhongyi Pharmaceutical. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors have declared that no competing interests exist. Several authors have received speaking honoraria from several pharmaceutical companies as follows: Dr. Ji reports receiving consulting and lecture fees from Eli Lilly, Bristol-Myers Squibb, Novartis, Novo Nordisk, Merck, Bayer, Takeda, Sanofi-Aventis, GlaxoSmithKline, Roche, Johnson & Johnson, boehingeringelheim, and Guangzhou Zhongyi Pharmaceutical, and grants from Guangzhou Zhongyi Pharmaceutical and Bayer. Dr. Q Li reports receiving consulting and lecture fees from Eli Lilly, Novo Nordisk, and Sanofi-Aventis. Dr. Tian reports receiving lecture fees from Bristol-Myers Squibb, Novo Nordisk, Bayer, and Sanofi-Aventis. Dr. Y. Li reports receiving consulting fees from Novartis, Novo Nordisk, and Sanofi-Aventis and lecture fees from Novo Nordisk and Sanofi-Aventis. Dr. Guo reports receiving consulting fees from Novartis, Sanofi-Aventis, and Guangzhou Zhongyi Pharmaceutical and lecture fees from Sanofi-Aventis, Guangzhou Zhongyi Pharmaceutical, and Novo Nordisk. Dr. Y. Gao reports receiving consulting fees from Novartis, Sanofi-Aventis, and Guangzhou Zhongyi Pharmaceutical and lecture fees from Sanofi-Aventis, Guangzhou Zhongyi Pharmaceutical, and Novo Nordisk. Dr. M. Liu reports receiving lecture fees from Eli Lilly, Novo Nordisk, and Bayer. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.	Cang Chung-Ching HH, 1983, CHIN KUEI YOU LUEH; Chen G, 2003, ZHONG YAO XIN YAO YU, V14, P84; Cheng JT, 2000, J CLIN PHARMACOL, V40, P445, DOI 10.1177/00912700022009198; E Demidenko, 2004, MIXED MODELS THEORY; European Medicines Agency, 2005, PUBL STAT RISK ASS U; Home PD, 2007, DIABETIC MED, V24, P626, DOI 10.1111/j.1464-5491.2007.02160.x; Hsu HY, 1978, B ORIENTAL HEALING A, V3, P12; Kenward MG, 2007, STAT METHODS MED RES, V16, P199, DOI 10.1177/0962280206075304; Li M, 2009, INT J OBESITY, V33, P424, DOI 10.1038/ijo.2009.44; Li WL, 2004, J ETHNOPHARMACOL, V92, P1, DOI 10.1016/j.jep.2003.12.031; Liu J.P., 2004, COCHRANE DB SYST REV, V3; Ni M., 1995, YELLOW EMPERORS CLAS; Pharmacopoeia Commission, 2010, PHARM PEOPL REP CHIN; Sang Z, 2010, AM J CHINESE MED, V38, P1027, DOI 10.1142/S0192415X10008445; Sena M, 2009, FASEB J, V23, P900; Tang JL, 1999, BMJ-BRIT MED J, V319, P160, DOI 10.1136/bmj.319.7203.160; Wang E, 2008, DIABETES EDUCATOR, V34, P645, DOI 10.1177/0145721708320559; Wang G, 2007, CLIN THER, V29, P1456, DOI 10.1016/j.clinthera.2007.07.023; Wu JL, 2005, SHI YONG ZHONG XI YI, V5, P18; Xie W., 2011, EVID-BASED COMPL ALT, V2011, DOI DOI 10.1155/2011/726723; [徐晓虹 XU Xiaohong], 2008, [中国药学杂志, Chinese Pharmaceutical Journal], V43, P1308; Ye TS, 2006, RECORD MED PRACTICE; Yeh GY, 2003, DIABETES CARE, V26, P1277, DOI 10.2337/diacare.26.4.1277; Zhang H, 2010, EUR J INTEGR MED, V2, P41, DOI 10.1016/j.eujim.2010.02.004; Zhang HZ, 1999, ZHONG YI YAO YAN JIU, V15, P19; Zhang YX, 2004, INT CONGR SER, V1260, P421, DOI 10.1016/S0531-5131(03)01684-4; Zhao YC, 1998, CHANGCHUN ZHONG YI X, V14, P15; Zheng X, 2010, PRINCIPAL GUIDELINE; Zhou R, 2003, ZHONGGUO YAOWU YU LI, V3, P131; Zhu DX, 1993, HEART ESSENCE DAN XI	30	56	67	1	64	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2013	8	2							e56703	10.1371/journal.pone.0056703	http://dx.doi.org/10.1371/journal.pone.0056703			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	098BN	23460810	Green Published, gold			2023-01-03	WOS:000315519000033
J	Lee, M; Kim, SE; Kim, WS; Lee, J; Yoo, HK; Park, KD; Choi, KG; Jeong, SY; Kim, BG; Lee, HW				Lee, Mina; Kim, Song E.; Kim, Won Sup; Lee, Jungyeun; Yoo, Hye Kyung; Park, Kee-Duk; Choi, Kyoung-Gyu; Jeong, Seon-Yong; Kim, Byung Gon; Lee, Hyang Woon			Interaction of Motor Training and Intermittent Theta Burst Stimulation in Modulating Motor Cortical Plasticity: Influence of BDNF Val66Met Polymorphism	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; SYNAPTIC-TRANSMISSION; CORTICOSPINAL EXCITABILITY; ANTIDEPRESSANT RESPONSE; DEPENDENT PLASTICITY; BRAIN-STIMULATION; CHRONIC STROKE; CORTEX; METAPLASTICITY; RECOVERY	Cortical physiology in human motor cortex is influenced by behavioral motor training (MT) as well as repetitive transcranial magnetic stimulation protocol such as intermittent theta burst stimulation (iTBS). This study aimed to test whether MT and iTBS can interact with each other to produce additive changes in motor cortical physiology. We hypothesized that potential interaction between MT and iTBS would be dependent on BDNF Val66Met polymorphism, which is known to affect neuroplasticity in the human motor cortex. Eighty two healthy volunteers were genotyped for BDNF polymorphism. Thirty subjects were assigned for MT alone, 23 for iTBS alone, and 29 for MT + iTBS paradigms. TMS indices for cortical excitability and motor map areas were measured prior to and after each paradigm. MT alone significantly increased the motor cortical excitability and expanded the motor map areas. The iTBS alone paradigm also enhanced excitability and increased the motor map areas to a slightly greater extent than MT alone. A combination of MT and iTBS resulted in the largest increases in the cortical excitability, and the representational motor map expansion of MT + iTBS was significantly greater than MT or iTBS alone only in Val/Val genotype. As a result, the additive interaction between MT and iTBS was highly dependent on BDNF Val66Met polymorphism. Our results may have clinical relevance in designing rehabilitative strategies that combine therapeutic cortical stimulation and physical exercise for patients with motor disabilities.	[Lee, Mina; Kim, Song E.; Kim, Won Sup; Lee, Jungyeun; Yoo, Hye Kyung; Park, Kee-Duk; Choi, Kyoung-Gyu; Lee, Hyang Woon] Ewha Womans Univ, Dept Neurol, Sch Med, Seoul, South Korea; [Lee, Mina; Kim, Song E.; Kim, Won Sup; Lee, Hyang Woon] Ewha Med Res Inst, Seoul, South Korea; [Jeong, Seon-Yong] Ajou Univ, Sch Med, Dept Med Genet, Suwon 441749, South Korea; [Kim, Byung Gon] Ajou Univ, Sch Med, Dept Neurol, Suwon 441749, South Korea	Ewha Womans University; Ewha Womans University; Ajou University; Ajou University	Kim, BG (corresponding author), Ajou Univ, Sch Med, Dept Neurol, Suwon 441749, South Korea.	kimbg@ajou.ac.kr; leeh@ewha.ac.kr	Kim, Byung Gon/L-6884-2019	Kim, Byung Gon/0000-0003-2233-9569; LEE, Jungyeun/0000-0002-3544-1098	Chronic Inflammatory Disease Research Center through the National Research Foundation of Korea; Ministry of Education, Science and Technology [2012051429, R01-2001-0015788, KRF-2009-006-5721, 2009-007-2164]; Ewha Global Top 5 Grant of Ewha Womans University; Korean Science and Engineering Foundation Grant; South Korean government (MOST) [R01-2007-000-11080-0]; Basic Science Research Program through the National Research Foundation of Korea	Chronic Inflammatory Disease Research Center through the National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Ewha Global Top 5 Grant of Ewha Womans University; Korean Science and Engineering Foundation Grant(Korea Science and Engineering Foundation); South Korean government (MOST)(Ministry of Science & Technology (MOST), Republic of Korea); Basic Science Research Program through the National Research Foundation of Korea(National Research Foundation of Korea)	This work was supported by the Chronic Inflammatory Disease Research Center through the National Research Foundation of Korea (http://www.nrf.re.kr/html/en/) funded by the Ministry of Education, Science and Technology 2012051429) to BGK, and by the Ewha Global Top 5 Grant 2011 of Ewha Womans University and by the Korean Science and Engineering Foundation Grant (http://www.kosef.re.kr/) funded by the South Korean government (MOST) (R01-2007-000-11080-0), and by the Basic Science Research Program through the National Research Foundation of Korea (http://www.nrf.re.kr/html/en/) funded by the Ministry of Education, Science and Technology (R01-2001-0015788, KRF-2009-006-5721 and 2009-007-2164) to HWL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; Abraham WC, 2008, NAT REV NEUROSCI, V9, P387, DOI 10.1038/nrn2356; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; Butefisch CM, 2002, ANN NEUROL, V51, P59, DOI 10.1002/ana.10056; Cheeran B, 2008, J PHYSIOL-LONDON, V586, P5717, DOI 10.1113/jphysiol.2008.159905; Classen J, 1998, J NEUROPHYSIOL, V79, P1117, DOI 10.1152/jn.1998.79.2.1117; Dayan E, 2011, NEURON, V72, P443, DOI 10.1016/j.neuron.2011.10.008; Dobkin BH, 2008, NAT CLIN PRACT NEURO, V4, P76, DOI 10.1038/ncpneuro0709; Duncan PW, 2011, NEW ENGL J MED, V364, P2026, DOI 10.1056/NEJMoa1010790; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Esser SK, 2006, BRAIN RES BULL, V69, P86, DOI 10.1016/j.brainresbull.2005.11.003; Fritsch B, 2010, NEURON, V66, P198, DOI 10.1016/j.neuron.2010.03.035; Gentner R, 2008, CEREB CORTEX, V18, P2046, DOI 10.1093/cercor/bhm239; Gersner R, 2011, J NEUROSCI, V31, P7521, DOI 10.1523/JNEUROSCI.6751-10.2011; Green EK, 2006, BRIT J PSYCHIAT, V188, P21, DOI 10.1192/bjp.bp.105.009969; Gur RC, 2002, AM J GERIAT PSYCHIAT, V10, P72, DOI 10.1176/appi.ajgp.10.1.72; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Huang YZ, 2011, CLIN NEUROPHYSIOL, V122, P1011, DOI 10.1016/j.clinph.2010.08.016; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Hummel F, 2005, BRAIN, V128, P490, DOI 10.1093/brain/awh369; Hummel FC, 2006, LANCET NEUROL, V5, P708, DOI 10.1016/S1474-4422(06)70525-7; Iezzi E, 2008, J NEUROPHYSIOL, V100, P2070, DOI 10.1152/jn.90521.2008; Iezzi E, 2011, EUR J NEUROSCI, V33, P1908, DOI 10.1111/j.1460-9568.2011.07674.x; Iyer MB, 2003, J NEUROSCI, V23, P10867; Jung P, 2009, J NEUROSCI, V29, P5597, DOI 10.1523/JNEUROSCI.0222-09.2009; Kaneko K, 1996, ELECTROMYOGR MOTOR C, V101, P478, DOI 10.1016/S0921-884X(96)96021-X; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Khedr EM, 2005, NEUROLOGY, V65, P466, DOI 10.1212/01.wnl.0000173067.84247.36; Kleim JA, 2006, NAT NEUROSCI, V9, P735, DOI 10.1038/nn1699; Kozel FA, 2000, J NEUROPSYCH CLIN N, V12, P376, DOI 10.1176/appi.neuropsych.12.3.376; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; Malcolm MP, 2007, AM J PHYS MED REHAB, V86, P707, DOI 10.1097/PHM.0b013e31813e0de0; McConnell KA, 2001, BIOL PSYCHIAT, V49, P454, DOI 10.1016/S0006-3223(00)01039-8; Nudo RJ, 1996, J NEUROSCI, V16, P785; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Paulus W, 2005, NEURON, V45, P181, DOI 10.1016/j.neuron.2005.01.008; Rose CR, 2004, BIOESSAYS, V26, P1185, DOI 10.1002/bies.20118; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Schwenkreis P, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-35; Siebner HR, 2003, EXP BRAIN RES, V148, P1, DOI 10.1007/s00221-002-1234-2; Siebner HR, 2004, J NEUROSCI, V24, P3379, DOI 10.1523/JNEUROSCI.5316-03.2004; Suen PC, 1997, P NATL ACAD SCI USA, V94, P8191, DOI 10.1073/pnas.94.15.8191; Talelli P, 2007, CLIN NEUROPHYSIOL, V118, P333, DOI 10.1016/j.clinph.2006.10.014; Tsai SJ, 2003, AM J MED GENET B, V123B, P19, DOI 10.1002/ajmg.b.20026; Tyc F, 2006, REV NEUROSCIENCE, V17, P469; Wassermann EM, 2002, CLIN NEUROPHYSIOL, V113, P1165, DOI 10.1016/S1388-2457(02)00144-X; Wu K, 2004, MOL BRAIN RES, V130, P178, DOI 10.1016/j.molbrainres.2004.07.019; Xi B, 2011, AM J EPIDEMIOL, V173, P1256, DOI 10.1093/aje/kwr008; Ziemann U, 2008, BRAIN STIMUL, V1, P60, DOI 10.1016/j.brs.2007.08.003	51	35	36	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2013	8	2							e57690	10.1371/journal.pone.0057690	http://dx.doi.org/10.1371/journal.pone.0057690			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115ZB	23451258	gold, Green Submitted, Green Published			2023-01-03	WOS:000316849500125
J	de la Ossa, DHP; Lorente, M; Gil-Alegre, ME; Torres, S; Garcia-Taboada, E; Aberturas, MD; Molpeceres, J; Velasco, G; Torres-Suarez, AI				Hernan Perez de la Ossa, Dolores; Lorente, Mar; Esther Gil-Alegre, Maria; Torres, Sofia; Garcia-Taboada, Elena; del Rosario Aberturas, Maria; Molpeceres, Jesus; Velasco, Guillermo; Isabel Torres-Suarez, Ana			Local Delivery of Cannabinoid-Loaded Microparticles Inhibits Tumor Growth in a Murine Xenograft Model of Glioblastoma Multiforme	PLOS ONE			English	Article							HUMAN GLIOMA-CELLS; DRUG-DELIVERY; IN-VITRO; HEPATOCELLULAR-CARCINOMA; ANTITUMOR-ACTIVITY; SUSTAINED-RELEASE; MICROSPHERES; CANNABIDIOL; CANCER; DOXORUBICIN	Cannabinoids, the active components of marijuana and their derivatives, are currently investigated due to their potential therapeutic application for the management of many different diseases, including cancer. Specifically, Delta(9)- Tetrahydrocannabinol (THC) and Cannabidiol (CBD) - the two major ingredients of marijuana - have been shown to inhibit tumor growth in a number of animal models of cancer, including glioma. Although there are several pharmaceutical preparations that permit the oral administration of THC or its analogue nabilone or the oromucosal delivery of a THC- and CBD- enriched cannabis extract, the systemic administration of cannabinoids has several limitations in part derived from the high lipophilicity exhibited by these compounds. In this work we analyzed CBD- and THC-loaded poly-epsilon- caprolactone microparticles as an alternative delivery system for long-term cannabinoid administration in a murine xenograft model of glioma. In vitro characterization of THC- and CBD-loaded microparticles showed that this method of microencapsulation facilitates a sustained release of the two cannabinoids for several days. Local administration of THC-, CBD- or a mixture (1:1 w:w) of THC- and CBD- loaded microparticles every 5 days to mice bearing glioma xenografts reduced tumour growth with the same efficacy than a daily local administration of the equivalent amount of those cannabinoids in solution. Moreover, treatment with cannabinoid-loaded microparticles enhanced apoptosis and decreased cell proliferation and angiogenesis in these tumours. Our findings support that THC- and CBD- loaded microparticles could be used as an alternative method of cannabinoid delivery in anticancer therapies.	[Hernan Perez de la Ossa, Dolores; Esther Gil-Alegre, Maria; Isabel Torres-Suarez, Ana] Univ Complutense, Sch Pharm, Dept Pharm & Pharmaceut Technol, E-28040 Madrid, Spain; [Lorente, Mar; Torres, Sofia; Garcia-Taboada, Elena; Velasco, Guillermo] Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain; [Lorente, Mar; Velasco, Guillermo] Hosp Clin San Carlos, Inst Invest Sanitaria, Madrid, Spain; [del Rosario Aberturas, Maria; Molpeceres, Jesus] Alcala Univ, Sch Pharm, Dept Pharm & Pharmaceut Technol, Madrid, Spain; [Esther Gil-Alegre, Maria; Isabel Torres-Suarez, Ana] Univ Complutense, Inst Farm Ind, E-28040 Madrid, Spain	Complutense University of Madrid; Complutense University of Madrid; Hospital Clinico San Carlos; Universidad de Alcala; Complutense University of Madrid	Velasco, G (corresponding author), Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain.	gvd@bbm1.ucm.es	del Rosario Aberturas, María/AAA-9014-2019; Torres-SuÃrez, Ana Isabel/AAR-9320-2020; Lorente, Mar/K-2401-2014; Torres-Suárez, Ana/N-4666-2013; Lorente, Mar/O-5106-2017; Velasco, Guillermo/H-5260-2012; /Y-9512-2019; Velasco, Guillermo/AAU-9189-2020	del Rosario Aberturas, María/0000-0001-7875-6009; Torres-SuÃrez, Ana Isabel/0000-0003-2468-6177; Torres-Suárez, Ana/0000-0003-2468-6177; Lorente, Mar/0000-0003-0982-0956; Velasco, Guillermo/0000-0002-1994-2386; /0000-0003-4201-0795; Velasco, Guillermo/0000-0002-1994-2386; Torres, Sofia/0000-0002-9007-8105; GIL-ALEGRE, MARIA ESTHER/0000-0002-8313-8261	Spanish Ministry of Science and Innovation (MICINN) [PS09/01401]; Comunidad Autonoma de Madrid [PR1/06-14474-B]; Complutense University [CCG07-UCM/BIO-2824]; Juan de la Cierva; Spanish Ministry of Education and Science; Comunidad de Madrid; GW Pharmaceuticals	Spanish Ministry of Science and Innovation (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Comunidad Autonoma de Madrid(Comunidad de Madrid); Complutense University; Juan de la Cierva(Instituto de Salud Carlos III); Spanish Ministry of Education and Science(Spanish Government); Comunidad de Madrid(Comunidad de Madrid); GW Pharmaceuticals	This work was supported by grants from the Spanish Ministry of Science and Innovation (MICINN) (PS09/01401 to GV), Comunidad Autonoma de Madrid (PR1/06-14474-B to AITS) and Complutense University (CCG07-UCM/BIO-2824 to AITS). DH was recipient of a FPU fellowship from MICINN. ML was sequentially recipient of a "Juan de la Cierva'' contract, a postdoctoral contract from Spanish Ministry of Education and Science and a postdoctoral contract from Comunidad de Madrid. ST was recipient of a research training contract from Comunidad de Madrid. GW Pharmaceuticals funded part of the research that was performed in GV's laboratory. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ateh DD, 2011, BIOMATERIALS, V32, P8538, DOI 10.1016/j.biomaterials.2011.07.060; Benny O, 2009, CLIN CANCER RES, V15, P1222, DOI 10.1158/1078-0432.CCR-08-1316; Benoit JP, 2000, J CONTROL RELEASE, V65, P285, DOI 10.1016/S0168-3659(99)00250-3; Carracedo A, 2006, CANCER CELL, V9, P301, DOI 10.1016/j.ccr.2006.03.005; Carracedo A, 2006, CANCER RES, V66, P6748, DOI 10.1158/0008-5472.CAN-06-0169; Chakravarthi SS, 2011, INT J PHARMACEUT, V409, P111, DOI 10.1016/j.ijpharm.2011.02.034; Di Marzo V, 2009, PHARMACOL RES, V60, P77, DOI 10.1016/j.phrs.2009.02.010; Dubernet C, 2011, B CANCER, V98, P1363, DOI 10.1684/bdc.2011.1468; Gil-Alegre ME, 2008, J MICROENCAPSUL, V25, P561, DOI [10.1080/02652040802075799, 10.1080/02652040802075799 ]; Fernandez-Ruiz J, 2007, TRENDS PHARMACOL SCI, V28, P39, DOI 10.1016/j.tips.2006.11.001; Freiberg S, 2004, INT J PHARMACEUT, V282, P1, DOI 10.1016/j.ijpharm.2004.04.013; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046; GARRETT ER, 1974, J PHARM SCI-US, V63, P1056, DOI 10.1002/jps.2600630705; Guzman M, 2005, HANDB EXP PHARMACOL, V168, P627; Hillegass JM, 2011, INT J CANCER, V129, P233, DOI 10.1002/ijc.25666; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Izzo AA, 2009, TRENDS PHARMACOL SCI, V30, P515, DOI 10.1016/j.tips.2009.07.006; Kim I, 2012, BIOMATERIALS, V33, P5574, DOI 10.1016/j.biomaterials.2012.04.018; Ligresti A, 2006, J PHARMACOL EXP THER, V318, P1375, DOI 10.1124/jpet.106.105247; Lin RY, 2005, BIOMATERIALS, V26, P4476, DOI 10.1016/j.biomaterials.2004.11.014; Marcu JP, 2010, MOL CANCER THER, V9, P180, DOI 10.1158/1535-7163.MCT-09-0407; Massi P, 2008, J NEUROCHEM, V104, P1091, DOI 10.1111/j.1471-4159.2007.05073.x; Massi P, 2006, CELL MOL LIFE SCI, V63, P2057, DOI 10.1007/s00018-006-6156-x; McAllister SD, 2007, MOL CANCER THER, V6, P2921, DOI 10.1158/1535-7163.MCT-07-0371; McAllister SD, 2011, BREAST CANCER RES TR, V129, P37, DOI 10.1007/s10549-010-1177-4; Menei Philippe, 2005, Expert Opin Drug Deliv, V2, P363, DOI 10.1517/17425247.2.2.363; Moses MA, 2003, CANCER CELL, V4, P337, DOI 10.1016/S1535-6108(03)00276-9; Nguyen TLU, 2007, J POLYM SCI POL CHEM, V45, P3256, DOI 10.1002/pola.22074; Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2; de la Ossa DHP, 2012, J CONTROL RELEASE, V161, P927, DOI 10.1016/j.jconrel.2012.05.003; Pertwee RG, 2009, BRIT J PHARMACOL, V156, P397, DOI 10.1111/j.1476-5381.2008.00048.x; Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948; Sarfaraz S, 2008, CANCER RES, V68, P339, DOI 10.1158/0008-5472.CAN-07-2785; Sastre RL, 2004, DRUG DEVELOP RES, V63, P41, DOI 10.1002/ddr.10396; Soma CE, 2000, J CONTROL RELEASE, V68, P283, DOI 10.1016/S0168-3659(00)00269-8; Soma CE, 2000, BIOMATERIALS, V21, P1; Torelli-Souza RR, 2012, J APPL POLYM SCI, V126, pE408, DOI 10.1002/app.36928; Torres S, 2011, MOL CANCER THER, V10, P90, DOI 10.1158/1535-7163.MCT-10-0688; Vara D, 2011, CELL DEATH DIFFER, V18, P1099, DOI 10.1038/cdd.2011.32; Velasco G, 2012, NAT REV CANCER, V12, P436, DOI 10.1038/nrc3247	41	58	61	1	64	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2013	8	1							e54795	10.1371/journal.pone.0054795	http://dx.doi.org/10.1371/journal.pone.0054795			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	077HS	23349970	Green Published, gold			2023-01-03	WOS:000314019100098
J	Volz, MS; Suarez-Contreras, V; Mendonca, ME; Pinheiro, FS; Merabet, LB; Fregni, F				Volz, Magdalena Sarah; Suarez-Contreras, Vanessa; Mendonca, Mariana E.; Pinheiro, Fernando Santos; Merabet, Lotfi B.; Fregni, Felipe			Effects of Sensory Behavioral Tasks on Pain Threshold and Cortical Excitability	PLOS ONE			English	Article							DIRECT-CURRENT STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; ELECTRICAL NERVE-STIMULATION; PRIMARY SOMATOSENSORY CORTEX; MOTOR CORTEX; NEUROPATHIC PAIN; MACAQUE MONKEY; MEDIAL PAIN; SYSTEM; PLASTICITY	Background/Objective: Transcutaneous electrical stimulation has been proven to modulate nervous system activity, leading to changes in pain perception, via the peripheral sensory system, in a bottom up approach. We tested whether different sensory behavioral tasks induce significant effects in pain processing and whether these changes correlate with cortical plasticity. Methodology/Principal Findings: This randomized parallel designed experiment included forty healthy right-handed males. Three different somatosensory tasks, including learning tasks with and without visual feedback and simple somatosensory input, were tested on pressure pain threshold and motor cortex excitability using transcranial magnetic stimulation (TMS). Sensory tasks induced hand-specific pain modulation effects. They increased pain thresholds of the left hand ( which was the target to the sensory tasks) and decreased them in the right hand. TMS showed that somatosensory input decreased cortical excitability, as indexed by reduced MEP amplitudes and increased SICI. Although somatosensory tasks similarly altered pain thresholds and cortical excitability, there was no significant correlation between these variables and only the visual feedback task showed significant somatosensory learning. Conclusions/Significance: Lack of correlation between cortical excitability and pain thresholds and lack of differential effects across tasks, but significant changes in pain thresholds suggest that analgesic effects of somatosensory tasks are not primarily associated with motor cortical neural mechanisms, thus, suggesting that subcortical neural circuits and/or spinal cord are involved with the observed effects. Identifying the neural mechanisms of somatosensory stimulation on pain may open novel possibilities for combining different targeted therapies for pain control.	[Volz, Magdalena Sarah; Suarez-Contreras, Vanessa; Mendonca, Mariana E.; Pinheiro, Fernando Santos; Fregni, Felipe] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Lab Neuromodulat,Dept Phys Med & Rehabil, Boston, MA 02115 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA; [Volz, Magdalena Sarah] Charite Univ Med Berlin, Charite Ctr Neurol Neurosurg & Psychiat, Berlin, Germany; [Merabet, Lotfi B.] Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA USA	Harvard University; Harvard Medical School; Spaulding Rehabilitation Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary	Fregni, F (corresponding author), Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Lab Neuromodulat,Dept Phys Med & Rehabil, Boston, MA 02115 USA.	fregni.felipe@mgh.harvard.edu	Merabet, Lotfi B./V-2735-2017; merabet, lotfi/AAU-8259-2020	Merabet, Lotfi B./0000-0002-8094-9536; merabet, lotfi/0000-0002-8094-9536; Pruss, Magdalena Sarah/0000-0002-4522-7482; Fregni, Felipe/0000-0001-9359-8643	National Institutes of Health (NIH) grant [R21 DK081773-03]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK081773] Funding Source: NIH RePORTER	National Institutes of Health (NIH) grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by a National Institutes of Health (NIH) grant (R21 DK081773-03). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BECK AT, 1984, J CLIN PSYCHOL, V40, P1365, DOI 10.1002/1097-4679(198411)40:6<1365::AID-JCLP2270400615>3.0.CO;2-D; Busch A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003786.pub2; Chesterton LS, 2002, PAIN, V99, P253, DOI 10.1016/S0304-3959(02)00118-5; DARIANSMITH C, 1993, J COMP NEUROL, V335, P200, DOI 10.1002/cne.903350205; DARIANSMITH C, 1993, J COMP NEUROL, V335, P173, DOI 10.1002/cne.903350204; Dietrich C, 2011, NEUROSCI LETT; Dionne JK, 2010, HUM BRAIN MAPP, V31, P14, DOI 10.1002/hbm.20841; Fischer AA, 1987, CLIN J PAIN, V2, P207; Fregni F, 2006, ARTHRITIS RHEUM-US, V54, P3988, DOI 10.1002/art.22195; Fregni F, 2007, LANCET NEUROL, V6, P188, DOI 10.1016/S1474-4422(07)70032-7; Fregni F, 2006, PAIN, V122, P197, DOI 10.1016/j.pain.2006.02.023; Freitas C, 2011, FRONT AGING NEUROSCI, V3, DOI [10.3389/fnagi.2011.00005, 10.3389/fnagi.2011.00006]; Heed T, 2011, J EXP PSYCHOL HUM PE; Hirayama A, 2006, PAIN, V122, P22, DOI 10.1016/j.pain.2005.12.001; Imamura M, 2008, ARTHRIT RHEUM-ARTHR, V59, P1424, DOI 10.1002/art.24120; Johnson MI, 2011, EXPERT REV NEUROTHER, V11, P735, DOI [10.1586/ern.11.48, 10.1586/ERN.11.48]; Knudsen L, 2011, J PAIN, V12, P451, DOI 10.1016/j.jpain.2010.10.008; Lane JW, 2010, J NEUROSCI METH, V185, P221, DOI 10.1016/j.jneumeth.2009.09.025; Lefaucheur JP, 2006, NEUROLOGY, V67, P1568, DOI 10.1212/01.wnl.0000242731.10074.3c; Lefaucheur JP, 2008, CLIN NEUROPHYSIOL, V119, P2179, DOI 10.1016/j.clinph.2008.07.007; Lefaucheur JP, 2008, BRAIN STIMUL, V1, P337, DOI 10.1016/j.brs.2008.07.003; Merabet L, 2004, NEURON, V42, P173, DOI 10.1016/S0896-6273(04)00147-3; Mulvey MR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007264.pub2; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Ostry DJ, 2010, J NEUROSCI, V30, P5384, DOI 10.1523/JNEUROSCI.4571-09.2010; Pleger B, 2006, J NEUROSCI, V26, P12596, DOI 10.1523/JNEUROSCI.4275-06.2006; Price DD, 2000, SCIENCE, V288, P1769, DOI 10.1126/science.288.5472.1769; Reed JL, 2011, J NEUROSCI, V31, P3589, DOI 10.1523/JNEUROSCI.4310-10.2011; REEVES JL, 1986, PAIN, V24, P313, DOI 10.1016/0304-3959(86)90117-X; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Sewards TV, 2002, BRAIN RES BULL, V58, P243, DOI 10.1016/S0361-9230(02)00783-9; Sewards TV, 2002, BRAIN RES BULL, V59, P163, DOI 10.1016/S0361-9230(02)00864-X; Sluka KA, 2003, J PAIN, V4, P109, DOI 10.1054/jpai.2003.434; Smith MJ, 1999, NEUROLOGY, V53, P2069, DOI 10.1212/WNL.53.9.2069; Staines WR, 2002, NEUROIMAGE, V15, P190, DOI 10.1006/nimg.2001.0953; Tokimura H, 2000, J PHYSIOL-LONDON, V523, P503, DOI 10.1111/j.1469-7793.2000.t01-1-00503.x; van Vliet PM, 2006, MANUAL THER, V11, P208, DOI 10.1016/j.math.2006.03.009; Vogt BA, 2005, NAT REV NEUROSCI, V6, P533, DOI 10.1038/nrn1704; Vogt BA, 2000, PROG BRAIN RES, V122, P223; Volz MS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034273; Wang L, 2006, CLIN NEUROPHYSIOL, V117, P1075, DOI 10.1016/j.clinph.2006.01.007; Xie YF, 2009, ACTA PHARMACOL SIN, V30, P31, DOI 10.1038/aps.2008.14	42	14	15	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2013	8	1							e52968	10.1371/journal.pone.0052968	http://dx.doi.org/10.1371/journal.pone.0052968			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	070BE	23301010	gold, Green Submitted, Green Published			2023-01-03	WOS:000313480000022
J	Braun, N; Alscher, MD; Fritz, P; Latus, J; Edenhofer, I; Reimold, F; Alper, SL; Kimmel, M; Biegger, D; Lindenmeyer, M; Cohen, CD; Wuthrich, RP; Segerer, S				Braun, Niko; Alscher, M. Dominik; Fritz, Peter; Latus, Joerg; Edenhofer, Ilka; Reimold, Fabian; Alper, Seth L.; Kimmel, Martin; Biegger, Dagmar; Lindenmeyer, Maja; Cohen, Clemens D.; Wuethrich, Rudolf P.; Segerer, Stephan			The Spectrum of Podoplanin Expression in Encapsulating Peritoneal Sclerosis	PLOS ONE			English	Article							CELLS; INFLAMMATION	Encapsulating peritoneal sclerosis (EPS) is a life threatening complication of peritoneal dialysis (PD). Podoplanin is a glycoprotein expressed by mesothelial cells, lymphatic endothelial cells, and myofibroblasts in peritoneal biopsies from patients with EPS. To evaluate podoplanin as a marker of EPS we measured podoplanin mRNA and described the morphological patterns of podoplanin-positive cells in EPS. Included were 20 peritoneal biopsies from patients with the diagnosis of EPS (n = 5), patients on PD without signs of EPS (n = 5), and control patients (uremic patients not on PD, n = 5, non-uremic patients n = 5). EPS patient biopsies revealed significantly elevated levels of podoplanin mRNA (p < 0.05). In 24 peritoneal biopsies from patients with EPS, podoplanin and smooth muscle actin (SMA) were localized by immunohistochemistry. Four patterns of podoplanin distribution were distinguishable. The most common pattern (8 of 24) consisted of organized, longitudinal layers of podoplanin-positive cells and vessels in the fibrotic zone ("organized'' pattern). 7 of 24 biopsies demonstrated a diffuse distribution of podoplanin-positive cells, accompanied by occasional, dense clusters of podoplanin-positive cells. Five biopsies exhibited a mixed pattern, with some diffuse areas and some organized areas ("mixed"). These contained cuboidal podoplanin-positive cells within SMA-negative epithelial structures embedded in extracellular matrix. Less frequently observed was the complete absence of, or only focal accumulations of podoplanin-positive fibroblasts outside of lymphatic vessels (podoplanin "low'', 4 of 24 biopsies). Patients in this group exhibited a lower index of systemic inflammation and a longer symptomatic period than in EPS patients with biopsies of the "mixed" type (p < 0.05). In summary we confirm the increased expression of podoplanin in EPS, and distinguish EPS biopsies according to different podoplanin expression patterns which are associated with clinical parameters. Podoplanin might serve as a useful adjunct to the morphological workup of peritoneal biopsies.	[Braun, Niko; Alscher, M. Dominik; Latus, Joerg; Reimold, Fabian; Kimmel, Martin] Robert Bosch Krankenhaus, Dept Internal Med, Div Gen Internal Med & Nephrol, Stuttgart, Germany; [Alscher, M. Dominik; Fritz, Peter] Inst Digital Med, Stuttgart, Germany; [Fritz, Peter] Robert Bosch Krankenhaus, Div Pathol, Dept Diagnost Med, Stuttgart, Germany; [Edenhofer, Ilka; Lindenmeyer, Maja; Cohen, Clemens D.; Wuethrich, Rudolf P.; Segerer, Stephan] Univ Zurich Hosp, Div Nephrol, CH-8091 Zurich, Switzerland; [Edenhofer, Ilka; Segerer, Stephan] Univ Zurich, Inst Anat, Zurich, Switzerland; [Reimold, Fabian; Alper, Seth L.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Nephrol,Dept Med, Boston, MA 02215 USA; [Biegger, Dagmar] Univ Tubingen, Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany; [Lindenmeyer, Maja; Cohen, Clemens D.] Univ Zurich, Inst Physiol, Zurich, Switzerland	Bosch; Robert Bosch Krankenhaus; Bosch; Robert Bosch Krankenhaus; University of Zurich; University Zurich Hospital; University of Zurich; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Eberhard Karls University of Tubingen; University of Zurich	Segerer, S (corresponding author), Univ Zurich Hosp, Div Nephrol, CH-8091 Zurich, Switzerland.	Stephan.segerer@usz.ch	Kimmel, Martin/AAM-2514-2021	Segerer, Stephan/0000-0002-1936-9719; Latus, Joerg/0000-0003-0584-4870; Alscher, Mark Dominik/0000-0002-9658-1211; Lindenmeyer, Maja/0000-0003-4162-9107	Baxter; Swiss National Science Foundation [SNF 32003B_129710]; Robert-Bosch Foundation; SNF [32-122439/1]; Harvard Digestive Diseases Center [DK34854]	Baxter; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Robert-Bosch Foundation; SNF; Harvard Digestive Diseases Center	SS is supported by a grant by Baxter and a grant by the Swiss National Science Foundation (SNF 32003B_129710); NB by the Robert-Bosch Foundation and a grant by Baxter, FR by the Robert-Bosch Foundation; CDC by SNF (32-122439/1); SLA by the Harvard Digestive Diseases Center (DK34854). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alscher DM, 2007, AM J KIDNEY DIS, V49, P452, DOI 10.1053/j.ajkd.2006.11.040; Augustine T, 2009, NEPHRON CLIN PRACT, V111, pC149, DOI 10.1159/000191214; Braun N, 2011, NEPHROL THER, V7, P162, DOI 10.1016/j.nephro.2010.12.011; Braun N, 2011, NEPHROL DIAL TRANSPL, V26, P1033, DOI 10.1093/ndt/gfq488; Brown MC, 2009, CLIN J AM SOC NEPHRO; Cohen CD, 2002, KIDNEY INT, V61, P133, DOI 10.1046/j.1523-1755.2002.00113.x; Garosi G, 2001, J NEPHROL, V14, pS30; Heller F, 2007, AM J PATHOL, V170, P457, DOI 10.2353/ajpath.2007.060554; Honda Kazuho, 2003, Adv Perit Dial, V19, P169; Hou TZ, 2010, FEBS LETT, V584, P3955, DOI 10.1016/j.febslet.2010.07.053; Kalof AN, 2009, ADV ANAT PATHOL, V16, P62, DOI 10.1097/PAP.0b013e3181915e94; Kimura N, 2005, PATHOL INT, V55, P83, DOI 10.1111/j.1440-1827.2005.01791.x; Korte MR, 2011, NAT REV NEPHROL, V7, P528, DOI 10.1038/nrneph.2011.93; Link A, 2007, NAT IMMUNOL, V8, P1255, DOI 10.1038/ni1513; Link A, 2011, AM J PATHOL, V178, P1662, DOI 10.1016/j.ajpath.2010.12.039; Nakamoto H, 2005, PERITON DIALYSIS INT, V25, pS30; Neusser MA, 2010, KIDNEY INT, V77, P801, DOI 10.1038/ki.2010.6; Peduto L, 2009, J IMMUNOL, V182, P5789, DOI 10.4049/jimmunol.0803974; Raica M, 2008, ANTICANCER RES, V28, P2997; Vlijm A, 2009, PERITON DIALYSIS INT, V29, P517; Yaginuma T, 2012, PERIT DIAL INT	21	10	10	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2012	7	12							e53382	10.1371/journal.pone.0053382	http://dx.doi.org/10.1371/journal.pone.0053382			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	075GO	23300922	Green Submitted, Green Published, Green Accepted, gold			2023-01-03	WOS:000313872600093
J	Nabar, NR; Yuan, F; Lin, XY; Wang, L; Bai, G; Mayl, J; Li, YQ; Zhou, SF; Wang, JH; Cai, JF; Cao, CH				Nabar, Neel R.; Yuan, Fang; Lin, Xiaoyang; Wang, Li; Bai, Ge; Mayl, Jonathan; Li, Yaqiong; Zhou, Shu-Feng; Wang, Jinhuan; Cai, Jianfeng; Cao, Chuanhai			Cell Therapy: A Safe and Efficacious Therapeutic Treatment for Alzheimer's Disease in APP+PS1 Mice	PLOS ONE			English	Article							AMYLOID-PRECURSOR-PROTEIN; TRANSGENIC MICE; DENDRITIC CELLS; BETA-PEPTIDE; MOUSE MODEL; PRESENILIN-1 TRANSGENES; IMMUNE-RESPONSE; MEMORY DEFICITS; ANIMAL-MODEL; T-CELLS	Previously, our lab was the first to report the use of antigen-sensitized dendritic cells as a vaccine against Alzheimer's disease (AD). In preparation of this vaccine, we sensitized the isolated dendritic cells ex vivo with A beta peptide, and administered these sensitized dendritic cells as a therapeutic agent. This form of cell therapy has had success in preventing and/or slowing the rate of cognitive decline when administered prior to the appearance of A beta plaques in PDAPP mice, but has not been tested in 2 x Tg models. Herein, we test the efficacy and safety of this vaccine in halting and reversing Alzheimer's pathology in 9-month-old APP+PS1 mice. The results showed that administration of this vaccine elicits a long-lasting antibody titer, which correlated well with a reduction of A beta burden upon histological analysis. Cognitive function in transgenic responders to the vaccine was rescued to levels similar to those found in non-transgenic mice, indicating that the vaccine is capable of providing therapeutic benefit in APP+PS1 mice when administered after the onset of AD pathology. The vaccine also shows indications of circumventing past safety problems observed in AD immunotherapy, as Th1 pro-inflammatory cytokines were not elevated after long-term vaccine administration. Moreover, microhemorrhaging and T-cell infiltration into the brain are not observed in any of the treated subjects. All in all, this vaccine has many advantages over contemporary vaccines against Alzheimer's disease, and may lead to a viable treatment for the disease in the future.	[Nabar, Neel R.; Zhou, Shu-Feng; Cao, Chuanhai] Univ S Florida, Coll Pharm, Dept Pharmaceut Sci, Tampa, FL 33620 USA; [Nabar, Neel R.; Lin, Xiaoyang; Wang, Li; Mayl, Jonathan; Cao, Chuanhai] Univ S Florida, USF Hlth Byrd Alzheimers Inst, Tampa, FL USA; [Yuan, Fang] Chinese People Liberty Army Gen Hosp, Beijing, Peoples R China; [Yuan, Fang] Third Mil Med Univ, Chongqing, Peoples R China; [Bai, Ge; Li, Yaqiong; Cai, Jianfeng] Univ S Florida, Dept Chem, Tampa, FL 33620 USA; [Wang, Jinhuan] Tianjin Huanhu Hosp, Tianjin, Peoples R China	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Chinese People's Liberation Army General Hospital; Army Medical University; State University System of Florida; University of South Florida	Cao, CH (corresponding author), Univ S Florida, Coll Pharm, Dept Pharmaceut Sci, Tampa, FL 33620 USA.	ccao@health.usf.edu	Zhou, Shu-Feng/E-3166-2013	Zhou, Shu-Feng/0000-0002-5542-6119; Cao, Chuanhai/0000-0002-5765-6401; Nabar, Neel/0000-0002-9704-3570	USF; Tianjin Municipal Science and Technology Commission [09JCZDJC20200]; Tianjin Public Health Bureau [06KG 09]; Byrd Alzheimer's Center start-up grant; University of South Florida College of Pharmacy's start up grant	USF; Tianjin Municipal Science and Technology Commission; Tianjin Public Health Bureau; Byrd Alzheimer's Center start-up grant; University of South Florida College of Pharmacy's start up grant	This research was supported by funds from startup fund of USF and key project of Tianjin Municipal Science and Technology Commission (09JCZDJC20200), as well as by the funds from key project of Tianjin Public Health Bureau (06KG 09). This study was supported by the Byrd Alzheimer's Center start-up grant and the University of South Florida College of Pharmacy's start up grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Alcantar NA, 2010, ALZHEIMERS DEMENT, V6, pS247; Arendash GW, 2001, BRAIN RES, V891, P42, DOI 10.1016/S0006-8993(00)03186-3; Association As, 2012, ALZHEIMERS DEMENT, P131; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bayer AJ, 2005, NEUROLOGY, V64, P94, DOI 10.1212/01.WNL.0000148604.77591.67; Boyd TD, 2010, J ALZHEIMERS DIS, V21, P507, DOI 10.3233/JAD-2010-091471; Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381; Bryan K.J., 2009, TRANSGENIC MOUSE MOD; Cao CH, 2008, J NEUROIMMUNOL, V200, P1, DOI 10.1016/j.jneuroim.2008.05.017; Cao CH, 2009, NEUROBIOL DIS, V34, P63, DOI 10.1016/j.nbd.2008.12.015; Cohen S, 2005, J IMMUNOTHER, V28, P461, DOI 10.1097/01.cji.0000171312.16171.77; Deane R, 2003, NAT MED, V9, P907, DOI 10.1038/nm890; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; Dodart JC, 1999, BEHAV NEUROSCI, V113, P982, DOI 10.1037/0735-7044.113.5.982; Ethell DW, 2006, NEUROBIOL DIS, V23, P351, DOI 10.1016/j.nbd.2006.03.008; Fulop T, 2003, ARTHRITIS RES THER, V5, P290, DOI 10.1186/ar1019; Gajewski TF, 2001, CLIN CANCER RES, V7, p895S; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gandy S, 2011, NATURE, V475, pS15, DOI 10.1038/475S15a; Gordon MN, 2002, EXP NEUROL, V173, P183, DOI 10.1006/exnr.2001.7754; Gotz J, 2011, CELLULAR MOL LIFE SC, P1; Greter M, 2005, NAT MED, V11, P328, DOI 10.1038/nm1197; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Holcomb LA, 1999, BEHAV GENET, V29, P177, DOI 10.1023/A:1021691918517; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Ja H, 1992, SCIENCE, V256, P184; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Katsel P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007642; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kim HD, 2005, BIOCHEM BIOPH RES CO, V336, P84, DOI 10.1016/j.bbrc.2005.08.044; Kutzler MA, 2006, VACCINE, V24, P4630, DOI 10.1016/j.vaccine.2005.08.036; Leighty RE, 2004, BEHAV BRAIN RES, V153, P107, DOI 10.1016/j.bbr.2003.11.004; Loveland BE, 2006, CLIN CANCER RES, V12, P869, DOI 10.1158/1078-0432.CCR-05-1574; Luo Z, 2012, J NEUROIMMUNE PHARM; Maier M, 2006, J NEUROSCI, V26, P4717, DOI 10.1523/JNEUROSCI.0381-06.2006; Merck, 2007, STUD V950 PEOPL ALZH; Mittendorf EA, 2006, CANCER-AM CANCER SOC, V106, P2309, DOI 10.1002/cncr.21849; Monsonego A, 2001, P NATL ACAD SCI USA, V98, P10273, DOI 10.1073/pnas.191118298; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Morgan D, 2003, NEUROCHEM RES, V28, P1029, DOI 10.1023/A:1023255106106; Morgan D, 2011, J INTERN MED, V269, P54, DOI 10.1111/j.1365-2796.2010.02315.x; Novartus, 2011, INV SAF TOL REP SUBC; Octave JN, 1995, REV NEUROSCIENCE, V6, P287; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; PARKER KC, 1994, J IMMUNOL, V152, P163; Pashenkov M, 2001, BRAIN, V124, P480, DOI 10.1093/brain/124.3.480; Pfizer JANSSEN Alzheimer Immunotherapy Research & Development L, 2007, STUD EV ACC 001 SUBJ; Pillay Nirvana S., 2004, Current Alzheimer Research, V1, P295, DOI 10.2174/1567205043331965; Postupna N, 2011, BRAIN PATHOL; Puolivali J, 2002, NEUROBIOL DIS, V9, P339, DOI 10.1006/nbdi.2002.0481; Reitz C, 2011, NAT REV NEUROL, V7, P137, DOI 10.1101/cshperspect.a006239; Satthaporn S, 2001, J ROY COLL SURG EDIN, V46, P159; Saxena Uday, 2011, Int J Physiol Pathophysiol Pharmacol, V3, P133; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Sigurdsson EM, 2002, NEUROBIOL AGING, V23, P1001, DOI 10.1016/S0197-4580(02)00124-0; Smit WM, 1997, HUM IMMUNOL, V53, P216, DOI 10.1016/S0198-8859(96)00285-6; Solomon B, 1997, P NATL ACAD SCI USA, V94, P4109, DOI 10.1073/pnas.94.8.4109; Tabira T, 2010, TOHOKU J EXP MED, V220, P95, DOI 10.1620/tjem.220.95; Toellner KM, 1998, J EXP MED, V187, P1193, DOI 10.1084/jem.187.8.1193; Trinchese F, 2004, ANN NEUROL, V55, P801, DOI 10.1002/ana.20101; Tsai KJ, 2007, J EXP MED, V204, P1273, DOI 10.1084/jem.20062481; Tuppo EE, 2005, INT J BIOCHEM CELL B, V37, P289, DOI 10.1016/j.biocel.2004.07.009; Vellas B, 2009, CURR ALZHEIMER RES, V6, P144, DOI 10.2174/156720509787602852	66	14	15	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 3	2012	7	12							e49468	10.1371/journal.pone.0049468	http://dx.doi.org/10.1371/journal.pone.0049468			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	051DH	23226497	gold, Green Submitted, Green Published			2023-01-03	WOS:000312104700006
J	Alvarez-Breckenridge, CA; Yu, JH; Price, R; Wojton, J; Pradarelli, J; Mao, HY; Wei, M; Wang, Y; He, S; Hardcastle, J; Fernandez, SA; Kaur, B; Lawler, SE; Vivier, E; Mandelboim, O; Moretta, A; Caligiuri, MA; Chiocca, EA				Alvarez-Breckenridge, Christopher A.; Yu, Jianhua; Price, Richard; Wojton, Jeffrey; Pradarelli, Jason; Mao, Hsiaoyin; Wei, Min; Wang, Yan; He, Shun; Hardcastle, Jayson; Fernandez, Soledad A.; Kaur, Balveen; Lawler, Sean E.; Vivier, Eric; Mandelboim, Ofer; Moretta, Alessandro; Caligiuri, Michael A.; Chiocca, E. Antonio			NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors	NATURE MEDICINE			English	Article							HERPES-SIMPLEX-VIRUS; VESICULAR STOMATITIS-VIRUS; HUMAN DENDRITIC CELLS; KILLER-CELLS; TUMOR MICROENVIRONMENT; DEPENDENT MECHANISMS; TRIGGERING RECEPTOR; GLIOMA VIROTHERAPY; ONCOLYTIC VIRUSES; IMMUNE-RESPONSES	The role of the immune response to oncolytic Herpes simplex viral (oHSV) therapy for glioblastoma is controversial because it might enhance or inhibit efficacy. We found that within hours of oHSV infection of glioblastomas in mice, activated natural killer (NK) cells are recruited to the site of infection. This response substantially diminished the efficacy of glioblastoma virotherapy. oHSV-activated NK cells coordinated macrophage and microglia activation within tumors. In vitro, human NK cells preferentially lysed oHSV-infected human glioblastoma cell lines. This enhanced killing depended on the NK cell natural cytotoxicity receptors (NCRs) NKp30 and NKp46, whose ligands are upregulated in oHSV-infected glioblastoma cells. We found that HSV titers and oHSV efficacy are increased in Ncr1(-/-) mice and a Ncr1(-/-) NK cell adoptive transfer model of glioma, respectively. These results demonstrate that glioblastoma virotherapy is limited partially by an antiviral NK cell response involving specific NCRs, uncovering new potential targets to enhance cancer virotherapy.	[Alvarez-Breckenridge, Christopher A.; Price, Richard; Wojton, Jeffrey; Pradarelli, Jason; Wang, Yan; Hardcastle, Jayson; Kaur, Balveen; Lawler, Sean E.; Chiocca, E. Antonio] Ohio State Univ, Med Ctr, Dept Neurol Surg, Dardinger Lab Neurooncol & Neurosci, Columbus, OH 43210 USA; [Alvarez-Breckenridge, Christopher A.; Yu, Jianhua; Price, Richard; Wojton, Jeffrey; Pradarelli, Jason; Mao, Hsiaoyin; Wei, Min; Wang, Yan; He, Shun; Hardcastle, Jayson; Fernandez, Soledad A.; Kaur, Balveen; Lawler, Sean E.; Caligiuri, Michael A.; Chiocca, E. Antonio] James Canc Hosp, Columbus, OH USA; [Alvarez-Breckenridge, Christopher A.; Yu, Jianhua; Price, Richard; Wojton, Jeffrey; Pradarelli, Jason; Mao, Hsiaoyin; Wei, Min; Wang, Yan; He, Shun; Hardcastle, Jayson; Fernandez, Soledad A.; Kaur, Balveen; Lawler, Sean E.; Caligiuri, Michael A.; Chiocca, E. Antonio] Solove Res Inst, Columbus, OH USA; [Alvarez-Breckenridge, Christopher A.; Price, Richard] Ohio State Univ, Med Ctr, Med Scientist Training Program, Columbus, OH 43210 USA; [Yu, Jianhua; Caligiuri, Michael A.] Ohio State Univ, Med Ctr, Div Hematol, Columbus, OH 43210 USA; [Yu, Jianhua; Mao, Hsiaoyin; Wei, Min; He, Shun; Fernandez, Soledad A.; Kaur, Balveen; Caligiuri, Michael A.; Chiocca, E. Antonio] Ohio State Univ, Med Ctr, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Fernandez, Soledad A.] Ohio State Univ, Med Ctr, Ctr Biostat, Columbus, OH 43210 USA; [Vivier, Eric] Univ Aix Marseille 2, INSERM, U631, Ctr Immunol Marseille Luminy, Marseille, France; [Mandelboim, Ofer] Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, Inst Med Res Israel Canada, IL-91010 Jerusalem, Israel; [Moretta, Alessandro] Univ Genoa, Dipartimento Med Sperimentale, Genoa, Italy; [Moretta, Alessandro] Univ Genoa, Ctr Eccellenza Ric Biomed, Genoa, Italy; [Chiocca, E. Antonio] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Sch Med,Dept Neurosurg, Boston, MA 02115 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Hebrew University of Jerusalem; University of Genoa; University of Genoa; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	Chiocca, EA (corresponding author), Ohio State Univ, Med Ctr, Dept Neurol Surg, Dardinger Lab Neurooncol & Neurosci, Columbus, OH 43210 USA.	michael.caligiuri@osumc.edu; eachiocca@partners.org	Vivier, Eric/F-8939-2010; He, Shun/K-7448-2014; kaur, Balveen/E-3355-2011; Wei, Min/GSI-8510-2022	Vivier, Eric/0000-0001-7022-8287; Mandelboim, Ofer/0000-0002-9354-1855	US National Institutes of Health [7U01NS061811, CA069246, CA068458, CA095426, TL1RR025753, CA163205]; American Medical Association Foundation Seed Grant; Dardinger Neuro-oncology Laboratory; NATIONAL CANCER INSTITUTE [P30CA016058, P01CA069246, R01CA155521, R01CA068458, P01CA095426, R37CA068458, R01CA150153, R01CA098472, P01CA163205] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [TL1RR025753] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS064607, U01NS061811] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Medical Association Foundation Seed Grant; Dardinger Neuro-oncology Laboratory; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by US National Institutes of Health grants 7U01NS061811 (to E.A.C.), CA069246 (to E.A.C.), CA068458 (to M.A.C.), CA095426 (to M.A.C.), TL1RR025753 (to C.A.A.-B.) and CA163205 (to E.A.C., M.A.C. and B.K.). C.A.A.-B. was supported by an American Medical Association Foundation Seed Grant. This work was also supported by the Dardinger Neuro-oncology Laboratory.	Aghi M, 2008, ONCOGENE, V27, P4249, DOI 10.1038/onc.2008.53; Altomonte J, 2009, CANCER GENE THER, V16, P266, DOI 10.1038/cgt.2008.74; Altomonte J, 2008, MOL THER, V16, P146, DOI 10.1038/sj.mt.6300343; Arnon TI, 2006, SEMIN CANCER BIOL, V16, P348, DOI 10.1016/j.semcancer.2006.07.005; Arnon TI, 2005, NAT IMMUNOL, V6, P515, DOI 10.1038/ni1190; Bloushtain N, 2004, J IMMUNOL, V173, P2392, DOI 10.4049/jimmunol.173.4.2392; Brandt CS, 2009, J EXP MED, V206, P1495, DOI 10.1084/jem.20090681; Castriconi R, 2009, J IMMUNOL, V182, P3530, DOI 10.4049/jimmunol.0802845; Chiocca EA, 2008, CURR OPIN MOL THER, V10, P38; Chiocca EA, 2002, NAT REV CANCER, V2, P938, DOI 10.1038/nrc948; Chisholm SE, 2007, J INFECT DIS, V195, P1160, DOI 10.1086/512862; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; Degli-Esposti MA, 2005, NAT REV IMMUNOL, V5, P112, DOI 10.1038/nri1549; DeRubertis BG, 2007, CANCER GENE THER, V14, P590, DOI 10.1038/sj.cgt.7701053; Errington F, 2008, J IMMUNOL, V180, P6018, DOI 10.4049/jimmunol.180.9.6018; Farrell CJ, 2008, CLIN CANCER RES, V14, P7711, DOI 10.1158/1078-0432.CCR-08-1364; Ferlazzo G, 2002, J EXP MED, V195, P343, DOI 10.1084/jem.20011149; Friedman A, 2006, CANCER RES, V66, P2314, DOI 10.1158/0008-5472.CAN-05-2661; Fulci G, 2007, CANCER RES, V67, P9398, DOI 10.1158/0008-5472.CAN-07-1063; Fulci G, 2006, P NATL ACAD SCI USA, V103, P12873, DOI 10.1073/pnas.0605496103; Galivo F, 2010, GENE THER, V17, P158, DOI 10.1038/gt.2009.161; Galivo F, 2010, HUM GENE THER, V21, P439, DOI 10.1089/hum.2009.143; Gazit R, 2006, NAT IMMUNOL, V7, P517, DOI 10.1038/ni1322; Ghiasi H, 2000, ANTIVIR RES, V45, P33, DOI 10.1016/S0166-3542(99)00075-3; Giannini C, 2005, NEURO-ONCOLOGY, V7, P164, DOI 10.1215/S1152851704000821; Hayakawa Y, 2006, J IMMUNOL, V176, P1517, DOI 10.4049/jimmunol.176.3.1517; Hellums EK, 2005, NEURO-ONCOLOGY, V7, P213, DOI 10.1215/S1152851705000074; Ikeda K, 1999, NAT MED, V5, P881, DOI 10.1038/11320; Kambara H, 2005, CANCER RES, V65, P2832, DOI 10.1158/0008-5472.CAN-04-3227; Kottke T, 2008, MOL THER, V16, P1910, DOI 10.1038/mt.2008.212; Kottke T, 2009, CLIN CANCER RES, V15, P561, DOI 10.1158/1078-0432.CCR-08-1688; Kurozumi K, 2007, JNCI-J NATL CANCER I, V99, P1768, DOI 10.1093/jnci/djm229; Lundberg P, 2003, J VIROL, V77, P11661, DOI 10.1128/JVI.77.21.11661-11673.2003; Markert JM, 2009, MOL THER, V17, P199, DOI 10.1038/mt.2008.228; Marques CP, 2008, J IMMUNOL, V181, P6417, DOI 10.4049/jimmunol.181.9.6417; Marques CP, 2006, VIRUS RES, V121, P1, DOI 10.1016/j.virusres.2006.03.009; Orange JS, 2006, CURR OPIN ALLERGY CL, V6, P399, DOI 10.1097/ACI.0b013e3280106b65; Prestwich RJ, 2009, HUM GENE THER, V20, P1119, DOI 10.1089/hum.2009.135; Prestwich RJ, 2009, J IMMUNOL, V183, P4312, DOI 10.4049/jimmunol.0901074; Randolph GJ, 2008, CURR OPIN IMMUNOL, V20, P52, DOI 10.1016/j.coi.2007.10.010; Reilly KM, 2000, NAT GENET, V26, P109, DOI 10.1038/79075; Savarin C, 2008, CURR OPIN PHARMACOL, V8, P472, DOI 10.1016/j.coph.2008.05.002; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Sivori S, 1999, EUR J IMMUNOL, V29, P1656, DOI 10.1002/(SICI)1521-4141(199905)29:05<1656::AID-IMMU1656>3.0.CO;2-1; Stanford MM, 2008, CURR OPIN MOL THER, V10, P32; Taylor MA, 2002, EUR J IMMUNOL, V32, P793, DOI 10.1002/1521-4141(200203)32:3<793::AID-IMMU793>3.0.CO;2-M; Todo T, 2001, P NATL ACAD SCI USA, V98, P6396, DOI 10.1073/pnas.101136398; Trotta R, 1998, J IMMUNOL, V161, P6648; Varghese S, 2006, CLIN CANCER RES, V12, P2919, DOI 10.1158/1078-0432.CCR-05-1187; Vitale M, 2005, BLOOD, V106, P566, DOI 10.1182/blood-2004-10-4035; von Strandmann EP, 2007, IMMUNITY, V27, P965, DOI 10.1016/j.immuni.2007.10.010; Wakimoto H, 2004, GENE THER, V11, P214, DOI 10.1038/sj.gt.3302143; Walzer T, 2007, P NATL ACAD SCI USA, V104, P3384, DOI 10.1073/pnas.0609692104; Weiner NE, 1999, J NEUROPATH EXP NEUR, V58, P54, DOI 10.1097/00005072-199901000-00007; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wu AH, 2007, J NEURO-ONCOL, V83, P121, DOI 10.1007/s11060-006-9265-3; Yoshino H, 2000, BONE MARROW TRANSPL, V26, P1211, DOI 10.1038/sj.bmt.1702702; Yu JH, 2011, J CLIN INVEST, V121, P1456, DOI 10.1172/JCI43242; Yu JH, 2010, BLOOD, V115, P274, DOI 10.1182/blood-2009-04-215491	59	138	141	1	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2012	18	12					1827	+		10.1038/nm.3013	http://dx.doi.org/10.1038/nm.3013			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	049QZ	23178246	Green Accepted			2023-01-03	WOS:000311999800031
J	Mackey, TK; Liang, BA				Mackey, Tim K.; Liang, Bryan A.			Patent and Exclusivity Status of Essential Medicines for Non-Communicable Disease	PLOS ONE			English	Article							LOW-INCOME; ACCESS; AVAILABILITY	Objective: The threat of non-communicable diseases ("NCDs") is increasingly becoming a global health crisis and are pervasive in high, middle, and low-income populations resulting in an estimated 36 million deaths per year. There is a need to assess intellectual property rights ("IPRs") that may impede generic production and availability and affordability to essential NCD medicines. Methods: Using the data sources listed below, the study design systematically eliminated NCD drugs that had no patent/exclusivity provisions on API, dosage, or administration route. The first step identified essential medicines that treat certain high disease burden NCDs. A second step examined the patent and exclusivity status of active ingredient, dosage and listed route of administration using exclusion criteria outlined in this study. Materials: We examined the patent and exclusivity status of medicines listed in the World Health Organization's ("WHO") Model List of Essential Drugs (Medicines) ("MLEM") and other WHO sources for drugs treating certain NCDs. i.e., cardiovascular and respiratory disease, cancers, and diabetes. We utilized the USA Food and Drug Administration Orange Book and the USA Patent and Trademark Office databases as references given the predominant number of medicines registered in the USA. Results: Of the 359 MLEM medicines identified, 22% (79/359) address targeted NCDs. Of these 79, only eight required in-depth patent or exclusivity assessment. Upon further review, no NCD MLEM medicines had study patent or exclusivity protection for reviewed criteria. Conclusions: We find that ensuring availability and affordability of potential generic formulations of NCD MLEM medicines appears to be more complex than the presence of IPRs with API, dosage, or administration patent or exclusivity protection. Hence, more sophisticated analysis of NCD barriers to generic availability and affordability should be conducted in order to ensure equitable access to global populations for these essential medicines.	[Mackey, Tim K.; Liang, Bryan A.] Calif Western Sch Law, Inst Hlth Law Studies, San Diego, CA USA; [Mackey, Tim K.] San Diego State Univ, Univ Calif San Diego, Joint Doctoral Program Global Hlth, San Diego, CA 92182 USA; [Liang, Bryan A.] Univ Calif San Diego, Sch Med, San Diego Ctr Patient Safety, San Diego, CA 92103 USA; [Liang, Bryan A.] Univ Calif San Diego, Sch Med, Dept Anesthesiol, San Diego, CA 92103 USA	California State University System; San Diego State University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Mackey, TK (corresponding author), Calif Western Sch Law, Inst Hlth Law Studies, San Diego, CA USA.	tmackey@ucsd.edu	Mackey, Tim/H-9156-2013	Mackey, Tim/0000-0002-2191-7833; Liang, Bryan/0000-0001-7801-5673				Abegunde D, 2011, BACKGROUND PAPER ESS; Alawan A, 2011, WHO NCDS NOW THE LEA; [Anonymous], 2002, PHARMACEUTICAL PRODU; [Anonymous], 2000, DEFINING AND MEASURI; [Anonymous], WHO MODEL LIST OF ES; Attaran A, 2004, HEALTH AFFAIR, V23, P155, DOI 10.1377/hlthaff.23.3.155; Beran D, 2008, B WORLD HEALTH ORGAN, V86, P648, DOI 10.2471/BLT.07.048710; Cameron A, 2009, LANCET, V373, P240, DOI 10.1016/S0140-6736(08)61762-6; Cameron A, 2011, B WORLD HEALTH ORGAN, V89, P412, DOI 10.2471/BLT.10.084327; Carrera PM, 2009, HEALTH AFFAIR, V28, P1861, DOI 10.1377/hlthaff.28.6.1861-a; Chua GN, 2010, HEALTH POLICY, V95, P229, DOI 10.1016/j.healthpol.2009.11.019; Cohen Jillian Clare, 2003, Dev World Bioeth, V3, P27, DOI 10.1111/1471-8847.00058; Connelly P, 2011, SCIENCE, V333, P156, DOI 10.1126/science.333.6039.156-b; Cruz AA, 2009, ALLERGY, V64, P319, DOI 10.1111/j.1398-9995.2009.02026.x; Daar AS, 2007, NATURE, V450, P494, DOI 10.1038/450494a; Farmer P, 2010, LANCET, V376, P1186, DOI 10.1016/S0140-6736(10)61152-X; Gill GV, 2011, DIABETOLOGIA, V54, P19, DOI 10.1007/s00125-010-1897-3; Guglietta A, 2009, NAT CLIN PRACT CARD, V6, P112, DOI 10.1038/ncpcardio1424; Harrison C, 2011, NAT REV DRUG DISCOV, V10, P12, DOI 10.1038/nrd3356; Hollis A, 2006, AN ASSESSMENT OF THE; IMS, 2010, IMS HEALTH FORECASTS; Kishore SP, 2011, J AM COLL CARDIOL, V57, P1980, DOI 10.1016/j.jacc.2010.12.029; Mackey TK, 2012, DRUG DISCOV TODAY, V17, P1254, DOI 10.1016/j.drudis.2012.06.012; Mamudu HM, 2011, GLOB PUBLIC HEALTH, V6, P347, DOI 10.1080/17441692.2011.574230; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Mendis S, 2007, B WORLD HEALTH ORGAN, V85, P279, DOI 10.2471/BLT.06.033647; Metered Dose Inhalers: The Transition to Ozone-Safe Propellants, METERED DOSE INHALER; Miano P, 2011, APPROVAL OWNERSHIP M; Miranda JJ, 2008, TROP MED INT HEALTH, V13, P1225, DOI 10.1111/j.1365-3156.2008.02116.x; Mirza Zafar, 2008, Eastern Mediterranean Health Journal, V14, pS74; Patel A, 2010, HEALTH POLICY PLANN, V25, P61, DOI 10.1093/heapol/czp039; Peters DH, 2008, ANN NY ACAD SCI, V1136, P161, DOI 10.1196/annals.1425.011; Rodgers A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019857; Steinbrook R, 2009, NEW ENGL J MED, V361, P1525, DOI 10.1056/NEJMp0906922; 't Hoen E, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-15; US Food and Drug Administration, 2011, APPROVED DRUG PRODUC, V31st; US Food and Drug Administration, FREQUENTLY ASKED QUE; WHO, 2011, GLOBAL STATUS REPORT; World Health Organization, THE TOP 10 CAUSES OF; World Health Organization, 2008, 2008 2013 ACTION PLA; World Health Organization, 2000, THE USE OF ESSENTIAL	41	10	10	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2012	7	11							e51022	10.1371/journal.pone.0051022	http://dx.doi.org/10.1371/journal.pone.0051022			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	054WM	23226453	Green Published, gold			2023-01-03	WOS:000312376100264
J	Ball, C; Krogstad, E; Chaowanachan, T; Woodrow, KA				Ball, Cameron; Krogstad, Emily; Chaowanachan, Thanyanan; Woodrow, Kim A.			Drug-Eluting Fibers for HIV-1 Inhibition and Contraception	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; SEXUALLY-TRANSMITTED INFECTIONS; SHOCK-SYNDROME TOXIN-1; GLYCEROL MONOLAURATE; TOPICAL MICROBICIDES; VAGINAL LACTOBACILLI; CONTROLLED-RELEASE; SOLID DISPERSIONS; IN-VITRO; DELIVERY	Multipurpose prevention technologies (MPTs) that simultaneously prevent sexually transmitted infections (STIs) and unintended pregnancy are a global health priority. Combining chemical and physical barriers offers the greatest potential to design effective MPTs, but integrating both functional modalities into a single device has been challenging. Here we show that drug-eluting fiber meshes designed for topical drug delivery can function as a combination chemical and physical barrier MPT. Using FDA-approved polymers, we fabricated nanofiber meshes with tunable fiber size and controlled degradation kinetics that facilitate simultaneous release of multiple agents against HIV-1, HSV-2, and sperm. We observed that drug-loaded meshes inhibited HIV-1 infection in vitro and physically obstructed sperm penetration. Furthermore, we report on a previously unknown activity of glycerol monolaurate (GML) to potently inhibit sperm motility and viability. The application of drug-eluting nanofibers for HIV-1 prevention and sperm inhibition may serve as an innovative platform technology for drug delivery to the lower female reproductive tract.	[Ball, Cameron; Krogstad, Emily; Chaowanachan, Thanyanan; Woodrow, Kim A.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Woodrow, KA (corresponding author), Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.	woodrow@u.washington.edu		Mudzingwa, Emily/0000-0003-2736-8350	United States National Institutes of Health (NIH) [5U54HD042454]; University of Washington; Creative and Novel Ideas in HIV Research award [AI027767]; NIH [AI094412, AI098648]; NSF Graduate Research Fellowships; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD042454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI094412, R33AI094412, P30AI027767, R21AI098648] Funding Source: NIH RePORTER	United States National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Washington(University of Washington); Creative and Novel Ideas in HIV Research award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF Graduate Research Fellowships(National Science Foundation (NSF)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Collection of human semen samples from volunteers was performed at the University of Washington Male Fertility Laboratory and was supported by an United States National Institutes of Health (NIH) grant to J. Amory (5U54HD042454). The research was supported by funding to K.A.W. from the University of Washington, the Creative and Novel Ideas in HIV Research award (AI027767), and by partial support from NIH grants AI094412 and AI098648. C.B. and E.K. are partially supported by NSF Graduate Research Fellowships.	Abner SR, 2005, J INFECT DIS, V192, P1545, DOI 10.1086/462424; Akil A, 2011, DRUG DELIV TRANSL RE, V1, P209, DOI 10.1007/s13346-011-0022-6; Anderson JM, 1997, ADV DRUG DELIVER REV, V28, P5, DOI 10.1016/S0169-409X(97)00048-3; [Anonymous], 2012, CAMI MULTIPURPOSE PR, P1; Auras R., 2022, POLY LACTIC ACID SYN; Baeten JM, 2007, CLIN INFECT DIS, V45, P360, DOI 10.1086/519432; Ballagh SA, 2008, CONTRACEPTION, V77, P130, DOI 10.1016/j.contraception.2007.10.003; Blish CA, 2011, AM J REPROD IMMUNOL, V65, P302, DOI 10.1111/j.1600-0897.2010.00930.x; Boulmedarat L, 2005, J PHARM SCI-US, V94, P1300, DOI 10.1002/jps.20350; Cui WG, 2006, BIOMACROMOLECULES, V7, P1623, DOI 10.1021/bm060057z; Cummins JE, 2007, ANTIMICROB AGENTS CH, V51, P1770, DOI 10.1128/AAC.01129-06; Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000; Dorr P, 2005, ANTIMICROB AGENTS CH, V49, P4721, DOI 10.1128/AAC.49.11.4721-4732.2005; Fichorova RN, 2001, J INFECT DIS, V184, P418, DOI 10.1086/322047; Forbes CJ, 2011, J CONTROL RELEASE, V156, P161, DOI 10.1016/j.jconrel.2011.08.006; Free MJ, 1996, CONTRACEPTION, V53, P221, DOI 10.1016/0010-7824(96)00041-8; Friend DR, 2010, ANTIVIR RES, V88, pS47, DOI 10.1016/j.antiviral.2010.09.005; Garg S, 2010, ANTIVIR RES, V88, pS19, DOI 10.1016/j.antiviral.2010.09.010; Glasier A, 2006, LANCET, V368, P1595, DOI 10.1016/S0140-6736(06)69478-6; Graver MA, 2011, ANN CLIN MICROB ANTI, V10, DOI 10.1186/1476-0711-10-8; Ham AS, 2012, PHARM RES-DORDR, V29, P1897, DOI 10.1007/s11095-012-0715-7; Ham AS, 2009, PHARM RES-DORDR, V26, P502, DOI 10.1007/s11095-008-9765-2; Han YA, 2007, CONTRACEPTION, V76, P132, DOI 10.1016/j.contraception.2007.04.006; Herrera C, 2009, ANTIMICROB AGENTS CH, V53, P1797, DOI 10.1128/AAC.01096-08; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; Kieweg SL, 2006, J BIOMECH ENG-T ASME, V128, P540, DOI 10.1115/1.2206198; Li QS, 2009, NATURE, V458, P1034, DOI 10.1038/nature07831; Lin YC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007499; Major I, 2010, IEEE ENG MED BIO, P1089, DOI 10.1109/IEMBS.2010.5627333; Malcolm K, 2003, J CONTROL RELEASE, V91, P355, DOI 10.1016/S0168-3659(03)00260-8; Malcolm RK, 2010, ANTIVIR RES, V88, pS30, DOI 10.1016/j.antiviral.2010.09.003; Malcolm RK, 2005, J ANTIMICROB CHEMOTH, V56, P954, DOI 10.1093/jac/dki326; Minnis AM, 2005, SEX TRANSM INFECT, V81, P193, DOI 10.1136/sti.2003.007153; Moench TR, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-331; Notari S, 2009, IUBMB LIFE, V61, P470, DOI 10.1002/iub.181; Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4; Patton DL, 1999, AM J OBSTET GYNECOL, V180, P1080, DOI 10.1016/S0002-9378(99)70598-3; Peterson ML, 2006, BIOCHEMISTRY-US, V45, P2387, DOI 10.1021/bi051992u; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; PRIME KL, 1991, SCIENCE, V252, P1164, DOI 10.1126/science.252.5009.1164; PROJAN SJ, 1994, J BACTERIOL, V176, P4204, DOI 10.1128/jb.176.14.4204-4209.1994; Rohan LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009310; Saxena BB, 2004, CONTRACEPTION, V70, P213, DOI 10.1016/j.contraception.2004.02.015; Schlievert PM, 2008, ANTIMICROB AGENTS CH, V52, P4448, DOI 10.1128/AAC.00989-08; SCHLIEVERT PM, 1992, ANTIMICROB AGENTS CH, V36, P626, DOI 10.1128/AAC.36.3.626; Schwartz JL, 2008, CONTRACEPTION, V78, P237, DOI 10.1016/j.contraception.2008.04.118; Singer R, 2011, J VIROL, V85, P5504, DOI 10.1128/JVI.02422-10; Strandberg KL, 2010, ANTIMICROB AGENTS CH, V54, P597, DOI 10.1128/AAC.01151-09; Szentivanyi A, 2011, ADV DRUG DELIVER REV, V63, P209, DOI 10.1016/j.addr.2010.12.002; Takeuchi Y, 2008, J VIROL, V82, P12585, DOI 10.1128/JVI.01726-08; Teo Wee-Eong, 2006, Biotechnology Journal, V1, P918, DOI 10.1002/biot.200600044; Teo WE, 2011, SCI TECHNOL ADV MAT, V12, DOI 10.1088/1468-6996/12/1/013002; Van Damme L, 2002, LANCET, V360, P971, DOI 10.1016/S0140-6736(02)11079-8; Vetter SM, 2005, ANTIMICROB AGENTS CH, V49, P1302, DOI 10.1128/AAC.49.4.1302-1305.2005; Wald A, 2002, J INFECT DIS, V185, P45, DOI 10.1086/338231; Watts DH, 1999, J INFECT DIS, V180, P426, DOI 10.1086/314881; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; World Health Organization,, 2010, WHO LAB MAN EX PROC, V5th; Yohe ST, 2012, J AM CHEM SOC, V134, P2016, DOI 10.1021/ja211148a; Yu DG, 2010, INT J PHARMACEUT, V400, P158, DOI 10.1016/j.ijpharm.2010.08.010; Yu DG, 2010, AAPS PHARMSCITECH, V11, P809, DOI 10.1208/s12249-010-9438-4; Zidovetzki R, 2007, BBA-BIOMEMBRANES, V1768, P1311, DOI 10.1016/j.bbamem.2007.03.026	62	25	27	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2012	7	11							e49792	10.1371/journal.pone.0049792	http://dx.doi.org/10.1371/journal.pone.0049792			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	057YW	23209601	Green Submitted, Green Published, gold			2023-01-03	WOS:000312601700019
J	Kong, SS; Liu, JJ; Hwang, TC; Yu, XJ; Zhao, M; Zhao, M; Yuan, BX; Lu, Y; Kang, YM; Wang, B; Zang, WJ				Kong, Shan-Shan; Liu, Jin-Jun; Hwang, Tyzh-Chang; Yu, Xiao-Jiang; Zhao, Mei; Zhao, Ming; Yuan, Bing-Xiang; Lu, Yi; Kang, Yu-Ming; Wang, Bing; Zang, Wei-Jin			Optimizing the Parameters of Vagus Nerve Stimulation by Uniform Design in Rats with Acute Myocardial Infarction	PLOS ONE			English	Article							CHOLINERGIC ANTIINFLAMMATORY PATHWAY; CONGESTIVE-HEART-FAILURE; NECROSIS-FACTOR-ALPHA; VAGAL-STIMULATION; REPERFUSION INJURY; ISCHEMIA; ACTIVATION; PROTECTS; ACETYLCHOLINE; INFLAMMATION	Vagus nerve stimulation (VNS) has been shown to improve left ventricular function and survival in rats with acute myocardial infarction (AMI), and this maneuver has also been adopted clinically for the treatment of patients with chronic heart failure (CHF). Recent in vitro and in vivo studies have suggested that VNS can modulate the level of pro-inflammatory factors. Despite the beneficial effects of VNS, the stimulation parameters for obtaining favorable outcomes appear highly variable. To optimize VNS parameters, we set up different stimulation protocols with different pulse width (1-2 ms), frequency (1-6 Hz), voltage (1-6 V) and duration (40-240 min) of VNS by uniform design (UD). Rats were divided into seven groups with (Group1-Group6) or without VNS (MI group). Our results demonstrate that (1) the parameter sets in Group1, Group2 and Group3 yield the best post-MI protection by VNS, while the protective role were not observed in Group4, Group5 and Group6; (2) baroreflex sensitivity and the alpha 7 nicotinic acetylcholine receptor level were also increased in Group1, Group2 and Group3. (3) the parameter set in Group1 (G1:1 ms, 2 Hz, 3 V, 240 min) is judged the most optimal parameter in this study as rats in this group not only showed a reduced myocardial injury with better-preserved cardiac function compared with other groups, more important, but also exhibited minimal heart rate (HR) reduction. (4) the duration of VNS plays an important role in determining the protection effect of VNS. In conclusion, VNS displays a beneficial role in Group1, Group2 and Group3. Of note, the parameter set in Group1 provides the most optimal cardioprotective effect. These results may provide insight into development of novel treatment for ischemic heart diseases.	[Kong, Shan-Shan; Liu, Jin-Jun; Yu, Xiao-Jiang; Zhao, Mei; Zhao, Ming; Yuan, Bing-Xiang; Lu, Yi; Zang, Wei-Jin] Xi An Jiao Tong Univ, Dept Pharmacol, Coll Med, Xian 710049, Peoples R China; [Hwang, Tyzh-Chang] Univ Missouri, Dept Med Pharmacol & Physiol, Columbia, MO USA; [Hwang, Tyzh-Chang] Univ Missouri, Dalton Cardiovasc Res Ctr, Columbia, MO USA; [Kang, Yu-Ming] Xi An Jiao Tong Univ, Dept Physiol & Pathophysiol, Coll Med, Xian 710049, Peoples R China; [Wang, Bing] Xi An Jiao Tong Univ, Dept Pathol, Coll Med, Xian 710049, Peoples R China	Xi'an Jiaotong University; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; Xi'an Jiaotong University; Xi'an Jiaotong University	Zang, WJ (corresponding author), Xi An Jiao Tong Univ, Dept Pharmacol, Coll Med, Xian 710049, Peoples R China.	zwj@mail.xjtu.edu.cn			Key Project of National Natural Science Foundation of China (NSFC) [30930105]; Major International (Regional) Joint Research Project of NSFC [81120108002]; CMB (China Medical Board) Distinguished Professorships Award [F510000/G16916404]	Key Project of National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Major International (Regional) Joint Research Project of NSFC; CMB (China Medical Board) Distinguished Professorships Award	This work is supported by Key Project of National Natural Science Foundation of China (NSFC) (No. 30930105), Major International (Regional) Joint Research Project of NSFC (No. 81120108002) and CMB (China Medical Board) Distinguished Professorships Award (No. F510000/G16916404). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ando M, 2005, CIRCULATION, V112, P164, DOI 10.1161/CIRCULATIONAHA.104.525493; Aukrust P, 1998, CIRCULATION, V97, P1136, DOI 10.1161/01.CIR.97.12.1136; Aukrust P, 1999, AM J CARDIOL, V83, P376, DOI 10.1016/S0002-9149(98)00872-8; Bernik TR, 2002, J EXP MED, V195, P781, DOI 10.1084/jem.20011714; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Daosukho C, 2007, FREE RADICAL BIO MED, V42, P1818, DOI 10.1016/j.freeradbiomed.2007.03.007; De Ferrari GM, 2011, HEART FAIL REV, V16, P195, DOI 10.1007/s10741-010-9216-0; Fang K, 1980, ACTA ATHEMATICAE APP, P363; Guarini S, 2003, CIRCULATION, V107, P1189, DOI 10.1161/01.CIR.0000050627.90734.ED; Haq S, 2003, NAT MED, V9, P944, DOI 10.1038/nm891; Huston JM, 2006, J EXP MED, V203, P1623, DOI 10.1084/jem.20052362; Irwin MW, 1999, CIRCULATION, V99, P1492, DOI 10.1161/01.CIR.99.11.1492; Jankowska EA, 2006, CARDIOVASC RES, V70, P434, DOI 10.1016/j.cardiores.2006.01.013; Jardine DL, 2005, J PHYSIOL-LONDON, V565, P325, DOI 10.1113/jphysiol.2004.082198; Kakinuma Y, 2005, FEBS LETT, V579, P2111, DOI 10.1016/j.febslet.2005.02.065; Katare RG, 2009, J THORAC CARDIOV SUR, V137, P223, DOI 10.1016/j.jtcvs.2008.08.020; Kawada T, 2006, LIFE SCI, V78, P882, DOI 10.1016/j.lfs.2005.05.087; Kawada T, 2008, LIFE SCI, V83, P490, DOI 10.1016/j.lfs.2008.07.013; Kong SS, 2011, CLIN EXP PHARMACOL P, V38, P300, DOI 10.1111/j.1440-1681.2011.05505.x; Krishnamurthy P, 2009, CIRC RES, V104, pE9, DOI 10.1161/CIRCRESAHA.108.188243; Li M, 2004, CIRCULATION, V109, P120, DOI 10.1161/01.CIR.0000105721.71640.DA; Liakopoulos OJ, 2006, EUR J CARDIO-THORAC, V30, P263, DOI 10.1016/j.ejcts.2006.04.019; Mariappan N, 2009, FREE RADICAL BIO MED, V46, P462, DOI 10.1016/j.freeradbiomed.2008.10.049; Mioni C, 2005, CRIT CARE MED, V33, P2621, DOI 10.1097/01.CCM.0000186762.05301.13; Nakahara T, 1998, AM J PHYSIOL-HEART C, V275, pH562, DOI 10.1152/ajpheart.1998.275.2.H562; SAPER CB, 1990, CIRC RES, V67, P1345, DOI 10.1161/01.RES.67.6.1345; Schachter SC, 1998, EPILEPSIA, V39, P677, DOI 10.1111/j.1528-1157.1998.tb01151.x; Schwartz PJ, 2008, EUR J HEART FAIL, V10, P884, DOI 10.1016/j.ejheart.2008.07.016; Shames BD, 2002, SHOCK, V17, P114, DOI 10.1097/00024382-200202000-00006; Tsutsumi T, 2008, CARDIOVASC RES, V77, P713, DOI 10.1093/cvr/cvm092; Uemura K, 2007, AM J PHYSIOL-HEART C, V293, pH2254, DOI 10.1152/ajpheart.00490.2007; Uemura K, 2010, J CARD FAIL, V16, P689, DOI 10.1016/j.cardfail.2010.03.001; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Yao YY, 2007, J CARD FAIL, V13, P588, DOI 10.1016/j.cardfail.2007.04.009; Yu JG, 2011, EUR HEART J	35	20	22	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 26	2012	7	11							e42799	10.1371/journal.pone.0042799	http://dx.doi.org/10.1371/journal.pone.0042799			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	048RI	23189120	gold, Green Published, Green Submitted			2023-01-03	WOS:000311929800001
J	Moussa, L; Bezirard, V; Salvador-Cartier, C; Bacquie, V; Lencina, C; Leveque, M; Braniste, V; Menard, S; Theodorou, V; Houdeau, E				Moussa, Lara; Bezirard, Valerie; Salvador-Cartier, Christel; Bacquie, Valerie; Lencina, Corinne; Leveque, Mathilde; Braniste, Viorica; Menard, Sandrine; Theodorou, Vassilia; Houdeau, Eric			A Low Dose of Fermented Soy Germ Alleviates Gut Barrier Injury, Hyperalgesia and Faecal Protease Activity in a Rat Model of Inflammatory Bowel Disease	PLOS ONE			English	Article							MIGRATION-INHIBITORY FACTOR; DEXTRAN SULFATE SODIUM; BOWMAN-BIRK INHIBITOR; NECROSIS-FACTOR-ALPHA; ULCERATIVE-COLITIS; COLONIC INFLAMMATION; FACTOR ANTIBODY; CROHNS-DISEASE; ESTROGEN; INTERLEUKIN-10	Pro-inflammatory cytokines like macrophage migration inhibitory factor (MIF), IL-1 beta and TNF-alpha predominate in inflammatory bowel diseases (IBD) and TNBS colitis. Increased levels of serine proteases activating protease-activated receptor 2 (PAR-2) are found in the lumen and colonic tissue of IBD patients. PAR-2 activity and pro-inflammatory cytokines impair epithelial barrier, facilitating the uptake of luminal aggressors that perpetuate inflammation and visceral pain. Soy extracts contain phytoestrogens (isoflavones) and serine protease inhibitors namely Bowman-Birk Inhibitors (BBI). Since estrogens exhibit anti-inflammatory and epithelial barrier enhancing properties, and that a BBI concentrate improves ulcerative colitis, we aimed to evaluate if a fermented soy germ extract (FSG) with standardized isoflavone profile and stable BBI content exert cumulative or synergistic protection based on protease inhibition and estrogen receptor (ER)-ligand activity in colitic rats. Female rats received orally for 15 d either vehicle or FSG with or without an ER antagonist ICI 182.780 before TNBS intracolonic instillation. Macroscopic and microscopic damages, myeloperoxidase activity, cytokine levels, intestinal paracellular permeability, visceral sensitivity, faecal proteolytic activity and PAR-2 expression were assessed 24 h, 3 d and 5 d post-TNBS. FSG treatment improved the severity of colitis, by decreasing the TNBS-induced rise in gut permeability, visceral sensitivity, faecal proteolytic activity and PAR-2 expression at all post-TNBS points. All FSG effects were reversed by the ICI 182.780 except the decrease in faecal proteolytic activity and PAR-2 expression. In conclusion, the anti-inflammatory properties of FSG treatment result from two distinct but synergic pathways i.e an ER-ligand and a PAR-2 mediated pathway, providing rationale for potential use as adjuvant therapy in IBD.	[Moussa, Lara; Bezirard, Valerie; Salvador-Cartier, Christel; Bacquie, Valerie; Lencina, Corinne; Leveque, Mathilde; Braniste, Viorica; Menard, Sandrine; Theodorou, Vassilia; Houdeau, Eric] INRA INPT UPS, Inst Natl Rech Agron, Toxalim UMR1331, Toulouse, France	INRAE; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite Federale Toulouse Midi-Pyrenees (ComUE); Institut National Polytechnique de Toulouse	Moussa, L (corresponding author), INRA INPT UPS, Inst Natl Rech Agron, Toxalim UMR1331, Toulouse, France.	Eric.Houdeau@toulouse.inra.fr	Menard, Sandrine/ABF-8935-2021	Menard, Sandrine/0000-0001-8867-199X; Braniste, Viorica/0000-0003-1992-3609; Leveque, Mathilde/0000-0003-1253-3798				ADAMS RB, 1993, J IMMUNOL, V150, P2356; Alzoghaibi Mohammed Abdullah, 2005, Saudi J Gastroenterol, V11, P63; APPLEYARD CB, 1995, AM J PHYSIOL-GASTR L, V269, pG119, DOI 10.1152/ajpgi.1995.269.1.G119; Arai Y, 1998, CYTOKINE, V10, P890, DOI 10.1006/cyto.1998.0355; Baumgart DC, 2007, LANCET, V369, P1641, DOI 10.1016/S0140-6736(07)60751-X; BIRK Y, 1985, INT J PEPT PROT RES, V25, P113, DOI 10.1111/j.1399-3011.1985.tb02155.x; Braniste V, 2009, J PHYSIOL-LONDON, V587, P3317, DOI 10.1113/jphysiol.2009.169300; Brown AC, 2011, EXPERT REV GASTROENT, V5, P411, DOI [10.1586/EGH.11.29, 10.1586/egh.11.29]; Bueno L, 2000, AM J PHYSIOL-GASTR L, V278, pG670, DOI 10.1152/ajpgi.2000.278.5.G670; Cattaruzza F, 2011, GASTROENTEROLOGY, V141, P1864, DOI 10.1053/j.gastro.2011.07.035; Cenac N, 2003, J IMMUNOL, V170, P4296, DOI 10.4049/jimmunol.170.8.4296; de Jong YP, 2001, NAT IMMUNOL, V2, P1061, DOI 10.1038/ni720; Drewes AM, 2006, INFLAMM BOWEL DIS, V12, P294, DOI 10.1097/01.MIB.0000209365.09189.04; Eijkelkamp N, 2009, BRAIN BEHAV IMMUN, V23, P18, DOI 10.1016/j.bbi.2008.07.006; FABIA R, 1993, DIGESTION, V54, P248, DOI 10.1159/000201045; Filipe P, 2005, PHOTOCH PHOTOBIO SCI, V4, P420, DOI 10.1039/b416811a; Glocker EO, 2009, NEW ENGL J MED, V361, P2033, DOI 10.1056/NEJMoa0907206; HACHET T, 1993, GASTROEN CLIN BIOL, V17, P347; Harnish DC, 2004, AM J PHYSIOL-GASTR L, V286, pG118, DOI 10.1152/ajpgi.00024.2003; Hawkins JV, 1997, DIGEST DIS SCI, V42, P1969, DOI 10.1023/A:1018887832465; Hering NA, 2012, J PHYSIOL-LONDON, V590, P1035, DOI 10.1113/jphysiol.2011.224568; Houdeau E, 2007, GASTROENTEROLOGY, V132, P982, DOI 10.1053/j.gastro.2006.12.028; Hubert J, 2008, FOOD CHEM, V109, P709, DOI 10.1016/j.foodchem.2007.12.081; Hyun E, 2008, GUT, V57, P1222, DOI 10.1136/gut.2008.150722; Ji YP, 2005, PAIN, V117, P433, DOI 10.1016/j.pain.2005.07.011; Kim JA, 2003, INFLAMM BOWEL DIS, V9, P224, DOI 10.1097/00054725-200307000-00002; Konstantinopoulos PA, 2003, EUR J CANCER, V39, P1251, DOI 10.1016/S0959-8049(03)00239-9; Kruidenier L, 2003, FREE RADICAL BIO MED, V34, P753, DOI 10.1016/S0891-5849(02)01426-0; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lichtenstein GR, 2008, DIGEST DIS SCI, V53, P175, DOI 10.1007/s10620-007-9840-2; Madsen KL, 1999, INFLAMM BOWEL DIS, V5, P262, DOI 10.1097/00054725-199911000-00004; Makita H, 1998, AM J RESP CRIT CARE, V158, P573, DOI 10.1164/ajrccm.158.2.9707086; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Morimoto M, 2009, J GASTROENTEROL HEPA; MORTEAU O, 1994, DIGEST DIS SCI, V39, P1239, DOI 10.1007/BF02093789; Moussa L, 2013, CLIN NUTR, V32, P51, DOI 10.1016/j.clnu.2012.05.021; Murakami H, 2002, CLIN EXP IMMUNOL, V128, P504, DOI 10.1046/j.1365-2249.2002.01838.x; Ohkawara T, 2002, GASTROENTEROLOGY, V123, P256, DOI 10.1053/gast.2002.34236; Paul G, 2012, EUR J CLIN INVEST, V42, P95, DOI 10.1111/j.1365-2362.2011.02552.x; Raithel H, 2001, SCAND J GASTROENTERO, V36, P174, DOI 10.1080/003655201750065933; REINECKER HC, 1993, CLIN EXP IMMUNOL, V94, P174; Roka R, 2007, CLIN GASTROENTEROL H, V5, P550, DOI 10.1016/j.cgh.2006.12.004; Seibel J, 2009, EUR J NUTR; Setchell KDR, 2002, AM J CLIN NUTR, V76, P447, DOI 10.1093/ajcn/76.2.447; Shih DQ, 2008, WORLD J GASTROENTERO, V14, P390, DOI 10.3748/wjg.14.390; Soderholm JD, 2004, GUT, V53, P1817, DOI 10.1136/gut.2004.041426; Suzuki T, 2011, J NUTR BIOCHEM, V22, P401, DOI 10.1016/j.jnutbio.2010.08.001; Turner JR, 2006, AM J PATHOL, V169, P1901, DOI 10.2353/ajpath.2006.060681; Verdu EF, 2002, AM J PHYSIOL-GASTR L, V283, pG27, DOI 10.1152/ajpgi.00460.2001; WALLACE JL, 1992, GASTROENTEROLOGY, V102, P1176; Wang FJ, 2005, AM J PATHOL, V166, P409, DOI 10.1016/S0002-9440(10)62264-X; Weber CR, 2007, GUT, V56, P6, DOI 10.1136/gut.2006.104182; Williamson G, 2005, AM J CLIN NUTR, V81, p243S, DOI [10.1093/ajcn/81.1.230S, 10.1093/ajcn/81.1.243S]; Young D, 2012, J NUTR, V142, P363, DOI 10.3945/jn.111.149104	54	45	45	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2012	7	11							e49547	10.1371/journal.pone.0049547	http://dx.doi.org/10.1371/journal.pone.0049547			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	038CD	23166707	Green Published, Green Submitted, gold			2023-01-03	WOS:000311151900161
J	Mi, XS; Feng, Q; Lo, ACY; Chang, RCC; Lin, B; Chung, SK; So, KF				Mi, Xue-Song; Feng, Qian; Lo, Amy Cheuk Yin; Chang, Raymond Chuen-Chung; Lin, Bin; Chung, Sookja Kim; So, Kwok-Fai			Protection of Retinal Ganglion Cells and Retinal Vasculature by Lycium Barbarum Polysaccharides in a Mouse Model of Acute Ocular Hypertension	PLOS ONE			English	Article							AMYLOID PEPTIDE NEUROTOXICITY; ISCHEMIA-REPERFUSION INJURY; GLYCATION END-PRODUCTS; BLOOD-BRAIN-BARRIER; OPEN-ANGLE GLAUCOMA; INTRAOCULAR-PRESSURE; ENDOTHELIAL-CELLS; PRECURSOR PROTEIN; RATS; ACCUMULATION	Acute ocular hypertension (AOH) is a condition found in acute glaucoma. The purpose of this study is to investigate the protective effect of Lycium barbarum polysaccharides (LBP) and its protective mechanisms in the AOH insult. LBP has been shown to exhibit neuroprotective effect in the chronic ocular hypertension (COH) experiments. AOH mouse model was induced in unilateral eye for one hour by introducing 90 mmHg ocular pressure. The animal was fed with LBP solution (1 mg/kg) or vehicle daily from 7 days before the AOH insult till sacrifice at either day 4 or day 7 post insult. The neuroprotective effects of LBP on retinal ganglion cells (RGCs) and blood-retinal-barrier (BRB) were evaluated. In control AOH retina, loss of RGCs, thinning of IRL thickness, increased IgG leakage, broken tight junctions, and decreased density of retinal blood vessels were observed. However, in LBP-treated AOH retina, there was less loss of RGCs with thinning of IRL thickness, IgG leakage, more continued structure of tight junctions associated with higher level of occludin protein and the recovery of the blood vessel density when compared with vehicle-treated AOH retina. Moreover, we found that LBP provides neuroprotection by down-regulating RAGE, ET-1, A beta and AGE in the retina, as well as their related signaling pathways, which was related to inhibiting vascular damages and the neuronal degeneration in AOH insults. The present study suggests that LBP could prevent damage to RGCs from AOH-induced ischemic injury; furthermore, through its effects on blood vessel protection, LBP would also be a potential treatment for vascular-related retinopathy.	[Mi, Xue-Song] Jinan Univ, Affiliated Hosp 1, Dept Ophthalmol, Guangzhou, Guangdong, Peoples R China; [Mi, Xue-Song; Feng, Qian; Chang, Raymond Chuen-Chung; Lin, Bin; Chung, Sookja Kim; So, Kwok-Fai] Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Hong Kong, Hong Kong, Peoples R China; [Mi, Xue-Song; Feng, Qian; Chang, Raymond Chuen-Chung; Lin, Bin; Chung, Sookja Kim; So, Kwok-Fai] Univ Hong Kong, Li Ka Shing Fac Med, State Key Lab Brain & Cognit Sci, Hong Kong, Hong Kong, Peoples R China; [So, Kwok-Fai] Univ Hong Kong, Li Ka Shing Fac Med, Res Ctr Heart Brain Hormone & Healthy Aging, Hong Kong, Hong Kong, Peoples R China; [Lo, Amy Cheuk Yin; Lin, Bin] Univ Hong Kong, Li Ka Shing Fac Med, Inst Eye, Hong Kong, Hong Kong, Peoples R China; [So, Kwok-Fai] Jinan Univ, Joint Lab Brain Funct & Hlth BFAH, Hong Kong, Hong Kong, Peoples R China	Jinan University; University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong	So, KF (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Hong Kong, Hong Kong, Peoples R China.	hrmaskf@hkucc.hku.hk	Lo, Amy C. Y./C-1195-2009; Chang, Raymond Chuen-Chung/C-1107-2009; Lin, Bin/E-9871-2010	Lo, Amy C. Y./0000-0003-4239-6851; Chang, Raymond Chuen-Chung/0000-0001-8538-7993; So, Kwok-Fai/0000-0003-4039-4246; Lin, Bin/0000-0003-1309-3480	Hong Kong Research Grant Council [2011CB707501]; fundamental Research Funds for The Central Universities [21609101]; Azalea Foundation	Hong Kong Research Grant Council(Hong Kong Research Grants Council); fundamental Research Funds for The Central Universities(Fundamental Research Funds for the Central Universities); Azalea Foundation	This study was supported by a GRF (General Research Fund) grant from Hong Kong Research Grant Council (National Basic Research Program of China (2011CB707501)), the fundamental Research Funds for The Central Universities (21609101), and Azalea (1972) Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arai-Gaun S, 2004, INVEST OPHTH VIS SCI, V45, P4226, DOI 10.1167/iovs.04-0450; Bierhaus A, 2005, J MOL MED, V83, P876, DOI 10.1007/s00109-005-0688-7; Bui BV, 2005, INVEST OPHTH VIS SCI, V46, P202, DOI 10.1167/iovs.04-0421; Chan HC, 2007, EXP NEUROL, V203, P269, DOI 10.1016/j.expneurol.2006.05.031; Chen HH, 2011, INVEST OPHTH VIS SCI, V52, P36, DOI 10.1167/iovs.09-5115; Cheung AKH, 2005, DIABETES, V54, P3119, DOI 10.2337/diabetes.54.11.3119; Chi ZL, 2010, HUM MOL GENET, V19, P2606, DOI 10.1093/hmg/ddq146; Chiu Kin, 2009, J Ocul Biol Dis Infor, V2, P127; Chiu K, 2010, J CELL BIOCHEM, V110, P311, DOI 10.1002/jcb.22539; Clark AF, 2003, NAT REV DRUG DISCOV, V2, P448, DOI 10.1038/nrd1106; Cui Q, 2007, NEUROSCIENCE, V146, P986, DOI 10.1016/j.neuroscience.2007.02.034; Da T, 2004, INVEST OPHTH VIS SCI, V45, P4477, DOI 10.1167/iovs.04-0940; Deane R, 2003, NAT MED, V9, P907, DOI 10.1038/nm890; Donello JE, 2001, J PHARMACOL EXP THER, V296, P216; Farrall AJ, 2009, NEUROBIOL AGING, V30, P337, DOI 10.1016/j.neurobiolaging.2007.07.015; FECHTNER RD, 1994, SURV OPHTHALMOL, V39, P23, DOI 10.1016/S0039-6257(05)80042-6; Flammer J, 2002, PROG RETIN EYE RES, V21, P359, DOI 10.1016/S1350-9462(02)00008-3; Fu QL, 2008, INVEST OPHTH VIS SCI, V49, P975, DOI 10.1167/iovs.07-1199; Goldblum D, 2007, INVEST OPHTH VIS SCI, V48, P5085, DOI 10.1167/iovs.06-1249; Hammes HP, 2005, HORM METAB RES, V37, pS39, DOI 10.1055/s-2005-861361; Harada C, 2000, NEUROSCI LETT, V292, P134, DOI 10.1016/S0304-3940(00)01444-0; Ho YS, 2007, BRAIN RES, V1158, P123, DOI 10.1016/j.brainres.2007.04.075; Ho YS, 2009, CELL MOL NEUROBIOL, V29, P1233, DOI 10.1007/s10571-009-9419-x; Huang H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021411; Jablonski M, 2011, PHYSIOL RES, V60, pS113, DOI 10.33549/physiolres.932186; Leung JWC, 2009, BRAIN RES, V1266, P121, DOI 10.1016/j.brainres.2009.01.070; Li LL, 2011, NEURAL REGEN RES, V6, P1720, DOI 10.3969/j.issn.1673-5374.2011.22.007; Li RS, 2006, CLIN EXP OPHTHALMOL, V34, P575, DOI 10.1111/j.1442-9071.2006.01279.x; Li SY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016380; Lo ACY, 2005, J CEREBR BLOOD F MET, V25, P998, DOI 10.1038/sj.jcbfm.9600108; Maczurek A, 2008, ANN NY ACAD SCI, V1126, P147, DOI 10.1196/annals.1433.026; McKinnon SJ, 2002, INVEST OPHTH VIS SCI, V43, P1077; Murata H, 2008, INVEST OPHTH VIS SCI, V49, P5546, DOI 10.1167/iovs.07-1211; PENG XD, 2002, J NINGXIA MED COLL, V24, P79; Quehenberger P, 2000, DIABETES, V49, P1561, DOI 10.2337/diabetes.49.9.1561; Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224; Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7; Sakamoto K, 2009, EXP EYE RES, V88, P974, DOI 10.1016/j.exer.2008.12.011; Shen B, 2010, BRAIN RES, V1342, P118, DOI 10.1016/j.brainres.2010.04.032; Shields MB, 2008, CURR OPIN OPHTHALMOL, V19, P85, DOI 10.1097/ICU.0b013e3282f3919b; SONG Y, 1995, J NINGXIA MED COLL, V17, P12; Stitt AW, 2001, BRIT J OPHTHALMOL, V85, P746, DOI 10.1136/bjo.85.6.746; Takita H, 2003, INVEST OPHTH VIS SCI, V44, P4497, DOI 10.1167/iovs.03-0052; Tezel G, 2007, INVEST OPHTH VIS SCI, V48, P1201, DOI 10.1167/iovs.06-0737; Tombran-Tink J., 2008, MECH GLAUCOMAS DIS P; Wall DS, 2004, INVEST OPHTH VIS SCI, V45, P3704, DOI 10.1167/iovs.03-1410; Whiteley W, 2011, STROKE, V42, P10, DOI 10.1161/STROKEAHA.110.588954; Yamagishi S, 1998, DIABETOLOGIA, V41, P1435, DOI 10.1007/s001250051089; Yang D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033596; Yang LP, 2010, NEURAL REGEN RES, V5, P273, DOI 10.3969/j.issn.1673-5374.2010.04.006; Yu MS, 2007, INT J MOL MED, V20, P261; Yu MS, 2005, EXP GERONTOL, V40, P716, DOI 10.1016/j.exger.2005.06.010; Zheng L, 2007, INVEST OPHTH VIS SCI, V48, P361, DOI 10.1167/iovs.06-0510	53	74	82	1	54	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 19	2012	7	10							e45469	10.1371/journal.pone.0045469	http://dx.doi.org/10.1371/journal.pone.0045469			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	023QT	23094016	Green Published, Green Submitted, gold			2023-01-03	WOS:000310050200001
J	Di Rienzo, F; Collet, C; Hoyek, N; Guillot, A				Di Rienzo, Franck; Collet, Christian; Hoyek, Nady; Guillot, Aymeric			Selective Effect of Physical Fatigue on Motor Imagery Accuracy	PLOS ONE			English	Article							POSTURAL CONTROL; MENTAL PRACTICE; MOVEMENT; REPRESENTATIONS; MOTONEURONS; PERFORMANCE; EMERGENCE; QUALITY	While the use of motor imagery (the mental representation of an action without overt execution) during actual training sessions is usually recommended, experimental studies examining the effect of physical fatigue on subsequent motor imagery performance are sparse and yielded divergent findings. Here, we investigated whether physical fatigue occurring during an intense sport training session affected motor imagery ability. Twelve swimmers (nine males, mean age 15.5 years) conducted a 45 min physically-fatiguing protocol where they swam from 70% to 100% of their maximal aerobic speed. We tested motor imagery ability immediately before and after fatigue state. Participants randomly imagined performing a swim turn using internal and external visual imagery. Self-reports ratings, imagery times and electrodermal responses, an index of alertness from the autonomic nervous system, were the dependent variables. Self-reports ratings indicated that participants did not encounter difficulty when performing motor imagery after fatigue. However, motor imagery times were significantly shortened during posttest compared to both pretest and actual turn times, thus indicating reduced timing accuracy. Looking at the selective effect of physical fatigue on external visual imagery did not reveal any difference before and after fatigue, whereas significantly shorter imagined times and electrodermal responses (respectively 15% and 48% decrease, p < 0.001) were observed during the posttest for internal visual imagery. A significant correlation (r = 0.64; p < 0.05) was observed between motor imagery vividness (estimated through imagery questionnaire) and autonomic responses during motor imagery after fatigue. These data support that unlike local muscle fatigue, physical fatigue occurring during intense sport training sessions is likely to affect motor imagery accuracy. These results might be explained by the updating of the internal representation of the motor sequence, due to temporary feedback originating from actual motor practice under fatigue. These findings provide insights to the co-dependent relationship between mental and motor processes.	[Di Rienzo, Franck; Collet, Christian; Hoyek, Nady; Guillot, Aymeric] Univ Lyon 1, CRIS EA Performance Mentale Motrice & Mat P3M 647, F-69000 Villeurbanne, France; [Guillot, Aymeric] Inst Univ France, F-75000 Paris, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut Universitaire de France	Guillot, A (corresponding author), Univ Lyon 1, CRIS EA Performance Mentale Motrice & Mat P3M 647, F-69000 Villeurbanne, France.	aymeric.guillot@univ-lyon1.fr						Borg G. A., 1998, BORGS RATING PERCEIV; Caeyenberghs K, 2009, DEVELOPMENTAL SCI, V12, P474, DOI 10.1111/j.1467-7687.2008.00803.x; Callow N., 2006, Journal of Imagery Research in Sport and Physical Activity, V1, P2, DOI 10.2202/1932-0191.1001; Choudhury S, 2007, CONSCIOUS COGN, V16, P886, DOI 10.1016/j.concog.2006.11.001; Collet C, 2011, EXERC SPORT SCI REV, V39, P85, DOI 10.1097/JES.0b013e31820ac5e0; Cumming J., 2008, ADV APPL SPORT PSYCH, P5, DOI [10.4324/9780203887073, DOI 10.4324/9780203887073]; Cumming JL, 2001, SPORT PSYCHOL, V15, P276, DOI 10.1123/tsp.15.3.276; Decety J, 1999, TRENDS COGN SCI, V3, P172, DOI 10.1016/S1364-6613(99)01312-1; Demougeot L, 2011, J NEUROSCI, V31, P10712, DOI 10.1523/JNEUROSCI.6032-10.2011; DRISKELL JE, 1994, J APPL PSYCHOL, V79, P481, DOI 10.1037/0021-9010.79.4.481; Ehrsson HH, 2003, J NEUROPHYSIOL, V90, P3304, DOI 10.1152/jn.01113.2002; FELTZ DL, 1983, J SPORT PSYCHOL, V5, P25, DOI 10.1123/jsp.5.1.25; Gandevia SC, 1997, J PHYSIOL-LONDON, V505, P259, DOI 10.1111/j.1469-7793.1997.259bc.x; Grangeon M, 2011, APPL PSYCHOPHYS BIOF, V36, P47, DOI 10.1007/s10484-011-9145-2; Guillot A, 2005, BRAIN RES REV, V50, P387, DOI 10.1016/j.brainresrev.2005.09.004; Guillot A, 2004, J PSYCHOPHYSIOL, V18, P190, DOI 10.1027/0269-8803.18.4.190; Guillot A, 2005, EUR J APPL PHYSIOL, V95, P186, DOI 10.1007/s00421-005-1400-x; Guillot A, 2005, BIOL SPORT, V22, P215; Guillot A, 2011, FUNCTIONAL MAGNETIC, V1; Guillot A., 2008, INT REV SPORT EXER P, V1, P31, DOI [10.1080/17509840701823139, DOI 10.1080/17509840701823139]; Guillot A, 2008, NEUROIMAGE, V41, P1471, DOI 10.1016/j.neuroimage.2008.03.042; Guillot A, 2012, INT REV SPORT EXER P, V5, P3, DOI 10.1080/1750984X.2011.623787; Hall CR, 1998, INT J SPORT PSYCHOL, V29, P73; Holmes PS, 2001, J APPL SPORT PSYCHOL, V13, P60, DOI 10.1080/10413200109339004; JEANNEROD M, 1994, BEHAV BRAIN SCI, V17, P187, DOI 10.1017/S0140525X00034026; Kanekar N, 2008, CLIN NEUROPHYSIOL, V119, P2304, DOI 10.1016/j.clinph.2008.06.015; Lorey B, 2009, EXP BRAIN RES, V194, P233, DOI 10.1007/s00221-008-1693-1; Louis M, 2011, J COGN PSYCHOL, V23, P374, DOI 10.1080/20445911.2011.521739; MacIntyre T, 2007, J IMAGERY RES SPORT, V2; Macuga KL, 2012, NEUROIMAGE, V59, P2798, DOI 10.1016/j.neuroimage.2011.09.083; Molina M, 2008, J EXP CHILD PSYCHOL, V99, P196, DOI 10.1016/j.jecp.2007.10.001; Morris T., 2005, IMAGERY SPORT; Munroe KJ, 2000, SPORT PSYCHOL, V14, P119, DOI 10.1123/tsp.14.2.119; Munroe-Chandler KJ, 2007, RES Q EXERCISE SPORT, V78, P103; Munzert J, 2009, BRAIN RES REV, V60, P306, DOI 10.1016/j.brainresrev.2008.12.024; Olsson CJ, 2012, EXP NEUROL, V236, P46, DOI 10.1016/j.expneurol.2012.03.022; Paillard T, 2012, NEUROSCI BIOBEHAV R, V36, P162, DOI 10.1016/j.neubiorev.2011.05.009; Paivio A., 1985, CANADIAN J APPL SPOR, V10, P22; PASCUALLEONE A, 1995, J NEUROPHYSIOL, V74, P1037, DOI 10.1152/jn.1995.74.3.1037; Roberts R, 2008, J SPORT EXERCISE PSY, V30, P200, DOI 10.1123/jsep.30.2.200; Roure R, 1999, PHYSIOL BEHAV, V66, P63, DOI 10.1016/S0031-9384(99)00026-8; Schuster C, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-75; Schwoebel J, 2002, BRAIN COGNITION, V50, P1, DOI 10.1016/S0278-2626(02)00005-2; SIRIGU A, 1995, NEUROREPORT, V6, P997, DOI 10.1097/00001756-199505090-00012; Stinear C.M., 2010, NEUROPHYSIOLOGICAL F, P47, DOI DOI 10.1093/ACPROF:OSO/9780199546251.003.0004; Stinear CM, 2003, CLIN NEUROPHYSIOL, V114, P909, DOI 10.1016/S1388-2457(02)00373-5; Taylor JL, 2000, EUR J APPL PHYSIOL, V83, P106, DOI 10.1007/s004210000269; VERNETMAURY E, 1995, BEHAV BRAIN RES, V67, P103, DOI 10.1016/0166-4328(94)00148-9; Wolpert DM, 2001, CURR BIOL, V11, pR729, DOI 10.1016/S0960-9822(01)00432-8	49	18	19	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2012	7	10							e47207	10.1371/journal.pone.0047207	http://dx.doi.org/10.1371/journal.pone.0047207			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	038AF	23082148	gold, Green Published			2023-01-03	WOS:000311146900044
J	Nair, H; Simoes, EAF; Rudan, I; Gessner, BD; Azziz-Baumgartner, E; Zhang, JSF; Feikin, DR; Mackenzie, GA; Moisi, JC; Roca, A; Baggett, HC; Zaman, SMA; Singleton, RJ; Lucero, MG; Chandran, A; Gentile, A; Cohen, C; Krishnan, A; Bhutta, ZA; Arguedas, A; Clara, AW; Andrade, AL; Ope, M; Ruvinsky, RO; Hortal, M; McCracken, JP; Madhi, SA; Bruce, N; Qazi, SA; Morris, SS; El Arifeen, S; Weber, MW; Scott, JAG; Brooks, WA; Breiman, RF; Campbell, H				Nair, Harish; Simoes, Eric A. F.; Rudan, Igor; Gessner, Bradford D.; Azziz-Baumgartner, Eduardo; Zhang, Jian Shayne F.; Feikin, Daniel R.; Mackenzie, Grant A.; Moisi, Jennifer C.; Roca, Anna; Baggett, Henry C.; Zaman, Syed M. A.; Singleton, Rosalyn J.; Lucero, Marilla G.; Chandran, Aruna; Gentile, Angela; Cohen, Cheryl; Krishnan, Anand; Bhutta, Zulfiqar A.; Arguedas, Adriano; Clara, Alexey Wilfrido; Andrade, Ana Lucia; Ope, Maurice; Ruvinsky, Raul Oscar; Hortal, Maria; McCracken, John P.; Madhi, Shabir A.; Bruce, Nigel; Qazi, Shamim A.; Morris, Saul S.; El Arifeen, Shams; Weber, Martin W.; Scott, J. Anthony G.; Brooks, W. Abdullah; Breiman, Robert F.; Campbell, Harry		Severe Acute Lower Resp Infections	Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis	LANCET			English	Article							INVASIVE PNEUMOCOCCAL DISEASE; COMMUNITY CASE-MANAGEMENT; AGED 2-59 MONTHS; SEVERE PNEUMONIA; TRACT INFECTIONS; CONJUGATE VACCINE; ORAL AMOXICILLIN; SYNCYTIAL VIRUS; TIME TRENDS; POPULATION	Background The annual number of hospital admissions and in-hospital deaths due to severe acute lower respiratory infections (ALRI) in young children worldwide is unknown. We aimed to estimate the incidence of admissions and deaths for such infections in children younger than 5 years in 2010. Methods We estimated the incidence of admissions for severe and very severe ALRI in children younger than 5 years, stratified by age and region, with data from a systematic review of studies published between Jan 1, 1990, and March 31, 2012, and from 28 unpublished population-based studies. We applied these incidence estimates to population estimates for 2010, to calculate the global and regional burden in children admitted with severe ALRI in that year. We estimated in-hospital mortality due to severe and very severe ALRI by combining incidence estimates with case fatality ratios from hospital-based studies. Findings We identified 89 eligible studies and estimated that in 2010, 11.9 million (95% CI 10.3-13.9 million) episodes of severe and 3.0 million (2.1-4.2 million) episodes of very severe ALRI resulted in hospital admissions in young children worldwide. Incidence was higher in boys than in girls, the sex disparity being greatest in South Asian studies. On the basis of data from 37 hospital studies reporting case fatality ratios for severe ALRI, we estimated that roughly 265 000 (95% CI 160 000-450 000) in-hospital deaths took place in young children, with 99% of these deaths in developing countries. Therefore, the data suggest that although 62% of children with severe ALRI are treated in hospitals, 81% of deaths happen outside hospitals. Interpretation Severe ALRI is a substantial burden on health services worldwide and a major cause of hospital referral and admission in young children. Improved hospital access and reduced inequities, such as those related to sex and rural status, could substantially decrease mortality related to such infection. Community-based management of severe disease could be an important complementary strategy to reduce pneumonia mortality and health inequities.	[Nair, Harish; Rudan, Igor; Campbell, Harry] Univ Edinburgh, Global Hlth Acad, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland; [Nair, Harish] Publ Hlth Fdn India, New Delhi, India; [Simoes, Eric A. F.] Univ Colorado Denver, Denver, CO USA; [Simoes, Eric A. F.] Childrens Hosp, Denver, CO 80218 USA; [Simoes, Eric A. F.] Padjadjaran State Univ, Bandung, Indonesia; [Gessner, Bradford D.] Agence Med Prevent, Paris, France; [Azziz-Baumgartner, Eduardo] Ctr Dis Control & Prevent CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA; [Zhang, Jian Shayne F.] Univ Melbourne, Sch Populat Hlth, Melbourne, Vic 3010, Australia; [Feikin, Daniel R.; Breiman, Robert F.] Ctr Dis Control & Prevent, Nairobi, Kenya; [Feikin, Daniel R.; Chandran, Aruna] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Mackenzie, Grant A.; Zaman, Syed M. A.] Gambia Unit, MRC, Banjul, Gambia; [Moisi, Jennifer C.; Scott, J. Anthony G.] Wellcome Trust Res Programme, Kenya Med Res Inst, Kilifi, Kenya; [Roca, Anna] Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona Ctr Int Hlth Res CRESIB, Barcelona, Spain; [Roca, Anna] Minist Saude, Ctr Invest Saude Manhica, Maputo, Mozambique; [Baggett, Henry C.] Thailand MOPH US CDC Collaborat, Global Dis Detect Reg Ctr, Int Emerging Infect Program, Nonthaburi, Thailand; [Zaman, Syed M. A.] Hlth Protect Agcy, Hlth Protect Serv Colindale, London, England; [Singleton, Rosalyn J.] CDC, Arctic Invest Program, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA; [Singleton, Rosalyn J.] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA; [Lucero, Marilla G.] Res Inst Trop Med, Dept Hlth, Alabang, Muntinlupa, Philippines; [Gentile, Angela] Ricardo Gutierrez Childrens Hosp, Buenos Aires, DF, Argentina; [Cohen, Cheryl; Madhi, Shabir A.] Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Johannesburg, South Africa; [Cohen, Cheryl] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa; [Madhi, Shabir A.] Univ Witwatersrand, MRC, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa; [Madhi, Shabir A.] Univ Witwatersrand, Dept Sci & Technol, Johannesburg, South Africa; [Madhi, Shabir A.] Univ Witwatersrand, Natl Res Fdn Vaccine Preventable Dis, Johannesburg, South Africa; [Krishnan, Anand] All India Inst Med Sci, Ctr Community Med, New Delhi, India; [Bhutta, Zulfiqar A.] Aga Khan Univ, Div Women & Child Hlth, Karachi, Pakistan; [Arguedas, Adriano] Univ Ciencias Med Ctr Amer, Inst Atenc Pediat, San Jose, Costa Rica; [Clara, Alexey Wilfrido] CDC Cent Amer Reg, Guatemala City, Guatemala; [Andrade, Ana Lucia] Univ Fed Goias, Goiania, Go, Brazil; [Ope, Maurice] East African Community Secretariat, Arusha, Tanzania; [Ruvinsky, Raul Oscar] Natl Univ Buenos Aires, Buenos Aires, DF, Argentina; [Hortal, Maria] Natl Univ PNUD, Program Basic Sci Dev, Montevideo, Uruguay; [McCracken, John P.] Univ Valle Guatemala, Ctr Hlth Studies, Guatemala City, Guatemala; [Bruce, Nigel] Univ Liverpool, Liverpool L69 3BX, Merseyside, England; [Qazi, Shamim A.] WHO, Dept Maternal Neonatal & Child & Adolescent Hlth, CH-1211 Geneva, Switzerland; [Morris, Saul S.] Bill & Melinda Gates Fdn, Seattle, WA USA; [El Arifeen, Shams; Brooks, W. Abdullah] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh; [Weber, Martin W.] WHO, Indonesia Country Off, Jakarta, Indonesia	University of Edinburgh; Public Health Foundation of India; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Colorado; Universitas Padjadjaran; Agence de Medecine Preventive; Centers for Disease Control & Prevention - USA; University of Melbourne; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of London; London School of Hygiene & Tropical Medicine; Kenya Medical Research Institute; ISGlobal; CRESIB; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Centro de Investigacao em Saude de Manhica; Health Protection Agency; Centers for Disease Control & Prevention - USA; Alaska Native Tribal Health Consortium; Philippine Department Health; Research Institute for Tropical Medicine - Philippines; Hospital de Ninos Doctor Ricardo Gutierrez; Instituto Nacional de Saude Dr. Ricardo Jorge; University of Buenos Aires; National Institute for Communicable Diseases (NICD); University of Witwatersrand; University of Witwatersrand; University of Witwatersrand; National Research Foundation - South Africa; University of Witwatersrand; All India Institute of Medical Sciences (AIIMS) New Delhi; Aga Khan University; Universidade Federal de Goias; Universidad del Valle de Guatemala; University of Liverpool; World Health Organization; Bill & Melinda Gates Foundation; International Centre for Diarrhoeal Disease Research (ICDDR); World Health Organization	Nair, H (corresponding author), Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland.	harish.nair@ed.ac.uk	Campbell, Harry/E-2959-2010; Rudan, Igor/I-1467-2012; Weber, Martin/GPW-6095-2022; Andrade, Ana Lucia/L-5751-2013; Nair, Harish/E-7431-2010; Krishnan, Anand/D-8537-2012; Theodoratou, Evropi/C-3430-2014; Brooks, W. Abdullah/AAD-3876-2021	Campbell, Harry/0000-0002-6169-6262; Rudan, Igor/0000-0001-6993-6884; Nair, Harish/0000-0002-9432-9100; Krishnan, Anand/0000-0002-9173-7811; Theodoratou, Evropi/0000-0001-5887-9132; Brooks, W. Abdullah/0000-0001-9871-5546; Morris, Saul/0000-0002-9372-7342; Hanlon, Peter/0000-0002-5828-3934; Mackenzie, Grant/0000-0002-4994-2627; Munywoki, Patrick K./0000-0001-9419-7155; McAllister, David/0000-0003-3550-1764; Arifeen, Shams/0000-0002-5372-5932; Cohen, Cheryl/0000-0003-0376-2302; Gupta, Vivek/0000-0002-6157-3705	WHO Global Influenza Program [HQGIP1002906]; GlaxoSmithKline (GSK); Wyeth; Pfizer; Sanofi Pasteur; Crucell; Merck; Novartis; Bill & Melinda Gates Foundation; MRC [MC_UP_A900_1124] Funding Source: UKRI; Medical Research Council [MC_UP_A900_1124] Funding Source: researchfish	WHO Global Influenza Program; GlaxoSmithKline (GSK)(GlaxoSmithKline); Wyeth(Wyeth); Pfizer(Pfizer); Sanofi Pasteur; Crucell; Merck(Merck & Company); Novartis(Novartis); Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	AA has received research grants, honoraria for participation in advisory boards, and travel grants from GlaxoSmithKline (GSK), Wyeth, and Pfizer. BDG works for Agence de Medecine Preventive, which receives unrestricted funding from Sanofi Pasteur, and has received grant support from Crucell, GSK, Merck, Pfizer, and Sanofi Pasteur. JAGS has received research funding from GSK and a travel grant from Merck. SAM has been a clinical trialist in studies of vaccines against pneumonia-causing pathogens from GSK, Pfizer, Sanofi-Aventis, Novartis, and Medimmune; his institution has received research grants from GSK, Pfizer, and Novartis; and he has been on the speaker's bureau of GSK, Pfizer, and Sanofi-Aventis, has received travel support and honoraria, and has acted on advisory boards of GSK, Pfizer, and Novartis. HNo is part of ARIVAC consortium that includes Sanofi Pasteur, undertook a phase 3 trial of an 11-valent pneumococcal conjugate vaccine (Sanofi Pasteur, Lyon, France) in the Philippines in 2002-04, and has received research funding from GSK. ALA has received research grant from GSK, financial support from Pfizer and GSK to attend meetings, and has served as an adviser to Pfizer. WAB has received funding from the Bill & Melinda Gates Foundation for vaccine-related work related to childhood pneumonia; donation of vaccine from Sanofi Pasteur for a vaccine trial against early childhood pneumonia; project funding from Sanofi Pasteur for pneumococcal vaccine trials and a study in pneumococcal pneumonia disease burden in young children; and has been on the speakers bureau for Sanofi Pasteur. SSM is an employee of the Bill & Melinda Gates Foundation. SAQ, AWM, and MWW are WHO staff members. All other authors declare that they have no conflicts of interest.; Financial support for this work was provided by WHO Global Influenza Program (Grant number HQGIP1002906). The findings and conclusions in this report are those of the authors and do not necessarily represent the policies of the United States Centers for Disease Control and Prevention or WHO. This work was done as part of the wider programme of the Child Health Epidemiology Working Group (CHERG) and Global Health Epidemiology Reference Group (GHERG) to establish the major causes of global childhood disease burden. Endang Sedyaningsih sadly died suddenly and unexpectedly while this paper was being prepared for publication. We would like to acknowledge her important contribution to this study and her role as a promoter of child health in Indonesia. We thank Johannes Forster (Department of Paediatrics, St Josefskrankenhaus Freiburg and University of Freiburg, Freiburg, Germany); Gabriele Ihorst (Clinical Trials Center, University Medical Center Freiburg, Freiburg, Germany); and Carlos G Grijalva (Vanderbilt University, US) for providing additional data from their published papers. We are grateful to Felicity Cutts (London School of Hygiene and Tropical Medicine, London, UK); Fatema Khatun, Peter Kim Streatfield, Sajal Kumar Saha, Kamrun Nahar, Amina Tahia Sharmeen, Anjali Bilkis Ara, Sultana Yeasmin (International Centre for Diarrhoeal Disease Research, Bangladesh); Leilani T Nillos (Research Institute for Tropical Medicine, Philippines); Elias Jimenez, Ana Laura Jimenez, Carolina Soley (Instituto de Atencion Pediatrica, Costa Rica); Ron Dagan, Nurith Porat (Pediatric Infectious Disease Unit, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Guiron University of the Negav, Beer-Sheva, Israel); Gail Rodgers, Sharon Gray, Darmendra Ramcharran (Pfizer Inc. Collegeville, PA, USA); Uchendu Uchendu, David Ameh, Bolanle Akinsola, Readon Ideh, Bernard Ebruke, Debasish Saha, Momodou Jasseh (MRC Unit, The Gambia); Pedro L Alonso, Llorenc Quinto (Barcelona Centre for International Health Research (CRESIB, Hospital Clinic-Universitat de Barcelona) and Centro de Investigacao em Saude de Manhica, Mozambique); Maria Aparecida da Silva Vieira (Pontifical Catholic University of Goias, Goiania, Brazil); Renato Mauricio Oliveira (Federal University of Goias, Goiania, Brazil); Vicente Porfirio Pessoa-Jr (Secretariat of Health of Municipality of Goiania, Brazil); Simonne Nouer (UTHSC-Department of Preventive Medicine, Memphis, TN, USA); Licia Kamilla Assis Melo Thorn (Karolinska Institutet, Stockholm); Luiza Helena Ribeiro (Samaritano Hospital, Goiania, Brazil); Jose Cassio de Moraes (Santa Casa School of Medical Sciences, Sao Paulo, Brazil); David Rodriguez (Ministry of Health of El Salvador); Celina de Lozano (National Influenza Center of El Salvador); Kim A Lindblade, Jennifer Verani (US Centers for Disease Control and Prevention Regional Office for Central America and Panama, International Emerging Infections Program, Guatemala); Somsak Thamthitiwat, Sununta Henchaichon, Prabda Prapasiri, Sathapana Naorat (International Emerging Infections Program, Global Disease Detection Regional Center, Thailand Ministry of Public Health - U. S. Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand); Peera Areerat (Nakhon Phanom Provincial Health Office, Nakhon Phanom, Thailand); Asadang Ruayajin (Sa Kaeo Provincial Health Office, Sa Kaeo, Thailand) for their assistance.; The Indian Council for Medical Research (ICMR) led a multisite study with funding provided by the Hib Initiative; we thank the investigators at ICMR and the study sites of Christian Medical College, Vellore; Post Graduate Institute of Medical Education and Research, Chandigarh; and the National Institute of Cholera and Enteric Diseases, Kolkata. Costa Rica's LEAP study team thank all the physicians within the study area, in private practice, and from the Caja Costarricense de Seguro Social for referring their patients to participate in the active epidemiological surveillance. We thank the South African Severe Acute Respiratory Infections Surveillance Group, Wyeth-Pfizer, CNPq-Brazilian Council for Scientific Development and Technology, MRC Gambia Pneumococcal Surveillance Project and Severe Pneumonia Studies teams, MRC Gambia Basse Health and Demographic Surveillance System, Gambia Government, Basse Health Centre staff, the MRC Gambia Pneumococcal Vaccine Trial team for their assistance; Ana Ceballos, (CEDEPAP, Cordoba, Argentina), Jane Crawley (University of Oxford), and Olaf Muller (Ruprecht-Karls-University Heidelberg, Germany) for participating in the Working Group Meeting and providing valuable inputs; and Arti Nair (University of Edinburgh) for assistance with extracting data from the DHS and MICS databases.	Alam N, 2009, MATERN CHILD HLTH J, V13, P119, DOI 10.1007/s10995-008-0320-x; Anh DD, 2009, CLIN INFECT DIS, V48, pS57, DOI 10.1086/596483; [Anonymous], 2012, REC MAN COMM CHILDH; Ansaldi F, 2008, J INT MED RES, V36, P1255, DOI 10.1177/147323000803600612; Banajeh SM, 1998, J TROP PEDIATRICS, V44, P343, DOI 10.1093/tropej/44.6.343; Baqui AH, 2007, J HEALTH POPUL NUTR, V25, P179; Bari A, 2011, LANCET, V378, P1796, DOI 10.1016/S0140-6736(11)61140-9; Brooks WA, 2005, LANCET, V366, P999, DOI 10.1016/S0140-6736(05)67109-7; BYASS P, 1991, J TROP MED HYG, V94, P22; Campbell D, 2004, J TROP PEDIATRICS, V50, P158, DOI 10.1093/tropej/50.3.158; Carroll KN, 2008, PEDIATRICS, V122, P58, DOI 10.1542/peds.2007-2087; Chandyo RK, 2010, J NUTR, V140, P1677, DOI 10.3945/jn.109.117978; Che D, 2010, EPIDEMIOL INFECT, V138, P573, DOI 10.1017/S0950268809990951; Chen W, 1997, CHINESE J RURAL MED, V25, P25; Cheng P, 1996, JIANGSU J PREV MED, V2, P48; Chi XX, 1996, STRAIT J PREV MED, V2, P1; Chowdhury EK, 2008, LANCET, V372, P822, DOI 10.1016/S0140-6736(08)61166-6; Cilla G, 2009, EPIDEMIOL INFECT, V137, P66, DOI 10.1017/S0950268808000666; Comes Castellano A M, 2005, An Med Interna, V22, P118; Department of Child and Adolescent Health, 2005, HDB IMCI INT MAN CHI; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Forster J, 2004, EUR J PEDIATR, V163, P709, DOI 10.1007/s00431-004-1523-9; Gao JY, 2004, CHINESE J MATERNAL C, V19, P13; Garces-Sanchez M D, 2005, An Pediatr (Barc), V63, P125; Gil A, 2002, J INFECTION, V44, P84, DOI 10.1053/jinf.2002.0966; Grant CC, 1998, J PAEDIATR CHILD H, V34, P355, DOI 10.1046/j.1440-1754.1998.00237.x; Grijalva CG, 2010, CLIN INFECT DIS, V50, P805, DOI 10.1086/650573; Henrickson KJ, 2004, PEDIATR INFECT DIS J, V23, pS11, DOI 10.1097/01.inf.0000108188.37237.48; Ho PL, 2007, VACCINE, V25, P6837, DOI 10.1016/j.vaccine.2007.07.039; Hoo AF, 2002, AM J RESP CRIT CARE, V165, P1084, DOI 10.1164/ajrccm.165.8.2103035; Hu YC, 1996, SHANGHAI J PREV MED, V8, P94; Huang WH, 1999, STRAIT J PREV MED, V5, P21; JOKINEN C, 1993, AM J EPIDEMIOL, V137, P977, DOI 10.1093/oxfordjournals.aje.a116770; Lee GE, 2010, PEDIATRICS, V126, P204, DOI 10.1542/peds.2009-3109; Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1; Liu Q, 1994, ACTA ACAD MED QINGDA, V30, P232; Lou LY, 1995, CHINESE J PRIMARY HL, V9, P39; Lowther SA, 2000, PEDIATR INFECT DIS J, V19, P11, DOI 10.1097/00006454-200001000-00004; Madhi SA, 2005, CLIN INFECT DIS, V40, P1511, DOI 10.1086/429828; Magree HC, 2005, B WORLD HEALTH ORGAN, V83, P427; Mo JZ, 1998, CHINESE J PRIMARY HL, V12, P26; Monge V, 2001, INFECTION, V29, P3, DOI 10.1007/s15010-001-0024-2; Moore HC, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-757; Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7; Nair H, 2011, LANCET, V378, P1917, DOI 10.1016/S0140-6736(11)61051-9; Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1; Nizami Shaikh Qamaruddin, 2006, JPMA Journal of the Pakistan Medical Association, V56, P163; Owais A, 2010, TROP MED INT HEALTH, V15, P1029, DOI 10.1111/j.1365-3156.2010.02591.x; Palacios G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008540; Pandey A, 2002, J HEALTH POPUL NUTR, V20, P306; Peck AJ, 2005, PEDIATR INFECT DIS J, V24, P342, DOI 10.1097/01.inf.0000157250.95880.91; Qu JS, 2009, QILU J MED, V24, P37; Robertson SE, 2004, B WORLD HEALTH ORGAN, V82, P914; Roxburgh CSD, 2008, ARCH DIS CHILD, V93, P316, DOI 10.1136/adc.2007.126540; Rudan I, 2005, LANCET, V365, P2031, DOI 10.1016/S0140-6736(05)66697-4; Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769; Russell FM, 2009, ANN TROP PAEDIATR, V29, P111, DOI 10.1179/146532809X440725; Shah AS, 2009, CLIN INFECT DIS, V48, pS123, DOI 10.1086/596490; Shah Aparna S, 2009, Indian J Med Sci, V63, P498; Soofi S, 2012, LANCET, V379, P729, DOI 10.1016/S0140-6736(11)61714-5; Subhi R, 2009, LANCET INFECT DIS, V9, P219, DOI 10.1016/S1473-3099(09)70071-4; Sun YF, 1992, CHINESE MATERNAL CHI, V7, P42; Sutanto A, 2002, AM J TROP MED HYG, V66, P175, DOI 10.4269/ajtmh.2002.66.175; Tornheim JA, 2007, INT J INFECT DIS, V11, P536, DOI 10.1016/j.ijid.2007.03.006; TUPASI TE, 1990, REV INFECT DIS, V12, pS940; van Gageldonk-Lafeber AB, 2009, EPIDEMIOL INFECT, V137, P1472, DOI 10.1017/S0950268809002258; Vicente D, 2003, EPIDEMIOL INFECT, V131, P867, DOI 10.1017/S0950268803008926; Wang L, 1997, CHINESE J PRIMARY HL, V11, P28; Weber MW, 2002, B WORLD HEALTH ORGAN, V80, P562; Weigl JAI, 2005, KLIN PADIATR, V217, P211, DOI 10.1055/s-2004-822699; Weinberg GA, 2009, J PEDIATR-US, V154, P694, DOI 10.1016/j.jpeds.2008.11.034; Williams EJ, 2009, CLIN INFECT DIS, V48, pS114, DOI 10.1086/596488; Williams P, 1997, INT J EPIDEMIOL, V26, P797, DOI 10.1093/ije/26.4.797; Wu PS, 2009, PEDIATR PULM, V44, P162, DOI 10.1002/ppul.20969; Xie SM, 1993, CHONGQING MED J, V22, P375; Xu GL, 2000, MATERN CHILD HLTH J, V14, P36; Yorita KL, 2008, PEDIATRICS, V121, P244, DOI 10.1542/peds.2007-1392; Yoshida LM, 2010, PEDIATR INFECT DIS J, V29, P75, DOI 10.1097/INF.0b013e3181af61e9; Zaman K, 1997, J TROP PEDIATRICS, V43, P133, DOI 10.1093/tropej/43.3.133	79	448	466	4	68	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 20	2013	381	9875					1380	1390		10.1016/S0140-6736(12)61901-1	http://dx.doi.org/10.1016/S0140-6736(12)61901-1			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130EF	23369797	Green Published, Green Accepted			2023-01-03	WOS:000317894800035
J	Chinthapalli, K				Chinthapalli, Krishna			The Liverpool care pathway: what do specialists think?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												kchinthapalli@bmj.com	Chinthapalli, Krishna/P-8428-2019	Chinthapalli, Krishna/0000-0003-4136-4882				[Anonymous], 2012, DAILY TELEGRAPH; Bingham J., 2012, DAILY TELEGRAPH; Chan R, 2010, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008006.pub2, 10.1002/14651858.CD008006.pub4]; DAVIES HTO, 1994, BRIT MED J, V309, P1579, DOI 10.1136/bmj.309.6968.1579a; Department of Health, 2013, LIV CAR PATHW IND RE; Department of Health, 2011, OP FRAM NHS ENGL 201; Ellershaw J, 2003, BRIT MED J, V326, P30, DOI 10.1136/bmj.326.7379.30; Heatherwood and Wexham Park Hospitals NHS Foundation Trust, 2012, LIV CAR PATHW CQUINS; McCartney M, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e7316; MILLS M, 1994, BRIT MED J, V309, P583, DOI 10.1136/bmj.309.6954.583; National End of Life Care Programme, 2012, LEARN PEOPL EXP LAST; National Institute for Health and Clinical Excellence, 2011, GUID COMM END LIF CA; Phillips M., 2012, DAILY MAIL; Royal Brompton and Harefield NHS Foundation Trust, QUAL ACC 2010 11; Torjesen I, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f175; VanGeest JB, 2007, EVAL HEALTH PROF, V30, P303, DOI 10.1177/0163278707307899	16	11	11	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 1	2013	346								f1184	10.1136/bmj.f1184	http://dx.doi.org/10.1136/bmj.f1184			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	149WE	23449644				2023-01-03	WOS:000319351300002
J	De Sibio, MT; Luvizotto, RAM; Olimpio, RMC; Correa, CR; Marino, J; de Oliveira, M; Conde, SJ; Ferreira, ALD; Padovani, CR; Nogueira, CR				De Sibio, Maria Teresa; Melo Luvizotto, Renata Azevedo; Castro Olimpio, Regiane Marques; Correa, Camila Renata; Marino, Juliana; de Oliveira, Miriane; Conde, Sandro Jose; dos Anjos Ferreira, Ana Lucia; Padovani, Carlos Roberto; Nogueira, Celia Regina			A Comparative Genotoxicity Study of a Supraphysiological Dose of Triiodothyronine (T-3) in Obese Rats Subjected to Either Calorie-Restricted Diet or Hyperthyroidism	PLOS ONE			English	Article							HIGH-FAT DIET; BODY-WEIGHT GAIN; OXIDATIVE STRESS; GENE-EXPRESSION; THYROID-HORMONE; LEPTIN CONCENTRATIONS; RADICAL GENERATION; CIRCULATING LEPTIN; BLOOD-PRESSURE; PLASMA LEPTIN	This study was designed to determine the genotoxicity of a supraphysiological dose of triiodothyronine (T-3) in both obese and calorie-restricted obese animals. Fifty male Wistar rats were randomly assigned to one of the two following groups: control (C; n = 10) and obese (OB; n = 40). The C group received standard food, whereas the OB group was fed a hypercaloric diet for 20 weeks. After this period, half of the OB animals (n = 20) were subjected to a 25%-calorie restriction of standard diet for 8 weeks forming thus a new group (OR), whereas the remaining OB animals were kept on the initial hypercaloric diet. During the following two weeks, 10 OR animals continued on the calorie restriction diet, whereas the remaining 10 rats of this group formed a new group (ORS) given a supraphysiological dose of T-3 (25 mu g/100 g body weight) along with the calorie restriction diet. Similarly, the remaining OB animals were divided into two groups, one that continued on the hypercaloric diet (OB, n = 10), and one that received the supraphysiological dose of T-3 (25 mu g/100 g body weight) along with the hypercaloric diet (OS, n = 10) for two weeks. The OB group showed weight gain, increased adiposity, insulin resistance, increased leptin levels and genotoxicity; T-3 administration in OS animals led to an increase in genotoxicity and oxidative stress when compared with the OB group. The OR group showed weight loss and normalized levels of adiposity, insulin resistance, serum leptin and genotoxicity, thus having features similar to those of the C group. On the other hand, the ORS group, compared to OR animals, showed higher genotoxicity. Our results indicate that regardless of diet, a supraphysiological dose of T-3 causes genotoxicity and potentiates oxidative stress.	[De Sibio, Maria Teresa; Melo Luvizotto, Renata Azevedo; Castro Olimpio, Regiane Marques; Marino, Juliana; de Oliveira, Miriane; Conde, Sandro Jose; dos Anjos Ferreira, Ana Lucia; Nogueira, Celia Regina] Univ Sao Paulo State UNESP, Botucatu Med Sch, Dept Internal Med, Botucatu, SP, Brazil; [Correa, Camila Renata] Univ Sao Paulo State UNESP, Botucatu Med Sch, Dept Pathol, Botucatu, SP, Brazil; [Padovani, Carlos Roberto] Univ Sao Paulo State UNESP, Biosci Inst, Dept Biostat, Botucatu, SP, Brazil	Universidade Estadual Paulista; Universidade Estadual Paulista; Universidade Estadual Paulista	De Sibio, MT (corresponding author), Univ Sao Paulo State UNESP, Botucatu Med Sch, Dept Internal Med, Botucatu, SP, Brazil.	mt_bio@yahoo.com.br	De Sibio, Maria/AAM-4561-2020; Padovani, Carlos Roberto/A-3656-2013; Nogueira, Celia Regina/AAF-7440-2022; Correa, Camila/Q-2071-2019; Conde, Sandro J/E-6249-2013; Nogueira, Celia Regina/AFK-0463-2022	Padovani, Carlos Roberto/0000-0002-7719-9682; Nogueira, Celia Regina/0000-0002-4014-0660; Correa, Camila/0000-0002-6915-4230; Conde, Sandro J/0000-0003-1876-5418; Nogueira, Celia Regina/0000-0002-4014-0660; Correa, Camila Renata/0000-0001-8493-5329	CAPES Coordenacao de Aperfeicoamento de Pessoal de Nivel; FAPESP Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [2008/57310-3]	CAPES Coordenacao de Aperfeicoamento de Pessoal de Nivel(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); FAPESP Fundacao de Amparo a Pesquisa do Estado de Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This study was supported by CAPES Coordenacao de Aperfeicoamento de Pessoal de Nivel and FAPESP Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (process no 2008/57310-3). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abel ED, 2003, MOL ENDOCRINOL, V17, P1767, DOI 10.1210/me.2003-0109; Ahmed OM, 2012, INT J DEV NEUROSCI, V30, P517, DOI 10.1016/j.ijdevneu.2012.04.005; Ainslie DA, 2000, AM J CLIN NUTR, V71, P438; ASTRUP A, 1994, AM J CLIN NUTR, V59, P350, DOI 10.1093/ajcn/59.2.350; Barnes MJ, 2003, BRAIN RES BULL, V61, P511, DOI 10.1016/S0361-9230(03)00188-6; Bell-Anderson Kim S, 2004, Treat Endocrinol, V3, P11, DOI 10.2165/00024677-200403010-00002; Brown JL, 2002, ENDOCRINE, V19, P327, DOI 10.1385/ENDO:19:3:327; Claret M, 2004, OBES RES, V12, P1596, DOI 10.1038/oby.2004.199; Cowburn G, 1997, BRIT MED BULL, V53, P389, DOI 10.1093/oxfordjournals.bmb.a011619; Daly ME, 2006, DIABETIC MED, V23, P15, DOI 10.1111/j.1464-5491.2005.01760.x; Dimitriadis GD, 2001, EXP CLIN ENDOCR DIAB, V109, pS225, DOI 10.1055/s-2001-18584; Elliott JC, 2004, MOL BRAIN RES, V128, P150, DOI 10.1016/j.molbrainres.2004.06.010; Estadella D, 2004, NUTRITION, V20, P218, DOI 10.1016/j.nut.2003.10.008; FERNANDEZ V, 1985, ENDOCRINOLOGY, V117, P496, DOI 10.1210/endo-117-2-496; Fukuchi M, 2002, LIFE SCI, V71, P1059, DOI 10.1016/S0024-3205(02)01791-5; Gaiva MHG, 2001, BRIT J NUTR, V86, P371, DOI 10.1079/BJN2001392; Giannocco G, 2004, MOL CELL ENDOCRINOL, V226, P19, DOI 10.1016/j.mce.2004.07.007; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; HARRIS RBS, 1994, INT J OBESITY, V18, P632; Henning B, 2001, J AM COLL NUTR, V20, P97, DOI 10.1080/07315724.2001.10719021; Heydari AR, 2007, NUCLEIC ACIDS RES, V35, P7485, DOI 10.1093/nar/gkm860; Hudig F, 1997, J ENDOCRINOL, V152, P413, DOI 10.1677/joe.0.1520413; Johnstone AM, 2005, AM J CLIN NUTR, V82, P941, DOI 10.1093/ajcn/82.5.941; Kautzky-Willer A, 1999, EUR J CLIN INVEST, V29, P395, DOI 10.1046/j.1365-2362.1999.00470.x; Levin BE, 2002, AM J PHYSIOL-REG I, V283, pR941, DOI 10.1152/ajpregu.00245.2002; Levin BE, 2004, AM J PHYSIOL-REG I, V286, pR771, DOI 10.1152/ajpregu.00650.2003; Li L, 2009, EYE, V23, P1464, DOI 10.1038/eye.2008.281; Lopez-Torres M, 2002, FREE RADICAL BIO MED, V32, P882, DOI 10.1016/S0891-5849(02)00773-6; Luvizotto RAM, 2011, HORM METAB RES, V43, P452, DOI 10.1055/s-0031-1277187; Magsino CH, 2000, METABOLISM, V49, P799, DOI 10.1053/meta.2000.6263; Mattson MP, 2005, J NUTR BIOCHEM, V16, P129, DOI 10.1016/j.jnutbio.2004.12.007; Miyamae Y, 1998, Mutat Res, V415, P229, DOI 10.1016/S1383-5718(97)00192-7; Nascimento AF, 2011, LIFE SCI, V88, P1031, DOI 10.1016/j.lfs.2011.03.015; Nikolich-Zugich J, 2005, EXP GERONTOL, V40, P884, DOI 10.1016/j.exger.2005.06.007; O'Brien PE, 2002, AM J SURG, V184, p4S, DOI 10.1016/S0002-9610(02)01172-8; Oldham KM, 2002, JPEN-PARENTER ENTER, V26, P189, DOI 10.1177/0148607102026003189; Parks E J, 2001, Curr Atheroscler Rep, V3, P462, DOI 10.1007/s11883-001-0036-5; Pinkney JH, 1998, CLIN ENDOCRINOL, V49, P583, DOI 10.1046/j.1365-2265.1998.00573.x; Reinehr T, 2010, MOL CELL ENDOCRINOL, V316, P165, DOI 10.1016/j.mce.2009.06.005; Roberts CK, 2002, CIRCULATION, V106, P2530, DOI 10.1161/01.CIR.0000040584.91836.0D; Rotondi M, 2011, J CLIN ENDOCR METAB, V96, P344, DOI 10.1210/jc.2010-2515; Rybus-Kalinowska Barbara, 2008, Pol Arch Med Wewn, V118, P420; Sanchez-Suarez P, 2008, MUTAT RES-FUND MOL M, V640, P8, DOI 10.1016/j.mrfmmm.2007.11.008; Schrauwen P, 2000, BRIT J NUTR, V84, P417, DOI 10.1017/S0007114500001720; Setia S, 2007, CLIN CHIM ACTA, V376, P37, DOI 10.1016/j.cca.2006.07.007; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Thompson WG, 2005, OBES RES, V13, P1344, DOI 10.1038/oby.2005.163; TICE RR, 1991, ADV EXP MED BIOL, V283, P157; van Dam RM, 2002, DIABETES CARE, V25, P417, DOI 10.2337/diacare.25.3.417; Vasselli JR, 2005, OBES RES, V13, P693, DOI 10.1038/oby.2005.78; Venditti P, 2006, CELL MOL LIFE SCI, V63, P414, DOI 10.1007/s00018-005-5457-9; Vendrell J, 2004, OBES RES, V12, P962, DOI 10.1038/oby.2004.118; Videla LA, 2000, REDOX REP, V5, P265, DOI 10.1179/135100000101535807; Viguerie N, 2005, DIABETOLOGIA, V48, P123, DOI 10.1007/s00125-004-1618-x; Willett WC, 2001, J INTERN MED, V249, P395, DOI 10.1046/j.1365-2796.2001.00822.x; Wolfe BE, 2004, CLIN ENDOCRINOL, V61, P332, DOI 10.1111/j.1365-2265.2004.02101.x; Wynder EL, 1997, JNCI-J NATL CANCER I, V89, P766, DOI 10.1093/jnci/89.11.766; Zabrocka L, 2006, LIFE SCI, V79, P1114, DOI 10.1016/j.lfs.2006.03.009	59	15	15	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2013	8	2							e56913	10.1371/journal.pone.0056913	http://dx.doi.org/10.1371/journal.pone.0056913			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	098DA	23468891	gold, Green Submitted, Green Published			2023-01-03	WOS:000315524900043
J	Ferrari, R				Ferrari, Robert			Rewriting the book on whiplash	LANCET			English	Editorial Material							INJURY; DISORDERS; TRAUMA; SPINE; RULE		[Ferrari, Robert] Univ Alberta, Dept Rheumat Dis, Edmonton, AB T6G 2P4, Canada; [Ferrari, Robert] Univ Alberta, Dept Med, Edmonton, AB T6G 2P4, Canada	University of Alberta; University of Alberta	Ferrari, R (corresponding author), Univ Alberta, Dept Rheumat Dis, Edmonton, AB T6G 2P4, Canada.	rferrari@shaw.ca						Carroll LJ, 2009, J RHEUMATOL, V36, P1063, DOI 10.3899/jrheum.080680; Cassidy JD, 2000, NEW ENGL J MED, V342, P1179, DOI 10.1056/NEJM200004203421606; Ferrari R, 2011, HEADACHE, V51, P163, DOI 10.1111/j.1526-4610.2010.01748.x; Hoffman JR, 2000, NEW ENGL J MED, V343, P94, DOI 10.1056/NEJM200007133430203; Lamb SE, 2012, LANCET; McClune T, 2003, EMERG MED J, V20, P514, DOI 10.1136/emj.20.6.514; Stiell IG, 2001, JAMA-J AM MED ASSOC, V286, P1841, DOI 10.1001/jama.286.15.1841	7	4	5	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 16	2013	381	9866					514	515		10.1016/S0140-6736(12)61416-0	http://dx.doi.org/10.1016/S0140-6736(12)61416-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	089RK	23260166				2023-01-03	WOS:000314927500007
J	Edwards, KM; Zhu, YW; Griffin, MR; Weinberg, GA; Hall, CB; Szilagyi, PG; Staat, MA; Iwane, M; Prill, MM; Williams, JV				Edwards, Kathryn M.; Zhu, Yuwei; Griffin, Marie R.; Weinberg, Geoffrey A.; Hall, Caroline B.; Szilagyi, Peter G.; Staat, Mary A.; Iwane, Marika; Prill, Mila M.; Williams, John V.		New Vaccine Surveillance Network	Burden of Human Metapneumovirus Infection in Young Children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY SYNCYTIAL VIRUS; OBSTRUCTIVE PULMONARY-DISEASE; LUNG-TRANSPLANT RECIPIENTS; POLYMERASE-CHAIN-REACTION; TERM-CARE FACILITY; HOSPITALIZED CHILDREN; TRACT INFECTIONS; HEMATOLOGIC MALIGNANCIES; INFLUENZA-VIRUS; VIRAL LOAD	BACKGROUND The inpatient and outpatient burden of human metapneumovirus (HMPV) infection among young children has not been well established. METHODS We conducted prospective, population-based surveillance for acute respiratory illness or fever among inpatient and outpatient children less than 5 years of age in three U.S. counties from 2003 through 2009. Clinical and demographic data were obtained from parents and medical records, HMPV was detected by means of a reverse-transcriptase polymerase-chain-reaction assay, and population-based rates of hospitalization and estimated rates of outpatient visits associated with HMPV infection were determined. RESULTS HMPV was detected in 200 of 3490 hospitalized children (6%), 222 of 3257 children in outpatient clinics (7%), 224 of 3001 children in the emergency department (7%), and 10 of 770 asymptomatic controls (1%). Overall annual rates of hospitalization associated with HMPV infection were 1 per 1000 children less than 5 years of age, 3 per 1000 infants less than 6 months of age, and 2 per 1000 children 6 to 11 months of age. Children hospitalized with HMPV infection, as compared with those hospitalized without HMPV infection, were older and more likely to receive a diagnosis of pneumonia or asthma, to require supplemental oxygen, and to have a longer stay in the intensive care unit. The estimated annual burden of outpatient visits associated with HMPV infection was 55 clinic visits and 13 emergency department visits per 1000 children. The majority of HMPV-positive inpatient and outpatient children had no underlying medical conditions, although premature birth and asthma were more frequent among hospitalized children with HMPV infection than among those without HMPV infection. CONCLUSIONS HMPV infection is associated with a substantial burden of hospitalizations and outpatient visits among children throughout the first 5 years of life, especially during the first year. Most children with HMPV infection were previously healthy.	[Edwards, Kathryn M.; Williams, John V.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA; [Zhu, Yuwei] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA; [Griffin, Marie R.] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37232 USA; [Williams, John V.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Weinberg, Geoffrey A.; Hall, Caroline B.; Szilagyi, Peter G.] Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA; [Hall, Caroline B.] Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA; [Staat, Mary A.] Cincinnati Childrens Hosp, Dept Pediat, Cincinnati, OH USA; [Iwane, Marika; Prill, Mila M.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Rochester; University of Rochester; Cincinnati Children's Hospital Medical Center; Centers for Disease Control & Prevention - USA	Williams, JV (corresponding author), Vanderbilt Univ, Med Ctr, D-7235 Med Ctr N,1161 21st Ave S, Nashville, TN 37232 USA.	john.williams@vanderbilt.edu	Weinberg, Geoffrey A./W-7510-2019; Williams, John/ABE-3227-2020; Williams, John/F-6962-2010	Weinberg, Geoffrey A./0000-0002-3900-379X; Williams, John/0000-0001-8377-5175; Williams, John/0000-0001-8377-5175	Centers for Disease Control and Prevention; National Institutes of Health; NATIONAL CENTER FOR IMMUNICATION AND RESPIRATORY DISEASES [U01IP000147, U01IP000017, U01IP000022] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI082417, R01AI085062] Funding Source: NIH RePORTER	Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR IMMUNICATION AND RESPIRATORY DISEASES(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Funded by the Centers for Disease Control and Prevention and the National Institutes of Health.)	Ali SA, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-332; Anderson Evan J, 2012, J Pediatric Infect Dis Soc, V1, P212, DOI 10.1093/jpids/pis069; Biacchesi S, 2004, J VIROL, V78, P12877, DOI 10.1128/JVI.78.23.12877-12887.2004; Boivin G, 2003, EMERG INFECT DIS, V9, P634; Boivin G, 2007, CLIN INFECT DIS, V44, P1152, DOI 10.1086/513204; Bosis S, 2008, J CLIN VIROL, V42, P286, DOI 10.1016/j.jcv.2008.03.029; Cane PA, 2003, BONE MARROW TRANSPL, V31, P309, DOI 10.1038/sj.bmt.1703849; Dollner H, 2004, PEDIATR INFECT DIS J, V23, P436, DOI [10.1097/01.inf.000126401.21779.7, 10.1097/01.inf.0000126401.21779.74]; Ebihara T, 2004, J CLIN MICROBIOL, V42, P126, DOI 10.1128/JCM.42.1.126-132.2004; Englund JA, 2006, ANN INTERN MED, V144, P344, DOI 10.7326/0003-4819-144-5-200603070-00010; Esper F, 2004, J INFECT DIS, V189, P1388, DOI 10.1086/382482; Falsey AR, 2003, J INFECT DIS, V187, P785, DOI 10.1086/367901; Freymuth F, 2003, PEDIATR INFECT DIS J, V22, P92, DOI 10.1097/00006454-200301000-00024; Gerna G, 2007, J CLIN VIROL, V40, P236, DOI 10.1016/j.jcv.2007.08.001; Gray GC, 2006, J CLIN VIROL, V37, P269, DOI 10.1016/j.jcv.2006.08.016; Griffin Marie R, 2004, Pediatr Infect Dis J, V23, pS188, DOI 10.1097/01.inf.0000144660.53024.64; Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877; Hamelin ME, 2005, J VIROL, V79, P8894, DOI 10.1128/JVI.79.14.8894-8903.2005; Hopkins P, 2008, AM J RESP CRIT CARE, V178, P876, DOI 10.1164/rccm.200711-1657OC; Iwane MK, 2004, PEDIATRICS, V113, P1758, DOI 10.1542/peds.113.6.1758; Kahn JS, 2006, CLIN MICROBIOL REV, V19, P546, DOI 10.1128/CMR.00014-06; Kuiken T, 2004, AM J PATHOL, V164, P1893, DOI 10.1016/S0002-9440(10)63750-9; Kunz AN, 2008, EUR J CLIN MICROBIOL, V27, P1245, DOI 10.1007/s10096-008-0558-7; Larcher C, 2005, J HEART LUNG TRANSPL, V24, P1891, DOI 10.1016/j.healun.2005.02.014; Liao RS, 2012, J CLIN VIROL, V53, P171, DOI 10.1016/j.jcv.2011.10.010; Madhi SA, 2007, PEDIATR INFECT DIS J, V26, P693, DOI 10.1097/INF.0b013e3180621192; Martin ET, 2008, DIAGN MICR INFEC DIS, V62, P382, DOI 10.1016/j.diagmicrobio.2008.08.002; Martinello RA, 2006, J INFECTION, V53, P248, DOI 10.1016/j.jinf.2005.11.010; Martino R, 2005, BIOL BLOOD MARROW TR, V11, P781, DOI 10.1016/j.bbmt.2005.07.007; McAdam AJ, 2004, J INFECT DIS, V190, P20, DOI 10.1086/421120; Miller EK, 2009, J ALLERGY CLIN IMMUN, V123, P98, DOI 10.1016/j.jaci.2008.10.007; Morrow BM, 2006, J PAEDIATR CHILD H, V42, P174, DOI 10.1111/j.1440-1754.2006.00825.x; Mullins JA, 2004, EMERG INFECT DIS, V10, P700, DOI 10.3201/eid1004.030555; Noyola DE, 2005, J MED MICROBIOL, V54, P969, DOI 10.1099/jmm.0.46052-0; Osterhaus A, 2003, LANCET, V361, P890, DOI 10.1016/S0140-6736(03)12785-7; Peiris JSM, 2003, EMERG INFECT DIS, V9, P628; Pelletier G, 2002, EMERG INFECT DIS, V8, P976, DOI 10.3201/eid0809.020238; Poehling KA, 2006, NEW ENGL J MED, V355, P31, DOI 10.1056/NEJMoa054869; Shahda S, 2011, TRANSPL INFECT DIS, V13, P324, DOI 10.1111/j.1399-3062.2010.00575.x; Sivaprakasam V, 2007, J CLIN VIROL, V39, P234, DOI 10.1016/j.jcv.2007.03.011; Skiadopoulos MH, 2004, J VIROL, V78, P6927, DOI 10.1128/JVI.78.13.6927-6937.2004; Sumino KC, 2005, J INFECT DIS, V192, P1052, DOI 10.1086/432728; Talbot HK, 2009, PEDIATR INFECT DIS J, V28, P682, DOI 10.1097/INF.0b013e31819d0d27; van den Hoogen BG, 2003, J INFECT DIS, V188, P1571, DOI 10.1086/379200; van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098; Vicente D, 2004, EMERG INFECT DIS, V10, P1338, DOI 10.3201/eid1007.030633; Walsh EE, 2008, ARCH INTERN MED, V168, P2489, DOI 10.1001/archinte.168.22.2489; Weinberg GA, 2009, J PEDIATR-US, V154, P694, DOI 10.1016/j.jpeds.2008.11.034; Widmer K, 2012, J INFECT DIS, V206, P56, DOI 10.1093/infdis/jis309; Williams JV, 2010, J INFECT DIS, V201, P1890, DOI 10.1086/652782; Williams JV, 2005, J INFECT DIS, V192, P1061, DOI 10.1086/432732; Williams JV, 2005, J INFECT DIS, V192, P1149, DOI 10.1086/444392; Williams JV, 2005, J VIROL, V79, P10944, DOI 10.1128/JVI.79.17.10944-10951.2005; Williams JV, 2004, NEW ENGL J MED, V350, P443, DOI 10.1056/NEJMoa025472; Wyde PR, 2005, ANTIVIR RES, V66, P57, DOI 10.1016/j.antiviral.2004.12.009	55	197	214	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 14	2013	368	7					633	643		10.1056/NEJMoa1204630	http://dx.doi.org/10.1056/NEJMoa1204630			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	194VA	23406028	Green Accepted			2023-01-03	WOS:000322659600008
J	McCarthy, D; Johnson, MB; Audet, AM				McCarthy, Douglas; Johnson, Marian Bihrle; Audet, Anne-Marie			Recasting Readmissions by Placing the Hospital Role in Community Context	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CARE; BUSINESS; QUALITY		[McCarthy, Douglas; Johnson, Marian Bihrle] Inst Healthcare Improvement, Cambridge, MA 02138 USA; [Audet, Anne-Marie] Commonwealth Fund, New York, NY USA	Institute for Healthcare Improvement; Commonwealth Fund	McCarthy, D (corresponding author), Inst Healthcare Improvement, 20 Univ Rd,7th Floor, Cambridge, MA 02138 USA.	dmccarthy@ihi.org	McCarthy, Douglas/GSJ-0784-2022	McCarthy, Douglas/0000-0002-3295-3522				Asch DA, 2012, NEW ENGL J MED, V367, P888, DOI 10.1056/NEJMp1206862; Boutwell AE, 2011, HEALTH AFFAIR, V30, P1272, DOI 10.1377/hlthaff.2011.0111; Engelberg Center for Health Care Reform at Brookings, IMPR CAR TRANS CAS S; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Johnson MB, VISITING NURSE SERVI; Kangovi S, 2011, JAMA-J AM MED ASSOC, V306, P1796, DOI 10.1001/jama.2011.1562; Kocher RP, 2011, JAMA-J AM MED ASSOC, V306, P1794, DOI 10.1001/jama.2011.1561; McCarthy D, U CALIFORNIA SAN FRA; Rutherford P, GUIDE IMPROVING TRAN; Siu AL, 2009, HEALTH AFFAIR, V28, P113, DOI 10.1377/hlthaff.28.1.113	10	43	43	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 23	2013	309	4					351	352		10.1001/jama.2013.1	http://dx.doi.org/10.1001/jama.2013.1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	074FT	23340635				2023-01-03	WOS:000313799000021
J	Hung, HI; Schwartz, JM; Maldonado, EN; Lemasters, JJ; Nieminen, AL				Hung, Hsin-I; Schwartz, Justin M.; Maldonado, Eduardo N.; Lemasters, John J.; Nieminen, Anna-Liisa			Mitoferrin-2-dependent Mitochondrial Iron Uptake Sensitizes Human Head and Neck Squamous Carcinoma Cells to Photodynamic Therapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER MEMBRANE; PHTHALOCYANINE PHOTOSENSITIZERS; CALCIUM UNIPORTER; OXIDATIVE STRESS; CANCER; LYSOSOMES; TRANSPORT; FUSION; AUTOPHAGOSOMES; REQUIREMENT	Photodynamic therapy (PDT) is a promising approach to treat head and neck cancer cells. Here, we investigated whether mitochondrial iron uptake through mitoferrin-2 (Mfrn2) enhanced PDT-induced cell killing. Three human head and neck squamous carcinoma cell lines (UMSCC1, UMSCC14A, and UMSCC22A) were exposed to light and Pc 4, a mitochondria-targeted photosensitizer. The three cell lines responded differently: UMSCC1 and UMSCC14A cells were more resistant, whereas UMSCC22A cells were more sensitive to Pc 4-PDT-induced cell death. In non-erythroid cells, Mfrn2 is an iron transporter in the mitochondrial inner membrane. PDT-sensitive cells expressed higher Mfrn2 mRNA and protein levels compared with PDT-resistant cells. High Mfrn2-expressing cells showed higher rates of mitochondrial Fe2+ uptake compared with low Mfrn2-expressing cells. Bafilomycin, an inhibitor of the vacuolar proton pump of lysosomes and endosomes that causes lysosomal iron release to the cytosol, enhanced PDT-induced cell killing of both resistant and sensitive cells. Iron chelators and the inhibitor of the mitochondrial Ca2+ (and Fe2+) uniporter, Ru360, protected against PDT plus bafilomycin toxicity. Knockdown of Mfrn2 in UMSCC22A cells decreased the rate of mitochondrial Fe2+ uptake and delayed PDT plus bafilomycin-induced mitochondrial depolarization and cell killing. Taken together, the data suggest that lysosomal iron release and Mfrn2-dependent mitochondrial iron uptake act synergistically to induce PDT-mediated and iron-dependent mitochondrial dysfunction and subsequent cell killing. Furthermore, Mfrn2 represents a possible biomarker of sensitivity of head and neck cancers to cell killing after PDT.	[Hung, Hsin-I; Schwartz, Justin M.; Maldonado, Eduardo N.; Lemasters, John J.; Nieminen, Anna-Liisa] Med Univ S Carolina, Ctr Cell Death Injury & Regenerat, Charleston, SC 29425 USA; [Hung, Hsin-I; Schwartz, Justin M.; Maldonado, Eduardo N.; Lemasters, John J.; Nieminen, Anna-Liisa] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA; [Lemasters, John J.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Maldonado, Eduardo N.; Lemasters, John J.; Nieminen, Anna-Liisa] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Nieminen, AL (corresponding author), Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, DD505 Drug Discovery Bldg,70 President St, Charleston, SC 29425 USA.	nieminen@musc.edu		Maldonado, Eduardo/0000-0002-5285-3027	U.S. National Cancer Institute [R01 CA119079, P30 CA138313]; Abney Cancer Foundation; government of Taiwan; NATIONAL CANCER INSTITUTE [P30CA138313, R01CA119079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073336, R56DK037034] Funding Source: NIH RePORTER	U.S. National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Abney Cancer Foundation; government of Taiwan; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by grants from the U.S. National Cancer Institute R01 CA119079 (A.-L. N.), P30 CA138313 (Hollings Cancer Center Cell and Molecular Imaging Shared Resource), Abney Cancer Foundation (H.-I. H.), and a scholarship from the government of Taiwan (H.-I. H.).	Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114; Amigo JD, 2011, MOL CELL BIOL, V31, P1344, DOI 10.1128/MCB.01010-10; Baron ED, 2010, LASER SURG MED, V42, P728, DOI 10.1002/lsm.20984; Baughman JM, 2011, NATURE, V476, P341, DOI 10.1038/nature10234; Berg TO, 1998, J BIOL CHEM, V273, P21883, DOI 10.1074/jbc.273.34.21883; Bihan H, 2012, HEAD NECK-J SCI SPEC, V34, P493, DOI 10.1002/hed.21763; BREUER W, 1995, AM J PHYSIOL-CELL PH, V268, pC1354, DOI 10.1152/ajpcell.1995.268.6.C1354; Carroll CB, 2011, NEUROCHEM INT, V59, P73, DOI 10.1016/j.neuint.2011.05.006; Chiu SM, 2010, PHOTOCHEM PHOTOBIOL, V86, P1161, DOI 10.1111/j.1751-1097.2010.00766.x; De Stefani D, 2011, NATURE, V476, P336, DOI 10.1038/nature10230; Duvvuri U, 2009, CURR PROB SURG, V46, P114, DOI [10.1067/j.cpsurg.2008.10.002, 10.1067/j.cpsurg.2008.10.001]; FLATMARK T, 1975, J BIOL CHEM, V250, P6433; Froschauer EM, 2009, BBA-BIOMEMBRANES, V1788, P1044, DOI 10.1016/j.bbamem.2009.03.004; Jerjes W, 2011, LASER SURG MED, V43, P463, DOI 10.1002/lsm.21071; Kawai A, 2007, AUTOPHAGY, V3, P154, DOI 10.4161/auto.3634; Kehrer JP, 2000, TOXICOLOGY, V149, P43, DOI 10.1016/S0300-483X(00)00231-6; Kon K, 2010, TOXICOL SCI, V117, P101, DOI 10.1093/toxsci/kfq175; Kurz T, 2011, FREE RADICAL BIO MED, V50, P1647, DOI 10.1016/j.freeradbiomed.2011.03.014; Lam M, 2001, J BIOL CHEM, V276, P47379, DOI 10.1074/jbc.M107678200; Li Z, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-34; Liu L, 2011, FREE RADICAL BIO MED, V51, P53, DOI 10.1016/j.freeradbiomed.2011.03.042; Messner DJ, 2009, LIVER INT, V29, P63, DOI 10.1111/j.1478-3231.2008.01793.x; NIEMINEN AL, 1992, TOXICOL APPL PHARM, V115, P147, DOI 10.1016/0041-008X(92)90317-L; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; Paradkar PN, 2009, MOL CELL BIOL, V29, P1007, DOI 10.1128/MCB.01685-08; POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665; Ren YG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029666; Rodriguez ME, 2009, PHOTOCHEM PHOTOBIOL, V85, P1189, DOI 10.1111/j.1751-1097.2009.00558.x; Saggu S, 2012, PHOTOCHEM PHOTOBIOL, V88, P461, DOI 10.1111/j.1751-1097.2012.01081.x; Satre M, 2007, BIOCHIMIE, V89, P1058, DOI 10.1016/j.biochi.2007.03.004; Shaw GC, 2006, NATURE, V440, P96, DOI 10.1038/nature04512; Tan IB, 2010, HEAD NECK-J SCI SPEC, V32, P1597, DOI 10.1002/hed.21368; Troadec MB, 2011, BLOOD, V117, P5494, DOI 10.1182/blood-2010-11-319483; Uchiyama A, 2008, HEPATOLOGY, V48, P1644, DOI 10.1002/hep.22498; Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33; YING WL, 1991, BIOCHEMISTRY-US, V30, P4949, DOI 10.1021/bi00234a016	36	43	44	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2013	288	1					677	686		10.1074/jbc.M112.422667	http://dx.doi.org/10.1074/jbc.M112.422667			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	066CJ	23135267	Green Published, hybrid			2023-01-03	WOS:000313197200068
J	Hastings, G; de Andrade, M; Moodie, C				Hastings, Gerard; de Andrade, Marisa; Moodie, Crawford			Tobacco harm reduction: the devil is in the deployment	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Hastings, Gerard; de Andrade, Marisa; Moodie, Crawford] Univ Stirling, Inst Social Mkt, Stirling FK9 4LA, Scotland	University of Stirling	Hastings, G (corresponding author), Univ Stirling, Inst Social Mkt, Stirling FK9 4LA, Scotland.	gerard.hastings@stir.ac.uk		Moodie, Crawford/0000-0002-1805-2509	Cancer Research UK [15192] Funding Source: researchfish	Cancer Research UK(Cancer Research UK)		[Anonymous], 2012, PRESCR COST AN ENGL; [Anonymous], 2009, NRT SMOK CESS AIDS U; British American Tobacco, 2011, SUST REP 2011; British American Tobacco, 2011, SUST REP 2011 HARM R; Buck D., 2012, IMPLICATIONS POLICY; Committee on Safety of Medicines, REP WORK GROUP NIC R; Davis RM, 2009, NCI TOBACCO CONTROL; Euromonitor, 2009, TOB UK COUNTR MARK I; Medsafe (Regulatory Information), GUID COD CAT EL CIG; MHRA, DRUG SAF UPD NIC REP; MHRA (Medicines Healthcare products Regulatory Agency), 2009, PUBL ASS REP US NIC; National Institute for Health and Clinical Excellence, 2012, TOB HARM RED APPR SM; Nicoventures, 2012, WHAT IS NIC; O'Reilly D, 2009, TOBACCO HARM REDUCTI; Oxfam, POL PRACT MUGG POV Y; Yeaman A, 1963, IMPLICATIONS BATTELL	16	13	13	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	DEC 17	2012	345								e8412	10.1136/bmj.e8412	http://dx.doi.org/10.1136/bmj.e8412			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	059IU	23248081	Green Submitted			2023-01-03	WOS:000312698700016
J	Klancnik, A; Mozina, SS; Zhang, QJ				Klancnik, Anja; Mozina, Sonja Smole; Zhang, Qijing			Anti-Campylobacter Activities and Resistance Mechanisms of Natural Phenolic Compounds in Campylobacter	PLOS ONE			English	Article							MULTIDRUG EFFLUX PUMP; ANTIMICROBIAL ACTIVITY; ERYTHROMYCIN RESISTANCE; ANTIBIOTIC-RESISTANCE; MACROLIDE RESISTANCE; CMER FUNCTIONS; CMEABC; JEJUNI; IDENTIFICATION; FOOD	Background: Campylobacter is a major foodborne pathogen and alternative antimicrobials are needed to prevent or decrease Campylobacter contamination in foods or food producing animals. The objectives of this study are to define the anti-Campylobacter activities of natural phenolic compounds of plant origin and to determine the roles of bacterial drug efflux systems in the resistance to these natural phenolics in Campylobacter jejuni. Methodology/Principal Findings: Anti-Campylobacter activities were evaluated by an MIC assay using microdilution coupled with ATP measurement. Mutants of the cmeB and cmeF efflux genes and the cmeR transcriptional repressor gene were compared with the wild-type strain for their susceptibilities to phenolics in the absence and presence of efflux-pump inhibitors (EPIs). The phenolic compounds produced significant, but variable activities against both antibiotic-susceptible and antibiotic resistant Campylobacter. The highest anti-Campylobacter activity was seen with carnosic and rosmarinic acids in their pure forms or in enriched plant extracts. Inactivation of cmeB rendered C. jejuni significantly more susceptible to the phenolic compounds, while mutation of cmeF or cmeR only produced a moderate effect on the MICs. Consistent with the results from the efflux pump mutants, EPIs, especially phenylalanine-arginine beta-naphthylamide and NMP, significantly reduced the MICs of the tested phenolic compounds. Further reduction of MICs by the EPIs was also observed in the cmeB and cmeF mutants, suggesting that other efflux systems are also involved in Campylobacter resistance to phenolic compounds. Conclusion/Significance: Natural phenolic compounds of plant origin have good anti-Campylobacter activities and can be further developed for potential use in controlling Campylobacter. The drug efflux systems in Campylobacter contribute significantly to its resistance to the phenolics and EPIs potentiate the anti-Campylobacter activities of plant phenolic compounds.	[Zhang, Qijing] Iowa State Univ, Dept Vet Microbiol & Prevent Med, Ames, IA 50011 USA; [Klancnik, Anja; Mozina, Sonja Smole] Univ Ljubljana, Biotech Fac, Dept Food Sci & Technol, Ljubljana, Slovenia	Iowa State University; University of Ljubljana	Zhang, QJ (corresponding author), Iowa State Univ, Dept Vet Microbiol & Prevent Med, Ames, IA 50011 USA.	zhang123@iastate.edu	Klančnik, Anja/I-4571-2012; Zhang, Qijing/B-7530-2012	Klančnik, Anja/0000-0003-1632-5785; 	Ministry of Higher Education, Science and Technology of the Republic of Slovenia [Z1-2190]; BI-SLO-USA; National Institutes of Health [R01DK063008]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063008] Funding Source: NIH RePORTER	Ministry of Higher Education, Science and Technology of the Republic of Slovenia; BI-SLO-USA; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was supported by the Ministry of Higher Education, Science and Technology of the Republic of Slovenia for the Z1-2190 Post-doctoral project of A.K., the bilateral project between Slovenia and the U.S.A. (BI-SLO-USA 2011/12), and the National Institutes of Health grant R01DK063008. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguilar F, 2008, EFSA J, V721, P1; Akiba M, 2006, J ANTIMICROB CHEMOTH, V57, P52, DOI 10.1093/jac/dki419; Altekruse SF, 2003, J AM VET MED ASSOC, V223, P445, DOI 10.2460/javma.2003.223.445; Baydar NG, 2004, FOOD CONTROL, V15, P335, DOI 10.1016/S0956-7135(03)00083-5; Cagliero C, 2005, J ANTIMICROB CHEMOTH, V56, P948, DOI 10.1093/jac/dki292; Cowan MM, 1999, CLIN MICROBIOL REV, V12, P564, DOI 10.1128/CMR.12.4.564; Cushnie TPT, 2005, INT J ANTIMICROB AG, V26, P343, DOI 10.1016/j.ijantimicag.2005.09.002; Gibreel A, 2005, ANTIMICROB AGENTS CH, V49, P2753, DOI 10.1128/AAC.49.7.2753-2759.2005; Guo BQ, 2008, J BACTERIOL, V190, P1879, DOI 10.1128/JB.01796-07; Guo BQ, 2010, FOODBORNE PATHOG DIS, V7, P77, DOI 10.1089/fpd.2009.0354; Hannula M, 2008, J MED MICROBIOL, V57, P851, DOI 10.1099/jmm.0.47823-0; Hemaiswarya S, 2008, PHYTOMEDICINE, V15, P639, DOI 10.1016/j.phymed.2008.06.008; Horiuchi K, 2007, BIOL PHARM BULL, V30, P287, DOI 10.1248/bpb.30.287; Katalinic V, 2013, INT J FOOD PROP, V16, P45, DOI 10.1080/10942912.2010.526274; Katalinic V, 2010, FOOD CHEM, V119, P715, DOI 10.1016/j.foodchem.2009.07.019; Klancnik A, 2010, J MICROBIOL METH, V81, P121, DOI 10.1016/j.mimet.2010.02.004; Klancnik A, 2009, J FOOD PROTECT, V72, P1744, DOI 10.4315/0362-028X-72.8.1744; Kurek A, 2011, POL J MICROBIOL, V60, P3, DOI 10.33073/pjm-2011-001; Kurincic M, 2007, INT J FOOD MICROBIOL, V120, P186, DOI 10.1016/j.ijfoodmicro.2007.03.012; Kurincic M, 2012, MICROBIAL D IN PRESS; Lin J, 2005, ANTIMICROB AGENTS CH, V49, P1067, DOI 10.1128/AAC.49.3.1067-1075.2005; Lin J, 2002, ANTIMICROB AGENTS CH, V46, P2124, DOI 10.1128/AAC.46.7.2124-2131.2002; Lin J, 2005, J BACTERIOL, V187, P7417, DOI 10.1128/JB.187.21.7417-7424.2005; Luangtongkum T, 2009, FUTURE MICROBIOL, V4, P189, DOI 10.2217/17460913.4.2.189; Mavri A, 2012, CHEM BIODIVERS, V9, P1545, DOI 10.1002/cbdv.201100337; Moore JE, 2006, MICROBES INFECT, V8, P1955, DOI 10.1016/j.micinf.2005.12.030; Moreno S, 2006, FREE RADICAL RES, V40, P223, DOI 10.1080/10715760500473834; Mozina SS, 2011, TRENDS FOOD SCI TECH, V22, P91, DOI 10.1016/j.tifs.2010.09.003; Murphy C, 2006, J APPL MICROBIOL, V100, P623, DOI 10.1111/j.1365-2672.2006.02903.x; Park SF, 2002, INT J FOOD MICROBIOL, V74, P177, DOI 10.1016/S0168-1605(01)00678-X; Payot S, 2004, INT J ANTIMICROB AG, V23, P468, DOI 10.1016/j.ijantimicag.2003.12.008; Pumbwe L, 2002, FEMS MICROBIOL LETT, V206, P185, DOI 10.1111/j.1574-6968.2002.tb11007.x; Puupponen-Pimia R, 2005, J APPL MICROBIOL, V98, P991, DOI 10.1111/j.1365-2672.2005.02547.x; Si WD, 2006, J CHROMATOGR A, V1125, P204, DOI 10.1016/j.chroma.2006.05.061; Taguri T, 2004, BIOL PHARM BULL, V27, P1965, DOI 10.1248/bpb.27.1965; WANG Y, 1990, J BACTERIOL, V172, P949, DOI 10.1128/JB.172.2.949-955.1990; Zorman T, 2002, FOOD TECHNOL BIOTECH, V40, P177	37	37	37	0	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 17	2012	7	12							e51800	10.1371/journal.pone.0051800	http://dx.doi.org/10.1371/journal.pone.0051800			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	055RZ	23284770	Green Published, Green Submitted, gold			2023-01-03	WOS:000312435900054
J	Kuo, KL; Hung, SC; Lin, YP; Tang, CF; Lee, TS; Lin, CP; Tarng, DC				Kuo, Ko-Lin; Hung, Szu-Chun; Lin, Yao-Ping; Tang, Ching-Fang; Lee, Tzong-Shyuan; Lin, Chih-Pei; Tarng, Der-Cherng			Intravenous Ferric Chloride Hexahydrate Supplementation Induced Endothelial Dysfunction and Increased Cardiovascular Risk among Hemodialysis Patients	PLOS ONE			English	Article							TRANSCRIPTION FACTOR ACTIVATION; ADHESION MOLECULE EXPRESSION; OXYGEN SPECIES GENERATION; MEDIATED FENTON REACTIONS; CARDIAC SYNDROME-X; BODY IRON STORES; NF-KAPPA B; MYOCARDIAL-INFARCTION; PARENTERAL IRON; NADPH OXIDASE	Background: The association between intravenous (IV) iron administration and outcomes in hemodialysis (HD) patients is still debated. Therefore, this study was aimed to assess the relationship between the IV administration of ferric chloride hexahydrate (Atofen (R)) and cardiovascular (CV) outcome and the interaction between iron-induced oxidative stress and endothelial dysfunction in chronic HD patients. Methodology/Principal Findings: A cohort of 1239 chronic HD patients was recruited. In a follow-up of 12 months, Kaplan-Meier survival curves showed that higher doses of IV Atofen associated with higher risks for CV events and deaths in HD patients. In multivariate Cox models, compared to no iron supplementation, IV Atofen administration was an independent predictor for CV events and overall mortality. However, the nature of the observational cohort study possibly bears selection bias. We further found that IV Atofen enhanced the superoxide production of mononuclear cells (MNCs), the levels of circulating soluble adhesion molecules, and the adhesion of MNCs to human aortic endothelial cells (HAECs). In vitro experiments showed that Atofen increased the expression of intracellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 in HAECs and aggravated the endothelial adhesiveness in a dose-dependent manner. These iron-induced changes were significantly attenuated by the co-treatment of HAECs with N-acetylcysteine and inhibitors of NADPH oxidase, nuclear factor kappa B, and activator protein-1. Conclusion: A cumulative dose of IV Atofen > 800 mg within 6 months was associated with an adverse CV outcome and a higher mortality among chronic HD patients. The detrimental effects of IV iron supplementation were partly due to the increased oxidative stress and induction of MNC adhesion to endothelial cells, a pivotal index of early atherogenesis. Citation: Kuo K-L, Hung S-C, Lin Y-P, Tang C-F, Lee T-S, et al. (2012) Intravenous Ferric Chloride Hexahydrate Supplementation Induced Endothelial Dysfunction and Increased Cardiovascular Risk among Hemodialysis Patients. PLoS ONE 7(12): e50295. doi:10.1371/journal.pone.0050295	[Kuo, Ko-Lin; Lee, Tzong-Shyuan; Tarng, Der-Cherng] Natl Yang Ming Univ, Dept & Inst Physiol, Taipei 112, Taiwan; [Tarng, Der-Cherng] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan; [Lin, Chih-Pei] Natl Yang Ming Univ, Dept Biotechnol & Lab Sci Med, Taipei 112, Taiwan; [Lin, Chih-Pei] Natl Yang Ming Univ, Inst Biotechnol Med, Taipei 112, Taiwan; [Kuo, Ko-Lin; Hung, Szu-Chun] Tzu Chi Univ, Sch Med, Hualien, Taiwan; [Kuo, Ko-Lin; Hung, Szu-Chun] Buddhist Tzu Chi Gen Hosp, Taipei Branch, Div Nephrol, Taipei, Taiwan; [Lin, Chih-Pei] Taipei Vet Gen Hosp, Dept Pathol & Lab Med, Div Gen Lab, Taipei, Taiwan; [Lin, Yao-Ping; Tang, Ching-Fang; Tarng, Der-Cherng] Taipei Vet Gen Hosp, Dept Med, Div Nephrol, Taipei, Taiwan; [Lin, Yao-Ping; Tang, Ching-Fang; Tarng, Der-Cherng] Taipei Vet Gen Hosp, Ctr Immunol, Taipei, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Tzu Chi University; Buddhist Tzu Chi General Hospital; Taipei Veterans General Hospital; Taipei Veterans General Hospital; Taipei Veterans General Hospital	Lin, CP (corresponding author), Natl Yang Ming Univ, Dept Biotechnol & Lab Sci Med, Taipei 112, Taiwan.	cplin@vghtpe.gov.tw; dctarng@vghtpe.gov.tw	Lee, Tzong-Shyuan/AAE-5803-2020	Lee, Tzong-Shyuan/0000-0002-9593-4062; Kuo, Ko-Lin/0000-0002-7477-0388	National Science Council [NSC 96-2628-B-010-001-MY3, NSC 99-2314-B-303-002-MY3]; Taipei Veterans General Hospital [V100C-143, V100E4-003]; Ministry of Education's Aim for the Top University Plan; Taipei Tzu Chi General Hospital [TCRD-TPE-97-15]	National Science Council(Ministry of Science and Technology, Taiwan); Taipei Veterans General Hospital(Taipei Veterans General Hospital); Ministry of Education's Aim for the Top University Plan(Ministry of Education, Taiwan); Taipei Tzu Chi General Hospital	This work was supported by grants from the National Science Council (NSC 96-2628-B-010-001-MY3 and NSC 99-2314-B-303-002-MY3), Taipei Veterans General Hospital (V100C-143 and V100E4-003), Ministry of Education's Aim for the Top University Plan, and Taipei Tzu Chi General Hospital (TCRD-TPE-97-15). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Besarab A, 2000, J AM SOC NEPHROL, V11, P530, DOI 10.1681/ASN.V113530; Carlini RG, 2006, NEPHROL DIAL TRANSPL, V21, P3055, DOI 10.1093/ndt/gfl341; Chen JW, 2004, ARTERIOSCL THROM VAS, V24, P2075, DOI 10.1161/01.ATV.0000145016.69181.fa; Chen JW, 2003, ARTERIOSCL THROM VAS, V23, P1559, DOI 10.1161/01.ATV.0000089012.73180.63; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Drueke T, 2002, CIRCULATION, V106, P2212, DOI 10.1161/01.CIR.0000035250.66458.67; EVANS PJ, 1995, FREE RADICAL RES, V23, P465, DOI 10.3109/10715769509065267; Feldman HI, 2004, J AM SOC NEPHROL, V15, P1623, DOI 10.1097/01.ASN.0000128009.69594.BE; Feldman HI, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133734; Griendling KK, 2000, ARTERIOSCL THROM VAS, V20, P2175, DOI 10.1161/01.ATV.20.10.2175; Griendling KK, 2001, J CLIN INVEST, V108, P1423, DOI 10.1172/JCI200114453; HEINECKE JW, 1984, J CLIN INVEST, V74, P1890, DOI 10.1172/JCI111609; Henle ES, 1996, J BIOL CHEM, V271, P21177, DOI 10.1074/jbc.271.35.21177; Hoen B, 1998, J AM SOC NEPHROL, V9, P869; Horl WH, 2007, J AM SOC NEPHROL, V18, P382, DOI 10.1681/ASN.2006080856; Ikeda Y, 2011, ATHEROSCLEROSIS, V215, P339, DOI 10.1016/j.atherosclerosis.2011.01.009; Kalantar-Zadeh K, 2005, J AM SOC NEPHROL, V16, P3070, DOI 10.1681/ASN.2005040423; Kartikasari AER, 2004, ARTERIOSCL THROM VAS, V24, P2257, DOI 10.1161/01.ATV.0000147406.00871.b3; Kiechl S, 1997, CIRCULATION, V96, P3300; Klipstein-Grobusch K, 1999, AM J CLIN NUTR, V69, P1231; Kuo KL, 2008, J AM SOC NEPHROL, V19, P1817, DOI 10.1681/ASN.2007101084; Kurtoglu E, 2003, BIOL TRACE ELEM RES, V96, P109, DOI 10.1385/BTER:96:1-3:109; Lee TS, 1999, CIRCULATION, V99, P1222, DOI 10.1161/01.CIR.99.9.1222; Leu HB, 2006, FREE RADICAL BIO MED, V40, P983, DOI 10.1016/j.freeradbiomed.2005.10.047; Li LX, 2009, ARTERIOSCL THROM VAS, V29, P732, DOI 10.1161/ATVBAHA.108.183210; Lim CS, 2004, KIDNEY INT, V65, P1802, DOI 10.1111/j.1523-1755.2004.00580.x; Lin CP, 2008, EUR J CLIN INVEST, V38, P106, DOI 10.1111/j.1365-2362.2007.01911.x; Lin CP, 2008, J BIOMED SCI, V15, P183, DOI 10.1007/s11373-007-9212-0; Lin CP, 2003, INT J CARDIOL, V89, P53, DOI 10.1016/S0167-5273(02)00428-X; Luo YZ, 1996, J BIOL CHEM, V271, P21167, DOI 10.1074/jbc.271.35.21167; Martin T, 1997, EUR J IMMUNOL, V27, P1091, DOI 10.1002/eji.1830270508; Parfrey PS, 2005, J AM SOC NEPHROL, V16, P2180, DOI 10.1681/ASN.2004121039; Rooyakkers TM, 2002, EUR J CLIN INVEST, V32, P9, DOI 10.1046/j.1365-2362.2002.0320s1009.x; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; Sengoelge G, 2003, J AM SOC NEPHROL, V14, P2639, DOI 10.1097/01.ASN.0000087087.61306.4A; SMITH C, 1992, BIOCHEM J, V286, P901, DOI 10.1042/bj2860901; Stadler N, 2004, ARTERIOSCL THROM VAS, V24, P949, DOI 10.1161/01.ATV.0000124892.90999.cb; SULLIVAN JL, 1981, LANCET, V1, P1293; SUNDERPLASSMANN G, 1995, NEPHROL DIAL TRANSPL, V10, P2070; Tuomainen TP, 1998, CIRCULATION, V97, P1461; Yin WH, 2007, INT J CARDIOL, V121, P276, DOI 10.1016/j.ijcard.2006.11.012; Zager RA, 2002, AM J KIDNEY DIS, V40, P90, DOI 10.1053/ajkd.2002.33917; Zager RA, 2004, KIDNEY INT, V66, P144, DOI 10.1111/j.1523-1755.2004.00716.x; Zhu Y, 1998, ARTERIOSCL THROM VAS, V18, P473, DOI 10.1161/01.ATV.18.3.473	45	58	59	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2012	7	12							e50295	10.1371/journal.pone.0050295	http://dx.doi.org/10.1371/journal.pone.0050295			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	057TZ	23227165	Green Published, gold, Green Submitted			2023-01-03	WOS:000312588200026
J	Xu, WB; Liu, WW; Huang, GY; Zou, ZJ; Cai, ZY; Xu, WG				Xu, Wenbing; Liu, Wenwu; Huang, Guoyang; Zou, ZiJiao; Cai, Zhiyu; Xu, Weigang			Decompression Illness: Clinical Aspects of 5278 Consecutive Cases Treated in a Single Hyperbaric Unit	PLOS ONE			English	Article							DIVERS	Background: Decompression illness (DCI) is a major concern in pressure-related activities. Due to its specific prerequisite conditions, DCI is rare in comparison with other illnesses and most physicians are inexperienced in treatment. In a fishery area in northern China, during the past decade, tens of thousands of divers engaged in seafood harvesting and thousands suffered from DCI. We established a hyperbaric facility there and treated the majority of the cases. Methods and Results: A total of 5,278 DCI cases were admitted in our facility from February 2000 through December 2010 and treated using our recompression schedules. Cutaneous abnormalities, joint and muscular pain and neurological manifestations were three most common symptoms. The initial symptom occurred within 6 h after surfacing in 98.9% of cases, with an overall median latency of 62 min. The shorter the latent time, the more serious the symptoms would be (P<0.0001). Nine cases died before recompression and 5,269 were treated using four recompression schedules, with an overall effectiveness rate of 99.3%. The full recovery rate decreased with the increase of the delay from the onset of symptoms to the treatment (P<0.0001). Conclusions: DCI presents specific occurrence rules. Recompression should be administered as soon as possible and should never be abandoned irrespective of the delay. The recompression schedules used were effective and flexible for variety conditions of DCI.	[Xu, Wenbing; Liu, Wenwu; Huang, Guoyang; Zou, ZiJiao; Cai, Zhiyu; Xu, Weigang] Second Mil Med Univ, Fac Naval Med, Dept Diving Med, Shanghai, Peoples R China	Naval Medical University	Xu, WG (corresponding author), Second Mil Med Univ, Fac Naval Med, Dept Diving Med, Shanghai, Peoples R China.	wgxu@hotmail.com	xu, wei/HHD-2891-2022	Liu, Wenwu/0000-0003-1530-8860	National Natural Science Foundation of China [81171873]; Science & Technology Program of Chinese Liberation Army [08G064]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science & Technology Program of Chinese Liberation Army	This work was supported partly by the National Natural Science Foundation of China No. 81171873 and the Science & Technology Program of Chinese Liberation Army No. 08G064. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], PROJ DIV EXPL PROJ O; Bennett PB, 1990, DIVING ACCIDENT MANA; Berghage TE, 1978, 7816 NAV MED RES DEV; Blatteau JE, 2011, DIVING HYPERB MED, V41, P129; FRANCIS TJR, 1988, UNDERSEA BIOMED RES, V15, P403; Gao GK, 2009, UNDERSEA HYPERBAR M, V36, P33; Gempp E, 2008, AVIAT SPACE ENVIR MD, V79, P1112, DOI 10.3357/ASEM.2376.2008; GOLDING F C, 1960, Br J Ind Med, V17, P167; Gorman DF, 1991, DESCRIBING DECOMPRES, P6; Kot Jacek, 2004, Int Marit Health, V55, P103; LEITCH DR, 1986, AVIAT SPACE ENVIR MD, V57, P931; Liu Y, 2010, CHIN J IND MED, V23, P52; Moon RE., 2003, ADJUNCTIVE THERAPY D; Pearson RR, 1984, PHYS GUIDE DIVING ME, P333; Ross JAS., 2000, CLIN AUDIT OUTCOME M; Stipp W., 2007, 550 RR, P1; Thalmann E, 1996, TREATMENT DECOMPRESS; Tourigny PD, 2012, EMERG MED CLIN N AM, V30, P501, DOI 10.1016/j.emc.2011.10.006; US Navy Department, 2008, 0910LP1060957 NAVSEA; Vann R.D., 2004, BOVE DAVIS DIVING ME, V4th ed., P127, DOI DOI 10.1016/B978-0-7216-9424-5.X5001-1; Vann RD, 2011, LANCET, V377, P153, DOI 10.1016/S0140-6736(10)61085-9; Weisher DD, 2008, UNDERSEA HYPERBAR M, V35, P159; Xu WG, 2010, DIVING MED, P99; 李学文, 2002, [中华航海医学与高气压医学杂志, Chinese journal of nautical medicine and hyperbaric medicine], V9, P105	24	21	26	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2012	7	11							e50079	10.1371/journal.pone.0050079	http://dx.doi.org/10.1371/journal.pone.0050079			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	047ER	23185538	Green Published, Green Submitted, gold			2023-01-03	WOS:000311821000178
J	Palgunow, D; Klapper, M; Doring, F				Palgunow, Daniela; Klapper, Maja; Doering, Frank			Dietary Restriction during Development Enlarges Intestinal and Hypodermal Lipid Droplets in Caenorhabditis elegans	PLOS ONE			English	Article							LIFE-SPAN EXTENSION; CALORIC RESTRICTION; C-ELEGANS; PHOSPHOCHOLINE BIOSYNTHESIS; N-METHYLTRANSFERASE; INDUCED LONGEVITY; METABOLIC-RATE; REGULATES FAT; PPAR-ALPHA; BODY-SIZE	Dietary restriction (DR) extends lifespan in man species and modulates evolutionary conserved signalling and metabolic pathways. Most of these studies were done in adult animals. Here we investigated fat phenotypes of C. elegans larvae and adults which were exposed to DR during development. This approach was named "developmental-DR'' (dDR). Moderate as well as stringent dDR increased the triglyceride to protein ratio in L4 larvae and adult worms. This alteration was accompanied by a marked expansion of intestinal and hypodermal lipid droplets. In comparison to ad libitum condition, the relative proportion of fat stored in large lipid droplets (>50 mu m(3)) was increased by a factor of about 5 to 6 in larvae exposed to dDR. Microarray-based expression profiling identified several dDR-regulated genes of lipolysis and lipogenesis which may contribute to the observed fat phenotypes. In conclusion, dDR increases the triglyceride to protein ratio, enlarges lipid droplets and alters the expression of genes functioning in lipid metabolism in C. elegans. These changes might be an effective adaptation to conserve fat stores in animals subjected to limiting food supply during development.	[Palgunow, Daniela; Klapper, Maja; Doering, Frank] Univ Kiel, Inst Human Nutr & Food Sci, Dept Mol Prevent, Kiel, Germany	University of Kiel	Doring, F (corresponding author), Univ Kiel, Inst Human Nutr & Food Sci, Dept Mol Prevent, Kiel, Germany.	sek@molprev.uni-kiel.de			Deutsche Forschungsgemeinschaft (DFG) in the context of the Cluster of Excellence "Inflammation at Interfaces'' at the University of Kiel; German Ministry of Education and Research [BMBF 0315681]	Deutsche Forschungsgemeinschaft (DFG) in the context of the Cluster of Excellence "Inflammation at Interfaces'' at the University of Kiel(German Research Foundation (DFG)); German Ministry of Education and Research(Federal Ministry of Education & Research (BMBF))	This work was supported by a structural grant from the Deutsche Forschungsgemeinschaft (DFG) in the context of the Cluster of Excellence "Inflammation at Interfaces'' at the University of Kiel and by a grant form the German Ministry of Education and Research (BMBF 0315681). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aarnio V, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00012; Angelo G, 2009, SCIENCE, V326, P954, DOI 10.1126/science.1178343; Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Atherton HJ, 2008, FEBS LETT, V582, P1661, DOI 10.1016/j.febslet.2008.04.020; Bartz R, 2007, J LIPID RES, V48, P837, DOI 10.1194/jlr.M600413-JLR200; Bishop NA, 2007, NATURE, V447, P545, DOI 10.1038/nature05904; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Brendza KM, 2007, BIOCHEM J, V404, P439, DOI 10.1042/BJ20061815; BRENNER S, 1974, GENETICS, V77, P71; Castro C, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-36; Chen D, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000486; Clancy DJ, 2002, SCIENCE, V296, P319, DOI 10.1126/science.1069366; Elle IC, 2011, BIOCHEM J, V437, P231, DOI 10.1042/BJ20102099; Greer ER, 2008, CELL METAB, V8, P118, DOI 10.1016/j.cmet.2008.06.005; Greer EL, 2007, CURR BIOL, V17, P1646, DOI 10.1016/j.cub.2007.08.047; Greer EL, 2009, ANN NY ACAD SCI, V1170, P688, DOI 10.1111/j.1749-6632.2009.04019.x; Guo Y, 2008, NATURE, V453, P657, DOI 10.1038/nature06928; HOSONO R, 1989, EXP GERONTOL, V24, P251, DOI 10.1016/0531-5565(89)90016-8; Houthoofd K, 2003, EXP GERONTOL, V38, P947, DOI 10.1016/S0531-5565(03)00161-X; Houthoofd K, 2002, EXP GERONTOL, V37, P1359, DOI 10.1016/S0531-5565(02)00172-9; Houthoofd K, 2002, EXP GERONTOL, V37, P1371, DOI 10.1016/S0531-5565(02)00173-0; Joo HJ, 2009, BIOCHEM J, V422, P61, DOI 10.1042/BJ20090513; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; Kaeberlein TL, 2006, AGING CELL, V5, P487, DOI 10.1111/j.1474-9726.2006.00238.x; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Klapper M, 2011, J LIPID RES, V52, P1281, DOI 10.1194/jlr.D011940; KLASS MR, 1977, MECH AGEING DEV, V6, P413, DOI 10.1016/0047-6374(77)90043-4; Knight CG, 2002, EVOL DEV, V4, P16, DOI 10.1046/j.1525-142x.2002.01058.x; Krahmer N, 2011, CELL METAB, V14, P504, DOI 10.1016/j.cmet.2011.07.013; Kuerschner L, 2008, TRAFFIC, V9, P338, DOI 10.1111/j.1600-0854.2007.00689.x; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Lee Eun-Young, 2009, V462, P167, DOI 10.1007/978-1-60327-115-8_11; Lee GD, 2006, AGING CELL, V5, P515, DOI 10.1111/j.1474-9726.2006.00241.x; Li XS, 2010, OBESITY, V18, P456, DOI 10.1038/oby.2009.312; Lillycrop KA, 2008, BRIT J NUTR, V100, P278, DOI 10.1017/S0007114507894438; Listenberger LL, 2001, J BIOL CHEM, V276, P14890, DOI 10.1074/jbc.M010286200; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Mair W, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004535; Masoro EJ, 2005, MECH AGEING DEV, V126, P913, DOI 10.1016/j.mad.2005.03.012; Matyash V, 2008, J LIPID RES, V49, P1137, DOI 10.1194/jlr.D700041-JLR200; McKay RM, 2003, DEV CELL, V4, P131, DOI 10.1016/S1534-5807(02)00411-2; Michels KB, 2004, JAMA-J AM MED ASSOC, V291, P1226, DOI 10.1001/jama.291.10.1226; Mullaney BC, 2010, CELL METAB, V12, P398, DOI 10.1016/j.cmet.2010.08.013; Nagayama M, 2007, J LIPID RES, V48, P9, DOI 10.1194/jlr.M600155-JLR200; Palavalli LH, 2006, BIOCHEMISTRY-US, V45, P6056, DOI 10.1021/bi060199d; Panowski SH, 2007, NATURE, V447, P550, DOI 10.1038/nature05837; Park SK, 2010, FASEB J, V24, P383, DOI 10.1096/fj.09-142984; ROBERTSON FW, 1959, GENETICS, V44, P869; Salomon MP, 2009, GENETICS, V183, P685, DOI 10.1534/genetics.109.107383; SATOUCHI K, 1993, LIPIDS, V28, P837, DOI 10.1007/BF02536239; Schlotterer A, 2010, AGING CELL, V9, P420, DOI 10.1111/j.1474-9726.2010.00572.x; So SH, 2011, GENES CELLS, V16, P639, DOI 10.1111/j.1365-2443.2011.01514.x; Soukas AA, 2009, GENE DEV, V23, P496, DOI 10.1101/gad.1775409; Steinkraus KA, 2008, AGING CELL, V7, P394, DOI 10.1111/j.1474-9726.2008.00385.x; Sze JY, 2000, NATURE, V403, P560, DOI 10.1038/35000609; Szewczyk NJ, 2006, J EXP BIOL, V209, P4129, DOI 10.1242/jeb.02492; Tain LS, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-28; Vance JE, 2004, BIOCHEM CELL BIOL, V82, P113, DOI 10.1139/o03-073; Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a; Walker AK, 2011, CELL, V147, P840, DOI 10.1016/j.cell.2011.09.045; Watts JL, 2002, P NATL ACAD SCI USA, V99, P5854, DOI 10.1073/pnas.092064799; Watts JL, 2000, BIOCHEM BIOPH RES CO, V272, P263, DOI 10.1006/bbrc.2000.2772; WEINDRUCH R, 1988, J GERONTOL, V43, pB40, DOI 10.1093/geronj/43.2.B40; WEINDRUCH R, 1986, J NUTR, V116, P641, DOI 10.1093/jn/116.4.641; Xu M, 2011, J BIOL CHEM, V286, P28111, DOI 10.1074/jbc.M111.227165; Yang FJ, 2006, NATURE, V442, P700, DOI 10.1038/nature04942; Yen CLE, 2008, J LIPID RES, V49, P2283, DOI 10.1194/jlr.R800018-JLR200; Zhang J, 2011, J MOL BIOL, V411, P537, DOI 10.1016/j.jmb.2011.06.011; Zhang SBO, 2010, P NATL ACAD SCI USA, V107, P4640, DOI 10.1073/pnas.0912308107	71	31	31	4	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 20	2012	7	11							e46198	10.1371/journal.pone.0046198	http://dx.doi.org/10.1371/journal.pone.0046198			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	043II	23185233	Green Published, gold, Green Submitted			2023-01-03	WOS:000311535700002
J	Hadorn, M; Boenzli, E; Hotz, PE; Hanczyc, MM				Hadorn, Maik; Boenzli, Eva; Hotz, Peter Eggenberger; Hanczyc, Martin M.			Hierarchical Unilamellar Vesicles of Controlled Compositional Heterogeneity	PLOS ONE			English	Article							GIANT VESICLES; LIPID VESICLES; LIPOSOMES; ENCAPSULATION; RELEASE; BILAYER	Eukaryotic life contains hierarchical vesicular architectures (i.e. organelles) that are crucial for material production and trafficking, information storage and access, as well as energy production. In order to perform specific tasks, these compartments differ among each other in their membrane composition and their internal cargo and also differ from the cell membrane and the cytosol. Man-made structures that reproduce this nested architecture not only offer a deeper understanding of the functionalities and evolution of organelle-bearing eukaryotic life but also allow the engineering of novel biomimetic technologies. Here, we show the newly developed vesicle-in-water-in-oil emulsion transfer preparation technique to result in giant unilamellar vesicles internally compartmentalized by unilamellar vesicles of different membrane composition and internal cargo, i.e. hierarchical unilamellar vesicles of controlled compositional heterogeneity. The compartmentalized giant unilamellar vesicles were subsequently isolated by a separation step exploiting the heterogeneity of the membrane composition and the encapsulated cargo. Due to the controlled, efficient, and technically straightforward character of the new preparation technique, this study allows the hierarchical fabrication of compartmentalized giant unilamellar vesicles of controlled compositional heterogeneity and will ease the development of eukaryotic cell mimics that resemble their natural templates as well as the fabrication of novel multi-agent drug delivery systems for combination therapies and complex artificial microreactors.	[Hadorn, Maik; Boenzli, Eva; Hanczyc, Martin M.] Univ So Denmark, Dept Phys Chem & Pharm, Odense, Denmark; [Hotz, Peter Eggenberger] Univ Zurich, Dept Informat, Zurich, Switzerland	University of Southern Denmark; University of Zurich	Hadorn, M (corresponding author), Univ So Denmark, Dept Phys Chem & Pharm, Odense, Denmark.	hadorn@sdu.dk	Hadorn, Maik/I-8909-2012	Hadorn, Maik/0000-0003-4530-9346; Hanczyc, Martin/0000-0002-5453-2139	Danish National Research Foundation through the Center for Fundamental Living technologies (FlinT); European Community's Seventh Framework Programme (FP7) [249032]	Danish National Research Foundation through the Center for Fundamental Living technologies (FlinT); European Community's Seventh Framework Programme (FP7)	The research leading to these results has received funding from the Danish National Research Foundation through the Center for Fundamental Living technologies (FlinT) and from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no 249032 (MATCHIT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahl PL, 2003, METHOD ENZYMOL, V367, P80; Bolinger PY, 2008, ANGEW CHEM INT EDIT, V47, P5544, DOI 10.1002/anie.200801606; Bolinger PY, 2004, J AM CHEM SOC, V126, P8594, DOI 10.1021/ja049023u; Boyer C, 2007, ACS NANO, V1, P176, DOI 10.1021/nn7002025; Bui AV, 2004, J FOOD ENG, V62, P345, DOI 10.1016/S0260-8774(03)00249-8; Chiu DT, 1999, SCIENCE, V283, P1892, DOI 10.1126/science.283.5409.1892; de Duve C, 2007, NAT REV GENET, V8, P395, DOI 10.1038/nrg2071; Dominak LM, 2007, LANGMUIR, V23, P7148, DOI 10.1021/la063687v; Fenz SF, 2012, INTEGR BIOL-UK, V4, P982, DOI 10.1039/c2ib00188h; Gomez-Hens A, 2005, TRAC-TREND ANAL CHEM, V24, P9, DOI 10.1016/j.trac.2004.07.017; Holmberg A, 2005, ELECTROPHORESIS, V26, P501, DOI 10.1002/elps.200410070; Ishii K, 2009, CHEMBIOCHEM, V10, P251, DOI 10.1002/cbic.200800482; Jesorka A, 2008, ANNU REV ANAL CHEM, V1, P801, DOI 10.1146/annurev.anchem.1.031207.112747; Katayama K, 2002, INT J PHARM, V248, P93, DOI 10.1016/S0378-5173(02)00427-1; KIM S, 1983, BIOCHIM BIOPHYS ACTA, V728, P339, DOI 10.1016/0005-2736(83)90504-7; KULKARNI SB, 1995, J MICROENCAPSUL, V12, P229, DOI 10.3109/02652049509010292; LASIC DD, 1988, BIOCHEM J, V256, P1; Menger FM, 1996, LANGMUIR, V12, P4479, DOI 10.1021/la960370u; Michel M, 2004, LANGMUIR, V20, P6127, DOI 10.1021/la049862u; Nardi J, 1999, PHYS REV LETT, V82, P5168, DOI 10.1103/PhysRevLett.82.5168; Noireaux V, 2004, P NATL ACAD SCI USA, V101, P17669, DOI 10.1073/pnas.0408236101; Nomura S, 2003, CHEMBIOCHEM, V4, P1172, DOI 10.1002/cbic.200300630; Okumura Y, 2011, MEMBRANES, V1, P265, DOI 10.3390/membranes1040265; Okumura Y, 2011, LANGMUIR, V27, P3279, DOI 10.1021/la2004485; Pautot S, 2003, P NATL ACAD SCI USA, V100, P10718, DOI 10.1073/pnas.1931005100; Pautot S, 2003, LANGMUIR, V19, P2870, DOI 10.1021/la026100v; Walde P, 2010, CHEMBIOCHEM, V11, P848, DOI 10.1002/cbic.201000010; Walker SA, 1997, NATURE, V387, P61, DOI 10.1038/387061a0; Yamabe K, 2003, J CONTROL RELEASE, V90, P71, DOI 10.1016/S0168-3659(03)00159-7; Zawada ZH, 2004, CELL MOL BIOL LETT, V9, P589; Zhang HB, 2011, EXPERT OPIN DRUG DEL, V8, P171, DOI 10.1517/17425247.2011.547470	31	24	24	0	51	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 19	2012	7	11							e50156	10.1371/journal.pone.0050156	http://dx.doi.org/10.1371/journal.pone.0050156			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	040PB	23185563	Green Published, Green Submitted, gold			2023-01-03	WOS:000311333800071
J	Lima, VD; Le, A; Nosyk, B; Barrios, R; Yip, B; Hogg, RS; Harrigan, PR; Montaner, JSG				Lima, Viviane D.; Le, Adrian; Nosyk, Bohdan; Barrios, Rolando; Yip, Benita; Hogg, Robert S.; Harrigan, P. Richard; Montaner, Julio S. G.			Development and Validation of a Composite Programmatic Assessment Tool for HIV Therapy	PLOS ONE			English	Article							SOCIETY-USA PANEL; ACTIVE ANTIRETROVIRAL THERAPY; UPDATED RECOMMENDATIONS; INFECTION; INDIVIDUALS; ADHERENCE	Background: We developed and validated a new and simple metric, the Programmatic Compliance Score (PCS), based on the IAS-USA antiretroviral therapy management guidelines for HIV-infected adults, as a predictor of all-cause mortality, at a program-wide level. We hypothesized that non-compliance would be associated with the highest probability of mortality. Methods and Findings: 3543 antiretroviral-naive HIV-infected patients aged >= 19 years who initiated antiretroviral therapy between January 1, 2000 and August 31, 2009 in British Columbia (BC), Canada, were followed until August 31, 2010. The PCS is composed by six non-performance indicators based on the IAS-USA guidelines: (1) having<3 CD4 count tests in the first year after starting antiretroviral therapy; (2) having<3 plasma viral load tests in the first year after starting antiretroviral therapy; (3) not having drug resistance testing done prior to starting antiretroviral therapy; (4) starting on a non-recommended antiretroviral therapy regimen; (5) starting therapy with CD<200 cells/mm(3); and (6) not achieving viral suppression within 6 months since antiretroviral therapy initiation. The sum of these six indicators was used to develop the PCS score-higher score indicates poorer performance. The main outcome was all-cause mortality. Each PCS component was independently associated with mortality. In the mortality analysis, the odds ratio (OR) for PCS >= 4 versus 0 was 22.37 (95% CI 10.46-47.84). Conclusions: PCS was strongly associated with all-cause mortality. These results lend independent validation to the IAS-USA treatment guidelines for HIV-infected adults. Further efforts are warranted to enhance the PCS as a means to further improve clinical outcomes. These should be specifically evaluated and targeted at healthcare providers and patients.	[Lima, Viviane D.] St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada; [Lima, Viviane D.; Harrigan, P. Richard; Montaner, Julio S. G.] Univ British Columbia, Fac Med, Dept Med, Div AIDS, Vancouver, BC, Canada; [Hogg, Robert S.] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada	B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of Saskatchewan; University of British Columbia; Simon Fraser University	Lima, VD (corresponding author), St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada.	vlima@cfenet.ubc.ca	Montaner, Julio/K-7621-2012; Le, Adrian/ABG-3288-2020	Hogg, Robert/0000-0003-3463-5488	Canadian Institutes of Health Research; Michael Smith Foundation for Health Research; Ministry of Health Services, Province of British Columbia, through a Knowledge Translation Award from the Canadian Institutes of Health Research [1DP1DA026182-01]; National Institute on Drug Abuse, at the United States National Institutes of Health; CIHR/GSK Research Chair in Clinical Virology; NATIONAL INSTITUTE ON DRUG ABUSE [R03DA033851, DP1DA026182] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research); Ministry of Health Services, Province of British Columbia, through a Knowledge Translation Award from the Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Institute on Drug Abuse, at the United States National Institutes of Health; CIHR/GSK Research Chair in Clinical Virology(Canadian Institutes of Health Research (CIHR)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	During this work, VDL was supported by the Canadian Institutes of Health Research and the Michael Smith Foundation for Health Research through Fellowship Awards. BN is a Canadian Institutes of Health Research Bisby Fellow. JSGM is supported by the Ministry of Health Services, Province of British Columbia, through a Knowledge Translation Award from the Canadian Institutes of Health Research and through an Avant-Garde Award (No. 1DP1DA026182-01) from the National Institute on Drug Abuse, at the United States National Institutes of Health. PRH is supported by CIHR/GSK Research Chair in Clinical Virology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; Cescon AM, 2011, HIV MED, V12, P352, DOI 10.1111/j.1468-1293.2010.00890.x; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Hammer SM, 2008, JAMA-J AM MED ASSOC, V300, P555, DOI 10.1001/jama.300.5.555; Hammer SM, 2006, JAMA-J AM MED ASSOC, V296, P827, DOI 10.1001/jama.296.7.827; Johnson Victoria A, 2010, Top HIV Med, V18, P156; Lima VD, 2009, JAIDS-J ACQ IMM DEF, V50, P529, DOI 10.1097/QAI.0b013e31819675e9; Lima VD, 2008, AIDS, V22, P2371, DOI 10.1097/QAD.0b013e328315cdd3; McNeil Jr DG, 2011, NEW WORK TIMES; Montaner JSG, 2006, LANCET, V368, P531, DOI 10.1016/S0140-6736(06)69162-9; Montaner JSG, 2010, LANCET, V376, P532, DOI 10.1016/S0140-6736(10)60936-1; Moore DM, 2009, JAIDS-J ACQ IMM DEF, V52, P357, DOI 10.1097/QAI.0b013e3181b62933; Sterne JAC, 2009, LANCET, V373, P1352, DOI 10.1016/S0140-6736(09)60612-7; Steyerberg E., 2010, CLIN PREDICTION MODE; Thompson MA, 2010, JAMA-J AM MED ASSOC, V304, P321, DOI 10.1001/jama.2010.1004; Wood E, 2008, JAMA-J AM MED ASSOC, V300, P550, DOI 10.1001/jama.300.5.550; Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222; Yeni PG, 2004, JAMA-J AM MED ASSOC, V292, P251, DOI 10.1001/jama.292.2.251	21	17	18	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 19	2012	7	11							e47859	10.1371/journal.pone.0047859	http://dx.doi.org/10.1371/journal.pone.0047859			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	040PB	23185244	Green Published, gold, Green Submitted			2023-01-03	WOS:000311333800005
J	Attaran, A; Barry, D; Basheer, S; Bate, R; Benton, D; Chauvin, J; Garrett, L; Kickbusch, I; Kohler, JC; Midha, K; Newton, PN; Nishtar, S; Orhii, P; McKee, M				Attaran, Amir; Barry, Donna; Basheer, Shamnad; Bate, Roger; Benton, David; Chauvin, James; Garrett, Laurie; Kickbusch, Ilona; Kohler, Jillian Clare; Midha, Kamal; Newton, Paul N.; Nishtar, Sania; Orhii, Paul; McKee, Martin			How to achieve international action on falsified and substandard medicines	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							DRUG QUALITY		[Attaran, Amir] Univ Ottawa, Ottawa, ON K1N 6N5, Canada; [Barry, Donna] Partners Hlth, Boston, MA USA; [Basheer, Shamnad] Natl Univ Jurid Sci, Kolkata, India; [Bate, Roger] Amer Enterprise Inst Publ Policy Res, Washington, DC USA; [Benton, David] Int Council Nurses, Geneva, Switzerland; [Chauvin, James] World Federat Publ Hlth Assoc, Geneva, Switzerland; [Garrett, Laurie] Council Foreign Relat, New York, NY USA; [Kickbusch, Ilona] Grad Inst, Global Hlth Programme, Geneva, Switzerland; [Kohler, Jillian Clare] Univ Toronto, Toronto, ON, Canada; [Midha, Kamal] Int Pharmaceut Federat, The Hague, Netherlands; [Newton, Paul N.] Univ Oxford, Oxford, England; [Nishtar, Sania] Heartfile, Islamabad, Pakistan; [Orhii, Paul] Natl Agcy Food & Drug Adm & Control, Abuja, Nigeria; [McKee, Martin] London Sch Hyg & Trop Med, London WC1, England	University of Ottawa; Partners Healthcare System; American Enterprise Institute for Public Policy Research; University of Toronto; University of Oxford; University of London; London School of Hygiene & Tropical Medicine	Attaran, A (corresponding author), Univ Ottawa, 1 Stewart St, Ottawa, ON K1N 6N5, Canada.	aattaran@uottawa.ca	benton, david/AAC-5298-2020; McKee, Marc D/E-2187-2011; Mckee, Martin/E-6673-2018	benton, david/0000-0001-8418-8618; McKee, Marc D/0000-0001-8349-965X; Mckee, Martin/0000-0002-0121-9683; Benton, David/0000-0002-4068-8124; Newton, Paul/0000-0002-4608-6431	Wellcome Trust [089275] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ahmad K, 2004, LANCET, V363, P713, DOI 10.1016/S0140-6736(04)15670-5; [Anonymous], 2011, LANCET, V377, P1626, DOI 10.1016/S0140-6736(11)60656-9; [Anonymous], 2010, BERKELEY DECLARATION; [Anonymous], 2011, HIV AIDS KENYA MAJOR; Attaran A, 2011, J INT CRIM JUSTICE, V9, P325, DOI 10.1093/jicj/mqr005; Bate R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002132; Bate R, 2010, LANCET, V376, P1446, DOI 10.1016/S0140-6736(10)61416-X; Beni S, 2011, ANAL BIOANAL CHEM, V399, P527, DOI 10.1007/s00216-010-4121-x; Callard C, 2010, TOB CONTROL, V19, P285, DOI 10.1136/tc.2009.035071; China State Council, 2012, NAT 12 5 YEAR PLAN D; Choudary A., 2012, POLICE BODY RECOMMEN; Cockburn R, 2005, PLOS MED, V2, P302, DOI 10.1371/journal.pmed.0020100; Council of Europe, 2011, CONV COUNT MED PROD; Erhun WO., 2001, J HLTH POPULATION DE, V4, P23; European Commission, 2011, REP EU CUST ENF INT; Fitz-Maurice E, 1932, AM J INT LAW, V26, P533, DOI 10.2307/2190203; Garrett L, ENSURING SAFETY INTE; India Parliamentary Standing Committee on Health and Family Welfare, 2012, 59 IND PARL STAND CO; Kubic TT, 2010, J BIOLAW BUS, V13, P38; Molzon JA, 2011, CLIN PHARMACOL THER, V89, P503, DOI 10.1038/clpt.2011.10; Mullard A, 2010, LANCET, V375, P1335, DOI 10.1016/S0140-6736(10)60560-0; Newton PN, 2006, PLOS MED, V3, P752, DOI 10.1371/journal.pmed.0030197; Newton PN, 2006, LANCET INFECT DIS, V6, P602, DOI 10.1016/S1473-3099(06)70581-3; Newton PN, 2002, BRIT MED J, V324, P800, DOI 10.1136/bmj.324.7341.800; Nordt SP, 2010, AM J CARDIOVASC DRUG, V10, P261, DOI 10.2165/11537640-000000000-00000; Okie S, 2009, NEW ENGL J MED, V361, P737, DOI 10.1056/NEJMp0903870; Oxfam, 2011, EYE BALL MED REG NOT; People's Health Movement, 2011, IT CONS 64 WHA; Pew Charitable Trusts, 2011, HEP PROT CONS RISKS; Schep LJ, 2009, CLIN TOXICOL, V47, P525, DOI 10.1080/15563650903086444; Third World Network, 2010, WHOS COUNT PROGR LEG; United Nations Office on Drugs and Crime, 2010, GLOBALIZATION CRIME; Von Braun J, 2010, AFR J INT COMP LAW, V18, P238, DOI 10.3366/ajicl.2010.0007; Weaver CM, 2012, WALL STREET J; WHO, 2011, WHOS ROL PREV CONTR; WHO, 2011, WHO PREQ MED PROGR F; WHO, 2011, FALS LAM ZID NEV TAB; WHO and IMPACT, 2006, COUNT MED UPD EST; World Health Organization, 2010, COUNT MED PROD REP S; World Health Organization, 2011, REP WORK GROUP MEMB; World Health Organization, INT PHARM; World Trade Organization, 1994, TRAD REL ASP INT PRO; [No title captured]	43	65	65	0	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 13	2012	345								e7381	10.1136/bmj.e7381	http://dx.doi.org/10.1136/bmj.e7381			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	040PU	23149211	Bronze, Green Submitted			2023-01-03	WOS:000311335800015
J	Jung, UJ; Park, YB; Kim, SR; Choi, MS				Jung, Un Ju; Park, Yong Bok; Kim, Sang Ryong; Choi, Myung-Sook			Supplementation of Persimmon Leaf Ameliorates Hyperglycemia, Dyslipidemia and Hepatic Fat Accumulation in Type 2 Diabetic Mice	PLOS ONE			English	Article							ACTIVATED-RECEPTOR-GAMMA; PHOSPHOENOLPYRUVATE-CARBOXYKINASE; INSULIN-RESISTANCE; DIOSPYROS-KAKI; PPAR-GAMMA; RAT-LIVER; OXIDATIVE STRESS; RESPONSE ELEMENT; GENE-EXPRESSION; ADIPOSE-TISSUE	Persimmon Leaf (PL), commonly consumed as herbal tea and traditional medicines, contains a variety of compounds that exert antioxidant, alpha-amylase and alpha-glucosidase inhibitory activity. However, little is known about the in vivo effects and underlying mechanisms of PL on hyperglycemia, hyperlipidemia and hepatic steatosis in type 2 diabetes. Powered PL (5%, w/w) was supplemented with a normal diet to C57BL/KsJ-db/db mice for 5 weeks. PL decreased blood glucose, HOMA-IR, plasma triglyceride and total cholesterol levels, as well as liver weight, hepatic lipid droplets, triglycerides and cholesterol contents, while increasing plasma HDL-cholesterol and adiponectin levels. The anti-hyperglycemic effect was linked to decreased activity of gluconeogenic enzymes as well as increased glycogen content, glucokinase activity and its mRNA level in the liver. PL also led to a decrease in lipogenic transcriptional factor PPAR gamma as well as gene expression and activity of enzymes involved in lipogenesis, with a simultaneous increase in fecal lipids, which are seemingly attributable to the improved hyperlipidemia and hepatic steatosis and decreased hepatic fatty acid oxidation. Furthermore, PL ameliorated plasma and hepatic oxidative stress. Supplementation with PL may be an effective dietary strategy to improve type 2 diabetes accompanied by dyslipidemia and hepatic steatosis by partly modulating the activity or gene expression of enzymes related to antioxidant, glucose and lipid homeostasis. Citation: Jung UJ, Park YB, Kim SR, Choi M-S (2012) Supplementation of Persimmon Leaf Ameliorates Hyperglycemia, Dyslipidemia and Hepatic Fat Accumulation in Type 2 Diabetic Mice. PLoS ONE 7(11): e49030. doi:10.1371/journal.pone.0049030	[Jung, Un Ju; Choi, Myung-Sook] Kyungpook Natl Univ, Dept Food Sci & Nutr, Taegu, South Korea; [Park, Yong Bok; Kim, Sang Ryong] Kyungpook Natl Univ, Sch Life Sci & Biotechnol, Taegu, South Korea; [Kim, Sang Ryong] Kyungpook Natl Univ, Brain Sci & Engn Inst, Taegu, South Korea	Kyungpook National University; Kyungpook National University; Kyungpook National University	Choi, MS (corresponding author), Kyungpook Natl Univ, Dept Food Sci & Nutr, Taegu, South Korea.	mschoi@knu.ac.kr			National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology (MEST) [2011-0000920, 2011-0022387]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science and Technology (MEST)(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by grants from the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (MEST) (No. 2011-0000920 and No. 2011-0022387). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABBOTT CA, 1995, ARTERIOSCL THROM VAS, V15, P1812, DOI 10.1161/01.ATV.15.11.1812; Abdul-Ghani MA, 2006, DIABETES CARE, V29, P1130, DOI 10.2337/dc05-2179; Aebi H., 1974, CATALASE METHODS ENZ, V2, P673; ALEGRE M, 1988, ANAL BIOCHEM, V173, P185, DOI 10.1016/0003-2697(88)90176-5; *AM I NUTR, 1980, J NUTR, V110, P1717; Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; Barthel A, 2003, AM J PHYSIOL-ENDOC M, V285, pE685, DOI 10.1152/ajpendo.00253.2003; BENTLE LA, 1976, J BIOL CHEM, V251, P2916; BIERI JG, 1977, J NUTR, V107, P1394; Bonnard C, 2008, J CLIN INVEST, V118, P789, DOI 10.1172/JCI32601; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cadoudal T, 2007, DIABETOLOGIA, V50, P666, DOI 10.1007/s00125-006-0560-5; Chakravarthy MV, 2011, P NATL ACAD SCI USA, V108, P5378; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cleasby ME, 2004, DIABETES, V53, P3258, DOI 10.2337/diabetes.53.12.3258; Daimon M, 2003, DIABETES CARE, V26, P2015, DOI 10.2337/diacare.26.7.2015; DAVIDSON AL, 1987, ARCH BIOCHEM BIOPHYS, V253, P156, DOI 10.1016/0003-9861(87)90648-5; Davies GF, 2001, BIOCHEM PHARMACOL, V62, P1071, DOI 10.1016/S0006-2952(01)00764-X; Davis RC, 2010, DIABETES, V59, P1616, DOI 10.2337/db09-0878; Devine JH, 1999, J BIOL CHEM, V274, P13604, DOI 10.1074/jbc.274.19.13604; ERICKSON SK, 1980, J LIPID RES, V21, P930; Ferre T, 2003, DIABETOLOGIA, V46, P1662, DOI 10.1007/s00125-003-1244-z; FOLCH J, 1957, J BIOL CHEM, V226, P497; Foster DW, 2004, ANN NY ACAD SCI, V1033, P1, DOI 10.1196/annals.1320.001; GIRALT M, 1991, J BIOL CHEM, V266, P21991; Glorian M, 2001, BIOCHIMIE, V83, P933, DOI 10.1016/S0300-9084(01)01343-8; Green K, 2004, DIABETES, V53, pS110, DOI 10.2337/diabetes.53.2007.S110; Haffner SM, 1997, DIABETES CARE, V20, P1087, DOI 10.2337/diacare.20.7.1087; Hallakou S, 1997, DIABETES, V46, P1393, DOI 10.2337/diabetes.46.9.1393; HULCHER FH, 1973, J LIPID RES, V14, P625; KAMEDA K, 1987, J NAT PROD, V50, P680, DOI 10.1021/np50052a017; Kawakami K, 2011, BIOSCI BIOTECH BIOCH, V75, P1435, DOI 10.1271/bbb.100926; Kawakami K, 2010, BIOSCI BIOTECH BIOCH, V74, P1380, DOI 10.1271/bbb.100056; Kotani M, 2000, J ALLERGY CLIN IMMUN, V106, P159, DOI 10.1067/mai.2000.107194; Kumashiro N, 2008, DIABETES, V57, P2083, DOI 10.2337/db08-0144; Lazarow P B, 1981, Methods Enzymol, V72, P315; Lee JS, 2006, FOOD CHEM TOXICOL, V44, P1875, DOI 10.1016/j.fct.2006.06.014; LEE SC, 1992, J AOAC INT, V75, P395; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; MACKNESS MI, 1991, FEBS LETT, V286, P152, DOI 10.1016/0014-5793(91)80962-3; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; MARKWELL MA, 1973, J BIOL CHEM, V248, P3426; Matsusue K, 2003, J CLIN INVEST, V111, P737, DOI 10.1172/JCI200317223; Memon RA, 2000, ENDOCRINOLOGY, V141, P4021, DOI 10.1210/en.141.11.4021; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Mithieux G, 2002, DIABETES, V51, P139, DOI 10.2337/diabetes.51.1.139; Moran-Salvador E, 2011, FASEB J, V25, P2538, DOI 10.1096/fj.10-173716; Moreno MIN, 2000, J ETHNOPHARMACOL, V71, P109, DOI 10.1016/S0378-8741(99)00189-0; Nakamura A, 2011, J DIABETES INVEST, V2, P276, DOI 10.1111/j.2040-1124.2011.00104.x; Nakamura S, 2009, J BIOL CHEM, V284, P14809, DOI 10.1074/jbc.M901488200; Nepokroeff C M, 1975, Methods Enzymol, V35, P37, DOI 10.1016/0076-6879(75)35136-7; NEWGARD CB, 1983, J BIOL CHEM, V258, P8046; O'Doherty RM, 1999, DIABETES, V48, P2022, DOI 10.2337/diabetes.48.10.2022; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Pal M, 2009, DRUG DISCOV TODAY, V14, P784, DOI 10.1016/j.drudis.2009.05.013; Postic C, 2008, J CLIN INVEST, V118, P829, DOI 10.1172/JCI34275; Randle PJ, 1998, DIABETES METAB REV, V14, P263, DOI 10.1002/(SICI)1099-0895(199812)14:4&lt;263::AID-DMR233&gt;3.0.CO;2-C; Rosenblat M, 2009, BIOFACTORS, V35, P98, DOI 10.1002/biof.16; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SEIFTER S, 1950, ARCH BIOCHEM, V25, P191; SHAFRIR E, 1992, DIABETES METAB REV, V8, P179, DOI 10.1002/dmr.5610080302; SHAPIRO DJ, 1974, BIOCHIM BIOPHYS ACTA, V370, P369, DOI 10.1016/0005-2744(74)90098-9; Singleton VL, 1999, METHOD ENZYMOL, V299, P152; Suh YH, 2005, J MOL ENDOCRINOL, V34, P299, DOI 10.1677/jme.1.01679; Sun LJ, 2011, FOOD CHEM TOXICOL, V49, P2689, DOI 10.1016/j.fct.2011.07.042; Tahrani AA, 2011, LANCET, V378, P182, DOI 10.1016/S0140-6736(11)60207-9; Thuong PT, 2008, J NAT PROD, V71, P1775, DOI 10.1021/np800298w; Torres TP, 2009, DIABETES, V58, P78, DOI 10.2337/db08-1119; Valentova K, 2007, J AGR FOOD CHEM, V55, P7726, DOI 10.1021/jf0712447; WALTON PA, 1984, BIOCHIM BIOPHYS ACTA, V796, P364, DOI 10.1016/0005-2760(84)90139-5; Wang L, 2011, CARBOHYD RES, V346, P1212, DOI 10.1016/j.carres.2011.04.021; WOLFF SP, 1994, METHOD ENZYMOL, V233, P182; Wu M, 2011, P NATL ACAD SCI USA, V108, P5378, DOI 10.1073/pnas.1002588108	74	42	45	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2012	7	11							e49030	10.1371/journal.pone.0049030	http://dx.doi.org/10.1371/journal.pone.0049030			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	053KE	23145054	Green Submitted, gold, Green Published			2023-01-03	WOS:000312269500062
J	Brock, J; Mitchell, J; Irby, K; Stevens, B; Archibald, T; Goroski, A; Lynn, J				Brock, Jane; Mitchell, Jason; Irby, Kimberly; Stevens, Beth; Archibald, Traci; Goroski, Alicia; Lynn, Joanne		Care Transitions Project Team	Association Between Quality Improvement for Care Transitions in Communities and Rehospitalizations Among Medicare Beneficiaries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRIAL; INTERVENTIONS; PROGRAM; SERVICE; ELDERS; ERRORS	Importance Medicare beneficiaries experience errors during transitions among care settings, yielding harms that include unnecessary rehospitalizations. Objective To evaluate whether implementation of improved care transitions for patients with Medicare fee-for-service (FFS) insurance is associated with reduced rehospitalizations and hospitalizations in geographic communities. Design, Setting, and Participants Quality improvement initiative for care transitions by health care and social services personnel and Medicare Quality Improvement Organization staff in defined geographic areas, with monitoring by community-specific and aggregate control charts and evaluation with pre-post comparison of performance differences for 14 intervention communities and 50 comparison communities from before (2006-2008) and during (2009-2010) implementation. Intervention communities had between 22 070 and 90 843 Medicare FFS beneficiaries. Intervention Quality Improvement Organizations facilitated community-wide quality improvement activities to implement evidence-based improvements in care transitions by community organizing, technical assistance, and monitoring of participation, implementation, effectiveness, and adverse effects. Main Outcome Measures The primary outcome measure was all-cause 30-day rehospitalizations per 1000 Medicare FFS beneficiaries; secondary outcome measures were all-cause hospitalizations per 1000 Medicare FFS beneficiaries and all-cause 30-day rehospitalizations as a percentage of hospital discharges. Results The mean rate of 30-day all-cause rehospitalizations per 1000 beneficiaries per quarter was 15.21 in 2006-2008 and 14.34 in 2009-2010 in the 14 intervention communities and was 15.03 in 2006-2008 and 14.72 in 2009-2010 in the 50 comparison communities, with the pre-post between-group difference showing larger reductions in rehospitalizations in intervention communities (by 0.56/1000 per quarter; 95% CI, 0.05-1.07; P=.03). The mean rate of hospitalizations per 1000 beneficiaries per quarter was 82.27 in 2006-2008 and 77.54 in 2009-2010 in intervention communities and was 82.09 in 2006-2008 and 79.48 in 2009-2010 in comparison communities, with the pre-post between-group difference showing larger reductions in hospitalizations in intervention communities (by 2.12/1000 per quarter; 95% CI, 0.47-3.77; P=.01). Mean community-wide rates of rehospitalizations as a percentage of hospital discharges in the intervention communities were 18.97% in 2006-2008 and 18.91% in 2009-2010 and were 18.76% in 2006-2008 and 18.91% in 2009-2010 in the comparison communities, with no significant difference in the pre-post between-group differences (0.22%; 95% CI, -0.08% to 0.51%; P=.14). Process control charts signaled onset of improvement coincident with initiating intervention. Conclusions and Relevance Among Medicare beneficiaries in intervention communities, compared with those in uninvolved communities, all-cause 30-day rehospitalization and all-cause hospitalization declined. However, there was no change in the rate of all-cause 30-day rehospitalizations as a percentage of hospital discharges. JAMA. 2013; 309(4): 381-391	[Brock, Jane; Mitchell, Jason; Irby, Kimberly; Stevens, Beth; Goroski, Alicia; Lynn, Joanne] Colorado Fdn Med Care, Englewood, CO USA; [Archibald, Traci; Lynn, Joanne] Ctr Medicare Serv, Baltimore, MD USA; [Archibald, Traci; Lynn, Joanne] Ctr Medicaid Serv, Baltimore, MD USA	Centers for Medicare & Medicaid Services; Centers for Medicare & Medicaid Services	Lynn, J (corresponding author), Altarum Inst, Ctr Elder Care & Adv Illness, 2000 M St NW,Ste 400, Washington, DC 20036 USA.	joanne.lynn@altarum.org		Sugarman, Jonathan/0000-0001-5588-0250	CMS	CMS	This project was funded through the CMS.	Alecxih L., 2010, INDIVIDUALS LIVING C; Bixby M Brian, 2010, Medsurg Nurs, V19, P62; Boutwell AE, 2011, HEALTH AFFAIR, V30, P1272, DOI 10.1377/hlthaff.2011.0111; Centers for Medicare and Medicaid Services, HCAHPS PAT PERSP CAR; Centers for Medicare & Medicaid Services, MED DEM DET COMM BAS; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Colorado Foundation for Medical Care, INT CAR POP COMM NAT; Counsell SR, 2006, J AM GERIATR SOC, V54, P1136, DOI 10.1111/j.1532-5415.2006.00791.x; Craig C, 2011, IHI INNOVATION SERIE; Deming WE, 2000, NEW EC IND GOVT ED, V2; Epstein AM, 2011, NEW ENGL J MED, V365, P2287, DOI 10.1056/NEJMsa1101942; FedBizOpps.gov, QIO 10 STAT WORK SOL; Hansen LO, 2011, ANN INTERN MED, V155, P520, DOI 10.7326/0003-4819-155-8-201110180-00008; HealthCare.gov, PAT PROT AFF CAR ACT; HealthCare. gov, PARTN PAT BETT CAR L; Home Health Quality Improvement, BEST PRACT INT PACK; Institute for Healthcare Improvement, PREV ADV DRUG EV MED; Jack BW, 2009, ANN INTERN MED, V150, P178, DOI 10.7326/0003-4819-150-3-200902030-00007; JAMAevidence, US ART QUAL IMPR; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Lu CY, 2011, INT J CLIN PRACT, V65, P733, DOI 10.1111/j.1742-1241.2011.02671.x; Moore C, 2003, J GEN INTERN MED, V18, P646, DOI 10.1046/j.1525-1497.2003.20722.x; Naylor MD, 2011, HEALTH AFFAIR, V30, P746, DOI 10.1377/hlthaff.2011.0041; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; Ouslander JG, 2011, J AM GERIATR SOC, V59, P745, DOI 10.1111/j.1532-5415.2011.03333.x; Provost LP, 2011, BMJ QUAL SAF, V20, pI92, DOI 10.1136/bmjqs.2011.051557; QualityNet, MEAS METH REP READM; Shewhart W., 1939, STAT METHOD VIEWPOIN; Social Security Administration, SOC SEC ACT TITL 11; Society of Hospital Medicine, BOOSTING CAR TRANS R; The Care Transitions Program, CAR TRANS MEAS CTM; Thor J, 2007, QUAL SAF HEALTH CARE, V16, P387, DOI 10.1136/qshc.2006.022194; Tilley N., 1997, REALIST EVALUATION; US Bureau of the Census, 2003, 2003 SMALL AR INC PO; Ventura T., 2010, REMINGTON REPORT, V18, P24; Wennberg, 2008, TRACKING CARE PATIEN; Wheeler D, 1993, UNDERSTANDING VARIAT; Wheeler DJ, 1992, UNDERSTANDING STAT P, V2nd; Wilcock PM, 2000, QUAL HEALTH CARE, V9, P199, DOI 10.1136/qhc.9.4.199	39	113	114	0	43	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 23	2013	309	4					381	391		10.1001/jama.2012.216607	http://dx.doi.org/10.1001/jama.2012.216607			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	074FT	23340640	Bronze			2023-01-03	WOS:000313799000026
J	Singh, AP; Sarkar, S; Tripathi, M; Rajender, S				Singh, Akhand Pratap; Sarkar, Saumya; Tripathi, Muktanand; Rajender, Singh			Mucuna pruriens and Its Major Constituent L-DOPA Recover Spermatogenic Loss by Combating ROS, Loss of Mitochondrial Membrane Potential and Apoptosis	PLOS ONE			English	Article							OXIDATIVE STRESS; ESTRADIOL TREATMENT; MALE-INFERTILITY; SPERM MOTILITY; ADULT-RAT; DAMAGE; UPDATE; TESTIS	Background: The Ayurvedic medicinal system claims Mucuna pruriens (MP) to possess pro-male fertility, aphrodisiac and adaptogenic properties. Some scientific evidence also supports its pro-male fertility properties; however, the mechanism of its action is not yet clear. The present study aimed at demonstrating spermatogenic restorative efficacy of MP and its major constituent L-DOPA (LD), and finding the possible mechanism of action thereof in a rat model. Methodology/Findings: Ethinyl estradiol (EE) was administered at a rate of 3 mg/kg body weight (BW)/day for a period of 14 days to generate a rat model with compromised spermatogenesis. MP and LD were administered in two separate groups of these animals starting 15th day for a period of 56 days, and the results were compared with an auto-recovery (AR) group. Sperm count and motility, testis histo-architecture, level of reactive oxygen species (ROS), mitochondrial membrane potential (MMP), apoptosis, peripheral hormone levels and testicular germ cell populations were analysed, in all experimental groups. We observed efficient and quick recovery of spermatogenesis in MP and LD groups in comparison to the auto-recovery group. The treatment regulated ROS level, apoptosis, and mitochondrial membrane potential (MMP), recovered the hypothalamic-pituitary-gonadal axis and the number of testicular germ cells, ultimately leading to increased sperm count and motility. Conclusion/Significance: M. pruriens efficiently recovers the spermatogenic loss induced due to EE administration. The recovery is mediated by reduction in ROS level, restoration of MMP, regulation of apoptosis and eventual increase in the number of germ cells and regulation of apoptosis. The present study simplified the complexity of mechanism involved and provided meaningful insights into MP/LD mediated correction of spermatogenic impairment caused by estrogens exposure. This is the first study demonstrating that L-DOPA largely accounts for pro-spermatogenic properties of M. pruriens. The manuscript bears CDRI communication number 8374.	[Singh, Akhand Pratap; Sarkar, Saumya; Tripathi, Muktanand; Rajender, Singh] Council Sci & Ind Res Cent Drug Res Inst, Div Endocrinol, Lucknow, Uttar Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI)	Rajender, S (corresponding author), Council Sci & Ind Res Cent Drug Res Inst, Div Endocrinol, Lucknow, Uttar Pradesh, India.	rajender_singh@cdri.res.in	Singh, Rajender/ABE-3512-2020	Sarkar, Saumya/0000-0003-2247-8796; Rajender, Singh/0000-0002-4592-6566	Ministry of Health and Family Welfare, Government of India	Ministry of Health and Family Welfare, Government of India	This study was supported by financial grant from Ministry of Health and Family Welfare, Government of India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal A, 2005, BJU INT, V95, P503, DOI 10.1111/j.1464-410X.2005.05328.x; Agarwal A, 2008, AM J REPROD IMMUNOL, V59, P2, DOI 10.1111/j.1600-0897.2007.00559.x; Ahmad MK, 2008, FERTIL STERIL, V90, P627, DOI 10.1016/j.fertnstert.2007.07.1314; [Anonymous], 1962, RAW MAT, V6, P47; [Anonymous], 1962, RAW MAT, V6, P337; [Anonymous], 1962, RAW MAT, V6, P220; [Anonymous], 1962, RAW MAT, V6, P439; Atanassova N, 1999, ENDOCRINOLOGY, V140, P5364, DOI 10.1210/en.140.11.5364; Atessahin A, 2006, REPROD TOXICOL, V21, P42, DOI 10.1016/j.reprotox.2005.05.003; Baumber J, 2000, J ANDROL, V21, P895; BlancoRodriguez J, 1997, J REPROD FERTIL, V110, P61, DOI 10.1530/jrf.0.1100061; BlancoRodriguez J, 1996, INT J ANDROL, V19, P237, DOI 10.1111/j.1365-2605.1996.tb00468.x; Carole M, 2002, HUM REPROD, V17, P1257; Chaki SP, 2006, APOPTOSIS, V11, P1427, DOI 10.1007/s10495-006-8761-4; Dama MS, 2011, J ANDROL; Daniel B, 1998, COVER CROPS HILLSIDE; Eduardo RP, 1998, CLIN CHEM, V44, P1616; GHOSAL S, 1971, PLANTA MED, V19, P279, DOI 10.1055/s-0028-1099642; Gow-Chin Yen, 1997, Bioscience, Biotechnology, and Biochemistry, V61, P1646; Gulcin I, 2007, AMINO ACIDS, V32, P431, DOI 10.1007/s00726-006-0379-x; Gupta N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022277; Iida Shigeru, 1997, Journal of Toxicological Sciences, V22, P397; Kasai T, 2002, ASIAN J ANDROL, V4, P97; Kazuki K, 2000, J AGR FOOD CHEM, V48, P844; King SR, 1992, DISCOVERY, V45, P23; Madhukar D, 2009, J ANDROL, V30, P95, DOI 10.2164/jandrol.108.005694; Masako K, 1999, REPROD TOXICOL, V13, P279; McLachlan RI, 2002, RECENT PROG HORM RES, V57, P149, DOI 10.1210/rp.57.1.149; MEHTA JC, 1994, INDIAN J PHARM SCI, V6, P92; Nadzialek S, 2010, ENVIRON TOXICOL CHEM, V29, P881, DOI 10.1002/etc.100; Newbold RR, 2006, ENDOCRINOLOGY, V147, pS11, DOI 10.1210/en.2005-1164; PANIKKAR KR, 1987, PLANTA MED, P503, DOI 10.1055/s-2006-962789; Peter S, 2001, J CELL SCI, V114, P1665; Prakash D, 2001, INT J FOOD SCI NUTR, V52, P79, DOI 10.1080/09637480020027264; Sharma BK, 2012, NOVEL SCI INT J PHAR, V1, P308; Shukla KK, 2011, REPROD BIOMED ONLINE, V22, P421, DOI 10.1016/j.rbmo.2011.01.010; Shukla KK, 2009, FERTIL STERIL, V92, P1934, DOI 10.1016/j.fertnstert.2008.09.045; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; Suresh S, 2010, J SEX MED; Suresh S, 2010, INT J ANDROL, V33, P22, DOI 10.1111/j.1365-2605.2008.00949.x; Suresh S, 2009, J ETHNOPHARMACOL, V122, P497, DOI 10.1016/j.jep.2009.01.032; Toshiko K, 2000, J TOXICOL SCI, V25, P43; Tremellen K, 2008, HUM REPROD UPDATE, V14, P243, DOI 10.1093/humupd/dmn004; Volpe S, 2009, REPROD DOMEST ANIM, V44, P275, DOI 10.1111/j.1439-0531.2009.01457.x	44	27	29	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2013	8	1							e54655	10.1371/journal.pone.0054655	http://dx.doi.org/10.1371/journal.pone.0054655			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	077HS	23349947	gold, Green Published, Green Submitted			2023-01-03	WOS:000314019100087
J	Pell, C; Menaca, A; Were, F; Afrah, NA; Chatio, S; Manda-Taylor, L; Hamel, MJ; Hodgson, A; Tagbor, H; Kalilani, L; Ouma, P; Pool, R				Pell, Christopher; Menaca, Arantza; Were, Florence; Afrah, Nana A.; Chatio, Samuel; Manda-Taylor, Lucinda; Hamel, Mary J.; Hodgson, Abraham; Tagbor, Harry; Kalilani, Linda; Ouma, Peter; Pool, Robert			Factors Affecting Antenatal Care Attendance: Results from Qualitative Studies in Ghana, Kenya and Malawi	PLOS ONE			English	Article							MATERNAL MORTALITY; PREGNANCY; PERSPECTIVES; STRATEGIES; MALARIA; BIRTH	Background: Antenatal care (ANC) is a key strategy to improve maternal and infant health. However, survey data from sub-Saharan Africa indicate that women often only initiate ANC after the first trimester and do not achieve the recommended number of ANC visits. Drawing on qualitative data, this article comparatively explores the factors that influence ANC attendance across four sub-Saharan African sites in three countries (Ghana, Kenya and Malawi) with varying levels of ANC attendance. Methods: Data were collected as part of a programme of qualitative research investigating the social and cultural context of malaria in pregnancy. A range of methods was employed interviews, focus groups with diverse respondents and observations in local communities and health facilities. Results: Across the sites, women attended ANC at least once. However, their descriptions of ANC were often vague. General ideas about pregnancy care - checking the foetus' position or monitoring its progress - motivated women to attend ANC; as did, especially in Kenya, obtaining the ANC card to avoid reprimands from health workers. Women's timing of ANC initiation was influenced by reproductive concerns and pregnancy uncertainties, particularly during the first trimester, and how ANC services responded to this uncertainty; age, parity and the associated implications for pregnancy disclosure; interactions with healthcare workers, particularly messages about timing of ANC; and the cost of ANC, including charges levied for ANC procedures - in spite of policies of free ANC - combined with ideas about the compulsory nature of follow-up appointments. Conclusion: In these socially and culturally diverse sites, the findings suggest that 'supply' side factors have an important influence on ANC attendance: the design of ANC and particularly how ANC deals with the needs and concerns of women during the first trimester has implications for timing of initiation.	[Pell, Christopher; Pool, Robert] Univ Amsterdam, Ctr Social Sci & Global Hlth, Amsterdam, Netherlands; [Pell, Christopher; Menaca, Arantza; Pool, Robert] Univ Barcelona, Hosp Clin, Barcelona Ctr Int Hlth Res CRESIB, Barcelona, Spain; [Were, Florence; Ouma, Peter] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya; [Afrah, Nana A.; Tagbor, Harry] Kwame Nkrumah Univ Sci & Technol, Sch Med Sci, Dept Community Hlth, Kumasi, Ghana; [Chatio, Samuel; Hodgson, Abraham] Navrongo Hlth Res Ctr, Navrongo, Upper East Regi, Ghana; [Manda-Taylor, Lucinda; Kalilani, Linda] Univ Malawi, Coll Med, Blantyre, Malawi; [Tagbor, Harry] London Sch Hyg & Trop Med, Dept Infect & Trop Med, London WC1, England; [Hamel, Mary J.; Ouma, Peter] Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA USA	University of Amsterdam; ISGlobal; CRESIB; University of Barcelona; Hospital Clinic de Barcelona; Kenya Medical Research Institute; Kwame Nkrumah University Science & Technology; Navrongo Health Research Center; University of Malawi; University of London; London School of Hygiene & Tropical Medicine; Centers for Disease Control & Prevention - USA	Pell, C (corresponding author), Univ Amsterdam, Ctr Social Sci & Global Hlth, Amsterdam, Netherlands.	c.l.pell@uva.nl	Manda-Taylor, Lucinda/AAK-2116-2021; Tagbor, Harry/B-9312-2018	Manda-Taylor, Lucinda/0000-0001-8149-0897; Tagbor, Harry/0000-0002-9300-665X; Pell, Christopher/0000-0001-9405-5851	Malaria in Pregnancy (MiP) Consortium; Bill and Melinda Gates Foundation [OPP46099]	Malaria in Pregnancy (MiP) Consortium; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation)	This research was supported and endorsed by the Malaria in Pregnancy (MiP) Consortium, which is funded by a grant from the Bill and Melinda Gates Foundation (www.gatesfoundation.org), Grant OPP46099. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abou-Zahr CL, 2003, ANTENATAL CARE DEV C; Allen DR, 2004, MANAGING MOTHERHOOD; Anya Samuel E, 2008, BMC Pregnancy Childbirth, V8, P9, DOI 10.1186/1471-2393-8-9; Bergsjo P, 1997, ACTA OBSTET GYN SCAN, V76, P15, DOI 10.3109/00016349709047779; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Carroli G, 2001, PAEDIATR PERINAT EP, V15, P1; Carroli G, 2001, LANCET, V357, P1565, DOI 10.1016/S0140-6736(00)04723-1; Central Statistical Agency,, 2012, ETH DEM HLTH SURV 20; Centre National de la Statistique et destudes Etudes Economiques (CNSEE) and ORC Macro, 2006, ENQ DEM SANT CONG 20; Chapman RR, 2003, SOC SCI MED, V57, P355, DOI 10.1016/S0277-9536(02)00363-5; Conrad P, 2012, TROP MED INT HEALTH, V17, P300, DOI 10.1111/j.1365-3156.2011.02923.x; Dowswell T, 2010, COCHRANE DATABASE SY, P10; Gamble C, 2007, PLOS MED, V4, P506, DOI 10.1371/journal.pmed.0040107; Ghana Statistical Service (GSS) Ghana Health Service (GHS) ICF Macro., 2009, GHAN DEM HLTH SURV 2; Gross K, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-36; Kenya National Bureau of Statistics (KNBS) ICF Macro, 2010, KEN DEM HLTH SURV 20; Kinney MV, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000294; Lambert H, 2002, BRIT MED J, V325, P210, DOI 10.1136/bmj.325.7357.210; Magoma M, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-64; Magoma M, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-13; Mathole T, 2004, MIDWIFERY, V20, P122, DOI 10.1016/j.midw.2003.10.003; Menendez C, 2007, LANCET INFECT DIS, V7, P126, DOI 10.1016/S1473-3099(07)70024-5; Myer L, 2003, J MIDWIFERY WOM HEAL, V48, P268, DOI 10.1016/S1526-9523(02)00421-X; National Statistical Office (NSO) and ICF Macro, 2011, MAL DEM HLTH SURV 20; Nikiema B, 2009, HEALTH POLICY PLANN, V24, P367, DOI 10.1093/heapol/czp017; NPC and ICF Macro, 2009, NIG DEM HLTH SURV 20; Pell C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022452; Service GS, 2008, GHAN POP HOUS CENS 2; Simkhada B, 2008, J ADV NURS, V61, P244, DOI 10.1111/j.1365-2648.2007.04532.x; Smith LA, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-18; Stanton C, 2007, J BIOSOC SCI, V39, P109, DOI 10.1017/S0021932006001271; Stokes E, 2008, BJOG-INT J OBSTET GY, V115, P1641, DOI 10.1111/j.1471-0528.2008.01950.x; Strauss A., 1997, GROUNDED THEORY PRAC; Wang W, 2011, DHS COMP REPORTS, P85; World Health Organization, 2002, ANT CAR RAND TRIAL M; World Health Organization, 2010, IMPAC INT MAN PREG C; World Health Organization, 2007, PROV EFF ANT CAR STA; World Health Organization, 2011, WHO STAT ANT CAR	38	196	197	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 15	2013	8	1							e53747	10.1371/journal.pone.0053747	http://dx.doi.org/10.1371/journal.pone.0053747			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	086SQ	23335973	Green Published, gold, Green Accepted			2023-01-03	WOS:000314707700029
J	Chakraborty, S; Gruber, T; Barry, CE; Boshoff, HI; Rhee, KY				Chakraborty, Sumit; Gruber, Todd; Barry, Clifton E., III; Boshoff, Helena I.; Rhee, Kyu Y.			Para-Aminosalicylic Acid Acts as an Alternative Substrate of Folate Metabolism in Mycobacterium tuberculosis	SCIENCE			English	Article							DIHYDROPTEROATE SYNTHASE; THYMIDYLATE SYNTHASE; ESCHERICHIA-COLI; LIGAND-BINDING; RESISTANCE; METHOTREXATE; INHIBITION; DEPLETION; THYX	Folate biosynthesis is an established anti-infective target, and the antifolate para-aminosalicylic acid (PAS) was one of the first anti-infectives introduced into clinical practice on the basis of target-based drug discovery. Fifty years later, PAS continues to be used to treat tuberculosis. PAS is assumed to inhibit dihydropteroate synthase (DHPS) in Mycobacterium tuberculosis by mimicking the substrate p-aminobenzoate (PABA). However, we found that sulfonamide inhibitors of DHPS inhibited growth of M. tuberculosis only weakly because of their intracellular metabolism. In contrast, PAS served as a replacement substrate for DHPS. Products of PAS metabolism at this and subsequent steps in folate metabolism inhibited those enzymes, competing with their substrates. PAS is thus a prodrug that blocks growth of M. tuberculosis when its active forms are generated by enzymes in the pathway they poison.	[Chakraborty, Sumit; Rhee, Kyu Y.] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA; [Chakraborty, Sumit; Rhee, Kyu Y.] Weill Cornell Med Coll, Dept Microbiol & Immunol, New York, NY 10065 USA; [Gruber, Todd; Barry, Clifton E., III; Boshoff, Helena I.] NIAID, TB Res Sect, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA	Cornell University; Cornell University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Rhee, KY (corresponding author), Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA.	kyr9001@med.cornell.edu	Barry, III, Clifton/H-3839-2012; Barry, Clifton E/ABE-7992-2020	Barry, III, Clifton/0000-0002-2927-270X; Barry, Clifton E/0000-0002-2927-270X	Burroughs Wellcome Career Award in the Biomedical Sciences; William Randolph Hearst Foundation; Bill and Melinda Gates TB Drug Accelerator Program [OPP1024050]; NIAID, NIH; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000783] Funding Source: NIH RePORTER	Burroughs Wellcome Career Award in the Biomedical Sciences(Burroughs Wellcome Fund); William Randolph Hearst Foundation; Bill and Melinda Gates TB Drug Accelerator Program; NIAID, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank C. Nathan for critical discussions and reading of the manuscript, D. Garboczi for assistance in preparing purified FolP1 and FolC, R. Lee and M. Serono for the generous gifts of pure folate intermediates and pteroate analogs, S. Fischer for expert mass spectrometric support, a Burroughs Wellcome Career Award in the Biomedical Sciences to K.Y.R., the William Randolph Hearst Foundation, and the Bill and Melinda Gates TB Drug Accelerator Program (OPP1024050) for support. This work was supported in part by the Intramural Research Program of NIAID, NIH. Primary data are deposited in Dryad; the provisional doi is 10.5061/dryad.vh36n.	ALLEGRA CJ, 1985, P NATL ACAD SCI USA, V82, P4881, DOI 10.1073/pnas.82.15.4881; ALLEGRA CJ, 1986, J BIOL CHEM, V261, P6478; Brauer MJ, 2006, P NATL ACAD SCI USA, V103, P19302, DOI 10.1073/pnas.0609508103; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; de Carvalho LPS, 2010, CHEM BIOL, V17, P1122, DOI 10.1016/j.chembiol.2010.08.009; ELION GERTRUDE B., 1965, ADVANCE CHEMOTHERAP, V2, P91; Fivian-Hughes AS, 2012, MICROBIOL-SGM, V158, P308, DOI 10.1099/mic.0.053983-0; Gengenbacher M, 2008, FEMS MICROBIOL LETT, V287, P128, DOI 10.1111/j.1574-6968.2008.01302.x; Huang TS, 2012, J ANTIMICROB CHEMOTH, V67, P633, DOI 10.1093/jac/dkr501; Hunter JH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002237; Kwon YK, 2010, ACS CHEM BIOL, V5, P787, DOI 10.1021/cb100096f; Long E. R, 1958, CHEM CHEMOTHERAPY TU, P347; Lu WY, 2007, J AM SOC MASS SPECTR, V18, P898, DOI 10.1016/j.jasms.2007.01.017; Mathys V, 2009, ANTIMICROB AGENTS CH, V53, P2100, DOI 10.1128/AAC.01197-08; Nathan C, 2009, CELL HOST MICROBE, V5, P220, DOI 10.1016/j.chom.2009.02.004; Nopponpunth V, 1999, J BACTERIOL, V181, P6814, DOI 10.1128/JB.181.21.6814-6821.1999; Raviglione M, 2012, LANCET, V379, P1902, DOI 10.1016/S0140-6736(12)60727-2; Rengarajan J, 2004, MOL MICROBIOL, V53, P275, DOI 10.1111/j.1365-2958.2004.04120.x; ROSDAHL K. -G, 1948, SVENSK KEMISK TIDSKR, V60, P12; Schuessler DL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034471; Spencer HT, 1997, BIOCHEMISTRY-US, V36, P4212, DOI 10.1021/bi961794q; Wei JR, 2011, P NATL ACAD SCI USA, V108, P4176, DOI 10.1073/pnas.1018301108	22	139	142	1	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 4	2013	339	6115					88	91		10.1126/science.1228980	http://dx.doi.org/10.1126/science.1228980			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	063HC	23118010	Green Accepted			2023-01-03	WOS:000312985800058
J	Li, QY; Jiang, Y; Wei, W; Yang, HW; Liu, JL				Li, Qiuyun; Jiang, Yi; Wei, Wei; Yang, Huawei; Liu, Jianlun			Clinical Efficacy of Including Capecitabine in Neoadjuvant Chemotherapy for Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials	PLOS ONE			English	Article							PHASE-II TRIAL; DOCETAXEL	Background: Capecitabine has proven effective as a chemotherapy for metastatic breast cancer. Though several Phase II/III studies of capecitabine as neoadjuvant chemotherapy have been conducted, the results still remain inconsistent. Therefore, we performed a meta-analysis to obtain more precise understanding of the role of capecitabine in neoadjuvant chemotherapy for breast cancer patients. Methods: The electronic database PubMed and online abstracts from ASCO and SABCS were searched to identify randomized clinical trials comparing neoadjuvant chemotherapy with or without capecitabine in early/operable breast cancer patients without distant metastasis. Risk ratios were used to estimate the association between capecitabine in neoadjuvant chemotherapy and various efficacy outcomes. Fixed- or random-effect models were adopted to pool data in RevMan 5.1. Results: Five studies were included in the meta-analysis. Neoadjuvant use of capecitabine with anthracycline and/or taxane based therapy was not associated with significant improvement in clinical outcomes including: pathologic complete response in breast (pCR; RR = 1.10, 95% CI 0.87-1.40, p = 0.43), pCR in breast tumor and nodes (tnpCR RR = 0.99, 95% CI 0.83-1.18, p = 0.90), overall response rate (ORR; RR = 1.00, 95% CI 0.94-1.07, p = 0.93), or breast-conserving surgery (BCS; RR = 0.98, 95% CI 0.93-1.04, p = 0.49). Conclusions: Neoadjuvant treatment of breast cancer involving capecitabine did not significantly improve pCR, tnpCR, BCS or ORR. Thus adding capecitabine to neoadjuvant chemotherapy regimes is unlikely to improve outcomes in breast cancer patients without distant metastasis. Further research is required to establish the condition that capecitabine may be useful in breast cancer neoadjuvant chemotherapy.	[Li, Qiuyun; Jiang, Yi; Wei, Wei; Yang, Huawei; Liu, Jianlun] Guangxi Med Univ, Affiliated Tumor Hosp, Dept Breast Surg, Nanning, Peoples R China	Guangxi Medical University	Liu, JL (corresponding author), Guangxi Med Univ, Affiliated Tumor Hosp, Dept Breast Surg, Nanning, Peoples R China.	jianlunliu@hotmail.com						Bear HD, 2012, NEW ENGL J MED, V366, P310, DOI 10.1056/NEJMoa1111097; Bevers TB, 2009, J NATL COMPR CANC NE, V7, P1060, DOI 10.6004/jnccn.2009.0070; Blum JL, 2001, ONCOLOGIST, V6, P56, DOI 10.1634/theoncologist.6-1-56; DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Goldhirsch A, 2003, J CLIN ONCOL, V21, P3357, DOI 10.1200/JCO.2003.04.576; Greil R, 2009, EJSO-EUR J SURG ONC, V35, P1048, DOI 10.1016/j.ejso.2009.01.014; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jinno H, 2010, ANN ONCOL, V21, P1262, DOI 10.1093/annonc/mdp428; Koukourakis GV, 2008, MOLECULES, V13, P1897, DOI 10.3390/molecules13081897; KURITZ SJ, 1988, ANNU REV PUBL HEALTH, V9, P123, DOI 10.1146/annurev.pu.09.050188.001011; Lebowitz PF, 2004, CLIN CANCER RES, V10, P6764, DOI 10.1158/1078-0432.CCR-04-0976; Lee KS, 2008, BREAST CANCER RES TR, V109, P481, DOI 10.1007/s10549-007-9672-y; Lu YS, 2011, CANCER CHEMOTH PHARM, V67, P1257, DOI 10.1007/s00280-010-1401-2; Lybaert W, 2005, EJC S, V105; O'Shaughnessy J, 2002, Eur J Cancer, V38 Suppl 2, P10, DOI 10.1016/S0959-8049(01)00416-6; Manga GP, 2010, BREAST CANCER-TOKYO, V17, P205, DOI 10.1007/s12282-009-0136-6; Perez-Manga G, 2005, EJC SUPPL, V3, P133; Reichardt P, 2003, ANN ONCOL, V14, P1227, DOI 10.1093/annonc/mdg346; Sawada N, 1998, CLIN CANCER RES, V4, P1013; Steger GG, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.530; van der Hage JA, 2001, J CLIN ONCOL, V19, P4224, DOI 10.1200/JCO.2001.19.22.4224; Villman K, 2007, EUR J CANCER, V43, P1153, DOI 10.1016/j.ejca.2007.02.002; von Minckwitz G, 2010, J CLIN ONCOL, V28, P2015, DOI 10.1200/JCO.2009.23.8303; Zambetti M, 2012, BREAST CANCER RES TR, V132, P843, DOI 10.1007/s10549-011-1660-6	25	15	18	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2013	8	1							e53403	10.1371/journal.pone.0053403	http://dx.doi.org/10.1371/journal.pone.0053403			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	070BE	23301067	gold, Green Submitted, Green Published			2023-01-03	WOS:000313480000054
J	Tolwani, A				Tolwani, Ashita			Continuous Renal-Replacement Therapy for Acute Kidney Injury	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; CONTINUOUS VENOVENOUS HEMODIAFILTRATION; ULTRASOUND GUIDANCE; CYTOKINE REMOVAL; SEPTIC PATIENTS; FAILURE; COMPLICATIONS; DIALYSIS; HEMODIALYSIS	Acute limb ischemia due to a perioperative type B (distal) thoracic aortic dissection develops in a 90-kg, 20-year-old man with Marfan's syndrome who is admitted to the hospital for elective aortic-valve replacement. On postoperative day 1, he undergoes endovascular repair of the thoracic aorta. On postoperative day 4, his urine output decreases to 420 ml over a 24-hour period. He requires mechanical ventilation with a fraction of inspired oxygen (FiO(2)) of 0.70; his mean arterial pressure is 74 mm Hg with vasopressor support. He has had a positive fluid balance of 9.8 liters since admission. The serum creatinine level has increased from a baseline of 0.6 mg per deciliter (53.0 mu mol per liter) to 4.4 mg per deciliter (389.0 mu mol per liter). The bicarbonate level is 19 mmol per liter despite bicarbonate infusion, and the potassium level is 6.1 mmol per liter. The creatine kinase level has increased to 129,040 U per liter. An intensive care specialist evaluates the patient and recommends initiation of continuous renal-replacement therapy.	Univ Alabama Birmingham, Div Nephrol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Tolwani, A (corresponding author), Univ Alabama Birmingham, Div Nephrol, 1720 2nd Ave S,Zeigler Res Bldg 604, Birmingham, AL 35294 USA.	atolwani@uab.edu						Augustine JJ, 2004, AM J KIDNEY DIS, V44, P1000, DOI 10.1053/j.ajkd.2004.08.022; BELLOMO R, 1993, INTENS CARE MED, V19, P329, DOI 10.1007/BF01694706; Bellomo R, 2009, NEW ENGL J MED, V361, P1627, DOI 10.1056/NEJMoa0902413; Bouchard J, 2009, KIDNEY INT, V76, P422, DOI 10.1038/ki.2009.159; Briglia A, 1999, CLIN CHEST MED, V20, P347, DOI 10.1016/S0272-5231(05)70146-5; Brivet FG, 1996, CRIT CARE MED, V24, P192, DOI 10.1097/00003246-199602000-00003; Brochard L, 2010, AM J RESP CRIT CARE, V181, P1128, DOI 10.1164/rccm.200711-1664ST; Cerda J, 2009, SEMIN DIALYSIS, V22, P114, DOI 10.1111/j.1525-139X.2008.00549.x; Clark WR, 2003, ARTIF ORGANS, V27, P815, DOI 10.1046/j.1525-1594.2003.07288.x; Claure-Del Gramdo R, 2011, CLIN J AM SOC NEPHRO, V6, P467, DOI 10.2215/CJN.02500310; Claure-Del Granado R, 2011, CLIN J AM SOC NEPHRO, V6, P1802; Conger J, 1998, SEMIN NEPHROL, V18, P533; Coryell L, 2009, J VASC INTERV RADIOL, V20, P1578, DOI 10.1016/j.jvir.2009.08.014; DAVENPORT A, 1993, CRIT CARE MED, V21, P328, DOI 10.1097/00003246-199303000-00007; De Vriese AS, 1999, J AM SOC NEPHROL, V10, P846; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Emili S, 1999, AM J KIDNEY DIS, V33, P1107, DOI 10.1016/S0272-6386(99)70148-4; Erickson J David, 2002, MMWR Recomm Rep, V51, P1; Farese S, 2009, ARTIF ORGANS, V33, P634, DOI 10.1111/j.1525-1594.2009.00794.x; Finkel KW, 2009, SEMIN DIALYSIS, V22, P155, DOI 10.1111/j.1525-139X.2008.00550.x; Hassan C, 2008, AM SURGEON, V74, P1111; Heering P, 1997, INTENS CARE MED, V23, P288, DOI 10.1007/s001340050330; Hoffmann JN, 1996, INTENS CARE MED, V22, P1360, DOI 10.1007/BF01709552; Karakitsos D, 2006, CRIT CARE, V10, DOI 10.1186/cc5101; Karvellas CJ, 2011, CRIT CARE, V15, DOI 10.1186/cc10061; KAUFMAN J, 1991, AM J KIDNEY DIS, V17, P191, DOI 10.1016/S0272-6386(12)81128-0; Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789; Klouche K, 2007, AM J KIDNEY DIS, V49, P99, DOI 10.1053/j.ajkd.2006.09.014; Lameire N, 2010, NAT CLIN PRACT NEPHR, V6, P446; Lameire N, 2006, NAT CLIN PRACT NEPHR, V2, P364, DOI 10.1038/ncpneph0218; Lins RL, 2009, NEPHROL DIAL TRANSPL, V24, P512, DOI 10.1093/ndt/gfn560; Lyndon WD, 2012, NEPHROL DIAL TRANSPL, V27, P952, DOI 10.1093/ndt/gfr480; Manns B, 2003, CRIT CARE MED, V31, P449, DOI 10.1097/01.CCM.0000045182.90302.B3; MANSFIELD PF, 1994, NEW ENGL J MED, V331, P1735, DOI 10.1056/NEJM199412293312602; Mehta RL, 2004, KIDNEY INT, V66, P1613, DOI 10.1111/j.1523-1755.2004.00927.x; Merrer J, 2001, JAMA-J AM MED ASSOC, V286, P700, DOI 10.1001/jama.286.6.700; Metcalfe W, 2002, QJM-INT J MED, V95, P579, DOI 10.1093/qjmed/95.9.579; Morgera S, 2004, AM J KIDNEY DIS, V43, P444, DOI 10.1053/j.ajkd.2003.11.006; Morgera S, 2011, CRIT CARE MED, V39, P399, DOI 10.1097/CCM.0b013e318205c500; Oliver MJ, 2001, SEMIN DIALYSIS, V14, P432, DOI 10.1046/j.1525-139x.2001.00107.x; Oudemans-van Straaten HM, 2011, CRIT CARE, V15, DOI 10.1186/cc9358; Paganini EP, 1996, NEPHROL DIAL TRANSPL, V11, P32; Palevsky PM, 2008, NEW ENGL J MED, V359, P7, DOI 10.1056/NEJMoa0802639; Palevsky PM, 2009, CRIT CARE, V13, DOI 10.1186/cc7901; Rabindranath K, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003773.pub3; Randolph AG, 1996, CRIT CARE MED, V24, P2053, DOI 10.1097/00003246-199612000-00020; Rauf Anis Abdul, 2008, J Intensive Care Med, V23, P195, DOI 10.1177/0885066608315743; Ronco C, 1996, INT J ARTIF ORGANS, V19, P95, DOI 10.1177/039139889601900207; Ronco C, 2008, INTENS CARE MED, V34, P2139, DOI 10.1007/s00134-008-1258-6; Schrier RW, 2004, J CLIN INVEST, V114, P5, DOI 10.1172/JC1200422353; Seabra VF, 2008, AM J KIDNEY DIS, V52, P272, DOI 10.1053/j.ajkd.2008.02.371; Selby NM, 2006, NEPHROL DIAL TRANSPL, V21, P1883, DOI 10.1093/ndt/gfl126; Sharfuddin AA, 2011, NAT REV NEPHROL, V7, P189, DOI 10.1038/nrneph.2011.16; Shingarev R, 2011, SEMIN DIALYSIS, V24, P164, DOI 10.1111/j.1525-139X.2011.00828.x; SZNAJDER JI, 1986, ARCH INTERN MED, V146, P259, DOI 10.1001/archinte.146.2.259; Tan HK, 2000, INTENS CARE MED, V26, P1652, DOI 10.1007/s001340000691; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; The VA/NIH Acute Renal Failure Trial Network, 2009, NEW ENGL J MED, V361, P2391; Tolwani AJ, 2006, CLIN J AM SOC NEPHRO, V1, P79, DOI 10.2215/CJN.00040505; Tolwani AJ, 2009, SEMIN DIALYSIS, V22, P141, DOI 10.1111/j.1525-139X.2008.00545.x; Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813; Uchino S, 2007, INTENS CARE MED, V33, P1563, DOI 10.1007/s00134-007-0754-4; Uchino S, 2009, CRIT CARE MED, V37, P2576, DOI 10.1097/CCM.0b013e3181a38241; van Deuren M, 2000, INTENS CARE MED, V26, P1176, DOI 10.1007/s001340000583; Venkataraman R, 2002, J CRIT CARE, V17, P246, DOI 10.1053/jcrc.2002.36757; Vinsonneau C, 2006, LANCET, V368, P379, DOI 10.1016/S0140-6736(06)69111-3; Wu VC, 2008, INTENS CARE MED, V34, P101, DOI 10.1007/s00134-007-0813-x	67	112	123	1	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 27	2012	367	26					2505	2514		10.1056/NEJMct1206045	http://dx.doi.org/10.1056/NEJMct1206045			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	059OG	23268665				2023-01-03	WOS:000312714200008
J	Lucas, BP; Trick, WE; Evans, AT; Mba, B; Smith, J; Das, K; Clarke, P; Varkey, A; Mathew, S; Weinstein, RA				Lucas, Brian P.; Trick, William E.; Evans, Arthur T.; Mba, Benjamin; Smith, Jennifer; Das, Krishna; Clarke, Peter; Varkey, Anita; Mathew, Suja; Weinstein, Robert A.			Effects of 2-vs 4-Week Attending Physician Inpatient Rotations on Unplanned Patient Revisits, Evaluations by Trainees, and Attending Physician Burnout A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-EDUCATION RESEARCH; CARE; OUTCOMES; SATISFACTION; STRESS; READMISSIONS; PERSPECTIVE; WORKLIFE; FACULTY; DESIGN	Context Data are sparse on the effect of varying the durations of internal medicine attending physician ward rotations. Objective To compare the effects of 2- vs 4-week inpatient attending physician rotations on unplanned patient revisits, attending evaluations by trainees, and attending propensity for burnout. Design, Setting, and Participants Cluster randomized crossover noninferiority trial, with attending physicians as the unit of crossover randomization and 4-week rotations as the active control, conducted in a US university-affiliated teaching hospital in academic year 2009. Participants were 62 attending physicians who staffed at least 6 weeks of inpatient service, the 8892 unique patients whom they discharged, and the 147 house staff and 229 medical students who evaluated their performance. Intervention Assignment to random sequences of 2- and 4-week rotations. Main Outcome Measures Primary outcome was 30-day unplanned revisits (visits to the hospital's emergency department or urgent ambulatory clinic, unplanned readmissions, and direct transfers from neighboring hospitals) for patients discharged from 2- vs 4-week within-attending-physician rotations. Noninferiority margin was a 2% increase (odds ratio [OR] of 1.13) in 30-day unplanned patient revisits. Secondary outcomes were length of stay; trainee evaluations of attending physicians; and attending physician reports of burnout, stress, and workplace control. Results Among the 8892 patients, there were 2437 unplanned revisits. The percentage of 30-day unplanned revisits for patients of attending physicians on 2-week rotations was 21.2% compared with 21.5% for 4-week rotations (mean difference, -0.3%; 95% CI, -1.8% to +1.2%). The adjusted OR of a patient having a 30-day unplanned revisit after 2-vs 4-week rotations was 0.97 (1-sided 97.5% upper confidence limit, 1.07; noninferiority P=.007). Average length of stay was not significantly different (geometric means for 2- vs 4-week rotations were 67.2 vs 67.5 hours; difference, -0.9%; 95% CI, -4.7% to +2.9%). Attending physicians were more likely to score lower in their ability to evaluate trainees after 2-vs 4-week rotations by both house staff (41% vs 28% rated less than perfect; adjusted OR, 2.10; 95% CI, 1.50-3.02) and medical students (82% vs 69% rated less than perfect; adjusted OR, 1.41; 95% CI, 1.06-2.10). They were less likely to report higher scores of both burnout severity (16% vs 35%; adjusted OR, 0.39; 95% CI, 0.26-0.58) and emotional exhaustion (19% vs 37%; adjusted OR, 0.45; 95% CI, 0.31 to 0.64) after 2- vs 4-week rotations. Conclusions The use of 2-week inpatient attending physician rotations compared with 4-week rotations did not result in an increase in unplanned patient revisits. It was associated with better self-rated measures of attending physician burnout and emotional exhaustion but worse evaluations by trainees.	[Lucas, Brian P.; Trick, William E.; Mba, Benjamin; Smith, Jennifer; Das, Krishna; Clarke, Peter; Mathew, Suja; Weinstein, Robert A.] Cook Cty Hlth & Hosp Syst, Dept Med, Chicago, IL 60612 USA; [Lucas, Brian P.; Trick, William E.; Mba, Benjamin; Smith, Jennifer; Das, Krishna; Clarke, Peter; Mathew, Suja; Weinstein, Robert A.] Rush Med Coll, Chicago, IL 60612 USA; [Varkey, Anita] Loyola Univ, Med Ctr, Dept Med, Chicago, IL 60611 USA; [Varkey, Anita] Stritch Sch Med, Chicago, IL USA; [Evans, Arthur T.] New York Presbyterian Hosp, Dept Med, New York, NY USA; [Evans, Arthur T.] Weill Cornell Med Coll, New York, NY USA	John H Stroger Junior Hospital Cook County; Rush University; Loyola University Chicago; Loyola University Chicago; NewYork-Presbyterian Hospital; Cornell University	Lucas, BP (corresponding author), Cook Cty Hlth & Hosp Syst, Dept Med, 1900 W Polk St,Room 520, Chicago, IL 60612 USA.	brian_lucas@rush.edu		Trick, William/0000-0002-3243-5098	Agency for Healthcare Research and Quality; Foglia Family Foundation	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Foglia Family Foundation	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Trick reports receiving research support from the Agency for Healthcare Research and Quality, but this support was not used for any portion of the current article. No other disclosures were reported.; Support for this study was provided by a philanthropic gift from the Foglia Family Foundation.	Akl EA, 2004, J GEN INTERN MED, V19, P1133, DOI 10.1111/j.1525-1497.2004.30408.x; Arora VM, 2008, MED CLIN N AM, V92, P315, DOI 10.1016/j.mcna.2007.11.002; Ashforth BE, 1997, J ORGAN BEHAV, V18, P703, DOI 10.1002/(SICI)1099-1379(199711)18:6<703::AID-JOB847>3.0.CO;2-1; Berkowitz SA, 2012, ARCH INTERN MED, V172, P269, DOI 10.1001/archinternmed.2011.606; Carney PA, 2004, JAMA-J AM MED ASSOC, V292, P1044, DOI 10.1001/jama.292.9.1044; Chen FM, 2005, MED EDUC, V39, P350, DOI 10.1111/j.1365-2929.2005.02117.x; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; DIMATTEO MR, 1993, HEALTH PSYCHOL, V12, P93, DOI 10.1037/0278-6133.12.2.93; DONOVAN JL, 1992, SOC SCI MED, V34, P507, DOI 10.1016/0277-9536(92)90206-6; Dyrbye LN, 2011, ARCH INTERN MED, V171, P1207, DOI 10.1001/archinternmed.2011.289; Elnicki DM, 2011, TEACH LEARN MED, V23, P37, DOI 10.1080/10401334.2011.536889; Folkman S., 1984, STRESS APPRAISAL COP; Freeborn DK, 2001, WESTERN J MED, V174, P13, DOI 10.1136/ewjm.174.1.13; Ivancevich JM., 1980, STRESS WORK MANAGERI; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Jones B., 2003, DESIGN ANAL CROSS OV, V2nd; Joynt KE, 2012, NEW ENGL J MED, V366, P1366, DOI 10.1056/NEJMp1201598; Kaul S, 2006, ANN INTERN MED, V145, P62, DOI 10.7326/0003-4819-145-1-200607040-00011; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; Leckie G., 2011, RUNMLWIN STATA MODUL; Linzer M, 2002, STRESS HEALTH, V18, P37, DOI 10.1002/smi.917; Linzer M, 2001, AM J MED, V111, P170, DOI 10.1016/S0002-9343(01)00814-2; LINZER M, 2005, AHRQ PUBLICATION; Lurie SJ, 2003, JAMA-J AM MED ASSOC, V290, P1210, DOI 10.1001/jama.290.9.1210; MASLACH C, 1981, J OCCUP BEHAV, V2, P99, DOI 10.1002/job.4030020205; Maslach C., 1996, MASLACH BURNOUT INVE, V3rd; McMahon GT, 2010, NEW ENGL J MED, V362, P1304, DOI 10.1056/NEJMsa0908136; Norris CM, 2006, J CLIN EPIDEMIOL, V59, P448, DOI 10.1016/j.jclinepi.2005.09.007; Nutter D, AAMC PROJECT CLIN ED; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; Pocock SJ, 1997, CONTROL CLIN TRIALS, V18, P530, DOI 10.1016/S0197-2456(97)00008-1; Prystowsky JB, 2001, MED EDUC, V35, P331, DOI 10.1046/j.1365-2923.2001.00910.x; Sackett D, 2006, PRINCIPLES TACTICS P; Schmoldt R A, 1994, HMO Pract, V8, P58; Senn S, 2002, CROSS OVER TRIALS CL; Shanafelt TD, 2009, JAMA-J AM MED ASSOC, V302, P1338, DOI 10.1001/jama.2009.1385; Smith CA, 2004, J GEN INTERN MED, V19, P766, DOI 10.1111/j.1525-1497.2004.30269.x; Smith MEB, 2009, AM J MED, V122, P96, DOI 10.1016/j.amjmed.2008.09.031; Spellberg B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035576; STOUT JK, 1983, PSYCHOL REP, V53, P283, DOI 10.2466/pr0.1983.53.1.283; Streiner D, 2008, HLTH MEASUREMENT SCA; Todres M, 2007, BMJ-BRIT MED J, V335, P333, DOI 10.1136/bmj.39253.544688.94; Veninga RL, 1981, WORK STRESS CONNECTI; Williams ES, 2007, HEALTH CARE MANAGE R, V32, P203, DOI 10.1097/01.HMR.0000281626.28363.59; Williams ES, 2002, HEALTH SERV RES, V37, P121; Williams RL, 2000, BIOMETRICS, V56, P645, DOI 10.1111/j.0006-341X.2000.00645.x	46	40	39	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 5	2012	308	21					2199	2207		10.1001/jama.2012.36522	http://dx.doi.org/10.1001/jama.2012.36522			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	047HI	23212497	Bronze			2023-01-03	WOS:000311829500011
J	Fan, SJ; Zhang, Y; Hu, N; Sun, QH; Ding, XB; Li, GW; Zheng, B; Gu, M; Huang, FS; Sun, YQ; Zhou, ZQ; Lu, X; Huang, C; Ji, G				Fan, Shengjie; Zhang, Yu; Hu, Na; Sun, Qinhu; Ding, Xiaobo; Li, Guowen; Zheng, Bin; Gu, Ming; Huang, Feisi; Sun, Yin-Qiang; Zhou, Zhiqin; Lu, Xiong; Huang, Cheng; Ji, Guang			Extract of Kuding Tea Prevents High-Fat Diet-Induced Metabolic Disorders in C57BL/6 Mice via Liver X Receptor (LXR) beta Antagonism	PLOS ONE			English	Article							NUCLEAR RECEPTORS; URSOLIC ACID; ADIPOCYTE DIFFERENTIATION; INSULIN-RESISTANCE; GREEN TEA; INTESTINAL-ABSORPTION; LIPID-METABOLISM; GENE-EXPRESSION; ILEX-KUDINGCHA; PPAR-GAMMA	Objective: To investigate the effects of ilex kudingcha C. J. Tseng (kuding tea), a traditional beverage in China, on the metabolic disorders in C57BL/6 mice induced by high-fat diets. Design: For the preventive experiment, the female C57BL/6 mice were fed with a standard diet (Chow), high-fat diet (HF), and high-fat diet mixed with 0.05% ethanol extract of kuding tea (EK) for 5 weeks. For the therapeutic experiment, the C57BL/6 mice were fed high-fat diet for 3 months, and then mice were split and EK was given with oral gavages for 2 weeks at 50 mg/day/kg. Body weight and daily food intake amounts were measured. At the end of treatment, the adipocyte images were assayed with a scanning electron microscope, and the fasting blood glucose, glucose tolerance test, serum lipid profile and lipids in the livers were analyzed. A reporter gene assay system was used to test the whether EK could act on nuclear receptor transcription factors, and the gene expression analysis was performed with a quantitative PCR assay. Results: In the preventive treatment, EK blocked the body weight gain, reduced the size of the adipocytes, lowered serum triglyceride, cholesterol, LDL-cholesterol, fasting blood glucose levels and glucose tolerance in high-fat diet-fed C57BL/6 mice. In the therapeutic treatment, EK reduced the size of the white adipocytes, serum TG and fasting blood glucose levels in obese mice. With the reporter assay, EK inhibited LXR beta transactivity and mRNA expression of LXRb target genes. Conclusion: We observed that EK has both preventive and therapeutic roles in metabolic disorders in mice induced with high-fat diets. The effects appear to be mediated through the antagonism of LXRb transactivity. Our data indicate that kuding tea is a useful dietary therapy and a potential source for the development of novel anti-obesity and lipid lowering drugs. Citation: Fan S, Zhang Y, Hu N, Sun Q, Ding X, et al. (2012) Extract of Kuding Tea Prevents High-Fat Diet-Induced Metabolic Disorders in C57BL/6 Mice via Liver X Receptor (LXR) beta Antagonism. PLoS ONE 7(12): e51007. doi: 10.1371/journal.pone.0051007	[Fan, Shengjie; Zhang, Yu; Ding, Xiaobo; Zheng, Bin; Gu, Ming; Huang, Feisi; Huang, Cheng] Shanghai Univ Tradit Chinese Med, Sch Pharm, Drug Discovery Lab, Shanghai, Peoples R China; [Hu, Na; Sun, Yin-Qiang; Lu, Xiong] Shanghai Univ Tradit Chinese Med, Sci Expt Ctr, Shanghai, Peoples R China; [Sun, Qinhu] Shanghai Univ Tradit Chinese Med, Inst Chinese Mat Med, Shanghai, Peoples R China; [Ding, Xiaobo; Zhou, Zhiqin; Ji, Guang] Southwest Univ, Coll Hort & Landscape Architecture, Chongqing, Peoples R China; [Ding, Xiaobo; Zhou, Zhiqin] Minist Educ, Key Lab Hort Sci So Mountainous Reg, Chongqing, Peoples R China; [Li, Guowen] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Inst Digest Dis, Shanghai, Peoples R China	Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine; Southwest University - China; Shanghai University of Traditional Chinese Medicine	Huang, C (corresponding author), Shanghai Univ Tradit Chinese Med, Sch Pharm, Drug Discovery Lab, Shanghai, Peoples R China.	chuang.shutcm@gmail.com; jiliver@vip.sina.com			National Natural Science Foundation of China [30873260]; Talents Scheme from the Science and Technology Commission of Shanghai Municipality [09XD1403800]; Supporting Project for Elitists in the New Century from The Ministry of Education [NCET-07563]; Shanghai Leading Academic Discipline Project [J50305, E3008]; XinLin Scholar and Outstanding Team Training Plan of Shanghai University of Traditional Chinese Medicine	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Talents Scheme from the Science and Technology Commission of Shanghai Municipality; Supporting Project for Elitists in the New Century from The Ministry of Education; Shanghai Leading Academic Discipline Project(Shanghai Leading Academic Discipline Project); XinLin Scholar and Outstanding Team Training Plan of Shanghai University of Traditional Chinese Medicine	This work was supported by National Natural Science Foundation of China (no. 30873260), the Talents Scheme from the Science and Technology Commission of Shanghai Municipality (no. 09XD1403800), the Supporting Project for Elitists in the New Century from The Ministry of Education (no. NCET-07563), the Shanghai Leading Academic Discipline Project (no. J50305 and E3008), and the XinLin Scholar and Outstanding Team Training Plan of Shanghai University of Traditional Chinese Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alberti S, 2001, J CLIN INVEST, V107, P565, DOI 10.1172/JCI9794; Azevedo MF, 2010, PHYTOTHER RES, V24, pS220, DOI 10.1002/ptr.3118; Chinetti G, 2004, BIOCHEM BIOPH RES CO, V314, P151, DOI 10.1016/j.bbrc.2003.12.058; Chun TH, 2010, DIABETES, V59, P2484, DOI 10.2337/db10-0073; Edwards PA, 2002, VASC PHARMACOL, V38, P249, DOI 10.1016/S1537-1891(02)00175-1; Finucane MM, 2011, LANCET, V377, P557, DOI 10.1016/S0140-6736(10)62037-5; Flier JS, 2004, CELL, V116, P337, DOI 10.1016/S0092-8674(03)01081-X; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gerhold DL, 2002, ENDOCRINOLOGY, V143, P2106, DOI 10.1210/en.143.6.2106; Goldwasser J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012399; Gong HB, 2004, EXPERT OPIN THER TAR, V8, P49, DOI 10.1517/14728222.8.1.49; Gong ZW, 2009, ENDOCRINOLOGY, V150, P104, DOI 10.1210/en.2008-0322; Gupta R, 2012, NAT PROD RES, V26, P1125, DOI 10.1080/14786419.2011.560845; Huang C, 2006, BIOCHEM BIOPH RES CO, V348, P571, DOI 10.1016/j.bbrc.2006.07.095; Huang Z, 1997, CHIN J INFOR TRADIT, V4, P25; Jia Y, 2011, BIOORG MED CHEM LETT, V21, P5876, DOI 10.1016/j.bmcl.2011.07.095; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Joseph SB, 2004, CELL, V119, P299, DOI 10.1016/j.cell.2004.09.032; Kanaya N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026654; Kim JY, 2011, J ETHNOPHARMACOL, V133, P558, DOI 10.1016/j.jep.2010.10.037; Kim J, 2009, ARCH PHARM RES, V32, P983, DOI 10.1007/s12272-009-1702-3; Koo SI, 2007, J NUTR BIOCHEM, V18, P179, DOI 10.1016/j.jnutbio.2006.12.005; Kraegen EW, 2001, EXP CLIN ENDOCR DIAB, V109, pS516; Kratzer A, 2009, J LIPID RES, V50, P312, DOI 10.1194/jlr.M800376-JLR200; Laffitte BA, 2003, P NATL ACAD SCI USA, V100, P5419, DOI 10.1073/pnas.0830671100; Lewis GF, 2002, ENDOCR REV, V23, P201, DOI 10.1210/er.23.2.201; Liu Aihua, 2002, Zhong Yao Cai, V25, P148; Liu B, 2005, CHIN NUR RES, V19, P21; Loest HB, 2002, J NUTR, V132, P1282, DOI 10.1093/jn/132.6.1282; Lund EG, 2003, ARTERIOSCL THROM VAS, V23, P1169, DOI 10.1161/01.ATV.0000056743.42348.59; Mitro N, 2007, NATURE, V445, P219, DOI 10.1038/nature05449; Niesor EJ, 2001, CURR PHARM DESIGN, V7, P231, DOI 10.2174/1381612013398185; Ntambi JM, 2000, J NUTR, V130, p3122S, DOI 10.1093/jn/130.12.3122S; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Popovich N G, 1997, J Am Pharm Assoc (Wash), VNS37, P31; Popovich NG, 1997, J AM PHARM ASSOC, VNS37, P56; Rao VS, 2011, J MED FOOD, V14, P1375, DOI 10.1089/jmf.2010.0267; Raz I, 2005, DIABETES-METAB RES, V21, P3, DOI 10.1002/dmrr.493; Reddy KP, 2009, BIOORG MED CHEM LETT, V19, P4463, DOI 10.1016/j.bmcl.2009.05.034; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sheng XY, 2011, AM J PHYSIOL-ENDOC M, V300, pE886, DOI 10.1152/ajpendo.00332.2010; Song C, 2001, STEROIDS, V66, P473, DOI 10.1016/S0039-128X(00)00239-7; Visscher TLS, 2001, ANNU REV PUBL HEALTH, V22, P355, DOI 10.1146/annurev.publhealth.22.1.355; Wang Q, 1998, CHIN J ETHNOMED ETHN, V34, P12; Wang S, 1994, CHIN J INTEGR MED, V11, P670; Wang S, 2006, J NUTR BIOCHEM, V17, P492, DOI 10.1016/j.jnutbio.2006.03.004; Wong IYF, 2001, J AGR FOOD CHEM, V49, P3113, DOI 10.1021/jf0100604; [吴弢 Wu Tao], 2005, [中国药学杂志, Chinese Pharmaceutical Journal], V40, P1460; Zheng J, 2009, PLANTA MED, V75, P1410, DOI 10.1055/s-0029-1185722; Zheng J, 2009, CLIN HEMORHEOL MICRO, V42, P29, DOI 10.3233/CH-2009-1183; Zhu F, 2009, J AGR FOOD CHEM, V57, P6082, DOI 10.1021/jf901020h	51	57	59	1	48	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 4	2012	7	12							e51007	10.1371/journal.pone.0051007	http://dx.doi.org/10.1371/journal.pone.0051007			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	051EQ	23226556	gold, Green Published, Green Submitted			2023-01-03	WOS:000312108500039
J	McArdle, C				McArdle, Ciarstan			PERSONAL VIEW Patients with melanoma are avoiding follow-up to get insurance	BRITISH MEDICAL JOURNAL			English	Editorial Material							CUTANEOUS MELANOMA		James Cook Univ Hosp, Dept Plast Surg, Middlesbrough TS4 3BW, Cleveland, England	James Cook University Hospital	McArdle, C (corresponding author), James Cook Univ Hosp, Dept Plast Surg, Middlesbrough TS4 3BW, Cleveland, England.	ciarstanmcardle@gmail.com						American Cancer Society, 2012, LEARN CANC MAL SKIN; Cancer Research UK, 2012, SKIN CANC INC STAT T; DiFronzo LA, 1999, ANN SURG ONCOL, V6, P705, DOI 10.1007/s10434-999-0705-0; Marsden JR, 2010, BRIT J DERMATOL, V163, P238, DOI [10.1016/j.bjps.2010.07.006, 10.1111/j.1365-2133.2010.09883.x]	4	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	DEC 3	2012	345								e7803	10.1136/bmj.e7803	http://dx.doi.org/10.1136/bmj.e7803			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	052HO	23208251				2023-01-03	WOS:000312188700004
J	Salimath, AS; Phelps, EA; Boopathy, AV; Che, PL; Brown, M; Garcia, AJ; Davis, ME				Salimath, Apoorva S.; Phelps, Edward A.; Boopathy, Archana V.; Che, Pao-lin; Brown, Milton; Garcia, Andres J.; Davis, Michael E.			Dual Delivery of Hepatocyte and Vascular Endothelial Growth Factors via a Protease-Degradable Hydrogel Improves Cardiac Function in Rats	PLOS ONE			English	Article							ACUTE MYOCARDIAL-INFARCTION; ENGINEERED PEG HYDROGELS; PEPTIDE NANOFIBERS; CELL THERAPY; STEM-CELLS; INTRAMYOCARDIAL INJECTION; ALGINATE BIOMATERIAL; PROGENITOR CELLS; IN-VITRO; ANGIOGENESIS	Acute myocardial infarction (MI) caused by ischemia and reperfusion (IR) is the most common cause of cardiac dysfunction due to local cell death and a temporally regulated inflammatory response. Current therapeutics are limited by delivery vehicles that do not address spatial and temporal aspects of healing. The aim of this study was to engineer biotherapeutic delivery materials to harness endogenous cell repair to enhance myocardial repair and function. We have previously engineered poly(ethylene glycol) (PEG)-based hydrogels to present cell adhesive motifs and deliver VEGF to promote vascularization in vivo. In the current study, bioactive hydrogels with a protease-degradable crosslinker were loaded with hepatocyte and vascular endothelial growth factors (HGF and VEGF, respectively) and delivered to the infarcted myocardium of rats. Release of both growth factors was accelerated in the presence of collagenase due to hydrogel degradation. When delivered to the border zones following ischemia-reperfusion injury, there was no acute effect on cardiac function as measured by echocardiography. Over time there was a significant increase in angiogenesis, stem cell recruitment, and a decrease in fibrosis in the dual growth factor delivery group that was significant compared with single growth factor therapy. This led to an improvement in chronic function as measured by both invasive hemodynamics and echocardiography. These data demonstrate that dual growth factor release of HGF and VEGF from a bioactive hydrogel has the capacity to significantly improve cardiac remodeling and function following IR injury.	[Salimath, Apoorva S.; Phelps, Edward A.; Boopathy, Archana V.; Garcia, Andres J.; Davis, Michael E.] Georgia Inst Technol, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA; [Salimath, Apoorva S.; Phelps, Edward A.; Garcia, Andres J.] Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30332 USA; [Boopathy, Archana V.; Che, Pao-lin; Brown, Milton; Davis, Michael E.] Emory Univ, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30322 USA; [Boopathy, Archana V.; Che, Pao-lin; Brown, Milton; Davis, Michael E.] Emory Univ, Sch Med, Div Cardiol, Atlanta, GA USA	University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology; Emory University; Emory University	Davis, ME (corresponding author), Georgia Inst Technol, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA.	michael.davis@bme.emory.edu	Phelps, Edward A/Q-1302-2016	Phelps, Edward A/0000-0001-8666-805X	National Heart, Lung, and Blood Institute (NHLBI) [HHSN268201000043C]; American Heart Association (AHA) fellowship; National Science Foundation (NSF) Center Grant [CBET-0939511]; Georgia Tech/Emory Center for the Engineering of Living Tissues	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Heart Association (AHA) fellowship(American Heart Association); National Science Foundation (NSF) Center Grant(National Science Foundation (NSF)); Georgia Tech/Emory Center for the Engineering of Living Tissues	This work was supported by a contract from the National Heart, Lung, and Blood Institute (NHLBI) (HHSN268201000043C) as part of a Program of Excellence in Nanotechnology. Additionally, funding was received in the form of an American Heart Association (AHA) fellowship, National Science Foundation (NSF) Center Grant (CBET-0939511), and Georgia Tech/Emory Center for the Engineering of Living Tissues. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almeda FQ, 2001, CRIT CARE CLIN, V17, P411, DOI 10.1016/S0749-0704(05)70175-5; Angoulvant D, 2011, J HEART LUNG TRANSPL, V30, P95, DOI 10.1016/j.healun.2010.08.023; Anversa P, 2006, J AM COLL CARDIOL, V47, P1769, DOI 10.1016/j.jacc.2006.02.003; Anversa P, 1995, Cardiologia, V40, P909; Anversa P, 2000, CIRC RES, V86, P121, DOI 10.1161/01.RES.86.2.121; Assmus B, 2006, NEW ENGL J MED, V355, P1222, DOI 10.1056/NEJMoa051779; Chen RR, 2007, PHARM RES, V24, P258, DOI 10.1007/s11095-006-9173-4; Chimenti I, 2011, BIOMATERIALS, V32, P9271, DOI 10.1016/j.biomaterials.2011.08.049; Cho KR, 2008, EUR J CARDIO-THORAC, V34, P857, DOI 10.1016/j.ejcts.2008.05.045; Danielsen CC, 1998, J MOL CELL CARDIOL, V30, P1431; Davis ME, 2006, P NATL ACAD SCI USA, V103, P8155, DOI 10.1073/pnas.0602877103; Engel FB, 2006, P NATL ACAD SCI USA, V103, P15546, DOI 10.1073/pnas.0607382103; Epstein SE, 2001, CIRCULATION, V104, P115, DOI 10.1161/01.CIR.104.1.115; Fatma S, 2010, ANTIOXID REDOX SIGN, V13, P1857, DOI 10.1089/ars.2010.3104; French KM, 2012, ACTA BIOMATER; Hsieh PCH, 2006, J CLIN INVEST, V116, P237, DOI 10.1172/JCI25878; Ifkovits JL, 2010, P NATL ACAD SCI USA, V107, P11507, DOI 10.1073/pnas.1004097107; Jacot JG, 2008, BIOPHYS J, V95, P3479, DOI 10.1529/biophysj.107.124545; Jacot JG, 2006, J BIOMED MATER RES A, V79A, P485, DOI 10.1002/jbm.a.30812; Jacot JG, 2010, ANN NY ACAD SCI, V1188, P121, DOI 10.1111/j.1749-6632.2009.05091.x; Kadner K, 2012, BIOMATERIALS, V33, P2060, DOI 10.1016/j.biomaterials.2011.11.031; Kajstura J, 1996, LAB INVEST, V74, P86; Kang HJ, 2004, LANCET, V363, P751, DOI 10.1016/S0140-6736(04)15689-4; Kloner RA, 2000, J THROMB THROMBOLYS, V10, P285, DOI 10.1023/A:1026507627097; Leri A, 2001, Ital Heart J, V2 Suppl 3, p12S; Linke A, 2005, P NATL ACAD SCI USA, V102, P8966, DOI 10.1073/pnas.0502678102; Miyagawa S, 2006, TRANSPLANTATION, V81, P902, DOI 10.1097/01.tp.0000202843.86864.10; Morishita R, 2004, CURR GENE THER, V4, P199; Nakagawa K, 2000, SEMIN THROMB HEMOST, V26, P61, DOI 10.1055/s-2000-9805; Ozawa CR, 2004, J CLIN INVEST, V113, P516, DOI 10.1172/JCI200418420; Patterson J, 2011, BIOMATERIALS, V32, P1301, DOI 10.1016/j.biomaterials.2010.10.016; Patterson J, 2010, BIOMATERIALS, V31, P7836, DOI 10.1016/j.biomaterials.2010.06.061; Perez-Ilzarbe M, 2008, EUR J HEART FAIL, V10, P1065, DOI 10.1016/j.ejheart.2008.08.002; Phelps EA, 2012, ADV MATER, V24, P64, DOI 10.1002/adma.201103574; Phelps EA, 2010, P NATL ACAD SCI USA, V107, P3323, DOI 10.1073/pnas.0905447107; Rane AA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021571; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Ruvinov E, 2011, BIOMATERIALS, V32, P565, DOI 10.1016/j.biomaterials.2010.08.097; Ruvinov E, 2010, BIOMATERIALS, V31, P4573, DOI 10.1016/j.biomaterials.2010.02.026; Saif J, 2010, ARTERIOSCL THROM VAS, V30, P1897, DOI 10.1161/ATVBAHA.110.207928; Samuel SM, 2010, DIABETES, V59, P51, DOI 10.2337/db09-0336; Schwarz ER, 2000, J AM COLL CARDIOL, V35, P1323, DOI 10.1016/S0735-1097(00)00522-2; Siltanen A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019161; Sun QH, 2010, PHARM RES-DORDR, V27, P264, DOI 10.1007/s11095-009-0014-0; Sy JC, 2008, NAT MATER, V7, P863, DOI 10.1038/nmat2299; Sy JC, 2010, J CARDIOVASC TRANSL, V3, P461, DOI 10.1007/s12265-010-9210-x; Tang JM, 2009, EXP CELL RES, V315, P3521, DOI 10.1016/j.yexcr.2009.09.026; Vilahur G, 2011, J MOL CELL CARDIOL, V50, P522, DOI 10.1016/j.yjmcc.2010.12.021; Wall ST, 2010, J BIOMED MATER RES A, V95A, P1055, DOI 10.1002/jbm.a.32904; Wang YG, 2004, J MOL CELL CARDIOL, V37, P1041, DOI 10.1016/j.yjmcc.2004.09.004; Xaymardan M, 2009, STEM CELLS, V27, P1911, DOI 10.1002/stem.106; Yamaguchi T, 2005, SURG TODAY, V35, P855, DOI 10.1007/s00595-005-3042-3; Zentilin L, 2010, FASEB J, V24, P1467, DOI 10.1096/fj.09-143180; Zhu XY, 2009, BIOCHEM BIOPH RES CO, V379, P1084, DOI 10.1016/j.bbrc.2009.01.019	54	74	75	1	75	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2012	7	11							e50980	10.1371/journal.pone.0050980	http://dx.doi.org/10.1371/journal.pone.0050980			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	054WM	23226440	gold, Green Published, Green Submitted			2023-01-03	WOS:000312376100251
J	Alexander, GC; Kruszewski, SP; Webster, DW				Alexander, G. Caleb; Kruszewski, Stefan P.; Webster, Daniel W.			Rethinking Opioid Prescribing to Protect Patient Safety and Public Health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ASSOCIATION; PAIN		[Alexander, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; [Webster, Daniel W.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA; [Webster, Daniel W.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Gun Policy & Res, Baltimore, MD 21205 USA; [Alexander, G. Caleb] Johns Hopkins Med, Dept Med, Sect Gen Internal Med, Baltimore, MD USA; [Alexander, G. Caleb] Univ Illinois, Sch Pharm, Dept Pharm Practice, Chicago, IL USA; [Kruszewski, Stefan P.] Stefan P Kruszewski MD & Associates, Harrisburg, PA USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Alexander, GC (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St,W6035, Baltimore, MD 21205 USA.	galexand@jhsph.edu			AHRQ HHS [R01 HS0189960] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		American College of Emergency Physicians Opioid Guideline Writing Panel, CLIN POL CRIT ISS PR; Baucus, 2012, GRASSLEY SEEK ANSWER; Centers for Disease Control and Prevention (CDC), 2011, CDC VIT SIGNS PRESCR; Chou R, 2009, J PAIN, V10, P147, DOI 10.1016/j.jpain.2008.10.007; Dasgupta N, 2006, DRUG ALCOHOL DEPEN, V82, P135, DOI 10.1016/j.drugalcdep.2005.08.019; Martell BA, 2007, ANN INTERN MED, V146, P116, DOI 10.7326/0003-4819-146-2-200701160-00006; National Center for Injury Prevention and Control Division of Unintentional Injury Centers for Disease Control and Prevention, 2011, POL IMP PRESCR PAIN; University of Wisconsin Pain and Policy Group, CENTR PRINC BAL	8	70	70	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 14	2012	308	18					1865	1866		10.1001/jama.2012.14282	http://dx.doi.org/10.1001/jama.2012.14282			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	035NA	23150006				2023-01-03	WOS:000310952700020
J	Frokiaer, H; Henningsen, L; Metzdorff, SB; Weiss, G; Roller, M; Flanagan, J; Fromentin, E; Ibarra, A				Frokiaer, Hanne; Henningsen, Louise; Metzdorff, Stine Broeng; Weiss, Gudrun; Roller, Marc; Flanagan, John; Fromentin, Emilie; Ibarra, Alvin			Astragalus Root and Elderberry Fruit Extracts Enhance the IFN-beta Stimulatory Effects of Lactobacillus acidophilus in Murine-Derived Dendritic Cells	PLOS ONE			English	Article							POLYSACCHARIDES; INTERFERON; LIPOPOLYSACCHARIDE; MEMBRANACEUS; PROBIOTICS; RESPONSES; IMMUNITY; GENES; ALPHA	Many foods and food components boost the immune system, but little data are available regarding the mechanisms by which they do. Bacterial strains have disparate effects in stimulating the immune system. Indendritic cells, the gramnegative bacteria Escherichia coli upregulates proinflammatory cytokines, whereas gram-positive Lactobacillus acidophilus induces a robust interferon (IFN)-beta response. The immune-modulating effects of astragalus root and elderberry fruit extracts were examined in bone marrow-derived murine dendritic cells that were stimulated with L. acidophilus or E. coli. IFN-beta and other cytokines were measured by ELISA and RT-PCR. Endocytosis of fluorescence-labeled dextran and L. acidophilus in the presence of elderberry fruit or astragalus root extract was evaluated in dendritic cells. Our results show that both extracts enhanced L. acidophilus-induced IFN-beta production and slightly decreased the proinflammatory response to E. coli. The enhanced IFN-beta production was associated with upregulation of toll-like receptor 3 and to a varying degree, the cytokines IL-12, IL-6, IL-1 beta and TNF-alpha. Both extracts increased endocytosis in immature dendritic cells, and only slightly influenced the viability of the cells. In conclusion, astragalus root and elderberry fruit extracts increase the IFN-beta inducing activity of L. acidophilus in dendritic cells, suggesting that they may exert antiviral and immune-enhancing activity.	[Frokiaer, Hanne; Henningsen, Louise; Metzdorff, Stine Broeng; Weiss, Gudrun] Univ Copenhagen, Dept Vet Dis Biol, Frederiksberg, Denmark; [Roller, Marc] Naturex SA, Avignon, France; [Ibarra, Alvin] Naturex Inc, S Hackensack, NJ USA; [Flanagan, John; Fromentin, Emilie] Naturex Spain, Quart De Poblet, Spain	University of Copenhagen	Frokiaer, H (corresponding author), Univ Copenhagen, Dept Vet Dis Biol, Frederiksberg, Denmark.	hafr@sund.ku.dk		Ibarra, Alvin/0000-0003-3952-8489	Naturex	Naturex	Naturex is involved in the research/development and marketing/sales of astragalus root and elderberry fruit extracts as ingredients for the food, cosmetic, and nutraceutical industries. Therefore, Naturex has a commercial interest in this publication. The University of Copenhagen was paid by Naturex to perform and report the scientific work that formed the basis of this publication. The University of Copenhagen and Naturex declare that the data in this report represent a true and faithful representation of the work that has been performed. The financial assistance from Naturex is gratefully acknowledged. The study was designed in collaboration between Naturex and the University of Copenhagen, data collection and analysis was conducted by the University of Copenhagen, the decision to publish and preparation of the manuscript was done in collaboration between the two institutions.; The authors have read the journal's policy and have the following conflicts: Naturex is involved in the research/development and marketing/sales of astragalus root and elderberry fruit extracts as ingredients for the food, cosmetic, and nutraceutical industries. Therefore, Naturex has a commercial interest in this publication. The University of Copenhagen was paid by Naturex to perform and report the scientific work that formed the basis of this publication. The University of Copenhagen and Naturex declare that the data in this report represent a true and faithful representation of the work that has been performed. The financial assistance from Naturex is gratefully acknowledged. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. The following authors are employees at Naturex: Marc Roller: Naturex SA, Site d'Agroparc BP 1218, 84911 Avignon Cedex 9, France, Emilie Fromentin: Naturex Spain, S. L. Autovia A3, Salida 343, 46930 Quart de Poblet, Spain, and Alvin Ibarra: Naturex Inc, 375 Huyler St., South Hackensack, NJ 07606, USA. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. There is no patent to declare..	[Anonymous], 2005, Altern Med Rev, V10, P51; [Anonymous], 2003, ALTERN MED REV, V8, P72; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Christensen HR, 2002, J IMMUNOL, V168, P171, DOI 10.4049/jimmunol.168.1.171; Cummings JH, 2004, EUR J NUTR, V43, P118, DOI 10.1007/s00394-004-1205-4; Denzler KL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012561; Durgnat JM, 2005, FOOD ADDIT CONTAM A, V22, P1224, DOI 10.1080/02652030500199439; Girbes T, 1996, BIOCHEM J, V315, P343, DOI 10.1042/bj3150343; Guarda G, 2011, IMMUNITY, V34, P213, DOI 10.1016/j.immuni.2011.02.006; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jungo F, 2001, CYTOKINE, V14, P272, DOI 10.1006/cyto.2001.0884; Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888; Li SP, 2009, POULTRY SCI, V88, P519, DOI 10.3382/ps.2008-00365; Lien Eric Jung-Chi, 2010, Curr Drug Discov Technol, V7, P13; Liu J, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/479426; Liu QY, 2010, J ETHNOPHARMACOL, pS0378; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Mach L, 1996, BIOCHEM J, V315, P1061, DOI 10.1042/bj3151061; Mao XF, 2005, J ANIM SCI, V83, P2775; MUMCUOGLU M, 1986, EXP HEMATOL, V14, P946; Pan MH, 2009, J AGR FOOD CHEM, V57, P4467, DOI 10.1021/jf900612n; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Puertollano MA, 2011, CURR TOP MED CHEM, V11, P1752; Rogers J, 2005, EXP BIOL MED, V230, P645; Sciacca FL, 2000, J NEUROVIROL, V6, pS33; Shao BM, 2004, BIOCHEM BIOPH RES CO, V320, P1103, DOI 10.1016/j.bbrc.2004.06.065; Takei M, 2004, BIOCHEM PHARMACOL, V68, P441, DOI 10.1016/j.bcp.2004.04.015; van Baarlen P, 2011, P NATL ACAD SCI USA, V108, P4562, DOI 10.1073/pnas.1000079107; Vlachojannis JE, 2010, PHYTOTHER RES, V24, P1, DOI 10.1002/ptr.2729; Weiss G, 2010, IMMUNOLOGY, V131, P268, DOI 10.1111/j.1365-2567.2010.03301.x; Weiss G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011065; West MA, 2004, SCIENCE, V305, P1153, DOI 10.1126/science.1099153; Wismar R, 2011, MOL NUTR FOOD RES, V55, P443, DOI 10.1002/mnfr.201000230; Zeuthen LH, 2006, CLIN VACCINE IMMUNOL, V13, P365, DOI 10.1128/CVI.13.3.365-375.2006; Zeuthen LH, 2008, IMMUNOLOGY, V124, P489, DOI 10.1111/j.1365-2567.2007.02800.x	35	16	18	0	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2012	7	10							e47878	10.1371/journal.pone.0047878	http://dx.doi.org/10.1371/journal.pone.0047878			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	032HJ	23118903	Green Published, gold, Green Submitted			2023-01-03	WOS:000310705600019
J	Lyubomir, GN; Vuorinen, A; Praxmarer, L; Chantong, B; Cereghetti, D; Winiger, R; Schuster, D; Odermatt, A				Lyubomir, G. Nashev; Vuorinen, Anna; Praxmarer, Lukas; Chantong, Boonrat; Cereghetti, Diego; Winiger, Rahel; Schuster, Daniela; Odermatt, Alex			Virtual Screening as a Strategy for the Identification of Xenobiotics Disrupting Corticosteroid Action	PLOS ONE			English	Article							11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-2; BETA-HYDROXYSTEROID DEHYDROGENASE; MINERALOCORTICOID RECEPTOR; 17-BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE-3; BLOOD-PRESSURE; INHIBITORS; ACID; ALDOSTERONE; DISCOVERY; HYPERTENSION	Background: Impaired corticosteroid action caused by genetic and environmental influence, including exposure to hazardous xenobiotics, contributes to the development and progression of metabolic diseases, cardiovascular complications and immune disorders. Novel strategies are thus needed for identifying xenobiotics that interfere with corticosteroid homeostasis. 11 beta-hydroxysteroid dehydrogenase 2 (11 beta-HSD2) and mineralocorticoid receptors (MR) are major regulators of corticosteroid action. 11 beta-HSD2 converts the active glucocorticoid cortisol to the inactive cortisone and protects MR from activation by glucocorticoids. 11 beta-HSD2 has also an essential role in the placenta to protect the fetus from high maternal cortisol concentrations. Methods and Principal Findings: We employed a previously constructed 3D-structural library of chemicals with proven and suspected endocrine disrupting effects for virtual screening using a chemical feature-based 11 beta-HSD pharmacophore. We tested several in silico predicted chemicals in a 11 beta-HSD2 bioassay. The identified antibiotic lasalocid and the silanecoupling agent AB110873 were found to concentration-dependently inhibit 11 beta-HSD2. Moreover, the silane AB110873 was shown to activate MR and stimulate mitochondrial ROS generation and the production of the proinflammatory cytokine interleukin-6 (IL-6). Finally, we constructed a MR pharmacophore, which successfully identified the silane AB110873. Conclusions: Screening of virtual chemical structure libraries can facilitate the identification of xenobiotics inhibiting 11 beta-HSD2 and/or activating MR. Lasalocid and AB110873 belong to new classes of 11 beta-HSD2 inhibitors. The silane AB110873 represents to the best of our knowledge the first industrial chemical shown to activate MR. Furthermore, the MR pharmacophore can now be used for future screening purposes.	[Vuorinen, Anna; Praxmarer, Lukas; Schuster, Daniela] Univ Innsbruck, Inst Pharmacy Pharmaceut Chem, A-6020 Innsbruck, Austria; [Vuorinen, Anna; Praxmarer, Lukas; Schuster, Daniela] Univ Innsbruck, CMBI, A-6020 Innsbruck, Austria; [Lyubomir, G. Nashev; Chantong, Boonrat; Cereghetti, Diego; Winiger, Rahel; Odermatt, Alex] Univ Basel, Dept Pharmaceut Sci, Swiss Ctr Appl Human Toxicol, Basel, Switzerland; [Lyubomir, G. Nashev; Chantong, Boonrat; Cereghetti, Diego; Winiger, Rahel; Odermatt, Alex] Univ Basel, Dept Pharmaceut Sci, Div Mol & Syst Toxicol, Basel, Switzerland	University of Innsbruck; University of Innsbruck; University of Basel; University of Basel	Schuster, D (corresponding author), Univ Innsbruck, Inst Pharmacy Pharmaceut Chem, A-6020 Innsbruck, Austria.	daniela.schuster@uibk.ac.at; alex.odermatt@unibas.ch	Schuster, Daniela/C-1024-2014	Schuster, Daniela/0000-0002-9933-8938; Chantong, Boonrat/0000-0002-8638-2948; Winiger, Rahel/0000-0001-9796-5543; Odermatt, Alex/0000-0002-6820-2712	Swiss National Science Foundation [31003A-124912]; Swiss Center for Applied Human Toxicology; University of Innsbruck (Nachwuchsforderung)	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Center for Applied Human Toxicology; University of Innsbruck (Nachwuchsforderung)	This work was supported by the Swiss National Science Foundation (No. 31003A-124912, http://www.snf.ch) and the Swiss Center for Applied Human Toxicology (www.scaht.org). A.O. has a Chair for Molecular and Systems Toxicology by the Novartis Research Foundation. D.S. and A.V. are grateful for their Young Talents Grants from the University of Innsbruck (Nachwuchsforderung). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allera A, 2004, TOXICOLOGY, V205, P75, DOI 10.1016/j.tox.2004.06.039; Atanasov AG, 2003, BIOCHEM BIOPH RES CO, V308, P257, DOI 10.1016/S0006-291X(03)01359-7; Benediktsson R, 1997, CLIN ENDOCRINOL, V46, P161, DOI 10.1046/j.1365-2265.1997.1230939.x; Bledsoe RK, 2005, J BIOL CHEM, V280, P31283, DOI 10.1074/jbc.M504098200; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; Briet M, 2010, NAT REV NEPHROL, V6, P261, DOI 10.1038/nrneph.2010.30; Classen-Houben D, 2009, J STEROID BIOCHEM, V113, P248, DOI 10.1016/j.jsbmb.2009.01.009; Deuchar GA, 2011, ENDOCRINOLOGY, V152, P236, DOI 10.1210/en.2010-0925; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Diederich S, 2000, EUR J ENDOCRINOL, V142, P200, DOI 10.1530/eje.0.1420200; Duwensee K, 2011, ATHEROSCLEROSIS, V219, P109, DOI 10.1016/j.atherosclerosis.2011.07.023; EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140-6736(88)90742-8; Ferrari P, 2010, BBA-MOL BASIS DIS, V1802, P1178, DOI 10.1016/j.bbadis.2009.10.017; Friedman A, 2009, EXPERT OPIN DRUG DEL, V6, P1113, DOI 10.1517/17425240903196743; Frieler RA, 2011, STROKE, V42, P179, DOI 10.1161/STROKEAHA.110.598441; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; Gomez-Sanchez EP, 2012, MOL CELL ENDOCRINOL, V350, P289, DOI 10.1016/j.mce.2011.05.005; Groeneweg FL, 2012, MOL CELL ENDOCRINOL, V350, P299, DOI 10.1016/j.mce.2011.06.020; Hadoke PWF, 2009, BRIT J PHARMACOL, V156, P689, DOI 10.1111/j.1476-5381.2008.00047.x; Hein M., 2010, DRUG DISCOV TODAY-TE, V7, pe229, DOI [10.1016/j.ddtec.2010.12.003, DOI 10.1016/J.DDTEC.2010.12.003]; Huang N, 2006, J MED CHEM, V49, P6789, DOI 10.1021/jm0608356; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; Kim CH, 2010, MOL CELL BIOCHEM, V344, P91, DOI 10.1007/s11010-010-0532-4; Kratschmar DV, 2011, J STEROID BIOCHEM, V125, P129, DOI 10.1016/j.jsbmb.2010.12.019; Lastra G, 2010, NAT REV CARDIOL, V7, P577, DOI 10.1038/nrcardio.2010.123; Lindsay RS, 1996, HYPERTENSION, V27, P1200, DOI 10.1161/01.HYP.27.6.1200; Luccio-Camelo DC, 2011, J STEROID BIOCHEM, V127, P74, DOI 10.1016/j.jsbmb.2011.04.004; Luther JM, 2006, HYPERTENSION, V48, P1050, DOI 10.1161/01.HYP.0000248135.97380.76; Ma X, 2011, TOXICOLOGY, V285, P83, DOI 10.1016/j.tox.2011.04.007; Markt P, 2009, J MED CHEM, V52, P369, DOI 10.1021/jm801044g; Matinlinna J, 2008, ACTA ODONTOL SCAND, V66, P250, DOI 10.1080/00016350802247131; McCurley A, 2012, MOL CELL ENDOCRINOL, V350, P256, DOI 10.1016/j.mce.2011.06.014; Messaoudi S, 2012, MOL CELL ENDOCRINOL, V350, P266, DOI 10.1016/j.mce.2011.06.038; MUNE T, 1995, NAT GENET, V10, P394, DOI 10.1038/ng0895-394; Nashev LG, 2010, BIOCHEM PHARMACOL, V79, P1189, DOI 10.1016/j.bcp.2009.12.005; Neel BA, 2011, DIABETES, V60, P1838, DOI 10.2337/db11-0153; Odermatt A, 2008, BIOCHEM PHARMACOL, V76, P1184, DOI 10.1016/j.bcp.2008.07.019; Odermatt A, 2012, MOL CELL ENDOCRINOL, V350, P168, DOI 10.1016/j.mce.2011.07.020; Pan GR, 2006, J COLLOID INTERF SCI, V302, P287, DOI 10.1016/j.jcis.2006.06.031; Schug TT, 2011, J STEROID BIOCHEM, V127, P204, DOI 10.1016/j.jsbmb.2011.08.007; Schuster D., 2010, DRUG DISCOV TODAY, V7, P205; Schuster D, 2006, J CHEM INF MODEL, V46, P1301, DOI 10.1021/ci050237k; Schuster D, 2006, J MED CHEM, V49, P3454, DOI 10.1021/jm0600794; Schuster D, 2011, BIOORGAN MED CHEM, V19, P7168, DOI 10.1016/j.bmc.2011.09.056; Schuster D, 2011, J STEROID BIOCHEM, V125, P148, DOI 10.1016/j.jsbmb.2011.01.016; Seppa L, 2004, MED PRIN PRACT, V13, P307, DOI 10.1159/000080466; Verdonk ML, 2003, PROTEINS, V52, P609, DOI 10.1002/prot.10465; Wermuth G, 1998, PURE APPL CHEM, V70, P1129, DOI 10.1351/pac199870051129; WILSON RC, 1995, J CLIN ENDOCR METAB, V80, P3145, DOI 10.1210/jc.80.11.3145; Wolber G, 2005, J CHEM INF MODEL, V45, P160, DOI 10.1021/ci049885e; Young MJ, 2012, MOL CELL ENDOCRINOL, V350, P248, DOI 10.1016/j.mce.2011.09.008	51	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2012	7	10							e46958	10.1371/journal.pone.0046958	http://dx.doi.org/10.1371/journal.pone.0046958			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017HM	23056542	gold, Green Published, Green Submitted			2023-01-03	WOS:000309580800064
J	Fritz, V; Benfodda, Z; Henriquet, C; Hure, S; Cristol, JP; Michel, F; Carbonneau, MA; Casas, F; Fajas, L				Fritz, V.; Benfodda, Z.; Henriquet, C.; Hure, S.; Cristol, J-P; Michel, F.; Carbonneau, M-A; Casas, F.; Fajas, L.			Metabolic intervention on lipid synthesis converging pathways abrogates prostate cancer growth	ONCOGENE			English	Article						lipids; cancer; FAS; metabolism; prostate	FATTY-ACID SYNTHASE; PROTEIN-KINASE; MALIC ENZYME; CELLS; INHIBITION; TISSUES; TARGET; AMPK; CYTOTOXICITY; LIPOGENESIS	One of the most conserved features of all cancers is a profound reprogramming of cellular metabolism, favoring biosynthetic processes and limiting catalytic processes. With the acquired knowledge of some of these important changes, we have designed a combination therapy in order to force cancer cells to use a particular metabolic pathway that ultimately results in the accumulation of toxic products. This innovative approach consists of blocking lipid synthesis, at the same time that we force the cell, through the inhibition of AMP-activated kinase, to accumulate toxic intermediates, such as malonyl-coenzyme A (malonyl-CoA) or nicotinamide adenine dinucleotide phosphate. This results in excess of oxidative stress and cancer cell death. Our new therapeutic strategy, based on the manipulation of metabolic pathways, will certainly set up the basis for new upcoming studies defining a new paradigm of cancer treatment.	[Fritz, V.; Hure, S.; Fajas, L.] CNRS, IGMM, Inst Genet Mol Montpellier, F-34293 Montpellier, France; [Fritz, V.; Hure, S.; Fajas, L.] CNRS, UMR5535, F-34293 Montpellier, France; [Fritz, V.; Hure, S.; Fajas, L.] Univ Montpellier 2, Montpellier, France; [Benfodda, Z.] Univ Montpellier 2, IBMM, Inst Biomol Max Mousseron, Lab Acides Amines Peptides & Prot,CNRS UMR5247 CC, Montpellier, France; [Benfodda, Z.] Univ Nimes, Chim Bioorgan Lab, Nimes, France; [Henriquet, C.] Inst Rech Cancerol Montpellier, IRCM, Montpellier, France; [Cristol, J-P; Michel, F.] Ctr Hosp Univ Lapeyronie, Biochim Lab, Montpellier, France; [Cristol, J-P; Michel, F.] Inst Univ Rech Clin, UMR Prevent Malnutr & Pathol Associees 204, Montpellier, France; [Carbonneau, M-A] Inst Univ Rech Clin, UMR NUTRIPASS 204, Montpellier, France; [Casas, F.] INRA, UMR 0866, F-34060 Montpellier, France; [Fajas, L.] Ctr Hosp Reg Univ Montpellier, Montpellier, France; [Fajas, L.] Univ Lausanne, Dept Physiol, Lausanne, Switzerland	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Ecole nationale superieure de chimie de Montpellier; Universite de Montpellier; Universite de Nimes; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Universite de Montpellier; CHU de Montpellier; Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; INRAE; Universite de Montpellier; CHU de Montpellier; University of Lausanne	Fajas, L (corresponding author), CNRS, IGMM, Inst Genet Mol Montpellier, 1919 Route Mende, F-34293 Montpellier, France.	lluis.fajas@unil.ch	Coll, Lluis Fajas/C-8567-2014; BENFODDA, Zohra/P-4355-2017	BENFODDA, Zohra/0000-0001-7574-4977; Fajas, Lluis/0000-0002-1283-9503; Francois, Casas/0000-0002-5535-8195	Ligue Contre le Cancer; Agence Nationale de la Recherche (ANR); Institut National du Cancer (INCA)	Ligue Contre le Cancer(Ligue nationale contre le cancer); Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR)); Institut National du Cancer (INCA)(Institut National du Cancer (INCA) France)	Members of Fajas' lab are acknowledged for support and discussions. This work was supported by grants from Ligue Contre le Cancer, Agence Nationale de la Recherche (ANR) and Institut National du Cancer (INCA).	Brusselmans K, 2005, CANCER RES, V65, P6719, DOI 10.1158/0008-5472.CAN-05-0571; Brusselmans K, 2005, J BIOL CHEM, V280, P5636, DOI 10.1074/jbc.M408177200; Eid AA, 2010, J BIOL CHEM, V285, P37503, DOI 10.1074/jbc.M110.136796; Fogarty S, 2010, BBA-PROTEINS PROTEOM, V1804, P581, DOI 10.1016/j.bbapap.2009.09.012; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fritz V, 2010, ONCOGENE, V29, P4369, DOI 10.1038/onc.2010.182; Fritz V, 2010, MOL CANCER THER, V9, P1740, DOI 10.1158/1535-7163.MCT-09-1064; GEER BW, 1979, BIOCHEM GENET, V17, P867, DOI 10.1007/BF00504309; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Korczynska J, 2004, METABOLISM, V53, P1060, DOI 10.1016/j.metabol.2004.02.015; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Menendez JA, 2004, INT J ONCOL, V24, P1369; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Pizer ES, 2000, CANCER RES, V60, P213; Sarruf DA, 2005, MOL CELL BIOL, V25, P9985, DOI 10.1128/MCB.25.22.9985-9995.2005; Stelmanska E, 2004, ACTA BIOCHIM POL, V51, P805; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Thupari JN, 2001, BIOCHEM BIOPH RES CO, V285, P217, DOI 10.1006/bbrc.2001.5146; Viollet B, 2010, CRIT REV BIOCHEM MOL, V45, P276, DOI 10.3109/10409238.2010.488215; Zhang J, 2008, MOL CARCINOGEN, V47, P974, DOI 10.1002/mc.20450	22	32	32	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5101	5110		10.1038/onc.2012.523	http://dx.doi.org/10.1038/onc.2012.523			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23208508	Green Published, hybrid			2023-01-03	WOS:000325937900011
J	Estruch, R; Ros, E; Salas-Salvado, J; Covas, MI; Corella, D; Aros, F; Gomez-Gracia, E; Ruiz-Gutierrez, V; Fiol, M; Lapetra, J; Lamuela-Raventos, RM; Serra-Majem, L; Pinto, X; Basora, J; Munoz, MA; Sorli, JV; Martinez, JA; Martinez-Gonzalez, MA				Estruch, Ramon; Ros, Emilio; Salas-Salvado, Jordi; Covas, Maria-Isabel; Corella, Dolores; Aros, Fernando; Gomez-Gracia, Enrique; Ruiz-Gutierrez, Valentina; Fiol, Miquel; Lapetra, Jose; Maria Lamuela-Raventos, Rosa; Serra-Majem, Lluis; Pinto, Xavier; Basora, Josep; Angel Munoz, Miguel; Sorli, Jose V.; Alfredo Martinez, Jose; Angel Martinez-Gonzalez, Miguel		PREDIMED Study Investigators	RETRACTED: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet (Retracted article. See vol. 378, pg. 2441, 2018)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Retracted Publication							OLIVE OIL INTAKE; METABOLIC SYNDROME; RISK-FACTORS; STYLE DIET; ADHERENCE; INTERVENTION; HEALTH; POPULATION; REDUCTION; BENEFITS	BACKGROUND Observational cohort studies and a secondary prevention trial have shown an inverse association between adherence to the Mediterranean diet and cardiovascular risk. We conducted a randomized trial of this diet pattern for the primary prevention of cardiovascular events. METHODS In a multicenter trial in Spain, we randomly assigned participants who were at high cardiovascular risk, but with no cardiovascular disease at enrollment, to one of three diets: a Mediterranean diet supplemented with extra-virgin olive oil, a Mediterranean diet supplemented with mixed nuts, or a control diet (advice to reduce dietary fat). Participants received quarterly individual and group educational sessions and, depending on group assignment, free provision of extra-virgin olive oil, mixed nuts, or small nonfood gifts. The primary end point was the rate of major cardiovascular events (myocardial infarction, stroke, or death from cardiovascular causes). On the basis of the results of an interim analysis, the trial was stopped after a median follow-up of 4.8 years. RESULTS A total of 7447 persons were enrolled (age range, 55 to 80 years); 57% were women. The two Mediterranean-diet groups had good adherence to the intervention, according to self-reported intake and biomarker analyses. A primary end-point event occurred in 288 participants. The multivariable-adjusted hazard ratios were 0.70 (95% confidence interval [CI], 0.54 to 0.92) and 0.72 (95% CI, 0.54 to 0.96) for the group assigned to a Mediterranean diet with extra-virgin olive oil (96 events) and the group assigned to a Mediterranean diet with nuts (83 events), respectively, versus the control group (109 events). No diet-related adverse effects were reported. CONCLUSIONS Among persons at high cardiovascular risk, a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced the incidence of major cardiovascular events. (Funded by the Spanish government's Instituto de Salud Carlos III and others; Controlled-Trials.com number, ISRCTN35739639.)	[Estruch, Ramon; Ros, Emilio; Salas-Salvado, Jordi; Covas, Maria-Isabel; Corella, Dolores; Fiol, Miquel; Lapetra, Jose; Maria Lamuela-Raventos, Rosa; Basora, Josep; Sorli, Jose V.; Alfredo Martinez, Jose] Inst Salud Carlos III, Ctr Invest Biomed Red Fisiopatol Obesidad & Nutr, Madrid, Spain; [Estruch, Ramon; Salas-Salvado, Jordi; Aros, Fernando; Gomez-Gracia, Enrique; Ruiz-Gutierrez, Valentina; Maria Lamuela-Raventos, Rosa; Serra-Majem, Lluis; Pinto, Xavier; Basora, Josep; Sorli, Jose V.; Alfredo Martinez, Jose; Angel Martinez-Gonzalez, Miguel] Inst Salud Carlos III, PREDIMED Prevenc Dieta Mediterranea Network RD 06, Madrid, Spain; [Estruch, Ramon] Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Dept Internal Med, Barcelona, Spain; [Ros, Emilio] Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi & Sunyer, Lipid Clin,Dept Endocrinol & Nutr, Barcelona, Spain; [Salas-Salvado, Jordi] Univ Rovira & Virgili, Inst Invest Sanitaria Pere Virgili, Hosp Univ St Joan, Dept Human Nutr, E-43201 Reus, Spain; [Covas, Maria-Isabel] Inst Recerca Hosp del Mar, Cardiovasc & Nutr Res Grp, Barcelona, Spain; [Corella, Dolores] Univ Valencia, Dept Prevent Med, Valencia, Spain; [Aros, Fernando] Univ Hosp Alava, Dept Cardiol, Vitoria, Spain; [Gomez-Gracia, Enrique] Univ Malaga, Dept Prevent Med, E-29071 Malaga, Spain; [Ruiz-Gutierrez, Valentina] CSIC, Inst Grasa, E-41080 Seville, Spain; [Fiol, Miquel] Univ Balearic Isl, Inst Hlth Sci IUNICS, Palma De Mallorca, Spain; [Fiol, Miquel] Hosp Son Espases, Palma De Mallorca, Spain; [Lapetra, Jose] San Pablo Hlth Ctr, Primary Care Div Seville, Dept Family Med, Seville, Spain; [Maria Lamuela-Raventos, Rosa] Univ Barcelona, Inst Invest Nutr & Seguridad Alimentaria, Sch Pharm, Dept Nutr & Food Sci,Xarxa Referencia Tecnol Alim, Barcelona, Spain; [Serra-Majem, Lluis] Univ Palmas de Gran Canaria, Dept Clin Sci, Las Palmas Gran Canaria, Spain; [Pinto, Xavier] Hosp Univ Bellvitge, Lipids & Vasc Risk Unit, Barcelona, Spain; [Basora, Josep] Inst Invest Atencio Primaria Jordi Gol, Catalan Inst Hlth, Primary Care Div, Tarragona, Spain; [Angel Munoz, Miguel] Inst Invest Atencio Primaria Jordi Gol, Catalan Inst Hlth, Primary Care Div, Barcelona, Spain; [Sorli, Jose V.] Valencia Inst Hlth, Primary Care Div, Valencia, Spain; [Alfredo Martinez, Jose] Univ Navarra, Dept Nutr & Food Sci, E-31080 Pamplona, Spain; [Alfredo Martinez, Jose] Univ Navarra, Dept Physiol, E-31080 Pamplona, Spain; [Alfredo Martinez, Jose] Univ Navarra, Dept Toxicol, E-31080 Pamplona, Spain; [Angel Martinez-Gonzalez, Miguel] Univ Navarra, Dept Prevent Med, E-31080 Pamplona, Spain; [Angel Martinez-Gonzalez, Miguel] Univ Navarra, Dept Publ Hlth, E-31080 Pamplona, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Instituto de Salud Carlos III; Instituto de Salud Carlos III; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Universitat Rovira i Virgili; Institut d'Investigacio Sanitaria Pere Virgili (IISPV); Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; University of Valencia; Universidad de Malaga; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de la Grasa (IG); Universitat de les Illes Balears; Hospital Universitari Son Espases; University of Barcelona; Universidad de Las Palmas de Gran Canaria; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; University of Navarra; University of Navarra; University of Navarra; University of Navarra; University of Navarra	Estruch, R (corresponding author), Hosp Clin Barcelona, Dept Internal Med, Villarroel 170, Barcelona 08036, Spain.	restruch@clinic.ub.es; mamartinez@unav.es	Serra-Majem, Lluis/I-6708-2019; Martinez-Gonzalez, Miguel A./AAE-7669-2019; Martínez-Lapiscina, Elena H/L-1161-2014; Sorlí, José V/L-8758-2014; Deschepper, Reginald/B-8103-2013; Bes-Rastrollo, Maira/A-1329-2009; Estruch, Ramon/AAZ-3723-2020; Algorta, Jaime/CAF-7793-2022; Babio, Nancy/AAN-2715-2020; Razquin, Cristina/H-2366-2017; González, Carlos A A/O-4651-2014; Sanchez-Villegas, Almudena/T-6733-2019; perez, miguel/GXF-5077-2022; Corbella, Emili/AGI-4105-2022; Ortega-Calvo, Manuel/I-4089-2019; Bulló, Mònica/F-2925-2016; IBIS, ATENCION PRIMARIA/I-3524-2016; Robles-Sardin, Alma E/M-7714-2015; Fiol, Miguel/F-6793-2016; Pintó, Xavier/AGI-4297-2022; Prieto, Rafel M./J-3995-2017; Lapetra, Jose/F-2552-2015; Ortega-Calvo, Manuel/D-6960-2015; Muñoz, Miguel Angel/X-3511-2019; Fito, Montserrat/C-1822-2012; Martí, Amelia/H-1192-2017; Mitjavila, Maria Teresa/D-7474-2014; Algorta, Jaime/K-9002-2012; Salas-Salvado, Jordi/C-7229-2017; Santos-Lozano, JM/J-9312-2018; Casas, Rosa/ABD-1915-2020; Toledo, Estefania/H-6211-2014; Carrasco, Paula/D-7864-2019; Lamuela-Raventos, Rosa M/F-3986-2016; ZAZPE, ITZIAR/B-1970-2017	Serra-Majem, Lluis/0000-0002-9658-9061; Martínez-Lapiscina, Elena H/0000-0003-4272-0826; Sorlí, José V/0000-0002-0130-2006; Deschepper, Reginald/0000-0002-4222-3945; Bes-Rastrollo, Maira/0000-0002-9139-4206; Algorta, Jaime/0000-0002-7042-5675; Babio, Nancy/0000-0003-3527-5277; Razquin, Cristina/0000-0003-3480-2645; González, Carlos A A/0000-0003-2822-9715; Sanchez-Villegas, Almudena/0000-0001-7733-9238; Corbella, Emili/0000-0001-8818-1907; Ortega-Calvo, Manuel/0000-0003-2391-0106; Bulló, Mònica/0000-0002-0218-7046; Robles-Sardin, Alma E/0000-0003-2044-7793; Fiol, Miguel/0000-0002-5370-1391; Pintó, Xavier/0000-0002-2216-2444; Prieto, Rafel M./0000-0001-8814-900X; Ortega-Calvo, Manuel/0000-0003-2391-0106; Muñoz, Miguel Angel/0000-0002-4083-3248; Fito, Montserrat/0000-0002-1817-483X; Martí, Amelia/0000-0001-9832-7981; Mitjavila, Maria Teresa/0000-0002-1550-6253; Algorta, Jaime/0000-0002-7042-5675; Salas-Salvado, Jordi/0000-0003-2700-7459; Santos-Lozano, JM/0000-0001-7097-5653; Casas, Rosa/0000-0002-0211-9166; Toledo, Estefania/0000-0002-6263-4434; Carrasco, Paula/0000-0002-7170-4318; Fernandez-Crehuet Navajas, Joaquin/0000-0002-1173-9906; Costa, Bernardo/0000-0003-1985-8376; Marrugat, Jaume/0000-0003-3320-554X; Cabre Vila, Juan Jose/0000-0003-1082-6861; Martinez-Gonzalez, Miguel A./0000-0002-3917-9808; Solanich, Xavier/0000-0002-2572-2187; Lamuela-Raventos, Rosa M/0000-0002-1287-4560; ZAZPE, ITZIAR/0000-0002-8787-2981; Martin Lujan, Francisco M/0000-0003-0359-3588; Medina-Remon, Alexander/0000-0003-1985-7592; Fernandez-Ballart, Joan D./0000-0002-1320-6484; Basora, Josep/0000-0003-0278-1149	Spanish government, Instituto de Salud Carlos III (ISCIII) [RTIC G03/140, RTIC RD 06/0045]; Centro Nacional de Investigaciones Cardiovasculares [CNIC 06/2007]; Fondo de Investigacion Sanitaria-Fondo Europeo de Desarrollo Regional [PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505]; Ministerio de Ciencia e Innovacion [AGL-2009-13906-C02, AGL2010-22319-C03]; Fundacion Mapfre, Consejeria de Salud de la Junta de Andalucia [PI0105/2007]; Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana [ACOMP06109, GVACOMP2010-181, GVACOMP2011-151, CS2010-AP-111, CS2011-AP-042]; Regional Government of Navarra [P27/2011]	Spanish government, Instituto de Salud Carlos III (ISCIII); Centro Nacional de Investigaciones Cardiovasculares; Fondo de Investigacion Sanitaria-Fondo Europeo de Desarrollo Regional; Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Fundacion Mapfre, Consejeria de Salud de la Junta de Andalucia; Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana; Regional Government of Navarra	Supported by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII), through grants provided to research networks specifically developed for the trial (RTIC G03/140, to Dr. Estruch; RTIC RD 06/0045, to Dr. Martinez-Gonzalez and through Centro de Investigacion Biomedica en Red de Fisiopatologia de la Obesidad y Nutricion [CIBERobn]), and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), Fondo de Investigacion Sanitaria-Fondo Europeo de Desarrollo Regional (PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, and P11/02505), Ministerio de Ciencia e Innovacion (AGL-2009-13906-C02 and AGL2010-22319-C03), Fundacion Mapfre 2010, Consejeria de Salud de la Junta de Andalucia (PI0105/2007), Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (ACOMP06109, GVACOMP2010-181, GVACOMP2011-151, CS2010-AP-111, and CS2011-AP-042), and Regional Government of Navarra (P27/2011).	Martinez-Gonzalez MA, 2012, INT J EPIDEMIOL, V41, P377, DOI 10.1093/ije/dyq250; Bendinelli B, 2011, AM J CLIN NUTR, V93, P275, DOI 10.3945/ajcn.110.000521; Buckland G, 2012, BRIT J NUTR, V108, P2075, DOI 10.1017/S000711451200298X; Buckland G, 2012, AM J CLIN NUTR, V96, P142, DOI 10.3945/ajcn.111.024216; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; DELORGERIL, 1995, LANCET, V345, P738; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; Esposito K, 2004, JAMA-J AM MED ASSOC, V292, P1440, DOI 10.1001/jama.292.12.1440; Esposito K, 2010, DIABETES RES CLIN PR, V89, P97, DOI 10.1016/j.diabres.2010.04.019; Estruch R, 2006, ANN INTERN MED, V145, P1, DOI 10.7326/0003-4819-145-1-200607040-00004; Fernandez-Ballarth JD, 2010, BRIT J NUTR, V103, P1808, DOI 10.1017/S0007114509993837; Fito M, 2007, ARCH INTERN MED, V167, P1195, DOI 10.1001/archinte.167.11.1195; Fuentes F, 2001, ANN INTERN MED, V134, P1115, DOI 10.7326/0003-4819-134-12-200106190-00011; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2998, DOI 10.1001/jama.288.23.2998; Howard BV, 2006, JAMA-J AM MED ASSOC, V295, P655, DOI 10.1001/jama.295.6.655; Jacobs DR, 2009, AM J CLIN NUTR, V89, pS1543, DOI 10.3945/ajcn.2009.26736B; Kastorini CM, 2011, AM HEART J, V162, P717, DOI 10.1016/j.ahj.2011.07.012; Kastorini CM, 2011, J AM COLL CARDIOL, V57, P1299, DOI 10.1016/j.jacc.2010.09.073; Kris-Etherton P, 2001, CIRCULATION, V103, P1823, DOI 10.1161/01.CIR.103.13.1823; Kris-Etherton PN, 2008, J NUTR, V138, p1746S; Martinez-Gonzalez MA, 2008, BMJ-BRIT MED J, V336, P1348, DOI 10.1136/bmj.39561.501007.BE; Mena MP, 2009, AM J CLIN NUTR, V89, P248, DOI 10.3945/ajcn.2008.26094; Mente A, 2009, ARCH INTERN MED, V169, P659, DOI 10.1001/archinternmed.2009.38; Mueller-Nordhorn J, 2008, EUR HEART J, V29, P1316, DOI 10.1093/eurheartj/ehm604; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Ros E, 2010, CURR ATHEROSCLER REP, V12, P397, DOI 10.1007/s11883-010-0132-5; Salas-Salvado J, 2008, ARCH INTERN MED, V168, P2449, DOI 10.1001/archinte.168.22.2449; Salas-Salvado J, 2011, DIABETES CARE, V34, P14, DOI 10.2337/dc10-1288; Samieri C, 2011, NEUROLOGY, V77, P418, DOI 10.1212/WNL.0b013e318220abeb; Schroder H, 2011, J NUTR, V141, P1140, DOI 10.3945/jn.110.135566; Serra-Majem L, 2006, NUTR REV, V64, pS27, DOI 10.1301/nr.2006.feb.S27-S47; Shai I, 2009, NEW ENGL J MED, V361, P2681; Sofi F, 2010, AM J CLIN NUTR, V92, P1189, DOI 10.3945/ajcn.2010.29673; Trichopoulou A, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b2337; Vincent-Baudry S, 2005, AM J CLIN NUTR, V82, P964, DOI 10.1093/ajcn/82.5.964; WILLETT WC, 1995, AM J CLIN NUTR, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S; Zazpe I, 2008, J AM DIET ASSOC, V108, P1134, DOI 10.1016/j.jada.2008.04.011	37	2845	2911	17	1249	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 4	2013	368	14					1279	1290		10.1056/NEJMoa1200303	http://dx.doi.org/10.1056/NEJMoa1200303			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117YT	23432189	Green Published			2023-01-03	WOS:000316989900005
J	Katiyar, S; Kufareva, I; Behera, R; Thomas, SM; Ogata, Y; Pollastri, M; Abagyan, R; Mensa-Wilmot, K				Katiyar, Samiksha; Kufareva, Irina; Behera, Ranjan; Thomas, Sarah M.; Ogata, Yuko; Pollastri, Michael; Abagyan, Ruben; Mensa-Wilmot, Kojo			Lapatinib-Binding Protein Kinases in the African Trypanosome: Identification of Cellular Targets for Kinase-Directed Chemical Scaffolds	PLOS ONE			English	Article							CHROMOSOMAL PASSENGER COMPLEX; BLOOD-STREAM FORM; TYROSINE KINASE; GROWTH-FACTOR; ONCOGENE ADDICTION; DUAL INHIBITOR; DESIGN; EGFR; TRANSFERRIN; GW572016	Human African trypanosomiasis is caused by the eukaryotic microbe Trypanosoma brucei. To discover new drugs against the disease, one may use drugs in the clinic for other indications whose chemical scaffolds can be optimized via a medicinal chemistry campaign to achieve greater potency against the trypanosome. Towards this goal, we tested inhibitors of human EGFR and/or VEGFR as possible anti-trypanosome compounds. The 4-anilinoquinazolines canertinib and lapatinib, and the pyrrolopyrimidine AEE788 killed bloodstream T. brucei in vitro with GI(50) in the low micromolar range. Curiously, the genome of T. brucei does not encode EGFR or VEGFR, indicating that the drugs recognize alternate proteins. To discover these novel targets, a trypanosome lysate was adsorbed to an ATP-sepharose matrix and washed with a high salt solution followed by nicotinamide adenine dinucleotide (NAD+). Proteins that remained bound to the column were eluted with drugs, and identified by mass spectrometry/bioinformatics. Lapatinib bound to Tb927.4.5180 (termed T. brucei lapatinib-binding protein kinase-1 (TbLBPK1)) while AEE788 bound Tb927.5.800 (TbLBPK2). When the NAD+ wash was omitted from the protocol, AEE788, canertinib and lapatinib eluted TbLBPK1, TbLBPK2, and Tb927.3.1570 (TbLBPK3). In addition, both canertinib and lapatinib eluted Tb10.60.3140 (TbLBPK4), whereas only canertinib desorbed Tb10.61.1880 (TbCBPK1). Lapatinib binds to a unique conformation of protein kinases. To gain insight into the structural basis for lapatinib interaction with TbLBPKs, we constructed three-dimensional models of lapatinib center dot TbLBPK complexes, which confirmed that TbLBPKs can adopt lapatinib-compatible conformations. Further, lapatinib, AEE788, and canertinib were docked to TbLBPKs with favorable scores. Our studies (a) present novel targets of kinase-directed drugs in the trypanosome, and (b) offer the 4-anilinoquinazoline and pyrrolopyrimidines as scaffolds worthy of medicinal chemistry and structural biology campaigns to develop them into anti-trypanosome drugs.	[Katiyar, Samiksha; Behera, Ranjan; Thomas, Sarah M.; Mensa-Wilmot, Kojo] Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA; [Kufareva, Irina; Abagyan, Ruben] UCSD Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA; [Pollastri, Michael] Northeastern Univ, Dept Chem & Chem Biol, Boston, MA 02115 USA; [Ogata, Yuko] Fred Hutchinson Canc Res Ctr, Prote Facil, Seattle, WA 98104 USA	University System of Georgia; University of Georgia; Northeastern University; Fred Hutchinson Cancer Center	Abagyan, R (corresponding author), UCSD Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA.	rabagyan@ucsd.edu; mensawil@uga.edu	Bansal, Reema/AAH-6896-2019; pollastri, Michael/AAR-5790-2020	pollastri, Michael/0000-0001-9943-7197; Kufareva, Irina/0000-0001-9083-7039	National Institutes of Health [AI076647]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI076647] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by National Institutes of Health AI076647. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abagyan R, 1997, PROTEINS, P29; ABAGYAN R, 1994, J MOL BIOL, V235, P983, DOI 10.1006/jmbi.1994.1052; ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; Arnautova YA, 2011, PROTEINS, V79, P477, DOI 10.1002/prot.22896; Arora A, 2005, J PHARMACOL EXP THER, V315, P971, DOI 10.1124/jpet.105.084145; Atwell S, 2004, J BIOL CHEM, V279, P55827, DOI 10.1074/jbc.M409792200; Bantscheff M, 2007, NAT BIOTECHNOL, V25, P1035, DOI 10.1038/nbt1328; Barbarroja N, 2010, EXP HEMATOL; Barrett MP, 2007, BRIT J PHARMACOL, V152, P1155, DOI 10.1038/sj.bjp.0707354; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; Brehmer D, 2005, CANCER RES, V65, P379; Brun R, 2006, CURR OPIN INFECT DIS, V19, P415, DOI 10.1097/01.qco.0000244045.93016.b1; Burris HA, 2005, J CLIN ONCOL, V23, P5305, DOI 10.1200/JCO.2005.16.584; Calvo E, 2004, CLIN CANCER RES, V10, P7112, DOI 10.1158/1078-0432.CCR-04-1187; Chen R, 2006, CANCER RES, V66, P10959, DOI 10.1158/0008-5472.CAN-06-1216; Deutsch EW, 2010, PROTEOMICS, V10, P1150, DOI 10.1002/pmic.200900375; Duncan JS, 2012, METHODS MOL BIOL, V795, P119, DOI 10.1007/978-1-61779-337-0_8; El-Sayed NM, 2005, SCIENCE, V309, P409, DOI 10.1126/science.1112631; Gafken Philip R., 2009, V527, P159, DOI 10.1007/978-1-60327-834-8_12; Goldammer T, 2006, CYTOGENET GENOME RES, V112, p341C, DOI 10.1159/000089893; Hamadien M, 2000, PARASITOLOGY, V120, P281, DOI 10.1017/S0031182099005521; Haystead TAJ, 2006, CURR TOP MED CHEM, V6, P1117; Heymach JV, 2006, CLIN CANCER RES, V12, p4441S, DOI 10.1158/1078-0432.CCR-06-0286; Higdon R, 2007, OMICS, V11, P351, DOI 10.1089/omi.2007.0040; HIRUMI H, 1994, PARASITOL TODAY, V10, P80, DOI 10.1016/0169-4758(94)90402-2; Hubbard RD, 2008, BIOORG MED CHEM LETT, V18, P5738, DOI 10.1016/j.bmcl.2008.09.090; Johnson LN, 2009, Q REV BIOPHYS, V42, P1, DOI 10.1017/S0033583508004745; Kaouass M, 1997, MOL CELL BIOL, V17, P2994, DOI 10.1128/MCB.17.6.2994; Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Kim JW, 2008, CANCER LETT, V272, P296, DOI 10.1016/j.canlet.2008.07.018; Kufareva I, 2011, STRUCTURE IN PRESS; Lackey KE, 2006, CURR TOP MED CHEM, V6, P435, DOI 10.2174/156802606776743156; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; Li ZY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002354; Li ZY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003814; Lim WA, 2010, CELL, V142, P661, DOI 10.1016/j.cell.2010.08.023; Lochhead PA, 2003, BIOCHEM J, V374, P381, DOI 10.1042/BJ20030500; Lu C, 2007, CLIN CANCER RES, V13, P4209, DOI 10.1158/1078-0432.ccr-07-0197; MYERS T, 2007, CURR PROTOC BIOINFOR, pCH13; Nett IR, 2009, MOL CELL PROTEOMICS; Nett IRE, 2009, EUKARYOT CELL, V8, P617, DOI 10.1128/EC.00366-08; Ojo KK, 2008, ANTIMICROB AGENTS CH, V52, P3710, DOI 10.1128/AAC.00364-08; Olaussen KA, 2009, ONCOGENE, V28, P4249, DOI 10.1038/onc.2009.277; Panigrahi AK, 2009, PROTEOMICS, V9, P434, DOI 10.1002/pmic.200800477; Park YW, 2005, CLIN CANCER RES, V11, P1963, DOI 10.1158/1078-0432.CCR-04-1665; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; Parsons M, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-127; Rauch A, 2006, J PROTEOME RES, V5, P112, DOI 10.1021/pr0503533; Rixe O, 2009, CANCER CHEMOTH PHARM, V64, P1139, DOI 10.1007/s00280-009-0975-z; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Rost B, 1999, PROTEIN ENG, V12, P85, DOI 10.1093/protein/12.2.85; Schapira M, 1999, J MOL RECOGNIT, V12, P177, DOI 10.1002/(SICI)1099-1352(199905/06)12:3<177::AID-JMR451>3.0.CO;2-Z; SCHELL D, 1991, PARASITOL RES, V77, P558, DOI 10.1007/BF00931012; Sessa G, 1996, PLANT CELL, V8, P2223, DOI 10.1105/tpc.8.12.2223; Sharma SV, 2006, CANCER CELL, V10, P425, DOI 10.1016/j.ccr.2006.09.014; Slichenmyer WJ, 2001, SEMIN ONCOL, V28, P80, DOI 10.1016/S0093-7754(01)90285-4; Smaill JB, 2001, J MED CHEM, V44, P429, DOI 10.1021/jm000372i; Subramanya S, 2009, BIOCHEM J, V417, P685, DOI 10.1042/BJ20080167; Subramanya S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008538; Traxler P, 2004, CANCER RES, V64, P4931, DOI 10.1158/0008-5472.CAN-03-3681; Trinks C, 2010, BIOCHEM BIOPH RES CO, V393, P6, DOI 10.1016/j.bbrc.2010.01.055; Urbaniak MD, 2009, MOL BIOCHEM PARASIT, V166, P183, DOI 10.1016/j.molbiopara.2009.03.001; Vema A, 2003, BIOORGAN MED CHEM, V11, P4643, DOI 10.1016/S0968-0896(03)00482-6; Walter SA, 2003, J BIOL CHEM, V278, P18221, DOI 10.1074/jbc.M212556200; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; WHEELERALM E, 1992, J PROTOZOOL, V39, P413, DOI 10.1111/j.1550-7408.1992.tb01473.x; Wissner A, 2003, J MED CHEM, V46, P49, DOI 10.1021/jm020241c; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017	73	30	30	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2013	8	2							e56150	10.1371/journal.pone.0056150	http://dx.doi.org/10.1371/journal.pone.0056150			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	093IE	23437089	Green Published, gold			2023-01-03	WOS:000315184200043
J	Ransom, JI; Hobbs, NT; Bruemmer, J				Ransom, Jason I.; Hobbs, N. Thompson; Bruemmer, Jason			Contraception can Lead to Trophic Asynchrony between Birth Pulse and Resources	PLOS ONE			English	Article							PORCINE ZONAE-PELLUCIDAE; CLIMATE-CHANGE; IMMUNIZATION; PHENOLOGY; IMMUNOCONTRACEPTION; MARES; MECHANISMS; FERTILITY; ADJUVANTS	Abiotic inputs such as photoperiod and temperature can regulate reproductive cyclicity in many species. When humans perturb this process by intervening in reproductive cycles, the ecological consequences may be profound. Trophic mismatches between birth pulse and resources in wildlife species may cascade toward decreased survival and threaten the viability of small populations. We followed feral horses (Equus caballus) in three populations for a longitudinal study of the transient immunocontraceptive porcine zona pellucida (PZP), and found that repeated vaccinations extended the duration of infertility far beyond the targeted period. After the targeted years of infertility, the probability of parturition from post-treated females was 25.6% compared to 64.1% for untreated females, when the data were constrained only to females that had demonstrated fertility prior to the study. Estimated time to parturition increased 411.3 days per year of consecutive historical treatment. Births from untreated females in these temperate latitude populations were observed to peak in the middle of May, indicating peak conception occurred around the previous summer solstice. When the post-treated females did conceive and give birth, parturition was an estimated 31.5 days later than births from untreated females, resulting in asynchrony with peak forage availability. The latest neonate born to a post-treated female arrived 7.5 months after the peak in births from untreated females, indicating conception occurred within 24-31 days of the winter solstice. These results demonstrate surprising physiological plasticity for temperate latitude horses, and indicate that while photoperiod and temperature are powerful inputs driving the biological rhythms of conception and birth in horses, these inputs may not limit their ability to conceive under perturbed conditions. The protracted infertility observed in PZP-treated horses may be of benefit for managing overabundant wildlife, but also suggests caution for use in small refugia or rare species.	[Ransom, Jason I.] US Geol Survey, Ft Collins Sci Ctr, Ft Collins, CO USA; [Hobbs, N. Thompson] Colorado State Univ, Nat Resource Ecol Lab, Ft Collins, CO 80523 USA; [Bruemmer, Jason] Colorado State Univ, Dept Anim Sci, Ft Collins, CO 80523 USA	United States Department of the Interior; United States Geological Survey; Colorado State University; Colorado State University	Ransom, JI (corresponding author), Natl Pk Serv, Biol Resource Management Div, Ft Collins, CO USA.	Jason_I_Ransom@nps.gov	Ransom, Jason/AAT-4025-2020; Hobbs, Tom/C-5263-2016	Ransom, Jason/0000-0002-5930-4004; Bruemmer, Jason/0000-0002-4236-756X	United States Geological Survey (USGS) Wildlife Program	United States Geological Survey (USGS) Wildlife Program	The late F.J. Singer acquired funding and initiated the precursor to this project with the assistance of L. Coates-Markle and A.J. Kane. This research was funded by the United States Geological Survey (USGS) Wildlife Program and conducted through a cooperative effort between the USGS Fort Collins Science Center, Bureau of Land Management, United States Department of Agriculture Animal and Plant Health Inspection Service, and Colorado State University. No agency administration or funding program had a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Any use of trade, product, or firm names is for descriptive purposes only and does not imply endorsement by the United States Government.	Berger J., 1986, WILD HORSES GREAT BA; Card C, 1993, EQUINE REPROD, P567; DUNBAR BS, 1989, FERTIL STERIL, V52, P311; Edwards M, 2004, NATURE, V430, P881, DOI 10.1038/nature02808; Feh C, 2012, INT WILD EQ C, P69; Forrest J, 2010, PHILOS T R SOC B, V365, P3101, DOI 10.1098/rstb.2010.0145; GARROTT RA, 1992, J WILDLIFE MANAGE, V56, P456, DOI 10.2307/3808859; Ginther OJ, 2001, ANIM REPROD, V1, P31; Goldman BD, 2001, J BIOL RHYTHM, V16, P283, DOI 10.1177/074873001129001980; Gray ME, 2010, REPRODUCTION, V139, P45, DOI 10.1530/REP-08-0456; Grubaugh W, 1982, J Reprod Fertil Suppl, V32, P293; HARVILLE DA, 1977, J AM STAT ASSOC, V72, P320, DOI 10.2307/2286796; HENNEKE DR, 1983, EQUINE VET J, V15, P371, DOI 10.1111/j.2042-3306.1983.tb01826.x; Hone J., 2007, WILDLIFE DAMAGE CONT; HOWELL CE, 1951, J ANIM SCI, V10, P789, DOI 10.2527/jas1951.104789x; Kirkpatrick JF, 2011, AM J REPROD IMMUNOL, V66, P40, DOI 10.1111/j.1600-0897.2011.01003.x; Kirkpatrick JF, 2002, REPRODUCTION, P197; LIU IKM, 1989, J REPROD FERTIL, V85, P19, DOI 10.1530/jrf.0.0850019; Lyda RO, 2005, J ZOO WILDLIFE MED, V36, P610, DOI 10.1638/04104.1; Madosky JM, 2010, APPL ANIM BEHAV SCI, V128, P50, DOI 10.1016/j.applanim.2010.09.013; MAHIBROWN CA, 1985, BIOL REPROD, V32, P761, DOI 10.1095/biolreprod32.4.761; Munson Linda, 2005, P66; National Research Council, 2007, NUTR REQ HORS; Nunez CMV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013635; Nunez CMV, 2009, APPL ANIM BEHAV SCI, V117, P74, DOI 10.1016/j.applanim.2008.12.001; Palmer E, 1982, J Reprod Fertil Suppl, V32, P275; Palmer E, 1998, REPROD DOMEST ANIM, V33, P205, DOI 10.1111/j.1439-0531.1998.tb01343.x; Parmesan C, 2003, NATURE, V421, P37, DOI 10.1038/nature01286; Post E, 2008, PHILOS T R SOC B, V363, P2369, DOI 10.1098/rstb.2007.2207; Powell D. M., 2001, Journal of Applied Animal Welfare Science, V4, P271, DOI 10.1207/S15327604JAWS0404_04; Ransom JI, 2011, WILDLIFE SOC B, V35, P343, DOI 10.1002/wsb.66; Ransom JI, 2010, APPL ANIM BEHAV SCI, V124, P51, DOI 10.1016/j.applanim.2010.01.015; Ransom JI, 2012, POPULATION ECOLOGY F; Reitor RJ, 1983, PINEAL; Roelle JE, 2010, US GEOLOGICAL SURVEY; Stenseth NC, 2002, P NATL ACAD SCI USA, V99, P13379, DOI 10.1073/pnas.212519399; Stoops MA, 2006, REPROD FERT DEVELOP, V18, P667, DOI 10.1071/RD05045; Tan B, 2011, IEEE J-STARS, V4, P361, DOI 10.1109/JSTARS.2010.2075916; Thomas DW, 2001, SCIENCE, V291, P2598, DOI 10.1126/science.1057487; Turner A, 2002, REPRODUCTION, P187; Turner JW, 2002, REPRODUCTION, P177; Walther GR, 2002, NATURE, V416, P389, DOI 10.1038/416389a; Waring G, 1983, HORSE BEHAV; WOOD DM, 1981, BIOL REPROD, V25, P439, DOI 10.1095/biolreprod25.2.439	44	13	13	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2013	8	1							e54972	10.1371/journal.pone.0054972	http://dx.doi.org/10.1371/journal.pone.0054972			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	093SF	23383018	Green Submitted, Green Published, gold			2023-01-03	WOS:000315211500043
J	Ralston, ME; Day, LT; Slusher, TM; Musa, NL; Doss, HS				Ralston, Mark E.; Day, Louise T.; Slusher, Tina M.; Musa, Ndidiamaka L.; Doss, Helen S.			Global paediatric advanced life support: improving child survival in limited-resource settings	LANCET			English	Review							COMMUNITY-ACQUIRED PNEUMONIA; ACUTE RESPIRATORY-INFECTIONS; EMERGENCY TRIAGE ASSESSMENT; POSITIVE AIRWAY PRESSURE; CRITICALLY-ILL CHILDREN; DENGUE-SHOCK-SYNDROME; DEVELOPING-COUNTRIES; CLINICAL SIGNS; INTENSIVE-CARE; HOSPITAL-CARE	Nearly all global mortality in children younger than 5 years (99%) occurs in developing countries. The leading causes of mortality in children younger than 5 years worldwide, pneumonia and diarrhoeal illness, account for 1.396 and 0.801 million annual deaths, respectively. Although important advances in prevention are being made, advanced life support management in children in developing countries is often incomplete because of limited resources. Existing advanced life support management guidelines for children in limited-resource settings are mainly empirical, rather than evidence-based, written for the hospital setting, not standardised with a systematic approach to patient assessment and categorisation of illness, and taught in current paediatric advanced life support training courses from the perspective of full-resource settings. In this Review, we focus on extension of higher quality emergency and critical care services to children in developing countries. When integrated into existing primary care programmes, simple inexpensive advanced life support management can improve child survival worldwide.	[Ralston, Mark E.] Naval Hosp, Dept Pediat, Oak Harbor, WA 98278 USA; [Ralston, Mark E.] Uniformed Serv Univ Hlth Sci, Dept Pediat, Bethesda, MD 20814 USA; [Day, Louise T.] LAMB Hosp, Dept Pediat, Parbatipur 5250, Dinajpur, Bangladesh; [Slusher, Tina M.] Univ Minnesota, Hennepin Cty Med Ctr, Pediat Intens Care Unit, Ctr Global Pediat, Minneapolis, MN 55415 USA; [Musa, Ndidiamaka L.] Med Coll Wisconsin, Dept Pediat, Div Crit Care, Milwaukee, WI 53226 USA; [Doss, Helen S.] SIL Clin, Ukarumpa, Papua N Guinea	United States Department of Defense; United States Navy; Uniformed Services University of the Health Sciences - USA; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities; Medical College of Wisconsin	Ralston, ME (corresponding author), Naval Hosp, Dept Pediat, Oak Harbor, WA 98278 USA.	mark.ralston@med.navy.mil						Akech S, 2010, BMJ-BRIT MED J, V341, pc4416; Akech SO, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-71; American Heart Association, 2011, PED ADV LIF SUPP PRO; American Heart Association, 2006, PED ADV LIF SUPP PRO; [Anonymous], 2005, HOSP CAR CHILDR GUID; [Anonymous], 2011, MILL DEV GOALS REP; [Anonymous], 2010, INT MAN CHILDH ILLN; Baker T, 2009, PEDIATR ANESTH, V19, P23, DOI 10.1111/j.1460-9592.2008.02868.x; Baqui AH, 2002, BRIT MED J, V325, P1059, DOI 10.1136/bmj.325.7372.1059; Bataar O, 2010, B WORLD HEALTH ORGAN, V88, P839, DOI 10.2471/BLT.10.077073; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Cam BV, 2002, J TROP PEDIATRICS, V48, P335, DOI 10.1093/tropej/48.6.335; Campbell H, 2008, PEDIATRICS, V121, pE984, DOI 10.1542/peds.2007-1395; Carcillo JA, 2006, INTENS CARE MED, V32, P958, DOI 10.1007/s00134-006-0189-3; Chan PWK, 2001, PEDIATR INT, V43, P53, DOI 10.1046/j.1442-200x.2001.01340.x; Chisti MJ, 2009, TROP MED INT HEALTH, V14, P1173, DOI 10.1111/j.1365-3156.2009.02364.x; DAI YH, 1995, PEDIATR INFECT DIS J, V14, P48, DOI 10.1097/00006454-199501000-00010; Demers AM, 2000, PEDIATR INFECT DIS J, V19, P424, DOI 10.1097/00006454-200005000-00007; Dubey SP, 1999, J LARYNGOL OTOL, V113, P645, DOI 10.1017/S0022215100144743; Duke T, 2010, INT J TUBERC LUNG D, V14, P1362; Duke T, 2009, ANN TROP PAEDIATR, V29, P165, DOI 10.1179/027249309X12467994190011; Duke T, 2001, INT J TUBERC LUNG D, V5, P511; Duke T, 2002, ARCH DIS CHILD, V86, P108, DOI 10.1136/adc.86.2.108; Duke T, 2008, LANCET, V372, P1328, DOI 10.1016/S0140-6736(08)61164-2; Dung NM, 1999, CLIN INFECT DIS, V29, P787, DOI 10.1086/520435; Dunser MW, 2006, CRIT CARE MED, V34, P1234, DOI 10.1097/01.CCM.0000208360.70835.87; Edejer TTT, 2005, BMJ-BRIT MED J, V331, P1177, DOI 10.1136/bmj.38652.550278.7C; Enarson P, 2008, B WORLD HEALTH ORGAN, V86, P344, DOI 10.2471/BLT.07.048017; English M, 2004, LANCET, V364, P1622, DOI 10.1016/S0140-6736(04)17318-2; English M, 2004, LANCET, V363, P1948, DOI 10.1016/S0140-6736(04)16408-8; English M, 2011, ARCH DIS CHILD, V96, P285, DOI 10.1136/adc.2010.189126; English M, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-42; FALADE AG, 1995, B WORLD HEALTH ORGAN, V73, P299; Font Fidel, 2002, BMC Int Health Hum Rights, V2, P4, DOI 10.1186/1472-698X-2-4; FULTON DR, 1985, AM J CARDIOL, V55, P1328, DOI 10.1016/0002-9149(85)90498-9; George Ige Abraham, 2007, Indian J Med Sci, V61, P495; Gove S, 1999, ARCH DIS CHILD, V81, P473, DOI 10.1136/adc.81.6.473; Graham SM, 2008, B WORLD HEALTH ORGAN, V86, P349, DOI 10.2471/BLT.07.048512; Gray D, 2009, EXPERT REV ANTI-INFE, V7, P437, DOI [10.1586/eri.09.14, 10.1586/ERI.09.14]; Guiscafre H, 2001, B WORLD HEALTH ORGAN, V79, P434; Hahn S., 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002847; Hatherill M, 2003, INTENS CARE MED, V29, P1547, DOI 10.1007/s00134-003-1888-7; Hazir T, 2008, LANCET, V371, P49, DOI 10.1016/S0140-6736(08)60071-9; Hildenwall H, 2009, ANN TROP PAEDIATR, V29, P281, DOI 10.1179/027249309X12547917869005; Hodges SC, 2007, ANAESTHESIA, V62, P4, DOI 10.1111/j.1365-2044.2006.04907.x; Hussain H, 2006, INT J HEALTH PLAN M, V21, P229, DOI 10.1002/hpm.847; Irimu G, 2008, ARCH DIS CHILD, V93, P799, DOI 10.1136/adc.2007.126508; Jochberger S, 2008, ANESTH ANALG, V106, P942, DOI 10.1213/ane.0b013e318166ecb8; Kallander K, 2008, B WORLD HEALTH ORGAN, V86, P332, DOI 10.2471/BLT.07.049353; KALTER HD, 1990, INT J EPIDEMIOL, V19, P380, DOI 10.1093/ije/19.2.380; Kalter HD, 1997, B WORLD HEALTH ORGAN, V75, P65; Khan WA, 2002, LANCET, V360, P1722, DOI 10.1016/S0140-6736(02)11680-1; Khilnani P, 2008, INDIAN J PEDIATR, V75, P591, DOI 10.1007/s12098-008-0115-5; Khilnani P, 2010, INDIAN J CRIT CARE M, V14, P41, DOI 10.4103/0972-5229.63029; Kissoon N, 2008, SAUDI MED J, V29, P1383; Kobusingye OC, 2005, B WORLD HEALTH ORGAN, V83, P626; Kolstad PR, 1997, B WORLD HEALTH ORGAN, V75, P77; Koyamaibole L, 2006, J TROP PEDIATRICS, V52, P249, DOI 10.1093/tropej/fmi109; Kugler JD, 1996, J PEDIATR-US, V129, P324, DOI 10.1016/S0022-3476(96)70063-X; Liu L, 2012, LANCET, V375, P1969; Maitland K, 2011, NEW ENGL J MED, V364, P2483, DOI 10.1056/NEJMoa1101549; Maitland K, 2009, P NUTR SOC, V68, P274, DOI 10.1017/S0029665109001359; Mamtani M, 2009, PEDIATR PULM, V44, P379, DOI 10.1002/ppul.21014; Maternova&TRADE;, INSP LOW COST BREATH; Mathers C. D., 2004, 54 WHO GLOB PROGR EV; McCollum ED, 2011, INT J TUBERC LUNG D, V15, P562, DOI 10.5588/ijtld.10.0583; McNally LM, 2007, LANCET, V369, P1440, DOI 10.1016/S0140-6736(07)60670-9; Molyneux E, 2006, B WORLD HEALTH ORGAN, V84, P314, DOI 10.2471/BLT.04.019505; Molyneux E, 2001, LANCET, V357, P86, DOI 10.1016/S0140-6736(00)03536-4; Muhe L, 2001, INT J TUBERC LUNG D, V5, P527; Munos MK, 2010, INT J EPIDEMIOL, V39, P75, DOI 10.1093/ije/dyq025; Murray C.J.L., 2004, COMP QUANTIFICATION, V1, P257, DOI DOI 10.1007/S12263-011-0248-4; Nhan NT, 2001, CLIN INFECT DIS, V32, P204, DOI 10.1086/318479; Nolan T, 2001, LANCET, V357, P106, DOI 10.1016/S0140-6736(00)03542-X; Nutrition Division Ministry of Health Malaysia, 2015, GUID REH PROGR MALN; Oliveira CF, 2008, PEDIATR EMERG CARE, V24, P810, DOI 10.1097/PEC.0b013e31818e9f3a; Olotu A, 2009, RESUSCITATION, V80, P69, DOI 10.1016/j.resuscitation.2008.09.019; OPIYO N, 2010, COCHRANE DB SYST REV, V4; Otieno H, 2004, ARCH DIS CHILD, V89, P977, DOI 10.1136/adc.2003.043901; Peterson S, 2004, LANCET, V363, P1955, DOI 10.1016/S0140-6736(04)16411-8; Raimer PL, 2011, J PEDIATR-US, V158, P968, DOI 10.1016/j.jpeds.2010.11.062; Ranjit Suchitra, 2005, Pediatr Crit Care Med, V6, P412, DOI 10.1097/01.PCC.0000163676.75693.BF; Razzak JA, 2002, B WORLD HEALTH ORGAN, V80, P900; Reyes H, 1997, HEALTH POLICY PLANN, V12, P214, DOI 10.1093/heapol/12.3.214; Rice AL., 2004, COMP QUANTIFICATION, V1, P0211; Robertson MA, 2001, ARCH DIS CHILD, V85, P208, DOI 10.1136/adc.85.3.208; ROCCHINI AP, 1981, AM J CARDIOL, V47, P1091, DOI 10.1016/0002-9149(81)90218-6; ROJAS MX, 2009, COCHRANE DB SYST REV, V1; Sazawal S, 2003, LANCET INFECT DIS, V3, P547, DOI 10.1016/S1473-3099(03)00737-0; SHANN F, 1989, PEDIATR INFECT DIS J, V8, P852, DOI 10.1097/00006454-198912000-00005; Simoes EAF, 2003, B WORLD HEALTH ORGAN, V81, P522; SINGHI S, 1994, ANN TROP PAEDIATR, V14, P53, DOI 10.1080/02724936.1994.11747692; Smart K, 2009, J TROP PEDIATRICS, V55, P145, DOI 10.1093/tropej/fmp046; Sodemann M, 1997, B WORLD HEALTH ORGAN, V75, P205; Soni Arun, 2001, Indian Journal of Pediatrics, V68, P1051, DOI 10.1007/BF02722356; Su L, 2010, MANAGEMENT SEPTIC SH; Tamburlini G, 1999, ARCH DIS CHILD, V81, P478, DOI 10.1136/adc.81.6.478; Tecklenburg FW, 2010, PEDIATR EMERG CARE, V26, P554, DOI 10.1097/PEC.0b013e3181ea71ca; Thirsk ER, 2003, SAMJ S AFR MED J, V93, P617; Thomson N, 2005, RESUSCITATION, V65, P15, DOI 10.1016/j.resuscitation.2005.01.008; Towey RM, 2007, ANAESTHESIA, V62, P32, DOI 10.1111/j.1365-2044.2007.05295.x; UNICEF, LEV TRENDS CHILD MOR; UNICEF, 2010, STAT AR CHILD SURV H; Van den Heuvel M, 2011, ANN TROP PAEDIATR, V31, P59, DOI 10.1179/1465328110Y.0000000001; Van der Merwe D M, 2004, Cardiovasc J S Afr, V15, P64; Viana ME, 1998, NEW HORIZ-SCI PRACT, V6, P226; WAISMAN Y, 1992, PEDIATRICS, V89, P302; Walker CLF, 2010, INT J EPIDEMIOL, V39, P63, DOI 10.1093/ije/dyq023; Wandi F, 2006, ANN TROP PAEDIATR, V26, P277, DOI 10.1179/146532806X152791; WHO, 2012, REC MAN COMM CHILDH; WHO, 2005, HDB IMCI INT MAN CHI; Wills BA, 2005, NEW ENGL J MED, V353, P877, DOI 10.1056/NEJMoa044057; World Health Organization, 2005, EM TRIAG ASS TREATM; World Health Organization, 2005, TREATM DIARRH MAN PH; Zar HJ, 2004, CURR OPIN PULM MED, V10, P176, DOI 10.1097/00063198-200405000-00006; Zar HJ, 1999, LANCET, V354, P979, DOI 10.1016/S0140-6736(98)12445-5	116	49	51	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 19	2013	381	9862					256	265		10.1016/S0140-6736(12)61191-X	http://dx.doi.org/10.1016/S0140-6736(12)61191-X			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	075LL	23332963				2023-01-03	WOS:000313887600037
J	Marklein, D; Graab, U; Naumann, I; Yan, TD; Ridzewski, R; Nitzki, F; Rosenberger, A; Dittmann, K; Wienands, J; Wojnowski, L; Fulda, S; Hahn, H				Marklein, Diana; Graab, Ulrike; Naumann, Ivonne; Yan, Tiandong; Ridzewski, Rosalie; Nitzki, Frauke; Rosenberger, Albert; Dittmann, Kai; Wienands, Juergen; Wojnowski, Leszek; Fulda, Simone; Hahn, Heidi			PI3K Inhibition Enhances Doxorubicin-Induced Apoptosis in Sarcoma Cells	PLOS ONE			English	Article							TOPOISOMERASE-II INHIBITORS; FLOW-CYTOMETRIC ANALYSIS; CYTOCHROME-C RELEASE; SOFT-TISSUE SARCOMAS; BREAST-CANCER CELLS; MULTIDRUG-RESISTANCE; INTERGROUP RHABDOMYOSARCOMA; MTOR INHIBITION; PHASE-II; PROTEIN-1 EXPRESSION	We searched for a drug capable of sensitization of sarcoma cells to doxorubicin (DOX). We report that the dual PI3K/mTOR inhibitor PI103 enhances the efficacy of DOX in several sarcoma cell lines and interacts with DOX in the induction of apoptosis. PI103 decreased the expression of MDR1 and MRP1, which resulted in DOX accumulation. However, the enhancement of DOX-induced apoptosis was unrelated to DOX accumulation. Neither did it involve inhibition of mTOR. Instead, the combination treatment of DOX plus PI103 activated Bax, the mitochondrial apoptosis pathway, and caspase 3. Caspase 3 activation was also observed in xenografts of sarcoma cells in nude mice upon combination of DOX with the specific PI3K inhibitor GDC-0941. Although the increase in apoptosis did not further impact on tumor growth when compared to the efficient growth inhibition by GDC-0941 alone, these findings suggest that inhibition of PI3K may improve DOX-induced proapoptotic effects in sarcoma. Taken together with similar recent studies of neuroblastoma- and glioblastoma-derived cells, PI3K inhibition seems to be a more general option to sensitize tumor cells to anthracyclines.	[Marklein, Diana; Ridzewski, Rosalie; Nitzki, Frauke; Hahn, Heidi] Univ Med Ctr, Inst Human Genet, Gottingen, Germany; [Graab, Ulrike; Naumann, Ivonne; Fulda, Simone] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60054 Frankfurt, Germany; [Yan, Tiandong; Wojnowski, Leszek] Univ Med Ctr, Dept Pharmacol, Mainz, Germany; [Rosenberger, Albert] Univ Med Ctr, Dept Genet Epidemiol, Gottingen, Germany; [Dittmann, Kai; Wienands, Juergen] Univ Med Ctr, Dept Cellular & Mol Immunol, Gottingen, Germany	University of Gottingen; Goethe University Frankfurt; Johannes Gutenberg University of Mainz; University of Gottingen; University of Gottingen	Hahn, H (corresponding author), Univ Med Ctr, Inst Human Genet, Gottingen, Germany.	hhahn@gwdg.de		Fulda, Simone/0000-0002-0459-6417	DFG [GRK 1034, WO505/3-1]; Deutsche Krebshilfe [109837 (KoSAR)]	DFG(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe)	The work was supported by the DFG GRK 1034 (to H. H.), by the grant 109837 (KoSAR) from the Deutsche Krebshilfe (to H. H. and S. F.) and by the DFG grant WO505/3-1 (to L. W.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baird K, 2005, CANCER RES, V65, P9226, DOI 10.1158/0008-5472.CAN-05-1699; Beck WT, 1999, DRUG RESIST UPDATE, V2, P382, DOI 10.1054/drup.1999.0110; Bender A, 2011, ONCOGENE, V30, P494, DOI 10.1038/onc.2010.429; Bergeron C, 2008, EUR J CANCER, V44, P427, DOI 10.1016/j.ejca.2007.12.007; Biehn SE, 2007, ANN HEMATOL, V86, P211, DOI 10.1007/s00277-006-0220-3; Blay JY, 2011, ANN ONCOL, V22, P280, DOI 10.1093/annonc/mdq307; BONADONNA G, 1970, CANCER RES, V30, P2572; Congdon LM, 2008, BIOCHEM PHARMACOL, V75, P883, DOI 10.1016/j.bcp.2007.10.026; Cortes F, 2003, MUTAGENESIS, V18, P105, DOI 10.1093/mutage/18.2.105; CRIST W, 1995, J CLIN ONCOL, V13, P610, DOI 10.1200/JCO.1995.13.3.610; Crose Lisa E. S., 2011, Sarcoma, V2011, P1, DOI 10.1155/2011/756982; Das CM, 2007, J NEURO-ONCOL, V85, P159, DOI 10.1007/s11060-007-9402-7; Fan L, 2004, ENDOCRINOLOGY, V145, P3961, DOI 10.1210/en.2004-0079; Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d; Frustaci S, 2001, J CLIN ONCOL, V19, P1238, DOI 10.1200/JCO.2001.19.5.1238; Gatta G, 2003, EUR J CANCER, V39, P2600, DOI 10.1016/j.ejca.2003.09.004; Giantris A, 1998, CRIT REV ONCOL HEMAT, V27, P53, DOI 10.1016/S1040-8428(97)10007-5; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Gortzak E, 2001, EUR J CANCER, V37, P1096, DOI 10.1016/S0959-8049(01)00083-1; GREENE RF, 1983, CANCER RES, V43, P3417; Hacker S, 2009, ONCOGENE, V28, P3097, DOI 10.1038/onc.2009.161; Han Z, 2007, J EXP CLIN CANC RES, V26, P261; Hideshima T, 2001, CANCER RES, V61, P3071; Kanbe E, 2003, EXP HEMATOL, V31, P300, DOI 10.1016/S0301-472X(03)00003-1; Kotamraju S, 2000, J BIOL CHEM, V275, P33585, DOI 10.1074/jbc.M003890200; Lee JT, 2004, CANCER RES, V64, P8397, DOI 10.1158/0008-5472.CAN-04-1612; Liu F, 2010, ONCOL REP, V23, P1469, DOI 10.3892/or_00000786; Manara MC, 2010, CLIN CANCER RES, V16, P530, DOI 10.1158/1078-0432.CCR-09-0816; MAURER HM, 1993, CANCER-AM CANCER SOC, V71, P1904, DOI 10.1002/1097-0142(19930301)71:5<1904::AID-CNCR2820710530>3.0.CO;2-X; MAURER HM, 1988, CANCER-AM CANCER SOC, V61, P209, DOI 10.1002/1097-0142(19880115)61:2<209::AID-CNCR2820610202>3.0.CO;2-L; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; Mohr A, 2004, CELL DEATH DIFFER, V11, P1153, DOI 10.1038/sj.cdd.4401480; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; OBRYAN RM, 1973, CANCER-AM CANCER SOC, V32, P1, DOI 10.1002/1097-0142(197307)32:1<1::AID-CNCR2820320101>3.0.CO;2-X; Opel D, 2008, CANCER RES, V68, P6271, DOI 10.1158/0008-5472.CAN-07-6769; Rabbani A, 2005, BIOESSAYS, V27, P50, DOI 10.1002/bies.20160; Raynaud FI, 2009, MOL CANCER THER, V8, P1725, DOI 10.1158/1535-7163.MCT-08-1200; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Simbre Valeriano C, 2005, Paediatr Drugs, V7, P187, DOI 10.2165/00148581-200507030-00005; Stahnke K, 2004, APOPTOSIS, V9, P457, DOI 10.1023/B:APPT.0000031454.62937.fa; STILLER CA, 1994, PAEDIATR PERINAT EP, V8, P107, DOI 10.1111/j.1365-3016.1994.tb00439.x; Takahashi-Hyodo SA, 1999, MUTAT RES-FUND MOL M, V431, P13, DOI 10.1016/S0027-5107(99)00151-7; Tamburini J, 2008, BLOOD, V111, P379, DOI 10.1182/blood-2007-03-080796; TAN C, 1973, CANCER-AM CANCER SOC, V32, P9, DOI 10.1002/1097-0142(197307)32:1<9::AID-CNCR2820320102>3.0.CO;2-6; Tazzari PL, 2007, LEUKEMIA, V21, P427, DOI 10.1038/sj.leu.2404523; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; Wan XL, 2007, ONCOLOGIST, V12, P1007, DOI 10.1634/theoncologist.12-8-1007; Xu J, 2007, CANCER RES, V67, P1203, DOI 10.1158/0008-5472.CAN-06-2310; Zhang LL, 2002, CANCER RES, V62, P2034	51	26	27	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2012	7	12							e52898	10.1371/journal.pone.0052898	http://dx.doi.org/10.1371/journal.pone.0052898			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	075GO	23300809	Green Published, gold			2023-01-03	WOS:000313872600033
J	Critselis, E; Nastos, PT; Theodoridou, K; Theodoridou, M; Tsolia, MN; Hadjichristodoulou, C; Papaevangelou, V				Critselis, Elena; Nastos, Panagiotis T.; Theodoridou, Kalliopi; Theodoridou, Maria; Tsolia, Maria N.; Hadjichristodoulou, Christos; Papaevangelou, Vassiliki			Time Trends in Pediatric Hospitalizations for Varicella Infection Are Associated with Climatic Changes: A 22-Year Retrospective Study in a Tertiary Greek Referral Center	PLOS ONE			English	Article							ZOSTER-VIRUS; CHICKENPOX INCIDENCE; SEROPREVALENCE; EPIDEMIOLOGY; POPULATION; CHILDREN; TRANSMISSION; TEMPERATURE; VACCINATION; ANTIBODIES	Background/Aims: The transmission rate of air-borne infectious diseases may vary secondary to climate conditions. The study assessed time trends in the seasonality of hospitalized varicella cases in a temperate region in relation to climatic parameters prior to the implementation of universal varicella immunization. Methods: A retrospective descriptive study was conducted among all pediatric and adolescent varicella patients (n = 2366) hospitalized at the "Aghia Sophia" Children's Hospital during 1982-2003 in Athens, Greece. Date of infection was computed based on hospital admission date. Seasonal and monthly trends in the epidemiology of varicella infection were assessed with time series analysis (ARIMA modeling procedure). The correlation between the frequency of varicella patients and the meteorological parameters was examined by the application of Generalized Linear Models with Gamma distribution. Results: During 1982-2003, the occurrence of hospitalized varicella cases increased during summer (p = 0.025) and decreased during autumn (p = 0.021), and particularly in September (p = 0.003). The frequency of hospitalized varicella cases was inversely associated with air temperature (p<0.001). In contrast, the occurrence of hospitalized varicella cases was positively associated with wind speed (p = 0.009). Conclusions: Pediatric hospitalizations for varicella infection rates have increased during summer and decreased during autumn in the examined temperate region. Time trends in hospitalized varicella cases are associated with climatic variables.	[Critselis, Elena; Tsolia, Maria N.; Papaevangelou, Vassiliki] Univ Athens, Sch Med, P&A Kyriakou Childrens Hosp, Univ Dept Pediat 2, Athens 11528, Greece; [Nastos, Panagiotis T.] Univ Athens, Dept Geol & Geoenvironm, Lab Climatol & Atmospher Environm, Athens 11528, Greece; [Theodoridou, Kalliopi; Theodoridou, Maria] Univ Athens, Sch Med, Aghia Sophia Childrens Hosp, Univ Dept Pediat 1, Athens 11528, Greece; [Hadjichristodoulou, Christos] Univ Thessaly, Sch Med, Dept Hyg & Epidemiol, Thessaly, Greece	Athens Medical School; National & Kapodistrian University of Athens; National & Kapodistrian University of Athens; Athens Medical School; National & Kapodistrian University of Athens; The Aghia Sophia Children's Hospital; University of Thessaly	Papaevangelou, V (corresponding author), Univ Athens, Sch Med, P&A Kyriakou Childrens Hosp, Univ Dept Pediat 2, Athens 11528, Greece.	vpapaev@med.uoa.gr	Nastos, Panagiotis/Q-5419-2019; Nastos, Panagiotis T/E-7455-2015	Nastos, Panagiotis/0000-0001-9336-6586; Nastos, Panagiotis T/0000-0001-9336-6586; Hadjichristodoulou, Christos/0000-0002-4769-8376	Second University Department of Pediatrics, "P. & A. Kyriakou" Children's Hospital, of the National and Kapodistrian University of Athens School of Medicine	Second University Department of Pediatrics, "P. & A. Kyriakou" Children's Hospital, of the National and Kapodistrian University of Athens School of Medicine	The present work was funded by the Second University Department of Pediatrics, "P. & A. Kyriakou" Children's Hospital, of the National and Kapodistrian University of Athens School of Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1996, MMWR Recomm Rep, V45, P1; Bonanni P, 2009, BMC MED, V7, P26, DOI DOI 10.1186/1741-7015-7-26; Chan JYC, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-366; de Melker H, 2006, VACCINE, V24, P3946, DOI 10.1016/j.vaccine.2006.02.017; GARNETT GP, 1993, EPIDEMIOL INFECT, V110, P361, DOI 10.1017/S0950268800068308; Gustin KM, 2011, P NATL ACAD SCI USA, V108, P8432, DOI 10.1073/pnas.1100768108; Katsafadou A, 2008, EUR J CLIN MICROBIOL, V27, P223, DOI 10.1007/s10096-007-0418-x; Khoshnood B, 2006, PEDIATR INFECT DIS J, V25, P41, DOI 10.1097/01.inf.0000195636.43584.bb; Knibbs LD, 2012, EPIDEMIOL INFECT, V140, P474, DOI 10.1017/S0950268811000835; Kokaze A, 2001, EPIDEMIOL INFECT, V126, P269, DOI 10.1017/S0950268801005246; Lee BW, 1998, TROP MED INT HEALTH, V3, P886; Liyanage N P M, 2007, Indian J Med Sci, V61, P128; Lolekha S, 2001, AM J TROP MED HYG, V64, P131, DOI 10.4269/ajtmh.2001.64.131; Mandal BK, 1998, J INFECT DIS, V178, pS52, DOI 10.1086/514262; McGullagh P., 1997, GEN LINEAR MODELS; Nastos PT, 2011, INT J REMOTE SENS, V32, P737, DOI 10.1080/01431161.2010.517796; NEDLER JA, 1972, J ROY STAT SOC A STA, V135, P370; O'Grady KA, 2000, TROP MED INT HEALTH, V5, P732, DOI 10.1046/j.1365-3156.2000.00622.x; Red Book, 2009, RED BOOK; Sauerbrei Andreas, 2007, Indian J Med Sci, V61, P123; Teunis PFM, 2010, EPIDEMICS-NETH, V2, P215, DOI 10.1016/j.epidem.2010.10.001; Theodoridou M, 2006, EUR J PEDIATR, V165, P273, DOI 10.1007/s00431-005-0043-6; Tseng H. F., 2005, Southeast Asian Journal of Tropical Medicine and Public Health, V36, P1201; VENKITARAMAN AR, 1984, J CLIN MICROBIOL, V20, P582, DOI 10.1128/JCM.20.3.582-583.1984; Vyse AJ, 2004, EPIDEMIOL INFECT, V132, P1129, DOI 10.1017/S0950268804003140; Wu PY, 2007, INT J DERMATOL, V46, P362, DOI 10.1111/j.1365-4632.2006.03050.x; Yang W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021481; Yawn BP, 1997, J PEDIATR-US, V130, P759, DOI 10.1016/S0022-3476(97)80019-4; Zak-Prelich M, 2002, EPIDEMIOL INFECT, V129, P593, DOI 10.1017/S0950268802007793	29	21	22	3	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 28	2012	7	12							e52016	10.1371/journal.pone.0052016	http://dx.doi.org/10.1371/journal.pone.0052016			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	064DQ	23284855	Green Published, gold, Green Submitted			2023-01-03	WOS:000313051500020
J	Han, Y; Huang, H; Xiao, Z; Zhang, W; Cao, YF; Qu, LK; Shou, CC				Han, Yong; Huang, Hao; Xiao, Zhen; Zhang, Wei; Cao, Yanfei; Qu, Like; Shou, Chengchao			Integrated Analysis of Gene Expression Profiles Associated with Response of Platinum/Paclitaxel-Based Treatment in Epithelial Ovarian Cancer	PLOS ONE			English	Article							DNA METHYLATION; AKT INHIBITORS; COLON-CANCER; CELLS; PACLITAXEL; CHEMOTHERAPY; RESISTANCE; SIGNATURES; CISPLATIN; BETA	Purpose: This study aims to explore gene expression signatures and serum biomarkers to predict intrinsic chemoresistance in epithelial ovarian cancer (EOC). Patients and Methods: Gene expression profiling data of 322 high-grade EOC cases between 2009 and 2010 in The Cancer Genome Atlas project (TCGA) were used to develop and validate gene expression signatures that could discriminate different responses to first-line platinum/paclitaxel-based treatments. A gene regulation network was then built to further identify hub genes responsible for differential gene expression between the complete response (CR) group and the progressive disease (PD) group. Further, to find more robust serum biomarkers for clinical application, we integrated our gene signatures and gene signatures reported previously to identify secretory protein-encoding genes by searching the DAVID database. In the end, gene-drug interaction network was constructed by searching Comparative Toxicogenomics Database (CTD) and literature. Results: A 349-gene predictive model and an 18-gene model independent of key clinical features with high accuracy were developed for prediction of chemoresistance in EOC. Among them, ten important hub genes and six critical signaling pathways were identified to have important implications in chemotherapeutic response. Further, ten potential serum biomarkers were identified for predicting chemoresistance in EOC. Finally, we suggested some drugs for individualized treatment. Conclusion: We have developed the predictive models and serum biomarkers for platinum/paclitaxel response and established the new approach to discover potential serum biomarkers from gene expression profiles. The potential drugs that target hub genes are also suggested.	[Han, Yong; Huang, Hao; Cao, Yanfei; Qu, Like; Shou, Chengchao] Peking Univ, Canc Hosp & Inst, Dept Biochem & Mol Biol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100871, Peoples R China; [Xiao, Zhen; Zhang, Wei] Wuhan Univ, Renmin Hosp, Dept Gynecol, Wuhan 430072, Hubei, Peoples R China; [Cao, Yanfei] Changzhi Med Coll, Changzhi, Shanxi, Peoples R China	Peking University; Wuhan University; Changzhi Medical College	Shou, CC (corresponding author), Peking Univ, Canc Hosp & Inst, Dept Biochem & Mol Biol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100871, Peoples R China.	scc@bjcancer.org		Han, Yong/0000-0001-9935-2978	National 973 Program of China [2009CB521805]	National 973 Program of China(National Basic Research Program of China)	This study was funded by the National 973 Program of China (2009CB521805). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alibes A, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-9; Altay G, 2011, BIOL DIRECT, V6, DOI 10.1186/1745-6150-6-31; An J, 2012, J BIOL CHEM, V287, P7411, DOI 10.1074/jbc.M111.277103; [Anonymous], 2011, GENE EXPRESSION PROF; Aquila S, 2004, J CLIN ENDOCR METAB, V89, P1443, DOI 10.1210/jc.2003-031681; Bair E, 2004, PLOS BIOL, V2, P511, DOI 10.1371/journal.pbio.0020108; Barrett T, 2011, NUCLEIC ACIDS RES, V39, pD1005, DOI 10.1093/nar/gkq1184; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bordonaro M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027308; Chang JT, 2006, BIOINFORMATICS, V22, P2926, DOI 10.1093/bioinformatics/btl483; Davies S, 2011, ONCOL REP, V25, P855, DOI 10.3892/or.2011.1147; Dieplinger H, 2009, CANCER EPIDEM BIOMAR, V18, P1127, DOI 10.1158/1055-9965.EPI-08-0653; Dressman HK, 2007, J CLIN ONCOL, V25, P517, DOI 10.1200/JCO.2006.06.3743; Fransson A, 2003, J BIOL CHEM, V278, P6495, DOI 10.1074/jbc.M208609200; Gamarra-Luques CD, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-200; Gao J, 2009, BIOINFORMATICS, V25, P137, DOI 10.1093/bioinformatics/btn501; Garcia-Pedrero JM, 2006, J BIOL CHEM, V281, P22656, DOI 10.1074/jbc.M602561200; Guo Y, 2012, ONCOL REP, V27, P286, DOI 10.3892/or.2011.1483; Hartmann LC, 2005, CLIN CANCER RES, V11, P2149, DOI 10.1158/1078-0432.CCR-04-1673; Helleman J, 2006, INT J CANCER, V118, P1963, DOI 10.1002/ijc.21599; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Iozzo RV, 2011, J CELL MOL MED, V15, P1013, DOI 10.1111/j.1582-4934.2010.01236.x; Jackson D, 2007, CLIN CANCER RES, V13, P7370, DOI 10.1158/1078-0432.CCR-07-0747; Jazaeri AA, 2005, CLIN CANCER RES, V11, P6300, DOI 10.1158/1078-0432.CCR-04-2682; Jelovac D, 2011, CA-CANCER J CLIN, V61, P183, DOI 10.3322/caac.20113; Ju W, 2009, ONCOL RES, V18, P47, DOI 10.3727/096504009789954672; Kanda N, 2003, J INVEST DERMATOL, V120, P1058, DOI 10.1046/j.1523-1747.2003.12255.x; Khalil H, 2012, MOL CELL BIOL, V32, P4523, DOI 10.1128/MCB.00774-12; Kim YJ, 2012, ANTICANCER RES, V32, P799; Kim YM, 2002, J BIOL CHEM, V277, P6799, DOI 10.1074/jbc.M109434200; Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271; L'Esperance S, 2006, INT J ONCOL, V29, P5; Lachmann A, 2010, BIOINFORMATICS, V26, P2438, DOI 10.1093/bioinformatics/btq466; Laursen LS, 2002, BIOCHEM J, V367, P31, DOI 10.1042/BJ20020831; Li M, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-34; Lu ZH, 2006, EXP CELL RES, V312, P1865, DOI 10.1016/j.yexcr.2006.02.017; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; Mehnert JM, 2011, MOL CANCER THER, V10, P1509, DOI 10.1158/1535-7163.MCT-10-0944; Min JK, 2007, BLOOD, V109, P1495, DOI 10.1182/blood-2006-06-029298; Mo YY, 2005, ONCOGENE, V24, P2677, DOI 10.1038/sj.onc.1208210; Montojo J, 2010, BIOINFORMATICS, V26, P2927, DOI 10.1093/bioinformatics/btq562; Rosano L, 2011, CLIN CANCER RES, V17, P2350, DOI 10.1158/1078-0432.CCR-10-2325; Sabatier R, 2011, BRIT J CANCER, V105, P304, DOI 10.1038/bjc.2011.219; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Si HP, 2012, INT J ONCOL, V40, P1291, DOI 10.3892/ijo.2011.1303; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675; Spentzos D, 2005, J CLIN ONCOL, V23, P7911, DOI 10.1200/JCO.2005.02.9363; Steg AD, 2012, CLIN CANCER RES, V18, P869, DOI 10.1158/1078-0432.CCR-11-2188; Su JL, 2011, CANCER RES, V71, P6878, DOI 10.1158/0008-5472.CAN-11-0295; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Tumbarello DA, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-36; Vergote I, 2010, NEW ENGL J MED, V363, P943, DOI 10.1056/NEJMoa0908806; Xu R, 2009, ANTICANCER RES, V29, P261; Yoon H, 2011, BIOCHEM BIOPH RES CO, V405, P333, DOI 10.1016/j.bbrc.2010.11.130; Zeller C, 2012, ONCOGENE, V31, P4567, DOI 10.1038/onc.2011.611; Zhang CY, 2011, MOL CANCER THER, V10, P1137, DOI 10.1158/1535-7163.MCT-10-1028	58	17	18	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2012	7	12							e52745	10.1371/journal.pone.0052745	http://dx.doi.org/10.1371/journal.pone.0052745			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	061EA	23300757	Green Published, gold, Green Submitted			2023-01-03	WOS:000312829100076
J	Schwarzer, A; Wolf, B; Fisher, JL; Schwaab, T; Olek, S; Baron, U; Tomlinson, CR; Seigne, JD; Crosby, NA; Gui, J; Hampton, TH; Fadul, CE; Heaney, JA; Ernstoff, MS				Schwarzer, Adrian; Wolf, Benita; Fisher, Jan L.; Schwaab, Thomas; Olek, Sven; Baron, Udo; Tomlinson, Craig R.; Seigne, John D.; Crosby, Nancy A.; Gui, Jiang; Hampton, Thomas H.; Fadul, Camilo E.; Heaney, John A.; Ernstoff, Marc S.			Regulatory T-Cells and Associated Pathways in Metastatic Renal Cell Carcinoma (mRCC) Patients Undergoing DC-Vaccination and Cytokine-Therapy	PLOS ONE			English	Article							HIGH-DOSE INTERLEUKIN-2; PERIPHERAL-BLOOD; FOXP3 EXPRESSION; IMMUNOTHERAPY; MELANOMA; TRIAL	Purpose: To evaluate CD4(+)CD25(+)FOXP3(+) T regulatory cells (T-REG) and associated immune-regulatory pathways in peripheral blood lymphocytes (PBL) of metastatic renal cell carcinoma (mRCC) patients and healthy volunteers. We subsequently investigated the effects of immunotherapy on circulating T-REG combining an extensive phenotype examination, DNA methylation analysis and global transcriptome analysis. Design: Eighteen patients with mRCC and twelve volunteers (controls) were available for analysis. T-REG phenotype was examined using flow cytometry (FCM). T-REG were also quantified by analyzing the epigenetic status of the FOXP3 locus using methylation specific PCR. As a third approach, RNA of the PBL was hybridized to Affymetrix GeneChip Human Gene 1.0 ST Arrays and the gene signatures were explored using pathway analysis. Results: We observed higher numbers of T-REG in pre-treatment PBL of mRCC patients compared to controls. A significant increase in T-REG was detected in all mRCC patients after the two cycles of immunotherapy. The expansion of T-REG was significantly higher in non-responders than in responding patients. Methylation specific PCR confirmed the FCM data and circumvented the variability and subjectivity of the FCM method. Gene Set Enrichment Analysis (GSEA) of the microarray data showed significant enrichment of FOXP3 target genes, CTLA-4 and TGF-beta associated pathways in the patient cohort. Conclusion: Immune monitoring of the peripheral blood and tumor tissue is important for a wide range of diseases and treatment strategies. Adoption of methodology for quantifying TREG with the least variability and subjectivity will enhance the ability to compare and interpret findings across studies.	[Schwarzer, Adrian; Wolf, Benita; Fisher, Jan L.; Schwaab, Thomas; Crosby, Nancy A.; Fadul, Camilo E.; Ernstoff, Marc S.] Geisel Sch Med Dartmouth, Med Oncol Immunotherapy Grp, Hanover, NH USA; [Fisher, Jan L.; Crosby, Nancy A.; Fadul, Camilo E.; Ernstoff, Marc S.] Geisel Sch Med Dartmouth, Sect Hematol Oncol, Hanover, NH USA; [Olek, Sven; Baron, Udo] Epiontis GmbH, Berlin, Germany; [Tomlinson, Craig R.; Hampton, Thomas H.] Geisel Sch Med Dartmouth, Dept Pharmacol & Toxicol, Hanover, NH USA; [Seigne, John D.; Heaney, John A.] Geisel Sch Med Dartmouth, Urol Sect, Dept Surg, Hanover, NH USA; [Gui, Jiang] Geisel Sch Med Dartmouth, Sect Biostat & Epidemiol, Dept Family & Community Med, Hanover, NH USA; [Fadul, Camilo E.; Ernstoff, Marc S.] Geisel Sch Med Dartmouth, Immunotherapy Program, Hanover, NH USA; [Fadul, Camilo E.] Geisel Sch Med Dartmouth, Dept Neurol, Hanover, NH USA	Dartmouth College; Dartmouth College; Epiontis GmbH; Dartmouth College; Dartmouth College; Dartmouth College; Dartmouth College; Dartmouth College	Ernstoff, MS (corresponding author), Geisel Sch Med Dartmouth, Med Oncol Immunotherapy Grp, Hanover, NH USA.	Marc.S.Ernstoff@Hitchcock.ORG	Schwarzer, Adrian/AAA-2571-2022; Tomlinson, Craig/F-1319-2017; Wolf, Benita/AAX-4507-2020	Wolf, Benita/0000-0001-5673-4239; Tomlinson, Craig/0000-0003-0923-1449; Baron, Udo/0000-0001-7432-3601; Schwarzer, Adrian/0000-0001-5684-2280; Hampton, Thomas/0000-0003-0543-402X	NIH [RO1 CA095648, P20RR016437, P20GM103413, P30CA023108, P42ES007373]; Berlex, Inc. [D0238]; NATIONAL CANCER INSTITUTE [P30CA023108, R01CA095648] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016437] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES007373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103413] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Berlex, Inc.; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from the NIH (RO1 CA095648, P20RR016437, P20GM103413, P30CA023108 and P42ES007373) and Berlex, Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Sven Olek and Udo Baron work at Epiontis who did contract testing for this study under a collaborative agreement. The authors received funding from Berlex, Inc. for the clinical trial (Protocol D0238) from which patient samples reported on in this paper originated. This does not alter the authors' adherence to all PLOS ONE policies on sharing data and materials.	Ahmadzadeh M, 2006, BLOOD, V107, P2409, DOI 10.1182/blood-2005-06-2399; ATKINS MB, 1993, J CLIN ONCOL, V11, P661, DOI 10.1200/JCO.1993.11.4.661; Atzpodien J, 2004, J CLIN ONCOL, V22, P1188, DOI 10.1200/JCO.2004.06.155; Baron U, 2007, EUR J IMMUNOL, V37, P2378, DOI 10.1002/eji.200737594; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Cesana GC, 2006, J CLIN ONCOL, V24, P1169, DOI 10.1200/JCO.2005.03.6830; de Lafaille MAC, 2009, IMMUNITY, V30, P626, DOI 10.1016/j.immuni.2009.05.002; Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038; Fontenot JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Huehn J, 2009, NAT REV IMMUNOL, V9, P83, DOI 10.1038/nri2474; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jacobs JFM, 2012, LANCET ONCOL, V13, pE32, DOI 10.1016/S1470-2045(11)70155-3; Jensen HK, 2009, CLIN CANCER RES, V15, P1052, DOI 10.1158/1078-0432.CCR-08-1296; Jiang Z, 2007, BIOINFORMATICS, V23, P306, DOI 10.1093/bioinformatics/btl599; Kauffmann Audrey, 2009, Bioinformatics, V25, P415, DOI 10.1093/bioinformatics/btn647; Liyanage UK, 2002, J IMMUNOL, V169, P2756, DOI 10.4049/jimmunol.169.5.2756; Motzer RJ, 2000, J CLIN ONCOL, V18, P1928, DOI 10.1200/JCO.2000.18.9.1928; Oberg HH, 2006, SCAND J IMMUNOL, V64, P353, DOI 10.1111/j.1365-3083.2006.01825.x; Onishi H, 2012, ANTICANCER RES, V32, P997; Pillai V, 2007, CLIN IMMUNOL, V123, P18, DOI 10.1016/j.clim.2006.10.014; Polansky JK, 2008, EUR J IMMUNOL, V38, P1654, DOI 10.1002/eji.200838105; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785; Schwaab T, 2009, CLIN CANCER RES, V15, P4986, DOI 10.1158/1078-0432.CCR-08-3240; Sehouli J, 2011, EPIGENETICS-US, V6, P236, DOI 10.4161/epi.6.2.13755; Showe MK, 2009, CANCER RES, V69, P9202, DOI 10.1158/0008-5472.CAN-09-1378; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tatsugami K, 2010, J INTERF CYTOK RES, V30, P43, DOI 10.1089/jir.2009.0014; Team RDC, 2010, R LANG ENV STAT COMP; Twine N, 2003, CANCER RES, P1; Wang Y, 2012, J CELL MOL MED, V16, P425, DOI 10.1111/j.1582-4934.2011.01437.x; Wieczorek G, 2009, CANCER RES, V69, P599, DOI 10.1158/0008-5472.CAN-08-2361; Wolf AM, 2003, CLIN CANCER RES, V9, P606; Wolf B, 2012, PLOS ONE; Yao X, 2012, BLOOD, V119, P5688, DOI 10.1182/blood-2011-10-386482; Yi HF, 2006, CELL MOL IMMUNOL, V3, P189; Ziegler SF, 2006, ANNU REV IMMUNOL, V24, P209, DOI 10.1146/annurev.immunol.24.021605.090547; Zorn E, 2006, BLOOD, V108, P1571, DOI 10.1182/blood-2006-02-004747; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586	41	12	16	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2012	7	10							e46600	10.1371/journal.pone.0046600	http://dx.doi.org/10.1371/journal.pone.0046600			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	030WJ	23118856	Green Submitted, Green Published, gold			2023-01-03	WOS:000310600500007
J	Sliva, D; Loganathan, J; Jiang, JH; Jedinak, A; Lamb, JG; Terry, C; Baldridge, LA; Adamec, J; Sandusky, GE; Dudhgaonkar, S				Sliva, Daniel; Loganathan, Jagadish; Jiang, Jiahua; Jedinak, Andrej; Lamb, John G.; Terry, Colin; Baldridge, Lee Ann; Adamec, Jiri; Sandusky, George E.; Dudhgaonkar, Shailesh			Mushroom Ganoderma lucidum Prevents Colitis-Associated Carcinogenesis in Mice	PLOS ONE			English	Article							DEXTRAN SULFATE SODIUM; ABERRANT CRYPT FOCI; WATER-SOLUBLE EXTRACT; REI-SHI MYCELIA; MALE ICR MICE; BREAST-CANCER; PRENEOPLASTIC LESIONS; COLORECTAL ADENOMA; CULTURED MEDIUM; COLON TUMORS	Background: Epidemiological studies suggest that mushroom intake is inversely correlated with gastric, gastrointestinal and breast cancers. We have recently demonstrated anticancer and anti-inflammatory activity of triterpene extract isolated from mushroom Ganoderma lucidum (GLT). The aim of the present study was to evaluate whether GLT prevents colitis-associated carcinogenesis in mice. Methods/Principal Findings: Colon carcinogenesis was induced by the food-borne carcinogen (2-Amino-1-methyl-6-phenylimidazol[4,5-b]pyridine [PhIP]) and inflammation (dextran sodium sulfate [DSS]) in mice. Mice were treated with 0, 100, 300 and 500 mg GLT/kg of body weight 3 times per week for 4 months. Cell proliferation, expression of cyclin D1 and COX-2 and macrophage infiltration was assessed by immunohistochemistry. The effect of GLT on XRE/AhR, PXR and rPXR was evaluated by the reporter gene assays. Expression of metabolizing enzymes CYP1A2, CYP3A1 and CYP3A4 in colon tissue was determined by immunohistochemistry. GLT treatment significantly suppressed focal hyperplasia, aberrant crypt foci (ACF) formation and tumor formation in mice exposed to PhIP/DSS. The anti-proliferative effects of GLT were further confirmed by the decreased staining with Ki-67 in colon tissues. PhIP/DSS-induced colon inflammation was demonstrated by the significant shortening of the large intestine and macrophage infiltrations, whereas GLT treatment prevented the shortening of colon lengths, and reduced infiltration of macrophages in colon tissue. GLT treatment also significantly down-regulated PhIP/DSS-dependent expression of cyclin D1, COX-2, CYP1A2 and CYP3A4 in colon tissue. Conclusions: Our data suggest that GLT could be considered as an alternative dietary approach for the prevention of colitisassociated cancer.	[Sliva, Daniel; Loganathan, Jagadish; Jiang, Jiahua; Jedinak, Andrej; Terry, Colin; Dudhgaonkar, Shailesh] Indiana Univ Hlth, Methodist Res Inst, Canc Res Lab, Indianapolis, IN USA; [Sliva, Daniel] Indiana Univ Sch Med, Dept Med, Indianapolis, IN USA; [Baldridge, Lee Ann; Sandusky, George E.] Indiana Univ Sch Med, Dept Pathol, Indianapolis, IN USA; [Sliva, Daniel] Indiana Univ Sch Med, Indiana Univ, Ctr Canc, Indianapolis, IN USA; [Lamb, John G.] Univ Utah, Dept Pharmacol & Toxicol, Salt Lake City, UT 84112 USA; [Adamec, Jiri] Purdue Univ, Bindley Biosci Ctr, W Lafayette, IN 47907 USA	Indiana University System; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University-Purdue University Indianapolis; Utah System of Higher Education; University of Utah; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Sliva, D (corresponding author), Indiana Univ Hlth, Methodist Res Inst, Canc Res Lab, Indianapolis, IN USA.	dsliva@iuhealth.org	Jedinak, Andrej/AAB-7354-2020		Purdue-UAB Botanicals Research Center [P50 AT00477]; National Center for Complementary and Alternative Medicine; National Institutes of Health Office of Dietary Supplements; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [P50AT000477] Funding Source: NIH RePORTER	Purdue-UAB Botanicals Research Center; National Center for Complementary and Alternative Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Institutes of Health Office of Dietary Supplements(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	This study was supported by the pilot grant to D.S. and J.A. from the Purdue-UAB Botanicals Research Center for age-related diseases (P50 AT00477, Connie M. Weaver, PI) from the National Center for Complementary and Alternative Medicine and the National Institutes of Health Office of Dietary Supplements. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamec J, 2009, J SEP SCI, V32, P4052, DOI 10.1002/jssc.200900496; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Bobek P, 2001, BRIT J BIOMED SCI, V58, P164; Borchers AT, 2008, EXP BIOL MED, V233, P259, DOI 10.3181/0708-MR-227; Cheung C, 2005, CHEM RES TOXICOL, V18, P1471, DOI 10.1021/tx050136g; Dudhgaonkar S, 2009, INT IMMUNOPHARMACOL, V9, P1272, DOI 10.1016/j.intimp.2009.07.011; Dutra RC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027122; Graham MJ, 2008, TOXICOLOGY, V254, P184, DOI 10.1016/j.tox.2008.09.002; Gupta AK, 2009, CURR OPIN GASTROEN, V25, P59, DOI 10.1097/MOG.0b013e32831db286; Hara M, 2003, NUTR CANCER, V46, P138, DOI 10.1207/S15327914NC4602_06; Hou XL, 2007, INT J PHARM, V337, P169, DOI 10.1016/j.ijpharm.2006.12.035; Hussain SP, 2007, INT J CANCER, V121, P2373, DOI 10.1002/ijc.23173; Ishikawa TO, 2011, CARCINOGENESIS, V32, P417, DOI 10.1093/carcin/bgq268; Ishikawa TO, 2010, CARCINOGENESIS, V31, P729, DOI 10.1093/carcin/bgq002; Islam MS, 2008, BRIT J PHARMACOL, V154, P812, DOI 10.1038/bjp.2008.137; Jiang JH, 2004, NUTR CANCER, V49, P209, DOI 10.1207/s15327914nc4902_13; Kikuchi Y, 1997, VIRCHOWS ARCH, V431, P111, DOI 10.1007/s004280050076; Kim HJ, 2002, INT J CANCER, V97, P531, DOI 10.1002/ijc.10111; Kimura Y, 2002, ANTICANCER RES, V22, P3309; Kuhnel D, 2009, ARCH TOXICOL, V83, P763, DOI 10.1007/s00204-009-0406-2; Langmann T, 2004, GASTROENTEROLOGY, V127, P26, DOI 10.1053/j.gastro.2004.04.019; Lu HM, 2002, INT J MOL MED, V9, P113; Lu HM, 2001, ONCOL REP, V8, P1341; Mabley JG, 2003, AM J PHYSIOL-GASTR L, V284, pG138, DOI 10.1152/ajpgi.00060.2002; Mattila P, 2000, NUTRITION, V16, P694, DOI 10.1016/S0899-9007(00)00341-5; Mori Y, 2005, MUTAGENESIS, V20, P15, DOI 10.1093/mutage/gei001; Nakagama H, 2005, CANCER SCI, V96, P627, DOI 10.1111/j.1349-7006.2005.00107.x; Nakanishi M, 2007, CANCER SCI, V98, P1157, DOI 10.1111/j.1349-7006.2007.00528.x; Nishikawa A, 2005, TOXICOL SCI, V84, P243, DOI 10.1093/toxsci/kfi079; OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016-5085(90)90290-H; Pascussi JM, 2008, ANNU REV PHARMACOL, V48, P1, DOI 10.1146/annurev.pharmtox.47.120505.105349; Rohrmann S, 2009, AM J CLIN NUTR, V89, P1418, DOI 10.3945/ajcn.2008.26658; Shan L, 2002, CARCINOGENESIS, V23, P1561, DOI 10.1093/carcin/23.10.1561; Shin A, 2010, NUTR CANCER, V62, P476, DOI 10.1080/01635580903441212; Sinha R, 2005, CANCER RES, V65, P8034, DOI 10.1158/0008-5472.CAN-04-3429; Sliva D, 2006, LEUKEMIA RES, V30, P767, DOI 10.1016/j.leukres.2005.12.015; Smina TP, 2011, ENVIRON TOXICOL PHAR, V32, P438, DOI 10.1016/j.etap.2011.08.011; Steffensen IL, 1997, CARCINOGENESIS, V18, P1049, DOI 10.1093/carcin/18.5.1049; Sugimura T, 2000, CARCINOGENESIS, V21, P387, DOI 10.1093/carcin/21.3.387; Tanaka T, 2005, CARCINOGENESIS, V26, P229, DOI 10.1093/carcin/bgh292; Tanaka Takuji, 2009, J Carcinog, V8, P5; van Hogezand RA, 2002, SCAND J GASTROENTERO, V37, P48, DOI 10.1080/003655202320621454; Vrekoussis T, 2009, ANTICANCER RES, V29, P4995; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421; Wang X, 2007, BIOL PHARM BULL, V30, P1702, DOI 10.1248/bpb.30.1702; WARD JM, 1974, LAB INVEST, V30, P505; Weng CJ, 2009, J AGR FOOD CHEM, V57, P5049, DOI 10.1021/jf900828k; World Cancer Research Fund & American Institute for Cancer Research, 2007, FOOD NUTR PHYS ACT P; Yang XX, 2010, AM J PATHOL, V176, P733, DOI 10.2353/ajpath.2010.090524; Zhang M, 2009, INT J CANCER, V124, P1404, DOI 10.1002/ijc.24047	51	51	51	1	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2012	7	10							e47873	10.1371/journal.pone.0047873	http://dx.doi.org/10.1371/journal.pone.0047873			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	032HJ	23118901	Green Published, gold			2023-01-03	WOS:000310705600018
J	Somasagara, RR; Hegde, M; Chiruvella, KK; Musini, A; Choudhary, B; Raghavan, SC				Somasagara, Ranganatha R.; Hegde, Mahesh; Chiruvella, Kishore K.; Musini, Anjaneyulu; Choudhary, Bibha; Raghavan, Sathees C.			Extracts of Strawberry Fruits Induce Intrinsic Pathway of Apoptosis in Breast Cancer Cells and Inhibits Tumor Progression in Mice	PLOS ONE			English	Article							TOTAL ANTIOXIDANT CAPACITY; LEUKEMIC-CELLS; PROTEIN; PREVENTION; VEGETABLES; P73; P53; PROLIFERATION; POLYPHENOLS; ACTIVATION	Background: The consumption of berry fruits, including strawberries, has been suggested to have beneficial effects against oxidative stress mediated diseases. Berries contain multiple phenolic compounds and secondary metabolites that contribute to their biological properties. Methodology/Principal Findings: Current study investigates the anticancer activity of the methanolic extract of strawberry (MESB) fruits in leukaemia (CEM) and breast cancer (T47D) cell lines ex vivo, and its cancer therapeutic and chemopreventive potential in mice models. Results of MTT, trypan blue and LDH assays suggested that MESB can induce cytotoxicity in cancer cells, irrespective of origin, in a concentration-and time-dependent manner. Treatment of mice bearing breast adenocarcinoma with MESB blocked the proliferation of tumor cells in a time-dependent manner and resulted in extended life span. Histological and immunohistochemical studies suggest that MESB treatment affected tumor cell proliferation by activating apoptosis and did not result in any side effects. Finally, we show that MESB can induce intrinsic pathway of apoptosis by activating p73 in breast cancer cells, when tumor suppressor gene p53 is mutated. Conclusions/Significance: The present study reveals that strawberry fruits possess both cancer preventive and therapeutic values and we discuss the mechanism by which it is achieved.	[Somasagara, Ranganatha R.; Hegde, Mahesh; Chiruvella, Kishore K.; Musini, Anjaneyulu; Raghavan, Sathees C.] Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India; [Choudhary, Bibha] IBAB, Bangalore, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Raghavan, SC (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	sathees@biochem.iisc.ernet.in	Chiruvella, Kishore Kumar/AAH-3131-2022; chiruvella, kishore k/I-2074-2014; Hegde, MahesH/ABE-2057-2020; Chiruvella, Kishore Kumar/AEU-8773-2022	chiruvella, kishore k/0000-0002-4997-5875; Hegde, MahesH/0000-0002-7853-6281; Chiruvella, Kishore Kumar/0000-0002-4997-5875	Indian Institute of Science, Bangalore, India; UGC Khothari postdoctoral fellowship programme, India	Indian Institute of Science, Bangalore, India; UGC Khothari postdoctoral fellowship programme, India	This study was supported by start-up grants from Indian Institute of Science, Bangalore, India for SCR. RSR is supported by UGC Khothari postdoctoral fellowship programme, India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ATTIA MAM, 1966, CANCER RES, V26, P1787; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; Boivin D, 2007, ANTICANCER RES, V27, P937; Chiruvella KK, 2012, J MOL BIOL, V417, P197, DOI 10.1016/j.jmb.2012.01.029; Chiruvella KK, 2008, FEBS LETT, V582, P4066, DOI 10.1016/j.febslet.2008.11.001; Clifford MN, 2000, J SCI FOOD AGR, V80, P1118, DOI [10.1002/(SICI)1097-0010(20000515)80:7<1118::AID-JSFA570>3.0.CO;2-9, 10.1002/(SICI)1097-0010(20000515)80:7&lt;1118::AID-JSFA570&gt;3.0.CO;2-9]; Conney AH, 2003, CANCER RES, V63, P7005; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; GERDES J, 1984, J IMMUNOL, V133, P1710; Hannum SM, 2004, CRIT REV FOOD SCI, V44, P1, DOI 10.1080/10408690490263756; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kavitha CV, 2009, BIOCHEM PHARMACOL, V77, P348, DOI 10.1016/j.bcp.2008.10.018; Kumagai H, 2004, CARCINOGENESIS, V25, P723, DOI 10.1093/carcin/bgh067; Kumar TS, 2010, J BIOL CHEM, V285, P32657, DOI 10.1074/jbc.M110.140350; Liu RH, 2004, J NUTR, V134, p3479S, DOI 10.1093/jn/134.12.3479S; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Meyers KJ, 2003, J AGR FOOD CHEM, V51, P6887, DOI 10.1021/jf034506n; Noaman E, 2008, CANCER LETT, V268, P348, DOI 10.1016/j.canlet.2008.04.012; Olsson ME, 2004, J AGR FOOD CHEM, V52, P2490, DOI 10.1021/jf030461e; Pink JJ, 1996, BRIT J CANCER, V74, P1227, DOI 10.1038/bjc.1996.521; Rijken PJ, 1999, CARCINOGENESIS, V20, P2267, DOI 10.1093/carcin/20.12.2267; Seeram NP, 2006, J AGR FOOD CHEM, V54, P9329, DOI 10.1021/jf061750g; Shahabuddin MS, 2011, INVEST NEW DRUG, V29, P523, DOI 10.1007/s10637-009-9379-5; Sharif T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032526; Sharif T, 2010, EUR J CANCER, V46, P983, DOI 10.1016/j.ejca.2009.12.029; Sharma S, 2012, MOL CARCINOG; Sharma S, 2011, CELL MOL LIFE SCI, V68, P661, DOI 10.1007/s00018-010-0472-x; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P325, DOI 10.1007/BF00051672; Steinmetz KA, 1996, J AM DIET ASSOC, V96, P1027, DOI 10.1016/S0002-8223(96)00273-8; Sun J, 2002, J AGR FOOD CHEM, V50, P7449, DOI 10.1021/jf0207530; VOJTESEK B, 1993, J CELL SCI, V105, P607; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Walter A, 2010, FASEB J, V24, P3360, DOI 10.1096/fj.09-149419; Wang H, 1996, J AGR FOOD CHEM, V44, P701, DOI 10.1021/jf950579y; Wang JYJ, 2005, CELL RES, V15, P43, DOI 10.1038/sj.cr.7290263; Wang SY, 2000, J AGR FOOD CHEM, V48, P5677, DOI 10.1021/jf000766i; Weaver J, 2009, INT J ONCOL, V34, P777, DOI 10.3892/ijo_00000203; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	40	76	77	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2012	7	10							e47021	10.1371/journal.pone.0047021	http://dx.doi.org/10.1371/journal.pone.0047021			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	054ZU	23071702	gold, Green Submitted, Green Published, Green Accepted			2023-01-03	WOS:000312385200069
J	Hoque, ME; Ghuman, S				Hoque, Muhammad Ehsanul; Ghuman, Shanaz			Knowledge, Practices, and Attitudes of Emergency Contraception among Female University Students in KwaZulu-Natal, South Africa	PLOS ONE			English	Article							LEVONORGESTREL; GHANA	Objective: The purpose of this study is to investigate the knowledge, practices, and attitudes among female university students in South Africa regarding emergency contraceptives (EC). Methods: A cross-sectional study was conducted among 582 female university students who were selected using multi-stage sampling techniques. Multivariate logistic regression analysis was used to find significant predictors for EC awareness. Results: The average age of the female students was 20.9 years (SD = 3.0) and 57.2% were presently sexually active. Overall, 49.8% of the participants reported having heard about EC prior to the study. Regarding sexual activities among the female students, 53.2% reported to have sex, and 21.2% of the sexually experienced students used EC prior to the study. Regarding the effectiveness of EC, 29.5% students said it could be used up to 72 hours after unprotected sexual intercourse, and 8% said it could be used just before sex. About two-thirds (61.8%) would recommend the use of EC and 63.2% would use it if they needed. The multivariate analysis indicated that students who were older (>20 years), presently sexually active, and living with their parents were more likely to be aware of EC (p<0.05). Conclusion: The students' knowledge and utilization of EC were low. Health education and promotion should be targeted towards these students, and the EC services should be offered on campus.	[Hoque, Muhammad Ehsanul] Univ Limpopo, Sch Hlth Care Sci, Dept Publ Hlth, Pretoria, South Africa; [Ghuman, Shanaz] Mangosuthu Univ Technol, Dept Environm Hlth, Durban, South Africa	University of Limpopo; Mangosuthu University of Technology	Hoque, ME (corresponding author), Univ Limpopo, Sch Hlth Care Sci, Dept Publ Hlth, Medunsa Campus, Pretoria, South Africa.	muhammad.ehsanul@gmail.com			Academic Board & Research & Ethics Committee of Mangosuthu University of Technology	Academic Board & Research & Ethics Committee of Mangosuthu University of Technology	The authors wish to acknowledge the Academic Board & Research & Ethics Committee of Mangosuthu University of Technology for supporting the study. Also acknowledge Mrs. Chetty for editing the manuscript.	Abasiattai A M, 2007, Niger J Clin Pract, V10, P30; Addo VN, 2009, INT J GYNECOL OBSTET, V105, P206, DOI 10.1016/j.ijgo.2009.01.008; Adhikari Ramesh, 2009, BMC Womens Health, V9, P27, DOI 10.1186/1472-6874-9-27; Akani Ci, 2008, Ghana Med J, V42, P68; Baiden F, 2002, CONTRACEPTION, V66, P23, DOI 10.1016/S0010-7824(02)00315-3; CHENG L, 2004, COCHRANE DB SYST REV, V3; Croxatto HB, 2004, CONTRACEPTION, V70, P442, DOI 10.1016/j.contraception.2004.05.007; Department of Health Republic of South Africa, 2001, S AFR DEM HLTH SURV; Ebuehi O M, 2006, East Afr Med J, V83, P90; Ellertson C, 2003, OBSTET GYNECOL, V101, P1168, DOI 10.1016/S0029-7844(03)00352-1; Gemzell-Danielsson K, 2004, HUM REPROD UPDATE, V10, P341, DOI 10.1093/humupd/dmh027; Grimes DA, 2002, ANN INTERN MED, V137, P180, DOI 10.7326/0003-4819-137-3-200208060-00010; Hariparsad N, 2001, EUR J CONTRACEP REPR, V6, P21; Hoque ME, 2011, GENDER BEHAV, V9, P3710; International Consortium for Emergency Contraception, 2004, EM CONTR PILLS; Jewkes R, 2002, SOC SCI MED, V55, P1231, DOI 10.1016/S0277-9536(01)00242-8; Kistnasamy EJ, 2009, S AFR FAM PRACT, V51, P423, DOI 10.1080/20786204.2009.10873896; Kongnyuy EJ, 2007, BMC EMERG MED, V7, DOI 10.1186/1471-227X-7-7; Makiwane M, 2010, DEV SO AFR, V27, P193, DOI 10.1080/03768351003740498; Morroni Chelsea, 2006, BMC Pregnancy Childbirth, V6, P26, DOI 10.1186/1471-2393-6-26; Morroni C, 2006, SAMJ S AFR MED J, V96, P620; Mqhayi Mmabatho Margaret, 2004, Afr J Reprod Health, V8, P137, DOI 10.2307/3583187; Myer Landon, 2007, BMC Womens Health, V7, P14, DOI 10.1186/1472-6874-7-14; Nworah JAO, 2010, INT J MED SCI, V2, P001; Roberts Candice, 2004, J Obstet Gynaecol, V24, P441, DOI 10.1080/01443610410001685619; Rodrigues I, 2001, AM J OBSTET GYNECOL, V184, P531, DOI 10.1067/mob.2001.111102; Tamire W., 2007, Ethiopian Journal of Health Development, V21, P111; Tapia-Curiel Amparo, 2008, Rev Med Inst Mex Seguro Soc, V46, P33; Vahratian A, 2008, J WOMENS HEALTH, V17, P103, DOI 10.1089/jwh.2007.0391	29	20	20	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2012	7	9							e46346	10.1371/journal.pone.0046346	http://dx.doi.org/10.1371/journal.pone.0046346			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	016KP	23050018	Green Published, Green Submitted, gold			2023-01-03	WOS:000309517300108
J	Milstone, AM; Elward, A; Song, XY; Zerr, DM; Orscheln, R; Speck, K; Obeng, D; Reich, NG; Coffin, SE; Perl, TM				Milstone, Aaron M.; Elward, Alexis; Song, Xiaoyan; Zerr, Danielle M.; Orscheln, Rachel; Speck, Kathleen; Obeng, Daniel; Reich, Nicholas G.; Coffin, Susan E.; Perl, Trish M.		Pediat SCRUB Trial Study Grp	Daily chlorhexidine bathing to reduce bacteraemia in critically ill children: a multicentre, cluster-randomised, crossover trial	LANCET			English	Article							BLOOD-STREAM INFECTIONS; INTENSIVE-CARE-UNIT; COAGULASE-NEGATIVE STAPHYLOCOCCI; HOSPITALIZED CHILDREN; RESOURCE UTILIZATION; CLINICAL IMPACT; SAFETY NETWORK; RISK; MORTALITY; CULTURES	Background Bacteraemia is an important cause of morbidity and mortality in critically ill children. Our objective was to assess whether daily bathing in chlorhexidine gluconate (CHG) compared with standard bathing practices would reduce bacteraemia in critically ill children. Methods In an unmasked, cluster-randomised, two-period crossover trial, ten paediatric intensive-care units at five hospitals in the USA were randomly assigned a daily bathing routine for admitted patients older than 2 months, either standard bathing practices or using a cloth impregnated with 2% CHG, for a 6-month period. Units switched to the alternative bathing method for a second 6-month period. 6482 admissions were screened for eligibility. The primary outcome was an episode of bacteraemia. We did intention-to-treat (ITT) and per-protocol (PP) analyses. This study is registered with ClinicalTrials.gov (identifier NCT00549393). Findings 1521 admitted patients were excluded because their length of stay was less than 2 days, and 14 refused to participate. 4947 admissions were eligible for analysis. In the ITT population, a non-significant reduction in incidence of bacteraemia was noted with CHG bathing (3.52 per 1000 days, 95% CI 2.64-4.61) compared with standard practices (4.93 per 1000 days, 3.91-6.15; adjusted incidence rate ratio [aIRR] 0.71, 95% CI 0.42-1.20). In the PP population, incidence of bacteraemia was lower in patients receiving CHG bathing (3.28 per 1000 days, 2.27-4.58) compared with standard practices (4.93 per 1000 days, 3.91-6.15; aIRR 0.64, 0.42-0.98). No serious study-related adverse events were recorded, and the incidence of CHG-associated skin reactions was 1.2 per 1000 days (95% CI 0.60-2.02). Interpretation Critically ill children receiving daily CHG bathing had a lower incidence of bacteraemia compared with those receiving a standard bathing routine. Furthermore, the treatment was well tolerated.	[Milstone, Aaron M.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Pediat Infect Dis, Baltimore, MD 21205 USA; [Speck, Kathleen; Perl, Trish M.] Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA; [Milstone, Aaron M.; Reich, Nicholas G.; Perl, Trish M.] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Obeng, Daniel] Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Elward, Alexis; Orscheln, Rachel] Washington Univ, Sch Med, Dept Pediat, Div Pediat Infect Dis, St Louis, MO 63110 USA; [Song, Xiaoyan] George Washington Univ, Med Ctr, Dept Pediat, Div Pediat Infect Dis, Washington, DC 20037 USA; [Zerr, Danielle M.] Univ Washington, Sch Med, Dept Pediat, Div Pediat Infect Dis, Seattle, WA 98195 USA; [Coffin, Susan E.] Univ Penn, Sch Med, Dept Pediat, Div Pediat Infect Dis, Philadelphia, PA 19104 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Washington University (WUSTL); George Washington University; University of Washington; University of Washington Seattle; University of Pennsylvania	Milstone, AM (corresponding author), JHU, Dept Pediat, Baltimore, MD 21287 USA.	amilsto1@jhmi.edu	Reich, Nicholas/L-1168-2019	Reich, Nicholas/0000-0003-3503-9899; Orscheln, Rachel/0000-0003-3865-2728; Milstone, Aaron/0000-0001-8498-8682	Sage Products; US National Institutes of Health; BioMerieux; Vioguard; Merck; Optimer Pharmaceuticals; NIH/NIAID [1 K23 AI081752]; National Center for Research Resources (NCRR), part of the National Institutes of Health (NIH) [UL1 RR 025005]; NIH Roadmap for Medical Research; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI081752] Funding Source: NIH RePORTER	Sage Products(General Electric); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); BioMerieux; Vioguard; Merck(Merck & Company); Optimer Pharmaceuticals; NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources (NCRR), part of the National Institutes of Health (NIH); NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Sage Products, US National Institutes of Health.; AMM, TMP, DMZ, SEC, XS, and AE have received grant support from Sage Products. Furthermore, AMM has received grant support from BioMerieux, DMZ has received grant support from Vioguard, TMP has received grant support from Merck and is on an advisory board for Pfizer and Hospira, and XS has received grant support from Optimer Pharmaceuticals. All other authors report no conflicts of interest.; This study was funded mainly by grants from Sage Products (to AE, XS, DMZ, SEC, and TMP), with additional funding from NIH/NIAID 1 K23 AI081752 (to AMM) and UL1 RR 025005 from the National Center for Research Resources (NCRR), part of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research. This research does not represent the official view of NCRR or NIH. We thank Evan Anderson (Northwestern University), Howard Lederman (Johns Hopkins University), the Johns Hopkins Biostatistics Center, Michael Climo (Medical College of Virginia), the intensive-care nurses at every site, and families and patients for their participation. Data were presented in part at the annual scientific meetings of the Society of Healthcare Epidemiology of America, held in Dallas, TX, USA, April, 2011 (abstract LB-14), and the Infectious Diseases Society of America, held in Boston, MA, USA, October, 2011 (abstract LB-36).	Advani S, 2011, CLIN INFECT DIS, V52, P1108, DOI 10.1093/cid/cir145; Armenian SH, 2005, PEDIATR INFECT DIS J, V24, P309, DOI 10.1097/01.inf.0000157086.97503.bd; BATES DW, 1991, JAMA-J AM MED ASSOC, V265, P365, DOI 10.1001/jama.265.3.365; Bleasdale SC, 2005, INT C ANT AG CHEM WA; Bleasdale SC, 2007, ARCH INTERN MED, V167, P2073, DOI 10.1001/archinte.167.19.2073; Climo M, 2007, 17 ANN SCI M SOC HEA; Derde LPG, 2012, INTENS CARE MED, V38, P931, DOI 10.1007/s00134-012-2542-z; Edwards JR, 2009, AM J INFECT CONTROL, V37, P783, DOI 10.1016/j.ajic.2009.10.001; Elward AM, 2005, PEDIATRICS, V115, P868, DOI 10.1542/peds.2004-0256; Favre B, 2005, INFECT CONT HOSP EP, V26, P697, DOI 10.1086/502605; Feudtner C, 2000, PEDIATRICS, V106, P205; Gray J, 2001, PEDIATR INFECT DIS J, V20, P416, DOI 10.1097/00006454-200104000-00009; Hidron AI, 2008, INFECT CONT HOSP EP, V29, P996, DOI 10.1086/591861; Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.2307/1390807; Krautheim AB, 2004, CONTACT DERMATITIS, V50, P113, DOI 10.1111/j.0105-1873.2004.00308.x; Lee A, 2011, INFECT CONT HOSP EP, V32, P395, DOI 10.1086/659154; Mermel LA, 2009, CLIN INFECT DIS, V49, P1, DOI 10.1086/599376; Miller MR, 2010, PEDIATRICS, V125, P206, DOI 10.1542/peds.2009-1382; Milstone AM, 2008, CLIN INFECT DIS, V46, P274, DOI 10.1086/524736; Niedner MF, 2011, INFECT CONT HOSP EP, V32, P1200, DOI 10.1086/662621; O'Horo JC, 2012, INFECT CONT HOSP EP, V33, P257, DOI 10.1086/664496; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; Schulman J, 2011, PEDIATRICS, V127, P436, DOI 10.1542/peds.2010-2873; Segal GS, 2000, ARCH PEDIAT ADOL MED, V154, P469, DOI 10.1001/archpedi.154.5.469; SHUMAN RM, 1974, PEDIATRICS, V54, P689; van der Heijden YF, 2011, INFECT CONT HOSP EP, V32, P623, DOI 10.1086/660096; Waltzman ML, 2001, CLIN INFECT DIS, V33, P296, DOI 10.1086/321881	30	130	128	0	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 30	2013	381	9872					1099	1106		10.1016/S0140-6736(12)61687-0	http://dx.doi.org/10.1016/S0140-6736(12)61687-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122WL	23363666	Green Accepted			2023-01-03	WOS:000317348900028
J	Chang, TI; Kang, EW; Lee, YK; Shin, SK				Chang, Tae Ik; Kang, Ea Wha; Lee, Yong Kyu; Shin, Sug Kyun			Higher Peritoneal Protein Clearance as a Risk Factor for Cardiovascular Disease in Peritoneal Dialysis Patient	PLOS ONE			English	Article							MEMBRANE-TRANSPORT STATUS; TECHNIQUE FAILURE; CAPACITY TEST; SURVIVAL; MORTALITY; ALBUMIN; HYPOALBUMINEMIA; NUTRITION; INFLAMMATION; SUPERIOR	Background and Aims: Although a number of studies have been published on peritoneal protein clearance (PrCl) and its association with patient outcomes, the results have been inconsistent. Therefore, the intent of this study was to evaluate the impact of PrCl on cardiovascular disease (CVD) and mortality in peritoneal dialysis (PD) patients. Methods: This prospective observational study included a total of 540 incident patients who started PD at NHIC Ilsan Hospital, Korea from January 2000 to December 2009. Two different types of analyses such as intention-to-treat and astreated were used. Results: Correlation analyses revealed that PrCl was positively correlated with diabetes, pulse pressure, C-reactive protein (CRP) level, dialysate/plasma creatinine ratio (D/P cr) at 4 h, and peritoneal Kt/V urea. PrCl was inversely correlated with serum albumin and triglyceride levels. On multivariate analysis, serum albumin, pulse pressure, D/P cr at 4 h, and peritoneal Kt/V urea were found to be independent determinants of PrCl. A total of 129 (23.9%) patients in intention-to-treat analysis and 117 (21.7%) patients in as-treated analysis developed new cardiovascular events. Time to occurrence of cardiovascular event was significantly longer in patients with a value of PrCl below the median (89.4 ml/day). In multivariate analysis, older age, presence of diabetes or previous CVD, and higher PrCl were independent predictors of cardiovascular events. Patients above the median value of PrCl had a significantly lower rate of survival than those below the median. However, a higher PrCl was not associated with increased mortality in multivariate Cox analysis. Conclusions: A higher PrCl is a risk for occurrence of cardiovascular event, but not mortality in PD patients. Large randomized clinical trials are warranted to confirm this finding.	[Chang, Tae Ik; Kang, Ea Wha; Lee, Yong Kyu; Shin, Sug Kyun] Ilsan Hosp, NHIC Med Ctr, Dept Internal Med, Goyangshi, Gyeonggi Do, South Korea	NHIS Ilsan Hospital	Shin, SK (corresponding author), Ilsan Hosp, NHIC Med Ctr, Dept Internal Med, Goyangshi, Gyeonggi Do, South Korea.	sskyun@hotmail.com		Lee, Yong Kyu/0000-0002-8262-601X				Balafa O, 2011, CLIN J AM SOC NEPHRO, V6, P561, DOI 10.2215/CJN.05540610; BLUMENKRANTZ MJ, 1981, KIDNEY INT, V19, P593, DOI 10.1038/ki.1981.57; Brimble KS, 2006, J AM SOC NEPHROL, V17, P2591, DOI 10.1681/ASN.2006030194; Churchill DN, 1996, J AM SOC NEPHROL, V7, P198; Churchill DN, 1998, J AM SOC NEPHROL, V9, P1285; de Mutsert R, 2009, J RENAL NUTR, V19, P127, DOI 10.1053/j.jrn.2008.08.003; Dukkipati R, 2009, SEMIN NEPHROL, V29, P39, DOI 10.1016/j.semnephrol.2008.10.006; Elsurer R, 2009, NEPHROLOGY, V14, P712, DOI 10.1111/j.1440-1797.2009.01103.x; Friedman AN, 2010, J AM SOC NEPHROL, V21, P223, DOI 10.1681/ASN.2009020213; Grassmann A, 2005, NEPHROL DIAL TRANSPL, V20, P2587, DOI 10.1093/ndt/gfi159; Han SH, 2012, NAT REV NEPHROL, V8, P163, DOI 10.1038/nrneph.2012.12; Heaf JG, 2005, NEPHROL DIAL TRANSPL, V20, P2194, DOI 10.1093/ndt/gfi008; Johnson DW, 2010, NEPHROL DIAL TRANSPL, V25, P1973, DOI 10.1093/ndt/gfp780; Kathuria P, 1997, PERITON DIALYSIS INT, V17, P449; Kaysen GA, 1998, J AM SOC NEPHROL, V9, P2368; KOPPLE JD, 1994, AM J KIDNEY DIS, V24, P1002, DOI 10.1016/S0272-6386(12)81075-4; Krediet RT, 2010, NAT REV NEPHROL, V6, P451, DOI 10.1038/nrneph.2010.68; Lee H, 2009, NEPHROLOGY CARLTON, V16, P656; Malone AF, 2010, PERITON DIALYSIS INT, V30, P265, DOI 10.3747/pdi.2010.00002; Margetts PJ, 2000, PERITON DIALYSIS INT, V20, P14; Nakamoto H, 2002, AM J KIDNEY DIS, V40, P1045, DOI 10.1053/ajkd.2002.36343; NOLPH KD, 1993, PERITON DIALYSIS INT, V13, P178; Oh KH, 2010, NEPHROL DIAL TRANSPL, V25, P1639, DOI 10.1093/ndt/gfp670; Pecoits R, 2002, NEPHROL DIAL TRANSPL, V17, P28, DOI 10.1093/ndt/17.suppl_11.28; Perl J, 2009, CLIN J AM SOC NEPHRO, V4, P1201, DOI 10.2215/CJN.01910309; Rippe B, 1993, Perit Dial Int, V13 Suppl 2, pS35; Rodrigues AS, 2006, NEPHROL DIAL TRANSPL, V21, P763, DOI 10.1093/ndt/gfi245; Rumpsfeld M, 2006, J AM SOC NEPHROL, V17, P271, DOI 10.1681/ASN.2005050566; Sanchez-Villanueva R, 2009, NEPHROL DIAL TRANSPL, V24, P1009, DOI 10.1093/ndt/gfn595; Szeto CC, 2005, PERITON DIALYSIS INT, V25, P445; Van Biesen W, 2006, CLIN J AM SOC NEPHRO, V1, P269, DOI 10.2215/CJN.00820805; Wang T, 1999, PERITON DIALYSIS INT, V19, P17; Weir MR, 2007, CLIN J AM SOC NEPHRO, V2, P581, DOI 10.2215/CJN.03190906; Wiggins KJ, 2007, NEPHROL DIAL TRANSPL, V22, P3005, DOI 10.1093/ndt/gfm324; Zoccali C, 2006, KIDNEY INT, V70, P26, DOI 10.1038/sj.ki.5000417	35	16	18	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2013	8	2							e56223	10.1371/journal.pone.0056223	http://dx.doi.org/10.1371/journal.pone.0056223			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104DM	23418538	Green Submitted, gold, Green Published			2023-01-03	WOS:000315970300130
J	Tamokou, JD; Chouna, JR; Fischer-Fodor, E; Chereches, G; Barbos, O; Damian, G; Benedec, D; Duma, M; Efouet, APN; Wabo, HK; Kuiate, JR; Mot, A; Silaghi-Dumitrescu, R				Tamokou, Jean de Dieu; Chouna, Jean Rodolphe; Fischer-Fodor, Eva; Chereches, Gabriela; Barbos, Otilia; Damian, Grigore; Benedec, Daniela; Duma, Mihaela; Efouet, Alango Pepin Nkeng; Wabo, Hippolyte Kamdem; Kuiate, Jules Roger; Mot, Augustin; Silaghi-Dumitrescu, Radu			Anticancer and Antimicrobial Activities of Some Antioxidant-Rich Cameroonian Medicinal Plants	PLOS ONE			English	Article							OVARIAN-CANCER CELLS; INDUCED APOPTOSIS; ANTILEUKEMIC XANTHONE; IN-VITRO; EXTRACTS; PSOROSPERMUM; PROLIFERATION; CONSTITUENTS; ASSAY; PEROXIDASE	Traditional remedies have a long-standing history in Cameroon and continue to provide useful and applicable tools for treating ailments. Here, the anticancer, antimicrobial and antioxidant activities of ten antioxidant-rich Cameroonian medicinal plants and of some of their isolated compounds are evaluated. The plant extracts were prepared by maceration in organic solvents. Fractionation of plant extract was performed by column chromatography and the structures of isolated compounds (emodin, 3-geranyloxyemodin, 2-geranylemodin) were confirmed spectroscopically. The antioxidant activity (AOA) was determined using the 1,1-diphenyl-2-picrylhydrazyl (DPPH) bleaching method, the trolox equivalent antioxidant capacity (TEAC), and the hemoglobin ascorbate peroxidase activity inhibition (HAPX) assays. The anticancer activity was evaluated against A431 squamous epidermal carcinoma, WM35 melanoma, A2780 ovary carcinoma and cisplatin-resistant A2780cis cells, using a direct colorimetric assay. The total phenolic content in the extracts was determined spectrophotometrically by the Folin-Ciocalteu method. Rumex abyssinicus showed the best AOA among the three assays employed. The AOA of emodin was significantly higher than that of 3-geranyloxyemodin and 2-geranylemodin for both TEAC and HAPX methods. The lowest IC50 values (i.e., highest cytotoxicity) were found for the extracts of Vismia laurentii, Psorospermum febrifugum, Pentadesma butyracea and Ficus asperifolia. The Ficus asperifolia and Psorospermum febrifugum extracts are selective against A2780cis ovary cells, a cell line which is resistant to the standard anticancer drug cisplatin. Emodin is more toxic compared to the whole extract, 3-geranyloxyemodin and 2-geranylemodin. Its selectivity against the platinum-resistant A2780cis cell line is highest. All of the extracts display antimicrobial activity, in some cases comparable to that of gentamycin.	[Tamokou, Jean de Dieu; Chouna, Jean Rodolphe; Mot, Augustin; Silaghi-Dumitrescu, Radu] Univ Babes Bolyai, Dept Chem & Chem Engn, R-3400 Cluj Napoca, Romania; [Fischer-Fodor, Eva; Chereches, Gabriela; Barbos, Otilia] I Chiricuta Oncol Inst, Tumor Biol Lab, Cluj Napoca, Romania; [Damian, Grigore] Univ Babes Bolyai, Dept Phys, R-3400 Cluj Napoca, Romania; [Benedec, Daniela] Iuliu Hatieganu Univ Med & Pharm, Fac Pharm, Cluj Napoca, Romania; [Duma, Mihaela] State Vet Lab Anim Hlth & Safety, Cluj Napoca, Romania; [Tamokou, Jean de Dieu; Kuiate, Jules Roger] Univ Dschang, Dept Biochem, Dschang, Cameroon; [Chouna, Jean Rodolphe; Efouet, Alango Pepin Nkeng; Wabo, Hippolyte Kamdem] Univ Dschang, Dept Chem, Dschang, Cameroon	Babes Bolyai University from Cluj; Oncology Institute Prof. Dr. Ion Chiricuta; Babes Bolyai University from Cluj; Iuliu Hatieganu University of Medicine & Pharmacy	Mot, A (corresponding author), Univ Babes Bolyai, Dept Chem & Chem Engn, R-3400 Cluj Napoca, Romania.	augustinmot@chem.ubbcluj.ro; rsilaghi@chem.ubbcluj.ro	Mot, Augustin C./D-3017-2011; Mot, Augustin/AAP-4356-2021; Silaghi-Dumitrescu, Radu/A-2883-2008; Fischer-Fodor, Eva/C-4506-2011; DAMIAN, Grigore/B-6010-2011	Mot, Augustin C./0000-0002-1679-0487; Mot, Augustin/0000-0002-1679-0487; Silaghi-Dumitrescu, Radu/0000-0003-3038-7747; Fischer-Fodor, Eva/0000-0002-0898-0547; DAMIAN, Grigore/0000-0003-4127-8140; TAMOKOU, Jean de Dieu/0000-0002-8088-463X	Agence Universitaire de la Francophonie (AUF); Romanian Ministry of Education and Research; Romanian Ministry for Education and Research [PCCE 140/2008, POSDRU/88/1.5/S/60185]	Agence Universitaire de la Francophonie (AUF); Romanian Ministry of Education and Research(Ministry of Education and Research - Romania); Romanian Ministry for Education and Research(Ministry of Education and Research - Romania)	JDT acknowledges funding from the Agence Universitaire de la Francophonie (AUF) and the Romanian Ministry of Education and Research through their Eugen-Ionescu fellowship grant. Also acknowledged is funding from the Romanian Ministry for Education and Research grant PCCE 140/2008 (to RSD and EFF) and a PhD scholarship from Contract POSDRU/88/1.5/S/60185-"Innovative doctoral studies in a knowledge based society'' (to ACM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbiw D., 1990, USEFUL PLANTS GHANA, P182; Annan K, 2008, J ETHNOPHARMACOL, V119, P141, DOI 10.1016/j.jep.2008.06.017; Annan K, 2010, J PHARM PHARMACOL, V62, P663, DOI 10.1211/jpp.62.05.0016; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; Bamps P, 1966, JARD BOT N AT BRUXEL, V36, P315; BEHRENS BC, 1987, CANCER RES, V47, P414; BOTTA B, 1985, PHYTOCHEMISTRY, V24, P827, DOI 10.1016/S0031-9422(00)84902-X; BOTTA B, 1983, PHYTOCHEMISTRY, V22, P539, DOI 10.1016/0031-9422(83)83041-6; BRAND-WILLIAMS W, 1995, FOOD SCI TECHNOL-LEB, V28, P25; Cooper CE, 2008, BBA-PROTEINS PROTEOM, V1784, P1415, DOI 10.1016/j.bbapap.2008.03.019; Cos P, 2002, PHYTOMEDICINE, V9, P62, DOI 10.1078/0944-7113-00083; Fankam AG, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-104; Foyet HS, 2011, J ETHNOPHARMACOL, V133, P773, DOI 10.1016/j.jep.2010.11.011; Getie M, 2003, FITOTERAPIA, V74, P139, DOI 10.1016/S0367-326X(02)00315-5; Hritcu L, 2011, J ETHNOPHARMACOL, V137, P585, DOI 10.1016/j.jep.2011.06.008; ISO, 2005, ISO145021; Jagetia GC, 2004, J MED FOOD, V7, P343, DOI 10.1089/jmf.2004.7.343; Jimoh FO, 2007, J MED FOOD, V10, P707, DOI 10.1089/jmf.2006.253; Karasic TB, 2010, EXP CELL RES, V316, P1994, DOI 10.1016/j.yexcr.2010.04.014; Kerharo J., 1974, PHARMACOPEE SENEGALA; Khan RM, 1999, PHYTOCHEMISTRY, V50, P439, DOI 10.1016/S0031-9422(98)00478-6; Khare C.P., 2007, INDIAN MED PLANTS AN; Kisangau DP, 2007, AFR J TRADIT COMPLEM, V4, P510; Kofi A, 2009, PHARMACOGN MAG, V5, P119; KOUDOU J, 1994, PLANTA MED, V60, P96, DOI 10.1055/s-2006-959422; Koyama J, 2008, BIOORG MED CHEM LETT, V18, P4106, DOI 10.1016/j.bmcl.2008.05.109; Krishna M.S., 2010, INT J PHARM SCI DRUG, V2, P155; Kuete V, 2007, J ETHNOPHARMACOL, V109, P372, DOI 10.1016/j.jep.2006.07.044; Kuete V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021762; KUPCHAN SM, 1980, J NAT PROD, V43, P296, DOI 10.1021/np50008a010; Lacret R, 2011, J CHEM ECOL, V37, P1341, DOI 10.1007/s10886-011-0048-8; Lad L, 2002, EUR J BIOCHEM, V269, P3182, DOI 10.1046/j.1432-1033.2002.02998.x; Lazar-Molnar E, 2002, EUR J CLIN INVEST, V32, P743, DOI 10.1046/j.1365-2362.2002.01020.x; Lenta BN, 2011, PLANTA MED, V77, P377, DOI 10.1055/s-0030-1250384; Li J, 2009, ONCOL REP, V21, P1605, DOI 10.3892/or_00000394; Liu DL, 2012, INT J ONCOL, V40, P1049, DOI 10.3892/ijo.2011.1285; MAHATO SB, 1994, PHYTOCHEMISTRY, V37, P1517, DOI 10.1016/S0031-9422(00)89569-2; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mot AC, 2012, PROCESS BIOCHEM, V47, P968, DOI 10.1016/j.procbio.2012.03.006; Mot AC, 2011, J FOOD COMPOS ANAL, V24, P516, DOI 10.1016/j.jfca.2010.11.006; Mot AC, 2009, REDOX REP, V14, P267, DOI 10.1179/135100009X12525712409814; Muscolini M, 2011, J BIOL CHEM, V286, P39693, DOI 10.1074/jbc.M111.279539; Muscolini M, 2009, CELL CYCLE, V8, P3396, DOI 10.4161/cc.8.20.9910; Neamatallah A, 2005, LETT APPL MICROBIOL, V41, P94, DOI 10.1111/j.1472-765X.2005.01680.x; Nguemeving JR, 2006, PHYTOCHEMISTRY, V67, P1341, DOI 10.1016/j.phytochem.2006.03.018; Noungoue DT, 2009, Z NATURFORSCH C, V64, P210; Noungoue DT, 2008, PHYTOCHEMISTRY, V69, P1024, DOI 10.1016/j.phytochem.2007.10.026; Ok S, 2012, IMMUNOPHARM IMMUNOT, V34, P768, DOI 10.3109/08923973.2012.654494; Perde-Schrepler M, 2011, J ENVIRON PATHOL TOX, V30, P323, DOI 10.1615/JEnvironPatholToxicolOncol.v30.i4.50; PERMANA PA, 1994, CANCER RES, V54, P3191; Pietta P, 1998, J AGR FOOD CHEM, V46, P4487, DOI 10.1021/jf980310p; Rao K. N. V., 2011, Hygeia - Journal for Drugs and Medicine, V3, P76; REEVES DS, 1983, PRINCIPLES METHODS A, P140; RICEEVANS C, 1994, METHOD ENZYMOL, V234, P279; Singleton VL, 1999, METHOD ENZYMOL, V299, P152; Sinsin Brice, 2003, Cahiers Agricultures, V12, P75; Su YJ, 2010, MOL PHARMACOL, V77, P633, DOI 10.1124/mol.109.061887; Suboj P, 2012, PHARMACOLOGY, V89, P91, DOI 10.1159/000335659; Tchobo FP, 2007, J AM OIL CHEM SOC, V84, P755, DOI 10.1007/s11746-007-1102-0; Tsaffack M, 2009, CHEM PHARM BULL, V57, P1113, DOI 10.1248/cpb.57.1113; Uphof J.C.T, 1968, DICT EC PLANTS; Virag P, 2009, TOXICOL IND HEALTH, V25, P253, DOI 10.1177/0748233709103411; Vorauer K, 1996, J BIOCHEM BIOPH METH, V32, P85, DOI 10.1016/0165-022X(96)00002-4; Wabo HK, 2007, CHEM PHARM BULL, V55, P1640, DOI 10.1248/cpb.55.1640; Wang XD, 2007, BIOL PHARM BULL, V30, P1113, DOI 10.1248/bpb.30.1113; Watcho P, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep221; Watt JM, 1962, MED POISONOUS PLANTS, P494; Wright CW., 2007, J SCI TECHNOL GHANA, V27, P16; Yan XJ, 2006, GYNECOL ONCOL, V102, P348, DOI 10.1016/j.ygyno.2005.12.033; Zamble A, 2006, J CARDIOVASC PHARM, V47, P599, DOI 10.1097/01.fjc.0000211734.53798.1d; Zelefack F, 2009, J NAT PROD, V72, P954, DOI 10.1021/np8005953	75	45	45	0	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 11	2013	8	2							e55880	10.1371/journal.pone.0055880	http://dx.doi.org/10.1371/journal.pone.0055880			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	092DU	23409075	Green Published, gold			2023-01-03	WOS:000315100000029
J	McLaughlin, MF; Woodward, J; Boll, RA; Wall, JS; Rondinone, AJ; Kennel, SJ; Mirzadeh, S; Robertson, JD				McLaughlin, Mark F.; Woodward, Jonathan; Boll, Rose A.; Wall, Jonathan S.; Rondinone, Adam J.; Kennel, Stephen J.; Mirzadeh, Saed; Robertson, J. David			Gold Coated Lanthanide Phosphate Nanoparticles for Targeted Alpha Generator Radiotherapy	PLOS ONE			English	Article							RADIOIMMUNOTHERAPY; THERAPY; FATE	Targeted radiotherapies maximize cytotoxicty to cancer cells. In vivo a-generator targeted radiotherapies can deliver multiple alpha particles to a receptor site dramatically amplifying the radiation dose delivered to the target. The major challenge with alpha-generator radiotherapies is that traditional chelating moieties are unable to sequester the radioactive daughters in the bioconjugate which is critical to minimize toxicity to healthy, non-target tissue. The recoil energy of the Ac-225 daughters following alpha decay will sever any metal-ligand bond used to form the bioconjugate. This work demonstrates that an engineered multilayered nanoparticle-antibody conjugate can deliver multiple alpha radiations and contain the decay daughters of Ac-225 while targeting biologically relevant receptors in a female BALB/c mouse model. These multi-shell nanoparticles combine the radiation resistance of lanthanide phosphate to contain Ac-225 and its radioactive decay daughters, the magnetic properties of gadolinium phosphate for easy separation, and established gold chemistry for attachment of targeting moieties.	[McLaughlin, Mark F.; Robertson, J. David] Univ Missouri, Dept Chem, Columbia, MO 65211 USA; [McLaughlin, Mark F.; Robertson, J. David] Univ Missouri, Univ Missouri Res Reactor, Columbia, MO USA; [McLaughlin, Mark F.; Woodward, Jonathan; Boll, Rose A.; Rondinone, Adam J.; Mirzadeh, Saed] Oak Ridge Natl Lab, Oak Ridge, TN USA; [Wall, Jonathan S.; Kennel, Stephen J.] Univ Tennessee, Grad Sch Med, Knoxville, TN USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Health Science Center	Robertson, JD (corresponding author), Univ Missouri, Dept Chem, Columbia, MO 65211 USA.	robertsonjo@missouri.edu	Rondinone, Adam J/F-6489-2013; Boll, Rose/C-4138-2016	Rondinone, Adam J/0000-0003-0020-4612; Boll, Rose/0000-0003-2507-4834; Robertson, John/0000-0002-6675-8469; Wall, Jonathan/0000-0002-5516-8578	Isotope Production/Distribution Program; Office of Nuclear Physics of the U. S. Department of Energy (DOE); DOE Nuclear Energy University Program Graduate Fellowship; University of Tennessee; Graduate School of Medicine; Center for Nanophase Materials Sciences, which is sponsored at Oak Ridge National Laboratory by the Office of Basic Energy Sciences, U.S. Department of Energy; ORNL is managed by UT-Battelle, LLC, for the U.S. Department of energy [DE-AC05-00OR22725]	Isotope Production/Distribution Program; Office of Nuclear Physics of the U. S. Department of Energy (DOE)(United States Department of Energy (DOE)); DOE Nuclear Energy University Program Graduate Fellowship; University of Tennessee; Graduate School of Medicine; Center for Nanophase Materials Sciences, which is sponsored at Oak Ridge National Laboratory by the Office of Basic Energy Sciences, U.S. Department of Energy; ORNL is managed by UT-Battelle, LLC, for the U.S. Department of energy(United States Department of Energy (DOE))	Research supported in part by the Isotope Production/Distribution Program, Office of Nuclear Physics of the U. S. Department of Energy (DOE), and under a DOE Nuclear Energy University Program Graduate Fellowship. The work was also supported by the University of Tennessee, Graduate School of Medicine through funding of the cancer imaging and tracer development program. A portion of this research was conducted at the Center for Nanophase Materials Sciences, which is sponsored at Oak Ridge National Laboratory by the Office of Basic Energy Sciences, U.S. Department of Energy. ORNL is managed by UT-Battelle, LLC, for the U.S. Department of energy under contract DE-AC05-00OR22725. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2011, FDA GRANTS FAST TRAC; Bruland OS, 2006, CLIN CANCER RES, V12, p6250S, DOI 10.1158/1078-0432.CCR-06-0841; Buissette V, 2006, J MATER CHEM, V16, P529, DOI 10.1039/b508656f; Burdick M.J., 2010, DRUG DISC TODAY THER, V7, P23; Essler M, 2012, EUR J NUCL MED MOL I, V39, P602, DOI 10.1007/s00259-011-2023-6; EWING RC, 1975, AM MINERAL, V60, P728; Gadbois DM, 1996, RADIAT RES, V146, P414, DOI 10.2307/3579303; Hall EJ, RADIOBIOLOGY RADIOLO, V7th; Hifumi H, 2009, J MATER CHEM, V19, P6393, DOI 10.1039/b902134e; HUMM JL, 1986, J NUCL MED, V27, P1490; Jacene HA, 2007, J NUCL MED, V48, P1767, DOI 10.2967/jnumed.107.043489; Jaggi JS, 2005, CANCER RES, V65, P4888; KAMPF G, 1988, Radiobiologia Radiotherapia, V29, P631; KARIORIS FG, 1981, RADIAT EFF LETT, V58, P1, DOI 10.1080/01422448108226520; Kennel SJ, 2008, NUCL MED BIOL, V35, P501, DOI 10.1016/j.nucmedbio.2008.02.001; Kennel Stephen J., 2010, Current Drug Delivery, V7, P428; Kim YS, 2012, TUMOR BIOL, V33, P573, DOI 10.1007/s13277-011-0286-y; KOLSKY KL, 1993, APPL RADIAT ISOTOPES, V44, P553, DOI 10.1016/0969-8043(93)90169-B; Lasbury ME, 2006, J IMMUNOL, V176, P6443, DOI 10.4049/jimmunol.176.11.6443; McDevitt MR, 1998, EUR J NUCL MED, V25, P1341, DOI 10.1007/s002590050306; McDevitt MR, 2001, SCIENCE, V294, P1537, DOI 10.1126/science.1064126; Meiser F, 2004, ANGEW CHEM INT EDIT, V43, P5954, DOI 10.1002/anie.200460856; Milenic DE, 2004, NAT REV DRUG DISCOV, V3, P488, DOI 10.1038/nrd1413; MIRZADEH S, 1993, RADIOCHIM ACTA, V60, P1; Mulford DA, 2005, J NUCL MED, V46, p199S; Schwartz J, 2011, PHYS MED BIOL, V56, P721, DOI 10.1088/0031-9155/56/3/012; Sofou S, 2004, J NUCL MED, V45, P253; Song H, 2009, CANCER RES, V69, P8941, DOI 10.1158/0008-5472.CAN-09-1828; TABUTEAU A, 1988, J MATER SCI LETT, V7, P1315, DOI 10.1007/BF00719969; van Vlerken LE, 2007, PHARM RES-DORDR, V24, P1405, DOI 10.1007/s11095-007-9284-6; VANROOIJEN N, 1989, J IMMUNOL METHODS, V124, P1, DOI 10.1016/0022-1759(89)90178-6; Woodward J, 2011, BIOCONJUGATE CHEM, V22, P766, DOI 10.1021/bc100574f; Woodward JD, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/17/175103; Zalutsky MR, 2004, Q J NUCL MED MOL IM, V48, P289	34	94	97	1	63	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 18	2013	8	1							e54531	10.1371/journal.pone.0054531	http://dx.doi.org/10.1371/journal.pone.0054531			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	075GQ	23349921	Green Published, gold, Green Submitted			2023-01-03	WOS:000313872800061
J	Westphal, CH; Chandra, SS				Westphal, Christopher H.; Chandra, Sreeganga S.			Monomeric Synucleins Generate Membrane Curvature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; MICE LACKING; SECONDARY STRUCTURE; SYNAPTIC VESICLES; GAMMA-SYNUCLEIN; LIPID VESICLES; CSP-ALPHA; BINDING; MUTATION	Synucleins are a family of presynaptic membrane binding proteins. alpha-Synuclein, the principal member of this family, is mutated in familial Parkinson disease. To gain insight into the molecular functions of synucleins, we performed an unbiased proteomic screen and identified synaptic protein changes in alpha beta gamma-synuclein knock-out brains. We observed increases in the levels of select membrane curvature sensing/generating proteins. One of the most prominent changes was for the N-BAR protein endophilin A1. Here we demonstrate that the levels of synucleins and endophilin A1 are reciprocally regulated and that they are functionally related. We show that all synucleins can robustly generate membrane curvature similar to endophilins. However, only monomeric but not tetrameric alpha-synuclein can bend membranes. Further, A30P alpha-synuclein, a Parkinson disease mutant that disrupts protein folding, is also deficient in this activity. This suggests that synucleins generate membrane curvature through the asymmetric insertion of their N-terminal amphipathic helix. Based on our findings, we propose to include synucleins in the class of amphipathic helix-containing proteins that sense and generate membrane curvature. These results advance our understanding of the physiological function of synucleins.	[Chandra, Sreeganga S.] Yale Univ, Dept Neurol, Program Cellular Neurosci Neurodegenerat & Repair, New Haven, CT 06536 USA; [Westphal, Christopher H.] Yale Univ, Dept Cell Biol, New Haven, CT 06536 USA; [Chandra, Sreeganga S.] Yale Univ, Dept Mol Cell & Dev Biol, New Haven, CT 06536 USA	Yale University; Yale University; Yale University	Chandra, SS (corresponding author), Yale Univ, Dept Neurol, Program Cellular Neurosci Neurodegenerat & Repair, 295 Congress Ave, New Haven, CT 06536 USA.	sreeganga.chandra@yale.edu			National Institutes of Health [R01 NS064963, T32GM7223]; Bumpus Foundation; Anonymous Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007223] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS064963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P30DA018343] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bumpus Foundation; Anonymous Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported, in whole or in part, by grants from the National Institutes of Health (R01 NS064963), the Bumpus Foundation, and an Anonymous Foundation grant (to S. S. C.). The proteomics was done with the support of the Yale Keck NIDA Neuroproteomic Center (P30 DA018343).; Supported in part by NIH Grant T32GM7223.	Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Anwar S, 2011, J NEUROSCI, V31, P7264, DOI 10.1523/JNEUROSCI.6194-10.2011; Bartels T, 2011, NATURE, V477, P107, DOI 10.1038/nature10324; Blondeau F, 2004, P NATL ACAD SCI USA, V101, P3833, DOI 10.1073/pnas.0308186101; Burre J, 2010, SCIENCE, V329, P1663, DOI 10.1126/science.1195227; Cabin DE, 2002, J NEUROSCI, V22, P8797; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; Chandra S, 2005, CELL, V123, P383, DOI 10.1016/j.cell.2005.09.028; Choi W, 2004, FEBS LETT, V576, P363, DOI 10.1016/j.febslet.2004.09.038; Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.3.CO;2-5; Davalos A, 2010, MOL CELL PROTEOMICS, V9, P2109, DOI 10.1074/mcp.M110.001289; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; Drescher M, 2012, CHEMBIOCHEM, V13, P761, DOI 10.1002/cbic.201200059; Drin G, 2010, FEBS LETT, V584, P1840, DOI 10.1016/j.febslet.2009.10.022; Farrer M, 2004, ANN NEUROL, V55, P174, DOI 10.1002/ana.10846; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Fauvet B, 2012, J BIOL CHEM, V287, P15345, DOI 10.1074/jbc.M111.318949; Fernandez-Busnadiego R, 2011, J ELECTRON MICROSC, V60, pS137, DOI 10.1093/jmicro/dfr018; Ferreon ACM, 2009, P NATL ACAD SCI USA, V106, P5645, DOI 10.1073/pnas.0809232106; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Gallop JL, 2006, EMBO J, V25, P2898, DOI 10.1038/sj.emboj.7601174; Gaugler MN, 2012, ACTA NEUROPATHOL, V123, P653, DOI 10.1007/s00401-012-0963-y; Greten-Harrison B, 2010, P NATL ACAD SCI USA, V107, P19573, DOI 10.1073/pnas.1005005107; Haucke V, 2011, NAT REV NEUROSCI, V12, P127, DOI 10.1038/nrn2948; Henne WM, 2007, STRUCTURE, V15, P839, DOI 10.1016/j.str.2007.05.002; Hosaka M, 1999, NEURON, V24, P377, DOI 10.1016/S0896-6273(00)80851-X; Hui EF, 2009, CELL, V138, P709, DOI 10.1016/j.cell.2009.05.049; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Itoh T, 2005, DEV CELL, V9, P791, DOI 10.1016/j.devcel.2005.11.005; JAHN R, 1993, J NEUROCHEM, V61, P12, DOI 10.1111/j.1471-4159.1993.tb03533.x; Jao CC, 2004, P NATL ACAD SCI USA, V101, P8331, DOI 10.1073/pnas.0400553101; Jao CC, 2008, P NATL ACAD SCI USA, V105, P19666, DOI 10.1073/pnas.0807826105; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jo EJ, 2002, J MOL BIOL, V315, P799, DOI 10.1006/jmbi.2001.5269; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; McMahon HT, 2010, CELL, V140, P601, DOI 10.1016/j.cell.2010.02.017; Middleton ER, 2010, BIOPHYS J, V99, P2279, DOI 10.1016/j.bpj.2010.07.056; Miller DW, 2004, NEUROLOGY, V62, P1835, DOI 10.1212/01.WNL.0000127517.33208.F4; Mim C, 2012, CELL, V149, P137, DOI 10.1016/j.cell.2012.01.048; Mizuno N, 2012, J BIOL CHEM, V287, P29301, DOI 10.1074/jbc.M112.365817; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Nakajo S, 1996, BRAIN RES, V741, P180, DOI 10.1016/S0006-8993(96)00914-6; Nemani VM, 2010, NEURON, V65, P66, DOI 10.1016/j.neuron.2009.12.023; Oling F, 2000, J MOL BIOL, V304, P561, DOI 10.1006/jmbi.2000.4183; Pandey AP, 2011, J PHYS CHEM B, V115, P5886, DOI 10.1021/jp1121917; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pranke IM, 2011, J CELL BIOL, V194, P88, DOI 10.1083/jcb.201011118; Satake W, 2009, NAT GENET, V41, P1303, DOI 10.1038/ng.485; Shilov IV, 2007, MOL CELL PROTEOMICS, V6, P1638, DOI 10.1074/mcp.T600050-MCP200; Simon-Sanchez J, 2009, NAT GENET, V41, P1308, DOI 10.1038/ng.487; Sorre B, 2012, P NATL ACAD SCI USA, V109, P173, DOI 10.1073/pnas.1103594108; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Sung YH, 2006, PROTEIN SCI, V15, P1162, DOI 10.1110/ps.051803606; Takamori S, 2006, CELL, V127, P831, DOI 10.1016/j.cell.2006.10.030; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Tannu NS, 2006, PROG BRAIN RES, V158, P41, DOI 10.1016/S0079-6123(06)58003-3; Ulmer TS, 2005, J BIOL CHEM, V280, P43179, DOI 10.1074/jbc.M507624200; Ulmer TS, 2005, J BIOL CHEM, V280, P9595, DOI 10.1074/jbc.M411805200; Varkey J, 2010, J BIOL CHEM, V285, P32486, DOI 10.1074/jbc.M110.139576; Wang WJ, 2011, APPL CATAL B-ENVIRON, V108, P108, DOI 10.1016/j.apcatb.2011.08.015; Wu Terence L., 2006, V328, P71; Yoon Y, 2010, J BIOL CHEM, V285, P531, DOI 10.1074/jbc.M109.068015; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zhang YQ, 2012, NEURON, V74, P136, DOI 10.1016/j.neuron.2012.01.029	65	127	128	0	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2013	288	3					1829	1840		10.1074/jbc.M112.418871	http://dx.doi.org/10.1074/jbc.M112.418871			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	073OC	23184946	Green Published, hybrid			2023-01-03	WOS:000313751400038
J	Xuan, WJ; Vatansever, F; Huang, LY; Wu, QH; Xuan, Y; Dai, TH; Ando, T; Xu, T; Huang, YY; Hamblin, MR				Xuan, Weijun; Vatansever, Fatma; Huang, Liyi; Wu, Qiuhe; Xuan, Yi; Dai, Tianhong; Ando, Takahiro; Xu, Tao; Huang, Ying-Ying; Hamblin, Michael R.			Transcranial Low-Level Laser Therapy Improves Neurological Performance in Traumatic Brain Injury in Mice: Effect of Treatment Repetition Regimen	PLOS ONE			English	Article							BIPHASIC DOSE-RESPONSE; ACUTE ISCHEMIC-STROKE; LIGHT THERAPY; FLUORO-JADE; ADULT BRAIN; NEURONAL DEGENERATION; SUBVENTRICULAR ZONE; STEM-CELLS; DEFICITS; NEUROGENESIS	Low-level laser (light) therapy (LLLT) has been clinically applied around the world for a spectrum of disorders requiring healing, regeneration and prevention of tissue death. One area that is attracting growing interest in this scope is the use of transcranial LLLT to treat stroke and traumatic brain injury (TBI). We developed a mouse model of severe TBI induced by controlled cortical impact and explored the effect of different treatment schedules. Adult male BALB/c mice were divided into 3 broad groups (a) sham-TBI sham-treatment, (b) real-TBI sham-treatment, and (c) real-TBI active-treatment. Mice received active-treatment (transcranial LLLT by continuous wave 810 nm laser, 25 mW/cm(2), 18 J/cm(2), spot diameter 1 cm) while sham-treatment was immobilization only, delivered either as a single treatment at 4 hours post TBI, as 3 daily treatments commencing at 4 hours post TBI or as 14 daily treatments. Mice were sacrificed at 0, 4, 7, 14 and 28 days post-TBI for histology or histomorphometry, and injected with bromodeoxyuridine (BrdU) at days 21-27 to allow identification of proliferating cells. Mice with severe TBI treated with 1-laser Tx (and to a greater extent 3-laser Tx) had significant improvements in neurological severity score (NSS), and wire-grip and motion test (WGMT). However 14-laser Tx provided no benefit over TBI-sham control. Mice receiving 1-and 3-laser Tx had smaller lesion size at 28-days (although the size increased over 4 weeks in all TBI-groups) and less Fluoro-Jade staining for degenerating neurons (at 14 days) than in TBI control and 14-laser Tx groups. There were more BrdU-positive cells in the lesion in 1-and 3-laser groups suggesting LLLT may increase neurogenesis. Transcranial NIR laser may provide benefit in cases of acute TBI provided the optimum treatment regimen is employed.	[Xuan, Weijun; Vatansever, Fatma; Huang, Liyi; Wu, Qiuhe; Xuan, Yi; Dai, Tianhong; Ando, Takahiro; Xu, Tao; Huang, Ying-Ying; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Xuan, Weijun; Vatansever, Fatma; Huang, Liyi; Wu, Qiuhe; Dai, Tianhong; Xu, Tao; Huang, Ying-Ying; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Xuan, Weijun] Tradit Chinese Med Univ Guangxi, Dept Otolaryngol, Nanning, Peoples R China; [Huang, Liyi] Guangxi Med Univ, Affiliated Coll & Hosp 1, Dept Infect Dis, Nanning, Peoples R China; [Wu, Qiuhe] Jinan Ctr Hosp, Dept Burn, Jinan, Peoples R China; [Xuan, Yi] Tufts Univ, Sch Engn, Medford, MA USA; [Ando, Takahiro] Keio Univ, Dept Elect & Elect Engn, Kohoku Ku, Yokohama, Kanagawa 223, Japan; [Xu, Tao] Shanghai Jiao Tong Univ, Lab Anesthesiol, Shanghai 200030, Peoples R China; [Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning, Peoples R China; [Hamblin, Michael R.] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Guangxi Medical University; Tufts University; Keio University; Shanghai Jiao Tong University; Guangxi Medical University; Harvard University	Hamblin, MR (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.	hamblin@helix.mgh.harvard.edu	Dai, Tianhong/P-5961-2018; Ando, Takahiro/H-5209-2019; Huang, Ying-ying/G-3153-2011; Huang, yingying/J-7329-2012; Ando, Takahiro/R-8374-2019; Hamblin, Michael R/H-2758-2019; Hamblin, Mike/AAB-2511-2022	Dai, Tianhong/0000-0001-8960-8896; Huang, Ying-ying/0000-0003-3066-6981; Huang, yingying/0000-0002-4038-0277; Hamblin, Michael R/0000-0001-6431-4605; Xu, Tao/0000-0001-5868-4079	NIH [R01AI050875]; Center for Integration of Medicine and Innovative Technology [DAMD17-02-2-0006]; CDMRP Program in TBI [W81XWH-09-1-0514]; Air Force Office of Scientific Research Military Photomedicine Program [FA9550-11-1-0331]; Grants-in-Aid for Scientific Research [10J04881] Funding Source: KAKEN; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050875] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for Integration of Medicine and Innovative Technology; CDMRP Program in TBI; Air Force Office of Scientific Research Military Photomedicine Program; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	NIH grant R01AI050875, Center for Integration of Medicine and Innovative Technology (DAMD17-02-2-0006), CDMRP Program in TBI (W81XWH-09-1-0514) and Air Force Office of Scientific Research Military Photomedicine Program (FA9550-11-1-0331). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Barker JM, 2011, EUR J NEUROSCI, V34, P963, DOI 10.1111/j.1460-9568.2011.07823.x; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Chen ACH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022453; Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7; Davis P.J., 2007, METHODS NUMERICAL IN; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Feeser VR, 2011, J NEUROIMMUNOL, V237, P4, DOI 10.1016/j.jneuroim.2011.06.007; Frenette AJ, 2012, J NEUROTRAUM, V29, P1, DOI 10.1089/neu.2011.1812; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; Heile Anna, 2011, Dialogues Clin Neurosci, V13, P279; Huang YY, 2012, J BIOPHOTONICS, V5, P827, DOI 10.1002/jbio.201200077; Huang YY, 2011, DOSE-RESPONSE, V9, P602, DOI 10.2203/dose-response.11-009.Hamblin; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Karonen JO, 1999, STROKE, V30, P1583, DOI 10.1161/01.STR.30.8.1583; KARU T, 1995, J PHOTOCH PHOTOBIO B, V27, P219, DOI 10.1016/1011-1344(94)07078-3; Karu TI, 2005, LASER SURG MED, V36, P307, DOI 10.1002/lsm.20148; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kokaia Z, 2006, CEREB CORTEX, V16, pI162, DOI 10.1093/cercor/bhj174; Kuo JR, 2011, J TRAUMA, V71, pE87, DOI 10.1097/TA.0b013e31820932e2; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lampl Yair, 2007, Expert Rev Neurother, V7, P961, DOI 10.1586/14737175.7.8.961; Lapchak PA, 2004, STROKE, V35, P1985, DOI 10.1161/01.STR.0000131808.69640.b7; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; Ling GSF, 2005, NEUROCRIT CARE, V2, P75, DOI 10.1385/NCC:2:1:075; Lulic D, 2011, NEUROSURGERY, V68, P1172, DOI 10.1227/NEU.0b013e31820c6cdc; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McIntosh TK, 1996, EUR J ANAESTH, V13, P291, DOI 10.1046/j.1365-2346.1996.00981.x; Muller CJ, 2009, EXP NEUROL, V219, P284, DOI 10.1016/j.expneurol.2009.05.035; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P443, DOI 10.1089/pho.2011.9908; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; Nichol AD, 2011, LANCET NEUROL, V10, P405, DOI 10.1016/S1474-4422(11)70085-0; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron A, 2012, J NEUROTRAUM, V29, P401, DOI 10.1089/neu.2011.2062; Pascual JL, 2011, J TRAUMA, V70, P535, DOI 10.1097/TA.0b013e31820b59de; Quirk BJ, 2012, PHOTOMED LASER SURG, V30, P523, DOI 10.1089/pho.2012.3261; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Sharma SK, 2011, LASER SURG MED, V43, P851, DOI 10.1002/lsm.21100; Stemer Andrew B, 2010, Curr Cardiol Rep, V12, P29, DOI 10.1007/s11886-009-0071-3; Streeter J, 2004, MITOCHONDRION, V4, P569, DOI 10.1016/j.mito.2004.07.037; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Xiong Y, 2010, DISCOV MED, V10, P434; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zhang RL, 2008, NEUROPHARMACOLOGY, V55, P345, DOI 10.1016/j.neuropharm.2008.05.027; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	55	88	103	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2013	8	1							e53454	10.1371/journal.pone.0053454	http://dx.doi.org/10.1371/journal.pone.0053454			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	069IS	23308226	Green Submitted, Green Published, gold			2023-01-03	WOS:000313429100069
J	Essig, S; Skinner, R; von der Weid, NX; Kuehni, CE; Michel, G				Essig, Stefan; Skinner, Roderick; von der Weid, Nicolas X.; Kuehni, Claudia E.; Michel, Gisela			Follow-Up Programs for Childhood Cancer Survivors in Europe: A Questionnaire Survey	PLOS ONE			English	Article							LONG-TERM SURVIVORS; ADULT SURVIVORS; CARE; DIAGNOSIS; OUTCOMES; CHILDREN	Background: For many childhood cancer survivors follow-up care is important long after treatment completion. We aimed to describe the availability and characteristics of long-term follow-up programs (LTFU) across Europe, their content and aims, their problems, and to assess opinions on different models of LTFU. Methodology/Principal Findings: We asked 179 pediatric oncology institutions in 20 European countries to complete an online survey on LTFU available at their institution. Of 110 respondents (62% response), 66% reported having LTFU for pediatric survivors, 38% for adult survivors of childhood cancer. Availability varied widely across European regions, from 9% of institutions in Northern Europe reporting LTFU for adult survivors to 83% of institution on the British Isles reporting LTFU for pediatric survivors. Pediatric and adult LTFU were usually located in pediatric hospitals and run by pediatric oncologists. Content of follow-up included screening for adverse outcomes and health education. Important problems included lack of time, personnel and funding. Most institutions without LTFU reported that they would like to offer a program (86%). Conclusion/Significance: Despite general agreement on the need of follow-up care, there is still a lack of well-organized LTFU for survivors of childhood cancer across Europe.	[Essig, Stefan; Kuehni, Claudia E.; Michel, Gisela] Univ Bern, ISPM, Bern, Switzerland; [Skinner, Roderick] Great N Childrens Hosp, Dept Pediat & Adolescent Hematol Oncol, Newcastle Upon Tyne, Tyne & Wear, England; [Skinner, Roderick] Great N Childrens Hosp, Childrens BMT Unit, Newcastle Upon Tyne, Tyne & Wear, England; [von der Weid, Nicolas X.] Univ Childrens Hosp Basel UKBB, Basel, Switzerland	University of Bern; University of Basel	Michel, G (corresponding author), Univ Bern, ISPM, Bern, Switzerland.	michel@ispm.unibe.ch	Michel, Gisela/G-1081-2018	Michel, Gisela/0000-0002-9589-0928; Essig, Stefan/0000-0003-3228-7010; Kuehni, Claudia E./0000-0001-8957-2002	Swiss National Science Foundation [PZ00P3-121682, PZ00P3-141722, 323630-133897]; Cancer Research Switzerland [KFS 02606-06-2010]; Swiss Cancer League [KFS 02631-08-2010]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Cancer Research Switzerland; Swiss Cancer League	Funding came from Swiss National Science Foundation (PZ00P3-121682, PZ00P3-141722, 323630-133897) http://www.snf.ch/, Cancer Research Switzerland (KFS 02606-06-2010) http://www.krebsforschung.ch/, and the Swiss Cancer League (KFS 02631-08-2010) http://www.krebsliga.ch/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Absolom K, 2009, BRIT J CANCER, V101, P561, DOI 10.1038/sj.bjc.6605213; Aziz NM, 2006, CANCER, V107, P841, DOI 10.1002/cncr.22096; Children's Oncology Group (COG), 2008, LONG TERM FOLL UP GU; Economic and Social Research Council, 2010, EC SOC RES COUNC RES; EISER C, 1994, PSYCHO-ONCOL, V3, P197, DOI 10.1002/pon.2960030306; Eshelman-Kent D, 2011, J CANCER SURVIV, V5, P345, DOI 10.1007/s11764-011-0192-8; Ethics Committee University of Zurich, 2012, CHECKL SELBSTB STUD; Geenen MM, 2007, JAMA-J AM MED ASSOC, V297, P2705, DOI 10.1001/jama.297.24.2705; Guilcher GMT, 2009, PEDIATR BLOOD CANCER, V52, P113, DOI 10.1002/pbc.21701; Henderson TO, 2010, J CLIN ONCOL, V28, P878, DOI 10.1200/JCO.2009.25.6107; Hess SL, 2011, ACTA ONCOL, V50, P653, DOI 10.3109/0284186X.2010.550934; Jenney M, 2008, BMJ-BRIT MED J, V336, P732, DOI 10.1136/bmj.39490.692627.80; Kadan-Lottick NS, 2002, JAMA-J AM MED ASSOC, V287, P1832, DOI 10.1001/jama.287.14.1832; Landier W, 2006, PEDIATR BLOOD CANCER, V46, P149, DOI 10.1002/pbc.20612; Michel G, 2009, EUR J CANCER, V45, P1616, DOI 10.1016/j.ejca.2009.02.026; Michel G, 2011, PSYCHO-ONCOLOGY, V20, P1034, DOI 10.1002/pon.1823; Michel G, 2010, J CLIN ONCOL, V28, P1740, DOI 10.1200/JCO.2009.23.4534; Mulrooney DA, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4606; Nathan PC, 2008, J CLIN ONCOL, V26, P4401, DOI 10.1200/JCO.2008.16.9607; National Health System (NHS), 2011, MOD CAR ACH BETT OUT; Oeffinger KC, 1998, J CLIN ONCOL, V16, P2864, DOI 10.1200/JCO.1998.16.8.2864; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Rebholz CE, 2011, EUR J CANCER, V47, P221, DOI 10.1016/j.ejca.2010.09.017; Reulen RC, 2011, JAMA-J AM MED ASSOC, V305, P2311, DOI 10.1001/jama.2011.747; Richards M, 2011, BRIT J CANCER, V105, pS1, DOI 10.1038/bjc.2011.416; Ristovski-Slijepcevic S, 2009, PAED CHILD HEALT-CAN, V14, P375, DOI 10.1093/pch/14.6.375; Scottish Intercollegiate Guidelines Network (SIGN), 2004, LONG TERM FOLL UP SU; SKINNER R, 2005, THERAPY BASED LONG T; Skinner R, 2007, ARCH DIS CHILD, V92, P257, DOI 10.1136/adc.2006.095513; Skinner R, 2006, LANCET ONCOL, V7, P489, DOI 10.1016/S1470-2045(06)70724-0; Stichting Kinderoncologie Nederland (SKION), 2010, RICHTL FOLL UP KIND; Tabone MD, 2006, ARCH PEDIATRIE, V13, P607, DOI 10.1016/j.arcped.2006.03.035; Tabone MD, 2006, SUIVI LONG TERME ENQ; Taylor A, 2004, PEDIATR BLOOD CANCER, V42, P161, DOI 10.1002/pbc.10482; United Nations Statistics Division, 2011, COMP MACR CONT REG G; von der Weid N, 2003, EUR J CANCER, V39, P1150, DOI 10.1016/S0959-8049(02)00874-2; Wallace WHB, 2001, BRIT MED J, V323, P271, DOI 10.1136/bmj.323.7307.271	37	32	32	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2012	7	12							e53201	10.1371/journal.pone.0053201	http://dx.doi.org/10.1371/journal.pone.0053201			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	075GO	23300889	gold, Green Published, Green Accepted, Green Submitted			2023-01-03	WOS:000313872600068
J	Leibly, DJ; Nguyen, TN; Kao, LT; Hewitt, SN; Barrett, LK; Van Voorhis, WC				Leibly, David J.; Trang Nhu Nguyen; Kao, Louis T.; Hewitt, Stephen N.; Barrett, Lynn K.; Van Voorhis, Wesley C.			Stabilizing Additives Added during Cell Lysis Aid in the Solubilization of Recombinant Proteins	PLOS ONE			English	Article							STRUCTURAL GENOMICS CENTER; MALTOSE-BINDING PROTEIN; THERMAL-STABILITY; MOLECULAR-MECHANISM; ESCHERICHIA-COLI; GLYCINE BETAINE; FUSION PROTEINS; AGGREGATION; TREHALOSE; ARGININE	Insoluble recombinant proteins are a major issue for both structural genomics and enzymology research. Greater than 30% of recombinant proteins expressed in Escherichia coli (E. coli) appear to be insoluble. The prevailing view is that insolubly expressed proteins cannot be easily solubilized, and are usually sequestered into inclusion bodies. However, we hypothesize that small molecules added during the cell lysis stage can yield soluble protein from insoluble protein previously screened without additives or ligands. We present a novel screening method that utilized 144 additive conditions to increase the solubility of recombinant proteins expressed in E. coli. These selected additives are natural ligands, detergents, salts, buffers, and chemicals that have been shown to increase the stability of proteins in vivo. We present the methods used for this additive solubility screen and detailed results for 41 potential drug target recombinant proteins from infectious organisms. Increased solubility was observed for 80% of the recombinant proteins during the primary and secondary screening of lysis with the additives; that is 33 of 41 target proteins had increased solubility compared with no additive controls. Eleven additives (trehalose, glycine betaine, mannitol, L-Arginine, potassium citrate, CuCl2, proline, xylitol, NDSB 201, CTAB and K2PO4) solubilized more than one of the 41 proteins; these additives can be easily screened to increase protein solubility. Large-scale purifications were attempted for 15 of the proteins using the additives identified and eight (40%) were prepared for crystallization trials during the first purification attempt. Thus, this protocol allowed us to recover about a third of seemingly insoluble proteins for crystallography and structure determination. If recombinant proteins are required in smaller quantities or less purity, the final success rate may be even higher.	[Leibly, David J.; Trang Nhu Nguyen; Kao, Louis T.; Hewitt, Stephen N.; Barrett, Lynn K.; Van Voorhis, Wesley C.] Univ Washington, Sch Med, Dept Allergy & Infect Dis, Seattle, WA 98195 USA; [Leibly, David J.; Trang Nhu Nguyen; Kao, Louis T.; Hewitt, Stephen N.; Barrett, Lynn K.; Van Voorhis, Wesley C.] Seattle Struct Genom Ctr Infect Dis SSGCID, Seattle, WA USA	University of Washington; University of Washington Seattle	Van Voorhis, WC (corresponding author), Univ Washington, Sch Med, Dept Allergy & Infect Dis, Seattle, WA 98195 USA.	wesley@uw.edu			National Institute of Allergy and Infectious Diseases, National Institute of Health, Department of Health and Human Services [HHSN272200700057C]	National Institute of Allergy and Infectious Diseases, National Institute of Health, Department of Health and Human Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was funded under Federal Contract No. HHSN272200700057C from the National Institute of Allergy and Infectious Diseases, National Institute of Health, Department of Health and Human Services. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BACK JF, 1979, BIOCHEMISTRY-US, V18, P5191, DOI 10.1021/bi00590a025; Bandyopadhyay A, 2012, NAT CHEM BIOL, V8, P238, DOI [10.1038/NCHEMBIO.768, 10.1038/nchembio.768]; Beranger F, 2008, BIOCHEM BIOPH RES CO, V374, P44, DOI 10.1016/j.bbrc.2008.06.094; Bondos SE, 2003, ANAL BIOCHEM, V316, P223, DOI 10.1016/S0003-2697(03)00059-9; Bryan CM, 2011, ACTA CRYSTALLOGR F, V67, P1010, DOI 10.1107/S1744309111018367; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; Choi R, 2011, ACTA CRYSTALLOGR F, V67, P998, DOI 10.1107/S1744309111017374; Collins T, 2006, ANAL BIOCHEM, V352, P299, DOI 10.1016/j.ab.2006.01.035; Courtenay ES, 2000, BIOCHEMISTRY-US, V39, P4455, DOI 10.1021/bi992887l; de Lencastre Novaes L. C., 2010, BIOTECHNOL PROGR, V27, P269; Derewenda ZS, 2004, METHODS, V34, P354, DOI 10.1016/j.ymeth.2004.03.024; Dokmanic I, 2008, ACTA CRYSTALLOGR D, V64, P257, DOI 10.1107/S090744490706595X; Expert-Bezancon N, 2003, BIOPHYS CHEM, V100, P469, DOI 10.1016/S0301-4622(02)00299-5; Fisher MT, 2006, P NATL ACAD SCI USA, V103, P13265, DOI 10.1073/pnas.0606106103; Ghosh R, 2009, BIOCHEMISTRY-US, V48, P1135, DOI 10.1021/bi802065j; Golovanov AP, 2004, J AM CHEM SOC, V126, P8933, DOI 10.1021/ja049297h; Graslund S, 2008, PROTEIN EXPRES PURIF, V58, P210, DOI 10.1016/j.pep.2007.11.008; Hammarstrom M, 2002, PROTEIN SCI, V11, P313, DOI 10.1110/ps.22102; Hewitt SN, 2011, ACTA CRYSTALLOGR F, V67, P1006, DOI 10.1107/S1744309111022159; Hu CY, 2010, PROTEINS, V78, P695, DOI 10.1002/prot.22598; Ignatova Z, 2006, P NATL ACAD SCI USA, V103, P13357, DOI 10.1073/pnas.0603772103; Jain N. K., 2010, CURR PROTOC PROTEIN, V59, P4, DOI [10.1002/0471140864.ps0409-59, DOI 10.1002/0471140864.PS0409S59, 10.1002/0471140864.ps0409s59]; Jain NK, 2009, PROTEIN SCI, V18, P24, DOI 10.1002/pro.3; Jensen WA, 1996, BBA-PROTEIN STRUCT M, V1296, P23, DOI 10.1016/0167-4838(96)00049-0; Kapust RB, 1999, PROTEIN SCI, V8, P1668, DOI 10.1110/ps.8.8.1668; Kaushik JK, 1998, J PHYS CHEM B, V102, P7058, DOI 10.1021/jp981119l; Kaushik JK, 2003, J BIOL CHEM, V278, P26458, DOI 10.1074/jbc.M300815200; Lawal OS, 2006, FOOD CHEM, V95, P101, DOI 10.1016/j.foodchem.2004.12.041; Lindner AB, 2008, P NATL ACAD SCI USA, V105, P3076, DOI 10.1073/pnas.0708931105; Liu R, 2005, NEUROBIOL DIS, V20, P74, DOI 10.1016/j.nbd.2005.02.003; Mehlin C, 2006, MOL BIOCHEM PARASIT, V148, P144, DOI 10.1016/j.molbiopara.2006.03.011; Mello CC, 2003, PROTEIN SCI, V12, P1522, DOI 10.1110/ps.0372903; Merchant SS, 2006, BBA-MOL CELL RES, V1763, P578, DOI 10.1016/j.bbamcr.2006.04.007; Miller L K, 1988, Biotechnology, V10, P457; Myler P. J., 2009, Infectious Disorders - Drug Targets, V9, P493; PALEG LG, 1984, PLANT PHYSIOL, V75, P974, DOI 10.1104/pp.75.4.974; Prajapati RS, 2007, PROTEINS, V66, P480, DOI 10.1002/prot.21215; Qing GL, 2004, NAT BIOTECHNOL, V22, P877, DOI 10.1038/nbt984; Remmele RL, 1998, PHARMACEUT RES, V15, P200; Rishi V, 1998, BIOCHEM J, V329, P137, DOI 10.1042/bj3290137; Savchenko A, 2003, PROTEINS, V50, P392, DOI 10.1002/prot.10282; Schlieker C, 2002, J BIOTECHNOL, V96, P13, DOI 10.1016/S0168-1656(02)00033-0; Schneider CP, 2011, J PHYS CHEM B, V115, P7447, DOI 10.1021/jp111920y; Singh LR, 2009, BBA-PROTEINS PROTEOM, V1794, P929, DOI 10.1016/j.bbapap.2009.02.005; Singh SM, 2005, J BIOSCI BIOENG, V99, P303, DOI 10.1263/jbb.99.303; SPIRIN AS, 1988, SCIENCE, V242, P1162, DOI 10.1126/science.3055301; Street TO, 2006, P NATL ACAD SCI USA, V103, P13997, DOI 10.1073/pnas.0606236103; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Tiwari A, 2006, BIOPHYS CHEM, V124, P90, DOI 10.1016/j.bpc.2006.06.003; WILLIAMS DC, 1982, SCIENCE, V215, P687, DOI 10.1126/science.7036343; Won CM, 1998, INT J PHARM, V167, P25; Yee A, 2003, ACCOUNTS CHEM RES, V36, P183, DOI 10.1021/ar010126g; Zhao DX, 2007, CHINESE CHEM LETT, V18, P355, DOI 10.1016/j.cclet.2007.01.017; Zou Q, 2002, J AM CHEM SOC, V124, P1192, DOI 10.1021/ja004206b	54	62	69	0	53	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2012	7	12							e52482	10.1371/journal.pone.0052482	http://dx.doi.org/10.1371/journal.pone.0052482			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	060RA	23285060	gold, Green Published, Green Submitted			2023-01-03	WOS:000312794500180
J	Helfrich, C; Pierau, SS; Freitag, CM; Roeper, J; Ziemann, U; Bender, S				Helfrich, Christian; Pierau, Simone S.; Freitag, Christine M.; Roeper, Jochen; Ziemann, Ulf; Bender, Stephan			Monitoring Cortical Excitability during Repetitive Transcranial Magnetic Stimulation in Children with ADHD: A Single-Blind, Sham-Controlled TMS-EEG Study	PLOS ONE			English	Article							DEFICIT-HYPERACTIVITY DISORDER; HUMAN MOTOR CORTEX; THETA-BURST STIMULATION; 1 HZ RTMS; INTRACORTICAL INHIBITION; AUDITORY-STIMULI; ATTENTION; RESPONSES; MOVEMENT; CIRCUITS	Background: Repetitive transcranial magnetic stimulation (rTMS) allows non-invasive stimulation of the human brain. However, no suitable marker has yet been established to monitor the immediate rTMS effects on cortical areas in children. Objective: TMS-evoked EEG potentials (TEPs) could present a well-suited marker for real-time monitoring. Monitoring is particularly important in children where only few data about rTMS effects and safety are currently available. Methods: In a single-blind sham-controlled study, twenty-five school-aged children with ADHD received subthreshold 1 Hz-rTMS to the primary motor cortex. The TMS-evoked N100 was measured by 64-channel-EEG pre, during and post rTMS, and compared to sham stimulation as an intraindividual control condition. Results: TMS-evoked N100 amplitude decreased during 1 Hz-rTMS and, at the group level, reached a stable plateau after approximately 500 pulses. N100 amplitude to supra-threshold single pulses post rTMS confirmed the amplitude reduction in comparison to the pre-rTMS level while sham stimulation had no influence. EEG source analysis indicated that the TMS-evoked N100 change reflected rTMS effects in the stimulated motor cortex. Amplitude changes in TMS-evoked N100 and MEPs (pre versus post 1 Hz-rTMS) correlated significantly, but this correlation was also found for pre versus post sham stimulation. Conclusion: The TMS-evoked N100 represents a promising candidate marker to monitor rTMS effects on cortical excitability in children with ADHD. TMS-evoked N100 can be employed to monitor real-time effects of TMS for subthreshold intensities. Though TMS-evoked N100 was a more sensitive parameter for rTMS-specific changes than MEPs in our sample, further studies are necessary to demonstrate whether clinical rTMS effects can be predicted from rTMS-induced changes in TMS-evoked N100 amplitude and to clarify the relationship between rTMS-induced changes in TMS-evoked N100 and MEP amplitudes. The TMS-evoked N100 amplitude reduction after 1 Hz-rTMS could either reflect a globally decreased cortical response to the TMS pulse or a specific decrease in inhibition.	[Helfrich, Christian; Pierau, Simone S.; Freitag, Christine M.; Bender, Stephan] Goethe Univ Frankfurt, Univ Hosp Child & Adolescent Psychiat Psychosomat, Frankfurt, Germany; [Bender, Stephan] Carl Gustav Carus Univ Technol, Child & Adolescent Psychiat Hosp, Fac Med, Sect Clin Neurophysiol & Multimodal Imaging, Dresden, Germany; [Helfrich, Christian; Roeper, Jochen] Goethe Univ Frankfurt, Inst Neurophysiol, Frankfurt, Germany; [Ziemann, Ulf] Univ Tubingen, Hertie Inst Clin Brain Res, Dept Neurol & Stroke, Tubingen, Germany	Goethe University Frankfurt; Technische Universitat Dresden; Goethe University Frankfurt; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Bender, S (corresponding author), Goethe Univ Frankfurt, Univ Hosp Child & Adolescent Psychiat Psychosomat, Frankfurt, Germany.	Stephan.Bender@uniklinikum-dresden.de	Ziemann, Ulf/AAY-9125-2020; Bender, Stephan/AAT-1266-2021	Roeper, Jochen/0000-0003-2145-8742; Freitag, Christine Margarete/0000-0001-9676-4782	Medical Faculty at the Goethe University; Frankfurt/Main; Interdisciplinary Center for Neurosciences Frankfurt	Medical Faculty at the Goethe University; Frankfurt/Main; Interdisciplinary Center for Neurosciences Frankfurt	The study was supported by the Medical Faculty at the Goethe University, Frankfurt/Main via a grant (Young Scientists Program) to SB as well as by the Interdisciplinary Center for Neurosciences Frankfurt; Plasticity via magnetic brain stimulation: cellular mechanism - modeling - modulation via a grant to JR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bender S, 2005, ANN NEUROL, V58, P58, DOI 10.1002/ana.20521; Bender S, 2006, NEUROIMAGE, V32, P333, DOI 10.1016/j.neuroimage.2006.03.009; Bender S, 2006, NEUROIMAGE, V33, P759, DOI 10.1016/j.neuroimage.2006.07.003; Bikmullina R, 2009, EXP BRAIN RES, V194, P517, DOI 10.1007/s00221-009-1723-7; Bloch Y, 2010, WORLD J BIOL PSYCHIA, V11, P755, DOI 10.3109/15622975.2010.484466; Bonnard M, 2009, EUR J NEUROSCI, V30, P913, DOI 10.1111/j.1460-9568.2009.06864.x; Bruckmann S, 2012, BRAIN, V135, P2215, DOI 10.1093/brain/aws071; Buchmann J, 2007, BIOL PSYCHIAT, V62, P963, DOI 10.1016/j.biopsych.2007.05.010; Di Lazzaro V, 1998, EXP BRAIN RES, V119, P265; Fierro B, 2007, EXP BRAIN RES, V176, P440, DOI 10.1007/s00221-006-0628-y; Fitzgerald PB, 2006, CLIN NEUROPHYSIOL, V117, P2584, DOI 10.1016/j.clinph.2006.06.712; Fitzgerald PB, 2009, CLIN NEUROPHYSIOL, V120, P1706, DOI 10.1016/j.clinph.2009.06.019; Fregni F, 2006, CLIN NEUROPHYSIOL, V117, P1217, DOI 10.1016/j.clinph.2006.02.015; Garvey MA, 2001, J CHILD NEUROL, V16, P891, DOI 10.1177/088307380101601205; Gilbert DL, 2011, NEUROLOGY, V76, P615, DOI 10.1212/WNL.0b013e31820c2ebd; Gilbert DL, 2006, NEUROPSYCHOPHARMACOL, V31, P442, DOI 10.1038/sj.npp.1300806; Gilbert DL, 2004, CLIN NEUROPHYSIOL, V115, P1730, DOI 10.1016/j.clinph.2003.10.037; HAMBURGER H L, 1991, Brain Topography, V3, P391, DOI 10.1007/BF01129642; Hansenne M, 2004, BIOL PSYCHOL, V67, P331, DOI 10.1016/j.biopsycho.2004.01.004; Huang YZ, 2009, CLIN NEUROPHYSIOL, V120, P796, DOI 10.1016/j.clinph.2009.01.003; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Ilmoniemi RJ, 2010, BRAIN TOPOGR, V22, P233, DOI 10.1007/s10548-009-0123-4; Kahkonen S, 2005, NEUROIMAGE, V24, P955, DOI 10.1016/j.neuroimage.2004.09.048; Kahkonen S, 2007, J NEUROSCI METH, V166, P104, DOI 10.1016/j.jneumeth.2007.06.030; Kicic D, 2008, NEUROSCIENCE, V152, P1119, DOI 10.1016/j.neuroscience.2008.01.043; Koch G, 2008, CLIN NEUROPHYSIOL, V119, P2559, DOI 10.1016/j.clinph.2008.08.008; Komssi S, 2004, HUM BRAIN MAPP, V21, P154, DOI 10.1002/hbm.10159; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Maki H, 2011, NEUROIMAGE, V54, P2706, DOI 10.1016/j.neuroimage.2010.11.041; Merrin EL, 2006, INT J PSYCHOPHYSIOL, V60, P330, DOI 10.1016/j.ijpsycho.2005.05.012; Moll GH, 2000, NEUROSCI LETT, V284, P121, DOI 10.1016/S0304-3940(00)00980-0; Moll GH, 2001, ANN NEUROL, V49, P393, DOI 10.1002/ana.77.abs; Moll GH, 2001, Z KINDER JUG-PSYCH, V29, P312, DOI 10.1024//1422-4917.29.4.312; Mosher JC, 1999, IEEE T SIGNAL PROCES, V47, P332, DOI 10.1109/78.740118; Niederhofer H, 2008, PSYCHIAT DANUB, V20, P91; Nikulin VV, 2003, EUR J NEUROSCI, V18, P1206, DOI 10.1046/j.1460-9568.2003.02858.x; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PICTON T, 1995, HDB NEUROPHYSIOLOGY; Quintana H, 2005, J ECT, V21, P88, DOI 10.1097/01.yct.0000162556.02720.58; Rosanova M, 2009, J NEUROSCI, V29, P7679, DOI 10.1523/JNEUROSCI.0445-09.2009; Rossi S, 2000, CEREB CORTEX, V10, P802, DOI 10.1093/cercor/10.8.802; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Schneider M, 2007, J NEURAL TRANSM-SUPP, P303; Schneider S., 2009, KINDER DIPS DIAGNOST, V2nd; SCHRODER J, 1993, Z KLIN PSYCHOL PSYCH, V41, P190; Siebner HR, 2004, J NEUROSCI, V24, P3379, DOI 10.1523/JNEUROSCI.5316-03.2004; SKRANDIES W, 1989, Brain Topography, V2, P73, DOI 10.1007/BF01128845; Spieser L, 2010, NEUROIMAGE, V52, P316, DOI 10.1016/j.neuroimage.2010.04.020; Taylor PCJ, 2010, HUM BRAIN MAPP, V31, P1408, DOI 10.1002/hbm.20941; Veniero D, 2010, J NEUROPHYSIOL, V104, P1578, DOI 10.1152/jn.00172.2010; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; World Medical Association, WMA DECL HELS ETH PR; Ziemann U, 1996, J PHYSIOL-LONDON, V496, P873, DOI 10.1113/jphysiol.1996.sp021734; Ziemann U, 2008, BRAIN STIMUL, V1, P164, DOI 10.1016/j.brs.2008.06.006	54	33	36	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2012	7	11							e50073	10.1371/journal.pone.0050073	http://dx.doi.org/10.1371/journal.pone.0050073			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	047ER	23185537	Green Submitted, gold, Green Published			2023-01-03	WOS:000311821000177
J	Stevenson, DG				Stevenson, David G.			Growing Pains for the Medicare Hospice Benefit	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PALLIATIVE CARE		Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Stevenson, DG (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.							Byock I, 1998, J Palliat Med, V1, P165, DOI 10.1089/jpm.1998.1.165; Groninger H, 2012, HEALTH AFFAIR, V31, P452, DOI [10.1377/hlthaff.2011.0473, 10.1377/HLTHAFF.2011.0473]; Meier DE, 2011, MILBANK Q, V89, P343, DOI 10.1111/j.1468-0009.2011.00632.x; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Waldman P, 2011, WASHINGTON POST	5	17	17	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 1	2012	367	18					1683	1685		10.1056/NEJMp1208465	http://dx.doi.org/10.1056/NEJMp1208465			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	028RS	23113479				2023-01-03	WOS:000310440800004
J	Weeks, JC; Catalano, PJ; Cronin, A; Finkelman, MD; Mack, JW; Keating, NL; Schrag, D				Weeks, Jane C.; Catalano, Paul J.; Cronin, Angel; Finkelman, Matthew D.; Mack, Jennifer W.; Keating, Nancy L.; Schrag, Deborah			Patients' Expectations about Effects of Chemotherapy for Advanced Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELL LUNG-CANCER; ADVANCED COLORECTAL-CANCER; CARE OUTCOMES RESEARCH; QUALITY-OF-LIFE; SURVEILLANCE CONSORTIUM; MULTIPLE IMPUTATION; RANDOMIZED-TRIAL; PALLIATIVE CARE; SUPPORTIVE CARE; TREATMENT GOALS	Background Chemotherapy for metastatic lung or colorectal cancer can prolong life by weeks or months and may provide palliation, but it is not curative. Methods We studied 1193 patients participating in the Cancer Care Outcomes Research and Surveillance (CanCORS) study (a national, prospective, observational cohort study) who were alive 4 months after diagnosis and received chemotherapy for newly diagnosed metastatic (stage IV) lung or colorectal cancer. We sought to characterize the prevalence of the expectation that chemotherapy might be curative and to identify the clinical, sociodemographic, and health-system factors associated with this expectation. Data were obtained from a patient survey by professional interviewers in addition to a comprehensive review of medical records. Results Overall, 69% of patients with lung cancer and 81% of those with colorectal cancer did not report understanding that chemotherapy was not at all likely to cure their cancer. In multivariable logistic regression, the risk of reporting inaccurate beliefs about chemotherapy was higher among patients with colorectal cancer, as compared with those with lung cancer (odds ratio, 1.75; 95% confidence interval [CI], 1.29 to 2.37); among nonwhite and Hispanic patients, as compared with non-Hispanic white patients (odds ratio for Hispanic patients, 2.82; 95% CI, 1.51 to 5.27; odds ratio for black patients, 2.93; 95% CI, 1.80 to 4.78); and among patients who rated their communication with their physician very favorably, as compared with less favorably (odds ratio for highest third vs. lowest third, 1.90; 95% CI, 1.33 to 2.72). Educational level, functional status, and the patient's role in decision making were not associated with such inaccurate beliefs about chemotherapy. Conclusions Many patients receiving chemotherapy for incurable cancers may not understand that chemotherapy is unlikely to be curative, which could compromise their ability to make informed treatment decisions that are consonant with their preferences. Physicians may be able to improve patients' understanding, but this may come at the cost of patients' satisfaction with them. (Funded by the National Cancer Institute and others.)	[Weeks, Jane C.; Cronin, Angel; Schrag, Deborah] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Catalano, Paul J.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA; [Mack, Jennifer W.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA; [Finkelman, Matthew D.] Tufts Univ, Sch Dent Med, Dept Publ Hlth & Community Serv, Boston, MA 02111 USA; [Keating, Nancy L.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; [Keating, Nancy L.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Tufts University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Weeks, JC (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA.	jane_weeks@dfci.harvard.edu	Maslov, Victor Pavlovich/M-9068-2015; Keating, Nancy L/I-9968-2019	Maslov, Victor Pavlovich/0000-0003-2599-5086; Keating, Nancy L/0000-0002-8274-4681	National Cancer Institute (NCI) [U01 CA093344]; NCI; Dana-Farber Cancer Institute/Cancer Research Network [U01 CA093332]; Harvard Medical School/Northern California Cancer Center [U01 CA093324, RAND/UCLA U01 CA093348]; University of Alabama at Birmingham [U01 CA093329]; University of Iowa [U01 CA093339]; University of North Carolina [U01 CA093326]; Department of Veterans Affairs [CRS 02-164]; NATIONAL CANCER INSTITUTE [U01CA093329, U01CA093332, U01CA093348, U01CA093324, U01CA093326, U01CA093344, U01CA093339] Funding Source: NIH RePORTER	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Dana-Farber Cancer Institute/Cancer Research Network; Harvard Medical School/Northern California Cancer Center; University of Alabama at Birmingham; University of Iowa; University of North Carolina; Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by grants from the National Cancer Institute (NCI) to the Statistical Coordinating Center (U01 CA093344) and the NCI-supported Primary Data Collection and Research Centers, Dana-Farber Cancer Institute/Cancer Research Network (U01 CA093332), Harvard Medical School/Northern California Cancer Center (U01 CA093324, RAND/UCLA U01 CA093348), University of Alabama at Birmingham (U01 CA093329), University of Iowa (U01 CA093339), and University of North Carolina (U01 CA093326); and by a Department of Veterans Affairs grant to the Durham Veterans Affairs Medical Center (CRS 02-164).	[Anonymous], 2004, J PALLIAT MED, V7, P637; Ayanian JZ, 2010, J CLIN ONCOL, V28, P4154, DOI 10.1200/JCO.2009.27.3268; Ayanian JZ, 2004, J CLIN ONCOL, V22, P2992, DOI 10.1200/JCO.2004.06.020; Burdett S, 2008, J CLIN ONCOL, V26, P4617, DOI 10.1200/JCO.2008.17.7162; Burns CM, 2007, SUPPORT CARE CANCER, V15, P187, DOI 10.1007/s00520-006-0116-8; Catalano P, 2012, MED CARE APPL M 0307; Char SJL, 2010, AM J RESP CRIT CARE, V182, P905, DOI 10.1164/rccm.201002-0262OC; Chen JY, 2008, MED CARE, V46, P1157, DOI 10.1097/MLR.0b013e31817924bc; Chow E, 2001, CLIN ONCOL-UK, V13, P204, DOI 10.1053/clon.2001.9255; de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938; EIDINGER RN, 1984, CANCER, V53, P2736, DOI 10.1002/1097-0142(19840615)53:12<2736::AID-CNCR2820531233>3.0.CO;2-W; Gabrijel S, 2008, J CLIN ONCOL, V26, P297, DOI 10.1200/JCO.2007.13.0609; Gattellari M, 2002, J CLIN ONCOL, V20, P503, DOI 10.1200/JCO.20.2.503; GLIMELIUS B, 1994, CANCER, V73, P556, DOI 10.1002/1097-0142(19940201)73:3<556::AID-CNCR2820730310>3.0.CO;2-8; Gridelli C, 1999, JNCI-J NATL CANCER I, V91, P66; Hays RD, 1999, MED CARE, V37, pMS22, DOI 10.1097/00005650-199903001-00003; He Y, 2010, STAT METHODS MED RES, V19, P653, DOI 10.1177/0962280208101273; He YL, 2010, CIRC-CARDIOVASC QUAL, V3, P98, DOI 10.1161/CIRCOUTCOMES.109.875658; Helsing M, 1998, EUR J CANCER, V34, P1036, DOI 10.1016/S0959-8049(97)10122-8; Keating NL, 2010, J CLIN ONCOL, V28, P4364, DOI 10.1200/JCO.2009.26.8870; Leighl NB, 2011, J CLIN ONCOL, V29, P2077, DOI 10.1200/JCO.2010.32.0754; LIDZ CW, 1988, ARCH INTERN MED, V148, P1385, DOI 10.1001/archinte.148.6.1385; Mack JW, 2007, J CLIN ONCOL, V25, P1357, DOI 10.1200/JCO.2006.08.3170; MACKILLOP WJ, 1988, BRIT J CANCER, V58, P355, DOI 10.1038/bjc.1988.218; Malin JL, 2006, SUPPORT CARE CANCER, V14, P837, DOI 10.1007/s00520-005-0902-8; MCQUELLON RP, 1995, J CLIN ONCOL, V13, P858, DOI 10.1200/JCO.1995.13.4.858; Peppercorn JM, 2011, J CLIN ONCOL, V29, P755, DOI 10.1200/JCO.2010.33.1744; PRONZATO P, 1994, SUPPORT CARE CANCER, V2, P242, DOI 10.1007/BF00365729; Shaw JW, 2005, MED CARE, V43, P203, DOI 10.1097/00005650-200503000-00003; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; Smith Thomas J, 2011, J Support Oncol, V9, P79; Smith TJ, 2010, CLIN CANCER RES, V16, P5981, DOI 10.1158/1078-0432.CCR-10-1278; Temel JS, 2011, J CLIN ONCOL, V29, P2319, DOI 10.1200/JCO.2010.32.4459; The AM, 2000, BRIT MED J, V321, P1376, DOI 10.1136/bmj.321.7273.1376; Tourangeau R., 2000, PSYCHOL SURVEY RESPO; von Gunten Charles F, 2004, J Palliat Med, V7, P209, DOI 10.1089/109662104773709332; von Roenn JH, 2003, J CLIN ONCOL, V21, P570, DOI 10.1200/JCO.2003.10.161; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Wolfe J, 2000, JAMA-J AM MED ASSOC, V284, P2469, DOI 10.1001/jama.284.19.2469	39	771	777	3	95	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 25	2012	367	17					1616	1625		10.1056/NEJMoa1204410	http://dx.doi.org/10.1056/NEJMoa1204410			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	024TO	23094723	Green Accepted			2023-01-03	WOS:000310131700008
J	Lubkowska, A; Dolegowska, B; Szygula, Z				Lubkowska, Anna; Dolegowska, Barbara; Szygula, Zbigniew			Whole-Body Cryostimulation - Potential Beneficial Treatment for Improving Antioxidant Capacity in Healthy Men - Significance of the Number of Sessions	PLOS ONE			English	Article							OXIDATIVE STRESS; URIC-ACID; SERUM-ALBUMIN; COLD-EXPOSURE; IN-VIVO; ERYTHROCYTES; CRYOTHERAPY; ENZYMES; VASOCONSTRICTION; F2-ISOPROSTANES	It is claimed that WBC (whole-body cryotherapy) enhances the resistance of the human body, also thanks to the beneficial effect on the antioxidant system. Accordingly, this research aimed to evaluate the effect of a series of whole-body cryostimulations on the level of non-enzymatic antioxidants and the activity of antioxidant enzymes in healthy men. The study was carried out on 30 young and healthy men aged 27.8 +/- 6.1 years with average body mass index and peak oxygen consumption (46.34 +/- 6.15 ml kg(-1).min(-1)). The participants were daily exposed for 3 minutes to cryogenic temperatures (-130 degrees C). Blood samples were obtained in the morning before cryostimulation, again 30 min after exposure and the following day in the morning, during the 1st, 10th and 20th session. Analysis concerned changes in plasma concentrations of total protein, albumin, glucose, uric acid and ceruloplasmin, and the most important components of the antioxidant system in red blood cells: superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, reduced and oxidized glutathione. To assess the oxidative stress level the 8-isoprostane concentration in plasma was measured. The obtained results indicate that cryogenic temperatures in repeated daily treatments result in changes in the peroxidant and antioxidant status. These changes seem to depend on the number of cryostimulations. After 20 daily treatments there was an increase in SOD, SOD: CAT ratio, a decrease in the concentration of reduced and oxidized glutathione and in the activity of GPx. It could be possible that differences in the activity of GSSG-R after 20 treatments depended on the body mass index of participants.	[Lubkowska, Anna] Pomeranian Med Univ, Fac Hlth Sci, Szczecin, Poland; [Lubkowska, Anna] Szczecin Univ, Fac Biol, Dept Physiol, Szczecin, Poland; [Dolegowska, Barbara] Pomeranian Med Univ, Dept Lab Diagnost & Mol Med, Szczecin, Poland; [Szygula, Zbigniew] Univ Sch Phys Educ, Inst Human Physiol, Krakow, Poland	Pomeranian Medical University; University of Szczecin; Pomeranian Medical University	Lubkowska, A (corresponding author), Pomeranian Med Univ, Fac Hlth Sci, Szczecin, Poland.	annalubkowska@gmail.com	Lubkowska, Anna/A-4623-2015; Dolegowska, Barbara/O-4851-2014	Lubkowska, Anna/0000-0002-5378-5409; Dolegowska, Barbara/0000-0003-3138-1013; Szygula, Zbigniew/0000-0002-6685-6579	Ministry of Science and Higher Education [NN404 027235]; National Science Centre [N N404 312940]	Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland); National Science Centre(National Science Centre, Poland)	This paper was supported by the Ministry of Science and Higher Education, Grant No: NN404 027235 and National Science Centre No: N N404 312940. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersen HR, 1997, CLIN CHEM, V43, P562; Bailey SR, 2005, AM J PHYSIOL-HEART C, V289, pH243, DOI 10.1152/ajpheart.01305.2004; Banfi G, 2009, J THERM BIOL, V34, P55, DOI 10.1016/j.jtherbio.2008.10.003; Bartosz G, 2003, WARSZAWA PWN; BECKER BF, 1993, FREE RADICAL BIO MED, V14, P615, DOI 10.1016/0891-5849(93)90143-I; Belik J, 2010, FREE RADICAL BIO MED, V48, P177, DOI 10.1016/j.freeradbiomed.2009.10.043; Clarkson PM, 2000, AM J CLIN NUTR, V72, p637S, DOI 10.1093/ajcn/72.2.637S; Comporti M, 2008, FREE RADICAL BIO MED, V44, P247, DOI 10.1016/j.freeradbiomed.2007.10.004; Djousse L, 2003, STROKE, V34, P53, DOI 10.1161/01.STR.0000048675.97975.84; Dugue B, 2005, SCAND J CLIN LAB INV, V65, P395, DOI 10.1080/00365510510025728; Dugue B, 2000, CLIN PHYSIOL, V20, P114; Edwards CJ, 1996, COMP HAEMATOL INT, V6, P24, DOI 10.1007/BF00368098; Ferrucci L, 1999, J AM GERIATR SOC, V47, P639, DOI 10.1111/j.1532-5415.1999.tb01583.x; FLAVAHAN NA, 1991, NEWS PHYSIOL SCI, V6, P251; Ganta CK, 2006, AM J PHYSIOL-REG I, V291, pR558, DOI 10.1152/ajpregu.00846.2005; Giurgea N, 2005, MED SCI MONITOR, V11, pRA48; GOPAUL NK, 1994, BIOCHEM BIOPH RES CO, V200, P338, DOI 10.1006/bbrc.1994.1453; Hausswirth C, 2010, SCI SPORT, V25, P121, DOI 10.1016/j.scispo.2009.12.001; Jacobs I, 1994, Exerc Sport Sci Rev, V22, P221; Ji LL, 1999, P SOC EXP BIOL MED, V222, P283, DOI 10.1046/j.1525-1373.1999.d01-145.x; Kawakami A, 2006, FEBS J, V273, P3346, DOI 10.1111/j.1742-4658.2006.05341.x; Korac B, 2003, J THERM BIOL, V28, P245, DOI 10.1016/S0306-4565(02)00070-0; Kumar A, 2005, FASEB J, V19, P443, DOI 10.1096/fj.03-1364fje; Lubkowska A, 2009, SCAND J CLIN LAB INV, V69, P387, DOI 10.1080/00365510802699246; Lubkowska A, 2011, 2 POL C BIOCH CELL B; Lubkowska A, 2011, SCAND J CLIN LAB INV, V71, P419, DOI 10.3109/00365513.2011.580859; Lubkowska A, 2010, INT J OCCUP MED ENV, V23, P367, DOI 10.2478/v10001-010-0037-0; Lubkowska A, 2010, CRYOBIOLOGY, V61, P22, DOI 10.1016/j.cryobiol.2010.03.010; Lubkowska A, 2010, EUR J APPL PHYSIOL, V109, P67, DOI 10.1007/s00421-009-1207-2; Lubkowska A, 2008, J THERM BIOL, V33, P464, DOI 10.1016/j.jtherbio.2008.08.003; Luszczewski Adam, 2007, Reumatologia (Warsaw), V45, P284; Miller E, 2012, EUR J APPL PHYSIOL, V112, P1645, DOI 10.1007/s00421-011-2122-x; Miller E, 2010, J THERM BIOL, V35, P406, DOI 10.1016/j.jtherbio.2010.08.006; Milne GL, 2007, METHOD ENZYMOL, V433, P113, DOI 10.1016/S0076-6879(07)33006-1; Montuschi P, 2007, CURR MED CHEM, V14, P703, DOI 10.2174/092986707780059607; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; Nagashima K, 2000, AUTON NEUROSCI-BASIC, V85, P18, DOI 10.1016/S1566-0702(00)00216-2; Nourooz-Zadeh J, 1998, BIOCHEM BIOPH RES CO, V242, P338, DOI 10.1006/bbrc.1997.7883; Prohaska JR, 2008, AM J CLIN NUTR, V88, p826S, DOI 10.1093/ajcn/88.3.826S; Rizvi SI, 2007, MOL BIOTECHNOL, V37, P58, DOI 10.1007/s12033-007-0048-7; Roberts LJ, 2006, FREE RADIC BIOL MED, V28, P505; Siems W, 1992, Arctic Med Res, V51, P3; SIEMS WG, 1994, FREE RADICAL BIO MED, V16, P299, DOI 10.1016/0891-5849(94)90030-2; Siems WG, 1999, QJM-INT J MED, V92, P193, DOI 10.1093/qjmed/92.4.193; Squadrito GL, 2000, ARCH BIOCHEM BIOPHYS, V376, P333, DOI 10.1006/abbi.2000.1721; Stocks JM, 2004, AVIAT SPACE ENVIR MD, V75, P444; Suzuki T, 2007, NITRIC OXIDE-BIOL CH, V16, P266, DOI 10.1016/j.niox.2006.10.008; Swenson C, 1996, SCAND J MED SCI SPOR, V6, P193, DOI 10.1111/j.1600-0838.1996.tb00090.x; Teixeira CE, 2004, CIRC RES, V94, P1273, DOI 10.1161/01.RES.0000131755.49084.04; Thompson-Torgerson CS, 2007, AM J PHYSIOL-HEART C, V292, pH1700, DOI 10.1152/ajpheart.01078.2006; Wozniak A, 2007, EUR J APPL PHYSIOL, V100, P137, DOI 10.1007/s00421-007-0404-0	51	48	50	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2012	7	10							e46352	10.1371/journal.pone.0046352	http://dx.doi.org/10.1371/journal.pone.0046352			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022WO	23077506	Green Published, gold			2023-01-03	WOS:000309995100028
J	Arie, S				Arie, Sophie			Inquiry launched into newspaper story about babies on "death pathway"	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												sophiearie@fmail.co.uk						[Anonymous], 2012, BMJ, V345, pe7319, DOI 10.1136/bmj.e7319	1	1	1	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 1	2013	346								f1273	10.1136/bmj.f1273	http://dx.doi.org/10.1136/bmj.f1273			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	149WE	23447346				2023-01-03	WOS:000319351300004
J	Spence, D				Spence, Des			A conspiracy of anonymity	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk							0	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 7	2013	346								f32	10.1136/bmj.f32	http://dx.doi.org/10.1136/bmj.f32			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	070YU	23295249				2023-01-03	WOS:000313552300008
J	Kim, KH; Song, K; Yoon, SH; Shehzad, O; Kim, YS; Son, JH				Kim, Kyung-Hee; Song, Karen; Yoon, Seung-Hee; Shehzad, Omer; Kim, Yeong-Shik; Son, Jin H.			Rescue of PINK1 Protein Null-specific Mitochondrial Complex IV Deficits by Ginsenoside Re Activation of Nitric Oxide Signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; PARKINSONS-DISEASE; OXIDATIVE-PHOSPHORYLATION; MOLECULAR CHAPERONES; ALZHEIMERS-DISEASE; DOPAMINERGIC CELLS; LEIGH-SYNDROME; BIOGENESIS; MUTATIONS; GENE	PINK1, linked to familial Parkinson's disease, is known to affect mitochondrial function. Here we identified a novel regulatory role of PINK1 in the maintenance of complex IV activity and characterized a novel mechanism by which NO signaling restored complex IV deficiency in PINK1 null dopaminergic neuronal cells. In PINK1 null cells, levels of specific chaperones, including Hsp60, leucine-rich pentatricopeptide repeat-containing (LRPPRC), and Hsp90, were severely decreased. LRP-PRC and Hsp90 were found to act upstream of Hsp60 to regulate complex IV activity. Specifically, knockdown of Hsp60 resulted in a decrease in complex IV activity, whereas antagonistic inhibition of Hsp90 by 17-(allylamino) geldanamycin decreased both Hsp60 and complex IV activity. In contrast, overexpression of the PINK1-interacting factor LRPPRC augmented complex IV activity by up-regulating Hsp60. A similar recovery of complex IV activity was also induced by coexpression of Hsp90 and Hsp60. Drug screening identified ginsenoside Re as a compound capable of reversing the deficit in complex IV activity in PINK1 null cells through specific increases of LRPPRC, Hsp90, and Hsp60 levels. The pharmacological effects of ginsenoside Re could be reversed by treatment of the pan-NOS inhibitor L-NG-Nitroarginine Methyl Ester (L-NAME) and could also be reproduced by low-level NO treatment. These results suggest that PINK1 regulates complex IV activity via interactions with upstream regulators of Hsp60, such as LRPPRC and Hsp90. Furthermore, they demonstrate that treatment with ginsenoside Re enhances functioning of the defective PINK1-Hsp90/LRPPRC-Hsp60-complex IV signaling axis in PINK1 null neurons by restoring NO levels, providing potential for new therapeutics targeting mitochondrial dysfunction in Parkinson's disease.	[Kim, Kyung-Hee; Son, Jin H.] Ewha Womans Univ, Brain Dis Res Inst, Coll Pharm, Dept Brain & Cognit Sci, Seoul 120750, South Korea; [Song, Karen; Yoon, Seung-Hee; Son, Jin H.] Ewha Womans Univ, Brain Dis Res Inst, Coll Pharm, Div Life & Pharmaceut Sci, Seoul 120750, South Korea; [Shehzad, Omer; Kim, Yeong-Shik] Seoul Natl Univ, Coll Pharm, Seoul, South Korea	Ewha Womans University; Ewha Womans University; Seoul National University (SNU)	Son, JH (corresponding author), Ewha Womans Univ, Brain Dis Res Inst, Coll Pharm, Dept Brain & Cognit Sci, Sci Bldg C,Rm C307,11-1 Daehyun Dong, Seoul 120750, South Korea.	hjson@ewha.ac.kr	Kim, Hyung-Kwan/R-8375-2019		National Research Foundation [2010-0009233]; National Core Research Center, Republic of Korea [2012-0000952]	National Research Foundation; National Core Research Center, Republic of Korea	This work was supported in part by National Research Foundation Grant 2010-0009233 and National Core Research Center Program Grant 2012-0000952, Republic of Korea.	Atamna H, 2006, P NATL ACAD SCI USA, V103, P3381, DOI 10.1073/pnas.0600134103; Barrientos A, 2009, BBA-MOL CELL RES, V1793, P97, DOI 10.1016/j.bbamcr.2008.05.003; Borniquel S, 2006, FASEB J, V20, P1889, DOI 10.1096/fj.05-5189fje; BROWN GC, 1995, NEUROSCI LETT, V193, P201, DOI 10.1016/0304-3940(95)11703-Y; Brown GC, 2010, NITRIC OXIDE-BIOL CH, V23, P153, DOI 10.1016/j.niox.2010.06.001; Canevari L, 1999, FEBS LETT, V457, P131, DOI 10.1016/S0014-5793(99)01028-5; Chen X, 1997, CLIN EXP PHARMACOL P, V24, P958, DOI 10.1111/j.1440-1681.1997.tb02727.x; Coenen MJH, 2004, ANN NEUROL, V56, P560, DOI 10.1002/ana.20229; Diaz F, 2010, BBA-MOL BASIS DIS, V1802, P100, DOI 10.1016/j.bbadis.2009.07.013; DRAPIER JC, 1988, J IMMUNOL, V140, P2829; Gegg ME, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004756; Guix FX, 2005, PROG NEUROBIOL, V76, P126, DOI 10.1016/j.pneurobio.2005.06.001; Hall CN, 2009, NITRIC OXIDE-BIOL CH, V21, P92, DOI 10.1016/j.niox.2009.07.002; Hunot S, 1996, NEUROSCIENCE, V72, P355, DOI 10.1016/0306-4522(95)00578-1; KISH SJ, 1992, J NEUROCHEM, V59, P776, DOI 10.1111/j.1471-4159.1992.tb09439.x; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; Leung KW, 2007, NEUROPHARMACOLOGY, V52, P827, DOI 10.1016/j.neuropharm.2006.10.001; Lin KM, 2001, CIRCULATION, V103, P1787, DOI 10.1161/01.CIR.103.13.1787; Liu WC, 2011, P NATL ACAD SCI USA, V108, P12920, DOI 10.1073/pnas.1107332108; LUNDBERG JON, 1995, NAT MED, V1, P370, DOI 10.1038/nm0495-370; Meissner WG, 2011, NAT REV DRUG DISCOV, V10, P377, DOI 10.1038/nrd3430; Mohanakumar KP, 2002, ANN NY ACAD SCI, V962, P389, DOI 10.1111/j.1749-6632.2002.tb04083.x; Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699; Nah SY, 2007, CNS DRUG REV, V13, P381; Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; Nisoli E, 2004, P NATL ACAD SCI USA, V101, P16507, DOI 10.1073/pnas.0405432101; Papadopoulou LC, 1999, NAT GENET, V23, P333; Pequignot MO, 2001, HUM MUTAT, V17, P374, DOI 10.1002/humu.1112.abs; Radi R, 2002, BIOL CHEM, V383, P401, DOI 10.1515/BC.2002.044; Rakovic A, 2011, PARKINSONS DIS-US, V2011, DOI 10.4061/2011/153979; Ruzzenente B, 2012, EMBO J, V31, P443, DOI 10.1038/emboj.2011.392; Schapira AHV, 2012, ANTIOXID REDOX SIGN, V16, P965, DOI 10.1089/ars.2011.4419; Shehzad O, 2011, J SEP SCI, V34, P1116, DOI 10.1002/jssc.201000932; SHEN WQ, 1995, CIRCULATION, V92, P3505, DOI 10.1161/01.CIR.92.12.3505; Shim JH, 2011, MITOCHONDRION, V11, P707, DOI 10.1016/j.mito.2011.05.013; Sim CH, 2006, HUM MOL GENET, V15, P3251, DOI 10.1093/hmg/ddl398; Son JH, 1999, J NEUROSCI, V19, P10, DOI 10.1523/JNEUROSCI.19-01-00010.1999; Stiburek L, 2010, BBA-BIOENERGETICS, V1797, P1149, DOI 10.1016/j.bbabio.2010.04.006; Stiburek L, 2009, AM J PHYSIOL-CELL PH, V296, pC1218, DOI 10.1152/ajpcell.00564.2008; Tian JW, 2009, PHYTOTHER RES, V23, P486, DOI 10.1002/ptr.2653; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Veereshwarayya V, 2006, J BIOL CHEM, V281, P29468, DOI 10.1074/jbc.M602533200; Yang YF, 2008, P NATL ACAD SCI USA, V105, P7070, DOI 10.1073/pnas.0711845105; Ye R, 2011, NEUROSCIENCE, V178, P169, DOI 10.1016/j.neuroscience.2011.01.007; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3; Zhang H, 2007, MOL REPROD DEV, V74, P497, DOI 10.1002/mrd.20583; Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804	48	28	31	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2012	287	53					44109	44120		10.1074/jbc.M112.408146	http://dx.doi.org/10.1074/jbc.M112.408146			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	062RI	23144451	Green Published, hybrid			2023-01-03	WOS:000312938600010
J	Campos, JC; Queliconi, BB; Dourado, PMM; Cunha, TF; Zambelli, VO; Bechara, LRG; Kowaltowski, AJ; Brum, PC; Mochly-Rosen, D; Ferreira, JCB				Campos, Juliane C.; Queliconi, Bruno B.; Dourado, Paulo M. M.; Cunha, Telma F.; Zambelli, Vanessa O.; Bechara, Luiz R. G.; Kowaltowski, Alicia J.; Brum, Patricia C.; Mochly-Rosen, Daria; Ferreira, Julio C. B.			Exercise Training Restores Cardiac Protein Quality Control in Heart Failure	PLOS ONE			English	Article							UBIQUITIN-PROTEASOME SYSTEM; 20S PROTEASOME; MICE; DYSFUNCTION; MITOCHONDRIA; DEGRADATION; PROGRESSION; ACTIVATION; DEHYDROGENASE; INACTIVATION	Exercise training is a well-known coadjuvant in heart failure treatment; however, the molecular mechanisms underlying its beneficial effects remain elusive. Despite the primary cause, heart failure is often preceded by two distinct phenomena: mitochondria dysfunction and cytosolic protein quality control disruption. The objective of the study was to determine the contribution of exercise training in regulating cardiac mitochondria metabolism and cytosolic protein quality control in a post-myocardial infarction-induced heart failure (MI-HF) animal model. Our data demonstrated that isolated cardiac mitochondria from MI-HF rats displayed decreased oxygen consumption, reduced maximum calcium uptake and elevated H2O2 release. These changes were accompanied by exacerbated cardiac oxidative stress and proteasomal insufficiency. Declined proteasomal activity contributes to cardiac protein quality control disruption in our MI-HF model. Using cultured neonatal cardiomyocytes, we showed that either antimycin A or H2O2 resulted in inactivation of proteasomal peptidase activity, accumulation of oxidized proteins and cell death, recapitulating our in vivo model. Of interest, eight weeks of exercise training improved cardiac function, peak oxygen uptake and exercise tolerance in MI-HF rats. Moreover, exercise training restored mitochondrial oxygen consumption, increased Ca2+-induced permeability transition and reduced H2O2 release in MI-HF rats. These changes were followed by reduced oxidative stress and better cardiac protein quality control. Taken together, our findings uncover the potential contribution of mitochondrial dysfunction and cytosolic protein quality control disruption to heart failure and highlight the positive effects of exercise training in re-establishing cardiac mitochondrial physiology and protein quality control, reinforcing the importance of this intervention as a nonpharmacological tool for heart failure therapy.	[Campos, Juliane C.; Ferreira, Julio C. B.] Univ Sao Paulo, Inst Biomed Sci, Dept Anat, Sao Paulo, Brazil; [Queliconi, Bruno B.; Kowaltowski, Alicia J.] Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-01498 Sao Paulo, Brazil; [Dourado, Paulo M. M.] Univ Sao Paulo, Inst Heart, Sao Paulo, Brazil; [Cunha, Telma F.; Bechara, Luiz R. G.; Brum, Patricia C.] Univ Sao Paulo, Sch Phys Educ & Sport, Sao Paulo, Brazil; [Zambelli, Vanessa O.] Butantan Inst, Sao Paulo, Brazil; [Mochly-Rosen, Daria; Ferreira, Julio C. B.] Stanford Univ, Sch Med, Dept Chem & Syst Biol, Stanford, CA 94305 USA	Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Instituto Butantan; Stanford University	Ferreira, JCB (corresponding author), Univ Sao Paulo, Inst Biomed Sci, Dept Anat, Sao Paulo, Brazil.	jcesarbf@usp.br	Kowaltowski, Alicia J/H-8698-2012; Ferreira, Julio Cesar Batista/I-3177-2012; Bechara, Luiz R G/K-4095-2012; Ferreira, Julio/L-4687-2019; Ferreira, Julio Cesar Batista/AEU-0494-2022; Zambelli, Vanessa O/C-2716-2013; Cunha, Telma F/I-5222-2016; Campos, Juliane/G-5997-2014; Brum, Patricia C/E-6605-2011	Ferreira, Julio Cesar Batista/0000-0003-2694-239X; Ferreira, Julio Cesar Batista/0000-0003-2694-239X; Campos, Juliane/0000-0003-0075-7209; Brum, Patricia C/0000-0002-4750-6506; Zambelli, Vanessa/0000-0003-0890-9561; Queliconi, Bruno Barros/0000-0001-7361-5573; Mochly-Rosen, Daria/0000-0002-6691-8733; Bechara, Luiz/0000-0002-1642-1008	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Sao Paulo - SP (FAPESP) [2009/18546-4, 2010/00028-4, 2012/05765-2]; Conselho Nacional de Pesquisa e Desenvolvimento - Brasil (CNPq) [479407/2010-0]; Instituto Nacional de Ciencia e Tecnologia; Nucleo de Apoio a Pesquisa de Processos Redox em Biomedicina; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2009/12349-2]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052141] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA011147] Funding Source: NIH RePORTER	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Sao Paulo - SP (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Pesquisa e Desenvolvimento - Brasil (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Instituto Nacional de Ciencia e Tecnologia; Nucleo de Apoio a Pesquisa de Processos Redox em Biomedicina; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This study was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Sao Paulo - SP (FAPESP #2009/18546-4, #2010/00028-4 and #2012/05765-2), Conselho Nacional de Pesquisa e Desenvolvimento - Brasil (CNPq, 479407/2010-0), Instituto Nacional de Ciencia e Tecnologia and Nucleo de Apoio a Pesquisa de Processos Redox em Biomedicina. JCC held a master's fellowship from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP #2009/12349-2). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALP PR, 1976, BIOCHEM J, V154, P689, DOI 10.1042/bj1540689; Antony JM, 2004, NAT NEUROSCI, V7, P1088, DOI 10.1038/nn1319; Bulteau AL, 2001, J BIOL CHEM, V276, P30057, DOI 10.1074/jbc.M100142200; Cancherini DV, 2007, CARDIOVASC RES, V73, P720, DOI 10.1016/j.cardiores.2006.11.035; Chen CH, 2008, SCIENCE, V321, P1493, DOI 10.1126/science.1158554; Chen CH, 2010, CARDIOVASC RES, V88, P51, DOI 10.1093/cvr/cvq192; Chen Y, 2011, CIRC RES, V109, P1327, DOI 10.1161/CIRCRESAHA.111.258723; Churchill EN, 2010, CARDIOVASC RES, V85, P385, DOI 10.1093/cvr/cvp334; da Cunha FM, 2011, FREE RADICAL BIO MED, V51, P664, DOI 10.1016/j.freeradbiomed.2011.05.035; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Emter CA, 2005, AM J PHYSIOL-HEART C, V289, pH2030, DOI 10.1152/ajpheart.00526.2005; Farout L, 2006, ARCH BIOCHEM BIOPHYS, V453, P135, DOI 10.1016/j.abb.2006.02.003; Ferreira JCB, 2008, AM J PHYSIOL-REG I, V294, pR26, DOI 10.1152/ajpregu.00424.2007; Ferreira JCB, 2007, CLIN EXP PHARMACOL P, V34, P760, DOI 10.1111/j.1440-1681.2007.04635.x; Ferreira JCB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033175; Ferreira JCB, 2011, LIFE SCI, V88, P578, DOI 10.1016/j.lfs.2011.01.009; Ferreira JCB, 2010, EXP BIOL MED, V235, P497, DOI 10.1258/ebm.2009.009165; Ferrington DA, 2004, FEBS LETT, V578, P217, DOI 10.1016/j.febslet.2004.11.003; Gheorghiade M, 1998, CIRCULATION, V97, P282, DOI 10.1161/01.CIR.97.3.282; Glabe CG, 2004, TRENDS BIOCHEM SCI, V29, P542, DOI 10.1016/j.tibs.2004.08.009; Grune Tilman, 2003, Molecular Aspects of Medicine, V24, P195, DOI 10.1016/S0098-2997(03)00014-1; Guyatt GH, 2004, MT SINAI J MED, V71, P47; Hein S, 2003, CIRCULATION, V107, P984, DOI 10.1161/01.CIR.0000051865.66123.B7; Hunt SA, 2009, CIRCULATION, V119, pE391, DOI 10.1161/CIRCULATIONAHA.109.192065; Isom AL, 2004, J AM SOC MASS SPECTR, V15, P1136, DOI 10.1016/j.jasms.2004.03.013; JOHNS TNP, 1954, ANN SURG, V140, P675, DOI 10.1097/00000658-195411000-00006; Jonsdottir S, 2006, EUR J HEART FAIL, V8, P97, DOI 10.1016/j.ejheart.2005.05.002; Kido M, 2005, J AM COLL CARDIOL, V46, P2116, DOI 10.1016/j.jacc.2005.08.045; Li J, 2011, J CLIN INVEST, V121, P3689, DOI 10.1172/JCI45709; Liberek K, 2008, EMBO J, V27, P328, DOI 10.1038/sj.emboj.7601970; Maki CG, 1996, CANCER RES, V56, P2649; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Myers J, 2002, NEW ENGL J MED, V346, P793, DOI 10.1056/NEJMoa011858; Oliveira RSF, 2009, J PHYSIOL-LONDON, V587, P3899, DOI 10.1113/jphysiol.2009.173948; Patterson C, 2007, CIRCULATION, V115, P1456, DOI 10.1161/CIRCULATIONAHA.106.649863; Powell SR, 2005, ANTIOXID REDOX SIGN, V7, P538, DOI 10.1089/ars.2005.7.538; Powers SK, 2002, CURR OPIN CARDIOL, V17, P495, DOI 10.1097/00001573-200209000-00009; Qi ZT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021140; Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637; Roede JR, 2010, ENVIRON MOL MUTAGEN, V51, P380, DOI 10.1002/em.20553; Rosca MG, 2010, CARDIOVASC RES, V88, P40, DOI 10.1093/cvr/cvq240; Roveda F, 2003, J AM COLL CARDIOL, V42, P854, DOI 10.1016/S0735-1097(03)00831-3; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Schatz G, 2007, ANNU REV BIOCHEM, V76, P673, DOI 10.1146/annurev.biochem.76.060806.091141; Shin JH, 2009, NEUROSCI RES; Tahara EB, 2009, FREE RADICAL BIO MED, V46, P1283, DOI 10.1016/j.freeradbiomed.2009.02.008; Tsukamoto O, 2006, BIOCHEM BIOPH RES CO, V340, P1125, DOI 10.1016/j.bbrc.2005.12.120; Vallentin A, 2007, J BIOL CHEM, V282, P1650, DOI 10.1074/jbc.M601710200; Wang XJ, 2006, CIRC RES, V99, P1315, DOI 10.1161/01.RES.0000252342.61447.a2; Wisloff U, 2007, CIRCULATION, V115, P3086, DOI 10.1161/CIRCULATIONAHA.106.675041	50	56	57	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2012	7	12							e52764	10.1371/journal.pone.0052764	http://dx.doi.org/10.1371/journal.pone.0052764			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	061EA	23300764	Green Published, Green Submitted, gold			2023-01-03	WOS:000312829100078
J	Vaucher, YE; Peralta-Carcelen, M; Finer, NN; Carlo, WA; Gantz, MG; Walsh, MC; Laptook, AR; Yoder, BA; Faix, RG; Das, A; Schibler, K; Rich, W; Newman, NS; Vohr, BR; Yolton, K; Heyne, RJ; Wilson-Costello, DE; Evans, PW; Goldstein, RF; Acarregui, MJ; Adams-Chapman, I; Pappas, A; Hintz, SR; Poindexter, B; Dusick, AM; McGowan, EC; Ehrenkranz, RA; Bodnar, A; Bauer, CR; Fuller, J; O'Shea, TM; Myers, GJ; Higgins, RD				Vaucher, Yvonne E.; Peralta-Carcelen, Myriam; Finer, Neil N.; Carlo, Waldemar A.; Gantz, Marie G.; Walsh, Michele C.; Laptook, Abbot R.; Yoder, Bradley A.; Faix, Roger G.; Das, Abhik; Schibler, Kurt; Rich, Wade; Newman, Nancy S.; Vohr, Betty R.; Yolton, Kimberly; Heyne, Roy J.; Wilson-Costello, Deanne E.; Evans, Patricia W.; Goldstein, Ricki F.; Acarregui, Michael J.; Adams-Chapman, Ira; Pappas, Athina; Hintz, Susan R.; Poindexter, Brenda; Dusick, Anna M.; McGowan, Elisabeth C.; Ehrenkranz, Richard A.; Bodnar, Anna; Bauer, Charles R.; Fuller, Janell; O'Shea, T. Michael; Myers, Gary J.; Higgins, Rosemary D.		Eunice Kennedy Shriver NICHD Neona	Neurodevelopmental Outcomes in the Early CPAP and Pulse Oximetry Trial	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BIRTH-WEIGHT INFANTS; FREQUENCY OSCILLATORY VENTILATION; PRETERM INFANTS; CEREBRAL-PALSY; CONVENTIONAL VENTILATION; NEONATAL MORBIDITIES; OXYGEN-SATURATION; AGE; RETINOPATHY; PREMATURITY	BACKGROUND Previous results from our trial of early treatment with continuous positive airway pressure (CPAP) versus early surfactant treatment in infants showed no significant difference in the outcome of death or bronchopulmonary dysplasia. A lower (vs. higher) target range of oxygen saturation was associated with a lower rate of severe retinopathy but higher mortality. We now report longer-term results from our prespecified hypotheses. METHODS Using a 2-by-2 factorial design, we randomly assigned infants born between 24 weeks 0 days and 27 weeks 6 days of gestation to early CPAP with a limited ventilation strategy or early surfactant administration and to lower or higher target ranges of oxygen saturation (85 to 89% or 91 to 95%). The primary composite outcome for the longer-term analysis was death before assessment at 18 to 22 months or neurodevelopmental impairment at 18 to 22 months of corrected age. RESULTS The primary outcome was determined for 1234 of 1316 enrolled infants (93.8%); 990 of the 1058 surviving infants (93.6%) were evaluated at 18 to 22 months of corrected age. Death or neurodevelopmental impairment occurred in 27.9% of the infants in the CPAP group (173 of 621 infants), versus 29.9% of those in the surfactant group (183 of 613) (relative risk, 0.93; 95% confidence interval [CI], 0.78 to 1.10; P = 0.38), and in 30.2% of the infants in the lower-oxygen-saturation group (185 of 612), versus 27.5% of those in the higher-oxygen-saturation group (171 of 622) (relative risk, 1.12; 95% CI, 0.94 to 1.32; P = 0.21). Mortality was increased with the lower-oxygen-saturation target (22.1%, vs. 18.2% with the higher-oxygen-saturation target; relative risk, 1.25; 95% CI, 1.00 to 1.55; P = 0.046). CONCLUSIONS We found no significant differences in the composite outcome of death or neurodevelopmental impairment among extremely premature infants randomly assigned to early CPAP or early surfactant administration and to a lower or higher target range of oxygen saturation. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Heart, Lung, and Blood Institute; SUPPORT ClinicalTrials.gov number, NCT00233324.)	[Finer, Neil N.] Univ Calif San Diego, Div Neonatol, Dept Pediat, San Diego, CA 92013 USA; [Hintz, Susan R.] Stanford Univ, Sch Med, Dept Pediat, Div Neonatal & Dev Med, Palo Alto, CA 94304 USA; [Hintz, Susan R.] Lucile Packard Childrens Hosp, Palo Alto, CA USA; [Peralta-Carcelen, Myriam; Carlo, Waldemar A.] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL USA; [Gantz, Marie G.] RTI Int, Stat & Epidemiol Unit, Res Triangle Pk, NC USA; [Goldstein, Ricki F.] Duke Univ, Dept Pediat, Durham, NC 27706 USA; [O'Shea, T. Michael] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; [Walsh, Michele C.; Newman, Nancy S.; Wilson-Costello, Deanne E.] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; [Schibler, Kurt; Yolton, Kimberly] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH USA; [Schibler, Kurt; Yolton, Kimberly] Univ Cincinnati, Cincinnati, OH 45221 USA; [Laptook, Abbot R.; Vohr, Betty R.] Brown Univ, Women & Infants Hosp, Dept Pediat, Providence, RI 02908 USA; [Yoder, Bradley A.; Faix, Roger G.; Bodnar, Anna] Univ Utah, Sch Med, Dept Pediat, Div Neonatol, Salt Lake City, UT USA; [Das, Abhik] RTI Int, Stat & Epidemiol Unit, Rockville, MD USA; [Higgins, Rosemary D.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA; [Heyne, Roy J.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Evans, Patricia W.] Univ Texas Houston, Med Sch Houston, Houston, TX USA; [Acarregui, Michael J.] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; [Adams-Chapman, Ira] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA; [Adams-Chapman, Ira] Childrens Healthcare Atlanta, Atlanta, GA USA; [Pappas, Athina] Wayne State Univ, Dept Pediat, Detroit, MI 48202 USA; [Poindexter, Brenda; Dusick, Anna M.] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN USA; [McGowan, Elisabeth C.] Floating Hosp Children, Tufts Med Ctr, Div Newborn Med, Dept Pediat, Boston, MA USA; [Ehrenkranz, Richard A.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; [Bauer, Charles R.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA; [Fuller, Janell] Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA; [Myers, Gary J.] Univ Rochester, Med Ctr, Dept Pediat, Rochester, NY 14642 USA	University of California System; University of California San Diego; Stanford University; Lucile Packard Children's Hospital (LPCH); University of Alabama System; University of Alabama Birmingham; Research Triangle Institute; Duke University; Wake Forest University; Wake Forest Baptist Medical Center; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Brown University; Women & Infants Hospital Rhode Island; Utah System of Higher Education; University of Utah; Research Triangle Institute; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Health Science Center Houston; University of Iowa; Emory University; Children's Healthcare of Atlanta (CHOA); Wayne State University; Indiana University System; Indiana University Bloomington; Floating Hospital For Children; Tufts Medical Center; Yale University; University of Miami; University of New Mexico; University of New Mexico's Health Sciences Center; University of Rochester	Finer, NN (corresponding author), Univ Calif San Diego, Div Neonatol, Dept Pediat, 200 W Arbor Dr, San Diego, CA 92013 USA.	nfiner@ucsd.edu	Das, Abhik/AAF-1883-2020; Yunkunis, Kimberly/AAO-5605-2021	Das, Abhik/0000-0003-2722-0479; Gantz, Marie/0000-0001-8528-0184; Gelbard, Harris/0000-0001-5095-7976; Hintz, Susan/0000-0001-7023-4433	Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Heart, Lung, and Blood Institute; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD040461, U10HD021373, UG1HD053089, U10HD053089] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000041] Funding Source: NIH RePORTER	Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Heart, Lung, and Blood Institute.	Amiel-Tison C., 1998, NEUROLOGICAL DEV BIR; [Anonymous], 2006, BAYLEY SCALES INFANT; Arpino C, 2010, CHILD NERV SYST, V26, P1139, DOI 10.1007/s00381-010-1125-y; Askie LM, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-6; Barrington KJ, 2010, COCHRANE DB SYST REV, V12; Bassler D, 2009, PEDIATRICS, V123, P313, DOI 10.1542/peds.2008-0377; Beaino G, 2010, DEV MED CHILD NEUROL, V52, pE119, DOI 10.1111/j.1469-8749.2010.03612.x; Carlo WA, 2010, NEW ENGL J MED, V362, P1959, DOI 10.1056/NEJMoa0911781; Chen J, 2011, CURR OPIN PEDIATR, V23, P173, DOI 10.1097/MOP.0b013e3283423f35; Collins MP, 2001, PEDIATR RES, V50, P712, DOI 10.1203/00006450-200112000-00014; Donohue PK, 2011, PEDIATRICS, V127, pE414, DOI 10.1542/peds.2010-3428; Farooqi A, 2011, PEDIATRICS, V127, pE1247, DOI 10.1542/peds.2010-0806; Finer NN, 2010, NEW ENGL J MED, V362, P2235; Finer NN, 2010, NEW ENGL J MED, V362, P1970, DOI 10.1056/NEJMoa0911783; Haynes RL, 2003, J NEUROPATH EXP NEUR, V62, P441, DOI 10.1093/jnen/62.5.441; Kenward MG, 2007, STAT METHODS MED RES, V16, P199, DOI 10.1177/0962280206075304; Kobaly K, 2008, PEDIATRICS, V121, P73, DOI 10.1542/peds.2007-1444; Laptook AR, 2005, PEDIATRICS, V115, P673, DOI 10.1542/peds.2004-0667; Marlow N, 2006, ARCH DIS CHILD-FETAL, V91, P320, DOI 10.1136/adc.2005.079632; Mikkola K, 2005, PEDIATRICS, V116, P1391, DOI 10.1542/peds.2005-0171; Neubauer AP, 2008, EUR J PEDIATR, V167, P87, DOI 10.1007/s00431-007-0435-x; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; Palmer EA, 2005, ARCH OPHTHALMOL-CHIC, V123, P311; Rich W, 2012, PEDIATRICS, V129, P480, DOI 10.1542/peds.2011-2121; Rich WD, 2010, PEDIATRICS, V126, pE215, DOI 10.1542/peds.2009-3353; Rosenbaum P, 2007, DEV MED CHILD NEUROL, V49, P8, DOI 10.1111/j.1469-8749.2007.tb12610.x; Saugstad Ola Didrik, 2003, J Matern Fetal Neonatal Med, V14, P145, DOI 10.1080/713606611; Saugstad OD, 2011, NEONATOLOGY, V100, P1, DOI 10.1159/000322001; Schulzke SM, 2007, ARCH PEDIAT ADOL MED, V161, P583, DOI 10.1001/archpedi.161.6.583; Sinn JKH, 2002, J PAEDIATR CHILD H, V38, P597, DOI 10.1046/j.1440-1754.2002.00061.x; Stenson B, 2011, NEW ENGL J MED, V364, P1680, DOI 10.1056/NEJMc1101319; Tin W, 2001, ARCH DIS CHILD-FETAL, V84, pF106, DOI 10.1136/fn.84.2.F106; Truffert P, 2007, PEDIATRICS, V119, pE860, DOI 10.1542/peds.2006-2082; Vohr BR, 2000, PEDIATRICS, V105, P1216, DOI 10.1542/peds.105.6.1216; Vohr BR, 2012, J PEDIAT, V161; Walsh MC, 2005, J PEDIATR-US, V146, P798, DOI 10.1016/j.jpeds.2005.01.047; Wood NS, 2000, NEW ENGL J MED, V343, P378, DOI 10.1056/NEJM200008103430601	37	134	140	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 27	2012	367	26					2495	2504		10.1056/NEJMoa1208506	http://dx.doi.org/10.1056/NEJMoa1208506			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	059OG	23268664	Green Accepted, Bronze			2023-01-03	WOS:000312714200007
J	Qin, H; Luo, J; Zhu, YP; Xie, HL; Yang, WQ; Lei, WB				Qin, Hao; Luo, Jie; Zhu, Yuan-Ping; Xie, Hai-Li; Yang, Wei-Qiang; Lei, Wen-Bin			Combination of Taxanes, Cisplatin and Fluorouracil as Induction Chemotherapy for Locally Advanced Head and Neck Cancer: A Meta-Analysis	PLOS ONE			English	Article							SQUAMOUS-CELL CARCINOMA; PHASE-III; RANDOMIZED-TRIAL; DOCETAXEL; CHEMORADIOTHERAPY; RADIOTHERAPY; PACLITAXEL; STANDARD; SURVIVAL; THERAPY	Background: Some investigations have suggested that induction chemotherapy with a combination of taxanes, cisplatin and fluorouracil (TPF) is effective in locally advanced head and neck cancer. However, other trials have indicated that TPF does not improve outcomes. The objective of this study was to compare the efficacy and safety of TPF with a cisplatin and fluorouracil (PF) regimen through a meta-analysis. Methods: Four randomized clinical trials were identified, which included 1,552 patients with locally advanced head and neck cancer who underwent induction chemotherapy with either a TPF or PF protocol. The outcomes included the 3-year survival rate, overall response rate and different types of adverse events. Risk ratios (RRs) and their 95% confidence intervals (CIs) were pooled using RevMan 5.1 software. Results: The 3-year survival rate (51.0% vs. 42.4%; p = 0.002), 3-year progression-free survival rate (35.9% vs. 27.2%; p = 0.007) and overall response to chemotherapy (72.9% vs. 62.1%; p < 0.00001) of the patients in the TPF group was statistically superior to those in the PF group. In terms of toxicities, the incidence of febrile neutropenia (7.0% vs. 3.2%; p = 0.001) and alopecia (10.8% vs. 1.1%; p < 0.00001) was higher in the TPF group. Conclusion: The TPF induction chemotherapy regimen leads to a significant survival advantage with acceptable toxicity rates for patients with locally advanced head and neck cancer compared with the PF regimen.	[Qin, Hao; Luo, Jie; Zhu, Yuan-Ping; Yang, Wei-Qiang; Lei, Wen-Bin] Sun Yat Sen Univ, Otorhinolaryngol Inst, Affiliated Hosp 1, Dept Otorhinolaryngol, Guangzhou 510275, Guangdong, Peoples R China; [Xie, Hai-Li] Sun Yat Sen Univ, Sch Publ Hlth, Dept Biostat & Epidemiol, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Lei, WB (corresponding author), Sun Yat Sen Univ, Otorhinolaryngol Inst, Affiliated Hosp 1, Dept Otorhinolaryngol, Guangzhou 510275, Guangdong, Peoples R China.	leiwb2003@yahoo.com.cn	Zhu, Yuanping/AAM-2950-2021	Zhu, Yuanping/0000-0001-8057-8061	National Natural Science Foundation of China [81072224]; Young Faculty Cultivation Project of Sun Yat-sen University [10ykpy10]; Science and Technology Planning Project of Guangdong Province [2009B030801109]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Young Faculty Cultivation Project of Sun Yat-sen University; Science and Technology Planning Project of Guangdong Province	This study was supported by National Natural Science Foundation of China (81072224), Young Faculty Cultivation Project of Sun Yat-sen University (10ykpy10) and Science and Technology Planning Project of Guangdong Province (2009B030801109). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adelstein DJ, 2003, J CLIN ONCOL, V21, P92, DOI 10.1200/JCO.2003.01.008; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Brockstein B, 2004, ANN ONCOL, V15, P1179, DOI 10.1093/annonc/mdh308; Chandana SR, 2009, CURR OPIN ONCOL, V21, P218, DOI 10.1097/CCO.0b013e328329abe5; Denis F, 2004, J CLIN ONCOL, V22, P69, DOI 10.1200/JCO.2004.08.021; Forastiere AA, 2006, LONG TERM RESULTS IN; FRANCIS PA, 1995, LUNG CANCER-J IASLC, V12, pS163, DOI 10.1016/0169-5002(95)00432-Z; Harari PM, 1997, J CLIN ONCOL, V15, P2050, DOI 10.1200/JCO.1997.15.5.2050; Hitt R, 2005, J CLIN ONCOL, V23, P8636, DOI 10.1200/JCO.2004.00.1990; Hitt R, 2009, ASCO M, V27, P6009; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kutter J, 2005, EUR ARCH OTO-RHINO-L, V262, P1, DOI 10.1007/s00405-003-0725-5; Lefebvre JL, 1996, J NATL CANCER I, V88, P890, DOI 10.1093/jnci/88.13.890; Lorch JH, 2011, LANCET ONCOL, V12, P153, DOI 10.1016/S1470-2045(10)70279-5; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; PACCAGNELLA A, 1994, J NATL CANCER I, V86, P265, DOI 10.1093/jnci/86.4.265; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Parthan A, 2009, HEAD NECK-J SCI SPEC, V31, P1255, DOI 10.1002/hed.21096; Pignon JP, 2000, LANCET, V355, P949, DOI 10.1016/S0140-6736(00)90011-4; Pignon JP, 2004, ANTI-CANCER DRUG, V15, P331, DOI 10.1097/00001813-200404000-00004; Pointreau Y, 2009, JNCI-J NATL CANCER I, V101, P498, DOI 10.1093/jnci/djp007; Posner MR, 2007, NEW ENGL J MED, V357, P1705, DOI 10.1056/NEJMoa070956; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; Schrijvers D, 2000, Oncologist, V5, P199, DOI 10.1634/theoncologist.5-3-199; Seiwert TY, 2005, BRIT J CANCER, V92, P1341, DOI 10.1038/sj.bjc.6602510; Vermorken JB, 2007, NEW ENGL J MED, V357, P1695, DOI 10.1056/NEJMoa071028; Yano R, 2011, INT J CLIN ONCOL	28	15	16	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 7	2012	7	12							e51526	10.1371/journal.pone.0051526	http://dx.doi.org/10.1371/journal.pone.0051526			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	050OT	23236511	Green Submitted, Green Published, gold			2023-01-03	WOS:000312064100127
J	Hitchings, AW; Baker, EH; Khong, TK				Hitchings, Andrew W.; Baker, Emma H.; Khong, Teck K.			Making medicines evergreen	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Hitchings, Andrew W.; Baker, Emma H.; Khong, Teck K.] Univ London, Div Biomed Sci, London SW17 0RE, England	University of London	Hitchings, AW (corresponding author), Univ London, Div Biomed Sci, London SW17 0RE, England.	ahitchin@sgul.ac.uk		Hitchings, Andrew/0000-0002-2802-1466; Baker, Emma/0000-0002-0871-3721				[Anonymous], 2010, Drug Ther Bull, V48, P61, DOI 10.1136/dtb.2010.04.0029; [Anonymous], 2006, Drug Ther Bull, V44, P73; [Anonymous], 2003, Drug Ther Bull, V41, P17; General Medical Council, 2011, GOOD PRACT IN PRESS; General Medical Council, 2008, GOOD PRACT PRESCR ME; Greene JA, 2011, NEW ENGL J MED, V365, P83, DOI 10.1056/NEJMhle1101722; Health and Social Care Information Centre, PRESCR DISP COMM ENG; Health and Social Care Information Centre, 1998, PRESCR COST AN ENGL; Joint Formulary Committee, BRIT NAT FORM ONL; National Institute for Health and Clinical Excellence, 2010, NEUR PAIN PHARM MAN, V96; National Prescribing Centre, 2011, MEREC B, V21; Nussbaum A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006369.pub2; Nussbaum AM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008296.pub2; Office of Health Economics, ABPI UK NHS MED BILL; Paul SM, 2010, NAT REV DRUG DISCOV, V9, P203, DOI 10.1038/nrd3078; Pharmaceuticals Janssen, AT ANT MED INV PAL; Rang H. P., 2006, DRUG DISCOVERY DEV; Schwartz LM, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e1086; 2002, DRUG THER B, V40, P57	19	22	22	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 29	2012	345								e7941	10.1136/bmj.e7941	http://dx.doi.org/10.1136/bmj.e7941			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	048FR	23197598				2023-01-03	WOS:000311896300003
J	O'Dowd, A				O'Dowd, Adrian			Liverpool care pathway: doctors speak out	BRITISH MEDICAL JOURNAL			English	Editorial Material												adrianodowd@aol.com						[Anonymous], 2012, DAILY TELEGRAPH; Kmietowicz Z, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e7511; McCartney M, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e7316	3	3	3	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	NOV 14	2012	345								e7644	10.1136/bmj.e7644	http://dx.doi.org/10.1136/bmj.e7644			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	040PZ	23152572				2023-01-03	WOS:000311336400012
J	Bey, A; Leue, S; Wienbruch, C				Bey, Alina; Leue, Stefan; Wienbruch, Christian			A Neuronal Network Model for Simulating the Effects of Repetitive Transcranial Magnetic Stimulation on Local Field Potential Power Spectra	PLOS ONE			English	Article							LOW-FREQUENCY; PREFRONTAL CORTEX; MOTOR CORTEX; EXCITABILITY; FACILITATION; DEPRESSION; RTMS	Repetitive transcranial magnetic stimulation (rTMS) holds promise as a non-invasive therapy for the treatment of neurological disorders such as depression, schizophrenia, tinnitus, and epilepsy. Complex interdependencies between stimulus duration, frequency and intensity obscure the exact effects of rTMS stimulation on neural activity in the cortex, making evaluation of and comparison between rTMS studies difficult. To explain the influence of rTMS on neural activity (e.g. in the motor cortex), we use a neuronal network model. The results demonstrate that the model adequately explains experimentally observed short term effects of rTMS on the band power in common frequency bands used in electroencephalography (EEG). We show that the equivalent local field potential (eLFP) band power depends on stimulation intensity rather than on stimulation frequency. Additionally, our model resolves contradictions in experiments.	[Bey, Alina; Leue, Stefan] Univ Konstanz, Dept Comp & Informat Sci, Constance, Germany; [Wienbruch, Christian] Univ Konstanz, Dept Psychol, Constance, Germany	University of Konstanz; University of Konstanz	Bey, A (corresponding author), Univ Konstanz, Dept Comp & Informat Sci, Constance, Germany.	alina.bey@uni-konstanz.de						Barr MS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022627; Barr MS, 2009, NEUROPSYCHOPHARMACOL, V34, P2359, DOI 10.1038/npp.2009.79; Berardelli A, 1998, EXP BRAIN RES, V122, P79, DOI 10.1007/s002210050493; Braitenberg V., 1998, CORTEX STAT GEOMETRY; Buzsaki G., 2006, RHYTHMS BRAIN; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; Fitzgerald PB, 2006, CLIN NEUROPHYSIOL, V117, P2584, DOI 10.1016/j.clinph.2006.06.712; Gangitano M, 2001, J CLIN NEUROPHYSIOLO, P18; GILBERT EN, 1959, ANN MATH STAT, V30, P1141, DOI 10.1214/aoms/1177706098; Graf T, 2001, PSYCHIAT RES-NEUROIM, V107, P1, DOI 10.1016/S0925-4927(01)00083-X; Griskova I, 2007, NEUROSCI LETT, V419, P162, DOI 10.1016/j.neulet.2007.04.030; Hamidi M, 2009, FRONT INTEGR NEUROSC, V3, DOI 10.3389/neuro.07.014.2009; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HOPFIELD JJ, 1984, P NATL ACAD SCI-BIOL, V81, P3088, DOI 10.1073/pnas.81.10.3088; HOPFIELD JJ, 1982, P NATL ACAD SCI-BIOL, V79, P2554, DOI 10.1073/pnas.79.8.2554; Houdayer E, 2008, EXP BRAIN RES, V187, P207, DOI 10.1007/s00221-008-1294-z; Husain FT, 2002, NEUROIMAGE, V15, P58, DOI 10.1006/nimg.2001.0966; Kandel E.R., 2000, PRINCIPLES NEURAL SC, VXLI; Kuramoto Y., 1975, International Symposium on Mathematical Problems in Theoretical Physics, P420, DOI 10.1007/BFb0013365; Langguth B, 2010, NEUROPHYSIOL CLIN, V40, P45, DOI 10.1016/j.neucli.2009.03.001; Maeda F, 2000, CLIN NEUROPHYSIOL, V111, P800, DOI 10.1016/S1388-2457(99)00323-5; MCCULLOCH WS, 1990, B MATH BIOL, V52, P99, DOI 10.1016/S0092-8240(05)80006-0; Miyawaki Y, 2004, ADV NEUR IN, V16, P1295; O'Reardon JP, 2007, BIOL PSYCHIAT, V62, P1208, DOI 10.1016/j.biopsych.2007.01.018; Okamura H, 2001, J CLIN NEUROPHYSIOL, V18, P318, DOI 10.1097/00004691-200107000-00003; Pascual-Leone A., 2002, HDB TRANSCRANIAL MAG; PASCUALLEONE A, 1994, BRAIN, V117, P847, DOI 10.1093/brain/117.4.847; Romero JR, 2002, CLIN NEUROPHYSIOL, V113, P101, DOI 10.1016/S1388-2457(01)00693-9; Simpson SL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020039; Wallace E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014804	30	3	4	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2012	7	11							e49097	10.1371/journal.pone.0049097	http://dx.doi.org/10.1371/journal.pone.0049097			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	048TK	23145082	Green Submitted, Green Published, gold			2023-01-03	WOS:000311935800203
J	Li, J; Wu, RG; Meng, FY; Wang, Z; Wang, CM; Wang, YY; Zhang, ZJ				Li, Jian; Wu, Run-guo; Meng, Fan-yun; Wang, Zhong; Wang, Chang-ming; Wang, Yong-yan; Zhang, Zhan-jun			Synergism and Rules from Combination of Baicalin, Jasminoidin and Desoxycholic acid in Refined Qing Kai Ling for Treat Ischemic Stroke Mice Model	PLOS ONE			English	Article							ACTIVATED PROTEIN-KINASE; TRADITIONAL CHINESE MEDICINE; MIDDLE CEREBRAL-ARTERY; NITRIC-OXIDE SYNTHASE; INJURY IN-VIVO; GENE-EXPRESSION; REPERFUSION INJURY; FOCAL ISCHEMIA; GROWTH-FACTOR; CELL-DEATH	Refined Qing-Kai-Ling (QKL), a modified Chinese medicine, consists of three main ingredients (Baicalin, Jasminoidin and Desoxycholic acid), plays a synergistic effect on the treatment of the acute stage of ischemic stroke. However, the rules of the combination and synergism are still unknown. Based on the ischemic stroke mice model, all different kinds of combination of Baicalin, Jasminoidin, and Desoxycholic acid were investigated by the methods of neurological examination, microarray, and genomics analysis. As a result, it confirmed that the combination of three drugs offered a better therapeutical effect on ischemic stroke than monotherapy of each drug. Additionally, we used Ingenuity pathway Analysis (IPA) and principal component analysis (PCA) to extract the dominant information of expression changes in 373 ischemia-related genes. The results suggested that 5 principal components (PC1-5) could account for more than 95% energy in the gene data. Moreover, 3 clusters (PC1, PC2+PC5, and PC3+PC4) were addressed with cluster analysis. Furthermore, we matched PCs on the drug-target networks, the findings demonstrated that Baicalin related with PC1 that played the leading role in the combination; Jasminoidin related with PC2+PC5 that played a compensatory role; while Desoxycholic acid had the least performance alone which could relate with PC3+PC4 that played a compatible role. These manifestations were accorded with the principle of herbal formulae of Traditional Chinese Medicine (TCM), emperor-minister-adjuvant-courier. In conclusion, we firstly provided scientific evidence to the classic theory of TCM formulae, an initiating holistic viewpoint of combination therapy of TCM. This study also illustrated that PCA might be an applicable method to analyze the complicated data of drug combination.	[Wu, Run-guo; Wang, Chang-ming; Zhang, Zhan-jun] Beijing Normal Univ, State Key Lab Cognit Neurosci & Learning, Beijing 100875, Peoples R China; [Li, Jian] Beijing Univ Chinese Med, Sch Basic Med Sci, Beijing, Peoples R China; [Meng, Fan-yun] Beijing Normal Univ, Sch Resources Sci & Technol, Beijing 100875, Peoples R China; [Wang, Zhong; Wang, Yong-yan] China Acad Tradit Chinese Med, Inst Basic Res Clin Med, Beijing, Peoples R China	Beijing Normal University; Beijing University of Chinese Medicine; Beijing Normal University; China Academy of Chinese Medical Sciences; Institute of Basic Research In Clinical Medicine, CACMS	Zhang, ZJ (corresponding author), Beijing Normal Univ, State Key Lab Cognit Neurosci & Learning, Beijing 100875, Peoples R China.	zhang_rzs@bnu.edu.cn		Wu, Runguo/0000-0002-6523-5754	program for new century excellent talents in University [NCET-10-0249]; Program for excellent doctoral dissertation foundation [2007B7]; project of institute of basic research in clinical medicine [Z0175]	program for new century excellent talents in University(Program for New Century Excellent Talents in University (NCET)); Program for excellent doctoral dissertation foundation; project of institute of basic research in clinical medicine	This work was funded by the program for new century excellent talents in University (No. NCET-10-0249), the Program for excellent doctoral dissertation foundation (No. 2007B7) and by the project of institute of basic research in clinical medicine (No. Z0175). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amarenco Pierre, 2006, Cerebrovasc Dis, V21 Suppl 1, P35, DOI 10.1159/000090360; Ballif BA, 2004, CURR BIOL, V14, P606, DOI 10.1016/j.cub.2004.03.038; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Berezovskaya O, 1996, ACTA NEUROPATHOL, V92, P479, DOI 10.1007/s004010050550; Cao Chunyu, 2009, Zhongguo Zhong Yao Za Zhi, V34, P1549; Carey KM, 2012, ANN PHARMACOTHER, V46, P688, DOI 10.1345/aph.1Q621; Carlson NG, 1999, J IMMUNOL, V163, P3963; Carpi A, 2009, BBA-BIOENERGETICS, V1787, P774, DOI 10.1016/j.bbabio.2009.04.001; Chen YC, 2006, TOXICOL APPL PHARM, V216, P263, DOI 10.1016/j.taap.2006.05.008; Cheng FF, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/567872; CLARK RK, 1993, BRAIN RES BULL, V31, P565, DOI 10.1016/0361-9230(93)90124-T; de Lecinana MA, 2006, J NEUROL SCI, V247, P121, DOI 10.1016/j.jns.2006.03.022; Docagne F, 2002, MOL CELL NEUROSCI, V21, P634, DOI 10.1006/mcne.2002.1206; Dufourcq P, 2008, AM J PATHOL, V172, P37, DOI 10.2353/ajpath.2008.070130; Efferth T, 2007, CURR MED CHEM, V14, P2024; Fisher M, 2008, STROKE, V39, P250, DOI 10.1161/STROKEAHA.107.512244; Fujimoto H, 2004, ARTERIOSCL THROM VAS, V24, P1848, DOI 10.1161/01.ATV.0000142364.85911.0e; Gao Yong-Hong, 2009, Zhong Xi Yi Jie He Xue Bao, V7, P135, DOI 10.3736/jcim20090208; Gorelick PB, 2002, STROKE, V33, P862, DOI 10.1161/hs0302.103657; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; HSU CY, 1993, STROKE, V24, pI78; Hua Q, 2008, BIOL PHARM BULL, V31, P633, DOI 10.1248/bpb.31.633; Keith CT, 2005, NAT REV DRUG DISCOV, V4, P71, DOI 10.1038/nrd1609; Kernan WN, 2010, STROKE, V41, pS35, DOI 10.1161/STROKEAHA.110.592022; Koizumi S, 2002, J BIOL CHEM, V277, P30315, DOI 10.1074/jbc.M201132200; Li C, 1999, Zhongguo Zhong Xi Yi Jie He Za Zhi, V19, P212; Li H, 2003, J CHROMATOGR B, V788, P93, DOI 10.1016/S1570-0232(02)01032-2; Li S, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-S1-S10; Liu Qingyun SJ, 2000, CHIN J IINTEGRATED T, V20, P4; Liu R, 2000, Zhonghua Kou Qiang Yi Xue Za Zhi, V35, P327; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Luo CX, 2007, J NEUROCHEM, V103, P1872, DOI 10.1111/j.1471-4159.2007.04915.x; Mao HP, 2004, J BIOL CHEM, V279, P15472, DOI 10.1074/jbc.M313484200; Marini AM, 2004, RESTOR NEUROL NEUROS, V22, P121; Mastroiacovo F, 2009, J CEREBR BLOOD F MET, V29, P264, DOI 10.1038/jcbfm.2008.111; Nguyen DV, 2002, BIOINFORMATICS, V18, P39, DOI 10.1093/bioinformatics/18.1.39; Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Read SJ, 2001, J CEREBR BLOOD F MET, V21, P755, DOI 10.1097/00004647-200107000-00001; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Saito A, 2004, J NEUROSCI, V24, P1584, DOI 10.1523/JNEUROSCI.5209-03.2004; Shi QD, 2009, NEUROSCI LETT, V465, P220, DOI 10.1016/j.neulet.2009.08.049; Shinozaki Y, 2007, NEUROSCIENCE, V147, P153, DOI 10.1016/j.neuroscience.2007.04.032; Simpson JE, 2009, STROKE, V40, P369, DOI 10.1161/STROKEAHA.108.529214; Szewka Aimee Joy, 2009, Comprehensive Therapy, V35, P72; Tureyen K, 2008, J NEUROCHEM, V105, P1313, DOI 10.1111/j.1471-4159.2008.05233.x; van den Berg RA, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-142; van der Greef J, 2004, CURR OPIN CHEM BIOL, V8, P559, DOI 10.1016/j.cbpa.2004.08.013; Vikman P, 2006, EUR J NEUROL, V13, P1324, DOI 10.1111/j.1468-1331.2006.01496.x; Wang L, 2008, P NATL ACAD SCI USA, V105, P4826, DOI 10.1073/pnas.0712365105; Wang Q, 2002, J BIOL CHEM, V277, P24949, DOI 10.1074/jbc.M203802200; Watanabe S, 2009, J ETHNOPHARMACOL, V125, P203, DOI 10.1016/j.jep.2009.07.014; Woo KJ, 2006, IMMUNOBIOLOGY, V211, P359, DOI 10.1016/j.imbio.2006.02.002; Wu B, 2007, STROKE, V38, P1973, DOI 10.1161/STROKEAHA.106.473165; Xu Lirong, 2004, Zhong Yao Cai, V27, P348; Yang Yan, 2010, Zhongguo Zhong Xi Yi Jie He Za Zhi, V30, P908; Yen CLE, 2002, P NATL ACAD SCI USA, V99, P8512, DOI 10.1073/pnas.132274899; Zhang Chun-ying, 2005, Zhongguo Zhongyao Zazhi, V30, P686; Zhang RL, 2007, CURR MOL MED, V7, P459; Zhang Z.J., 2005, ACTA PHARM SIN, V26, P8; Zhang ZJ, 2006, BRAIN RES, V1123, P188, DOI 10.1016/j.brainres.2006.09.063; Zhang ZJ, 2005, ACTA PHARMACOL SIN, V26, P307, DOI 10.1111/j.1745-7254.2005.00051.x; Zimmermann GR, 2007, DRUG DISCOV TODAY, V12, P34, DOI 10.1016/j.drudis.2006.11.008	63	15	17	0	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2012	7	9							e45811	10.1371/journal.pone.0045811	http://dx.doi.org/10.1371/journal.pone.0045811			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	016KP	23049867	Green Submitted, Green Published, gold			2023-01-03	WOS:000309517300055
J	Rodriguez, PL; Harada, T; Christian, DA; Pantano, DA; Tsai, RK; Discher, DE				Rodriguez, Pia L.; Harada, Takamasa; Christian, David A.; Pantano, Diego A.; Tsai, Richard K.; Discher, Dennis E.			Minimal "Self" Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles	SCIENCE			English	Article							RECEPTOR-MEDIATED PHAGOCYTOSIS; SIGNAL-REGULATORY PROTEIN; IN-VIVO; CD47; CELLS; MEMBRANE; TARGET; ALPHA; ENGRAFTMENT; ACTIVATION	Foreign particles and cells are cleared from the body by phagocytes that must also recognize and avoid clearance of "self" cells. The membrane protein CD47 is reportedly a "marker of self" in mice that impedes phagocytosis of self by signaling through the phagocyte receptor CD172a. Minimal "Self" peptides were computationally designed from human CD47 and then synthesized and attached to virus-size particles for intravenous injection into mice that express a CD172a variant compatible with hCD47. Self peptides delay macrophage-mediated clearance of nanoparticles, which promotes persistent circulation that enhances dye and drug delivery to tumors. Self-peptide affinity for CD172a is near the optimum measured for human CD172a variants, and Self peptide also potently inhibits nanoparticle uptake mediated by the contractile cytoskeleton. The reductionist approach reveals the importance of human Self peptides and their utility in enhancing drug delivery and imaging.	[Rodriguez, Pia L.; Harada, Takamasa; Christian, David A.; Pantano, Diego A.; Tsai, Richard K.; Discher, Dennis E.] Univ Penn, Mol & Cell Biophys & NanoBioPolymers Lab, Philadelphia, PA 19104 USA; [Discher, Dennis E.] Univ Penn, Pharmacol Sci Grad Grp, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Discher, DE (corresponding author), Univ Penn, Mol & Cell Biophys & NanoBioPolymers Lab, Philadelphia, PA 19104 USA.	discher@seas.upenn.edu	Christian, David/AAE-6425-2019	discher, dennis/0000-0001-6163-2229	NIH [R01-EB007049, R01-HL062352, P01-DK032094, NCATS-8UL1TR000003, P30-DK090969]; NSF (Materials Research Science and Engineering Center, and Nano Science and Engineering Center-Nano Bio Interface Center); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000003] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB007049] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK090969, P01DK032094] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF (Materials Research Science and Engineering Center, and Nano Science and Engineering Center-Nano Bio Interface Center); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The assistance of A. Secreto, J. Glover, and G. Danet-Desnoyers of the Stem Cell Xenograft Core at the University of Pennsylvania is very gratefully acknowledged as is technical assistance of K. Hsu, P. Bhoorasingh, and V. Carnevale. Support from the NIH (R01-EB007049, R01-HL062352, P01-DK032094, NCATS-8UL1TR000003, P30-DK090969) and NSF (Materials Research Science and Engineering Center, and Nano Science and Engineering Center-Nano Bio Interface Center) is also very gratefully acknowledged. P. L. R., D. A. P., and D. E. D. are authors on a patent applied for by the University of Pennsylvania on the Self peptide with first disclosure filed on 16 August 2010.	Armstrong JK, 2007, CANCER-AM CANCER SOC, V110, P103, DOI 10.1002/cncr.22739; Bartlett DW, 2007, P NATL ACAD SCI USA, V104, P15549, DOI 10.1073/pnas.0707461104; Bentley AA, 2010, MOL BIOL EVOL, V27, P2187, DOI 10.1093/molbev/msq107; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Bruce LJ, 2003, BLOOD, V101, P4180, DOI 10.1182/blood-2002-09-2824; Cameron CM, 2005, VIROLOGY, V337, P55, DOI 10.1016/j.virol.2005.03.037; Cox D, 2001, SEMIN IMMUNOL, V13, P339, DOI 10.1006/smim.2001.0330; Glodek AM, 2010, BLOOD, V116, P6063, DOI 10.1182/blood-2010-04-273904; Hatherley D, 2008, MOL CELL, V31, P266, DOI 10.1016/j.molcel.2008.05.026; Hong RL, 1999, CLIN CANCER RES, V5, P3645; KLIBANOV AL, 1991, BIOCHIM BIOPHYS ACTA, V1062, P142, DOI 10.1016/0005-2736(91)90385-L; Lundqvist M, 2008, P NATL ACAD SCI USA, V105, P14265, DOI 10.1073/pnas.0805135105; MACDONALD IC, 1991, MICROVASC RES, V42, P60, DOI 10.1016/0026-2862(91)90075-M; Matozaki T, 2009, TRENDS CELL BIOL, V19, P72, DOI 10.1016/j.tcb.2008.12.001; MATSUMURA Y, 1986, CANCER RES, V46, P6387; Mouro-Chanteloup I, 2003, BLOOD, V101, P338, DOI 10.1182/blood-2002-04-1285; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Photos PJ, 2003, J CONTROL RELEASE, V90, P323, DOI 10.1016/S0168-3659(03)00201-3; Rossin R, 2008, J NUCL MED, V49, P103, DOI 10.2967/jnumed.107.045302; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; Stachelek SJ, 2011, BIOMATERIALS, V32, P4317, DOI 10.1016/j.biomaterials.2011.02.053; Strowig T, 2011, P NATL ACAD SCI USA, V108, P13218, DOI 10.1073/pnas.1109769108; Subramanian S, 2006, BLOOD, V107, P2548, DOI 10.1182/blood-2005-04-1463; Subramanian S, 2007, J BIOL CHEM, V282, P1805, DOI 10.1074/jbc.M603923200; Swanson JA, 2004, J LEUKOCYTE BIOL, V76, P1093, DOI 10.1189/jlb.0804439; Takenaka K, 2007, NAT IMMUNOL, V8, P1313, DOI 10.1038/ni1527; Tsai RK, 2008, J CELL BIOL, V180, P989, DOI 10.1083/jcb.200708043; Turk MJ, 2004, CANCER LETT, V213, P165, DOI 10.1016/j.canlet.2003.12.028; TURRINI F, 1993, BLOOD, V81, P3146; Wilflingseder D, 2007, J IMMUNOL, V178, P7840, DOI 10.4049/jimmunol.178.12.7840; Willingham SB, 2012, P NATL ACAD SCI USA, V109, P6662, DOI 10.1073/pnas.1121623109	31	661	727	19	602	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 22	2013	339	6122					971	975		10.1126/science.1229568	http://dx.doi.org/10.1126/science.1229568			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	092UX	23430657	Green Accepted			2023-01-03	WOS:000315149600053
J	Zarychanski, R; Abou-Setta, AM; Turgeon, AF; Houston, BL; McIntyre, L; Marshall, JC; Fergusson, DA				Zarychanski, Ryan; Abou-Setta, Ahmed M.; Turgeon, Alexis F.; Houston, Brett L.; McIntyre, Lauralyn; Marshall, John C.; Fergusson, Dean A.			Association of Hydroxyethyl Starch Administration With Mortality and Acute Kidney Injury in Critically Ill Patients Requiring Volume Resuscitation A Systematic Review and Meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							MODIFIED FLUID GELATIN; RENAL-FUNCTION; SEVERE SEPSIS; 6-PERCENT HYDROXYETHYLSTARCH; PENTOXIFYLLINE INFUSION; ADHESION MOLECULES; ALBUMIN; THERAPY; PENTASTARCH; COAGULATION	Importance Hydroxyethyl starch is commonly used for volume resuscitation yet has been associated with serious adverse events, including acute kidney injury and death. Clinical trials of hydroxyethyl starch are conflicting. Moreover, multiple trials from one investigator have been retracted because of scientific misconduct. Objectives To evaluate the association of hydroxyethyl starch use with mortality and acute kidney injury. Data Sources Randomized controlled trials from MEDLINE, EMBASE, CENTRAL, Global Health, HealthStar, Scopus, Web of Science, the International Clinical Trials Registry Platform (inception to October 2012), reference lists of relevant articles, and gray literature. Study Selection Two reviewers independently identified randomized controlled trials comparing hydroxyethyl starch with other resuscitation fluids in critically ill patients receiving acute volume resuscitation. Data Extraction Two reviewers independently extracted trial-level data including population characteristics, interventions, outcomes, and funding sources. Risk of bias was assessed using the risk of bias tool; the strength of evidence was adjudicated using the GRADE methodology. Results We included 38 eligible trials comparing hydroxyethyl starch to crystalloids, albumin, or gelatin. The majority of trials were categorized as having an unclear risk or high risk of bias. For the 10 880 patients in studies contributing mortality data, the risk ratio (RR) for death among patients randomized to receive hydroxyethyl starch was 1.07 (95% CI, 1.00 to 1.14; I-2, 0%; absolute risk [AR], 1.20%; 95% CI, -0.26% to 2.66%). This summary effect measure included results from 7 trials performed by an investigator whose subsequent research had been retracted because of scientific misconduct. When we excluded these 7 trials that involved 590 patients, hydroxyethyl starch was found to be associated with increased mortality among 10 290 patients (RR, 1.09; 95% CI, 1.02 to 1.17; I-2, 0%; AR, 1.51%; 95% CI, 0.02% to 3.00%), increased renal failure among 8725 patients (RR, 1.27; 95% CI, 1.09 to 1.47; I-2, 26%; AR, 5.45%; 95% CI, 0.44% to 10.47%), and increased use of renal replacement therapy among 9258 patients (RR, 1.32; 95% CI, 1.15 to 1.50; I-2, 0%; AR, 3.12%; 95% CI, 0.47% to 5.78%). Conclusion and Relevance In critically ill patients requiring acute volume resuscitation, use of hydroxyethyl starch compared with other resuscitation solutions was not associated with a decrease in mortality. Moreover, after exclusion of 7 trials performed by an investigator whose research has been retracted because of scientific misconduct, hydroxyethyl starch was associated with a significant increased risk of mortality and acute kidney injury. Clinical use of hydroxyethyl starch for acute volume resuscitation is not warranted due to serious safety concerns. JAMA. 2013;309(7):678-688 www.jama.com	[Zarychanski, Ryan] Univ Manitoba, Dept Internal Med, Sect Crit Care, Winnipeg, MB R3E 0V9, Canada; [Zarychanski, Ryan] Univ Manitoba, Dept Internal Med, Sect Hematol & Med Oncol, Winnipeg, MB R3E 0V9, Canada; [Zarychanski, Ryan; Abou-Setta, Ahmed M.] Univ Manitoba, George & Fay Yee Ctr Healthcare Innovat, Winnipeg, MB R3E 0V9, Canada; [Zarychanski, Ryan; Abou-Setta, Ahmed M.] Winnipeg Reg Hlth Author, Winnipeg, MB, Canada; [Zarychanski, Ryan] Cancercare Manitoba, Winnipeg, MB, Canada; [Turgeon, Alexis F.] Univ Laval, Hop Enfants Jesus, CHU Quebec, Ctr Rech,Dept Anesthesiol,Div Crit Care Med, Quebec City, PQ, Canada; [Houston, Brett L.] Univ Manitoba, Fac Med, Winnipeg, MB R3E 0V9, Canada; [McIntyre, Lauralyn; Fergusson, Dean A.] Univ Ottawa, Dept Med, Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada; [Marshall, John C.] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Marshall, John C.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada	University of Manitoba; University of Manitoba; University of Manitoba; CancerCare Manitoba Foundation; Laval University; University of Manitoba; University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto	Zarychanski, R (corresponding author), Univ Manitoba, Dept Internal Med, Sect Crit Care, ON2056-675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.	ryan.zarychanski@cancercare.mb.ca	McIntyre, Lauralyn/AAR-7710-2021; Zarychanski, Ryan/AAB-6369-2022	McIntyre, Lauralyn/0000-0001-7421-1407; Zarychanski, Ryan/0000-0001-9455-6138; NOIRI, Eisei/0000-0002-9515-7582; Fergusson, Dean/0000-0002-3389-2485; Houston, Brett/0000-0002-8776-4083	Fonds de la Recherche du Quebec - Sante du (FRQ-S); Bristol-Myers Squibb; Abbott Laboratories; Canadian Institutes of Health Research (CIHR)	Fonds de la Recherche du Quebec - Sante du (FRQ-S); Bristol-Myers Squibb(Bristol-Myers Squibb); Abbott Laboratories(Abbott Laboratories); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Zarychanski and McIntyre reported that they receive salary support from the Canadian Institutes of Health Research (CIHR). Dr Turgeon reported that he receives salary support from the Fonds de la Recherche du Quebec - Sante du (FRQ-S). Dr McIntyre reported that she has received unrestricted grant support from Bristol-Myers Squibb and Abbott Laboratories.	[Anonymous], 2011, COMMUNICATION; [Anonymous], 2010, LANCET, V375, P445; [Anonymous], 2012, HOSP PRES RES FIN RE; Asfar P, 2000, INTENS CARE MED, V26, P1282, DOI 10.1007/s001340000606; BEARDS SC, 1994, CRIT CARE MED, V22, P600, DOI 10.1097/00003246-199404000-00015; BERARD JP, 1995, ANN FRANCAISES ANAES, V14, pR335; Boldt J, 1998, INTENS CARE MED, V24, P28, DOI 10.1007/s001340050511; Boldt J, 1996, INTENS CARE MED, V22, P1075, DOI 10.1007/s001340050216; Boldt J, 1996, ANAESTHESIA, V51, P529, DOI 10.1111/j.1365-2044.1996.tb12557.x; BOLDT J, 1995, BRIT J ANAESTH, V75, P740, DOI 10.1093/bja/75.6.740; Boldt J, 1996, CRIT CARE MED, V24, P385, DOI 10.1097/00003246-199603000-00005; Boldt J, 1996, BRIT J ANAESTH, V77, P480, DOI 10.1093/bja/77.4.480; Boldt J, 1996, ANESTH ANALG, V83, P254, DOI 10.1097/00000539-199608000-00010; Bradburn MJ, 2007, STAT MED, V26, P53, DOI 10.1002/sim.2528; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Bunn F, 2012, COCHRANE DB SYST REV, V7; Carli P, 2000, J EUROPEEN URGENCES, V13, P101; Carlisle JB, 2012, ANAESTHESIA, V67, P521, DOI 10.1111/j.1365-2044.2012.07128.x; Chen Jiong, 2006, Zhonghua Shao Shang Za Zhi, V22, P333; Cittanova ML, 1996, LANCET, V348, P1620, DOI 10.1016/S0140-6736(96)07588-5; Dolecek M, 2009, HEPATO-GASTROENTEROL, V56, P1622; Du XJ, 2011, PANCREAS, V40, P1220, DOI 10.1097/MPA.0b013e3182217f17; Dubin Arnaldo, 2010, J Crit Care, V25, DOI 10.1016/j.jcrc.2010.04.007; FALK JL, 1988, J CLIN PHARMACOL, V28, P412, DOI 10.1002/j.1552-4604.1988.tb05751.x; Gattas DJ, 2012, ANESTH ANALG, V114, P159, DOI 10.1213/ANE.0b013e318236b4d6; Gondos T, 2010, EUR J ANAESTH, V27, P794, DOI 10.1097/EJA.0b013e32833b3504; Guidet B, 2012, CRIT CARE, V16, DOI 10.1186/cc11358; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Hartog CS, 2012, INTENS CARE MED, V38, P1258, DOI 10.1007/s00134-012-2614-0; HAUPT MT, 1982, CRIT CARE MED, V10, P159, DOI 10.1097/00003246-198203000-00004; Hayashino Y, 2005, J EPIDEMIOL, V15, P235, DOI 10.2188/jea.15.235; Heradstveit BE, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-29; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hoste EAJ, 2006, CRIT CARE, V10, DOI 10.1186/cc4915; Inal MT, 2010, J CRIT CARE, V25, DOI 10.1016/j.jcrc.2009.06.013; James MFM, 2011, BRIT J ANAESTH, V107, P693, DOI 10.1093/bja/aer229; Jungheinrich C, 2005, CLIN PHARMACOKINET, V44, P681, DOI 10.2165/00003088-200544070-00002; Kamann Stefanie, 2007, J Dtsch Dermatol Ges, V5, P204, DOI 10.1111/j.1610-0387.2007.06239.x; Li Feng, 2008, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V20, P472; Lv Jie, 2012, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V24, P38; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; McIntyre LA, 2008, CAN J ANAESTH, V55, P819, DOI 10.1007/BF03034053; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Molnar Z, 2004, INTENS CARE MED, V30, P1356, DOI 10.1007/s00134-004-2278-5; Myburgh JA, 2012, NEW ENGL J MED, V367, P1901, DOI 10.1056/NEJMoa1209759; NAGY KK, 1993, CIRC SHOCK, V40, P289; Perel P, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000567.pub5; Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242; RACKOW EC, 1989, CRIT CARE MED, V17, P394, DOI 10.1097/00003246-198905000-00003; Rama-Maceiras P, 2009, REV ESP ANEST REANIM, V56, P372, DOI 10.1016/S0034-9356(09)70410-4; RANDELL T, 1990, ACTA ANAESTH SCAND, V34, P592, DOI 10.1111/j.1399-6576.1990.tb03151.x; Sadaka F., 2012, EFFECT 3 DIFFERENT F; Schortgen F, 2001, LANCET, V357, P911, DOI 10.1016/S0140-6736(00)04211-2; Siegemund M., 2012, BASES TRIAL BASEL ST; Sirtl C, 1999, BRIT J ANAESTH, V82, P510, DOI 10.1093/bja/82.4.510; van der Heijden M, 2009, CRIT CARE MED, V37, P1275, DOI 10.1097/CCM.0b013e31819cedfd; Veneman TF, 2004, WIEN KLIN WOCHENSCHR, V116, P305, DOI 10.1007/BF03040900; VERMEULEN LC, 1995, ARCH INTERN MED, V155, P373, DOI 10.1001/archinte.155.4.373; Vlachou E, 2010, BURNS, V36, P984, DOI 10.1016/j.burns.2010.04.001; Younes RN, 1998, WORLD J SURG, V22, P2; Zarychanski R, SERIOUS ADVERSE EVEN; Zarychanski Ryan, 2009, Open Med, V3, pe196; Zhao G, 2011, HPB OXFORD S2, V13, P1; Zhu Guo-chao, 2011, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V23, P150	66	410	448	3	74	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	2013	309	7					678	688		10.1001/jama.2013.430	http://dx.doi.org/10.1001/jama.2013.430			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	091EK	23423413	Bronze			2023-01-03	WOS:000315032000023
J	Thriemer, K; Katuala, Y; Batoko, B; Alworonga, JP; Devlieger, H; Van Geet, C; Ngbonda, D; Jacobs, J				Thriemer, Kamala; Katuala, Yves; Batoko, Bibi; Alworonga, Jean-Pierre; Devlieger, Hugo; Van Geet, Christel; Ngbonda, Dauly; Jacobs, Jan			Antibiotic Prescribing in DR Congo: A Knowledge, Attitude and Practice Survey among Medical Doctors and Students	PLOS ONE			English	Article							ANTIMICROBIAL RESISTANCE; PERCEPTIONS; EXPECTATIONS; PHYSICIANS; BELIEFS	Objectives: Antibiotic resistance (ABR) particularly hits resource poor countries, and is fuelled by irrational antibiotic (AB) prescribing. We surveyed knowledge, attitudes and practices of AB prescribing among medical students and doctors in Kisangani, DR Congo. Methods: Self-administered questionnaires. Results: A total of 184 questionnaires were completed (response rate 94.4%). Knowledge about AB was low (mean score 4.9/8 points), as was the estimation of local resistance rates of S. Typhi and Klebsiella spp.(correct by 42.5% and 6.9% of respondents respectively). ABR was recognized as a problem though less in their own practice (67.4%) than nation- or worldwide (92.9% and 85.5%, p<.0001). Confidence in AB prescribing was high (88.6%) and students consulted more frequently colleagues than medical doctors when prescribing (25.4% versus 11.6%, p = 0.19). Sources of AB prescribing included pharmaceutical companies (73.9%), antibiotic guidelines (66.3%), university courses (63.6%), internet-sites (45.7%) and WHO guidelines (26.6%). Only 30.4% and 16.3% respondents perceived AB procured through the central procurement and local pharmacies as of good quality. Local AB guidelines and courses about AB prescribing are welcomed (73.4% and 98.8% respectively). Conclusions: This data shows the need for interventions that support rational AB prescribing.	[Thriemer, Kamala; Jacobs, Jan] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [Katuala, Yves; Batoko, Bibi; Alworonga, Jean-Pierre; Ngbonda, Dauly] Univ Hosp Kisangani, Dept Pediat, Kisangani, DEM REP CONGO; [Devlieger, Hugo; Van Geet, Christel] Katholieke Univ Leuven Hosp, Dept Pediat, Louvain, Belgium	Institute of Tropical Medicine (ITM); Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven	Thriemer, K (corresponding author), Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium.	kthriemer@itg.be	Jacobs, Jan/GRX-7316-2022	Thriemer, Kamala/0000-0001-7536-7497	Flemish Interuniversity Council [ZRDC2009EIN6]	Flemish Interuniversity Council	This study was sponsored by the Flemish Interuniversity Council Project ZRDC2009EIN6. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aranda CMA, 2010, ANTIMICROBIAL RESISTANCE IN DEVELOPING COUNTRIES, P491, DOI 10.1007/978-0-387-89370-9_28; Britten N, 1997, BRIT MED J, V315, P1506, DOI 10.1136/bmj.315.7121.1506; Garcia Coralith, 2011, BMC Clin Pharmacol, V11, P18, DOI 10.1186/1472-6904-11-18; Gaudiano MC, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-22; Giblin TB, 2004, ARCH INTERN MED, V164, P1662, DOI 10.1001/archinte.164.15.1662; Guerra CM, 2007, INFECT CONT HOSP EP, V28, P1411, DOI 10.1086/523278; Karras DJ, 2003, ANN EMERG MED, V42, P835, DOI 10.1016/S0196-0644(03)00602-4; Kinshasa Ud, 2009, ANN AFRICAINES MED; Lunguya Octavie, 2012, PLoS Negl Trop Dis, V6, pe1921, DOI 10.1371/journal.pntd.0001921; Macfarlane J, 1997, BMJ-BRIT MED J, V315, P1211, DOI 10.1136/bmj.315.7117.1211; Mangione-Smith R, 1999, PEDIATRICS, V103, P711, DOI 10.1542/peds.103.4.711; MULLER C, 1972, SCIENCE, V176, P488, DOI 10.1126/science.176.4034.488; Okeke IN, 2010, ANTIMICROBIAL RESISTANCE IN DEVELOPING COUNTRIES, P27, DOI 10.1007/978-0-387-89370-9_3; Olivier C, 2010, ANTIMICROBIAL RESISTANCE IN DEVELOPING COUNTRIES, P505, DOI 10.1007/978-0-387-89370-9_29; Pulcini C, 2011, CLIN MICROBIOL INFEC, V17, P80, DOI 10.1111/j.1469-0691.2010.03179.x; Srinivasan A, 2004, ARCH INTERN MED, V164, P1451, DOI 10.1001/archinte.164.13.1451; Vlieghe E, 2009, INT J ANTIMICROB AG, V34, P295, DOI 10.1016/j.ijantimicag.2009.04.015; Wester CW, 2002, ARCH INTERN MED, V162, P2210, DOI 10.1001/archinte.162.19.2210; WHO, 2012, EVOLVING THREAT OF ANTIMICROBIAL RESISTANCE: OPTIONS FOR ACTION, P1	19	97	99	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2013	8	2							e55495	10.1371/journal.pone.0055495	http://dx.doi.org/10.1371/journal.pone.0055495			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	092YP	23441152	Green Published, gold			2023-01-03	WOS:000315159200010
J	Schuepbach, WMM; Rau, J; Knudsen, K; Volkmann, J; Krack, P; Timmermann, L; Halbig, TD; Hesekamp, H; Navarro, SM; Meier, N; Falk, D; Mehdorn, M; Paschen, S; Maarouf, M; Barbe, MT; Fink, GR; Kupsch, A; Gruber, D; Schneider, GH; Seigneuret, E; Kistner, A; Chaynes, P; Ory-Magne, F; Courbon, CB; Vesper, J; Schnitzler, A; Wojtecki, L; Houeto, JL; Bataille, B; Maltete, D; Damier, P; Raoul, S; Sixel-Doering, F; Hellwig, D; Gharabaghi, A; Kruger, R; Pinsker, MO; Amtage, F; Regis, JM; Witjas, T; Thobois, S; Mertens, P; Kloss, M; Hartmann, A; Oertel, WH; Post, B; Speelman, H; Agid, Y; Schade-Brittinger, C; Deuschl, G				Schuepbach, W. M. M.; Rau, J.; Knudsen, K.; Volkmann, J.; Krack, P.; Timmermann, L.; Haelbig, T. D.; Hesekamp, H.; Navarro, S. M.; Meier, N.; Falk, D.; Mehdorn, M.; Paschen, S.; Maarouf, M.; Barbe, M. T.; Fink, G. R.; Kupsch, A.; Gruber, D.; Schneider, G. -H.; Seigneuret, E.; Kistner, A.; Chaynes, P.; Ory-Magne, F.; Courbon, C. Brefel; Vesper, J.; Schnitzler, A.; Wojtecki, L.; Houeto, J-L.; Bataille, B.; Maltete, D.; Damier, P.; Raoul, S.; Sixel-Doering, F.; Hellwig, D.; Gharabaghi, A.; Krueger, R.; Pinsker, M. O.; Amtage, F.; Regis, J. -M.; Witjas, T.; Thobois, S.; Mertens, P.; Kloss, M.; Hartmann, A.; Oertel, W. H.; Post, B.; Speelman, H.; Agid, Y.; Schade-Brittinger, C.; Deuschl, G.		EARLYSTIM Study Grp	Neurostimulation for Parkinson's Disease with Early Motor Complications	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-BRAIN-STIMULATION; QUALITY-OF-LIFE; SUBTHALAMIC NUCLEUS; MOVEMENT-DISORDERS; CONTROLLED-TRIAL; RATING-SCALE; QUESTIONNAIRE; MULTICENTER; RELIABILITY; DEPRESSION	BACKGROUND Subthalamic stimulation reduces motor disability and improves quality of life in patients with advanced Parkinson's disease who have severe levodopa-induced motor complications. We hypothesized that neurostimulation would be beneficial at an earlier stage of Parkinson's disease. METHODS In this 2-year trial, we randomly assigned 251 patients with Parkinson's disease and early motor complications (mean age, 52 years; mean duration of disease, 7.5 years) to undergo neurostimulation plus medical therapy or medical therapy alone. The primary end point was quality of life, as assessed with the use of the Parkinson's Disease Questionnaire (PDQ-39) summary index (with scores ranging from 0 to 100 and higher scores indicating worse function). Major secondary outcomes included parkinsonian motor disability, activities of daily living, levodopa-induced motor complications (as assessed with the use of the Unified Parkinson's Disease Rating Scale, parts III, II, and IV, respectively), and time with good mobility and no dyskinesia. RESULTS For the primary outcome of quality of life, the mean score for the neurostimulation group improved by 7.8 points, and that for the medical-therapy group worsened by 0.2 points (between-group difference in mean change from baseline to 2 years, 8.0 points; P = 0.002). Neurostimulation was superior to medical therapy with respect to motor disability (P<0.001), activities of daily living (P<0.001), levodopa-induced motor complications (P<0.001), and time with good mobility and no dyskinesia (P = 0.01). Serious adverse events occurred in 54.8% of the patients in the neurostimulation group and in 44.1% of those in the medical-therapy group. Serious adverse events related to surgical implantation or the neurostimulation device occurred in 17.7% of patients. An expert panel confirmed that medical therapy was consistent with practice guidelines for 96.8% of the patients in the neurostimulation group and for 94.5% of those in the medical-therapy group. CONCLUSIONS Subthalamic stimulation was superior to medical therapy in patients with Parkinson's disease and early motor complications.	[Schuepbach, W. M. M.; Haelbig, T. D.; Hesekamp, H.; Meier, N.; Hartmann, A.; Agid, Y.] Univ Paris 06, AP HP, CIC 9503, Inst Cerveau & Moelle Epiniere,Dept Neurol, Paris, France; [Schuepbach, W. M. M.; Haelbig, T. D.; Hesekamp, H.; Meier, N.; Hartmann, A.; Agid, Y.] CHU Pitie Salpetriere, INSERM, Paris, France; [Navarro, S. M.] CHU Pitie Salpetriere, Dept Neurosurg, Paris, France; [Krack, P.; Kistner, A.] Univ Hosp, INSERM, U836, Dept Neurol, Grenoble, France; [Seigneuret, E.] Univ Hosp, INSERM, U836, Dept Neurosurg, Grenoble, France; [Chaynes, P.; Ory-Magne, F.; Courbon, C. Brefel] Univ Hosp, Dept Neurol Neurosurg & Pharmacol, Toulouse, France; [Houeto, J-L.] Univ Poitiers, Serv Neurol, CIC INSERM INSERM Unite 1084 0802, Lab Neurosci Expt & Clin, Poitiers, France; [Bataille, B.] Univ Poitiers, Dept Neurosurg, Poitiers, France; [Maltete, D.] Univ Hosp, Dept Neurol, Rouen, France; [Damier, P.; Raoul, S.] CHU Nantes, CIC, F-44035 Nantes 01, France; [Regis, J. -M.] Aix Marseille Univ, Dept Funct Neurosurg, Marseille, France; [Witjas, T.] Univ Hosp Timone, Dept Neurol, Marseille, France; [Thobois, S.] Univ Lyon 1, Hosp Civils Lyon, Hop Neurol Pierre Wertheimer, F-69365 Lyon, France; [Mertens, P.] Univ Hosp, Dept Neurosurg, Lyon, France; [Rau, J.; Schade-Brittinger, C.] Philipps Univ, Coordinating Ctr Clin Trials, Marburg, Germany; [Hellwig, D.] Philipps Univ, Dept Neurosurg, Marburg, Germany; [Oertel, W. H.] Philipps Univ, Dept Neurol, Marburg, Germany; [Knudsen, K.; Volkmann, J.; Paschen, S.; Deuschl, G.] Univ Hosp Schleswig Holstein, Dept Neurol, Kiel, Germany; [Falk, D.; Mehdorn, M.] Univ Hosp Schleswig Holstein, Dept Neurosurg, Kiel, Germany; [Timmermann, L.; Barbe, M. T.; Fink, G. R.] Univ Cologne, Dept Neurol, D-50931 Cologne, Germany; [Maarouf, M.] Univ Cologne, Dept Neurosurg, D-50931 Cologne, Germany; [Kupsch, A.; Gruber, D.] Charite Campus Virchow Hosp, Dept Neurol, Berlin, Germany; [Schneider, G. -H.] Charite Campus Virchow Hosp, Dept Neurosurg, Berlin, Germany; [Vesper, J.] Univ Dusseldorf, Dept Neurosurg, D-40225 Dusseldorf, Germany; [Schnitzler, A.; Wojtecki, L.] Univ Dusseldorf, Dept Neurol, Inst Clin Neurosci & Med Psychol, Dusseldorf, Germany; [Sixel-Doering, F.] Paracelsus Elena Klin, Kassel, Germany; [Gharabaghi, A.] Univ Hosp, Dept Neurosurg, Tubingen, Germany; [Krueger, R.] Univ Hosp, Ctr Neurol, Tubingen, Germany; [Krueger, R.] Univ Hosp, Hertie Inst Clin Brain Res, Tubingen, Germany; [Pinsker, M. O.] Univ Hosp, Dept Neurosurg, Freiburg, Germany; [Amtage, F.] Univ Hosp, Dept Neurol, Freiburg, Germany; [Kloss, M.] Univ Hosp, Dept Neurol, Heidelberg, Germany; [Post, B.] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, NL-6525 ED Nijmegen, Netherlands; [Speelman, H.] Univ Amsterdam, Dept Neurol, Amsterdam, Netherlands	Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Grenoble Alpes; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Grenoble Alpes; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Universite de Poitiers; Universite de Poitiers; CHU de Rouen; Nantes Universite; CHU de Nantes; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Philipps University Marburg; Philipps University Marburg; Philipps University Marburg; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Cologne; University of Cologne; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Freiburg; University of Freiburg; Ruprecht Karls University Heidelberg; Radboud University Nijmegen; University of Amsterdam	Deuschl, G (corresponding author), Univ Kiel, Dept Neurol, Univ Hosp Schleswig Holstein, Campus Kiel,Arnold Heller Str 3, D-24105 Kiel, Germany.	g.deuschl@neurologie.uni-kiel.de	Schnitzler, Alfons/AAT-1054-2021; Kistner, Andrea/AAE-8812-2020; Fink, Gereon R./E-1616-2012; Wojtecki, Lars/AAT-6604-2021; Thobois, Stephane/H-5083-2017; Fink, Gereon R./AFW-9377-2022; corvol, jean-christophe/I-6387-2012; Volkmann, Jens/AAK-7570-2020; Deuschl, Gunther/A-7986-2010; Damier, Philippe/T-7829-2019; Schnitzler, Alfons/K-4625-2014; Schnitzler, Alfons/Q-5520-2019; Levin, Johannes/E-4052-2010; Corvol, Jean-Christophe/F-2124-2017	Fink, Gereon R./0000-0002-8230-1856; Wojtecki, Lars/0000-0002-6205-4405; Fink, Gereon R./0000-0002-8230-1856; corvol, jean-christophe/0000-0001-7325-0199; Deuschl, Gunther/0000-0002-4176-9196; Schnitzler, Alfons/0000-0002-6414-7939; Schnitzler, Alfons/0000-0002-6414-7939; Levin, Johannes/0000-0001-5092-4306; Corvol, Jean-Christophe/0000-0001-7325-0199; Gharabaghi, Alireza/0000-0002-9782-5281; Krack, Paul/0000-0002-3508-7295; Barbe, Michael T./0000-0003-1149-8054; Schneider, Gerd-Helge/0000-0002-1301-2938; Krueger, Rejko/0000-0003-4258-6241; Volkmann, Jens/0000-0002-9570-593X; Timmermann, Lars/0000-0002-5301-3580; Mertens, Patrick/0000-0001-5272-261X	German Ministry of Research	German Ministry of Research	Funded by the German Ministry of Research and others; EARLYSTIM ClinicalTrials.gov number, NCT00354133.)	BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Beunckens C, 2005, CLIN TRIALS, V2, P379, DOI 10.1191/1740774505cn119oa; Daniels C, 2011, MOVEMENT DISORD, V26, P2516, DOI 10.1002/mds.23907; Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281; Deuschl G, 2013, PARKINSONISM RELAT D, V19, P56, DOI 10.1016/j.parkreldis.2012.07.004; Fahn S, 1987, RECENT DEV PARKINSON, V2, P153; Fasano A, 2010, BRAIN, V133, P2664, DOI 10.1093/brain/awq221; Fitzpatrick R, 1997, MOVEMENT DISORD, V12, P916, DOI 10.1002/mds.870120613; FLEMENBAUM A, 1973, PSYCHOL REP, V32, P783, DOI 10.2466/pr0.1973.33.3.783; Follett KA, 2010, NEW ENGL J MED, V362, P2077, DOI 10.1056/NEJMoa0907083; Fox SH, 2011, MOVEMENT DISORD, V26, pS2, DOI 10.1002/mds.23829; GOLDMAN HH, 1992, AM J PSYCHIAT, V149, P1148; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Horstink M, 2006, EUR J NEUROL, V13, P1186, DOI 10.1111/j.1468-1331.2006.01548.x; Kleiner-Fisman G, 2006, MOVEMENT DISORD, V21, pS290, DOI 10.1002/mds.20962; Krack P, 2003, NEW ENGL J MED, V349, P1925, DOI 10.1056/NEJMoa035275; Limousin P, 1998, NEW ENGL J MED, V339, P1105, DOI 10.1056/NEJM199810153391603; Mallinckrodt C H, 2001, J Biopharm Stat, V11, P9, DOI 10.1081/BIP-100104194; Marinus J, 2003, J CLIN EPIDEMIOL, V56, P61, DOI 10.1016/S0895-4356(02)00569-3; Martinez-Martin P, 2011, MOVEMENT DISORD, V26, P2371, DOI 10.1002/mds.23834; Mattis S., 1976, GERIATRIC PSYCHIAT, P77; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Moro E, 2010, MOVEMENT DISORD, V25, P578, DOI 10.1002/mds.22735; Okun MS, 2012, LANCET NEUROL, V11, P208, DOI 10.1016/S1474-4422(11)70308-8; Okun MS, 2012, LANCET NEUROL, V11, P140, DOI 10.1016/S1474-4422(11)70308-8; Peto V, 2001, AGE AGEING, V30, P299, DOI 10.1093/ageing/30.4.299; Post B, 2005, MOVEMENT DISORD, V20, P1577, DOI 10.1002/mds.20640; Post B, 2011, MOVEMENT DISORD, V26, P449, DOI 10.1002/mds.23467; Schrag A, 2000, MOVEMENT DISORD, V15, P1112, DOI 10.1002/1531-8257(200011)15:6<1112::AID-MDS1008>3.0.CO;2-A; Schrag A, 2009, MOVEMENT DISORD, V24, P813, DOI 10.1002/mds.22438; Schupbach WMM, 2007, NEUROLOGY, V68, P267, DOI 10.1212/01.wnl.0000250253.03919.fb; Smeding HMM, 2011, J NEUROL NEUROSUR PS, V82, P754, DOI 10.1136/jnnp.2007.140012; STARKSTEIN SE, 1992, J NEUROPSYCH CLIN N, V4, P134; Tomlinson CL, 2010, MOVEMENT DISORD, V25, P2649, DOI 10.1002/mds.23429; Vidailhet M, 2011, NAT REV NEUROL, V7, P70, DOI 10.1038/nrneurol.2010.216; Voon V, 2008, BRAIN, V131, P2720, DOI 10.1093/brain/awn214; Williams A, 2010, LANCET NEUROL, V9, P581, DOI 10.1016/S1474-4422(10)70093-4	38	834	859	2	155	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 14	2013	368	7					610	622		10.1056/NEJMoa1205158	http://dx.doi.org/10.1056/NEJMoa1205158			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	194VA	23406026	Green Published			2023-01-03	WOS:000322659600006
J	Rotman, SR; Bishop, TF				Rotman, Stephen R.; Bishop, Tara F.			Proton Pump Inhibitor Use in the US Ambulatory Setting, 2002-2009	PLOS ONE			English	Article							GASTROESOPHAGEAL-REFLUX DISEASE; COMMUNITY-ACQUIRED PNEUMONIA; HEALTH-CARE SERVICES; ENTERIC INFECTION; ACID SUPPRESSION; UNITED-STATES; HIP FRACTURE; RISK; THERAPY; OVERUSE	Background and Aims: Anecdotal reports and studies of select populations suggest that the use of proton pump inhibitors (PPIs) has increased since their introduction. We sought to determine recent trends in PPI use in the U. S. outpatient setting and characteristics of patients and physicians that may predict their use. Methods: We used data from the National Ambulatory Medical Care Survey (NAMCS) and the National Hospital Ambulatory Medical Care Survey (NHAMCS) to estimate the prevalence of visits in which patients used PPIs from 2002 to 2009. We tested for associations between PPI use and patient, physician, and practice characteristics using data from 2009. We also estimated the prevalence of visits in which PPIs were used by patients without gastrointestinal complaints, diagnoses, or other indications for their use and tested for associations between patient and physician characteristics and PPI use in patients with no documented indication. Results: PPIs were used in 4.0% of visits in 2002 and 9.2% in 2009 (p < 0.001 for trend across years). The use of omeprazole (0.9% in 2002 to 3.9% in 2009, p < 0.001), esomeprazole (0.9% in 2002 to 2.3% in 2009, p < 0.001), and pantoprazole (0.6% in 2002 to 1.6% in 2009, p < 0.001) increased significantly over the study period. Among visits by patients using PPIs, 62.9% documented no gastrointestinal complaints, gastrointestinal diagnoses, or other indicated reason for their use. Conclusions: We found that PPI use increased significantly from 2002 to 2009 as did documented indications for their use. Newly-prescribed PPI use did not change from 2006 to 2009. More research is needed to determine whether PPIs are overused in the U. S. outpatient setting.	[Rotman, Stephen R.] New York Presbyterian Hosp, Dept Med, New York, NY USA; [Bishop, Tara F.] Weill Cornell Med Coll, Dept Publ Hlth, Div Outcomes & Effectiveness, New York, NY USA; [Bishop, Tara F.] Weill Cornell Med Coll, Dept Med, New York, NY USA	NewYork-Presbyterian Hospital; Cornell University; Cornell University	Bishop, TF (corresponding author), Weill Cornell Med Coll, Dept Publ Hlth, Div Outcomes & Effectiveness, New York, NY USA.	tlfernan@med.cornell.edu			National Institute On Aging Career Development Award [K23AG043499]; NATIONAL INSTITUTE ON AGING [K23AG043499] Funding Source: NIH RePORTER	National Institute On Aging Career Development Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	TFB is supported by a National Institute On Aging Career Development Award (K23AG043499) and in by funds provided to her as a Nanette Laitman Clinical Scholar in Public Health at Weill Cornell Medical College. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agency for Healthcare Research and Quality website, UND HEALTHC QUAL; Arasaradnam RP, 2003, CLIN MED, V3, P387, DOI 10.7861/clinmedicine.3-4-387; Barozzi N, 2009, CLIN THER, V31, P849, DOI 10.1016/j.clinthera.2009.04.012; Bavishi C, 2011, ALIMENT PHARM THER, V34, P1269, DOI 10.1111/j.1365-2036.2011.04874.x; Canani RB, 2006, PEDIATRICS, V117, pE817, DOI 10.1542/peds.2005-1655; Centers for Disease Control and Prevention, NAMCS EST PROC; Centers for Disease Control and Prevention, NAMCS SCOP SAMPL DES; Chen TJ, 2003, INT J CLIN PHARM TH, V41, P207; Friedenberg FK, 2010, DIGEST DIS SCI, V55, P1911, DOI 10.1007/s10620-009-1004-0; George CJ, 2008, AM J GERIATR PHARMAC, V6, P249, DOI 10.1016/j.amjopharm.2008.12.001; Gottlieb DJ, 2010, HEALTH AFFAIR, V29, P537, DOI 10.1377/hlthaff.2009.0609; Gray SL, 2010, ARCH INTERN MED, V170, P765, DOI 10.1001/archinternmed.2010.94; Heidelbaugh JJ, 2010, AM J MANAG CARE, V16, pE228; Herzig SJ, 2009, JAMA-J AM MED ASSOC, V301, P2120, DOI 10.1001/jama.2009.722; Hollingworth S, 2010, PHARMACOEPIDEM DR S, V19, P1019, DOI 10.1002/pds.1969; Howell MD, 2010, ARCH INTERN MED, V170, P784, DOI 10.1001/archinternmed.2010.89; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; Kantorova I, 2004, HEPATO-GASTROENTEROL, V51, P757; Keyhani S, 2012, MED CARE, V50, P257, DOI 10.1097/MLR.0b013e3182422b0f; Korenstein D, 2012, ARCH INTERN MED, V172, P171, DOI 10.1001/archinternmed.2011.772; Laheij RJF, 2004, JAMA-J AM MED ASSOC, V292, P1955, DOI 10.1001/jama.292.16.1955; Lanza FL, 2009, AM J GASTROENTEROL, V104, P728, DOI 10.1038/ajg.2009.115; Leonard J, 2007, AM J GASTROENTEROL, V102, P2047, DOI 10.1111/j.1572-0241.2007.01275.x; National Committee for Quality Assurance, 2007, ESS GUID HEALTHC QUA; Polinski JM, 2011, J AM GERIATR SOC, V59, P1922, DOI 10.1111/j.1532-5415.2011.03537.x; Sutherland JM, 2009, NEW ENGL J MED, V361, P1227, DOI 10.1056/NEJMp0907172; van der Velden AW, 2010, DIGESTION, V81, P43, DOI 10.1159/000236025; Yang YX, 2006, JAMA-J AM MED ASSOC, V296, P2947, DOI 10.1001/jama.296.24.2947; Yu EW, 2011, AM J MED, V124, P519, DOI 10.1016/j.amjmed.2011.01.007	29	94	96	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2013	8	2							e56060	10.1371/journal.pone.0056060	http://dx.doi.org/10.1371/journal.pone.0056060			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104DM	23418510	Green Submitted, Green Published, gold			2023-01-03	WOS:000315970300102
J	Premanand, B; Prabakaran, M; Kiener, TK; Kwang, J				Premanand, Balraj; Prabakaran, Mookkan; Kiener, Tanja K.; Kwang, Jimmy			Recombinant Baculovirus Associated with Bilosomes as an Oral Vaccine Candidate against HEV71 Infection in Mice	PLOS ONE			English	Article							LETHAL ENTEROVIRUS-71 INFECTION; T-CELL RESPONSES; TOXIN B-SUBUNIT; INFLUENZA-VIRUS; NEUTRALIZING ANTIBODIES; IMMUNE-RESPONSES; GENE-DELIVERY; NEWBORN MICE; IMMUNIZATION; PROTECTION	Background: Human enterovirus 71 (HEV71) is one of the major pathogen responsible for hand, foot and mouth disease (HFMD). Currently no effective vaccine or antiviral drugs are available. Like poliovirus, EV71 is transmitted mainly by the feco-oral route. To date the majority of the studied EV71 vaccine candidates are administered parenterally. Injectable vaccines induce good systemic immunity but mucosal responses are often unsatisfactory, whereas mucosal vaccines provide both systemic and mucosal immunity. Therefore, oral immunization appears to be an attractive alternative to parenteral immunization. Methodology/Principal Findings: In this report, we studied the efficacy of an orally administered vaccine candidate developed using recombinant baculovirus displaying VP1 (Bac-VP1) in a murine model. Gastrointestinal delivery of Bac-VP1 significantly induced VP1-specific humoral (IgG) and mucosal (IgA) immune responses. Further, we studied the efficacy of the Bac-VP1 associated with bilosomes and observed that the Bac-VP1 associated with bilosomes elicited significantly higher immune responses compared to bilosomes non-associated with Bac-VP1. However, mice immunized subcutaneously with live Bac-VP1 had significantly enhanced VP1 specific serum IgG levels and higher neutralizing antibody titers compared with mice orally immunized with live Bac-VP1 alone or associated with bilosomes. Conclusion: Bilosomes have been shown to possess inherent adjuvant properties when associated with antigen. Therefore Bac-VP1 with bilosomes could be a promising oral vaccine candidate against EV71 infections. Thus, Bac-VP1 loaded bilosomes may provide a needle free, painless approach for immunization against EV71, thereby increasing patient compliance and consequently increasing vaccination coverage.	[Premanand, Balraj; Prabakaran, Mookkan; Kiener, Tanja K.; Kwang, Jimmy] Natl Univ Singapore, Temasek Life Sci Lab, Singapore 117548, Singapore; [Kwang, Jimmy] Natl Univ Singapore, Fac Med, Dept Microbiol, Singapore 117548, Singapore	National University of Singapore; National University of Singapore	Kwang, J (corresponding author), Natl Univ Singapore, Temasek Life Sci Lab, Singapore 117548, Singapore.	kwang@tll.org.sg		Prabakaran, Mookkan/0000-0002-9816-5908	Temasek Life Sciences Laboratory	Temasek Life Sciences Laboratory(National University of Singapore)	This project is funded by Temasek Life Sciences Laboratory (http://www.tll.org.sg). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aarthi D, 2004, BIOLOGICALS, V32, P153, DOI 10.1016/j.biologicals.2004.09.001; Allaoui-Attarki K, 1998, VACCINE, V16, P685, DOI 10.1016/S0264-410X(97)00261-2; Ang LW, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-270; BREWER JM, 1995, VACCINE, V13, P1441, DOI 10.1016/0264-410X(95)00065-9; Chen SC, 1998, J VIROL, V72, P5757, DOI 10.1128/JVI.72.7.5757-5761.1998; Cheng XJ, 2001, PARASITOL RES, V87, P126, DOI 10.1007/s004360000323; Chiu CH, 2006, MICROBES INFECT, V8, P1671, DOI 10.1016/j.micinf.2006.01.021; Conacher M, 2001, VACCINE, V19, P2965, DOI 10.1016/S0264-410X(00)00537-5; Foo DGW, 2007, MICROBES INFECT, V9, P1299, DOI 10.1016/j.micinf.2007.06.002; FOX G, 1989, J GEN VIROL, V70, P625, DOI 10.1099/0022-1317-70-3-625; FRY DW, 1978, ANAL BIOCHEM, V90, P809, DOI 10.1016/0003-2697(78)90172-0; GHAZI HO, 1995, J MED MICROBIOL, V42, P53, DOI 10.1099/00222615-42-1-53; Kroger Andrew T., 2011, Morbidity and Mortality Weekly Report, V60, P3; Hu YC, 2003, ENZYME MICROB TECH, V33, P445, DOI 10.1016/S0141-0229(03)00143-1; Isaka M, 2001, VACCINE, V19, P1460, DOI 10.1016/S0264-410X(00)00348-0; Kinnunen K, 2009, J GENE MED, V11, P382, DOI 10.1002/jgm.1311; Kolpe AB, 2012, VIRUS RES, V168, P64, DOI 10.1016/j.virusres.2012.06.014; Kost TA, 2002, TRENDS BIOTECHNOL, V20, P173, DOI 10.1016/S0167-7799(01)01911-4; LaBarre DD, 2001, J VIROL METHODS, V96, P107, DOI 10.1016/S0166-0934(01)00316-0; Lavelle Ed C, 2006, Expert Opin Drug Deliv, V3, P747, DOI 10.1517/17425247.3.6.747; Li XL, 2009, BIOCHEM BIOPH RES CO, V390, P1126, DOI 10.1016/j.bbrc.2009.09.103; Liu JN, 2010, VACCINE, V28, P7444, DOI 10.1016/j.vaccine.2010.08.080; Lotter H, 2004, INFECT IMMUN, V72, P7318, DOI 10.1128/IAI.72.12.7318-7321.2004; Lotter H, 2008, INT J MED MICROBIOL, V298, P79, DOI 10.1016/j.ijmm.2007.07.001; MALOY KJ, 1995, EUR J IMMUNOL, V25, P2835, DOI 10.1002/eji.1830251019; Mann BJ, 1997, VACCINE, V15, P659, DOI 10.1016/S0264-410X(96)00236-8; Mann JFS, 2009, VACCINE, V27, P3643, DOI 10.1016/j.vaccine.2009.03.040; Mann JFS, 2006, METHODS, V38, P90, DOI 10.1016/j.ymeth.2005.11.002; Mann JFS, 2004, VACCINE, V22, P2425, DOI 10.1016/j.vaccine.2003.11.067; McMinn PC, 2002, FEMS MICROBIOL REV, V26, P91, DOI 10.1016/S0168-6445(02)00070-0; McMinn PC, 2012, CURR OPIN VIROL, V2, P199, DOI 10.1016/j.coviro.2012.02.009; Meng T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021757; MOLDOVEANU Z, 1993, J INFECT DIS, V167, P84, DOI 10.1093/infdis/167.1.84; Musthaq SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026428; O'Reilly DR, 1992, BACULOVIRUS EXPRESSI, P60; Ogra PL, 2001, CLIN MICROBIOL REV, V14, P430, DOI 10.1128/CMR.14.2.430-445.2001; Pauletti GM, 1996, J CONTROL RELEASE, V41, P3, DOI 10.1016/0168-3659(96)01352-1; PFAFF E, 1988, J VIROL, V62, P2033, DOI 10.1128/JVI.62.6.2033-2040.1988; Prabakaran M, 2010, J VIROL, V84, P3201, DOI 10.1128/JVI.02175-09; Premanand B, 2012, ANTIVIR RES, V95, P311, DOI 10.1016/j.antiviral.2012.05.017; RUECKERT R R, 1990, P507; Rueda P, 2000, VACCINE, V19, P726, DOI 10.1016/S0264-410X(00)00259-0; SHALABY WSW, 1995, CLIN IMMUNOL IMMUNOP, V74, P127, DOI 10.1006/clin.1995.1019; Shoji I, 1997, J GEN VIROL, V78, P2657, DOI 10.1099/0022-1317-78-10-2657; Singh P, 2004, INT J PHARMACEUT, V278, P379, DOI 10.1016/j.ijpharm.2004.03.014; Strauss R, 2007, MOL THER, V15, P193, DOI 10.1038/sj.mt.6300008; Tan CS, 2007, ARCH VIROL, V152, P1069, DOI 10.1007/s00705-007-0941-1; Tani H, 2003, J VIROL, V77, P9799, DOI 10.1128/JVI.77.18.9799-9808.2003; TJIA ST, 1983, VIROLOGY, V125, P107; Tung Wong Siew, 2007, Genet Vaccines Ther, V5, P6, DOI 10.1186/1479-0556-5-6; Watarai S, 1998, J VET MED SCI, V60, P1047, DOI 10.1292/jvms.60.1047; Wu CN, 2001, VACCINE, V20, P895, DOI 10.1016/S0264-410X(01)00385-1	52	33	33	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 4	2013	8	2							e55536	10.1371/journal.pone.0055536	http://dx.doi.org/10.1371/journal.pone.0055536			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	086NH	23390538	gold, Green Published, Green Submitted			2023-01-03	WOS:000314691100054
J	Williams, C; Wilson, P; Morrison, J; McMahon, A; Andrew, W; Allan, L; McConnachie, A; McNeill, Y; Tansey, L				Williams, Christopher; Wilson, Philip; Morrison, Jill; McMahon, Alex; Andrew, Walker; Allan, Lesley; McConnachie, Alex; McNeill, Yvonne; Tansey, Louise			Guided Self-Help Cognitive Behavioural Therapy for Depression in Primary Care: A Randomised Controlled Trial	PLOS ONE			English	Article							CLINICAL EFFECTIVENESS	Background: Access to Cognitive behavioural therapy (CBT) for depression is limited. One solution is CBT self-help books. Trial Objectives: To assess the impact of a guided self-help CBT book (GSH-CBT) on mood, compared to treatment as usual (TAU). Hypotheses: 1. GSH-CBT will have improved mood and knowledge of the causes and treatment of depression compared to the control receiving TAU 2. Guided self-help will be acceptable to patients and staff. Methods and Findings: Participants: Adults attending seven general practices in Glasgow, UK with a BDI-II score of >= 14. 141 randomised to GSH-CBT and 140 to TAU. Interventions: RCT comparing 'Overcoming Depression: A Five Areas Approach' book plus 3-4 short face to face support appointments totalling up to 2 hours of guided support, compared with general practitioner TAU. Primary outcome: The BDI (II) score at 4 months. Numbers analysed: 281 at baseline, 203 at 4 months (primary outcome), 117 at 12 months. Outcome: Mean BDI-II scores were lower in the GSH-CBT group at 4 months by 5.3 points (2.6 to 7.9, p<0.001). At 4 and 12 months there were also significantly higher proportions of participants achieving a 50% reduction in BDI-II in the GSH-CBT arm. The mean support was 2 sessions with 42.7 minutes for session 1, 41.4 minutes for session 2 and 40.2 minutes of support for session 3. Adverse effects/Harms: Significantly less deterioration in mood in GSH-CBT (2.0% compared to 9.8% in the TAU group for BDI-II category change). Limitations: Weaknesses: Our follow-up rate of 72.2% at 4 months is better than predicted but is poorer at 12 months (41.6%). In the GSH-CBT arm, around 50% of people attended 2 or fewer sessions. 22% failed to take up treatment. Conclusions: GSH-CBT is substantially more effective than TAU.	[Williams, Christopher; Wilson, Philip; Morrison, Jill; Andrew, Walker; Allan, Lesley; McNeill, Yvonne; Tansey, Louise] Univ Glasgow, Inst Hlth & Wellbeing, Strathclyde, Scotland; [McMahon, Alex] Univ Glasgow, Sch Dent, Strathclyde, Scotland; [McConnachie, Alex] Univ Glasgow, Robertson Ctr, Strathclyde, Scotland	University of Glasgow; University of Glasgow; University of Glasgow	Williams, C (corresponding author), Univ Glasgow, Inst Hlth & Wellbeing, Strathclyde, Scotland.	chris.williams@glasgow.ac.uk	Wilson, Philip/V-6519-2019	Wilson, Philip/0000-0002-4123-8248	Chief Scientist Office; National Health Service Greater Glasgow and Clyde [CZH/4/61]	Chief Scientist Office; National Health Service Greater Glasgow and Clyde	Funding: The authors acknowledge the Chief Scientist Office and National Health Service Greater Glasgow and Clyde for funding and supporting this study Ref CZH/4/61. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson L, 2005, BRIT J GEN PRACT, V55, P387; Barnhofer T, 2009, BEHAV RES THER, V47, P366, DOI 10.1016/j.brat.2009.01.019; Beck A.T., 1996, MANUAL BDI 2, DOI [10.1037/t00742-000, DOI 10.1037/T00742-000]; Carstairs V., 1991, DEPRIVATION HLTH SCO; de Graaf LE, 2009, BRIT J PSYCHIAT, V195, P73, DOI 10.1192/bjp.bp.108.054429; Evans C, 2002, BRIT J PSYCHIAT, V180, P51, DOI 10.1192/bjp.180.1.51; Gellatly J, 2007, PSYCHOL MED, V37, P1217, DOI 10.1017/S0033291707000062; Jorm AF, 2000, BRIT J PSYCHIAT, V177, P396, DOI 10.1192/bjp.177.5.396; Larsen D L, 1979, Eval Program Plann, V2, P197, DOI 10.1016/0149-7189(79)90094-6; Martinez R, 2008, BEHAV COGN PSYCHOTH, V36, P89, DOI 10.1017/S1352465807004067; McLoone P., 1994, CARSTAIRS SCORES SCO; National Institute for Clinical Excellence, 2009, PART UPD CG23 DEPR M; Richards A, 2003, BRIT J GEN PRACT, V53, P764; Ward E, 2000, BRIT MED J, V321, P1383, DOI 10.1136/bmj.321.7273.1383; Whitfield GE, 2001, BEHAV COGN PSYCHOTH, V29, P333, DOI 10.1017/S135246580100306X; Williams C, 2001, BRIT MED BULL, V57, P133, DOI 10.1093/bmb/57.1.133; WILLIAMS C, 2001, OVERCOMING DEPRESSIO; Williams C, 2010, CLIN GUIDE USING 5 A, P179	18	37	40	0	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2013	8	1							e52735	10.1371/journal.pone.0052735	http://dx.doi.org/10.1371/journal.pone.0052735			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	086RY	23326352	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000314705800023
J	Grayson, M				Grayson, Michelle			Ageing	NATURE			English	Editorial Material																			0	2	2	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 6	2012	492	7427					S1	S1		10.1038/492S1a	http://dx.doi.org/10.1038/492S1a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	048EQ	23222665	Bronze			2023-01-03	WOS:000311893400001
J	Gallagher, RM; Mason, JR; Bird, KA; Kirkham, JJ; Peak, M; Williamson, PR; Nunn, AJ; Turner, MA; Pirmohamed, M; Smyth, RL				Gallagher, Ruairi M.; Mason, Jennifer R.; Bird, Kim A.; Kirkham, Jamie J.; Peak, Matthew; Williamson, Paula R.; Nunn, Anthony J.; Turner, Mark A.; Pirmohamed, Munir; Smyth, Rosalind L.			Adverse Drug Reactions Causing Admission to a Paediatric Hospital	PLOS ONE			English	Article							CHILDREN; METAANALYSIS; PREVENTABILITY; DEXAMETHASONE; TONSILLECTOMY; DEFINITIONS; MANAGEMENT; FREQUENCY; MIDAZOLAM; SEIZURES	Objective(s): To obtain reliable information about the incidence of adverse drug reactions, and identify potential areas where intervention may reduce the burden of ill-health. Design: Prospective observational study. Setting: A large tertiary children's hospital providing general and specialty care in the UK. Participants: All acute paediatric admissions over a one year period. Main Exposure: Any medication taken in the two weeks prior to admission. Outcome Measures: Occurrence of adverse drug reaction. Results: 240/8345 admissions in 178/6821 patients admitted acutely to a paediatric hospital were thought to be related to an adverse drug reaction, giving an estimated incidence of 2.9% (95% CI 2.5, 3.3), with the reaction directly causing, or contributing to the cause, of admission in 97.1% of cases. No deaths were attributable to an adverse drug reaction. 22.1% (95% CI 17%, 28%) of the reactions were either definitely or possibly avoidable. Prescriptions originating in the community accounted for 44/249 (17.7%) of adverse drug reactions, the remainder originating from hospital. 120/249 (48.2%) reactions resulted from treatment for malignancies. The drugs most commonly implicated in causing admissions were cytotoxic agents, corticosteroids, non-steroidal anti-inflammatory drugs, vaccines and immunosuppressants. The most common reactions were neutropenia, immunosuppression and thrombocytopenia. Conclusions: Adverse drug reactions in children are an important public health problem. Most of those serious enough to require hospital admission are due to hospital-based prescribing, of which just over a fifth may be avoidable. Strategies to reduce the burden of ill-health from adverse drug reactions causing admission are needed. Citation: Gallagher RM, Mason JR, Bird KA, Kirkham JJ, Peak M, et al. (2012) Adverse Drug Reactions Causing Admission to a Paediatric Hospital. PLoS ONE 7(12): e50127. doi: 10.1371/journal.pone.0050127	[Gallagher, Ruairi M.; Turner, Mark A.; Smyth, Rosalind L.] Univ Liverpool, Dept Womens & Childrens Hlth, Liverpool L69 3BX, Merseyside, England; [Mason, Jennifer R.; Bird, Kim A.; Peak, Matthew] Alder Hey Childrens Hosp NHS Fdn Trust, Liverpool, Merseyside, England; [Kirkham, Jamie J.; Williamson, Paula R.] Univ Liverpool, Dept Biostat, Liverpool L69 3BX, Merseyside, England; [Nunn, Anthony J.] Univ Liverpool, Natl Inst Hlth Res Med Children Res Network, Alder Hey Hosp, Liverpool L69 3BX, Merseyside, England; [Nunn, Anthony J.] Alder Hey Childrens NHS Fdn Trust, Dept Pharm, Liverpool, Merseyside, England; [Pirmohamed, Munir] Univ Liverpool, Dept Pharmacol, Liverpool L69 3BX, Merseyside, England	University of Liverpool; Alder Hey Children's NHS Foundation Trust; University of Liverpool; Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; University of Liverpool; Alder Hey Children's NHS Foundation Trust; University of Liverpool	Gallagher, RM (corresponding author), Univ Liverpool, Dept Womens & Childrens Hlth, Liverpool L69 3BX, Merseyside, England.	ruairi.gallagher@nhs.net	Kirkham, Jamie/AAD-4490-2019; Williamson, Paula R/B-6425-2016; Pirmohamed, Munir/H-6004-2011	Kirkham, Jamie/0000-0003-2579-9325; Williamson, Paula R/0000-0001-9802-6636; Pirmohamed, Munir/0000-0002-7534-7266; Peak, Matthew/0000-0003-1909-3211; Mason, Jennifer/0000-0002-1576-7234; Turner, Mark/0000-0002-5299-8656	National Institute for Health Research (NIHR [RP-PG-0606-1170]; Department of Health (England); National Institute for Health Research [RP-PG-0606-1170] Funding Source: researchfish	National Institute for Health Research (NIHR(National Institute for Health Research (NIHR)); Department of Health (England); National Institute for Health Research(National Institute for Health Research (NIHR))	This paper presents independent research commissioned by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research scheme (RP-PG-0606-1170). The views expressed are those of the author(s) and not necessarily those of the National Health Service, the NIHR or the Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors have declared that no competing interests exist. Munir Pirmohamed is NHS Chair of Pharmacogenetics (funded by Department of Health (England)). Rosalind Smyth and Munir Pirmohamed are members of the Commission on Human Medicines. Munir Pirmohamed Chairs the Pharmacovigilance Expert Advisory Group, while Rosalind Smyth Chairs the Paediatric Medicines Expert Advisory Group.	[Anonymous], 2008, BRIT NATL FORMULARY; Appleton R, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001905.pub2; Cardwell M, 2005, ANESTH ANALG, V101, P1558; Clavenna A, 2009, ARCH DIS CHILD, V94, P724, DOI 10.1136/adc.2008.154377; Czarnetzki C, 2008, JAMA-J AM MED ASSOC, V300, P2621, DOI 10.1001/jama.2008.794; Easton KL, 2004, BRIT J CLIN PHARMACO, V57, P611, DOI 10.1111/j.1365-2125.2003.02052.x; Edwards IR, 2000, LANCET, V356, P1255, DOI 10.1016/S0140-6736(00)02799-9; Ferner RE, 2010, DRUG SAFETY, V33, P985, DOI 10.2165/11538270-000000000-00000; Gallagher RM, 2011, J CLIN PHARM THER, V36, P194, DOI 10.1111/j.1365-2710.2010.01194.x; Gallagher RM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028096; Goldman AC, 2000, OTOLARYNG HEAD NECK, V123, P682, DOI 10.1067/mhn.2000.111354; HALLAS J, 1990, J INTERN MED, V228, P83, DOI 10.1111/j.1365-2796.1990.tb00199.x; HARTWIG SC, 1992, AM J HOSP PHARM, V49, P2229, DOI 10.1093/ajhp/49.9.2229; Hazell L, 2006, DRUG SAFETY, V29, P385, DOI 10.2165/00002018-200629050-00003; HospitalEpisodeStatistics, 2010, HOSPITALEPISODESTATI; Impicciatore P, 2001, BRIT J CLIN PHARMACO, V52, P77, DOI 10.1046/j.0306-5251.2001.01407.x; Jonville-Bera AP, 2002, BRIT J CLIN PHARMACO, V53, P207, DOI 10.1046/j.0306-5251.2001.01535.x; Kelly ME, 2010, ARCH DERMATOL, V146, P767, DOI 10.1001/archdermatol.2010.90; Lau PM, 2004, SUPPORT CARE CANCER, V12, P626, DOI 10.1007/s00520-004-0622-5; Le J, 2006, PEDIATRICS, V118, P555, DOI 10.1542/peds.2005-2429; MartinezMir I, 1996, BRIT J CLIN PHARMACO, V42, P319, DOI 10.1046/j.1365-2125.1996.04076.x; McIntyre J, 2005, LANCET, V366, P205, DOI 10.1016/S0140-6736(05)66909-7; MCKENZIE MW, 1976, J PEDIATR-US, V89, P487, DOI 10.1016/S0022-3476(76)80560-4; McMullan J, 2010, ACAD EMERG MED, V17, P575, DOI 10.1111/j.1553-2712.2010.00751.x; Medicines and Healthcare products Regulatory Agency, REP SUSP ADV DRUG RE; MITCHELL AA, 1988, PEDIATRICS, V82, P24; Rawlins MDTJ, 1977, TXB ADVERSE DRUG REA; Sasse EC, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004139.pub2; Smyth RMD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0024061; Steward DL, 2003, COCHRANE DB SYST REV, V1; Stewart WA, 2002, ARCH DIS CHILD, V87, P225, DOI 10.1136/adc.87.3.225; Sung L, 2004, J CLIN ONCOL, V22, P3350, DOI 10.1200/JCO.2004.09.106	32	52	54	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 4	2012	7	12							e50127	10.1371/journal.pone.0050127	http://dx.doi.org/10.1371/journal.pone.0050127			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	051EQ	23226510	Green Published, Green Submitted, gold			2023-01-03	WOS:000312108500009
J	Bischoff, EWMA; Akkermans, R; Bourbeau, J; van Weel, C; Vercoulen, JH; Schermer, TRJ				Bischoff, Erik W. M. A.; Akkermans, Reinier; Bourbeau, Jean; van Weel, Chris; Vercoulen, Jan H.; Schermer, Tjard R. J.			Comprehensive self management and routine monitoring in chronic obstructive pulmonary disease patients in general practice: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COPD; EXACERBATIONS; EFFICACY; MODERATE; SYSTEM; CARE	Objective To assess the long term effects of two different modes of disease management (comprehensive self management and routine monitoring) on quality of life (primary objective), frequency and patients' management of exacerbations, and self efficacy (secondary objectives) in patients with chronic obstructive pulmonary disease (COPD) in general practice. Design 24 month, multicentre, investigator blinded, three arm, pragmatic, randomised controlled trial. Setting 15 general practices in the eastern part of the Netherlands. Participants Patients with COPD confirmed by spirometry and treated in general practice. Patients with very severe COPD or treated by a respiratory physician were excluded. Interventions A comprehensive self management programme as an adjunct to usual care, consisting of four tailored sessions with ongoing telephone support by a practice nurse; routine monitoring as an adjunct to usual care, consisting of 2-4 structured consultations a year with a practice nurse; or usual care alone (contacts with the general practitioner at the patients' own initiative). Outcome measures The primary outcome was the change in COPD specific quality of life at 24 months as measured with the chronic respiratory questionnaire total score. Secondary outcomes were chronic respiratory questionnaire domain scores, frequency and patients' management of exacerbations measured with the Nijmegen telephonic exacerbation assessment system, and self efficacy measured with the COPD self-efficacy scale. Results 165 patients were allocated to self management (n=55), routine monitoring (n=55), or usual care alone (n=55). At 24 months, adjusted treatment differences between the three groups in mean chronic respiratory questionnaire total score were not significant. Secondary outcomes did not differ, except for exacerbation management. Compared with usual care, more exacerbations in the self management group were managed with bronchodilators (odds ratio 2.81, 95% confidence interval 1.16 to 6.82) and with prednisolone, antibiotics, or both (3.98, 1.10 to 15.58). Conclusions Comprehensive self management or routine monitoring did not show long term benefits in terms of quality of life or self efficacy over usual care alone in COPD patients in general practice. Patients in the self management group seemed to be more capable of appropriately managing exacerbations than did those in the usual care group.	[Bischoff, Erik W. M. A.; Akkermans, Reinier; van Weel, Chris; Schermer, Tjard R. J.] Radboud Univ Nijmegen, Med Ctr, Dept Primary & Community Care, NL-6500 HB Nijmegen, Netherlands; [Bourbeau, Jean] McGill Univ, Ctr Hlth, Resp Epidemiol & Clin Res Unit, Montreal Chest Inst, Montreal, PQ, Canada; [Vercoulen, Jan H.] Radboud Univ Nijmegen, Med Ctr, Dept Pulm Dis, NL-6500 HB Nijmegen, Netherlands; [Vercoulen, Jan H.] Radboud Univ Nijmegen, Med Ctr, Dept Med Psychol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; McGill University; Radboud University Nijmegen; Radboud University Nijmegen	Bischoff, EWMA (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Primary & Community Care, POB 9101, NL-6500 HB Nijmegen, Netherlands.	E.Bischoff@elg.umcn.nl	van Weel, Chris/D-4375-2009; Schermer, Tjard RJ/A-8511-2011; Bischoff, Erik W.M.A./L-4201-2015; Vercoulen, J.H.M.M./L-4706-2015	van Weel, Chris/0000-0003-3653-4701; Schermer, Tjard RJ/0000-0002-1391-2995; 	Netherlands Organisation for Health Research and Development (ZonMw); Partners in Care Solutions for COPD (PICASSO)	Netherlands Organisation for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development); Partners in Care Solutions for COPD (PICASSO)	This study was funded by the Netherlands Organisation for Health Research and Development (ZonMw) and Partners in Care Solutions for COPD (PICASSO). The funding sources had no role in the design, conduct, or reporting of the study.	Aaron SD, 2008, THORAX, V63, P122, DOI 10.1136/thx.2007.082636; Adams SG, 2007, ARCH INTERN MED, V167, P551, DOI 10.1001/archinte.167.6.551; BANDURA A, 1982, J BEHAV THER EXP PSY, V13, P195, DOI 10.1016/0005-7916(82)90004-0; Bellamy David, 2006, Prim Care Respir J, V15, P48, DOI 10.1016/j.pcrj.2005.11.003; Bestall JC, 1999, THORAX, V54, P581, DOI 10.1136/thx.54.7.581; Bischoff EWMA, 2012, EUR RESPIR J, V39, P1090, DOI 10.1183/09031936.00057811; Bischoff EWMA, 2011, THORAX, V66, P26, DOI 10.1136/thx.2009.127621; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Bourbeau J, 2004, PATIENT EDUC COUNS, V52, P271, DOI 10.1016/S0738-3991(03)00102-2; Bourbeau J, 2003, ARCH INTERN MED, V163, P585, DOI 10.1001/archinte.163.5.585; Bourbeau J, 2008, INFORMA HEALTHCARE, P357; Bucknall CE, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1060; Campbell MK, 2004, BMJ-BRIT MED J, V328, P702, DOI 10.1136/bmj.328.7441.702; Cranston JM, 2008, MED J AUSTRALIA, V188, pS50; Donaldson GC, 2002, THORAX, V57, P847, DOI 10.1136/thorax.57.10.847; Effing T, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002990.pub2; Geijer RM, 2001, HUISARTS WET, V44, P207; Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2011, GLOB STRAT DIAGN MAN; Kara M, 2004, PATIENT EDUC COUNS, V55, P114, DOI 10.1016/j.pec.2003.08.006; Lacasse Y, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003793.pub2; Langsetmo L, 2008, AM J RESP CRIT CARE, V177, P396, DOI 10.1164/rccm.200708-1290OC; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Moody A, 2004, THORAX, V59, P1; Poels PJP, 2006, BRIT MED J, V333, P870, DOI 10.1136/bmj.38987.478727.80; Puhan MA, 2007, RESP MED, V101, P308, DOI 10.1016/j.rmed.2006.04.023; Redelmeier DA, 1996, J CLIN EPIDEMIOL, V49, P1215, DOI 10.1016/S0895-4356(96)00206-5; Rice KL, 2010, AM J RESP CRIT CARE, V182, P890, DOI 10.1164/rccm.200910-1579OC; Schermer T, 2009, RESP MED, V103, P542, DOI 10.1016/j.rmed.2008.11.003; Schunemann HJ, 2005, EUR RESPIR J, V25, P31, DOI 10.1183/09031936.04.00029704; Seemungal TAR, 2000, AM J RESP CRIT CARE, V161, P1608, DOI 10.1164/ajrccm.161.5.9908022; Simpson CR, 2010, BRIT J GEN PRACT, V60, DOI 10.3399/bjgp10X514729; Suissa S, 2006, AM J RESP CRIT CARE, V173, P842, DOI 10.1164/rccm.200508-1338PP; van den Bemt L, 2008, RESP MED, V102, P633, DOI 10.1016/j.rmed.2007.12.014; van den Bemt L, 2009, MED J AUSTRALIA, V191, P249; WIGAL JK, 1991, CHEST, V99, P1193, DOI 10.1378/chest.99.5.1193; Wilkinson TMA, 2004, AM J RESP CRIT CARE, V169, P1298, DOI 10.1164/rccm.200310-1443OC	36	89	94	0	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 28	2012	345								e7642	10.1136/bmj.e7642	http://dx.doi.org/10.1136/bmj.e7642			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	048FO	23190905	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000311895900003
J	Cao, H; Li, LP; Zhang, MZ				Cao, He; Li, Liping; Zhang, Mingzhi			Epidemiology of Patients Hospitalized for Ocular Trauma in the Chaoshan Region of China, 2001-2010	PLOS ONE			English	Article							EYE INJURY; OPEN-GLOBE; RISK-FACTORS; UNITED-STATES; POPULATION; SINGAPORE; PREVALENCE; TRENDS	Background: The burden and pattern of ocular trauma in China are poorly known and not well studied. We aimed at studying the epidemiological characteristics of patients hospitalized for ocular trauma at major ophthalmology departments in the largest industrial base of plastic toys in China. Methods: A retrospective study of ocular trauma cases admitted to 3 tertiary hospitals in China from 1st January 2001 to 31st December 2010 was performed. Results: The study included a total of 3,644 injured eyes from 3,559 patients over the 10-year period: 2,008 (55.1%) openg-lobe injuries, 1,580 (43.4%) closed-globe injuries, 41 (1.1%) chemical injuries, 15 (0.4%) thermal injuries and 678 (18.6%) ocular adnexal injuries. The mean age of the patients was 29.0 +/- 16.8 years with a male-to-female ratio of 5.2:1 (P=0.007). The most frequent types of injury were work-related injuries (1,656, 46.5%) and home-related injuries (715, 20.1%). The majority of injuries in males (56.2%) and females (36.0%) occurred in the 15-44 age group and 0-14 age group, respectively. The final visual acuity correlated with the initial visual acuity (Spearman's correlation coefficient = 0.659; P<0.001). The Ocular Trauma Score also correlated with the final visual acuity (Spearman's correlation coefficient = 0.655; P<0.001). Conclusions: This analysis provides an epidemiological study of patients who were hospitalized for ocular trauma. Preventive efforts are important for both work-related and home-related eye injuries.	[Cao, He; Li, Liping] Shantou Univ, Coll Med, Injury Prevent Res Ctr, Shantou, Guangdong, Peoples R China; [Zhang, Mingzhi] Joint Shantou Int Eye Ctr, Shantou, Guangdong, Peoples R China	Shantou University	Li, LP (corresponding author), Shantou Univ, Coll Med, Injury Prevent Res Ctr, Shantou, Guangdong, Peoples R China.	lpli@stu.edu.cn						Altintas L, 2011, ULUS TRAVMA ACIL CER, V17, P334, DOI 10.5505/tjtes.2011.78861; Augsberger J, 2008, GEN OPHTHALMOLOGY; Bhogal G, 2007, J PUBLIC HEALTH, V29, P72, DOI 10.1093/pubmed/fdl074; Blackburn J, 2012, J OCCUP ENVIRON MED, V54, P42, DOI 10.1097/JOM.0b013e3182398e1a; BLOMDAHL S, 1984, ACTA OPHTHALMOL, V62, P378; Brophy M, 2006, PEDIATRICS, V117, pE1263, DOI 10.1542/peds.2005-1950; Chang CH, 2008, GRAEF ARCH CLIN EXP, V246, P223, DOI 10.1007/s00417-007-0733-z; Chua D, 2011, OPHTHAL EPIDEMIOL, V18, P281, DOI 10.3109/09286586.2011.628775; Cillino S, 2008, BMC OPHTHALMOL, V8, DOI 10.1186/1471-2415-8-6; Desai P, 1996, BRIT J OPHTHALMOL, V80, P592, DOI 10.1136/bjo.80.7.592; El-Mekawey HE, 2011, CLIN OPHTHALMOL, V5, P955, DOI 10.2147/OPTH.S21761; Han SB, 2010, J TRAUMA, V69, pE66, DOI 10.1097/TA.0b013e3181cc8461; Hossain M M, 2011, Mymensingh Med J, V20, P377; Jafari Alireza Keshtkar, 2010, International Ophthalmology, V30, P691, DOI 10.1007/s10792-010-9401-0; Kanoff JM, 2010, AM J OPHTHALMOL, V150, P265, DOI 10.1016/j.ajo.2010.02.015; Khatry SK, 2004, BRIT J OPHTHALMOL, V88, P456, DOI 10.1136/bjo.2003.030700; Kim JH, 2007, J TRAUMA, V62, P746, DOI 10.1097/01.ta.0000231557.58471.e3; KLOPFER J, 1992, ARCH OPHTHALMOL-CHIC, V110, P838, DOI 10.1001/archopht.1992.01080180110037; Kuhn F, 2004, J FR OPHTALMOL, V27, P206, DOI 10.1016/S0181-5512(04)96122-0; Kuhn F, 1996, OPHTHALMOLOGY, V103, P240; Kuhn Ferenc, 2002, Ophthalmol Clin North Am, V15, P163, DOI 10.1016/S0896-1549(02)00007-X; Loon SC, 2009, CLIN EXP OPHTHALMOL, V37, P362, DOI 10.1111/j.1442-9071.2009.02035.x; Macdonald ECA, 2009, BRIT J OPHTHALMOL, V93, P1177, DOI 10.1136/bjo.2008.154831; Maneschg OA, 2011, KLIN MONATSBL AUGENH, V228, P801, DOI 10.1055/s-0029-1245756; Mansouri M, 2009, RETINA, V29, P114; McCarty CA, 1999, OPHTHALMOLOGY, V106, P1847, DOI 10.1016/S0161-6420(99)90361-5; McGwin G, 2006, INVEST OPHTH VIS SCI, V47, P521, DOI 10.1167/iovs.05-0909; McGwin G, 2005, ARCH OPHTHALMOL-CHIC, V123, P970, DOI 10.1001/archopht.123.7.970; McGwin G, 2005, ARCH OPHTHALMOL-CHIC, V123, P662, DOI 10.1001/archopht.123.5.662; Mela EK, 2005, OPHTHAL EPIDEMIOL, V12, P185, DOI 10.1080/09286580590964801; Mieler W, 2001, PRINCIPLES PRACTICE, V2, P5179; Negrel A D, 1998, Ophthalmic Epidemiol, V5, P143, DOI 10.1076/opep.5.3.143.8364; Nordberg E, 2000, E AFR MED J, V77, pS1; Ojabo C O, 2011, Niger J Med, V20, P114; Onakpoya OH, 2010, OPHTHAL EPIDEMIOL, V17, P315, DOI 10.3109/09286586.2010.508352; Owens PL, 2011, HEALTHCARE COST UTIL; Pandita A, 2012, NEW ZEAL MED J, V125, P61; Rao LG, 2010, INDIAN J OPHTHALMOL, V58, P321, DOI 10.4103/0301-4738.64116; Raymond S, 2010, CLIN EXP OPHTHALMOL, V38, P566, DOI 10.1111/j.1442-9071.2010.02296.x; Rofail M, 2006, CLIN EXP OPHTHALMOL, V34, P783, DOI 10.1111/j.1442-9071.2006.01309.x; Saeed A, 2010, INJURY, V41, P86, DOI 10.1016/j.injury.2009.01.118; Shah M, 2008, GRAEF ARCH CLIN EXP, V246, P191, DOI 10.1007/s00417-007-0698-y; Smith ARE, 2006, CLIN EXP OPHTHALMOL, V34, P252, DOI 10.1111/j.1442-9071.2006.01200.x; Soliman MM, 2008, GRAEF ARCH CLIN EXP, V246, P205, DOI 10.1007/s00417-007-0720-4; Soylu Merih, 2010, International Ophthalmology, V30, P143, DOI 10.1007/s10792-009-9300-4; TIELSCH JM, 1989, ARCH OPHTHALMOL-CHIC, V107, P519, DOI 10.1001/archopht.1989.01070010533025; Tomazzoli L, 2003, EUR J OPHTHALMOL, V13, P710, DOI 10.1177/112067210301300808; Vats S, 2008, INDIAN J OPHTHALMOL, V56, P313; Woo JH, 2006, ANN ACAD MED SINGAP, V35, P706	49	40	44	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2012	7	10							e48377	10.1371/journal.pone.0048377	http://dx.doi.org/10.1371/journal.pone.0048377			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	030WJ	23118997	Green Published, Green Submitted, gold			2023-01-03	WOS:000310600500117
J	Montgomery, P; Ryus, CR; Dolan, CS; Dopson, S; Scott, LM				Montgomery, Paul; Ryus, Caitlin R.; Dolan, Catherine S.; Dopson, Sue; Scott, Linda M.			Sanitary Pad Interventions for Girls' Education in Ghana: A Pilot Study	PLOS ONE			English	Article								Background: Increased education of girls in developing contexts is associated with a number of important positive health, social, and economic outcomes for a community. The event of menarche tends to coincide with girls' transitions from primary to secondary education and may constitute a barrier for continued school attendance and performance. Following the MRC Framework for Complex Interventions, a pilot controlled study was conducted in Ghana to assess the role of sanitary pads in girls' education. Methods: A sample of 120 schoolgirls between the ages of 12 and 18 from four villages in Ghana participated in a non-randomized trial of sanitary pad provision with education. The trial had three levels of treatment: provision of pads with puberty education; puberty education alone; or control (no pads or education). The primary outcome was school attendance. Results: After 3 months, providing pads with education significantly improved attendance among participants, (lambda 0.824, F = 3.760, p<.001). After 5 months, puberty education alone improved attendance to a similar level (M = 91.26, SD = 7.82) as sites where pads were provided with puberty education (Rural M=89.74, SD = 9.34; Periurban M=90.54, SD = 17.37), all of which were higher than control (M = 84.48, SD = 12.39). The total improvement through pads with education intervention after 5 months was a 9% increase in attendance. After 3 months, providing pads with education significantly improved attendance among participants. The changes in attendance at the end of the trial, after 5 months, were found to be significant by site over time. With puberty education alone resulting in a similar attendance level. Conclusion: This pilot study demonstrated promising results of a low-cost, rapid-return intervention for girls' education in a developing context. Given the considerable development needs of poorer countries and the potential of young women there, these results suggest that a large-scale cluster randomized trial is warranted.	[Montgomery, Paul] Univ Oxford, Ctr Evidence Based Intervent, Oxford, Oxon, England; [Ryus, Caitlin R.; Dolan, Catherine S.; Dopson, Sue; Scott, Linda M.] Univ Oxford, Said Business Sch, Oxford, Oxon, England	University of Oxford; University of Oxford	Montgomery, P (corresponding author), Univ Oxford, Ctr Evidence Based Intervent, Oxford, Oxon, England.	paul.montgomery@spi.ox.ac.uk	Ryus, Caitlin/AAJ-5207-2021	Ryus, Caitlin/0000-0001-5526-030X; Dolan, catherine/0000-0003-3939-6607	Templeton College at Oxford University; John Fell Fund at Oxford University; Green Templeton College - at Oxford University	Templeton College at Oxford University; John Fell Fund at Oxford University; Green Templeton College - at Oxford University	The study was funded by Templeton College, the John Fell Fund and Green Templeton College - all at Oxford University. Pads were supplied by Proctor and Gamble. No supporter of the study had any influence over the publication of any results. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alkire S, 2007, OXF DEV STUD, V35, P347, DOI 10.1080/13600810701701863; Bollen KA, 2002, POP STUD-J DEMOG, V56, P81, DOI 10.1080/00324720213796; Buckley T, 1988, BLOOD MAGIC THE ANTH; Burrows A, 2005, J REPROD INFANT PSYC, V23, P235, DOI 10.1080/02646830500165846; CARE, 2010, POWER WITHIN; Commonwealth Secretariat and Healthlink Worldwide, 2001, GENDER AND RELATIONS; Craig P, 2008, BMJ, V337; Dasgupta A, 2008, Indian J Community Med, V33, P77, DOI 10.4103/0970-0218.40872; Des Jarlais DC, 2004, AM J PUBLIC HEALTH, V94, P361, DOI 10.2105/AJPH.94.3.361; Dolan C, MENSTRUATION SANITAR; Kirk J, 2006, MENSTRUATION AND BOD; Lloyd CB, 2009, NEW LESSONS THE POWE; Mahon T., 2010, Gender and Development, V18, P99, DOI 10.1080/13552071003600083; McGregor JA, 2009, STUDIES IOD; Plan International, 2009, BECAUSE I AM A GIRL; Sen Amartya, 1999, DEV FREEDOM; Sommer M, 2009, J ADOLESCENCE, V30, P1; Ten V. T. A., 2007, MENSTRUAL HYGIENE A; United Nations, 2004, WORLD POPULATION MON	20	78	79	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2012	7	10							e48274	10.1371/journal.pone.0048274	http://dx.doi.org/10.1371/journal.pone.0048274			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	030WJ	23118968	gold, Green Submitted, Green Published			2023-01-03	WOS:000310600500087
J	Liang, XD; Zhang, L; Wan, YF; Yu, XY; Guo, YM; Chen, XP; Tan, C; Huang, TL; Shen, HJ; Chen, XY; Li, H; Lv, K; Sun, F; Chen, SG; Guo, J				Liang, Xiaodi; Zhang, Lin; Wan, Yufeng; Yu, Xinyang; Guo, Yiming; Chen, Xiaoping; Tan, Cheng; Huang, Tianle; Shen, Hanjie; Chen, Xianyun; Li, Hongying; Lv, Ke; Sun, Fei; Chen, Shanguang; Guo, Jinhu			Changes in the Diurnal Rhythms during a 45-Day Head-Down Bed Rest	PLOS ONE			English	Article							CIRCADIAN-RHYTHMS; TRIGONOSCELIS-GIGAS; DESERT BEETLE; SPACE; HUMANS; CLOCK; SLEEP; SPACEFLIGHT; CORTISOL; COUNTERMEASURE	In spaceflight human circadian rhythms and sleep patterns are likely subject to change, which consequently disturbs human physiology, cognitive abilities and performance efficiency. However, the influence of microgravity on sleep and circadian clock as well as the underlying mechanisms remain largely unknown. Placing volunteers in a prone position, whereby their heads rest at an angle of -6 degrees below horizontal, mimics the microgravity environment in orbital flight. Such positioning is termed head-down bed rest (HDBR). In this work, we analysed the influence of a 45-day HDBR on physiological diurnal rhythms. We examined urinary electrolyte and hormone excretion, and the results show a dramatic elevation of cortisol levels during HDBR and recovery. Increased diuresis, melatonin and testosterone were observed at certain periods during HDBR. In addition, we investigated the changes in urination and defecation frequencies and found that the rhythmicity of urinary frequency during lights-off during and after HDBR was higher than control. The grouped defecation frequency data exhibits rhythmicity before and during HDBR but not after HDBR. Together, these data demonstrate that HDBR can alter a number of physiological processes associated with diurnal rhythms.	[Liang, Xiaodi; Zhang, Lin; Wan, Yufeng; Yu, Xinyang; Guo, Yiming; Huang, Tianle; Shen, Hanjie; Chen, Xianyun; Li, Hongying; Guo, Jinhu] Sun Yat Sen Univ, Sch Life Sci, State Key Lab Biocontrol, Minist Educ,Key Lab Gene Engn, Guangzhou 510275, Guangdong, Peoples R China; [Chen, Xiaoping; Tan, Cheng; Lv, Ke; Chen, Shanguang] China Astronaut Res & Training Ctr, State Key Lab Space Med Fundamentals & Applicat, Beijing, Peoples R China; [Sun, Fei] Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Peoples R China; [Sun, Fei] Hefei Natl Lab Phys Sci Microscale, Hefei, Peoples R China	Sun Yat Sen University; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Guo, J (corresponding author), Sun Yat Sen Univ, Sch Life Sci, State Key Lab Biocontrol, Minist Educ,Key Lab Gene Engn, Guangzhou 510275, Guangdong, Peoples R China.	guojinhu@mail.sysu.edu.cn	Sun, Fei/N-2850-2013; ZHANG, LIN/GYD-9123-2022; zhan, lin/AAP-5149-2020	Guo, Yiming/0000-0002-4212-3784; Wan, Yufeng/0000-0002-5155-675X	National 973 Program of China [2011CB711000, 2012CB947600]; National Natural Science Foundation of China [31071122, 31171119]; Fundamental Research Funds for the Central Universities of China [11lgzd08]; Laboratory Opening Funds for Undergraduates of Sun Yat-sen University [KF201126]; Research Fund for the Doctoral Program of Higher Education of China [20110171110030]	National 973 Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities of China(Fundamental Research Funds for the Central Universities); Laboratory Opening Funds for Undergraduates of Sun Yat-sen University; Research Fund for the Doctoral Program of Higher Education of China(Research Fund for the Doctoral Program of Higher Education of China (RFDP)Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP))	This work was supported by the National 973 Program of China (No. 2011CB711000 and 2012CB947600), the National Natural Science Foundation of China (No. 31071122 and No. 31171119), the Fundamental Research Funds for the Central Universities of China (11lgzd08), the Laboratory Opening Funds for Undergraduates of Sun Yat-sen University (KF201126) and the Research Fund for the Doctoral Program of Higher Education of China (20110171110030). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALPATOV AM, 1994, BIOL RHYTHM RES, V25, P168, DOI 10.1080/09291019409360284; ARBEILLE P, 1992, AVIAT SPACE ENVIR MD, V63, P9; ASCHOFF J, 1965, SCIENCE, V148, P1427, DOI 10.1126/science.148.3676.1427; ASCHOFF J, 1971, SCIENCE, V171, P213, DOI 10.1126/science.171.3967.213; Bechtold DA, 2010, TRENDS PHARMACOL SCI, V31, P191, DOI 10.1016/j.tips.2010.01.002; Bell-Pedersen D, 2005, NAT REV GENET, V6, P544, DOI 10.1038/nrg1633; BOWDEN RE, 1977, PROSTAGLANDINS, V14, P151, DOI 10.1016/0090-6980(77)90164-2; Brown SA, 2012, DEV CELL, V22, P477, DOI 10.1016/j.devcel.2012.02.007; Cermakian N, 2009, OBES REV, V10, P25, DOI 10.1111/j.1467-789X.2009.00660.x; Dijk DJ, 2001, AM J PHYSIOL-REG I, V281, pR1647, DOI 10.1152/ajpregu.2001.281.5.R1647; Gettler LT, 2011, AM J HUM BIOL, V23, P609, DOI 10.1002/ajhb.21187; Gumz ML, 2009, J CLIN INVEST, V119, P2423, DOI 10.1172/JCI36908; Gundel A, 1997, J SLEEP RES, V6, P1, DOI 10.1046/j.1365-2869.1997.00028.x; Hoban-Higgins TM, 2003, J INSECT PHYSIOL, V49, P671, DOI 10.1016/S0022-1910(03)00068-4; Hoogerwerf WA, 2010, AM J PHYSIOL-GASTR L, V299, pG549, DOI 10.1152/ajpgi.00147.2010; Hoogerwerf WA, 2010, AM J PHYSIOL-GASTR L, V298, pG143, DOI 10.1152/ajpgi.00402.2009; Manolagas SC, 2009, BONE, V45, pS120, DOI 10.1016/j.bone.2009.07.021; Meza-Figueroa D, 2008, EPIDEMIOLOGY, V19, pS226; Millet C, 2001, CLIN PHYSIOL, V21, P172, DOI 10.1046/j.1365-2281.2001.00315.x; Monk TH, 1998, J BIOL RHYTHM, V13, P188, DOI 10.1177/074873098129000039; Morishima K, 1997, J Gravit Physiol, V4, pS41; NARDUCCI F, 1987, GUT, V28, P17, DOI 10.1136/gut.28.1.17; Pavy-Le Traon A, 1998, EUR J APPL PHYSIOL, V77, P50; Rao SSC, 2001, AM J PHYSIOL-GASTR L, V280, pG629, DOI 10.1152/ajpgi.2001.280.4.G629; Regnard J, 2001, AM J KIDNEY DIS, V38, P668, DOI 10.1053/ajkd.2001.27753; Rensing L, 2002, CHRONOBIOL INT, V19, P807, DOI 10.1081/CBI-120014569; ROSE RM, 1972, J ENDOCRINOL, V54, P177, DOI 10.1677/joe.0.0540177; Schimmel M, 2001, BIOL RHYTHM RES, V32, P341, DOI 10.1076/brhm.32.3.341.1340; Schimmerling W, 2003, ADV SPACE RES, V31, P27, DOI 10.1016/S0273-1177(02)00653-1; Sharpley CF, 2012, REV NEUROSCIENCE, V23, P111, DOI 10.1515/RNS.2011.058; Shiraishi M, 2003, BIOMED PHARMACOTHER, V57, p35S, DOI 10.1016/j.biopha.2003.08.005; STAMPI C, 1994, J CLIN PHARMACOL, V34, P518, DOI 10.1002/j.1552-4604.1994.tb04996.x; Stein TP, 1999, AM J PHYSIOL-ENDOC M, V276, pE155; SULZMAN FM, 1984, SCIENCE, V225, P232, DOI 10.1126/science.11540800; Traon APL, 2007, EUR J APPL PHYSIOL, V101, P143, DOI 10.1007/s00421-007-0474-z; Vuillerme N, 2008, EXP BRAIN RES, V186, P503, DOI 10.1007/s00221-007-1249-9; Zhang L, 2011, FEBS LETT, V585, P1400, DOI 10.1016/j.febslet.2011.03.018; Zuber AM, 2009, P NATL ACAD SCI USA, V106, P16523, DOI 10.1073/pnas.0904890106; Zwart SR, 2007, BONE, V40, P529, DOI 10.1016/j.bone.2006.09.014	39	15	18	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2012	7	10							e47984	10.1371/journal.pone.0047984	http://dx.doi.org/10.1371/journal.pone.0047984			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	026VC	23110150	Green Published, gold, Green Submitted			2023-01-03	WOS:000310310200127
J	Furlan, A; Roux, B; Lamballe, F; Conti, F; Issaly, N; Daian, F; Guillemot, JF; Richelme, S; Contensin, M; Bosch, J; Passarella, D; Piccolo, O; Dono, R; Maina, F				Furlan, Alessandro; Roux, Benjamin; Lamballe, Fabienne; Conti, Filippo; Issaly, Nathalie; Daian, Fabrice; Guillemot, Jean-Francois; Richelme, Sylvie; Contensin, Magali; Bosch, Joan; Passarella, Daniele; Piccolo, Oreste; Dono, Rosanna; Maina, Flavio			Combined Drug Action of 2-Phenylimidazo[2,1-b]Benzothiazole Derivatives on Cancer Cells According to Their Oncogenic Molecular Signatures	PLOS ONE			English	Article							HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; MET RECEPTOR; C-MET; TARGETED THERAPIES; IN-VIVO; CORE PATHWAYS; LUNG-CANCER; TUMOR-CELLS; INHIBITORS	The development of targeted molecular therapies has provided remarkable advances into the treatment of human cancers. However, in most tumors the selective pressure triggered by anticancer agents encourages cancer cells to acquire resistance mechanisms. The generation of new rationally designed targeting agents acting on the oncogenic path(s) at multiple levels is a promising approach for molecular therapies. 2-phenylimidazo[2,1-b]benzothiazole derivatives have been highlighted for their properties of targeting oncogenic Met receptor tyrosine kinase (RTK) signaling. In this study, we evaluated the mechanism of action of one of the most active imidazo[2,1-b]benzothiazol-2-ylphenyl moiety-based agents, Triflorcas, on a panel of cancer cells with distinct features. We show that Triflorcas impairs in vitro and in vivo tumorigenesis of cancer cells carrying Met mutations. Moreover, Triflorcas hampers survival and anchorage-independent growth of cancer cells characterized by "RTK swapping" by interfering with PDGFR beta phosphorylation. A restrained effect of Triflorcas on metabolic genes correlates with the absence of major side effects in vivo. Mechanistically, in addition to targeting Met, Triflorcas alters phosphorylation levels of the PI3K-Akt pathway, mediating oncogenic dependency to Met, in addition to Retinoblastoma and nucleophosmin/B23, resulting in altered cell cycle progression and mitotic failure. Our findings show how the unusual binding plasticity of the Met active site towards structurally different inhibitors can be exploited to generate drugs able to target Met oncogenic dependency at distinct levels. Moreover, the disease-oriented NCI Anticancer Drug Screen revealed that Triflorcas elicits a unique profile of growth inhibitory-responses on cancer cell lines, indicating a novel mechanism of drug action. The anti-tumor activity elicited by 2-phenylimidazo[2,1-b]benzothiazole derivatives through combined inhibition of distinct effectors in cancer cells reveal them to be promising anticancer agents for further investigation.	[Furlan, Alessandro; Roux, Benjamin; Lamballe, Fabienne; Conti, Filippo; Issaly, Nathalie; Daian, Fabrice; Guillemot, Jean-Francois; Richelme, Sylvie; Contensin, Magali; Dono, Rosanna; Maina, Flavio] Aix Marseille Univ, IBDML, CNRS UMR 7288, Marseille, France; [Bosch, Joan] Univ Barcelona, Fac Pharm, Organ Chem Lab, E-08028 Barcelona, Spain; [Bosch, Joan] Univ Barcelona, Inst Biomed IBUB, Barcelona, Spain; [Passarella, Daniele] Univ Milan, Dipartimento Chim Organ & Ind, Milan, Italy; [Piccolo, Oreste] Studio Consulenza Sci, Sirtori, LC, Italy	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Aix-Marseille Universite; University of Barcelona; University of Barcelona; University of Milan	Maina, F (corresponding author), Aix Marseille Univ, IBDML, CNRS UMR 7288, Marseille, France.	flavio.maina@univ-amu.fr	Lamballe, Fabienne/P-4293-2017; Bosch, Joan/B-1495-2013; DONO, ROSANNA/I-7821-2016; Passarella, Daniele/L-3495-2013; Maina, Flavio/J-9962-2019; FURLAN, Alessandro/O-3803-2019; Lamballe, Fabienne/GLT-0820-2022	Bosch, Joan/0000-0001-5974-1733; Passarella, Daniele/0000-0001-6180-9581; Maina, Flavio/0000-0001-6100-4695; FURLAN, Alessandro/0000-0001-6502-8416; Lamballe, Fabienne/0000-0001-7631-942X	INCa (Institut National du Cancer); ARC (Association pour la recherche contre le cancer); FRM (Fondation pour la recherche medicale); FdF (Fondation de France); Fondation Bettencourt-Schueller; Marie Curie Host Fellowship for the Transfer of Knowledge [MTKD-CT-2004-509804]; Protisvalor; Valorpaca; Oseo; INCa; Italian Association of Cancer Research (ARC)	INCa (Institut National du Cancer)(Institut National du Cancer (INCA) France); ARC (Association pour la recherche contre le cancer)(Fondation ARC pour la Recherche sur le Cancer); FRM (Fondation pour la recherche medicale)(Fondation pour la Recherche Medicale); FdF (Fondation de France); Fondation Bettencourt-Schueller; Marie Curie Host Fellowship for the Transfer of Knowledge; Protisvalor; Valorpaca; Oseo; INCa(Institut National du Cancer (INCA) France); Italian Association of Cancer Research (ARC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by funds from the INCa (Institut National du Cancer), ARC (Association pour la recherche contre le cancer), FRM (Fondation pour la recherche medicale), FdF (Fondation de France), Fondation Bettencourt-Schueller, Marie Curie Host Fellowship for the Transfer of Knowledge (MTKD-CT-2004-509804), Protisvalor, Valorpaca, and Oseo to FM. This research has been developed within the CM0602 COST Action "Inhibitors of Angiogenesis: design, synthesis and biological exploitation". AF was supported by the INCa and ARC; NI by Valorpaca, FC by the Italian Association of Cancer Research (ARC) and by Oseo. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arteaga CL, 2007, NAT MED, V13, P675, DOI 10.1038/nm0607-675; Asses Y, 2009, CHEM BIOL DRUG DES, V74, P560, DOI 10.1111/j.1747-0285.2009.00895.x; Bertotti A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000643; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bradshaw TD, 2002, MOL CANCER THER, V1, P239; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chua MS, 2000, CANCER RES, V60, P5196; Clague MJ, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002422; Colombo F, 2012, BIOORG MED CHEM LETT, V22, P4693, DOI 10.1016/j.bmcl.2012.05.078; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Corso S, 2005, TRENDS MOL MED, V11, P284, DOI 10.1016/j.molmed.2005.04.005; Cui JJ, 2007, EXPERT OPIN THER PAT, V17, P1035, DOI 10.1517/13543776.17.9.1035; Dancey JE, 2006, NAT REV DRUG DISCOV, V5, P649, DOI 10.1038/nrd2089; Doostdar H, 2000, TOXICOLOGY, V144, P31, DOI 10.1016/S0300-483X(99)00215-2; Druker BJ, 2004, ADV CANCER RES, V91, P1, DOI 10.1016/S0065-230X(04)91001-9; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Furlan A, 2011, CELL DEATH DIFFER, V18, P1608, DOI 10.1038/cdd.2011.23; Furlan A, 2012, J HEPATOL, DOI [10.1016/j.jhep.2012.07.044, DOI 10.1016/J.JHEP.2012.07.044(2012)]; Furlan A, 2012, EUR J MED CHEM, V47, P239, DOI 10.1016/j.ejmech.2011.10.051; Genestine M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.11; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; Helmbacher F, 2003, NEURON, V39, P767, DOI 10.1016/S0896-6273(03)00493-8; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hose CD, 2003, MOL CANCER THER, V2, P1265; Hunter T, 2009, CURR OPIN CELL BIOL, V21, P140, DOI 10.1016/j.ceb.2009.01.028; Joffre C, 2011, NAT CELL BIOL, V13, P827, DOI 10.1038/ncb2257; Knudsen BS, 2008, CURR OPIN GENET DEV, V18, P87, DOI 10.1016/j.gde.2008.02.001; Lamballe F, 2011, J NEUROSCI, V31, P11144, DOI 10.1523/JNEUROSCI.2198-11.2011; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Maina F, 1999, NAT NEUROSCI, V2, P213, DOI 10.1038/6310; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Maina F, 1998, NEURON, V20, P835, DOI 10.1016/S0896-6273(00)80466-3; Maina F, 2001, MOL CELL, V7, P1293, DOI 10.1016/S1097-2765(01)00261-1; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; Moumen A, 2007, DEVELOPMENT, V134, P1443, DOI 10.1242/dev.02820; Moumen A, 2007, HEPATOLOGY, V45, P1210, DOI 10.1002/hep.21604; Mukherjee A, 2006, INT J ONCOL, V29, P1287; Patane S, 2008, BIOCHEM BIOPH RES CO, V375, P184, DOI 10.1016/j.bbrc.2008.07.159; Segarra J, 2006, J BIOL CHEM, V281, P4771, DOI 10.1074/jbc.M508298200; Shattuck DL, 2008, CANCER RES, V68, P1471, DOI 10.1158/0008-5472.CAN-07-5962; Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Tanizaki J, 2011, J THORAC ONCOL, V6, P1624, DOI 10.1097/JTO.0b013e31822591e9; Tonges L, 2011, J NEUROCHEM, V117, P892, DOI 10.1111/j.1471-4159.2011.07257.x; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Underiner TL, 2010, ANTI-CANCER AGENT ME, V10, P7, DOI 10.2174/1871520611009010007; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130; Zwick E, 2002, TRENDS MOL MED, V8, P17, DOI 10.1016/S1471-4914(01)02217-1	52	9	9	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 5	2012	7	10							e46738	10.1371/journal.pone.0046738	http://dx.doi.org/10.1371/journal.pone.0046738			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	020QD	23071625	Green Published, gold, Green Submitted			2023-01-03	WOS:000309827300057
J	Juyal, RC; Negi, S; Wakhode, P; Bhat, S; Bhat, B; Thelma, BK				Juyal, Ramesh C.; Negi, Sapna; Wakhode, Preeti; Bhat, Sulekha; Bhat, Bheema; Thelma, B. K.			Potential of Ayurgenomics Approach in Complex Trait Research: Leads from a Pilot Study on Rheumatoid Arthritis	PLOS ONE			English	Article							LIPID-PEROXIDATION; DISEASE SEVERITY; REACTIVE OXYGEN; ASSOCIATION; GENE; POLYMORPHISMS; CLASSIFICATION; VARIABILITY; AYURVEDA; REGION	Background: Inconsistent results across association studies including Genome-wide association, have posed a major challenge in complex disease genetics. Of the several factors which contribute to this, phenotypic heterogeneity is a serious limitation encountered in modern medicine. On the other hand, Ayurveda, a holistic Indian traditional system of medicine, enables subgrouping of individuals into three major categories namely Vata, Pitta and Kapha, based on their physical and mental constitution, referred to as Prakriti. We hypothesised that conditioning association studies on prior risk, predictable in Ayurveda, will uncover much more variance and potentially open up more predictive health. Objectives and Methods: Identification of genetic susceptibility markers by combining the prakriti based subgrouping of individuals with genetic analysis tools was attempted in a Rheumatoid arthritis (RA) cohort. Association of 21 markers from commonly implicated inflammatory and oxidative stress pathways was tested using a case-control approach in a total cohort comprising 325 cases and 356 controls and in the three subgroups separately. We also tested few postulates of Ayurveda on the disease characteristics in different prakriti groups using clinico-genetic data. Results: Inflammatory genes like IL1 beta (C-C-C haplotype, p = 0.0005, OR = 3.09) and CD40 (rs4810485 allelic, p = 0.04, OR = 2.27) seem to be the determinants in Vata subgroup whereas oxidative stress pathway genes are observed in Pitta (SOD3 rs699473, p = 0.004, OR = 1.83; rs2536512 p = 0.005; OR = 1.88 and PON1 rs662, p = 0.04, OR = 1.53) and Kapha (SOD3 rs2536512, genotypic, p = 0.02, OR = 2.39) subgroups. Fixed effect analysis of the associated markers from CD40, SOD3 and TNF alpha with genotype X prakriti interaction terms suggests heterogeneity of effects within the subgroups. Further, disease characteristics such as severity was most pronounced in Vata group. Conclusions: This exploratory study suggests discrete causal pathways for RA etiology in prakriti based subgroups, thereby, validating concepts of prakriti and personalized medicine in Ayurveda. Ayurgenomics approach holds promise for biomarker discovery in complex diseases.	[Thelma, B. K.] Univ Delhi, Dept Genet, New Delhi, India; [Juyal, Ramesh C.; Negi, Sapna] Natl Inst Immunol, Expt Anim Facil, New Delhi 110067, India; [Wakhode, Preeti; Bhat, Sulekha; Bhat, Bheema] Holy Family Hosp, Dept Ayurveda, New Delhi, India	University of Delhi; Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Thelma, BK (corresponding author), Univ Delhi, Dept Genet, South Campus, New Delhi, India.	thelmabk@gmail.com	Negi, Sapna/HGA-5265-2022	Thelma, B.K/0000-0002-2154-5443	Central Council for Research in Ayurveda and Siddha, Department of AYUSH, Ministry of Health and Family Welfare, Government of India, New Delhi [Z.31018/18/2006-RP]	Central Council for Research in Ayurveda and Siddha, Department of AYUSH, Ministry of Health and Family Welfare, Government of India, New Delhi	The financial assistance for this work was provided by Central Council for Research in Ayurveda and Siddha, Department of AYUSH, Ministry of Health and Family Welfare, Government of India, New Delhi, vide F.No. Z.31018/18/2006-R&P. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afonso V, 2007, JOINT BONE SPINE, V74, P324, DOI 10.1016/j.jbspin.2007.02.002; Aggarwal S, 2010, P NATL ACAD SCI USA, V107, P18961, DOI 10.1073/pnas.1006108107; [Anonymous], 2000, SUSRUTA SAMHITA; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Baskol G, 2005, CLIN BIOCHEM, V38, P951, DOI 10.1016/j.clinbiochem.2005.06.010; Bauerova K, 1999, GEN PHYSIOL BIOPHYS, V18, P15; Bhushan P, 2005, J ALTERN COMPLEM MED, V11, P349, DOI 10.1089/acm.2005.11.349; Buchs N, 2001, GENES IMMUN, V2, P222, DOI 10.1038/sj.gene.6363766; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Dahabreh IJ, 2010, GENET MED, V12, P606, DOI 10.1097/GIM.0b013e3181ee81c6; Dasgupta S, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-7; Fishman D, 1998, J CLIN INVEST, V102, P1369, DOI 10.1172/JCI2629; Fonseca JE, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2173; Grabar PB, 2009, DIS MARKERS, V26, P41, DOI 10.3233/DMA-2009-0603; Harris ML, 2008, ARTHRITIS RHEUM-US, V58, P1958, DOI 10.1002/art.23596; Hee CS, 2007, MOD RHEUMATOL, V5, P429; Ichikawa N, 2009, MOD RHEUMATOL, V19, P134, DOI 10.1007/s10165-008-0134-0; Lee YH, 2012, INFLAMM RES, V61, P665, DOI 10.1007/s00011-012-0459-1; Martinez A, 2003, GENES IMMUN, V4, P117, DOI 10.1038/sj.gene.6363931; Mulcahy B, 1996, AM J HUM GENET, V59, P676; Naganuma T, 2008, HEREDITAS, V145, P283, DOI 10.1111/j.1601-5223.2008.02086.x; Patwardhan B, 2012, CURRENT SCI, V10, P1406; Plenge RM, 2007, NAT GENET, V39, P1477, DOI 10.1038/ng.2007.27; Prasher B, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-48; Raychaudhuri S, 2008, NAT GENET, V40, P1216, DOI 10.1038/ng.233; Rodriguez-Rodriguez L, 2011, ARTHRITIS RHEUM-US, V63, P365, DOI 10.1002/art.30145; Sarban S, 2005, CLIN BIOCHEM, V38, P981, DOI 10.1016/j.clinbiochem.2005.08.003; Sethi TP, 2011, ACS CHEM BIOL, V6, P875, DOI 10.1021/cb2003016; Sharma P., 2003, CHARAKA SAMHITA; Silman AJ, 2002, ARTHRITIS RES THER, V4, pS265, DOI 10.1186/ar578; Srikanthamurthy KR, 2001, MADHAVA NIDANAM MADH; Srikanthamurthy KR, 2003, ASHTANGA HRIDAYAM; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Tamiya G, 2005, HUM MOL GENET, V14, P2305, DOI 10.1093/hmg/ddi234; Taysi S, 2002, RHEUMATOL INT, V21, P200, DOI 10.1007/s00296-001-0163-x; Thelma B. K., 2008, PHISPC SERIES HIST S; Totaro MC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024292; Turesson C, 2006, MAYO CLIN PROC, V81, P94, DOI 10.4065/81.1.94; van der Linden MPM, 2009, ARTHRITIS RHEUM, V60, P2242, DOI 10.1002/art.24721; Wang MS, 2011, ATHEROSCLEROSIS, V214, P377, DOI 10.1016/j.atherosclerosis.2010.11.028; Wruck CJ, 2011, ANN RHEUM DIS, V70, P844, DOI 10.1136/ard.2010.132720	41	31	33	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2012	7	9							e45752	10.1371/journal.pone.0045752	http://dx.doi.org/10.1371/journal.pone.0045752			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	016KP	23049851	Green Submitted, Green Published, gold			2023-01-03	WOS:000309517300048
J	Joynt, KE; Jha, AK				Joynt, Karen E.; Jha, Ashish K.			A Path Forward on Medicare Readmissions	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HOSPITAL READMISSION; RATES		[Joynt, Karen E.; Jha, Ashish K.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Joynt, Karen E.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA; [Jha, Ashish K.] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA; [Joynt, Karen E.; Jha, Ashish K.] Vet Affairs Boston Healthcare Syst, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Joynt, KE (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.							Arbaje AI, 2008, GERONTOLOGIST, V48, P495, DOI 10.1093/geront/48.4.495; Glass D, 2012, REFINING HOSP READMI; Jha AK, 2009, NEW ENGL J MED, V361, P2637, DOI 10.1056/NEJMsa0904859; Joynt KE, 2013, JAMA-J AM MED ASSOC, V309, P342, DOI 10.1001/jama.2012.94856; Krumholz HM, 2013, JAMA-J AM MED ASSOC, V309, P587, DOI 10.1001/jama.2013.333	5	241	242	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 28	2013	368	13					1175	1177		10.1056/NEJMp1300122	http://dx.doi.org/10.1056/NEJMp1300122			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	116FU	23465069				2023-01-03	WOS:000316869000004
J	Binagwaho, A; Pegurri, E; Drobac, PC; Mugwaneza, P; Stulac, SN; Wagner, CM; Karema, C; Tsague, L				Binagwaho, Agnes; Pegurri, Elisabetta; Drobac, Peter C.; Mugwaneza, Placidie; Stulac, Sara N.; Wagner, Claire M.; Karema, Corine; Tsague, Landry			Prevention of Mother-To-Child Transmission of HIV: Cost-Effectiveness of Antiretroviral Regimens and Feeding Options in Rwanda	PLOS ONE			English	Article							SINGLE-DOSE NEVIRAPINE; FORMULA-FED INFANTS; HIV-1-INFECTED WOMEN; TREATMENT PROGRAM; INFECTED WOMEN; FREE SURVIVAL; MORTALITY; ZIDOVUDINE; THERAPY; MORBIDITY	Background: Rwanda's National PMTCT program aims to achieve elimination of new HIV infections in children by 2015. In November 2010, Rwanda adopted the WHO 2010 ARV guidelines for PMTCT recommending Option B (HAART) for all HIV-positive pregnant women extended throughout breastfeeding and discontinued (short course-HAART) only for those not eligible for life treatment. The current study aims to assess the cost-effectiveness of this policy choice. Methods: Based on a cohort of HIV-infected pregnant women in Rwanda, we modelled the cost-effectiveness of six regimens: dual ARV prophylaxis with either 12 months breastfeeding or replacement feeding; short course HAART (Sc-HAART) prophylaxis with either 6 months breastfeeding, 12 months breastfeeding, or 18 months breastfeeding; and Sc-HAART prophylaxis with replacement feeding. Direct costs were modelled based on all inputs in each scenario and related unit costs. Effectiveness was evaluated by measuring HIV-free survival at 18 months. Savings correspond to the lifetime costs of HIV treatment and care avoided as a result of all vertical HIV infections averted. Results: All PMTCT scenarios considered are cost saving compared to "no intervention." Sc-HAART with 12 months breastfeeding or 6 months breastfeeding dominate all other scenarios. Sc-HAART with 12 months breastfeeding allows for more children to be alive and HIV-uninfected by 18 months than Sc-HAART with 6 months breastfeeding for an incremental cost per child alive and uninfected of 11,882 USD. This conclusion is sensitive to changes in the relative risk of mortality by 18 months for exposed HIV-uninfected children on replacement feeding from birth and those who were breastfed for only 6 months compared to those breastfeeding for 12 months or more. Conclusion: Our findings support the earlier decision by Rwanda to adopt WHO Option B and could inform alternatives for breastfeeding duration. Local contexts and existing care delivery models should be part of national policy decisions.	[Binagwaho, Agnes] Minist Hlth, Kigali, Rwanda; [Binagwaho, Agnes; Drobac, Peter C.; Stulac, Sara N.] Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02115 USA; [Pegurri, Elisabetta] UNAIDS Ethiopia, Addis Ababa, Ethiopia; [Drobac, Peter C.] Partners Hlth Inshuti Mu Buzima, Kigali, Rwanda; [Drobac, Peter C.; Mugwaneza, Placidie; Karema, Corine] Rwanda Biomed Ctr, Kigali, Rwanda; [Stulac, Sara N.] Partners Hlth, Boston, MA USA; [Wagner, Claire M.] Global Hlth Delivery Partnership, Boston, MA USA; [Tsague, Landry] UNICEF Zambia, Lusaka, Zambia	Harvard University; Brigham & Women's Hospital; Rwanda Biomedical Center; Partners Healthcare System	Binagwaho, A (corresponding author), Minist Hlth, Kigali, Rwanda.	abinagwaho@gmail.com						Arrive E, 2008, INT J EPIDEMIOL, V37, P474, DOI 10.1093/ije/dym216; Banerjee T, 2010, ANN TROP PAEDIATR, V30, P27, DOI 10.1179/146532810X12637745451915; Becquet R, 2007, PLOS MED, V4, P139, DOI 10.1371/journal.pmed.0040017; Carter RJ, 2010, JAIDS-J ACQ IMM DEF, V55, P404, DOI 10.1097/QAI.0b013e3181e73f4b; Center for Treatment and Research on AIDS Malaria Tuberculosis and Other Epidemics (TRAC-Plus) & Rwanda Ministry of Health, 2010, NAT STAND GUID CLIN; Center for Treatment and Research on AIDS Malaria Tuberculosis and Other Epidemics (TRAC-Plus) & Rwanda Ministry of Health, 2010, RWAND NAT GUID PREV; Center for Treatment and Research on AIDS Malaria Tuberculosis and Other Epidemics (TRAC-Plus) & Rwanda National AIDS Control Commission, 2010, HIV AIDS RWAND 2010; Chasela CS, 2010, NEW ENGL J MED, V362, P2271, DOI 10.1056/NEJMoa0911486; Clinton Health Access Initiative, 2010, ANT ARV PRIC LIST VE; Cooper ER, 2002, J ACQ IMMUN DEF SYND, V29, P484, DOI 10.1097/00126334-200204150-00009; Coutsoudis A, 2004, J INFECT DIS, V189, P2154, DOI 10.1086/420834; Dabis F, 2005, AIDS, V19, P309; De Cock KM, 2000, JAMA-J AM MED ASSOC, V283, P1175, DOI 10.1001/jama.283.9.1175; Franke MF, 2011, PEDIATR INFECT DIS J, V30, P614, DOI 10.1097/INF.0b013e31820a599e; Homsy J, 2010, JAIDS-J ACQ IMM DEF, V53, P28, DOI 10.1097/QAI.0b013e3181bdf65a; Iliff PJ, 2005, AIDS, V19, P699, DOI 10.1097/01.aids.0000166093.16446.c9; Ivers LC, 2011, AIDS RES THER, V8, DOI 10.1186/1742-6405-8-37; Kagaayi J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003877; Kuhn L, 2008, NEW ENGL J MED, V359, P130, DOI 10.1056/NEJMoa073788; Kuhn L, 2010, CLIN PERINATOL, V37, P843, DOI 10.1016/j.clp.2010.08.011; Lallemant M, 2004, NEW ENGL J MED, V351, P217, DOI 10.1056/NEJMoa033500; Lowrance DW, 2009, JAIDS-J ACQ IMM DEF, V52, P49, DOI 10.1097/QAI.0b013e3181b03316; Mahy M, 2010, SEX TRANSM INFECT, V86, pI48, DOI 10.1136/sti.2010.045989; Marseille E, 1999, LANCET, V354, P803, DOI 10.1016/S0140-6736(99)80009-9; Mbori-Ngacha D, 2001, JAMA-J AM MED ASSOC, V286, P2413, DOI 10.1001/jama.286.19.2413; National Bank of Rwanda, 2009, EXCH RAT RWF USD; National Institute of Statistics of Rwanda World Food Programme UNICEF World Vision, 2009, RWAND COMPR FOOD SEC; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; Omes C, 2004, 15 INT AIDS C BANGK; Orlando S, 2010, JAIDS-J ACQ IMM DEF, V55, P631, DOI 10.1097/QAI.0b013e3181f9f9f5; Peltier CA, 2009, AIDS, V23, P2415, DOI 10.1097/QAD.0b013e32832ec20d; Rich ML, 2012, JAIDS-J ACQ IMM DEF, V59, pE35, DOI 10.1097/QAI.0b013e31824476c4; Robberstad B, 2010, JAIDS-J ACQ IMM DEF, V55, P397, DOI 10.1097/QAI.0b013e3181eef4d3; Rollins N, 2006, HIV TRANSMISSION MOR; Rwanda Ministry of Health, 2010, FIN REC; Rwanda Ministry of Health, 2007, SURV INF VIH SIT SEN; Rwanda Ministry of Health, 2011, DEM HLTH SURV 2010 P; Rwanda Ministry of Health, 2001, NAT STRAT APPL NSA B; Rwanda National AIDS Control Commission, 2007, DAT EST AM FIN RES N; Rwanda National AIDS Control Commission, 2008, UN GEN ASS SPEC SESS; Rwanda National AIDS Control Commission, 2009, RWAND NAT STRAT PLAN; Rwanda National Institute of Statistics & ORC Macro, 2008, RWAND INT DEM HLTH S; Rwanda National Institute of Statistics & ORC Macro, 2006, RWAND DEM HLTH SURV; Scotland GS, 2003, AIDS, V17, P1045, DOI 10.1097/00002030-200305020-00014; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Shapiro RL, 2010, NEW ENGL J MED, V362, P2282, DOI 10.1056/NEJMoa0907736; Soderlund N, 1999, BRIT MED J, V318, P1650, DOI 10.1136/bmj.318.7199.1650; Stover J, 2008, SEX TRANSM INFECT, V84, pI24, DOI 10.1136/sti.2008.029868; Stringer EM, 2010, JAMA-J AM MED ASSOC, V304, P293, DOI 10.1001/jama.2010.990; Stringer JSA, 2000, J ACQ IMMUN DEF SYND, V24, P369, DOI 10.1097/00126334-200008010-00012; Sweat MD, 2004, AIDS, V18, P1661, DOI 10.1097/01.aids.0000131353.06784.8f; Teerawattananon Y, 2005, COST EFFECTIVENESS R, V3; Thior I, 2006, JAMA-J AM MED ASSOC, V296, P794, DOI 10.1001/jama.296.7.794; Tsague L, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-753; *UNAIDS, 2009, AIDS EP UPD; UNAIDS & WHO, 2009, UNAIDS REP GLOB AIDS; Universite de Bordeaux Institut de Sante Publique dEedDIIU UNICEF, 2010, PMCT PED HIV AIDS CA; van Griensven J, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-39; Victora CG, 2000, LANCET, V355, P451, DOI 10.1016/S0140-6736(00)82011-5; Violari A, 2008, NEW ENGL J MED, V359, P2233, DOI 10.1056/NEJMoa0800971; WHO, 2006, ANT DRUGS TREAT PREG; WHO, 2002, REDUCING RISKS PROMO; World Health Organization, 2012, PROGR UPD US ANT DRU; World Health Organization, 2010, PMTCT STRAT VIS 2010; World Health Organization, 2021, ANT DRUGS TREAT PREG; World Health Organization, 2010, GUID HIV INF FEED 20	66	18	18	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2013	8	2							e54180	10.1371/journal.pone.0054180	http://dx.doi.org/10.1371/journal.pone.0054180			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	093IE	23437040	Green Published, gold, Green Submitted			2023-01-03	WOS:000315184200007
J	Ramsden, CE; Zamora, D; Leelarthaepin, B; Majchrzak-Hong, SF; Faurot, KR; Suchindran, CM; Ringel, A; Davis, JM; Hibbeln, JR				Ramsden, Christopher E.; Zamora, Daisy; Leelarthaepin, Boonseng; Majchrzak-Hong, Sharon F.; Faurot, Keturah R.; Suchindran, Chirayath M.; Ringel, Amit; Davis, John M.; Hibbeln, Joseph R.			Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POLYUNSATURATED FATTY-ACIDS; CARDIOVASCULAR-DISEASE; SERUM-CHOLESTEROL; EICOSAPENTAENOIC ACID; CONTROLLED-TRIALS; OXIDIZED LDL; FOLLOW-UP; RISK; LIPIDS; WOMEN	Objective To evaluate the effectiveness of replacing dietary saturated fat with omega 6 linoleic acid, for the secondary prevention of coronary heart disease and death. Design Evaluation of recovered data from the Sydney Diet Heart Study, a single blinded, parallel group, randomized controlled trial conducted in 1966-73; and an updated meta-analysis including these previously missing data. Setting Ambulatory, coronary care clinic in Sydney, Australia. Participants 458 men aged 30-59 years with a recent coronary event. Interventions Replacement of dietary saturated fats (from animal fats, common margarines, and shortenings) with omega 6 linoleic acid (from safflower oil and safflower oil polyunsaturated margarine). Controls received no specific dietary instruction or study foods. All non-dietary aspects were designed to be equivalent in both groups. Outcome measures All cause mortality (primary outcome), cardiovascular mortality, and mortality from coronary heart disease (secondary outcomes). We used an intention to treat, survival analysis approach to compare mortality outcomes by group. Results The intervention group (n=221) had higher rates of death than controls (n=237) (all cause 17.6% v 11.8%, hazard ratio 1.62 (95% confidence interval 1.00 to 2.64), P=0.05; cardiovascular disease 17.2% v 11.0%, 1.70 (1.03 to 2.80), P=0.04; coronary heart disease 16.3% v 10.1%, 1.74 (1.04 to 2.92), P=0.04). Inclusion of these recovered data in an updated meta-analysis of linoleic acid intervention trials showed non-significant trends toward increased risks of death from coronary heart disease (hazard ratio 1.33 (0.99 to 1.79); P=0.06) and cardiovascular disease (1.27 (0.98 to 1.65); P=0.07). Conclusions Advice to substitute polyunsaturated fats for saturated fats is a key component of worldwide dietary guidelines for coronary heart disease risk reduction. However, clinical benefits of the most abundant polyunsaturated fatty acid, omega 6 linoleic acid, have not been established. In this cohort, substituting dietary linoleic acid in place of saturated fats increased the rates of death from all causes, coronary heart disease, and cardiovascular disease. An updated meta-analysis of linoleic acid intervention trials showed no evidence of cardiovascular benefit. These findings could have important implications for worldwide dietary advice to substitute omega 6 linoleic acid, or polyunsaturated fats in general, for saturated fats. Trial registration Clinical trials NCT01621087.	[Ramsden, Christopher E.; Majchrzak-Hong, Sharon F.; Ringel, Amit; Hibbeln, Joseph R.] NIAAA, Lab Membrane Biophys & Biochem, NIH, Bethesda, MD 20892 USA; [Ramsden, Christopher E.; Zamora, Daisy; Faurot, Keturah R.] Univ N Carolina, Sch Med, Dept Phys Med & Rehabil, Chapel Hill, NC USA; [Leelarthaepin, Boonseng] Univ New S Wales, Sydney, NSW, Australia; [Suchindran, Chirayath M.] Univ N Carolina, Sch Publ Hlth, Dept Biostat, Chapel Hill, NC USA; [Davis, John M.] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of New South Wales Sydney; University of North Carolina; University of North Carolina Chapel Hill; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Ramsden, CE (corresponding author), NIAAA, Lab Membrane Biophys & Biochem, NIH, Bethesda, MD 20892 USA.	Chris.Ramsden@nih.gov	Zamora, Daisy/ABG-5162-2021; Ramsden, Christopher/AAW-9516-2021	Ramsden, Christopher/0000-0002-4058-7630; Zamora, Daisy/0000-0003-2114-5156; Faurot, Keturah/0000-0001-6122-7821	Life Insurance Medical Research Fund of Australia; Life Insurance Medical Research Fund of New Zealand; Intramural Program of the National Institute on Alcohol Abuse and Alcoholism; National Center for Complementary & Integrative Health [T32AT003378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000115, ZIAAA000235] Funding Source: NIH RePORTER	Life Insurance Medical Research Fund of Australia; Life Insurance Medical Research Fund of New Zealand; Intramural Program of the National Institute on Alcohol Abuse and Alcoholism; National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: support from the Life Insurance Medical Research Fund of Australia and New Zealand and the Intramural Program of the National Institute on Alcohol Abuse and Alcoholism for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.	Aarsetoey H, 2009, J NUTR, V139, P507, DOI 10.3945/jn.108.096446; Aarsetoy H, 2008, RESUSCITATION, V78, P258, DOI 10.1016/j.resuscitation.2008.04.007; ABELL LL, 1952, J BIOL CHEM, V195, P357; [Anonymous], 1968, LANCET, V2, P693; [Anonymous], 1961, JAMA, V175, P389; [Anonymous], 2012, USDA NAT NUTR DAT ST; Barlic J, 2007, J BIOL CHEM, V282, P19167, DOI 10.1074/jbc.M701642200; Bendsen NT, 2011, EUR J CLIN NUTR, V65, P773, DOI 10.1038/ejcn.2011.34; Blacket R B, 1973, Singapore Med J, V14, P344; BLACKET R B, 1965, Med J Aust, V1, P59; BLACKET RB, 1979, AUST NZ J MED, V9, P521, DOI 10.1111/j.1445-5994.1979.tb03388.x; BLACKET RB, 1973, MED J AUSTRALIA, V1, P969, DOI 10.5694/j.1326-5377.1973.tb110851.x; BLACKET RB, 1973, AUST NZ J MED, V3, P39, DOI 10.1111/j.1445-5994.1973.tb03956.x; Block RC, 2008, ATHEROSCLEROSIS, V197, P821, DOI 10.1016/j.atherosclerosis.2007.07.042; Bosch J, 2012, NEW ENGL J MED, V367, P309, DOI 10.1056/NEJMoa1203859; BREWER ER, 1975, CIRCULATION, V52, P269; CARPENTER DL, 1973, J AM OIL CHEM SOC, V50, P372, DOI 10.1007/BF02640843; CARPENTER KLH, 1995, BBA-LIPID LIPID MET, V1256, P141, DOI 10.1016/0005-2760(94)00247-V; Chardigny JM, 2006, CONTEMP CLIN TRIALS, V27, P364, DOI 10.1016/j.cct.2006.03.003; Chiuve SE, 2012, AM J CLIN NUTR, V96, P498, DOI 10.3945/ajcn.112.040287; Czernichow S, 2010, BRIT J NUTR, V104, P788, DOI 10.1017/S0007114510002096; DAYTON S, 1968, LANCET, V2, P1060, DOI 10.1016/S0140-6736(68)91531-6; De Caterina R, 2011, NEW ENGL J MED, V364, P2439, DOI 10.1056/NEJMra1008153; de Goede J, 2012, BRIT J NUTR, V107, P1070, DOI 10.1017/S0007114511003837; Dietary Guidelines Advisory Committee, 2010, WHAT IS EFF DIET INT; ESTERBAUER H, 1987, J LIPID RES, V28, P495; FISHER M, 1970, AUST QUART, V42, P20, DOI 10.2307/20634360; FitzSimons P., 2021, SYDNEY MORNING HERAL; FOLCIK VA, 1994, J LIPID RES, V35, P1570; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; HARLAND WA, 1971, ATHEROSCLEROSIS, V13, P239, DOI 10.1016/0021-9150(71)90026-8; Harris WS, 2013, INT J CARDIOL, V168, P53, DOI 10.1016/j.ijcard.2012.09.076; Harris WS, 2009, CIRCULATION, V119, P902, DOI 10.1161/CIRCULATIONAHA.108.191627; Heltianu C, 2011, CELL BIOCHEM BIOPHYS, V61, P209, DOI 10.1007/s12013-011-9190-8; Hooper L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002137.pub3; Jakobsen MU, 2009, AM J CLIN NUTR, V89, P1425, DOI 10.3945/ajcn.2008.27124; Joplin GF, 1968, CARBOHYDRATE METABOL; Katan MB, 2009, AM J CLIN NUTR, V89, P1283, DOI 10.3945/ajcn.2009.27744; KEYS A, 1965, METABOLIS, V14, P747, DOI 10.1016/0026-0495(65)90001-6; Kita T, 2001, ANN NY ACAD SCI, V947, P199; KUHN H, 1992, EICOSANOIDS, V5, P17; Kwak SM, 2012, ARCH INTERN MED, V172, P686, DOI 10.1001/archinternmed.2012.262; LENZ ML, 1990, J LIPID RES, V31, P1043; Leren P, 1966, Acta Med Scand Suppl, V466, P1; Lucas M, 2011, AM J CLIN NUTR, V93, P1337, DOI 10.3945/ajcn.111.011817; MacIntosh BA, 2013, BR J NUTR, V18, P1; MCGILCHRIST CA, 1976, J CHRON DIS, V29, P285, DOI 10.1016/0021-9681(76)90089-8; Mensink RP, 2003, AM J CLIN NUTR, V77, P1146, DOI 10.1093/ajcn/77.5.1146; Mozaffarian D, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000252; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Natarajan R, 2001, ARTERIOSCL THROM VAS, V21, P1408, DOI 10.1161/hq0901.095278; National Heart Foundation of Australia, 2009, POS STAT DIET FATS D; NESTEL PJ, 1971, MED J AUSTRALIA, V1, P1144; Oh K, 2005, AM J EPIDEMIOL, V161, P672, DOI 10.1093/aje/kwi085; PALMER AJ, 1973, MED J AUSTRALIA, V2, P19; Palmer J, 1977, Adv Exp Med Biol, V82, P115; PALMER J, 1969, ISRAEL J MED SCI, V5, P754; Ramsden CE, 2012, PROSTAG LEUKOTR ESS, V87, P135, DOI 10.1016/j.plefa.2012.08.004; Ramsden CE, 2011, BRIT J NUTR, V106, P953, DOI 10.1017/S0007114511001061; Ramsden CE, 2011, WORLD REV NUTR DIET, V102, P30, DOI 10.1159/000327789; Ramsden CE, 2010, BRIT J NUTR, V104, P1586, DOI 10.1017/S0007114510004010; Rizos EC, 2012, JAMA-J AM MED ASSOC, V308, P1024, DOI 10.1001/2012.jama.11374; ROSE GA, 1965, BMJ-BRIT MED J, V1, P1531, DOI 10.1136/bmj.1.5449.1531; SHERWIN R, 1978, AM J EPIDEMIOL, V108, P92, DOI 10.1093/oxfordjournals.aje.a112607; Shibata N, 2009, ACTA HISTOCHEM CYTOC, V42, P197, DOI 10.1267/ahc.09022; *USDA, 2008, WHAT WE EAT AM NHANE; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Vangaveti V, 2010, THER ADV ENDOCRINOL, V1, P51, DOI 10.1177/2042018810375656; VANHANDEL E, 1957, J LAB CLIN MED, V50, P152; Waddington EI, 2003, ATHEROSCLEROSIS, V167, P111, DOI 10.1016/S0021-9150(02)00391-X; Wang LM, 2009, J LIPID RES, V50, P204, DOI 10.1194/jlr.M700505-JLR200; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; WOODHILL J, 1969, Food Technology in Australia, V21, P264; Woodhill J M, 1978, Adv Exp Med Biol, V109, P317; WOODHILL JM, 1973, MED J AUSTRALIA, V1, P973, DOI 10.5694/j.1326-5377.1973.tb110852.x; WOODHILL JM, 1970, INT Z VITAMINFORSCH, V40, P520; World Health Organization, 1957, INT CLASS DIS 7 REV; Xie S, 2009, P NATL ACAD SCI USA, V106, P13353, DOI 10.1073/pnas.0905724106; Yang LL, 2010, J BIOL CHEM, V285, P22211, DOI 10.1074/jbc.M110.119982; Yokode M, 1996, ANN NY ACAD SCI, V786, P245, DOI 10.1111/j.1749-6632.1996.tb39067.x; Yokoyama M, 2007, LANCET, V369, P1090, DOI 10.1016/S0140-6736(07)60527-3	81	248	253	4	77	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 5	2013	346								e8707	10.1136/bmj.e8707	http://dx.doi.org/10.1136/bmj.e8707			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	088AR	23386268	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000314806700001
J	Roll, S; Reinhold, T; Pach, D; Brinkhaus, B; Icke, K; Staab, D; Jackel, T; Wegscheider, K; Willich, SN; Witt, CM				Roll, Stephanie; Reinhold, Thomas; Pach, Daniel; Brinkhaus, Benno; Icke, Katja; Staab, Doris; Jaeckel, Tanja; Wegscheider, Karl; Willich, Stefan N.; Witt, Claudia M.			Comparative Effectiveness of Homoeopathic vs. Conventional Therapy in Usual Care of Atopic Eczema in Children: Long-Term Medical and Economic Outcomes	PLOS ONE			English	Article							DERMATITIS; PREVALENCE; DISEASES	Background: One in five children visiting a homeopathic physician suffers from atopic eczema. Objectives: We aimed to examine the long-term effectiveness, safety and costs of homoeopathic vs. conventional treatment in usual medical care of children with atopic eczema. Methods: In this prospective multi-centre comparative observational non-randomized rater-blinded study, 135 children (48 homoeopathy, 87 conventional) with mild to moderate atopic eczema were included by their respective physicians. Depending on the specialisation of the physician, the primary treatment was either standard conventional treatment or individualized homeopathy as delivered in routine medical care. The main outcome was the SCORAD (SCORing Atopic Dermatitis) at 36 months by a blinded rater. Further outcomes included quality of life, conventional medicine consumption, safety and disease related costs at six, 12 and 36 months after baseline. A multilevel ANCOVA was used, with physician as random effect and the following fixed effects: age, gender, baseline value, severity score, social class and parents' expectation. Results: The adjusted mean SCORAD showed no significant differences between the groups at 36 months (13.7 95% CI [7.9-19.5] vs. 14.9 [10.4-19.4], p = 0.741). The SCORAD response rates at 36 months were similar in both groups (33% response: homoeopathic 63.9% vs. conventional 64.5%, p = 0.94; 50% response: 52.0% vs. 52.3%, p = 0.974). Total costs were higher in the homoeopathic versus the conventional group (months 31-36 200.54 Euro [132.33-268.76] vs. 68.86 Euro [9.13-128.58], p = 0.005). Conclusions: Taking patient preferences into account, while being unable to rule out residual confounding, in this long-term observational study, the effects of homoeopathic treatment were not superior to conventional treatment for children with mild to moderate atopic eczema, but involved higher costs.	[Roll, Stephanie; Reinhold, Thomas; Pach, Daniel; Brinkhaus, Benno; Icke, Katja; Jaeckel, Tanja; Willich, Stefan N.; Witt, Claudia M.] Charite, Med Ctr, Inst Social Med Epidemiol & Hlth Econ, D-13353 Berlin, Germany; [Staab, Doris] Charite, Med Ctr, Dept Paediat Pulmonol & Immunol, D-13353 Berlin, Germany; [Wegscheider, Karl] Univ Med Ctr, Dept Med Biometry & Epidemiol, Hamburg, Germany; [Witt, Claudia M.] Univ Maryland, Sch Med, Ctr Integrat Med, Baltimore, MD 21201 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg; University Medical Center Hamburg-Eppendorf; University System of Maryland; University of Maryland Baltimore	Roll, S (corresponding author), Charite, Med Ctr, Inst Social Med Epidemiol & Hlth Econ, D-13353 Berlin, Germany.	stephanie.roll@charite.de	Witt, Claudia M./AAX-2370-2021; Brinkhaus, Benno/AAU-2428-2021	Witt, Claudia M./0000-0002-5440-7805; Brinkhaus, Benno/0000-0001-6290-744X; Reinhold, Thomas/0000-0001-5169-7029; Roll, Stephanie/0000-0003-1191-3289; Pach, Daniel/0000-0002-2459-6596	Robert Bosch Foundation [12.5.1060.0083.1]	Robert Bosch Foundation	Funding source: Robert Bosch Foundation (grant number 12.5.1060.0083.1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson PC, 2009, CURR OPIN PEDIATR, V21, P131, DOI 10.1097/MOP.0b013e32832130a9; Augustin M, 2001, ALLERGOLOGIE, V24, P433; Becker-Witt C, 2004, FORSCH KOMP KLAS NAT, V11, P98, DOI 10.1159/000078231; [Committee on Comparative Effectiveness Research Prioritization Institute of Medicine], 2009, IN NAT PRIOR COMP EF, P29; Emerson RM, 2001, BRIT J DERMATOL, V144, P514, DOI 10.1046/j.1365-2133.2001.04077.x; Fineberg H, 2009, IN NAT PRIOR COMP EF; Herd RM, 2002, ARCH DERMATOL, V138, P819, DOI 10.1001/archderm.138.6.819; Hoare DY, 2000, HEALTH TECHNOL ASSES, V4, P1; Keil T, 2008, COMPLEMENT THER MED, V16, P15, DOI 10.1016/j.ctim.2006.10.001; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; Odhiambo JA, 2009, J ALLERGY CLIN IMMUN, V124, P1251, DOI 10.1016/j.jaci.2009.10.009; Schafer T, 2002, ALLERGY, V57, P694, DOI 10.1034/j.1398-9995.2002.23469.x; Schlaud M, 2007, BUNDESGESUNDHEITSBLA, V50, P701, DOI 10.1007/s00103-007-0231-9; Schwabe U, 2007, ARZNEIVERORDNUNGSREP; Siebenwirth J, 2009, FORSCH KOMPLEMENTMED, V16, P315, DOI 10.1159/000242434; Szucs T, 1995, SOZIOOKONOMISCHE ASP, P49; Witt CM, 2009, DERMATOLOGY, V219, P329, DOI 10.1159/000248854; Witt CM, 2009, ACTA DERM-VENEREOL, V89, P182, DOI 10.2340/00015555-0580	18	15	15	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2013	8	1							e54973	10.1371/journal.pone.0054973	http://dx.doi.org/10.1371/journal.pone.0054973			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	085JH	23383019	Green Published, Green Submitted, gold			2023-01-03	WOS:000314610600054
J	Eitan, R; Krissi, H; Levavi, H; Sabah, G; Peled, Y				Eitan, Ram; Krissi, Haim; Levavi, Hanoch; Sabah, Gad; Peled, Yoav			Clinical Course of Patients Treated for Advanced Ovarian Carcinoma without Surgical Intervention	PLOS ONE			English	Article							NEOADJUVANT CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; CANCER; SURVIVAL; METAANALYSIS; CARBOPLATIN; PACLITAXEL; CISPLATIN	Objective: To describe the clinical course and outcome of patients with non-surgically-treated advanced ovarian cancer attending a single institute. Methodology/Principal Findings: We reviewed the medical charts of all patients with advanced epithelial ovarian cancer who underwent chemotherapy at a tertiary medical center between January 2005 and December 2010 but were never operated. Data on patient characteristics, disease course, and outcome were collected from patient files. Sixteen patients met the inclusion criteria. Eight (50%) were diagnosed with apparent FIGO stage IIIC disease, and 8 with stage IV. Five patients (31%) achieved a complete clinical response, and 11 (69%) achieved a partial response. Among the complete responders, the median disease-free interval was 8 months (range 7-11 months). In all of them, the disease recurred and second-line chemotherapy was administered. Of them, four (80%) achieved a second complete response. Partial responders had up to four lines of chemotherapy, with continued disease progression. The median overall survival of the whole group was 19.5 months, and of the complete responders, 28 months. Conclusions/Significance: Most patients with advanced ovarian carcinoma who will not undergo surgery respond only partially to first-line chemotherapy. Having no surgery is associated with a short disease-free interval.	[Eitan, Ram] Helen Schneider Hosp Women, Rabin Med Ctr, Div Gynecol Oncol, Petah Tiqwa, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Eitan, R (corresponding author), Helen Schneider Hosp Women, Rabin Med Ctr, Div Gynecol Oncol, Petah Tiqwa, Israel.	eitanr@clalit.org.il						Aletti GD, 2006, OBSTET GYNECOL, V107, P77, DOI 10.1097/01.AOG.0000192407.04428.bb; Armstrong DK, 2006, NEW ENGL J MED, V354, P34, DOI 10.1056/NEJMoa052985; Bookman MA, 2003, INT J GYNECOL CANCER, V13, P735, DOI 10.1111/j.1525-1438.2003.13602.x; Bristow RE, 2002, J CLIN ONCOL, V20, P1248, DOI 10.1200/JCO.20.5.1248; Bristow RE, 2006, GYNECOL ONCOL, V103, P1070, DOI 10.1016/j.ygyno.2006.06.025; CHAMBERS JT, 1990, GYNECOL ONCOL, V37, P327, DOI 10.1016/0090-8258(90)90361-N; DeVita VT, 2001, CANC PRINCIPLES PRAC, P1092; du Bois A, 2004, ANN ONCOL S8, pviii7; du Bois A, 2009, CANCER-AM CANCER SOC, V115, P1234, DOI 10.1002/cncr.24149; HOSKINS WJ, 1994, AM J OBSTET GYNECOL, V170, P974, DOI 10.1016/S0002-9378(94)70090-7; Ozols RF, 2005, SEMIN ONCOL, V32, pS4, DOI 10.1053/j.seminoncol.2005.06.023; Schwartz PE, 2002, BEST PRACT RES CL OB, V16, P585, DOI 10.1053/beog.2002.0304; Vergote I, 1998, GYNECOL ONCOL, V71, P431, DOI 10.1006/gyno.1998.5213; Vergote I, 2010, NEW ENGL J MED, V363, P943, DOI 10.1056/NEJMoa0908806	14	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2013	8	1							e55645	10.1371/journal.pone.0055645	http://dx.doi.org/10.1371/journal.pone.0055645			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	098QM	23383254	gold, Green Published, Green Submitted			2023-01-03	WOS:000315563800179
J	Pechlaner, R; Knoflach, M; Matosevic, B; Ruecker, M; Schmidauer, C; Kiechl, S; Willeit, J				Pechlaner, Raimund; Knoflach, Michael; Matosevic, Benjamin; Ruecker, Michael; Schmidauer, Christoph; Kiechl, Stefan; Willeit, Johann			Recanalization of Extracranial Internal Carotid Artery Occlusion after i.v. Thrombolysis for Acute Ischemic Stroke	PLOS ONE			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; THERAPY	Background: Although extracranial internal carotid artery (e-ICA) occlusion is a common pathology in patients undergoing intravenous thrombolysis for treatment of acute ischemic stroke, no data on e-ICA recanalization rate or potential effects on outcome are yet available. Methods and Results: This study included 52 consecutive patients with e-ICA occlusion and ischemic stroke undergoing standard intravenous thrombolysis. The rate of e-ICA recanalization was 30.8% [95% CI, 18.2-43.3], documented at 3.5 [2.0-11.8] (median [IQR]) days after stroke, as compared to 8.6% [95% CI, 3.5-13.7] in a series of 116 consecutive patients with symptomatic e-ICA occlusion not undergoing thrombolysis (P < 0.001 for difference). Functional outcome three months after stroke did not significantly differ for those with or without e-ICA recanalization following intravenous thrombolysis (modified Rankin scale <= 2: 31.3% vs. 22.2%, odds ratio 1.6 [95% CI, 0.4-5.9], P = 0.506). In patients with e-ICA occlusion of atherothrombotic origin, recanalization resulted in most instances in residual high-grade stenosis (13 of 14). Conclusions: Recanalization of e-ICA occlusion after stroke thrombolysis occurred in about one third of patients. Although e-ICA recanalization had no significant effect on patient outcome, control sonography in the early days after thrombolysis is recommended for the detection of potential residual e-ICA stenosis.	[Pechlaner, Raimund; Knoflach, Michael; Matosevic, Benjamin; Ruecker, Michael; Schmidauer, Christoph; Kiechl, Stefan; Willeit, Johann] Med Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Tyrol, Austria	Medical University of Innsbruck	Willeit, J (corresponding author), Med Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Tyrol, Austria.	Johann.Willeit@i-med.ac.at		Pechlaner, Raimund/0000-0001-9006-5606; Knoflach, Michael/0000-0001-5576-6562				Christou I, 2001, INT ANGIOL, V20, P208; DELZOPPO GJ, 1992, ANN NEUROL, V32, P78, DOI 10.1002/ana.410320113; Georgiadis D, 2004, NEUROLOGY, V63, P22, DOI 10.1212/01.WNL.0000132524.82310.91; Linfante I, 2002, STROKE, V33, P2066, DOI 10.1161/01.STR.0000021001.18101.A5; Mokin M, 2012, STROKE, V43, P2362, DOI 10.1161/STROKEAHA.112.655621; Nederkoorn PJ, 2003, STROKE, V34, P1324, DOI 10.1161/01.STR.0000068367.08991.A2; Paciaroni M, 2005, CEREBROVASC DIS, V20, P108, DOI 10.1159/000086800; Papanagiotou P, 2011, J AM COLL CARDIOL, V58, P2363, DOI 10.1016/j.jacc.2011.08.044; Ruecker M, 2012, NEUROLOGY, V79, P31, DOI 10.1212/WNL.0b013e31825dcdf0; Seet RC, 2012, ARCH NEUROL-CHICAGO, V24, P1; WOLPERT SM, 1993, AM J NEURORADIOL, V14, P3; Zangerle A, 2007, NEUROLOGY, V68, P39, DOI 10.1212/01.wnl.0000250341.38014.d2	12	12	12	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2013	8	1							e55318	10.1371/journal.pone.0055318	http://dx.doi.org/10.1371/journal.pone.0055318			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	093SF	23383152	Green Published, Green Submitted, gold			2023-01-03	WOS:000315211500075
J	Cao, SR; Li, S; Li, HY; Xiong, LP; Zhou, Y; Fan, JJ; Yu, XQ; Mao, HP				Cao, Shirong; Li, Shu; Li, Huiyang; Xiong, Liping; Zhou, Yi; Fan, Jinjin; Yu, Xueqing; Mao, Haiping			The Potential Role of HMGB1 Release in Peritoneal Dialysis-Related Peritonitis	PLOS ONE			English	Article							MOBILITY GROUP BOX-1; MESOTHELIAL CELL; PROTEIN HMGB1; LATE MEDIATOR; INFLAMMATION; PATHWAY; DISEASE; SEPSIS; MECHANISM; INFECTION	High mobility group box 1 (HMGB1), a DNA-binding nuclear protein, has been implicated as an endogenous danger signal in the pathogenesis of infection diseases. However, the potential role and source of HMGB1 in the peritoneal dialysis (PD) effluence of patients with peritonitis are unknown. First, to evaluate HMDB1 levels in peritoneal dialysis effluence (PDE), a total of 61 PD patients were enrolled in this study, including 42 patients with peritonitis and 19 without peritonitis. Demographic characteristics, symptoms, physical examination findings and laboratory parameters were recorded. HMGB1 levels in PDE were determined by Western blot and ELISA. The concentrations of TNF-alpha and IL-6 in PDE were quantified by ELISA. By animal model, inhibition of HMGB1 with glycyrrhizin was performed to determine the effects of HMGB1 in LPS-induced mice peritonitis. In vitro, a human peritoneal mesothelial cell line (HMrSV5) was stimulated with lipopolysaccharide (LPS), HMGB1 extracellular content in the culture media and intracellular distribution in various cellular fractions were analyzed by Western blot or immunofluorescence. The results showed that the levels of HMGB1 in PDE were higher in patients with peritonitis than those in controls, and gradually declined during the period of effective antibiotic treatments. Furthermore, the levels of HMGB1 in PDE were positively correlated with white blood cells (WBCs) count, TNF-a and IL-6 levels. However, pretreatment with glycyrrhizin attenuated LPS-induced acute peritoneal inflammation and dysfunction in mice. In cultured HMrSV5 cells, LPS actively induced HMGB1 nuclear-cytoplasmic translocation and release in a time and dose-dependent fashion. Moreover, cytosolic HMGB1 was located in lysosomes and secreted via a lysosome-mediated secretory pathway following LPS stimulation. Our study demonstrates that elevated HMGB1 levels in PDE during PD-related peritonitis, at least partially, from peritoneal mesothelial cells, which may be involved in the process of PD-related peritonitis and play a critical role in acute peritoneal dysfunction.	[Cao, Shirong; Li, Shu; Li, Huiyang; Xiong, Liping; Zhou, Yi; Fan, Jinjin; Yu, Xueqing; Mao, Haiping] Sun Yat Sen Univ, Dept Nephrol, Affiliated Hosp 1, Key Lab Nephrol,Minist Hlth, Guangzhou 510275, Guangdong, Peoples R China; [Li, Shu] Cent S Univ, Xiangya Hosp 2, Dept Rheumatol, Changsha, Hunan, Peoples R China	Sun Yat Sen University; Central South University	Mao, HP (corresponding author), Sun Yat Sen Univ, Dept Nephrol, Affiliated Hosp 1, Key Lab Nephrol,Minist Hlth, Guangzhou 510275, Guangdong, Peoples R China.	haipingmao@126.com	cao, shirong/AAX-5688-2021	Mao, Haiping/0000-0002-3608-3851; Cao, Shirong/0000-0002-6593-4600	National Natural Science Foundation of China [81070553, 81270783]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Natural Science Foundation of China (81070553, 81270783). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Andersson U, 2010, BBA-GENE REGUL MECH, V1799, P141, DOI 10.1016/j.bbagrm.2009.11.003; Andrassy M, 2008, CIRCULATION, V117, P3216, DOI 10.1161/CIRCULATIONAHA.108.769331; Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154; Borde C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016145; Bruchfeld A, 2008, MOL MED, V14, P109, DOI 10.2119/2007-00107.Bruchfeld; Dehbi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044100; Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo-reports/kvf198; Goldstein RS, 2007, MOL MED, V13, P210, DOI 10.2119/2006-00108.Goldstein; Li PK, 2011, PERITON DIALYSIS INT, V30, P393; Li S, 2011, AM J PATHOL, V179, P2822, DOI 10.1016/j.ajpath.2011.08.013; Liu SG, 2006, AM J PHYSIOL-CELL PH, V290, pC990, DOI 10.1152/ajpcell.00308.2005; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Maugeri N, 2012, AUTOIMMUNITY, V45, P584, DOI 10.3109/08916934.2012.719946; Nessim SJ, 2011, SEMIN NEPHROL, V31, P199, DOI 10.1016/j.semnephrol.2011.01.008; Ni J, 2010, NEPHROL DIAL TRANSPL, V25, P86, DOI 10.1093/ndt/gfp415; Orlova VV, 2007, EMBO J, V26, P1129, DOI 10.1038/sj.emboj.7601552; Rendon-Mitchell B, 2003, J IMMUNOL, V170, P3890, DOI 10.4049/jimmunol.170.7.3890; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Sitia G, 2007, J LEUKOCYTE BIOL, V81, P100, DOI 10.1189/jlb.0306173; Sitia G, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002061; Sunden-Cullberg J, 2005, CRIT CARE MED, V33, P564, DOI [10.1097/01.CCM.0000155991.88802.4D, 10.1097/01.ccm.0000155991.88802.4D]; TOPLEY N, 1995, PERITON DIALYSIS INT, V15, P116; Wang H, 2004, J INTERN MED, V255, P320, DOI 10.1111/j.1365-2796.2003.01302.x; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Wang HC, 1999, SURGERY, V126, P389, DOI 10.1016/S0039-6060(99)70182-0; Wang HH, 2001, AM J RESP CRIT CARE, V164, P1768, DOI 10.1164/ajrccm.164.10.2106117; Yang H, 2004, P NATL ACAD SCI USA, V101, P296, DOI 10.1073/pnas.2434651100; Yung S, 1998, KIDNEY INT, V54, P2160, DOI 10.1046/j.1523-1755.1998.00177.x; Yung S, 2006, PERITON DIALYSIS INT, V26, P162; Zhou Y, 2010, J AM SOC NEPHROL, V21, P598, DOI 10.1681/ASN.2009050552	31	15	16	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2013	8	1							e54647	10.1371/journal.pone.0054647	http://dx.doi.org/10.1371/journal.pone.0054647			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	077JK	23359306	gold, Green Published, Green Submitted			2023-01-03	WOS:000314023600086
J	Chou, J; Ito, T; Bishop, D; Otsuka, M; Ben-Nissan, B; Milthorpe, B				Chou, Joshua; Ito, Tomoko; Bishop, David; Otsuka, Makoto; Ben-Nissan, Besim; Milthorpe, Bruce			Controlled Release of Simvastatin from Biomimetic beta-TCP Drug Delivery System	PLOS ONE			English	Article							BONE-FORMATION	Simvastatin have been shown to induce bone formation and there is currently a urgent need to develop an appropriate delivery system to sustain the release of the drug to increase therapeutic efficacy whilst reducing side effects. In this study, a novel drug delivery system for simvastatin by means of hydrothermally converting marine exoskeletons to biocompatible beta-tricalcium phosphate was investigated. Furthermore, the release of simvastatin was controlled by the addition of an outer apatite coating layer. The samples were characterized by x-ray diffraction analysis, fourier transform infrared spectroscopy, scanning electron microscopy and mass spectroscopy confirming the conversion process. The in-vitro dissolution of key chemical compositional elements and the release of simvastatin were measured in simulated body fluid solution showing controlled release with reduction of approximately 25% compared with un-coated samples. This study shows the potential applications of marine structures as a drug delivery system for simvastatin.	[Chou, Joshua] Univ Technol Sydney, Sch Med & Mol Sci, Adv Tissue Regenerat & Drug Delivery Grp, Sydney, NSW 2007, Australia; [Ito, Tomoko; Otsuka, Makoto] Musashino Univ, Pharmaceut Sci Res Inst, Fac Pharm, Nishi Tokyo, Japan; [Bishop, David; Ben-Nissan, Besim] Univ Technol Sydney, Sch Chem & Forens Sci, Sydney, NSW 2007, Australia; [Milthorpe, Bruce] Univ Technol Sydney, Fac Sci, Sydney, NSW 2007, Australia	University of Technology Sydney; University of Technology Sydney; University of Technology Sydney	Chou, J (corresponding author), Univ Technol Sydney, Sch Med & Mol Sci, Adv Tissue Regenerat & Drug Delivery Grp, Sydney, NSW 2007, Australia.	Joshua.chou@uts.edu.au	Milthorpe, Bruce/Z-1153-2019; Milthorpe, Bruce K/A-7014-2008; Bishop, David P/F-2891-2019; Ben-Nissan, Besim/AAR-4445-2020; Chou, Joshua/G-7746-2013	Milthorpe, Bruce/0000-0002-0867-9586; Bishop, David P/0000-0002-6533-4410; Ben-Nissan, Besim/0000-0003-0433-3593; Chou, Joshua/0000-0002-7472-8016	University of Technology Sydney Chancellor Postdoctoral Fellowship; Australia Endeavour Cheung Kuong Fellowship; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR057083, R01AR048756] Funding Source: NIH RePORTER	University of Technology Sydney Chancellor Postdoctoral Fellowship; Australia Endeavour Cheung Kuong Fellowship(Australian GovernmentDepartment of Industry, Innovation and Science); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This research was supported by the University of Technology Sydney Chancellor Postdoctoral Fellowship and the Australia Endeavour Cheung Kuong Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ayukawa Y, 2004, CLIN ORAL IMPLAN RES, V404, P343; Du ZB, 2009, CLIN ORAL IMPLAN RES, V20, P145, DOI 10.1111/j.1600-0501.2008.01630.x; Guyton JR, 2006, AM J CARDIOL, V97, p95C, DOI 10.1016/j.amjcard.2005.12.016; Junqueira Juliana C, 2002, J Oral Sci, V44, P117; Kiliccoglu SS, 2007, J TRAUMA, V63, P187, DOI 10.1097/01.TA.0000240974.07999.bc; KOKUBO T, 1990, J BIOMED MATER RES, V24, P721, DOI 10.1002/jbm.820240607; Lee YJ, 2008, BIOMATERIALS, V29, P1940, DOI 10.1016/j.biomaterials.2007.12.045; LeGeros RZ, 1996, ADV DENT RES, V10, P252; Maeda T, 2003, ENDOCRINOLOGY, V144, P681, DOI 10.1210/en.2002-220682; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; Nyan M, 2007, J PHARMACOL SCI, V104, P384, DOI 10.1254/jphs.SC0070184; Pytlik M, 2003, POL J PHARMACOL, V55, P63; Rizzoli R, 2005, J Endocrinol Invest, V28, P50; Skoglund B, 2002, J BONE MINER RES, V17, P2004, DOI 10.1359/jbmr.2002.17.11.2004; Stein D, 2005, J PERIODONTOL, V76, P1861, DOI 10.1902/jop.2005.76.11.1861; Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697; Wong RWK, 2003, BRIT J ORAL MAX SURG, V41, P244, DOI 10.1016/S0266-4356(03)00081-0	17	35	37	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 18	2013	8	1							e54676	10.1371/journal.pone.0054676	http://dx.doi.org/10.1371/journal.pone.0054676			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	075GQ	23349949	gold, Green Published, Green Submitted			2023-01-03	WOS:000313872800070
J	Maga, JA; Zhou, JH; Kambampati, R; Peng, S; Wang, X; Bohnsack, RN; Thomm, A; Golata, S; Tom, P; Dahms, NM; Byrne, BJ; LeBowitz, JH				Maga, John A.; Zhou, Jianghong; Kambampati, Ravi; Peng, Susan; Wang, Xu; Bohnsack, Richard N.; Thomm, Angela; Golata, Sarah; Tom, Peggy; Dahms, Nancy M.; Byrne, Barry J.; LeBowitz, Jonathan H.			Glycosylation-independent Lysosomal Targeting of Acid alpha-Glucosidase Enhances Muscle Glycogen Clearance in Pompe Mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; II BINDING-SITE; ALGLUCOSIDASE ALPHA; MOUSE MODEL; INSULIN; STORAGE; RECOMBINANT; DISEASE; INFANTILE; ENZYME	We have used a peptide-based targeting system to improve lysosomal delivery of acid alpha-glucosidase (GAA), the enzyme deficient in patients with Pompe disease. Human GAA was fused to the glycosylation-independent lysosomal targeting (GILT) tag, which contains a portion of insulin-like growth factor II, to create an active, chimeric enzyme with high affinity for the cation-independent mannose 6-phosphate receptor. GILT-tagged GAA was taken up by L6 myoblasts about 25-fold more efficiently than was recombinant human GAA (rhGAA). Once delivered to the lysosome, the mature form of GILT-tagged-GAA was indistinguishable from rhGAA and persisted with a half-life indistinguishable from rhGAA. GILT-tagged GAA was significantly more effective than rhGAA in clearing glycogen from numerous skeletal muscle tissues in the Pompe mouse model. The GILT-tagged GAA enzyme may provide an improved enzyme replacement therapy for Pompe disease patients.	[Maga, John A.; Zhou, Jianghong; Kambampati, Ravi; Peng, Susan; Thomm, Angela; Golata, Sarah; Tom, Peggy; LeBowitz, Jonathan H.] ZyStor Therapeut, Milwaukee, WI 53226 USA; [Wang, Xu; Byrne, Barry J.] Univ Florida, Coll Med, Powell Gene Therapy Ctr, Gainesville, FL 32610 USA; [Bohnsack, Richard N.; Dahms, Nancy M.] Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	BioMarin Pharmaceutical Inc.; ZyStor Therapeutics, Inc.; State University System of Florida; University of Florida; Medical College of Wisconsin	LeBowitz, JH (corresponding author), BioMarin Pharmaceut Inc, 105 Digital Dr, Novato, CA 94949 USA.	jlebowitz@bmrn.com		Byrne, Barry J./0000-0002-7302-1756	BioMarin Pharmaceuticals Inc.; Advancing a Healthier Wisconsin program; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042667] Funding Source: NIH RePORTER	BioMarin Pharmaceuticals Inc.; Advancing a Healthier Wisconsin program; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by ZyStor Therapeutics, Inc. (now BioMarin Pharmaceuticals Inc.).; The BIAcore 3000 instrument was purchased through a grant from the Advancing a Healthier Wisconsin program. The 129-GAA<SUP>-/-</SUP> Pompe mouse line used in these experiments was derived from the original strain kindly provided by Nina Raben. We thank Denise Cloutier for expert technical assistance with in vivo studies and Dr. Richard M. Bittman for statistical analysis. We also acknowledge the many thoughtful comments on the manuscript from colleagues at BioMarin.	Amalfitano A, 2001, GENET MED, V3, P132, DOI 10.1097/00125817-200103000-00008; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRAULKE T, 1989, EMBO J, V8, P681, DOI 10.1002/j.1460-2075.1989.tb03426.x; Bremel R. D., 2005, U. S. Patent, Patent No. 6852510; BROWN BI, 1970, BIOCHEMISTRY-US, V9, P1423, DOI 10.1021/bi00808a017; CHEN JW, 1985, ARCH BIOCHEM BIOPHYS, V239, P574, DOI 10.1016/0003-9861(85)90727-1; Dahms NM, 2002, BBA-GEN SUBJECTS, V1572, P317, DOI 10.1016/S0304-4165(02)00317-3; Fukuda T, 2006, ANN NEUROL, V59, P700, DOI 10.1002/ana.20807; Garmroudi F, 1996, MOL ENDOCRINOL, V10, P642, DOI 10.1210/me.10.6.642; HERS HG, 1963, BIOCHEM J, V86, P11, DOI 10.1042/bj0860011; Hirschhorn R., 2001, METABOLIC MOL BASIS, P3389; KIESS W, 1989, J BIOL CHEM, V264, P4710; Kishnani PS, 2007, NEUROLOGY, V68, P99, DOI 10.1212/01.wnl.0000251268.41188.04; Kishnani PS, 2006, J PEDIATR-US, V148, P671, DOI 10.1016/j.jpeds.2005.11.033; LeBowitz JH, 2004, P NATL ACAD SCI USA, V101, P3083, DOI 10.1073/pnas.0308728100; LEJEUNE N, 1963, BIOCHEM J, V86, P16, DOI 10.1042/bj0860016; Linnell J, 2001, J BIOL CHEM, V276, P23986, DOI 10.1074/jbc.M100700200; Mack GS, 2008, NAT BIOTECHNOL, V26, P1053, DOI [10.1038/nbt1008-1053, 10.1038/nbt0608-592]; McVie-Wylie AJ, 2008, MOL GENET METAB, V94, P448, DOI 10.1016/j.ymgme.2008.04.009; Moreland RJ, 2005, J BIOL CHEM, V280, P6780, DOI 10.1074/jbc.M404008200; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Myszka DG, 2000, METHOD ENZYMOL, V323, P325; Nicolino M, 2009, GENET MED, V11, P210, DOI 10.1097/GIM.0b013e31819d0996; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; Raben N, 2005, MOL THER, V11, P48, DOI 10.1016/j.ymthe.2004.09.017; Raben N, 2003, MOL GENET METAB, V80, P159, DOI 10.1016/j.ymgme.2003.08.022; Raben N, 1998, J BIOL CHEM, V273, P19086, DOI 10.1074/jbc.273.30.19086; REUSER AJJ, 1995, MUSCLE NERVE, pS61; SCHMIDT B, 1995, J BIOL CHEM, V270, P14975, DOI 10.1074/jbc.270.25.14975; TONG PY, 1988, J BIOL CHEM, V263, P2585; TONG PY, 1989, J BIOL CHEM, V264, P7970; Valenzano KJ, 1997, J BIOL CHEM, V272, P4804, DOI 10.1074/jbc.272.8.4804; van der Ploeg AT, 2010, NEW ENGL J MED, V362, P1396, DOI 10.1056/NEJMoa0909859; VANDERPLOEG AT, 1991, J CLIN INVEST, V87, P513, DOI 10.1172/JCI115025; Villevalois-Cam L, 2000, J CELL BIOCHEM, V77, P310, DOI 10.1002/(SICI)1097-4644(20000501)77:2<310::AID-JCB13>3.0.CO;2-4; Winkel LPF, 2005, J NEUROL, V252, P875, DOI 10.1007/s00415-005-0922-9; WISSELAAR HA, 1993, J BIOL CHEM, V268, P2223; Yang HW, 1998, PEDIATR RES, V43, P374, DOI 10.1203/00006450-199803000-00011; Zhu YX, 2009, MOL THER, V17, P954, DOI 10.1038/mt.2009.37; Zhu YX, 2005, BIOCHEM J, V389, P619, DOI 10.1042/BJ20050364	40	73	79	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2013	288	3					1428	1438		10.1074/jbc.M112.438663	http://dx.doi.org/10.1074/jbc.M112.438663			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	073OC	23188827	hybrid, Green Published			2023-01-03	WOS:000313751400001
J	Tikkanen, O; Haakana, P; Pesola, AJ; Hakkinen, K; Rantalainen, T; Havu, M; Pullinen, T; Finni, T				Tikkanen, Olli; Haakana, Piia; Pesola, Arto J.; Hakkinen, Keijo; Rantalainen, Timo; Havu, Marko; Pullinen, Teemu; Finni, Taija			Muscle Activity and Inactivity Periods during Normal Daily Life	PLOS ONE			English	Article							TIME PHYSICAL-ACTIVITY; TYPE-2 DIABETES-MELLITUS; METABOLIC SYNDROME; CARDIOVASCULAR-DISEASE; SEDENTARY BEHAVIORS; ENERGY-EXPENDITURE; SEASONAL-VARIATION; ADULTS; RISK; OBESITY	Recent findings suggest that not only the lack of physical activity, but also prolonged times of sedentary behaviour where major locomotor muscles are inactive, significantly increase the risk of chronic diseases. The purpose of this study was to provide details of quadriceps and hamstring muscle inactivity and activity during normal daily life of ordinary people. Eighty-four volunteers (44 females, 40 males, 44.1 +/- 17.3 years, 172.3 +/- 6.1 cm, 70.1 +/- 10.2 kg) were measured during normal daily life using shorts measuring muscle electromyographic (EMG) activity (recording time 11.3 +/- 2.0 hours). EMG was normalized to isometric MVC (EMG(MVC)) during knee flexion and extension, and inactivity threshold of each muscle group was defined as 90% of EMG activity during standing (2.5 +/- 1.7% of EMG(MVC)). During normal daily life the average EMG amplitude was 4.0 +/- 2.6% and average activity burst amplitude was 5.8 +/- 3.4% of EMG(MVC) (mean duration of 1.4 +/- 1.4 s) which is below the EMG level required for walking (5 km/h corresponding to EMG level of about 10% of EMG(MVC)). Using the proposed individual inactivity threshold, thigh muscles were inactive 67.5 +/- 11.9% of the total recording time and the longest inactivity periods lasted for 13.9 +/- 7.3 min (2.5-38.3 min). Women had more activity bursts and spent more time at intensities above 40% EMG(MVC) than men (p < 0.05). In conclusion, during normal daily life the locomotor muscles are inactive about 7.5 hours, and only a small fraction of muscle's maximal voluntary activation capacity is used averaging only 4% of the maximal recruitment of the thigh muscles. Some daily non-exercise activities such as stair climbing produce much higher muscle activity levels than brisk walking, and replacing sitting by standing can considerably increase cumulative daily muscle activity.	[Tikkanen, Olli; Haakana, Piia; Pesola, Arto J.; Hakkinen, Keijo; Havu, Marko; Pullinen, Teemu; Finni, Taija] Univ Jyvaskyla, Dept Biol Phys Act, Neuromuscular Res Ctr, SF-40100 Jyvaskyla, Finland; [Rantalainen, Timo] Univ Jyvaskyla, Dept Hlth Sci, SF-40100 Jyvaskyla, Finland	University of Jyvaskyla; University of Jyvaskyla	Tikkanen, O (corresponding author), Univ Jyvaskyla, Dept Biol Phys Act, Neuromuscular Res Ctr, SF-40100 Jyvaskyla, Finland.	olli.tikkanen@megaemg.com	Finni, Taija/F-6544-2014; Havu, Marko/AAJ-9720-2020; Pesola, Arto/AAF-2800-2020; Finni, Taija/AAV-9073-2020; Havu, Marko/Q-6259-2016	Finni, Taija/0000-0002-7697-2813; Havu, Marko/0000-0002-4109-6593; Pesola, Arto/0000-0002-2984-9847; Havu, Marko/0000-0002-4109-6593; Haakana, Piia/0000-0003-0005-3834; Rantalainen, Timo/0000-0001-6977-4782	Academy of Finland [128643]; Ministry of Education [42/627/2010]; Urheiluopistosaatio	Academy of Finland(Academy of Finland); Ministry of Education; Urheiluopistosaatio	This study was funded by Academy of Finland (# 128643/Finni), Ministry of Education (42/627/2010/Finni) and Urheiluopistosaatio (Tikkanen). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bertrais S, 2005, OBES RES, V13, P936, DOI 10.1038/oby.2005.108; Buchowski MS, 2009, J PHYS ACT HEALTH, V6, P252, DOI 10.1123/jpah.6.2.252; Byrne NM, 2005, J APPL PHYSIOL, V99, P1112, DOI 10.1152/japplphysiol.00023.2004; Crouter SE, 2006, EUR J APPL PHYSIOL, V98, P601, DOI 10.1007/s00421-006-0307-5; De Luca CJ, 2010, J NEUROPHYSIOL, V104, P1034, DOI 10.1152/jn.01018.2009; Desmedt J, 1977, J PHYSL, V234, P723; Dunstan DW, 2007, DIABETES CARE, V30, P516, DOI 10.2337/dc06-1996; Dunstan DW, 2005, DIABETOLOGIA, V48, P2254, DOI 10.1007/s00125-005-1963-4; Dunstan DW, 2004, DIABETES CARE, V27, P2603, DOI 10.2337/diacare.27.11.2603; Edgerton VR, 2001, J EXP BIOL, V204, P3217; Finni T, 2007, PHYSIOL MEAS, V28, P1405, DOI 10.1088/0967-3334/28/11/007; Finni T, 2014, SCAND J MED SCI SPOR, V24, P211, DOI 10.1111/j.1600-0838.2012.01456.x; Ford ES, 2005, OBES RES, V13, P608, DOI 10.1038/oby.2005.65; Hamilton MT, 2007, DIABETES, V56, P2655, DOI 10.2337/db07-0882; Hirvensalo M, 2011, SCAND J PUBLIC HEALT, V39, P669, DOI 10.1177/1403494811420324; Howe TE, 2009, J ELECTROMYOGR KINES, V19, pE78, DOI 10.1016/j.jelekin.2007.10.005; Hu FB, 2003, JAMA-J AM MED ASSOC, V289, P1785, DOI 10.1001/jama.289.14.1785; Hu FB, 2001, ARCH INTERN MED, V161, P1542, DOI 10.1001/archinte.161.12.1542; Jakes RW, 2003, EUR J CLIN NUTR, V57, P1089, DOI 10.1038/sj.ejcn.1601648; Kern DS, 2001, J APPL PHYSIOL, V91, P2224, DOI 10.1152/jappl.2001.91.5.2224; Klein CS, 2010, J APPL PHYSIOL, V108, P655, DOI 10.1152/japplphysiol.00757.2009; Kraemer WJ HK, 2002, STRENGTH TRAINING SP; Kronenberg F, 2000, ATHEROSCLEROSIS, V153, P433, DOI 10.1016/S0021-9150(00)00426-3; Masakado Yoshihisa, 1994, Keio Journal of Medicine, V43, P137; Matthews CE, 2001, AM J EPIDEMIOL, V153, P172, DOI 10.1093/aje/153.2.172; MONSTER AW, 1978, SCIENCE, V200, P314, DOI 10.1126/science.635587; Ochia RS, 2007, J ELECTROMYOGR KINES, V17, P365, DOI 10.1016/j.jelekin.2006.01.003; Pivarnik JM, 2003, MED SCI SPORT EXER, V35, P1004, DOI 10.1249/01.MSS.0000069747.55950.B1; Powell KE, 2011, ANNU REV PUBL HEALTH, V32, P349, DOI 10.1146/annurev-publhealth-031210-101151; Rassier DE, 1999, J APPL PHYSIOL, V86, P1445, DOI 10.1152/jappl.1999.86.5.1445; Scilingo EP, 2005, IEEE T INF TECHNOL B, V9, P345, DOI 10.1109/TITB.2005.854506; Stephens BR, 2011, METABOLISM, V60, P941, DOI 10.1016/j.metabol.2010.08.014; Wen CP, 2011, LANCET, V378, P1244, DOI 10.1016/S0140-6736(11)60749-6; Westerterp KR, 2009, EUR J APPL PHYSIOL, V105, P823, DOI 10.1007/s00421-009-1000-2	34	85	85	1	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 18	2013	8	1							e52228	10.1371/journal.pone.0052228	http://dx.doi.org/10.1371/journal.pone.0052228			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	075GQ	23349681	gold, Green Published, Green Submitted			2023-01-03	WOS:000313872800004
J	Su, LJ; Chang, CC; Yang, CH; Hsieh, SJ; Wu, YC; Lai, JM; Tseng, TL; Huang, CYF; Hsu, SL				Su, Li-Jen; Chang, Chia-Chuan; Yang, Chih-Hsueh; Hsieh, Shur-Jong; Wu, Yi-Chin; Lai, Jin-Mei; Tseng, Tzu-Ling; Huang, Chi-Ying F.; Hsu, Shih-Lan			Graptopetalum Paraguayense Ameliorates Chemical-Induced Rat Hepatic Fibrosis In Vivo and Inactivates Stellate Cells and Kupffer Cells In Vitro	PLOS ONE			English	Article							LIVER-INJURY; CARBON-TETRACHLORIDE; GENE-EXPRESSION; INTERLEUKIN-10; MECHANISMS; COLLAGEN; DIMETHYLNITROSAMINE; ALCOHOL; HEPATOTOXICITY; SENSITIZATION	Background: Graptopetalum paraguayense (GP) is a folk herbal medicine with hepatoprotective effects that is used in Taiwan. The aim of this study was to evaluate the hepatoprotective and antifibrotic effects of GP on experimental hepatic fibrosis in both dimethylnitrosamine (DMN)- and carbon tetrachloride (CCl4)-induced liver injury rats. Methods: Hepatic fibrosis- induced rats were fed with the methanolic extract of GP (MGP) by oral administration every day. Immunohistochemistry, biochemical assays, and Western blot analysis were performed. The effects of MGP on the expression of fibrotic markers and cytokines in the primary cultured hepatic stellate cells (HSCs) and Kupffer cells, respectively, were evaluated. Results: Oral administration of MGP significantly alleviated DMN- or CCl4-induced liver inflammation and fibrosis. High levels of alanine transaminase, aspartate transaminase, bilirubin, prothrombin activity and mortality rates also decreased in rats treated with MGP. There were significantly decreased hydroxyproline levels in therapeutic rats compared with those of the liver-damaged rats. Collagen I and alpha smooth muscle actin (alpha-SMA) expression were all reduced by incubation with MGP in primary cultured rat HSCs. Furthermore, MGP induced apoptotic cell death in activated HSCs. MGP also suppressed lipopolysaccharide-stimulated rat Kupffer cell activation by decreasing nitric oxide, tumor necrosis factor-alpha and interleukin-6 production, and increasing interleukin-10 expression. Conclusions: The results show that the administration of MGP attenuated toxin-induced hepatic damage and fibrosis in vivo and inhibited HSC and Kupffer cell activation in vitro, suggesting that MGP might be a promising complementary or alternative therapeutic agent for liver inflammation and fibrosis.	[Su, Li-Jen] Natl Cent Univ, Inst Syst Biol & Bioinformat, Jhongli, Taiwan; [Chang, Chia-Chuan] Natl Res Inst Chinese Med, Div Med Chem, Taipei, Taiwan; [Yang, Chih-Hsueh; Hsieh, Shur-Jong; Wu, Yi-Chin; Hsu, Shih-Lan] Taichung Vet Gen Hosp, Dept Educ & Res, Taichung, Taiwan; [Lai, Jin-Mei] Fu Jen Catholic Univ, Dept Life Sci, Taipei Cty, Taiwan; [Tseng, Tzu-Ling] Ind Technol Res Inst, Biomed Technol & Device Res Labs, Biomarker Technol Dev Div, Hsinchu, Taiwan; [Huang, Chi-Ying F.] Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei 112, Taiwan	National Central University; National Research Institute of Chinese Medicine; Taichung Veterans General Hospital; Fu Jen Catholic University; Industrial Technology Research Institute - Taiwan; National Yang Ming Chiao Tung University	Huang, CYF (corresponding author), Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei 112, Taiwan.	cyhuang5@ym.edu.tw; h2326@vghtc.gov.tw	Chang, Chia-Chuan/A-5518-2009; Lai, Jin-Mei/AAM-4119-2020; Huang, Chi-Ying/AAG-7672-2022; Huang, Chi-Ying/AFL-7729-2022	Chang, Chia-Chuan/0000-0002-1297-9602; Huang, Chi-Ying/0000-0003-4898-4937; Huang, Chi-Ying/0000-0003-4898-4937; Su, Li-Jen/0000-0002-8342-9800	National Science Council [NSC100-2627-B-010-005, NSC99-2112-M-008-012, NSC99-2811-M-008-053, NSC101-2320-B-008-001-MY3, NSC99-2627-B-030-001]; National Health Research Institutes [NHRI-EX101-10029BI]; Ministry of Economic Affairs [100-EC-17-A-17-S1-152]; Ministry of Education, Aim for the Top University Plan (National Yang Ming University); Committee on Chinese Medicine and Pharmacy [CCMP-RD-047, CCMP-95-RD-208, 94DOH028]	National Science Council(Ministry of Science and Technology, Taiwan); National Health Research Institutes(National Health Research Institutes, Japan); Ministry of Economic Affairs; Ministry of Education, Aim for the Top University Plan (National Yang Ming University); Committee on Chinese Medicine and Pharmacy	This research was supported by grants from the National Science Council (NSC100-2627-B-010-005), the National Health Research Institutes (NHRI-EX101-10029BI), Ministry of Economic Affairs (100-EC-17-A-17-S1-152) and the Ministry of Education, Aim for the Top University Plan (National Yang Ming University) to CYH. This work was supported in part by the grants from the Committee on Chinese Medicine and Pharmacy (CCMP-RD-047; CCMP-95-RD-208; 94DOH028) to SLH, the grants from National Science Council (NSC99-2112-M-008-012, NSC99-2811-M-008-053 and NSC101-2320-B-008-001-MY3) to LJS, and (NSC99-2627-B-030-001) to JML. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADACHI Y, 1994, HEPATOLOGY, V20, P453, DOI 10.1016/0270-9139(94)90199-6; Andres D, 2003, BIOCHEM PHARMACOL, V66, P917, DOI 10.1016/S0006-2952(03)00443-X; ARAI T, 1995, J IMMUNOL, V155, P5743; Bataller R, 2003, J CLIN INVEST, V112, P1383, DOI 10.1172/JCI200318212; Bilzer M, 2006, LIVER INT, V26, P1175, DOI 10.1111/j.1478-3231.2006.01342.x; Brenner David A, 2009, Trans Am Clin Climatol Assoc, V120, P361; Chen SJ, 2008, AM J CHINESE MED, V36, P369, DOI 10.1142/S0192415X08005837; Chen SJ, 2007, FOOD CHEM, V100, P5; Chung YC, 2005, FOOD CHEM, V91, P419, DOI 10.1016/j.foodchem.2004.06.022; Enomoto N, 2001, ALCOHOL CLIN EXP RES, V25, p51S, DOI 10.1097/00000374-200106001-00012; Enomoto N, 1998, GASTROENTEROLOGY, V115, P443, DOI 10.1016/S0016-5085(98)70211-2; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; GANDHI CR, 1990, J BIOL CHEM, V265, P18234; GASCONBARRE M, 1989, J HISTOCHEM CYTOCHEM, V37, P377, DOI 10.1177/37.3.2465335; Heymann Felix, 2009, Inflammation & Allergy Drug Targets, V8, P307; Huang B, 2010, J ETHNOPHARMACOL, V131, P276, DOI 10.1016/j.jep.2010.06.029; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; JEZEQUEL AM, 1987, J HEPATOL, V5, P174, DOI 10.1016/S0168-8278(87)80570-6; Kaplowitz N, 1997, GASTROENTEROLOGY, V113, P1408, DOI 10.1053/gast.1997.v113.agast971131408; Kisseleva T, 2007, J GASTROEN HEPATOL, V22, pS73, DOI 10.1111/j.1440-1746.2006.04658.x; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; LASKIN DL, 1990, SEMIN LIVER DIS, V10, P293, DOI 10.1055/s-2008-1040485; LIN JM, 1993, AM J CHINESE MED, V21, P59, DOI 10.1142/S0192415X9300008X; LISSOOS TW, 1992, J PEDIATR GASTR NUTR, V15, P225, DOI 10.1097/00005176-199210000-00001; Louis H, 1997, GASTROENTEROLOGY, V112, P935, DOI 10.1053/gast.1997.v112.pm9041256; Louis H, 1998, HEPATOLOGY, V28, P1607, DOI 10.1002/hep.510280621; Louis H, 1997, HEPATOLOGY, V25, P1382, DOI 10.1002/hep.510250614; MAVIER P, 1995, J HEPATOL, V22, P111; O'Shea JJ, 2008, IMMUNITY, V28, P477, DOI 10.1016/j.immuni.2008.03.002; Pines M, 1997, J HEPATOL, V27, P391, DOI 10.1016/S0168-8278(97)80186-9; Poli Giuseppe, 2000, Molecular Aspects of Medicine, V21, P49, DOI 10.1016/S0098-2997(00)00004-2; RECKNAGEL RO, 1989, PHARMACOL THERAPEUT, V43, P139, DOI 10.1016/0163-7258(89)90050-8; REITAMO S, 1994, J CLIN INVEST, V94, P2489, DOI 10.1172/JCI117618; ROJKIND M, 1974, ANAL BIOCHEM, V57, P1, DOI 10.1016/0003-2697(74)90043-8; Rosenbloom J, 2010, ANN INTERN MED, V152, P159, DOI 10.7326/0003-4819-152-3-201002020-00007; Su GL, 2002, AM J PHYSIOL-GASTR L, V283, pG256, DOI 10.1152/ajpgi.00550.2001; Su LJ, 2006, GENE EXPRESSION, V13, P107, DOI 10.3727/000000006783991872; Suzuki S, 1996, HEPATOLOGY, V24, P219; Tacke F, 2009, CLIN REV ALLERG IMMU, V36, P4, DOI 10.1007/s12016-008-8091-0; Thompson K, 1998, HEPATOLOGY, V28, P1597, DOI 10.1002/hep.510280620; VANVLASSELAER P, 1994, J CELL BIOL, V124, P569, DOI 10.1083/jcb.124.4.569; WINWOOD PJ, 1993, SEMIN LIVER DIS, V13, P50, DOI 10.1055/s-2007-1007337	42	22	28	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 15	2013	8	1							e53988	10.1371/journal.pone.0053988	http://dx.doi.org/10.1371/journal.pone.0053988			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	086SQ	23335984	Green Published, Green Submitted, gold			2023-01-03	WOS:000314707700042
J	Chan, DW; Hui, WWY; Cai, PCH; Liu, MX; Yung, MMH; Mak, CSL; Leung, THY; Chan, KKL; Ngan, HYS				Chan, David W.; Hui, Winnie W. Y.; Cai, Patty C. H.; Liu, Michelle X.; Yung, Mingo M. H.; Mak, Celia S. L.; Leung, Thomas H. Y.; Chan, Karen K. L.; Ngan, Hextan Y. S.			Targeting GRB7/ERK/FOXM1 Signaling Pathway Impairs Aggressiveness of Ovarian Cancer Cells	PLOS ONE			English	Article							CYCLIC PEPTIDE INHIBITOR; GROWTH-FACTOR RECEPTOR; RAF-MEK-ERK; TRANSCRIPTION FACTOR; TRANSDUCTION PROTEIN; ESOPHAGEAL-CARCINOMA; GRB7 FAMILY; SH2 DOMAIN; LOW-GRADE; IN-VITRO	Ovarian cancer is a highly lethal disease with poor prognosis and especially in high-grade tumor. Emerging evidence has reported that aberrant upregulation and activation of GRB7, ERK as well as FOXM1 are closely associated with aggresivenesss of human cancers. However, the interplay between these factors in the pathogenesis of human cancers still remains unclear. In this study, we found that GRB7 (P<0.0001), ERK phosphorylation (P<0.0001) and FOXM1 (P = 0.001) were frequently increased and associated with high-grade tumors, as well as a high tendency in association with advanced stage ovarian cancer by immunohistochemical analysis. Intriguingly, the expressions of GRB7 (P<0.0001), ERK phosphorylation (P<0.001) and FOXM1 (P<0.001) showed a significant stepwise increase pattern along Grade 1 to Grade 3 ovarian cancers. Biochemical studies using western blot analysis demonstrated that enforced expression or knockdown of GRB7 showed GRB7 could elevate the levels of ERK phosphorylation and FOXM1, whereas enforced expression of FOXM1 could not alter levels of GRB7 and ERK phosphorylation. But inhibition of ERK signaling by U0126 or PD98059 could reduce the level of FOXM1 in GRB7-overexpressing ovarian cancer cells, suggesting that GRB7, ERK and FOXM1 are regulated orderly. Moreover, inhibition of ERK activity by U0126 or PD98059, or decreased FOXM1 expression by Thiostrepton significantly inhibited cell migration/invasion, tumor growth in vitro and in vivo. Collectively, our findings confer that targeting GRB7/ERK/FOXM1 signaling cascade may be a promising molecular therapeutic choice in combating ovarian cancer.	[Chan, David W.; Hui, Winnie W. Y.; Cai, Patty C. H.; Liu, Michelle X.; Yung, Mingo M. H.; Mak, Celia S. L.; Leung, Thomas H. Y.; Chan, Karen K. L.; Ngan, Hextan Y. S.] Univ Hong Kong, Dept Obstet & Gynaecol, LKS Fac Med, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Chan, DW (corresponding author), Univ Hong Kong, Dept Obstet & Gynaecol, LKS Fac Med, Hong Kong, Hong Kong, Peoples R China.	dwchan@hku.hk; hysngan@hku.hk	Chan, David/O-9896-2018; YUNG, Mingo Ming Ho/AHB-5775-2022; Chan, Karen/E-4041-2015	Chan, David/0000-0002-6951-3467; YUNG, Mingo Ming Ho/0000-0003-0903-1164; Chan, Karen/0000-0001-9947-4713; Ngan, Hextan Y S/0000-0003-3945-159X	Wong Check She Charitable Foundation	Wong Check She Charitable Foundation	This study was supported by the Wong Check She Charitable Foundation. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ambaye ND, 2011, J MOL BIOL, V412, P397, DOI 10.1016/j.jmb.2011.07.030; Ambaye ND, 2011, BIOORGAN MED CHEM, V19, P693, DOI 10.1016/j.bmc.2010.10.030; Bai T, 2008, CARCINOGENESIS, V29, P473, DOI 10.1093/carcin/bgm221; Bessard A, 2008, ONCOGENE, V27, P5315, DOI 10.1038/onc.2008.163; Bristow RE, 2010, GYNECOL ONCOL, V118, P262, DOI 10.1016/j.ygyno.2010.05.025; Calvo F, 2010, BIOESSAYS, V32, P412, DOI 10.1002/bies.200900155; Chan DW, 2008, J PATHOL, V215, P245, DOI 10.1002/path.2355; Chan DW, 2008, CARCINOGENESIS, V29, P1742, DOI 10.1093/carcin/bgn167; CY Koo, 2011, BIOCH BIOPHYS ACTA; D'Alo D, 2010, EUR J GYNAECOL ONCOL, V31, P174; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Giricz O, 2011, BREAST CANC RES TREA; Gunzburg MJ, 2012, J MOL RECOGNIT, V25, P57, DOI 10.1002/jmr.2148; Han DC, 2001, ONCOGENE, V20, P6315, DOI 10.1038/sj.onc.1204775; Johnson TR, 2008, MOL CANCER RES, V6, P1639, DOI 10.1158/1541-7786.MCR-08-0052; Karst AM, 2010, J ONCOL, V2010, DOI 10.1155/2010/932371; Kohno M, 2006, ANN MED, V38, P200, DOI 10.1080/07853890600551037; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Lo HW, 2010, CURR CANCER DRUG TAR, V10, P840, DOI 10.2174/156800910793357970; Lok GTM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023790; Malpica A, 2004, AM J SURG PATHOL, V28, P496, DOI 10.1097/00000478-200404000-00009; McCubrey JA, 2010, EXPERT OPIN EMERG DR, V15, P203, DOI 10.1517/14728210903282760; Mebratu Y, 2009, CELL CYCLE, V8, P1168, DOI 10.4161/cc.8.8.8147; Montagut C, 2009, CANCER LETT, V283, P125, DOI 10.1016/j.canlet.2009.01.022; O'Neill CJ, 2005, AM J SURG PATHOL, V29, P1034; Pero SC, 2007, BRIT J CANCER, V96, P1520, DOI 10.1038/sj.bjc.6603732; Pero SC, 2002, J BIOL CHEM, V277, P11918, DOI 10.1074/jbc.M111816200; Pero Stephanie C, 2003, Expert Rev Mol Med, V5, P1, DOI 10.1017/S1462399403006227; Porter CJ, 2007, BIOPOLYMERS, V88, P174, DOI 10.1002/bip.20667; Porter CJ, 2007, BMC STRUCT BIOL, V7, DOI 10.1186/1472-6807-7-58; Priller M, 2011, CLIN CANCER RES, V17, P6791, DOI 10.1158/1078-0432.CCR-11-1214; Ramsey B, 2011, BREAST CANCER RES TR, V127, P659, DOI 10.1007/s10549-010-1010-0; Raychaudhuri P, 2011, CANCER RES, V71, P4329, DOI 10.1158/0008-5472.CAN-11-0640; Saad Antonio F., 2010, Hormones & Cancer, V1, P277, DOI 10.1007/s12672-010-0054-2; Schneiderman D, 1999, APOPTOSIS, V4, P271, DOI 10.1023/A:1008186323178; Steelman LS, 2011, AGING-US, V3, P192, DOI 10.18632/aging.100296; Tanaka S, 2000, J CELL PHYSIOL, V183, P411, DOI 10.1002/(SICI)1097-4652(200006)183:3<411::AID-JCP14>3.0.CO;2-Z; Tanaka S, 2006, JNCI-J NATL CANCER I, V98, P491, DOI 10.1093/jnci/djj105; Tanaka S, 1997, CANCER RES, V57, P28; Trujillo JI, 2011, EXPERT OPIN THER PAT, V21, P1045, DOI 10.1517/13543776.2011.577068; Vang R, 2009, ADV ANAT PATHOL, V16, P267, DOI 10.1097/PAP.0b013e3181b4fffa; Walch A, 2004, INT J CANCER, V112, P747, DOI 10.1002/ijc.20411; Wang YJ, 2010, CLIN CANCER RES, V16, P2529, DOI 10.1158/1078-0432.CCR-10-0018; Wang ZW, 2010, CANCER TREAT REV, V36, P151, DOI 10.1016/j.ctrv.2009.11.006; Wierstra I, 2007, BIOL CHEM, V388, P1257, DOI 10.1515/BC.2007.159; Wu QF, 2010, ACTA PHARMACOL SIN, V31, P361, DOI 10.1038/aps.2010.4; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942; Zebisch A, 2007, CURR MED CHEM, V14, P601, DOI 10.2174/092986707780059670; Zhang D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029902; ZYLBERBERG B, 1991, PRESSE MED, V20, P1320	50	41	45	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2012	7	12							e52578	10.1371/journal.pone.0052578	http://dx.doi.org/10.1371/journal.pone.0052578			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	060RA	23285101	Green Submitted, gold, Green Published			2023-01-03	WOS:000312794500205
J	Wehrwein, P				Wehrwein, Peter			STEM CELLS Repeat to fade	NATURE			English	Editorial Material																		Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Conboy IM, 2011, AGING-US, V3, P555, DOI 10.18632/aging.100333; Garbe JC, 2012, CANCER RES, V72, P3687, DOI 10.1158/0008-5472.CAN-12-0157; Jones DL, 2011, NAT CELL BIOL, V13, P506, DOI 10.1038/ncb0511-506; Naito AT, 2012, CELL, V149, P1298, DOI 10.1016/j.cell.2012.03.047; Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357	7	3	3	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 6	2012	492	7427					S12	S13		10.1038/492S12a	http://dx.doi.org/10.1038/492S12a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	048EQ	23222667	Bronze			2023-01-03	WOS:000311893400007
J	Bianco, A; Mole, A; Nobile, CGA; Di Giuseppe, G; Pileggi, C; Angelillo, IF				Bianco, Aida; Mole, Antonio; Nobile, Carmelo G. A.; Di Giuseppe, Gabriella; Pileggi, Claudia; Angelillo, Italo F.			Hospital Readmission Prevalence and Analysis of Those Potentially Avoidable in Southern Italy	PLOS ONE			English	Article							HEALTH-CARE; RATES; QUALITY; OLDER	Background: One quality indicator of hospital care, which can be used to judge the process of care, is the prevalence of hospital readmission because it reflects the impact of hospital care on the patient's condition after discharge. The purposes of the study were to measure the prevalence of hospital readmissions, to identify possible factors that influence such readmission and to measure the prevalence of readmissions potentially avoidable in Italy. Methods: A sample of 2289 medical records of patients aged 18 and over admitted for medical or surgical illness at one 502-bed community non-teaching hospital were randomly selected. Results: A total of 2252 patients were included in the final analysis, equaling a response rate of 98.4%. The overall hospital readmission prevalence within 30 days of discharge was 10.2%. Multivariate logistic regression analysis revealed that the proportion of patients readmitted within 30 days of discharge significantly increased regardless of Charlson et al. comorbidity score, among unemployed or retired patients, and in patients in general surgery. A total of 43.7% hospital readmissions were judged to be potentially avoidable. Multivariate logistic regression analysis showed that potentially avoidable readmissions were significantly higher in general surgery, in patients referred to hospital by an emergency department physician, and in those with a shortened time between discharge and readmission. Conclusion: Additional research on intervention or bundle of interventions applicable to acute inpatient populations that aim to reduce potentially avoidable readmissions is strongly needed, and health care providers are urged to implement evidence-based programs for more cost-effective delivery of health care.	[Di Giuseppe, Gabriella; Angelillo, Italo F.] Univ Naples 2, Dept Expt Med, Naples, Italy; [Bianco, Aida; Mole, Antonio; Nobile, Carmelo G. A.; Pileggi, Claudia] Univ Catanzaro Magna Graecia, Sch Med, Dept Hlth Sci, Catanzaro, Italy	Universita della Campania Vanvitelli; Magna Graecia University of Catanzaro	Angelillo, IF (corresponding author), Univ Naples 2, Dept Expt Med, Naples, Italy.	italof.angelillo@unina2.it	PILEGGI, Claudia/AGU-6397-2022; Bianco, Aida/R-6612-2016; Angelillo, Italo Francesco/AAK-1301-2021	PILEGGI, Claudia/0000-0002-6288-5540; Angelillo, Italo Francesco/0000-0003-1213-6602; DI GIUSEPPE, Gabriella/0000-0003-4466-6683; NOBILE, Carmelo Giuseppe Angelo/0000-0002-0762-513X; BIANCO, Aida/0000-0003-4674-0306	Ministry of Health [502/92]	Ministry of Health	This study was supported by a grant from the Ministry of Health (Research Projects ex artt.12 e 12bis, Legislative decree no. 502/92). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CLARKE A, 1990, BRIT MED J, V301, P1136, DOI 10.1136/bmj.301.6761.1136; Cornette P, 2005, AGING CLIN EXP RES, V17, P322, DOI 10.1007/BF03324617; FISHER ES, 1994, NEW ENGL J MED, V331, P989, DOI 10.1056/NEJM199410133311506; Friedman B, 2004, MED CARE RES REV, V61, P225, DOI 10.1177/1077558704263799; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Jimenez-Puente A, 2004, INT J TECHNOL ASSESS, V20, P385, DOI 10.1017/S0266462304001230; Jones J, 1986, Health Serv J, V96, P825; KATZ S, 1983, J AM GERIATR SOC, V31, P721, DOI 10.1111/j.1532-5415.1983.tb03391.x; Lai JK, 2007, J AM COLL SURGEONS, V204, P193, DOI 10.1016/j.jamcollsurg.2006.11.004; Maurer PP, 2004, SWISS MED WKLY, V134, P606; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Phillips CB, 2010, MED J AUSTRALIA, V193, P602, DOI 10.5694/j.1326-5377.2010.tb04071.x; Rizza P, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-134; Rutledge Valinda, 2010, Front Health Serv Manage, V27, P13; StataCorp, 2008, STAT STAT SOFTW REL; van Walraven C, 2011, CAN MED ASSOC J, V183, pE1067, DOI 10.1503/cmaj.110400; Varkevisser M, 2010, INT J HEALTH CARE FI, V10, P43, DOI 10.1007/s10754-009-9070-6; Westert GP, 2002, HEALTH POLICY, V61, P269, DOI 10.1016/S0168-8510(01)00236-6; Witherington EMA, 2008, QUAL SAF HEALTH CARE, V17, P71, DOI 10.1136/qshc.2006.020842; Wong ELY, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-149; Yam CHK, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-311; Zamir D, 2006, EUR J INTERN MED, V17, P20, DOI 10.1016/j.ejim.2005.10.004	23	27	27	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2012	7	11							e48263	10.1371/journal.pone.0048263	http://dx.doi.org/10.1371/journal.pone.0048263			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	032GO	23133624	Green Published, Green Submitted, gold			2023-01-03	WOS:000310702400029
J	Krogh, J; Videbech, P; Thomsen, C; Gluud, C; Nordentoft, M				Krogh, Jesper; Videbech, Poul; Thomsen, Carsten; Gluud, Christian; Nordentoft, Merete			DEMO-II Trial. Aerobic Exercise versus Stretching Exercise in Patients with Major Depression-A Randomised Clinical Trial	PLOS ONE			English	Article							RATING-SCALE; DISORDERS; METAANALYSIS; ASSOCIATION	Background: The effect of referring patients from a clinical setting to a pragmatic exercise intervention for depressive symptoms, cognitive function, and metabolic variables has yet to be determined. Methods: Outpatients with major depression (DSM-IV) were allocated to supervised aerobic or stretching exercise groups during a three months period. The primary outcome was the Hamilton depression score (HAM-D-17). Secondary outcomes were cognitive function, cardiovascular risk markers, and employment related outcomes. Results: 56 participants were allocated to the aerobic exercise intervention versus 59 participants to the stretching exercise group. Post intervention the mean difference between groups was -0.78 points on the HAM-D-17 (95% CI -3.2 to 1.6; P=.52). At follow-up, the participants in the aerobic exercise group had higher maximal oxygen uptake (mean difference 4.4 l/kg/min; 95% CI 1.7 to 7.0; P=.001) and visuospatial memory on Rey's Complex Figure Test (mean difference 3.2 points; 95% CI 0.9 to 5.5; P=.007) and lower blood glucose levels (mean difference 0.2 mmol/l; 95% CI 0.0 to 0.5; P=.04) and waist circumference (mean difference 2.2 cm; 95% CI 0.3 to 4.1; P=.02) compared with the stretching exercise group. Conclusions: The results of this trial does not support any antidepressant effect of referring patients with major depression to a three months aerobic exercise program. Due to lower recruitment than anticipated, the trial was terminated prior to reaching the pre-defined sample size of 212 participants; therefore the results should be interpreted in that context. However, the DEMO-II trial does suggest that an exercise program for patients with depression offer positive short-term effects on maximal oxygen uptake, visuospatial memory, fasting glucose levels, and waist circumference. Trial Registration: ClinicalTrials.gov NCT00695552	[Krogh, Jesper; Nordentoft, Merete] Univ Copenhagen, Fac Hlth Sci, Mental Hlth Ctr Copenhagen, Copenhagen, Denmark; [Videbech, Poul] Hosp Psychiat, Dept Biol Psychiat, Inst Basic Psychiat Res, Risskov, Denmark; [Thomsen, Carsten] Univ Copenhagen, Rigshosp, Fac Hlth Sci, Dept Radiol, DK-2100 Copenhagen, Denmark; [Gluud, Christian] Copenhagen Univ Hosp, Rigshosp, Ctr Clin Intervent Res, Copenhagen Trial Unit, Copenhagen, Denmark	University of Copenhagen; Aarhus University; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Krogh, J (corresponding author), Univ Copenhagen, Fac Hlth Sci, Mental Hlth Ctr Copenhagen, Copenhagen, Denmark.	jesper.krogh@regionh.dk	Gluud, Christian/AAY-1027-2021; Videbech, Poul/B-1924-2008; Gluud, Christian/HGB-3191-2022; Krogh, Jesper/C-6876-2013; Nordentoft, Merete/AAH-3253-2019	Gluud, Christian/0000-0002-8861-0799; Videbech, Poul/0000-0003-0127-4348; Nordentoft, Merete/0000-0003-4895-7023; Krogh, Jesper/0000-0003-4834-6724	Trygfonden; Nordea-Danmark fonden; Helsefonden; Ase and Ejnar Danielsen's fond	Trygfonden; Nordea-Danmark fonden; Helsefonden; Ase and Ejnar Danielsen's fond	Trygfonden (an insurance company), Nordea-Danmark fonden (a bank), Helsefonden (public fund), and Ase and Ejnar Danielsen's fond (a family foundation) funded this trial. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson IM, 2008, J PSYCHOPHARMACOL, V22, P343, DOI 10.1177/0269881107088441; Andersen L. B., 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P318; Angevaren M, 2008, COCHRANE DATABASE SY; Bagby RM, 2004, AM J PSYCHIAT, V161, P2163, DOI 10.1176/appi.ajp.161.12.2163; Bassler D, 2010, JAMA-J AM MED ASSOC, V303, P1180, DOI 10.1001/jama.2010.310; Bech P, 2009, ACTA PSYCHIAT SCAND, V120, P400, DOI 10.1111/j.1600-0447.2009.01445.x; Bech P, 1999, MINI INT NEUROPSYKIA; Blumenthal JA, 2007, PSYCHOSOM MED, V69, P587, DOI 10.1097/PSY.0b013e318148c19a; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; Brown G.K, 1996, PEARSON; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Cipriani A, 2009, LANCET, V373, P746, DOI 10.1016/S0140-6736(09)60046-5; Crone Diane, 2008, Issues Ment Health Nurs, V29, P1088, DOI 10.1080/01612840802319837; Dantzer R, 2008, NATURE REV, P946; Davidson JR, 2010, J CLIN PSYCHIAT SE1, V71; Dunn AL, 2005, AM J PREV MED, P281; ENDICOTT J, 1981, ARCH GEN PSYCHIAT, V38, P98; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; Gomez-Merino D, 2001, NEUROSCI LETT, V301, P143, DOI 10.1016/S0304-3940(01)01626-3; Hamilton M, 1959, BR J MED PSYCHOL, P3250; Hammar A, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.026.2009; Heran BS, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001800.pub3, 10.1002/14651858.CD001800.pub2]; Hoffman BM, 2008, MED SCI SPORT EXER, V40, P1344, DOI 10.1249/MSS.0b013e31816b877c; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; Kadoglou N, 2007, EUR J CARDIOV PREV R, P14837; Khatri P, 2001, J AGING PHYS ACTIV, V9, P43, DOI 10.1123/japa.9.1.43; Kirsch I, 2008, PLOS MED, V5, P260, DOI 10.1371/journal.pmed.0050045; Krogh J, 2011, J CLIN PSYCHIAT, V72, P529, DOI 10.4088/JCP.08r04913blu; Krogh J, 2009, J CLIN PSYCHIAT, V70, P790, DOI 10.4088/JCP.08m04241; Krogsboll LT, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-1; Laursen TM, 2007, J CLIN PSYCHIAT, V68, P899, DOI 10.4088/JCP.v68n0612; LIFE Grp, 2011, CLIN REHABIL, V25, P579, DOI 10.1177/0269215510392075; Mallinckrodt C H, 2001, J Biopharm Stat, V11, P9, DOI 10.1081/BIP-100104194; Mather AS, 2002, BRIT J PSYCHIAT, V180, P411, DOI 10.1192/bjp.180.5.411; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Mead GE, 2009, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004366.PUB6; Meyers J., 1995, REY COMPLEX FIGURES; MOSER MB, 1995, P NATL ACAD SCI USA, V92, P9697, DOI 10.1073/pnas.92.21.9697; NELSON HE, 1978, CORTEX, V14, P234, DOI 10.1016/S0010-9452(78)80049-5; Pajonk FG, 2010, ARCH GEN PSYCHIAT, V67, P133, DOI 10.1001/archgenpsychiatry.2009.193; Parker BA, 2011, RES Q EXERCISE SPORT, V82, P585, DOI 10.1080/02701367.2011.10599793; Pasco JA, 2010, BRIT J PSYCHIAT, V197, P372, DOI 10.1192/bjp.bp.109.076430; Pereira AC, 2007, P NATL ACAD SCI USA, V104, P5638, DOI 10.1073/pnas.0611721104; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Schiepers OJG, 2005, PROG NEURO-PSYCHOPH, V29, P201, DOI 10.1016/j.pnpbp.2004.11.003; SMITH A, 1967, ARCH NEUROL-CHICAGO, V17, P78, DOI 10.1001/archneur.1967.00470250082008; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Thomas GN, 2010, CURR DIABETES REV, V6, P378, DOI 10.2174/157339910793499092; Trivedi MH, 2011, J CLIN PSYCHIAT, V72, P677, DOI 10.4088/JCP.10m06743; Wechscler D, 1981, WECHSLER ADULT INTEL; Wechsler DW., 1955, WAIS 3 WECHSLER ADUL; Yau SY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024263	52	69	70	2	54	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2012	7	10							e48316	10.1371/journal.pone.0048316	http://dx.doi.org/10.1371/journal.pone.0048316			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	030WJ	23118981	gold, Green Submitted, Green Published			2023-01-03	WOS:000310600500101
J	McCartney, M				McCartney, Margaret			The assault on the Liverpool care pathway	BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				[Anonymous], 2010, DAILY MAIL; [Anonymous], 2004, DAILY MAIL; [Anonymous], 2012, DAILY MAIL; Boggan S., 2009, DAILY MAIL; Catholic Herald, 2010, CATHOLIC HERALD 0423; Christian Medical Comment, 2012, LIVERPOOL CARE PATHW; Clarke N., DIS NHS KILL MY MOTH; Doughty, 2012, DAILY MAIL; Kmietowicz Z, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e6654; Maes N., 2011, DAILY MAIL; Marie Curie Palliative Care Institute Liverpool, 2010, WHAT IS LIV CAR PATH; Phillips M., 2012, DAILY MAIL; Preston M, 2007, END LIFE CARE, V1, P1	13	14	14	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	OCT 30	2012	345								e7316	10.1136/bmj.e7316	http://dx.doi.org/10.1136/bmj.e7316			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	033EY	23112122				2023-01-03	WOS:000310778200019
J	Annadurai, RS; Neethiraj, R; Jayakumar, V; Damodaran, AC; Rao, SN; Katta, MAVSK; Gopinathan, S; Sarma, SP; Senthilkumar, V; Niranjan, V; Gopinath, A; Mugasimangalam, RC				Annadurai, Ramasamy S.; Neethiraj, Ramprasad; Jayakumar, Vasanthan; Damodaran, Anand C.; Rao, Sudha Narayana; Katta, Mohan A. V. S. K.; Gopinathan, Sreeja; Sarma, Santosh Prasad; Senthilkumar, Vanitha; Niranjan, Vidya; Gopinath, Ashok; Mugasimangalam, Raja C.			De Novo Transcriptome Assembly (NGS) of Curcuma longa L. Rhizome Reveals Novel Transcripts Related to Anticancer and Antimalarial Terpenoids	PLOS ONE			English	Article							CELL-CYCLE; MULTIDRUG-RESISTANCE; FRUIT-DEVELOPMENT; ESSENTIAL OILS; APOPTOSIS; EXPRESSION; HYPERICIN; DISCOVERY; PATHWAYS; MARKERS	Herbal remedies are increasingly being recognised in recent years as alternative medicine for a number of diseases including cancer. Curcuma longa L., commonly known as turmeric is used as a culinary spice in India and in many Asian countries has been attributed to lower incidences of gastrointestinal cancers. Curcumin, a secondary metabolite isolated from the rhizomes of this plant has been shown to have significant anticancer properties, in addition to antimalarial and antioxidant effects. We sequenced the transcriptome of the rhizome of the 3 varieties of Curcuma longa L. using Illumina reversible dye terminator sequencing followed by de novo transcriptome assembly. Multiple databases were used to obtain a comprehensive annotation and the transcripts were functionally classified using GO, KOG and PlantCyc. Special emphasis was given for annotating the secondary metabolite pathways and terpenoid biosynthesis pathways. We report for the first time, the presence of transcripts related to biosynthetic pathways of several anti-cancer compounds like taxol, curcumin, and vinblastine in addition to anti-malarial compounds like artemisinin and acridone alkaloids, emphasizing turmeric's importance as a highly potent phytochemical. Our data not only provides molecular signatures for several terpenoids but also a comprehensive molecular resource for facilitating deeper insights into the transcriptome of C. longa.	[Annadurai, Ramasamy S.; Neethiraj, Ramprasad; Jayakumar, Vasanthan; Damodaran, Anand C.; Rao, Sudha Narayana; Katta, Mohan A. V. S. K.; Gopinathan, Sreeja; Sarma, Santosh Prasad; Senthilkumar, Vanitha; Niranjan, Vidya; Gopinath, Ashok; Mugasimangalam, Raja C.] Genotyp Technol Private Ltd, Res & Dev Unit, Bangalore, Karnataka, India		Mugasimangalam, RC (corresponding author), Genotyp Technol Private Ltd, Res & Dev Unit, Bangalore, Karnataka, India.	raja@genotypic.co.in	Niranjan, Vidya/O-6464-2016; Niranjan, Vidya/AAF-5553-2019	Niranjan, Vidya/0000-0001-9187-7753; Niranjan, Vidya/0000-0001-9187-7753; Jayakumar, Vasanthan/0000-0002-6067-4184	Genotypic Technology Research and Development Fund; Genotypic Technology Private Limited	Genotypic Technology Research and Development Fund; Genotypic Technology Private Limited	The funds for this study were provided by Genotypic Technology Research and Development Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The following authors have affiliations to Genotypic Technology Private Limited, the commercial funders of this research, and confirm that this affiliation does not in anyway alter the authors adherence of all PLOS ONE policies on sharing data and materials. 1. Ramasamy S Annadurai 2. Ramprasad Neethiraj 3. Vasanthan Jayakumar 4. Anand C Damodaran 5. Sudha Narayana Rao 6. Mohan AVSK Katta 7. Sreeja Gopinathan 8. Santosh Prasad Sarma 9. Vanitha Senthilkumar 10. Vidya Niranjan 11. Ashok Gopinath 12. Raja C Mugasimangalam The authors Ramasamy S Annadurai and Ashok Gopinath were working at Genotypic Technology Pvt Ltd when they carried out their work. Dr. Ramasamy S Annadurai and Dr. Ashok Gopinath's affiliations to ITC Limited and Sanofi Synthelabo India Limited respectively does not affect the project in any way. These companies were neither funders nor sponsors for this study.	Agostinis P, 2002, INT J BIOCHEM CELL B, V34, P221, DOI 10.1016/S1357-2725(01)00126-1; Ajaiyeoba EO, 2008, PHARM BIOL, V46, P279, DOI 10.1080/13880200701741138; Alappat L, 2010, NUTR REV, V68, P729, DOI 10.1111/j.1753-4887.2010.00341.x; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Barrero RA, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-600; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421; Carnesecchi S, 2001, J PHARMACOL EXP THER, V298, P197; Chae L, 2012, CURR OPIN PLANT BIOL, V15, P177, DOI 10.1016/j.pbi.2012.01.006; Choudhuri T, 2005, J BIOL CHEM, V280, P20059, DOI 10.1074/jbc.M410670200; Cui L, 2007, ANTIMICROB AGENTS CH, V51, P488, DOI 10.1128/AAC.01238-06; Du HY, 2003, INT J ONCOL, V23, P1401; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Feng C, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-19; Gajate C, 2005, J BIOL CHEM, V280, P11641, DOI 10.1074/jbc.M411781200; Ganta S, 2009, MOL PHARMACEUT, V6, P928, DOI 10.1021/mp800240j; Garg R, 2011, DNA RES, V18, P53, DOI 10.1093/dnares/dsq028; Gore MA, 2009, SCIENCE, V326, P1115, DOI 10.1126/science.1177837; Gupta SC, 2013, MOL NUTR FOOD RES, V57, P1510, DOI 10.1002/mnfr.201100741; Gupta SC, 2012, CLIN EXP PHARMACOL P, V39, P283, DOI 10.1111/j.1440-1681.2011.05648.x; Haddad M, 2011, PLANTA MED, V77, P672, DOI 10.1055/s-0030-1250549; Hamaguchi T, 2010, CNS NEUROSCI THER, V16, P285, DOI 10.1111/j.1755-5949.2010.00147.x; Honda S, 2006, J AGR FOOD CHEM, V54, P9055, DOI 10.1021/jf061788t; Iorizzo M, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-389; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kashi Y, 2006, TRENDS GENET, V22, P253, DOI 10.1016/j.tig.2006.03.005; Kawase M, 2005, IN VIVO, V19, P705; Kelly JX, 2009, NATURE, V459, P270, DOI 10.1038/nature07937; Krazeisen A, 2001, MOL CELL ENDOCRINOL, V171, P151, DOI 10.1016/S0303-7207(00)00422-6; Kudapa H, 2012, MOL PLANT, V5, P1020, DOI 10.1093/mp/ssr111; La Rota M, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-23; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lee B, 2012, BIOCHEM BIOPH RES CO, V421, P76, DOI 10.1016/j.bbrc.2012.03.114; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li Q, 2009, ONCOLOGY-BASEL, V77, P335, DOI 10.1159/000264627; Li S.Y., 2011, PHARM CROPS, V2, P28, DOI [10.2174/2210290601102010028, DOI 10.2174/2210290601102010028]; Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158; Lu HF, 2009, ONCOL REP, V22, P97, DOI 10.3892/or_00000411; Magrane M, 2011, DATABASE-OXFORD, DOI 10.1093/database/bar009; Meshnick SR, 2002, INT J PARASITOL, V32, P1655, DOI 10.1016/S0020-7519(02)00194-7; Mohan R, 2000, J BIOL CHEM, V275, P10405, DOI 10.1074/jbc.275.14.10405; Mohandas K M, 1999, Indian J Gastroenterol, V18, P118; Nandakumar DN, 2006, ANTIMICROB AGENTS CH, V50, P1859, DOI 10.1128/AAC.50.5.1859-1860.2006; Negi PS, 1999, J AGR FOOD CHEM, V47, P4297, DOI 10.1021/jf990308d; Park MJ, 2002, INT J ONCOL, V21, P379; Peuhu E, 2010, ONCOGENE, V29, P898, DOI 10.1038/onc.2009.386; Quevillon E, 2005, NUCLEIC ACIDS RES, V33, pW116, DOI 10.1093/nar/gki442; Salminen A, 2008, CELL MOL LIFE SCI, V65, P2979, DOI 10.1007/s00018-008-8103-5; Schatz MC, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-4-243; Schulz MH, 2012, BIOINFORMATICS, V28, P1086, DOI 10.1093/bioinformatics/bts094; Shi CY, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-131; Shinojima N, 2007, AUTOPHAGY, V3, P635, DOI 10.4161/auto.4916; Shytle RD, 2009, CURR ALZHEIMER RES, V6, P564, DOI 10.2174/156720509790147115; Stevens JF, 2004, PHYTOCHEMISTRY, V65, P1317, DOI 10.1016/j.phytochem.2004.04.025; Subramaniyam S, 2011, PLANT CELL REP, V30, P2075, DOI 10.1007/s00299-011-1114-y; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; WANG YS, 1995, CELL GROWTH DIFFER, V6, P1071; Wang ZY, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-726; Wei WL, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-451; Wong MML, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-342; Xia ZH, 2011, PLANT MOL BIOL, V77, P299, DOI 10.1007/s11103-011-9811-z; Yow CMN, 2012, PHOTOCHEM PHOTOBIOL, V88, P626, DOI 10.1111/j.1751-1097.2012.01085.x; Yoysungnoen P, 2006, CLIN HEMORHEOL MICRO, V34, P109; Yu KQ, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-10; Zerbino DR, 2008, GENOME RES, V18, P821, DOI 10.1101/gr.074492.107	65	58	61	1	60	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2013	8	2							e56217	10.1371/journal.pone.0056217	http://dx.doi.org/10.1371/journal.pone.0056217			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	098DA	23468859	Green Published, Green Submitted, gold			2023-01-03	WOS:000315524900021
J	Zhang, JK; Yang, L; Meng, GL; Yuan, Z; Fan, J; Li, D; Chen, JZ; Shi, TY; Hu, HM; Wei, BY; Luo, ZJ; Liu, J				Zhang, Jin-Kang; Yang, Liu; Meng, Guo-Lin; Yuan, Zhi; Fan, Jing; Li, Dan; Chen, Jian-Zong; Shi, Tian-Yao; Hu, Hui-Min; Wei, Bo-Yuan; Luo, Zhuo-Jing; Liu, Jian			Protection by Salidroside against Bone Loss via Inhibition of Oxidative Stress and Bone-Resorbing Mediators	PLOS ONE			English	Article							NF-KAPPA-B; HYDROGEN-PEROXIDE; OSTEOBLASTIC DIFFERENTIATION; POSTMENOPAUSAL OSTEOPOROSIS; OSTEOCLAST FORMATION; MECHANICAL-PROPERTIES; ANTIOXIDANT SYSTEM; LIPID-PEROXIDATION; MC3T3-E1 CELLS; STROMAL CELLS	Oxidative stress is a pivotal pathogenic factor for bone loss in mouse model. Salidroside, a phenylpropanoid glycoside extracted from Rhodiola rosea L, exhibits potent antioxidative effects. In the present study, we used an in vitro oxidative stress model induced by hydrogen peroxide (H2O2) in MC3T3-E1 cells and a murine ovariectomized (OVX) osteoporosis model to investigate the protective effects of salidroside on bone loss and the related mechanisms. We demonstrated that salidroside caused a significant (P < 0.05) elevation of cell survival, alkaline phosphatase (ALP) staining and activity, calcium deposition, and the transcriptional expression of Alp, Col1a1 and Osteocalcin (Ocn) in the presence of H2O2. Moreover, salidroside decreased the production of intracellular reactive oxygen species (ROS), and osteoclast differentiation inducing factors such as receptor activator of nuclear factor-kB ligand (RANKL) and IL-6 induced by H2O2. In vivo studies further demonstrated that salidroside supplementation for 3 months caused a decrease in malondialdehyde (MDA) and an increase in reduced glutathione (GSH) concentration in blood of ovariectomized mouse (P < 0.05), it also improved trabecular bone microarchitecture and bone mineral density in the fourth lumbar vertebra and distal femur. Our study indicated that the protection provided by salidroside in alleviating bone loss was mediated, at least in part, via inhibition of the release of bone-resorbing mediators and oxidative damage to bone-forming cells, suggesting that salidroside can be used as an effective remedy in the treatment or prevention of osteoporosis.	[Zhang, Jin-Kang; Yang, Liu; Meng, Guo-Lin; Yuan, Zhi; Fan, Jing; Li, Dan; Hu, Hui-Min; Wei, Bo-Yuan; Luo, Zhuo-Jing; Liu, Jian] Fourth Mil Med Univ, Xijing Hosp, Inst Orthoped Surg, Xian 710032, Peoples R China; [Chen, Jian-Zong] Fourth Mil Med Univ, Xijing Hosp, Res Ctr Tradit Chinese Med, Xian 710032, Peoples R China; [Shi, Tian-Yao] Fourth Mil Med Univ, Sch Pharm, Dept Pharmacol, Xian 710032, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University	Luo, ZJ (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Inst Orthoped Surg, Xian 710032, Peoples R China.	zjluo@fmmu.edu.cn; zjk1271984@21cn.com			Ministry of Science and Technology of China [2011CB964703]; National High Technology Research and Development Program 863 [2012AA020502]; China Postdoctoral Science Foundation [20100480093]; National Natural Science Foundation of China [30901504]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National High Technology Research and Development Program 863(National High Technology Research and Development Program of China); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by Ministry of Science and Technology of China (2011CB964703), National High Technology Research and Development Program 863 (2012AA020502), China Postdoctoral Science Foundation (20100480093) and National Natural Science Foundation of China (30901504). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arai M, 2007, IUBMB LIFE, V59, P27, DOI 10.1080/15216540601156188; Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223-010-9393-9; Bai XC, 2005, J BIOL CHEM, V280, P17497, DOI 10.1074/jbc.M409332200; Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Fatokun AA, 2008, EUR J PHARMACOL, V587, P35, DOI 10.1016/j.ejphar.2008.03.024; Fatokun AA, 2006, BONE, V39, P542, DOI 10.1016/j.bone.2006.02.062; GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668; Hessle L, 2002, P NATL ACAD SCI USA, V99, P9445, DOI 10.1073/pnas.142063399; Isomura H, 2004, TOXICOLOGY, V197, P93, DOI 10.1016/j.tox.2003.12.006; Kazakia GJ, 2006, REV ENDOCR METAB DIS, V7, P67, DOI 10.1007/s11154-006-9004-2; Kinov P, 2006, J ORTHOP RES, V24, P55, DOI 10.1002/jor.20013; KITAZAWA R, 1994, J CLIN INVEST, V94, P2397, DOI 10.1172/JCI117606; KURIHARA N, 1990, J IMMUNOL, V144, P4226; Lean JM, 2005, ENDOCRINOLOGY, V146, P728, DOI 10.1210/en.2004-1021; Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood-2004-09-3662; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Li XF, 2011, BRAIN RES, V1382, P9, DOI 10.1016/j.brainres.2011.01.015; Li Y, 2012, J BIOMED MAT RES B; Li Yongming, 2010, BMC Res Notes, V3, P309, DOI 10.1186/1756-0500-3-309; Liu AL, 2004, CELL BIOL INT, V28, P905, DOI 10.1016/j.cellbi.2004.09.004; Maggio D, 2003, J CLIN ENDOCR METAB, V88, P1523, DOI 10.1210/jc.2002-021496; Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009-0024; Mao GX, 2010, BIOMED ENVIRON SCI, V23, P161, DOI 10.1016/S0895-3988(10)60047-5; Muthusami S, 2005, CLIN CHIM ACTA, V360, P81, DOI 10.1016/j.cccn.2005.04.014; Naka K, 2008, ANTIOXID REDOX SIGN, V10, P1883, DOI 10.1089/ars.2008.2114; Nielsen F, 1997, CLIN CHEM, V43, P1209; Ning J, 2000, TOXICOL IN VITRO, V14, P329, DOI 10.1016/S0887-2333(00)00024-2; Ozgocmen S, 2007, ARCH MED RES, V38, P196, DOI 10.1016/j.arcmed.2006.09.010; Ozgocmen S, 2007, MOL CELL BIOCHEM, V295, P45, DOI 10.1007/s11010-006-9270-z; Papanicolaou DA, 2000, J CLIN ENDOCR METAB, V85, P1331, DOI 10.1210/jc.85.3.1331; Peng ZQ, 1997, BONE, V20, P207, DOI 10.1016/S8756-3282(96)00369-9; Qian EW, 2012, J NAT PROD, V75, P531, DOI 10.1021/np200555s; Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077; Sendur OF, 2009, JOINT BONE SPINE, V76, P514, DOI 10.1016/j.jbspin.2009.02.005; Shi TY, 2012, NEUROTOX RES, V21, P358, DOI 10.1007/s12640-011-9290-7; Skopinska-Rozewska E, 2008, POL J VET SCI, V11, P97; STANFORD CM, 1995, J BIOL CHEM, V270, P9420, DOI 10.1074/jbc.270.16.9420; Teo JCM, 2006, CLIN BIOMECH, V21, P235, DOI 10.1016/j.clinbiomech.2005.11.001; Wiegant FAC, 2009, BIOGERONTOLOGY, V10, P27, DOI 10.1007/s10522-008-9151-9; Yang P, 2007, J TOXICOL ENV HEAL A, V70, P976, DOI 10.1080/15287390701290832; Yu PZ, 2007, CHEM BIODIVERS, V4, P508, DOI 10.1002/cbdv.200790043; Yu S, 2008, CELL MOL NEUROBIOL, V28, P1067, DOI 10.1007/s10571-008-9284-z; Zhu Y, 2011, DNA CELL BIOL, V30, P809, DOI 10.1089/dna.2010.1183; 2001, JAMA, V285, P785	45	66	74	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2013	8	2							e57251	10.1371/journal.pone.0057251	http://dx.doi.org/10.1371/journal.pone.0057251			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	093IE	23437352	Green Published, gold, Green Submitted			2023-01-03	WOS:000315184200230
J	Flouty, OE; Oya, H; Kawasaki, H; Reddy, CG; Fredericks, DC; Gibson-Corley, KN; Jeffery, ND; Gillies, GT; Howard, MA				Flouty, Oliver E.; Oya, Hiroyuki; Kawasaki, Hiroto; Reddy, Chandan G.; Fredericks, Douglas C.; Gibson-Corley, Katherine N.; Jeffery, Nicholas D.; Gillies, George T.; Howard, Matthew A., III			Intracranial Somatosensory Responses with Direct Spinal Cord Stimulation in Anesthetized Sheep	PLOS ONE			English	Article							BACK SURGERY SYNDROME; BRAIN-STEM IMPLANT; ELECTRICAL-STIMULATION; NONHUMAN-PRIMATES; PAIN; EFFICACY; COLUMNS; FIBERS; DORSAL	The efficacy of spinal cord stimulators is dependent on the ability of the device to functionally activate targeted structures within the spinal cord, while avoiding activation of near-by non-targeted structures. In theory, these objectives can best be achieved by delivering electrical stimuli directly to the surface of the spinal cord. The current experiments were performed to study the influence of different stimulating electrode positions on patterns of spinal cord electrophysiological activation. A custom-designed spinal cord neurostimulator was used to investigate the effects of lead position and stimulus amplitude on cortical electrophysiological responses to spinal cord stimulation. Brain recordings were obtained from subdural grids placed in four adult sheep. We systematically varied the position of the stimulating lead relative to the spinal cord and the voltage delivered by the device at each position, and then examined how these variables influenced cortical responses. A clear relationship was observed between voltage and electrode position, and the magnitude of high gamma-band oscillations. Direct stimulation of the dorsal column contralateral to the grid required the lowest voltage to evoke brain responses to spinal cord stimulation. Given the lower voltage thresholds associated with direct stimulation of the dorsal column, and its possible impact on the therapeutic window, this intradural modality may have particular clinical advantages over standard epidural techniques now in routine use.	[Flouty, Oliver E.; Oya, Hiroyuki; Kawasaki, Hiroto; Reddy, Chandan G.; Howard, Matthew A., III] Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA; [Fredericks, Douglas C.] Univ Iowa Hosp & Clin, Dept Orthopaed Surg, Iowa City, IA 52242 USA; [Gibson-Corley, Katherine N.] Univ Iowa Hosp & Clin, Dept Pathol, Iowa City, IA 52242 USA; [Jeffery, Nicholas D.] Iowa State Univ, Dept Vet Clin Sci, Ames, IA USA; [Gillies, George T.] Univ Virginia, Dept Mech & Aerosp Engn, Charlottesville, VA USA	University of Iowa; University of Iowa; University of Iowa; Iowa State University; University of Virginia	Howard, MA (corresponding author), Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA.	matthew-howard@uiowa.edu	flouty, oliver/AAO-2469-2021; Oya, Hiroyuki/Q-2989-2018	Oya, Hiroyuki/0000-0002-1733-5478; Kawasaki, Hiroto/0000-0002-7688-9171; Reddy, Chandan/0000-0001-5053-8085; Gibson-Corley, Katherine/0000-0002-1846-1580; Jeffery, Nick/0000-0002-9812-1788; Howard, Matthew/0000-0003-3935-8889				Cameron T, 2004, J NEUROSURG, V100, P254, DOI 10.3171/spi.2004.100.3.0254; Feirabend HKP, 2002, BRAIN, V125, P1137, DOI 10.1093/brain/awf111; Flouty O, 2012, PHYSIOL MEAS, V33, P2003, DOI 10.1088/0967-3334/33/12/2003; Gabriel C, 2009, PHYS MED BIOL, V54, P4863, DOI 10.1088/0031-9155/54/16/002; Gibson-Corley KN, 2012, J INVEST SURG, V25, P366, DOI 10.3109/08941939.2012.677967; Hamilton L, 2009, BMC VET RES, V4, DOI 10.1186/1746-6148-4-47; Hamilton L, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-77; Holsheimer J, 2002, NEUROMODULATION, V5, P25, DOI 10.1046/j.1525-1403.2002._2005.x; Howard MA, 2011, J APPL PHYS, V110, DOI 10.1063/1.3626469; Kishima H, 2010, NEUROIMAGE, V49, P2564, DOI 10.1016/j.neuroimage.2009.10.054; Kumar K, 2007, PAIN, V132, P179, DOI 10.1016/j.pain.2007.07.028; Kumar K, 2009, J NEUROSURG-SPINE, V10, P564, DOI 10.3171/2009.2.SPINE0865; KUPERS RC, 1994, PAIN, V56, P211, DOI 10.1016/0304-3959(94)90096-5; LINTHICUM FH, 1991, AM J OTOL, V12, P245; Manrique M, 2000, ANN OTO RHINOL LARYN, V109, P163, DOI 10.1177/000348940010900210; Manrique M, 2008, ANN OTO RHINOL LARYN, V117, P212, DOI 10.1177/000348940811700309; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Meyerson Bjorn A, 2006, J Pain Symptom Manage, V31, pS6, DOI 10.1016/j.jpainsymman.2005.12.009; Nourski KV, 2009, J NEUROSCI, V29, P15564, DOI 10.1523/JNEUROSCI.3065-09.2009; Otto SR, 2012, LARYNGOSCOPE, V122, P645, DOI 10.1002/lary.22491; Oya H., 2012, Journal of Medical Engineering & Technology, V36, P169, DOI 10.3109/03091902.2011.649884; SHEALY CN, 1967, ANESTH ANAL CURR RES, V46, P489; SMITH MC, 1984, BRAIN, V107, P671, DOI 10.1093/brain/107.3.671; Stancak A, 2008, EUR J PAIN, V12, P137, DOI 10.1016/j.ejpain.2007.03.003; SUTTON D, 1984, ARCH OTOLARYNGOL, V110, P164; THOMSON DJ, 1982, P IEEE, V70, P1055, DOI 10.1109/PROC.1982.12433; Turner JA, 2010, PAIN, V148, P14, DOI 10.1016/j.pain.2009.08.014; Ulink NCC, 1999, NEURMODULATION, V2, P33; Utz M, 2011, J APPL PHYS, V110; WALL PD, 1960, J NEUROPHYSIOL, V23, P197, DOI 10.1152/jn.1960.23.2.197; Wilson S., 2012, Journal of Medical Engineering & Technology, V36, P22, DOI 10.3109/03091902.2011.632061; Xu J, 1997, HEARING RES, V105, P1, DOI 10.1016/S0378-5955(96)00193-1	32	19	25	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 15	2013	8	2							e56266	10.1371/journal.pone.0056266	http://dx.doi.org/10.1371/journal.pone.0056266			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	099EQ	23457542	Green Published, Green Submitted, gold			2023-01-03	WOS:000315603700038
J	Kim, JH; Choi, KH; Jang, YJ; Bae, SS; Shin, BC; Choi, BT; Shin, HK				Kim, Ji Hyun; Choi, Kyung Ha; Jang, Young Jung; Bae, Sun Sik; Shin, Byung-Cheul; Choi, Byung Tae; Shin, Hwa Kyoung			Electroacupuncture Acutely Improves Cerebral Blood Flow and Attenuates Moderate Ischemic Injury via an Endothelial Mechanism in Mice	PLOS ONE			English	Article							NITRIC-OXIDE; STROKE PATIENTS; FUNCTIONAL RECOVERY; ARTERY OCCLUSION; BRAIN-INJURY; ACUPUNCTURE; STIMULATION; ARTERIOLES; EXPRESSION; RECEPTORS	Electroacupuncture (EA) is a novel therapy based on traditional acupuncture combined with modern eletrotherapy that is currently being investigated as a treatment for acute ischemic stroke. Here, we studied whether acute EA stimulation improves tissue and functional outcome following experimentally induced cerebral ischemia in mice. We hypothesized that endothelial nitric oxide synthase (eNOS)-mediated perfusion augmentation was related to the beneficial effects of EA by interventions in acute ischemic injury. EA stimulation at Baihui (GV20) and Dazhui (GV14) increased cerebral perfusion in the cerebral cortex, which was suppressed in eNOS KO, but there was no mean arterial blood pressure (MABP) response. The increased perfusion elicited by EA were completely abolished by a muscarinic acetylcholine receptor (mAChR) blocker (atropine), but not a beta-adrenergic receptor blocker (propranolol), an a-adrenergic receptor blocker (phentolamine), or a nicotinic acetylcholine receptor (nAChR) blocker (mecamylamine). In addition, EA increased acetylcholine (ACh) release and mAChR M3 expression in the cerebral cortex. Acute EA stimulation after occlusion significantly reduced infarct volume by 34.5% when compared to a control group of mice at 24 h after 60 min-middle cerebral artery occlusion (MCAO) (moderate ischemic injury), but not 90-min MCAO (severe ischemic injury). Furthermore, the impact of EA on moderate ischemic injury was totally abolished in eNOS KO. Consistent with a smaller infarct size, acute EA stimulation led to prominent improvement of neurological function and vestibule-motor function. Our results suggest that acute EA stimulation after moderate focal cerebral ischemia, but not severe ischemia improves tissue and functional recovery and ACh/eNOS-mediated perfusion augmentation might be related to these beneficial effects of EA by interventions in acute ischemic injury.	[Kim, Ji Hyun; Choi, Kyung Ha; Jang, Young Jung; Choi, Byung Tae; Shin, Hwa Kyoung] Pusan Natl Univ, Sch Korean Med, Div Meridian & Struct Med, Yangsan, Gyeongnam, South Korea; [Bae, Sun Sik] Pusan Natl Univ, Sch Med, Dept Pharmacol, Yangsan, Gyeongnam, South Korea; [Shin, Byung-Cheul] Pusan Natl Univ, Sch Korean Med, Div Clin Med, Yangsan, Gyeongnam, South Korea	Pusan National University; Pusan National University; Pusan National University Hospital; Pusan National University	Choi, BT (corresponding author), Pusan Natl Univ, Sch Korean Med, Div Meridian & Struct Med, Yangsan, Gyeongnam, South Korea.	choibt@pusan.ac.kr; julie@pusan.ac.kr			National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology [2010-0007470]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2010-0007470). The funders had no role in study design, data collection and analysis.	Chen T, 2011, BRAIN RES BULL, V84, P163, DOI 10.1016/j.brainresbull.2010.11.015; Cummings M, 2001, Acupunct Med, V19, P64; DACEY RG, 1987, AM J PHYSIOL, V253, pH1253, DOI 10.1152/ajpheart.1987.253.5.H1253; DAUPHIN F, 1995, PHARMACOL THERAPEUT, V67, P385, DOI 10.1016/0163-7258(95)00022-4; DAUPHIN F, 1990, EUR J PHARMACOL, V178, P203, DOI 10.1016/0014-2999(90)90476-M; Dong H, 2009, NEUROL RES, V31, P853, DOI 10.1179/174313209X393960; Du YH, 2011, NEUROL RES, V33, P101, DOI 10.1179/016164110X12714125204317; Elhusseiny A, 2000, J CEREBR BLOOD F MET, V20, P298, DOI 10.1097/00004647-200002000-00011; Elhusseiny A, 1999, J CEREBR BLOOD F MET, V19, P794, DOI 10.1097/00004647-199907000-00010; ESTRADA C, 1983, BRAIN RES, V266, P261, DOI 10.1016/0006-8993(83)90657-1; FARACI FM, 1994, STROKE, V25, P692, DOI 10.1161/01.STR.25.3.692; Gao HM, 2002, ACUPUNCTURE ELECTRO, V27, P45, DOI 10.3727/036012902816026112; Gao HM, 2006, ACUPUNCTURE ELECTRO, V31, P259, DOI 10.3727/036012906815844247; Hamel E, 2004, PROG BRAIN RES, V145, P171, DOI 10.1016/S0079-6123(02)45012-7; Han XH, 2010, BRAIN INJURY, V24, P773, DOI 10.3109/02699051003610482; Hartig W, 2002, REV NEUROSCIENCE, V13, P95; Hopwood V, 2005, J ALTERN COMPLEM MED, V11, P175, DOI 10.1089/acm.2005.11.175; Huang Y, 2007, INT J NEUROSCI, V117, P1029, DOI 10.1080/00207450600936825; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; KALARIA RN, 1994, J AUTONOM NERV SYST, V49, pS3; Kang KA, 2010, NEUROL RES, V32, pS84, DOI 10.1179/016164109X12537002794246; Kim DD, 2006, MICROCIRCULATION, V13, P577, DOI 10.1080/10739680600885210; Lee JD, 2003, NEURORADIOLOGY, V45, P780, DOI 10.1007/s00234-003-1080-3; Li XL, 2004, EXP NEUROL, V187, P94, DOI 10.1016/j.expneurol.2004.01.004; Limbourg FP, 2002, J CLIN INVEST, V110, P1729, DOI 10.1172/JCI200215481; Liu Ruihua, 2005, J Tradit Chin Med, V25, P190; Liu SY, 2009, AM J CHINESE MED, V37, P483, DOI 10.1142/S0192415X09006990; Liu Y, 2010, NEUROSCI LETT, V485, P74, DOI 10.1016/j.neulet.2010.08.068; NAESER MA, 1994, ACUPUNCTURE ELECTRO, V19, P227, DOI 10.3727/036012994816357231; Ren L, 2008, NEUROL RES, V30, P985, DOI 10.1179/174313208X325182; SAGHER O, 1993, J CEREBR BLOOD F MET, V13, P676, DOI 10.1038/jcbfm.1993.86; SATO A, 1995, ALZ DIS ASSOC DIS, V9, P28, DOI 10.1097/00002093-199505000-00007; Shiflett SC, 2007, TOP STROKE REHABIL, V14, P40, DOI 10.1310/tsr1404-40; SHIMIZU T, 1993, AM J PHYSIOL, V264, pH665, DOI 10.1152/ajpheart.1993.264.3.H665; Si QM, 1998, ACUPUNCTURE ELECTRO, V23, P117, DOI 10.3727/036012998816356562; Siu FKW, 2004, NEUROSCI LETT, V354, P158, DOI 10.1016/j.neulet.2003.10.009; Sun N, 2005, BRAIN RES, V1064, P98, DOI 10.1016/j.brainres.2005.09.060; Tao J, 2010, NEUROL RES, V32, P198, DOI 10.1179/174313209X414506; Tsuchiya M, 2007, ANESTH ANALG, V104, P301, DOI 10.1213/01.ane.0000230622.16367.fb; Uchida S, 2000, JPN J PHYSIOL, V50, P495, DOI 10.2170/jjphysiol.50.495; Wang QA, 2011, STROKE, V42, P389, DOI 10.1161/STROKEAHA.110.597336; Wang Q, 2009, STROKE, V40, P2157, DOI 10.1161/STROKEAHA.108.541490; Wang SJ, 2002, NEUROSCI LETT, V331, P115, DOI 10.1016/S0304-3940(02)00866-2; Yin CS, 2008, RES VET SCI, V84, P159, DOI 10.1016/j.rvsc.2007.04.004; Zhong SB, 2009, EVID-BASED COMPL ALT, V6, P51, DOI 10.1093/ecam/nem062; Zhou F, 2011, J APPL PHYSIOL, V111, P1877, DOI 10.1152/japplphysiol.00313.2011	47	53	57	1	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2013	8	2							e56736	10.1371/journal.pone.0056736	http://dx.doi.org/10.1371/journal.pone.0056736			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104DM	23418594	Green Published, Green Submitted, gold			2023-01-03	WOS:000315970300187
J	Audet, GN; Fulks, D; Stricker, JC; Olfert, IM				Audet, Gerald N.; Fulks, Daniel; Stricker, Janelle C.; Olfert, I. Mark			Chronic Delivery of a Thrombospondin-1 Mimetic Decreases Skeletal Muscle Capillarity in Mice	PLOS ONE			English	Article							ENDOTHELIAL-CELL APOPTOSIS; LOW-DENSITY-LIPOPROTEIN; NITRIC-OXIDE; TUMOR-GROWTH; ANGIOGENESIS; ABT-510; PEPTIDE; CD36; INFLAMMATION; ACTIVATION	Angiogenesis is an essential process for normal skeletal muscle function. There is a growing body of evidence suggesting that thrombospondin-1 (TSP-1), a potent antiangiogenic protein in tumorigenesis, is an important regulator of both physiological and pathological skeletal muscle angiogenesis. We tested the hypothesis that chronic exposure to a TSP-1 mimetic (ABT-510), which targets the CD36 TSP-1 receptor, would decrease skeletal muscle capillarity as well as alter the balance between positive and negative angiogenic proteins under basal conditions. Osmotic minipumps with either ABT-510 or vehicle (5% dextrose) were implanted subcutaneously in the subscapular region of C57/BL6 mice for 14 days. When compared to the vehicle treated mice, the ABT-510 group had a 20% decrease in capillarity in the superficial region of the gastrocnemius (GA), 11% decrease in the plantaris (PLT), and a 35% decrease in the soleus (SOL). ABT-510 also decreased muscle protein expression of vascular endothelial growth factor (VEGF) in both the GA (-140%) and SOL (-62%); however there was no change in VEGF in the PLT. Serum VEGF was not altered in ABT-510 treated animals. Endogenous TSP-1 protein expression in all muscles remained unaltered. Tunnel staining revealed no difference in muscle apoptosis between ABT-510 and vehicle treated groups. These data provide evidence that the anti-angiogenic effects of TSP-1 are mediated, at least in part, via the CD36 receptor. It also suggests that under physiologic conditions the TSP-1/CD36 axis plays a role in regulating basal skeletal muscle microvessel density.	[Audet, Gerald N.; Fulks, Daniel; Stricker, Janelle C.; Olfert, I. Mark] W Virginia Univ, Sch Med, Ctr Cardiovasc & Resp Sci, Div Exercise Physiol, Morgantown, WV 26506 USA	West Virginia University	Olfert, IM (corresponding author), W Virginia Univ, Sch Med, Ctr Cardiovasc & Resp Sci, Div Exercise Physiol, Morgantown, WV 26506 USA.	molfert@hsc.wvu.edu			National Institutes of Health T32 student training grant [NIH5T32HL090610]; American Heart Association [AHA10BGIA3630002]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL090610] Funding Source: NIH RePORTER	National Institutes of Health T32 student training grant; American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This project was supported by funding from the National Institutes of Health T32 student training grant NIH5T32HL090610 (GNA) and by the American Heart Association AHA10BGIA3630002 (IMO). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen DL, 1997, AM J PHYSIOL-CELL PH, V273, pC579, DOI 10.1152/ajpcell.1997.273.2.C579; Anderson JC, 2007, CANCER BIOL THER, V6, P454, DOI 10.4161/cbt.6.3.3630; Bornstein P, 2009, J CELL COMMUN SIGNAL, V3, P189, DOI 10.1007/s12079-009-0060-8; Breen EC, 1996, J APPL PHYSIOL, V81, P355, DOI 10.1152/jappl.1996.81.1.355; Campbell NE, THROMBOSPONDIN 1 MIM; Chen H, 2000, MATRIX BIOL, V19, P597, DOI 10.1016/S0945-053X(00)00107-4; Dalla Libera L, 1999, AM J PHYSIOL-CELL PH, V277, pC982, DOI 10.1152/ajpcell.1999.277.5.C982; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Degens H, 2006, INT J SPORTS MED, V27, P94, DOI 10.1055/s-2005-837571; Dimmeler S, 2000, CIRC RES, V87, P434; Dupont-Versteegden EE, 2005, EXP GERONTOL, V40, P473, DOI 10.1016/j.exger.2005.04.003; Duscha BD, 1999, J AM COLL CARDIOL, V33, P1956, DOI 10.1016/S0735-1097(99)00101-1; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Frazier EP, 2011, MATRIX BIOL; Friedl P, 2002, CELL MOL LIFE SCI, V59, P1347, DOI 10.1007/s00018-002-8512-9; Greenaway J, 2007, J CELL PHYSIOL, V210, P807, DOI 10.1002/jcp.20904; Greenaway J, 2009, MOL CANCER THER, V8, P64, DOI 10.1158/1535-7163.MCT-08-0864; Guo NH, 1997, CANCER RES, V57, P1735; Gupta K, 1999, Angiogenesis, V3, P147, DOI 10.1023/A:1009018702832; Hasina R, 2009, CANCER PREV RES, V2, P385, DOI 10.1158/1940-6207.CAPR-08-0211; Haviv F, 2005, J MED CHEM, V48, P2838, DOI 10.1021/jm0401560; Hoekstra R, 2005, J CLIN ONCOL, V23, P5188, DOI 10.1200/JCO.2005.05.013; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; Isenberg JS, 2008, CELL MOL LIFE SCI, V65, P728, DOI 10.1007/s00018-007-7488-x; Isenberg JS, 2008, BIOCHEM PHARMACOL, V75, P875, DOI 10.1016/j.bcp.2007.10.025; Isenberg JS, 2007, BLOOD, V109, P1945, DOI 10.1182/blood-2006-08-041368; Isenberg JS, 2005, P NATL ACAD SCI USA, V102, P13141, DOI 10.1073/pnas.0502977102; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Joyce D, 2006, J CLIN ONCOL S, V24, P13545; Kaur S, 2010, J BIOL CHEM, V285, P38923, DOI 10.1074/jbc.M110.172304; Kivela R, 2006, FASEB J, V20, P1570, DOI 10.1096/fj.05-4780fje; Kivela R, 2008, CARDIOVASC DIABETOL, V7, DOI 10.1186/1475-2840-7-13; Kvansakul M, 2004, EMBO J, V23, P1223, DOI 10.1038/sj.emboj.7600166; Lange-Asschenfeldt B, 2002, BLOOD, V99, P538, DOI 10.1182/blood.V99.2.538; Lawler J, 2000, CURR OPIN CELL BIOL, V12, P634, DOI 10.1016/S0955-0674(00)00143-5; Lawler J, 2004, INT J BIOCHEM CELL B, V36, P1038, DOI 10.1016/j.biocel.2004.01.008; LOJDA Z, 1979, HISTOCHEMISTRY, V59, P153, DOI 10.1007/BF00495663; Malek MH, 2009, EXP PHYSIOL, V94, P749, DOI 10.1113/expphysiol.2008.045989; Meeson A, 1996, DEVELOPMENT, V122, P3929; Meeson AP, 1999, DEVELOPMENT, V126, P1407; Miao WM, 2001, CANCER RES, V61, P7830; MRAZKOVA O, 1986, AM J ANAT, V177, P141, DOI 10.1002/aja.1001770203; Nor JE, 2000, J VASC RES, V37, P209, DOI 10.1159/000025733; Olfert IM, 2006, GROWTH FACTORS, V24, P253, DOI 10.1080/08977190601000111; Olfert IM, 2011, MICROCIRCULATION, V18, P316, DOI 10.1111/j.1549-8719.2011.00092.x; Olfert IM, 2009, J PHYSIOL-LONDON, V587, P1755, DOI 10.1113/jphysiol.2008.164384; Olfert IM, 2012, UNPUB; Primo L, 2005, FASEB J, V19, P1713, DOI 10.1096/fj.05-3697fje; Reiher FK, 2002, INT J CANCER, V98, P682, DOI 10.1002/ijc.10247; Ren B, 2006, BBA-REV CANCER, V1765, P178, DOI 10.1016/j.bbcan.2005.11.002; Ridnour LA, 2005, P NATL ACAD SCI USA, V102, P13147, DOI 10.1073/pnas.0502979102; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Roudier E, 2010, J PHYSIOL-LONDON, V588, P4579, DOI 10.1113/jphysiol.2010.193243; Rusk A, 2006, CLIN CANCER RES, V12, P7444, DOI 10.1158/1078-0432.CCR-06-0109; Simons M, 2012, PHYSIOLOGY, V27, P213, DOI 10.1152/physiol.00016.2012; Siu PM, 2005, AM J PHYSIOL-CELL PH, V288, pC338, DOI 10.1152/ajpcell.00239.2004; Sun JF, 2009, AM J PHYSIOL-HEART C, V296, pH1344, DOI 10.1152/ajpheart.01246.2008; Tang K, 2004, PHYSIOL GENOMICS, V18, P63, DOI 10.1152/physiolgenomics.00023.2004; Varma V, 2008, DIABETES, V57, P432, DOI 10.2337/db07-0840; Wintergerst ES, 2000, EUR J BIOCHEM, V267, P6050, DOI 10.1046/j.1432-1327.2000.01682.x; Yap R, 2005, CLIN CANCER RES, V11, P6678, DOI 10.1158/1078-0432.CCR-05-0621; Zhang XF, 2007, MICROVASC RES, V74, P90, DOI 10.1016/j.mvr.2007.04.007; Zhang XF, 2009, FASEB J, V23, P3368, DOI 10.1096/fj.09-131649	63	18	18	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2013	8	2							e55953	10.1371/journal.pone.0055953	http://dx.doi.org/10.1371/journal.pone.0055953			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	092WJ	23405239	Green Published, Green Submitted, gold			2023-01-03	WOS:000315153400184
J	Kwiatek, JM; Owen, DM; Abu-Siniyeh, A; Yan, P; Loew, LM; Gaus, K				Kwiatek, Joanna M.; Owen, Dylan M.; Abu-Siniyeh, Ahmed; Yan, Ping; Loew, Leslie M.; Gaus, Katharina			Characterization of a New Series of Fluorescent Probes for Imaging Membrane Order	PLOS ONE			English	Article							LIPID RAFTS; GENERALIZED POLARIZATION; PLASMA-MEMBRANE; LAURDAN FLUORESCENCE; CELL-MEMBRANES; LIVING CELLS; DOMAINS; MICROSCOPY; DI-4-ANEPPDHQ; MODEL	Visualization and quantification of lipid order is an important tool in membrane biophysics and cell biology, but the availability of environmentally sensitive fluorescent membrane probes is limited. Here, we present the characterization of the novel fluorescent dyes PY3304, PY3174 and PY3184, whose fluorescence properties are sensitive to membrane lipid order. In artificial bilayers, the fluorescence emission spectra are red-shifted between the liquid-ordered and liquid-disordered phases. Using ratiometric imaging we demonstrate that the degree of membrane order can be quantitatively determined in artificial liposomes as well as live cells and intact, live zebrafish embryos. Finally, we show that the fluorescence lifetime of the dyes is also dependent on bilayer order. These probes expand the current palate of lipid excitation/emission wavelengths and possibly new opportunities in membrane biology.	[Kwiatek, Joanna M.; Owen, Dylan M.; Abu-Siniyeh, Ahmed; Gaus, Katharina] Univ New S Wales, Ctr Vasc Res, Sydney, NSW, Australia; [Kwiatek, Joanna M.; Owen, Dylan M.; Abu-Siniyeh, Ahmed; Gaus, Katharina] Univ New S Wales, Australian Ctr Nanomed, Sydney, NSW, Australia; [Yan, Ping; Loew, Leslie M.] Univ Connecticut, Ctr Hlth, Ctr Cell Anal & Modelling, Farmington, CT USA	University of New South Wales Sydney; University of New South Wales Sydney; University of Connecticut	Owen, DM (corresponding author), Univ New S Wales, Ctr Vasc Res, Sydney, NSW, Australia.	dylan.owen@unsw.edu.au; les@volt.uchc.edu; k.gaus@unsw.edu.au	Wunder, Stephanie L/B-5066-2012; Zdilla, Michael J/B-4145-2011; Abu siniyeh, Ahmed/M-5591-2019	Abu siniyeh, Ahmed/0000-0002-1175-5017; Yan, Ping/0000-0001-6472-150X; Loew, Leslie/0000-0002-1851-4646; Gaus, Katharina/0000-0002-8009-9658; Kwiatek, Joanna/0000-0001-8934-0922	Australian Research Council (ARC) [DE130100251]; National Institutes of Health (NIH) [R01 EB001963]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB001963] Funding Source: NIH RePORTER	Australian Research Council (ARC)(Australian Research Council); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	DMO and KG acknowledge funding from the Australian Research Council (ARC), grant DE130100251. LML and PY acknowledge support from the National Institutes of Health (NIH) grant R01 EB001963. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bagatolli LA, 2006, BBA-BIOMEMBRANES, V1758, P1541, DOI 10.1016/j.bbamem.2006.05.019; Carter GC, 2009, VIROLOGY, V386, P192, DOI 10.1016/j.virol.2008.12.031; de Almeida RFM, 2003, BIOPHYS J, V85, P2406, DOI 10.1016/S0006-3495(03)74664-5; Demchenko AP, 2009, BIOPHYS J, V96, P3461, DOI 10.1016/j.bpj.2009.02.012; Gaus K, 2005, J CELL BIOL, V171, P121, DOI 10.1083/jcb.200505047; Gaus K, 2003, P NATL ACAD SCI USA, V100, P15554, DOI 10.1073/pnas.2534386100; Hanzal-Bayer MF, 2007, FEBS LETT, V581, P2098, DOI 10.1016/j.febslet.2007.03.019; Jin L, 2006, BIOPHYS J, V90, P2563, DOI 10.1529/biophysj.105.072884; Jin L, 2005, BIOPHYS J, V89, pL4, DOI 10.1529/biophysj.105.064816; Kaiser HJ, 2009, P NATL ACAD SCI USA, V106, P16645, DOI 10.1073/pnas.0908987106; Kim HM, 2007, CHEMBIOCHEM, V8, P553, DOI 10.1002/cbic.200700003; Lagerholm BC, 2005, ANNU REV PHYS CHEM, V56, P309, DOI 10.1146/annurev.physchem.56.092503.141211; Lingwood D, 2010, SCIENCE, V327, P46, DOI 10.1126/science.1174621; Miguel L, 2011, J IMMUNOL, V186, P3505, DOI 10.4049/jimmunol.1002980; Obaid AL, 2004, J NEUROSCI METH, V134, P179, DOI 10.1016/j.jneumeth.2003.11.011; Owen DM, 2007, SEMIN CELL DEV BIOL, V18, P591, DOI 10.1016/j.semcdb.2007.07.011; Owen DM, 2006, BIOPHYS J, V90, pL80, DOI 10.1529/biophysj.106.084673; Owen DM, 2012, NAT PROTOC, V7, P24, DOI 10.1038/nprot.2011.419; Owen DM, 2010, MOL MEMBR BIOL, V27, P178, DOI 10.3109/09687688.2010.495353; Owen DM, 2010, BIOPHYS J, V99, pL7, DOI 10.1016/j.bpj.2010.04.022; Owen DM, 2010, MICROSC RES TECHNIQ, V73, P618, DOI 10.1002/jemt.20801; Owen DM, 2009, TRAFFIC, V10, P962, DOI 10.1111/j.1600-0854.2009.00908.x; PARASASSI T, 1991, BIOPHYS J, V60, P179, DOI 10.1016/S0006-3495(91)82041-0; PARASASSI T, 1990, BIOPHYS J, V57, P1179, DOI 10.1016/S0006-3495(90)82637-0; Parasassi T, 1998, J FLUORESC, V8, P365, DOI 10.1023/A:1020528716621; Parasassi T, 1997, BIOPHYS J, V72, P2413, DOI 10.1016/S0006-3495(97)78887-8; Pike LJ, 2006, J LIPID RES, V47, P1597, DOI 10.1194/jlr.E600002-JLR200; Scheiffele P, 1999, J BIOL CHEM, V274, P2038, DOI 10.1074/jbc.274.4.2038; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons K, 2010, NAT REV MOL CELL BIO, V11, P688, DOI 10.1038/nrm2977; Tanaka KAK, 2010, NAT METHODS, V7, P865, DOI 10.1038/nmeth.f.314; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; WEBER G, 1979, BIOCHEMISTRY-US, V18, P3075, DOI 10.1021/bi00581a025; Weber P, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3470446	34	52	53	2	79	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 4	2013	8	2							e52960	10.1371/journal.pone.0052960	http://dx.doi.org/10.1371/journal.pone.0052960			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	086NH	23390489	gold, Green Published, Green Submitted			2023-01-03	WOS:000314691100005
J	Efrati, S; Fishlev, G; Bechor, Y; Volkov, O; Bergan, J; Kliakhandler, K; Kamiager, I; Gal, N; Friedman, M; Ben-Jacob, E; Golan, H				Efrati, Shai; Fishlev, Gregori; Bechor, Yair; Volkov, Olga; Bergan, Jacob; Kliakhandler, Kostantin; Kamiager, Izhak; Gal, Nachum; Friedman, Mony; Ben-Jacob, Eshel; Golan, Haim			Hyperbaric Oxygen Induces Late Neuroplasticity in Post Stroke Patients - Randomized, Prospective Trial	PLOS ONE			English	Article							CYSTIC-FIBROSIS PATIENTS; ISCHEMIC BRAIN-DAMAGE; DEAD-SEA; LOW-ALTITUDE; TISSUE OXYGEN; THERAPY; REHABILITATION; PRESSURE; DISEASE; INJURY	Background: Recovery after stroke correlates with non-active (stunned) brain regions, which may persist for years. The current study aimed to evaluate whether increasing the level of dissolved oxygen by Hyperbaric Oxygen Therapy (HBOT) could activate neuroplasticity in patients with chronic neurologic deficiencies due to stroke. Methods and Findings: A prospective, randomized, controlled trial including 74 patients (15 were excluded). All participants suffered a stroke 6-36 months prior to inclusion and had at least one motor dysfunction. After inclusion, patients were randomly assigned to "treated" or "cross" groups. Brain activity was assessed by SPECT imaging; neurologic functions were evaluated by NIHSS, ADL, and life quality. Patients in the treated group were evaluated twice: at baseline and after 40 HBOT sessions. Patients in the cross group were evaluated three times: at baseline, after a 2-month control period of no treatment, and after subsequent 2-months of 40 HBOT sessions. HBOT protocol: Two months of 40 sessions (5 days/week), 90 minutes each, 100% oxygen at 2 ATA. We found that the neurological functions and life quality of all patients in both groups were significantly improved following the HBOT sessions while no improvement was found during the control period of the patients in the cross group. Results of SPECT imaging were well correlated with clinical improvement. Elevated brain activity was detected mostly in regions of live cells (as confirmed by CT) with low activity (based on SPECT) - regions of noticeable discrepancy between anatomy and physiology. Conclusions: The results indicate that HBOT can lead to significant neurological improvements in post stroke patients even at chronic late stages. The observed clinical improvements imply that neuroplasticity can still be activated long after damage onset in regions where there is a brain SPECT/CT (anatomy/physiology) mismatch.	[Efrati, Shai; Fishlev, Gregori; Bechor, Yair; Bergan, Jacob; Gal, Nachum; Friedman, Mony] Assaf Harofeh Med Ctr, Inst Hyperbar Med, IL-70300 Zerifin, Israel; [Efrati, Shai; Ben-Jacob, Eshel] Assaf Harofeh Med Ctr, Res & Dev Unit, IL-70300 Zerifin, Israel; [Efrati, Shai; Volkov, Olga; Kamiager, Izhak; Golan, Haim] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Volkov, Olga; Golan, Haim] Assaf Harofeh Med Ctr, Inst Nucl Med, IL-70300 Zerifin, Israel; [Kliakhandler, Kostantin; Ben-Jacob, Eshel] Tel Aviv Univ, Raymond & Beverly Sackler Fac Exact Sci, Sch Phys & Astron, IL-69978 Tel Aviv, Israel; [Kamiager, Izhak] Assaf Harofeh Med Ctr, Dept Neurol, IL-70300 Zerifin, Israel; [Ben-Jacob, Eshel] Rice Univ, Ctr Theoret Biol Phys, Houston, TX USA	Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Rice University	Efrati, S (corresponding author), Assaf Harofeh Med Ctr, Inst Hyperbar Med, IL-70300 Zerifin, Israel.	efratishai@013.net	Golan, Haim/K-2831-2019		Assaf-Harofeh medical center; Tauber Family Foundation; Maguy-Glass Chair in Physics of Complex Systems at Tel Aviv University; Joseph Hackmey; Division Of Physics [1308264] Funding Source: National Science Foundation	Assaf-Harofeh medical center; Tauber Family Foundation; Maguy-Glass Chair in Physics of Complex Systems at Tel Aviv University; Joseph Hackmey; Division Of Physics(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS))	The study was supported by the research fund of Assaf-Harofeh medical center, by the Tauber Family Foundation and the Maguy-Glass Chair in Physics of Complex Systems at Tel Aviv University and by Joseph Hackmey. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abinader EG, 1999, AM J CARDIOL, V83, P250, DOI 10.1016/S0002-9149(98)00829-7; ANDERSON DC, 1991, STROKE, V22, P1137, DOI 10.1161/01.STR.22.9.1137; ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; Austin D, 1998, LANCET, V351, P1815, DOI 10.1016/S0140-6736(05)78781-X; Bettger JAP, 2007, ARCH PHYS MED REHAB, V88, P1526, DOI 10.1016/j.apmr.2007.06.768; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Calvert JW, 2007, NEUROL RES, V29, P132, DOI 10.1179/016164107X174156; Culmsee C, 2007, EMBO REP, V8, P129, DOI 10.1038/sj.embor.7400892; DUNCAN PW, 1992, STROKE, V23, P1084, DOI 10.1161/01.STR.23.8.1084; Falk B, 2006, PEDIATR PULM, V41, P234, DOI 10.1002/ppul.20342; Fernandez-Bouzas A, 2000, CLIN ELECTROENCEPHAL, V31, P165, DOI 10.1177/155005940003100403; Gabizon I, 2011, ISR MED ASSOC J, V13, P402; Goldbart AD, 2007, ISR MED ASSOC J, V9, P806; Golden ZL, 2002, INT J NEUROSCI, V112, P119, DOI 10.1080/00207450212027; GOLDING F C, 1960, Br J Ind Med, V17, P167; Gunther A, 2005, EUR J NEUROSCI, V21, P3189, DOI 10.1111/j.1460-9568.2005.04151.x; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Hossmann KA, 2006, CELL MOL NEUROBIOL, V26, P1057, DOI 10.1007/s10571-006-9008-1; Imai K, 2006, NEUROL MED-CHIR, V46, P373, DOI 10.2176/nmc.46.373; James PB, 2001, LANCET, V357, P2052, DOI 10.1016/S0140-6736(00)05137-0; JASZCZAK RJ, 1979, PHYS MED BIOL, V24, P1123, DOI 10.1088/0031-9155/24/6/003; Kasner SE, 1999, STROKE, V30, P1534, DOI 10.1161/01.STR.30.8.1534; Kattenstroth JC, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00244; KOL S, 1993, ANN THORAC SURG, V55, P401, DOI 10.1016/0003-4975(93)91010-K; Kramer MR, 1998, CHEST, V113, P571, DOI 10.1378/chest.113.3.571; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; Mahadeva S, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-20; Muth CM, 2003, INT J SPORTS MED, V24, P104, DOI 10.1055/s-2003-38401; Neubauer RA, 1998, NEUROL RES, V20, pS33; NIGHOGHOSSIAN N, 1995, STROKE, V26, P1369, DOI 10.1161/01.STR.26.8.1369; Niklas A, 2004, J NEUROL SCI, V219, P77, DOI 10.1016/j.jns.2003.12.013; Rakic P, 2002, NAT REV NEUROSCI, V3, P65, DOI 10.1038/nrn700; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Rusyniak DE, 2003, STROKE, V34, P571, DOI 10.1161/01.STR.0000050644.48393.D0; Siddique MS, 2002, J NEUROSURG, V96, P736, DOI 10.3171/jns.2002.96.4.0736; Sterr A, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/970136; Teasell R, 2009, TOP STROKE REHABIL, V16, pV; Vila JF, 2005, UNDERSEA HYPERBAR M, V32, P341; Yang YJ, 2008, UNDERSEA HYPERBAR M, V35, P113; Zhang John H, 2005, Pathophysiology, V12, P63, DOI 10.1016/j.pathophys.2005.01.003; Zimerman M, 2012, STROKE, V43, P2185, DOI 10.1161/STROKEAHA.111.645382	41	103	112	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 15	2013	8	1							e53716	10.1371/journal.pone.0053716	http://dx.doi.org/10.1371/journal.pone.0053716			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	086SQ	23335971	Green Published, gold			2023-01-03	WOS:000314707700027
J	Mandel, Y; Malki, G; Adawi, E; Glassberg, E; Afek, A; Zagetzki, M; Barnea, O				Mandel, Yossi; Malki, Guy; Adawi, Eid; Glassberg, Elon; Afek, Arnon; Zagetzki, Michael; Barnea, Ofer			Hemorrhage Control of Liver Injury by Short Electrical Pulses	PLOS ONE			English	Article							IRREVERSIBLE ELECTROPORATION; THERMAL COAGULATION; ARTERIAL THROMBOSIS; TISSUE ABLATION; HEPATIC-ARTERY; SMOOTH-MUSCLE; PORTAL-VEIN; RESUSCITATION; STIMULATION; MODEL	Trauma is a leading cause of death among young individuals globally and uncontrolled hemorrhage is the leading cause of preventable death. Controlling hemorrhage from a solid organ is often very challenging in military as well as civilian setting. Recent studies demonstrated reversible vasoconstriction and irreversible thrombosis following application of microseconds-long electrical pulses. The current paper describes for the first time reduction in bleeding from the injured liver in rat and rabbit model in-vivo. We applied short (25 and 50 mu s) electrical pulses of 1250 V/cm to rats and rabbit liver following induction of standardized penetrating injury and measured the amount of bleeding into the abdominal cavity one hour post injury. We found a 60 and 36 percent reduction in blood volume in rats treated by 25 mu s and 50 mu s, respectively (P<0.001). Similar results were found for the rabbit model. Finite element simulation revealed that the effect was likely non-thermal. Histological evaluation found local cellular injury with intravascular thrombosis. Further research should be done to fully explore the mechanism of action and the potential use of short electric pulses for hemorrhage control.	[Mandel, Yossi; Glassberg, Elon] IDF Med Corps, Ramat Gan, Israel; [Mandel, Yossi; Malki, Guy; Adawi, Eid; Barnea, Ofer] Tel Aviv Univ, Dept Biomed Engn, IL-69978 Tel Aviv, Israel; [Afek, Arnon; Zagetzki, Michael] Chaim Sheba Med Ctr, Ramat Gan, Israel	Tel Aviv University; Chaim Sheba Medical Center	Mandel, Y (corresponding author), IDF Med Corps, Ramat Gan, Israel.	yossi.mandel@gmail.com			Israeli Ministry of defence; IDF (Israel Defense Forces) Medical Corps	Israeli Ministry of defence; IDF (Israel Defense Forces) Medical Corps	This study was supported by a grant from the Israeli Ministry of defence and the IDF (Israel Defense Forces) Medical Corps. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmadi-Noorbakhsh S, 2012, J SURG RES; Al-Sakere B, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001135; AYUSE T, 1994, AM J PHYSIOL-HEART C, V267, pH1233, DOI 10.1152/ajpheart.1994.267.4.H1233; Blackbourne LH, 2010, J TRAUMA, V69, pS1, DOI 10.1097/TA.0b013e3181e4206f; BOURGAIN RH, 1974, THROMB RES, V4, P599, DOI 10.1016/0049-3848(74)90234-5; Davalos RV, 2005, ANN BIOMED ENG, V33, P223, DOI 10.1007/s10439-005-8981-8; Edd JF, 2006, IEEE T BIO-MED ENG, V53, P1409, DOI 10.1109/TBME.2006.873745; EZZAT WR, 1987, AM J PHYSIOL, V252, pH836, DOI 10.1152/ajpheart.1987.252.4.H836; Gehl J, 2002, BBA-GEN SUBJECTS, V1569, P51, DOI 10.1016/S0304-4165(01)00233-1; Graham SJ, 1998, MAGNET RESON MED, V39, P198, DOI 10.1002/mrm.1910390206; Guarini S, 1996, J PHARMACOL TOXICOL, V35, P101, DOI 10.1016/1056-8719(96)00006-8; Haemmerich D, 2002, IEEE T BIO-MED ENG, V49, P836, DOI 10.1109/TBME.2002.800790; HLADOVEC J, 1973, THROMB DIATH HAEMOST, V29, P196, DOI 10.1055/s-0038-1647760; Holcomb JB, 2000, J TRAUMA, V49, P246, DOI 10.1097/00005373-200008000-00010; Ivorra A, 2007, BIOELECTROCHEMISTRY, V70, P287, DOI 10.1016/j.bioelechem.2006.10.005; Ivorra Antoni, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P5056; Ivorra A, 2009, PHYS MED BIOL, V54, P5949, DOI 10.1088/0031-9155/54/19/019; Kanthou C, 2006, MOL CANCER THER, V5, P3145, DOI 10.1158/1535-7163.MCT-06-0410; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; Kelly JF, 2008, J TRAUMA, V64, pS21, DOI 10.1097/TA.0b013e318160b9fb; Kragh JF, 2011, J EMERG MED, V41, P590, DOI 10.1016/j.jemermed.2009.07.022; Kragh John F Jr, 2011, US Army Med Dep J, P38; Mandel Y, J HEAT TRAN IN PRESS; Maor E, 2007, TECHNOL CANCER RES T, V6, P307, DOI 10.1177/153303460700600407; Maor E, 2010, J VASC INTERV RADIOL, V21, P1708, DOI 10.1016/j.jvir.2010.06.024; Matsuoka C, 2004, J MAGN MAGN MATER, V272, P2426, DOI 10.1016/j.j,,,.2003.12.848; Matsuoka T, 1996, J TRAUMA, V40, P915, DOI 10.1097/00005373-199606000-00009; Matsuoka T, 1996, J TRAUMA, V41, P439, DOI 10.1097/00005373-199609000-00009; MATSUOKA T, 1995, J TRAUMA, V39, P674, DOI 10.1097/00005373-199510000-00010; MATSUSHIMA Y, 1994, EUR J SURG, P59; McManus JG, 2007, J TRAUMA, V62, pS14, DOI 10.1097/TA.0b013e3180653b6d; MOUCHAWAR GA, 1992, MED BIOL ENG COMPUT, V30, P162, DOI 10.1007/BF02446126; Onik G, 2007, TECHNOL CANCER RES T, V6, P295, DOI 10.1177/153303460700600405; Palanker D, 2008, BIOELECTROMAGNETICS, V29, P100, DOI 10.1002/bem.20368; PENNES HH, 1948, J APPL PHYSIOL, V1, P93, DOI 10.1152/jappl.1948.1.2.93; Phillips M, 2011, J HEAT TRANS-T ASME, V133, DOI 10.1115/1.4002301; Poliachik SL, 2001, ULTRASOUND MED BIOL, V27, P1567, DOI 10.1016/S0301-5629(01)00444-6; Precup CG, 2010, CHIRURGIA-BUCHAREST, V105, P71; Pusateri AE, 2003, J TRAUMA, V55, P518, DOI 10.1097/01.TA.0000075336.92129.27; Ramirez LH, 1998, BRIT J CANCER, V77, P2104, DOI 10.1038/bjc.1998.354; Rossini PM, 2007, NEUROLOGY, V68, P484, DOI 10.1212/01.wnl.0000250268.13789.b2; Rubinsky B, 2007, TECHNOL CANCER RES T, V6, P255, DOI 10.1177/153303460700600401; Rubinsky B, 2007, TECHNOL CANCER RES T, V6, P37, DOI 10.1177/153303460700600106; Rubinsky J, 2008, J UROLOGY, V180, P2668, DOI 10.1016/j.juro.2008.08.003; Scope A, 2001, INJURY, V32, P1, DOI 10.1016/S0020-1383(00)00101-7; Sersa G, 2008, BRIT J CANCER, V98, P388, DOI 10.1038/sj.bjc.6604168; SONG YQ, 1994, EUR J SURG, P41; Tangwongsan C, 2003, MEASUREMENT IN VIVO; Vaezy S, 2004, J ULTRAS MED, V23, P217, DOI 10.7863/jum.2004.23.2.217; Vaezy S, 1997, ULTRASOUND MED BIOL, V23, P1413, DOI 10.1016/S0301-5629(97)00143-9; Velmahos GC, 2007, J TRAUMA, V63, P285, DOI 10.1097/TA.0b013e3180d0a6ea; Xin YL, 1997, BIOELECTROMAGNETICS, V18, P8, DOI 10.1002/(SICI)1521-186X(1997)18:1<8::AID-BEM3>3.0.CO;2-6; YEAGER VL, 1985, EXPERIENTIA, V41, P262, DOI 10.1007/BF02002627	53	10	10	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2013	8	1							e49852	10.1371/journal.pone.0049852	http://dx.doi.org/10.1371/journal.pone.0049852			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	069IY	23320063	gold, Green Submitted, Green Published			2023-01-03	WOS:000313429800002
J	Powell, T; Hanfling, D; Gostin, LO				Powell, Tia; Hanfling, Dan; Gostin, Lawrence O.			Emergency Preparedness and Public Health The Lessons of Hurricane Sandy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Powell, Tia] Albert Einstein Coll Med, Montefiore Einstein Ctr Bioeth, Bronx, NY 10467 USA; [Hanfling, Dan] Inova Hlth Syst, Falls Church, VA USA; [Hanfling, Dan] Georgetown Univ, Dept Emergency Med, Washington, DC 20001 USA; [Gostin, Lawrence O.] Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, Washington, DC 20001 USA	Yeshiva University; Albert Einstein College of Medicine; Inova Health System; Georgetown University; Georgetown University	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu						Committee on Guidance for Establishing Crisis Standards of Care for Use in Disaster Situations; Institute of Medicine, 2012, CRIS STAND CAR SYST, DOI DOI 10.17226/13351; Hartocollis A, 2012, NY TIMES; Katz C, 2012, NYC             1027; Kolker Robert, 2021, NEW YORK TIMES MAGAZ; Ofri D, 2012, NEW ENGL J MED, V367, P2265, DOI 10.1056/NEJMp1213843; Shapiro J, BELLEVUE HOSP EVACUA	6	85	86	0	60	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 26	2012	308	24					2569	2570		10.1001/jama.2012.108940	http://dx.doi.org/10.1001/jama.2012.108940			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	062JR	23281545				2023-01-03	WOS:000312916600019
J	Spitzer, M; Basaria, S; Travison, TG; Davda, MN; Paley, A; Cohen, B; Mazer, NA; Knapp, PE; Hanka, S; Lakshman, KM; Ulloor, J; Zhang, AQ; Orwoll, K; Eder, R; Collins, L; Mohammed, N; Rosen, RC; DeRogatis, L; Bhasin, S				Spitzer, Matthew; Basaria, Shehzad; Travison, Thomas G.; Davda, Maithili N.; Paley, Amanda; Cohen, Beth; Mazer, Norman A.; Knapp, Philip E.; Hanka, Samson; Lakshman, Kishore M.; Ulloor, Jagadish; Zhang, Anqi; Orwoll, Katie; Eder, Richard; Collins, Lauren; Mohammed, Nurahmed; Rosen, Raymond C.; DeRogatis, Leonard; Bhasin, Shalender			Effect of Testosterone Replacement on Response to Sildenafil Citrate in Men With Erectile Dysfunction A Parallel, Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL-PRACTICE GUIDELINE; MULTIPLY-IMPUTED DATA; VIRUS-INFECTED WOMEN; HYPOGONADAL MEN; INTERNATIONAL INDEX; SEXUAL DYSFUNCTION; ANDROGENIC MAINTENANCE; ORAL SILDENAFIL; UNITED-STATES; FUNCTION IIEF	Background: Erectile dysfunction and low testosterone levels frequently occur together. Objective: To determine whether addition of testosterone to sildenafil therapy improves erectile response in men with erectile dysfunction and low testosterone levels. Design: Randomized, double-blind, parallel, placebo-controlled trial. (ClinicalTrials.gov registration number: NCT00512707) Setting: Outpatient academic research center. Participants: Men aged 40 to 70 years with scores of 25 or less for the erectile function domain (EFD) of the International Index of Erectile Function, total testosterone levels less than 11.45 nmol/L (<330 ng/dL), or free testosterone levels less than 173.35 pmol/L (<50 pg/mL). Intervention: Sildenafil dose was optimized, and 140 participants were then randomly assigned to 14 weeks of daily transdermal gel that contained 10-g testosterone for 70 participants and placebo for the remaining 70 participants. All participants were included in the primary analysis, although 10 in the testosterone group and 12 in the placebo group did not complete the study. Results: At baseline, the 2 groups had similar EFD scores. Administration of sildenafil alone was associated with a substantial increase in EFD score (mean, 7.7 [95% CI, 6.5 to 8.8]), but change in EFD score after randomization did not differ between the groups (difference, 2.2 [CI, -0.8 to 5.1]; P = 0.150). The findings were similar for other domains of sexual function in younger men, more obese men, and men with lower baseline testosterone levels or an inadequate response to sildenafil alone. Frequency of adverse events was similar for testosterone and placebo groups. Limitation: Whether testosterone could improve erectile function without sildenafil was not studied. Conclusion: Sildenafil plus testosterone was not superior to sildenafil plus placebo in improving erectile function in men with erectile dysfunction and low testosterone levels. Primary Funding Source: National Institute of Child Health and Human Development.	[Spitzer, Matthew] Boston Univ, Sch Med, Med Ctr, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA; New England Res Inst, Watertown, MA 02472 USA; F Hoffmann La Roche, Basel, Switzerland; Johns Hopkins Univ, Baltimore, MD USA	Boston University; Boston University; HealthCore, Inc; Roche Holding; Johns Hopkins University	Spitzer, M (corresponding author), Boston Univ, Sch Med, Med Ctr, 670 Albany St, Boston, MA 02118 USA.	matthew.spitzer@bmc.org	Mazer, Norman A/HGU-8266-2022	Zhang, Anqi/0000-0003-3723-8293; Basaria, Shehzad/0000-0002-8533-2383; Knapp, Philip/0000-0002-5290-6125	National Institute of Child Health and Human Development [5R01HD047722]; Boston University Clinical and Translational Science Institute [1UL1RR025771]; Boston Claude D. Pepper Older Americans Independence Center (National Institute on Aging) [5P30AG031679]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD047722] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025771] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG031679] Funding Source: NIH RePORTER	National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Boston University Clinical and Translational Science Institute; Boston Claude D. Pepper Older Americans Independence Center (National Institute on Aging); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	By the National Institute of Child Health and Human Development (5R01HD047722). Additional support was provided by the Boston University Clinical and Translational Science Institute (1UL1RR025771) and Boston Claude D. Pepper Older Americans Independence Center (grant 5P30AG031679 from the National Institute on Aging).	ALEXANDER GM, 1991, HORM BEHAV, V25, P367, DOI 10.1016/0018-506X(91)90008-6; Andric SA, 2010, AM J PHYSIOL-ENDOC M, V299, pE544, DOI 10.1152/ajpendo.00337.2010; Aversa A, 2003, CLIN ENDOCRINOL, V58, P632, DOI 10.1046/j.1365-2265.2003.01764.x; Basaria S, 2010, NEW ENGL J MED, V363, P109, DOI 10.1056/NEJMoa1000485; Bhasin S, 2007, LANCET, V369, P597, DOI 10.1016/S0140-6736(07)60280-3; Bhasin S, 2012, JAMA-J AM MED ASSOC, V307, P931, DOI 10.1001/jama.2012.227; Bhasin S, 2011, J CLIN ENDOCR METAB, V96, P2430, DOI 10.1210/jc.2010-3012; Bhasin S, 2010, J CLIN ENDOCR METAB, V95, P2536, DOI 10.1210/jc.2009-2354; BUENA F, 1993, FERTIL STERIL, V59, P1118; BURRIS AS, 1992, J ANDROL, V13, P297; Buvat J, 2011, J SEX MED, V8, P284, DOI 10.1111/j.1743-6109.2010.01956.x; Carosa E, 2004, CLIN ENDOCRINOL, V61, P382, DOI 10.1111/j.1365-2265.2004.02108.x; Cavallini G, 2004, UROLOGY, V63, P641, DOI 10.1016/j.urology.2003.11.009; Choi HH, 2005, J CLIN ENDOCR METAB, V90, P1531, DOI 10.1210/jc.2004-1677; DEROGATIS LR, 1998, EVALUATING STRESS BO, V2, P89; Dong JY, 2011, J AM COLL CARDIOL, V58, P1378, DOI 10.1016/j.jacc.2011.06.024; Dupuy HJ, 1984, ASSESSMENT QUALITY L, P170; Fisher WA, 2009, J SEX MED, V6, P2746, DOI 10.1111/j.1743-6109.2009.01457.x; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; Guay Andre T, 2003, Endocr Pract, V9, P77; Hatzimouratidis K, 2010, EUR UROL, V57, P804, DOI 10.1016/j.eururo.2010.02.020; Janjic MM, 2012, J SEX MED; Khera M, 2011, J SEX MED, V8, P3204, DOI 10.1111/j.1743-6109.2011.02436.x; LI KH, 1991, STAT SINICA, V1, P65; Lindau ST, 2007, NEW ENGL J MED, V357, P762, DOI 10.1056/NEJMoa067423; MENG XL, 1992, BIOMETRIKA, V79, P103, DOI 10.1093/biomet/79.1.103; Mills TM, 1999, STEROIDS, V64, P605, DOI 10.1016/S0039-128X(99)00040-9; Mills TM, 1998, BIOL REPROD, V59, P1413, DOI 10.1095/biolreprod59.6.1413; Montorsi F, 1999, UROLOGY, V53, P1011, DOI 10.1016/S0090-4295(98)00643-8; Montorsi F, 2010, J SEX MED, V7, P3572, DOI 10.1111/j.1743-6109.2010.02062.x; Padma-Nathan H, 2001, INT J IMPOT RES, V13, P2, DOI 10.1038/sj.ijir.3900631; Paige NM, 2001, J UROLOGY, V166, P1774, DOI 10.1016/S0022-5347(05)65673-X; Qaseem A, 2009, ANN INTERN MED, V151, P639, DOI 10.7326/0003-4819-151-9-200911030-00151; Reilly CM, 1997, J ANDROL, V18, P110; Rosen RC, 2011, EUR UROL, V60, P1010, DOI 10.1016/j.eururo.2011.07.053; Rosen RC, 1997, UROLOGY, V49, P822, DOI 10.1016/S0090-4295(97)00238-0; Rosen RC, 2004, UROLOGY, V64, P777, DOI 10.1016/j.urology.2004.04.056; Rosen RC, 2002, INT J IMPOT RES, V14, P226, DOI 10.1038/sj.ijir.3900857; SCHAG CAC, 1991, CANCER, V68, P1406, DOI 10.1002/1097-0142(19910915)68:6<1406::AID-CNCR2820680638>3.0.CO;2-2; Seftel AD, 2004, J UROLOGY, V171, P2341, DOI 10.1097/01.ju.0000125198.32936.38; Shabsigh R, 2004, J UROLOGY, V172, P658, DOI 10.1097/01.ju.0000132389.97804.d7; Sinha-Hikim I, 1998, J CLIN ENDOCR METAB, V83, P1312, DOI 10.1210/jc.83.4.1312; Steidle C, 2003, J CLIN ENDOCR METAB, V88, P2673, DOI 10.1210/jc.2002-021058; Traish AM, 2009, J ANDROL, V30, P363, DOI 10.2164/jandrol.108.006007; Traish AM, 1999, ENDOCRINOLOGY, V140, P1861, DOI 10.1210/en.140.4.1861; Tsertsvadze A, 2009, ANN INTERN MED, V151, P650, DOI 10.7326/0003-4819-151-9-200911030-00150; van Buuren S, 2007, STAT METHODS MED RES, V16, P219, DOI 10.1177/0962280206074463; Wagner TH, 1996, QUAL LIFE RES, V5, P443, DOI 10.1007/BF00449919; Wang C, 2009, J ANDROL, V30, P1, DOI 10.2164/jandrol.108.006486; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	51	106	109	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 20	2012	157	10					681	+		10.7326/0003-4819-157-10-201211200-00004	http://dx.doi.org/10.7326/0003-4819-157-10-201211200-00004			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	043VZ	23165659				2023-01-03	WOS:000311580000013
J	Mestre, G; Berbel, C; Tortajada, P; Alarcia, M; Coca, R; Gallemi, G; Garcia, I; Fernandez, MM; Aguilar, MC; Martinez, JA; Rodriguez-Bano, J				Mestre, Gabriel; Berbel, Cristina; Tortajada, Purificacion; Alarcia, Margarita; Coca, Roser; Gallemi, Gema; Garcia, Irene; Mar Fernandez, Mari; Carmen Aguilar, Mari; Antonio Martinez, Jose; Rodriguez-Bano, Jesus			"The 3/3 Strategy'': A Successful Multifaceted Hospital Wide Hand Hygiene Intervention Based on WHO and Continuous Quality Improvement Methodology	PLOS ONE			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; STATISTICAL PROCESS-CONTROL; PROCESS-CONTROL CHARTS; HEALTH-CARE WORKERS; INFECTION-CONTROL; PROGRAM; IMPACT; EPIDEMIOLOGY; PERFORMANCE; GUIDELINES	Background: Only multifaceted hospital wide interventions have been successful in achieving sustained improvements in hand hygiene (HH) compliance. Methodology/Principal Findings: Pre-post intervention study of HH performance at baseline (October 2007-December 2009) and during intervention, which included two phases. Phase 1 (2010) included multimodal WHO approach. Phase 2 (2011) added Continuous Quality Improvement (CQI) tools and was based on: a) Increase of alcohol hand rub (AHR) solution placement (from 0.57 dispensers/bed to 1.56); b) Increase in frequency of audits (three days every three weeks: "3/3 strategy''); c) Implementation of a standardized register form of HH corrective actions; d) Statistical Process Control (SPC) as time series analysis methodology through appropriate control charts. During the intervention period we performed 819 scheduled direct observation audits which provided data from 11,714 HH opportunities. The most remarkable findings were: a) significant improvements in HH compliance with respect to baseline (25% mean increase); b) sustained high level (82%) of HH compliance during intervention; c) significant increase in AHRs consumption over time; c) significant decrease in the rate of healthcare-acquired MRSA; d) small but significant improvements in HH compliance when comparing phase 2 to phase 1 [79.5% (95% CI: 78.2-80.7) vs 84.6% (95% CI: 83.8-85.4), p, 0.05]; e) successful use of control charts to identify significant negative and positive deviations (special causes) related to the HH compliance process over time ("positive'': 90.1% as highest HH compliance coinciding with the "World hygiene day''; and "negative'': 73.7% as lowest HH compliance coinciding with a statutory lay-off proceeding). Conclusions/Significance: CQI tools may be a key addition to WHO strategy to maintain a good HH performance over time. In addition, SPC has shown to be a powerful methodology to detect special causes in HH performance (positive and negative) and to help establishing adequate feedback to healthcare workers.	[Mestre, Gabriel; Berbel, Cristina; Tortajada, Purificacion] Delfos Med Ctr, Nosocomial Infect Control Unit, Barcelona, Catalonia, Spain; [Alarcia, Margarita; Coca, Roser; Gallemi, Gema; Garcia, Irene; Mar Fernandez, Mari; Carmen Aguilar, Mari] Delfos Med Ctr, Supervisor Nursing Dept, Barcelona, Catalonia, Spain; [Antonio Martinez, Jose] Hosp Clin Barcelona, Infect Dis Unit, Barcelona, Catalonia, Spain; [Rodriguez-Bano, Jesus] Univ Hosp Virgen Macarena, Infect Dis & Microbiol Unit, Seville, Spain	University of Barcelona; Hospital Clinic de Barcelona; Hospital Universitario Virgen Macarena	Mestre, G (corresponding author), Delfos Med Ctr, Nosocomial Infect Control Unit, Barcelona, Catalonia, Spain.	mestre.ucin@centromedicodelfos.es	Rodríguez-Baño, Jesús/F-2453-2011	Rodríguez-Baño, Jesús/0000-0001-6732-9001	Ministerio de Ciencia e Innovacion, Instituto de Salud Carlos III; European Development Regional Fund "A way to achieve Europe'' ERDF, Spanish Network for the Research in Infectious Diseases [REIPI RD06/0008]	Ministerio de Ciencia e Innovacion, Instituto de Salud Carlos III(Instituto de Salud Carlos IIIMinistry of Science and Innovation, Spain (MICINN)Spanish Government); European Development Regional Fund "A way to achieve Europe'' ERDF, Spanish Network for the Research in Infectious Diseases	In January 2011, Lab HARTMANN S.A, provided 200 bottles of hydroalcoholic gel and gel dispensers as an unrestricted collaboration for an educational program in infection control in Delfos Medical Center. GMR provides part-time consultancy activities for Lab HARTMANN S.A since April 2011. JRB received funding for research from Ministerio de Ciencia e Innovacion, Instituto de Salud Carlos III - co-financed by European Development Regional Fund "A way to achieve Europe'' ERDF, Spanish Network for the Research in Infectious Diseases (REIPI RD06/0008). The other authors declare no conflicts of interest. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data. The funders had no role in the design of the study, analysis of the data, writing of the manuscript, or decision to publish.	Aboumatar H, 2012, INFECT CONT HOSP EP, V33, P144, DOI 10.1086/663707; Allegranzi B, 2009, J HOSP INFECT, V73, P305, DOI 10.1016/j.jhin.2009.04.019; Allegranzi B, 2011, LANCET, V377, P228, DOI 10.1016/S0140-6736(10)61458-4; Benneyan JC, 1998, INFECT CONT HOSP EP, V19, P265; Benneyan JC, 1998, INFECT CONT HOSP EP, V19, P194; Bero LA, 1998, BMJ-BRIT MED J, V317, P465; Boyce JM, 2011, INFECT CONT HOSP EP, V32, P1016, DOI 10.1086/662015; Carey R.G., 2003, IMPROVING HEALTHCARE; Cockburn J, 2004, MED J AUSTRALIA, V180, pS66; Cohen AL, 2008, INFECT CONT HOSP EP, V29, P901, DOI 10.1086/591741; Cummings KL, 2010, INFECT CONT HOSP EP, V31, P357, DOI 10.1086/651096; Curran E, 2008, J HOSP INFECT, V70, P127, DOI 10.1016/j.jhin.2008.06.013; D'Agata EMC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030170; Ebnother C, 2008, INFECT CONT HOSP EP, V29, P38, DOI 10.1086/524330; Eckmanns T, 2006, INFECT CONT HOSP EP, V27, P931, DOI 10.1086/507294; Erasmus V, 2009, INFECT CONT HOSP EP, V30, P415, DOI 10.1086/596773; Erasmus V, 2010, INFECT CONT HOSP EP, V31, P283, DOI 10.1086/650451; Gill AW, 2011, J HOSP INFECT, V78, P20, DOI 10.1016/j.jhin.2010.12.018; Gould DJ, 2007, J HOSP INFECT, V66, P109, DOI 10.1016/j.jhin.2007.02.009; Gould DJ, 2011, J HOSP INFECT, V77, P290, DOI 10.1016/j.jhin.2010.12.011; Grayson ML, 2008, MED J AUSTRALIA, V188, P633, DOI 10.5694/j.1326-5377.2008.tb01820.x; Hysong SJ, 2009, MED CARE, V47, P356, DOI 10.1097/MLR.0b013e3181893f6b; Jang JH, 2010, INFECT CONT HOSP EP, V31, P144, DOI 10.1086/649792; Johnson PDR, 2005, MED J AUSTRALIA, V183, P509, DOI 10.5694/j.1326-5377.2005.tb07151.x; Kohli E, 2009, INFECT CONT HOSP EP, V30, P222, DOI 10.1086/595692; Kretzer EK, 1998, AM J INFECT CONTROL, V26, P245, DOI 10.1016/S0196-6553(98)80008-4; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869, DOI DOI 10.1001/JAMA.1989.03430200113036; Larson EL, 2007, AM J INFECT CONTROL, V35, P666, DOI 10.1016/j.ajic.2006.10.006; Lee TC, 2009, INFECT CONT HOSP EP, V30, P249, DOI 10.1086/596042; MacDonald A, 2004, J HOSP INFECT, V56, P56, DOI 10.1016/S0195-6701(03)00293-7; MAYER JA, 1986, INFECT CONT HOSP EP, V7, P259, DOI 10.1017/S0195941700064171; Mohammed MA, 2008, QUAL SAF HEALTH CARE, V17, P137, DOI 10.1136/qshc.2004.012047; Mohammed MA, 2004, QUAL SAF HEALTH CARE, V13, P243, DOI 10.1136/qshc.2004.011650; Mohammed MA, 2001, LANCET, V357, P463, DOI 10.1016/S0140-6736(00)04019-8; Montgomery DC., 1991, INTRO STAT QUALITY C, V2nd ed.; Morton AP, 2007, J HOSP INFECT, V66, P296, DOI 10.1016/j.jhin.2007.04.019; Moulding NT, 1999, QUAL HEALTH CARE, V8, P177, DOI 10.1136/qshc.8.3.177; O'Boyle CA, 2001, AM J INFECT CONTROL, V29, P352, DOI 10.1067/mic.2001.18405; Pessoa-Silva CL, 2007, PEDIATRICS, V120, pE382, DOI 10.1542/peds.2006-3712; Pittet D, 2000, LANCET, V356, P1307, DOI 10.1016/S0140-6736(00)02814-2; Pittet D, 2004, ANN INTERN MED, V141, P1, DOI 10.7326/0003-4819-141-1-200407060-00008; Pittet D, 2001, EMERG INFECT DIS, V7, P234, DOI 10.3201/eid0702.010217; Pittet D, 2004, INFECT CONT HOSP EP, V25, P264, DOI 10.1086/502389; Pittet D, 2006, LANCET INFECT DIS, V6, P641, DOI 10.1016/S1473-3099(06)70600-4; Rose Louise, 2009, Intensive Crit Care Nurs, V25, P57, DOI 10.1016/j.iccn.2008.09.002; Sax H, 2007, J HOSP INFECT, V67, P9, DOI 10.1016/j.jhin.2007.06.004; Sax H, 2009, AM J INFECT CONTROL, V37, P827, DOI 10.1016/j.ajic.2009.07.003; SELLICK JA, 1993, INFECT CONT HOSP EP, V14, P649; Shewhart WA., 1931, EC CONTROL QUALITY M; Stewardson A, 2011, INFECT CONT HOSP EP, V32, P1029, DOI 10.1086/662023; Stone SP, 2007, LANCET INFECT DIS, V7, P282, DOI 10.1016/S1473-3099(07)70082-8; Thomas M, 2005, AM J INFECT CONTROL, V33, P368, DOI 10.1016/j.ajic.2005.03.011; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; Whitby M, 2007, J HOSP INFECT, V65, P1, DOI 10.1016/j.jhin.2006.09.026; Whitby M, 2006, INFECT CONT HOSP EP, V27, P484, DOI 10.1086/503335; Zerr DM, 2005, PEDIATR INFECT DIS J, V24, P397, DOI 10.1097/01.inf.0000160944.14878.2b	56	31	32	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 22	2012	7	10							e47200	10.1371/journal.pone.0047200	http://dx.doi.org/10.1371/journal.pone.0047200			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	025MM	23110061	Green Published, Green Submitted, gold			2023-01-03	WOS:000310193400007
J	Badri, DV; Chaparro, JM; Zhang, RF; Shen, QR; Vivanco, JM				Badri, Dayakar V.; Chaparro, Jacqueline M.; Zhang, Ruifu; Shen, Qirong; Vivanco, Jorge M.			Application of Natural Blends of Phytochemicals Derived from the Root Exudates of Arabidopsis to the Soil Reveal That Phenolic-related Compounds Predominantly Modulate the Soil Microbiome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL COMMUNITY STRUCTURE; RIBOSOMAL-RNA; PLANTS; PSEUDOMONAS; THALIANA; SIGNALS; IMPACT; ACTINOBACTERIA; STRIGOLACTONES; FLAVONOIDS	The roots of plants have the ability to influence its surrounding microbiology, the so-called rhizosphere microbiome, through the creation of specific chemical niches in the soil mediated by the release of phytochemicals. Here we report how these phytochemicals could modulate the microbial composition of a soil in the absence of the plant. For this purpose, root exudates of Arabidopsis were collected and fractionated to obtain natural blends of phytochemicals at various relative concentrations that were characterized by GC-MS and applied repeatedly to a soil. Soil bacterial changes were monitored by amplifying and pyro-sequencing the 16 S ribosomal small subunit region. Our analyses reveal that one phytochemical can culture different operational taxonomic units (OTUs), mixtures of phytochemicals synergistically culture groups of OTUs, and the same phytochemical can act as a stimulator or deterrent to different groups of OTUs. Furthermore, phenolic-related compounds showed positive correlation with a higher number of unique OTUs compared with other groups of compounds (i.e. sugars, sugar alcohols, and amino acids). For instance, salicylic acid showed positive correlations with species of Corynebacterineae, Pseudonocardineae and Streptomycineae, and GABA correlated with species of Sphingomonas, Methylobacterium, Frankineae, Variovorax, Micromonosporineae, and Skermanella. These results imply that phenolic compounds act as specific substrates or signaling molecules for a large group of microbial species in the soil.	[Badri, Dayakar V.; Chaparro, Jacqueline M.; Vivanco, Jorge M.] Colorado State Univ, Dept Hort & Landscape Architecture, Ft Collins, CO 80523 USA; [Badri, Dayakar V.; Chaparro, Jacqueline M.; Vivanco, Jorge M.] Colorado State Univ, Ctr Rhizosphere Biol, Ft Collins, CO 80523 USA; [Zhang, Ruifu; Shen, Qirong] Nanjing Agr Univ, Coll Resources & Environm Sci, Nanjing 210095, Jiangsu, Peoples R China	Colorado State University; Colorado State University; Nanjing Agricultural University	Zhang, RF (corresponding author), Nanjing Agr Univ, Coll Resources & Environm Sci, Nanjing 210095, Jiangsu, Peoples R China.	rfzhang@njau.edu.cn; j.vivanco@colostate.edu	Zhang, Ruifu/HDN-0340-2022; Zhang, Ruifu/HDN-0417-2022; Shen, Qirong/AAB-6531-2020		National Science Foundation [MCB0950857]; National Natural Science Foundation of China [41271271]; Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions; 111 Project [B12009]	National Science Foundation(National Science Foundation (NSF)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions; 111 Project(Ministry of Education, China - 111 Project)	This work was supported by National Science Foundation Grant MCB0950857 (to J.M.V.).; Supported by the National Natural Science Foundation of China (41271271) and the Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions.; Part of the 111 Project (B12009).	Abdel-Lateif K, 2012, PLANT SIGNAL BEHAV, V7, P636, DOI 10.4161/psb.20039; Akiyama K, 2005, NATURE, V435, P824, DOI 10.1038/nature03608; Arndt D, 2012, NUCLEIC ACIDS RES, V40, pW88, DOI 10.1093/nar/gks497; Badri DV, 2008, NEW PHYTOL, V179, P209, DOI 10.1111/j.1469-8137.2008.02458.x; Badri DV, 2008, PLANT PHYSIOL, V146, P762, DOI 10.1104/pp.107.109587; Badri DV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046640; Badri Dayakar V, 2012, Front Plant Sci, V3, P149, DOI 10.3389/fpls.2012.00149; Badri DV, 2009, CURR OPIN BIOTECH, V20, P642, DOI 10.1016/j.copbio.2009.09.014; Badri DV, 2009, PLANT PHYSIOL, V151, P2006, DOI 10.1104/pp.109.147462; Badri DV, 2009, PLANT CELL ENVIRON, V32, P666, DOI [10.1111/j.1365-3040.2009.01926.x, 10.1111/j.1365-3040.2008.01926.x]; Bais HP, 2004, TRENDS PLANT SCI, V9, P26, DOI 10.1016/j.tplants.2003.11.008; Bakker MG, 2012, PLANT SOIL, V360, P1, DOI 10.1007/s11104-012-1361-x; Barberan A, 2012, ISME J, V6, P343, DOI 10.1038/ismej.2011.119; Baudoin E, 2003, SOIL BIOL BIOCHEM, V35, P1183, DOI 10.1016/S0038-0717(03)00179-2; BEHERA B, 1974, SOIL SCI SOC AM J, V38, P591, DOI 10.2136/sssaj1974.03615995003800040021x; Berendsen RL, 2012, TRENDS PLANT SCI, V17, P478, DOI 10.1016/j.tplants.2012.04.001; Berg G, 2009, FEMS MICROBIOL ECOL, V68, P1, DOI 10.1111/j.1574-6941.2009.00654.x; Broeckling CD, 2008, APPL ENVIRON MICROB, V74, P738, DOI 10.1128/AEM.02188-07; Broughton WJ, 2003, PLANT SOIL, V252, P129, DOI 10.1023/A:1024179717780; Bulgarelli D, 2012, NATURE, V488, P91, DOI 10.1038/nature11336; Cai T, 2009, MOL MICROBIOL, V73, P507, DOI 10.1111/j.1365-2958.2009.06790.x; Castillo UF, 2007, MICROB ECOL, V53, P12, DOI 10.1007/s00248-006-9129-6; Chaparro JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055731; Chaparro JM, 2012, BIOL FERT SOILS, V48, P489, DOI 10.1007/s00374-012-0691-4; Chen G, 2003, RES MICROBIOL, V154, P393, DOI 10.1016/S0923-2508(03)00082-2; Chevrot R, 2006, P NATL ACAD SCI USA, V103, P7460, DOI 10.1073/pnas.0600313103; Conn VM, 2008, MOL PLANT MICROBE IN, V21, P208, DOI 10.1094/MPMI-21-2-0208; de Weert S, 2002, MOL PLANT MICROBE IN, V15, P1173, DOI 10.1094/MPMI.2002.15.11.1173; Dennis PG, 2010, FEMS MICROBIOL ECOL, V72, P313, DOI 10.1111/j.1574-6941.2010.00860.x; Dixon RA, 2001, NATURE, V411, P843, DOI 10.1038/35081178; Doornbos RF, 2012, AGRON SUSTAIN DEV, V32, P227, DOI 10.1007/s13593-011-0028-y; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Eilers KG, 2010, SOIL BIOL BIOCHEM, V42, P896, DOI 10.1016/j.soilbio.2010.02.003; Fiehn O, 2005, LECT NOTES COMPUT SC, V3615, P224; Fiehn O, 2008, PLANT J, V53, P691, DOI 10.1111/j.1365-313X.2007.03387.x; Hartmann A, 2009, PLANT SOIL, V321, P235, DOI 10.1007/s11104-008-9814-y; Hosie AHF, 2002, J BACTERIOL, V184, P4071, DOI 10.1128/JB.184.15.4071-4080.2002; Janssen PH, 2006, APPL ENVIRON MICROB, V72, P1719, DOI 10.1128/AEM.72.3.1719-1728.2006; Li X, 2010, MOL PLANT, V3, P91, DOI 10.1093/mp/ssp090; Lin YT, 2012, APPL SOIL ECOL, V60, P49, DOI 10.1016/j.apsoil.2012.03.001; Lundberg DS, 2012, NATURE, V488, P86, DOI 10.1038/nature11237; Mercado-Blanco J, 2007, ANTON LEEUW INT J G, V92, P367, DOI 10.1007/s10482-007-9167-1; Micallef SA, 2009, PLANT SIGNAL BEHAV, V4, P777, DOI 10.1093/jxb/erp053; Micallef SA, 2009, J EXP BOT, V60, P1729, DOI 10.1093/jxb/erp053; Neal AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035498; Nemergut DR, 2011, ENVIRON MICROBIOL, V13, P135, DOI 10.1111/j.1462-2920.2010.02315.x; Omrane S, 2009, PLANT SIGNAL BEHAV, V4, P1066, DOI 10.4161/psb.4.11.9735; Philippot L, 2010, NAT REV MICROBIOL, V8, P523, DOI 10.1038/nrmicro2367; Prithiviraj B, 2005, INFECT IMMUN, V73, P5319, DOI 10.1128/IAI.73.9.5319-5328.2005; Pruesse E, 2007, NUCLEIC ACIDS RES, V35, P7188, DOI 10.1093/nar/gkm864; Qin S, 2009, APPL ENVIRON MICROB, V75, P6176, DOI 10.1128/AEM.01034-09; Quince C, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-38; Raaijmakers JM, 2009, PLANT SOIL, V321, P341, DOI 10.1007/s11104-008-9568-6; Rudrappa T, 2008, PLANT PHYSIOL, V148, P1547, DOI 10.1104/pp.108.127613; Saleem M, 2007, J IND MICROBIOL BIOT, V34, P635, DOI 10.1007/s10295-007-0240-6; Sana TR, 2010, METABOLOMICS, V6, P451, DOI 10.1007/s11306-010-0218-7; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Singh BK, 2007, APPL SOIL ECOL, V36, P147, DOI 10.1016/j.apsoil.2007.01.004; Somers E, 2004, CRIT REV MICROBIOL, V30, P205, DOI 10.1080/10408410490468786; Sood SG, 2003, FEMS MICROBIOL ECOL, V45, P219, DOI 10.1016/S0168-6496(03)00155-7; Speed T. P., 2003, STAT ANAL GENE EXPRE, P222; Steinkellner S, 2007, MOLECULES, V12, P1290, DOI 10.3390/12071290; Walker TS, 2003, PLANT PHYSIOL, V132, P44, DOI 10.1104/pp.102.019661; Wallace RJ, 2004, P NUTR SOC, V63, P621, DOI 10.1079/PNS2004393; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Yoneyama K, 2008, NEW PHYTOL, V179, P484, DOI 10.1111/j.1469-8137.2008.02462.x; Zhang J, 2009, PLANT J, V57, P171, DOI 10.1111/j.1365-313X.2008.03676.x	67	291	307	15	52	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2013	288	7					4502	4512		10.1074/jbc.M112.433300	http://dx.doi.org/10.1074/jbc.M112.433300			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	095ND	23293028	hybrid, Green Published			2023-01-03	WOS:000315340400001
J	Kim, BW; Koppula, S; Hong, SS; Jeon, SB; Kwon, JH; Hwang, BY; Park, EJ; Choi, DK				Kim, Byung-Wook; Koppula, Sushruta; Hong, Seong-Su; Jeon, Sae-Bom; Kwon, Ji-Hye; Hwang, Bang-Yeon; Park, Eun-Jung; Choi, Dong-Kug			Regulation of Microglia Activity by Glaucocalyxin-A: Attenuation of Lipopolysaccharide-Stimulated Neuroinflammation through NF-kappa B and p38 MAPK Signaling Pathways	PLOS ONE			English	Article							ACTIVATED PROTEIN-KINASE; NITRIC-OXIDE SYNTHASE; LIPOCALIN 2 REGULATION; TNF-ALPHA RELEASE; INFLAMMATORY RESPONSE; KAURANE DITERPENOIDS; PARKINSONS-DISEASE; INTERFERON-GAMMA; ISODON-JAPONICUS; GLIAL-CELLS	Microglial cells are the resident macrophages and intrinsic arm of the central nervous system innate immune defense. Microglial cells become activated in response to injury, infection, environmental toxins, and other stimuli that threaten neuronal survival. Therefore, regulating microglial activation may have therapeutic benefits that lead to alleviating the progression of inflammatory-mediated neurodegeneration. In the present study, we investigated the effect of glaucocalyxin A (GLA) isolated from Rabdosia japonica on the production of pro-inflammatory mediators in lipopolysaccharide (LPS)-stimulated primary microglia and BV-2 cells. GLA significantly inhibited LPS-induced production of nitric oxide and reversed the morphological changes in primary microglia. Further, GLA suppressed expression of inducible nitric oxide synthase and cyclooxygenase-2 dose-dependently at the mRNA and protein levels. The production of proinflammatory cytokines such as tumor necrosis factor-alpha, interleukin-1 beta (IL)-1 beta, and IL-6 were inhibited by suppressing their transcriptional activity. Furthermore, GLA suppressed nuclear factor-kappa B activation by blocking degradation of I kappa B-alpha and inhibited the induction of lipocalin-2 expression in LPS-stimulated BV-2 cells. Mechanistic study revealed that the inhibitory effects of GLA were accompanied by blocking the p38 mitogen activated protein kinase signaling pathway in activated microglia. In conclusion, given that microglial activation contributes to the pathogenesis of neurodegenerative diseases, GLA could be developed as a potential therapeutic agent for treating microglia-mediated neuroinflammatory diseases.	[Kim, Byung-Wook; Koppula, Sushruta; Kwon, Ji-Hye; Choi, Dong-Kug] Konkuk Univ, Coll Biomed & Hlth Sci, Dept Biotechnol, Chungju, South Korea; [Hong, Seong-Su; Hwang, Bang-Yeon] Chungbuk Natl Univ, Coll Pharm, Cheongju, South Korea; [Hong, Seong-Su; Hwang, Bang-Yeon] Chungbuk Natl Univ, Med Res Ctr CICT, Cheongju, South Korea; [Jeon, Sae-Bom; Park, Eun-Jung] Natl Canc Ctr, Branch Immune Therapy, Goyang, South Korea; [Jeon, Sae-Bom; Park, Eun-Jung] Natl Canc Ctr, Branch Cell Therapy, Goyang, South Korea	Konkuk University; Chungbuk National University; Chungbuk National University; National Cancer Center - Korea (NCC); National Cancer Center - Korea (NCC)	Choi, DK (corresponding author), Konkuk Univ, Coll Biomed & Hlth Sci, Dept Biotechnol, Chungju, South Korea.	choidk@kku.ac.kr	Koppula, Sushruta/F-2817-2013; KIM, Byungwook/U-2187-2017	Koppula, Sushruta/0000-0002-8597-7763; KIM, Byungwook/0000-0001-8390-7713; Choi, Dong-Kug/0000-0001-7041-1524	Basic Science Research Program through the National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology [2011-0014923]; Regional Innovation Center (RIC) Program of the Ministry of Knowledge Economy through the Bio-Food & Drug Research Center at Konkuk University, Korea	Basic Science Research Program through the National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Regional Innovation Center (RIC) Program of the Ministry of Knowledge Economy through the Bio-Food & Drug Research Center at Konkuk University, Korea	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2011-0014923) and also supported by the Regional Innovation Center (RIC) Program of the Ministry of Knowledge Economy through the Bio-Food & Drug Research Center at Konkuk University, Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aigner F, 2007, AM J TRANSPLANT, V7, P779, DOI 10.1111/j.1600-6143.2006.01723.x; Ashwell JD, 2006, NAT REV IMMUNOL, V6, P532, DOI 10.1038/nri1865; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Block ML, 2006, FASEB J, V20, P251, DOI 10.1096/fj.05-4553com; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; Boche D, 2003, J CEREBR BLOOD F MET, V23, P1174, DOI 10.1097/01.WCB.0000090080.64176.44; Boche D, 2006, NEUROBIOL DIS, V22, P638, DOI 10.1016/j.nbd.2006.01.004; Bonaiuto C, 1997, J NEUROIMMUNOL, V77, P51, DOI 10.1016/S0165-5728(97)00054-4; Branger J, 2002, J IMMUNOL, V168, P4070, DOI 10.4049/jimmunol.168.8.4070; Brenneman DE, 1996, J CLIN INVEST, V97, P2299, DOI 10.1172/JCI118672; Caivano M, 1998, FEBS LETT, V429, P249, DOI 10.1016/S0014-5793(98)00578-X; Carmody RJ, 2007, CELL MOL IMMUNOL, V4, P31; Choi Y, 2008, INT IMMUNOPHARMACOL, V8, P548, DOI 10.1016/j.intimp.2007.12.010; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; Couch Y, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-166; Cowland JB, 2003, J IMMUNOL, V171, P6630, DOI 10.4049/jimmunol.171.12.6630; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; Devireddy LR, 2005, CELL, V123, P1293, DOI 10.1016/j.cell.2005.10.027; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104; Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097-2765(02)00708-6; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Hong SS, 2008, J NAT PROD, V71, P1055, DOI 10.1021/np0705965; Hong SS, 2007, J NAT PROD, V70, P632, DOI 10.1021/np060638+; Ip JPK, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-124; Jeohn GH, 2002, NEUROSCIENCE, V114, P689, DOI 10.1016/S0306-4522(02)00356-1; Jung WK, 2009, FOOD CHEM TOXICOL, V47, P410, DOI 10.1016/j.fct.2008.11.041; Kim BW, 2011, J PHARMACOL SCI, V116, P296, DOI 10.1254/jphs.10324FP; KIM DS, 1992, PHYTOCHEMISTRY, V31, P697, DOI 10.1016/0031-9422(92)90064-W; Le WD, 2001, J NEUROSCI, V21, P8447, DOI 10.1523/JNEUROSCI.21-21-08447.2001; LEE SC, 1993, J IMMUNOL, V150, P2659; Lee S, 2007, J IMMUNOL, V179, P3231, DOI 10.4049/jimmunol.179.5.3231; Lee S, 2011, J BIOL CHEM, V286, P43855, DOI 10.1074/jbc.M111.299248; Li C, 2011, CYTOKINE, V56, P435, DOI 10.1016/j.cyto.2011.07.021; Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006; Miharada K, 2008, J CELL PHYSIOL, V215, P526, DOI 10.1002/jcp.21334; Minghetti L, 2004, J NEUROPATH EXP NEUR, V63, P901, DOI 10.1093/jnen/63.9.901; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Moss DW, 2001, EUR J NEUROSCI, V13, P529, DOI 10.1046/j.1460-9568.2001.01418.x; Murphy S, 2000, GLIA, V29, P1, DOI 10.1002/(SICI)1098-1136(20000101)29:1<1::AID-GLIA1>3.0.CO;2-N; Oh YT, 2009, NEUROSCI LETT, V464, P93, DOI 10.1016/j.neulet.2009.08.040; Qin LY, 2005, ANN NY ACAD SCI, V1053, P107, DOI 10.1196/annals.1344.009; Ramirez BG, 2005, J NEUROSCI, V25, P1904, DOI 10.1523/JNEUROSCI.4540-04.2005; Rivest S, 2006, NEURON, V49, P4, DOI 10.1016/j.neuron.2005.12.004; Roudkenar MH, 2009, EXP CELL RES, V315, P3140, DOI 10.1016/j.yexcr.2009.08.019; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; St-Onge M, 2007, BBA-MOL CELL BIOL L, V1771, P1235, DOI 10.1016/j.bbalip.2007.06.002; Sun HD, 2006, NAT PROD REP, V23, P673, DOI 10.1039/b604174d; Svensson CI, 2003, J NEUROCHEM, V86, P1534, DOI 10.1046/j.1471-4159.2003.01969.x; Teismann P, 2003, MOVEMENT DISORD, V18, P121, DOI 10.1002/mds.10332; Wang W, 2003, J NEUROCHEM, V84, P189, DOI 10.1046/j.1471-4159.2003.01544.x; Zhang JH, 2008, MOL ENDOCRINOL, V22, P1416, DOI 10.1210/me.2007-0420	54	81	83	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2013	8	2							e55792	10.1371/journal.pone.0055792	http://dx.doi.org/10.1371/journal.pone.0055792			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	086NV	23393601	Green Submitted, gold, Green Published			2023-01-03	WOS:000314692800056
J	Joynt, KE; Jha, AK				Joynt, Karen E.; Jha, Ashish K.			Characteristics of Hospitals Receiving Penalties Under the Hospital Readmissions Reduction Program	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							RATES; RACE; CARE		[Joynt, Karen E.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; [Jha, Ashish K.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Joynt, KE (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.	kjoynt@partners.org			NHLBI NIH HHS [1K23HL109177-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL109177] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Centers for Medicare & Medicaid Services, 2012, FY 2013 IPPS FIN RUL; Jha AK, 2009, NEW ENGL J MED, V361, P2637, DOI 10.1056/NEJMsa0904859; Joynt KE, 2011, JAMA-J AM MED ASSOC, V305, P675, DOI 10.1001/jama.2011.123; Rathore SS, 2003, JAMA-J AM MED ASSOC, V289, P2517, DOI 10.1001/jama.289.19.2517; Vartak S, 2008, MED CARE, V46, P25, DOI 10.1097/MLR.0b013e3181484927	5	381	381	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 23	2013	309	4					342	343		10.1001/jama.2012.94856	http://dx.doi.org/10.1001/jama.2012.94856			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074FT	23340629	Bronze			2023-01-03	WOS:000313799000015
J	Klein, HG				Klein, Harvey G.			Should Blood Be an Essential Medicine?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NIH, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Klein, HG (corresponding author), NIH, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA.							Akech SO, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-256; American Association of Blood Banks (AABB), 2012, AABB STAND BLOOD BAN; European Directorate for the Quality of Medicines & Health Care, 2010, GUID PREP US QUAL AS; Klein HG, 2007, LANCET, V370, P415, DOI 10.1016/S0140-6736(07)61197-0; World Health organization, 2003, SEL US ESS MED	5	20	21	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 17	2013	368	3					199	201		10.1056/NEJMp1213134	http://dx.doi.org/10.1056/NEJMp1213134			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	070YG	23323895				2023-01-03	WOS:000313549900002
J	Walensky, RP; Sax, PE; Nakamura, YM; Weinstein, MC; Pei, PP; Freedberg, KA; Paltiel, AD; Schackman, BR				Walensky, Rochelle P.; Sax, Paul E.; Nakamura, Yoriko M.; Weinstein, Milton C.; Pei, Pamela P.; Freedberg, Kenneth A.; Paltiel, A. David; Schackman, Bruce R.			Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States	ANNALS OF INTERNAL MEDICINE			English	Article							TREATMENT-NAIVE PATIENTS; COMBINATION THERAPY; HIV-1 INFECTION; DOUBLE-BLIND; EFFICACY; EMTRICITABINE; TENOFOVIR; VIRUS; ADHERENCE; REGIMEN	Background: U. S. HIV treatment guidelines recommend branded once-daily, 1-pill efavirenz-emtricitabine-tenofovir as first-line antiretroviral therapy (ART). With the anticipated approval of generic efavirenz in the United States, a once-daily, 3-pill alternative (generic efavirenz, generic lamivudine, and tenofovir) will decrease cost but may reduce adherence and virologic suppression. Objective: To assess the clinical effect, costs, and cost-effectiveness of a 3-pill, generic-based regimen compared with a branded, co-formulated regimen and to project the potential national savings in the first year of a switch to generic-based ART. Design: Mathematical simulation of HIV disease. Setting: United States. Patients: HIV-infected persons. Intervention: No ART (for comparison); 3-pill, generic-based ART; and branded ART. Measurements: Quality-adjusted life expectancy, costs, and incremental cost-effectiveness ratios (ICERs) in dollars per qualityadjusted life-year (QALY). Results: Compared with no ART, generic-based ART has an ICER of $ 21 100/QALY. Compared with generic-based ART, branded ART increases lifetime costs by $ 42 500 and per-person survival gains by 0.37 QALYs for an ICER of $ 114 800/QALY. Estimated first-year savings, if all eligible U. S. patients start or switch to generic-based ART, are $ 920 million. Most plausible assumptions about generic-based ART efficacy and costs lead to branded ART ICERs greater than $ 100 000/QALY. Limitation: The efficacy and price reduction associated with generic drugs are unknown, and estimates are intended to be conservative. Conclusion: Compared with a slightly less effective generic-based regimen, the cost-effectiveness of first-line branded ART exceeds $ 100 000/QALY. Generic-based ART in the United States could yield substantial budgetary savings to HIV programs.	[Walensky, Rochelle P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Brigham & Womens Hosp, Div Infect Dis,Med Practice Evaluat Ctr, Boston, MA 02114 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02114 USA; Yale Univ, Sch Med, New Haven, CT USA; Weill Cornell Med Coll, New York, NY USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Yale University; Cornell University	Walensky, RP (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,Brigham & Womens Hosp, Div Infect Dis,Med Practice Evaluat Ctr, 50 Staniford St,9th Floor, Boston, MA 02114 USA.		Schackman, Bruce R./J-8208-2019	Schackman, Bruce R./0000-0002-1132-2932; Walensky, Rochelle P./0000-0002-8795-379X	National Institute of Allergy and Infectious Diseases [R37-AI42006, R01-AI093269]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI042006, R01AI093269, R01AI042006, P30AI060354] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	By grants R37-AI42006 and R01-AI093269 from the National Institute of Allergy and Infectious Diseases.	Althoff KN, 2010, CLIN INFECT DIS, V50, P1512, DOI 10.1086/652650; [Anonymous], 2010, NAT HIV AIDS STRAT U; Bamezai A, 2005, ANN EMERG MED, V45, P483, DOI 10.1016/j.annemergmed.2004.08.029; Bangsberg DR, 2010, AIDS, V24, P2835, DOI 10.1097/QAD.0b013e328340a209; Berndt ER, 2007, HEALTH AFFAIR, V26, P790, DOI 10.1377/hlthaff.26.3.790; Braithwaite RS, 2008, MED CARE, V46, P349, DOI 10.1097/MLR.0b013e31815c31a7; Braithwaite RS, 2003, MED DECIS MAKING, V23, P562; Buscher A, 2012, INT J STD AIDS, V23, P351, DOI 10.1258/ijsa.2011.011292; Centers for Disease Control and Prevention, 2011, NEW HOP STOPP HIV TE; Centers for Medicare & Medicaid Services, 2012, CLIN LAB FEE SHED; Cohen C, 2012, 52 INT C ANT CHEM SA; Cutler DM, 2006, NEW ENGL J MED, V355, P920, DOI 10.1056/NEJMsa054744; Department of Economic and Social Affairs Population Division, 2009, WORLD POP PROSP 2008; Freedberg KA, 2001, NEW ENGL J MED, V344, P824, DOI 10.1056/NEJM200103153441108; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243; Gebo KA, 2005, JAIDS-J ACQ IMM DEF, V38, P96, DOI 10.1097/00126334-200501010-00017; Gopalappa C, 2012, JAIDS-J ACQ IMM DEF, V61, P99, DOI 10.1097/QAI.0b013e31825bd862; Grinsztejn B, 2007, LANCET, V369, P1261, DOI 10.1016/S0140-6736(07)60597-2; Gulick RM, 2008, NEW ENGL J MED, V359, P1429, DOI 10.1056/NEJMoa0803152; Hoerger TJ, 2002, JAMA-J AM MED ASSOC, V287, P2542; *I MED, 2003, HIDD COSTS VAL LOST; Johnson M, 2005, AIDS, V19, P685, DOI 10.1097/01.aids.0000166091.39317.99; Johnson MA, 2006, JAIDS-J ACQ IMM DEF, V43, P153, DOI 10.1097/01.qai.0000242449.67155.1a; Lennox JL, 2009, LANCET, V374, P796, DOI 10.1016/S0140-6736(09)60918-1; Levinson D., 2005, MEDICAID DRUG PRICE; Linas BP, 2012, CLIN INFECT DIS, V55, P279, DOI 10.1093/cid/cis382; Martin EG, 2012, JAIDS-J ACQ IMM DEF, V60, P72, DOI 10.1097/QAI.0b013e31824c0dd4; McKinnell JA, 2010, AIDS PATIENT CARE ST, V24, P79, DOI 10.1089/apc.2009.0220; *NAT TECHN INF SER, 1995, MULT AIDS COH STUD M; National Alliance of State & Territorial AIDS Directors, 2011, HIV VIR HEP COINF; Nelson M, 2005, JAIDS-J ACQ IMM DEF, V40, P404, DOI 10.1097/01.qai.0000185314.56556.c3; Oguamanam A. C. O., 2012, THESIS MORGAN STATE; Paltiel AD, 2009, CLIN INFECT DIS, V48, P806, DOI 10.1086/597095; Paltiel AD, 2005, NEW ENGL J MED, V352, P586, DOI 10.1056/NEJMsa042088; Panel on Antiretroviral Guidelines for Adults and Adolescents, 2012, GUID US ANT AG HIV 1; Prejean J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017502; Rousseau FS, 2003, J INFECT DIS, V188, P1652, DOI 10.1086/379667; Rydzak CE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012647; Sax PE, 2012, LANCET, V379, P2439, DOI 10.1016/S0140-6736(12)60917-9; Sax PE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031591; Sax PE, 2012, GEN LAM HAS ARR HIV; Schinazi RF, 2003, JAIDS-J ACQ IMM DEF, V34, P243, DOI 10.1097/00126334-200310010-00017; Seage GR, 2001, AM J EPIDEMIOL, V153, P619, DOI 10.1093/aje/153.7.619; Shenouda N., 2009, RED BOOK; Svicher V, 2010, JAIDS-J ACQ IMM DEF, V55, P336, DOI 10.1097/QAI.0b013e3181e6763f; Swiss HIV Cohort Study & Mother and Child HIV Cohort Study, 2012, SWISS HIV COHORT STU; Tang MW, 2012, CLIN INFECT DIS, V54, P862, DOI 10.1093/cid/cir1034; The Economist, 2012, ECONOMIST; The Henry J. Kaiser Family Foundation, 2012, US FED FUND HIV AIDS; Thompson MA, 2012, ANN INTERN MED, V156, P817, DOI 10.7326/0003-4819-156-11-201206050-00419; U.S. Food and Drug Administration, 2012, FACTS GEN DRUGS; U.S. Food and Drug Administration, 2012, APPR TENT APPR ANT A; Ubel PA, 2003, ARCH INTERN MED, V163, P1637, DOI 10.1001/archinte.163.14.1637; United States Food and Drug Administration, 2012, OR BOOK APPR DRUG PR; University HealthSystem Consortium, 2009, 2006 2008 COST DAT; Valdiserri R, 2011, PROPOSED NATL HIV AI; Walensky RP, 2010, CLIN INFECT DIS, V51, P392, DOI 10.1086/655130; Weinstein M C, 2001, Value Health, V4, P348, DOI 10.1046/j.1524-4733.2001.45061.x; Weinstein MC., 1996, COST EFFECTIVENESS H	60	111	111	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	2013	158	2					84	+		10.7326/0003-4819-158-2-201301150-00002	http://dx.doi.org/10.7326/0003-4819-158-2-201301150-00002			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	077LO	23318310	Green Accepted			2023-01-03	WOS:000314029400014
J	Eckert, JJ; Porter, R; Watkins, AJ; Burt, E; Brooks, S; Leese, HJ; Humpherson, PG; Cameron, IT; Fleming, TP				Eckert, Judith J.; Porter, Richard; Watkins, Adam J.; Burt, Elizabeth; Brooks, Suzanne; Leese, Henry J.; Humpherson, Peter G.; Cameron, Iain T.; Fleming, Tom P.			Metabolic Induction and Early Responses of Mouse Blastocyst Developmental Programming following Maternal Low Protein Diet Affecting Life-Long Health	PLOS ONE			English	Article							IN-VITRO CULTURE; FEMALE REPRODUCTIVE-TRACT; SYSTOLIC BLOOD-PRESSURE; MTOR COMPLEX 1; AMINO-ACIDS; LONG-TERM; PREIMPLANTATION EMBRYO; FETAL-GROWTH; EARLY-PREGNANCY; DISEASE	Previously, we have shown that a maternal low protein diet, fed exclusively during the preimplantation period of mouse development (Emb-LPD), is sufficient to induce by the blastocyst stage a compensatory growth phenotype in late gestation and postnatally, correlating with increased risk of adult onset cardiovascular disease and behavioural dysfunction. Here, we examine mechanisms of induction of maternal Emb-LPD programming and early compensatory responses by the embryo. Emb-LPD induced changes in maternal serum metabolites at the time of blastocyst formation (E3.5), notably reduced insulin and increased glucose, together with reduced levels of free amino acids (AAs) including branched chain AAs leucine, isoleucine and valine. Emb-LPD also caused reduction in the branched chain AAs within uterine fluid at the blastocyst stage. These maternal changes coincided with an altered content of blastocyst AAs and reduced mTORC1 signalling within blastocysts evident in reduced phosphorylation of effector S6 ribosomal protein and its ratio to total S6 protein but no change in effector 4E-BP1 phosphorylated and total pools. These changes were accompanied by increased proliferation of blastocyst trophectoderm and total cells and subsequent increased spreading of trophoblast cells in blastocyst outgrowths. We propose that induction of metabolic programming following Emb-LPD is achieved through mTORC1signalling which acts as a sensor for preimplantation embryos to detect maternal nutrient levels via branched chain AAs and/or insulin availability. Moreover, this induction step associates with changes in extra-embryonic trophectoderm behaviour occurring as early compensatory responses leading to later nutrient recovery.	[Eckert, Judith J.; Porter, Richard; Watkins, Adam J.; Burt, Elizabeth; Brooks, Suzanne; Fleming, Tom P.] Univ Southampton, Southampton Gen Hosp, Ctr Biol Sci, Southampton, Hants, England; [Eckert, Judith J.; Cameron, Iain T.] Univ Southampton, Fac Med, Southampton Gen Hosp, Southampton SO9 5NH, Hants, England; [Leese, Henry J.] Univ Hull, Hull York Med Sch, Ctr Cardiovasc & Metab Res, Kingston Upon Hull HU6 7RX, N Humberside, England; [Humpherson, Peter G.] Univ York, Dept Biol, York YO10 5DD, N Yorkshire, England	University of Southampton; University of Southampton; University of Hull; University of York - UK; University of York - UK	Fleming, TP (corresponding author), Univ Southampton, Southampton Gen Hosp, Ctr Biol Sci, Southampton, Hants, England.	tpf@soton.ac.uk	Watkins, Adam/AAH-9401-2021; Watkins, Adam J/J-4839-2013	Watkins, Adam/0000-0002-0842-1251; Watkins, Adam J/0000-0002-0842-1251; Burt, Elizabeth/0000-0003-3801-0151	BBSRC [BB/F007450/1, BB/I001840/1]; Biotechnology and Biological Sciences Research Council [BB/I001840/1, BB/F007450/1] Funding Source: researchfish	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The authors are grateful for BBSRC funding (BB/F007450/1, BB/I001840/1) to TPF and JJE in support of this research project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Armant DR, 2005, DEV BIOL, V280, P260, DOI 10.1016/j.ydbio.2005.02.009; Banrezes B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029388; Barker DJP, 2007, J INTERN MED, V261, P412, DOI 10.1111/j.1365-2796.2007.01809.x; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; Basatemur E, 2008, PLACENTA, V29, pS135, DOI 10.1016/j.placenta.2008.08.013; Carling D, 2012, BIOCHEM J, V445, P11, DOI 10.1042/BJ20120546; Ceelen M, 2008, J CLIN ENDOCR METAB, V93, P1682, DOI 10.1210/jc.2007-2432; Cheng ZY, 2010, TRENDS ENDOCRIN MET, V21, P589, DOI 10.1016/j.tem.2010.06.005; CHISHOLM JC, 1985, J EMBRYOL EXP MORPH, V86, P311; Choo AY, 2009, CELL CYCLE, V8, P567, DOI 10.4161/cc.8.4.7659; Coan PM, 2011, J PHYSIOL-LONDON, V589, P3659, DOI 10.1113/jphysiol.2011.208629; Douglas AJ, 2011, PROG NEURO-PSYCHOPH, V35, P1167, DOI 10.1016/j.pnpbp.2010.07.024; Dowling RJO, 2010, BBA-PROTEINS PROTEOM, V1804, P433, DOI 10.1016/j.bbapap.2009.12.001; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Dumoulin JC, 2010, HUM REPROD, V25, P605, DOI 10.1093/humrep/dep456; DUNGLISON GF, 1995, J REPROD FERTIL, V105, P115, DOI 10.1530/jrf.0.1050115; Duranthon V, 2008, REPRODUCTION, V135, P141, DOI 10.1530/REP-07-0324; Ecker DJ, 2004, P NATL ACAD SCI USA, V101, P1595, DOI 10.1073/pnas.0306846101; Fernandez-Gonzalez R, 2004, P NATL ACAD SCI USA, V101, P5880, DOI 10.1073/pnas.0308560101; Fernandez-Gonzalez R, 2007, MOL REPROD DEV, V74, P1149, DOI 10.1002/mrd.20746; Fleming TP, 2012, ANIM REPROD SCI, V130, P193, DOI 10.1016/j.anireprosci.2012.01.015; Fleming TP, 2004, BIOL REPROD, V71, P1046, DOI 10.1095/biolreprod.104.030957; Gangloff YG, 2004, MOL CELL BIOL, V24, P9508, DOI 10.1128/MCB.24.21.9508-9516.2004; Gardner DS, 2004, HYPERTENSION, V43, P1290, DOI 10.1161/01.HYP.0000126991.67203.7b; Godfrey KM, 2010, TRENDS ENDOCRIN MET, V21, P199, DOI 10.1016/j.tem.2009.12.008; Gonzalez IM, 2012, DEV BIOL, V361, P286, DOI 10.1016/j.ydbio.2011.10.021; Groebner AE, 2011, REPRODUCTION, V141, P685, DOI 10.1530/REP-10-0533; Guzelogiu-Kayisli Z, 2009, SEMIN REPROD MED, V27, P62, DOI 10.1055/s-0028-1108011; HANDYSIDE AH, 1984, J EXP ZOOL, V231, P429, DOI 10.1002/jez.1402310317; Hardy K, 2002, J ENDOCRINOL, V172, P221, DOI 10.1677/joe.0.1720221; Harris SE, 2005, THERIOGENOLOGY, V64, P992, DOI 10.1016/j.theriogenology.2005.01.004; Hernandez CE, 2010, PHYSIOL BEHAV, V101, P588, DOI 10.1016/j.physbeh.2010.08.020; Heyner S, 1997, Early Pregnancy, V3, P153; Hong J, 2007, THERIOGENOLOGY, V68, P728, DOI 10.1016/j.theriogenology.2007.06.002; Jungheim ES, 2008, SEMIN REPROD MED, V26, P186, DOI 10.1055/s-2008-1042957; Kaye Peter L., 1995, Progress in Growth Factor Research, V6, P1, DOI 10.1016/0955-2235(95)00001-1; Kaye PL, 1999, HUM REPROD, V14, P3052, DOI 10.1093/humrep/14.12.3052; Kim E, 2009, NUTR RES PRACT, V3, P64, DOI 10.4162/nrp.2009.3.1.64; Koga K, 2008, REPROD SCI, V15, P231, DOI 10.1177/1933719108316391; Kwong WY, 2000, DEVELOPMENT, V127, P4195; LAMB VK, 1994, J REPROD FERTIL, V102, P169, DOI 10.1530/jrf.0.1020169; Lane M, 1997, J REPROD FERTIL, V109, P153, DOI 10.1530/jrf.0.1090153; LANGLEY SC, 1994, CLIN SCI, V86, P217, DOI 10.1042/cs0860217; Langley-Evans SC, 2010, MED PRIN PRACT, V19, P87, DOI 10.1159/000273066; Leese HJ, 2008, REPROD FERT DEVELOP, V20, P1, DOI 10.1071/RD07153; Mahsoudi B, 2007, BIOL REPROD, V77, P889, DOI 10.1095/biolreprod.106.057885; Martin PM, 2003, BIOL REPROD, V69, P1101, DOI 10.1095/biolreprod.103.018010; Martin PM, 2001, DEV BIOL, V240, P182, DOI 10.1006/dbio.2001.0461; Mitchell M, 2009, BIOL REPROD, V80, P622, DOI 10.1095/biolreprod.108.072595; Morgan HD, 2008, BIOL REPROD, V79, P618, DOI 10.1095/biolreprod.108.068213; Nawroth R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027509; Pampfer S, 2000, J REPROD FERTIL, P129; Partridge RJ, 1996, REPROD FERT DEVELOP, V8, P945, DOI 10.1071/RD9960945; Peterson RT, 1998, CURR BIOL, V8, pR248, DOI 10.1016/S0960-9822(98)70152-6; Petrie L, 2002, BRIT J NUTR, V88, P471, DOI 10.1079/BJN2002695; Proud CG, 2007, BIOCHEM SOC T, V35, P1187, DOI 10.1042/BST0351187; Richards T, 2010, BIOL REPROD, V82, P769, DOI 10.1095/biolreprod.109.081646; Robertson SA, 2007, CYTOKINE GROWTH F R, V18, P287, DOI 10.1016/j.cytogfr.2007.04.008; Satterfield MC, 2010, BIOL REPROD, V82, P224, DOI 10.1095/biolreprod.109.076729; SCHULTZ GA, 1981, J REPROD FERTIL, V61, P387, DOI 10.1530/jrf.0.0610387; Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026; Sinclair KD, 2007, P NATL ACAD SCI USA, V104, P19351, DOI 10.1073/pnas.0707258104; Sinclair KD, 2007, THERIOGENOLOGY, V67, P43, DOI 10.1016/j.theriogenology.2006.09.017; Sjoblom C, 2005, ENDOCRINOLOGY, V146, P2142, DOI 10.1210/en.2004-1260; SPINDLE A, 1995, THERIOGENOLOGY, V44, P761, DOI 10.1016/0093-691X(95)00275-D; Suzuki C, 2007, ZYGOTE, V15, P317, DOI 10.1017/S0967199407004273; Taylor PM, 2009, BIOCHEM SOC T, V37, P237, DOI 10.1042/BST0370237; Thompson JG, 2007, REPROD FERT DEVELOP, V19, P43, DOI 10.1071/RD06129; Torrens C, 2009, EXP PHYSIOL, V94, P1024, DOI 10.1113/expphysiol.2009.047340; Van Winkle LJ, 2006, HUM REPROD UPDATE, V12, P145, DOI 10.1093/humupd/dmi044; VANWINKLE LJ, 1995, BIOL REPROD, V52, P96, DOI 10.1095/biolreprod52.1.96; Wang XZ, 2009, STUD FUZZ SOFT COMP, V245, P1; Watkins AJ, 2008, SEMIN REPROD MED, V26, P175, DOI 10.1055/s-2008-1042956; Watkins AJ, 2008, BIOL REPROD, V78, P299, DOI 10.1095/biolreprod.107.064220; Watkins AJ, 2007, P NATL ACAD SCI USA, V104, P5449, DOI 10.1073/pnas.0610317104; Watkins AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028745; Watkins AJ, 2010, BRIT J NUTR, V103, P1762, DOI 10.1017/S0007114509993783; Zhao XM, 2000, DEVELOPMENT, V127, P2643	78	82	84	0	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2012	7	12							e52791	10.1371/journal.pone.0052791	http://dx.doi.org/10.1371/journal.pone.0052791			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	061EA	23300778	gold, Green Published, Green Accepted			2023-01-03	WOS:000312829100083
J	Dube, ALN; Baschieri, A; Cleland, J; Floyd, S; Molesworth, A; Parrott, F; French, N; Glynn, JR				Dube, Albert L. N.; Baschieri, Angela; Cleland, John; Floyd, Sian; Molesworth, Anna; Parrott, Fiona; French, Neil; Glynn, Judith R.			Fertility Intentions and Use of Contraception among Monogamous Couples in Northern Malawi in the Context of HIV Testing: A Cross-Sectional Analysis	PLOS ONE			English	Article							POSITIVE WOMEN; ANTIRETROVIRAL THERAPY; REPRODUCTIVE HEALTH; SOUTH-AFRICA; DESIRES; MEN; PREFERENCES; INFECTION; PREGNANCY; HIV/AIDS	Context: Knowledge of HIV status may influence fertility desires of married men and women. There is little knowledge about the importance of this influence among monogamously married couples and how knowledge of HIV status influences use of contraception among these couples. Methodology: We carried out a cross-sectional analysis of interview data collected between October 2008 and September 2009 on men aged 15-59 years and women aged 15-49 years who formed 1766 monogamously married couples within the Karonga Prevention Study demographic surveillance study in northern Malawi. Results: 5% of men and 4% of women knew that they were HIV positive at the time of interview and 81% of men and 89% of women knew that they were HIV negative. 73% of men and 83% of women who knew that they were HIV positive stated that they did not want more children, compared to 35% of men and 38% of women who knew they were HIV negative. Concordant HIV positive couples were more likely than concordant negative couples to desire to stop child bearing (odds ratio 11.5, 95%CI 4.3-30.7, after adjusting for other factors) but only slightly more likely to use contraceptives (adjusted odds ratio 1.5 (95%CI 0.8-3.3). Conclusion: Knowledge of HIV positive status is associated with an increase in the reported desire to cease childbearing but there was limited evidence that this desire led to higher use of contraception. More efforts directed towards assisting HIV positive couples to access and use reproductive health services and limit HIV transmission among couples are recommended.	[Dube, Albert L. N.; Molesworth, Anna; Parrott, Fiona; French, Neil] London Sch Hyg & Trop Med, Karonga Prevent Study, Karonga, Malawi; [Baschieri, Angela; Cleland, John; French, Neil] London Sch Hyg & Trop Med, Dept Populat Hlth, London WC1, England; [Floyd, Sian; Glynn, Judith R.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1, England; [French, Neil] Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England	Malawi Epidemiology and Intervention Research Unit; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of Liverpool	Dube, ALN (corresponding author), London Sch Hyg & Trop Med, Karonga Prevent Study, Karonga, Malawi.	ankhata@gmail.com	Cleland, John G./AAZ-4185-2020	Cleland, John G./0000-0002-1471-7016; French, Neil/0000-0003-4814-8293; Dube, Albert/0000-0002-6392-0475; Houben, Fiona/0000-0002-5630-3516	Wellcome Trust; Joint Hewlett; Economic and Social Research Council; ESRC [ES/F038437/1] Funding Source: UKRI; Economic and Social Research Council [ES/F038437/1, ES/F038437/2] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); Joint Hewlett; Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))	This work was supported by The Wellcome Trust, Joint Hewlett and Economic and Social Research Council. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anglewicz P, 2011, AIDS CARE, V23, P998, DOI 10.1080/09540121.2010.542130; [Anonymous], 2002, N INDIA HUMAN DEV RE, P1; [Anonymous], 2010, MAL DEM HLTH SURV 20; Bankole A, 1998, INT FAM PLAN PERSPEC, V24, P15, DOI 10.2307/2991915; Becker S, 1996, STUD FAMILY PLANN, V27, P291, DOI 10.2307/2138025; Becker S, 2007, J BIOSOC SCI, V39, P137, DOI 10.1017/S0021932006001283; Blanc AK, 2001, STUD FAMILY PLANN, V32, P189, DOI 10.1111/j.1728-4465.2001.00189.x; Chimbiri AM, 2007, SOC SCI MED, V64, P1102, DOI 10.1016/j.socscimed.2006.10.012; Cooper D, 2007, SOC SCI MED, V65, P274, DOI 10.1016/j.socscimed.2007.03.019; Cooper D, 2009, AIDS BEHAV, V13, pS38, DOI 10.1007/s10461-009-9550-1; Dodoo FNA, 1998, DEMOGRAPHY, V35, P229, DOI 10.2307/3004054; Floyd S, 2010, PLOS ONE, V10; Heys J, 2009, AIDS, V23, pS37, DOI 10.1097/01.aids.0000363776.76129.fd; Hoffman IF, 2008, JAIDS-J ACQ IMM DEF, V47, P477, DOI 10.1097/QAI.0b013e318165dc52; Jahn A, 2007, DEMOGR RES, V16, P219, DOI 10.4054/DemRes.2007.16.8; Laher F, 2009, AIDS BEHAV, V13, pS47, DOI 10.1007/s10461-009-9544-z; Loutfy MR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007925; Magadi MA, 2010, SOC SCI MED, V71, P335, DOI 10.1016/j.socscimed.2010.03.040; Maier M, 2009, AIDS BEHAV, V13, pS28, DOI 10.1007/s10461-008-9371-7; Molesworth AM, 2010, JAIDS-J ACQ IMM DEF, V55, P625, DOI 10.1097/QAI.0b013e3181f98628; Myer L, 2007, AIDS PATIENT CARE ST, V21, P278, DOI 10.1089/apc.2006.0108; Nattabi B, 2009, AIDS BEHAV, V13, P949, DOI 10.1007/s10461-009-9537-y; Nduna M, 2009, AIDS BEHAV, V13, pS62, DOI 10.1007/s10461-009-9545-y; Panozzo L, 2003, SWISS MED WKLY, V133, P124; Setel P, 1995, Health Transit Rev, V5 Suppl, P179; Taulo F, 2009, AIDS BEHAV, V13, pS20, DOI 10.1007/s10461-009-9547-9; Yeatman S, 2009, STUD FAMILY PLANN, V40, P261, DOI 10.1111/j.1728-4465.2009.00210.x; Yeatman SE, 2009, AIDS BEHAV, V13, pS12, DOI 10.1007/s10461-009-9534-1; Zaba B, 1998, AIDS, V12, pS41	29	19	19	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2012	7	12							e51861	10.1371/journal.pone.0051861	http://dx.doi.org/10.1371/journal.pone.0051861			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	060RA	23284791	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000312794500054
J	Liu, Q; Zhou, RL; Chen, SG; Tan, C				Liu, Qing; Zhou, Renlai; Chen, Shanguang; Tan, Cheng			Effects of Head-Down Bed Rest on the Executive Functions and Emotional Response	PLOS ONE			English	Article							RATE-VARIABILITY; COGNITIVE PERFORMANCE; STRESS	Prolonged bed rest may cause changes in the autonomic nervous system that are related to cognition and emotion. This study adopted an emotional flanker task to evaluate the effect of 45 days -6 degrees head-down bed rest (HDBR) on executive functioning in 16 healthy young men at each of six time points: the second-to-last day before the bed rest period, the eleventh, twentieth, thirty-second and fortieth day during the bed rest period, and the eighth day after the bed rest period. In addition, self-report inventories (Beck Anxiety Inventory, BAI; Beck Depression Inventory, BDI; Positive Affect and Negative Affect Scale, PANAS) were conducted to record emotional changes, and the participants' galvanic skin response (GSR), heart rate (HR) and heart rate variability (HRV) were assessed as measures of physiological activity. The results showed that the participants' reaction time on the flanker task increased significantly relative to their responses on the second-to-last day before the period of bed rest, their galvanic skin response weakened and their degrees of positive affect declined during the bed rest period. Our results provide some evidence for a detrimental effect of prolonged bed rest on executive functioning and positive affect. Whether this stems from a lack of aerobic physical activity and/or the effect of HDBR itself remains to be determined.	[Liu, Qing; Zhou, Renlai] Beijing Normal Univ, Sch Psychol, Beijing Key Lab Appl Expt Psychol, Beijing 100875, Peoples R China; [Zhou, Renlai] Beijing Normal Univ, State Key Lab Cognit Neurosci & Learning, Beijing 100875, Peoples R China; [Chen, Shanguang; Tan, Cheng] China Astronaut Res & Training Ctr, Beijing, Peoples R China	Beijing Normal University; Beijing Normal University	Zhou, RL (corresponding author), Beijing Normal Univ, Sch Psychol, Beijing Key Lab Appl Expt Psychol, Beijing 100875, Peoples R China.	rlzhou@bnu.edu.cn; tigercsg@163.com	liu, qingqing/HHD-0360-2022; Liu, Qing/GWC-9222-2022; Zhou, Renlai/ABA-1226-2021	Zhou, Renlai/0000-0001-7035-7097	National Basic Research Program of China [2011CB7110001]	National Basic Research Program of China(National Basic Research Program of China)	This work was funded by the National Basic Research Program of China (2011CB7110001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[陈思佚 CHEN Siyi], 2011, [航天医学与医学工程, Space Medicine & Medical Engineering], V24, P253; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Crucian BE, 2009, AVIAT SPACE ENVIR MD, V80, pA37, DOI 10.3357/ASEM.BR05.2009; Hansen AL, 2004, EUR J APPL PHYSIOL, V93, P263, DOI 10.1007/s00421-004-1208-0; Hirayanagi K, 2004, EUR J APPL PHYSIOL, V92, P160, DOI 10.1007/s00421-004-1067-8; Hockey GRJ, 1997, BIOL PSYCHOL, V45, P73; Ishizaki Y, 2002, ACTA ASTRONAUT, V50, P453, DOI 10.1016/S0094-5765(01)00189-8; Ishizaki Y, 2009, ACTA ASTRONAUT, V64, P864, DOI 10.1016/j.actaastro.2008.10.006; Jo NY, 2012, LECT NOTES ARTIF INT, V7198, P19, DOI 10.1007/978-3-642-28493-9_3; Lane RD, 2009, NEUROIMAGE, V44, P213, DOI 10.1016/j.neuroimage.2008.07.056; Leon GR, 2011, J ENVIRON PSYCHOL, V31, P353, DOI 10.1016/j.jenvp.2011.08.001; Lipnicki DM, 2009, AVIAT SPACE ENVIR MD, V80, P1018, DOI 10.3357/ASEM.2581.2009; Lipnicki DM, 2009, EUR J APPL PHYSIOL, V105, P27, DOI 10.1007/s00421-008-0869-5; Messerotti Benvenuti S, 2011, PHYSIOL BEHAV, V104, P503, DOI 10.1016/j.physbeh.2011.05.019; Moore ST, 2010, EXP BRAIN RES, V204, P617, DOI 10.1007/s00221-010-2317-0; PAVYLETRAON A, 1994, ACTA ASTRONAUT, V32, P319, DOI 10.1016/0094-5765(94)90083-3; [秦海波 Qin Haibo], 2010, [航天医学与医学工程, Space Medicine & Medical Engineering], V23, P163; Qiu L., 2008, APPL PSYCHOL, P249, DOI 10.1093/molbev/msx285/4596561; Richard LH, 2009, RESP PHYSIOL NEUROBI, V169, P38; Shehab RL, 1998, ACTA ASTRONAUT, V43, P223, DOI 10.1016/S0094-5765(98)00156-8; Svensson EAI, 2002, INT J AVIAT PSYCHOL, V12, P95, DOI 10.1207/S15327108IJAP1201_8; Thayer JF, 2009, ANN BEHAV MED, V37, P141, DOI 10.1007/s12160-009-9101-z; Traon APL, 2007, EUR J APPL PHYSIOL, V101, P143, DOI 10.1007/s00421-007-0474-z; Wang XD, 1999, MENTAL HLTH ASSESS S, P91; [王妍 Wang Yan], 2005, [中国临床心理学杂志, Chinese Journal of Clinical Psychology], V13, P396; Zhao X, 2011, ACTA ASTRONAUT, V69, P969, DOI 10.1016/j.actaastro.2011.07.003	26	13	17	0	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 17	2012	7	12							e52160	10.1371/journal.pone.0052160	http://dx.doi.org/10.1371/journal.pone.0052160			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	055RZ	23284916	Green Published, Green Submitted, gold			2023-01-03	WOS:000312435900082
J	Wong, FY; Liem, N; Xie, C; Yan, FL; Wong, WC; Wang, LZ; Yong, WP				Wong, Foong Ying; Liem, Natalia; Xie, Chen; Yan, Fui Leng; Wong, Wing Cheong; Wang, Lingzhi; Yong, Wei-Peng			Combination Therapy with Gossypol Reveals Synergism against Gemcitabine Resistance in Cancer Cells with High BCL-2 Expression	PLOS ONE			English	Article							SMALL-MOLECULE INHIBITOR; PROSTATE-CANCER; X-L; PANCREATIC-CANCER; INDUCED APOPTOSIS; CARCINOMA-CELLS; LUNG-CANCER; MEDIATED APOPTOSIS; BREAST-CANCER; IN-VITRO	Although gemcitabine is highly active in several cancer types, intrinsic and acquired drug resistance remains a major challenge. Overexpression of Bcl-2 has been associated with gemcitabine resistance. The aim of this study is to determine whether gossypol can overcome gemcitabine resistance in cell lines with high level of Bcl-2 expression in combination drug therapy. Our study demonstrated that in 10 cell lines derived from different cancers, high Bcl-2 baseline expression was observed in cell lines that were resistant to gemcitabine (GEM-R). Furthermore, synergistic effect of combination therapy was observed in gemcitabine-resistant (GEM-R) cell lines with high Bcl-2 expression, but not in a gemcitabine-sensitive (GEM-S) cell lines regardless of Bcl-2 expression. Gossypol treatment resulted in the decrease of anti-apoptotic genes such as Bcl-2 and Bcl-xl and an upregulation of the pro-apoptotic gene, Noxa. Furthermore, the addition of gossypol to gemcitabine resulted in lower expressions of anti-apoptotic genes compared to gemcitabine alone. Gene expression profiling in GEM-R and GEM-S cell lines suggest that anti-apoptotic genes such as pAkt and PI3KR2 may play important role in gemcitabine resistance, while pro-apoptotic Bcl-2 related genes (Bad, Caspase-6 and Calpain-1) may regulate synergistic interaction in combination therapy.	[Wong, Foong Ying; Liem, Natalia; Xie, Chen; Yan, Fui Leng; Yong, Wei-Peng] Natl Univ Hlth Syst, Dept Haematol Oncol, Singapore, Singapore; [Wong, Wing Cheong] Agcy Sci Technol & Res, Bioinformat Inst, Singapore, Singapore; [Wang, Lingzhi; Yong, Wei-Peng] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore	National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Bioinformatics Institute (BII); National University of Singapore	Wong, FY (corresponding author), Natl Univ Hlth Syst, Dept Haematol Oncol, Singapore, Singapore.	wf_ying@hotmail.com			National Medical Research Council, Singapore [NMRC/TCR/001-NUH/2007]	National Medical Research Council, Singapore(National Medical Research Council, Singapore)	This work is supported by grant NMRC/TCR/001-NUH/2007 from National Medical Research Council, Singapore. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Balakrishnan K, 2008, BLOOD, V112, P1971, DOI 10.1182/blood-2007-12-126946; Barba-Barajas M, 2009, IMMUNOPHARM IMMUNOT, V31, P320, DOI 10.1080/08923970902718049; Bauer JA, 2005, MOL CANCER THER, V4, P1096, DOI 10.1158/1535-7163.MCT-05-0081; Bergman AM, 2002, DRUG RESIST UPDATE, V5, P19, DOI 10.1016/S1368-7646(02)00002-X; Bold RJ, 1999, ANN SURG ONCOL, V6, P279, DOI 10.1007/s10434-999-0279-x; Buchholz TA, 2003, CANCER J, V9, P33, DOI 10.1097/00130404-200301000-00007; Castilla C, 2006, ENDOCRINOLOGY, V147, P4960, DOI 10.1210/en.2006-0502; Cengiz E, 2010, MOL BIOL REP, V37, P1269, DOI 10.1007/s11033-009-9501-y; Chang JS, 2004, CLIN EXP PHARMACOL P, V31, P716, DOI 10.1111/j.1440-1681.2004.04078.x; Chou TC, 1984, ADV ENZYME REGUL, V22, P22; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; Chun EY, 2004, BIOCHEM BIOPH RES CO, V315, P771, DOI 10.1016/j.bbrc.2004.01.118; Coutinho EM, 2002, CONTRACEPTION, V65, P259, DOI 10.1016/S0010-7824(02)00294-9; Dent S, 2008, BREAST CANCER RES TR, V108, P319, DOI 10.1007/s10549-007-9610-z; Fahy BN, 2005, CANCER CHEMOTH PHARM, V56, P46, DOI 10.1007/s00280-004-0944-5; Galmarini CM, 2001, LEUKEMIA, V15, P875, DOI 10.1038/sj.leu.2402114; GILBERT NE, 1995, LIFE SCI, V57, P61, DOI 10.1016/0024-3205(95)00243-Y; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; Han JY, 2003, MED ONCOL, V20, P355, DOI 10.1385/MO:20:4:355; Hilbig A, 2008, EXPERT REV ANTICANC, V8, P511, DOI 10.1586/14737140.8.4.511; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Humbert M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009430; Jiang JH, 2009, INT J MOL MED, V24, P69, DOI 10.3892/ijmm_00000208; Karakas T, 1998, ANN ONCOL, V9, P159, DOI 10.1023/A:1008255511404; Kitada S, 2003, J MED CHEM, V46, P4259, DOI 10.1021/jm030190z; Labi V, 2008, CELL DEATH DIFFER, V15, P977, DOI 10.1038/cdd.2008.37; Lo KW, 2001, CANCER RES, V61, P3877; Lorusso D, 2006, ANN ONCOL, V17, pV188, DOI 10.1093/annonc/mdj979; Macoska JA, 2008, PHARMACOL RES, V58, P323, DOI 10.1016/j.phrs.2008.09.005; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; Meng Y, 2008, MOL CANCER THER, V7, P2192, DOI 10.1158/1535-7163.MCT-08-0333; Mohammad RM, 2005, PANCREAS, V31, P317, DOI 10.1097/01.mpa.0000179731.46210.01; Mohammad RM, 2005, MOL CANCER THER, V4, P13; Natale R, 2005, LUNG CANCER-J IASLC, V50, pS2, DOI 10.1016/S0169-5002(05)81549-1; Oliver CL, 2005, MOL CANCER THER, V4, P23; Oliver CL, 2004, CLIN CANCER RES, V10, P7757, DOI 10.1158/1078-0432.CCR-04-0551; PLUNKETT W, 1995, SEMIN ONCOL, V22, P3; Sartorius UA, 2002, INT J CANCER, V97, P584, DOI 10.1002/ijc.10096; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schniewind B, 2004, INT J CANCER, V109, P182, DOI 10.1002/ijc.11679; Shi X, 2002, ONCOLOGY-BASEL, V62, P354, DOI 10.1159/000065068; Shieh JJ, 2009, J INVEST DERMATOL, V129, P2497, DOI 10.1038/jid.2009.83; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Tan YF, 2006, J BIOL CHEM, V281, P16016, DOI 10.1074/jbc.M601299200; Volate SR, 2010, MOL CANCER THER, V9, P461, DOI 10.1158/1535-7163.MCT-09-0507; Voutsadakis IA, 2011, WORLD J GASTRO ONCOL, V3, P153, DOI 10.4251/wjgo.v3.i11.153; Williams J, 2005, GYNECOL ONCOL, V96, P287, DOI 10.1016/j.ygyno.2004.10.026; Wong WC, 2008, BIOL DIRECT, V3, DOI 10.1186/1745-6150-3-23; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yu B, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-107; Zhang MC, 2007, LIFE SCI, V80, P767, DOI 10.1016/j.lfs.2006.11.004; Zhang MC, 2003, BIOCHEM PHARMACOL, V66, P93, DOI 10.1016/S0006-2952(03)00248-X	52	26	26	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 4	2012	7	12							e50786	10.1371/journal.pone.0050786	http://dx.doi.org/10.1371/journal.pone.0050786			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	051EQ	23226540	Green Published, gold, Green Submitted			2023-01-03	WOS:000312108500031
J	Lee, MJ; Shin, DH; Kim, SJ; Oh, HJ; Yoo, DE; Ko, KI; Koo, HM; Kim, CH; Doh, FM; Park, JT; Han, SH; Yoo, TH; Choi, KH; Kang, SW				Lee, Mi Jung; Shin, Dong Ho; Kim, Seung Jun; Oh, Hyung Jung; Yoo, Dong Eun; Ko, Kwang Il; Koo, Hyang Mo; Kim, Chan Ho; Doh, Fa Mee; Park, Jung Tak; Han, Seung Hyeok; Yoo, Tae-Hyun; Choi, Kyu Hun; Kang, Shin-Wook			Progression of Aortic Arch Calcification Over 1 Year Is an Independent Predictor of Mortality in Incident Peritoneal Dialysis Patients	PLOS ONE			English	Article							CHRONIC-KIDNEY-DISEASE; STAGE RENAL-DISEASE; CORONARY-ARTERY CALCIFICATION; CHEST-X-RAY; VASCULAR CALCIFICATION; HEMODIALYSIS-PATIENTS; MAINTENANCE HEMODIALYSIS; CARDIOVASCULAR-DISEASE; MINERAL METABOLISM; RISK-FACTORS	Backgrounds and Aims: The presence and progression of vascular calcification have been demonstrated as important risk factors for mortality in dialysis patients. However, since the majority of subjects included in most previous studies were hemodialysis patients, limited information was available in peritoneal dialysis (PD) patients. Therefore, the aim of this study was to investigate the prevalence of aortic arch calcification (AoAC) and prognostic value of AoAC progression in PD patients. Methods: We prospectively determined AoAC by chest X-ray at PD start and after 12 months, and evaluated the impact of AoAC progression on mortality in 415 incident PD patients. Results: Of 415 patients, 169 patients (40.7%) had AoAC at baseline with a mean of 18.1+/-11.2%. The presence of baseline AoAC was an independent predictor of all-cause [Hazard ratio (HR): 2.181, 95% confidence interval (CI): 1.336-3.561, P = 0.002] and cardiovascular mortality (HR: 3.582, 95% CI: 1.577-8.132, P = 0.002). Among 363 patients with follow-up chest X-rays at 12 months after PD start, the proportion of patients with AoAC progression was significantly higher in patients with baseline AoAC (64.2 vs. 5.3%, P<0.001). Moreover, all-cause and cardiovascular death rates were significantly higher in the progression groups than in the non-progression group (P<0.001). Multivariate Cox analysis revealed that AoAC progression was an independent predictor for all-cause (HR: 2.625, 95% CI: 1.150-5.991, P = 0.022) and cardiovascular mortality (HR: 4.008, 95% CI: 1.079-14.890, P = 0.038) in patients with AoAC at baseline. Conclusions: The presence and progression of AoAC assessed by chest X-ray were independently associated with unfavorable outcomes in incident PD patients. Regular follow-up by chest X-ray could be a simple and useful method to stratify mortality risk in these patients.	[Lee, Mi Jung; Shin, Dong Ho; Kim, Seung Jun; Oh, Hyung Jung; Yoo, Dong Eun; Ko, Kwang Il; Koo, Hyang Mo; Kim, Chan Ho; Doh, Fa Mee; Park, Jung Tak; Han, Seung Hyeok; Yoo, Tae-Hyun; Choi, Kyu Hun; Kang, Shin-Wook] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Yoo, Tae-Hyun; Kang, Shin-Wook] Yonsei Univ, Severance Biomed Sci Inst, Seoul 120749, South Korea	Yonsei University; Yonsei University Health System; Yonsei University	Kang, SW (corresponding author), Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea.	kswkidney@yumc.yonsei.ac.kr	Kim, Seung Jun/N-5248-2019; Han, Seung Hyeok/K-4559-2018; Han, Seung Hyeok/W-8825-2019	Kim, Seung Jun/0000-0002-6913-6358; Han, Seung Hyeok/0000-0001-7923-5635; Han, Seung Hyeok/0000-0001-7923-5635; Park, Jung Tak/0000-0002-2325-8982; Choi, Kyu Hun/0000-0003-0095-9011; Kang, Shin-Wook/0000-0002-5677-4756; Yoo, Tae-Hyun/0000-0002-9183-4507; doh, fa mee/0000-0002-4780-6728; Lee, Mi Jung/0000-0001-8888-029X	Brain Korea 21 Project for Medical Science, Yonsei University; National Research Foundation of Korea; Korea government (MEST) [2011-0030711]; Korea Healthcare Technology Research & Development project, Ministry of Health and Welfare, Republic of Korea [A102065]	Brain Korea 21 Project for Medical Science, Yonsei University(Ministry of Education & Human Resources Development (MOEHRD), Republic of Korea); National Research Foundation of Korea(National Research Foundation of Korea); Korea government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government); Korea Healthcare Technology Research & Development project, Ministry of Health and Welfare, Republic of Korea	This work was supported by the Brain Korea 21 Project for Medical Science, Yonsei University, by the National Research Foundation of Korea grant funded by the Korea government (MEST) (No. 2011-0030711), and by a grant of the Korea Healthcare Technology Research & Development project, Ministry of Health and Welfare, Republic of Korea (A102065). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ammirati AL, 2007, PERITON DIALYSIS INT, V27, P340; Blacher J, 2001, HYPERTENSION, V38, P938, DOI 10.1161/hy1001.096358; Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2; Braun J, 1996, AM J KIDNEY DIS, V27, P394, DOI 10.1016/S0272-6386(96)90363-7; Chertow GM, 2002, KIDNEY INT, V62, P245, DOI 10.1046/j.1523-1755.2002.00434.x; Drueke TB, 2010, NAT REV NEPHROL, V6, P723, DOI 10.1038/nrneph.2010.143; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; FOLEY RN, 1995, KIDNEY INT, V47, P186, DOI 10.1038/ki.1995.22; Garland JS, 2008, AM J KIDNEY DIS, V52, P849, DOI 10.1053/j.ajkd.2008.04.012; Hashimoto H, 2009, J ATHEROSCLER THROMB, V16, P256, DOI 10.5551/jat.E570; Inoue T, 2011, HEART VESSELS, DOI 10,1007/S00380-011-0129-1; Iribarren C, 2000, JAMA-J AM MED ASSOC, V283, P2810, DOI 10.1001/jama.283.21.2810; Jiang CQ, 2009, ATHEROSCLEROSIS, V202, P529, DOI 10.1016/j.atherosclerosis.2008.03.004; Jung HH, 2006, NEPHROL DIAL TRANSPL, V21, P1915, DOI 10.1093/ndt/gfl118; Karohl C, 2011, NAT REV NEPHROL, V7, P567, DOI 10.1038/nrneph.2011.110; Kim HG, 2011, HEMODIAL INT, V15, P460, DOI 10.1111/j.1542-4758.2011.00571.x; Klassen PS, 2002, JAMA-J AM MED ASSOC, V287, P1548, DOI 10.1001/jama.287.12.1548; Koo HM, 2011, ATHEROSCLEROSIS, V219, P925, DOI 10.1016/j.atherosclerosis.2011.09.025; Kurita N, 2011, NEPHROL DIAL TRANSPL, V26, P1747, DOI 10.1093/ndt/gfr087; Leskinen Y, 2009, J HEART VALVE DIS, V18, P429; London GM, 2003, NEPHROL DIAL TRANSPL, V18, P1731, DOI 10.1093/ndt/gfg414; Momiyama Y, 2010, ATHEROSCLEROSIS, V210, P668, DOI 10.1016/j.atherosclerosis.2009.12.024; Nitta K, 2004, HYPERTENS RES, V27, P47, DOI 10.1291/hypres.27.47; Noordzij M, 2011, NEPHROL DIAL TRANSPL, V26, P1662, DOI 10.1093/ndt/gfq582; Ogawa T, 2010, INT UROL NEPHROL, V42, P187, DOI 10.1007/s11255-009-9574-5; Ogawa T, 2009, HEMODIAL INT, V13, P301, DOI 10.1111/j.1542-4758.2009.00366.x; Okuno S, 2007, AM J KIDNEY DIS, V49, P417, DOI 10.1053/j.ajkd.2006.12.017; Rana JS, 2012, AM J CARDIOL; Shanahan CM, 2011, CIRC RES, V109, P697, DOI 10.1161/CIRCRESAHA.110.234914; Sigrist M, 2006, NEPHROL DIAL TRANSPL, V21, P707, DOI 10.1093/ndt/gfi236; Sigrist MK, 2007, CLIN J AM SOC NEPHRO, V2, P1241, DOI 10.2215/CJN.02190507; Taniwaki H, 2005, NEPHROL DIAL TRANSPL, V20, P2472, DOI 10.1093/ndt/gfi039; Temmar M, 2010, J HYPERTENS, V28, P163, DOI 10.1097/HJH.0b013e328331b81e; Turkmen K, 2011, CLIN J AM SOC NEPHRO, V6, P1920, DOI 10.2215/CJN.00890111; TWARDOWSKI ZJ, 1989, BLOOD PURIFICAT, V7, P95, DOI 10.1159/000169582; Wang AYM, 2005, NEPHROL DIAL TRANSPL, V20, P1676, DOI 10.1093/ndt/gfh891; WITTEMAN JCM, 1986, LANCET, V2, P1120; Woodward M, 2005, INT J EPIDEMIOL, V34, P1036, DOI 10.1093/ije/dyi104; Yamada K, 2007, NEPHROL DIAL TRANSPL, V22, P2032, DOI 10.1093/ndt/gfm031	39	5	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2012	7	11							e48793	10.1371/journal.pone.0048793	http://dx.doi.org/10.1371/journal.pone.0048793			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	048TK	23144974	Green Published, gold, Green Submitted			2023-01-03	WOS:000311935800136
J	Wang, SY; Olson-Kellogg, B; Shamliyan, TA; Choi, JY; Ramakrishnan, R; Kane, RL				Wang, Shi-Yi; Olson-Kellogg, Becky; Shamliyan, Tatyana A.; Choi, Jae-Young; Ramakrishnan, Rema; Kane, Robert L.			Physical Therapy Interventions for Knee Pain Secondary to Osteoarthritis A Systematic Review	ANNALS OF INTERNAL MEDICINE			English	Review							ELECTRICAL NERVE-STIMULATION; MEDIAL COMPARTMENT OSTEOARTHRITIS; PULSED ELECTROMAGNETIC-FIELDS; SHORT-WAVE DIATHERMY; QUALITY-OF-LIFE; VARUS DEFORMITY OSTEOARTHRITIS; RANDOMIZED CONTROLLED-TRIAL; SUPERVISED FITNESS WALKING; LATERALLY WEDGED INSOLES; LAND-BASED EXERCISE	Background: Osteoarthritis is a leading cause of disability. Nonsurgical treatment is a key first step. Purpose: Systematic literature review of physical therapy (PT) interventions for community-dwelling adults with knee osteoarthritis. Data Sources: MEDLINE, the Cochrane Library, the Physiotherapy Evidence Database, Scirus, Allied and Complementary Medicine, and the Health and Psychosocial Instruments bibliography database. Study Selection: 193 randomized, controlled trials (RCTs) published in English from 1970 to 29 February 2012. Data Extraction: Means of outcomes, PT interventions, and risk of bias were extracted to pool standardized mean differences. Disagreements between reviewers abstracting and checking data were resolved through discussion. Data Synthesis: Meta-analyses of 84 RCTs provided evidence for 13 PT interventions on pain (58 RCTs), physical function (36 RCTs), and disability (29 RCTs). Meta-analyses provided low-strength evidence that aerobic (11 RCTs) and aquatic (3 RCTs) exercise improved disability and that aerobic exercise (19 RCTs), strengthening exercise (17 RCTs), and ultrasonography (6 RCTs) reduced pain and improved function. Several individual RCTs demonstrated clinically important improvements in pain and disability with aerobic exercise. Other PT interventions demonstrated no sustained benefit. Individual RCTs showed similar benefits with aerobic, aquatic, and strengthening exercise. Adverse events were uncommon and did not deter participants from continuing treatment. Limitation: Variability in PT interventions and outcomes measures hampered synthesis of evidence. Conclusion: Low-strength evidence suggested that only a few PT interventions were effective. Future studies should compare combined PT interventions (which is how PT is generally administered for pain associated with knee osteoarthritis).	[Shamliyan, Tatyana A.] Univ Minnesota, Div Hlth Policy & Management, Sch Publ Hlth, Sch Med, Minneapolis, MN 55455 USA; Minnesota Evidence Based Practice Ctr, Minneapolis, MN USA	University of Minnesota System; University of Minnesota Twin Cities	Shamliyan, TA (corresponding author), Univ Minnesota, Div Hlth Policy & Management, Sch Publ Hlth, Sch Med, D330-5 Mayo,MMC 729,420 Delaware St SE, Minneapolis, MN 55455 USA.	shaml005@umn.edu	Ramakrishnan, Rema/AAE-1742-2022; Shamliyan, Tatyana/AAU-8323-2020; Ramakrishnan, Rema/AAM-7811-2020	Ramakrishnan, Rema/0000-0002-6784-8319; Wang, Shi-Yi/0000-0002-3294-5784; Shamliyan, Tatyana/0000-0003-3584-2008	AHRQ [290-2007-10064-I]	AHRQ(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Grant Support: By AHRQ (under contract 290-2007-10064-I).	Agency for Healthcare Research and Quality, 2011, EV BAS PRACT CTR SYS; Aglamis B, 2008, J BACK MUSCULOSKELET, V21, P121; Akyol Y, 2010, EUR J PHYS REHAB MED, V46, P325; Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905; American Academy of Orthopaedic Surgeons, 2008, TREATM OST KNEE NON; An BC, 2008, J ALTERN COMPLEM MED, V14, P167, DOI 10.1089/acm.2007.0600; Angst F, 2001, ARTHRIT RHEUM-ARTHR, V45, P384, DOI 10.1002/1529-0131(200108)45:4<384::AID-ART352>3.0.CO;2-0; Angst F, 2002, J RHEUMATOL, V29, P131; Ay S, 2009, RHEUMATOL INT, V29, P663, DOI 10.1007/s00296-008-0754-x; Baker KR, 2001, J RHEUMATOL, V28, P1655; Baker K, 2007, ARTHRITIS RHEUM, V56, P1198, DOI 10.1002/art.22516; Bar-Ziv Y, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-179; Bautch JC, 1997, ARTHRIT CARE RES, V10, P48, DOI 10.1002/art.1790100108; Bennell KL, 2010, OSTEOARTHR CARTILAGE, V18, P621, DOI 10.1016/j.joca.2010.01.010; Bennell KL, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2912; Bennell KL, 2005, ANN RHEUM DIS, V64, P906, DOI 10.1136/ard.2004.026526; Bernstein AB, 2003, DHHS PUBLICATION, V2004-1031; Borenstein DM, 2009, INTRO METAANALYSIS S; Borjesson M, 1996, Physiother Res Int, V1, P89; Brand C, 2009, GUIDELINE NONSURGICA; Brismee JM, 2007, CLIN REHABIL, V21, P99, DOI 10.1177/0269215506070505; Brouwer RW, 2006, OSTEOARTHR CARTILAGE, V14, P777, DOI 10.1016/j.joca.2006.02.004; Bruckenthal Patricia, 2007, ANS Adv Nurs Sci, V30, pE72; Burch FX, 2008, OSTEOARTHR CARTILAGE, V16, P865, DOI 10.1016/j.joca.2007.11.013; Callaghan MJ, 2005, JOINT BONE SPINE, V72, P150, DOI 10.1016/j.jbspin.2004.03.010; Cetin N, 2008, AM J PHYS MED REHAB, V87, P443, DOI 10.1097/PHM.0b013e318174e467; Cheing GLY, 2004, CLIN REHABIL, V18, P487, DOI 10.1191/0269215504cr760oa; Cheing GLY, 2002, CLIN REHABIL, V16, P749, DOI 10.1191/0269215502cr549oa; Chou R, 2006, AHRQ PUBLICATION; Chou R, 2010, J CLIN EPIDEMIOL, V63, P502, DOI 10.1016/j.jclinepi.2008.06.007; Christensen R, 2007, ANN RHEUM DIS, V66, P433, DOI 10.1136/ard.2006.065904; Cohen J., 2013, STAT POWER ANAL BEHA; CUSHNAGHAN J, 1994, BRIT MED J, V308, P753, DOI 10.1136/bmj.308.6931.753; Denegar CR, 2010, CLIN INTERV AGING, V5, P199; Deyle GD, 2000, ANN INTERN MED, V132, P173, DOI 10.7326/0003-4819-132-3-200002010-00002; Deyle GD, 2005, PHYS THER, V85, P1301, DOI 10.1093/ptj/85.12.1301; Dickersin K, 1993, ONLINE J CURRENT CLI, V50, P4967; Dillon CF, 2006, J RHEUMATOL, V33, P2271; Doherty M, 1998, OSTEOARTHR CARTILAGE, V6, P371, DOI 10.1053/joca.1998.0139; Doi T, 2008, AM J PHYS MED REHAB, V87, P258, DOI 10.1097/PHM.0b013e318168c02d; Durmus D, 2007, CLIN RHEUMATOL, V26, P674, DOI 10.1007/s10067-006-0358-3; Eberle E, 1999, OSTEOARTHR CARTILAGE, V7, P502, DOI 10.1053/joca.1999.0246; Egger M, 2001, SYSTEMATIC REV HLTH; Ehrich EW, 2000, J RHEUMATOL, V27, P2635; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; Farr JN, 2010, PHYS THER, V90, P356, DOI 10.2522/ptj.20090041; Fe RW, 2011, J CLIN EPIDEMIOL, V64, P1187, DOI 10.1016/j.jclinepi.2010.08.010; FISHER NM, 1993, ARCH PHYS MED REHAB, V74, P1319, DOI 10.1016/0003-9993(93)90087-Q; Fitzgerald GK, 2001, PHYS THER, V81, P1446, DOI 10.1093/ptj/81.8.1446; Focht BC, 2005, ARTHRIT RHEUM-ARTHR, V53, P659, DOI 10.1002/art.21466; Fukuda TY, 2011, PHYS THER, V91, P1009, DOI 10.2522/ptj.20100306; Gaines JM, 2004, APPL NURS RES, V17, P201, DOI 10.1016/j.apnr.2004.06.004; Garland D, 2007, OSTEOARTHR CARTILAGE, V15, P630, DOI 10.1016/j.joca.2007.01.004; Grimmer K, 1992, Aust J Physiother, V38, P49, DOI 10.1016/S0004-9514(14)60551-1; Gur H, 2002, ARCH PHYS MED REHAB, V83, P308, DOI 10.1053/apmr.2002.30620; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Hay EM, 2006, BRIT MED J, V333, P995, DOI 10.1136/BMJ.38977.590752.0B; Herbison P, 2006, J CLIN EPIDEMIOL, V59, P1249, DOI 10.1016/j.jclinepi.2006.03.008; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hinman RS, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-146; Hinman RS, 2003, RHEUMATOLOGY, V42, P865, DOI 10.1093/rheumatology/keg233; Hinman RS, 2003, BRIT MED J, V327, P135, DOI 10.1136/bmj.327.7407.135; Huang MH, 2005, ARTHRIT RHEUM-ARTHR, V53, P812, DOI 10.1002/art.21590; Huang MH, 2005, ARCH PHYS MED REHAB, V86, P1545, DOI 10.1016/j.apmr.2005.02.007; Huang MH, 2000, ARTHRIT CARE RES, V13, P398, DOI 10.1002/1529-0131(200012)13:6<398::AID-ART10>3.0.CO;2-E; Imboden J, 2007, CURRENT RHEUMATOLOGY; Itoh Kazunori, 2008, Chin Med, V3, P2, DOI 10.1186/1749-8546-3-2; Jan MH, 2008, PHYS THER, V88, P427, DOI 10.2522/ptj.20060300; Jan MH, 2008, J ORTHOP SPORT PHYS, V38, P19, DOI 10.2519/jospt.2008.2512; Jan MH, 2009, ARCH PHYS MED REHAB, V90, P897, DOI 10.1016/j.apmr.2008.11.018; Jordan JM, 2007, J RHEUMATOL, V34, P172; Jordan KM, 2003, ANN RHEUM DIS, V62, P1145, DOI 10.1136/ard.2003.011742; Kang RW, 2007, ORTHOPEDICS, V30, P439, DOI 10.3928/01477447-20070601-11; Keefe FJ, 2004, PAIN, V110, P539, DOI 10.1016/j.pain.2004.03.022; Keller C, 2009, WESTERN J NURS RES, V31, P289, DOI 10.1177/0193945908326067; Kennedy DM, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-3; Kerrigan DC, 2002, ARCH PHYS MED REHAB, V83, P889, DOI 10.1053/apmr.2002.33225; Khanna D, 2011, QUAL LIFE RES, V20, P1131, DOI 10.1007/s11136-011-9849-z; Knapp G, 2006, BIOMETRICAL J, V48, P271, DOI 10.1002/bimj.200510175; Ko T, 2009, J PHYS THER SCI, V21, P293, DOI 10.1589/jpts.21.293; KOVAR PA, 1992, ANN INTERN MED, V116, P529, DOI 10.7326/0003-4819-116-7-529; Kuptniratsaikul Vilai, 2002, J Med Assoc Thai, V85, P33; Kuroyanagi Y, 2007, OSTEOARTHR CARTILAGE, V15, P932, DOI 10.1016/j.joca.2007.02.004; Laufer Y, 2005, CLIN REHABIL, V19, P255, DOI 10.1191/0269215505cr864oa; Law PPW, 2004, JCR-J CLIN RHEUMATOL, V10, P295, DOI 10.1097/01.rhu.0000147047.77460.b0; Law PPW, 2004, J REHABIL MED, V36, P220, DOI 10.1080/16501970410029834; Lawrence RC, 2008, ARTHRITIS RHEUM, V58, P26, DOI 10.1002/art.23176; Lee HJ, 2009, CLIN REHABIL, V23, P504, DOI 10.1177/0269215508101746; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lim BW, 2008, ARTHRIT RHEUM-ARTHR, V59, P943, DOI 10.1002/art.23823; Lin DH, 2009, J ORTHOP SPORT PHYS, V39, P450, DOI 10.2519/jospt.2009.2923; Lingard EA, 2001, J BONE JOINT SURG AM, V83A, P1856, DOI 10.2106/00004623-200112000-00014; Loyola-Sanchez A, 2012, ARCH PHYS MED REHAB, V93, P35, DOI 10.1016/j.apmr.2011.07.196; Lund H, 2008, J REHABIL MED, V40, P137, DOI 10.2340/16501977-0134; Macdonald GM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub2; Maillefert JF, 2001, OSTEOARTHR CARTILAGE, V9, P738, DOI 10.1053/joca.2001.0470; Maly MR, 2002, CLIN BIOMECH, V17, P603, DOI 10.1016/S0268-0033(02)00073-6; Mangani I, 2006, AGING CLIN EXP RES, V18, P374; Mangione KK, 2010, PHYS THER, V90, P921, DOI 10.2522/ptj.20090363; Massey B, 2001, PHYS THER, V81, P9; Mazieres B, 2001, JOINT BONE SPINE, V68, P231, DOI 10.1016/S1297-319X(01)00271-8; Mazzuca SA, 2004, ARTHRIT RHEUM-ARTHR, V51, P716, DOI 10.1002/art.20683; Messier SP, 2004, ARTHRITIS RHEUM-US, V50, P1501, DOI 10.1002/art.20256; Messier SP, 1997, J APPL BIOMECH, V13, P205, DOI 10.1123/jab.13.2.205; Mikesky AE, 2006, ARTHRIT RHEUM-ARTHR, V55, P690, DOI 10.1002/art.22245; Moss P, 2007, MANUAL THER, V12, P109, DOI 10.1016/j.math.2006.02.009; National Collaborating Centre for Chronic Conditions, 2008, OST NAT CLIN GUID CA; Nicolakis P, 2002, WIEN KLIN WOCHENSCHR, V114, P678; Nigg BM, 2006, MED SCI SPORT EXER, V38, P1701, DOI 10.1249/01.mss.0000228364.93703.53; Ozgonenel L, 2009, ULTRASOUND MED BIOL, V35, P44, DOI 10.1016/j.ultrasmedbio.2008.07.009; Owens DK, 2010, J CLIN EPIDEMIOL, V63, P513, DOI 10.1016/j.jclinepi.2009.03.009; Patrick DL, 2001, MED CARE, V39, P413, DOI 10.1097/00005650-200105000-00002; Peloquin L, 1999, JCR-J CLIN RHEUMATOL, V5, P126, DOI 10.1097/00124743-199906000-00004; Penninx BWJH, 2002, J GERONTOL B-PSYCHOL, V57, pP124, DOI 10.1093/geronb/57.2.P124; Penninx BWJH, 2001, ARCH INTERN MED, V161, P2309, DOI 10.1001/archinte.161.19.2309; Perlman AI, 2006, ARCH INTERN MED, V166, P2533, DOI 10.1001/archinte.166.22.2533; Peterson M G, 1993, Arthritis Care Res, V6, P11, DOI 10.1002/art.1790060104; Petrella RJ, 2000, J RHEUMATOL, V27, P2215; Pham T, 2003, J RHEUMATOL, V30, P1648; Pham T, 2004, OSTEOARTHR CARTILAGE, V12, P389, DOI 10.1016/j.joca.2004.02.001; Pietrosimone BG, 2010, CLIN REHABIL, V24, P1091, DOI 10.1177/0269215510375903; Pietrosimone BG, 2009, MED SCI SPORT EXER, V41, P1175, DOI 10.1249/MSS.0b013e3181982557; Pollard Henry, 2008, J Can Chiropr Assoc, V52, P229; Rattanachaiyanont M, 2008, OSTEOARTHR CARTILAGE, V16, P823, DOI 10.1016/j.joca.2007.10.013; REDELMEIER DA, 1993, ARCH INTERN MED, V153, P1337, DOI 10.1001/archinte.153.11.1337; Rejeski WJ, 1997, MED SCI SPORT EXER, V29, P977, DOI 10.1097/00005768-199708000-00001; Rejeski WJ, 2002, HEALTH PSYCHOL, V21, P419, DOI 10.1037/0278-6133.21.5.419; Richmond J, 2010, J BONE JOINT SURG AM, V92A, P990, DOI 10.2106/JBJS.I.00982; Rooks DS, 2006, ARTHRIT RHEUM-ARTHR, V55, P700, DOI 10.1002/art.22223; Rutjes AWS, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003132.pub2; Rutjes AWS, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002823.pub2; Salaffi F, 2004, EUR J PAIN, V8, P283, DOI 10.1016/j.ejpain.2003.09.004; Sayers SP, 2012, ARTHRIT CARE RES, V64, P46, DOI 10.1002/acr.20675; Schilke JM, 1996, NURS RES, V45, P68, DOI 10.1097/00006199-199603000-00002; Selfe TK, 2008, J ALTERN COMPLEM MED, V14, P1075, DOI 10.1089/acm.2008.0305; Shakoor M A, 2007, Bangladesh Med Res Counc Bull, V33, P55; Shamliyan T, 2012, COMP EFFECTIVENSS RE; Shamliyan TA, 2012, COMP EFFECTIVENESS P; Shaw JW, 2005, MED CARE, V43, P203, DOI 10.1097/00005650-200503000-00003; Silva LE, 2008, PHYS THER, V88, P12, DOI 10.2522/ptj.20060040; Song R, 2010, J ALTERN COMPLEM MED, V16, P227, DOI 10.1089/acm.2009.0165; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; Stratford PW, 2007, OSTEOARTHR CARTILAGE, V15, P266, DOI 10.1016/j.joca.2006.09.005; Sullivan T, 1998, ARTHRIT CARE RES, V11, P228, DOI 10.1002/art.1790110403; Swank AM, 2011, J STRENGTH COND RES, V25, P318, DOI 10.1519/JSC.0b013e318202e431; Talbot LA, 2003, J AM GERIATR SOC, V51, P387, DOI 10.1046/j.1532-5415.2003.51113.x; Talbot LA, 2003, J RHEUMATOL, V30, P1571; Tascioglu F, 2010, J INT MED RES, V38, P1233, DOI 10.1177/147323001003800404; TAYLOR P, 1981, PAIN, V11, P233, DOI 10.1016/0304-3959(81)90008-7; Thamsborg G, 2005, OSTEOARTHR CARTILAGE, V13, P575, DOI 10.1016/j.joca.2005.02.012; Thomas KS, 2002, BMJ-BRIT MED J, V325, P752, DOI 10.1136/bmj.325.7367.752; Thornton A, 2000, J CLIN EPIDEMIOL, V53, P207, DOI 10.1016/S0895-4356(99)00161-4; Thorstensson CA, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-27; Toda Y, 2008, OSTEOARTHR CARTILAGE, V16, P244, DOI 10.1016/j.joca.2007.06.010; Toda Y, 2005, OSTEOARTHR CARTILAGE, V13, P353, DOI 10.1016/j.joca.2004.12.012; Toda Y, 2004, ARTHRITIS RHEUM-US, V50, P3129, DOI 10.1002/art.20569; Toda Y, 2004, ARCH PHYS MED REHAB, V85, P673, DOI 10.1016/j.apmr.2003.06.011; Toda Y, 2001, J RHEUMATOL, V28, P2705; Topp R, 2002, ARCH PHYS MED REHAB, V83, P1187, DOI 10.1053/apmr.2002.33988; TROCK DH, 1994, J RHEUMATOL, V21, P1903; Tsauo JY, 2008, CLIN REHABIL, V22, P448, DOI 10.1177/0269215507084597; Tubach F, 2005, J RHEUMATOL, V32, P2025; Tubach F, 2005, ANN RHEUM DIS, V64, P29, DOI 10.1136/ard.2004.022905; van Gool CH, 2005, ARTHRIT RHEUM-ARTHR, V53, P24, DOI 10.1002/art.20902; Viechtbauer W, 2007, STAT MED, V26, P37, DOI 10.1002/sim.2514; Viswanathan M, 2012, ASSESSING RISK BIAS; Wang CC, 2009, ARTHRIT RHEUM-ARTHR, V61, P1545, DOI 10.1002/art.24832; WARE JE, 1995, MED CARE, V33, pAS264, DOI 10.1097/00005650-199501001-00005; Weng MC, 2009, KAOHSIUNG J MED SCI, V25, P306, DOI 10.1016/S1607-551X(09)70521-2; White DK, 2010, J RHEUMATOL, V37, P1244, DOI 10.3899/jrheum.090989; Wyatt FB, 2001, J STRENGTH COND RES, V15, P337; Yip YB, 2007, PATIENT EDUC COUNS, V65, P113, DOI 10.1016/j.pec.2006.06.019; Yip YB, 2008, COMPLEMENT THER MED, V16, P131, DOI 10.1016/j.ctim.2007.12.003; Yip Yin-Bing, 2008, Psychol Health Med, V13, P402, DOI 10.1080/13548500701584030; Yurtkuran M, 1999, Am J Acupunct, V27, P133; Zhang W, 2008, OSTEOARTHR CARTILAGE, V16, P137, DOI 10.1016/j.joca.2007.12.013; ZIZIC TM, 1995, J RHEUMATOL, V22, P1757	177	62	62	0	48	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 6	2012	157	9					632	+		10.7326/0003-4819-157-9-201211060-00007	http://dx.doi.org/10.7326/0003-4819-157-9-201211060-00007			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	033GX	23128863				2023-01-03	WOS:000310783300004
J	Kim, S; Chang, KA; Kim, JA; Park, HG; Ra, JC; Kim, HS; Suh, YH				Kim, Saeromi; Chang, Keun-A; Kim, Jeong A.; Park, Hyeong-Geun; Ra, Jeong Chan; Kim, Hye-Sun; Suh, Yoo-Hun			The Preventive and Therapeutic Effects of Intravenous Human Adipose-Derived Stem Cells in Alzheimer's Disease Mice	PLOS ONE			English	Article							STROMAL CELLS; NEURONAL DIFFERENTIATION; NEUROTROPHIC FACTORS; TRANSGENIC MODEL; AMYLOID-PROTEIN; NERVOUS-SYSTEM; GROWTH-FACTOR; MOUSE MODEL; IN-VITRO; TRANSPLANTATION	Alzheimer's disease (AD) is characterized by the accumulation of amyloid plaques and neurofibrillary tangles accompanied by cognitive dysfunction. The aim of the present study was to elucidate preventive and therapeutic potential of stem cells for AD. Among stem cells, autologous human adipose-derived stem cells (hASCs) elicit no immune rejection responses, tumorigenesis, or ethical problems. We found that intravenously transplanted hASCs passed through the BBB and migrated into the brain. The learning, memory and pathology in an AD mouse model (Tg2576) mice greatly improved for at least 4 months after intravenous injection of hASC. The number of amyloid plaques and A beta levels decreased significantly in the brains of hASC-injected Tg mice compared to those of Tg-sham mice. Here, we first report that intravenously or intracerebrally transplanted hASCs significantly rescues memory deficit and neuropathology, in the brains of Tg mice by upregulating IL-10 and VEGF and be a possible use for the prevention and treatment of AD.	[Kim, Saeromi; Chang, Keun-A; Kim, Jeong A.; Kim, Hye-Sun; Suh, Yoo-Hun] Seoul Natl Univ, Coll Med, Neurosci Res Inst, MRC,Dept Pharmacol, Seoul, South Korea; [Park, Hyeong-Geun; Ra, Jeong Chan] RNL Bio Co Ltd, Stem Cell Res Ctr, Seoul, South Korea; [Suh, Yoo-Hun] Korea Brain Res Inst, Taegu, South Korea; [Chang, Keun-A] Gachon Univ Med & Sci, Dept Pharmacol, Inchon, South Korea	Seoul National University (SNU); Korea Brain Research Institute (KBRI); Gachon University	Suh, YH (corresponding author), Seoul Natl Univ, Coll Med, Neurosci Res Inst, MRC,Dept Pharmacol, Seoul, South Korea.	yhsuh@snu.ac.kr	Suh, Yoo-Hun/J-2761-2012		Conversing Research Center Program through the National Research Foundation of Korea (NRF) [2011K000678]; Mid-career Researcher Program through NRF grant; MEST [20110027566]; Brain Research Center of the 21st Century Frontier Research Program, Science and Technology, the Republic of Korea [2011K000270]	Conversing Research Center Program through the National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Mid-career Researcher Program through NRF grant(National Research Foundation of Korea); MEST(Ministry of Education, Science & Technology (MEST), Republic of Korea); Brain Research Center of the 21st Century Frontier Research Program, Science and Technology, the Republic of Korea	This research was supported by the Conversing Research Center Program through the National Research Foundation of Korea (NRF) (2011K000678), Mid-career Researcher Program through NRF grant funded by the MEST (20110027566), and a grant (2011K000270) from Brain Research Center of the 21st Century Frontier Research Program, Science and Technology, the Republic of Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alzheimer's Association, 2010, Alzheimers Dement, V6, P158, DOI 10.1016/j.jalz.2010.01.009; Anghileri E, 2008, STEM CELLS DEV, V17, P909, DOI 10.1089/scd.2007.0197; Bao XJ, 2011, BRAIN RES, V1367, P103, DOI 10.1016/j.brainres.2010.10.063; Bhang SH, 2009, STEM CELLS, V27, P1976, DOI 10.1002/stem.115; Blurton-Jones M, 2009, P NATL ACAD SCI USA, V106, P13594, DOI 10.1073/pnas.0901402106; Carpentier PA, 2009, NEURON, V64, P79, DOI 10.1016/j.neuron.2009.08.038; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; De Almodovar CR, 2009, PHYSIOL REV, V89, P607, DOI 10.1152/physrev.00031.2008; Dezawa M, 2001, EUR J NEUROSCI, V14, P1771, DOI 10.1046/j.0953-816x.2001.01814.x; Ebert AD, 2008, EXP NEUROL, V209, P213, DOI 10.1016/j.expneurol.2007.09.022; Enzmann GU, 2006, J NEUROTRAUM, V23, P479, DOI 10.1089/neu.2006.23.479; Gimble JM, 2003, EXPERT OPIN BIOL TH, V3, P705, DOI 10.1517/14712598.3.5.705; Ha TY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008840; Heese K, 2006, NEUROSIGNALS, V15, P1, DOI 10.1159/000094383; HOCKFIELD S, 1985, J NEUROSCI, V5, P3310; Huang TT, 2007, J SPINAL CORD MED, V30, pS35, DOI 10.1080/10790268.2007.11753967; Ikegaya Y, 2001, J CELL SCI, V114, P4083; Jeynes B, 2011, J NEUROSCI RES, V89, P22, DOI 10.1002/jnr.22527; Kalbermatten DF, 2011, CELL TISSUE RES, V344, P251, DOI 10.1007/s00441-011-1142-5; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Lee E, 2009, BMB REP, V42, P239, DOI 10.5483/BMBRep.2009.42.5.239; Lee HJ, 2010, NEUROSCI LETT, V481, P30, DOI 10.1016/j.neulet.2010.06.045; Lee JK, 2010, STEM CELLS, V28, P329, DOI 10.1002/stem.277; Lee ST, 2009, ANN NEUROL, V66, P671, DOI 10.1002/ana.21788; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; Lesne S, 2005, J NEUROSCI, V25, P9367, DOI 10.1523/JNEUROSCI.0849-05.2005; Liu N, 2009, CELL MOL IMMUNOL, V6, P207, DOI 10.1038/cmi.2009.28; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; Martino G, 2006, NAT REV NEUROSCI, V7, P395, DOI 10.1038/nrn1908; Mathieu P, 2010, J NEUROCHEM, V112, P1368, DOI 10.1111/j.1471-4159.2009.06548.x; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Oddo S, 2003, NEUROBIOL AGING, V24, P1063, DOI 10.1016/j.neurobiolaging.2003.08.012; Park KI, 2006, EXP NEUROL, V199, P179, DOI 10.1016/j.expneurol.2006.03.016; Ra JC, 2011, SAFETY INTRAVENOUS I; Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Yamasaki TR, 2007, J NEUROSCI, V27, P11925, DOI 10.1523/JNEUROSCI.1627-07.2007; Yang SH, 2009, EXP MOL MED, V41, P315, DOI 10.3858/emm.2009.41.5.035; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105	41	97	105	0	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2012	7	9							e45757	10.1371/journal.pone.0045757	http://dx.doi.org/10.1371/journal.pone.0045757			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	016KP	23049854	gold, Green Submitted, Green Published			2023-01-03	WOS:000309517300051
J	Hopton, A; Thomas, K; MacPherson, H				Hopton, Ann; Thomas, Kate; MacPherson, Hugh			The Acceptability of Acupuncture for Low Back Pain: A Qualitative Study of Patient's Experiences Nested within a Randomised Controlled Trial	PLOS ONE			English	Article							FEAR-AVOIDANCE BELIEFS; EXPECTATIONS; OUTCOMES; PLACEBO; CARE	Introduction: The National Institute for Health and Clinical Excellence guidelines recommend acupuncture as a clinically effective treatment for chronic back pain. However, there is insufficient knowledge of what factors contribute to patients' positive and negative experiences of acupuncture, and how those factors interact in terms of the acceptability of treatment. This study used patient interviews following acupuncture treatment for back pain to identify, understand and describe the elements that contribute or detract from acceptability of treatment. Methods: The study used semi-structured interviews. Twelve patients were interviewed using an interview schedule as a sub-study nested within a randomised controlled trial of acupuncture for chronic back pain. The interviews were analysed using thematic analysis. Results and Discussion: Three over-arching themes emerged from the analysis. The first entitled facilitators of acceptability contained five subthemes; experience of pain relief, improvements in physical activity, relaxation, psychological benefit, reduced reliance on medication. The second over-arching theme identified barriers to acceptability, which included needle-related discomfort and temporary worsening of symptoms, pressure to continue treatment and financial cost. The third over-arching theme comprised mediators of acceptability, which included pre-treatment mediators such as expectation and previous experience, and treatment-related mediators of time, therapeutic alliance, lifestyle advice and the patient's active involvement in recovery. These themes inform our understanding of the acceptability of acupuncture to patients with low back pain. Conclusion: The acceptability of acupuncture treatment for low back pain is complex and multifaceted. The therapeutic relationship between the practitioner and patient emerged as a strong driver for acceptability, and as a useful vehicle to develop the patients' self-efficacy in pain management in the longer term. Unpleasant treatment related effects do not necessarily detract from patients' overall perception of acceptability.	[Hopton, Ann; MacPherson, Hugh] Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England; [Thomas, Kate] Univ Sheffield, Hlth Serv Res Unit, Sheffield, S Yorkshire, England	University of York - UK; University of Sheffield	Hopton, A (corresponding author), Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England.	ann.hopton@york.ac.uk		Hopton, Ann/0000-0002-2505-1176; MacPherson, Hugh/0000-0003-4255-4768	National Institute for Health Research (NIHR) Health Technology Assessment programme; NIHR Career Scientist Award [PAS/03/07/CSA/008]	National Institute for Health Research (NIHR) Health Technology Assessment programme(National Institute for Health Research (NIHR)); NIHR Career Scientist Award	This research was supported by the National Institute for Health Research (NIHR) Health Technology Assessment programme and in part by a NIHR Career Scientist Award, grant number PAS/03/07/CSA/008 awarded to HM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2009, NICE GUID 88, V1, P61; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Breen A, 2007, EUR J PAIN, V11, P21, DOI 10.1016/j.ejpain.2005.12.006; Cedraschi C, 2005, BEST PRACT RES CL RH, V19, P577, DOI 10.1016/j.berh.2005.03.002; Corbett M, 2009, FAM PRACT, V26, P359, DOI 10.1093/fampra/cmp042; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; Evans M, 2011, J ALTERN COMPLEM MED, V17, P519, DOI 10.1089/acm.2010.0749; Foster NE, 2010, PAIN, V148, P398, DOI 10.1016/j.pain.2009.11.002; Hopton AK, 2010, ACUPUNCT MED, V28, P185, DOI 10.1136/aim.2010.002279; Linde K, 2007, PAIN, V128, P264, DOI 10.1016/j.pain.2006.12.006; MacPherson H, 2004, COMPLEMENT THER MED, V12, P136, DOI 10.1016/j.ctim.2004.07.043; MacPherson H, 2006, J ALTERN COMPLEM MED, V12, P873, DOI 10.1089/acm.2006.12.873; Newcomer KL, 2010, PM&R, V2, P514, DOI 10.1016/j.pmrj.2010.03.034; Nicholas MK, 2007, EUR J PAIN, V11, P153, DOI 10.1016/j.ejpain.2005.12.008; Rainville J, 2011, SPINE J, V11, P895, DOI 10.1016/j.spinee.2011.08.006; Ratcliffe J, 2006, BRIT MED J, V333, P626, DOI 10.1136/bmj.38932.806134.7C; So DW, 2002, AM J PUBLIC HEALTH, V92, P1662, DOI 10.2105/AJPH.92.10.1662; Thomas KJ, 2006, BMJ-BRIT MED J, V333, P623, DOI 10.1136/bmj.38878.907361.7C; Thomas K. J., 2005, HEALTH TECHNOL ASSES, V9, P1, DOI DOI 10.3310/hta9320; Toye Francine, 2012, Prim Health Care Res Dev, V13, P72, DOI 10.1017/S1463423611000387; Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654; Wasan AD, 2010, J PAIN, V11, P555, DOI 10.1016/j.jpain.2009.09.013; Webb R, 2003, SPINE, V28, P1195, DOI 10.1097/00007632-200306010-00021; White P, 2012, PAIN, V153, P455, DOI 10.1016/j.pain.2011.11.007	24	21	21	0	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2013	8	2							e56806	10.1371/journal.pone.0056806	http://dx.doi.org/10.1371/journal.pone.0056806			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	093IT	23437246	Green Published, gold, Green Accepted			2023-01-03	WOS:000315186000047
J	Huveldt, D; Lewis-Tuffin, LJ; Carlson, BL; Schroeder, MA; Rodriguez, F; Giannini, C; Galanis, E; Sarkaria, JN; Anastasiadis, PZ				Huveldt, Deborah; Lewis-Tuffin, Laura J.; Carlson, Brett L.; Schroeder, Mark A.; Rodriguez, Fausto; Giannini, Caterina; Galanis, Evanthia; Sarkaria, Jann N.; Anastasiadis, Panos Z.			Targeting Src Family Kinases Inhibits Bevacizumab-Induced Glioma Cell Invasion	PLOS ONE			English	Article							FACTOR-KAPPA-B; P120 CATENIN; DASATINIB BMS-354825; TUMOR ANGIOGENESIS; MALIGNANT GLIOMAS; TYROSINE KINASES; PROSTATE-CANCER; XENOGRAFT MODEL; RHO-GTPASES; IN-VIVO	Anti-VEGF antibody therapy with bevacizumab provides significant clinical benefit in patients with recurrent glioblastoma multiforme (GBM). Unfortunately, progression on bevacizumab therapy is often associated with a diffuse disease recurrence pattern, which limits subsequent therapeutic options. Therefore, there is an urgent need to understand bevacizumab's influence on glioma biology and block it's actions towards cell invasion. To explore the mechanism(s) of GBM cell invasion we have examined a panel of serially transplanted human GBM lines grown either in short-term culture, as xenografts in mouse flank, or injected orthotopically in mouse brain. Using an orthotopic xenograft model that exhibits increased invasiveness upon bevacizumab treatment, we also tested the effect of dasatinib, a broad spectrum SFK inhibitor, on bevacizumab-induced invasion. We show that 1) activation of Src family kinases (SFKs) is common in GBM, 2) the relative invasiveness of 17 serially transplanted GBM xenografts correlates strongly with p120 catenin phosphorylation at Y228, a Src kinase site, and 3) SFK activation assessed immunohistochemically in orthotopic xenografts, as well as the phosphorylation of downstream substrates occurs specifically at the invasive tumor edge. Further, we show that SFK signaling is markedly elevated at the invasive tumor front upon bevacizumab administration, and that dasatinib treatment effectively blocked the increased invasion induced by bevacizumab. Our data are consistent with the hypothesis that the increased invasiveness associated with anti-VEGF therapy is due to increased SFK signaling, and support testing the combination of dasatinib with bevacizumab in the clinic.	[Huveldt, Deborah; Lewis-Tuffin, Laura J.; Anastasiadis, Panos Z.] Mayo Clin, Dept Canc Biol, Jacksonville, FL 32224 USA; [Rodriguez, Fausto; Giannini, Caterina] Mayo Clin, Dept Pathol, Rochester, MN USA; [Galanis, Evanthia] Mayo Clin, Dept Oncol, Rochester, MN USA; [Carlson, Brett L.; Schroeder, Mark A.; Sarkaria, Jann N.] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Anastasiadis, PZ (corresponding author), Mayo Clin, Dept Canc Biol, Jacksonville, FL 32224 USA.	panos@mayo.edu	Ramos, Joe W./L-6189-2013; Giannini, Caterina/AAB-7551-2022	Ramos, Joe W./0000-0002-9708-2115; 	National Institutes of Health [R01 CA100467, R01 NS069753, P50 CA108961]; NATIONAL CANCER INSTITUTE [R01CA154348, R01CA100467, P50CA108961] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS069753] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The work was supported by National Institutes of Health R01 CA100467, R01 NS069753, and a career development project P50 CA108961 (PZA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali SA, 2008, J NEUROSURG, V109, P268, DOI 10.3171/JNS/2008/109/8/0268; Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Angers-Loustau A, 2004, MOL CANCER RES, V2, P595; Bible KC, 1999, ANAL BIOCHEM, V267, P217, DOI 10.1006/abio.1998.2980; Bokstein F, 2008, CANCER-AM CANCER SOC, V112, P2267, DOI 10.1002/cncr.23401; Brunton VG, 2004, BBA-MOL CELL RES, V1692, P121, DOI 10.1016/j.bbamcr.2004.04.010; Carlson Brett L, 2011, Curr Protoc Pharmacol, VChapter 14, DOI 10.1002/0471141755.ph1416s52; Christopher LJ, 2008, DRUG METAB DISPOS, V36, P1357, DOI 10.1124/dmd.107.018267; Cloughesy TF, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.2010b; Coluccia AML, 2006, CANCER RES, V66, P2279, DOI 10.1158/0008-5472.CAN-05-2057; de Groot JF, 2010, NEURO-ONCOLOGY, V12, P233, DOI 10.1093/neuonc/nop027; Ding Q, 2003, J BIOL CHEM, V278, P39882, DOI 10.1074/jbc.M304685200; Du JY, 2009, NAT BIOTECHNOL, V27, P77, DOI 10.1038/nbt.1513; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Fong TAT, 1999, CANCER RES, V59, P99; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Garrett TA, 2007, EXP CELL RES, V313, P3285, DOI 10.1016/j.yexcr.2007.05.027; Giannini C, 2005, NEURO-ONCOLOGY, V7, P164, DOI 10.1215/S1152851704000821; Golas JM, 2005, CANCER RES, V65, P5358, DOI 10.1158/0008-5472.CAN-04-2484; Goldbrunner RH, 2004, NEUROSURGERY, V55, P426, DOI 10.1227/01.NEU.0000129551.64651.74; Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891; Jallal H, 2007, CANCER RES, V67, P1580, DOI 10.1158/0008-5472.CAN-06-2027; Johnson FM, 2005, CLIN CANCER RES, V11, P6924, DOI 10.1158/1078-0432.CCR-05-0757; Keunen O, 2011, P NATL ACAD SCI USA, V108, P3749, DOI 10.1073/pnas.1014480108; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Kleber S, 2008, CANCER CELL, V13, P235, DOI 10.1016/j.ccr.2008.02.003; Kunkel P, 2001, CANCER RES, V61, P6624; Laird AD, 2000, CANCER RES, V60, P4152; Lewis-Tuffin LJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013665; Li LM, 2003, MOL CELL BIOL, V23, P2883, DOI 10.1128/MCB.23.8.2883-2892.2003; Li Q, 2008, BIOCHEM J, V411, P531, DOI 10.1042/BJ20071534; Lluis JM, 2007, CANCER RES, V67, P7368, DOI 10.1158/0008-5472.CAN-07-0515; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Lu KV, 2009, CANCER RES, V69, P6889, DOI 10.1158/0008-5472.CAN-09-0347; Lund CV, 2006, J NEURO-ONCOL, V78, P19, DOI 10.1007/s11060-005-9068-y; Mariner DJ, 2001, J BIOL CHEM, V276, P28006, DOI 10.1074/jbc.M102443200; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Morton JP, 2010, GASTROENTEROLOGY, V139, P292, DOI 10.1053/j.gastro.2010.03.034; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nam S, 2005, CANCER RES, V65, P9185, DOI 10.1158/0008-5472.CAN-05-1731; Narayana A, 2012, J NEUROSURG, V116, P341, DOI 10.3171/2011.9.JNS11656; Norden AD, 2008, NEUROLOGY, V70, P779, DOI 10.1212/01.wnl.0000304121.57857.38; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Park CM, 2006, CANCER RES, V66, P8511, DOI 10.1158/0008-5472.CAN-05-4340; Park SI, 2008, CANCER RES, V68, P3323, DOI 10.1158/0008-5472.CAN-07-2997; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Plate KH, 2012, ACTA NEUROPATHOL, V124, P763, DOI 10.1007/s00401-012-1066-5; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Rubenstein JL, 2000, NEOPLASIA, V2, P306, DOI 10.1038/sj.neo.7900102; Salhia B, 2005, CANCER RES, V65, P8792, DOI 10.1158/0008-5472.CAN-05-0160; Sarkaria JN, 2007, MOL CANCER THER, V6, P1167, DOI 10.1158/1535-7163.MCT-06-0691; Sarkaria JN, 2006, CLIN CANCER RES, V12, P2264, DOI 10.1158/1078-0432.CCR-05-2510; Serrels A, 2006, MOL CANCER THER, V5, P3014, DOI 10.1158/1535-7163.MCT-06-0382; Shor AC, 2007, CANCER RES, V67, P2800, DOI 10.1158/0008-5472.CAN-06-3469; Soto E, 2008, J CELL BIOL, V183, P737, DOI 10.1083/jcb.200805113; Theurillat JP, 1999, AM J PATHOL, V154, P581, DOI 10.1016/S0002-9440(10)65303-5; Tran NL, 2006, CANCER RES, V66, P9535, DOI 10.1158/0008-5472.CAN-06-0418; Vredenburgh JJ, 2007, J CLIN ONCOL, V25, P4722, DOI 10.1200/JCO.2007.12.2440; Vredenburgh JJ, 2007, CLIN CANCER RES, V13, P1253, DOI 10.1158/1078-0432.CCR-06-2309; Vultur A, 2008, MOL CANCER THER, V7, P1185, DOI 10.1158/1535-7163.MCT-08-0126; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wick A, 2011, ANN NEUROL, V69, P586, DOI 10.1002/ana.22336; Yanagisawa M, 2006, J CELL BIOL, V174, P1087, DOI 10.1083/jcb.200605022; Yang L, 2008, CLIN CANCER RES, V14, P3993, DOI 10.1158/1078-0432.CCR-07-4152; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Zagzag D, 2000, PEDIATR NEUROSURG, V33, P49, DOI 10.1159/000028975	68	62	66	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2013	8	2							e56505	10.1371/journal.pone.0056505	http://dx.doi.org/10.1371/journal.pone.0056505			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	099EJ	23457577	Green Published, gold, Green Submitted			2023-01-03	WOS:000315602700077
J	Coombes, BK; Bisset, L; Brooks, P; Khan, A; Vicenzino, B				Coombes, Brooke K.; Bisset, Leanne; Brooks, Peter; Khan, Asad; Vicenzino, Bill			Effect of Corticosteroid Injection, Physiotherapy, or Both on Clinical Outcomes in Patients With Unilateral Lateral Epicondylalgia A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TENNIS ELBOW; ACHILLES-TENDON; NO SIGNS; INFLAMMATION; MICRODIALYSIS; GLUTAMATE; TISSUE; TENDINOPATHY; EFFICACY; THERAPY	Importance Corticosteroid injection and physiotherapy, common treatments for lateral epicondylalgia, are frequently combined in clinical practice. However, evidence on their combined efficacy is lacking. Objective To investigate the effectiveness of corticosteroid injection, multimodal physiotherapy, or both in patients with unilateral lateral epicondylalgia. Design, Setting, and Patients A2 x 2 factorial, randomized, injection-blinded, placebocontrolled trial was conducted at a single university research center and 16 primary care settings in Brisbane, Australia. A total of 165 patients aged 18 years or older with unilateral lateral epicondylalgia of longer than 6 weeks' duration were enrolled between July 2008 and May 2010; 1-year follow-up was completed in May 2011. Interventions Corticosteroid injection (n=43), placebo injection (n=41), corticosteroid injection plus physiotherapy (n=40), or placebo injection plus physiotherapy (n=41). Main Outcome Measures The 2 primary outcomes were 1-year global rating of change scores for complete recovery or much improvement and 1-year recurrence (defined as complete recovery or much improvement at 4 or 8 weeks, but not later) analyzed on an intention-to-treat basis (P < .01). Secondary outcomes included complete recovery or much improvement at 4 and 26 weeks. Results Corticosteroid injection resulted in lower complete recovery or much improvement at 1 year vs placebo injection (83% vs 96%, respectively; relative risk [RR], 0.86 [99% CI, 0.75-0.99]; P=.01) and greater 1-year recurrence (54% vs 12%; RR, 0.23 [99% CI, 0.10-0.51]; P < .001). The physiotherapy and no physiotherapy groups did not differ on 1-year ratings of complete recovery or much improvement (91% vs 88%, respectively; RR, 1.04 [99% CI, 0.90-1.19]; P=.56) or recurrence (29% vs 38%; RR, 1.31 [99% CI, 0.73-2.35]; P=.25). Similar patterns were found at 26 weeks, with lower complete recovery or much improvement after corticosteroid injection vs placebo injection (55% vs 85%, respectively; RR, 0.79 [99% CI, 0.62-0.99]; P < .001) and no difference between the physiotherapy and no physiotherapy groups (71% vs 69%, respectively; RR, 1.22 [99% CI, 0.97-1.53]; P=.84). At 4 weeks, there was a significant interaction between corticosteroid injection and physiotherapy (P=.01), whereby patients receiving the placebo injection plus physiotherapy had greater complete recovery or much improvement vs no physiotherapy (39% vs 10%, respectively; RR, 4.00 [99% CI, 1.07-15.00]; P=.004). However, there was no difference between patients receiving the corticosteroid injection plus physiotherapy vs corticosteroid alone (68% vs 71%, respectively; RR, 0.95 [99% CI, 0.65-1.38]; P=.57). Conclusion and Relevance Among patients with chronic unilateral lateral epicondylalgia, the use of corticosteroid injection vs placebo injection resulted in worse clinical outcomes after 1 year, and physiotherapy did not result in any significant differences.	[Coombes, Brooke K.; Khan, Asad; Vicenzino, Bill] Univ Queensland, Sch Hlth & Rehabil Sci, Div Physiotherapy, St Lucia, Qld 4072, Australia; [Bisset, Leanne] Griffith Univ, Griffith Hlth Inst, Southport, Qld 4215, Australia; [Bisset, Leanne] Gold Coast Hosp & Hlth Serv, Southport, Qld, Australia; [Brooks, Peter] Univ Melbourne, Australian Hlth Workforce Inst, Melbourne, Vic 3010, Australia	University of Queensland; Griffith University; Menzies Health Institute Queensland; Gold Coast University Hospital; University of Melbourne	Vicenzino, B (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Bldg 84A, St Lucia, Qld 4072, Australia.	b.vicenzino@uq.edu.au	Vicenzino, Bill/A-8492-2011; Khan, Asad/N-7481-2019; Khan, Asad/F-8739-2010; Coombes, Brooke/AAV-9060-2021; Coombes, Brooke/D-3456-2015; Bisset, Leanne/AAS-8947-2021	Vicenzino, Bill/0000-0003-0253-5933; Khan, Asad/0000-0003-4188-2065; Khan, Asad/0000-0003-4188-2065; Coombes, Brooke/0000-0002-6163-1047; Bisset, Leanne/0000-0001-8807-7093	Australian National Health and Medical Research Council [511238]	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	This study was supported by the Australian National Health and Medical Research Council grant 511238 awarded to Drs Bisset, Brooks, and Vicenzino.	Alfredson H, 1999, KNEE SURG SPORT TR A, V7, P378, DOI 10.1007/s001670050184; Alfredson H, 2000, ACTA ORTHOP SCAND, V71, P475, DOI 10.1080/000164700317381162; Alfredson H, 2001, J ORTHOPAED RES, V19, P881, DOI 10.1016/S0736-0266(01)00016-X; Bennell K, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2756; Bisset L, 2006, BMJ-BRIT MED J, V333, P939, DOI 10.1136/bmj.38961.584653.AE; Cetti R, 2003, ACTA ORTHOP SCAND, V74, P78, DOI 10.1080/00016470310013707; Cohen J., 2013, STAT POWER ANAL BEHA; Coombes BK, 2010, LANCET, V376, P1751, DOI 10.1016/S0140-6736(10)61160-9; Coombes BK, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-76; Fredberg U, 2008, SCAND J MED SCI SPOR, V18, P3, DOI 10.1111/j.1600-0838.2007.00746.x; Hay EM, 1999, BRIT MED J, V319, P964, DOI 10.1136/bmj.319.7215.964; Herbert RD, 2000, AUST J PHYSIOTHER, V46, P309, DOI 10.1016/S0004-9514(14)60292-0; Hsieh FY, 2003, EVAL HEALTH PROF, V26, P239, DOI 10.1177/0163278703255230; Ljung BO, 2004, J ORTHOPAED RES, V22, P321, DOI 10.1016/S0736-0266(03)00183-9; McAlister FA, 2003, JAMA-J AM MED ASSOC, V289, P2545, DOI 10.1001/jama.289.19.2545; Millar NL, 2010, AM J SPORT MED, V38, P2085, DOI 10.1177/0363546510372613; Newcomer Karen L, 2005, J Hand Ther, V18, P400, DOI 10.1197/j.jht.2005.07.001; Newcomer KL, 2001, CLIN J SPORT MED, V11, P214, DOI 10.1097/00042752-200110000-00002; Okcu G, 2002, CLIN RES, V13, P158; Osborne H, 2010, J SCI MED SPORT, V13, P380, DOI 10.1016/j.jsams.2009.09.009; Paavola Mika, 2002, Foot Ankle Clin, V7, P501, DOI 10.1016/S1083-7515(02)00056-6; Poltawski L, 2011, HAND THER, V16, P52, DOI 10.1258/ht.2011.011013; QUIN CE, 1954, LANCET, V2, P221; Rompe JD, 2007, J HAND THER, V20, P3, DOI 10.1197/j.jht.2006.10.003; Scott A, 2010, LANCET, V376, P1714, DOI 10.1016/S0140-6736(10)61308-6; Smidt N, 2002, LANCET, V359, P657, DOI 10.1016/S0140-6736(02)07811-X; Smidt N, 2006, J RHEUMATOL, V33, P2053; Tonks JH, 2007, INT J CLIN PRACT, V61, P240, DOI 10.1111/j.1742-1241.2006.01140.x; Vicenzino B, 2003, MANUAL THER, V8, P66, DOI 10.1016/S1356-689X(02)00157-1; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	30	193	193	2	45	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 6	2013	309	5					461	469		10.1001/jama.2013.129	http://dx.doi.org/10.1001/jama.2013.129			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	083LY	23385272	Green Submitted, Bronze			2023-01-03	WOS:000314466900027
J	Xing, H; Ruan, YH; Li, JY; Shang, H; Zhong, P; Wang, X; Liao, LJ; Li, HP; Zhang, M; Xue, YL; Wang, Z; Su, B; Liu, W; Dong, YH; Ma, YL; Li, HQ; Qin, GM; Chen, L; Pan, XH; Chen, X; Peng, G; Fu, JH; Chen, RY; Kang, LY; Shao, YM				Xing, Hui; Ruan, Yuhua; Li, Jingyun; Shang, Hong; Zhong, Ping; Wang, Xia; Liao, Lingjie; Li, Hanping; Zhang, Min; Xue, Yile; Wang, Zhe; Su, Bin; Liu, Wei; Dong, Yonghui; Ma, Yanling; Li, Huiqin; Qin, Guangming; Chen, Lin; Pan, Xiaohong; Chen, Xi; Peng, Guoping; Fu, Jihua; Chen, Ray Y.; Kang, Laiyi; Shao, Yiming		Chinese Natl HIVDR Surveillance Mo	HIV Drug Resistance and Its Impact on Antiretroviral Therapy in Chinese HIV-Infected Patients	PLOS ONE			English	Article							ZIDOVUDINE; OUTCOMES	Background: Highly active antiretroviral therapy (HAART) has significantly decreased mortality among Chinese HIV patients. However, emerging HIV drug resistance (HIVDR) poses a growing threat to the long-term success and durability of HAART. Methods: Three cross-sectional surveys were conducted across the country from 2004 to 2006, respectively. Patients completed a questionnaire and provided blood for CD4 cell count, HIV viral load (VL), and HIV resistance genotyping. Factors associated with HIVDR were identified by logistic regression. Results: 3667 unique patients were included across the three surveys. Among 2826 treatment-experienced patients, median duration of treatment was 17.4 (IQR 8.6-28.4) months and HIVDR was identified in 543 (19.2%). Factors significantly associated with HIVDR included ART drug distribution location, CD4 cell count, initial HAART regimen, self-reported medication adherence, and province. Conclusions: Virologic failure increased over time on therapy but a significant proportion of patients in failure had no resistance mutations identified, suggesting that treatment adherence is suboptimal and must be emphasized. Due to the significantly higher risk of HIVDR in certain provinces, additional steps to reduce HIVDR should be taken.	[Xing, Hui; Ruan, Yuhua; Wang, Xia; Liao, Lingjie; Shao, Yiming] Chinese Ctr Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Beijing, Peoples R China; [Xing, Hui; Ruan, Yuhua; Wang, Xia; Liao, Lingjie; Shao, Yiming] Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Beijing, Peoples R China; [Li, Jingyun; Li, Hanping] Acad Mil Med Sci, Inst Microbiol & Epidemiol, AIDS Res Dept, Beijing, Peoples R China; [Shang, Hong; Zhang, Min] China Med Univ, Affiliated Hosp 1, Minist Hlth, Key Lab Immunol AIDS, Shenyang, Peoples R China; [Zhong, Ping; Xue, Yile; Kang, Laiyi] Shanghai Municipal Ctr Dis Control & Prevent, Dept AIDS & STD, Shanghai, Peoples R China; [Wang, Zhe] Henan Ctr Dis Control & Prevent, Zhengzhou, Peoples R China; [Su, Bin] Anhui Ctr Dis Control & Prevent, Hefei, Peoples R China; [Liu, Wei] Guangxi Ctr Dis Control & Prevent, Nanning, Peoples R China; [Dong, Yonghui] Xinjiang Ctr Dis Control & Prevent, Urumqi, Peoples R China; [Ma, Yanling] Yunnan Ctr Dis Control & Prevent, Kunming, Peoples R China; [Li, Huiqin] Yunnan Infect Dis Hosp, Kunming, Peoples R China; [Qin, Guangming] Sichuan Ctr Dis Control & Prevent, Chengdu, Peoples R China; [Chen, Lin] Shenzhen Ctr Dis Control & Prevent, Shenzhen, Peoples R China; [Pan, Xiaohong] Zhejiang Ctr Dis Control & Prevent, Hangzhou, Zhejiang, Peoples R China; [Chen, Xi] Hunan Ctr Dis Control & Prevent, Changsha, Hunan, Peoples R China; [Peng, Guoping] Hubei Ctr Dis Control & Prevent, Wuhan, Peoples R China; [Fu, Jihua] Shandong Ctr Dis Control & Prevent, Jinan, Peoples R China; [Chen, Ray Y.] US Embassy Beijing, Natl Inst Allergy & Infect Dis, US Natl Inst Hlth, Beijing, Peoples R China	Chinese Center for Disease Control & Prevention; Chinese Center for Disease Control & Prevention; National Center for AIDS/STD Control & Prevention, Chinese Center for Disease Control & Prevention; Academy of Military Medical Sciences - China; China Medical University; Shanghai Center for Disease Control & Prevention; Shenzhen Center for Disease Control & Prevention (SZCDC)	Shao, YM (corresponding author), Chinese Ctr Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Beijing, Peoples R China.	yshao08@gmail.com	MA, YAN/HHN-2912-2022; Wang, Xia/C-3298-2018; Chen, Ray/T-5102-2019; Chen, Ray/GRJ-6736-2022	Wang, Xia/0000-0002-1684-7076; Chen, Ray/0000-0001-6344-1442	Ministry of Science and Technology of China [2012ZX10001-002, 2009DFB30420]; International Development Research Center of Canada [104519-010]; Chinese State Key Laboratory for Infectious Disease Develop Grant [2011SKLID102]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); International Development Research Center of Canada; Chinese State Key Laboratory for Infectious Disease Develop Grant	The Ministry of Science and Technology of China (2012ZX10001-002 and 2009DFB30420) and the International Development Research Center of Canada (#104519-010), and Chinese State Key Laboratory for Infectious Disease Develop Grant (2011SKLID102). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Boden D, 1999, JAMA-J AM MED ASSOC, V282, P1135, DOI 10.1001/jama.282.12.1135; Casado JL, 2000, AIDS, V14, pF1, DOI 10.1097/00002030-200001280-00001; DAQUILA RT, 1995, ANN INTERN MED, V122, P401, DOI 10.7326/0003-4819-122-6-199503150-00001; DeGruttola V, 2000, ANTIVIR THER, V5, P41; Dou ZH, 2010, INT J EPIDEMIOL, V39, pII56, DOI 10.1093/ije/dyq215; Dou ZH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013737; Garrido C, 2008, J ANTIMICROB CHEMOTH, V61, P694, DOI 10.1093/jac/dkm515; Joly V, 2000, ANTIMICROB AGENTS CH, V44, P3155, DOI 10.1128/AAC.44.11.3155-3157.2000; Liao LJ, 2010, JAIDS-J ACQ IMM DEF, V53, pS10, DOI 10.1097/QAI.0b013e3181c7d363; Liu TF, 2006, CLIN INFECT DIS, V42, P1608, DOI 10.1086/503914; Ma Y, 2010, INT J EPIDEMIOL, V39, P973, DOI 10.1093/ije/dyp233; Ruan YH, 2010, TROP MED INT HEALTH, V15, P1357, DOI 10.1111/j.1365-3156.2010.02621.x; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; Zhang F, 2008, NATL FREE HIV ANTIRE; Zhang FJ, 2007, AIDS, V21, pS143, DOI 10.1097/01.aids.0000304710.10036.2b; Zhang FJ, 2011, LANCET INFECT DIS, V11, P516, DOI 10.1016/S1473-3099(11)70097-4; Zhang FJ, 2009, ANN INTERN MED, V151, P241, DOI 10.7326/0003-4819-151-4-200908180-00006; Zhong P, 2007, AIDS RES HUM RETROV, V23, P847, DOI 10.1089/aid.2006.0196; Zolopa AR, 1999, ANN INTERN MED, V131, P813, DOI 10.7326/0003-4819-131-11-199912070-00003	19	32	46	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2013	8	2							e54917	10.1371/journal.pone.0054917	http://dx.doi.org/10.1371/journal.pone.0054917			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	092WJ	23405098	Green Published, gold, Green Submitted			2023-01-03	WOS:000315153400042
J	Malmo, J; Sandvig, A; Varum, KM; Strand, SP				Malmo, Jostein; Sandvig, Axel; Varum, Kjell M.; Strand, Sabina P.			Nanoparticle Mediated P-Glycoprotein Silencing for Improved Drug Delivery across the Blood-Brain Barrier: A siRNA-Chitosan Approach	PLOS ONE			English	Article							N-ACETYLATED CHITOSANS; IN-VITRO; ENDOTHELIAL-CELLS; RNA INTERFERENCE; MOLECULAR-WEIGHT; DOWN-REGULATION; GENE; RESISTANCE; EXPRESSION; MDR1	The blood-brain barrier (BBB), composed of tightly organized endothelial cells, limits the availability of drugs to therapeutic targets in the central nervous system. The barrier is maintained by membrane bound efflux pumps efficiently transporting specific xenobiotics back into the blood. The efflux pump P-glycoprotein (P-gp), expressed at high levels in brain endothelial cells, has several drug substrates. Consequently, siRNA mediated silencing of the P-gp gene is one possible strategy how to improve the delivery of drugs to the brain. Herein, we investigated the potential of siRNA-chitosan nanoparticles in silencing P-gp in a BBB model. We show that the transfection of rat brain endothelial cells mediated effective knockdown of P-gp with subsequent decrease in P-gp substrate efflux. This resulted in increased cellular delivery and efficacy of the model drug doxorubicin.	[Malmo, Jostein; Varum, Kjell M.; Strand, Sabina P.] Norwegian Univ Sci & Technol NTNU, Dept Biotechnol, Norwegian Biopolymer Lab NOBIPOL, Trondheim, Norway; [Malmo, Jostein; Sandvig, Axel] Norwegian Univ Sci & Technol NTNU, Dept Lab Med, Trondheim, Norway; [Sandvig, Axel] Norwegian Univ Sci & Technol NTNU, MI Lab, Trondheim, Norway; [Sandvig, Axel] Norwegian Univ Sci & Technol NTNU, Dept Circulat & Med Imaging, Trondheim, Norway; [Sandvig, Axel] Umea Univ Hosp, Dept Neurosurg, S-90185 Umea, Sweden	Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Umea University	Malmo, J (corresponding author), Norwegian Univ Sci & Technol NTNU, Dept Biotechnol, Norwegian Biopolymer Lab NOBIPOL, Trondheim, Norway.	jostein.malmo@ntnu.no			NTNU (Norges Teknisk-Naturvitenskapelige Universitet) (Norwegian University of Science and Technology)	NTNU (Norges Teknisk-Naturvitenskapelige Universitet) (Norwegian University of Science and Technology)	This work was supported by a Ph.D. grant from NTNU (Norges Teknisk-Naturvitenskapelige Universitet) (Norwegian University of Science and Technology) to JM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Babakhanian K, 2007, BIOCHEM BIOPH RES CO, V361, P301, DOI 10.1016/j.bbrc.2007.06.176; Baldrick P, 2010, REGUL TOXICOL PHARM, V56, P290, DOI 10.1016/j.yrtph.2009.09.015; Begley DJ, 1996, J NEUROCHEM, V67, P988; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; Daoud R, 2000, BIOCHEMISTRY-US, V39, P15344, DOI 10.1021/bi0020574; de Klerk OL, 2010, PSYCHIAT RES-NEUROIM, V183, P151, DOI 10.1016/j.pscychresns.2010.05.002; Demeule M, 2001, BIOCHEM BIOPH RES CO, V281, P827, DOI 10.1006/bbrc.2001.4312; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fellner S, 2002, J CLIN INVEST, V110, P1309, DOI 10.1172/JCI200215451; Fuest C, 2009, NEUROSCI LETT, V464, P47, DOI 10.1016/j.neulet.2009.08.014; Goralski KB, 2003, BRIT J PHARMACOL, V139, P35, DOI 10.1038/sj.bjp.0705227; Grayson ACR, 2006, PHARM RES-DORDR, V23, P1868, DOI 10.1007/s11095-006-9009-2; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; Gupta Y, 2007, J PHARM PHARMACOL, V59, P935, DOI 10.1211/jpp.59.7.0004; Han HD, 2010, CLIN CANCER RES, V16, P3910, DOI 10.1158/1078-0432.CCR-10-0005; Howard KA, 2006, MOL THER, V14, P476, DOI 10.1016/j.ymthe.2006.04.010; Jeong JH, 2007, BIOMATERIALS, V28, P1912, DOI 10.1016/j.biomaterials.2006.12.019; Kemper EM, 2003, CLIN CANCER RES, V9, P2849; Khoury M, 2006, ARTHRITIS RHEUM, V54, P1867, DOI 10.1002/art.21876; Larsson E, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.89; Lavertu M, 2006, BIOMATERIALS, V27, P4815, DOI 10.1016/j.biomaterials.2006.04.029; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; Liu XD, 2007, BIOMATERIALS, V28, P1280, DOI 10.1016/j.biomaterials.2006.11.004; Malmo J, 2012, J CONTROL RELEASE, V158, P261, DOI 10.1016/j.jconrel.2011.11.012; Malmo J, 2011, BIOMACROMOLECULES, V12, P721, DOI 10.1021/bm1013525; Matsui Y, 2005, PHARM RES-DORDR, V22, P2091, DOI 10.1007/s11095-005-8178-8; Meng HA, 2010, ACS NANO, V4, P4539, DOI 10.1021/nn100690m; MULLER C, 1995, J CELL PHYSIOL, V163, P538, DOI 10.1002/jcp.1041630314; Nordtveit RJ, 1996, CARBOHYD POLYM, V29, P163, DOI 10.1016/0144-8617(96)00003-3; Regina A, 1998, J NEUROCHEM, V71, P705; Rojanarata T, 2008, PHARM RES-DORDR, V25, P2807, DOI 10.1007/s11095-008-9648-6; ROUX F, 1994, J CELL PHYSIOL, V159, P101, DOI 10.1002/jcp.1041590114; Saito Takaya, 2012, Silence, V3, P3, DOI 10.1186/1758-907X-3-3; Sauna ZE, 2001, J BIOENERG BIOMEMBR, V33, P481, DOI 10.1023/A:1012875105006; Scheffer GL, 2002, J CLIN PATHOL, V55, P332, DOI 10.1136/jcp.55.5.332; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Strand SP, 2010, BIOMATERIALS, V31, P975, DOI 10.1016/j.biomaterials.2009.09.102; Susa M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010764; Techaarpornkul S, 2010, AAPS PHARMSCITECH, V11, P64, DOI 10.1208/s12249-009-9355-6; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; TISHLER DM, 1995, EPILEPSIA, V36, P1, DOI 10.1111/j.1528-1157.1995.tb01657.x; Tommeraas K, 2001, CARBOHYD RES, V333, P137, DOI 10.1016/S0008-6215(01)00130-6; Varum K.M., 2005, VERSATILITY, P625; Varum KM, 1997, CARBOHYD RES, V299, P99, DOI 10.1016/S0008-6215(96)00332-1; Weiss J, 2003, J PHARMACOL EXP THER, V305, P197, DOI 10.1124/jpet.102.046532; Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742; Wu H, 2003, CANCER RES, V63, P1515	49	62	63	2	90	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2013	8	1							e54182	10.1371/journal.pone.0054182	http://dx.doi.org/10.1371/journal.pone.0054182			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	077IQ	23372682	Green Published, gold, Green Submitted			2023-01-03	WOS:000314021500036
J	Borel, JC; Burel, B; Tamisier, R; Dias-Domingos, S; Baguet, JP; Levy, P; Pepin, JL				Borel, Jean-Christian; Burel, Benoit; Tamisier, Renaud; Dias-Domingos, Sonia; Baguet, Jean-Philippe; Levy, Patrick; Pepin, Jean-Louis			Comorbidities and Mortality in Hypercapnic Obese under Domiciliary Noninvasive Ventilation	PLOS ONE			English	Article							POSITIVE-PRESSURE VENTILATION; OBSTRUCTIVE SLEEP-APNEA; HYPOVENTILATION SYNDROME; ADULTS; PREVALENCE; PREDICTORS; COMMUNITY; SURVIVAL; OUTCOMES; THERAPY	Background: The higher mortality rate in untreated patients with obesity-associated hypoventilation is a strong rationale for long-term noninvasive ventilation (NIV). The impacts of comorbidities, medications and NIV compliance on survival of these patients remain largely unexplored. Methods: Observational cohort of hypercapnic obese patients initiated on NIV between March 2003 and July 2008. Survival curves were estimated by the Kaplan-Meier method. Anthropometric measurements, pulmonary function, blood gases, nocturnal SpO(2) indices, comorbidities, medications, conditions of NIV initiation and NIV compliance were used as covariates. Univariate and multivariate Cox models allowed to assess predictive factors of mortality. Results: One hundred and seven patients (56% women), in whom NIV was initiated in acute (36%) or chronic conditions, were followed during 43 +/- 14 months. The 1, 2, 3 years survival rates were 99%, 94%, and 89%, respectively. In univariate analysis, death was associated with older age (>61 years), low FEV1 (<66% predicted value), male gender, BMIxtime, concomitant COPD, NIV initiation in acute condition, use of inhaled corticosteroids, beta-blockers, nonthiazide diuretics, angiotensin-converting enzyme inhibitors and combination of cardiovascular drugs (one diuretic and at least one other cardiovascular agent). In multivariate analysis, combination of cardiovascular agents was the only factor independently associated with higher risk of death (HR = 5.3; 95% CI 1.18; 23.9). Female gender was associated with lower risk of death. Conclusion: Cardiovascular comorbidities represent the main factor predicting mortality in patient with obesity-associated hypoventilation treated by NIV. In this population, NIV should be associated with a combination of treatment modalities to reduce cardiovascular risk.	[Borel, Jean-Christian; Tamisier, Renaud; Dias-Domingos, Sonia; Levy, Patrick; Pepin, Jean-Louis] Univ Grenoble 1, Fac Med, INSERM, Lab HP2,U1042, Grenoble, France; [Baguet, Jean-Philippe] CHU Grenoble, Hop A Michallon, Dept Cardiol, F-38043 Grenoble, France; [Borel, Jean-Christian] AGIRadom, Dept Res & Dev, Meylan, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Borel, JC (corresponding author), Univ Grenoble 1, Fac Med, INSERM, Lab HP2,U1042, Grenoble, France.	j.borel@agiradom.com; jpepin@chu-grenoble.fr	Tamisier, Renaud/M-6858-2014; Borel, Jean Christian/AAC-5950-2019; LEVY, Patrick/AAX-2802-2020; Borel, Jean Christian JC/M-7135-2014; Lévy, Patrick/M-6903-2014; PEPIN, Jean-Louis/M-6549-2014; Baguet, Jean-Philippe/M-5536-2014	Tamisier, Renaud/0000-0003-1128-6529; Borel, Jean Christian/0000-0003-4140-6210; LEVY, Patrick/0000-0003-3174-7935; Lévy, Patrick/0000-0003-3632-1327; Pepin, Jean Louis/0000-0003-3832-2358				Adams TD, 2007, NEW ENGL J MED, V357, P753, DOI 10.1056/NEJMoa066603; Berg G, 2001, CHEST, V120, P377, DOI 10.1378/chest.120.2.377; Borel JC, 2011, RESPIROLOGY; Borel JC, 2012, CHEST, V141, P692, DOI 10.1378/chest.10-2531; Budweiser S, 2007, J INTERN MED, V261, P375, DOI 10.1111/j.1365-2796.2007.01765.x; Chaouat A, 2001, EUR RESPIR J, V17, P848, DOI 10.1183/09031936.01.17508480; Chaouat A, 1999, EUR RESPIR J, V13, P1091, DOI 10.1034/j.1399-3003.1999.13e25.x; Garcia-Aymerich J, 2011, THORAX, V66, P430, DOI 10.1136/thx.2010.154484; Heinemann F, 2007, RESP MED, V101, P1229, DOI 10.1016/j.rmed.2006.10.027; Kessler R, 2001, CHEST, V120, P369, DOI 10.1378/chest.120.2.369; Laub M, 2007, RESP MED, V101, P1074, DOI 10.1016/j.rmed.2006.10.007; Lee R, 2011, CURR OPIN PULM MED, V17, P79, DOI 10.1097/MCP.0b013e32834317bb; Machado MCL, 2010, EUR RESPIR J, V35, P132, DOI 10.1183/09031936.00192008; Marin JM, 2010, AM J RESP CRIT CARE, V182, P325, DOI 10.1164/rccm.200912-1869OC; Mokhlesi B, 2007, SLEEP BREATH, V11, P117, DOI 10.1007/s11325-006-0092-8; Mokhlesi B, 2010, RESP CARE, V55, P1347; Nowbar S, 2004, AM J MED, V116, P1, DOI 10.1016/j.amjmed.2003.08.022; Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901; Priou P, 2010, CHEST, V138, P84, DOI 10.1378/chest.09-2472; Quint JK, 2007, THORAX, V62, P462, DOI 10.1136/thx.2006.074245; Sanders MH, 2003, AM J RESP CRIT CARE, V167, P7, DOI 10.1164/rccm.2203046; Sharma SK, 2011, NEW ENGL J MED, V365, P2277, DOI 10.1056/NEJMoa1103944; Weber MA, 2012, J HYPERTENS, V30, P2213, DOI 10.1097/HJH.0b013e3283582ed6; Whitlock G, 2009, LANCET, V373, P1083, DOI 10.1016/S0140-6736(09)60318-4; Young T, 2002, ARCH INTERN MED, V162, P893, DOI 10.1001/archinte.162.8.893; Yusuf S, 2011, LANCET, V378, P1231, DOI 10.1016/S0140-6736(11)61215-4; Zhang YQ, 2012, J HYPERTENS, V30, P2202, DOI 10.1097/HJH.0b013e3283582eec	27	50	50	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2013	8	1							e52006	10.1371/journal.pone.0052006	http://dx.doi.org/10.1371/journal.pone.0052006			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072OV	23341888	Green Published, Green Submitted, gold			2023-01-03	WOS:000313682700011
J	Kumari, P; Sahal, D; Jain, SK; Chauhan, VS				Kumari, Pinky; Sahal, Dinkar; Jain, S. K.; Chauhan, Virander S.			Bioactivity Guided Fractionation of Leaves Extract of Nyctanthes arbor tristis (Harshringar) against P falciparum	PLOS ONE			English	Article							ANTIMALARIAL ACTIVITY; MEDICINAL-PLANTS; IN-VITRO	Background: Nyctanthes arbor-tristis (Harshringar, Night Jasmine) has been traditionally used in Ayurveda, Unani and other systems of medicine in India. The juice of its leaves has been used by various tribal populations of India in treatment of fevers resembling malaria. Aim of the study: This work reports the antiplasmodial activity guided fractionation of Harshringar leaves extract. Methodology: Crude ethanolic Harshringar leaves extract and its RPHPLC purified fractions were studied for antiplasmodial potency against 3D7 (CQ sensitive) and Dd2 (CQ resistant) strains of P. falciparum and subsequently subjected to bioassay guided fractionation using reverse phase chromatography to pursue the isolation of active fractions. Principal Findings: Harshringar crude leaves extract and some of its RPHPLC purified fractions exhibited promising antiplasmodial potency against 3D7 and Dd2 strains of P. falciparum. Conclusions: The present study has provided scientific validity to the traditional use of leaves extract of Harshringar against malaria leading to the conclusion that this plant holds promise with respect to antimalarial phytotherapy. This is the first scientific report of antiplasmodial activity of RPHPLC fractions of Harshringar leaves extract against P. falciparum strains.	[Kumari, Pinky; Sahal, Dinkar; Chauhan, Virander S.] Int Ctr Genet Engn & Biotechnol, Malaria Res Lab, New Delhi, India; [Jain, S. K.] Jamia Hamdard, Dept Biotechnol, New Delhi, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi; Jamia Hamdard University	Chauhan, VS (corresponding author), Int Ctr Genet Engn & Biotechnol, Malaria Res Lab, Aruna Asaf Ali Marg, New Delhi, India.	virander@icgeb.res.in	SAHAL, DINKAR/GYD-7570-2022; Chauhan, Virander S./K-5276-2019		Malaria Core Fund, ICGEB, New Delhi; University Grants Commission, New Delhi, India in the form of "CSIR-UGC Research Fellowship" [10-2(5)/2005(i)-E.U.II]	Malaria Core Fund, ICGEB, New Delhi; University Grants Commission, New Delhi, India in the form of "CSIR-UGC Research Fellowship"	This study was supported by Malaria Core Fund, ICGEB, New Delhi. All studies were conducted at ICGEB, New Delhi. Pinky Kumari got financial assistance from University Grants Commission, New Delhi, India in the form of "CSIR-UGC Research Fellowship, Award No - F.No. 10-2(5)/2005(i)-E.U.II". The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asase A, 2005, J ETHNOPHARMACOL, V99, P273, DOI 10.1016/j.jep.2005.02.020; BADAM L, 1988, INDIAN J MED RES, V87, P379; Bhattacharya S, 2009, INT J AESTHETIC ANTI, p[2, 1]; Bombardelli E, 1989, FITOTERAPIA, V60, P1; Charak S, 1949, SHRI GULABKUNVERBA A, VV, P23; CHITRAVANSHI V C, 1992, International Journal of Pharmacognosy, V30, P71; Chopra RN., 1958, INDIGENOUS DRUGS IND, P408; Eberle C, 2011, CHEMMEDCHEM, V6, P292, DOI 10.1002/cmdc.201000420; Ekland EH, 2008, INT J PARASITOL, V38, P743, DOI 10.1016/j.ijpara.2008.03.004; Gilberger TW, 1997, J BIOL CHEM, V272, P29584, DOI 10.1074/jbc.272.47.29584; Ginsburg H, 2011, MALARIA J, V10; Jonville MC, 2008, J ETHNOPHARMACOL, V120, P382, DOI 10.1016/j.jep.2008.09.005; Karnik SR, 2008, INDIAN J TRADIT KNOW, V7, P330; Kirtikar K. R., 1935, INDIAN MED PLANT, V2nd, P1526; LAL J, 1976, Indian Journal of Physiology and Pharmacology, V20, P64; Lusakibanza M, 2010, J ETHNOPHARMACOL, V129, P398, DOI 10.1016/j.jep.2010.04.007; MISRA P, 1991, International Journal of Pharmacognosy, V29, P19; Nadkarni K. M., 1976, INDIAN MAT MED, V1, P857; Pink R, 2005, NAT REV DRUG DISCOV, V4, P727, DOI 10.1038/nrd1824; Ramalhete C, 2008, WORKSHOP PLANTAS MED; RATHORE A, 1990, PHYTOCHEMISTRY, V29, P1917, DOI 10.1016/0031-9422(90)85040-M; Saxena RS, 2002, J ETHNOPHARMACOL, V81, P321, DOI 10.1016/S0378-8741(02)00088-0; SAXENA RS, 1987, J ETHNOPHARMACOL, V19, P193, DOI 10.1016/0378-8741(87)90041-9; Shandhar HK., 2011, J INT PHARMACEUTICA, V1, P77; Shukla AK, 2011, J ETHNOPHARMACOL, V134, P996, DOI 10.1016/j.jep.2011.01.044; Singha U. K., 1992, International Journal of Pharmacognosy, V30, P289; Smilkstein M, 2004, ANTIMICROB AGENTS CH, V48, P1803, DOI 10.1128/AAC.48.5.1803-1806.2004; TANDON JS, 1991, J NAT PROD, V54, P1102, DOI 10.1021/np50076a030; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; WHO, 2011, WORLD MALARIA REPORT 2011, P1; Willcox ML, 2000, PARASITOL TODAY, V16, P220, DOI 10.1016/S0169-4758(00)01678-1	31	11	12	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 26	2012	7	12							e51714	10.1371/journal.pone.0051714	http://dx.doi.org/10.1371/journal.pone.0051714			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	071TV	23300557	Green Published, Green Submitted, gold			2023-01-03	WOS:000313618800023
J	Papaxanthis, C; Paizis, C; White, O; Pozzo, T; Stucchi, N				Papaxanthis, Charalambos; Paizis, Christos; White, Olivier; Pozzo, Thierry; Stucchi, Natale			The Relation between Geometry and Time in Mental Actions	PLOS ONE			English	Article							MOTOR IMAGERY; POWER-LAW; REPRESENTATIONAL MOMENTUM; MOVEMENT VELOCITY; DRAWING MOVEMENTS; CURVATURE; MOTION; MEMORY; TRANSFORMATIONS; PERFORMANCE	Mental imagery is a cognitive tool that helps humans take decisions by simulating past and future events. The hypothesis has been advanced that there is a functional equivalence between actual and mental movements. Yet, we do not know whether there are any limitations to its validity even in terms of some fundamental features of actual movements, such as the relationship between space and time. Although it is impossible to directly measure the spatiotemporal features of mental actions, an indirect investigation can be conducted by taking advantage of the constraints existing in planar drawing movements and described by the two-thirds power law (2/3PL). This kinematic law describes one of the most impressive regularities observed in biological movements: movement speed decreases when curvature increases. Here, we compared the duration of identical actual and mental arm movements by changing the constraints imposed by the 2/3PL. In the first two experiments, the length of the trajectory remained constant, while its curvature (Experiment 1) or its number of inflexions (Experiment 2) was manipulated. The results showed that curvature, but not the number of inflexions, proportionally and similarly affected actual and mental movement duration, as expected from the 2/3PL. Two other control experiments confirmed that the results of Experiment 1 were not attributable to eye movements (Experiment 3) or to the perceived length of the displayed trajectory (Experiment 4). Altogether, our findings suggest that mental movement simulation is tuned to the kinematic laws characterizing actions and that kinematics of actual and mental movements is completely specified by the representation of their geometry.	[Papaxanthis, Charalambos; Paizis, Christos] Univ Bourgogne, Unite Format & Rech Sci & Tech Activites Phys & S, Ctr Expertise & Performance, F-21078 Dijon, France; [Papaxanthis, Charalambos; White, Olivier; Pozzo, Thierry] INSERM, U1093, F-21078 Dijon, France; [Pozzo, Thierry] Ist Italiano Tecnol, Dept Robot Brain & Cognit Sci, Genoa, Italy; [Stucchi, Natale] Univ Milano Bicocca, Dept Psychol, Milan, Italy; [Pozzo, Thierry] Inst Univ France, Paris, France	Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Istituto Italiano di Tecnologia - IIT; University of Milano-Bicocca; Institut Universitaire de France	Papaxanthis, C (corresponding author), Univ Bourgogne, Unite Format & Rech Sci & Tech Activites Phys & S, Ctr Expertise & Performance, F-21078 Dijon, France.	charalambos.papaxanthis@u-bourgogne.fr	White, Olivier/AAJ-6914-2020; PAIZIS, CHRISTOS/P-1848-2019	White, Olivier/0000-0002-9119-1329; Pozzo, Thierry/0000-0002-0585-7965; Stucchi, Natale/0000-0002-7695-4068				Bakker M, 2007, EXP BRAIN RES, V179, P497, DOI 10.1007/s00221-006-0807-x; Binet A, 1893, REV PHILOS, V35, P664; Courtine G, 2004, COGNITIVE BRAIN RES, V22, P67, DOI 10.1016/j.cogbrainres.2004.07.008; Dayan E, 2007, P NATL ACAD SCI USA, V104, P20582, DOI 10.1073/pnas.0710033104; de'Sperati C, 2003, J COGNITIVE NEUROSCI, V15, P1244, DOI 10.1162/089892903322598184; DECETY J, 1991, BEHAV BRAIN RES, V42, P1, DOI 10.1016/S0166-4328(05)80033-6; Decety Jean, 1995, Behavioural Brain Research, V72, P127, DOI 10.1016/0166-4328(96)00141-6; Demougeot L, 2011, J NEUROSCI, V31, P10712, DOI 10.1523/JNEUROSCI.6032-10.2011; Demougeot L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006769; deSperati C, 1997, J NEUROSCI, V17, P3932; Dounskaia N, 2007, BIOL CYBERN, V96, P147, DOI 10.1007/s00422-006-0109-1; Ehrsson HH, 2003, J NEUROPHYSIOL, V90, P3304, DOI 10.1152/jn.01113.2002; FINKE RA, 1986, J EXP PSYCHOL GEN, V115, P175, DOI 10.1037/0096-3445.115.2.175; FINKE RA, 1985, J EXP PSYCHOL LEARN, V11, P780, DOI 10.1037/0278-7393.11.1-4.780; Flash T, 2007, BIOL CYBERN, V96, P577, DOI 10.1007/s00422-007-0145-5; Freeman FN, 1914, PSYCHOL MONOGR, V17, P1, DOI 10.1037/h0093085; Gentili R, 2006, NEUROSCIENCE, V137, P761, DOI 10.1016/j.neuroscience.2005.10.013; Gentili R, 2010, J NEUROPHYSIOL, V104, P774, DOI 10.1152/jn.00257.2010; Gribble PL, 1996, J NEUROPHYSIOL, V76, P2853, DOI 10.1152/jn.1996.76.5.2853; Gueugneau N, 2008, BRAIN RES, V1187, P95, DOI 10.1016/j.brainres.2007.10.042; Guillot A, 2005, BRAIN RES REV, V50, P387, DOI 10.1016/j.brainresrev.2005.09.004; Hall C. R., 1997, J MENTAL IMAG, V21, P143, DOI DOI 10.1037/T07979-000; Harris CM, 1998, NATURE, V394, P780, DOI 10.1038/29528; Hubbard TL, 2005, PSYCHON B REV, V12, P822, DOI 10.3758/BF03196775; HUBBARD TL, 1995, PSYCHON B REV, V2, P322, DOI 10.3758/BF03210971; Ivanenko YP, 2002, NEUROREPORT, V13, P1171, DOI 10.1097/00001756-200207020-00020; Jeannerod M, 2001, NEUROIMAGE, V14, pS103, DOI 10.1006/nimg.2001.0832; KOSSLYN SM, 1978, J EXP PSYCHOL HUMAN, V4, P47, DOI 10.1037/0096-1523.4.1.47; LACQUANITI F, 1983, ACTA PSYCHOL, V54, P115, DOI 10.1016/0001-6918(83)90027-6; Maoz U, 2009, J NEUROPHYSIOL, V101, P1002, DOI 10.1152/jn.90702.2008; Munzert J, 2009, BRAIN RES REV, V60, P306, DOI 10.1016/j.brainresrev.2008.12.024; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PELLIZZER G, 1992, EXP BRAIN RES, V92, P326; Pellizzer G, 2009, CORTEX, V45, P356, DOI 10.1016/j.cortex.2008.04.008; Personnier P, 2010, BEHAV BRAIN RES, V206, P184, DOI 10.1016/j.bbr.2009.09.011; Pollick FE, 2009, CORTEX, V45, P325, DOI 10.1016/j.cortex.2008.03.010; Ranganathan VK, 2004, NEUROPSYCHOLOGIA, V42, P944, DOI 10.1016/j.neuropsychologia.2003.11.018; Rodriguez M, 2009, NEUROPSYCHOLOGIA, V47, P489, DOI 10.1016/j.neuropsychologia.2008.10.009; Schaal S, 2001, EXP BRAIN RES, V136, P60, DOI 10.1007/s002210000505; Schwartz AB, 2000, EUR J NEUROSCI, V12, P1851, DOI 10.1046/j.1460-9568.2000.00097.x; Schwartz AB, 1999, J NEUROPHYSIOL, V82, P2705, DOI 10.1152/jn.1999.82.5.2705; SHEPARD RN, 1971, SCIENCE, V171, P701, DOI 10.1126/science.171.3972.701; Shepard RN, 1986, MENTAL IMAGES THEIR, Vviii, P364; Sirigu A, 1996, SCIENCE, V273, P1564, DOI 10.1126/science.273.5281.1564; Skoura X, 2008, CORTEX, V44, P1271, DOI 10.1016/j.cortex.2007.07.008; Stinear CM, 2006, EXP BRAIN RES, V168, P157, DOI 10.1007/s00221-005-0078-y; Tasko SM, 2004, J PHONETICS, V32, P65, DOI 10.1016/S0095-4470(03)00006-8; THURSTONE LL, 1994, PSYCHOL REV, V101, P266, DOI 10.1037/0033-295X.101.2.266; Thurstone LL, 1927, PSYCHOL REV, V34, P273, DOI 10.1037/h0070288; Viviani P, 1997, J EXP PSYCHOL HUMAN, V23, P1232, DOI 10.1037/0096-1523.23.4.1232; VIVIANI P, 1989, PERCEPT PSYCHOPHYS, V46, P266, DOI 10.3758/BF03208089; VIVIANI P, 1992, J EXP PSYCHOL HUMAN, V18, P603, DOI 10.1037/0096-1523.18.3.603; VIVIANI P, 1995, J EXP PSYCHOL HUMAN, V21, P32, DOI 10.1037/0096-1523.21.1.32; VIVIANI P, 1982, NEUROSCIENCE, V7, P431, DOI 10.1016/0306-4522(82)90277-9; Wolpert DM, 2001, CURR BIOL, V11, pR729, DOI 10.1016/S0960-9822(01)00432-8	55	27	27	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2012	7	11							e51191	10.1371/journal.pone.0051191	http://dx.doi.org/10.1371/journal.pone.0051191			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	054WM	23226487	Green Submitted, gold, Green Published			2023-01-03	WOS:000312376100298
J	Auerbach, BJ; Reynolds, SJ; Lamorde, M; Merry, C; Kukunda-Byobona, C; Ocama, P; Semeere, AS; Ndyanabo, A; Boaz, I; Kiggundu, V; Nalugoda, F; Gray, RH; Wawer, MJ; Thomas, DL; Kirk, GD; Quinn, TC; Stabinski, L				Auerbach, Brandon J.; Reynolds, Steven J.; Lamorde, Mohammed; Merry, Concepta; Kukunda-Byobona, Collins; Ocama, Ponsiano; Semeere, Aggrey S.; Ndyanabo, Anthony; Boaz, Iga; Kiggundu, Valerian; Nalugoda, Fred; Gray, Ron H.; Wawer, Maria J.; Thomas, David L.; Kirk, Gregory D.; Quinn, Thomas C.; Stabinski, Lara		Rakai Hlth Sci Program	Traditional Herbal Medicine Use Associated with Liver Fibrosis in Rural Rakai, Uganda	PLOS ONE			English	Article							PYRROLIZIDINE ALKALOIDS; TRANSIENT ELASTOGRAPHY; VERNONIA-AMYGDALINA; ESSENTIAL OILS; PHARMACOKINETICS; TOXICITY; PLANTS; HEPATOTOXICITY; INFECTION; EXTRACTS	Background: Traditional herbal medicines are commonly used in sub-Saharan Africa and some herbs are known to be hepatotoxic. However little is known about the effect of herbal medicines on liver disease in sub-Saharan Africa. Methods: 500 HIV-infected participants in a rural HIV care program in Rakai, Uganda, were frequency matched to 500 HIV-uninfected participants. Participants were asked about traditional herbal medicine use and assessed for other potential risk factors for liver disease. All participants underwent transient elastography (FibroScanH) to quantify liver fibrosis. The association between herb use and significant liver fibrosis was measured with adjusted prevalence risk ratios (adjPRR) and 95% confidence intervals (CI) using modified Poisson multivariable logistic regression. Results: 19 unique herbs from 13 plant families were used by 42/1000 of all participants, including 9/500 HIV-infected participants. The three most-used plant families were Asteraceae, Fabaceae, and Lamiaceae. Among all participants, use of any herb (adjPRR = 2.2, 95% CI 1.3-3.5, p = 0.002), herbs from the Asteraceae family (adjPRR = 5.0, 95% CI 2.9-8.7, p<0.001), and herbs from the Lamiaceae family (adjPRR = 3.4, 95% CI 1.2-9.2, p = 0.017) were associated with significant liver fibrosis. Among HIV infected participants, use of any herb (adjPRR = 2.3, 95% CI 1.0-5.0, p = 0.044) and use of herbs from the Asteraceae family (adjPRR = 5.0, 95% CI 1.7-14.7, p = 0.004) were associated with increased liver fibrosis. Conclusions: Traditional herbal medicine use was independently associated with a substantial increase in significant liver fibrosis in both HIV-infected and HIV-uninfected study participants. Pharmacokinetic and prospective clinical studies are needed to inform herb safety recommendations in sub-Saharan Africa. Counseling about herb use should be part of routine health counseling and counseling of HIV-infected persons in Uganda.	[Auerbach, Brandon J.; Lamorde, Mohammed; Merry, Concepta; Semeere, Aggrey S.] Makerere Univ, Coll Hlth Sci, Infect Dis Inst, Kampala, Uganda; [Auerbach, Brandon J.; Ocama, Ponsiano] Harvard Univ, Sch Med, Boston, MA USA; [Reynolds, Steven J.; Quinn, Thomas C.; Stabinski, Lara] NIAID, Div Intramural Res, NIH, Bethesda, MD 20892 USA; [Reynolds, Steven J.; Thomas, David L.; Quinn, Thomas C.] Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA; [Lamorde, Mohammed; Merry, Concepta] Univ Dublin Trinity Coll, Dept Pharmacol & Therapeut, Sch Med, Dublin 2, Ireland; [Merry, Concepta] St James Hosp, Dublin, Ireland; [Ocama, Ponsiano; Semeere, Aggrey S.] Makerere Univ, Dept Med, Coll Hlth Sci, Kampala, Uganda; [Kukunda-Byobona, Collins] Makerere Univ, Dept Bot, Kampala, Uganda; [Ndyanabo, Anthony; Boaz, Iga; Kiggundu, Valerian; Nalugoda, Fred; Gray, Ron H.; Wawer, Maria J.] Rakai Hlth Sci Program, Entebbe, Uganda; [Gray, Ron H.; Wawer, Maria J.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Baltimore, MD USA; [Kirk, Gregory D.; Stabinski, Lara] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA	Makerere University; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; Trinity College Dublin; Trinity College Dublin; Makerere University; Makerere University; Rakai Health Sciences Program; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Auerbach, BJ (corresponding author), Makerere Univ, Coll Hlth Sci, Infect Dis Inst, Kampala, Uganda.	brandon_auerbach@hms.harvard.edu	Merry, Concepta/AAM-7887-2021; Kukunda, Collins B./AAA-3350-2021	Kukunda, Collins B./0000-0002-6586-6468; Semeere, Aggrey/0000-0003-1826-2239; Reynolds, Steven/0000-0002-5403-2759	United States National Institutes of Health (NIH) Bench; Division of Intramural Research, National Institutes of Allergy and Infectious Diseases, National Institutes of Health; National Institute on Drug Abuse [R01-AI-16078]; American Cancer Society [MRSG-07-284-01-CCE]; Department of the Army, United States Army Medical Research and Material Command [DAMD17-98-2-8007, R01 A134826, R01 A134265]; National Institute of Allergy and Infectious Diseases [R01 016078]; National Institute on Drug Abuse; National Institute of Child and Health Development. BJA [5P30HD06826]; Fogarty International Clinical Research Scholars (FICRS) program of the NIH [R24 TW007988]; FOGARTY INTERNATIONAL CENTER [R24TW007988] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001040, ZIAAI000361] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA016078] Funding Source: NIH RePORTER	United States National Institutes of Health (NIH) Bench; Division of Intramural Research, National Institutes of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); American Cancer Society(American Cancer Society); Department of the Army, United States Army Medical Research and Material Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); National Institute of Child and Health Development. BJA; Fogarty International Clinical Research Scholars (FICRS) program of the NIH; FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The study was primarily funded by the United States National Institutes of Health (NIH) Bench to Bedside Program. Additional support was provided by the Division of Intramural Research, National Institutes of Allergy and Infectious Diseases, National Institutes of Health. Support was also provided by the National Institute on Drug Abuse (PI: DLT, R01-AI-16078) and the American Cancer Society (PI: GDK, MRSG-07-284-01-CCE). The study was jointly conducted and benefited from close collaboration of researchers from the intramural NIH Laboratory of Immunoregulation, Johns Hopkins University, the Infectious Diseases Institute of Makerere University, and the Rakai Health Sciences Program. Support for the RHSP HIV Care Program was provided by the President's Emergency Fund for AIDS Relief (PEPFAR) and support for the Rakai Community Cohort Study was provided by the Department of the Army, United States Army Medical Research and Material Command Cooperative Agreement DAMD17-98-2-8007; grants R01 A134826 and R01 A134265 from the National Institute of Allergy and Infectious Diseases; grant R01 016078 (DLT) from the National Institute on Drug Abuse; and grant 5P30HD06826 from the National Institute of Child and Health Development. BJA and ASS were funded by the Fogarty International Clinical Research Scholars (FICRS) program of the NIH, administered by the Vanderbilt University Institute for Global Health (R24 TW007988). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adesanoye OA, 2010, EXP TOXICOL PATHOL, V62, P197, DOI 10.1016/j.etp.2009.05.008; Adesegun S A, 2008, Pak J Biol Sci, V11, P453, DOI 10.3923/pjbs.2008.453.457; AIDS Clinical Trials Group, 1994, TABL GRAD SEV AD PED; Ajila CM, 2010, FOOD CHEM TOXICOL, V48, P3406, DOI 10.1016/j.fct.2010.09.012; AKAH PA, 1992, PHYTOTHER RES, V6, P171, DOI 10.1002/ptr.2650060318; Al-Duais M, 2009, J AGR FOOD CHEM, V57, P5420, DOI 10.1021/jf9003626; Andersen ES, 2009, EUR J INTERN MED, V20, P339, DOI 10.1016/j.ejim.2008.09.020; Ashafa AOT, 2010, FOOD CHEM TOXICOL, V48, P1886, DOI 10.1016/j.fct.2010.04.029; Asres K, 2007, PHARMAZIE, V62, P709, DOI 10.1691/ph.2007.9.6766; Bakasso S, 2008, Pak J Biol Sci, V11, P1429, DOI 10.3923/pjbs.2008.1429.1435; Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21; Barry M, 1999, CLIN PHARMACOKINET, V36, P289, DOI 10.2165/00003088-199936040-00004; Beaman-Mbaya V, 1976, ANTIBIOTIC ACTION SO; Chen T, 2010, J APPL TOXICOL, V30, P183, DOI 10.1002/jat.1504; Chen Z, 2010, NETH J MED, V68, P252; Dara L, 2008, WORLD J GASTROENTERO, V14, P6999, DOI 10.3748/wjg.14.6999; Dickinson L, 2010, ANTIVIR RES, V85, P176, DOI 10.1016/j.antiviral.2009.07.017; Effraim K, 2002, AFR J BIOMED RES, V6, P21; Foubert K, 2010, TALANTA, V81, P1258, DOI 10.1016/j.talanta.2010.02.018; GUNDIDZA GM, 1992, CENT AFR J MED, V38, P290; Hamill FA, 2000, J ETHNOPHARMACOL, V70, P281, DOI 10.1016/S0378-8741(00)00180-X; Iwalokun BA, 2006, J MED FOOD, V9, P524, DOI 10.1089/jmf.2006.9.524; Kanwal Q, 2010, ANTIFUNGAL ACTIVITY; Kirk GD, 2009, CLIN INFECT DIS, V48, P963, DOI 10.1086/597350; Kuiate JR, 1999, FLAVOUR FRAG J, V14, P167, DOI 10.1002/(SICI)1099-1026(199905/06)14:3&lt;167::AID-FFJ802&gt;3.0.CO;2-O; Lamorde M, 2010, J ETHNOPHARMACOL, V130, P43, DOI 10.1016/j.jep.2010.04.004; Langlois-Klassen D, 2008, SOC SCI MED, V67, P165, DOI 10.1016/j.socscimed.2008.02.027; Manguro LOA, 2003, PHYTOCHEMISTRY, V64, P855, DOI 10.1016/S0031-9422(03)00428-X; Matias EF, 2010, BIOMED PHARMACOTHER, V23, P23; Mills E, 2005, AIDS, V19, P95, DOI 10.1097/00002030-200501030-00013; Mukazayire MJ, 2010, EXP TOXICOL PATHOL, V62, P289, DOI 10.1016/j.etp.2009.04.005; Nahdi A, 2010, NUTR RES, V30, P85, DOI 10.1016/j.nutres.2010.01.004; NGOUELA S, 1988, PLANTA MED, P476, DOI 10.1055/s-2006-962516; Njamen D, 2008, PHARMAZIE, V63, P164, DOI 10.1691/ph.2008.7639; Oyedeji OO, 2009, MOLECULES, V14, P1990, DOI 10.3390/molecules14061990; Piscitelli SC, 2002, CLIN INFECT DIS, V34, P234, DOI 10.1086/324351; Prakash AS, 1999, MUTAT RES-GEN TOX EN, V443, P53, DOI 10.1016/S1383-5742(99)00010-1; Prati D, 2002, ANN INTERN MED, V137, P1, DOI 10.7326/0003-4819-137-1-200207020-00006; RIDKER PM, 1989, LANCET, V1, P657, DOI 10.1016/S0140-6736(89)92154-5; Ruhl CE, 2012, HEPATOLOGY, V55, P447, DOI 10.1002/hep.24725; Stabinski L, 2011, ANTIVIR THER, V16, P405, DOI 10.3851/IMP1783; Tabuti JRS, 2010, J ETHNOPHARMACOL, V127, P130, DOI 10.1016/j.jep.2009.09.035; Tabuti JRS, 2003, J ETHNOPHARMACOL, V88, P19, DOI 10.1016/S0378-8741(03)00161-2; Tamokou JD, 2009, INDIAN J PHARMACOL, V41, P60, DOI 10.4103/0253-7613.51340; Taziebou LC, 2007, AFR J TRADIT COMPLEM, V4, P127; Teschke R, 2010, J CLIN PHARM THER, V35, P545, DOI 10.1111/j.1365-2710.2009.01131.x; van den Bout-van den Beukel CJP, 2006, DRUG METAB REV, V38, P477, DOI 10.1080/03602530600754065; Wawer MJ, 1998, AIDS, V12, P1211, DOI 10.1097/00002030-199810000-00014; Yang HN, 2010, J KOREAN MED SCI, V25, P492, DOI 10.3346/jkms.2010.25.3.492; YEONG ML, 1993, INT J EXP PATHOL, V74, P211	50	35	36	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 27	2012	7	11							e41737	10.1371/journal.pone.0041737	http://dx.doi.org/10.1371/journal.pone.0041737			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	048BS	23209545	Green Submitted, Green Published, gold			2023-01-03	WOS:000311885800001
J	Martinez, GJ; Rao, A				Martinez, Gustavo J.; Rao, Anjana			Cooperative Transcription Factor Complexes in Control	SCIENCE			English	Editorial Material							CRYSTAL-STRUCTURE; TERNARY COMPLEX; T-CELLS; JUN; STAT3; NFAT; IRF		[Martinez, Gustavo J.; Rao, Anjana] La Jolla Inst Allergy & Immunol, La Jolla, CA 92037 USA	La Jolla Institute for Immunology	Martinez, GJ (corresponding author), La Jolla Inst Allergy & Immunol, La Jolla, CA 92037 USA.	arao@liai.org		Martinez, Gustavo/0000-0003-0178-3329	NCI NIH HHS [R01 CA42471, R01 CA042471] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ansel KM, 2006, ANNU REV IMMUNOL, V24, P607, DOI 10.1146/annurev.immunol.23.021704.115821; Brass AL, 1996, GENE DEV, V10, P2335, DOI 10.1101/gad.10.18.2335; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Ciofani M, 2012, CELL, V151, P289, DOI 10.1016/j.cell.2012.09.016; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Escalante CR, 2002, MOL CELL, V10, P1097, DOI 10.1016/S1097-2765(02)00703-7; Glasmacher E, 2012, SCIENCE, V338, P975, DOI 10.1126/science.1228309; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Kwon H, 2009, IMMUNITY, V31, P941, DOI 10.1016/j.immuni.2009.10.008; Li P, 2012, NATURE, V490, P543, DOI 10.1038/nature11530; Martinez GJ, 2008, ANN NY ACAD SCI, V1143, P188, DOI 10.1196/annals.1443.021; Panne D, 2004, EMBO J, V23, P4384, DOI 10.1038/sj.emboj.7600453; Panne D, 2007, CELL, V129, P1111, DOI 10.1016/j.cell.2007.05.019; Tussiwand R, 2012, NATURE, V490, P502, DOI 10.1038/nature11531; Zhang XK, 1999, MOL CELL BIOL, V19, P7138	15	29	29	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 16	2012	338	6109					891	892		10.1126/science.1231310	http://dx.doi.org/10.1126/science.1231310			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	037DY	23161983	Green Accepted			2023-01-03	WOS:000311083600027
J	Myburgh, JA; Finfer, S; Bellomo, R; Billot, L; Cass, A; Gattas, D; Glass, P; Lipman, J; Liu, B; McArthur, C; McGuinness, S; Rajbhandari, D; Taylor, CB; Webb, SAR				Myburgh, John A.; Finfer, Simon; Bellomo, Rinaldo; Billot, Laurent; Cass, Alan; Gattas, David; Glass, Parisa; Lipman, Jeffrey; Liu, Bette; McArthur, Colin; McGuinness, Shay; Rajbhandari, Dorrilyn; Taylor, Colman B.; Webb, Steven A. R.		CHEST Investigators; Australian New Zealand Intensive	Hydroxyethyl Starch or Saline for Fluid Resuscitation in Intensive Care	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE KIDNEY INJURY; CRITICALLY-ILL PATIENTS; SEVERE SEPSIS; RENAL-FUNCTION; MULTICENTER; TRIAL; REPLACEMENT; THERAPY; UNITS	BACKGROUND The safety and efficacy of hydroxyethyl starch (HES) for fluid resuscitation have not been fully evaluated, and adverse effects of HES on survival and renal function have been reported. METHODS We randomly assigned 7000 patients who had been admitted to an intensive care unit (ICU) in a 1:1 ratio to receive either 6% HES with a molecular weight of 130 kD and a molar substitution ratio of 0.4 (130/0.4, Voluven) in 0.9% sodium chloride or 0.9% sodium chloride (saline) for all fluid resuscitation until ICU discharge, death, or 90 days after randomization. The primary outcome was death within 90 days. Secondary outcomes included acute kidney injury and failure and treatment with renal-replacement therapy. RESULTS A total of 597 of 3315 patients (18.0%) in the HES group and 566 of 3336 (17.0%) in the saline group died (relative risk in the HES group, 1.06; 95% confidence interval [CI], 0.96 to 1.18; P = 0.26). There was no significant difference in mortality in six predefined subgroups. Renal-replacement therapy was used in 235 of 3352 patients (7.0%) in the HES group and 196 of 3375 (5.8%) in the saline group (relative risk, 1.21; 95% CI, 1.00 to 1.45; P = 0.04). In the HES and saline groups, renal injury occurred in 34.6% and 38.0% of patients, respectively (P = 0.005), and renal failure occurred in 10.4% and 9.2% of patients, respectively (P = 0.12). HES was associated with significantly more adverse events (5.3% vs. 2.8%, P < 0.001). CONCLUSIONS In patients in the ICU, there was no significant difference in 90-day mortality between patients resuscitated with 6% HES (130/0.4) or saline. However, more patients who received resuscitation with HES were treated with renal-replacement therapy. (Funded by the National Health and Medical Research Council of Australia and others; CHEST ClinicalTrials.gov number, NCT00935168.)	[Myburgh, John A.] George Inst Global Hlth, Div Crit Care & Trauma, Sydney, NSW 2000, Australia; [Myburgh, John A.; Liu, Bette] Univ New S Wales, Sydney, NSW, Australia; [Myburgh, John A.] St George Hosp, Sydney, NSW, Australia; [Myburgh, John A.; Finfer, Simon; Cass, Alan; Gattas, David; Taylor, Colman B.] Univ Sydney, Sydney, NSW 2006, Australia; [Finfer, Simon] Royal N Shore Hosp, Sydney, NSW, Australia; [Gattas, David; Rajbhandari, Dorrilyn] Royal Prince Alfred Hosp, Sydney, NSW, Australia; [Bellomo, Rinaldo] Univ Melbourne, Melbourne, Vic, Australia; [Bellomo, Rinaldo] Austin Hosp, Melbourne, Vic 3084, Australia; [Lipman, Jeffrey] Univ Queensland, Brisbane, Qld, Australia; [Lipman, Jeffrey] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia; [Webb, Steven A. R.] Univ Western Australia, Perth, WA 6009, Australia; [Webb, Steven A. R.] Royal Perth Hosp, Perth, WA, Australia; [McArthur, Colin; McGuinness, Shay] Auckland City Hosp, Auckland, New Zealand	George Institute for Global Health; University of Sydney; University of New South Wales Sydney; St George Hospital; University of Sydney; Royal North Shore Hospital; University of Sydney; University of Sydney; University of Melbourne; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Queensland; Royal Brisbane & Women's Hospital; University of Western Australia; Royal Perth Hospital; University of Western Australia; Auckland City Hospital	Myburgh, JA (corresponding author), George Inst Global Hlth, Div Crit Care & Trauma, Level 13,321 Kent St, Sydney, NSW 2000, Australia.	jmyburgh@georgeinstitute.org.au	Lipman, Jeffrey/G-2211-2010; Leditschke, Isabel A/M-1186-2015; Billot, Laurent/Y-1241-2019; Presneill, Jeffrey J/B-4894-2012; Liu, Bette C/A-7581-2013; Gattas, David/AAN-9668-2020	Lipman, Jeffrey/0000-0002-5965-9876; Leditschke, Isabel A/0000-0003-2212-2140; Billot, Laurent/0000-0002-4975-9793; Presneill, Jeffrey J/0000-0001-7177-7667; Liu, Bette C/0000-0002-0787-5825; Gattas, David/0000-0002-9282-7093; Rajbhandari, Dorrilyn/0000-0001-8883-0428; Myburgh, John/0000-0003-4088-7016; Finfer, Simon/0000-0002-2785-5864; Aneman, Anders/0000-0003-2096-5304; Venkatesh, Bala/0000-0002-3234-5244; Whitehead, Christina/0000-0003-4561-7082; Jan, Stephen/0000-0003-2839-1405; Micallef, Sharon/0000-0002-8496-2324; SHEHABI, Yahya/0000-0003-4707-7462; Glass, Parisa/0000-0002-1334-7156; Thompson, Kelly/0000-0003-2304-8931; Bompoint, Severine/0000-0001-5226-4321; Bellomo, Rinaldo/0000-0002-1650-8939; McGuinness, Shay/0000-0003-0620-4787; Cass, Alan/0000-0002-3923-3173	National Health and Medical Research Council of Australia; Ministry of Health, New South Wales Government, Australia; Fresenius Kabi; Practitioner Fellowship from the National Health and Medical Research Council of Australia; Principal Research Fellowship from the National Health and Medical Research Council of Australia; Practitioner Fellowship from the Medical Research Foundation of the Royal Perth Hospital	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Ministry of Health, New South Wales Government, Australia; Fresenius Kabi; Practitioner Fellowship from the National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Principal Research Fellowship from the National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Practitioner Fellowship from the Medical Research Foundation of the Royal Perth Hospital	Supported by the National Health and Medical Research Council of Australia; the Ministry of Health, New South Wales Government, Australia; and Fresenius Kabi; and by a Practitioner Fellowship from the National Health and Medical Research Council of Australia (to Drs. Myburgh and Bellomo), by a Principal Research Fellowship from the National Health and Medical Research Council of Australia (to Dr. Cass), and by a Practitioner Fellowship from the Medical Research Foundation of the Royal Perth Hospital (to Dr. Webb).; Funded by the National Health and Medical Research Council of Australia and others; CHEST ClinicalTrials.gov number, NCT00935168.	[Anonymous], COCHRANE DATABASE SY; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Bunn F, 2012, COCHRANE DB SYST REV, V7; Christidis C, 2001, J HEPATOL, V35, P726, DOI 10.1016/S0168-8278(01)00200-8; Cohen J, 2001, CRIT CARE MED, V29, P880, DOI 10.1097/00003246-200104000-00039; Dart AB, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007594.pub2; Dickenmann M, 2008, AM J KIDNEY DIS, V51, P491, DOI 10.1053/j.ajkd.2007.10.044; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Finfer S, 2010, CRIT CARE, V14, DOI 10.1186/cc9293; Gattas DJ, 2012, ANESTH ANALG, V114, P159, DOI 10.1213/ANE.0b013e318236b4d6; Guidet B, 2012, CRIT CARE, V16, DOI 10.1186/cc11358; James MFM, 2011, BRIT J ANAESTH, V107, P693, DOI 10.1093/bja/aer229; Jover JL, 2009, REV ESP ANEST REANIM, V56, P27, DOI 10.1016/S0034-9356(09)70317-2; Kamann Stefanie, 2007, J Dtsch Dermatol Ges, V5, P204, DOI 10.1111/j.1610-0387.2007.06239.x; Kellum JA, 2007, CONTRIB NEPHROL, V156, P10; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Myburgh J, 2012, CRIT CARE RESUSC, V14, P44; Myburgh J, 2011, INTENS CARE MED, V37, P816, DOI 10.1007/s00134-010-2117-9; Ostermann M, 2012, NEPHROL DIAL TRANSPL, V27, P2242, DOI 10.1093/ndt/gfr707; Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242; Schortgen F, 2001, LANCET, V357, P911, DOI 10.1016/S0140-6736(00)04211-2; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016	24	1065	1147	2	90	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 15	2012	367	20					1901	1911		10.1056/NEJMoa1209759	http://dx.doi.org/10.1056/NEJMoa1209759			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	036MB	23075127	Bronze, Green Published			2023-01-03	WOS:000311029300006
J	Wang, YF; Wang, Y; Breed, DR; Manoharan, VN; Feng, L; Hollingsworth, AD; Weck, M; Pine, DJ				Wang, Yufeng; Wang, Yu; Breed, Dana R.; Manoharan, Vinothan N.; Feng, Lang; Hollingsworth, Andrew D.; Weck, Marcus; Pine, David J.			Colloids with valence and specific directional bonding	NATURE			English	Article							ASYMMETRIC FUNCTIONALIZATION; CLUSTERS; NANOPARTICLES; PARTICLES; ANISOTROPY	The ability to design and assemble three-dimensional structures from colloidal particles is limited by the absence of specific directional bonds. As a result, complex or low-coordination structures, common in atomic and molecular systems, are rare in the colloidal domain. Here we demonstrate a general method for creating the colloidal analogues of atoms with valence: colloidal particles with chemically distinct surface patches that imitate hybridized atomic orbitals, including sp, sp(2), sp(3), sp(3)d, sp(3)d(2) and sp(3)d(3). Functionalized with DNA with single-stranded sticky ends, patches on different particles can form highly directional bonds through programmable, specific and reversible DNA hybridization. These features allow the particles to self-assemble into 'colloidal molecules' with triangular, tetrahedral and other bonding symmetries, and should also give access to a rich variety of new microstructured colloidal materials.	[Feng, Lang; Hollingsworth, Andrew D.; Pine, David J.] NYU, Ctr Soft Matter Res, New York, NY 10003 USA; [Feng, Lang; Hollingsworth, Andrew D.; Pine, David J.] NYU, Dept Phys, New York, NY 10003 USA; [Wang, Yufeng; Wang, Yu; Weck, Marcus] NYU, Inst Mol Design, New York, NY 10003 USA; [Wang, Yufeng; Wang, Yu; Weck, Marcus] NYU, Dept Chem, New York, NY 10003 USA; [Breed, Dana R.] Dow Chem Co USA, Freeport, TX 77541 USA; [Manoharan, Vinothan N.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA; [Manoharan, Vinothan N.] Harvard Univ, Dept Phys, Cambridge, MA 02138 USA	New York University; New York University; New York University; New York University; Dow Chemical Company; Harvard University; Harvard University	Pine, DJ (corresponding author), NYU, Ctr Soft Matter Res, New York, NY 10003 USA.	marcus.weck@nyu.edu; pine@nyu.edu	Pine, David J/B-7740-2016; Feng, Lang/P-7891-2014; Manoharan, Vinothan N/C-1292-2008; Wang, Yu/E-7358-2015	Pine, David J/0000-0002-3304-6684; Manoharan, Vinothan N/0000-0003-0370-6095; Wang, Yu/0000-0003-1286-2401; Weck, Marcus/0000-0002-6486-4268; Wang, Yufeng/0000-0001-9409-7250	MRSEC Program of the National Science Foundation [DMR-0820341]; National Science Foundation [ChE-0911460]; MRI programme of the National Science Foundation [DMR-0923251]	MRSEC Program of the National Science Foundation(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS)); National Science Foundation(National Science Foundation (NSF)); MRI programme of the National Science Foundation	We thank M. T. Elsesser, D. Kraft, and G.-R. Yi for discussions. This work was supported partially by the MRSEC Program of the National Science Foundation under award number DMR-0820341. Additional financial support was provided by the National Science Foundation (ChE-0911460). We acknowledge support from the MRI programme of the National Science Foundation under award number DMR-0923251 for the purchase of a Zeiss field emission scanning electron microscope.	Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; Bianchi E, 2011, PHYS CHEM CHEM PHYS, V13, P6397, DOI 10.1039/c0cp02296a; Breed D. R., 2007, THESIS U CALIFORNIA; Chen Q, 2011, NATURE, V469, P381, DOI 10.1038/nature09713; Chen Q, 2011, SCIENCE, V331, P199, DOI 10.1126/science.1197451; Cho YS, 2007, CHEM MATER, V19, P3183, DOI 10.1021/cm070051w; Dreyfus R, 2010, PHYS REV E, V81, DOI 10.1103/PhysRevE.81.041404; Frenkel D, 2002, SCIENCE, V296, P65, DOI 10.1126/science.1070865; Glotzer SC, 2004, SCIENCE, V306, P419, DOI 10.1126/science.1099988; Glotzer SC, 2007, NAT MATER, V6, P557, DOI 10.1038/nmat1949; HO KM, 1990, PHYS REV LETT, V65, P3152, DOI 10.1103/PhysRevLett.65.3152; Hong L, 2008, LANGMUIR, V24, P621, DOI 10.1021/la7030818; Huo FW, 2006, ADV MATER, V18, P2304, DOI 10.1002/adma.200601178; Johnson PM, 2005, LANGMUIR, V21, P11510, DOI 10.1021/la0518750; Jones MR, 2011, J AM CHEM SOC, V133, P18865, DOI 10.1021/ja206777k; Khan A., 1985, MAKROMOL CHEM, V10, P215; Kraft DJ, 2009, SOFT MATTER, V5, P3823, DOI 10.1039/b910593j; Kraft DJ, 2009, J AM CHEM SOC, V131, P1182, DOI 10.1021/ja8079803; Leunissen ME, 2005, NATURE, V437, P235, DOI 10.1038/nature03946; Leunissen ME, 2009, NAT MATER, V8, P590, DOI [10.1038/nmat2471, 10.1038/NMAT2471]; Li F, 2011, ANGEW CHEM INT EDIT, V50, P360, DOI 10.1002/anie.201001451; Macfarlane RJ, 2011, SCIENCE, V334, P204, DOI 10.1126/science.1210493; Manoharan V. N., 2004, THESIS U CALIFORNIA; Manoharan VN, 2003, SCIENCE, V301, P483, DOI 10.1126/science.1086189; Meng GN, 2010, SCIENCE, V327, P560, DOI 10.1126/science.1181263; Miller MA, 2005, J PHYS CHEM B, V109, P23109, DOI 10.1021/jp0549632; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; Nelson DR, 2002, NANO LETT, V2, P1125, DOI [10.1021/nl0202096, 10.1021/n10202096]; Nykypanchuk D, 2008, NATURE, V451, P549, DOI 10.1038/nature06560; OTTEWILL RH, 1967, KOLLOID Z Z POLYM, V215, P161, DOI 10.1007/BF01520398; Pawar AB, 2010, MACROMOL RAPID COMM, V31, P150, DOI 10.1002/marc.200900614; Pawar AB, 2009, LANGMUIR, V25, P9057, DOI 10.1021/la900809b; Perro A, 2009, ANGEW CHEM INT EDIT, V48, P361, DOI 10.1002/anie.200802562; Romano F, 2011, J CHEM PHYS, V134, DOI 10.1063/1.3578182; Rossi L, 2011, SOFT MATTER, V7, P4139, DOI 10.1039/c0sm01246g; Sacanna S, 2010, NATURE, V464, P575, DOI 10.1038/nature08906; Sacanna S, 2011, CURR OPIN COLLOID IN, V16, P96, DOI 10.1016/j.cocis.2011.01.003; UGELSTAD J, 1979, MAKROMOL CHEM, V180, P737; van Kampen NG, 2007, NORTH-HOLL PERS LIBR, P292; Velikov KP, 2002, SCIENCE, V296, P106, DOI 10.1126/science.1067141; Walther A, 2008, SOFT MATTER, V4, P663, DOI 10.1039/b718131k; Xu XY, 2006, J AM CHEM SOC, V128, P9286, DOI 10.1021/ja061980b; Zerrouki D, 2006, LANGMUIR, V22, P57, DOI 10.1021/la051765t; Zhang G, 2005, NANO LETT, V5, P143, DOI 10.1012/nl048121a; Zhang ZL, 2005, LANGMUIR, V21, P11547, DOI 10.1021/la0513611; Zhang ZL, 2004, NANO LETT, V4, P1407, DOI 10.1021/nl0493500; Zoldesi CI, 2006, LANGMUIR, V22, P4343, DOI 10.1021/la060101w	47	786	795	16	677	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 1	2012	491	7422					51	U61		10.1038/nature11564	http://dx.doi.org/10.1038/nature11564			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	028PM	23128225	Green Submitted			2023-01-03	WOS:000310434500029
J	Regier, DA; Diorio, C; Ethier, MC; Alli, A; Alexander, S; Boydell, KM; Gassas, A; Taylor, J; Kellow, C; Mills, D; Sung, L				Regier, Dean A.; Diorio, Caroline; Ethier, Marie-Chantal; Alli, Amanda; Alexander, Sarah; Boydell, Katherine M.; Gassas, Adam; Taylor, Jonathan; Kellow, Charis; Mills, Denise; Sung, Lillian			Discrete Choice Experiment to Evaluate Factors That Influence Preferences for Antibiotic Prophylaxis in Pediatric Oncology	PLOS ONE			English	Article							MORTALITY	Background: Bacterial and fungal infections in pediatric oncology patients cause morbidity and mortality. The clinical utility of antimicrobial prophylaxis in children is uncertain and the personal utility of these agents is disputed. Objectives were to use a discrete choice experiment to: (1) describe the importance of attributes to parents and healthcare providers when deciding between use and non-use of antibacterial and antifungal prophylaxis; and (2) estimate willingness-to-pay for prophylactic strategies. Methods: Attributes were chances of infection, death and side effects, route of administration and cost of pharmacotherapy. Respondents were randomized to a discrete choice experiment outlining hypothetical treatment options to prevent antibacterial or antifungal infections. Each respondent was presented 16 choice tasks and was asked to choose between two unlabeled treatment options and an opt-out alternative (no prophylaxis). Results: 102 parents and 60 healthcare providers participated. For the antibacterial discrete choice experiment, frequency of administration was significantly associated with utility for parents but not for healthcare providers. Increasing chances of infection, death, side effects and cost were all significantly associated with decreased utility for parents and healthcare providers in both the antibacterial and antifungal discrete choice experiment. Parental willingness-to-pay was higher than healthcare providers for both strategies. Conclusion: Chances of infection, death, side effects and costs were all significantly associated with utility. Parents have higher willingness-to-pay for these strategies compared with healthcare providers. This knowledge can help to develop prophylaxis programs.	[Regier, Dean A.] British Columbia Canc Res Agcy, Canadian Ctr Appl Res Canc Control, Vancouver, BC, Canada; [Diorio, Caroline; Ethier, Marie-Chantal; Alli, Amanda; Taylor, Jonathan; Kellow, Charis; Sung, Lillian] Hosp Sick Children, Program Child Hlth Evaluat Sci, Toronto, ON M5G 1X8, Canada; [Alexander, Sarah; Gassas, Adam; Mills, Denise; Sung, Lillian] Hosp Sick Children, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada; [Boydell, Katherine M.] Hosp Sick Children, Community Hlth Syst Resource Grp, Toronto, ON M5G 1X8, Canada; [Ethier, Marie-Chantal] McMaster Univ, Program Hlth Res Methodol, Hamilton, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McMaster University	Sung, L (corresponding author), British Columbia Canc Res Agcy, Canadian Ctr Appl Res Canc Control, Vancouver, BC, Canada.	lillian.sung@sickkids.ca	Boydell, Katherine/AAR-2918-2021	Boydell, Katherine/0000-0002-1464-8532; Regier, Dean/0000-0001-8876-0511; Diorio, Caroline/0000-0002-8005-3836	Canadian Institutes of Health Research [87719]; Pediatric Oncology Group of Ontario Research Unit	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Pediatric Oncology Group of Ontario Research Unit	LS is supported by a New Investigator Award from the Canadian Institutes of Health Research (Grant no. 87719). This research is supported by the Pediatric Oncology Group of Ontario Research Unit. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Gafter-Gvili A, 2005, ANN INTERN MED, V142, P979, DOI 10.7326/0003-4819-142-12_Part_1-200506210-00008; Kuderer NM, 2006, CANCER-AM CANCER SOC, V106, P2258, DOI 10.1002/cncr.21847; LANCASTER KJ, 1966, J POLIT ECON, V74, P132, DOI 10.1086/259131; Lehrnbecher T, 2009, BRIT J HAEMATOL, V147, P125, DOI 10.1111/j.1365-2141.2009.07844.x; Louviere J., 2002, STATED CHOICE METHOD; Louviere J.J., 2000, STATED CHOICE METHOD; Regier DA, 2010, AM J HUM GENET, V86, P765, DOI 10.1016/j.ajhg.2010.03.009; Robenshtok E, 2007, J CLIN ONCOL, V25, P5471, DOI 10.1200/JCO.2007.12.3851; Ryan M, 2000, BMJ-BRIT MED J, V320, P1530, DOI 10.1136/bmj.320.7248.1530; SMALL KA, 1981, ECONOMETRICA, V49, P105, DOI 10.2307/1911129; Street D. J., 2007, CONSTRUCTION OPTIMAL; Sung LL, 2007, BLOOD, V110, P3532, DOI 10.1182/blood-2007-05-091942; Telser H, 2002, HEALTH ECON, V11, P129, DOI 10.1002/hec.653	13	23	23	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2012	7	10							e47470	10.1371/journal.pone.0047470	http://dx.doi.org/10.1371/journal.pone.0047470			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	038AF	23082169	gold, Green Published, Green Submitted			2023-01-03	WOS:000311146900065
J	Patil, SS; Gentschev, I; Adelfinger, M; Donat, U; Hess, M; Weibel, S; Nolte, I; Frentzen, A; Szalay, AA				Patil, Sandeep S.; Gentschev, Ivaylo; Adelfinger, Marion; Donat, Ulrike; Hess, Michael; Weibel, Stephanie; Nolte, Ingo; Frentzen, Alexa; Szalay, Aladar A.			Virotherapy of Canine Tumors with Oncolytic Vaccinia Virus GLV-1h109 Expressing an Anti-VEGF Single-Chain Antibody	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; MICROVASCULAR DENSITY; BREAST-TUMORS; NUDE-MICE; PET DOGS; THERAPY; CANCER; MODEL; MICROENVIRONMENT; ANGIOGENESIS	Virotherapy using oncolytic vaccinia virus (VACV) strains is one promising new strategy for cancer therapy. We have previously reported that oncolytic vaccinia virus strains expressing an anti-VEGF (Vascular Endothelial Growth Factor) single-chain antibody (scAb) GLAF-1 exhibited significant therapeutic efficacy for treatment of human tumor xenografts. Here, we describe the use of oncolytic vaccinia virus GLV-1h109 encoding GLAF-1 for canine cancer therapy. In this study we analyzed the virus-mediated delivery and production of scAb GLAF-1 and the oncolytic and immunological effects of the GLV-1h109 vaccinia virus strain against canine soft tissue sarcoma and canine prostate carcinoma in xenograft models. Cell culture data demonstrated that the GLV-1h109 virus efficiently infect, replicate in and destroy both tested canine cancer cell lines. In addition, successful expression of GLAF-1 was demonstrated in virus-infected canine cancer cells and the antibody specifically recognized canine VEGF. In two different xenograft models, the systemic administration of the GLV-1h109 virus was found to be safe and led to anti-tumor and immunological effects resulting in the significant reduction of tumor growth in comparison to untreated control mice. Furthermore, tumor-specific virus infection led to a continued production of functional scAb GLAF-1, resulting in inhibition of angiogenesis. Overall, the GLV-1h109-mediated cancer therapy and production of immunotherapeutic anti-VEGF scAb may open the way for combination therapy concept i.e. vaccinia virus mediated oncolysis and intratumoral production of therapeutic drugs in canine cancer patients.	[Patil, Sandeep S.; Gentschev, Ivaylo; Adelfinger, Marion; Donat, Ulrike; Hess, Michael; Weibel, Stephanie; Szalay, Aladar A.] Univ Wurzburg, Dept Biochem, Wurzburg, Germany; [Gentschev, Ivaylo; Frentzen, Alexa; Szalay, Aladar A.] Genelux Corp, San Diego Sci Ctr, San Diego, CA USA; [Nolte, Ingo] Univ Vet Med, Small Anim Clin, Hannover, Germany; [Szalay, Aladar A.] Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, Wurzburg, Germany; [Szalay, Aladar A.] Univ Wurzburg, Inst Mol Infect Biol, Wurzburg, Germany; [Szalay, Aladar A.] Univ Calif San Diego, Moores Canc Ctr, Dept Radiat Oncol, La Jolla, CA 92093 USA	University of Wurzburg; University of Veterinary Medicine Hannover, Foundation; University of Wurzburg; University of Wurzburg; University of California System; University of California San Diego	Szalay, AA (corresponding author), Univ Wurzburg, Dept Biochem, Wurzburg, Germany.	aaszalay@genelux.com	Gentschev, Ivaylo/F-9454-2011; Gentschev, Ivaylo/AAJ-5819-2021	Gentschev, Ivaylo/0000-0003-3743-6329; 	Research and Development Division of Genelux Corporation, San Diego, USA; Genelux Corp., San Diego, USA; Genelux Corporation; German Excellence Initiative; German Research Foundation (DFG); University of Wuerzburg in the funding programme Open Access Publishing; Genelux	Research and Development Division of Genelux Corporation, San Diego, USA; Genelux Corp., San Diego, USA; Genelux Corporation; German Excellence Initiative; German Research Foundation (DFG)(German Research Foundation (DFG)); University of Wuerzburg in the funding programme Open Access Publishing; Genelux	The research was supported by the Research and Development Division of Genelux Corporation, San Diego, USA, and a Service Grant to the University of Wurzburg, Germany also funded by Genelux Corp., San Diego, USA. IG AF and AAS are employees and shareholders of Genelux. MA, UD, MH and SW were supported by grants of Genelux Corporation. SSP is a graduate fellow and supported by a grant of the German Excellence Initiative to the Graduate School of Life Sciences, University of Wuerzburg. This publication was funded by the German Research Foundation (DFG) and the University of Wuerzburg in the funding programme Open Access Publishing. No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; I. Gentschev, A. Frentzen and A. A. Szalay have financial interests in Genelux Corporation, and M. Adelfinger U. Donar, M. Hess and S. Weibel were supported by grants of Genelux Corporation. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. However, no direct financial support was provided by Genelux for the completion of this study.	Arendt M, 2009, VET COMP ONCOL, V7, P153, DOI 10.1111/j.1476-5829.2009.00187.x; Breitbach CJ, 2007, MOL THER, V15, P1686, DOI 10.1038/sj.mt.6300215; de Queiroz GF, 2010, J VET DIAGN INVEST, V22, P105, DOI 10.1177/104063871002200121; FALKNER FG, 1990, J VIROL, V64, P3108, DOI 10.1128/JVI.64.6.3108-3111.1990; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Frentzen A, 2009, P NATL ACAD SCI USA, V106, P12915, DOI 10.1073/pnas.0900660106; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Gentschev I, 2009, CANCER GENE THER, V16, P320, DOI 10.1038/cgt.2008.87; Gentschev I, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/489759; Gentschev I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037239; Gentschev I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022069; Gentschev I, 2010, J ONCOL, V2010, DOI 10.1155/2010/736907; Gerber HP, 2000, CANCER RES, V60, P6253; Gerber HP, 2005, CANCER RES, V65, P671; Gil M, 2011, BRIT J CANCER, V105, P1512, DOI 10.1038/bjc.2011.429; Gregory AD, 2011, CANCER RES, V71, P2411, DOI 10.1158/0008-5472.CAN-10-2583; Hemminki A, 2003, MOL THER, V7, P163, DOI 10.1016/S1525-0016(02)00049-7; Hess M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-172; Jain RK, 2001, ADV DRUG DELIVER REV, V46, P149, DOI 10.1016/S0169-409X(00)00131-9; John LB, 2012, CANCER RES, V72, P1651, DOI 10.1158/0008-5472.CAN-11-2788; Kamstock D, 2007, CANCER IMMUNOL IMMUN, V56, P1299, DOI 10.1007/s00262-007-0282-7; Kelsey JL, 1998, EPIDEMIOL REV, V20, P204, DOI 10.1093/oxfordjournals.epirev.a017981; Liang WC, 2006, J BIOL CHEM, V281, P951, DOI 10.1074/jbc.M508199200; Merlo DF, 2008, J VET INTERN MED, V22, P976, DOI 10.1111/j.1939-1676.2008.0133.x; Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785; Ochando JC, 2012, IMMUNOL RES; Padera TP, 2004, NATURE, V427, P695, DOI 10.1038/427695a; Patil SS, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-3; Patruno R, 2009, J CELL MOL MED, V13, P555, DOI 10.1111/j.1582-4934.2008.00355.x; Peranzoni E, 2010, CURR OPIN IMMUNOL, V22, P238, DOI 10.1016/j.coi.2010.01.021; Quesada AR, 2007, BIOESSAYS, V29, P1159, DOI 10.1002/bies.20655; Reimann-Berg N, 2011, CYTOGENET GENOME RES, V132, P16, DOI 10.1159/000317077; Ruffell B, 2012, TRENDS IMMUNOL, V33, P119, DOI 10.1016/j.it.2011.12.001; Suter SE, 2005, CLIN CANCER RES, V11, P1579, DOI 10.1158/1078-0432.CCR-04-1944; Weibel S, 2008, CELL MICROBIOL, V10, P1235, DOI 10.1111/j.1462-5822.2008.01122.x; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/j.ccr.2004.10.011; Zhang Q, 2007, CANCER RES, V67, P10038, DOI 10.1158/0008-5472.CAN-07-0146; Zizzo N, 2010, LEUKEMIA LYMPHOMA, V51, P291, DOI 10.3109/10428190903452818	39	25	35	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2012	7	10							e47472	10.1371/journal.pone.0047472	http://dx.doi.org/10.1371/journal.pone.0047472			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	024UX	23091626	Green Published, gold, Green Submitted			2023-01-03	WOS:000310135800049
J	Vukoti, K; Kimura, T; Macke, L; Gawrisch, K; Yeliseev, A				Vukoti, Krishna; Kimura, Tomohiro; Macke, Laura; Gawrisch, Klaus; Yeliseev, Alexei			Stabilization of Functional Recombinant Cannabinoid Receptor CB2 in Detergent Micelles and Lipid Bilayers	PLOS ONE			English	Article							PROTEIN-COUPLED-RECEPTORS; ADENOSINE A(2A) RECEPTOR; ESCHERICHIA-COLI; LIGAND STABILIZATION; CRYSTAL-STRUCTURE; PICHIA-PASTORIS; DRUG DISCOVERY; EXPRESSION; PURIFICATION; ACTIVATION	Elucidation of the molecular mechanisms of activation of G protein-coupled receptors (GPCRs) is among the most challenging tasks for modern membrane biology. For studies by high resolution analytical methods, these integral membrane receptors have to be expressed in large quantities, solubilized from cell membranes and purified in detergent micelles, which may result in a severe destabilization and a loss of function. Here, we report insights into differential effects of detergents, lipids and cannabinoid ligands on stability of the recombinant cannabinoid receptor CB2, and provide guidelines for preparation and handling of the fully functional receptor suitable for a wide array of downstream applications. While we previously described the expression in Escherichia coli, purification and liposome-reconstitution of multi-milligram quantities of CB2, here we report an efficient stabilization of the recombinant receptor in micelles - crucial for functional and structural characterization. The effects of detergents, lipids and specific ligands on structural stability of CB2 were assessed by studying activation of G proteins by the purified receptor reconstituted into liposomes. Functional structure of the ligand binding pocket of the receptor was confirmed by binding of H-2-labeled ligand measured by solid-state NMR. We demonstrate that a concerted action of an anionic cholesterol derivative, cholesteryl hemisuccinate (CHS) and high affinity cannabinoid ligands CP-55,940 or SR-144,528 are required for efficient stabilization of the functional fold of CB2 in dodecyl maltoside (DDM)/CHAPS detergent solutions. Similar to CHS, the negatively charged phospholipids with the serine headgroup (PS) exerted significant stabilizing effects in micelles while uncharged phospholipids were not effective. The purified CB2 reconstituted into lipid bilayers retained functionality for up to several weeks enabling high resolution structural studies of this GPCR at physiologically relevant conditions.	[Vukoti, Krishna; Kimura, Tomohiro; Macke, Laura; Gawrisch, Klaus; Yeliseev, Alexei] NIAAA, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Yeliseev, A (corresponding author), NIAAA, NIH, Bethesda, MD USA.	yeliseeva@mail.nih.gov	Yeliseev, Alexei A/B-3143-2009; Kimura, Tomohiro/AEJ-1621-2022	Kimura, Tomohiro/0000-0002-4192-7852	intramural research program of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000003] Funding Source: NIH RePORTER	intramural research program of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This study was supported by the intramural research program of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH), to KG. KG participated in study design, data collection and analysis, decision to publish, and preparation of the manuscript.	Attrill H, 2009, PROTEIN EXPRES PURIF, V64, P32, DOI 10.1016/j.pep.2008.10.001; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Feng W, 2002, PROTEIN EXPRES PURIF, V26, P496, DOI 10.1016/S1046-5928(02)00569-7; Filppula S, 2004, J PEPT RES, V64, P225, DOI 10.1111/j.1399-3011.2004.00188.x; Gawrisch K, 2008, CHEM PHYS LIPIDS, V153, P64, DOI 10.1016/j.chemphyslip.2008.02.016; Glass M, 1999, MOL PHARMACOL, V56, P1362, DOI 10.1124/mol.56.6.1362; Grisshammer R, 1999, BIOCHEM SOC T, V27, P899, DOI 10.1042/bst0270899; Grisshammer R, 2009, METHOD ENZYMOL, V463, P631, DOI 10.1016/S0076-6879(09)63036-6; Harrison C, 2003, LIFE SCI, V74, P489, DOI 10.1016/j.lfs.2003.07.005; Inagaki S, 2012, J MOL BIOL, V417, P95, DOI 10.1016/j.jmb.2012.01.023; Jaakola VP, 2008, SCIENCE, V322, P1211, DOI 10.1126/science.1164772; Kimura T, 2012, J BIOL CHEM, V287, P4076, DOI 10.1074/jbc.M111.268425; Kimura T, 2009, BIOPHYS J, V96, P4916, DOI 10.1016/j.bpj.2009.03.033; Kobilka BK, 2007, BBA-BIOMEMBRANES, V1768, P794, DOI 10.1016/j.bbamem.2006.10.021; Krepkiy D, 2006, PROTEIN EXPRES PURIF, V49, P60, DOI 10.1016/j.pep.2006.03.002; Kubota M, 2009, J BIOCHEM, V146, P875, DOI 10.1093/jb/mvp132; Lebon G, 2011, NATURE, V474, P521, DOI 10.1038/nature10136; Lin SS, 1996, BIOCHEMISTRY-US, V35, P14445, DOI 10.1021/bi961619+; LINDER ME, 1990, J BIOL CHEM, V265, P8243; Link AJ, 2008, PROTEIN SCI, V17, P1857, DOI 10.1110/ps.035980.108; Lorch M, 2011, PRODUCTION OF MEMBRANE PROTEINS: STRATEGIES FOR EXPRESSION AND ISOLATION, P361; Magnani F, 2008, P NATL ACAD SCI USA, V105, P10744, DOI 10.1073/pnas.0804396105; Magnin T, 2009, PROTEIN EXPRES PURIF, V64, P1, DOI 10.1016/j.pep.2008.09.007; Mancia F, 2007, MOL BIOSYST, V3, P723, DOI 10.1039/B713558K; McKallip RJ, 2002, BLOOD, V100, P627, DOI 10.1182/blood-2002-01-0098; Mumby SM, 1994, HETEROTRIMERIC G, V237, P254; Niu SL, 2004, J BIOL CHEM, V279, P31098, DOI 10.1074/jbc.M404376200; O'Malley MA, 2011, BIOPHYS J, V100, pL11, DOI 10.1016/j.bpj.2010.12.3698; Ott D, 2005, PROTEIN ENG DES SEL, V18, P153, DOI 10.1093/protein/gzi012; Pello OM, 2008, EUR J IMMUNOL, V38, P537, DOI 10.1002/eji.200737630; Pertwee RG, 2002, PHARMACOL THERAPEUT, V95, P165, DOI 10.1016/S0163-7258(02)00255-3; Ratnala VRP, 2006, BIOTECHNOL LETT, V28, P767, DOI 10.1007/s10529-006-9005-y; Robertson N, 2011, NEUROPHARMACOLOGY, V60, P36, DOI 10.1016/j.neuropharm.2010.07.001; Sanchez C, 2001, CANCER RES, V61, P5784; Sarramegna V, 2006, CELL MOL LIFE SCI, V63, P1149, DOI 10.1007/s00018-005-5557-6; Sarvazyan NA, 1998, J BIOL CHEM, V273, P7934, DOI 10.1074/jbc.273.14.7934; Serrano-Vega MJ, 2008, P NATL ACAD SCI USA, V105, P877, DOI 10.1073/pnas.0711253105; Serrano-Vega MJ, 2009, MOL MEMBR BIOL, V26, P385, DOI 10.3109/09687680903208239; Shibata Y, 2009, J MOL BIOL, V390, P262, DOI 10.1016/j.jmb.2009.04.068; Sykora J, 2009, BBA-BIOMEMBRANES, V1788, P324, DOI 10.1016/j.bbamem.2008.11.008; THOMAS BF, 1990, J PHARMACOL EXP THER, V255, P624; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794; Yao ZP, 2005, ANAL BIOCHEM, V343, P344, DOI 10.1016/j.ab.2005.05.002; Yeliseev AA, 2005, PROTEIN SCI, V14, P2638, DOI 10.1110/ps.051550305; Yeliseev A, 2011, PRODUCTION OF MEMBRANE PROTEINS: STRATEGIES FOR EXPRESSION AND ISOLATION, P219; Yeliseev A, 2007, PROTEIN EXPRES PURIF, V53, P153, DOI 10.1016/j.pep.2006.12.003; Zhang RD, 2007, PROTEIN EXPRES PURIF, V55, P225, DOI 10.1016/j.pep.2007.03.018	48	37	37	0	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2012	7	10							e46290	10.1371/journal.pone.0046290	http://dx.doi.org/10.1371/journal.pone.0046290			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	015NU	23056277	Green Published, Green Submitted, gold			2023-01-03	WOS:000309454000030
J	Smith, ZJ; Chu, KQ; Wachsmann-Hogiu, S				Smith, Zachary J.; Chu, Kaiqin; Wachsmann-Hogiu, Sebastian			Nanometer-Scale Sizing Accuracy of Particle Suspensions on an Unmodified Cell Phone Using Elastic Light Scattering	PLOS ONE			English	Article							SIZE DISTRIBUTION; MICROSCOPY; CYTOMETRY	We report on the construction of a Fourier plane imaging system attached to a cell phone. By illuminating particle suspensions with a collimated beam from an inexpensive diode laser, angularly resolved scattering patterns are imaged by the phone's camera. Analyzing these patterns with Mie theory results in predictions of size distributions of the particles in suspension. Despite using consumer grade electronics, we extracted size distributions of sphere suspensions with better than 20 nm accuracy in determining the mean size. We also show results from milk, yeast, and blood cells. Performing these measurements on a portable device presents opportunities for field-testing of food quality, process monitoring, and medical diagnosis.	[Smith, Zachary J.; Chu, Kaiqin; Wachsmann-Hogiu, Sebastian] Univ Calif Davis, Ctr Biophoton Sci & Technol, Sacramento, CA 95817 USA; [Wachsmann-Hogiu, Sebastian] Univ Calif Davis, Dept Pathol & Lab Med, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis	Smith, ZJ (corresponding author), Univ Calif Davis, Ctr Biophoton Sci & Technol, Sacramento, CA 95817 USA.	zsmith@ucdavis.edu; swachsmann@ucdavis.edu	Smith, Zachary/S-2211-2019; Smith, Zachary/K-6888-2016	Smith, Zachary/0000-0002-7946-7863; 	Center for Biophotonics Science and Technology;  [PHY0120999]	Center for Biophotonics Science and Technology; 	This work was supported by the Center for Biophotonics Science and Technology, a designated NSF Science and Technology Center managed by the University of California Davis, under Cooperative Agreement No. PHY0120999. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BESSMAN JD, 1983, AM J CLIN PATHOL, V80, P322, DOI 10.1093/ajcp/80.3.322; Breslauer DN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006320; Collins TJ, 2007, BIOTECHNIQUES, V43, P25, DOI 10.2144/000112517; Damania D, 2012, CANCER RES, V72, P2720, DOI 10.1158/0008-5472.CAN-11-3807; GREEN R, 1989, BLOOD CELLS, V15, P481; Hammer M, 1998, APPL OPTICS, V37, P7410, DOI 10.1364/AO.37.007410; KIM YR, 1983, CYTOMETRY, V3, P419, DOI 10.1002/cyto.990030606; LATIMER P, 1968, J COLLOID INTERF SCI, V27, P475, DOI 10.1016/0021-9797(68)90184-7; LIN SHC, 1971, BIOCHEMISTRY-US, V10, P4788, DOI 10.1021/bi00801a029; Michalski MC, 2002, LAIT, V82, P193, DOI 10.1051/lait:2002004; Mudanyali O, 2010, LAB CHIP, V10, P2419, DOI 10.1039/c004829a; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; Paquin P, 1999, INT DAIRY J, V9, P329, DOI 10.1016/S0958-6946(99)00083-7; Pasternack RM, 2011, CYTOM PART A, V79A, P137, DOI 10.1002/cyto.a.21011; Smith ZJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017150; Smith ZJ, 2009, REV SCI INSTRUM, V80, DOI 10.1063/1.3124797; Terry NG, 2011, GASTROENTEROLOGY, V140, P42, DOI 10.1053/j.gastro.2010.09.008; Wax A, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2102767; Wilson JD, 2005, BIOPHYS J, V88, P2929, DOI 10.1529/biophysj.104.054528; Wilson JD, 2007, THESIS U ROCHESTER; Zhu HY, 2011, ANAL CHEM, V83, P6641, DOI 10.1021/ac201587a	21	15	17	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2012	7	10							e46030	10.1371/journal.pone.0046030	http://dx.doi.org/10.1371/journal.pone.0046030			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	015NG	23056228	Green Submitted, Green Published, gold			2023-01-03	WOS:000309452600021
J	Jenkins, R; Cooper, R				Jenkins, Rowena; Cooper, Rose			Improving Antibiotic Activity against Wound Pathogens with Manuka Honey In Vitro	PLOS ONE			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; PSEUDOMONAS-AERUGINOSA; ANTIMICROBIAL ACTIVITY; BACTERIAL-RESISTANCE; COMBINATIONS; INFECTIONS; INHIBITION; DRUGS; ACID	Following the discovery of synergistic action between oxacillin and manuka honey against methicillin-resistant Staphylococcus aureus, this study was undertaken to search for further synergistic combinations of antibiotics and honey that might have potential in treating wounds. Fifteen antibiotics were tested with and without sublethal concentrations of manuka honey against each of MRSA and Pseudomonas aeruginosa using disc diffusion, broth dilution, E strip, chequerboard titration and growth curves. Five novel antibiotic and manuka honey combinations were found that improved antibacterial effectiveness in vitro and these offer a new avenue of future topical treatments for wound infections caused by these two important pathogens.	[Jenkins, Rowena; Cooper, Rose] Cardiff Metropolitan Univ, Cardiff Sch Hlth Sci, Ctr Biomed Sci, Cardiff, S Glam, Wales	Cardiff Metropolitan University; Cardiff University	Jenkins, R (corresponding author), Cardiff Metropolitan Univ, Cardiff Sch Hlth Sci, Ctr Biomed Sci, Cardiff, S Glam, Wales.	rojenkins@cardiffmet.ac.uk		Jenkins, Rowena/0000-0001-6664-6099	Waterloo Foundation [1117535]; Sir Halley Stewart trust [208491]	Waterloo Foundation; Sir Halley Stewart trust	Funding was provided by the Waterloo Foundation (Charity number 1117535) (http://www.waterloofoundation.org.uk/) and the Sir Halley Stewart trust (Charity number 208491) (http://www.sirhalleystewart.org.uk/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Jabri AA, 2005, SAUDI MED J, V26, P767; Andrews JM, 2009, J ANTIMICROB CHEMOTH, V64, P454, DOI 10.1093/jac/dkp244; Blair SE, 2009, EUR J CLIN MICROBIOL, V28, P1199, DOI 10.1007/s10096-009-0763-z; Breidenstein EBM, 2011, TRENDS MICROBIOL, V19, P419, DOI 10.1016/j.tim.2011.04.005; Campbell EA, 2001, CELL, V104, P901, DOI 10.1016/S0092-8674(01)00286-0; Chopra I, 2001, MICROBIOL MOL BIOL R, V65, P232, DOI 10.1128/MMBR.65.2.232-260.2001; Cooper RA, 2010, EUR J CLIN MICROBIOL, V29, P1237, DOI 10.1007/s10096-010-0992-1; Cooper RA, 2002, J APPL MICROBIOL, V93, P857, DOI 10.1046/j.1365-2672.2002.01761.x; Cooper RA, 2002, J BURN CARE REHABIL, V23, P366, DOI 10.1097/00004630-200211000-00002; Drawz SM, 2010, CLIN MICROBIOL REV, V23, P160, DOI 10.1128/CMR.00037-09; Ejim L, 2011, NAT CHEM BIOL, V7, P348, DOI [10.1038/NCHEMBIO.559, 10.1038/nchembio.559]; Gibbons S, 2008, PLANTA MED, V74, P594, DOI 10.1055/s-2008-1074518; Henriques AF, 2011, EUR J CLIN MICROBIOL, V30, P167, DOI 10.1007/s10096-010-1065-1; Henriques AF, 2010, EUR J CLIN MICROBIOL, V29, P45, DOI 10.1007/s10096-009-0817-2; Hiramatsu K, 2002, CURR OPIN INFECT DIS, V15, P407, DOI 10.1097/00001432-200208000-00009; HUGHES J, 1978, BIOCHEM J, V176, P305, DOI 10.1042/bj1760305; Jayaraman P, 2010, INT J BIOL SCI, V6, P556; Jenkins R, 2011, INT J ANTIMICROB AG, V37, P373, DOI 10.1016/j.ijantimicag.2010.11.036; Jenkins RE, 2012, J ANTIMICROB CHEMOTH, V67, P1405, DOI 10.1093/jac/dks071; Karayil S, 1998, J Postgrad Med, V44, P93; Kwakman PHS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017709; Lee JW, 2007, J MICROBIOL, V45, P350; Mendoza N, 2010, EXPERT OPIN EMERG DR, V15, P509, DOI 10.1517/14728214.2010.497486; Mukherjee S, 2011, INDIAN J EXP BIOL, V49, P547; Natarajan S, 2001, J DERMATOL TREAT, V12, P33, DOI 10.1080/095466301750163563; Page MGP, 2009, CURR OPIN PHARMACOL, V9, P558, DOI 10.1016/j.coph.2009.08.006; Rahal JJ, 2006, CLIN INFECT DIS, V43, pS95, DOI 10.1086/504486; SUZUKI T, 1963, J BIOCHEM-TOKYO, V54, P25, DOI 10.1093/oxfordjournals.jbchem.a127742; Tiwari RP, 2005, INDIAN J MED RES, V122, P80; Wagner H, 2011, FITOTERAPIA, V82, P34, DOI 10.1016/j.fitote.2010.11.016	30	55	56	1	68	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2012	7	9							e45600	10.1371/journal.pone.0045600	http://dx.doi.org/10.1371/journal.pone.0045600			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	016KP	23049822	Green Published, Green Submitted, gold			2023-01-03	WOS:000309517300038
J	Fox, KCR; Zakarauskas, P; Dixon, M; Ellamil, M; Thompson, E; Christoff, K				Fox, Kieran C. R.; Zakarauskas, Pierre; Dixon, Matt; Ellamil, Melissa; Thompson, Evan; Christoff, Kalina			Meditation Experience Predicts Introspective Accuracy	PLOS ONE			English	Article							EVOKED-POTENTIALS; CEREBRAL-CORTEX; BRAIN DYNAMICS; REPRESENTATION; PRACTITIONERS; ORGANIZATION; AWARENESS; ACUITY; MOTOR	The accuracy of subjective reports, especially those involving introspection of one's own internal processes, remains unclear, and research has demonstrated large individual differences in introspective accuracy. It has been hypothesized that introspective accuracy may be heightened in persons who engage in meditation practices, due to the highly introspective nature of such practices. We undertook a preliminary exploration of this hypothesis, examining introspective accuracy in a cross-section of meditation practitioners (1-15,000 hrs experience). Introspective accuracy was assessed by comparing subjective reports of tactile sensitivity for each of 20 body regions during a 'body-scanning' meditation with averaged, objective measures of tactile sensitivity (mean size of body representation area in primary somatosensory cortex; two-point discrimination threshold) as reported in prior research. Expert meditators showed significantly better introspective accuracy than novices; overall meditation experience also significantly predicted individual introspective accuracy. These results suggest that long-term meditators provide more accurate introspective reports than novices.	[Fox, Kieran C. R.; Dixon, Matt; Ellamil, Melissa; Christoff, Kalina] Univ British Columbia, Dept Psychol, Vancouver, BC, Canada; [Zakarauskas, Pierre; Christoff, Kalina] Univ British Columbia, Brain Res Ctr, Vancouver, BC V5Z 1M9, Canada; [Thompson, Evan] Univ Toronto, Dept Philosophy, Toronto, ON M5S 1A1, Canada	University of British Columbia; University of British Columbia; University of Toronto	Fox, KCR (corresponding author), Univ British Columbia, Dept Psychol, Vancouver, BC, Canada.	kfox@psych.ubc.ca		Thompson, Evan/0000-0003-0084-8477; Dixon, Matthew/0000-0001-8033-8113	Hampton Research Endowment Fund [F08-05696]; UBC	Hampton Research Endowment Fund; UBC	This research was supported in part by Hampton Research Endowment Fund grant F08-05696 to Kalina Christoff and a UBC First-Year Fellowship to Kieran Fox. No additional external funding was received. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Analayo B., 2003, SATIPATTHANA DIRECT; CELESIA GG, 1979, ARCH NEUROL-CHICAGO, V36, P399, DOI 10.1001/archneur.1979.00500430029003; Christoff K, 2000, PSYCHOBIOLOGY, V28, P168; Corallo G, 2008, PSYCHOL SCI, V19, P1110, DOI 10.1111/j.1467-9280.2008.02211.x; Critchley HD, 2004, NAT NEUROSCI, V7, P189, DOI 10.1038/nn1176; Disbrow EA, 2000, P NATL ACAD SCI USA, V97, P9718, DOI 10.1073/pnas.170205497; ELBERT T, 1995, SCIENCE, V270, P305, DOI 10.1126/science.270.5234.305; ERICSSON KA, 1993, PSYCHOL REV, V100, P363, DOI 10.1037/0033-295X.100.3.363; Farb NAS, 2007, SOC COGN AFFECT NEUR, V2, P313, DOI 10.1093/scan/nsm030; Fisher RA, 1914, BIOMETRIKA, V10, P507; Fleming SM, 2012, PHILOS T R SOC B, V367, P1338, DOI 10.1098/rstb.2011.0417; Fleming SM, 2010, SCIENCE, V329, P1541, DOI 10.1126/science.1191883; FREDRICK WC, 1980, J EDUC RES, V73, P183, DOI 10.1080/00220671.1980.10885233; Goenka S.N., 2000, DISCOURSE SUMMARIES; Grant JA, 2010, EMOTION, V10, P43, DOI 10.1037/a0018334; HAMMEKE TA, 1994, NEUROSURGERY, V35, P677, DOI 10.1227/00006123-199410000-00014; HARI R, 1993, EUR J NEUROSCI, V5, P724, DOI 10.1111/j.1460-9568.1993.tb00536.x; Holzel BK, 2008, SOC COGN AFFECT NEUR, V3, P55, DOI 10.1093/scan/nsm038; Jack AI, 2002, TRENDS COGN SCI, V6, P333, DOI 10.1016/S1364-6613(02)01941-1; James W, 1890, PRINCIPLES PSYCHOL, V1; Jha AP, 2010, EMOTION, V10, P54, DOI 10.1037/a0018438; Kabat-Zinn J., 1994, MINDFULNESS MEDITATI; Kerr CE, 2008, EXP BRAIN RES, V188, P317, DOI 10.1007/s00221-008-1409-6; Khalsa SS, 2008, PSYCHOPHYSIOLOGY, V45, P671, DOI 10.1111/j.1469-8986.2008.00666.x; KNIBESTOL M, 1980, J PHYSIOL-LONDON, V300, P251, DOI 10.1113/jphysiol.1980.sp013160; Kozhevnikov M, 2009, PSYCHOL SCI, V20, P645, DOI 10.1111/j.1467-9280.2009.02345.x; Lazar SW, 2005, NEUROREPORT, V16, P1893, DOI 10.1097/01.wnr.0000186598.66243.19; Lutz A, 2003, J CONSCIOUSNESS STUD, V10, P31; Lutz A, 2002, P NATL ACAD SCI USA, V99, P1586, DOI 10.1073/pnas.032658199; Lutz A, 2008, TRENDS COGN SCI, V12, P163, DOI 10.1016/j.tics.2008.01.005; MacLean KA, 2010, PSYCHOL SCI, V21, P829, DOI 10.1177/0956797610371339; McCaig RG, 2011, NEUROIMAGE, V55, P1298, DOI 10.1016/j.neuroimage.2010.12.016; Michael GA, 2011, CONSCIOUS COGN, V20, P603, DOI 10.1016/j.concog.2010.11.013; Nielsen L, 2006, EMOTION, V6, P392, DOI 10.1037/1528-3542.6.3.392; NISBETT RE, 1977, PSYCHOL REV, V84, P231, DOI 10.1037/0033-295X.84.3.231; Pantev C, 2001, ANN NY ACAD SCI, V930, P300, DOI 10.1111/j.1749-6632.2001.tb05740.x; Penfield W, 1937, BRAIN, V60, P389, DOI 10.1093/brain/60.4.389; Penfield W., 1950, CEREBRAL CORTEX MAN; Rolke R, 2006, PAIN, V123, P231, DOI 10.1016/j.pain.2006.01.041; Slagter HA, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00017; Song C, 2011, CONSCIOUS COGN, V20, P1787, DOI 10.1016/j.concog.2010.12.011; Stevens JC, 1996, SOMATOSENS MOT RES, V13, P153, DOI 10.3109/08990229609051403; Sze JA, 2010, EMOTION, V10, P803, DOI 10.1037/a0020146; Vestergaard-Poulsen P, 2009, NEUROREPORT, V20, P170, DOI 10.1097/WNR.0b013e328320012a; Weber EH., 1978, EH WEBER SENSE TOUCH; WEINSTEIN SIDNEY, 1968, P195; WOOLSEY CN, 1979, J NEUROSURG, V51, P476, DOI 10.3171/jns.1979.51.4.0476	47	103	103	3	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2012	7	9							e45370	10.1371/journal.pone.0045370	http://dx.doi.org/10.1371/journal.pone.0045370			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	016YP	23049790	Green Published, gold, Green Submitted			2023-01-03	WOS:000309556100041
J	Creamean, JM; Suski, KJ; Rosenfeld, D; Cazorla, A; DeMott, PJ; Sullivan, RC; White, AB; Ralph, FM; Minnis, P; Comstock, JM; Tomlinson, JM; Prather, KA				Creamean, Jessie M.; Suski, Kaitlyn J.; Rosenfeld, Daniel; Cazorla, Alberto; DeMott, Paul J.; Sullivan, Ryan C.; White, Allen B.; Ralph, F. Martin; Minnis, Patrick; Comstock, Jennifer M.; Tomlinson, Jason M.; Prather, Kimberly A.			Dust and Biological Aerosols from the Sahara and Asia Influence Precipitation in the Western U.S.	SCIENCE			English	Article							ATMOSPHERIC ICE NUCLEI; OROGRAPHIC ENHANCEMENT; LIQUID WATER; MIXED-PHASE; CLOUD; PARTICLES; SUPPRESSION; DEPOSITION; RANGE; RADAR	Winter storms in California's Sierra Nevada increase seasonal snowpack and provide critical water resources and hydropower for the state. Thus, the mechanisms influencing precipitation in this region have been the subject of research for decades. Previous studies suggest Asian dust enhances cloud ice and precipitation, whereas few studies consider biological aerosols as an important global source of ice nuclei (IN). Here, we show that dust and biological aerosols transported from as far as the Sahara were present in glaciated high-altitude clouds coincident with elevated IN concentrations and ice-induced precipitation. This study presents the first direct cloud and precipitation measurements showing that Saharan and Asian dust and biological aerosols probably serve as IN and play an important role in orographic precipitation processes over the western United States.	[Creamean, Jessie M.; Suski, Kaitlyn J.; Cazorla, Alberto; Prather, Kimberly A.] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; [Rosenfeld, Daniel] Hebrew Univ Jerusalem, Inst Earth Sci, IL-91904 Jerusalem, Israel; [DeMott, Paul J.] Colorado State Univ, Dept Atmospher Sci, Ft Collins, CO 80523 USA; [Sullivan, Ryan C.] Carnegie Mellon Univ, Ctr Atmospher Particle Studies, Pittsburgh, PA 15213 USA; [White, Allen B.; Ralph, F. Martin] NOAA, PSD, ESRL, Boulder, CO 80305 USA; [Ralph, F. Martin; Prather, Kimberly A.] Univ Calif San Diego, SIO, La Jolla, CA 92093 USA; [Minnis, Patrick] NASA, Langley Res Ctr, Hampton, VA 23681 USA; [Comstock, Jennifer M.; Tomlinson, Jason M.] Pacific NW Natl Lab, Atmospher Sci & Global Change Div, Richland, WA 99352 USA	University of California System; University of California San Diego; Hebrew University of Jerusalem; Colorado State University; Carnegie Mellon University; National Oceanic Atmospheric Admin (NOAA) - USA; University of California System; University of California San Diego; National Aeronautics & Space Administration (NASA); NASA Langley Research Center; United States Department of Energy (DOE); Pacific Northwest National Laboratory	Prather, KA (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.	kprather@ucsd.edu	Sullivan, Ryan/B-4674-2008; Minnis, Patrick/G-1902-2010; DeMott, Paul J/C-4389-2011; Tomlinson, Jason M/C-6566-2009; Rosenfeld, Daniel/F-6077-2016; Prather, Kim/A-3892-2008; Cazorla, Alberto/G-2097-2017; Studies, Center for Atmospheric Particle/AAR-6731-2020; Rosenfeld, Daniel/AAJ-4617-2021	Sullivan, Ryan/0000-0003-0701-7158; Minnis, Patrick/0000-0002-4733-6148; DeMott, Paul J/0000-0002-3719-1889; Tomlinson, Jason M/0000-0002-0734-3298; Rosenfeld, Daniel/0000-0002-0784-7656; Prather, Kim/0000-0003-3048-9890; Cazorla, Alberto/0000-0002-0901-1609; Rosenfeld, Daniel/0000-0002-0784-7656; Comstock, Jennifer/0000-0002-4183-7355; Creamean, Jessie/0000-0003-3819-5600	California Energy Commission [CEC 500-09-043]; Atmospheric System Research (ASR)/U.S. Department of Energy (DOE) program; ASR/DOE program [DE-SC0000991/003]; NASA MAPS Program	California Energy Commission; Atmospheric System Research (ASR)/U.S. Department of Energy (DOE) program; ASR/DOE program; NASA MAPS Program	Funding was provided by the California Energy Commission under contract CEC 500-09-043. D. R. was funded under the Atmospheric System Research (ASR)/U.S. Department of Energy (DOE) program. P. M. was supported by the ASR/DOE program under DE-SC0000991/003 and the NASA MAPS Program. J. Mayer, E. Fitzgerald, D. Collins, and J. Cahill provided assistance with UCSD/SIO equipment setup. The authors gratefully acknowledge the NOAA Air Resources Laboratory (ARL) for the provision of the HYSPLIT transport and dispersion model and READY website (www.arl.noaa.gov/ready.php) used in this publication and the Office of Naval Research for provision of NAAPS data. J. Ayers and R. Palikonda (Science Systems and Applications) provided GOES-11 cloud top heights used for HYSPLIT back trajectory analysis and %Ice in cloud. The deployment of the NOAA and UCSD/SIO equipment at the Sugar Pine site involved many field staff, particularly C. King (NOAA/ESRL/PSD). The deployment of the DOE Gulfstream-1 involved many PNNL/Atmospheric Radiation Measurement field staff, particularly E. Dukes, J. Hubbe, C. Kluzek, H. Jonsson, M. Pekour, and B. Schmid. M. Hubbell and B. Svancara flew the G-1 for the CalWater flight campaign. D. Collins and R. Spackman provided insightful discussions during the editing stages of this manuscript. T. Lersch of R. J. Lee provided TEM analyses of collected IN. Data available in this paper are available in the supplementary materials.	Andreae MO, 2008, EARTH-SCI REV, V89, P13, DOI 10.1016/j.earscirev.2008.03.001; Ault AP, 2011, J GEOPHYS RES-ATMOS, V116, DOI 10.1029/2010JD015351; Borys RD, 2000, ATMOS ENVIRON, V34, P2593, DOI 10.1016/S1352-2310(99)00492-6; Choi YS, 2010, P NATL ACAD SCI USA, V107, P11211, DOI 10.1073/pnas.1006241107; CHOULARTON TW, 1986, Q J ROY METEOR SOC, V112, P335, DOI 10.1002/qj.49711247204; DeMott PJ, 2010, P NATL ACAD SCI USA, V107, P11217, DOI 10.1073/pnas.0910818107; DeMott PJ, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017410; DESHLER T, 1990, J APPL METEOROL, V29, P288, DOI 10.1175/1520-0450(1990)029&lt;0288:PROWOC&gt;2.0.CO;2; Dore AJ, 1999, ATMOS ENVIRON, V33, P3301, DOI 10.1016/S1352-2310(98)00294-5; Draxler R., 2013, HYSPLIT HYBRID SINGL; Fowler D, 1995, WATER AIR SOIL POLL, V85, P2107, DOI 10.1007/BF01186145; Gard E, 1997, ANAL CHEM, V69, P4083, DOI 10.1021/ac970540n; Givati A, 2004, J APPL METEOROL, V43, P1038, DOI [10.1175/1520-0450(2004)043<1038:QPSDTA>2.0.CO;2, 10.1175/1520-0450(2004)043&lt;1038:QPSDTA&gt;2.0.CO;2]; Guan B, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL044696; Hallar AG, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL048166; Hara K, 2012, ATMOS ENVIRON, V47, P20, DOI 10.1016/j.atmosenv.2011.11.050; Hoose C, 2010, ENVIRON RES LETT, V5, DOI 10.1088/1748-9326/5/2/024009; HOSLER CL, 1957, J METEOROL, V14, P415, DOI 10.1175/1520-0469(1957)014<0415:OTAOIC>2.0.CO;2; Houze R.A., 1993, CLOUD DYNAMICS; Hsu SC, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL051962; Husar RB, 2001, J GEOPHYS RES-ATMOS, V106, P18317, DOI 10.1029/2000JD900788; Iannone R, 2011, ATMOS CHEM PHYS, V11, P1191, DOI 10.5194/acp-11-1191-2011; Isono K., 1959, J METEOR SOC JAPAN, V37, P211, DOI DOI 10.2151/JMSJ1923.37.6_211; Korolev A, 2007, J ATMOS SCI, V64, P3372, DOI 10.1175/JAS4035.1; Lau KM, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018567; McKendry IG, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2006JD007129; MEYERS MP, 1992, J APPL METEOROL, V31, P708, DOI 10.1175/1520-0450(1992)031<0708:NPINPI>2.0.CO;2; Morris CE, 2004, J PHYS IV, V121, P87, DOI 10.1051/jp4:2004121004; Pinsky M, 1998, ATMOS RES, V49, P99, DOI 10.1016/S0169-8095(98)00073-8; Pratt KA, 2009, NAT GEOSCI, V2, P397, DOI 10.1038/NGEO521; Pratt KA, 2009, ANAL CHEM, V81, P1792, DOI 10.1021/ac801942r; Prospero JM, 2002, REV GEOPHYS, V40, DOI 10.1029/2000RG000095; Reinking RF, 2000, J APPL METEOROL, V39, P733, DOI 10.1175/1520-0450(2000)039<0733:IOSEOG>2.0.CO;2; REYNOLDS DW, 1986, B AM METEOROL SOC, V67, P513, DOI 10.1175/1520-0477(1986)067<0513:AROTSC>2.0.CO;2; Rogers DC, 2001, J ATMOS OCEAN TECH, V18, P725, DOI 10.1175/1520-0426(2001)018<0725:ACFDCF>2.0.CO;2; Rosenfeld D, 2000, SCIENCE, V287, P1793, DOI 10.1126/science.287.5459.1793; Rosenfeld D, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL049423; Saleeby SM, 2009, J APPL METEOROL CLIM, V48, P903, DOI 10.1175/2008JAMC1989.1; Sun JM, 2001, J GEOPHYS RES-ATMOS, V106, P10325, DOI 10.1029/2000JD900665; Uno I, 2011, ATMOS CHEM PHYS, V11, P7333, DOI 10.5194/acp-11-7333-2011; Uno I, 2009, NAT GEOSCI, V2, P557, DOI 10.1038/NGEO583; White AB, 2000, J ATMOS OCEAN TECH, V17, P1226, DOI 10.1175/1520-0426(2000)017<1226:ETDROA>2.0.CO;2; White AB, 2003, J HYDROMETEOROL, V4, P264, DOI 10.1175/1525-7541(2003)4<264:CORPOB>2.0.CO;2; Wiacek A, 2010, ATMOS CHEM PHYS, V10, P8649, DOI 10.5194/acp-10-8649-2010	44	400	409	22	414	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	2013	339	6127					1572	1578		10.1126/science.1227279	http://dx.doi.org/10.1126/science.1227279			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	114HL	23449996				2023-01-03	WOS:000316731600040
J	Quill, TE; Abernethy, AP				Quill, Timothy E.; Abernethy, Amy P.			Generalist plus Specialist Palliative Care - Creating a More Sustainable Model	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Quill, Timothy E.] Univ Rochester, Med Ctr, Dept Med, Palliat Care Div, Rochester, NY 14642 USA; [Abernethy, Amy P.] Duke Univ, Med Ctr, Duke Ctr Learning Hlth Care, Durham, NC USA; [Abernethy, Amy P.] Duke Univ, Med Ctr, Duke Canc Care Res Program, Durham, NC USA	University of Rochester; Duke University; Duke University	Quill, TE (corresponding author), Univ Rochester, Med Ctr, Dept Med, Palliat Care Div, Rochester, NY 14642 USA.			Abernethy, Amy/0000-0001-6930-8722				Back AL, 2009, J CLIN ONCOL, V27, P1137, DOI 10.1200/JCO.2008.20.2408; Kamal AH, 2012, J PAIN SYMPTOM MANAG; Morrison RS, 2011, HEALTH AFFAIR, V30, P454, DOI 10.1377/hlthaff.2010.0929; Quill Timothy E, 2003, J Palliat Med, V6, P365, DOI 10.1089/109662103322144682; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678	5	854	857	3	47	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 28	2013	368	13					1173	1175		10.1056/NEJMp1215620	http://dx.doi.org/10.1056/NEJMp1215620			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	116FU	23465068				2023-01-03	WOS:000316869000003
J	Kwan, JL; Lo, LS; Sampson, M; Shojania, KG				Kwan, Janice L.; Lo, Lisha; Sampson, Margaret; Shojania, Kaveh G.			Medication Reconciliation During Transitions of Care as a Patient Safety Strategy A Systematic Review	ANNALS OF INTERNAL MEDICINE			English	Article							ADVERSE DRUG EVENTS; HOSPITAL DISCHARGE PROGRAM; PATIENTS AFTER-DISCHARGE; PHARMACIST INTERVENTION; CLINICAL PHARMACISTS; ERRORS; ADMISSION; DISCREPANCIES; INFORMATION; QUALITY	Medication reconciliation identifies and resolves unintentional discrepancies between patients' medication lists across transitions in care. The purpose of this review is to summarize evidence about the effectiveness of hospital-based medication reconciliation interventions. Searches encompassed MEDLINE through November 2012 and EMBASE and the Cochrane Central Register of Controlled Trials through July 2012. Eligible studies evaluated the effects of hospital-based medication reconciliation on unintentional discrepancies with nontrivial risks for harm to patients or 30-day postdischarge emergency department visits and readmission. Two reviewers evaluated study eligibility, abstracted data, and assessed study quality. Eighteen studies evaluating 20 interventions met the selection criteria. Pharmacists performed medication reconciliation in 17 of the 20 interventions. Most unintentional discrepancies identified had no clinical significance. Medication reconciliation alone probably does not reduce postdischarge hospital utilization but may do so when bundled with interventions aimed at improving care transitions. Ann Intern Med. 2013;158:397-403. www.annals.org	[Kwan, Janice L.; Shojania, Kaveh G.] Univ Toronto, Toronto, ON M5G 2L3, Canada; Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada	University of Toronto; University of Ottawa; Children's Hospital of Eastern Ontario	Shojania, KG (corresponding author), Sunnybrook Hlth Sci Ctr, Dept Med, Room H468,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	kaveh.shojania@sunnybrook.ca	Sampson, Margaret/A-9128-2011	Sampson, Margaret/0000-0003-2550-9893	Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services [HHSA-290-2007-10062I]; University of California, Los Angeles-RAND Evidence-Based Practice Centre	Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); University of California, Los Angeles-RAND Evidence-Based Practice Centre	Financial Support: From the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services (contract HHSA-290-2007-10062I).; Potential Conflicts of Interest: Dr. Shojania: Other: Agency for Healthcare Research and Quality as a subcontract from the University of California, Los Angeles-RAND Evidence-Based Practice Centre. All other authors have no disclosures. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M12-2634.	Abdel-Qader DH, 2010, DRUG SAFETY, V33, P1027, DOI 10.2165/11538310-000000000-00000; Accreditation Canada, 2012, REQ ORG PRACT 2012; [Anonymous], 2006, ACT PAT SAF HIGH 5S; Bayoumi I, 2009, ANN PHARMACOTHER, V43, P1667, DOI 10.1345/aph.1M059; Bell CM, 2011, JAMA-J AM MED ASSOC, V306, P840, DOI 10.1001/jama.2011.1206; Climente-Marti M, 2010, ANN PHARMACOTHER, V44, P1747, DOI 10.1345/aph.1P184; Coffey M, 2009, ACAD PEDIATR, V9, P360, DOI 10.1016/j.acap.2009.04.007; Coleman EA, 2005, ARCH INTERN MED, V165, P1842, DOI 10.1001/archinte.165.16.1842; Coleman EA, 2004, ANN INTERN MED, V141, P533, DOI 10.7326/0003-4819-141-7-200410050-00009; Cornish PL, 2005, ARCH INTERN MED, V165, P424, DOI 10.1001/archinte.165.4.424; Dedhia P, 2009, J AM GERIATR SOC, V57, P1540, DOI 10.1111/j.1532-5415.2009.02430.x; Etchells E, 2012, BMJ QUAL SAF, V21, P448, DOI 10.1136/bmjqs-2011-000585; Femandes O, 2012, HEALTHC Q, P15; Forster AJ, 2004, CAN MED ASSOC J, V170, P345; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; Gillespie U, 2009, ARCH INTERN MED, V169, P894, DOI 10.1001/archinternmed.2009.71; Gleason KM, 2004, AM J HEALTH-SYST PH, V61, P1689, DOI 10.1093/ajhp/61.16.1689; Gleason KM, 2010, J GEN INTERN MED, V25, P441, DOI 10.1007/s11606-010-1256-6; Grimshaw JM, 2004, HEALTH TECHNOL ASSES, V8, P1, DOI 10.3310/hta8060; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Institute for Healthcare Improvement, 2006, OV 100000 LIV CAMP; Jack BW, 2009, ANN INTERN MED, V150, P178, DOI 10.7326/0003-4819-150-3-200902030-00007; Jamtvedt G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000259.pub2; Kaboli PJ, 2006, ARCH INTERN MED, V166, P955, DOI 10.1001/archinte.166.9.955; Karnon J, 2009, J EVAL CLIN PRACT, V15, P299, DOI 10.1111/j.1365-2753.2008.01000.x; Koehler BE, 2009, J HOSP MED, V4, P211, DOI 10.1002/jhm.427; Kramer JS, 2007, AM J HEALTH-SYST PH, V64, P404, DOI 10.2146/ajhp060506; Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831; Kripalani S, 2012, ANN INTERN MED, V157, P1, DOI 10.7326/0003-4819-157-1-201207030-00003; Kucukarslan SN, 2003, ARCH INTERN MED, V163, P2014, DOI 10.1001/archinte.163.17.2014; Kwan Y, 2007, ARCH INTERN MED, V167, P1034, DOI 10.1001/archinte.167.10.1034; Leape LL, 1999, JAMA-J AM MED ASSOC, V282, P267, DOI 10.1001/jama.282.3.267; Lee JY, 2010, ANN PHARMACOTHER, V44, P1887, DOI 10.1345/aph.1P314; Midlov P, 2012, INT J CLIN PHARM-NET, V34, P113, DOI 10.1007/s11096-011-9599-6; Mueller SK, 2012, ARCH INTERN MED, V172, P1057, DOI 10.1001/archinternmed.2012.2246; NORRIS CM, 2001, PHARM J, V267, P857; Pippins JR, 2008, J GEN INTERN MED, V23, P1414, DOI 10.1007/s11606-008-0687-9; Ranji SR, 2008, MED CARE, V46, P847, DOI 10.1097/MLR.0b013e318178eabd; Schnipper JL, 2011, J AM MED INFORM ASSN, V18, P309, DOI 10.1136/amiajnl-2010-000040; Schnipper JL, 2009, ARCH INTERN MED, V169, P771, DOI 10.1001/archinternmed.2009.51; Schnipper JL, 2006, ARCH INTERN MED, V166, P565, DOI 10.1001/archinte.166.5.565; Shojania KG, 2010, CAN MED ASSOC J, V182, pE216, DOI 10.1503/cmaj.090578; Showalter JW, 2011, J GEN INTERN MED, V26, P718, DOI 10.1007/s11606-011-1712-y; Steinman MA, 2006, MED CARE, V44, P617, DOI 10.1097/01.mlr.0000215846.25591.22; Steurbaut S, 2010, ANN PHARMACOTHER, V44, P1596, DOI 10.1345/aph.1P192; Stone BL, 2010, ARCH DIS CHILD, V95, P250, DOI 10.1136/adc.2009.167528; Tam VC, 2005, CAN MED ASSOC J, V173, P510, DOI 10.1503/cmaj.045311; The Joint Commission, 2011, 2011 NAT PAT SAF GOA; van Walraven C, 2010, J HOSP MED, V5, P398, DOI 10.1002/jhm.716; Vira T, 2006, QUAL SAF HEALTH CARE, V15, P122, DOI 10.1136/qshc.2005.015347; Walker PC, 2009, ARCH INTERN MED, V169, P2003, DOI 10.1001/archinternmed.2009.398; Wong JD, 2008, ANN PHARMACOTHER, V42, P1373, DOI 10.1345/aph.1L190	52	287	298	2	67	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 5	2013	158	5	2				397	+		10.7326/0003-4819-158-5-201303051-00006	http://dx.doi.org/10.7326/0003-4819-158-5-201303051-00006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105HX	23460096				2023-01-03	WOS:000316058600006
J	Al Dhaheri, Y; Eid, A; AbuQamar, S; Attoub, S; Khasawneh, M; Aiche, G; Hisaindee, S; Iratni, R				Al Dhaheri, Yusra; Eid, Ali; AbuQamar, Synan; Attoub, Samir; Khasawneh, Mohammad; Aiche, Ghenima; Hisaindee, Soleiman; Iratni, Rabah			Mitotic Arrest and Apoptosis in Breast Cancer Cells Induced by Origanum majorana Extract: Upregulation of TNF-alpha and Downregulation of Survivin and Mutant p53	PLOS ONE			English	Article							VOLATILE OIL; INHIBITION; PHYTOCHEMICALS; EXPRESSION; TOXICITY; PROTEINS; RECEPTOR	Background: In the present study, we investigated the effect of Origanum majorana ethanolic extract on the survival of the highly proliferative and invasive triple-negative p53 mutant breast cancer cell line MDA-MB-231. Results: We found that O. majorana extract (OME) was able to inhibit the viability of the MDA-MB-231 cells in a time- and concentration-dependent manner. The effect of OME on cellular viability was further confirmed by the inhibition of colony growth. We showed, depending on the concentration used, that OME elicited different effects on the MDA-MB 231 cells. Concentrations of 150 and 300 mu g/mL induced an accumulation of apoptotic-resistant population of cells arrested in mitotis and overexpressing the cyclin-dependent kinase inhibitor, p21 and the inhibitor of apoptosis, survivin. On the other hand, higher concentrations of OME (450 and 600 mu g/mL) triggered a massive apoptosis through the extrinsic pathway, including the activation of tumor necrosis factor-alpha (TNF-alpha), caspase 8, caspase 3, and cleavage of PARP, downregulation of survivin as well as depletion of the mutant p53 in MDA-MB-231 cells. Furthermore, OME induced an upregulation of gamma-H2AX, a marker of double strand DNA breaks and an overall histone H3 and H4 hyperacetylation. Conclusion: Our findings provide strong evidence that O. majorana may be a promising chemopreventive and therapeutic candidate against cancer especially for highly invasive triple negative p53 mutant breast cancer; thus validating its complementary and alternative medicinal use.	[Al Dhaheri, Yusra; Eid, Ali; AbuQamar, Synan; Iratni, Rabah] United Arab Emirates Univ, Dept Biol, Coll Sci, Al Ain, U Arab Emirates; [Attoub, Samir] United Arab Emirates Univ, Dept Pharmacol & Therapeut, Fac Med & Hlth Sci, Al Ain, U Arab Emirates; [Khasawneh, Mohammad; Hisaindee, Soleiman] United Arab Emirates Univ, Dept Chem, Coll Sci, UAE Univ, Al Ain, U Arab Emirates; [Aiche, Ghenima] Univ Mouloud Mammeri, Dept Biochem & Microbiol, Fac Sci Biol & Agron, Tizi Ouzou, Algeria	United Arab Emirates University; United Arab Emirates University; United Arab Emirates University; Universite Mouloud Mammeri de Tizi Ouzou	Iratni, R (corresponding author), United Arab Emirates Univ, Dept Biol, Coll Sci, Al Ain, U Arab Emirates.	R_iratni@uaeu.ac.ae	Attoub, Samir/N-6852-2018; Eid, Ali Hussein/ABD-6291-2021; Hisaindee, Soleiman/AAK-4862-2020; AbuQamar, Synan/AAV-1229-2021	Eid, Ali Hussein/0000-0003-3004-5675; Hisaindee, Soleiman/0000-0003-0084-8362; AbuQamar, Synan/0000-0002-2129-7689	Faculty of Science interdisciplinary research grant UAE University; Emirates Foundation research grant [2009-80]	Faculty of Science interdisciplinary research grant UAE University; Emirates Foundation research grant	This work was supported by the Faculty of Science interdisciplinary research grant UAE University and by the Emirates Foundation research grant (2009-80) to R. Iratni. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams LS, 2010, CANCER RES, V70, P3594, DOI 10.1158/0008-5472.CAN-09-3565; Al-Harbi NO, 2011, J MED PLANTS RES, V5, P5479; American Cancer Society, 2012, CANC FACTS FIG; Attoub S, 2011, EUR J PHARMACOL, V651, P18, DOI 10.1016/j.ejphar.2010.10.063; Bossi G, 2006, ONCOGENE, V25, P304, DOI 10.1038/sj.onc.1209026; Cai Y, 2007, CANCER BIOL THER, V6, P1794, DOI 10.4161/cbt.6.11.4860; Chandele A, 2004, NEOPLASIA, V6, P29, DOI 10.1016/S1476-5586(04)80051-4; Choi HJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024312; Cragg GM, 2000, EXPERT OPIN INV DRUG, V9, P2783, DOI 10.1517/13543784.9.12.2783; El-Ashmawy I.M., 2007, ALEX J PHARM SCI, V21, P29; El-Ashmawy IM, 2007, BASIC CLIN PHARMACOL, V101, P320, DOI 10.1111/j.1742-7835.2007.00125.x; El-Ashmawy IM, 2005, BASIC CLIN PHARMACOL, V97, P238, DOI 10.1111/j.1742-7843.2005.pto_136.x; Fojo T, 2002, DRUG RESIST UPDATE, V5, P209, DOI 10.1016/S1368-7646(02)00119-X; Gu YH, 2006, ONCOL REP, V15, P417; Gupta S, 2003, INT J ONCOL, V22, P15; Han J, 2012, ONCOL REP, V27, P517, DOI 10.3892/or.2011.1511; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Kaczirek K, 2004, J CLIN ENDOCR METAB, V89, P2397, DOI 10.1210/jc.2003-031314; Konopleva M, 1999, ADV EXP MED BIOL, V457, P217; Kuno T., 2012, Journal of Biophysical Chemistry, V3, P156, DOI 10.4236/jbpc.2012.32018; Lee HS, 2008, J NUTR BIOCHEM, V19, P313, DOI 10.1016/j.jnutbio.2007.05.008; Leeja L, 2007, J ENVIRON BIOL, V28, P145; Lin LT, 2002, PHYTOTHER RES, V16, P440, DOI 10.1002/ptr.937; Ljungman M, 2010, ENVIRON MOL MUTAGEN, V51, P879, DOI 10.1002/em.20597; Maurer M, 2009, ANN NY ACAD SCI, V1171, P250, DOI 10.1111/j.1749-6632.2009.04717.x; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Miron TL, 2011, J CHROMATOGR A, V1218, P4918, DOI 10.1016/j.chroma.2010.11.055; Nawab A., 2011, Molecular and Cellular Pharmacology, V3, P21; Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532; Rajendran P, 2011, CLIN EPIGENETICS, V3, DOI 10.1186/1868-7083-3-4; Reed JC, 2001, TRENDS MOL MED, V7, P314, DOI 10.1016/S1471-4914(01)02026-3; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Selivanova G, 2001, Curr Opin Investig Drugs, V2, P1136; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Tamm I, 1998, CANCER RES, V58, P5315; Teiten MH, 2010, GENES NUTR, V5, P61, DOI 10.1007/s12263-009-0152-3; Tsimogiannis D, 2006, INT J FOOD SCI TECH, V41, P39, DOI 10.1111/j.1365-2621.2006.01259.x; Vagi E, 2005, J AGR FOOD CHEM, V53, P17, DOI 10.1021/jf048777p; Vogel C, 2007, CANCER RES, V67, P339, DOI 10.1158/0008-5472.CAN-06-2548; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang XT, 2011, J MED CHEM, V54, P809, DOI 10.1021/jm101199t; Watson WH, 2000, ANNU REV NUTR, V20, P485, DOI 10.1146/annurev.nutr.20.1.485; Yazdanparast R, 2008, VASC PHARMACOL, V48, P32, DOI 10.1016/j.vph.2007.11.003; Zhu H, 2007, MOL CANCER THER, V6, P484, DOI 10.1158/1535-7163.MCT-06-0584; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	46	30	30	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2013	8	2							e56649	10.1371/journal.pone.0056649	http://dx.doi.org/10.1371/journal.pone.0056649			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113IC	23451065	Green Published, Green Submitted, gold			2023-01-03	WOS:000316658800024
J	Gilks, CF; Walker, AS; Munderi, P; Kityo, C; Reid, A; Katabira, E; Goodall, RL; Grosskurth, H; Mugyenyi, P; Hakim, J; Gibb, DM				Gilks, Charles F.; Walker, A. Sarah; Munderi, Paula; Kityo, Cissy; Reid, Andrew; Katabira, Elly; Goodall, Ruth L.; Grosskurth, Heiner; Mugyenyi, Peter; Hakim, James; Gibb, Diana M.		DART Virology Grp; DART Trial Team	Single CD4 Test with 250 Cells/Mm(3) Threshold Predicts Viral Suppression in HIV-Infected Adults Failing First-Line Therapy by Clinical Criteria	PLOS ONE			English	Article							RECEIVING ANTIRETROVIRAL THERAPY; RESOURCE-LIMITED SETTINGS; NON-INFERIORITY TRIAL; CELL COUNT; TREATMENT FAILURE; UGANDA; COMBINATION; ROUTINE; LOAD	Background: In low-income countries, viral load (VL) monitoring of antiretroviral therapy (ART) is rarely available in the public sector for HIV-infected adults or children. Using clinical failure alone to identify first-line ART failure and trigger regimen switch may result in unnecessary use of costly second-line therapy. Our objective was to identify CD4 threshold values to confirm clinically-determined ART failure when VL is unavailable. Methods: 3316 HIV-infected Ugandan/Zimbabwean adults were randomised to first-line ART with Clinically-Driven (CDM, CD4s measured but blinded) or routine Laboratory and Clinical Monitoring (LCM, 12-weekly CD4s) in the DART trial. CD4 at switch and ART failure criteria (new/recurrent WHO 4, single/multiple WHO 3 event; LCM: CD4<100 cells/mm(3)) were reviewed in 361 LCM, 314 CDM participants who switched over median 5 years follow-up. Retrospective VLs were available in 368 (55%) participants. Results: Overall, 265/361 (73%) LCM participants failed with CD4<100 cells/mm(3); only 7 (2%) switched with CD4 >= 250 cells/mm(3), four switches triggered by WHO events. Without CD4 monitoring, 207/314 (66%) CDM participants failed with WHO 4 events, and 77(25%)/30(10%) with single/multiple WHO 3 events. Failure/switching with single WHO 3 events was more likely with CD4 >= 250 cells/mm(3) (28/77; 36%) (p=0.0002). CD4 monitoring reduced switching with viral suppression: 23/187 (12%) LCM versus 49/181 (27%) CDM had VL, 400 copies/ml at failure/switch (p<0.0001). Amongst CDM participants with CD4<250 cells/mm(3) only 11/133 (8%) had VL<400copies/ml, compared with 38/48 (79%) with CD4 >= 250 cells/mm(3) (p<0.0001). Conclusion: Multiple, but not single, WHO 3 events predicted first-line ART failure. A CD4 threshold 'tiebreaker' of >= 250 cells/mm(3) for clinically-monitored patients failing first-line could identify similar to 80% with VL<400 copies/ml, who are unlikely to benefit from second-line. Targeting CD4s to single WHO stage 3 'clinical failures' would particularly avoid premature, costly switch to second-line ART.	[Gilks, Charles F.] Univ London Imperial Coll Sci Technol & Med, Dept Med, London, England; [Walker, A. Sarah; Goodall, Ruth L.; Gibb, Diana M.] MRC, Clin Trials Unit, London, England; [Munderi, Paula; Grosskurth, Heiner] MRC, Uganda Virus Res Inst, Uganda Res Unit AIDS, Entebbe, Uganda; [Kityo, Cissy; Mugyenyi, Peter] Joint Clin Res Ctr, Kampala, Uganda; [Reid, Andrew; Hakim, James] Univ Zimbabwe, Clin Res Ctr, Harare, Zimbabwe; [Katabira, Elly] Infect Dis Inst, Mulago, Uganda	Imperial College London; Medical Research Council Clinical Trials Unit; Uganda Virus Research Institute; Joint Clinic Research Center - United Arab Emirates; University of Zimbabwe	Walker, AS (corresponding author), MRC, Clin Trials Unit, London, England.	asw@ctu.mrc.ac.uk	Walker, Sarah/HDM-8717-2022; Gilks, Charles/B-4184-2012	Gilks, Charles/0000-0002-8953-3123; Goodall, Ruth/0000-0003-0622-5035; Gibb, Diana/0000-0002-9738-5490; Grosskurth, Heiner/0000-0001-9960-7280	United Kingdom Medical Research Council [G0600344]; United Kingdom Department for International Development; Rockefeller Foundation; Medical Research Council [MC_U950080931, G0600344, MC_U950080932] Funding Source: researchfish; MRC [G0600344, MC_U950080932, MC_U950080931] Funding Source: UKRI	United Kingdom Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); United Kingdom Department for International Development; Rockefeller Foundation; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	DART was funded by the United Kingdom Medical Research Council [grant number G0600344], the United Kingdom Department for International Development, and the Rockefeller Foundation. Viiv Healthcare/GlaxoSmithKline, Gilead and Boehringer-Ingelheim donated first-line drugs for DART, and Abbott provided Kaletra/Aluvia as part of the second-line regimen for DART. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abongomera G, 2012, 19 INT AIDS C WASH D; [Anonymous], 2011, HIV TREATM REACH 6 6; Brennan A, 2011, 18 C RETR OPP INF BO; Gilks CF, 2006, LANCET, V368, P505, DOI 10.1016/S0140-6736(06)69158-7; Government of Malawi Ministry of Health, 2011, Q HIV PROGR REP; Hoffmann CJ, 2009, CLIN INFECT DIS, V49, P1928, DOI 10.1086/648444; Jani IV, 2011, LANCET; Jourdain G, 2011, 18 C RETR OPP INF BO; Kahn JG, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6884; Kantor R, 2009, CLIN INFECT DIS, V49, P454, DOI 10.1086/600396; Laurent C, 2011, LANCET INFECT DIS, V11, P825, DOI 10.1016/S1473-3099(11)70168-2; Loutfy MR, 2011, J ACQ IMMUN DEF SYND, V55, P451; Mambule I, 2011, 18 C RETR OPP INF BO; Medina Lara A, PLOSONE IN PRESS; Mermin J, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6792; Mocroft A, 2007, AIDS, V21, P1867, DOI 10.1097/QAD.0b013e328270b877; Moore DM, 2008, JAIDS-J ACQ IMM DEF, V49, P477, DOI 10.1097/QAI.0b013e318186eb18; Mugyenyi P, 2010, LANCET, V375, P123, DOI 10.1016/S0140-6736(09)62067-5; Munderi P, 2008, TROP MED INT HEALTH, V13, P6, DOI 10.1111/j.1365-3156.2007.01973.x; Reynolds SJ, 2009, AIDS, V23, P697, DOI 10.1097/QAD.0b013e3283262a78; van Oosterhout JJG, 2009, TROP MED INT HEALTH, V14, P856, DOI 10.1111/j.1365-3156.2009.02309.x; Walker AS, 2008, AIDS, V22, P237, DOI 10.1097/QAD.0b013e3282f2d760; Walker AS, 2011, CURR OPIN INFECT DIS, V24, P27, DOI 10.1097/QCO.0b013e3283423e0e; Walker AS, ANTIVIR THE IN PRESS; WHO, 2010, ANT THER HIV INF AD; World Health Organization, 2006, ANT THER HIV INF AD	26	15	15	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2013	8	2							e57580	10.1371/journal.pone.0057580	http://dx.doi.org/10.1371/journal.pone.0057580			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	093IT	23437399	Green Published, gold, Green Accepted, Green Submitted			2023-01-03	WOS:000315186000112
J	Park, CY; Kim, HS; Jang, J; Lee, H; Lee, JS; Yoo, JE; Lee, DR; Kim, DW				Park, Chul-Yong; Kim, Han-Soo; Jang, Jiho; Lee, Hyunji; Lee, Jae Souk; Yoo, Jeong-Eun; Lee, Dongjin R.; Kim, Dong-Wook			ABCD2 Is a Direct Target of beta-Catenin and TCF-4: Implications for X- Linked Adrenoleukodystrophy Therapy	PLOS ONE			English	Article							CHAIN FATTY-ACIDS; WNT/BETA-CATENIN; SKIN FIBROBLASTS; GENE-THERAPY; EXPRESSION; LOVASTATIN; PROTEIN; ACTIVATION; ALD; METABOLISM	X-linked adrenoleukodystrophy (X-ALD) is a peroxisomal disorder caused by mutations in the ABCD1 gene that encodes the peroxisomal ATP-binding cassette (ABC) transporter subfamily D member 1 protein (ABCD1), which is referred to as the adrenoleukodystrophy protein (ALDP). Induction of the ABCD2 gene, the closest homolog of ABCD1, has been mentioned as a possible therapeutic option for the defective ABCD1 protein in X-ALD. However, little is known about the transcriptional regulation of ABCD2 gene expression. Here, through in silico analysis, we found two putative TCF-4 binding elements between nucleotide positions -360 and -260 of the promoter region of the ABCD2 gene. The transcriptional activity of the ABCD2 promoter was strongly increased by ectopic expression of beta-catenin and TCF-4. In addition, mutation of either or both TCF-4 binding elements by site-directed mutagenesis decreased promoter activity. This was further validated by the finding that beta-catenin and the promoter of the ABCD2 gene were pulled down with a beta-catenin antibody in a chromatin immunoprecipitation assay. Moreover, real-time PCR analysis revealed that beta-catenin and TCF-4 increased mRNA levels of ABCD2 in both a hepatocellular carcinoma cell line and primary fibroblasts from an X-ALD patient. Interestingly, we found that the levels of very long chain fatty acids were decreased by ectopic expression of ABCD2-GFP as well as beta-catenin and TCF-4. Taken together, our results demonstrate for the first time the direct regulation of ABCD2 by beta-catenin and TCF-4.	[Park, Chul-Yong; Jang, Jiho; Lee, Hyunji; Lee, Jae Souk; Yoo, Jeong-Eun; Lee, Dongjin R.; Kim, Dong-Wook] Yonsei Univ, Coll Med, Dept Physiol, Seoul, South Korea; [Park, Chul-Yong; Jang, Jiho; Lee, Hyunji; Lee, Jae Souk; Yoo, Jeong-Eun; Lee, Dongjin R.; Kim, Dong-Wook] Yonsei Univ, Coll Med, Severance Biomed Res Inst, Seoul, South Korea; [Kim, Han-Soo] Yonsei Univ, Coll Med, Dept Lab Med, Seoul, South Korea; [Kim, Han-Soo] Yonsei Univ, Coll Med, Cell Therapy Ctr, Seoul, South Korea; [Lee, Jae Souk; Yoo, Jeong-Eun; Lee, Dongjin R.; Kim, Dong-Wook] Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Kim, DW (corresponding author), Yonsei Univ, Coll Med, Dept Physiol, Seoul, South Korea.	dwkim2@yuhs.ac			National Research Foundation; Korean Ministry of Education, Science and Technology (the Bio & Medical Technology Development Program) [2012M3A9B4028631, 2012M3A9C7050126]; Korea Health technology R&D Project, Korean Ministry of Health Welfare [A120254, A100694]	National Research Foundation; Korean Ministry of Education, Science and Technology (the Bio & Medical Technology Development Program); Korea Health technology R&D Project, Korean Ministry of Health Welfare	This research was supported by grants from the National Research Foundation, Korean Ministry of Education, Science and Technology (the Bio & Medical Technology Development Program, 2012M3A9B4028631 and 2012M3A9C7050126), Korea Health technology R&D Project, Korean Ministry of Health & Welfare (A120254 and A100694). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arce L, 2006, ONCOGENE, V25, P7492, DOI 10.1038/sj.onc.1210056; AUBOURG P, 1993, NEW ENGL J MED, V329, P745, DOI 10.1056/NEJM199309093291101; Cadigan KM, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a002881; Cartier N, 2009, SCIENCE, V326, P818, DOI 10.1126/science.1171242; Cha MY, 2004, HEPATOLOGY, V39, P1683, DOI 10.1002/hep.20245; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Engelen M, 2010, NEW ENGL J MED, V362, P276, DOI 10.1056/NEJMc0907735; Flavigny E, 1999, FEBS LETT, V448, P261, DOI 10.1016/S0014-5793(99)00379-8; Fourcade S, 2001, EUR J BIOCHEM, V268, P3490, DOI 10.1046/j.1432-1327.2001.02249.x; Fuerer C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009370; Gondcaille C, 2005, J CELL BIOL, V169, P93, DOI 10.1083/jcb.200501036; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holzinger A, 1997, BIOCHEM BIOPH RES CO, V239, P261, DOI 10.1006/bbrc.1997.7391; Jang J, 2011, ANN NEUROL, V70, P402, DOI 10.1002/ana.22486; Kemp S, 2001, HUM MUTAT, V18, P499, DOI 10.1002/humu.1227; Kemp S, 1998, NAT MED, V4, P1261, DOI 10.1038/3242; Kemp S, 2010, BRAIN PATHOL, V20, P831, DOI 10.1111/j.1750-3639.2010.00391.x; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lee HY, 2004, SCIENCE, V303, P1020, DOI 10.1126/science.1091611; Malhotra S, 2009, CELL STEM CELL, V4, P27, DOI 10.1016/j.stem.2008.12.004; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morita M, 2011, CURR DRUG TARGETS, V12, P694, DOI 10.2174/138945011795378577; Moser AB, 1999, ANN NEUROL, V45, P100, DOI 10.1002/1531-8249(199901)45:1<100::AID-ART16>3.0.CO;2-U; Moser HW, 2007, NAT CLIN PRACT NEURO, V3, P140, DOI 10.1038/ncpneuro0421; MOSER HW, 1980, ANN NEUROL, V7, P542, DOI 10.1002/ana.410070607; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Netik A, 1999, HUM MOL GENET, V8, P907, DOI 10.1093/hmg/8.5.907; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Pai GS, 2000, MOL GENET METAB, V69, P312; Paik MJ, 2001, J CHROMATOGR B, V760, P149, DOI 10.1016/S0378-4347(01)00263-8; Park CY, 2009, J BIOL CHEM, V284, P9237, DOI 10.1074/jbc.M808773200; Pujol A, 2004, HUM MOL GENET, V13, P2997, DOI 10.1093/hmg/ddh323; Pujol A, 2000, GENOMICS, V70, P131, DOI 10.1006/geno.2000.6367; Pulukuri SMK, 2007, J BIOL CHEM, V282, P35594, DOI 10.1074/jbc.M705867200; Singh I, 1998, FEBS LETT, V426, P342, DOI 10.1016/S0014-5793(98)00370-6; Singh I, 1998, NEW ENGL J MED, V339, P702, DOI 10.1056/NEJM199809033391012; Singh I, 2010, BRAIN PATHOL, V20, P838, DOI 10.1111/j.1750-3639.2010.00392.x; Singh J, 2011, J LIPID RES, V52, P2056, DOI 10.1194/jlr.M017491; van Roermund CWT, 2008, FASEB J, V22, P4201, DOI 10.1096/fj.08-110866; Weinhofer I, 2005, J BIOL CHEM, V280, P41243, DOI 10.1074/jbc.M509450200; Weinhofer I, 2002, HUM MOL GENET, V11, P2701, DOI 10.1093/hmg/11.22.2701; Weinhofer I, 2008, EUR J CELL BIOL, V87, P933, DOI 10.1016/j.ejcb.2008.08.002	45	11	11	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2013	8	2							e56242	10.1371/journal.pone.0056242	http://dx.doi.org/10.1371/journal.pone.0056242			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	093IT	23437103	Green Submitted, Green Published, gold			2023-01-03	WOS:000315186000020
J	Patel, K				Patel, Kinesh			End the silence on animal products in drugs	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												kinesh_patel@yahoo.co.uk						Humane Research Council, 2012, VEG FOODS MARK ASS 2	1	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 5	2013	346								f722	10.1136/bmj.f722	http://dx.doi.org/10.1136/bmj.f722			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	088AR	23386407				2023-01-03	WOS:000314806700009
J	Lombardi, G; Lanteri, P; Porcelli, S; Mauri, C; Colombini, A; Grasso, D; Zani, V; Bonomi, FG; Melegati, G; Banfi, G				Lombardi, Giovanni; Lanteri, Patrizia; Porcelli, Simone; Mauri, Clara; Colombini, Alessandra; Grasso, Dalila; Zani, Viviana; Bonomi, Felice Giulio; Melegati, Gianluca; Banfi, Giuseppe			Hematological Profile and Martial Status in Rugby Players during Whole Body Cryostimulation	PLOS ONE			English	Article							IRON-DEFICIENCY; BLOOD; CRYOTHERAPY; INFLAMMATION	Cold-based therapies are commonly applied to alleviate pain symptoms secondary to inflammatory diseases, but also to treat injuries or overuse, as done in sports rehabilitation. Whole body cryotherapy, a relatively new form of cold therapy, consists of short whole-body exposure to extremely cold air (-110 degrees C to -140 degrees C). Cryostimulation is gaining wider acceptance as an effective part of physical therapy to accelerate muscle recovery in rugby players. The aim of this study was to evaluate the effect of repeated cryostimulation sessions on the hematological profile and martial status markers in professional rugby players. Twenty-seven professional rugby players received 2 daily cryostimulation treatments for 7 consecutive days. Blood samples were collected before and after administration of the cryotherapic protocol and hematological profiles were obtained. No changes in the leukocyte count or composition were seen. There was a decrease in the values for erythrocytes, hematocrit, hemoglobin and mean corpuscular hemoglobin content, and an increase in mean corpuscular volume and red cell distribution width. Platelet count and mean volume remained unchanged. Serum transferrin and ferritin decreased, while soluble transferrin receptor increased. Serum iron and transferrin saturation were unchanged, as was reticulocyte count, whereas the immature reticulocyte fraction decreased substantially. In conclusion, in this sample of professional rugby players, cryostimulation modified the hematological profile, with a reduction in erythrocyte count and hemoglobinization paralleled by a change in martial status markers.	[Lombardi, Giovanni; Lanteri, Patrizia; Colombini, Alessandra; Grasso, Dalila; Banfi, Giuseppe] IRCCS Ist Ortoped Galeazzi, Lab Expt Biochem & Mol Biol, Milan, Italy; [Porcelli, Simone] CNR, Inst Bioimaging & Mol Physiol, Milan, Italy; [Mauri, Clara; Melegati, Gianluca] IRCCS Ist Ortoped Galeazzi, Dept Multifunct Rehabil, Milan, Italy; [Zani, Viviana; Bonomi, Felice Giulio] Poliambulatorio Bongi, Ctr Syst Cryotherapy, Orzinuovi, Italy; [Bonomi, Felice Giulio] Humanitas Gavazzeni, Cardiovasc Dept, OU Cardiol, Bergamo, Italy; [Banfi, Giuseppe] Univ Milan, Dept Biomed Sci Hlth, Milan, Italy	IRCCS Istituto Ortopedico Galeazzi; Consiglio Nazionale delle Ricerche (CNR); IRCCS Istituto Ortopedico Galeazzi; Istituto Clinico Humanitas Gavazzeni; University of Milan	Lombardi, G (corresponding author), IRCCS Ist Ortoped Galeazzi, Lab Expt Biochem & Mol Biol, Milan, Italy.	giovanni.lombardi@grupposandonato.it	Colombini, Alessandra/I-2441-2012; Lombardi, Giovanni/I-2414-2012; Mauri, Chiara/GXN-0766-2022; porcelli, simone/A-1977-2016; Banfi, Giuseppe/K-6585-2015	Colombini, Alessandra/0000-0002-1800-3424; Lombardi, Giovanni/0000-0002-8365-985X; porcelli, simone/0000-0002-9494-0858; Mauri, Claudia/0000-0001-9761-2625; Banfi, Giuseppe/0000-0001-9578-5338	Italian Ministry of Health	Italian Ministry of Health(Ministry of Health, Italy)	This work has been funded by Italian Ministry of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Banffi G, 2008, BRIT J SPORT MED, V42, P858; Banfi G, 2006, CLIN LAB HAEMATOL, V28, P183, DOI 10.1111/j.1365-2257.2006.00771.x; Banfi G, 2003, J SPORT MED PHYS FIT, V43, P223; Banfi G, 2010, SPORTS MED, V40, P509, DOI 10.2165/11531940-000000000-00000; Banfi G, 2009, J SCI MED SPORT, V12, P609, DOI [10.1016/j.jsams.2008.06.004, 10.1016/j.jsams.2008.02.004]; Banfi G, 2009, J THERM BIOL, V34, P55, DOI 10.1016/j.jtherbio.2008.10.003; DILL DB, 1974, J APPL PHYSIOL, V37, P247, DOI 10.1152/jappl.1974.37.2.247; Hallberg L, 2003, AM J CLIN NUTR, V78, P1225, DOI 10.1093/ajcn/78.6.1225; HARRISON MH, 1985, PHYSIOL REV, V65, P149, DOI 10.1152/physrev.1985.65.1.149; Hausswirth C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027749; Lubkowska A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046352; Lubkowska A, 2010, INT J OCCUP MED ENV, V23, P367, DOI 10.2478/v10001-010-0037-0; Lubkowska A, 2010, CRYOBIOLOGY, V61, P22, DOI 10.1016/j.cryobiol.2010.03.010; Lubkowska A, 2010, EUR J APPL PHYSIOL, V109, P67, DOI 10.1007/s00421-009-1207-2; Munoz M, 2009, WORLD J GASTROENTERO, V15, P4617, DOI 10.3748/wjg.15.4617; Nachtigall D, 1996, INT J SPORTS MED, V17, P473, DOI 10.1055/s-2007-972881; Peeling P, 2008, EUR J APPL PHYSIOL, V103, P381, DOI 10.1007/s00421-008-0726-6; Pournot H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022748; Robinson N, 2011, INT J LAB HEMATOL, V33, P146, DOI 10.1111/j.1751-553X.2010.01256.x; Sottas Pierre-Edouard, 2010, Handb Exp Pharmacol, P305, DOI 10.1007/978-3-540-79088-4_14; Suedekum Natalie A, 2005, Curr Sports Med Rep, V4, P199, DOI 10.1097/01.CSMR.0000306207.79809.7f; Tomkins A, 2003, J NUTR, V133, p1649S, DOI 10.1093/jn/133.5.1649S; World Anti-doping Agency, 2011, REQ PASSP OP INT STA; Zoller H, 2004, NUTRITION, V20, P615, DOI 10.1016/j.nut.2004.04.006	24	18	18	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 1	2013	8	2							e55803	10.1371/journal.pone.0055803	http://dx.doi.org/10.1371/journal.pone.0055803			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	085EU	23383348	gold, Green Published, Green Submitted			2023-01-03	WOS:000314597900055
J	Berry, JG; Toomey, SL; Zaslavsky, AM; Jha, AK; Nakamura, MM; Klein, DJ; Feng, JY; Shulman, S; Chiang, VK; Kaplan, W; Hall, M; Schuster, MA				Berry, Jay G.; Toomey, Sara L.; Zaslavsky, Alan M.; Jha, Ashish K.; Nakamura, Mari M.; Klein, David J.; Feng, Jeremy Y.; Shulman, Shanna; Chiang, Vincent K.; Kaplan, William; Hall, Matt; Schuster, Mark A.			Pediatric Readmission Prevalence and Variability Across Hospitals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE; CHILDRENS HOSPITALS; SOCIOECONOMIC-STATUS; QUALITY MEASURES; HEART-FAILURE; INSURANCE; OUTCOMES; PROGRAM; INITIATIVES; PERFORMANCE	Importance Readmission rates are used as an indicator of the quality of care that patients receive during a hospital admission and after discharge. Objective To determine the prevalence of pediatric readmissions and the magnitude of variation in pediatric readmission rates across hospitals. Design, Setting, and Patients We analyzed 568 845 admissions at 72 children's hospitals between July 1, 2009, and June 30, 2010, in the National Association of Children's Hospitals and Related Institutions Case Mix Comparative data set. We estimated hierarchical regression models for 30-day readmission rates by hospital, accounting for age and Chronic Condition Indicators. Hospitals with adjusted readmission rates that were 1 SD above and below the mean were defined as having "high" and "low" rates, respectively. Main Outcome Measures Thirty-day unplanned readmissions following admission for any diagnosis and for the 10 admission diagnoses with the highest readmission prevalence. Planned readmissions were identified with procedure codes from the International Classification of Diseases, Ninth Revision, Clinical Modification. Results The 30-day unadjusted readmission rate for all hospitalized children was 6.5% (n=36 734). Adjusted rates were 28.6% greater in hospitals with high vs low readmission rates (7.2% [95% CI, 7.1%-7.2%] vs 5.6% [95% CI, 5.6%-5.6%]). For the 10 admission diagnoses with the highest readmission prevalence, the adjusted rates were 17.0% to 66.0% greater in hospitals with high vs low readmission rates. For example, sickle cell rates were 20.1% (95% CI, 20.0%-20.3%) vs 12.7% (95% CI, 12.6%-12.8%) in high vs low hospitals, respectively. Conclusions and Relevance Among patients admitted to acute care pediatric hospitals, the rate of unplanned readmissions at 30 days was 6.5%. There was significant variability in readmission rates across conditions and hospitals. These data may be useful for hospitals' quality improvement efforts. JAMA. 2013;309(4):372-380 www.jama.com	[Berry, Jay G.] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Gen Pediat, Boston, MA 02115 USA; [Nakamura, Mari M.] Boston Childrens Hosp, Div Infect Dis, Boston, MA USA; [Chiang, Vincent K.] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Zaslavsky, Alan M.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; [Berry, Jay G.; Toomey, Sara L.; Nakamura, Mari M.; Chiang, Vincent K.; Schuster, Mark A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Jha, Ashish K.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Hall, Matt] Childrens Hosp Assoc, Overland Pk, KS USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Children's Mercy Hospital	Berry, JG (corresponding author), Harvard Univ, Sch Med, Boston Childrens Hosp, Div Gen Pediat, 300 Longwood Ave, Boston, MA 02115 USA.	jay.berry@childrens.harvard.edu	Hall, Matt/AAT-1349-2021; Feng, Jeremy Y/A-4592-2014	Hall, Matt/0000-0001-7778-5887; Feng, Jeremy Y/0000-0002-6912-1922	Agency for Healthcare Research and Quality [U18 HS020513]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [K23 HD058092]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS020513] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K23HD058092] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	Funding was provided by the Agency for Healthcare Research and Quality (U18 HS020513, Principal Investigator: Dr Schuster). Dr Berry was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (K23 HD058092).	3M Health Information Systems, ALL PAT REF DIAGN RE; Agency for Healthcare Research and Quality, CHIPRA MEAS CHIPRA C; Agency for Healthcare Research and Quality, CHRON COND IND; Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project, 2016, INTR HCUP KIDS INP D; [Anonymous], US ADM DAT MON ACC I; [Anonymous], CREAT NAT CHILDR HOS; [Anonymous], CAS MIX PROGR DAT; [Anonymous], HOSP CAR OUTC EFF ME; [Anonymous], VAR HEALTHC DOES IT; Axon RN, 2011, JAMA-J AM MED ASSOC, V305, P504, DOI 10.1001/jama.2011.72; Bautista J, 2012, 2012 AM ASS NEUR M A; Bernheim SM, 2011, 2011 MEASURES MAINTE; Bernheim SM, 2010, CIRC-CARDIOVASC QUAL, V3, P459, DOI 10.1161/CIRCOUTCOMES.110.957613; Berry JG, 2008, NEUROSURGERY, V62, P445, DOI 10.1227/01.neu.0000316012.20797.04; Berry JG, 2011, JAMA-J AM MED ASSOC, V305, P682, DOI 10.1001/jama.2011.122; BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; Bourgeois FC, 2010, ARCH INTERN MED, V170, P1989, DOI 10.1001/archinternmed.2010.439; Bradley EH, 2012, J AM COLL CARDIOL, V60, P607, DOI 10.1016/j.jacc.2012.03.067; Burnham K.P., 2002, MODEL SELECTION MULT; Campbell SE, 2001, J PUBLIC HEALTH MED, V23, P205, DOI 10.1093/pubmed/23.3.205; Carrns Ann, 2010, US News World Rep, V147, P22; Cassedy A, 2008, AMBUL PEDIATR, V8, P321, DOI 10.1016/j.ambp.2008.04.007; Castro M, 2003, AM J RESP CRIT CARE, V168, P1095, DOI 10.1164/rccm.200208-877OC; Cheney J, 2005, J PEDIATR-US, V147, P622, DOI 10.1016/j.jpeds.2005.06.040; Chi MJ, 2011, ARCH GERONTOL GERIAT, V52, P284, DOI 10.1016/j.archger.2010.04.017; Cohen E, 2011, PEDIATRICS, V127, P529, DOI 10.1542/peds.2010-0910; Coye Molly Joel, 2008, Hosp Health Netw, V82, P24; Dougherty D, 2011, ACAD PEDIATR, V11, pS1, DOI 10.1016/j.acap.2011.02.009; Eselius LL, 2008, HEALTH SERV RES, V43, P2014, DOI 10.1111/j.1475-6773.2008.00894.x; Farewell Carrns A., 2010, US NEWS WORLD REP, V147, P22; Favole JA, 2009, WALL STREET J, pD4; Feudtner C, 2010, J PEDIATR-US, V157, P98, DOI 10.1016/j.jpeds.2010.01.049; Feudtner C, 2009, PEDIATRICS, V123, P286, DOI 10.1542/peds.2007-3395; Frei-Jones MJ, 2009, PEDIATR BLOOD CANCER, V52, P481, DOI 10.1002/pbc.21854; Friedman B, 2006, MED CARE RES REV, V63, P327, DOI 10.1177/1077558706287042; Fung V, 2010, MED CARE, V48, P140, DOI 10.1097/MLR.0b013e3181bd4dc3; HealthCare. gov, PARTN PAT BETT CAR L; Hernandez AF, 2011, JAMA-J AM MED ASSOC, V305, P715, DOI 10.1001/jama.2011.167; Ho C, 2013, J CHILD NEUROL, V28, P40, DOI 10.1177/0883073812439345; Hong R, 2007, J EMERG MED, V32, P149, DOI 10.1016/j.jemermed.2006.05.042; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Joynt KE, 2011, JAMA-J AM MED ASSOC, V305, P675, DOI 10.1001/jama.2011.123; Morse RB, 2011, JAMA-J AM MED ASSOC, V306, P1454, DOI 10.1001/jama.2011.1385; Nasir K, 2010, MED CARE, V48, P477, DOI 10.1097/MLR.0b013e3181d5fb24; Parker JD, 2000, PEDIATRICS, V106, P942; Rice-Townsend S, 2013, ANN SURG, V257, P758, DOI 10.1097/SLA.0b013e318268a663; Rice-Townsend S, 2012, J PEDIATR SURG, V47, P1170, DOI 10.1016/j.jpedsurg.2012.03.025; Schuster MA, 2008, JAMA-J AM MED ASSOC, V300, P1047, DOI 10.1001/jama.300.9.1047; Sedman AB, 2004, PEDIATRICS, V114, P965, DOI 10.1542/peds.2004-0650; Sommers A, PHYS VISITS HOSP DIS; van Walraven C, 2011, CAN MED ASSOC J, V183, pE391, DOI 10.1503/cmaj.101860; VINSON JM, 1990, J AM GERIATR SOC, V38, P1290, DOI 10.1111/j.1532-5415.1990.tb03450.x; Wennberg JE, 2002, BRIT MED J, V325, P961, DOI 10.1136/bmj.325.7370.961; Zickafoose JS, 2011, ACAD PEDIATR, V11, P305, DOI 10.1016/j.acap.2011.03.006	54	274	274	3	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 23	2013	309	4					372	380		10.1001/jama.2012.188351	http://dx.doi.org/10.1001/jama.2012.188351			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	074FT	23340639	Bronze, Green Accepted			2023-01-03	WOS:000313799000025
J	Auld, AF; Mbofana, F; Shiraishi, RW; Alfredo, C; Sanchez, M; Ellerbrock, TV; Nelson, LJ				Auld, Andrew F.; Mbofana, Francisco; Shiraishi, Ray W.; Alfredo, Charity; Sanchez, Mauro; Ellerbrock, Tedd V.; Nelson, Lisa J.			Incidence and Determinants of Tuberculosis among Adults Initiating Antiretroviral Therapy - Mozambique, 2004-2008	PLOS ONE			English	Article							ISONIAZID PREVENTIVE THERAPY; HIV-ASSOCIATED TUBERCULOSIS; RESOURCE-LIMITED SETTINGS; RISK-FACTORS; MULTIPLE IMPUTATION; POSITIVE PATIENTS; MISSING VALUES; SOUTH-AFRICA; TERM; ADHERENCE	Background: In Mozambique, tuberculosis (TB) is thought to be the most common cause of death among antiretroviral therapy (ART) enrollees. Monitoring proportions of enrollees screened for TB, and incidence and determinants of TB during ART can help clinicians and program managers identify program improvement opportunities. Methodology/Principal Findings: We conducted a retrospective cohort study among a nationally representative sample of the 79,500 adults (>14 years old) initiating ART during 2004-2007 to estimate clinician compliance with TB screening guidelines, factors associated with active TB at ART initiation, and incidence and predictors of documented TB during ART follow-up. Of 94 sites enrolling >= 50 adults on ART, 30 were selected using probability-proportional-to-size sampling; 2,596 medical records at these sites were randomly selected for abstraction and analysis. At ART initiation, median age of patients was 34, 62% were female, median baseline CD4(+) T-cell count was 153/mu L, and 11% were taking TB treatment. Proportions of records with TB screening documentation before ART initiation improved from 31% to 66% during 2004-2007 (p<0.001). TB screening compliance varied widely by ART clinic [n = 30, 2%-98% (p<0.001)] and supporting non-Governmental Organization (NGO) [n = 7, 27%-83% (p<0.001)]. Receiving TB treatment at ART enrollment was associated with male sex (p<0.001), weight <45 kg (p<0.001) and CD4<50/mu L (p=0.001). Isoniazid preventive therapy (IPT) was prescribed to <1% of ART enrollees not taking TB treatment. TB incidence during ART was 2.32 cases per 100 person-years. Factors associated with TB incidence included adherence to ART<95% (AHR 2.06; 95% CI, 1.32-3.21). Conclusion: Variations in TB screening by clinic and NGO may reflect differing investments in TB screening activities. Future scale-up should target under-performing clinics. Scale-up of TB screening at ART initiation, IPT, and ART adherence interventions could significantly reduce incident TB during ART.	[Auld, Andrew F.; Shiraishi, Ray W.; Ellerbrock, Tedd V.] Ctr Dis Control & Prevent, DGHA, CGH, Atlanta, GA 30333 USA; [Mbofana, Francisco] Minist Hlth, Insituto Nacl Saude, Maputo, Mozambique; [Alfredo, Charity] Ctr Dis Control & Prevent, DGHA, CGH, Maputo, Mozambique; [Sanchez, Mauro] Univ Brasilia, Sch Hlth Sci, Dept Publ Hlth, Brasilia, DF, Brazil	Centers for Disease Control & Prevention - USA; Universidade de Brasilia	Auld, AF (corresponding author), Ctr Dis Control & Prevent, DGHA, CGH, Atlanta, GA 30333 USA.	aauld@cdc.gov	Sanchez, Mauro/AAU-2404-2020	Sanchez, Mauro/0000-0002-0472-1804; Auld, Andrew/0000-0001-5089-9163; Shiraishi, Ray/0000-0001-7640-0666	United States (U.S.) President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC)	United States (U.S.) President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC)	All parts of the study were funded by the United States (U.S.) President's Emergency Plan for AIDS Relief (PEPFAR) (http://www.pepfar.gov/) through the U.S. Centers for Disease Control and Prevention (CDC) (http://www.cdc.gov/). Authors Auld, Shiraishi, Alfredo, Nelson, and Ellerbrock are employed by the CDC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2011, GLOB TUB CONTR 2011; Ansari NA, 2002, INT J TUBERC LUNG D, V6, P55; Auld AF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018453; Balcells ME, 2006, EMERG INFECT DIS, V12, P744; Bassett IV, 2010, CLIN INFECT DIS, V51, P823, DOI 10.1086/656282; Cohen T, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000296; Costagliola D, 2005, CLIN INFECT DIS, V41, P1772, DOI 10.1086/498315; Dembele M, 2010, INT J TUBERC LUNG D, V14, P318; Fairley CK, 2005, HIV MED, V6, P366, DOI 10.1111/j.1468-1293.2005.00322.x; Gandhi RT, 2006, JAIDS-J ACQ IMM DEF, V42, P426, DOI 10.1097/01.qai.0000226789.51992.3f; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Grossberg R, 2004, J CLIN EPIDEMIOL, V57, P1107, DOI 10.1016/j.jclinepi.2004.04.002; Gutierrez F, 2008, CURR HIV RES, V6, P100, DOI 10.2174/157016208783885038; Hermans SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010527; Lawn SD, 2011, INT J TUBERC LUNG D, V15, P571, DOI 10.5588/ijtld.10.0483; Lawn SD, 2005, AIDS, V19, P2109, DOI 10.1097/01.aids.0000194808.20035.c1; Lawn SD, 2011, J INFECT DIS, V204, pS1159, DOI 10.1093/infdis/jir411; Lawn SD, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001067; Lawn SD, 2010, LANCET INFECT DIS, V10, P489, DOI 10.1016/S1473-3099(10)70078-5; Lawn SD, 2010, AIDS, V24, P1323, DOI 10.1097/QAD.0b013e3283390dd1; Lawn SD, 2009, CLIN CHEST MED, V30, P685, DOI 10.1016/j.ccm.2009.08.010; Lawn SD, 2009, AIDS, V23, P1875, DOI 10.1097/QAD.0b013e32832e05c8; Lawn SD, 2009, AIDS, V23, P1717, DOI 10.1097/QAD.0b013e32832d3b6d; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; Nachega J, 2011, 6 INT AIDS SOC C ROM; Namuwenge PM, 2012, T ROY SOC TROP MED H, V106, P84, DOI 10.1016/j.trstmh.2011.10.015; Prasso JE, 2010, 18 INT AIDS C 18 23; Rana F, 1997, J ACQ IMMUN DEF SYND, V14, P83, DOI 10.1097/00042560-199701010-00017; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Royston P, 2005, STATA J, V5, P188, DOI 10.1177/1536867X0500500204; Royston P, 2005, STATA J, V5, P527, DOI 10.1177/1536867X0500500404; Royston P, 2004, STATA J, V4, P227, DOI 10.1177/1536867X0400400301; Royston P, 2009, STATA J, V9, P252, DOI 10.1177/1536867X0900900205; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Seyler C, 2005, AM J RESP CRIT CARE, V172, P123, DOI 10.1164/rccm.200410-1342OC; Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782; UNAIDS, 2012, GLOB REP GLOB AIDS E; Van Rie A, 2011, JAIDS-J ACQ IMM DEF, V56, P349, DOI 10.1097/QAI.0b013e3181f9fb39; White IR, 2009, STAT MED, V28, P1982, DOI 10.1002/sim.3618; WHO, 2010, GUID INT TUB CAS FIN; World Health Organization, 2006, ANT THER HIV INF AD	42	31	31	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2013	8	1							e54665	10.1371/journal.pone.0054665	http://dx.doi.org/10.1371/journal.pone.0054665			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	077HS	23349948	Green Published, gold, Green Submitted			2023-01-03	WOS:000314019100089
J	Vera, E; de Jesus, BB; Foronda, M; Flores, JM; Blasco, MA				Vera, Elsa; Bernardes de Jesus, Bruno; Foronda, Miguel; Flores, Juana M.; Blasco, Maria A.			Telomerase Reverse Transcriptase Synergizes with Calorie Restriction to Increase Health Span and Extend Mouse Longevity	PLOS ONE			English	Article							LIFE-SPAN; DIETARY RESTRICTION; CELLULAR SENESCENCE; OXIDATIVE STRESS; HUMAN-DISEASE; CANCER; LENGTH; MICE; GROWTH; AGE	Caloric restriction (CR), a reduction of food intake while avoiding malnutrition, can delay the onset of cancer and age-related diseases in several species, including mice. In addition, depending of the genetic background, CR can also increase or decrease mouse longevity. This has highlighted the importance of identifying the molecular pathways that interplay with CR in modulating longevity. Significant lifespan extension in mice has been recently achieved through over-expression of the catalytic subunit of mouse telomerase (mTERT) in a cancer protective background. Given the CR cancer-protective effects in rodents, we set to address here whether CR impacts on telomere length and synergizes with mTERT to extend mouse longevity. CR significantly decreased tumor incidence in TERT transgenic (TgTERT) mice and extended their lifespan compared to wild-type (WT) controls under the same diet, indicating a synergy between TgTERT and CR in increasing mouse longevity. In addition, longitudinal telomere length measurements in peripheral blood leukocytes from individual mice showed that CR resulted in maintenance and/or elongation telomeres in a percentage of WT mice, a situation that mimics telomere dynamics in TgTERT cohorts. These results demonstrate that CR attenuates telomere erosion associated to aging and that synergizes with TERT over-expression in increasing "health span'' and extending mouse longevity.	[Vera, Elsa; Bernardes de Jesus, Bruno; Foronda, Miguel; Blasco, Maria A.] Spanish Natl Canc Res Ctr, Mol Oncol Program, Telomeres & Telomerase Grp, Madrid, Spain; [Flores, Juana M.] Univ Complutense Madrid, Fac Vet, Anim Surg & Med Dept, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Complutense University of Madrid	Blasco, MA (corresponding author), Spanish Natl Canc Res Ctr, Mol Oncol Program, Telomeres & Telomerase Grp, Melchor Fernandez Almagro 3, Madrid, Spain.	mblasco@cnio.es	Bernardes de Jesus, Bruno/GLQ-7625-2022; Blasco, Maria A./M-1694-2014	Bernardes de Jesus, Bruno/0000-0002-6407-3466; Blasco, Maria A./0000-0002-4211-233X; Foronda, Miguel/0000-0001-9590-9281; Nobrega-Pereira, Sandrina/0000-0002-9652-1382	Spanish Ministry of Science and Innovation; European Union; European Research Council; Fundacion Botin; Fundacion Lilly	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); European Union(European Commission); European Research Council(European Research Council (ERC)European Commission); Fundacion Botin; Fundacion Lilly	Blasco lab is funded by Spanish Ministry of Science and Innovation, European Union (GENICA and TELOMARKER), European Research Council Advanced Grant, Fundacion Botin and Fundacion Lilly. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson RM, 2009, TOXICOL PATHOL, V37, P47, DOI 10.1177/0192623308329476; Argentino DP, 2005, EXP GERONTOL, V40, P27, DOI 10.1016/j.exger.2004.09.005; Armanios MY, 2007, NEW ENGL J MED, V356, P1317, DOI 10.1056/NEJMoa066157; Bartke A, 2005, ENDOCRINOLOGY, V146, P3718, DOI 10.1210/en.2005-0411; de Jesus BB, 2012, EMBO MOL MED, V4, P691, DOI 10.1002/emmm.201200245; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Blasco MA, 2007, NAT CHEM BIOL, V3, P640, DOI 10.1038/nchembio.2007.38; Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Burnett C, 2011, NATURE, V477, P482, DOI 10.1038/nature10296; Calado RT, 2009, NEW ENGL J MED, V361, P2353, DOI 10.1056/NEJMra0903373; Canela A, 2007, P NATL ACAD SCI USA, V104, P5300, DOI 10.1073/pnas.0609367104; Canto C, 2009, TRENDS ENDOCRIN MET, V20, P325, DOI 10.1016/j.tem.2009.03.008; Chan SWL, 2002, ONCOGENE, V21, P553, DOI 10.1038/sj.onc.1205082; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Dhahbi JM, 2004, P NATL ACAD SCI USA, V101, P5524, DOI 10.1073/pnas.0305300101; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; Dunn SE, 1997, CANCER RES, V57, P4667; Elyada E, 2011, NATURE, V470, P409, DOI 10.1038/nature09673; Epel ES, 2004, P NATL ACAD SCI USA, V101, P17312, DOI 10.1073/pnas.0407162101; Ferguson VL, 2003, BONE, V33, P387, DOI 10.1016/S8756-3282(03)00199-6; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Flores I, 2006, CURR OPIN CELL BIOL, V18, P254, DOI 10.1016/j.ceb.2006.03.003; Fontana L, 2007, JAMA-J AM MED ASSOC, V297, P986, DOI 10.1001/jama.297.9.986; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Gonzalez-Suarez E, 2005, ONCOGENE, V24, P2256, DOI 10.1038/sj.onc.1208413; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029; Hamrick MW, 2008, J BONE MINER RES, V23, P870, DOI [10.1359/jbmr.080213, 10.1359/JBMR.080213]; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Heikkinen S, 2007, CURR PROTOC MOL BIOL, DOI DOI 10.1002/0471142727.MB29B03S77; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Hempenstall S, 2010, MECH AGEING DEV, V131, P111, DOI 10.1016/j.mad.2009.12.008; Herbig U, 2006, SCIENCE, V311, P1257, DOI 10.1126/science.1122446; Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; INGRAM DK, 1986, EXP AGING RES, V12, P155; Jaskelioff M, 2011, NATURE, V469, P102, DOI 10.1038/nature09603; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Koubova J, 2003, GENE DEV, V17, P313, DOI 10.1101/gad.1052903; Liao CY, 2010, AGING CELL, V9, P92, DOI 10.1111/j.1474-9726.2009.00533.x; Longo VD, 2010, TRENDS PHARMACOL SCI, V31, P89, DOI 10.1016/j.tips.2009.11.004; Martinez P, 2009, GENE DEV, V23, P2060, DOI 10.1101/gad.543509; Mattison JA, 2012, NATURE, V489, P318, DOI 10.1038/nature11432; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; McIlrath J, 2001, CANCER RES, V61, P912; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Pugh TD, 1999, NEUROBIOL AGING, V20, P157, DOI 10.1016/S0197-4580(99)00043-3; Sedelnikova OA, 2008, AGING CELL, V7, P89, DOI 10.1111/j.1474-9726.2007.00354.x; Spindler SR, 2010, AGEING RES REV, V9, P324, DOI 10.1016/j.arr.2009.10.003; Tomas-Loba A, 2008, CELL, V135, P609, DOI 10.1016/j.cell.2008.09.034; Turturro A, 1999, J GERONTOL A-BIOL, V54, pB492, DOI 10.1093/gerona/54.11.B492; Vera E, 2012, CELL REP, V2, P732, DOI 10.1016/j.celrep.2012.08.023; von Zglinicki T, 2002, TRENDS BIOCHEM SCI, V27, P339, DOI 10.1016/S0968-0004(02)02110-2; Wang CF, 2009, AGING CELL, V8, P311, DOI 10.1111/j.1474-9726.2009.00481.x; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854; WEINDRUCH R, 1986, J NUTR, V116, P641, DOI 10.1093/jn/116.4.641; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	61	63	66	0	65	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2013	8	1							e53760	10.1371/journal.pone.0053760	http://dx.doi.org/10.1371/journal.pone.0053760			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	077HS	23349740	Green Published, gold			2023-01-03	WOS:000314019100029
J	Dauplais, M; Lazard, M; Blanquet, S; Plateau, P				Dauplais, Marc; Lazard, Myriam; Blanquet, Sylvain; Plateau, Pierre			Neutralization by Metal Ions of the Toxicity of Sodium Selenide	PLOS ONE			English	Article							RAT PLASMA INVIVO; POSSIBLE MECHANISM; INORGANIC MERCURY; HYDROGEN-SULFIDE; CADMIUM; OXIDATION; CANCER; DETOXIFICATION; METHYLMERCURY; PREVENTION	Inert metal-selenide colloids are found in animals. They are believed to afford cross-protection against the toxicities of both metals and selenocompounds. Here, the toxicities of metal salt and sodium selenide mixtures were systematically studied using the death rate of Saccharomyces cerevisiae cells as an indicator. In parallel, the abilities of these mixtures to produce colloids were assessed. Studied metal cations could be classified in three groups: (i) metal ions that protect cells against selenium toxicity and form insoluble colloids with selenide (Ag+, Cd2+, Cu2+, Hg2+, Pb2+ and Zn2+), (ii) metal ions which protect cells by producing insoluble metal-selenide complexes and by catalyzing hydrogen selenide oxidation in the presence of dioxygen (Co2+ and Ni2+) and, finally, (iii) metal ions which do not afford protection and do not interact (Ca2+, Mg2+, Mn2+) or weakly interact (Fe2+) with selenide under the assayed conditions. When occurring, the insoluble complexes formed from divalent metal ions and selenide contained equimolar amounts of metal and selenium atoms. With the monovalent silver ion, the complex contained two silver atoms per selenium atom. Next, because selenides are compounds prone to oxidation, the stabilities of the above colloids were evaluated under oxidizing conditions. 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB), the reduction of which can be optically followed, was used to promote selenide oxidation. Complexes with cadmium, copper, lead, mercury or silver resisted dissolution by DTNB treatment over several hours. With nickel and cobalt, partial oxidation by DTNB occurred. On the other hand, when starting from ZnSe or FeSe complexes, full decompositions were obtained within a few tens of minutes. The above properties possibly explain why ZnSe and FeSe nanoparticles were not detected in animals exposed to selenocompounds.	[Dauplais, Marc; Lazard, Myriam; Blanquet, Sylvain; Plateau, Pierre] Ecole Polytech, CNRS, Biochim Lab, F-91128 Palaiseau, France	Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris	Plateau, P (corresponding author), Ecole Polytech, CNRS, Biochim Lab, F-91128 Palaiseau, France.	pierre.plateau@polytechnique.edu		Lazard, Myriam/0000-0002-7154-1352	CNRS; Ecole polytechnique	CNRS(Centre National de la Recherche Scientifique (CNRS)); Ecole polytechnique	This study was funded by the CNRS and the Ecole polytechnique. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AASETH J, 1981, SCAND J CLIN LAB INV, V41, P247, DOI 10.3109/00365518109092041; Arai T, 2004, ENVIRON SCI TECHNOL, V38, P6468, DOI 10.1021/es040367u; BLEEHEN SS, 1981, BRIT J DERMATOL, V104, P19, DOI 10.1111/j.1365-2133.1981.tb01706.x; Brozmanova J, 2010, ARCH TOXICOL, V84, P919, DOI 10.1007/s00204-010-0595-8; CHABEREK S, 1952, J AM CHEM SOC, V74, P6228, DOI 10.1021/ja01144a022; CHEN KY, 1972, ENVIRON SCI TECHNOL, V6, P529, DOI 10.1021/es60065a008; CHEN KY, 1972, J SANIT ENG DIV ASCE, V98, P215; CHEN RW, 1975, BIOINORG CHEM, V4, P125, DOI 10.1016/S0006-3061(00)81021-2; ESAKI N, 1982, J BIOL CHEM, V257, P4386; FRIEDEN E, 1985, J CHEM EDUC, V62, P917, DOI 10.1021/ed062p917; Gailer J, 2000, CHEM RES TOXICOL, V13, P1135, DOI 10.1021/tx000050h; Gailer J, 2012, J INORG BIOCHEM, V108, P128, DOI 10.1016/j.jinorgbio.2011.12.001; GASIEWICZ TA, 1976, BIOCHIM BIOPHYS ACTA, V428, P113, DOI 10.1016/0304-4165(76)90113-6; GASIEWICZ TA, 1978, CHEM-BIOL INTERACT, V23, P171, DOI 10.1016/0009-2797(78)90004-2; Glattre E, 2012, J TRACE ELEM MED BIO, V26, P168, DOI 10.1016/j.jtemb.2012.04.021; Gueldry O, 2003, EUR J BIOCHEM, V270, P2486, DOI 10.1046/j.1432-1033.2003.03620.x; HILL CH, 1975, FED PROC, V34, P2096; HILL CH, 1974, J NUTR, V104, P593, DOI 10.1093/jn/104.5.593; Jackson MI, 2008, CURR OPIN CLIN NUTR, V11, P718, DOI 10.1097/MCO.0b013e3283139674; JENSEN LS, 1975, J NUTR, V105, P769, DOI 10.1093/jn/105.6.769; Khan MAK, 2010, CHEM RES TOXICOL, V23, P1202, DOI 10.1021/tx100080s; Kobayashi Y, 2001, J CHROMATOGR B, V760, P73, DOI 10.1016/S0378-4347(01)00252-3; KOEMAN JH, 1973, NATURE, V245, P385, DOI 10.1038/245385a0; KOSTA L, 1975, NATURE, V254, P238, DOI 10.1038/254238a0; Kungolos A, 1999, ECOTOX ENVIRON SAFE, V43, P149, DOI 10.1006/eesa.1999.1767; Lailson-Brito J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042162; Letavayova L, 2008, MUTAT RES-GEN TOX EN, V652, P198, DOI 10.1016/j.mrgentox.2008.03.001; Letavayova L, 2008, MUTAT RES-FUND MOL M, V638, P1, DOI 10.1016/j.mrfmmm.2007.08.009; Manikova D, 2012, CHEM RES TOXICOL, V25, P1598, DOI 10.1021/tx300061n; MARTOJA R, 1977, CR ACAD SCI D NAT, V285, P109; MATSUMURA T, 1992, Journal of Dermatology (Tokyo), V19, P87; Muecke R, 2010, INTEGR CANCER THER, V9, P136, DOI 10.1177/1534735410367648; NAGANUMA A, 1983, TOXICOLOGY, V29, P77, DOI 10.1016/0300-483X(83)90040-9; Nakazawa E, 2011, METALLOMICS, V3, P719, DOI 10.1039/c0mt00106f; Nakazawa E, 2011, J ENVIRON MONITOR, V13, P1678, DOI 10.1039/c1em10115c; NASHEF AS, 1977, ANAL BIOCHEM, V79, P394, DOI 10.1016/0003-2697(77)90413-4; Nigro M, 1996, MAR ECOL PROG SER, V135, P137, DOI 10.3354/meps135137; NIGRO M, 1994, J MAR BIOL ASSOC UK, V74, P975, DOI 10.1017/S0025315400090226; NUTTALL KL, 1984, INORG CHIM A-BIOINOR, V91, P243, DOI 10.1016/S0020-1693(00)81844-7; NUTTALL KL, 1987, MED HYPOTHESES, V24, P217, DOI 10.1016/0306-9877(87)90107-1; Odian G, 1981, PRINCIPLES POLYM, P282; Perego P, 1997, TOXICOL APPL PHARM, V147, P312, DOI 10.1006/taap.1997.8271; Peyroche G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036343; Ralston NVC, 2010, TOXICOLOGY, V278, P112, DOI 10.1016/j.tox.2010.06.004; RAWSON AJ, 1995, ECOTOX ENVIRON SAFE, V30, P309, DOI 10.1006/eesa.1995.1035; Rayman MP, 2012, LANCET, V379, P1256, DOI 10.1016/S0140-6736(11)61452-9; Richman EL, 2012, AM J CLIN NUTR, V96, P1, DOI 10.3945/ajcn.112.042119; Rickard D, 2007, CHEM REV, V107, P514, DOI 10.1021/cr0503658; Sadauskas Evaldas, 2007, Part Fibre Toxicol, V4, P10, DOI 10.1186/1743-8977-4-10; Sanmartin C, 2012, INT J MOL SCI, V13, P9649, DOI 10.3390/ijms13089649; Sasakura C, 1998, J INORG BIOCHEM, V71, P159, DOI 10.1016/S0162-0134(98)10048-X; Seby F, 2001, CHEM GEOL, V171, P173, DOI 10.1016/S0009-2541(00)00246-1; Seko Y, 1997, BIOMED ENVIRON SCI, V10, P333; Selenius M, 2010, ANTIOXID REDOX SIGN, V12, P867, DOI 10.1089/ars.2009.2884; Sigel A, 2009, METALLOTHIONEINS REL; Singh VP, 2005, METAL TOXICITY TOLER; Smith RM, 1974, CRITICAL STABILITY C, V1-6; Tarze A, 2007, J BIOL CHEM, V282, P8759, DOI 10.1074/jbc.M610078200; Tatum L, 2000, BIOL TRACE ELEM RES, V77, P241, DOI 10.1385/BTER:77:3:241; Wang L, 1997, COLLOID POLYM SCI, V275, P593, DOI 10.1007/s003960050123; WERES O, 1985, CORROSION, V41, P307, DOI 10.5006/1.3582010; WHANGER PD, 1985, ADV NUTR RES, V7, P221; Wu M, 2010, J BIOL CHEM, V285, P12055, DOI 10.1074/jbc.M109.088781; Wysocki R, 2010, FEMS MICROBIOL REV, V34, P925, DOI 10.1111/j.1574-6976.2010.00217.x; Yoneda S, 1997, BIOCHEM BIOPH RES CO, V231, P7, DOI 10.1006/bbrc.1996.6036	65	23	23	4	68	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2013	8	1							e54353	10.1371/journal.pone.0054353	http://dx.doi.org/10.1371/journal.pone.0054353			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	087KE	23342137	Green Submitted, Green Published, gold			2023-01-03	WOS:000314759400152
J	Boumil, MM				Boumil, Marcia M.			Off-Label Marketing and the First Amendment	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Tufts Univ, Sch Med, Dept Publ Hlth & Community Med, Boston, MA 02111 USA	Massachusetts Department of Public Health; Tufts University	Boumil, MM (corresponding author), Tufts Univ, Sch Med, Dept Publ Hlth & Community Med, Boston, MA 02111 USA.								0	9	9	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 10	2013	368	2					103	105		10.1056/NEJMp1214926	http://dx.doi.org/10.1056/NEJMp1214926			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	066RO	23234470				2023-01-03	WOS:000313238100014
J	Thammanomai, A; Hamakawa, H; Bartolak-Suki, E; Suki, B				Thammanomai, Apiradee; Hamakawa, Hiroshi; Bartolak-Suki, Erzsebet; Suki, Bela			Combined Effects of Ventilation Mode and Positive End-Expiratory Pressure on Mechanics, Gas Exchange and the Epithelium in Mice with Acute Lung Injury	PLOS ONE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; BIOLOGICALLY VARIABLE VENTILATION; TIDAL VOLUME VENTILATION; RECRUITMENT MANEUVERS; DEEP INFLATION; ARTERIAL OXYGENATION; ALVEOLAR COLLAPSE; PORCINE MODEL; MOUSE LUNG; E-CADHERIN	The accepted protocol to ventilate patients with acute lung injury is to use low tidal volume (V-T) in combination with recruitment maneuvers or positive end-expiratory pressure (PEEP). However, an important aspect of mechanical ventilation has not been considered: the combined effects of PEEP and ventilation modes on the integrity of the epithelium. Additionally, it is implicitly assumed that the best PEEP-V-T combination also protects the epithelium. We aimed to investigate the effects of ventilation mode and PEEP on respiratory mechanics, peak airway pressures and gas exchange as well as on lung surfactant and epithelial cell integrity in mice with acute lung injury. HCl-injured mice were ventilated at PEEPs of 3 and 6 cmH(2)O with conventional ventilation (CV), CV with intermittent large breaths (CVLB) to promote recruitment, and a new mode, variable ventilation, optimized for mice (VVN). Mechanics and gas exchange were measured during ventilation and surfactant protein (SP)-B, proSP-B and E-cadherin levels were determined from lavage and lung homogenate. PEEP had a significant effect on mechanics, gas exchange and the epithelium. The higher PEEP reduced lung collapse and improved mechanics and gas exchange but it also down regulated surfactant release and production and increased epithelial cell injury. While CVLB was better than CV, VVN outperformed CVLB in recruitment, reduced epithelial injury and, via a dynamic mechanotransduction, it also triggered increased release and production of surfactant. For long-term outcome, selection of optimal PEEP and ventilation mode may be based on balancing lung physiology with epithelial injury.	[Thammanomai, Apiradee; Hamakawa, Hiroshi; Bartolak-Suki, Erzsebet; Suki, Bela] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA	Boston University	Suki, B (corresponding author), Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.	bsuki@bu.edu			National Institutes of Health (NIH) [HL-098976]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL098976] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was funded by National Institutes of Health (NIH) HL-098976. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen G, 2004, J APPL PHYSIOL, V96, P293, DOI 10.1152/japplphysiol.00270.2003; Allen G, 2002, J APPL PHYSIOL, V93, P1709, DOI 10.1152/japplphysiol.00473.2002; Allen GB, 2007, AM J PHYSIOL-LUNG C, V292, pL1580, DOI 10.1152/ajplung.00483.2006; Allen GB, 2006, AM J PHYSIOL-LUNG C, V291, pL710, DOI 10.1152/ajplung.00532.2005; AMATO MBP, 1995, AM J RESP CRIT CARE, V152, P1835, DOI 10.1164/ajrccm.152.6.8520744; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Arold SP, 2003, AM J PHYSIOL-LUNG C, V285, pL370, DOI 10.1152/ajplung.00036.2003; Arold SP, 2002, AM J RESP CRIT CARE, V165, P366, DOI 10.1164/ajrccm.165.3.2010155; Azeloglu EU, 2008, J APPL PHYSIOL, V105, P652, DOI 10.1152/japplphysiol.00958.2007; Badet M, 2009, RESP CARE, V54, P847, DOI 10.4187/002013209793800448; Black CLB, 2007, CRIT CARE MED, V35, P870, DOI 10.1097/01.CCM.0000257331.42485.94; Bellardine CL, 2006, CRIT CARE MED, V34, P439, DOI 10.1097/01.CCM.0000196208.01682.87; Bilek AM, 2003, J APPL PHYSIOL, V94, P770, DOI 10.1152/japplphysiol.00764.2002; BO G, 1977, J APPL PHYSIOL, V42, P476, DOI 10.1152/jappl.1977.42.4.476; Briel M, 2010, JAMA-J AM MED ASSOC, V303, P865, DOI 10.1001/jama.2010.218; Brunner JX, 2009, INTENS CARE MED, V35, P1479, DOI 10.1007/s00134-009-1510-8; Carvalho AR, 2011, J APPL PHYSIOL, V110, P1083, DOI 10.1152/japplphysiol.00804.2010; Chiumello D, 1999, AM J RESP CRIT CARE, V160, P109, DOI 10.1164/ajrccm.160.1.9803046; Chiumello D, 2008, AM J RESP CRIT CARE, V178, P346, DOI 10.1164/rccm.200710-1589OC; Csendes T., 1988, Acta Cybernetica, V8, P361; Funk DJ, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-22; Gattinoni L, 2005, CURR OPIN CRIT CARE, V11, P69, DOI 10.1097/00075198-200502000-00011; Goto T, 2010, EUR J CARDIO-THORAC, V37, P426, DOI 10.1016/j.ejcts.2009.06.041; Goto Y, 2000, AM J RESP CELL MOL, V23, P712, DOI 10.1165/ajrcmb.23.6.4031; Halter JM, 2003, AM J RESP CRIT CARE, V167, P1620, DOI 10.1164/rccm.200205-435OC; HANTOS Z, 1992, J APPL PHYSIOL, V72, P168, DOI 10.1152/jappl.1992.72.1.168; Hodgson Carol L, 2011, J Intensive Care Med, V26, P41, DOI 10.1177/0885066610383953; Ito S, 2004, J APPL PHYSIOL, V97, P204, DOI 10.1152/japplphysiol.01246.2003; JARDIN F, 1981, NEW ENGL J MED, V304, P387, DOI 10.1056/NEJM198102123040703; Kaczka DW, 2005, ANESTHESIOLOGY, V103, P306, DOI 10.1097/00000542-200508000-00014; Kostic P, 2011, CRIT CARE, V15, DOI 10.1186/cc10236; Krebs J, 2009, CRIT CARE, V13, DOI 10.1186/cc8118; le Duc Q, 2010, J CELL BIOL, V189, P1107, DOI 10.1083/jcb.201001149; Lefevre GR, 1996, AM J RESP CRIT CARE, V154, P1567, DOI 10.1164/ajrccm.154.5.8912782; LUTCHEN KR, 1993, J APPL PHYSIOL, V75, P478, DOI 10.1152/jappl.1993.75.1.478; Martynowicz MA, 2001, J APPL PHYSIOL, V90, P1744, DOI 10.1152/jappl.2001.90.5.1744; Meade MO, 2008, RESP CARE, V53, P1441; Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637; Mergoni M, 2001, J APPL PHYSIOL, V91, P441, DOI 10.1152/jappl.2001.91.1.441; MUSCEDERE JG, 1994, AM J RESP CRIT CARE, V149, P1327, DOI 10.1164/ajrccm.149.5.8173774; Mutch WAC, 2000, AM J RESP CRIT CARE, V162, P319, DOI 10.1164/ajrccm.162.1.9903120; Mutch WAC, 2000, CRIT CARE MED, V28, P2457, DOI 10.1097/00003246-200007000-00045; Santiago VR, 2010, CRIT CARE MED, V38, P2207, DOI 10.1097/CCM.0b013e3181f3e076; Spieth PM, 2009, AM J RESP CRIT CARE, V179, P684, DOI 10.1164/rccm.200806-975OC; Suki B, 1998, NATURE, V393, P127, DOI 10.1038/30130; Thammanomai A, 2008, J APPL PHYSIOL, V104, P1329, DOI 10.1152/japplphysiol.01002.2007; Thammanomai A, 2007, J APPL PHYSIOL, V103, P1551, DOI 10.1152/japplphysiol.00006.2007; Tomashefski JF, 2000, CLIN CHEST MED, V21, P435, DOI 10.1016/S0272-5231(05)70158-1; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; Tremblay LN, 1998, P ASSOC AM PHYSICIAN, V110, P482; Zhao ZQ, 2010, CRIT CARE, V14, DOI 10.1186/cc8860; 2000, N ENGL J MED, V342, P1301	52	40	45	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2013	8	1							e53934	10.1371/journal.pone.0053934	http://dx.doi.org/10.1371/journal.pone.0053934			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	070YR	23326543	gold, Green Submitted, Green Published			2023-01-03	WOS:000313551500102
J	Kanitz, E; Otten, W; Tuchscherer, M; Grabner, M; Brussow, KP; Rehfeldt, C; Metges, CC				Kanitz, Ellen; Otten, Winfried; Tuchscherer, Margret; Graebner, Maria; Bruessow, Klaus-Peter; Rehfeldt, Charlotte; Metges, Cornelia C.			High and Low Protein: Carbohydrate Dietary Ratios during Gestation Alter Maternal-Fetal Cortisol Regulation in Pigs	PLOS ONE			English	Article							BETA-HYDROXYSTEROID DEHYDROGENASE; MESSENGER-RNA EXPRESSION; TYPE-2 11-BETA-HYDROXYSTEROID DEHYDROGENASE; GLUCOCORTICOID-RECEPTOR; GENE-EXPRESSION; PLACENTAL METABOLISM; RIBONUCLEIC-ACID; PLASMA-CORTISOL; BIRTH-WEIGHT; PREGNANCY	Imbalanced maternal nutrition during gestation can cause alterations of the hypothalamic-pituitary-adrenal (HPA) system in offspring. The present study investigated the effects of maternal low-and high-protein diets during gestation in pigs on the maternal-fetal HPA regulation and expression of the glucocorticoid receptor (GR), mineralocorticoid receptor (MR), 11 beta-hydroxysteroid dehydrogenase 1 and 2 (11 beta-HSD1 and 11 beta-HSD2) and c-fos mRNAs in the placenta and fetal brain. Twenty-seven German Landrace sows were fed diets with high (HP, 30%), low (LP, 6.5%) or adequate (AP, 12.1%) protein levels made isoenergetic by varying the carbohydrate levels. On gestational day 94, fetuses were recovered under general anesthesia for the collection of blood, brain and placenta samples. The LP diet in sows increased salivary cortisol levels during gestation compared to the HP and AP sows and caused an increase of placental GR and c-fos mRNA expression. However, the diurnal rhythm of plasma cortisol was disturbed in both LP and HP sows. Total plasma cortisol concentrations in the umbilical cord vessels were elevated in fetuses from HP sows, whereas corticosteroid-binding globulin levels were decreased in LP fetuses. In the hypothalamus, LP fetuses displayed an enhanced mRNA expression of 11b-HSD1 and a reduced expression of c-fos. Additionally, the 11b-HSD2 mRNA expression was decreased in both LP and HP fetuses. The present results suggest that both low and high protein: carbohydrate dietary ratios during gestation may alter the expression of genes encoding key determinants of glucocorticoid hormone action in the fetus with potential long-lasting consequences for stress adaptation and health.	[Kanitz, Ellen; Otten, Winfried; Tuchscherer, Margret; Graebner, Maria] Leibniz Inst Farm Anim Biol, Res Unit Behav Physiol, Dummerstorf, Germany; [Bruessow, Klaus-Peter] Leibniz Inst Farm Anim Biol, Res Unit Reprod Biol, Dummerstorf, Germany; [Rehfeldt, Charlotte] Leibniz Inst Farm Anim Biol, Res Unit Muscle Biol & Growth, Dummerstorf, Germany; [Metges, Cornelia C.] Leibniz Inst Farm Anim Biol, Res Unit Nutr Physiol Oskar Kellner, Dummerstorf, Germany	Forschungsinstitut fur Nutztierbiologie (FBN); Forschungsinstitut fur Nutztierbiologie (FBN); Forschungsinstitut fur Nutztierbiologie (FBN); Forschungsinstitut fur Nutztierbiologie (FBN)	Kanitz, E (corresponding author), Leibniz Inst Farm Anim Biol, Res Unit Behav Physiol, Dummerstorf, Germany.	ekanitz@fbn-dummerstorf.de	Otten, Winfried/V-8376-2019	Otten, Winfried/0000-0002-5613-5356	German Research Foundation, Bonn [PAK 24: OT 137/3-1, ME 1420/8-1]	German Research Foundation, Bonn(German Research Foundation (DFG))	The study was supported by grants from the German Research Foundation, Bonn (PAK 24: OT 137/3-1; ME 1420/8-1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; Belda X, 2005, PHARMACOL BIOCHEM BE, V81, P41, DOI 10.1016/j.pbb.2005.02.009; Benediktsson R, 1997, CLIN ENDOCRINOL, V46, P161, DOI 10.1046/j.1365-2265.1997.1230939.x; Bertram C, 2001, ENDOCRINOLOGY, V142, P2841, DOI 10.1210/en.142.7.2841; Bertram CE, 2002, REPRODUCTION, V124, P459, DOI 10.1530/rep.0.1240459; BRIGHT GM, 1995, J CLIN ENDOCR METAB, V80, P770, DOI 10.1210/jc.80.3.770; BURTON PJ, 1994, J ENDOCRINOL, V143, P505, DOI 10.1677/joe.0.1430505; Clarke KA, 2002, J ENDOCRINOL, V172, P527, DOI 10.1677/joe.0.1720527; Daenzer M, 2002, J NUTR, V132, P142, DOI 10.1093/jn/132.2.142; Draper N, 2005, J ENDOCRINOL, V186, P251, DOI 10.1677/joe.1.06019; Felix B, 1999, STEREOTAXIC ATLAS PI; Galler JR, 1993, TXB PEDIAT NUTR, P173; Galler JR, 1997, NUTR PEDIAT 2, P196; GfE, 2006, EMPFEHLUNGEN ENERGIE; Gnanalingham MG, 2007, REPRODUCTION, V134, P615, DOI 10.1530/REP-06-0369; GOLD PW, 1986, NEW ENGL J MED, V314, P1335, DOI 10.1056/NEJM198605223142102; GOMEZSANCHEZ EP, 1992, AM J PHYSIOL, V263, pE1125; GOMEZSANCHEZ EP, 1986, ENDOCRINOLOGY, V118, P819, DOI 10.1210/endo-118-2-819; Heo J, 2005, J ANIM SCI, V83, P208; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Herrick K, 2003, J CLIN ENDOCR METAB, V88, P3554, DOI 10.1210/jc.2003-030287; Holmes MC, 2006, MOL CELL ENDOCRINOL, V248, P9, DOI 10.1016/j.mce.2005.12.002; Jacobson L, 1997, ENDOCRINOLOGY, V138, P1048, DOI 10.1210/en.138.3.1048; Kanitz E, 2002, BIOL NEONATE, V81, P203, DOI 10.1159/000051535; Kanitz E, 2009, PHYSIOL BEHAV, V98, P176, DOI 10.1016/j.physbeh.2009.05.007; Kapoor A, 2006, J PHYSIOL-LONDON, V572, P31, DOI 10.1113/jphysiol.2006.105254; Kattesh HG, 1997, BIOL NEONATE, V72, P192, DOI 10.1159/000244484; Klemcke HG, 2003, BIOL REPROD, V69, P1945, DOI 10.1095/biolreprod.103.018150; KLEMCKE HG, 1995, BIOL REPROD, V53, P1293, DOI 10.1095/biolreprod53.6.1293; Klemcke HG, 2000, LIFE SCI, V66, P1045, DOI 10.1016/S0024-3205(99)00669-4; Klemcke HG, 1996, BIOL REPROD, V55, P217, DOI 10.1095/biolreprod55.1.217; LangleyEvans SC, 1996, PLACENTA, V17, P169, DOI 10.1016/S0143-4004(96)80010-5; Lesage J, 2001, ENDOCRINOLOGY, V142, P1692, DOI 10.1210/en.142.5.1692; Lesage J, 2006, STRESS, V9, P183, DOI 10.1080/10253890601056192; Lind NM, 2007, NEUROSCI BIOBEHAV R, V31, P728, DOI 10.1016/j.neubiorev.2007.02.003; Lohrke B, 2005, J MOL ENDOCRINOL, V35, P531, DOI 10.1677/jme.1.01852; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mairesse J, 2007, AM J PHYSIOL-ENDOC M, V292, pE1526, DOI 10.1152/ajpendo.00574.2006; McNeil CJ, 2007, REPRODUCTION, V133, P653, DOI 10.1530/rep.1.01198; Metges CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031390; Metzler-Zebeli BU, 2012, BRIT J NUTR, V108, P2176, DOI 10.1017/S0007114512000414; MOISAN MP, 1990, ENDOCRINOLOGY, V127, P1450, DOI 10.1210/endo-127-3-1450; Phillips DI, 1998, J CLIN ENDOCR METAB, V83, P747; POND WG, 1992, GROWTH DEVELOP AGING, V56, P115; Pruessner JC, 2003, PSYCHONEUROENDOCRINO, V28, P916, DOI 10.1016/S0306-4530(02)00108-7; Rehfeldt C, 2012, J ANIM SCI, V90, P184, DOI 10.2527/jas.2011-4234; Rehfeldt C, 2011, J ANIM SCI, V89, P329, DOI 10.2527/jas.2010-2970; Rehfeldt C, 2012, EUR J NUTR, V51, P151, DOI 10.1007/s00394-011-0201-8; Reynolds RM, 2001, J CLIN ENDOCR METAB, V86, P245, DOI 10.1210/jc.86.1.245; SAS S., 2009, STAT US GUID VERS 9; SCHOKNECHT PA, 1994, THERIOGENOLOGY, V42, P217, DOI 10.1016/0093-691X(94)90265-8; Seckl JR, 2007, NAT CLIN PRACT ENDOC, V3, P479, DOI 10.1038/ncpendmet0515; Seckl JR, 1995, J STEROID BIOCHEM, V55, P447, DOI 10.1016/0960-0760(95)00193-X; Seckl JR, 2004, CURR OPIN PHARMACOL, V4, P597, DOI 10.1016/j.coph.2004.09.001; Seckl JR, 2001, MOL CELL ENDOCRINOL, V185, P61, DOI 10.1016/S0303-7207(01)00633-5; SIITERI PK, 1982, RECENT PROG HORM RES, V38, P457; Spurlock ME, 2008, J NUTR, V138, P397, DOI 10.1093/jn/138.2.397; STEWART PM, 1995, J CLIN ENDOCR METAB, V80, P885, DOI 10.1210/jc.80.3.885; Stimson RH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008779; Sun K, 2002, BIOL REPROD, V67, P1450, DOI 10.1095/biolreprod.102.005892; Thone-Reineke C, 2006, AM J PHYSIOL-REG I, V291, pR1025, DOI 10.1152/ajpregu.00898.2005; Umemoto S, 1997, NEUROSCIENCE, V80, P763, DOI 10.1016/S0306-4522(97)00050-X; UNO H, 1990, DEV BRAIN RES, V53, P157, DOI 10.1016/0165-3806(90)90002-G; WALKER CD, 1990, ENDOCRINOLOGY, V127, P832, DOI 10.1210/endo-127-2-832; Wan SL, 2005, NEUROSCI LETT, V382, P96, DOI 10.1016/j.neulet.2005.02.066; White PC, 1997, ENDOCR REV, V18, P135, DOI 10.1210/er.18.1.135; Whorwood CB, 2001, ENDOCRINOLOGY, V142, P2854, DOI 10.1210/en.142.7.2854	68	28	29	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 26	2012	7	12							e52748	10.1371/journal.pone.0052748	http://dx.doi.org/10.1371/journal.pone.0052748			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	071TV	23300759	Green Published, Green Submitted, gold			2023-01-03	WOS:000313618800137
J	Ouelaa, W; Ghouzali, I; Langlois, L; Fetissov, S; Dechelotte, P; Ducrotte, P; Leroi, AM; Gourcerol, G				Ouelaa, Wassila; Ghouzali, Ibtissem; Langlois, Ludovic; Fetissov, Serguei; Dechelotte, Pierre; Ducrotte, Philippe; Leroi, Anne Marie; Gourcerol, Guillaume			Gastric Electrical Stimulation Decreases Gastric Distension-Induced Central Nociception Response through Direct Action on Primary Afferents	PLOS ONE			English	Article							COLORECTAL DISTENSION; VISCERAL PAIN; NEURONS; GASTROPARESIS; ACTIVATION; MECHANISMS; OUTCOMES; STRESS	Background & Aims: Gastric electrical stimulation (GES) is an effective therapy to treat patients with chronic dyspepsia refractory to medical management. However, its mechanisms of action remain poorly understood. Methods: Gastric pain was induced by performing gastric distension (GD) in anesthetized rats. Pain response was monitored by measuring the pseudo-affective reflex (e.g., blood pressure variation), while neuronal activation was determined using c-fos immunochemistry in the central nervous system. Involvement of primary afferents was assessed by measuring phosphorylation of ERK1/2 in dorsal root ganglia. Results: GES decreased blood pressure variation induced by GD, and prevented GD-induced neuronal activation in the dorsal horn of the spinal cord (T9-T10), the nucleus of the solitary tract and in CRF neurons of the hypothalamic paraventricular nucleus. This effect remained unaltered within the spinal cord when sectioning the medulla at the T5 level. Furthermore, GES prevented GD-induced phosphorylation of ERK1/2 in dorsal root ganglia. Conclusions: GES decreases GD-induced pain and/or discomfort likely through a direct modulation of gastric spinal afferents reducing central processing of visceral nociception. Citation: Ouelaa W, Ghouzali I, Langlois L, Fetissov S, Dechelotte P, et al. (2012) Gastric Electrical Stimulation Decreases Gastric Distension-Induced Central Nociception Response through Direct Action on Primary Afferents. PLoS ONE 7(12): e47849. doi:10.1371/journal.pone.0047849	[Ouelaa, Wassila; Ghouzali, Ibtissem; Langlois, Ludovic; Fetissov, Serguei; Dechelotte, Pierre; Ducrotte, Philippe; Leroi, Anne Marie; Gourcerol, Guillaume] Univ Rouen, Nutr Gut & Brain Unit, ADEN INSERM U1073, Inst Biomed Res & Innovat, Rouen, France; [Dechelotte, Pierre; Ducrotte, Philippe; Leroi, Anne Marie; Gourcerol, Guillaume] Rouen Univ Hosp, Dept Nutr, Rouen, France; [Ducrotte, Philippe; Leroi, Anne Marie; Gourcerol, Guillaume] Rouen Univ Hosp, Dept Gastroenterol, Rouen, France; [Leroi, Anne Marie; Gourcerol, Guillaume] Rouen Univ Hosp, Dept Physiol, Rouen, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie; CHU de Rouen; CHU de Rouen; CHU de Rouen	Gourcerol, G (corresponding author), Univ Rouen, Nutr Gut & Brain Unit, ADEN INSERM U1073, Inst Biomed Res & Innovat, Rouen, France.	Gourcerol.Guillaume@chu-rouen.fr	Fetissov, Sergueï O/H-6023-2016	Fetissov, Sergueï O/0000-0002-2491-4945; Gourcerol, Guillaume/0000-0001-8220-9155	University of Rouen, Institute for Research and Innovation in Biomedicine (IRIB); French Ministry of Health Grants for therapeutic innovation (STIC); French Society of Gastroenterology (SNFGE)	University of Rouen, Institute for Research and Innovation in Biomedicine (IRIB); French Ministry of Health Grants for therapeutic innovation (STIC); French Society of Gastroenterology (SNFGE)	This work was supported by the University of Rouen, Institute for Research and Innovation in Biomedicine (IRIB), by the French Ministry of Health Grants for therapeutic innovation (STIC). WO was the recipient of a fellowship from the French Society of Gastroenterology (SNFGE). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abell T, 2003, JPEN-PARENTER ENTER, V27, P277, DOI 10.1177/0148607103027004277; Abell T, 2003, GASTROENTEROLOGY, V125, P421, DOI 10.1016/S0016-5085(03)00878-3; Chen JDZ, 2003, GASTROENTEROLOGY, V124, P401, DOI 10.1053/gast.2003.50048; Derrey S, 2011, NEUROSCIENCE, V195, P89, DOI 10.1016/j.neuroscience.2011.08.004; Erriquez J, 2009, CELL CALCIUM, V46, P197, DOI 10.1016/j.ceca.2009.07.003; Familoni BO, 1997, DIGEST DIS SCI, V42, P885, DOI 10.1023/A:1018852011857; Gallas S, 2011, EUR J NEUROSCI, V33, P276, DOI 10.1111/j.1460-9568.2010.07474.x; Gourcerol G, 2007, NEUROSCIENCE, V148, P775, DOI 10.1016/j.neuroscience.2007.07.001; Gourcerol G, 2007, EUR J GASTROEN HEPAT, V19, P29, DOI 10.1097/01.meg.0000250584.15490.b4; Gourcerol G, 2009, J AM COLL SURGEONS, V209, P215, DOI 10.1016/j.jamcollsurg.2009.04.009; Larauche M, 2008, AM J PHYSIOL-GASTR L, V294, pG1033, DOI 10.1152/ajpgi.00507.2007; Lin Z, 2006, NEUROGASTROENT MOTIL, V18, P18, DOI 10.1111/j.1365-2982.2005.00732.x; Lin Z, 2004, NEUROGASTROENT MOTIL, V16, P205, DOI 10.1111/j.1365-2982.2004.00503.x; Lin ZY, 2004, DIABETES CARE, V27, P1071, DOI 10.2337/diacare.27.5.1071; Marion R, 2006, INFECT IMMUN, V74, P4387, DOI 10.1128/IAI.02055-05; McCallum R, 2005, CLIN GASTROENTEROL H, V3, P49, DOI 10.1016/S1542-3565(04)00605-6; McCallum RW, 2010, NEUROGASTROENT MOTIL, V22, DOI 10.1111/j.1365-2982.2009.01389.x; McCallum RW, 2011, CLIN GASTROENTEROL H, V9, P314, DOI 10.1016/j.cgh.2010.12.013; Million M, 2006, GUT, V55, P172, DOI 10.1136/gut.2004.051391; NESS TJ, 1988, BRAIN RES, V450, P153, DOI 10.1016/0006-8993(88)91555-7; Peng YB, 2003, J NEUROSCI, V23, P4766; Reddymasu SC, 2010, DIGEST DIS SCI, V55, P983, DOI 10.1007/s10620-009-0818-0; Sakurai J, 2008, GASTROENTEROLOGY, V134, P1094, DOI 10.1053/j.gastro.2008.01.031; Stengel A, 2009, ANNU REV PHYSIOL, V71, P219, DOI 10.1146/annurev.physiol.010908.163221; Tache Yvette, 2009, Curr Gastroenterol Rep, V11, P270; Tang M, 2006, OBES SURG, V16, P344, DOI 10.1381/096089206776116372; Vergnano AM, 2008, ENDOCRINOLOGY, V149, P2306, DOI 10.1210/en.2007-1164	27	11	11	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2012	7	12							e47849	10.1371/journal.pone.0047849	http://dx.doi.org/10.1371/journal.pone.0047849			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	060RA	23284611	gold, Green Submitted, Green Published			2023-01-03	WOS:000312794500002
J	Wu, ZH; Lu, MK; Hu, LY; Li, XT				Wu, Zhen Hua; Lu, Ming-ke; Hu, Long Yu; Li, Xiaotong			Praziquantel Synergistically Enhances Paclitaxel Efficacy to Inhibit Cancer Cell Growth	PLOS ONE			English	Article							X-LINKED-INHIBITOR; COLORECTAL-CANCER; MITOTIC ARREST; SCHISTOSOMA-MANSONI; APOPTOSIS-PROTEIN; TUMOR-CELLS; ARTEMISININ; DRUGS; ANTICANCER; CYTOTOXICITY	The major challenges we are facing in cancer therapy with paclitaxel (PTX) are the drug resistance and severe side effects. Massive efforts have been made to overcome these clinical challenges by combining PTX with other drugs. In this study, we reported the first preclinical data that praziquantel (PZQ), an anti-parasite agent, could greatly enhance the anticancer efficacy of PTX in various cancer cell lines, including PTX-resistant cell lines. Based on the combination index value, we demonstrated that PZQ synergistically enhanced PTX-induced cell growth inhibition. The co-treatment of PZQ and PTX also induced significant mitotic arrest and activated the apoptotic cascade. Moreover, PZQ combined with PTX resulted in a more pronounced inhibition of tumor growth compared with either drug alone in a mouse xenograft model. We tried to investigate the possible mechanisms of this synergistic efficacy induced by PZQ and PTX, and we found that the co-treatment of the two drugs could markedly decrease expression of X-linked inhibitor of apoptosis protein (XIAP), an antiapoptotic protein. Our data further demonstrated that down-regulation of XIAP was required for the synergistic interaction between PZQ and PTX. Together, this study suggested that the combination of PZQ and PTX may represent a novel and effective anticancer strategy for optimizing PTX therapy.	[Wu, Zhen Hua; Lu, Ming-ke; Hu, Long Yu; Li, Xiaotong] Xiamen Univ, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen, Fujian, Peoples R China	Xiamen University	Li, XT (corresponding author), Xiamen Univ, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen, Fujian, Peoples R China.	xtli@xmu.edu.cn	Li, xiaotong/GYV-4890-2022		National Foundation for Fostering Talents of Basic Science, China [J1030626]; Key Project of Fujian Provincial Programs for Science and Technology [2011Y0050]; Technology Innovation Foundation of Science and Technology Bureau of Xiamen, China [2011S0567]	National Foundation for Fostering Talents of Basic Science, China; Key Project of Fujian Provincial Programs for Science and Technology; Technology Innovation Foundation of Science and Technology Bureau of Xiamen, China	This work was supported by the National Foundation for Fostering Talents of Basic Science, China (J1030626) (http://www.nsfc.gov.cn/Portal0/default152.htm); The Key Project of Fujian Provincial Programs for Science and Technology (2011Y0050); and The Technology Innovation Foundation of Science and Technology Bureau of Xiamen, China (2011S0567). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akiyoshi T, 2008, GASTROENTEROLOGY, V134, P131, DOI 10.1053/j.gastro.2007.10.008; Aoki D, 2009, CLIN CANCER RES, V15, P1473, DOI 10.1158/1078-0432.CCR-08-1274; Barlogie B, 2006, NEW ENGL J MED, V354, P1021, DOI 10.1056/NEJMoa053583; Boguski MS, 2009, SCIENCE, V324, P1394, DOI 10.1126/science.1169920; BRINDLEY PJ, 1987, J IMMUNOL, V139, P215; Chen Q, 2008, P NATL ACAD SCI USA, V105, P11105, DOI 10.1073/pnas.0804226105; Chong CR, 2007, NATURE, V448, P645, DOI 10.1038/448645a; Efferth T, 2001, INT J ONCOL, V18, P767; Flossmann E, 2007, LANCET, V369, P1603, DOI 10.1016/S0140-6736(07)60747-8; Fromberg A, 2011, CANCER CHEMOTH PHARM, V67, P1157, DOI 10.1007/s00280-010-1418-6; GONNERT R, 1977, Z PARASITENKD, V52, P129, DOI 10.1007/BF00389899; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; Grosch S, 2006, JNCI-J NATL CANCER I, V98, P736, DOI 10.1093/jnci/djj206; Haanen C, 2001, Curr Opin Investig Drugs, V2, P677; HARASAWA R, 1993, RES MICROBIOL, V144, P489, DOI 10.1016/0923-2508(93)90057-9; Hou JM, 2008, CLIN CANCER RES, V14, P5519, DOI 10.1158/1078-0432.CCR-08-0197; Ichim TE, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-25; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Joseph S, 2004, J INFECT DIS, V190, P835, DOI 10.1086/422604; Keiser J, 2007, TRENDS PARASITOL, V23, P555, DOI 10.1016/j.pt.2007.07.012; Le XF, 2011, JNCI-J NATL CANCER I, V103, P1403, DOI 10.1093/jnci/djr280; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Milross CG, 1996, JNCI-J NATL CANCER I, V88, P1308, DOI 10.1093/jnci/88.18.1308; Nakase I, 2008, INT J PHARM, V354, P28, DOI 10.1016/j.ijpharm.2007.09.003; O'Connor CL, 2008, BBA-MOL CELL RES, V1783, P1903, DOI 10.1016/j.bbamcr.2008.05.025; Posner GH, 2003, J MED CHEM, V46, P1060, DOI 10.1021/jm020461q; Qi YF, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0031539, 10.1371/journal.pone.0033859]; Rodriguez-Antona C, 2010, PHARMACOGENOMICS, V11, P621, DOI [10.2217/pgs.10.32, 10.2217/PGS.10.32]; Rothwell PM, 2010, LANCET, V376, P1741, DOI 10.1016/S0140-6736(10)61543-7; Schimmer AD, 2006, CELL DEATH DIFFER, V13, P179, DOI 10.1038/sj.cdd.4401826; Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011; Takeuchi H, 2005, CLIN CANCER RES, V11, P7621, DOI 10.1158/1078-0432.CCR-05-0479; Tang J, 1999, IN VITRO CELL DEV-AN, V35, P1; WOERDENBAG HJ, 1993, J NAT PROD, V56, P849, DOI 10.1021/np50096a007; Wu ZH, 2012, ASSAY DRUG DEV TECHN, V10, P344, DOI 10.1089/adt.2011.416; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zhou H, 2010, CANCER CELL, V17, P560, DOI 10.1016/j.ccr.2010.04.023	38	14	15	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2012	7	12							e51721	10.1371/journal.pone.0051721	http://dx.doi.org/10.1371/journal.pone.0051721			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	066QV	23251610	Green Published, gold, Green Submitted			2023-01-03	WOS:000313236200156
J	Stewart, S; Carrington, MJ; Swemmer, CH; Anderson, C; Kurstjens, NP; Amerena, J; Brown, A; Burrell, LM; de Looze, FJ; Harris, M; Hung, J; Krum, H; Nelson, M; Schlaich, M; Stocks, NP; Jennings, GL				Stewart, Simon; Carrington, Melinda J.; Swemmer, Carla H.; Anderson, Craig; Kurstjens, Nicol P.; Amerena, John; Brown, Alex; Burrell, Louise M.; de Looze, Ferdinandus J.; Harris, Mark; Hung, Joseph; Krum, Henry; Nelson, Mark; Schlaich, Markus; Stocks, Nigel P.; Jennings, Garry L.		VIPER-BP Study Investigators	Effect of intensive structured care on individual blood pressure targets in primary care: multicentre randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANTIHYPERTENSIVE TREATMENT; ALL-CAUSE; HYPERTENSION; OUTCOMES; MORTALITY; PEOPLE; HOME	Objective To determine the effectiveness of intensive structured care to optimise blood pressure control based on individual absolute risk targets in primary care. Design Pragmatic multicentre randomised controlled trial. Setting General practices throughout Australia, except Northern Territory, 2009-11. Participants Of 2185 patients from 119 general practices who were eligible for drug treatment for hypertension according to national guidelines 416 (19.0%) achieved their individual blood pressure target during a 28 day run-in period of monotherapy. After exclusions, 1562 participants not at target blood pressure (systolic 150 (SD 17) mm Hg, diastolic 88 (SD 11) mm Hg) were randomised (1: 2 ratio) to usual care (n=524) or the intervention (n=1038). Intervention Computer assisted clinical profiling and risk target setting (all participants) with intensified follow-up and stepwise drug titration (initial angiotensin receptor blocker monotherapy or two forms of combination therapy using angiotensin receptor blockers) for those randomised to the intervention. The control group received usual care. Main outcome measures The primary outcome was individual blood pressure target achieved at 26 weeks. Secondary outcomes were change in mean sitting systolic and diastolic blood pressure, absolute risk for cardiovascular disease within five years based on the Framingham risk score, and proportion and rate of adverse events. Results On an intention to treat basis, there was an 8.8% absolute difference in individual blood pressure target achieved at 26 weeks in favour of the intervention group compared with usual care group (358/988 (36.2%) v 138/504 (27.4%)): adjusted relative risk 1.28 (95% confidence interval 1.10 to 1.49, P=0.0013). There was also a 9.5% absolute difference in favour of the intervention group for achieving the classic blood pressure target of <= 140/90 mm Hg (627/988 (63.5%) v 272/504 (54.0%)): adjusted relative risk 1.18 (1.07 to 1.29, P<0.001). The intervention group achieved a mean adjusted reduction in systolic blood pressure of 13.2 mm Hg (95% confidence interval -12.3 to -14.2 mm Hg) and diastolic blood pressure of 7.7 mm Hg (-7.1 to -8.3 mm Hg) v 10.1 mm Hg (-8.8 to 11.3 mm Hg) and 5.5 mm Hg (-4.7 to -6.2 mm Hg) in the usual care group (P<0.001). Among 1141 participants in whom five year absolute cardiovascular risk scores were calculated from baseline to the 26 week follow-up, the reduction in risk scores was greater in the intervention group than usual care group (14.7% (SD 9.3%) to 10.9% (SD 8.0%); difference -3.7% (SD 4.5%) and 15.0% (SD 10.1%) to 12.4% (SD 9.4%); -2.6% (SD 4.5%): adjusted mean difference -1.13% (95% confidence interval -0.69% to -1.63%; P<0.001). Owing to adverse events 82 (7.9%) participants in the intervention group and 10 (1.9%) in the usual care group had their drug treatment modified. Conclusions In a primary care setting intensive structured care resulted in higher levels of blood pressure control, with clinically lower blood pressure and absolute risk of future cardiovascular events overall and with more people achieving their target blood pressure. An important gap in treatment remains though and applying intensive management and achieving currently advocated risk based blood pressure targets is challenging.	[Stewart, Simon] Baker IDI Heart & Diabet Inst, Preventat Hlth Grp, Melbourne, Vic 8008, Australia; [Schlaich, Markus] Baker IDI Heart & Diabet Inst, Hypertens & Kidney Dis Lab, Melbourne, Vic 8008, Australia; [Swemmer, Carla H.] Novartis Pharmaceut Australia, Med Operat, Sydney, NSW, Australia; [Anderson, Craig] Univ Sydney, George Inst, Neurol & Mental Hlth Div, Sydney, NSW 2006, Australia; [Amerena, John] Deakin Univ, Geelong Cardiol Res Dept, Geelong, Vic 3217, Australia; [Brown, Alex] Baker IDI Heart & Diabet Inst, Alice Springs, NT, Australia; [Burrell, Louise M.] Univ Melbourne, Austin Hlth, Dept Med, Melbourne, Vic 3010, Australia; [Burrell, Louise M.] Univ Melbourne, Austin Hlth, Dept Cardiol, Melbourne, Vic 3010, Australia; [de Looze, Ferdinandus J.] Univ Queensland, Sch Med, Brisbane, Qld, Australia; [Harris, Mark] Univ New S Wales, Ctr Primary Hlth Care & Equ, Sydney, NSW, Australia; [Hung, Joseph] Univ Western Australia, Sir Charles Gairdner Hosp Unit, Sch Med & Pharmacol, Perth, WA 6009, Australia; [Krum, Henry] Monash Univ, Sch Publ Hlth & Prevent Med, Monash Ctr Cardiovasc Res & Educ Therapeut, Melbourne, Vic 3004, Australia; [Nelson, Mark] Univ Tasmania, Menzies Res Inst Tasmania, Discipline Gen Practice, Hobart, Tas, Australia; [Stocks, Nigel P.] Univ Adelaide, Discipline Gen Practice, Adelaide, SA, Australia	Baker Heart and Diabetes Institute; Baker Heart and Diabetes Institute; Novartis; University of Sydney; Deakin University; Baker Heart and Diabetes Institute; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Florey Institute of Neuroscience & Mental Health; University of Melbourne; University of Queensland; University of New South Wales Sydney; University of Western Australia; Monash University; University of Tasmania; Menzies Institute for Medical Research; University of Adelaide	Stewart, S (corresponding author), Baker IDI Heart & Diabet Inst, Preventat Hlth Grp, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.	simon.stewart@bakeridi.edu.au	Harris, Mark F/I-2793-2019; Stewart, Simon/M-3316-2016; Jennings, Garry/B-3914-2009; Stocks, Nigel P/I-1083-2012	Harris, Mark F/0000-0002-0705-8913; Stewart, Simon/0000-0001-9032-8998; Anderson, Craig/0000-0002-7248-4863; Jennings, Garry/0000-0002-7865-5483; Stocks, Nigel/0000-0002-9018-0361; Brown, Alex/0000-0003-2112-3918; Carrington, Melinda J/0000-0003-3865-1645; Schlaich, Markus/0000-0002-1765-0195	Novartis Pharmaceuticals Australia; National Health and Medical Research Council of Australia; Victoria government's operational infrastructure support program	Novartis Pharmaceuticals Australia; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Victoria government's operational infrastructure support program	The VIPER-BP study was sponsored by Novartis Pharmaceuticals Australia. The sponsors participated in discussions on the design and conduct of the study and provided logistical support during the trial. The study statistician (Adrian Esterman, University of South Australia) independently generated analyses on behalf of the other members of the clinical safety and efficacy committee (Colin Johnston, MN, Richard Gerraty) who received remuneration from Novartis Pharmaceuticals Australia as study consultants. The study investigators and sponsor jointly assessed study data. All the investigators received remuneration from Baker IDI for the research component of clinical study activities.; All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that all authors had a form of support (as described above) and specific relationships (as described above) with Novartis Pharmaceuticals Australia for the submitted work. SS, GLJ, and MJC are supported by the National Health and Medical Research Council of Australia. VIPER-BP study was supported by the Victoria government's operational infrastructure support program.	Carrington MJ, 2010, INT J CARDIOL, V145, P461, DOI 10.1016/j.ijcard.2009.06.003; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Clark CE, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3995; Ernst ME, 2011, HYPERTENSION, V58, P987, DOI 10.1161/HYPERTENSIONAHA.111.183459; Fahey T, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005182.pub3; Feldman RD, 2009, HYPERTENSION, V53, P646, DOI 10.1161/HYPERTENSIONAHA.108.123455; Franklin SS, 2012, HYPERTENSION, V59, P564, DOI 10.1161/HYPERTENSIONAHA.111.180653; Julius S, 2006, HYPERTENSION, V48, P385, DOI 10.1161/01.HYP.0000236119.96301.f2; Kjeldsen SE, 2008, BLOOD PRESSURE, V17, P7, DOI 10.1080/08037050801972857; Law MR, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1665; National Blood Pressure and Vascular Disease Advisory Committee, 2008, GUIDE TO MANAGEMENT; National Institute for Health and Clinical Excellence, 2011, HYPERTENSION CLINICA; National Vascular Disease Prevention Alliance, 2009, GUIDELINES FOR THE A; Sliwa K, 2011, CIRCULATION, V123, P2892, DOI 10.1161/CIRCULATIONAHA.110.992362; Staessen JA, 2004, JAMA-J AM MED ASSOC, V291, P955, DOI 10.1001/jama.291.8.955; Stewart S, 2012, J AM COLL CARDIOL, V60, P1239, DOI 10.1016/j.jacc.2012.06.025; Stewart S, 2011, INT J CARDIOL, V153, P317, DOI 10.1016/j.ijcard.2010.12.055; Vamos EP, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5567; Weber MA, 2004, LANCET, V363, P2049, DOI 10.1016/S0140-6736(04)16456-8; Wing LMH, 2003, NEW ENGL J MED, V348, P583, DOI 10.1056/NEJMoa021716; World Health Organization, 2008, 2008 2013 ACTION PLA; Yang QH, 2012, JAMA-J AM MED ASSOC, V307, P1273, DOI 10.1001/jama.2012.339	22	22	23	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 20	2012	345								e7156	10.1136/bmj.e7156	http://dx.doi.org/10.1136/bmj.e7156			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	044GT	23169801	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000311608200001
J	Tyagi, P; Kadam, RS; Kompella, UB				Tyagi, Puneet; Kadam, Rajendra S.; Kompella, Uday B.			Comparison of Suprachoroidal Drug Delivery with Subconjunctival and Intravitreal Routes Using Noninvasive Fluorophotometry	PLOS ONE			English	Article							BLOOD-FLOW; OCULAR FLUOROPHOTOMETRY; MACULAR DEGENERATION; TISSUE DISTRIBUTION; IN-VIVO; EYE; TRIAMCINOLONE; INJECTION; SPACE; PHARMACOKINETICS	Purpose: To determine whether exposure of sodium fluorescein (NaF) to the choroid-retina region in the posterior segment of the eye is greater with suprachoroidal injection when compared to intravitreal and transscleral routes. Methods: Suprachoroidal injection, a new approach for drug delivery to the posterior segment of the eye was validated using a 34 G needle and Indian ink injections in Sprague Dawley rats, followed by histology. Delivery of NaF was compared in Sprague Dawley rats after suprachoroidal, posterior subconjunctival, or intravitreal injections. NaF levels were monitored noninvasively up to 6 hours using Fluorotron Master (TM), an ocular fluorophotometer Pharmacokinetic parameters were estimated using WinNonlin. Results: Histological analysis indicated localization of India ink to the suprachoroidal space below sclera, following injection. NaF delivery to choroid-retina was in the order: suprachoroidal > intravitreal >posterior subconjunctival injection. Peak NaF concentration (C-max) in choroid-retina was 36-fold (p = 0.001) and 25-fold (p = 0.001) higher after suprachoroidal (2744 +/- 1111 ng/ml) injection when compared to posterior subconjunctival (76 +/- 6 ng/ml) and intravitreal (108 +/- 39 ng/ml) injections, respectively. NaF exposure (AUC(0-360min)) to choroid-retina after suprachoroidal injection was 6-fold (p = 0.001) and 2-fold (p = 0.03) higher than posterior subconjunctival and intravitreal injections, respectively. Choroid-retina T-max was observed immediately after dosing with suprachoroidal injections and at 10 and 27.5 minutes, respectively, with subconjunctival and intravitreal injections. Conclusions: Suprachoroidal injections are feasible in a rat model. Suprachoroidal injections resulted in the highest bioavailability, that is, the extent and rate of delivery of NaF to choroid-retina, when compared to intravitreal and posterior subconjunctival injections. Ocular fluorophotometry is useful for noninvasive monitoring of NaF in rats following administration by various routes including suprachoroidal route.	[Tyagi, Puneet; Kadam, Rajendra S.; Kompella, Uday B.] Univ Colorado, Dept Pharmaceut Sci, Nanomed & Drug Delivery Lab, Aurora, CO USA; [Kompella, Uday B.] Univ Colorado, Dept Ophthalmol, Aurora, CO USA; [Kompella, Uday B.] Univ Colorado, Dept Bioengn, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Kompella, UB (corresponding author), Univ Colorado, Dept Pharmaceut Sci, Nanomed & Drug Delivery Lab, Anschutz Med Campus, Aurora, CO USA.	uday.kompella@ucdenver.edu			NIH [EY018940, EY017533, EY017045]; NATIONAL EYE INSTITUTE [R24EY017045, R01EY017533, R01EY018940] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported by NIH grants EY018940, EY017533, and EY017045 (through Emory University). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amrite AC, 2006, INVEST OPHTH VIS SCI, V47, P1149, DOI 10.1167/iovs.05-0531; Amrite AC, 2008, MOL VIS, V14, P150; Anderson OA, 2010, DRUG DISCOV TODAY, V15, P272, DOI 10.1016/j.drudis.2010.02.004; ARAIE M, 1991, EXP EYE RES, V52, P27, DOI 10.1016/0014-4835(91)90125-X; BATEY DW, 1992, EXP EYE RES, V54, P605, DOI 10.1016/0014-4835(92)90139-J; Berezovsky DE, 2011, INVEST OPHTH VIS SCI, V52, P7038, DOI 10.1167/iovs.11-7207; BRADLEY SE, 1945, J CLIN INVEST, V24, P890, DOI 10.1172/JCI101676; CARLISLE KM, 1992, GUT, V33, P92, DOI 10.1136/gut.33.1.92; Cheruvu NP, 2003, DRUG DEV DELIVERY, P3; Das T, 2004, CLIN EXP OPHTHALMOL, V32, P55, DOI 10.1046/j.1442-9071.2003.00758.x; Einmahl S, 2002, INVEST OPHTH VIS SCI, V43, P1533; ELDRED GE, 1982, SCIENCE, V216, P757, DOI 10.1126/science.7079738; Fariss RN, 1997, AM J PATHOL, V150, P323; FRIEDMAN E, 1964, INVEST OPHTH VISUAL, V3, P539; Ghate D, 2007, INVEST OPHTH VIS SCI, V48, P2230, DOI 10.1167/iovs.06-0954; GRAY JR, 1985, GRAEF ARCH CLIN EXP, V222, P225, DOI 10.1007/BF02133684; Hubner GH, 2000, J HEPATOL, V32, P893, DOI 10.1016/S0168-8278(00)80093-8; Ishiko S, 1996, JPN J OPHTHALMOL, V40, P310; Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537; Jonas JB, 2008, EYE, V22, P590, DOI 10.1038/eye.2008.10; KATZ ML, 1984, MECH AGEING DEV, V25, P149, DOI 10.1016/0047-6374(84)90137-4; Krohn J, 1997, ACTA OPHTHALMOL SCAN, V75, P32; LEE SM, 1985, BIOCHIM BIOPHYS ACTA, V841, P247, DOI 10.1016/0304-4165(85)90065-0; Lee SJ, 2008, INVEST OPHTH VIS SCI, V49, P4506, DOI 10.1167/iovs.08-1989; Lee V H, 1986, J Ocul Pharmacol, V2, P67, DOI 10.1089/jop.1986.2.67; MAURICE DM, 1976, S OCULAR THERAPY, P59; Negi AK, 2006, J CATARACT REFR SURG, V32, P468, DOI 10.1016/j.jcrs.2005.12.102; Olsen TW, 2006, AM J OPHTHALMOL, V142, P777, DOI 10.1016/j.ajo.2006.05.045; Olsen TW, 2011, INVEST OPHTH VIS SCI, V52, P4749, DOI 10.1167/iovs.10-6291; Park Ji-Hyun, 2009, Korean J Ophthalmol, V23, P40, DOI 10.3341/kjo.2009.23.1.40; Patel SR, 2011, PHARM RES-DORDR, V28, P166, DOI 10.1007/s11095-010-0271-y; Polska E, 2004, BRIT J OPHTHALMOL, V88, P533, DOI 10.1136/bjo.2003.028480; POOLE TA, 1986, OPHTHALMOLOGY, V93, P1408; Raghava Swita, 2004, Expert Opin Drug Deliv, V1, P99, DOI 10.1517/17425247.1.1.99; RAINES MF, 1988, J ROY SOC MED, V81, P403, DOI 10.1177/014107688808100714; RIEDEL J, 2006, DRUG DISCOVERY EVALU, P473; Robinson MR, 2006, EXP EYE RES, V82, P479, DOI 10.1016/j.exer.2005.08.007; Saaddine JB, 2008, ARCH OPHTHALMOL-CHIC, V126, P1740, DOI 10.1001/archopht.126.12.1740; Seiler GS, 2011, INVEST OPHTH VIS SCI, V52, P5730, DOI 10.1167/iovs.11-7525; Shelke NB, 2011, DRUG DELIV TRANSL RE, V1, P76, DOI 10.1007/s13346-010-0009-8; SJOBACK R, 1995, SPECTROCHIM ACTA A, V51, pL7, DOI 10.1016/0584-8539(95)01421-P; Smiddy WE, 2007, OPHTHALMOLOGY, V114, P847, DOI 10.1016/j.ophtha.2006.10.038; TSUBOTA K, 1987, INVEST OPHTH VIS SCI, V28, P785; Van Schaik HJ, 1999, EXP EYE RES, V68, P1, DOI 10.1006/exer.1998.0575	44	38	38	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2012	7	10							e48188	10.1371/journal.pone.0048188	http://dx.doi.org/10.1371/journal.pone.0048188			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	030WJ	23118950	gold, Green Published, Green Submitted			2023-01-03	WOS:000310600500079
J	Clevers, H				Clevers, Hans			The Paneth Cell, Caloric Restriction, and Intestinal Integrity	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Clevers, Hans] Hubrecht Inst, Utrecht, Netherlands; [Clevers, Hans] Univ Med Ctr Utrecht, Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center	Clevers, H (corresponding author), Hubrecht Inst, Utrecht, Netherlands.							CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; Ouellette AJ, 2010, CURR OPIN GASTROEN, V26, P547, DOI 10.1097/MOG.0b013e32833dccde; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Yilmaz OH, 2012, NATURE, V486, P490, DOI 10.1038/nature11163	4	5	5	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 18	2012	367	16					1560	1561		10.1056/NEJMcibr1208353	http://dx.doi.org/10.1056/NEJMcibr1208353			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	021SA	23075184				2023-01-03	WOS:000309904500015
J	O'Connell, NE; Cossar, J; Marston, L; Wand, BM; Bunce, D; Moseley, GL; De Souza, LH				O'Connell, Neil E.; Cossar, John; Marston, Louise; Wand, Benedict M.; Bunce, David; Moseley, G. Lorimer; De Souza, Lorraine H.			Rethinking Clinical Trials of Transcranial Direct Current Stimulation: Participant and Assessor Blinding Is Inadequate at Intensities of 2mA	PLOS ONE			English	Article							PREFRONTAL CORTEX; PAIN; DEPRESSION; MODULATION	Background: Many double-blind clinical trials of transcranial direct current stimulation (tDCS) use stimulus intensities of 2 mA despite the fact that blinding has not been formally validated under these conditions. The aim of this study was to test the assumption that sham 2 mA tDCS achieves effective blinding. Methods: A randomised double blind crossover trial. 100 tDCS-naive healthy volunteers were incorrectly advised that they there were taking part in a trial of tDCS on word memory. Participants attended for two separate sessions. In each session, they completed a word memory task, then received active or sham tDCS (order randomised) at 2 mA stimulation intensity for 20 minutes and then repeated the word memory task. They then judged whether they believed they had received active stimulation and rated their confidence in that judgement. The blinded assessor noted when red marks were observed at the electrode sites post-stimulation. Results: tDCS at 2 mA was not effectively blinded. That is, participants correctly judged the stimulation condition greater than would be expected to by chance at both the first session (kappa level of agreement (kappa) 0.28, 95% confidence interval (CI) 0.09 to 0.47 p = 0.005) and the second session (kappa = 0.77, 95% CI 0.64 to 0.90), p = <0.001) indicating inadequate participant blinding. Redness at the reference electrode site was noticeable following active stimulation more than sham stimulation (session one, kappa = 0.512, 95% CI 0.363 to 0.66, p<0.001; session two, kappa = 0.677, 95%CI 0.534 to 0.82) indicating inadequate assessor blinding. Conclusions: Our results suggest that blinding in studies using tDCS at intensities of 2 mA is inadequate. Positive results from such studies should be interpreted with caution.	[O'Connell, Neil E.; Cossar, John; De Souza, Lorraine H.] Brunel Univ, Sch Hlth Sci & Social Care, Rehabil Res Ctr, London, England; [Marston, Louise] UCL, Res Dept Primary Care & Populat Hlth, London, England; [Wand, Benedict M.] Univ Notre Dame Australia, Sch Physiotherapy, Fremantle, WA, Australia; [Bunce, David] Brunel Univ, Ctr Cognit & Neuroimaging, London, England; [Moseley, G. Lorimer] Univ S Australia, Sansom Inst Hlth Res, Adelaide, SA 5001, Australia; [Moseley, G. Lorimer] Neurosci Res Australia, Sydney, NSW, Australia	Brunel University; University of London; University College London; University of Notre Dame Australia; Brunel University; University of South Australia; Neuroscience Research Australia	O'Connell, NE (corresponding author), Brunel Univ, Sch Hlth Sci & Social Care, Rehabil Res Ctr, London, England.	neil.oconnell@brunel.ac.uk	O'CONNELL, NEIL/A-6907-2014; Marston, Louise/A-8535-2012; Wand, Benedict/C-3341-2011; Moseley, Lorimer/A-7095-2009	O'CONNELL, NEIL/0000-0003-1989-4537; Marston, Louise/0000-0002-9973-1131; Moseley, Lorimer/0000-0002-3750-4945; Wand, Benedict/0000-0002-0297-0292; Bunce, David/0000-0003-3265-2700	National Health & Medical Research Council of Australia [571090]	National Health & Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	GLM is supported by the National Health & Medical Research Council of Australia ID 571090. This funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No corporate funding or sponsorship was received for the conduct of this study. No government or institutional funding was received for the conduct of this study.	Altman DG, 1991, PRACTICAL STAT MED R; Ambrus GG, 2012, BRAIN STIMUL, V5, P499, DOI 10.1016/j.brs.2011.12.001; Bartley EJ, 2012, ANN BEHAV MED, V43, P343, DOI 10.1007/s12160-012-9345-x; Bastani A, 2012, CLIN NEUROPHYSIOL, V123, P644, DOI 10.1016/j.clinph.2011.08.029; Berger VW., 2003, J MODERN APPL STAT M, V2, P8, DOI [10.22237/jmasm/1051747680, DOI 10.22237/JMASM/1051747680]; Berger VW, 2012, J CLIN EPID IN PRESS; Boggio PS, 2008, DRUG ALCOHOL DEPEN, V92, P55, DOI 10.1016/j.drugalcdep.2007.06.011; Boggio PS, 2009, CLIN J PAIN, V25, P691, DOI 10.1097/AJP.0b013e3181af1414; Brunoni AR, 2012, BRAIN STIMUL, V5, P175, DOI 10.1016/j.brs.2011.03.002; Brunoni AR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004824; Butler DS., 2003, EXPLAIN PAIN, VSouth Australia; Fregni F, 2008, J CLIN PSYCHIAT, V69, P32, DOI 10.4088/JCP.v69n0105; Fregni F, 2006, ARTHRITIS RHEUM-US, V54, P3988, DOI 10.1002/art.22195; Fregni F, 2006, PAIN, V122, P197, DOI 10.1016/j.pain.2006.02.023; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Goldman RL, 2011, APPETITE, V56, P741, DOI 10.1016/j.appet.2011.02.013; Hopewell S, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000006.pub3; Hrobjartsson A, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003974.pub3; Klatzkin RR, 2010, EUR J PAIN, V14, P77, DOI 10.1016/j.ejpain.2009.01.002; Loo CK, 2012, BRIT J PSYCHIAT, V200, P52, DOI 10.1192/bjp.bp.111.097634; Loo CK, 2010, INT J NEUROPSYCHOPH, V13, P61, DOI 10.1017/S1461145709990411; McFadden JL, 2011, BRAIN STIMUL, V4, P38, DOI 10.1016/j.brs.2010.05.002; Montenegro RA, 2012, APPETITE, V58, P333, DOI 10.1016/j.appet.2011.11.008; Mori F, 2010, J PAIN, V11, P436, DOI 10.1016/j.jpain.2009.08.011; Nitsche MA, 2009, EXP NEUROL, V219, P14, DOI 10.1016/j.expneurol.2009.03.038; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Nuesch E, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3515; O'Connell NE, 2010, COCHRANE DB SYST REV, V9; O'Connell NE, 2011, CLIN J PAIN IN PRESS; Priori A, 2009, BRAIN STIMUL, V2, P241, DOI 10.1016/j.brs.2009.02.004; Rezaii T, 2012, J PAIN, V13, P646, DOI 10.1016/j.jpain.2012.04.002; Wood L, 2008, BMJ-BRIT MED J, V336, P601, DOI 10.1136/bmj.39465.451748.AD	32	182	183	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2012	7	10							e47514	10.1371/journal.pone.0047514	http://dx.doi.org/10.1371/journal.pone.0047514			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	038AF	23082174	Green Submitted, gold, Green Published, Green Accepted			2023-01-03	WOS:000311146900070
J	Pusic, K; Aguilar, Z; McLoughlin, J; Kobuch, S; Xu, H; Tsang, M; Wang, A; Hui, G				Pusic, Kae; Aguilar, Zoraida; McLoughlin, Jaclyn; Kobuch, Sophie; Xu, Hong; Tsang, Mazie; Wang, Andrew; Hui, George			Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine	FASEB JOURNAL			English	Article						adjuvant; particle-mediated immunizations; inhibitory antibodies	MEROZOITE SURFACE PROTEIN-1; VIRUS-LIKE PARTICLES; C-TERMINAL FRAGMENT; PLASMODIUM-FALCIPARUM; DENDRITIC CELLS; AOTUS MONKEYS; INHIBITORY ANTIBODIES; ADJUVANT FORMULATIONS; EFFICACY; IMMUNOGENICITY	This study explored the novel use of iron oxide (IO) nanoparticles (<20 nm) as a vaccine delivery platform without additional adjuvants. A recombinant malaria vaccine antigen, the merozoite surface protein 1 (rMSP1), was conjugated to IO nanoparticles (rMSP1-IO). Immunizations in outbred mice with rMSP1-IO achieved 100% responsiveness with antibody titers comparable to those obtained with rMSP1 formulated with a clinically acceptable adjuvant, Montanide ISA51 (2.7 x 10(-3) vs. 1.6 x 10(-3); respectively). Only rMSP1-1O could induce significant levels (80%) of parasite inhibitory antibodies. The rMSP1-IO was highly stable at 4 C and was amenable to lyophilization, maintaining its antigenicity, immunogenicity, and ability to induce inhibitory antibodies. Further testing in nonhuman primates, Aotus monkeys, also elicited 100% immune responsiveness and high levels of parasite inhibitory antibodies (55-100% inhibition). No apparent local or systemic toxicity was associated with IO immunizations. Murine macrophages and dendritic cells efficiently (>90%) internalized IO nanoparticles, but only the latter were significantly activated, with elevated expression/secretion of CD86, cytokines (IL-6, TNF-alpha, IL1-b, IFN-gamma, and IL-12), and chemokines (CXCL1, CXCL2, CCL2, CCL3, CCL4, and CXCL10). Thus, the IO nanoparticles is a novel, safe, and effective vaccine platform, with built-in adjuvancy, that is highly stable and field deployable for cost-effective vaccine delivery.-Pusic, K., Aguilar, Z., McLoughlin, J., Kobuch, S., Xu, H., Tsang, M., Wang, A., Hui, G. Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine. FASEB J. 27, 1153-1166 (2013). www.fasebj.org	[Pusic, Kae; McLoughlin, Jaclyn; Kobuch, Sophie; Hui, George] Univ Hawaii, Dept Trop Med, Honolulu, HI 96813 USA; [Tsang, Mazie] Univ Hawaii, Sch Med, Honolulu, HI 96813 USA; [Aguilar, Zoraida; Xu, Hong; Wang, Andrew] Ocean NanoTech LLC, Springdale, AR USA	University of Hawaii System; University of Hawaii System	Pusic, K (corresponding author), Univ Hawaii, Sch Med, Dept Trop Med, 651 Ilalo St,BSB320, Honolulu, HI 96813 USA.	kae@hawaii.edu			U.S. National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases [A1076955]; NIH/National Institutes of General Medical Sciences [P20GM103516]; NIH/National Institute of Diabetes and Digestive and Kidney Diseases [DK078386]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R25DK078386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103516] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases; NIH/National Institutes of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH/National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank S. Chang, W. Gosnell, K. Kramer, and S. Case for their help with the Aotus monkey immunizations. The authors also thank Dr. Lozanoff and Dr. Somponpun for their help with the toxicity studies. The authors additionally thank D. Clements of Hawaii Biotech Inc. (Aiea, HI, USA) for providing the MSP1 recombinant protein; and D. Clements and A. Stridiron for their technical support. This work was supported by a grant from the U.S. National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (A1076955) and NIH/National Institutes of General Medical Sciences (P20GM103516). K. P. was supported by NIH/National Institute of Diabetes and Digestive and Kidney Diseases (DK078386).	Akagi T, 2007, BIOMATERIALS, V28, P3427, DOI 10.1016/j.biomaterials.2007.04.023; Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m; AlYaman F, 1996, AM J TROP MED HYG, V54, P443, DOI 10.4269/ajtmh.1996.54.443; Anderson JM, 1997, ADV DRUG DELIVER REV, V28, P5, DOI 10.1016/S0169-409X(97)00048-3; Anzai Yoshimi, 2004, Top Magn Reson Imaging, V15, P103, DOI 10.1097/01.rmr.0000130602.65243.87; Barton GM, 2009, NAT REV IMMUNOL, V9, P535, DOI 10.1038/nri2587; Chackerian B, 2007, EXPERT REV VACCINES, V6, P381, DOI 10.1586/14760584.6.3.381; Chang SP, 1996, INFECT IMMUN, V64, P253, DOI 10.1128/IAI.64.1.253-261.1996; CHANG SP, 1992, J IMMUNOL, V149, P548; CHANG SP, 1989, P NATL ACAD SCI USA, V86, P6343, DOI 10.1073/pnas.86.16.6343; Egan AF, 1999, PARASITE IMMUNOL, V21, P133, DOI 10.1046/j.1365-3024.1999.00209.x; Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566; Figuerola A, 2010, PHARMACOL RES, V62, P126, DOI 10.1016/j.phrs.2009.12.012; Fischer NO, 2010, BIOCONJUGATE CHEM, V21, P1018, DOI 10.1021/bc100083d; Gao XH, 2004, NAT BIOTECHNOL, V22, P969, DOI 10.1038/nbt994; Harro CD, 2001, JNCI-J NATL CANCER I, V93, P284, DOI 10.1093/jnci/93.4.284; Hirosue S, 2010, VACCINE, V28, P7897, DOI 10.1016/j.vaccine.2010.09.077; HOLDER AA, 1984, J EXP MED, V160, P624, DOI 10.1084/jem.160.2.624; HOLDER AA, 1992, MEM I OSWALDO CRUZ, V87, P37, DOI 10.1590/S0074-02761992000700004; Holder AA, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P409; Hui G, 2008, CLIN VACCINE IMMUNOL, V15, P1145, DOI 10.1128/CVI.00058-08; Hui G, 2007, VACCINE, V25, P8549, DOI 10.1016/j.vaccine.2007.10.010; Hui G, 2007, VACCINE, V25, P948, DOI 10.1016/j.vaccine.2006.08.041; HUI GSN, 1992, EXP PARASITOL, V75, P155, DOI 10.1016/0014-4894(92)90131-S; HUI GSN, 1994, J IMMUNOL, V153, P2544; HUI GSN, 1991, J IMMUNOL, V147, P3935; HUI GSN, 1994, J IMMUNOL, V153, P1195; HUI GSN, 1994, AM J TROP MED HYG, V50, P41, DOI 10.4269/ajtmh.1994.50.41; HUI GSN, 1987, EXP PARASITOL, V64, P519, DOI 10.1016/0014-4894(87)90068-3; Illum L, 2001, ADV DRUG DELIVER REV, V51, P81, DOI 10.1016/S0169-409X(01)00171-5; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; John CC, 2004, J IMMUNOL, V173, P666, DOI 10.4049/jimmunol.173.1.666; Kaba SA, 2009, J IMMUNOL, V183, P7268, DOI 10.4049/jimmunol.0901957; Kirkpatrick RB, 1999, GENE EXPRESSION SYSTEMS, P289, DOI 10.1016/B978-012253840-7/50012-2; Kumar S, 2000, INFECT IMMUN, V68, P2215, DOI 10.1128/IAI.68.4.2215-2223.2000; Lambrecht BN, 2009, CURR OPIN IMMUNOL, V21, P23, DOI 10.1016/j.coi.2009.01.004; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Leung WH, 2004, BBA-GEN SUBJECTS, V1675, P62, DOI 10.1016/j.bbagen.2004.08.005; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ludwig C, 2007, CURR OPIN BIOTECH, V18, P537, DOI 10.1016/j.copbio.2007.10.013; Lu JM, 2009, EXPERT REV MOL DIAGN, V9, P325, DOI 10.1586/ERM.09.15; Masotti A, 2009, MINI-REV MED CHEM, V9, P463, DOI 10.2174/138955709787847976; Mbow ML, 2010, CURR OPIN IMMUNOL, V22, P411, DOI 10.1016/j.coi.2010.04.004; Mundargi RC, 2008, J CONTROL RELEASE, V125, P193, DOI 10.1016/j.jconrel.2007.09.013; O'Donnell RA, 2001, J EXP MED, V193, P1403, DOI 10.1084/jem.193.12.1403; Pang ALY, 2002, INFECT IMMUN, V70, P2772, DOI 10.1128/IAI.70.6.2772-2779.2002; Pasare C, 2005, ADV EXP MED BIOL, V560, P11; Peek LJ, 2008, ADV DRUG DELIVER REV, V60, P915, DOI 10.1016/j.addr.2007.05.017; Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387; Perraut R, 2005, J INFECT DIS, V191, P264, DOI 10.1086/426398; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pusic K, 2011, VACCINE, V29, P8898, DOI 10.1016/j.vaccine.2011.09.070; Pusic KM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024782; Rudra JS, 2012, BIOMATERIALS, V33, P6476, DOI 10.1016/j.biomaterials.2012.05.041; Shahiwala Aliasgar, 2007, Recent Pat Drug Deliv Formul, V1, P1, DOI 10.2174/187221107779814140; Singh S, 2006, INFECT IMMUN, V74, P4573, DOI 10.1128/IAI.01679-05; Skene CD, 2006, METHODS, V40, P53, DOI 10.1016/j.ymeth.2006.05.019; Stowers AW, 2001, INFECT IMMUN, V69, P1536, DOI 10.1128/IAI.69.3.1536-1546.2001; Sun HX, 2009, VACCINE, V27, P4388, DOI 10.1016/j.vaccine.2009.05.032; SZMUNESS W, 1980, NEW ENGL J MED, V303, P833, DOI 10.1056/NEJM198010093031501; Szymczak WA, 2010, INFECT IMMUN, V78, P2125, DOI 10.1128/IAI.00065-10; Ueno Y, 2005, J CONTROL RELEASE, V103, P93, DOI 10.1016/j.jconrel.2004.11.015; van der Lubben IM, 2001, ADV DRUG DELIVER REV, V52, P139, DOI 10.1016/S0169-409X(01)00197-1; Xu H., 2009, BIOMEDICAL ENG INFOR, DOI [10.1109/BMEI.2009.5305551, DOI 10.1109/BMEI.2009.5305551]; Xu HY, 2009, ECS TRANSACTIONS, V25, P69, DOI 10.1149/1.3236409; Xu HYY, 2010, ECS TRANSACTIONS, V25, P1, DOI 10.1149/1.3327196; Zhang Xia, 2008, Curr Protoc Immunol, VChapter 14, DOI 10.1002/0471142735.im1401s83	67	50	52	0	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					1153	1166		10.1096/fj.12-218362	http://dx.doi.org/10.1096/fj.12-218362			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23195035	Green Published			2023-01-03	WOS:000315585200028
J	Young, D; Lamb, SE; Shah, S; MacKenzie, I; Tunnicliffe, W; Lall, R; Rowan, K; Cuthbertson, BH				Young, Duncan; Lamb, Sarah E.; Shah, Sanjoy; MacKenzie, Iain; Tunnicliffe, William; Lall, Ranjit; Rowan, Kathy; Cuthbertson, Brian H.		Oscar Study Grp	High-Frequency Oscillation for Acute Respiratory Distress Syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE LUNG INJURY; TRIAL; ARDS; VENTILATION; MORTALITY; PRESSURE; OUTCOMES	BACKGROUND Patients with the acute respiratory distress syndrome (ARDS) require mechanical ventilation to maintain arterial oxygenation, but this treatment may produce secondary lung injury. High-frequency oscillatory ventilation (HFOV) may reduce this secondary damage. METHODS In a multicenter study, we randomly assigned adults requiring mechanical ventilation for ARDS to undergo either HFOV with a Novalung R100 ventilator (Metran) or usual ventilatory care. All the patients had a ratio of the partial pressure of arterial oxygen (Pao(2)) to the fraction of inspired oxygen (F-IO2) of 200 mm Hg (26.7 kPa) or less and an expected duration of ventilation of at least 2 days. The primary outcome was all-cause mortality 30 days after randomization. RESULTS There was no significant between-group difference in the primary outcome, which occurred in 166 of 398 patients (41.7%) in the HFOV group and 163 of 397 patients (41.1%) in the conventional-ventilation group (P = 0.85 by the chi-square test). After adjustment for study center, sex, score on the Acute Physiology and Chronic Health Evaluation (APACHE) II, and the initial Pao2:F-IO2 ratio, the odds ratio for survival in the conventional-ventilation group was 1.03 (95% confidence interval, 0.75 to 1.40; P = 0.87 by logistic regression). CONCLUSIONS The use of HFOV had no significant effect on 30-day mortality in patients undergoing mechanical ventilation for ARDS. (Funded by the National Institute for Health Research Health Technology Assessment Programme; OSCAR Current Controlled Trials number, ISRCTN10416500.)	[Young, Duncan] John Radcliffe Hosp, Oxford OX3 9DU, England; [Young, Duncan; Lamb, Sarah E.] Univ Oxford, Oxford, England; [Shah, Sanjoy] Bristol Royal Infirm & Gen Hosp, Bristol, Avon, England; [MacKenzie, Iain; Tunnicliffe, William] Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England; [Lall, Ranjit] Univ Warwick, Warwick Clin Trials Unit, Warwick, England; [Rowan, Kathy] Intens Care Natl Audit & Res Ctr, London, England; [Cuthbertson, Brian H.] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON M4N 3M5, Canada; [Cuthbertson, Brian H.] Univ Toronto, Dept Anesthesia, Toronto, ON, Canada	University of Oxford; University of Oxford; Bristol Royal Infirmary; University of Birmingham; University of Warwick; Intensive Care National Audit & Research Centre; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Young, D (corresponding author), John Radcliffe Hosp, Adult Intens Care Unit, Headley Way, Oxford OX3 9DU, England.	duncan.young@nda.ox.ac.uk	Young, John D/M-9756-2016	Lall, Ranjit/0000-0003-1737-2866; Lamb, Sarah/0000-0003-4349-7195; Young, John Duncan/0000-0002-6838-4835; Rowan, Kathryn/0000-0001-8217-5602	National Institute for Health Research Health Technology Assessment Programme [06/04/01]; National Institute for Health Research [06/04/501, 06/04/01] Funding Source: researchfish	National Institute for Health Research Health Technology Assessment Programme(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by the National Institute for Health Research Health Technology Assessment Programme (project number 06/04/01).	BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bollen CW, 2005, CRIT CARE, V9, pR430, DOI 10.1186/cc3737; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Derdak S, 2002, AM J RESP CRIT CARE, V166, P801, DOI 10.1164/rccm.2108052; Erickson SE, 2009, CRIT CARE MED, V37, P1574, DOI 10.1097/CCM.0b013e31819fefdf; Ferguson ND, 2013, NEW ENGL J MED, V368, P795, DOI 10.1056/NEJMoa1215554; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LUNKENHEIMER PP, 1972, BRIT J ANAESTH, V44, P627, DOI 10.1093/bja/44.6.627; Mehta S, 2001, CRIT CARE MED, V29, P1360, DOI 10.1097/00003246-200107000-00011; Metran, 2012, PROD INF R100; Perkins GD, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-113; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Sud S, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2327; Thorpe KE, 2009, CAN MED ASSOC J, V180, pE47, DOI 10.1503/cmaj.090523; Villar J, 2011, INTENS CARE MED, V37, P1932, DOI 10.1007/s00134-011-2380-4; Villar J, 2011, RESP CARE, V56, P420, DOI 10.4187/respcare.00811	18	390	434	0	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 28	2013	368	9					806	813		10.1056/NEJMoa1215716	http://dx.doi.org/10.1056/NEJMoa1215716			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	096ET	23339638				2023-01-03	WOS:000315387700006
J	Cervadoro, A; Giverso, C; Pande, R; Sarangi, S; Preziosi, L; Wosik, J; Brazdeikis, A; Decuzzi, P				Cervadoro, Antonio; Giverso, Chiara; Pande, Rohit; Sarangi, Subhasis; Preziosi, Luigi; Wosik, Jarek; Brazdeikis, Audrius; Decuzzi, Paolo			Design Maps for the Hyperthermic Treatment of Tumors with Superparamagnetic Nanoparticles	PLOS ONE			English	Article							IRON-OXIDE NANOPARTICLES; RADIOFREQUENCY ABLATION; DRUG-DELIVERY; HEAT-TRANSFER; TEMPERATURE; THERAPY; CYTOSKELETON; NANOCUBES; MELANOMA; TISSUE	A plethora of magnetic nanoparticles has been developed and investigated under different alternating magnetic fields (AMF) for the hyperthermic treatment of malignant tissues. Yet, clinical applications of magnetic hyperthermia are sporadic, mostly due to the low energy conversion efficiency of the metallic nanoparticles and the high tissue concentrations required. Here, we study the hyperthermic performance of commercially available formulations of superparamagnetic iron oxide nanoparticles (SPIOs), with core diameter of 5, 7 and 14 nm, in terms of absolute temperature increase Delta T and specific absorption rate (SAR). These nanoparticles are operated under a broad range of AMF conditions, with frequency f varying between 0.2 and 30 MHz; field strength H ranging from 4 to 10 kA m(-1); and concentration c(MNP) varying from 0.02 to 3.5 mg ml(-1). At high frequency field (similar to 30 MHz), non specific heating dominates and Delta T correlates with the electrical conductivity of the medium. At low frequency field (<1 MHz), non specific heating is negligible and the relaxation of the SPIO within the AMF is the sole energy source. We show that the Delta T of the medium grows linearly with c(MNP), whereas the SAR(MNP) of the magnetic nanoparticles is independent of c(MNP) and varies linearly with f and H-2. Using a computational model for heat transport in a biological tissue, the minimum requirements for local hyperthermia (T-tissue >42 degrees C) and thermal ablation (T-tissue >50 degrees C) are derived in terms of c(MNP), operating AMF conditions and blood perfusion. The resulting maps can be used to rationally design hyperthermic treatments and identifying the proper route of administration - systemic versus intratumor injection - depending on the magnetic and biodistribution properties of the nanoparticles.	[Cervadoro, Antonio; Decuzzi, Paolo] Methodist Hosp, Res Inst, Dept Translat Imaging, Houston, TX 77030 USA; [Cervadoro, Antonio] Politecn Torino, Dept Mech, Turin, Italy; [Giverso, Chiara; Preziosi, Luigi] Politecn Torino, Dept Math Sci, Turin, Italy; [Pande, Rohit; Wosik, Jarek] Univ Houston, Dept Elect & Comp Engn, Houston, TX USA; [Pande, Rohit; Sarangi, Subhasis; Wosik, Jarek; Brazdeikis, Audrius] Univ Houston, Texas Ctr Superconduct, Houston, TX USA; [Brazdeikis, Audrius] Univ Houston, Dept Phys, Houston, TX USA; [Decuzzi, Paolo] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy	The Methodist Hospital System; The Methodist Hospital - Houston; Polytechnic University of Turin; Polytechnic University of Turin; University of Houston System; University of Houston; University of Houston System; University of Houston; University of Houston System; University of Houston; Magna Graecia University of Catanzaro	Decuzzi, P (corresponding author), Methodist Hosp, Res Inst, Dept Translat Imaging, 6535 Fannin, Houston, TX 77030 USA.	pdecuzzi@tmhs.org	Decuzzi, Paolo/F-1899-2016; Preziosi, Luigi/AAF-4875-2020; Brazdeikis, Audrius/H-3837-2015	Decuzzi, Paolo/0000-0001-6050-4188; Brazdeikis, Audrius/0000-0001-9536-1586; CERVADORO, ANTONIO/0000-0003-3087-2363	Cancer Prevention Research Institute of Texas [CPRIT RP110262]; National Institutes of Health (United States of America) [U54CA143837, U54CA151668]; NATIONAL CANCER INSTITUTE [U54CA143837, U54CA151668] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024148] Funding Source: NIH RePORTER	Cancer Prevention Research Institute of Texas; National Institutes of Health (United States of America)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported by the Cancer Prevention Research Institute of Texas through the grant CPRIT RP110262. (CPRIT: www.cprit.state.tx.us/). PD also aknowledges partial support through grants from the National Institutes of Health (United States of America) U54CA143837 and U54CA151668 (www.cancer.gov). AC acknowledges travel support from the Scuola Interpolitecnica di Dottorato - SCUDO. (http://dottorato.polito.it/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by the Cancer Prevention Research Institute of Texas through the grant CPRIT RP110262. This work was also partially supported through grants from the National Institutes of Health (USA) (NIH) U54CA143837 and U54CA151668. AC acknowledges travel support from the Scuola Interpolitecnica di Dottorato - SCUDO.	Arciero CA, 2008, SEMIN ONCOL, V35, P147, DOI 10.1053/j.seminoncol.2007.12.004; ARKIN H, 1994, IEEE T BIO-MED ENG, V41, P97, DOI 10.1109/10.284920; ATKINSON WJ, 1984, IEEE T BIO-MED ENG, V31, P70, DOI 10.1109/TBME.1984.325372; Bae KH, 2012, ACS NANO, V6, P5266, DOI 10.1021/nn301046w; Bekovic M, 2010, IEEE T MAGN, V46, P4; Bulte JWM, 2004, NMR BIOMED, V17, P484, DOI 10.1002/nbm.924; Chertok B, 2008, BIOMATERIALS, V29, P487, DOI 10.1016/j.biomaterials.2007.08.050; Cherukuri P, 2010, ADV DRUG DELIVER REV, V62, P339, DOI 10.1016/j.addr.2009.11.006; Coleman A, 2009, EXPERT REV ANTICANC, V9, P1599, DOI 10.1586/ERA.09.126; Coss RA, 1996, INT J HYPERTHER, V12, P173, DOI 10.3109/02656739609022507; Crayton SH, 2012, BIOMATERIALS, V33, P1509, DOI 10.1016/j.biomaterials.2011.10.077; Curley SA, 2003, ANN SURG ONCOL, V10, P338, DOI 10.1245/ASO.2003.07.017; Dennis CL, 2008, J PHYS D APPL PHYS, V41, DOI 10.1088/0022-3727/41/13/134020; Dennis CL, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/39/395103; dos Santos I, 2008, BIOMED ENG ONLINE, V7, DOI 10.1186/1475-925X-7-21; Elsherbini AAM, 2011, MAGN RESON IMAGING, V29, P272, DOI 10.1016/j.mri.2010.08.010; Fortin JP, 2007, J AM CHEM SOC, V129, P2628, DOI 10.1021/ja067457e; Gannon CJ, 2007, CANCER-AM CANCER SOC, V110, P2654, DOI 10.1002/cncr.23155; Garcia MP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035489; Gasselhuber A, 2010, INT J HYPERTHER, V26, P499, DOI 10.3109/02656731003623590; Gobin AM, 2010, SMALL, V6, P745, DOI 10.1002/smll.200901557; Godin B, 2012, ADV FUNCT MATER, V22, P4225, DOI 10.1002/adfm.201200869; Guardia P, 2012, ACS NANO, V6, P3080, DOI 10.1021/nn2048137; Heidsieck A, 2012, MOL PHARM; Hergt R, 2008, J PHYS-CONDENS MAT, V20, DOI 10.1088/0953-8984/20/38/385214; Hildebrandt B, 2002, CRIT REV ONCOL HEMAT, V43, P33, DOI 10.1016/S1040-8428(01)00179-2; Hildebrandt B, 2007, Cancer Treat Res, V134, P171; Huang SH, 1999, J CELL BIOCHEM, V75, P327, DOI 10.1002/(SICI)1097-4644(19991101)75:2<327::AID-JCB14>3.3.CO;2-7; Huber DL, 2005, SMALL, V1, P482, DOI 10.1002/smll.200500006; Jia DW, 2010, EXPERT REV MED DEVIC, V7, P407, DOI [10.1586/erd.10.13, 10.1586/ERD.10.13]; Kallumadil M, 2009, J MAGN MAGN MATER, V321, P1509, DOI 10.1016/j.jmmm.2009.02.075; Kam NWS, 2005, P NATL ACAD SCI USA, V102, P11600, DOI 10.1073/pnas.0502680102; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Kumar CSSR, 2011, ADV DRUG DELIVER REV, V63, P789, DOI 10.1016/j.addr.2011.03.008; Laurent S, 2011, ADV COLLOID INTERFAC; Laurent S, 2010, FUTURE MED CHEM, V2, P427, DOI 10.4155/FMC.09.164; Lee JH, 2011, NAT NANOTECHNOL, V6, P418, DOI [10.1038/NNANO.2011.95, 10.1038/nnano.2011.95]; Levy M, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/39/395103; Lewinski N, 2008, SMALL, V4, P26, DOI 10.1002/smll.200700595; Li YF, 2011, SMALL, V7, P2965, DOI 10.1002/smll.201101059; Li ZX, 2010, MAT SCI ENG C-MATER, V30, P990, DOI 10.1016/j.msec.2010.04.016; Lobo SM, 2004, RADIOLOGY, V230, P175, DOI 10.1148/radiol.2301021512; Lu W, 2011, CANCER RES, V71, P6116, DOI 10.1158/0008-5472.CAN-10-4557; MAJDA JA, 1994, EXP CELL RES, V210, P46, DOI 10.1006/excr.1994.1007; Manthe RL, 2010, MOL PHARMACEUT, V7, P1880, DOI 10.1021/mp1001944; O'Neal DP, 2004, CANCER LETT, V209, P171, DOI 10.1016/j.canlet.2004.02.004; Pankhurst QA, 2009, J PHYS D APPL PHYS, V42, DOI 10.1088/0022-3727/42/22/224001; Pennes HH, 1998, J APPL PHYSIOL, V85, P5, DOI 10.1152/jappl.1998.85.1.5; Purushotham S, 2010, J APPL PHYS, V107, DOI 10.1063/1.3432757; Rao Wei, 2010, Critical Reviews in Biomedical Engineering, V38, P101, DOI 10.1615/CritRevBiomedEng.v38.i1.80; Rosensweig RE, 2002, J MAGN MAGN MATER, V252, P370, DOI 10.1016/S0304-8853(02)00706-0; Schutt DJ, 2008, MED PHYS, V35, P3462, DOI 10.1118/1.2948388; Shenoi MM, 2009, IEEE ENG MED BIO, P1979, DOI 10.1109/IEMBS.2009.5333447; Stafford RJ, 2011, INT J HYPERTHER, V27, P782, DOI 10.3109/02656736.2011.614671; Stern JM, 2008, J UROLOGY, V179, P748, DOI 10.1016/j.juro.2007.09.018; Suzuki M, 2003, MELANOMA RES, V13, P129, DOI 10.1097/00008390-200304000-00004; van de Ven AL, 2012, J CONTROL RELEASE, V158, P148, DOI 10.1016/j.jconrel.2011.10.021; van der Zee J, 2002, ANN ONCOL, V13, P1173, DOI 10.1093/annonc/mdf280; von Maltzahn G, 2009, CANCER RES, V69, P3892, DOI 10.1158/0008-5472.CAN-08-4242; Wust P, 2002, LANCET ONCOL, V3, P487, DOI 10.1016/S1470-2045(02)00818-5	60	73	74	2	48	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2013	8	2							e57332	10.1371/journal.pone.0057332	http://dx.doi.org/10.1371/journal.pone.0057332			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115ZB	23451208	Green Published, gold, Green Submitted			2023-01-03	WOS:000316849500091
J	Chakrabarti, M; Banik, NL; Ray, SK				Chakrabarti, Mrinmay; Banik, Naren L.; Ray, Swapan K.			Photofrin Based Photodynamic Therapy and miR-99a Transfection Inhibited FGFR3 and PI3K/Akt Signaling Mechanisms to Control Growth of Human Glioblastoma In Vitro and In Vivo	PLOS ONE			English	Article							MALIGNANT BRAIN-TUMORS; ANTITUMOR IMMUNITY; ENDOTHELIAL-CELLS; GENE-EXPRESSION; GLIOMA-CELLS; HUMAN CANCER; MICRORNAS; APOPTOSIS; SURVIVAL; RADIOTHERAPY	Glioblastoma is the most common malignant brain tumor in humans. We explored the molecular mechanisms how the efficacy of photofrin based photodynamic therapy (PDT) was enhanced by miR-99a transfection in human glioblastoma cells. Our results showed almost similar uptake of photofrin after 24 h in different glioblastoma cells, but p53 wild-type cells were more sensitive to radiation and photofrin doses than p53 mutant cells. Photofrin based PDT induced apoptosis, inhibited cell invasion, prevented angiogenic network formation, and promoted DNA fragmentation and laddering in U87MG and U118MG cells harvoring p53 wild-type. Western blotting showed that photofrin based PDT was efficient to block the angiogenesis and cell survival pathways. Further, photofrin based PDT followed by miR-99a transfection dramatically increased miR-99a expression and also increased apoptosis in glioblastoma cell cultures and drastically reduced tumor growth in athymic nude mice, due to down regulation of fibroblast growth factor receptor 3 (FGFR3) and PI3K/Akt signaling mechanisms leading to inhibition of cell proliferation and induction of molecular mechanisms of apoptosis. Therefore, our results indicated that the anti-tumor effects of photofrin based PDT was strongly augmented by miR-99a overexpression and this novel combination therapeutic strategy could be used for controlling growth of human p53 wildtype glioblastomas both in vitro and in vivo.	[Chakrabarti, Mrinmay; Ray, Swapan K.] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA; [Banik, Naren L.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Medical University of South Carolina	Ray, SK (corresponding author), Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA.	swapan.ray@uscmed.sc.edu	CHAKRABARTI, MRINMAY/M-5652-2019					Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Au CM, 2006, J PHOTOCH PHOTOBIO B, V85, P92, DOI 10.1016/j.jphotobiol.2006.06.002; Bonauer A, 2010, CURR DRUG TARGETS, V11, P943, DOI 10.2174/138945010791591313; Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894; Chen Y, 2008, BLOOD, V111, P1217, DOI 10.1182/blood-2007-07-104133; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Collins AR, 2004, MOL BIOTECHNOL, V26, P249, DOI 10.1385/MB:26:3:249; Doebele C, 2010, BLOOD, V115, P4944, DOI 10.1182/blood-2010-01-264812; Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071; Eljamel MS, 2008, LASER MED SCI, V23, P361, DOI 10.1007/s10103-007-0494-2; Eljamel MS, 2003, TECHNOL CANCER RES T, V2, P303, DOI 10.1177/153303460300200404; Eljamel S, 2010, PHOTODIAGN PHOTODYN, V7, P76, DOI 10.1016/j.pdpdt.2010.02.002; Engbrecht BW, 1999, CANCER RES, V59, P4334; Fasanaro P, 2008, J BIOL CHEM, V283, P15878, DOI 10.1074/jbc.M800731200; Fowler A, 2011, EUR J CANCER, V47, P953, DOI 10.1016/j.ejca.2010.11.026; Garg AD, 2010, APOPTOSIS, V15, P1050, DOI 10.1007/s10495-010-0479-7; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Gollnick SO, 2010, IMMUNOL RES, V46, P216, DOI 10.1007/s12026-009-8119-4; Goodell T T, 2001, J Neurosci Nurs, V33, P296; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Gupta AK, 2002, CLIN CANCER RES, V8, P885; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Hirschberg H, 2008, LASER SURG MED, V40, P535, DOI 10.1002/lsm.20670; Hsieh YJ, 2003, J CELL PHYSIOL, V194, P363, DOI 10.1002/jcp.10273; Hua Z, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000116; Jiang JM, 2005, NUCLEIC ACIDS RES, V33, P5394, DOI 10.1093/nar/gki863; Kabingu E, 2009, CLIN CANCER RES, V15, P4460, DOI 10.1158/1078-0432.CCR-09-0400; Karmakar S, 2008, CANCER, V112, P596, DOI 10.1002/cncr.23223; Karmakar Surajit, 2010, J Cancer Sci Ther, V2, P107; Krishnamurthy S, 2000, LASER SURG MED, V27, P224, DOI 10.1002/1096-9101(2000)27:3<224::AID-LSM4>3.0.CO;2-#; Lee DY, 2007, P NATL ACAD SCI USA, V104, P20350, DOI 10.1073/pnas.0706901104; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Marcu LG, 2010, CANCER TREAT REV, V36, P606, DOI 10.1016/j.ctrv.2010.04.004; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mueller AC, 2013, ONCOGENE, V32, P1164, DOI 10.1038/onc.2012.131; O'Gorman DM, 2001, LEUKEMIA, V15, P21, DOI 10.1038/sj.leu.2401998; Pawlik TM, 2004, INT J RADIAT ONCOL, V59, P928, DOI 10.1016/j.ijrobp.2004.03.005; Poliseno L, 2006, BLOOD, V108, P3068, DOI 10.1182/blood-2006-01-012369; Silbergeld DL, 1997, J NEUROSURG, V86, P525, DOI 10.3171/jns.1997.86.3.0525; Song GS, 2010, HEPATOLOGY, V51, P1735, DOI 10.1002/hep.23547; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stylli SS, 2004, J CLIN NEUROSCI, V11, P584, DOI 10.1016/j.jocn.2004.02.001; Suarez Y, 2007, CIRC RES, V100, P1164, DOI 10.1161/01.RES.0000265065.26744.17; Takeshita F, 2005, P NATL ACAD SCI USA, V102, P12177, DOI 10.1073/pnas.0501753102; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002; Wong TS, 2008, CLIN CANCER RES, V14, P2588, DOI 10.1158/1078-0432.CCR-07-0666; Yang VXD, 2003, LASER SURG MED, V32, P224, DOI 10.1002/lsm.10131; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; Zimmermann A, 2001, PHOTOCHEM PHOTOBIOL, V74, P611, DOI 10.1562/0031-8655(2001)074<0611:MMPDOM>2.0.CO;2	54	41	42	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2013	8	2							e55652	10.1371/journal.pone.0055652	http://dx.doi.org/10.1371/journal.pone.0055652			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	092XV	23409016	Green Published, Green Submitted, gold			2023-01-03	WOS:000315157200048
J	Gu, LW; Yue, JJ; Zheng, YL; Zheng, X; Wang, J; Wang, YZ; Li, JC; Jiang, YQ; Jiang, H				Gu, Liwei; Yue, Junjie; Zheng, Yuling; Zheng, Xin; Wang, Jun; Wang, Yanzi; Li, Jianchun; Jiang, Yongqiang; Jiang, Hua			Evaluation of a Recombinant Double Mutant of Staphylococcal Enterotoxin B (SEB-H32Q/K173E) with Enhanced Antitumor Activity Effects and Decreased Pyrexia	PLOS ONE			English	Article							RECEPTOR BETA-CHAIN; CLASS-II; BACTERIAL SUPERANTIGEN; TRANSGENIC MICE; CELL CARCINOMA; IN-VIVO; STRUCTURAL BASIS; CANCER; RESPONSES; IMMUNOTHERAPY	Background: Immunotherapy has been used to improve patient immune function, inhibit tumor growth and has become a highly promising method of cancer treatment. Highly agglutinative staphylococcin (HAS), a mixture of Staphylococcus aureus culture filtrates, which include staphylococcal enterotoxin (SE) C as the active ingredient, has been used clinically as an immunomodifier in the treatment of a number of tumors for many years. However, the use of HAS has been associated with some unavoidable side-effects such as fever. Previous studies have shown that SEB stimulates a more potent activation of T lymphocytes than SEC3, and mutations of the histidine residues eliminated the toxicity of SEB. SE mutants with decreased side-effects and/or more potent antitumor activities are required. Methodology/Principal Findings: We built a structural model of the MHC II-SEB-TCR complex and found that a mutation of SEB at Lys173 might decrease the repulsion force between the SEB-TCR, which would facilitate their interaction. From the above results, we designed SEB-H32Q/K173E (mSEB). Analysis of in vitro stimulation of the proliferation of human peripheral blood mononuclear cells (PBMCs), IFN-gamma secretion and inhibition of the growth of various tumor cell lines demonstrated that mSEB exhibited higher antitumor activity compared with wild-type SEB (wtSEB). Notably, mSEB inhibited the growth of various tumors at an extremely low concentration with little cytotoxicity against normal cells. Three animal tumor models (C57BL/6 mouse, New Zealand rabbit and a humanized NOD/SCID mouse) were used to evaluate the in vivo immunotherapeutic effects. Compared with wtSEB, mSEB significantly enhanced antitumor effect in more than one animal model with reduced pyrexia toxicity and prolonged the survival of tumor-bearing mice. Conclusions/Significance: Our results suggest that SEB-H32Q/K173E retains superantigen (SAg) characteristics	[Gu, Liwei; Zheng, Yuling; Zheng, Xin; Wang, Jun; Jiang, Yongqiang; Jiang, Hua] Acad Mil Med Sci, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China; [Gu, Liwei; Li, Jianchun] Shenyang Pharmaceut Univ, Dept Tradit Chinese Med Pharmacol, Shenyang, Peoples R China; [Yue, Junjie] Beijing Inst Biotechnol, Beijing, Peoples R China; [Zheng, Xin; Wang, Jun] Shenyang Pharmaceut Univ, Dept Pharmacol, Shenyang, Peoples R China; [Wang, Yanzi] Jiangsu Prov Xuzhou Pharmaceut Vocat Coll, Dept Pharm, Xuzhou, Peoples R China	Academy of Military Medical Sciences - China; Shenyang Pharmaceutical University; Shenyang Pharmaceutical University	Li, JC (corresponding author), Shenyang Pharmaceut Univ, Dept Tradit Chinese Med Pharmacol, Shenyang, Peoples R China.	lijianchun0317@gmail.com; jiangyq@nic.bmi.ac.cn; weishengwuliuxingbing@hotmail.com	Yue, Junjie/AFV-9667-2022	Yue, Junjie/0000-0002-2549-9261	Chinese State Key Project Specialized for new drugs [2009ZX09103-618]; National Natural Science Foundation of China [81071434]	Chinese State Key Project Specialized for new drugs; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from Chinese State Key Project Specialized for new drugs (2009ZX09103-618) and the National Natural Science Foundation of China (81071434). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alpaugh RK, 1998, CLIN CANCER RES, V4, P1903; BaoAn Ning, 2006, ANTITUMOR EFFECT SUP, P24; Buonpane RA, 2007, NAT MED, V13, P725, DOI 10.1038/nm1584; Cheng X, 2010, SCAND J IMMUNOL, V71, P169, DOI 10.1111/j.1365-3083.2009.02359.x; Dinges MM, 2000, CLIN MICROBIOL REV, V13, P16, DOI 10.1128/CMR.13.1.16-34.2000; DOHLSTEN M, 1995, CANCER IMMUNOL IMMUN, V41, P162, DOI 10.1007/s002620050214; DOHLSTEN M, 1993, INT J CANCER, V54, P482, DOI 10.1002/ijc.2910540321; Egwuagu CE, 2006, ONCOGENE, V25, P3670, DOI 10.1038/sj.onc.1209402; Gampfer J, 2002, VACCINE, V20, P1354, DOI 10.1016/S0264-410X(01)00470-4; Gunther S, 2007, J MOL BIOL, V371, P210, DOI 10.1016/j.jmb.2007.05.038; HARRIS TO, 1993, INFECT IMMUN, V61, P3175, DOI 10.1128/IAI.61.8.3175-3183.1993; Holzer U, 1997, IMMUNOLOGY, V90, P74, DOI 10.1046/j.1365-2567.1997.00141.x; Ilback NG, 2003, TOXICOLOGY, V185, P161, DOI 10.1016/S0300-483X(02)00591-7; Jardetzky TS, 1994, 3 DIMENSIONAL STRUCT; Jie KG, 2007, CANCER BIOL THER, V6, P1584, DOI 10.4161/cbt.6.10.4724; JOHNSON HM, 1991, FASEB J, V5, P2706, DOI 10.1096/fasebj.5.12.1916093; Kominsky SL, 2001, INT J CANCER, V94, P834, DOI 10.1002/ijc.1551; Komisar JL, 2001, TOXICOL PATHOL, V29, P369, DOI 10.1080/019262301316905336; Korolev S, 2003, TOXICOLOGY, V187, P229, DOI 10.1016/S0300-483X(03)00049-0; Kou ZC, 1998, J IMMUNOL, V160, P5170; Leder L, 1998, J EXP MED, V187, P823, DOI 10.1084/jem.187.6.823; Li HM, 1999, ANNU REV IMMUNOL, V17, P435, DOI 10.1146/annurev.immunol.17.1.435; Li HM, 1998, IMMUNITY, V9, P807, DOI 10.1016/S1074-7613(00)80646-9; Lu Da-Yong, 2004, BMC Pharmacology, V4, P32, DOI 10.1186/1471-2210-4-32; Moza B, 2007, EMBO J, V26, P1187, DOI 10.1038/sj.emboj.7601531; Perabo FG, 2005, INT J CANCER, V115, P591, DOI 10.1002/ijc.20941; Perabo FGE, 2005, ANTICANCER RES, V25, P3565; Rajagopalan G, 2008, TISSUE ANTIGENS, V71, P135, DOI 10.1111/j.1399-0039.2007.00986.x; Rajagopalan G, 2006, INFECT IMMUN, V74, P1284, DOI 10.1128/IAI.74.2.1284-1296.2006; Rajagopalan G, 2009, PHYSIOL GENOMICS, V37, P279, DOI 10.1152/physiolgenomics.90385.2008; RECK B, 1988, P NATL ACAD SCI USA, V85, P3170, DOI 10.1073/pnas.85.9.3170; Roy CJ, 2005, INFECT IMMUN, V73, P2452, DOI 10.1128/IAI.73.4.2452-2460.2005; Shaw DM, 2007, BRIT J CANCER, V96, P567, DOI 10.1038/sj.bjc.6603567; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Stohl W, 2001, INT IMMUNOL, V13, P1291, DOI 10.1093/intimm/13.10.1291; Sundberg EJ, 2002, STRUCTURE, V10, P687, DOI 10.1016/S0969-2126(02)00759-1; Sundberg EJ, 2007, SEMIN IMMUNOL, V19, P262, DOI 10.1016/j.smim.2007.04.006; TORBETT BE, 1991, IMMUNOL REV, V124, P139, DOI 10.1111/j.1600-065X.1991.tb00620.x; Wang HR, 2010, CANC INVESTIGATION; Wang LJ, 2010, TRANSPL IMMUNOL, V24, P64, DOI 10.1016/j.trim.2010.09.001; Wang XG, 2009, CANCER IMMUNOL IMMUN, V58, P677, DOI 10.1007/s00262-008-0590-6; Xu M., 2008, ASIAN J PHARMCODYN P, V8, P83; Xu MK, 2011, CANCER IMMUNOL IMMUN, V60, P705, DOI 10.1007/s00262-011-0986-6	43	5	5	2	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2013	8	2							e55892	10.1371/journal.pone.0055892	http://dx.doi.org/10.1371/journal.pone.0055892			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	092WJ	23405232	Green Submitted, Green Published, gold			2023-01-03	WOS:000315153400177
J	Couto, E; Sandin, S; Lof, M; Ursin, G; Adami, HO; Weiderpass, E				Couto, Elisabeth; Sandin, Sven; Lof, Marie; Ursin, Giske; Adami, Hans-Olov; Weiderpass, Elisabete			Mediterranean Dietary Pattern and Risk of Breast Cancer	PLOS ONE			English	Article							MENOPAUSAL HORMONE-THERAPY; HEALTH; MORTALITY; SURVIVAL; ALCOHOL; COHORT; WOMEN	Background: A Mediterranean diet has a recognized beneficial effect on health and longevity, with a protective influence on several cancers. However, its association with breast cancer risk remains unclear. Objective: We aimed to investigate whether adherence to a Mediterranean dietary pattern influences breast cancer risk. Design: The Swedish Women's Lifestyle and Health cohort study includes 49,258 women aged 30 to 49 years at recruitment in 1991-1992. Consumption of foods and beverages was measured at enrollment using a food frequency questionnaire. A Mediterranean diet score was constructed based on the consumption of alcohol, vegetables, fruits, legumes, cereals, fish, the ratio of unsaturated to saturated fat, and dairy and meat products. Relative risks (RR) for breast cancer and specific tumor characteristics (invasiveness, histological type, estrogen/progesterone receptor status, malignancy grade and stage) associated with this score were estimated using Cox regression controlling for potential confounders. Results: 1,278 incident breast cancers were diagnosed. Adherence to a Mediterranean dietary pattern was not statistically significantly associated with reduced risk of breast cancer overall, or with specific breast tumor characteristics. A RR (95% confidence interval) for breast cancer associated with a two-point increment in the Mediterranean diet score was 1.08 (1.00-1.15) in all women, and 1.10 (1.01-1.21) and 1.02 (0.91-1.15) in premenopausal and postmenopausal women, respectively. When alcohol was excluded from the Mediterranean diet score, results became not statistically significant. Conclusions: Adherence to a Mediterranean dietary pattern did not decrease breast cancer risk in this cohort of relatively young women.	[Couto, Elisabeth; Sandin, Sven; Adami, Hans-Olov; Weiderpass, Elisabete] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Couto, Elisabeth; Ursin, Giske; Weiderpass, Elisabete] Canc Registry Norway, Oslo, Norway; [Couto, Elisabeth] Norwegian Knowledge Ctr Hlth Serv, Hlth Econ & Drug Unit, Oslo, Norway; [Lof, Marie] Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden; [Lof, Marie] Karolinska Inst, Dept Biosci & Nutr, Huddinge, Sweden; [Ursin, Giske] Univ Oslo, Dept Nutr, Oslo, Norway; [Ursin, Giske] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA; [Adami, Hans-Olov] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Weiderpass, Elisabete] Folkhalsan Res Ctr, Dept Genet Epidemiol, Helsinki, Finland; [Weiderpass, Elisabete] Univ Tromso, Dept Community Med, Tromso, Norway	Karolinska Institutet; University of Oslo; Norwegian Knowledge Centre for Health Services; Linkoping University; Karolinska Institutet; University of Oslo; University of Southern California; Harvard University; Harvard T.H. Chan School of Public Health; Folkhalsan Research Center; UiT The Arctic University of Tromso	Weiderpass, E (corresponding author), Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.	Elisabete.Weiderpass@ki.se	Weiderpass, Elisabete/M-4029-2016; Weiderpass, Elisabete/AAP-2747-2021; Löf, Marie/AAW-3323-2020; Löf, Marie/ABB-2697-2020; Ursin, Giske/U-6637-2017; Sandin, Sven/L-5357-2015; Sandin, Sven/ABE-2959-2021	Weiderpass, Elisabete/0000-0003-2237-0128; Weiderpass, Elisabete/0000-0003-2237-0128; Löf, Marie/0000-0002-2273-4430; Ursin, Giske/0000-0002-0835-9507; Sandin, Sven/0000-0001-6994-4884; Sandin, Sven/0000-0001-6994-4884	Swedish Research Council (Vetenskapsradet) [K2012-69X-22062-01-3]; Swedish Cancer Society	Swedish Research Council (Vetenskapsradet)(Swedish Research Council); Swedish Cancer Society(Swedish Cancer Society)	Supported by the Swedish Research Council (Vetenskapsradet) grant K2012-69X-22062-01-3 and by the Swedish Cancer Society. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen NE, 2009, JNCI-J NATL CANCER I, V101, P296, DOI 10.1093/jnci/djn514; Benitez-Arciniega AA, 2011, PUBLIC HEALTH NUTR, V14, P2015, DOI 10.1017/S1368980011001212; Bergstrom L., 1991, Var Foda, V43, P439; Brinton LA, 2008, CANCER EPIDEM BIOMAR, V17, P3150, DOI 10.1158/1055-9965.EPI-08-0435; Cade JE, 2011, EUR J CLIN NUTR, V65, P920, DOI 10.1038/ejcn.2011.69; COLDITZ GA, 1992, CANCER CAUSE CONTROL, V3, P433, DOI 10.1007/BF00051356; Cottet V, 2009, AM J EPIDEMIOL, V170, P1257, DOI 10.1093/aje/kwp257; Couto E, 2011, BRIT J CANCER, V104, P1493, DOI 10.1038/bjc.2011.106; Edefonti V, 2009, NUTR REV, V67, P297, DOI 10.1111/j.1753-4887.2009.00203.x; Fung TT, 2009, CIRCULATION, V119, P1093, DOI 10.1161/CIRCULATIONAHA.108.816736; Fung TT, 2006, J NUTR, V136, P466, DOI 10.1093/jn/136.2.466; Glass AG, 2007, JNCI-J NATL CANCER I, V99, P1152, DOI 10.1093/jnci/djm059; Jacques PF, 2001, AM J CLIN NUTR, V73, P1, DOI 10.1093/ajcn/73.1.1; Key TJ, 2001, LANCET ONCOL, V2, P133, DOI 10.1016/S1470-2045(00)00254-0; Kumle M, 2002, CANCER EPIDEM BIOMAR, V11, P1375; Lagiou P, 2006, BRIT J NUTR, V96, P384, DOI 10.1079/BJN20061824; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Ma HY, 2006, BREAST CANCER RES, V8, DOI [10.1186/bcr1512, 10.1186/bcr1525]; Murtaugh MA, 2008, AM J CLIN NUTR, V87, P978, DOI 10.1093/ajcn/87.4.978; Saxena T, 2010, CANCER EPIDEM BIOMAR, V19, P2366, DOI 10.1158/1055-9965.EPI-10-0162; Secretan B, 2009, LANCET ONCOL, V10, P1033, DOI 10.1016/S1470-2045(09)70326-2; Sofi F, 2010, AM J CLIN NUTR, V92, P1189, DOI 10.3945/ajcn.2010.29673; Therneau TM, 2001, MODELING SURVIVAL DA; Thiebaut ACM, 2007, ANN INTERN MED, V146, P65, DOI 10.7326/0003-4819-146-1-200701020-00012; Trichopoulou A, 2004, PUBLIC HEALTH NUTR, V7, P943, DOI 10.1079/PHN2004558; TRICHOPOULOU A, 1995, BMJ-BRIT MED J, V311, P1457, DOI 10.1136/bmj.311.7018.1457; Trichopoulou A, 2005, BMJ-BRIT MED J, V330, P991, DOI 10.1136/bmj.38415.644155.8F; Trichopoulou A, 2010, AM J CLIN NUTR, V92, P620, DOI 10.3945/ajcn.2010.29619; Trichopoulou A, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b2337; United Nations Educational Scientific and Cultural Organization, 2011, INT HER LISTS MED DI; Wolk A, 1998, ARCH INTERN MED, V158, P41, DOI 10.1001/archinte.158.1.41; World Cancer Research Fund & American Institute for Cancer Research, 2007, FOOD NUTR PHYS ACT P; Wu AH, 2009, AM J CLIN NUTR, V89, P1145, DOI 10.3945/ajcn.2008.26915	33	65	68	1	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 4	2013	8	2							e55374	10.1371/journal.pone.0055374	http://dx.doi.org/10.1371/journal.pone.0055374			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	086NH	23390532	Green Published, gold			2023-01-03	WOS:000314691100048
J	McCarthy, JM; Franke, M; Resenberger, UK; Waldron, S; Simpson, JC; Tatzelt, J; Appelhans, D; Rogers, MS				McCarthy, James M.; Franke, Markus; Resenberger, Ulrike K.; Waldron, Sibeal; Simpson, Jeremy C.; Tatzelt, Joerg; Appelhans, Dietmar; Rogers, Mark S.			Anti- Prion Drug mPPIg5 Inhibits PrPC Conversion to PrPSc	PLOS ONE			English	Article							BRANCHED POLYAMINES; AMYLOID PEPTIDES; DENDRIMERS; PROTEIN; ACCUMULATION; AGGREGATION; ALZHEIMERS; VESICLES	Prion diseases, also known as transmissible spongiform encephalopathies, are a group of fatal neurodegenerative diseases that include scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle and Creutzfeldt-Jakob disease (CJD) in humans. The 'protein only hypothesis' advocates that PrPSc, an abnormal isoform of the cellular protein PrPC, is the main and possibly sole component of prion infectious agents. Currently, no effective therapy exists for these diseases at the symptomatic phase for either humans or animals, though a number of compounds have demonstrated the ability to eliminate PrPSc in cell culture models. Of particular interest are synthetic polymers known as dendrimers which possess the unique ability to eliminate PrPSc in both an intracellular and in vitro setting. The efficacy and mode of action of the novel anti-prion dendrimer mPPIg5 was investigated through the creation of a number of innovative bio-assays based upon the scrapie cell assay. These assays were used to demonstrate that mPPIg5 is a highly effective anti-prion drug which acts, at least in part, through the inhibition of PrPC to PrPSc conversion. Understanding how a drug works is a vital component in maximising its performance. By establishing the efficacy and method of action of mPPIg5, this study will help determine which drugs are most likely to enhance this effect and also aid the design of dendrimers with anti-prion capabilities for the future.	[McCarthy, James M.; Waldron, Sibeal; Simpson, Jeremy C.; Rogers, Mark S.] Univ Coll Dublin, Sch Biol & Environm Sci, Dublin 2, Ireland; [Franke, Markus; Appelhans, Dietmar] Leibniz Inst Polymer Res Dresden, Dresden, Germany; [Resenberger, Ulrike K.; Tatzelt, Joerg] Univ Munich, Adolf Butenandt Inst, Munich, Germany; [Tatzelt, Joerg] German Ctr Neurodegenerat Dis DZNE, Munich, Germany	University College Dublin; Leibniz Institut fur Polymerforschung Dresden; University of Munich; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE)	McCarthy, JM (corresponding author), Univ Coll Dublin, Sch Biol & Environm Sci, Dublin 2, Ireland.	jim.mccarthy@ucd.ie	Rogers, Mark/M-4524-2013	Rogers, Mark/0000-0002-5288-0295; Simpson, Jeremy/0000-0002-7956-7805; Tatzelt, Jorg/0000-0001-5017-5528	University College Dublin; Irish Research Council for Science, Engineering & Technology (IRCSET); European Union [COST TD0802, FOOD-CT-2004-506579]; Irish Department of Agriculture, Food and Rural Development [FIRM 01-RD-D-160]; Saxon Ministry for Science and Art; German Ministry for Education and Science; DFG [SFB 596]	University College Dublin; Irish Research Council for Science, Engineering & Technology (IRCSET)(Irish Research Council for Science, Engineering and Technology); European Union(European Commission); Irish Department of Agriculture, Food and Rural Development; Saxon Ministry for Science and Art; German Ministry for Education and Science; DFG(German Research Foundation (DFG))	This work was supported by funding from University College Dublin, the Irish Research Council for Science, Engineering & Technology (IRCSET) the European Union (Dendrimers in Biomedical Applications - COST TD0802, Neuroprion - FOOD-CT-2004-506579), the Irish Department of Agriculture, Food and Rural Development (FIRM 01-R&D-D-160), the Saxon Ministry for Science and Art and The German Ministry for Education and Science, as well as the DFG SFB 596 (to Jorg Tatzelt and Ulrike K. Resenberger). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; Bosque PJ, 2000, J VIROL, V74, P4377, DOI 10.1128/JVI.74.9.4377-4386.2000; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1992, J NEUROCHEM, V59, P768, DOI 10.1111/j.1471-4159.1992.tb09437.x; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; Deleault NR, 2010, BIOCHEMISTRY-US, V49, P3928, DOI 10.1021/bi100370b; Doh-Ura K, 2000, J VIROL, V74, P4894, DOI 10.1128/JVI.74.10.4894-4897.2000; Ertmer A, 2004, J BIOL CHEM, V279, P41918, DOI 10.1074/jbc.M405652200; Fischer M, 2010, BIOMACROMOLECULES, V11, P1314, DOI 10.1021/bm100101s; Ghaemmaghami S, 2010, J BIOL CHEM, V285, P10415, DOI 10.1074/jbc.M109.045112; Gilch S, 2001, EMBO J, V20, P3957, DOI 10.1093/emboj/20.15.3957; Heegaard PMH, 2007, MACROMOL BIOSCI, V7, P1047, DOI 10.1002/mabi.200700051; Heegaard PMH, 2004, FEBS LETT, V577, P127, DOI 10.1016/j.febslet.2004.09.073; Janaszewska A, 2012, NEW J CHEM, V36, P350, DOI 10.1039/c1nj20444k; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Klajnert B, 2006, BIOMACROMOLECULES, V7, P2186, DOI 10.1021/bm060229s; Klajnert B, 2006, BIOCHEM BIOPH RES CO, V345, P21, DOI 10.1016/j.bbrc.2006.04.041; Klajnert B, 2006, BIOCHEM BIOPH RES CO, V339, P577, DOI 10.1016/j.bbrc.2005.11.053; Klajnert B, 2008, CHEM-EUR J, V14, P7030, DOI 10.1002/chem.200800342; Klajnert B, 2007, BIOCHEM BIOPH RES CO, V364, P20, DOI 10.1016/j.bbrc.2007.09.083; Klajnert B, 2007, MACROMOL BIOSCI, V7, P1065, DOI 10.1002/mabi.200700049; KLEBE RJ, 1969, J CELL BIOL, V43, pA69; Klohn PC, 2003, P NATL ACAD SCI USA, V100, P11666, DOI 10.1073/pnas.1834432100; Lim YB, 2010, BIOMATERIALS, V31, P2025, DOI 10.1016/j.biomaterials.2009.11.085; Masel J, 2000, BIOPHYS CHEM, V88, P47, DOI 10.1016/S0301-4622(00)00197-6; MCKINLEY MP, 1991, LAB INVEST, V65, P622; Miesbauer M, 2009, J BIOL CHEM, V284, P24384, DOI 10.1074/jbc.M109.023135; Nishida N, 2000, J VIROL, V74, P320, DOI 10.1128/JVI.74.1.320-325.2000; Nishina KA, 2007, ANAL BIOCHEM, V363, P318, DOI 10.1016/j.ab.2007.01.032; Perez AP, 2011, INT J NANOMED, V6, P2715, DOI 10.2147/IJN.S25235; Pless DD, 1996, J CELL BIOCHEM, V62, P27, DOI 10.1002/(SICI)1097-4644(199607)62:1<27::AID-JCB4>3.0.CO;2-3; Priola SA, 2000, SCIENCE, V287, P1503, DOI 10.1126/science.287.5457.1503; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Solassol J, 2004, J GEN VIROL, V85, P1791, DOI 10.1099/vir.0.19726-0; Supattapone S, 1999, P NATL ACAD SCI USA, V96, P14529, DOI 10.1073/pnas.96.25.14529; Supattapone S, 2001, J VIROL, V75, P3453, DOI 10.1128/JVI.75.7.3453-3461.2001; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; Waldron S, 2008, THESIS U COLL DUBLIN; Winklhofer KF, 2003, TRAFFIC, V4, P313, DOI 10.1034/j.1600-0854.2003.00088.x; Winklhofer KF, 2003, J BIOL CHEM, V278, P14961, DOI 10.1074/jbc.M209942200; Yam AY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009316	42	28	28	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2013	8	1							e55282	10.1371/journal.pone.0055282	http://dx.doi.org/10.1371/journal.pone.0055282			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	093SF	23383136	Green Submitted, Green Published, gold			2023-01-03	WOS:000315211500071
J	Wong, MCS; Tam, WWS; Cheung, CSK; Tong, ELH; Sek, ACH; John, G; Cheung, NT; Yan, BPY; Yu, CM; Leeder, S; Griffiths, S				Wong, Martin C. S.; Tam, Wilson W. S.; Cheung, Clement S. K.; Tong, Ellen L. H.; Sek, Antonio C. H.; John, George; Cheung, N. T.; Yan, Bryan P. Y.; Yu, C. M.; Leeder, Stephen; Griffiths, Sian			Initial Antihypertensive Prescription and Switching: A 5 Year Cohort Study from 250,851 Patients	PLOS ONE			English	Article							DIAGNOSED HYPERTENSIVE PATIENTS; BLOOD-PRESSURE; UNITED-STATES; RISK-FACTORS; 33 COMMUNITIES; DRUG-THERAPY; URBAN ADULTS; HONG-KONG; DISCONTINUATION; PREVALENCE	Purpose: Adverse effects of antihypertensive therapy incur substantial cost. We evaluated whether any major classes of antihypertensive drugs were significantly associated with switching as a proxy measure of medication side effects in a large Chinese population in Hong Kong. Methods: From a clinical database, all adult patients newly prescribed an antihypertensive mono-therapy in Hong Kong between the years 2001-2003 and 2005 were included. Those who paid only one visit, died or stayed in the cohort for <180 days after the prescription, or prescribed more than one antihypertensive agent were excluded. The factors associated with switching at 180 days were evaluated by multivariate regression analyses. Age, gender, payment status, service type, district of residence, drug class, systolic and diastolic blood pressure levels were predictor variables. Results: From 250,851 subjects, 159,813 patients were eligible. A total of 6,163 (3.9%) switched their medications within 180 days. Patients prescribed thiazide diuretics had the highest switching rate (5.6%), followed by ACEIs (4.5%), CCBs (4.4%) and beta-blockers (3.2%). When compared with ACEIs, patients on thiazide diuretics were significantly more likely to be switchers (adjusted odds ratio [AOR] 1.49, 95% C. I. 1.31-1.69, p<0.001), whilst patients prescribed CCBs and beta-blockers were similarly likely to have switching. Following these patients up for 5 years showed that thiazide had the most marked increase in switching rate. Conclusions: The higher rates of switching among thiazide diuretics in this study might raise a probably greater incidence of their adverse effects in this Chinese population, yet other factors might also influence switching rates. Patients prescribed thiazide diuretics for longer term should be observed for their intolerability.	[Wong, Martin C. S.; Tam, Wilson W. S.; Griffiths, Sian] Chinese Univ Hong Kong, Fac Med, Sch Publ Hlth & Primary Care, Hong Kong, Hong Kong, Peoples R China; [Cheung, Clement S. K.; Tong, Ellen L. H.; Sek, Antonio C. H.; Cheung, N. T.] Hosp Author Informat Technol Serv, Hlth Informat Sect, Hong Kong, Hong Kong, Peoples R China; [John, George] Univ Oxford, Oxford, England; [Yan, Bryan P. Y.; Yu, C. M.] Chinese Univ Hong Kong, Fac Med, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; [Leeder, Stephen] Univ Sydney, Menzies Ctr Hlth Policy, Sydney, NSW 2006, Australia	Chinese University of Hong Kong; University of Oxford; Chinese University of Hong Kong; University of Sydney	Tam, WWS (corresponding author), Chinese Univ Hong Kong, Fac Med, Sch Publ Hlth & Primary Care, Hong Kong, Hong Kong, Peoples R China.	wilsontam@cuhk.edu.hk	Yan, Bryan P/P-5928-2015; Wong, Martin/L-4568-2014; TAM, Wilson W.S./H-5890-2019; Yu, Cheuk-man/P-3747-2015; Cheung, Clement Shek Kei/AAP-9969-2021; Tam, Wilson/K-1664-2019	Wong, Martin/0000-0001-7706-9370; TAM, Wilson W.S./0000-0003-0641-3060; Cheung, Clement Shek Kei/0000-0002-9014-8628; 				[Anonymous], 2006, POP CENS; Benetos A, 2003, J HYPERTENS, V21, P1635, DOI 10.1097/00004872-200309000-00011; Billups SJ, 2000, PHARMACOTHERAPY, V20, P941, DOI 10.1592/phco.20.11.941.35266; Brown MJ, 2006, BMJ-BRIT MED J, V332, P833, DOI 10.1136/bmj.332.7545.833; Burke TA, 2006, J HYPERTENS, V24, P1193, DOI 10.1097/01.hjh.0000226211.95936.f5; Caro JJ, 1999, CAN MED ASSOC J, V160, P31; Census and Statistics Department, GOV HONG KONG ADM RE; CHAN L, 2007, HONG KONG PRACTITION, V29, P470; Cheung NT, REALIZING BENEFITS E; CHOBANIAN AV, 2003, HYPERTENSION, V42, P1206, DOI [DOI 10.1161/01.HYP.0000107251.49515.c2, DOI 10.1161/01.HYP.0000107251.49515.C2]; Chou CC, 2005, INT J CLIN PRACT, V59, P85, DOI 10.1111/j.1742-1241.2005.00436.x; Corrao G, 2008, J HYPERTENS, V26, P819, DOI 10.1097/HJH.0b013e3282f4edd7; Erkens JA, 2005, PHARMACOEPIDEM DR S, V14, P795, DOI 10.1002/pds.1156; Esposti LD, 2002, CLIN THER, V24, P1347, DOI 10.1016/S0149-2918(02)80039-X; Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; Fields LE, 2004, HYPERTENSION, V44, P398, DOI 10.1161/01.HYP.0000142248.54761.56; Flack JM, 1996, EUR HEART J, V17, P16, DOI 10.1093/eurheartj/17.suppl_A.16; Gueyffier F, 1997, ANN INTERN MED, V126, P761, DOI 10.7326/0003-4819-126-10-199705150-00002; Hajjar I, 2003, JAMA-J AM MED ASSOC, V290, P199, DOI 10.1001/jama.290.2.199; Heidenreich PA, 2011, CIRCULATION, V123, P933, DOI 10.1161/CIR.0b013e31820a55f5; Kannel WB, 1996, JAMA-J AM MED ASSOC, V275, P1571, DOI 10.1001/jama.275.20.1571; Kearney PM, 2004, J HYPERTENS, V22, P11, DOI 10.1097/00004872-200401000-00003; Kearney PM, 2005, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)70151-3; Kim SJ, 2011, CIRC J, V75, P135, DOI 10.1253/circj.CJ-09-0948; Kokubo Y, 2009, CIRC J, V73, P1381, DOI 10.1253/circj.CJ-09-0336; Li H, 2010, J HYPERTENS, V28, P432, DOI 10.1097/HJH.0b013e328334b39e; Mazzaglia G, 2005, J HYPERTENS, V23, P2093, DOI 10.1097/01.hjh.0000186832.41125.8a; Meng XJ, 2012, CIRC J, V76, P900, DOI 10.1253/circj.CJ-11-1118; Meng XJ, 2011, J HYPERTENS, V29, P1303, DOI 10.1097/HJH.0b013e328347f79e; *NAT COLL CTR CHRO, 2006, HYP MAN AD PRIM CAR; Nicotra Federica, 2009, J Hypertens, V27, P1917, DOI 10.1097/HJH.0b013e32832d4692; Ong KL, 2007, HYPERTENSION, V49, P69, DOI 10.1161/01.HYP.0000252676.46043.18; Redon J, 2007, HYPERTENSION, V49, P799, DOI 10.1161/01.HYP.0000259104.60878.43; Shafi T, 2008, HYPERTENSION, V52, P1022, DOI 10.1161/HYPERTENSIONAHA.108.119438; The Hong Kong Government, 2010, HONG KONG REF FRAM H; Tseng CH, 2008, CIRC J, V72, P1419, DOI 10.1253/circj.CJ-08-0009; Vaur L, 1999, AM J HYPERTENS, V12, P374, DOI 10.1016/S0895-7061(00)86963-0; Wong MCS, 2008, J HUM HYPERTENS, V22, P714, DOI 10.1038/jhh.2008.83; Wong MCS, 2010, J HUM HYPERTENS, V24, P669, DOI 10.1038/jhh.2009.109; Wong MCS, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-138; Wong MCS, 2011, HYPERTENS RES, V34, P888, DOI 10.1038/hr.2011.43; Wong MCS, 2009, AM J HYPERTENS, V22, P904, DOI 10.1038/ajh.2009.95; Wong Martin Cs, 2011, Asia Pac Fam Med, V10, P10, DOI 10.1186/1447-056X-10-10	43	10	12	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2013	8	1							e53625	10.1371/journal.pone.0053625	http://dx.doi.org/10.1371/journal.pone.0053625			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	087KE	23341959	Green Submitted, Green Published, gold			2023-01-03	WOS:000314759400054
J	Chertow, GM; Block, GA; Correa-Rotter, R; Drueke, TB; Floege, J; Goodman, WG; Herzog, CA; Kubo, Y; London, GM; Mahaffey, KW; Mix, TCH; Moe, SM; Trotman, ML; Wheeler, DC; Parfrey, PS				Chertow, Glenn M.; Block, Geoffrey A.; Correa-Rotter, Ricardo; Drueeke, Tilman B.; Floege, Juergen; Goodman, William G.; Herzog, Charles A.; Kubo, Yumi; London, Gerard M.; Mahaffey, Kenneth W.; Mix, T. Christian H.; Moe, Sharon M.; Trotman, Marie-Louise; Wheeler, David C.; Parfrey, Patrick S.		EVOLVE Trial Investigators	Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC KIDNEY-DISEASE; CHRONIC HEART-FAILURE; QUALITY-OF-LIFE; SECONDARY HYPERPARATHYROIDISM; PARATHYROID-HORMONE; PERITONEAL-DIALYSIS; RENAL REPLACEMENT; EVENTS EVOLVE; DOUBLE-BLIND; HEMODIALYSIS	BACKGROUND Disorders of mineral metabolism, including secondary hyperparathyroidism, are thought to contribute to extraskeletal (including vascular) calcification among patients with chronic kidney disease. It has been hypothesized that treatment with the calcimimetic agent cinacalcet might reduce the risk of death or nonfatal cardiovascular events in such patients. METHODS In this clinical trial, we randomly assigned 3883 patients with moderate-to-severe secondary hyperparathyroidism (median level of intact parathyroid hormone, 693 pg per milliliter [10th to 90th percentile, 363 to 1694]) who were undergoing hemodialysis to receive either cinacalcet or placebo. All patients were eligible to receive conventional therapy, including phosphate binders, vitamin D sterols, or both. The patients were followed for up to 64 months. The primary composite end point was the time until death, myocardial infarction, hospitalization for unstable angina, heart failure, or a peripheral vascular event. The primary analysis was performed on the basis of the intention-to-treat principle. RESULTS The median duration of study-drug exposure was 21.2 months in the cinacalcet group, versus 17.5 months in the placebo group. The primary composite end point was reached in 938 of 1948 patients (48.2%) in the cinacalcet group and 952 of 1935 patients (49.2%) in the placebo group (relative hazard in the cinacalcet group vs. the placebo group, 0.93; 95% confidence interval, 0.85 to 1.02; P = 0.11). Hypocalcemia and gastrointestinal adverse events were significantly more frequent in patients receiving cinacalcet. CONCLUSIONS In an unadjusted intention-to-treat analysis, cinacalcet did not significantly reduce the risk of death or major cardiovascular events in patients with moderate-to-severe secondary hyperparathyroidism who were undergoing dialysis. (Funded by Amgen; EVOLVE ClinicalTrials.gov number, NCT00345839.)	[Chertow, Glenn M.] Stanford Univ, Sch Med, Palo Alto, CA 93034 USA; [Block, Geoffrey A.] Denver Nephrol, Denver, CO USA; [Correa-Rotter, Ricardo] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico; [Drueeke, Tilman B.] Univ Picardie, Sch Med & Pharm, Amiens, France; [Floege, Juergen] Rhein Westfal TH Aachen Univ Hosp, Aachen, Germany; [Goodman, William G.; Kubo, Yumi; Mix, T. Christian H.; Trotman, Marie-Louise] Amgen Inc, Thousand Oaks, CA USA; [Herzog, Charles A.] Univ Minnesota, Minneapolis, MN USA; [London, Gerard M.] Hop Manhes, Paris, France; [Mahaffey, Kenneth W.] Duke Clin Res Inst, Durham, NC USA; [Moe, Sharon M.] Indiana Univ Sch Med, Roudebush Vet Affairs Med Ctr, Indianapolis, IN USA; [Wheeler, David C.] UCL, London, England; [Parfrey, Patrick S.] Hlth Sci Ctr, St John, NF, Canada	Stanford University; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Picardie Universites; Universite de Picardie Jules Verne (UPJV); RWTH Aachen University; RWTH Aachen University Hospital; Amgen; University of Minnesota System; University of Minnesota Twin Cities; Duke University; Indiana University System; Indiana University Bloomington; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; University of London; University College London; Memorial University Newfoundland; University of Manitoba; Children's Hospital Research Institute of Manitoba	Chertow, GM (corresponding author), Stanford Univ, Sch Med, 780 Welch Rd,Suite 106, Palo Alto, CA 93034 USA.	gchertow@stanford.edu	JORGETTI, VANDA/C-9470-2012; Goldsmith, David J.A./H-8500-2013; Frazão, João/J-9811-2013; Combe, Christian/N-3726-2015; Fassett, Robert G/F-1752-2010; Healy, Helen/G-2686-2010; Cozzolino, Mario/AAB-9965-2022; Cappelli, Gianni/N-8812-2019; Moyses, Rosa M A/F-8268-2012; Block, Geoffrey/AAV-8070-2021; P, Evenepoel/D-9597-2018; DRUEKE, Tilman B./B-4958-2010; Salgado Filho, Natalino/P-2276-2014; Gesualdo, Loreto/K-7751-2016; Rozhinskaya, Liudmila/B-6618-2017	JORGETTI, VANDA/0000-0002-4824-8879; Frazão, João/0000-0002-8081-5474; Combe, Christian/0000-0002-0360-573X; Fassett, Robert G/0000-0002-5318-6940; Healy, Helen/0000-0003-4342-5300; Cozzolino, Mario/0000-0002-8494-6252; Cappelli, Gianni/0000-0003-2304-5001; Moyses, Rosa M A/0000-0002-7902-2127; Block, Geoffrey/0000-0002-4646-7074; P, Evenepoel/0000-0002-2846-2026; DRUEKE, Tilman B./0000-0002-0700-7681; Gesualdo, Loreto/0000-0002-4861-0911; Rizk, Dana/0000-0002-6877-2811; Chertow, Glenn/0000-0002-7599-0534; Galicia Basart, Maria/0000-0002-8125-5974; Hutchison, Alastair/0000-0003-3268-8324; Rozhinskaya, Liudmila/0000-0001-7041-0732; Tomson, Charles/0000-0002-0224-8726; MOYSES NETO, MIGUEL/0000-0003-1351-4775; Brown, Wendy/0000-0002-0137-2688; Capasso, Giovambattista/0000-0003-3469-8614; MacRae, Jennifer/0000-0002-4711-1440; Mount, Peter/0000-0001-7637-3661; Olgaard, Klaus/0000-0002-4063-1283; James, Martin/0000-0001-6065-6018; plumb, Troy/0000-0002-8517-0070; Lok, Charmaine/0000-0001-5365-0064; Shilo, Valeriy/0000-0001-9025-8061	Amgen	Amgen(Amgen)	Supported by Amgen.	Avram MM, 2001, AM J KIDNEY DIS, V38, P1351, DOI 10.1053/ajkd.2001.29254; Baigent C, 2011, LANCET, V377, P2181, DOI 10.1016/S0140-6736(11)60739-3; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633; Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2; Briet M, 2012, CLIN SCI, V123, P399, DOI 10.1042/CS20120074; Chertow GM, 2007, CLIN J AM SOC NEPHRO, V2, P898, DOI 10.2215/CJN.04381206; Chertow GM, 2012, NEPHROL DIAL TRANSPL, V27, P2872, DOI 10.1093/ndt/gfr777; Chiu YW, 2009, CLIN J AM SOC NEPHRO, V4, P1089, DOI 10.2215/CJN.00290109; Cunningham J, 2005, KIDNEY INT, V68, P1793, DOI 10.1111/j.1523-1755.2005.00596.x; Drechsler C, 2009, NEPHROL DIAL TRANSPL, V24, P3151, DOI 10.1093/ndt/gfp260; Eknoyan G, 2002, NEW ENGL J MED, V347, P2010, DOI 10.1056/NEJMoa021583; Fellstrom BC, 2010, NEW ENGL J MED, V362, P1450; Fishbane Steven, 2008, Heart Fail Clin, V4, P401, DOI 10.1016/j.hfc.2008.03.005; Floege J, 2011, NEPHROL DIAL TRANSPL, V26, P1948, DOI 10.1093/ndt/gfq219; Foley RN, 2005, J AM SOC NEPHROL, V16, P489, DOI 10.1681/ASN.2004030203; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Gutierrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130; Himmelfarb J, 2009, SEMIN DIALYSIS, V22, P636, DOI 10.1111/j.1525-139X.2009.00659.x; Jourde-Chiche N, 2011, SEMIN DIALYSIS, V24, P327, DOI 10.1111/j.1525-139X.2011.00925.x; Kalantar-Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514; Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188; Lindberg JS, 2005, J AM SOC NEPHROL, V16, P800, DOI 10.1681/ASN.2004060512; London GM, 2005, CURR OPIN NEPHROL HY, V14, P525, DOI 10.1097/01.mnh.0000168336.67499.c0; Mallamaci F, 2005, KIDNEY INT, V67, P2330, DOI 10.1111/j.1523-1755.2005.00338.x; Melamed ML, 2006, KIDNEY INT, V70, P351, DOI 10.1038/sj.ki.5001542; Mezzano D, 1996, THROMB HAEMOSTASIS, V76, P312; Nakamura H, 2009, ATHEROSCLEROSIS, V206, P512, DOI 10.1016/j.atherosclerosis.2009.03.031; Nusair MB, 2012, CARDIORENAL MED, V2, P117, DOI 10.1159/000337082; O'Connor CM, 2009, JAMA-J AM MED ASSOC, V301, P1439, DOI 10.1001/jama.2009.454; Pfeffer MA, 2003, LANCET, V362, P759, DOI 10.1016/S0140-6736(03)14282-1; Quarles LD, 2003, J AM SOC NEPHROL, V14, P575, DOI 10.1097/01.ASN.0000050224.03126.AD; Raggi P, 2011, NEPHROL DIAL TRANSPL, V26, P1327, DOI 10.1093/ndt/gfq725; Rubinger D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036943; Suzuki T, 2004, BLOOD PURIFICAT, V22, P293, DOI 10.1159/000078700; Tavazzi L, 2008, LANCET, V372, P1223, DOI 10.1016/S0140-6736(08)61239-8; Tonelli M, 2004, CIRCULATION, V110, P1557, DOI 10.1161/01.CIR.0000143892.84582.60; United States Renal Data System, 2011, USRDS 2011 ANN DAT R; Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545	39	616	639	5	111	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 27	2012	367	26					2482	2494		10.1056/NEJMoa1205624	http://dx.doi.org/10.1056/NEJMoa1205624			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	059OG	23121374	Green Published			2023-01-03	WOS:000312714200006
J	Leistner, S; Benik, S; Laumeier, I; Ziegler, A; Nieweler, G; Nolte, CH; Heuschmann, PU; Audebert, HJ				Leistner, Stefanie; Benik, Steffen; Laumeier, Inga; Ziegler, Annerose; Nieweler, Gabriele; Nolte, Christian H.; Heuschmann, Peter U.; Audebert, Heinrich J.			Secondary Prevention after Minor Stroke and TIA - Usual Care and Development of a Support Program	PLOS ONE			English	Article							TRANSIENT ISCHEMIC ATTACK; RANDOMIZED CONTROLLED-TRIAL; CARDIOVASCULAR RISK-FACTORS; BLOOD-PRESSURE; EVENT RATES; CLINICAL-TRIAL; HYPERTENSION; DISEASE; ATHEROTHROMBOSIS; MULTIFACTORIAL	Background: Effective methods of secondary prevention after stroke or TIA are available but adherence to recommended evidence-based treatments is often poor. The study aimed to determine the quality of secondary prevention in usual care and to develop a stepwise modeled support program. Methods: Two consecutive cohorts of patients with acute minor stroke or TIA undergoing usual outpatient care versus a secondary prevention program were compared. Risk factor control and medication adherence were assessed in 6-month follow-ups (6M-FU). Usual care consisted of detailed information concerning vascular risk factor targets given at discharge and regular outpatient care by primary care physicians. The stepwise modeled support program additionally employed up to four outpatient appointments. A combination of educational and behavioral strategies was employed. Results: 168 patients in the observational cohort who stated their openness to participate in a prevention program (mean age 64.7 y, admission blood pressure (BP): 155/84 mmHg) and 173 patients participating in the support program (mean age 67.6 y, BP: 161/84 mmHg) were assessed at 6 months. Proportions of patients with BP according to guidelines were 50% in usual-care and 77% in the support program (p<0.01). LDL<100 mg/dl was measured in 62 versus 71% (p = 0.12). Proportions of patients who stopped smoking were 50 versus 79% (p<0.01). 72 versus 89% of patients with atrial fibrillation were on oral anticoagulation (p = 0.09). Conclusions: Risk factor control remains unsatisfactory in usual care. Targets of secondary prevention were met more often within the supported cohort. Effects on (cerebro-)vascular recurrence rates are going to be assessed in a multicenter randomized trial.	[Leistner, Stefanie; Benik, Steffen; Laumeier, Inga; Ziegler, Annerose; Nieweler, Gabriele; Nolte, Christian H.] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany; [Heuschmann, Peter U.] Univ Wurzburg, Inst Clin Epidemiol & Biometry, Wurzburg, Germany; [Audebert, Heinrich J.] Charite Univ Med Berlin, Ctr Stroke Res, Dept Neurol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Wurzburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Leistner, S (corresponding author), Charite Univ Med Berlin, Dept Neurol, Berlin, Germany.	stefanie.leistner@charite.de	Nolte, Christian/AAA-2651-2022	Nolte, Christian/0000-0001-5577-1775; Audebert, Heinrich J./0000-0002-4785-0366	Lundbeck Pharma; Boehringer Ingelheim Pharma; Takeda Pharma; Sanofi Synthelabo; Bayer Vital; UCB Pharma; European Union; German Stroke Foundation; Stanley Thomas Johnson Foundation	Lundbeck Pharma(Lundbeck Corporation); Boehringer Ingelheim Pharma(Boehringer Ingelheim); Takeda Pharma(Takeda Pharmaceutical Company Ltd); Sanofi Synthelabo; Bayer Vital(Bayer AG); UCB Pharma(UCB Pharma SA); European Union(European Commission); German Stroke Foundation; Stanley Thomas Johnson Foundation	HJA received honoraria payment from Lundbeck Pharma, Boehringer Ingelheim Pharma, Takeda Pharma, Sanofi Synthelabo, Bayer Vital, UCB Pharma; Dr. C. H. Nolte from Boehringer Ingelheim Pharma, Takeda Pharma. PUH received research support from the European Union, the German Stroke Foundation, the Stanley Thomas Johnson Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Alberts MJ, 2009, EUR HEART J, V30, P2318, DOI 10.1093/eurheartj/ehp355; Amarenco P, 2006, NEW ENGL J MED, V355, P549; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; Bayerische Arbeitsgemeinschaft fur Qualitatssicherung in der stationaren Versorgung, 2010, JAHRESAUSWERTUNG MOD; Bhatt DL, 2010, JAMA-J AM MED ASSOC, V304, P1350, DOI 10.1001/jama.2010.1322; Bhatt DL, 2006, JAMA-J AM MED ASSOC, V295, P180, DOI 10.1001/jama.295.2.180; Bushnell CD, 2011, NEUROLOGY, V77, P1182, DOI 10.1212/WNL.0b013e31822f0423; Chimowitz MI, 2005, NEW ENGL J MED, V352, P1305, DOI 10.1056/NEJMoa043033; Dart RA, 2003, CHEST, V123, P244, DOI 10.1378/chest.123.1.244; DiClemente C.C., 2002, MOTIVATIONAL INTERVI, V2nd ed., P201; Diener HCPN, 2008, PRIMAR UND SEKUNDARP; Gaede P, 2003, NEW ENGL J MED, V348, P383, DOI 10.1056/NEJMoa021778; Geschaftsstelle Qualitatssicherung Hessen, 2010, EXTERNE QUALITATSSIC; Green BB, 2008, JAMA-J AM MED ASSOC, V299, P2857, DOI 10.1001/jama.299.24.2857; Halkes PHA, 2006, LANCET, V367, P1665; He FJ, 2006, LANCET, V367, P320, DOI 10.1016/S0140-6736(06)68069-0; Heuschmann PU, 2011, NEUROLOGY, V76, P159, DOI 10.1212/WNL.0b013e318206ca1e; Johnston SC, 2000, JAMA-J AM MED ASSOC, V284, P2901, DOI 10.1001/jama.284.22.2901; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; Mohan KM, 2011, STROKE, V42, P1489, DOI 10.1161/STROKEAHA.110.602615; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Palanco MAM, 2007, MED CLIN-BARCELONA, V129, P241, DOI 10.1157/13108346; Rother J, 2008, CEREBROVASC DIS, V25, P366, DOI 10.1159/000120687; Rothwell PM, 2007, LANCET, V370, P1432, DOI 10.1016/S0140-6736(07)61448-2; Rothwell PM, 2005, LANCET, V366, P29, DOI 10.1016/S0140-6736(05)66702-5; Sacco RL, 1997, NEUROLOGY S4, V49, P39; Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101; Vale MJ, 2003, ARCH INTERN MED, V163, P2775, DOI 10.1001/archinte.163.22.2775; Wolf-Maier K, 2003, JAMA-J AM MED ASSOC, V289, P2363, DOI 10.1001/jama.289.18.2363; Zeymer U, 2008, DTSCH ARZTEBL INT, V105, P769, DOI 10.3238/arztebl.2008.0769	33	21	22	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 17	2012	7	12							e49985	10.1371/journal.pone.0049985	http://dx.doi.org/10.1371/journal.pone.0049985			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	055RZ	23284630	Green Submitted, Green Published, gold			2023-01-03	WOS:000312435900005
J	Tran, BX; Ohinmaa, A; Mills, S; Duong, AT; Nguyen, LT; Jacobs, P; Houston, S				Bach Xuan Tran; Ohinmaa, Arto; Mills, Steve; Anh Thuy Duong; Long Thanh Nguyen; Jacobs, Philip; Houston, Stan			Multilevel Predictors of Concurrent Opioid Use during Methadone Maintenance Treatment among Drug Users with HIV/AIDS	PLOS ONE			English	Article							QUALITY-OF-LIFE; SOCIAL ECOLOGICAL MODEL; COST-EFFECTIVENESS; SUBSTANCE USE; HIV TREATMENT; RETENTION; THERAPY; RISK; COHORT; MANAGEMENT	Background: Ongoing drug use during methadone maintenance treatment (MMT) negatively affects outcomes of HIV/AIDS care and treatment for drug users. This study assessed changes in opioid use, and longitudinal predictors of continued opioid use during MMT among HIV-positive drug users in Vietnam, with the aim of identifying changes that might enhance program efficacy. Methods: We analyze data of 370 HIV-positive drug users (mean age 29.5; 95.7% male) taking MMT at multi-sites. Opioid use was assessed at baseline, 3, 6, and 9 months using interviews and heroin confirmatory urine tests. A social ecological model was applied to explore multilevel predictors of continued opioid use, including individual, interpersonal, community and service influences. Generalized estimating equations (GEE) statistical models were constructed to adjust for intra-individual correlations. Results: Over 9 month follow-up, self-reported opioid use and positive heroin urine test substantially decreased to 14.6% and 14.4%. MMT helped improve referrals and access to health care and social services. However, utilization of social integration services was small. GEE models determined that participants who were older (Adjusted Odd Ratio -AOR = 0.97 for 1 year increase), had economic dependents (AOR = 0.33), or were referred to TB treatment (AOR = 0.53) were less likely to continue opioid use. Significant positive predictors of ongoing opioid use included frequency of opioid use prior to MMT, peer pressure, living with sexual partners, taking antiretroviral treatment, other health concerns and TB treatment. Conclusion: These findings show that MMT in the Vietnamese context can dramatically reduce opioid use, which is known to be associated with reduced antiretroviral (ART) adherence. Disease stage and drug interactions between antiretrovirals or TB drugs and MMT could explain some of the observed predictors of ongoing drug use; these findings could inform changes in MMT program design and implementation.	[Bach Xuan Tran; Ohinmaa, Arto; Houston, Stan] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada; [Bach Xuan Tran] Hanoi Med Univ, Inst Prevent Med & Publ Hlth, Hanoi, Vietnam; [Ohinmaa, Arto; Jacobs, Philip] Inst Hlth Econ, Edmonton, AB, Canada; [Mills, Steve] Family Hlth Int, Hanoi, Vietnam; [Anh Thuy Duong; Long Thanh Nguyen] Minist Hlth, Adm HIV AIDS Control, Hanoi, Vietnam; [Jacobs, Philip; Houston, Stan] Univ Alberta, Fac Med & Dent, Edmonton, AB, Canada	University of Alberta; Hanoi Medical University; University of Alberta	Tran, BX (corresponding author), Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada.	bach@hmu.edu.vn	Duong, Anh/GPW-9558-2022					Tran BX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041062; Tran BX, 2012, AIDS CARE, V24, P1187, DOI 10.1080/09540121.2012.658752; Tran BX, 2012, QUAL LIFE RES, V21, P613, DOI 10.1007/s11136-011-9963-y; Tran BX, 2012, AIDS CARE, V24, P283, DOI 10.1080/09540121.2011.608420; Tran BX, 2011, AIDS CARE, V23, P1236, DOI 10.1080/09540121.2011.555749; Banta-Green CJ, 2009, ADDICTION, V104, P775, DOI 10.1111/j.1360-0443.2009.02538.x; Bao YP, 2009, AM J DRUG ALCOHOL AB, V35, P28, DOI 10.1080/00952990802342899; Bell J, 2009, ADDICTION, V104, P1193, DOI 10.1111/j.1360-0443.2009.02627.x; Bruce RD, 2006, JAIDS-J ACQ IMM DEF, V41, P563, DOI 10.1097/01.qai.0000219769.89679.ec; Connock M, 2007, HEALTH TECHNOL ASSES, V11, P1; Darke S, 1998, DRUG ALCOHOL DEPEN, V51, P253, DOI 10.1016/S0376-8716(98)00028-3; Do TN, 2012, CLIN INFECT DIS, V54, pS306, DOI 10.1093/cid/cir1045; El-Bassel N, 2006, J URBAN HEALTH, V83, P602, DOI 10.1007/s11524-006-9075-0; Fareed A, 2009, J PSYCHIATR PRACT, V15, P227, DOI 10.1097/01.pra.0000351884.83377.e2; Havens JR, 2009, J SUBST ABUSE TREAT, V36, P306, DOI 10.1016/j.jsat.2008.07.002; Larios SE, 2009, AIDS CARE, V21, P1335, DOI 10.1080/09540120902803190; Latkin CA, 2005, AIDS CARE, V17, pS102, DOI 10.1080/09540120500121185; Lawrinson P, 2008, ADDICTION, V103, P1484, DOI 10.1111/j.1360-0443.2008.02249.x; Lin C, 2011, PUBLIC HEALTH, V125, P269, DOI 10.1016/j.puhe.2011.01.009; Liu EW, 2009, INT J DRUG POLICY, V20, P304, DOI 10.1016/j.drugpo.2008.09.004; Ministry of Health, 2012, ANN REP HIV AIDS 201; Naar-King S, 2006, J CONSULT CLIN PSYCH, V74, P785, DOI 10.1037/0022-006X.74.4.785; Nosyk B, 2010, J SUBST ABUSE TREAT, V39, P22, DOI 10.1016/j.jsat.2010.03.008; Palepua A, 2006, DRUG ALCOHOL DEPEN, V84, P188, DOI 10.1016/j.drugalcdep.2006.02.003; Pan W, 2001, BIOMETRICS, V57, P120, DOI 10.1111/j.0006-341X.2001.00120.x; Raffa JD, 2007, DRUG ALCOHOL DEPEN, V89, P306, DOI 10.1016/j.drugalcdep.2007.02.007; Roux P, 2009, CLIN INFECT DIS, V49, P1433, DOI 10.1086/630209; Shah NG, 2006, DRUG ALCOHOL DEPEN, V83, P147, DOI 10.1016/j.drugalcdep.2005.11.007; Soyka M, 2008, INT J NEUROPSYCHOPH, V11, P641, DOI 10.1017/S146114570700836X; Tran BX, 2012, GLOBAL PUBLIC HLTH, P7; Villafranca SW, 2006, DRUG ALCOHOL DEPEN, V83, P218, DOI 10.1016/j.drugalcdep.2005.11.020; Wang PW, 2012, AM J DRUG ALCOHOL AB, V38, P213, DOI 10.3109/00952990.2011.649222; White B, 2007, AIDS CARE, V19, P441, DOI 10.1080/09540120701192837; Wolfe D, 2010, LANCET, V376, P355, DOI 10.1016/S0140-6736(10)60832-X; Wood E, 2008, AIDS, V22, P1247, DOI 10.1097/QAD.0b013e3282fbd1ed	35	28	29	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2012	7	12							e51569	10.1371/journal.pone.0051569	http://dx.doi.org/10.1371/journal.pone.0051569			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	066QV	23251580	Green Submitted, gold, Green Published			2023-01-03	WOS:000313236200137
J	Wang, JB; Zeng, LN; Zang, QC; Gong, QF; Li, BC; Zhang, XR; Chu, XH; Zhang, P; Zhao, YL; Xiao, XH				Wang, Jia-bo; Zeng, Ling-na; Zang, Qing-ce; Gong, Qian-feng; Li, Bao-cai; Zhang, Xue-ru; Chu, Xiao-hui; Zhang, Ping; Zhao, Yan-ling; Xiao, Xiao-he			Colorimetric Grading Scale Can Promote the Standardization of Experiential and Sensory Evaluation in Quality Control of Traditional Chinese Medicines	PLOS ONE			English	Article							RHUBARB EXTRACT; COLOR; RATS; SCIENCE	Experiential and sensory evaluation is an ancient method that remains important in the current quality control system of Traditional Chinese Medicines (TCMs). The process is rapid and convenient when evaluating the quality of crude materials in TCM markets. However, sensory evaluation has been met with skepticism because it is mainly based on experience and lacks a scientific basis. In this study, rhubarb was selected to demonstrate how color-based sensory evaluation could differentiate the quality of herbal medicines objectively. The colors of the rhubarb samples, expressed as RGB values, were obtained from different parts and forms of the plant, including the plant's surface, fracture surface color, and a powdered form with or without treatment with a color-developing reagent. We first divided the rhubarb samples into three grades based on the total content of five hydroxyanthraquinone derivatives, the major pharmacological components in rhubarb. Then, a three-layer back-propagation artificial neural network (BP-ANN), calibrated with selected training samples, was used to correlate the quality of the rhubarb with its color. The color of the rhubarb powder after coloration attained the highest accuracy (92.3%) in predicting the quality grade of the test samples with the established artificial neural networks. Finally, a standardized colorimetric grading scale was created based on the spatial distribution of the rhubarb samples in a two-dimensional chromaticity diagram according to the colors of the powdered rhubarb after color enhancement. By comparing the color between the scale and the tested samples, similar to performing a pH test with indicator paper, subjects without sensory evaluation experience could quickly determine the quality grade of rhubarb. This work illustrates the technical feasibility of the color-based grading of rhubarb quality and offers references for quantifying and standardizing the sensory evaluation of TCMs, foods and other products.	[Xiao, Xiao-he] 302 Mil Hosp, Integrat Med Ctr, Beijing, Peoples R China; [Wang, Jia-bo; Zeng, Ling-na; Zang, Qing-ce; Zhang, Xue-ru; Chu, Xiao-hui; Zhang, Ping; Zhao, Yan-ling] 302 Mil Hosp, China Mil Inst Chinese Med, Beijing, Peoples R China; [Zeng, Ling-na; Li, Bao-cai] Kunming Univ Sci & Technol, Fac Life Sci & Technol, Kunming, Peoples R China; [Zang, Qing-ce; Gong, Qian-feng] Jiangxi Univ Tradit Chinese Med, Coll Pharm, Nanchang, Peoples R China	Fifth Medical Center of Chinese PLA General Hospital; Fifth Medical Center of Chinese PLA General Hospital; Kunming University of Science & Technology; Jiangxi University of Traditional Chinese Medicine	Xiao, XH (corresponding author), 302 Mil Hosp, Integrat Med Ctr, Beijing, Peoples R China.	pharmacy302@126.com	xiao, xiang/GWU-6035-2022; Wang, Jiabo/B-6681-2015		Industry Research Program of Traditional Chinese Medicine [200807020, 201207002]; National Key Technology Research and Development Program [2012BAI29B02]; National Science Foundation of China [81274026, 30973947]	Industry Research Program of Traditional Chinese Medicine; National Key Technology Research and Development Program(National Key Technology R&D Program); National Science Foundation of China(National Natural Science Foundation of China (NSFC))	This research is supported by the Industry Research Program of Traditional Chinese Medicine (Nos. 200807020 and 201207002), the National Key Technology Research and Development Program (No. 2012BAI29B02), and the National Science Foundation of China (Nos. 81274026 and 30973947). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agatonovic-Kustrin S, 2000, J PHARMACEUT BIOMED, V22, P717, DOI 10.1016/S0731-7085(99)00272-1; [Anonymous], 2010, PHARMACOPOEIA PEOPLE, P22; [Anonymous], 2010, Pharmacopoeia of the People's Republic of China, First Div., P22, Patent No. [CN102042978A, 102042978]; Chu XH, 2011, WORLD SCI TECH MODER, V13, P321; Cuellar MJ, 2001, FITOTERAPIA, V72, P221, DOI 10.1016/S0367-326X(00)00305-1; Cunha CR, 2010, FOOD RES INT, V43, P723, DOI 10.1016/j.foodres.2009.11.009; Evin F, 2002, ENERG BUILDINGS, V34, P647, DOI 10.1016/S0378-7788(02)00015-4; Huang YQ, 2007, CRIT REV FOOD SCI, V47, P113, DOI 10.1080/10408390600626453; Li ZL, 2007, ORIGINS MAT MED; Mendoza F, 2006, POSTHARVEST BIOL TEC, V41, P285, DOI 10.1016/j.postharvbio.2006.04.004; Parpinello GP, 2009, FOOD RES INT, V42, P1389, DOI 10.1016/j.foodres.2009.07.005; Parpinello GP, 2006, FOOD RES INT, V39, P47, DOI 10.1016/j.foodres.2005.05.010; Elortondo FJP, 2007, FOOD QUAL PREFER, V18, P425, DOI 10.1016/j.foodqual.2006.05.002; Rossel RAV, 2006, GEODERMA, V133, P320, DOI 10.1016/j.geoderma.2005.07.017; SHAHIDI F, 1986, CRIT REV FOOD SCI, V24, P141, DOI 10.1080/10408398609527435; Wang Jiabo, 2010, Zhongguo Zhong Yao Za Zhi, V35, P2657; Wang JB, 2009, J ETHNOPHARMACOL, V124, P18, DOI 10.1016/j.jep.2009.04.018; World Health Organization, 1999, WHO MONOGRAPHS SELEC, P231; YOKOZAWA T, 1985, CHEM PHARM BULL, V33, P4508; Zhao YL, 2009, BASIC CLIN PHARMACOL, V104, P463, DOI 10.1111/j.1742-7843.2009.00389.x; Zhao ZZ, 2011, J ETHNOPHARMACOL, V134, P556, DOI 10.1016/j.jep.2011.01.018; Zhu SH, 2006, MODERN COMMODITY STU, P113	22	6	12	2	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2012	7	11							e48887	10.1371/journal.pone.0048887	http://dx.doi.org/10.1371/journal.pone.0048887			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	048TK	23145012	Green Submitted, Green Published, gold			2023-01-03	WOS:000311935800163
J	Awad, H; Abas, M; Elgharably, H; Tripathi, R; Theofilos, T; Bhandary, S; Sai-Sudhakar, C; Sen, CK; Roy, S				Awad, Hamdy; Abas, Motaz; Elgharably, Haytham; Tripathi, Ravi; Theofilos, Tykie; Bhandary, Sujatha; Sai-Sudhakar, Chittoor; Sen, Chandan K.; Roy, Sashwati			Endogenous Opioids in Wound-Site Neutrophils of Sternotomy Patients	PLOS ONE			English	Article							MESSENGER-RNA EXPRESSION; BETA-ENDORPHIN; LEUKOSIALIN CD43; PAIN; BLOOD; ACTIVATION; ENKEPHALIN; NB1; GLYCOPROTEIN; INFLAMMATION	Background: Postoperative pain management is a critical aspect of patient care. The inflammatory state of the post-sternotomy surgical wound sensitizes nerve endings, causing pain. Unrelieved or improperly managed pain compromises wound healing. Peripheral opioid receptors play a major role in analgesia, particularly under inflammatory conditions where both opioid receptor expression and efficacy are increased. Leukocytic opioid peptides include beta-endorphin (END), met-enkephalin (ENK), and dynorphin-A (DYN), with END and ENK being predominant. Methodology/Principal Findings: This work represents the first study of inflammatory cells collected from post-sternotomy wounds of patients undergoing cardiac surgery including coronary artery bypass grafting (CABG). Wound fluid (WF) and cells were collected from sternal wounds using a JP Blake drain at 24, 48, and 72 hours post sternum closure. Anti-CD15 staining and flow cytometry revealed that polymorphonuclear neutrophils (PMN) are the predominant cells present in wound fluid collected post-surgery. Compared to peripheral blood (PB) derived PMN, significant increases in CD177+/CD66b+ PMN were observed suggesting activation of wound-site PMN. Such activation was associated with higher levels of opioid peptide expression in PMN derived from WF. Indeed, increased level of opioid peptides in sternal wound environment was noted 72 h post-surgery. We demonstrate that WF contains factors that can significantly induce POMC transcription in human PMNs. IL-10 and IL-4 were abundant in WF and both cytokines significantly induced POMC gene expression suggesting that WF factors such as IL-10 and IL-4 contribute towards increased opioid peptide expression in wound-site PMN. Conclusions/Significance: This approach provided a unique opportunity to study the cross-talk between inflammation and opioid peptides in PMN at a sternotomy wound-site. Wound-site PMN exhibited induction of END and ENK. In addition, sternal wound fluid significantly induced END expression in PMN. Taken together, these data constitute first clinical evidence that human wound-site PMNs are direct contributors of opioids at the sternal wound-site.	[Awad, Hamdy; Abas, Motaz; Elgharably, Haytham; Tripathi, Ravi; Theofilos, Tykie; Bhandary, Sujatha; Sai-Sudhakar, Chittoor; Sen, Chandan K.; Roy, Sashwati] Ohio State Univ, Comprehens Wound Ctr, Columbus, OH 43210 USA; Ohio State Univ, Davis Heart & Lung Res Inst, Dept Surg, Wexner Med Ctr, Columbus, OH 43210 USA; [Awad, Hamdy; Abas, Motaz; Tripathi, Ravi; Theofilos, Tykie; Bhandary, Sujatha] Ohio State Univ, Davis Heart & Lung Res Inst, Dept Anesthesiol, Wexner Med Ctr, Columbus, OH 43210 USA	Ohio State University; Ohio State University; Ohio State University	Roy, S (corresponding author), Ohio State Univ, Comprehens Wound Ctr, Columbus, OH 43210 USA.	sashwati.roy@osumc.edu	Sen, Chandan K/A-8762-2013; Tripathi, Ravi/E-4210-2011; Roy, sashwati/E-3990-2011; Tripathi, Ravi/ABB-2563-2020		NIDDK [R01 DK076566]; NIGMS [GM069589, GM 077185]; NCRR [UL1RR025755]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM077185, R01GM069589] Funding Source: NIH RePORTER	NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Wound healing research in the authors' laboratory is funded by NIDDK R01 DK076566 (SR), NIGMS GM069589 & GM 077185 (CKS) and NCRR UL1RR025755. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; Bayat B, 2010, J IMMUNOL, V184, P3889, DOI 10.4049/jimmunol.0903136; BERKOW RL, 1985, BLOOD, V65, P71; Busch-Dienstfertig M, 2010, BRAIN BEHAV IMMUN, V24, P683, DOI 10.1016/j.bbi.2009.10.013; Buvanendran A, 2009, ANESTH ANALG, V109, P959, DOI 10.1213/ane.0b013e3181ac1746; Drinkwater S L, 2002, Int J Low Extrem Wounds, V1, P184; Ganesh K, 2012, J IMMUNOL; GUILLEMIN R, 1977, SCIENCE, V197, P1367, DOI 10.1126/science.197601; Kamphuis S, 1997, J NEUROIMMUNOL, V79, P91, DOI 10.1016/S0165-5728(97)00113-6; Kapitzke Daniel, 2005, Ther Clin Risk Manag, V1, P279; Kinhult J, 2003, CLIN EXP ALLERGY, V33, P1141, DOI 10.1046/j.1365-2222.2003.01682.x; Kissel K, 2001, EUR J IMMUNOL, V31, P1301, DOI 10.1002/1521-4141(200105)31:5<1301::AID-IMMU1301>3.0.CO;2-J; Kissin I, 2010, ANESTH ANALG, V110, P780, DOI 10.1213/ANE.0b013e3181cde882; KITA T, 1979, EUR J BIOCHEM, V93, P213, DOI 10.1111/j.1432-1033.1979.tb12813.x; LaMendola J, 1997, FEBS LETT, V404, P19, DOI 10.1016/S0014-5793(97)00078-1; Machelska H, 2007, NEUROPEPTIDES, V41, P355, DOI 10.1016/j.npep.2007.06.001; Mambole AS, 2008, J BIOL CHEM, V283, P23627, DOI 10.1074/jbc.M710286200; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Nijhuis J, 2009, OBESITY, V17, P2014, DOI 10.1038/oby.2009.113; Ohta K, 2000, ENDOCR J, V47, P487, DOI 10.1507/endocrj.47.487; RIEU P, 1992, EUR J IMMUNOL, V22, P3021, DOI 10.1002/eji.1830221138; Rittner HL, 2008, BRIT J ANAESTH, V101, P40, DOI 10.1093/bja/aen078; Rittner Heike L, 2007, Curr Rheumatol Rep, V9, P503, DOI 10.1007/s11926-007-0081-3; Rittner HL, 2005, J LEUKOCYTE BIOL, V78, P1215, DOI 10.1189/jlb.0405223; ROSSIER J, 1977, LIFE SCI, V21, P847, DOI 10.1016/0024-3205(77)90414-3; ROSSIER J, 1977, P NATL ACAD SCI USA, V74, P5162, DOI 10.1073/pnas.74.11.5162; SCHAFER M, 1994, P NATL ACAD SCI USA, V91, P4219, DOI 10.1073/pnas.91.10.4219; STEIN C, 1993, LANCET, V342, P321, DOI 10.1016/0140-6736(93)91471-W; STEIN C, 1990, P NATL ACAD SCI USA, V87, P5935, DOI 10.1073/pnas.87.15.5935; STEIN C, 1995, ANN MED, V27, P219, DOI 10.3109/07853899509031962; Stroncek DF, 2007, CURR OPIN HEMATOL, V14, P688, DOI 10.1097/MOH.0b013e3282efed9e; STRONCEK DF, 1990, BLOOD, V75, P744; SZEKANECZ Z, 1995, CLIN IMMUNOL IMMUNOP, V76, P180, DOI 10.1006/clin.1995.1113; Tazzari PL, 2003, VOX SANG, V85, P109, DOI 10.1046/j.1423-0410.2003.00326.x; Tegeder I, 2003, BRAIN, V126, P1092, DOI 10.1093/brain/awg115; White PF, 2003, ANESTHESIOLOGY, V99, P918, DOI 10.1097/00000542-200310000-00026; Wolff JC, 2006, TRANSFUSION, V46, P132, DOI 10.1111/j.1537-2995.2005.00676.x	37	19	20	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2012	7	10							e47569	10.1371/journal.pone.0047569	http://dx.doi.org/10.1371/journal.pone.0047569			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	030WJ	23118879	Green Published, Green Submitted, gold			2023-01-03	WOS:000310600500024
J	Farrell, L				Farrell, Liam			Breaking good news	BRITISH MEDICAL JOURNAL			English	Editorial Material												drfarrell@hotmail.co.uk							0	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	OCT 31	2012	345								e7355	10.1136/bmj.e7355	http://dx.doi.org/10.1136/bmj.e7355			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	033FF	23114076				2023-01-03	WOS:000310778900019
J	Kawahara, T; Miyoshi, Y; Sekiguchi, Z; Sano, F; Hayashi, N; Teranishi, J; Misaki, H; Noguchi, K; Kubota, Y; Uemura, H				Kawahara, Takashi; Miyoshi, Yasuhide; Sekiguchi, Zenkichi; Sano, Futoshi; Hayashi, Narihiko; Teranishi, Jun-ichi; Misaki, Hiroshi; Noguchi, Kazumi; Kubota, Yoshinobu; Uemura, Hiroji			Risk Factors for Metastatic Castration-Resistant Prostate Cancer (CRPC) Predict Long-Term Treatment with Docetaxel	PLOS ONE			English	Article							CELL LUNG-CANCER; PHASE-II; 3-WEEKLY DOCETAXEL; TRIAL; PREDNISONE; MULTICENTER; THERAPY; MODEL; MEN	Purpose: For patients with metastatic castration-resistant prostatic cancer (mCRPC), docetaxel plus prednisone leads to superior survival and a higher response rate compared with mitoxantrone plus prednisone. We analyzed the efficacy of long-term treatment with >= 10 cycles of docetaxel, and validated the risk group classification in predicting overall survival (OS) in Japanese patients with mCRPC. Patients and Methods: Fifty-two patients with mCRPC were administered 55 mg/m(2) docetaxel and 8 mg dexamethasone, every 3 or 4 weeks, simultaneously with hormonal therapy and daily oral dexamethasone. They were divided into two groups, short-term (9 or fewer cycles) and long-term (10 or more cycles). Four risk factors including the presence of anemia, bone metastases, significant pain and visceral metastases were utilized for the risk group classification. Results: Fourteen patients (27%) had an elevation of PSA in spite of docetaxel treatment, while 23 patients (44%) had a decline in PSA level, including 9 patients (17%) whose PSA level declined by >= 50%. The median duration of OS after the initiation of this therapy was 11.2 months in the short-term group and 28.5 months in the long-term group. The good risk group showed a significant difference in OS compared with the intermediate and poor risk groups (P<.001). The median number of cycles of treatment was 14, 4 and 3 for each risk group, respectively (p<.01). Conclusions: The present study indicated that >= 10 cycles of this docetaxel therapy can significantly prolong survival in Japanese men with CRPC. This risk group classification for men with mCRPC at the initiation of this chemotherapy is useful.	[Kawahara, Takashi; Sekiguchi, Zenkichi; Sano, Futoshi; Hayashi, Narihiko; Kubota, Yoshinobu; Uemura, Hiroji] Yokohama City Univ, Dept Urol, Grad Sch Med, Yokohama, Kanagawa 232, Japan; [Miyoshi, Yasuhide; Teranishi, Jun-ichi; Noguchi, Kazumi] Yokohama City Univ, Dept Urol, Med Ctr, Yokohama, Kanagawa 232, Japan; [Misaki, Hiroshi] Yamato City Hosp, Dept Urol, Yamato, Kanagawa, Japan	Yokohama City University; Yokohama City University	Uemura, H (corresponding author), Yokohama City Univ, Dept Urol, Grad Sch Med, Yokohama, Kanagawa 232, Japan.	hu0428@med.yokohama-cu.ac.jp						Armstrong AJ, EUR J CANC, V46, P517; Camps C, 2006, ANN ONCOL, V17, P467, DOI 10.1093/annonc/mdj115; Chevalier-Larsen ES, 2004, J NEUROSCI, V24, P4778, DOI 10.1523/JNEUROSCI.0808-04.2004; Cooperberg MR, 2009, J CLIN ONCOL, V27, P4306, DOI 10.1200/JCO.2008.21.5228; Gervais R, 2005, ANN ONCOL, V16, P90, DOI 10.1093/annonc/mdi018; Gridelli C, 2004, BRIT J CANCER, V91, P1996, DOI 10.1038/sj.bjc.6602241; Halabi S, 2003, J CLIN ONCOL, V21, P1232, DOI 10.1200/JCO.2003.06.100; Huggins C, 1972, CA Cancer J Clin, V22, P232, DOI 10.3322/canjclin.22.4.232; Kamiya N, 2012, INT J UROL; Millikan RE, 1999, SEMIN ONCOL, V26, P185; Miyoshi Yasuhide, 2005, Int J Clin Oncol, V10, P182, DOI 10.1007/s10147-005-0490-0; Naito S, 2008, JPN J CLIN ONCOL, V38, P365, DOI 10.1093/jjco/hyn029; Pond GR, 2012, EUR UROL, V61, P363, DOI 10.1016/j.eururo.2011.06.034; Shimazui T, 2007, JPN J CLIN ONCOL, V37, P603, DOI 10.1093/jjco/hym071; Tabernero J, 2004, ANN ONCOL, V15, P1358, DOI 10.1093/annonc/mdh349; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720	16	21	24	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2012	7	10							e48186	10.1371/journal.pone.0048186	http://dx.doi.org/10.1371/journal.pone.0048186			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	032HJ	23118948	gold, Green Published, Green Submitted			2023-01-03	WOS:000310705600028
J	Thurgood, J; Hooper, S; Siew, M; Wallace, M; Dubsky, S; Kitchen, M; Jamison, RA; Carnibella, R; Fouras, A				Thurgood, Jordan; Hooper, Stuart; Siew, Melissa; Wallace, Megan; Dubsky, Stephen; Kitchen, Marcus; Jamison, R. Aidan; Carnibella, Richard; Fouras, Andreas			Functional Lung Imaging during HFV in Preterm Rabbits	PLOS ONE			English	Article							FREQUENCY OSCILLATORY VENTILATION; ELECTRICAL-IMPEDANCE TOMOGRAPHY; END-EXPIRATORY PRESSURE; TIDAL VOLUME; CONVENTIONAL VENTILATION; GAS-TRANSPORT; INFANTS; INJURY; VELOCIMETRY; STRATEGIES	Although high frequency ventilation (HFV) is an effective mode of ventilation, there is limited information available in regard to lung dynamics during HFV. To improve the knowledge of lung function during HFV we have developed a novel lung imaging and analysis technique. The technique can determine complex lung motion information in vivo with a temporal resolution capable of observing HFV dynamics. Using high-speed synchrotron based phase contrast X-ray imaging and cross-correlation analysis, this method is capable of recording data in more than 60 independent regions across a preterm rabbit lung in excess of 300 frames per second (fps). This technique is utilised to determine regional intra-breath lung mechanics of preterm rabbit pups during HFV. Whilst ventilated at fixed pressures, each animal was ventilated at frequencies of 1, 3, 5 and 10 Hz. A 50% decrease in delivered tidal volume was measured at 10 Hz compared to 1 Hz, yet at the higher frequency a 500% increase in minute activity was measured. Additionally, HFV induced greater homogeneity of lung expansion activity suggesting this ventilation strategy potentially minimizes tissue damage and improves gas mixing. The development of this technique permits greater insight and further research into lung mechanics and may have implications for the improvement of ventilation strategies used to support severe pulmonary trauma and disease.	[Thurgood, Jordan; Dubsky, Stephen; Jamison, R. Aidan; Carnibella, Richard; Fouras, Andreas] Monash Univ, Dept Mech & Aerosp Engn, Melbourne, Vic 3004, Australia; [Hooper, Stuart; Siew, Melissa; Wallace, Megan] Monash Inst Med Res, Ritchie Ctr, Melbourne, Vic, Australia; [Kitchen, Marcus] Monash Univ, Sch Phys, Melbourne, Vic 3004, Australia	Monash University; Monash University; Monash University	Thurgood, J (corresponding author), Monash Univ, Dept Mech & Aerosp Engn, Melbourne, Vic 3004, Australia.	jordan.thurgood@monash.edu	Fouras, Andreas/A-9410-2008; Kitchen, Marcus/A-1355-2008	Fouras, Andreas/0000-0002-8933-1759; Kitchen, Marcus/0000-0002-0029-6660; Hooper, Stuart/0000-0003-1676-4825; Wallace, Megan/0000-0001-5785-5120; Dubsky, Stephen/0000-0001-8355-7362; Siew, Melissa/0000-0003-3014-2379	Australian Research Council [DP110101498]; National Health and Medical Research Council [491103]; Victorian Governments Operational Infrastructure Support Program; Japan Synchrotron Radiation Research Institute; International Synchrotron Access Program (ISAP); Australian Government	Australian Research Council(Australian Research Council); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Victorian Governments Operational Infrastructure Support Program; Japan Synchrotron Radiation Research Institute; International Synchrotron Access Program (ISAP); Australian Government(Australian GovernmentCGIAR)	Research is funded by the Australian Research Council (DP110101498), the National Health and Medical Research Council (491103), Victorian Governments Operational Infrastructure Support Program and supported by beamtime grants from the Japan Synchrotron Radiation Research Institute. We acknowledge travel funding provided by the International Synchrotron Access Program (ISAP) managed by the Australian Synchrotron and funded by the Australian Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Bayat S, 2008, EUR J RADIOL, V68, pS78, DOI 10.1016/j.ejrad.2008.04.043; Biederer J, 2010, J MAGN RESON IMAGING, V32, P1388, DOI 10.1002/jmri.22386; BOHN DJ, 1980, J APPL PHYSIOL, V48, P710, DOI 10.1152/jappl.1980.48.4.710; Brazelton TB, 2001, CRIT CARE MED, V29, P2349, DOI 10.1097/00003246-200112000-00018; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; BUTLER WJ, 1980, ANESTH ANALG, V59, P577; Carney David, 2005, Crit Care Med, V33, pS122, DOI 10.1097/01.CCM.0000155928.95341.BC; CHANG HK, 1984, J APPL PHYSIOL, V56, P553, DOI 10.1152/jappl.1984.56.3.553; Cheney M, 1999, SIAM REV, V41, P85, DOI 10.1137/S0036144598333613; CLARK RH, 1994, J PEDIATR-US, V124, P661, DOI 10.1016/S0022-3476(05)81352-6; Cools F, 2010, LANCET, V375, P2082, DOI 10.1016/S0140-6736(10)60278-4; Dunlop S, 2006, PHYSIOL MEAS, V27, P1151, DOI 10.1088/0967-3334/27/11/008; Easley RB, 2009, RESP PHYSIOL NEUROBI, V165, P54, DOI 10.1016/j.resp.2008.10.010; Fouras A, 2009, J APPL PHYS, V105, DOI 10.1063/1.3115643; Fouras A, 2007, J APPL PHYS, V102, DOI 10.1063/1.2783978; Fouras A, 2008, EXP FLUIDS, V44, P317, DOI 10.1007/s00348-007-0404-1; Fouras A, 2007, EXP FLUIDS, V42, P799, DOI 10.1007/s00348-007-0293-3; Fouras A, 2012, ANN BIOMED ENG, V40, P1160, DOI 10.1007/s10439-011-0493-0; Fouras A, 2009, CLIN EXP PHARMACOL P, V36, P238, DOI 10.1111/j.1440-1681.2008.05102.x; Frerichs I, 2007, PHYSIOL MEAS, V28, pS261, DOI 10.1088/0967-3334/28/7/S19; Habib RH, 2002, AM J RESP CRIT CARE, V166, P950, DOI 10.1164/rccm.200205-398OC; Hager DN, 2007, CRIT CARE MED, V35, P1522, DOI 10.1097/01.CCM.0000266586.04676.55; Hemberg O, 2003, APPL PHYS LETT, V83, P1483, DOI 10.1063/1.1602157; Heraty KB, 2008, ANN BIOMED ENG, V36, P1856, DOI 10.1007/s10439-008-9557-1; Hoffman EA, 2004, ACAD RADIOL, V11, P1370, DOI 10.1016/j.acra.2004.09.005; Hooper SB, 2007, FASEB J, V21, P3329, DOI 10.1096/fj.07-8208com; Imai Y, 2001, J APPL PHYSIOL, V91, P1836, DOI 10.1152/jappl.2001.91.4.1836; Jamison RA, 2011, ANN BIOMED ENG, V39, P1643, DOI 10.1007/s10439-011-0260-2; Kitchen MJ, 2008, PHYS MED BIOL, V53, P6065, DOI 10.1088/0031-9155/53/21/012; Kitchen MJ, 2010, J INSTRUM, V5, DOI 10.1088/1748-0221/5/02/T02002; Krishnan JA, 2000, CHEST, V118, P795, DOI 10.1378/chest.118.3.795; Lee SJ, 2003, J APPL PHYS, V94, P3620, DOI 10.1063/1.1599981; Lewis RA, 2005, PHYS MED BIOL, V50, P5031, DOI 10.1088/0031-9155/50/21/006; Luecke Thomas, 2005, Crit Care Med, V33, pS155, DOI 10.1097/01.CCM.0000155916.47455.DF; Mulreany DG, 2009, ACAD RADIOL, V16, P718, DOI 10.1016/j.acra.2008.12.003; Pellicano A, 2009, INTENS CARE MED, V35, P1990, DOI 10.1007/s00134-009-1628-8; Pillow J Jane, 2005, Crit Care Med, V33, pS135; Pillow JJ, 1999, J APPL PHYSIOL, V87, P407, DOI 10.1152/jappl.1999.87.1.407; Rimensberger PC, 1999, CRIT CARE MED, V27, P1940, DOI 10.1097/00003246-199909000-00037; Rimensberger PC, 2000, PEDIATRICS, V105, P1202, DOI 10.1542/peds.105.6.1202; Scalfaro P, 2001, CRIT CARE MED, V29, P1925, DOI 10.1097/00003246-200110000-00013; Seah AS, 2011, ANN BIOMED ENG, V39, P1505, DOI 10.1007/s10439-010-0237-6; SHABTAI Y, 1989, J APPL PHYSIOL, V66, P1127, DOI 10.1152/jappl.1989.66.3.1127; Siew ML, 2009, J APPL PHYSIOL, V106, P1487, DOI 10.1152/japplphysiol.91591.2008; SLUTSKY AS, 1981, J CLIN INVEST, V68, P1475, DOI 10.1172/JCI110400; Slutsky AS, 2002, NEW ENGL J MED, V347, P630, DOI 10.1056/NEJMp020082; SLUTSKY AS, 1980, SCIENCE, V209, P609, DOI 10.1126/science.6771872; SMITH BE, 1990, BRIT J ANAESTH, V65, P130, DOI 10.1093/bja/65.1.130; Sud S, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2327; Terekhov M, 2010, J MAGN RESON IMAGING, V32, P887, DOI 10.1002/jmri.22318; Thome U, 1998, J APPL PHYSIOL, V84, P1520, DOI 10.1152/jappl.1998.84.5.1520; Tustison NJ, 2011, ACAD RADIOL, V18, P402, DOI 10.1016/j.acra.2010.10.019; van Beek EJR, 2008, CLIN CHEST MED, V29, P195, DOI 10.1016/j.ccm.2007.12.003; van Genderingen HR, 2004, CRIT CARE MED, V32, P787, DOI 10.1097/01.CCM.0000114823.16604.19; van Kaam AH, 2007, CRIT CARE MED, V35, P925, DOI 10.1097/01.CCM.0000256724.70601.3A; Weber K, 2000, J APPL PHYSIOL, V89, P364, DOI 10.1152/jappl.2000.89.1.364; Wolf GK, 2010, PHYSIOL MEAS, V31, pS85, DOI 10.1088/0967-3334/31/8/S07; Wolf U, 2010, MAGN RESON MED, V64, P1479, DOI 10.1002/mrm.22528; Wood B, 2002, CRIT CARE MED, V30, P1523, DOI 10.1097/00003246-200207000-00021; Wunsch H, 2005, ANESTH ANALG, V100, P1765, DOI 10.1213/01.ANE.0000145070.52315.F2	61	7	7	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2012	7	10							e48122	10.1371/journal.pone.0048122	http://dx.doi.org/10.1371/journal.pone.0048122			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	032HJ	23118938	Green Published, gold, Green Submitted			2023-01-03	WOS:000310705600026
J	O'Driscoll, R				O'Driscoll, Ronan			Emergency oxygen use	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; ARTERIAL HYPEROXIA; MORTALITY; RESUSCITATION; ASSOCIATION; THERAPY; DISEASE	This is one of a series of occasional articles on therapeutics for common or serious conditions, covering new drugs and old drugs with important new indications or concerns. The series advisers are Robin Ferner, honorary professor of clinical pharmacology, University of Birmingham and Birmingham City Hospital, and Albert Ferro, professor of cardiovascular clinical pharmacology, King's College London. To suggest a topic for this series, please email us at practice@bmj.com.	Univ Manchester, Salford Royal Univ Hosp, Manchester Acad Hlth Sci Ctr, Salford, Lancs, England	Salford Royal NHS Foundation Trust; Salford Royal Hospital; University of Manchester	O'Driscoll, R (corresponding author), Univ Manchester, Salford Royal Univ Hosp, Manchester Acad Hlth Sci Ctr, Salford, Lancs, England.	ronan.o'driscoll@srft.nhs.uk						Austin MA, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5462; Bellomo R, 2011, CRIT CARE, V15, DOI 10.1186/cc10090; de Jonge E, 2008, CRIT CARE, V12, DOI 10.1186/cc7150; Downs John B, 2003, Respir Care, V48, P611; Eastwood G, 2012, INTENS CARE MED, V38, P91, DOI 10.1007/s00134-011-2419-6; Grocott MPW, 2009, NEW ENGL J MED, V360, P140, DOI 10.1056/NEJMoa0801581; Hale KE, 2008, EMERG MED J, V25, P773, DOI 10.1136/emj.2008.059287; HOFFMAN CE, 1946, AM J PHYSIOL, V145, P685, DOI 10.1152/ajplegacy.1946.145.5.685; Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707; Murphy R, 2001, EMERG MED J, V18, P333, DOI 10.1136/emj.18.5.333; National Patient Safety Agency, 2009, 2009RRR2006 NPAS NPS; O'Driscoll BR, 2008, THORAX, V63, DOI 10.1136/thx.2008.102947; O'Driscoll BR, 2011, THORAX, V66, P734, DOI 10.1136/thoraxjnl-2011-200078; O'Driscoll BR, 2012, CLIN MED, V12, P79, DOI 10.7861/clinmedicine.12-1-79; O'Driscoll BR, 2008, EMERGENCY OXYGEN USE; Pedersen T, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002013.pub2; Perrin K, 2011, THORAX, V66, P937, DOI 10.1136/thx.2010.155259; Roberts CM, 2011, THORAX, V66, P43, DOI 10.1136/thx.2010.153114; Smith J L, 1899, J Physiol, V24, P19; Wijesinghe M, 2012, J ROY SOC MED, V105, P208, DOI 10.1258/jrsm.2012.110084; Wijesinghe M, 2011, CHEST, V139, P1018, DOI 10.1378/chest.10-1280	21	8	8	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 18	2012	345								e6856	10.1136/bmj.e6856	http://dx.doi.org/10.1136/bmj.e6856			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	024WU	23078806				2023-01-03	WOS:000310142300009
J	Bostwick, JM				Bostwick, J. Michael			Recommend the Medicinal Use of Marijuana	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Mayo Clin, Dept Psychiat & Psychol, Rochester, MN 55905 USA	Mayo Clinic	Bostwick, JM (corresponding author), Mayo Clin, Dept Psychiat & Psychol, Rochester, MN 55905 USA.			DuPont, Robert/0000-0002-3345-0759					0	25	25	0	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 28	2013	368	9					866	867						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	096ET	23425133				2023-01-03	WOS:000315387700015
J	Ferguson, ND; Cook, DJ; Guyatt, GH; Mehta, S; Hand, L; Austin, P; Zhou, Q; Matte, A; Walter, SD; Lamontagne, F; Granton, JT; Arabi, YM; Arroliga, AC; Stewart, TE; Slutsky, AS; Meade, MO				Ferguson, Niall D.; Cook, Deborah J.; Guyatt, Gordon H.; Mehta, Sangeeta; Hand, Lori; Austin, Peggy; Zhou, Qi; Matte, Andrea; Walter, Stephen D.; Lamontagne, Francois; Granton, John T.; Arabi, Yaseen M.; Arroliga, Alejandro C.; Stewart, Thomas E.; Slutsky, Arthur S.; Meade, Maureen O.		OSCILLATE Trial Investigators; Canadian Critical Care Trials Grp	High-Frequency Oscillation in Early Acute Respiratory Distress Syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE LUNG INJURY; END-EXPIRATORY PRESSURE; CONVENTIONAL MECHANICAL VENTILATION; RECRUITMENT MANEUVERS; ADULTS; STRATEGY	Background Previous trials suggesting that high-frequency oscillatory ventilation (HFOV) reduced mortality among adults with the acute respiratory distress syndrome (ARDS) were limited by the use of outdated comparator ventilation strategies and small sample sizes. Methods In a multicenter, randomized, controlled trial conducted at 39 intensive care units in five countries, we randomly assigned adults with new-onset, moderate-to-severe ARDS to HFOV targeting lung recruitment or to a control ventilation strategy targeting lung recruitment with the use of low tidal volumes and high positive end-expiratory pressure. The primary outcome was the rate of in-hospital death from any cause. Results On the recommendation of the data monitoring committee, we stopped the trial after 548 of a planned 1200 patients had undergone randomization. The two study groups were well matched at baseline. The HFOV group underwent HFOV for a median of 3 days (interquartile range, 2 to 8); in addition, 34 of 273 patients (12%) in the control group received HFOV for refractory hypoxemia. In-hospital mortality was 47% in the HFOV group, as compared with 35% in the control group (relative risk of death with HFOV, 1.33; 95% confidence interval, 1.09 to 1.64; P = 0.005). This finding was independent of baseline abnormalities in oxygenation or respiratory compliance. Patients in the HFOV group received higher doses of midazolam than did patients in the control group (199 mg per day [interquartile range, 100 to 382] vs. 141 mg per day [interquartile range, 68 to 240], P<0.001), and more patients in the HFOV group than in the control group received neuromuscular blockers (83% vs. 68%, P<0.001). In addition, more patients in the HFOV group received vasoactive drugs (91% vs. 84%, P = 0.01) and received them for a longer period than did patients in the control group (5 days vs. 3 days, P = 0.01). Conclusions In adults with moderate-to-severe ARDS, early application of HFOV, as compared with a ventilation strategy of low tidal volume and high positive end-expiratory pressure, does not reduce, and may increase, in-hospital mortality. (Funded by the Canadian Institutes of Health Research; Current Controlled Trials numbers, ISRCTN42992782 and ISRCTN87124254, and ClinicalTrials.gov numbers, NCT00474656 and NCT01506401.)	[Ferguson, Niall D.; Mehta, Sangeeta; Granton, John T.; Stewart, Thomas E.; Slutsky, Arthur S.] Univ Toronto, Univ Hlth Network, Interdept Div Crit Care Med, Toronto, ON, Canada; [Ferguson, Niall D.; Slutsky, Arthur S.] Univ Toronto, Univ Hlth Network, Dept Med, Toronto, ON, Canada; [Ferguson, Niall D.] Univ Toronto, Univ Hlth Network, Dept Physiol, Toronto, ON, Canada; [Mehta, Sangeeta; Granton, John T.; Stewart, Thomas E.] Univ Toronto, Univ Hlth Network, Dept Med, Div Respirol, Toronto, ON, Canada; [Slutsky, Arthur S.] Univ Toronto, Univ Hlth Network, Dept Surg, Toronto, ON, Canada; [Slutsky, Arthur S.] Univ Toronto, Univ Hlth Network, Dept Biomed Engn, Toronto, ON, Canada; [Ferguson, Niall D.; Mehta, Sangeeta; Granton, John T.; Stewart, Thomas E.] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; [Slutsky, Arthur S.] St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Matte, Andrea] Univ Hlth Network, Crit Care Program, Toronto, ON, Canada; [Cook, Deborah J.; Meade, Maureen O.] McMaster Univ, Interdept Div Crit Care, Hamilton, ON, Canada; [Cook, Deborah J.; Guyatt, Gordon H.; Walter, Stephen D.; Meade, Maureen O.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Cook, Deborah J.; Guyatt, Gordon H.; Walter, Stephen D.; Meade, Maureen O.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Cook, Deborah J.; Guyatt, Gordon H.; Hand, Lori; Austin, Peggy; Zhou, Qi; Walter, Stephen D.; Meade, Maureen O.] McMaster Univ, CLAR Res Ctr, Hamilton, ON, Canada; [Lamontagne, Francois] Univ Sherbrooke, Ctr Rech Clin Etienne Le Bel, Sherbrooke, PQ J1K 2R1, Canada; [Arabi, Yaseen M.] King Saud bin Abdulaziz Univ Hlth Sci, Dept Intens Care, Riyadh, Saudi Arabia; [Arroliga, Alejandro C.] Scott & White Mem Hosp & Clin, Dept Med, Temple, TX 76508 USA; [Arroliga, Alejandro C.] Texas A&M Hlth Sci Ctr, Coll Med, Temple, TX USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; McMaster University; McMaster University; McMaster University; McMaster University; University of Sherbrooke; King Saud Bin Abdulaziz University for Health Sciences; Scott & White Medical Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Meade, MO (corresponding author), 1280 Main St W, Hamilton, ON L8N 3Z5, Canada.	meadema@hhsc.ca	Mehta, Sangeeta/C-4623-2015; Skrobik, Yoanna/K-8165-2014; Danesh, Valerie/AAZ-3014-2021; Zhou, Qi/GSM-9583-2022; Bosma, Karen/G-3281-2011; Ferguson, Niall/D-7619-2019; Arroliga, Alejandro/AAX-3933-2021; Slutsky, Arthur/M-3325-2019; Arabi, Yaseen/ABF-3316-2020; Walter, Stephen/AAB-5548-2022	Skrobik, Yoanna/0000-0002-5315-6020; Danesh, Valerie/0000-0002-2078-2578; Ferguson, Niall/0000-0002-6213-5264; Arabi, Yaseen/0000-0001-5735-6241; Walter, Stephen/0000-0003-4157-8928; Henzler, Dietrich/0000-0001-5511-6885; Friedrich, Jan/0000-0001-7248-2350; Lamontagne, Francois/0000-0002-0360-3427	Canadian Institutes of Health Research; Randomized Controlled Trial (RCT) Program (Ottawa); King Abdullah International Medical Research Center (Riyadh, Saudi Arabia); Canada Research Chair; Fonds de Recherche de Quebec-Sante Research Career Award; Physicians Services Incorporated Foundation; Ikaria; Actelion; Eli Lilly; Pfizer; GlaxoSmithKline; Bayer; Maquet Medical; Novalung; Gambro; Hemodec	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Randomized Controlled Trial (RCT) Program (Ottawa); King Abdullah International Medical Research Center (Riyadh, Saudi Arabia); Canada Research Chair(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs); Fonds de Recherche de Quebec-Sante Research Career Award; Physicians Services Incorporated Foundation; Ikaria; Actelion; Eli Lilly(Eli Lilly); Pfizer(Pfizer); GlaxoSmithKline(GlaxoSmithKline); Bayer(Bayer AG); Maquet Medical; Novalung; Gambro; Hemodec	Funded by the Canadian Institutes of Health Research; Supported by the Canadian Institutes of Health Research, Randomized Controlled Trial (RCT) Program (Ottawa) and the King Abdullah International Medical Research Center (Riyadh, Saudi Arabia). Dr. Ferguson is supported by a Canadian Institutes of Health Research New Investigator Award; Dr. Cook holds a Canada Research Chair; Dr. Lamontagne is supported by a Fonds de Recherche de Quebec-Sante Research Career Award; and Drs. Ferguson and Meade and Drs. Lamontagne and Meade were supported by Canadian Institutes of Health Research RCT Mentorship awards.; Dr. Ferguson reports receiving grant support through his institution from the Physicians Services Incorporated Foundation; Dr. Granton, receiving consulting fees from Ikaria, lecture fees from Actelion and Eli Lilly, grant support through his institution from Pfizer, Actelion, Eli Lilly, GlaxoSmithKline, and Bayer, payment through his institution from Telus for the sale of a software site license, and support from Actelion for his hospital foundation for pulmonary hypertension research and providing expert testimony for Pfizer regarding patent legal action; and Dr. Slutsky, receiving consulting fees from Maquet Medical, Novalung, Gambro, Ikaria, and Hemodec. No other potential conflict of interest relevant to this article was reported.	Adhikari NKJ, 2011, CRIT CARE MED, V39, P2631, DOI 10.1097/CCM.0b013e318226675e; Bollen CW, 2005, CRIT CARE, V9, pR430, DOI 10.1186/cc3737; Briel M, 2010, JAMA-J AM MED ASSOC, V303, P865, DOI 10.1001/jama.2010.218; Brower RG, 2004, NEW ENGL J MED, V351, P327; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; BRYAN AC, 1991, PEDIATRICS, V87, P565; Derdak S, 2002, AM J RESP CRIT CARE, V166, P801, DOI 10.1164/rccm.2108052; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Ferguson ND, 2005, CRIT CARE MED, V33, P479, DOI 10.1097/01.CCM.0000155785.23200.9E; Ferguson ND, 2008, J APPL PHYSIOL, V104, P1230, DOI 10.1152/japplphysiol.01226.2007; Fessler HE, 2008, CRIT CARE MED, V36, P1043, DOI 10.1097/01.CCM.0b013e318168fcab; Fessler HE, 2007, CRIT CARE MED, V35, P1649, DOI 10.1097/01.CCM.0000269026.40739.2E; Fort P, 1997, CRIT CARE MED, V25, P937, DOI 10.1097/00003246-199706000-00008; Froese AB, 1997, CRIT CARE MED, V25, P906, DOI 10.1097/00003246-199706000-00004; Gattinoni L, 2006, NEW ENGL J MED, V354, P1775, DOI 10.1056/NEJMoa052052; Guervilly C, 2012, CRIT CARE MED, V40, P1539, DOI 10.1097/CCM.0b013e3182451b4a; Hager DN, 2007, CRIT CARE MED, V35, P1522, DOI 10.1097/01.CCM.0000266586.04676.55; Hatcher D, 1998, CRIT CARE MED, V26, P1081, DOI 10.1097/00003246-199806000-00032; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; HIFI Study Group, 1989, N Engl J Med, V320, P88; Imai Y, 2001, J APPL PHYSIOL, V91, P1836, DOI 10.1152/jappl.2001.91.4.1836; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637; Mehta S, 2004, CHEST, V126, P518, DOI 10.1378/chest.126.2.518; Mentzelopoulos SD, 2010, INTENS CARE MED, V36, P810, DOI 10.1007/s00134-010-1822-8; Mercat A, 2008, JAMA-J AM MED ASSOC, V299, P646, DOI 10.1001/jama.299.6.646; Montori VM, 2005, JAMA-J AM MED ASSOC, V294, P2203, DOI 10.1001/jama.294.17.2203; Muellenbach RM, 2007, INTENS CARE MED, V33, P1423, DOI 10.1007/s00134-007-0708-x; Phua J, 2009, AM J RESP CRIT CARE, V179, P220, DOI 10.1164/rccm.200805-722OC; Pillow JJ, 1999, J APPL PHYSIOL, V87, P407, DOI 10.1152/jappl.1999.87.1.407; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Rimensberger PC, 2000, INTENS CARE MED, V26, P745, DOI 10.1007/s001340051242; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Sedeek KA, 2003, ANESTHESIOLOGY, V99, P1102, DOI 10.1097/00000542-200311000-00016; Sud S, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2327; Terragni PP, 2007, AM J RESP CRIT CARE, V175, P160, DOI 10.1164/rccm.200607-915OC; Terragni PP, 2009, ANESTHESIOLOGY, V111, P826, DOI 10.1097/ALN.0b013e3181b764d2; Tremblay LN, 2006, INTENS CARE MED, V32, P24, DOI 10.1007/s00134-005-2817-8; Young D, 2013, NEW ENGL J MED, V368, P806, DOI 10.1056/NEJMoa1215716	39	528	574	0	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 28	2013	368	9					795	805		10.1056/NEJMoa1215554	http://dx.doi.org/10.1056/NEJMoa1215554			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	096ET	23339639				2023-01-03	WOS:000315387700005
J	Hogerzeil, HV; Liberman, J; Wirtz, VJ; Kishore, SP; Selvaraj, S; Kiddell-Monroe, R; Mwangi-Powell, FN; von Schoen-Angerer, T				Hogerzeil, Hans V.; Liberman, Jonathan; Wirtz, Veronika J.; Kishore, Sandeep P.; Selvaraj, Sakthi; Kiddell-Monroe, Rachel; Mwangi-Powell, Faith N.; von Schoen-Angerer, Tido		Lancet NCD Action Grp	Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration	LANCET			English	Article							MIDDLE-INCOME COUNTRIES; SUB-SAHARAN AFRICA; ANTIRETROVIRAL THERAPY; CARDIOVASCULAR-DISEASE; PREVENTION; DRUGS; CHALLENGES; ADHERENCE; SETTINGS; COSTS	Access to medicines and vaccines to prevent and treat non-communicable diseases (NCDs) is unacceptably low worldwide. In the 2011 UN political declaration on the prevention and control of NCDs, heads of government made several commitments related to access to essential medicines, technologies, and vaccines for such diseases. 30 years of experience with policies for essential medicines and 10 years of scaling up of HIV treatment have provided the knowledge needed to address barriers to long-term effective treatment and prevention of NCDs. More medicines can be acquired within existing budgets with efficient selection, procurement, and use of generic medicines. Furthermore, low-income and middle-income countries need to increase mobilisation of domestic resources to cater for the many patients with NCDs who do not have access to treatment. Existing initiatives for HIV treatment off er useful lessons that can enhance access to pharmaceutical management of NCDs and improve adherence to long-term treatment of chronic illness; policy makers should also address unacceptable inequities in access to controlled opioid analgesics. In addition to off-patent medicines, governments can promote access to new and future on-patent medicinal products through coherent and equitable health and trade policies, particularly those for intellectual property. Frequent conflicts of interest need to be identified and managed, and indicators and targets for access to NCD medicines should be used to monitor progress. Only with these approaches can a difference be made to the lives of hundreds of millions of current and future patients with NCDs.	[Hogerzeil, Hans V.] Univ Groningen, Univ Med Ctr Groningen, Dept Global Hlth, NL-9713 AV Groningen, Netherlands; [Liberman, Jonathan] Canc Council Victoria, McCabe Ctr Law & Canc, Melbourne, Vic, Australia; [Liberman, Jonathan] Union Int Canc Control, Melbourne, Vic, Australia; [Wirtz, Veronika J.] Natl Inst Publ Hlth, Ctr Hlth Syst Res, Cuernavaca, Morelos, Mexico; [Kishore, Sandeep P.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Cambridge, MA 02138 USA; [Kishore, Sandeep P.] Young Profess Chron Dis Network, New York, NY USA; [Selvaraj, Sakthi] Publ Hlth Fdn India, New Delhi, India; [Kiddell-Monroe, Rachel] Univ Allied Essential Med, Montreal, PQ, Canada; [Mwangi-Powell, Faith N.] African Palliat Care Assoc, Kampala, Uganda; [Mwangi-Powell, Faith N.] Open Soc Fdn, New York, NY USA; [von Schoen-Angerer, Tido] Med Sans Frontieres, Geneva, Switzerland	University of Groningen; Cancer Council Victoria; Instituto Nacional de Salud Publica; Harvard University; Public Health Foundation of India; Doctors Without Borders	Hogerzeil, HV (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Global Hlth, NL-9713 AV Groningen, Netherlands.	h.v.hogerzeil@umcg.nl	Selvaraj, Sakthivel/ABD-5873-2021; Selvaraj, Sakthivel/ABE-6897-2020; Wirtz, Veornika/AAG-9712-2019	Selvaraj, Sakthivel/0000-0001-5940-1958; von Schoen-Angerer, Tido/0000-0003-3601-7480; Wirtz, Veronika J./0000-0002-0863-8768				Abdraimova A, 2009, REPORT RAPID ASSESSM; Alleyne G, 2013, LANCET; [Anonymous], 2001, MACR HLTH INV HLTH E; [Anonymous], 2008, HLTH POLICY B EUROPE; Atun R, 2013, LANCET; Barrington J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-298; Berne Declaration HAI IBFAN IFMSA KEI MSF TWN UAEM, 2011, NGO LETT CONFL INT F; Beyer P, 2016, OPTIONS GLOBAL DEV S; Bigdeli M, 2012, HLTH POLICY PLAN; Cameron A, 2009, LANCET, V373, P240, DOI 10.1016/S0140-6736(08)61762-6; Cameron A., 2011, WORLD MED SITUATION; Cameron Alexandra, 2010, 35 WHO; Caudron JM, 2008, TROP MED INT HEALTH, V13, P1062, DOI 10.1111/j.1365-3156.2008.02106.x; Chaudhuri S, 2011, MULTINATIONALS MONOP; Colombo C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034974; Di Cesare M, 2013, LANCET; Downing NS, 2012, ARCH INTERN MED, V172, P724, DOI 10.1001/archinternmed.2012.187; Ferraz Octavio Luiz Motta, 2009, Health Hum Rights, V11, P33; Ford N, 2011, GLOBALIZATION HEALTH, V7, DOI 10.1186/1744-8603-7-33; Ford N, 2009, LANCET, V374, P2064, DOI 10.1016/S0140-6736(09)61671-8; Frenk J, 2012, LANCET, V380, P862, DOI 10.1016/S0140-6736(12)61341-5; Frost LS, 2008, DO GOOD HLTH TECHNOL; Gale EAM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3974; Gilks CF, 2006, LANCET, V368, P505, DOI 10.1016/S0140-6736(06)69158-7; Goroff M, 2010, HEALTH AFFAIR, V29, P2206, DOI 10.1377/hlthaff.2009.0896; Hardon AP, 2007, AIDS CARE, V19, P658, DOI 10.1080/09540120701244943; Health Action International and World Health Organization, 2008, MED PRIC AV AFF PRIC; Heath I, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4239; Hogerzeil HV, 2006, LANCET, V368, P305, DOI 10.1016/S0140-6736(06)69076-4; Hogerzeil HV, 2006, B WORLD HEALTH ORGAN, V84, P371, DOI 10.2471/BLT.06.031153; Intellectual Property Watch, 2012, DRUG SAF NEEDS GLOB; International Narcotics Control Board, 2010, REP INT NARC CONTR B; Kishore SP, 2011, J AM COLL CARDIOL, V57, P1980, DOI 10.1016/j.jacc.2010.12.029; Laing RO, 2001, HEALTH POLICY PLANN, V16, P13, DOI 10.1093/heapol/16.1.13; Liberman J, 2011, PUBLIC HEALTH, V125, P840, DOI 10.1016/j.puhe.2011.09.032; Lim SS, 2007, LANCET, V370, P2054, DOI 10.1016/S0140-6736(07)61699-7; Lonn E, 2010, CIRCULATION, V122, P2078, DOI 10.1161/CIRCULATIONAHA.109.873232; Lu Y, 2011, WORLD MED SITUATION; Marquez PV, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5812; Maxmen A, 2012, NATURE, V489, P16, DOI 10.1038/489016a; MDG Gap Task Force, 2011, GLOB PARTN DEV TIM D; MDG Gap Task Force, 2010, GLOB PARTN DEV CRIT; MDG Gap Task Force, 2009, STRENGTH GLOB PARTN; MDG Gap Task Force, 2008, MILL DEV GOAL 8 DEL; Mills EJ, 2012, LANCET INFECT DIS, V12, P97, DOI 10.1016/S1473-3099(11)70354-1; Moodie R, 2013, LANCET; Moon S, 2011, GLOBALIZATION HEALTH, V7, DOI 10.1186/1744-8603-7-39; O'Brien M, LANCET ONCO IN PRESS; Office of the UN High Commissioner for Human Rights, 1966, INT COV EC SOC CULT; Office of the United Nations High Commissioner for Human Rights, 1989, CONV RIGHTS CHILD; Outterson K, 2008, AM J LAW MED, V34, P279, DOI 10.1177/009885880803400208; Panchagnula R, 2004, METHOD FIND EXP CLIN, V26, P703, DOI 10.1358/mf.2004.26.9.872568; Perehudoff SK, 2010, B WORLD HEALTH ORGAN, V88, P800, DOI 10.2471/BLT.10.078733; Prime Minister, 2012, DECISION NO 418QD TT; Quick JD, 2011, WHAT AIDS DEC TEACH; Reddy KS, 2011, LANCET, V377, P760, DOI 10.1016/S0140-6736(10)61960-5; Roderick P, 2012, LANCET, V380, pE2, DOI 10.1016/S0140-6736(12)61513-X; Sanne I, 2010, LANCET, V376, P33, DOI 10.1016/S0140-6736(10)60894-X; Smith RD, 2009, LANCET, V373, P684, DOI 10.1016/S0140-6736(08)61779-1; Stop Stock-Outs, 2012, ENS ACC ESS MED ALL; Szabo L, 2006, PRICES SOAR CANC DRU; Twagirumukiza M, 2010, TROP MED INT HEALTH, V15, P350, DOI 10.1111/j.1365-3156.2009.02453.x; Twagirumukiza M, 2009, AM J TROP MED HYG, V81, P776, DOI 10.4269/ajtmh.2009.09-0109; UN, 2009, REP SPEC RAPP RIGHT; UN Committee on Economic, 2000, GEN COMM 14 RIGHT HI; UN General Assembly, 2010, 64265 UN GEN ASS; United Nations Office of Drugs and Crime. Commission on Narcotic Drugs, 2011, ENS AV CONTR MED REL; United States Agency for International Development, 2009, SURV QUAL SEL ANT ME; Wagner AK, 2011, HEALTH POLICY, V100, P151, DOI 10.1016/j.healthpol.2010.08.004; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; Waning B, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-35; WHO, 2010, WOR HEALT REP, P1; WHO, CONST WORLD HLTH ORG; WHO, 2011, REP EXP COMM SELUS E; WHO, 2007, MOD QUAL ASS SYST PR; WHO, 2010, ASS MED REG AG SUBS; WHO, 2012, RES DEV MEET HLTH NE; WHO, 2009, CONSTR SCAL HLTH REL; WHO Expert Committee on Specifi cations for Pharmaceutical Preparations, 2005, 39 WHO EXP COMM; World Health Organization, 2011, SCAL NONC DIS MUCH W; World Health Organization, 2011, PRIOR RES AG PREV CO; World Health Organization, 2011, ENS BAL NAT POL CONT; World Health Organization, 2012, CONT IS IS MON INC L; World Health Organization, 2008, MED TERM STRAT PLAN; World Health Organization, 2007, EVERYBODYS BUSINESS; Yusuf S, 2011, LANCET, V378, P1231, DOI 10.1016/S0140-6736(11)61215-4	86	120	125	2	56	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 23	2013	381	9867					680	689		10.1016/S0140-6736(12)62128-X	http://dx.doi.org/10.1016/S0140-6736(12)62128-X			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	093JY	23410612				2023-01-03	WOS:000315189300038
J	Giubellino, A; Sourbier, C; Lee, MJ; Scroggins, B; Bullova, P; Landau, M; Ying, WW; Neckers, L; Trepel, JB; Pacak, K				Giubellino, Alessio; Sourbier, Carole; Lee, Min-Jung; Scroggins, Brad; Bullova, Petra; Landau, Michael; Ying, Weiwen; Neckers, Len; Trepel, Jane B.; Pacak, Karel			Targeting Heat Shock Protein 90 for the Treatment of Malignant Pheochromocytoma	PLOS ONE			English	Article							MOLECULAR CHAPERONE; HSP90 INHIBITORS; SIGNALING PATHWAYS; TUMOR-SUPPRESSOR; CANCER-THERAPY; GROWTH-FACTOR; PHASE-I; COMPLEX; PARAGANGLIOMAS; EXPRESSION	Metastatic pheochromocytoma represents one of the major clinical challenges in the field of neuroendocrine oncology. Recent molecular characterization of pheochromocytoma suggests new treatment options with targeted therapies. In this study we investigated the 90 kDa heat shock protein (Hsp90) as a potential therapeutic target for advanced pheochromocytoma. Both the first generation, natural product Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin), and the second-generation synthetic Hsp90 inhibitor STA-9090 (ganetespib) demonstrated potent inhibition of proliferation and migration of pheochromocytoma cell lines and induced degradation of key Hsp90 clients. Furthermore, ganetespib induced dose-dependent cytotoxicity in primary pheochromocytoma cells. Using metastatic models of pheochromocytoma, we demonstrate the efficacy of 17-AAG and ganetespib in reducing metastatic burden and increasing survival. Levels of Hsp70 in plasma from the xenograft studies served as a proximal biomarker of drug treatment. Our study suggests that targeting Hsp90 may benefit patients with advanced pheochromocytoma.	[Giubellino, Alessio; Bullova, Petra; Pacak, Karel] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Reprod & Adult Endocrinol, NIH, Bethesda, MD USA; [Sourbier, Carole; Scroggins, Brad; Neckers, Len] NCI, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA; [Lee, Min-Jung; Landau, Michael; Trepel, Jane B.] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA; [Ying, Weiwen] Synta Pharmaceut, Lexington, MA USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Giubellino, A (corresponding author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Reprod & Adult Endocrinol, NIH, Bethesda, MD USA.	giubella@mail.nih.gov; karel@mail.nih.gov	Bullova, Petra/ABG-5262-2020; Giubellino, Alessio/H-3432-2019	Bullova, Petra/0000-0002-5411-2185; Giubellino, Alessio/0000-0002-5352-0662	Eunice Kennedy Shriver National Institute of Child Health and Human Development; Center for Cancer Research, National Cancer Institute of the National Institutes of Health; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008735] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [ZICSC006743, ZIASC010074] Funding Source: NIH RePORTER	Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Center for Cancer Research, National Cancer Institute of the National Institutes of Health; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by intramural research funding of the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Center for Cancer Research, National Cancer Institute of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Banerji U, 2009, CLIN CANCER RES, V15, P9, DOI 10.1158/1078-0432.CCR-08-0132; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Benn DE, 2003, ONCOGENE, V22, P1358, DOI 10.1038/sj.onc.1206300; Bishop SC, 2007, CURR CANCER DRUG TAR, V7, P369, DOI 10.2174/156800907780809778; Boltze C, 2003, J CLIN ENDOCR METAB, V88, P4280, DOI 10.1210/jc.2002-021299; Brieger J, 2005, ORL-J OTO-RHIN-LARYN, V67, P119, DOI 10.1159/000085171; Buffet A, 2012, HORM METAB RES, V44, P359, DOI 10.1055/s-0032-1304594; Cascon A, 2012, ENDOCR PATHOL, V23, P15, DOI 10.1007/s12022-012-9195-x; DeZwaan DC, 2008, CELL CYCLE, V7, P1006, DOI 10.4161/cc.7.8.5723; Druce MR, 2009, HORM METAB RES, V41, P697, DOI 10.1055/s-0029-1220687; Engelman JA, 2008, CURR OPIN GENET DEV, V18, P73, DOI 10.1016/j.gde.2008.01.004; Favier J, 2005, HORM RES, V63, P171, DOI 10.1159/000084685; Favier J, 2002, AM J PATHOL, V161, P1235, DOI 10.1016/S0002-9440(10)64400-8; Favier J, 2012, ENDOCR PATHOL, V23, P34, DOI 10.1007/s12022-011-9189-0; Gimenez-Roqueplo AP, 2012, HORM METAB RES, V44, P328, DOI 10.1055/s-0031-1301302; Giubellino A, 2012, CANCER LETT, V316, P46, DOI 10.1016/j.canlet.2011.10.019; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grogan RH, 2011, CANCER CONTROL, V18, P104, DOI 10.1177/107327481101800205; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Jhaveri K, 2012, BBA-MOL CELL RES, V1823, P742, DOI 10.1016/j.bbamcr.2011.10.008; Jimenez C, 2009, J CLIN ENDOCR METAB, V94, P386, DOI 10.1210/jc.2008-1972; Jyung RW, 2000, LARYNGOSCOPE, V110, P161, DOI 10.1097/00005537-200001000-00029; Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502; Kim YS, 2009, CURR TOP MED CHEM, V9, P1479, DOI 10.2174/156802609789895728; Korpershoek E, 2012, ENDOCR PATHOL, V23, P43, DOI 10.1007/s12022-012-9194-y; Lai EW, 2007, CELL CYCLE, V6, P1946, DOI 10.4161/cc.6.15.4521; Lenders JWM, 2005, LANCET, V366, P665, DOI 10.1016/S0140-6736(05)67139-5; Lopez-Jimenez E, 2010, MOL ENDOCRINOL, V24, P2382, DOI 10.1210/me.2010-0256; Martiniova L, 2009, CLIN EXP METASTAS, V26, P239, DOI 10.1007/s10585-009-9236-0; Modi S, 2007, J CLIN ONCOL, V25, P5410, DOI 10.1200/JCO.2007.11.7960; Neckers L, 2012, CLIN CANCER RES, V18, P64, DOI 10.1158/1078-0432.CCR-11-1000; Neckers L, 2009, NAT STRUCT MOL BIOL, V16, P235, DOI 10.1038/nsmb0309-235; Neckers L, 2009, TRENDS BIOCHEM SCI, V34, P223, DOI 10.1016/j.tibs.2009.01.006; Nolting S, 2012, ENDOCR PATHOL, V23, P21, DOI 10.1007/s12022-012-9199-6; Pacak K, 2011, Endocr Regul, V45, P65; Powers JF, 2000, CELL TISSUE RES, V302, P309, DOI 10.1007/s004410000290; Proia DA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018552; Rajan A, 2011, CLIN CANCER RES, V17, P6831, DOI 10.1158/1078-0432.CCR-11-0821; Rooijens PPGM, 2004, ENDOCR PATHOL, V15, P39, DOI 10.1385/EP:15:1:39; Schlisio S, 2008, GENE DEV, V22, P884, DOI 10.1101/gad.1648608; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Taipale M, 2010, NAT REV MOL CELL BIO, V11, P515, DOI 10.1038/nrm2918; Taldone T, 2009, BIOORGAN MED CHEM, V17, P2225, DOI 10.1016/j.bmc.2008.10.087; Tischler AS, 2004, HISTOL HISTOPATHOL, V19, P883, DOI 10.14670/HH-19.883; Trepel J, 2010, NAT REV CANCER, V10, P537, DOI 10.1038/nrc2887; Wang YS, 2010, CURR OPIN INVEST DR, V11, P1466; Weber A, 2012, HORM CANC; Xu WP, 2007, CLIN CANCER RES, V13, P1625, DOI 10.1158/1078-0432.CCR-06-2966; Ying WW, 2012, MOL CANCER THER, V11, P475, DOI 10.1158/1535-7163.MCT-11-0755; Zhang H, 2006, MOL CANCER THER, V5, P1256, DOI 10.1158/1535-7163.MCT-05-0537; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	51	21	24	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2013	8	2							e56083	10.1371/journal.pone.0056083	http://dx.doi.org/10.1371/journal.pone.0056083			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	099EJ	23457505	Green Submitted, gold, Green Published			2023-01-03	WOS:000315602700042
J	Kataria, H; Wadhwa, R; Kaul, SC; Kaur, G				Kataria, Hardeep; Wadhwa, Renu; Kaul, Sunil C.; Kaur, Gurcharan			Withania somnifera Water Extract as a Potential Candidate for Differentiation Based Therapy of Human Neuroblastomas	PLOS ONE			English	Article							CELL-ADHESION MOLECULE; HEAT-SHOCK RESPONSE; POLYSIALIC ACID; CYCLIN D1; RETINOIC ACID; MATRIX METALLOPROTEINASES; NEURITE OUTGROWTH; NERVOUS-SYSTEM; CANCER-CELLS; TUMOR-CELLS	Neuroblastoma is an aggressive childhood disease of the sympathetic nervous system. Treatments are often ineffective and have serious side effects. Conventional therapy of neuroblastoma includes the differentiation agents. Unlike chemo-radiotherapy, differentiation therapy shows minimal side effects on normal cells, because normal non-malignant cells are already differentiated. Keeping in view the limited toxicity of Withania somnifera (Ashwagandha), the current study was aimed to investigate the efficacy of Ashwagandha water extract (ASH-WEX) for anti-proliferative potential in neuroblastoma and its underlying signalling mechanisms. ASH-WEX significantly reduced cell proliferation and induced cell differentiation as indicated by morphological changes and NF200 expression in human IMR-32 neuroblastoma cells. The induction of differentiation was accompanied by HSP70 and mortalin induction as well as pancytoplasmic translocation of the mortalin in ASH-WEX treated cells. Furthermore, the ASH-WEX treatment lead to induction of neural cell adhesion molecule (NCAM) expression and reduction in its polysialylation, thus elucidating its anti-migratory potential, which was also supported by downregulation of MMP 2 and 9 activity. ASH-WEX treatment led to cell cycle arrest at G0/G1 phase and increase in early apoptotic population. Modulation of cell cycle marker Cyclin D1, anti-apoptotic marker bcl-xl and Akt-P provide evidence that ASH-WEX may prove to be a promising phytotherapeutic intervention in neuroblatoma related malignancies.	[Kataria, Hardeep; Kaur, Gurcharan] Guru Nanak Dev Univ, Dept Biotechnol, Amritsar, Punjab, India; [Wadhwa, Renu; Kaul, Sunil C.] Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki, Japan	Guru Nanak Dev University; National Institute of Advanced Industrial Science & Technology (AIST)	Kaur, G (corresponding author), Guru Nanak Dev Univ, Dept Biotechnol, Amritsar, Punjab, India.	kgurcharan.neuro@yahoo.com	Kaur, Gurcharan/V-6033-2019; Wadhwa, Renu/L-8898-2018; Kataria, Hardeep/AAI-8411-2020; Kaul, Sunil C/L-8671-2018	Wadhwa, Renu/0000-0001-8248-5192; Kaul, Sunil C/0000-0002-0046-3916; Kataria, Hardeep/0000-0001-8413-0600	Department of Biotechnology, Government of India; Council of Scientific and Industrial Research (CSIR), India	Department of Biotechnology, Government of India(Department of Biotechnology (DBT) India); Council of Scientific and Industrial Research (CSIR), India(Council of Scientific & Industrial Research (CSIR) - India)	The study was supported by grants from the Department of Biotechnology, Government of India to Guru Nanak Dev University, under DBT-AIST, Japan collaboration program. H. K. is supported by fellowship grant from the Council of Scientific and Industrial Research (CSIR), India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arato-Ohshima T, 1999, INT J CANCER, V83, P387, DOI 10.1002/(SICI)1097-0215(19991029)83:3<387::AID-IJC15>3.0.CO;2-O; Armstrong JL, 2007, BRIT J CANCER, V96, P1675, DOI 10.1038/sj.bjc.6603779; Armstrong JL, 2005, BRIT J CANCER, V92, P696, DOI 10.1038/sj.bjc.6602398; BLACK MM, 1991, J NEUROSCI, V11, P1163; Bruses JL, 1998, J CELL BIOL, V140, P1177, DOI 10.1083/jcb.140.5.1177; Cavallaro U, 2001, NAT CELL BIOL, V3, P650, DOI 10.1038/35083041; Cesi V, 2002, CELL DEATH DIFFER, V9, P1232, DOI 10.1038/sj.cdd.4401103; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Chiasserini D, 2011, MOVEMENT DISORD, V26, P1639, DOI 10.1002/mds.23647; Deb S, 1996, J NEUROCHEM, V66, P1641; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; DOLE MG, 1995, CANCER RES, V55, P2576; Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1; Elder GA, 1998, J CELL BIOL, V143, P195, DOI 10.1083/jcb.143.1.195; Evangelopoulos ME, 2009, J NEUROSCI RES, V87, P2138, DOI 10.1002/jnr.22025; Evangelopoulos ME, 2005, ONCOGENE, V24, P3309, DOI 10.1038/sj.onc.1208494; Fukuda M, 1996, CANCER RES, V56, P2237; Gallagher HC, 2000, J NEUROSCI RES, V61, P636, DOI 10.1002/1097-4547(20000915)61:6<636::AID-JNR7>3.3.CO;2-6; Georgopoulou N, 2006, J BIOL CHEM, V281, P33606, DOI 10.1074/jbc.M602689200; Guan KM, 2001, CELL TISSUE RES, V305, P171, DOI 10.1007/s004410100416; Gupta Girdhari Lal, 2007, Indian J Physiol Pharmacol, V51, P345; HEIKKILA JJ, 1993, DEV GENET, V14, P87, DOI 10.1002/dvg.1020140202; Hildebrandt H, 1998, CANCER RES, V58, P779; Horstkorte R, 2004, EXP CELL RES, V298, P268, DOI 10.1016/j.yexcr.2004.04.014; Hsu WM, 2008, CLIN CANCER RES, V14, P6237, DOI 10.1158/1078-0432.CCR-07-4181; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Huerta S, 2001, SURGERY, V130, P834, DOI 10.1067/msy.2001.116415; Jayaprakasam B, 2010, PHYTOTHER RES, V24, P859, DOI 10.1002/ptr.3033; Kataria H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037080; Kataria H, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1093/ecam/nep188; Katayama M, 1997, EXP CELL RES, V236, P412, DOI 10.1006/excr.1997.3757; Kiss JZ, 1997, CURR OPIN NEUROBIOL, V7, P640, DOI 10.1016/S0959-4388(97)80083-9; Kuboyama T, 2005, BRIT J PHARMACOL, V144, P961, DOI 10.1038/sj.bjp.0706122; Kuboyama T, 2002, NEUROREPORT, V13, P1715, DOI 10.1097/00001756-200210070-00005; Kumar S, 2010, PHYTOTHER RES, V24, P1567, DOI 10.1002/ptr.3261; Loones MT, 2000, CELL STRESS CHAPERON, V5, P291, DOI 10.1379/1466-1268(2000)005<0291:TDOHSP>2.0.CO;2; Mahal LK, 2001, SCIENCE, V294, P380, DOI 10.1126/science.1062192; Malik F, 2007, APOPTOSIS, V12, P2115, DOI 10.1007/s10495-007-0129-x; MARTINI R, 1994, GLIA, V10, P70, DOI 10.1002/glia.440100109; Matsuda H, 2001, BIOORGAN MED CHEM, V9, P1499, DOI 10.1016/S0968-0896(01)00024-4; Matthay KK, 2007, J CLIN ONCOL, V25, P1054, DOI 10.1200/JCO.2006.09.3484; McClellan KA, 2006, CELL CYCLE, V5, P1506, DOI 10.4161/cc.5.14.2980; Misra L, 2008, PHYTOCHEMISTRY, V69, P1000, DOI 10.1016/j.phytochem.2007.10.024; Misra L, 2012, J ASIAN NAT PROD RES, V14, P39, DOI 10.1080/10286020.2011.622719; Miyazaki T, 2008, GLYCOBIOLOGY, V18, P187, DOI 10.1093/glycob/cwm132; Molenaar JJ, 2010, ONCOGENE, V29, P2739, DOI 10.1038/onc.2010.21; Molenaar JJ, 2008, CANCER RES, V68, P2599, DOI 10.1158/0008-5472.CAN-07-5032; Molenaar JJ, 2009, P NATL ACAD SCI USA, V106, P12968, DOI 10.1073/pnas.0901418106; Muhlenhoff M, 1998, CURR OPIN STRUC BIOL, V8, P558, DOI 10.1016/S0959-440X(98)80144-9; Mulabagal V, 2009, PHYTOTHER RES, V23, P987, DOI 10.1002/ptr.2736; Nakagawa S, 2002, J NEUROSCI, V22, P9868; Njar Vincent C O, 2006, Med Chem, V2, P431, DOI 10.2174/157340606777724022; Noujaim D, 2002, ONCOGENE, V21, P4549, DOI 10.1038/sj.onc.1205552; Perez-Tenorio G, 2002, BRIT J CANCER, V86, P540, DOI 10.1038/sj.bjc.6600126; Perl AK, 1999, NAT MED, V5, P286, DOI 10.1038/6502; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; Qu MY, 2011, BRAIN RES, V1368, P336, DOI 10.1016/j.brainres.2010.10.068; RAY SD, 1994, ARCH BIOCHEM BIOPHYS, V311, P180, DOI 10.1006/abbi.1994.1224; REICHARDT LF, 1989, DEV NEUROSCI-BASEL, V11, P332, DOI 10.1159/000111910; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; Sallinen SL, 1999, J PATHOL, V188, P289; Shah N, 2009, CANCER SCI, V100, P1740, DOI 10.1111/j.1349-7006.2009.01236.x; Shih YY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026236; Shim JW, 2004, J NEUROSCI, V24, P843, DOI 10.1523/JNEUROSCI.3977-03.2004; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; Singh AP, 2012, INT J ONCOL, V40, P99, DOI 10.3892/ijo.2011.1225; Spix C, 2006, EUR J CANCER, V42, P2081, DOI 10.1016/j.ejca.2006.05.008; Sukumari-Ramesh S, 2011, INT J DEV NEUROSCI, V29, P701, DOI 10.1016/j.ijdevneu.2011.06.002; Sumrejkanchanakij P, 2006, BIOCHEM BIOPH RES CO, V340, P302, DOI 10.1016/j.bbrc.2005.11.181; Sumrejkanchanakij P, 2003, ONCOGENE, V22, P8723, DOI 10.1038/sj.onc.1206870; Takahashi K, 2011, MOL CELL NEUROSCI, V48, P217, DOI 10.1016/j.mcn.2011.08.002; Takashima S, 1998, J BIOL CHEM, V273, P7675, DOI 10.1074/jbc.273.13.7675; Tanaka F, 2000, CANCER RES, V60, P3072; Wadhwa R, 2002, CELL STRESS CHAPERON, V7, P309, DOI 10.1379/1466-1268(2002)007<0309:AHFCMM>2.0.CO;2; WADHWA R, 1995, INT J ONCOL, V7, P69; Westerheide SD, 2004, J BIOL CHEM, V279, P56053, DOI 10.1074/jbc.M409267200; Widodo N, 2008, CANCER LETT, V262, P37, DOI 10.1016/j.canlet.2007.11.037; Yang JX, 2008, BRAIN RES, V1203, P39, DOI 10.1016/j.brainres.2008.01.082; Yang L, 2004, CANCER RES, V64, P4394, DOI 10.1158/0008-5472.CAN-04-0343; Yoshida Y, 1996, J BIOL CHEM, V271, P30167, DOI 10.1074/jbc.271.47.30167	80	20	20	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2013	8	1							e55316	10.1371/journal.pone.0055316	http://dx.doi.org/10.1371/journal.pone.0055316			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	085JH	23383150	Green Submitted, Green Published, gold			2023-01-03	WOS:000314610600087
J	Gustafson, DH				Gustafson, David H.			A Systems Engineer Meets the System	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Wisconsin, Ctr Hlth Enhancement Syst Studies, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Gustafson, DH (corresponding author), Univ Wisconsin, Ctr Hlth Enhancement Syst Studies, Madison, WI 53706 USA.	dhgustaf@wisc.edu						Gustafson D. H., 2011, NIATX MODEL PROCESS	1	0	0	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 16	2013	309	3					247	248		10.1001/jama.2012.176580	http://dx.doi.org/10.1001/jama.2012.176580			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	070XG	23321762				2023-01-03	WOS:000313546800024
J	Liu, XJ; Wang, MS; Chen, HL; Guo, YL; Ma, FG; Shi, F; Bi, YL; Li, Y				Liu, Xiaojie; Wang, Mingshan; Chen, Huailong; Guo, Yunliang; Ma, Fuguo; Shi, Fei; Bi, Yanlin; Li, Ying			Hypothermia Protects the Brain from Transient Global Ischemia/Reperfusion by Attenuating Endoplasmic Reticulum Response-Induced Apoptosis through CHOP	PLOS ONE			English	Article							CYTOCHROME-C RELEASE; NEURONAL CELL-DEATH; THERAPEUTIC HYPOTHERMIA; CEREBRAL-ISCHEMIA; NITRIC-OXIDE; STRESS; EXPRESSION; STROKE; INJURY; GRP78	Endoplasmic reticulum (ER) stress has been implicated in the pathology of cerebral ischemia. Apoptotic cell death occurs during prolonged period of stress or when the adaptive response fails. Hypothermia blocked the TNF or Fas-mediated extrinsic apoptosis pathway and the mitochondria pathway of apoptosis, however, whether hypothermia can block endoplasmic reticulum mediated apoptosis is never known. This study aimed to elucidate whether hypothermia attenuates brain cerebral ischemia/reperfusion (I/R) damage by suppressing ER stress-induced apoptosis. A 15 min global cerebral ischemia rat model was used in this study. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) positive cells in hippocampus CA1 were assessed after reperfusion of the brain. The expressions of C/EBP-homolo gous protein (CHOP) and glucose-regulated protein 78 (GRP78) in ischemic hippocampus CA1 were measured at 6, 12, 24 and 48 h after reperfusion. The results showed that hypothermia significantly attenuated brain I/R injury, as shown by reduction in cell apoptosis, CHOP expression, and increase in GRP78 expression. These results suggest that hypothermia could protect brain from I/R injury by suppressing ER stress-induced apoptosis.	[Liu, Xiaojie; Wang, Mingshan; Chen, Huailong; Guo, Yunliang; Ma, Fuguo; Shi, Fei; Bi, Yanlin; Li, Ying] Qingdao Municipal Hosp, Dept Anesthesiol, Qingdao, Shandong, Peoples R China	Qingdao Municipal Hospital	Wang, MS (corresponding author), Qingdao Municipal Hosp, Dept Anesthesiol, Qingdao, Shandong, Peoples R China.	slwangmingshan@163.com			Qingdao Municipal Science and Technology Bureau [11-2-3-2-5-nsh]; Shandong Provincial Health Department [2001CAICKAF]	Qingdao Municipal Science and Technology Bureau; Shandong Provincial Health Department	This work was supported by Qingdao Municipal Science and Technology Bureau 11-2-3-2-5-nsh Shandong Provincial Health Department 2001CAICKAF. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALBERTS MJ, 1995, ANN INTERN MED, V122, P622, DOI 10.7326/0003-4819-122-8-199504150-00013; Aoki M, 2001, MOL BRAIN RES, V95, P117, DOI 10.1016/S0169-328X(01)00255-8; Bossenmeyer-Pourie C, 2000, PEDIATR RES, V47, P385, DOI 10.1203/00006450-200003000-00017; Campos F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044191; DeGracia DJ, 2004, J NEUROCHEM, V91, P1, DOI 10.1111/j.1471-4159.2004.02703.x; Hayashi T, 2003, J CEREBR BLOOD F MET, V23, P949, DOI 10.1097/01.WCB.0000077641.41248.EA; Holzer M, 2002, NEW ENGL J MED, V346, P549; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Jiang YF, 2012, NEUROSCI LETT, V516, P182, DOI 10.1016/j.neulet.2012.03.074; Kawahara K, 2001, FEBS LETT, V506, P135, DOI 10.1016/S0014-5793(01)02898-8; Khar A, 2003, FREE RADICAL BIO MED, V35, P949, DOI 10.1016/S0891-5849(03)00469-6; Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kochanek PA, 2003, JAMA-J AM MED ASSOC, V289, P3007, DOI 10.1001/jama.289.22.3007; Kohno K, 1997, NEUROSCI LETT, V224, P17, DOI 10.1016/S0304-3940(97)13459-0; Krieger DW, 2004, STROKE, V35, P1482, DOI 10.1161/01.STR.0000126118.44249.5c; Liu L, 2008, J NEUROCHEM, V106, P541, DOI 10.1111/j.1471-4159.2008.05411.x; Liu LP, 2007, FRONT BIOSCI-LANDMRK, V12, P816, DOI 10.2741/2104; Lyden PD, 2006, INT J STROKE, V1, P9, DOI 10.1111/j.1747-4949.2005.00011.x; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; MacManus JP, 1997, J CEREBR BLOOD F MET, V17, P815, DOI 10.1038/aj.jcbfm.9590266; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Nakka VP, 2010, NEUROTOX RES, V17, P189, DOI 10.1007/s12640-009-9110-5; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; PULSINELLI WA, 1979, STROKE, V10, P267, DOI 10.1161/01.STR.10.3.267; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; Szegezdi E, 2009, AM J PHYSIOL-CELL PH, V296, pC941, DOI 10.1152/ajpcell.00612.2008; Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184; Tajiri S, 2004, CELL DEATH DIFFER, V11, P403, DOI 10.1038/sj.cdd.4401365; The Ministry of Science and Technology of the People's Republic of China, 2006, GUID SUGG CAR US LAB; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhao H, 2004, STROKE, V35, P572, DOI 10.1161/01.STR.0000110787.42083.58; Zhao H, 2005, J CEREBR BLOOD F MET, V25, P1119, DOI 10.1038/sj.jcbfm.9600111; Zhao H, 2007, J CEREBR BLOOD F MET, V27, P1879, DOI 10.1038/sj.jcbfm.9600540	36	36	51	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2013	8	1							e53431	10.1371/journal.pone.0053431	http://dx.doi.org/10.1371/journal.pone.0053431			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	070BE	23301071	Green Published, Green Submitted, gold			2023-01-03	WOS:000313480000057
J	Partridge, L				Partridge, Linda			Diet and Healthy Aging	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CALORIC RESTRICTION; RHESUS-MONKEYS		[Partridge, Linda] Max Planck Inst Biol Aging, Cologne, Germany; [Partridge, Linda] UCL, Inst Healthy Aging, Dept Genet Evolut & Environm, London, England	Max Planck Society; University of London; University College London	Partridge, L (corresponding author), Max Planck Inst Biol Aging, Cologne, Germany.		Partridge, Linda/A-5501-2010; Partridge, Linda/E-7342-2015	Partridge, Linda/0000-0001-9615-0094				Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Grandison RC, 2009, NATURE, V462, P1061, DOI 10.1038/nature08619; Mattison JA, 2012, NATURE, V489, P318, DOI 10.1038/nature11432; Weindruch R, 1988, RETARDATION AGING DI, P397	5	11	11	1	44	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 27	2012	367	26					2550	2551		10.1056/NEJMcibr1210447	http://dx.doi.org/10.1056/NEJMcibr1210447			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	059OG	23268671				2023-01-03	WOS:000312714200017
J	Woodcock, J; Khan, M; Yu, LX				Woodcock, Janet; Khan, Mansoor; Yu, Lawrence X.			Withdrawal of Generic Budeprion for Nonbioequivalence	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Woodcock, Janet; Khan, Mansoor; Yu, Lawrence X.] US FDA, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Woodcock, J (corresponding author), US FDA, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA.		/AAE-3713-2022; Yu, Lawrence/L-6280-2016	Khan, Mansoor/0000-0003-3649-3874				*FOOD DRUG ADM, 2003, GUIDANCE FOR INDUSTR, P77671	1	40	42	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 27	2012	367	26					2463	2465		10.1056/NEJMp1212969	http://dx.doi.org/10.1056/NEJMp1212969			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	059OG	23216549				2023-01-03	WOS:000312714200002
J	Raicek, JE; Stone, BH; Kaptchuk, TJ				Raicek, Jacqueline E.; Stone, Bradley H.; Kaptchuk, Ted J.			CHRISTMAS 2012: YESTERDAY'S WORLD Placebos in 19th century medicine: a quantitative analysis of the BMJ	BRITISH MEDICAL JOURNAL			English	Editorial Material								Objective To provide the first quantitative data on the use of the term "placebo" in the 19th century. Design Computer search of BMJ's archival database from January 1840 (the first issue) through December 1899 for uses of the words "placebo(s)." Grounded theory was used to categorise the implications of uses of the term. Results 71 citations contained the term "placebo(s)." Of these, 22 (31%) used the term to mean "no effect" or as a general pejorative term, 18 (25%) portrayed placebo treatment as permitting the unfolding of the natural history (the normal waxing and waning of illness), 14 (20%) described placebo as important to satisfy patients, 7 (10%) described it as fulfilling a physician's performance role, 3 (4%) described its use to buy time, 3 (4%) described its use for financial gain, 2 (3%) used it in a manner similar to a placebo control, and only one implied that placebo could have a clinical effect. Only one citation mentioned telling the patient about his placebo treatment. Conclusion Nineteenth century physicians had diverse a priori assumptions about placebos. These findings remind us that contemporary medicine needs to use rigorous science to separate fact from its own beliefs concerning the "provision of care." As in previous generations, ethical issues concerning placebos continue to challenge medicine.	[Raicek, Jacqueline E.; Stone, Bradley H.; Kaptchuk, Ted J.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Program Placebo Studies & Therapeut Encounter, Boston, MA 02215 USA; [Raicek, Jacqueline E.] Univ New England, Coll Osteopath Med, Biddeford, ME 04005 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of New England - Maine	Kaptchuk, TJ (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Program Placebo Studies & Therapeut Encounter, Boston, MA 02215 USA.	ted_kaptchuk@hms.harvard.edu			NIH NCCAM [K24 AT004095, R01 AT004662, R01AT005280, R01 AT006364, P01 AT006663]; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [R01AT004662, R01AT005280] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [P01AT006663, R01AT006364, K24AT004095] Funding Source: NIH RePORTER	NIH NCCAM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The paper is supported in part from NIH NCCAM grants K24 AT004095, R01 AT004662, R01AT005280, R01 AT006364, and P01 AT006663.	[Anonymous], 1871, BMJ, V2, P744; [Anonymous], 1897, BMJ, V1, P1543; [Anonymous], 1889, BMJ, V1, P1051; [Anonymous], 1889, BMJ, V1, P130; [Anonymous], 1869, BMJ, V2, P7; [Anonymous], 1851, BMJ, V0, P956; [Anonymous], 1853, BMJ, V0, P1047; [Anonymous], 1889, BMJ, V2, P844; Bostick NA, 2008, J CLIN ETHIC, V19, P58; Cargill J, 1891, BRIT MED J, V1, P87; Cormack JR, 1851, BRIT MED J, V0, P444; Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2; Glaster B. G., 1967, THEORETICAL SENSITIV; Hartridge G, 1886, Br Med J, V1, P200; Kaptchuk TJ, 1998, LANCET, V351, P1722, DOI 10.1016/S0140-6736(97)10111-8; Kaptchuk TJ, 1998, B HIST MED, V72, P389, DOI 10.1353/bhm.1998.0159; McKeown W A, 1879, Br Med J, V2, P1013; Miller FM, PLACEBO READER; Pepper O., 1945, AM J PHARM, V117, P409; Shears C, 1884, Br Med J, V1, P1199; Sloane J, 1857, BRIT MED J, V0, P363; Symonds, 1842, BRIT MED J, V0, P63; Symonds C J, 1899, Br Med J, V1, P517; Tilburt JC, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1938; Tracey I, 2010, NAT MED, V16, P1277, DOI 10.1038/nm.2229; Ward OT, 1848, BRIT MED J, V0, P5; West RU, 1849, BRIT MED J, V0, P391; Wills C J, 1879, Br Med J, V1, P623; WOLF S, 1950, J CLIN INVEST, V29, P100, DOI 10.1172/JCI102225	29	9	9	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	DEC 18	2012	345								e8326	10.1136/bmj.e8326	http://dx.doi.org/10.1136/bmj.e8326			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	059IW	23249668	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000312698900001
J	Charlier, P; Brun, L; Pretre, C; Huynh-Charlier, I				Charlier, Philippe; Brun, Luc; Pretre, Clarisse; Huynh-Charlier, Isabelle			CHRISTMAS 2012: Toilet hygiene in the classical era	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Charlier, Philippe] Univ Hosp, Dept Forens Med & Pathol, F-92380 Garches, France; [Charlier, Philippe] Fac Med, Lab Med Eth, Paris, France; [Brun, Luc] Univ Hosp, Dept Pathol, Parakou, Benin; [Pretre, Clarisse] Univ Lille 3, HALMA IPEL, Villeneuve Dascq, France; [Huynh-Charlier, Isabelle] Univ Hosp Pitie Salpetriere, Dept Radiol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; Universite de Lille - ISITE; Universite de Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Charlier, P (corresponding author), Univ Hosp, Dept Forens Med & Pathol, 104 R Poincare Blvd, F-92380 Garches, France.	ph_charlier@yahoo.fr		Brun, luc Valere C./0000-0002-6024-3982				Aristophanes, 1998, BIRDS OTHER PLAYS; Charlier P., 2011, FEUILLETS BIOL, V52, P61; Colozier E., 1952, MEFRA, V64, P67; Janicke David M., 1996, Emergency Medicine Clinics of North America, V14, P757, DOI 10.1016/S0733-8627(05)70278-9; Needham J., 1986, SCI CIVILIZATION CHI, V5, P122; Papadopoulos JK, 2002, HESPERIA, V71, P149, DOI 10.2307/3182005; Rabelais F., GARGANTUA PANTAGRUEL, V1, P13; Seneca, COMMUNICATION, V70, P20	8	6	6	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 17	2012	345								e8287	10.1136/bmj.e8287	http://dx.doi.org/10.1136/bmj.e8287			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	059IU	23247990	Bronze			2023-01-03	WOS:000312698700023
J	Regenbogen, C; De Vos, M; Debener, S; Turetsky, BI; Mossnang, C; Finkelmeyer, A; Habel, U; Neuner, I; Kellermann, T				Regenbogen, Christina; De Vos, Maarten; Debener, Stefan; Turetsky, Bruce I.; Moessnang, Carolin; Finkelmeyer, Andreas; Habel, Ute; Neuner, Irene; Kellermann, Thilo			Auditory Processing under Cross-Modal Visual Load Investigated with Simultaneous EEG-fMRI	PLOS ONE			English	Article							EVENT-RELATED POTENTIALS; MISMATCH NEGATIVITY MMN; WORKING-MEMORY; ATTENTIONAL LOAD; SELECTIVE-ATTENTION; MR SCANNER; DYNAMICS; REMOVAL; BRAIN; PERFORMANCE	Cognitive task demands in one sensory modality (T1) can have beneficial effects on a secondary task (T2) in a different modality, due to reduced top-down control needed to inhibit the secondary task, as well as crossmodal spread of attention. This contrasts findings of cognitive load compromising a secondary modality's processing. We manipulated cognitive load within one modality (visual) and studied the consequences of cognitive demands on secondary (auditory) processing. 15 healthy participants underwent a simultaneous EEG-fMRI experiment. Data from 8 participants were obtained outside the scanner for validation purposes. The primary task (T1) was to respond to a visual working memory (WM) task with four conditions, while the secondary task (T2) consisted of an auditory oddball stream, which participants were asked to ignore. The fMRI results revealed fronto-parietal WM network activations in response to T1 task manipulation. This was accompanied by significantly higher reaction times and lower hit rates with increasing task difficulty which confirmed successful manipulation of WM load. Amplitudes of auditory evoked potentials, representing fundamental auditory processing showed a continuous augmentation which demonstrated a systematic relation to cross-modal cognitive load. With increasing WM load, primary auditory cortices were increasingly deactivated while psychophysiological interaction results suggested the emergence of auditory cortices connectivity with visual WM regions. These results suggest differential effects of crossmodal attention on fundamental auditory processing. We suggest a continuous allocation of resources to brain regions processing primary tasks when challenging the central executive under high cognitive load. Citation: Regenbogen C, De Vos M, Debener S, Turetsky BI, Mossnang C, et al. (2012) Auditory Processing under Cross-Modal Visual Load Investigated with Simultaneous EEG-fMRI. PLoS ONE 7(12): e52267. doi:10.1371/journal.pone.0052267	[Regenbogen, Christina; Moessnang, Carolin; Finkelmeyer, Andreas; Habel, Ute; Neuner, Irene; Kellermann, Thilo] Rhein Westfal TH Aachen, Dept Psychiat Psychotherapy & Psychosomat, Sch Med, Aachen, Germany; [Regenbogen, Christina; Moessnang, Carolin; Habel, Ute; Neuner, Irene; Kellermann, Thilo] Carl von Ossietzky Univ Oldenburg, JARA Translat Brain Med, D-2900 Oldenburg, Germany; [De Vos, Maarten; Debener, Stefan] Carl von Ossietzky Univ Oldenburg, Dept Psychol, Neuropsychol Lab, D-2900 Oldenburg, Germany; [De Vos, Maarten] Katholieke Univ Leuven, ESAT SCD, Dept Elect Engn, Louvain, Belgium; [Debener, Stefan] Univ Hosp Jena, Biomagnet Ctr, Dept Neurol, Jena, Germany; [Turetsky, Bruce I.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA; [Finkelmeyer, Andreas] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	RWTH Aachen University; Carl von Ossietzky Universitat Oldenburg; Carl von Ossietzky Universitat Oldenburg; KU Leuven; Friedrich Schiller University of Jena; University of Pennsylvania; Newcastle University - UK	Regenbogen, C (corresponding author), Rhein Westfal TH Aachen, Dept Psychiat Psychotherapy & Psychosomat, Sch Med, Aachen, Germany.	cregenbogen@ukaachen.de	Regenbogen, Christina/A-9691-2016; Neuner, Irene/J-6619-2013; Kellermann, Thilo/B-1712-2012; Moessnang, Carolin/V-8095-2017	Regenbogen, Christina/0000-0001-5950-798X; Kellermann, Thilo/0000-0003-4081-5581; Moessnang, Carolin/0000-0003-4357-2706; Finkelmeyer, Andreas/0000-0001-7491-5113; Habel, Ute/0000-0003-0703-7722; Neuner, Irene/0000-0002-5164-8873	Deutsche Forschungsgemeinschaft [DFG: IRTG1328, KFO-112/TP9: Ha3202/2-2]; Interdisciplinary Center for Clinical Research of the Medical Faculty of the RWTH Aachen University [N2-6, N4-4]; Research Council KUL (GOA MaNet); Flemish Government [FWO G.0427.10N]; DFG [IRTG1328]; Alexander von Humboldt stipend	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Interdisciplinary Center for Clinical Research of the Medical Faculty of the RWTH Aachen University; Research Council KUL (GOA MaNet); Flemish Government(European Commission); DFG(German Research Foundation (DFG)); Alexander von Humboldt stipend(Alexander von Humboldt Foundation)	This work was supported by the Deutsche Forschungsgemeinschaft (DFG: IRTG1328, KFO-112/TP9: Ha3202/2-2), the Interdisciplinary Center for Clinical Research of the Medical Faculty of the RWTH Aachen University (N2-6, N4-4), the Research Council KUL (GOA MaNet), and the Flemish Government (FWO G.0427.10N, Integrated EEG-fMRI).CR is supported by a start-up grant of the IRTG1328 (DFG). MDV is supported by an Alexander von Humboldt stipend. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen PJ, 1998, NEUROIMAGE, V8, P229, DOI 10.1006/nimg.1998.0361; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Bendixen A, 2010, NEUROPSYCHOLOGIA, V48, P2130, DOI 10.1016/j.neuropsychologia.2010.04.004; Brett M., 2002, P 8 INT C FUNCT MAPP, V16, P497; Busse L, 2005, P NATL ACAD SCI USA, V102, P18751, DOI 10.1073/pnas.0507704102; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; de Fockert JW, 2011, COGNITION, V121, P400, DOI 10.1016/j.cognition.2011.08.016; De Vos M, 2011, SIGNAL PROCESS, V91, P1963, DOI 10.1016/j.sigpro.2011.02.019; Debener S, 2005, J NEUROSCI, V25, P11730, DOI 10.1523/JNEUROSCI.3286-05.2005; Debener S, 2005, COGNITIVE BRAIN RES, V22, P309, DOI 10.1016/j.cogbrainres.2004.09.006; Debener S, 2007, NEUROIMAGE, V34, P587, DOI 10.1016/j.neuroimage.2006.09.031; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Driver J, 1998, CURR OPIN NEUROBIOL, V8, P245, DOI 10.1016/S0959-4388(98)80147-5; Dux PE, 2009, ATTEN PERCEPT PSYCHO, V71, P1683, DOI 10.3758/APP.71.8.1683; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; ERNST RR, 1966, REV SCI INSTRUM, V37, P93, DOI 10.1063/1.1719961; Friston KJ, 1997, NEUROIMAGE, V6, P218, DOI 10.1006/nimg.1997.0291; Gallinat J, 2002, NEUROIMAGE, V17, P110, DOI 10.1006/nimg.2002.1213; Glover GH, 1999, NEUROIMAGE, V9, P416, DOI 10.1006/nimg.1998.0419; HARI R, 1980, EXP BRAIN RES, V40, P237, DOI 10.1007/BF00237543; Haroush K, 2011, J NEUROSCI, V31, P922, DOI 10.1523/JNEUROSCI.0420-10.2011; Haroush K, 2010, J COGNITIVE NEUROSCI, V22, P1440, DOI 10.1162/jocn.2009.21284; Hine J, 2007, CLIN NEUROPHYSIOL, V118, P1274, DOI 10.1016/j.clinph.2007.03.012; Jaeggi SM, 2010, MEMORY, V18, P394, DOI 10.1080/09658211003702171; Janson Jolanda, 2011, Adv Cogn Psychol, V7, P92, DOI 10.2478/v10053-008-0089-x; Johnson JA, 2005, CEREB CORTEX, V15, P1609, DOI 10.1093/cercor/bhi039; Karns CM, 2009, J COGNITIVE NEUROSCI, V21, P669, DOI 10.1162/jocn.2009.21037; Kranczioch C, 2007, NEUROIMAGE, V37, P947, DOI 10.1016/j.neuroimage.2007.05.044; Lavie N, 2004, J EXP PSYCHOL GEN, V133, P339, DOI 10.1037/0096-3445.133.3.339; Lazeyras F, 2001, J MAGN RESON IMAGING, V13, P943, DOI 10.1002/jmri.1135; Leavitt VM, 2011, FRONT INTEGR NEUROSC, V5, DOI 10.3389/fnint.2011.00023; Logothetis NK, 2003, J NEUROSCI, V23, P3963; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; Maldjian JA, 2004, NEUROIMAGE, V21, P450, DOI 10.1016/j.neuroimage.2003.09.032; Marois R, 2005, TRENDS COGN SCI, V9, P296, DOI 10.1016/j.tics.2005.04.010; May PJC, 2010, PSYCHOPHYSIOLOGY, V47, P66, DOI 10.1111/j.1469-8986.2009.00856.x; Mayhew SD, 2010, NEUROIMAGE, V49, P849, DOI 10.1016/j.neuroimage.2009.06.080; Mijovic B, 2012, NEUROIMAGE, V60, P1171, DOI 10.1016/j.neuroimage.2012.01.063; Mozolic JL, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-35; Mulert C., 2009, EEG FMRI PHYSL BASIS; Muller-Gass A, 2007, BRAIN RES, V1170, P71, DOI 10.1016/j.brainres.2007.07.023; Munka L, 2006, NEUROSCI LETT, V396, P177, DOI 10.1016/j.neulet.2005.11.035; Naatanen R, 2007, CLIN NEUROPHYSIOL, V118, P2544, DOI 10.1016/j.clinph.2007.04.026; NAATANEN R, 1978, ACTA PSYCHOL, V42, P313, DOI 10.1016/0001-6918(78)90006-9; NAATANEN R, 1990, BEHAV BRAIN SCI, V13, P201, DOI 10.1017/S0140525X00078407; Naatanen R, 2011, PSYCHOPHYSIOLOGY, V48, P4, DOI 10.1111/j.1469-8986.2010.01114.x; Neuner I, 2010, HUM BRAIN MAPP, V31, P1675, DOI 10.1002/hbm.20965; Niazy RK, 2005, NEUROIMAGE, V28, P720, DOI 10.1016/j.neuroimage.2005.06.067; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Otten LJ, 2000, NEUROREPORT, V11, P875, DOI 10.1097/00001756-200003200-00043; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Picton TW, 1999, AUDIOL NEURO-OTOL, V4, P64, DOI 10.1159/000013823; Restuccia D, 2005, COGNITIVE BRAIN RES, V25, P891, DOI 10.1016/j.cogbrainres.2005.09.023; Rottschy C, 2012, NEUROIMAGE, V60, P830, DOI 10.1016/j.neuroimage.2011.11.050; SanMiguel I, 2008, J COGNITIVE NEUROSCI, V20, P1131, DOI 10.1162/jocn.2008.20078; Spence C, 2011, ATTEN PERCEPT PSYCHO, V73, P971, DOI 10.3758/s13414-010-0073-7; Tellinghuisen DJ, 2003, PERCEPT PSYCHOPHYS, V65, P817, DOI 10.3758/BF03194817; Thorne JD, 2011, J NEUROSCI, V31, P3853, DOI 10.1523/JNEUROSCI.6176-10.2011; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Ullsperger M., 2010, SIMULTANEOUS EEG FMR; Vanderperren K, 2010, NEUROIMAGE, V50, P920, DOI 10.1016/j.neuroimage.2010.01.010; Warbrick T, 2008, INT J PSYCHOPHYSIOL, V67, P169, DOI 10.1016/j.ijpsycho.2007.05.014; Zhang P, 2006, NEUROIMAGE, V33, P715, DOI 10.1016/j.neuroimage.2006.07.015; Zimmer U, 2010, EUR J NEUROSCI, V31, P1744, DOI 10.1111/j.1460-9568.2010.07229.x	64	22	23	1	49	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2012	7	12							e52267	10.1371/journal.pone.0052267	http://dx.doi.org/10.1371/journal.pone.0052267			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	055AJ	23251704	gold, Green Published, Green Submitted			2023-01-03	WOS:000312386800155
J	Mason, C; McCall, MJ; Culme-Seymour, EJ; Suthasan, S; Edwards-Parton, S; Bonfiglio, GA; Reeve, BC				Mason, Chris; McCall, Mark J.; Culme-Seymour, Emily J.; Suthasan, Shalini; Edwards-Parton, Simon; Bonfiglio, Gregory A.; Reeve, Brock C.			The Global Cell Therapy Industry Continues to Rise during the Second and Third Quarters of 2012	CELL STEM CELL			English	Editorial Material							SIGNALS	During Q2-Q3 2012, the cell therapy industry benefited from a number of positive external influences including advantageous changes to future FDA regulation, but stock market activity was highly mixed. The FDA approved two more products and an appreciable number of public-company-sponsored clinical trials are progressing through phases 1-3.	[Mason, Chris; Suthasan, Shalini; Edwards-Parton, Simon] UCL, Adv Ctr Biochem Engn, London WC1E 6BT, England; [McCall, Mark J.] Univ Loughborough, Ctr Biol Engn, Loughborough LE11 3TU, Leics, England; [Culme-Seymour, Emily J.] London Regenerat Med Network, London EC1R 0DP, England; [Bonfiglio, Gregory A.] Proteus Venture Partners, Portola Valley, CA 94028 USA; [Bonfiglio, Gregory A.] Ctr Commercializat Regenerat Med, Toronto, ON M5G 1L5, Canada; [Reeve, Brock C.] Holyoke Ctr, Harvard Stem Cell Inst, Cambridge, MA 02138 USA	University of London; University College London; Loughborough University; Harvard University	Mason, C (corresponding author), UCL, Adv Ctr Biochem Engn, Torrington Pl, London WC1E 6BT, England.	chris.mason@ucl.ac.uk		McCall, Mark/0000-0002-8606-5280				Brindley DA, 2012, REGEN MED, V7, P7, DOI [10.2217/rme.11.112, 10.2217/RME.11.112]; Brindley DA, 2011, CELL STEM CELL, V9, P397, DOI 10.1016/j.stem.2011.10.010; Fox JL, 2012, NAT BIOTECHNOL, V30, P733, DOI 10.1038/nbt0812-733; Fox JL, 2012, NAT BIOTECHNOL, V30, P306, DOI 10.1038/nbt.2175; McKernan R, 2010, CELL STEM CELL, V6, P517, DOI 10.1016/j.stem.2010.05.012; Schmidt C, 2012, NAT BIOTECHNOL, V30, P479, DOI 10.1038/nbt0612-479; Trounson Alan, 2012, Nat Rev Drug Discov, V11, P512, DOI 10.1038/nrd3769; Yang W, 2012, NAT BIOTECHNOL, V30, P738, DOI 10.1038/nbt.2332	8	17	17	0	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	1934-5909			CELL STEM CELL	Cell Stem Cell	DEC 7	2012	11	6					735	739		10.1016/j.stem.2012.11.013	http://dx.doi.org/10.1016/j.stem.2012.11.013			5	Cell & Tissue Engineering; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	055MJ	23217418	Bronze			2023-01-03	WOS:000312420300005
J	DeMattos, RB; Lu, JR; Tang, Y; Racke, MM; DeLong, CA; Tzaferis, JA; Hole, JT; Forster, BM; McDonnell, PC; Liu, F; Kinley, RD; Jordan, WH; Hutton, ML				DeMattos, Ronald B.; Lu, Jirong; Tang, Ying; Racke, Margaret M.; DeLong, Cindy A.; Tzaferis, John A.; Hole, Justin T.; Forster, Beth M.; McDonnell, Peter C.; Liu, Feng; Kinley, Robert D.; Jordan, William H.; Hutton, Michael L.			A Plaque-Specific Antibody Clears Existing beta-amyloid Plaques in Alzheimer's Disease Mice	NEURON			English	Article							APP-TRANSGENIC MICE; A-BETA; MOUSE MODEL; CEREBROSPINAL-FLUID; DEPOSITION; IMMUNIZATION; IMMUNOTHERAPY; PEPTIDE; PLASMA; MICROHEMORRHAGE	A beta Imrnunotherapy is a promising therapeutic approach for Alzheimer's disease. Preclinical studies demonstrate that plaque prevention is possible; however, the more relevant therapeutic removal of existing plaque has proven elusive. Monoclonal antibodies in development target both soluble and insoluble A beta peptide. We hypothesized that antibody specificity for deposited plaque was critical for plaque removal since soluble A beta peptide would block recognition of deposited forms. We developed a plaque-specific antibody that targets a modified A beta peptide (A beta(p3-42)), which showed robust clearance of pre-existing plaque without causing microhemorrhage. Interestingly, a comparator N-terminal A beta antibody 3D6, which binds both soluble and insoluble A beta(p3-42), lacked efficacy for lowering existing plaque but manifested a significant microhemorrhage liability. Mechanistic studies suggested that the lack of efficacy for 3D6 was attributed to poor target engagement in plaques. These studies have profound implications for the development of therapeutic A beta antibodies for Alzheimer's disease.	[DeMattos, Ronald B.; Lu, Jirong; Tang, Ying; Racke, Margaret M.; DeLong, Cindy A.; Tzaferis, John A.; Hole, Justin T.; Forster, Beth M.; McDonnell, Peter C.; Liu, Feng; Kinley, Robert D.; Jordan, William H.; Hutton, Michael L.] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA	Eli Lilly	DeMattos, RB (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA.	demattosrb@lilly.com						Adolfsson O, 2012, J NEUROSCI, V32, P9677, DOI 10.1523/JNEUROSCI.4742-11.2012; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bard F, 2003, P NATL ACAD SCI USA, V100, P2023, DOI 10.1073/pnas.0436286100; Bibl M, 2012, PROTEOM CLIN APPL, V6, P163, DOI 10.1002/prca.201100082; Black RS, 2010, ALZ DIS ASSOC DIS, V24, P198, DOI 10.1097/WAD.0b013e3181c53b00; Boche D, 2008, BRAIN, V131, P3299, DOI 10.1093/brain/awn261; Bohrmann B, 2012, J ALZHEIMERS DIS, V28, P49, DOI 10.3233/JAD-2011-110977; Chelius D, 2006, ANAL CHEM, V78, P2370, DOI 10.1021/ac051827k; Cynis H, 2006, BBA-PROTEINS PROTEOM, V1764, P1618, DOI 10.1016/j.bbapap.2006.08.003; Das P, 2003, J NEUROSCI, V23, P8532; Das P, 2001, NEUROBIOL AGING, V22, P721, DOI 10.1016/S0197-4580(01)00245-7; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; DeMattos RB, 2002, J NEUROCHEM, V81, P229, DOI 10.1046/j.1471-4159.2002.00889.x; Esler WP, 1999, METHOD ENZYMOL, V309, P350; Farlow M, 2012, ALZHEIMERS DEMENT, V8, P261, DOI 10.1016/j.jalz.2011.09.224; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Giedraitis V, 2007, NEUROSCI LETT, V427, P127, DOI 10.1016/j.neulet.2007.09.023; Golde TE, 2003, J CLIN INVEST, V111, P11, DOI 10.1172/JCI200317527; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hong SY, 2011, J NEUROSCI, V31, P15861, DOI 10.1523/JNEUROSCI.3272-11.2011; Iwatsubo T, 1996, AM J PATHOL, V149, P1823; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Koffie RM, 2009, P NATL ACAD SCI USA, V106, P4012, DOI 10.1073/pnas.0811698106; Kuo YM, 1997, BIOCHEM BIOPH RES CO, V237, P188, DOI 10.1006/bbrc.1997.7083; La Porte SL, 2012, J MOL BIOL, V421, P525, DOI 10.1016/j.jmb.2011.11.047; Lee M, 2005, ANN NEUROL, V58, P430, DOI 10.1002/ana.20592; Levites Y, 2006, J CLIN INVEST, V116, P193, DOI 10.1172/JCI25410; Mehta PD, 2001, NEUROSCI LETT, V304, P102, DOI 10.1016/S0304-3940(01)01754-2; Morris JC, 2001, J MOL NEUROSCI, V17, P101, DOI 10.1385/JMN:17:2:101; Nimmerjahn F, 2005, SCIENCE, V310, P1510, DOI 10.1126/science.1118948; Ossenkoppele R, 2012, EUR J NUCL MED MOL I, V39, P990, DOI 10.1007/s00259-012-2102-3; Ostrowitzki S, 2012, ARCH NEUROL-CHICAGO, V69, P198, DOI 10.1001/archneurol.2011.1538; Pfeifer M, 2002, SCIENCE, V298, P1379, DOI 10.1126/science.1078259; Price JL, 2009, NEUROBIOL AGING, V30, P1026, DOI 10.1016/j.neurobiolaging.2009.04.002; Pul R, 2011, EXPERT OPIN BIOL TH, V11, P343, DOI 10.1517/14712598.2011.552884; Racke MM, 2005, J NEUROSCI, V25, P629, DOI 10.1523/JNEUROSCI.4337-04.2005; Rinne JO, 2010, LANCET NEUROL, V9, P363, DOI 10.1016/S1474-4422(10)70043-0; Saido TC, 1996, NEUROSCI LETT, V215, P173, DOI 10.1016/0304-3940(96)12970-0; Saido TC, 1998, NEUROBIOL AGING, V19, pS69, DOI 10.1016/S0197-4580(98)00033-5; SAIDO TC, 1995, NEURON, V14, P457, DOI 10.1016/0896-6273(95)90301-1; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Schilling S, 2008, NAT MED, V14, P1106, DOI 10.1038/nm.1872; Schilling S, 2006, BIOCHEMISTRY-US, V45, P12393, DOI 10.1021/bi0612667; Schlenzig D, 2009, BIOCHEMISTRY-US, V48, P7072, DOI 10.1021/bi900818a; Schroeter S, 2008, J NEUROSCI, V28, P6787, DOI 10.1523/JNEUROSCI.2377-07.2008; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P367, DOI 10.1016/j.jalz.2011.05.2351; Tseng BP, 1999, BIOCHEMISTRY-US, V38, P10424, DOI 10.1021/bi990718v; Villemagne VL, 2011, ANN NEUROL, V69, P181, DOI 10.1002/ana.22248; Wang A, 2011, J NEUROSCI, V31, P4124, DOI 10.1523/JNEUROSCI.5077-10.2011; Wilcock DM, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-24; Winkler DT, 2001, J NEUROSCI, V21, P1619, DOI 10.1523/JNEUROSCI.21-05-01619.2001; Yamada K, 2009, J NEUROSCI, V29, P11393, DOI 10.1523/JNEUROSCI.2021-09.2009; Yates PA, 2011, NEUROLOGY, V77, P48, DOI 10.1212/WNL.0b013e318221ad36	54	190	200	0	42	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	DEC 6	2012	76	5					908	920		10.1016/j.neuron.2012.10.029	http://dx.doi.org/10.1016/j.neuron.2012.10.029			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	053OX	23217740	Bronze			2023-01-03	WOS:000312283400008
J	Pawaria, S; Kropp, LE; Binder, RJ				Pawaria, Sudesh; Kropp, Laura E.; Binder, Robert J.			Immunotherapy of Tumors with alpha(2)-Macroglobulin-Antigen Complexes Pre-Formed In Vivo	PLOS ONE			English	Article							HEAT-SHOCK PROTEINS; PEPTIDE COMPLEXES; T-CELLS; BINDING-PROTEIN; RECEPTOR; ANTIGEN; VACCINE; CD91; INHIBITORS; CANCER	The cell surface receptor CD91/LRP-1 binds to immunogenic heat shock proteins (HSP) and alpha M-2 ligands to elicit T cell immune responses. In order to generate specific immune responses, the peptides chaperoned by HSPs or alpha M-2 are cross-presented on MHC molecules to T cells. While the immunogenic HSPs naturally chaperone peptides within cells and can be purified as an intact HSP-peptide complex, the peptides have had to be complexed artificially to alpha M-2 in previous studies. Here, we show that immunogenic alpha M-2-peptide complexes can be isolated from the blood of tumor-bearing mice without further experimental manipulation in vitro demonstrating the natural association of tumor antigens with alpha M-2. The naturally formed immunogenic alpha M-2-peptide complexes are effective in prophylaxis and therapy of cancer in mouse models. We investigate the mechanisms of cross-presentation of associated peptides and co-stimulation by APCs that interact with alpha M-2. These data have implications for vaccine design in immunotherapy of cancer and infectious disease.	[Binder, Robert J.] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15260 USA; [Pawaria, Sudesh] Univ Pittsburgh, Dept Rheumatol, Pittsburgh, PA USA; [Kropp, Laura E.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Binder, RJ (corresponding author), Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15260 USA.	rjb42@pitt.edu			National Institutes of Health [AI079057, CA137133, CA90440]; NATIONAL CANCER INSTITUTE [P50CA090440, K22CA137133] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI079057] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by National Institutes of Health Grant AI079057, CA137133 and CA90440 to RJB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Berwin B, 2003, EMBO J, V22, P6127, DOI 10.1093/emboj/cdg572; Binder RJ, 2005, NAT IMMUNOL, V6, P593, DOI 10.1038/ni1201; Binder RJ, 2004, METHODS, V32, P29, DOI 10.1016/S1046-2023(03)00184-1; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; Binder RJ, 2001, J IMMUNOL, V166, P4968, DOI 10.4049/jimmunol.166.8.4968; Binder Robert J, 2002, Cancer Immun, V2, P16; Binder RJ, 2009, CURR OPIN MOL THER, V11, P62; Birkenmeier G., 2001, MOD ASP IMMUNOBIOL, V2, P32; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; CHU CT, 1993, J IMMUNOL, V150, P48; Feige JJ, 1996, HORM RES, V45, P227, DOI 10.1159/000184793; Hekim C, 2010, PROSTATE, V70, P482, DOI 10.1002/pros.21082; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Jockheck-Clark AR, 2010, J IMMUNOL, V185, P6819, DOI 10.4049/jimmunol.1000448; Karanikas V, 2010, IMMUNOL CELL BIOL, V88, P575, DOI 10.1038/icb.2010.8; KLEIN G, 1960, CANCER RES, V20, P1561; LEGRES LG, 1995, J BIOL CHEM, V270, P8381, DOI 10.1074/jbc.270.15.8381; Misra UK, 2004, CELL SIGNAL, V16, P929, DOI 10.1016/j.cellsig.2004.01.003; MITSUDA S, 1993, BIOCHEM BIOPH RES CO, V194, P1155, DOI 10.1006/bbrc.1993.1943; Mo A, 2011, VACCINE, V29, P8530, DOI 10.1016/j.vaccine.2011.07.011; Pawaria S, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1524; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; SHASTRI N, 1993, J IMMUNOL, V150, P2724; Srivastava N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006094; Srivastava PK, 2009, EXPERT OPIN BIOL TH, V9, P179, DOI [10.1517/14712590802633918, 10.1517/14712590802633918 ]; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Tamura Y, 1997, SCIENCE, V278, P117, DOI 10.1126/science.278.5335.117; Testori A, 2008, J CLIN ONCOL, V26, P955, DOI 10.1200/JCO.2007.11.9941; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VANLEUVEN F, 1982, BIOCHEM J, V201, P119, DOI 10.1042/bj2010119; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; Wood C, 2008, LANCET, V372, P145, DOI 10.1016/S0140-6736(08)60697-2	36	6	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2012	7	11							e50365	10.1371/journal.pone.0050365	http://dx.doi.org/10.1371/journal.pone.0050365			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	054WM	23226267	gold, Green Submitted, Green Published			2023-01-03	WOS:000312376100077
J	Bianco, A; Flotta, D; Lotito, F; Nobile, CGA; Pileggi, C; Pavia, M				Bianco, Aida; Flotta, Domenico; Lotito, Francesca; Nobile, Carmelo G. A.; Pileggi, Claudia; Pavia, Maria		Collaborative Working Grp	Validity and Reliability of a Tool for Determining Appropriateness of Days of Stay: An Observational Study in the Orthopedic Intensive Rehabilitation Facilities in Italy	PLOS ONE			English	Article							HOSPITAL-CARE; VALIDATION; CENTERS	Objectives: To test the validity and reliability of a tool specifically developed for the evaluation of appropriateness in rehabilitation facilities and to assess the prevalence of appropriateness of the days of stay. Methods: The tool underwent a process of cross-cultural translation, content validity, and test-retest validity. Two hospital-based rehabilitation wards providing intensive rehabilitation care located in the Region of Calabria, Southern Italy, were randomly selected. A review of medical records on a random sample of patients aged 18 or more was performed. Results: The process of validation resulted in modifying some of the criteria used for the evaluation of appropriateness. Test-retest reliability showed that the agreement and the k statistic for the assessment of the appropriateness of days of stay were 93.4% and 0.82, respectively. A total of 371 patient days was reviewed, and 22.9% of the days of stay in the sample were judged to be inappropriate. The most frequently selected appropriateness criterion was the evaluation of patients by rehabilitation professionals for at least 3 hours on the index day (40.8%); moreover, the most frequent primary reason accounting for the inappropriate days of stay was social and/or family environment issues (34.1%). Conclusions: The findings showed that the tool used is reliable and have adequate validity to measure the extent of appropriateness of days of stay in rehabilitation facilities and that the prevalence of inappropriateness is contained in the investigated settings. Further research is needed to expand appropriateness evaluation to other rehabilitation settings, and to investigate more thoroughly internal and external causes of inappropriate use of rehabilitation services.	[Bianco, Aida; Flotta, Domenico; Lotito, Francesca; Nobile, Carmelo G. A.; Pileggi, Claudia; Pavia, Maria; Collaborative Working Grp] Univ Catanzaro Magna Graecia, Dept Hlth Sci, Catanzaro, Italy	Magna Graecia University of Catanzaro	Pavia, M (corresponding author), Univ Catanzaro Magna Graecia, Dept Hlth Sci, Catanzaro, Italy.	pavia@unicz.it	Bianco, Aida/R-6612-2016; PILEGGI, Claudia/AGU-6397-2022	PILEGGI, Claudia/0000-0002-6288-5540; BIANCO, Aida/0000-0003-4674-0306; NOBILE, Carmelo Giuseppe Angelo/0000-0002-0762-513X; PAVIA, Maria/0000-0003-3879-1322	Programs of Scientific Research of Relevant National Interest by the Italian Ministry of University and Research [MIUR/PRIN2008-H8YFRE]	Programs of Scientific Research of Relevant National Interest by the Italian Ministry of University and Research	This work was supported by the following Research Grants: Programs of Scientific Research of Relevant National Interest by the Italian Ministry of University and Research (MIUR/PRIN2008-H8YFRE). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angelillo IF, 2000, PUBLIC HEALTH, V114, P9, DOI 10.1038/sj.ph.1900609; [Anonymous], 2009, STAT REL 11 STAT SOF; Bianco A, 2003, PUBLIC HEALTH, V117, P250, DOI 10.1016/S0033-3506(03)00069-6; Bianco A, 2003, PEDIATRICS, V112, P124, DOI 10.1542/peds.112.1.124; Bianco A, 2002, PUBLIC HEALTH, V116, P368, DOI 10.1038/sj.ph.1900853; Bianco A, 2006, AGING CLIN EXP RES, V18, P249; Buntin MB, 2007, ARCH PHYS MED REHAB, V88, P1488, DOI 10.1016/j.apmr.2007.07.023; Castaldi S, 2010, J Prev Med Hyg, V51, P116; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chen LK, 2010, ANN MED, V42, P630, DOI 10.3109/07853890.2010.521763; GERTMAN PM, 1981, MED CARE, V19, P855, DOI 10.1097/00005650-198108000-00005; Gruppo di Lavoro sulla Riabilitazione Ministero della Salute, 2010, PIAN IND RIAB; Guile R, 2009, INT J QUAL HEALTH C, V21, P198, DOI 10.1093/intqhc/mzp008; GUILLEMIN F, 1993, J CLIN EPIDEMIOL, V46, P1417, DOI 10.1016/0895-4356(93)90142-N; Lim WK, 2003, MED J AUSTRALIA, V178, P262, DOI 10.5694/j.1326-5377.2003.tb05191.x; Ministero della Salute, 2012, PIAN NAZ PREV 2010 2; Paille-Ricolleau C, 2012, INT J QUAL HEALTH C, V24, P121, DOI 10.1093/intqhc/mzr089; Pileggi C, 2004, PUBLIC HEALTH, V118, P284, DOI 10.1016/j.puhe.2003.06.002; Poulos CJ, 2010, J REHABIL MED, V42, P246, DOI 10.2340/16501977-0506; Turner-Stokes L, 2008, J REHABIL MED, V40, P691, DOI 10.2340/16501977-0265	20	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2012	7	11							e50260	10.1371/journal.pone.0050260	http://dx.doi.org/10.1371/journal.pone.0050260			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	047ER	23185588	gold, Green Published, Green Submitted			2023-01-03	WOS:000311821000208
J	Mehta, S; Burry, L; Cook, D; Fergusson, D; Steinberg, M; Granton, J; Herridge, M; Ferguson, N; Devlin, J; Tanios, M; Dodek, P; Fowler, R; Burns, K; Jacka, M; Olafson, K; Skrobik, Y; Hebert, P; Sabri, E; Meade, M				Mehta, Sangeeta; Burry, Lisa; Cook, Deborah; Fergusson, Dean; Steinberg, Marilyn; Granton, John; Herridge, Margaret; Ferguson, Niall; Devlin, John; Tanios, Maged; Dodek, Peter; Fowler, Robert; Burns, Karen; Jacka, Michael; Olafson, Kendiss; Skrobik, Yoanna; Hebert, Paul; Sabri, Elham; Meade, Maureen		SLEAP Investigators; Canadian Critical Care Trials Grp	Daily Sedation Interruption in Mechanically Ventilated Critically Ill Patients Cared for With a Sedation Protocol A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEUROMUSCULAR BLOCKING-AGENTS; ANALGESICS; INFUSIONS; DELIRIUM; SCALE	Context Protocolized sedation and daily sedation interruption are 2 strategies to minimize sedation and reduce the duration of mechanical ventilation and intensive care unit (ICU) stay. Wehypothesized that combining these strategies would augment the benefits. Objective To compare protocolized sedation with protocolized sedation plus daily sedation interruption in critically ill patients. Design, Setting, and Patients Randomized controlled trial of 430 critically ill, mechanically ventilated adults conducted in 16 tertiary care medical and surgical ICUs in Canada and the United States between January 2008 and July 2011. Intervention Continuous opioid and/or benzodiazepine infusions and random allocation to protocolized sedation (n=209) (control) or to protocolized sedation plus daily sedation interruption (n=214). Using validated scales, nurses titrated infusions to achieve light sedation. For patients receiving daily interruption, nurses resumed infusions, if indicated, at half of previous doses. Patients were assessed for delirium and for readiness for unassisted breathing. Main Outcome Measure Time to successful extubation. Secondary outcomes included duration of stay, doses of sedatives and opioids, unintentional device removal, delirium, and nurse and respiratory therapist clinical workload (on a 10-point visual analog scale [VAS]). Results Median time to successful extubation was 7 days in both the interruption and control groups (median [IQR], 7 [4-13] vs 7 [3-12]; interruption group hazard ratio, 1.08; 95% CI, 0.86-1.35; P=.52). Duration of ICU stay (median [IQR], 10 [5-17] days vs 10 [6-20] days; P=.36) and hospital stay (median [IQR], 20 [10-36] days vs 20 [10-48] days; P=.42) did not differ between the daily interruption and control groups, respectively. Daily interruption was associated with higher mean daily doses of midazolam (102 mg/d vs 82 mg/d; P=.04) and fentanyl (median [IQR], 550 [50-1850] vs 260 [0-1400]; P<.001) and more daily boluses of benzodiazepines (mean, 0.253 vs 0.177; P=.007) and opiates (mean, 2.18 vs 1.79; P<.001). Unintentional endotracheal tube removal occurred in 10 of 214 (4.7%) vs 12 of 207 patients (5.8%) in the interruption and control groups, respectively (relative risk, 0.82; 95% CI, 0.36-1.84; P=.64). Rates of delirium were not significantly different between groups (53.3% vs 54.1%; relative risk, 0.98; 95% CI, 0.82-1.17; P=.83). Nurse workload was greater in the interruption group (VAS score, 4.22 vs 3.80; mean difference, 0.41; 95% CI, 0.17-0.66; P=.001). Conclusion For mechanically ventilated adults managed with protocolized sedation, the addition of daily sedation interruption did not reduce the duration of mechanical ventilation or ICU stay.	[Mehta, Sangeeta] Mt Sinai Hosp, Div Crit Care, Dept Med & Interdept, Toronto, ON M5G 1X5, Canada; [Mehta, Sangeeta; Burry, Lisa] Univ Toronto, Toronto, ON, Canada; [Burry, Lisa] Mt Sinai Hosp, Dept Pharm & Med, Toronto, ON M5G 1X5, Canada; [Cook, Deborah; Meade, Maureen] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Cook, Deborah; Meade, Maureen] McMaster Univ, Dept Clin Epidemiol, Hamilton, ON L8S 4L8, Canada; [Cook, Deborah; Meade, Maureen] McMaster Univ, Dept Biostat, Hamilton, ON, Canada; [Cook, Deborah] St Josephs Healthcare, Hamilton, ON, Canada; [Fergusson, Dean] Univ Ottawa, Clin Epidemiol Program, Ottawa Hosp, Res Inst, Ottawa, ON, Canada; [Fergusson, Dean] Univ Ottawa, Fac Med, Ottawa, ON, Canada; [Granton, John] Univ Toronto, Toronto Gen Hosp, Div Respirol, Interdept Div Crit Care,Fac Med, Toronto, ON M5S 1A1, Canada; [Devlin, John] Univ Toronto, Interdept Div Crit Care Med, Univ Hlth Network, Toronto, ON M5S 1A1, Canada; [Tanios, Maged] Long Beach Mem Med Ctr, Dept Med, Long Beach, CA USA; [Dodek, Peter] St Pauls Hosp, Div Crit Care Med, Vancouver, BC V6Z 1Y6, Canada; [Dodek, Peter] St Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC V6Z 1Y6, Canada; [Fowler, Robert] Sunnybrook Med Ctr, Dept Med, Toronto, ON, Canada; [Fowler, Robert] Sunnybrook Med Ctr, Dept Crit Care Med, Toronto, ON, Canada; [Fowler, Robert; Burns, Karen] St Michaels Hosp, Interdept Div Crit Care Med, Toronto, ON M5B 1W8, Canada; [Burns, Karen] St Michaels Hosp, Inst Hlth Policy Management & Evaluat, Toronto, ON M5B 1W8, Canada; [Burns, Karen] St Michaels Hosp, Keenan Res Ctr, Toronto, ON M5B 1W8, Canada; [Burns, Karen] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Jacka, Michael] Univ Alberta Hosp, Dept Anesthesiol, Edmonton, AB T6G 2B7, Canada; [Jacka, Michael] Univ Alberta Hosp, Dept Crit Care, Edmonton, AB T6G 2B7, Canada; [Olafson, Kendiss] Univ Manitoba, Fac Med, Sect Crit Care, Dept Med, Winnipeg, MB, Canada; [Skrobik, Yoanna] Univ Montreal, Dept Med, Hop Maison Neuve Rosemont, Montreal, PQ H3C 3J7, Canada; [Hebert, Paul] Univ Ottawa, Dept Crit Care, Ottawa, ON, Canada; [Meade, Maureen] Hamilton Hlth Sci, Dept Crit Care, Hamilton, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; McMaster University; McMaster University; McMaster University; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; St. Paul's Hospital; University of Saskatchewan; St. Paul's Hospital; University of Saskatchewan; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Alberta; University of Alberta; University of Manitoba; Universite de Montreal; University of Ottawa; McMaster University	Mehta, S (corresponding author), Mt Sinai Hosp, Div Crit Care, Dept Med & Interdept, 600 Univ Ave,Ste 18-216, Toronto, ON M5G 1X5, Canada.	geeta.mehta@utoronto.ca	Burry, Lisa D/C-6546-2017; Skrobik, Yoanna/K-8165-2014; Ferguson, Niall/D-7619-2019; Sabri, Elham/GXG-8198-2022; Mehta, Sangeeta/C-4623-2015	Burry, Lisa D/0000-0002-6545-3890; Skrobik, Yoanna/0000-0002-5315-6020; Ferguson, Niall/0000-0002-6213-5264; Herridge, Margaret/0000-0002-2903-1631; Fergusson, Dean/0000-0002-3389-2485	Canadian Institutes of Health Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Funding was provided by the Canadian Institutes of Health Research. Dr Cook is a Canada Research Chair of the Canadian Institutes for Health Research. Dr Burns holds a Clinician Scientist Phase 2 Award of the Canadian Institutes for Health Research. Dr Fowler is a Clinician Scientist of the Heart and Stroke Foundation (Ontario).	Anifantaki S, 2009, J ADV NURS, V65, P1054, DOI 10.1111/j.1365-2648.2009.04967.x; Arroliga AC, 2008, CRIT CARE MED, V36, P1083, DOI 10.1097/CCM.0B013E3181653895; Augustes R, 2011, ANAESTH INTENS CARE, V39, P401, DOI 10.1177/0310057X1103900310; Bergeron N, 2001, INTENS CARE MED, V27, P859, DOI 10.1007/s001340100909; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; Bucknall TK, 2008, CRIT CARE MED, V36, P1444, DOI 10.1097/CCM.0b013e318168f82d; Burry L, 2009, AM J RESP CRIT CARE, V179; Burry L, 2011, INTENS CARE MED, V37, pS83; de Wit M, 2008, CRIT CARE, V12, DOI 10.1186/cc6908; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Mehta S, 2006, CRIT CARE MED, V34, P374, DOI 10.1097/01.CCM.0000196830.61965.F1; Mehta S, 2008, CRIT CARE MED, V36, P2092, DOI 10.1097/CCM.0b013e31817bff85; O'Connor M, 2010, AM J CRIT CARE, V19, P285, DOI 10.4037/ajcc2009541; Ouimet S, 2007, INTENS CARE MED, V33, P66, DOI 10.1007/s00134-006-0399-8; Patanwala AE, 2007, ANN PHARMACOTHER, V41, P255, DOI 10.1345/aph.1H421; Patel RP, 2009, CRIT CARE MED, V37, P825, DOI 10.1097/CCM.0b013e31819b8608; Riker RR, 1999, CRIT CARE MED, V27, P1325, DOI 10.1097/00003246-199907000-00022; Roberts RJ, 2010, J CRIT CARE, V25; Ruokonen E, 2009, INTENS CARE MED, V35, P282, DOI 10.1007/s00134-008-1296-0; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Tanios MA, 2009, J CRIT CARE, V24, P66, DOI 10.1016/j.jcrc.2008.03.037; Weisbrodt L, 2011, AM J CRIT CARE, V20, pE90, DOI 10.4037/ajcc2011415; Yilmaz C, 2010, ULUS TRAVMA ACIL CER, V16, P521	26	301	323	4	135	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 21	2012	308	19					1985	1992		10.1001/jama.2012.13872	http://dx.doi.org/10.1001/jama.2012.13872			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	040AQ	23180503				2023-01-03	WOS:000311291400022
J	Yunos, NM; Bellomo, R; Hegarty, C; Story, D; Ho, L; Bailey, M				Yunos, Nor'azim Mohd; Bellomo, Rinaldo; Hegarty, Colin; Story, David; Ho, Lisa; Bailey, Michael			Association Between a Chloride-Liberal vs Chloride-Restrictive Intravenous Fluid Administration Strategy and Kidney Injury in Critically Ill Adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERNATIONAL CONSENSUS CONFERENCE; RENAL-REPLACEMENT THERAPY; HYPERONCOTIC COLLOIDS; SALINE RESUSCITATION; 0.9-PERCENT SALINE; CODE RATES; BLOOD-FLOW; ACID-BASE; MORTALITY; ALBUMIN	Context Administration of traditional chloride-liberal intravenous fluids may precipitate acute kidney injury (AKI). Objective To assess the association of a chloride-restrictive (vs chloride-liberal) intravenous fluid strategy with AKI in critically ill patients. Design, Setting, and Patients Prospective, open-label, sequential period pilot study of 760 patients admitted consecutively to the intensive care unit (ICU) during the control period (February 18 to August 17, 2008) compared with 773 patients admitted consecutively during the intervention period (February 18 to August 17, 2009) at a university-affiliated hospital in Melbourne, Australia. Interventions During the control period, patients received standard intravenous fluids. After a 6-month phase-out period (August 18, 2008, to February 17, 2009), any use of chloride-rich intravenous fluids (0.9% saline, 4% succinylated gelatin solution, or 4% albumin solution) was restricted to attending specialist approval only during the intervention period; patients instead received a lactated solution (Hartmann solution), a balanced solution (Plasma-Lyte 148), and chloride-poor 20% albumin. Main Outcome Measures The primary outcomes included increase from baseline to peak creatinine level in the ICU and incidence of AKI according to the risk, injury, failure, loss, end-stage (RIFLE) classification. Secondary post hoc analysis outcomes included the need for renal replacement therapy (RRT), length of stay in ICU and hospital, and survival. Results Chloride administration decreased by 144 504 mmol (from 694 to 496 mmol/patient) from the control period to the intervention period. Comparing the control period with the intervention period, the mean serum creatinine level increase while in the ICU was 22.6 mu mol/L (95% CI, 17.5-27.7 mu mol/L) vs 14.8 mu mol/L (95% CI, 9.8-19.9 mu mol/L) (P=.03), the incidence of injury and failure class of RIFLE-defined AKI was 14%(95% CI, 11%-16%; n=105) vs 8.4% (95% CI, 6.4%-10%; n=65) (P<.001), and the use of RRT was 10% (95% CI, 8.1%-12%; n=78) vs 6.3% (95% CI, 4.6%-8.1%; n=49) (P=.005). After adjustment for covariates, this association remained for incidence of injury and failure class of RIFLE-defined AKI (odds ratio, 0.52 [95% CI, 0.37-0.75]; P<.001) and use of RRT (odds ratio, 0.52 [95% CI, 0.33-0.81]; P=.004). There were no differences in hospital mortality, hospital or ICU length of stay, or need for RRT after hospital discharge. Conclusion The implementation of a chloride-restrictive strategy in a tertiary ICU was associated with a significant decrease in the incidence of AKI and use of RRT.	[Bellomo, Rinaldo] Austin Hosp, Dept Intens Care, Melbourne, Vic 3084, Australia; [Hegarty, Colin] Austin Hosp, Dept Lab Med, Melbourne, Vic 3084, Australia; [Story, David] Austin Hosp, Dept Anaesthesia, Melbourne, Vic 3084, Australia; [Ho, Lisa] Austin Hosp, Dept Pharm, Melbourne, Vic 3084, Australia; [Bellomo, Rinaldo; Bailey, Michael] Monash Univ, Dept Epidemiol & Prevent Med, Australia & New Zealand Intens Care Res Ctr, Melbourne, Vic 3004, Australia	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Monash University	Bellomo, R (corresponding author), Austin Hlth, Heidelberg, Vic 3084, Australia.	rinaldo.bellomo@austin.org.au	Bailey, Michael J/A-4499-2012; Yunos, Nor'azim Mohd/U-3994-2017	Bailey, Michael J/0000-0002-5551-1401; Yunos, Nor'azim Mohd/0000-0002-5890-4825; Bellomo, Rinaldo/0000-0002-1650-8939; Story, David/0000-0002-6479-1310	Baxter Healthcare	Baxter Healthcare	The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Story reported receiving an unconditional research grant from Baxter Healthcare to fund other fluid studies. No other authors reported disclosures.	Bagshaw SM, 2007, CRIT CARE, V11, DOI 10.1186/cc5949; Bagshaw SM, 2011, CRIT CARE RESUSC, V13, P201; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Bellomo R, 2009, NEW ENGL J MED, V361, P1627, DOI 10.1056/NEJMoa0902413; Brochard L, 2010, AM J RESP CRIT CARE, V181, P1128, DOI 10.1164/rccm.200711-1664ST; BULLIVANT EMA, 1989, AM J PHYSIOL, V256, pF152, DOI 10.1152/ajprenal.1989.256.1.F152; Chan PS, 2008, JAMA-J AM MED ASSOC, V300, P2506, DOI 10.1001/jama.2008.715; Chowdhury AH, 2012, ANN SURG, V256, P18, DOI 10.1097/SLA.0b013e318256be72; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Finfer S, 2010, CRIT CARE, V14, DOI 10.1186/cc9293; Guidet B, 2010, CRIT CARE, V14, DOI 10.1186/cc9230; HALL JE, 1976, AM J PHYSIOL, V231, P1550, DOI 10.1152/ajplegacy.1976.231.5.1550; Hashimoto S, 2004, KIDNEY BLOOD PRESS R, V27, P35, DOI 10.1159/000075621; Jacob M, 2008, CRIT CARE, V12, DOI 10.1186/cc6812; McIntyre LA, 2007, CRIT CARE, V11, DOI 10.1186/cc5962; Oliveira RP, 2002, CRIT CARE, V6, P418, DOI 10.1186/cc1541; Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242; QUILLEY CP, 1993, BRIT J PHARMACOL, V108, P106, DOI 10.1111/j.1476-5381.1993.tb13447.x; RENAL Study Investigators, 2008, Crit Care Resusc, V10, P225; SALOMONSSON M, 1993, ACTA PHYSIOL SCAND, V147, P305, DOI 10.1111/j.1748-1716.1993.tb09503.x; Saw MM, 2012, ANAESTH INTENS CARE, V40, P17, DOI 10.1177/0310057X1204000104; SCHNERMANN J, 1976, PFLUG ARCH EUR J PHY, V362, P229, DOI 10.1007/BF00581175; Schortgen F, 2001, LANCET, V357, P911, DOI 10.1016/S0140-6736(00)04211-2; Schortgen F, 2008, INTENS CARE MED, V34, P2157, DOI 10.1007/s00134-008-1225-2; Sharek PJ, 2007, JAMA-J AM MED ASSOC, V298, P2267, DOI 10.1001/jama.298.19.2267; Shaw AD, 2012, ANN SURG, V255, P821, DOI 10.1097/SLA.0b013e31825074f5; Smith RJ, 2010, CRIT CARE RESUSC, V12, P235; Srisawat N, 2010, CRIT CARE, V14, DOI 10.1186/cc8933; STOCKWELL MA, 1992, ANAESTHESIA, V47, P7, DOI 10.1111/j.1365-2044.1992.tb01942.x; WAKIM KG, 1970, J AMER MED ASSOC, V214, P1710, DOI 10.1001/jama.1970.03180090074027; Wan L, 2011, CRIT CARE RESUSC, V13, P262; Wiedermann CJ, 2010, CRIT CARE, V14, DOI 10.1186/cc9308; WILCOX CS, 1983, J CLIN INVEST, V71, P726, DOI 10.1172/JCI110820; Wilkes NJ, 2001, ANESTH ANALG, V93, P811, DOI 10.1097/00000539-200110000-00003; Williams EL, 1999, ANESTH ANALG, V88, P999, DOI 10.1097/00000539-199905000-00006; Yunos NM, 2011, CRIT CARE MED, V39, P2419, DOI 10.1097/CCM.0b013e31822571e5; Yunos NM, 2010, CRIT CARE, V14, DOI 10.1186/cc9052; Zavada J, 2010, NEPHROL DIAL TRANSPL, V25, P3911, DOI 10.1093/ndt/gfp766	39	747	786	1	29	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 17	2012	308	15					1566	1572		10.1001/jama.2012.13356	http://dx.doi.org/10.1001/jama.2012.13356			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	021AQ	23073953	Bronze			2023-01-03	WOS:000309858100023
J	Chang, YJ; Hsieh, BT				Chang, Yuan-Jen; Hsieh, Bor-Tsung			Effect of Composition Interactions on the Dose Response of an N-Isopropylacrylamide Gel Dosimeter	PLOS ONE			English	Article							OPTICAL-CT APPARATUS; ACID-BASED GEL; COMPUTED-TOMOGRAPHY; POLYMER GELS; FT-RAMAN; DISTRIBUTIONS; SENSITIVITY; STABILITY; SCANNER; NMR	In this study, a two-level full factorial design was used to identify the effects of the interactions between compositions in an N-isopropylacrylamide (NIPAM) gel dosimeter involving the following variables: (A) gelatin, (B) NIPAM, (C) the crosslinker N, N'-methylene-bis-acrylamide (Bis), and (D) the antioxidant tetrakis (hydroxymethyl) phosphonium chloride (THPC). The dose range was from 0 Gy to 5 Gy. Optical computed tomography was used to scan the polymer gel dosimeter. Each component was set to two levels for all four variables, including (A) 4% and 6%, (B) 4% and 6%, (C) 2% and 4%, as well as (D) 5 and 15 mM. Response surface methodology and a central composite design were adopted for the quantitative investigation of the respective interaction effects on the dose response curve of the gel. The results showed that the contributions of the interaction effects, i.e., AB (6.22%), AC (8.38%), AD (7.74%), BC (9.44%), ABC (18.24%), BCD (12.66%), and ABCD (13.4%), were greater than those of the four main effects, accounting for over 76.08% of the total variability. These results also indicated that the NIPAM gel recipe with the highest sensitivity was at 40%C (mass fraction of Bis).	[Chang, Yuan-Jen] Cent Taiwan Univ Sci & Technol, Dept Management Informat Syst, Taichung, Taiwan; [Chang, Yuan-Jen] Cent Taiwan Univ Sci & Technol, Inst Biomed Engn & Mat Sci, Taichung, Taiwan; [Hsieh, Bor-Tsung] Cent Taiwan Univ Sci & Technol, Dept Med Imaging & Radiol Sci, Taichung, Taiwan	Central Taiwan University Science & Technology; Central Taiwan University Science & Technology; Central Taiwan University Science & Technology	Chang, YJ (corresponding author), Cent Taiwan Univ Sci & Technol, Dept Management Informat Syst, Taichung, Taiwan.	ronchang@ctust.edu.tw			National Science Council of Taiwan [NSC 99-2632-B-166-001-MY3]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan)	This research was funded by the National Science Council of Taiwan (NSC 99-2632-B-166-001-MY3). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baldock C, 2010, PHYS MED BIOL, V55, pR1, DOI 10.1088/0031-9155/55/5/R01; Brindha S, 2004, PHYS MED BIOL, V49, pN353, DOI 10.1088/0031-9155/49/20/N01; Chang YJ, 2011, NUCL INSTRUM METH A, V652, P783, DOI 10.1016/j.nima.2010.09.097; Chen DC, 2012, J MED BIOL IN PRESS; Conklin J, 2008, J PHYS C SER, V56, P211; De Deene Y, 2007, PHYS MED BIOL, V52, P2719, DOI 10.1088/0031-9155/52/10/006; De Deene Y, 2006, PHYS MED BIOL, V51, P653, DOI 10.1088/0031-9155/51/3/012; De Deene Y, 2002, PHYS MED BIOL, V47, P2459, DOI 10.1088/0031-9155/47/14/307; De Deene Y, 2002, PHYS MED BIOL, V47, P3441, DOI 10.1088/0031-9155/47/19/301; De Deene Y, 2000, PHYS MED BIOL, V45, P859, DOI 10.1088/0031-9155/45/4/304; Fong PM, 2001, PHYS MED BIOL, V46, P3105, DOI 10.1088/0031-9155/46/12/303; Gore JC, 1996, PHYS MED BIOL, V41, P2695, DOI 10.1088/0031-9155/41/12/009; Guo PY, 2006, MED PHYS, V33, P3962, DOI 10.1118/1.2349686; Hayashi S, 2010, RADIAT PHYS CHEM, V79, P803, DOI 10.1016/j.radphyschem.2010.01.014; Jirasek A, 2006, PHYS MED BIOL, V51, P1891, DOI 10.1088/0031-9155/51/7/018; Jirasek AI, 2001, PHYS MED BIOL, V46, P1949, DOI 10.1088/0031-9155/46/7/315; Koeva VI, 2008, MACROMOL SYMP, V261, P157, DOI 10.1002/masy.200850121; Krstajic N, 2007, PHYS MED BIOL, V52, P3693, DOI 10.1088/0031-9155/52/13/003; Krstajic N, 2007, PHYS MED BIOL, V52, pN257, DOI 10.1088/0031-9155/52/11/N01; Krstajic N, 2006, PHYS MED BIOL, V51, P2055, DOI 10.1088/0031-9155/51/8/007; Lepage M, 2001, J APPL POLYM SCI, V79, P1572, DOI 10.1002/1097-4628(20010228)79:9<1572::AID-APP50>3.0.CO;2-B; Massillon-JL G, 2010, APPL RADIAT ISOTOPES, V68, P144, DOI 10.1016/j.apradiso.2009.08.016; Montgomery DC, 2005, DESIGN ANAL EXPT, p[203, 405]; Oldham M, 2001, MED PHYS, V28, P1436, DOI 10.1118/1.1380430; Olding T, 2011, PHYS MED BIOL, V55, P2819; Olding T, 2010, PHYS MED BIOL, V55, P2819, DOI 10.1088/0031-9155/55/10/003; Pak F, 2012, 54 ANN M AAPM; Senden RJ, 2006, PHYS MED BIOL, V51, P3301, DOI 10.1088/0031-9155/51/14/001; Van Doorn T, 2005, PHYS ENG SCI MED, V28, P76; Wuu C. S., 2010, J PHYS C SER, V250, P1; Wuu CS, 2006, MED PHYS, V33, P1412, DOI 10.1118/1.2188820; Wuu CS, 2003, MED PHYS, V30, P132, DOI 10.1118/1.1533749; Xu Y, 2004, MED PHYS, V31, P3024, DOI 10.1118/1.1803674; Xu Y, 2003, MED PHYS, V30, P2257, DOI 10.1118/1.1593837; Xu Y, 2010, MED PHYS, V37, P861, DOI 10.1118/1.3298017	35	4	4	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2012	7	10							e44905	10.1371/journal.pone.0044905	http://dx.doi.org/10.1371/journal.pone.0044905			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	020LH	23077487	Green Published, gold, Green Submitted			2023-01-03	WOS:000309809500005
J	Munugalavadla, V; Mariathasan, S; Slaga, D; Du, C; Berry, L; Del Rosario, G; Yan, Y; Boe, M; Sun, L; Friedman, LS; Chesi, M; Bergsagel, PL; Ebens, A				Munugalavadla, V.; Mariathasan, S.; Slaga, D.; Du, C.; Berry, L.; Del Rosario, G.; Yan, Y.; Boe, M.; Sun, L.; Friedman, L. S.; Chesi, M.; Bergsagel, P. Leif; Ebens, A.			The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma	ONCOGENE			English	Article						GDC-0941; PI3K; multiple myeloma; FoxO3A	ORALLY BIOAVAILABLE INHIBITOR; TARGET; IDENTIFICATION; RAPAMYCIN; PATHWAY; GROWTH; POTENT; KINASE	The phosphatidylinositol 3'-kinase (PI3K) pathway is dysregulated in multiple myeloma (MM); we therefore tested a highly selective class I PI3K inhibitor, GDC-0941, for anti-myeloma activity. Functional and mechanistic studies were first performed in MM cell lines, then extended to primary MM patient samples cultured in vitro. GDC-0941 was then assessed as a single agent and in various combinations in myeloma tumor xenograft models. We show p110 alpha and beta are the predominant PI3K catalytic subunits in MM and that a highly selective class I PI3K inhibitor, GDC-0941, has robust activity as a single agent to induce cell cycle arrest and apoptosis of both MM cell lines and patient myeloma cells. Mechanistic studies revealed an induction of cell cycle arrest at G(0)/G(1), with decreased phospho-FoxO1/3a levels, decreased cyclin D1 and c-myc expression, and an increase in the cell cycle inhibitor, p27kip. Induction of apoptosis correlated with increased expression of the pro-apoptotic BH3-only protein BIM, cleaved caspase 3 and cleaved poly (ADP-ribose) polymerase (PARP). In vitro, GDC-0941 synergized with dexamethasone (Dex) and lenalidomide (combination index values of 0.3-0.4 and 0.4-0.8, respectively); in vivo GDC-0941 has anti-myeloma activity and significantly increases the activity of the standard of care agents in several murine xenograft tumor models (additional tumor growth inhibition of 37-53% (Dex) and 22-72% (lenalidomide)). These data provide a clear therapeutic hypothesis for the inhibition of PI3K and provide a rationale for clinical development of GDC-0941 in myeloma.	[Munugalavadla, V.; Mariathasan, S.; Slaga, D.; Du, C.; Berry, L.; Del Rosario, G.; Sun, L.; Friedman, L. S.; Ebens, A.] Genentech Inc, Dept Canc Immunotherapy & Hematol, San Francisco, CA 94080 USA; [Yan, Y.; Boe, M.] Genentech Inc, Dept Oncol Biomarker Dev, San Francisco, CA 94080 USA; [Chesi, M.; Bergsagel, P. Leif] Mayo Clin, Dept Med, Ctr Comprehens Canc, Scottsdale, AZ USA	Roche Holding; Genentech; Roche Holding; Genentech; Mayo Clinic; Mayo Clinic Phoenix	Munugalavadla, V (corresponding author), Genentech Inc, Dept Canc Immunotherapy & Hematol, 1 DNA Way,MS 231C,Room 14-3166, San Francisco, CA 94080 USA.	veerendm@gene.com	Bergsagel, Peter Leif/A-7842-2011; Du, Changchun/AAW-6540-2020	Bergsagel, Peter Leif/0000-0003-1523-7388; 				Anderson KC, 2011, ANNU REV PATHOL-MECH, V6, P249, DOI 10.1146/annurev-pathol-011110-130249; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Baumann P, 2009, EXP CELL RES, V315, P485, DOI 10.1016/j.yexcr.2008.11.007; Chanan-Khan AA, BR J HAEMATOL, V151, P3; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Dib Amel, 2008, J Natl Cancer Inst Monogr, P25, DOI 10.1093/jncimonographs/lgn011; Drexler HG, 2000, LEUKEMIA RES, V24, P681, DOI 10.1016/S0145-2126(99)00195-2; Ebens A, 2010, ASH ANN M, V116, P3001; Feldman ME, CURR TOP MICROBIOL I, V347, P241; Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d; Gera J, 2011, LEUKEMIA LYMPHOMA, V52, P1857, DOI 10.3109/10428194.2011.580478; Harvey R Donald, 2007, Future Oncol, V3, P639, DOI 10.2217/14796694.3.6.639; Hoang B, 2010, BLOOD, V116, P4560, DOI 10.1182/blood-2010-05-285726; Ikeda H, 2010, BLOOD, V116, P1460, DOI 10.1182/blood-2009-06-222943; Ismail SI, 2010, LEUKEMIA RES, V34, P824, DOI 10.1016/j.leukres.2009.11.018; Jou ST, 2002, MOL CELL BIOL, V22, P8580, DOI 10.1128/MCB.22.24.8580-8591.2002; Kawauchi K, 2009, ANTI-CANCER AGENT ME, V9, P1024, DOI 10.2174/187152009789377772; Kawauchi K, 2009, ANTI-CANCER AGENT ME, V9, P550, DOI 10.2174/187152009788451851; Khwaja A, CURR TOP MICROBIOL I, V347, P169; Kyle RA, 2004, NEW ENGL J MED, V351, P1860, DOI 10.1056/NEJMra041875; Kyle RA, 2009, CLIN LYMPHOMA MYELOM, V9, P278, DOI 10.3816/CLM.2009.n.056; Lee T, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000013; McMillin DW, 2009, CANCER RES, V69, P5835, DOI 10.1158/0008-5472.CAN-08-4285; Munugalavadla V, 2010, ASH ANN M, V116, P4084; Munugalavadla V, 2008, MOL CELL BIOL, V28, P7182, DOI 10.1128/MCB.00920-08; O'Brien C, CLIN CANC RES, V16, P3670; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Podar K, 2009, LEUKEMIA, V23, P10, DOI 10.1038/leu.2008.259; Rahmani M, 2009, BLOOD, V114, P4507, DOI 10.1182/blood-2008-09-177881; Rajkurnar SV, 2007, BEST PRACT RES CL HA, V20, P665, DOI 10.1016/j.beha.2007.10.002; Raynaud FI, 2009, MOL CANCER THER, V8, P1725, DOI 10.1158/1535-7163.MCT-08-1200; Yasui H, 2006, BRIT J HAEMATOL, V132, P385, DOI 10.1111/j.1365-2141.2005.05860.x; Zhang J, 2003, ONCOGENE, V22, P6289, DOI 10.1038/sj.onc.1206718; Zhao L, 2004, CLIN CANCER RES, V10, P7994, DOI 10.1158/1078-0432.CCR-04-1087; Zollinger A, 2008, BLOOD, V112, P3403, DOI 10.1182/blood-2007-11-119362	35	31	34	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					316	325		10.1038/onc.2012.594	http://dx.doi.org/10.1038/onc.2012.594			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318440				2023-01-03	WOS:000330214000006
J	Tilburt, JC; Cassel, CK				Tilburt, Jon C.; Cassel, Christine K.			Why the Ethics of Parsimonious Medicine Is Not the Ethics of Rationing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CARE		[Tilburt, Jon C.] Mayo Clin, Div Gen Internal Med, Biomed Eth Res Unit, Ctr Sci Healthcare Delivery, Rochester, MN 55905 USA; [Cassel, Christine K.] Amer Board Internal Med, Philadelphia, PA USA	Mayo Clinic; American Board of Internal Medicine	Tilburt, JC (corresponding author), Mayo Clin, 200 1st St SW, Rochester, MN 55905 USA.	tilburt.jon@mayo.edu						Berwick DM, 2012, JAMA-J AM MED ASSOC, V307, P1513, DOI 10.1001/jama.2012.362; Brett AS, 2012, JAMA-J AM MED ASSOC, V307, P149, DOI 10.1001/jama.2011.1999; Cassel CK, 2012, JAMA-J AM MED ASSOC, V307, P1801, DOI 10.1001/jama.2012.476; Daniels N., 1985, JUST HLTH CARE STUDI; GRABER GC, 1989, THEORY PRACTICE MED; Institute of Medicine, 2001, COV MATT INS HLTH CA; Sulmasy DP, 2007, J CLIN ONCOL, V25, P217, DOI 10.1200/JCO.2006.08.0481; UBEL PA, 1995, ARCH INTERN MED, V155, P1837, DOI 10.1001/archinte.155.17.1837	8	44	44	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 27	2013	309	8					773	774		10.1001/jama.2013.368	http://dx.doi.org/10.1001/jama.2013.368			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	095KD	23443438				2023-01-03	WOS:000315332200019
J	Copeland, RA; Moyer, MP; Richon, VM				Copeland, R. A.; Moyer, M. P.; Richon, V. M.			Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics	ONCOGENE			English	Review						epigenetics; protein methyltransferases; personalized therapeutics; drug discovery; enzyme inhibitors	HISTONE METHYLTRANSFERASE; SOMATIC MUTATIONS; MULTIPLE-MYELOMA; CONFORMATIONAL ADAPTATION; ELONGATION COMPLEX; H3K79 METHYLATION; LYSINE 27; EZH2; LEUKEMIA; INHIBITORS	The human protein methyltransferases (PMTs) constitute a large enzyme class composed of two families, the protein lysine methyltransferases (PKMTs) and the protein arginine methyltransferases (PRMTs). Examples have been reported of both PKMTs and PRMTs that are genetically altered in specific human cancers, and in several cases these alterations have been demonstrated to confer a unique dependence of the cancer cells on PMT enzymatic activity for the tumorigenic phenotype. Examples of such driver alterations in PMTs will be presented together with a review of current efforts towards the discovery and development of small-molecule inhibitors of these enzymes as personalized cancer therapeutics. Oncogene (2013) 32, 939-946; doi:10.1038/onc.2012.552; published online 19 November 2012	[Copeland, R. A.; Moyer, M. P.; Richon, V. M.] R&D Epizyme Inc, Cambridge, MA 02139 USA		Copeland, RA (corresponding author), R&D Epizyme Inc, 325 Vassar St, Cambridge, MA 02139 USA.	RCopeland@Epizyme.com						Allan M, 2009, BIOORG MED CHEM LETT, V19, P1218, DOI 10.1016/j.bmcl.2008.12.075; Allis CD, 2007, CELL, V131, P633, DOI 10.1016/j.cell.2007.10.039; Arrowsmith CH, 2012, NAT REV DRUG DISCOV, V11, P384, DOI 10.1038/nrd3674; Ayton PM, 2004, MOL CELL BIOL, V24, P10470, DOI 10.1128/MCB.24.23.10470-10478.2004; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Basavapathruni A, 2012, CHEM BIOL DRUG DES, V80, P971, DOI 10.1111/cbdd.12050; Benedikt A, 2011, LEUKEMIA, V25, P135, DOI 10.1038/leu.2010.249; Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010; Burgess J. L., 2012, Patent No. [WO2012005805, 2012005805]; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Cheng XD, 2005, ANNU REV BIOPH BIOM, V34, P267, DOI 10.1146/annurev.biophys.34.040204.144452; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chiang PK, 1998, PHARMACOL THERAPEUT, V77, P115, DOI 10.1016/S0163-7258(97)00089-2; Copeland R. A., 2000, ENZYMES PRACTICAL IN; Copeland R. A., 2012, PCT Int. Appl. Pat., Patent No. [WO 2012034132, 2012034132]; Copeland RA, 2012, DRUG DISCOV TODAY TH, V9, pe83, DOI DOI 10.1016/J.DDSTR.2011.08.001; Copeland RA, 2006, NAT REV DRUG DISCOV, V5, P730, DOI 10.1038/nrd2082; Copeland RA, 2011, FUTURE MED CHEM, V3, P1491, DOI [10.4155/FMC.11.112, 10.4155/fmc.11.112]; Copeland RA, 2010, CURR OPIN CHEM BIOL, V14, P505, DOI 10.1016/j.cbpa.2010.06.174; Copeland RA, 2009, NAT REV DRUG DISCOV, V8, P724, DOI 10.1038/nrd2974; Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009; Duquenne C., 2011, Indazoles, Patent No. 2011140325; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Ferguson A. D., 2011, STRUCTURE; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; He NH, 2011, P NATL ACAD SCI USA, V108, pE636, DOI 10.1073/pnas.1107107108; Hess JL, 2004, P NATL ACAD SCI USA, V101, P16985, DOI 10.1073/pnas.0407898101; Huynh T, 2009, BIOORG MED CHEM LETT, V19, P2924, DOI 10.1016/j.bmcl.2009.04.075; Jo SY, 2011, BLOOD, V117, P4759, DOI 10.1182/blood-2010-12-327668; Keats JJ, 2005, BLOOD, V105, P4060, DOI 10.1182/blood-2004-09-3704; Keats JJ, 2003, BLOOD, V101, P1520, DOI 10.1182/blood-2002-06-1675; Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678; Knight S. D., 2012, PCT Int. Appl. Pat., Patent No. [WO 2012075080, 2012075080]; Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Krivtsov AV, 2008, CANCER CELL, V14, P355, DOI 10.1016/j.ccr.2008.10.001; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017; LaFrance L, 2011, Patent No. [WO2011140324, 2011140324]; Lee YH, 2009, MOL ENDOCRINOL, V23, P425, DOI 10.1210/me.2008-0380; Li B, 2009, J BIOL CHEM, V284, P7970, DOI 10.1074/jbc.M808220200; Lin CQ, 2010, MOL CELL, V37, P429, DOI 10.1016/j.molcel.2010.01.026; Liu F, 2009, J MED CHEM, V52, P7950, DOI 10.1021/jm901543m; Luo MK, 2012, ACS CHEM BIOL, V7, P443, DOI 10.1021/cb200519y; Mahmoudi T, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000539; Marango J, 2008, BLOOD, V111, P3145, DOI 10.1182/blood-2007-06-092122; Martinez-Garcia E, 2011, BLOOD, V117, P211, DOI 10.1182/blood-2010-07-298349; McCabe MT, 2012, P NATL ACAD SCI USA, V109, P2989, DOI 10.1073/pnas.1116418109; Mochizuki-Kashio M, 2011, BLOOD, V118, P6553, DOI 10.1182/blood-2011-03-340554; Mori S, 2010, BIOORGAN MED CHEM, V18, P8158, DOI 10.1016/j.bmc.2010.10.022; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Muntean AG, 2010, CANCER CELL, V17, P609, DOI 10.1016/j.ccr.2010.04.012; Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620; Ntziachristos P, 2012, NAT MED, V18, P298, DOI 10.1038/nm.2651; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Onder TT, 2012, NATURE, V483, P598, DOI 10.1038/nature10953; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Purandare AV, 2008, BIOORG MED CHEM LETT, V18, P4438, DOI 10.1016/j.bmcl.2008.06.026; Richon VM, 2011, CHEM BIOL DRUG DES, V78, P199, DOI 10.1111/j.1747-0285.2011.01135.x; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Slany RK, 2009, HAEMATOL-HEMATOL J, V94, P984, DOI 10.3324/haematol.2008.002436; Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107; Spannhoff A, 2007, BIOORG MED CHEM LETT, V17, P4150, DOI 10.1016/j.bmcl.2007.05.088; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thiel AT, 2010, CANCER CELL, V17, P148, DOI 10.1016/j.ccr.2009.12.034; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; Vedadi M, 2011, NAT CHEM BIOL, V7, P566, DOI [10.1038/NCHEMBIO.599, 10.1038/nchembio.599]; Webb KJ, 2010, BIOCHEMISTRY-US, V49, P5225, DOI 10.1021/bi100428x; Yao Y, 2011, J AM CHEM SOC, V133, P16746, DOI 10.1021/ja206312b; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	73	59	59	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2013	32	8					939	946		10.1038/onc.2012.552	http://dx.doi.org/10.1038/onc.2012.552			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	23160372	Green Published, hybrid			2023-01-03	WOS:000316523200001
J	Wang, ZY; Wang, DM; Han, SW; Wang, N; Mo, FZ; Loo, TY; Shen, JG; Huang, H; Chen, JP				Wang, Zhiyu; Wang, Dongmei; Han, Shouwei; Wang, Neng; Mo, Feizhi; Loo, Tjing Yung; Shen, Jiangang; Huang, Hui; Chen, Jianping			Bioactivity-Guided Identification and Cell Signaling Technology to Delineate the Lactate Dehydrogenase A Inhibition Effects of Spatholobus suberectus on Breast Cancer	PLOS ONE			English	Article							GLYCOLYSIS; (-)-EPIGALLOCATECHIN; METABOLISM; ACTIVATION; EXPRESSION; FLAVONOIDS; CARCINOMA; ESTROGEN; STRATEGY; HSP90	Aerobic glycolysis is an important feature of cancer cells. In recent years, lactate dehydrogenase A (LDH-A) is emerging as a novel therapeutic target for cancer treatment. Seeking LDH-A inhibitors from natural resources has been paid much attention for drug discovery. Spatholobus suberectus (SS) is a common herbal medicine used in China for treating blood-stasis related diseases such as cancer. This study aims to explore the potential medicinal application of SS for LDH-A inhibition on breast cancer and to determine its bioactive compounds. We found that SS manifested apoptosis-inducing, cell cycle arresting and anti-LDH-A activities in both estrogen-dependent human MCF-7 cells and estrogen-independent MDA-MB-231 cell. Oral herbal extracts (1 g/kg/d) administration attenuated tumor growth and LDH-A expression in both breast cancer xenografts. Bioactivity-guided fractionation finally identified epigallocatechin as a key compound in SS inhibiting LDH-A activity. Further studies revealed that LDH-A plays a critical role in mediating the apoptosis-induction effects of epigallocatechin. The inhibited LDH-A activities by epigallocatechin is attributed to disassociation of Hsp90 from HIF-1 alpha and subsequent accelerated HIF-1 alpha proteasome degradation. In vivo study also demonstrated that epigallocatechin could significantly inhibit breast cancer growth, HIF-1 alpha/LDH-A expression and trigger apoptosis without bringing toxic effects. The preclinical study thus suggests that the potential medicinal application of SS for inhibiting cancer LDH-A activity and the possibility to consider epigallocatechin as a lead compound to develop LDH-A inhibitors. Future studies of SS for chemoprevention or chemosensitization against breast cancer are thus warranted.	[Wang, Zhiyu; Wang, Neng; Mo, Feizhi; Loo, Tjing Yung; Shen, Jiangang; Chen, Jianping] Univ Hong Kong, Sch Chinese Med, Pokfulam, Hong Kong, Peoples R China; [Wang, Dongmei] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510275, Guangdong, Peoples R China; [Han, Shouwei] Univ Guangzhou Tradit Chinese Med, Clin Med Collage 2, Guangdong Prov Hosp Chinese Med, Guangzhou, Guangdong, Peoples R China; [Huang, Hui] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou 510275, Guangdong, Peoples R China	University of Hong Kong; Sun Yat Sen University; Guangzhou University of Chinese Medicine; Sun Yat Sen University	Chen, JP (corresponding author), Univ Hong Kong, Sch Chinese Med, Pokfulam, Hong Kong, Peoples R China.	jpjpchen@yahoo.com	wang, zhiyu/K-5255-2016	wang, zhiyu/0000-0002-5299-8410	Hong Kong Innovation and Technology Support Programme ITF funding [ITS/073/11FP]; National Natural Science Foundation of China [81170647]; Projects of International Cooperation program, Guangdong Province [2012B050300014]	Hong Kong Innovation and Technology Support Programme ITF funding; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Projects of International Cooperation program, Guangdong Province	The work was supported by the Hong Kong Innovation and Technology Support Programme ITF funding (ITS/073/11FP), National Natural Science Foundation of China (81170647) and Projects of International Cooperation program, Guangdong Province 2012B050300014. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BRENTANI MM, 1983, CANCER DETECT PREV, V6, P241; BURKE RE, 1978, CANCER RES, V38, P2773; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Chen Dong-hui, 2004, Zhongguo Zhong Yao Za Zhi, V29, P352; Cheng XL, 2011, J CHROMATOGR A, V1218, P5774, DOI 10.1016/j.chroma.2011.06.091; Clark AS, 2002, MOL CANCER THER, V1, P707; Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gatenby RA, 2007, INT J BIOCHEM CELL B, V39, P1358, DOI 10.1016/j.biocel.2007.03.021; Gordan JD, 2007, CANCER CELL, V12, P108, DOI 10.1016/j.ccr.2007.07.006; Granchi C, 2010, CURR MED CHEM, V17, P672, DOI 10.2174/092986710790416263; Gu LW, 2003, J AGR FOOD CHEM, V51, P7513, DOI 10.1021/jf034815d; Guo WM, 2009, NUTR CANCER, V61, P807, DOI 10.1080/01635580903285098; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hirschhaeuser F, 2011, CANCER RES, V71, P6921, DOI 10.1158/0008-5472.CAN-11-1457; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Kolev Y, 2008, ANN SURG ONCOL, V15, P2336, DOI 10.1245/s10434-008-9955-5; Kushima Y, 2009, BIOL PHARM BULL, V32, P899, DOI 10.1248/bpb.32.899; Kuzuhara T, 2008, CANCER LETT, V261, P12, DOI 10.1016/j.canlet.2007.10.037; Liu YV, 2007, CELL CYCLE, V6, P656, DOI 10.4161/cc.6.6.3981; Lu HS, 2002, J BIOL CHEM, V277, P23111, DOI 10.1074/jbc.M202487200; Minet E, 1999, FEBS LETT, V460, P251, DOI 10.1016/S0014-5793(99)01359-9; Ocana A, 2011, NAT REV CLIN ONCOL, V8, P200, DOI 10.1038/nrclinonc.2010.194; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Shi HS, 2010, CANCER SCI, V101, P1447, DOI 10.1111/j.1349-7006.2010.01562.x; TAKAHASHI Y, 1995, INTERNAL MED, V34, P326, DOI 10.2169/internalmedicine.34.326; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Vergote D, 2002, BREAST CANCER RES TR, V76, P195, DOI 10.1023/A:1020833410523; Wang Z, 2012, EVID-BASED COMPL ALT, V2012; Wang ZY, 2012, BREAST CANCER RES TR, V131, P791, DOI 10.1007/s10549-011-1466-6; Wang ZY, 2011, J ETHNOPHARMACOL, V133, P751, DOI 10.1016/j.jep.2010.11.004; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Xie H, 2009, MOL CANCER THER, V8, P626, DOI 10.1158/1535-7163.MCT-08-1049; Yang CS, 2009, NAT REV CANCER, V9, P429, DOI 10.1038/nrc2641; Yoon JS, 2004, ARCH PHARM RES, V27, P589, DOI 10.1007/BF02980154; 杨德明, 2003, [中医杂志, Journal of Traditional Chinese Medicine], V44, P730	37	52	54	1	39	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2013	8	2							e56631	10.1371/journal.pone.0056631	http://dx.doi.org/10.1371/journal.pone.0056631			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	099EJ	23457597	gold, Green Submitted, Green Published			2023-01-03	WOS:000315602700087
J	Vincent, JL; Preiser, JC				Vincent, Jean-Louis; Preiser, Jean-Charles			When should we add parenteral to enteral nutrition?	LANCET			English	Editorial Material							CRITICALLY-ILL PATIENTS; ENERGY-BALANCE; PROVISION; PROTEIN; GUIDELINES; SUPPORT		[Vincent, Jean-Louis; Preiser, Jean-Charles] Univ Libre Brussels, Dept Intens Care, Erasme Univ Hosp, B-1070 Brussels, Belgium	Universite Libre de Bruxelles	Vincent, JL (corresponding author), Univ Libre Brussels, Dept Intens Care, Erasme Univ Hosp, B-1070 Brussels, Belgium.	jlvincen@ulb.ac.be	Preiser, Jean-Charles/AAL-2355-2021	Preiser, Jean-Charles/0000-0003-3163-0390; Vincent, Jean-Louis/0000-0001-6011-6951				Allingstrup MJ, 2012, CLIN NUTR, V31, P462, DOI 10.1016/j.clnu.2011.12.006; Barr J, 2004, CHEST, V125, P1446, DOI 10.1378/chest.125.4.1446; Casaer MP, 2011, NEW ENGL J MED, V365, P506, DOI 10.1056/NEJMoa1102662; Dvir D, 2006, CLIN NUTR, V25, P37, DOI 10.1016/j.clnu.2005.10.010; Heidegger CP, 2012, LANCET; Heyland DK, 2003, JPEN-PARENTER ENTER, V27, P355, DOI 10.1177/0148607103027005355; Hoffer LJ, 2012, AM J CLIN NUTR, V96, P591, DOI 10.3945/ajcn.111.032078; Martindale RG, 2009, CRIT CARE MED, V37, P1757, DOI 10.1097/CCM.0b013e3181a40116; Singer P, 2009, CLIN NUTR, V28, P387, DOI 10.1016/j.clnu.2009.04.024; Villet S, 2005, CLIN NUTR, V24, P502, DOI 10.1016/j.clnu.2005.03.006; Weijs PJM, 2012, JPEN-PARENTER ENTER, V36, P60, DOI 10.1177/0148607111415109; Wolfe RR, 1999, EUR J CLIN NUTR, V53, pS136, DOI 10.1038/sj.ejcn.1600754	12	26	30	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 2	2013	381	9864					354	355		10.1016/S0140-6736(12)61893-5	http://dx.doi.org/10.1016/S0140-6736(12)61893-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	084ZA	23218814				2023-01-03	WOS:000314578900010
J	Noto, H; Goto, A; Tsujimoto, T; Noda, M				Noto, Hiroshi; Goto, Atsushi; Tsujimoto, Tetsuro; Noda, Mitsuhiko			Low-Carbohydrate Diets and All-Cause Mortality: A Systematic Review and Meta-Analysis of Observational Studies	PLOS ONE			English	Review							CORONARY-HEART-DISEASE; MAJOR CHRONIC DISEASE; CARDIOVASCULAR RISK-FACTORS; GUIDELINES-FOR-AMERICANS; HIGH-PROTEIN-DIET; LOW-FAT DIET; GLYCEMIC INDEX; WEIGHT-LOSS; HEALTH; LOAD	Objective: Low-carbohydrate diets and their combination with high-protein diets have been gaining widespread popularity to control weight. In addition to weight loss, they may have favorable short-term effects on the risk factors of cardiovascular disease (CVD). Our objective was to elucidate their long-term effects on mortality and CVD incidence. Data sources: MEDLINE, EMBASE, ISI Web of Science, Cochrane Library, and ClinicalTrials.gov for relevant articles published as of September 2012. Cohort studies of at least one year's follow-up period were included. Review methods: Identified articles were systematically reviewed and those with pertinent data were selected for meta-analysis. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) for all-cause mortality, CVD mortality and CVD incidence were calculated using the random-effects model with inverse-variance weighting. Results: We included 17 studies for a systematic review, followed by a meta-analysis using pertinent data. Of the 272,216 people in 4 cohort studies using the low-carbohydrate score, 15,981 (5.9%) cases of death from all-cause were reported. The risk of all-cause mortality among those with high low-carbohydrate score was significantly elevated: the pooled RR (95% CI) was 1.31 (1.07-1.59). A total of 3,214 (1.3%) cases of CVD death among 249,272 subjects in 3 cohort studies and 5,081 (2.3%) incident CVD cases among 220,691 people in different 4 cohort studies were reported. The risks of CVD mortality and incidence were not statistically increased: the pooled RRs (95% CIs) were 1.10 (0.98-1.24) and 0.98 (0.78-1.24), respectively. Analyses using low-carbohydrate/high-protein score yielded similar results. Conclusion: Low-carbohydrate diets were associated with a significantly higher risk of all-cause mortality and they were not significantly associated with a risk of CVD mortality and incidence. However, this analysis is based on limited observational studies and large-scale trials on the complex interactions between low-carbohydrate diets and long-term outcomes are needed.	[Noto, Hiroshi; Goto, Atsushi; Tsujimoto, Tetsuro; Noda, Mitsuhiko] Natl Ctr Global Hlth & Med, Ctr Hosp, Dept Diabet & Metab Med, Tokyo, Japan; [Noto, Hiroshi; Goto, Atsushi; Tsujimoto, Tetsuro; Noda, Mitsuhiko] Natl Ctr Global Hlth & Med, Res Inst, Diabet Res Ctr, Dept Diabet Res, Tokyo, Japan	National Center for Global Health & Medicine - Japan; National Center for Global Health & Medicine - Japan	Noto, H (corresponding author), Natl Ctr Global Hlth & Med, Ctr Hosp, Dept Diabet & Metab Med, Tokyo, Japan.	noto-tky@umin.net	Noda, Mitsuhiko/W-3905-2019	Noda, Mitsuhiko/0000-0003-0413-4631; Goto, Atsushi/0000-0003-0669-654X	Health Sciences Research Grant (Comprehensive Research on Diabetes/Cardiovascular and Life-Style Related Diseases from the Ministry of Health, Labour and Welfare of Japan [H22-019]	Health Sciences Research Grant (Comprehensive Research on Diabetes/Cardiovascular and Life-Style Related Diseases from the Ministry of Health, Labour and Welfare of Japan	This study was supported by a Health Sciences Research Grant (Comprehensive Research on Diabetes/Cardiovascular and Life-Style Related Diseases H22-019) from the Ministry of Health, Labour and Welfare of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Astrup A, 2004, LANCET, V364, P897, DOI 10.1016/S0140-6736(04)16986-9; Beulens JWJ, 2007, J AM COLL CARDIOL, V50, P14, DOI 10.1016/j.jacc.2007.02.068; Bravata DM, 2003, JAMA-J AM MED ASSOC, V289, P1837, DOI 10.1001/jama.289.14.1837; Diehr P, 2003, J CLIN EPIDEMIOL, V56, P1224, DOI 10.1016/S0895-4356(03)00202-6; Floegel A, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3801; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; Fung TT, 2010, ANN INTERN MED, V153, P289, DOI 10.7326/0003-4819-153-5-201009070-00003; Fung TT, 2001, ARCH INTERN MED, V161, P1857, DOI 10.1001/archinte.161.15.1857; GARCIAPALMIERI MR, 1980, AM J CLIN NUTR, V33, P1818, DOI 10.1093/ajcn/33.8.1818; Gogebakan O, 2011, CIRCULATION, V124, P2829, DOI 10.1161/CIRCULATIONAHA.111.033274; Halton TL, 2006, NEW ENGL J MED, V355, P1991, DOI 10.1056/NEJMoa055317; Hession M, 2009, OBES REV, V10, P36, DOI 10.1111/j.1467-789X.2008.00518.x; Johnson JA, 2010, DIABETES, V59, P1129, DOI 10.2337/db10-0334; Lagiou P, 2007, J INTERN MED, V261, P366, DOI 10.1111/j.1365-2796.2007.01774.x; Lagiou P, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4026; Larsson SC, 2006, INT J CANCER, V119, P2657, DOI 10.1002/ijc.22170; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Liu SM, 2000, AM J CLIN NUTR, V71, P1455; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Manzoli L, 2007, SOC SCI MED, V64, P77, DOI 10.1016/j.socscimed.2006.08.031; Massimino FC, 2007, CAD SAUDE PUBLICA, V23, P2145, DOI 10.1590/S0102-311X2007000900022; McCullough ML, 2000, AM J CLIN NUTR, V72, P1223; McCullough ML, 2000, AM J CLIN NUTR, V72, P1214; McCullough ML, 2002, AM J CLIN NUTR, V76, P1261, DOI 10.1093/ajcn/76.6.1261; MCGEE DL, 1984, AM J EPIDEMIOL, V119, P667, DOI 10.1093/oxfordjournals.aje.a113788; Nilsson LM, 2012, EUR J CLIN NUTR, V66, P694, DOI 10.1038/ejcn.2012.9; Noakes M, 2005, AM J CLIN NUTR, V81, P1298; Nordmann AJ, 2006, ARCH INTERN MED, V166, P285, DOI 10.1001/archinte.166.3.285; Oh K, 2005, AM J EPIDEMIOL, V161, P161, DOI 10.1093/aje/kwi026; Sacks FM, 2009, NEW ENGL J MED, V360, P859, DOI 10.1056/NEJMoa0804748; Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637; Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232; Sjogren P, 2010, AM J CLIN NUTR, V92, P967, DOI 10.3945/ajcn.2010.29345; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Trichopoulou A, 2007, EUR J CLIN NUTR, V61, P575, DOI 10.1038/sj.ejcn.1602557; von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI [10.1016/j.jclinepi.2007.11.008, 10.2471/BLT.07.045120]; Wells GA, NEWCASTLE OTTAWA SCA; Willett WC, 2007, J INTERN MED, V261, P363, DOI 10.1111/j.1365-2796.2007.01804.x; Yang YX, 2009, GASTROENTEROLOGY, V137, P412, DOI 10.1053/j.gastro.2009.06.022	39	122	126	0	55	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2013	8	1							e55030	10.1371/journal.pone.0055030	http://dx.doi.org/10.1371/journal.pone.0055030			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	093RV	23372809	Green Published, Green Submitted, gold			2023-01-03	WOS:000315210400052
J	Zhu, P; Zhu, Q; Zhang, YL; Ma, XJ; Li, ZZ; Li, J; Chen, JZ; Luo, L; Ring, HJZ; Ring, BZ; Su, L				Zhu, Peng; Zhu, Qian; Zhang, Yilei; Ma, Xuejun; Li, Zizhao; Li, Jie; Chen, Jiazhong; Luo, Le; Ring, Huijun Z.; Ring, Brian Z.; Su, Li			ABCB1 Variation and Treatment Response in AIDS Patients: Initial Results of the Henan Cohort	PLOS ONE			English	Article							HIV-INFECTED PATIENTS; P-GLYCOPROTEIN; ANTIRETROVIRAL TREATMENT; PLASMA-CONCENTRATIONS; POLYMORPHISMS; METABOLISM; CYP2B6; PHARMACOGENETICS; VARIANTS; BLOOD	HIV/AIDS has the highest mortality among infectious diseases in China. In ongoing efforts to alleviate this crisis, the national government has placed great emphasis on efforts in Henan province where HIV-infected former plasma donors in the 1990s contributed to AIDS becoming a public health crisis. Concomitant with a national initiative focusing the use of phamacogenetics for the better prediction of treatment response, we studied genetic variants with known pharmacokinetic phenotypes in a set of 298 HAART-treated (highly active antiretroviral therapy) patients infected with HIV from the Henan cohort. We measured the association of response to treatment, assessed as changes in CD4+ T cell counts after antiretroviral therapy, of five polymorphisms in four genes (CYP2B6, ABCB1/MDR1, ABCG2, and ABCC4) in which variation has been suggested to affect the pharmacokinetics of drugs commonly employed to treat HIV/AIDS. We show that genotyping for ABCB1 variations (rs1045642 and rs2032582) may help predict HIV treatment response. We found variations in this gene have a significant association with outcome as measured by CD4+ T cell counts in a discovery subset (N=197; odds ratio (OR)=1.58; 95% CI 1.02-2.45), these results were confirmed in a validation subset of the cohort (N=78; OR=2.81; 95% CI 1.32-5.96). Exploratory analysis suggests that this effect may be specific to NVP (nevirapine) or 3TC (lamivudine) response. This publication represents the first genetic analysis in a continuing effort to study and assist the patients in a very large, unique, and historically significant HIV-AIDS cohort. Genotyping of AIDS patients for ABCB1 variation may help predict outcome and potentially could help guide treatment strategies.	[Zhu, Peng; Zhang, Yilei; Su, Li] Huazhong Univ Sci & Technol, Minist Educ, Key Lab Mol Biophys, Wuhan 430074, Peoples R China; [Ring, Huijun Z.; Ring, Brian Z.] Huazhong Univ Sci & Technol, Sch Life Sci & Technol, Inst Genom & Personalized Med, Wuhan 430074, Peoples R China; [Chen, Jiazhong] Huazhong Univ Sci & Technol, Sch Comp Sci & Technol, Wuhan 430074, Peoples R China; [Zhu, Qian; Li, Jie] Henan Ctr Dis Prevent & Control, Inst AIDS STD Prevent & Control, Zhengzhou, Peoples R China; [Ma, Xuejun; Luo, Le] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, State Key Lab Mol Virol & Genet Engn, Beijing, Peoples R China; [Li, Zizhao] Hlth Dept Henan Prov, Zhengzhou, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Chinese Center for Disease Control & Prevention; National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control & Prevention	Ring, BZ (corresponding author), Huazhong Univ Sci & Technol, Sch Life Sci & Technol, Inst Genom & Personalized Med, Wuhan 430074, Peoples R China.	bzring@mail.hust.edu.cn; lisu@mail.hust.edu.cn	Zhang, Yilei/I-8997-2014	Zhang, Yilei/0000-0003-1407-0301	China Mega-Project for Infectious Diseases [2009ZX10017-016, 2011ZX10004-001, 2012ZX10004-215]	China Mega-Project for Infectious Diseases	This study was funded by grants from the China Mega-Project for Infectious Diseases (2009ZX10017-016, 2011ZX10004-001 and 2012ZX10004-215). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abla N, 2008, J PHARMACOL EXP THER, V325, P859, DOI 10.1124/jpet.108.136523; [Anonymous], 2011, MIN HLTH AIDS PREV C; Chen CL, 2002, DRUG METAB DISPOS, V30, P1523, DOI 10.1124/dmd.30.12.1523; Chen J, 2010, THER DRUG MONIT, V32, P573, DOI 10.1097/FTD.0b013e3181ea953c; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; di Iulio J, 2009, PHARMACOGENET GENOM, V19, P300, DOI 10.1097/FPC.0b013e328328d577; Estrela RC, 2009, PHARMACOGENOMICS, V10, P311, DOI 10.2217/14622416.10.2.311; Fellay J, 2002, LANCET, V359, P30, DOI 10.1016/S0140-6736(02)07276-8; Gisslen M, 1997, J INFECT DIS, V175, P434, DOI 10.1093/infdis/175.2.434; Haas DW, 2005, J INFECT DIS, V192, P1931, DOI 10.1086/497610; Kim HS, 2007, BRIT J CLIN PHARMACO, V64, P645, DOI 10.1111/j.1365-2125.2007.02944.x; Koralage Nadeeja, 2004, BMJ, V328, P975, DOI 10.1136/bmj.328.7446.975-a; Kwara A, 2009, AIDS, V23, P2101, DOI 10.1097/QAD.0b013e3283319908; Kwara A, 2009, BRIT J CLIN PHARMACO, V67, P427, DOI 10.1111/j.1365-2125.2009.03368.x; Leschziner GD, 2007, PHARMACOGENOMICS J, V7, P154, DOI 10.1038/sj.tpj.6500413; Li JY, 2005, CELL RES, V15, P843, DOI 10.1038/sj.cr.7290356; PILERI SA, 1991, HISTOPATHOLOGY, V19, P131, DOI 10.1111/j.1365-2559.1991.tb00003.x; Ribaudo HJ, 2010, J INFECT DIS, V202, P717, DOI 10.1086/655470; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Sakaeda T, 2003, PHARMACOGENOMICS, V4, P397, DOI 10.1517/phgs.4.4.397.22747; Smith MZ, 2012, CURR HIV-AIDS REP, V9, P5, DOI 10.1007/s11904-011-0108-2; Stormer E, 2002, PHARMACEUT RES, V19, P1038, DOI 10.1023/A:1016430825740; Sun XH, 2010, INT J EPIDEMIOL, V39, pII4, DOI 10.1093/ije/dyq217; UNAIDS, 2011, HIV AS PAC GETT ZER, P27; Veal GJ, 1995, GEN PHARMACOL, V26, P1469, DOI 10.1016/0306-3623(95)00047-X; Weinberg Jennifer L, 2010, Virtual Mentor, V12, P202, DOI 10.1001/virtualmentor.2010.12.3.cprl1-1003; WHO, 2010, ANT THER HIV INF AD; Zhang FJ, 2007, AIDS, V21, pS143, DOI 10.1097/01.aids.0000304710.10036.2b; Zhang FJ, 2011, LANCET INFECT DIS, V11, P516, DOI 10.1016/S1473-3099(11)70097-4; Zhang KL, 2002, BMJ-BRIT MED J, V324, P803, DOI 10.1136/bmj.324.7341.803; Zhou ZX, 2006, ANTIMICROB AGENTS CH, V50, P2686, DOI 10.1128/AAC.01637-05	31	8	10	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2013	8	1							e55197	10.1371/journal.pone.0055197	http://dx.doi.org/10.1371/journal.pone.0055197			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	093RV	23372834	gold, Green Published, Green Submitted			2023-01-03	WOS:000315210400074
J	Spence, D				Spence, Des			Are antidepressants overprescribed? Yes	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							SEROTONIN REUPTAKE INHIBITORS; PRIMARY-CARE; DEPRESSION; SEVERITY		Maryhill Hlth Ctr, Green Area, Glasgow G20 9DR, Lanark, Scotland		Spence, D (corresponding author), Maryhill Hlth Ctr, Green Area, Glasgow G20 9DR, Lanark, Scotland.	destwo@yahoo.co.uk						Arroll B, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007954; Barr B, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5142; Cameron IM, 2009, BRIT J GEN PRACT, V59, P644, DOI 10.3399/bjgp09X454061; Centers for Disease Control and Prevention, CDC MENT ILLN SURV; Cosgrove L, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001190; Deshauer D, 2008, CAN MED ASSOC J, V178, P1293, DOI 10.1503/cmaj.071068; Fournier JC, 2010, JAMA-J AM MED ASSOC, V303, P47, DOI 10.1001/jama.2009.1943; Geddes JR, 2003, LANCET, V361, P653, DOI 10.1016/S0140-6736(03)12599-8; Haddad PM, 2007, ADV PSYCHIAT TREAT, V13, P447, DOI DOI 10.1192/APT.BP.105.001966; Kirsch I, 2008, PLOS MED, V5, P260, DOI 10.1371/journal.pmed.0050045; Lacasse JR, 2005, PLOS MED, V2, P1211, DOI 10.1371/journal.pmed.0020392; MacDonald TM, 1996, BRIT MED J, V313, P860; National Institute for Health and Clinical Excellence (NICE), 2009, QUICK REF GUID DEPR; NHS Health and Social Care Information Centre, 2012, PRESCR DISP COMM ENG; NHS Health and Social Care Information Centre, HLTH CAR STAT PRESCR; Reid IC., 2011, BMJ; Reid S, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1468; Reseland S, 2006, BRIT J PSYCHIAT, V188, P354, DOI 10.1192/bjp.188.4.354	18	19	20	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 22	2013	346								f191	10.1136/bmj.f191	http://dx.doi.org/10.1136/bmj.f191			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	080BG	23341568				2023-01-03	WOS:000314215600011
J	Maurice, CF; Haiser, HJ; Turnbaugh, PJ				Maurice, Corinne Ferrier; Haiser, Henry Joseph; Turnbaugh, Peter James			Xenobiotics Shape the Physiology and Gene Expression of the Active Human Gut Microbiome	CELL			English	Article							FLOW-CYTOMETRY; BACTERIA; METABOLISM; ABSORPTION; DIVERSITY; COMMUNITY; DIGOXIN	The human gut contains trillions of microorganisms that influence our health by metabolizing xenobiotics, including host-targeted drugs and antibiotics. Recent efforts have characterized the diversity of this host-associated community, but it remains unclear which microorganisms are active and what perturbations influence this activity. Here, we combine flow cytometry, 16S rRNA gene sequencing, and metatranscriptomics to demonstrate that the gut contains a distinctive set of active microorganisms, primarily Firmicutes. Short-term exposure to a panel of xenobiotics significantly affected the physiology, structure, and gene expression of this active gut microbiome. Xenobiotic-responsive genes were found across multiple bacterial phyla, encoding antibiotic resistance, drug metabolism, and stress response pathways. These results demonstrate the power of moving beyond surveys of microbial diversity to better understand metabolic activity, highlight the unintended consequences of xenobiotics, and suggest that attempts at personalized medicine should consider interindividual variations in the active human gut microbiome.	[Maurice, Corinne Ferrier; Haiser, Henry Joseph; Turnbaugh, Peter James] Harvard Univ, FAS Ctr Syst Biol, Cambridge, MA 02138 USA	Harvard University	Turnbaugh, PJ (corresponding author), Harvard Univ, FAS Ctr Syst Biol, 52 Oxford St, Cambridge, MA 02138 USA.	pturnbaugh@fas.harvard.edu	Haiser, Henry/AAN-5187-2020	Turnbaugh, Peter/0000-0002-0888-2875; Maurice, Corinne/0000-0001-7187-3472	NIH [P50 GM068763]; Canadian Institutes of Health Research [MFE-112991]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM068763] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Rob Knight and Donna Berg-Lyons for contributing barcoded 16S rRNA primers; Claire Reardon, Jiangwen Zhang, and Christian Daly for sequencing support; Brian Tilton and Thierry Bouvier for flow cytometry assistance; and Curtis Huttenhower, Nicola Segata, and Jovian Yu for bioinformatics support. We are indebted to our colleagues Andrew Murray, Erin O'Shea, Bodo Stern, Lawrence David, Julie Button, Rachel Dutton, and Benjamin Wolfe for their helpful suggestions. This work was supported by the NIH (P50 GM068763) and the Canadian Institutes of Health Research (MFE-112991).	Baselt R.C., 2008, DISPOSITION TOXIC DR; Ben-Amor K, 2005, APPL ENVIRON MICROB, V71, P4679, DOI 10.1128/AEM.71.8.4679-4689.2005; Blaut M, 2011, CURR TOP MICROBIOL I; Bouvier T, 2007, ENVIRON MICROBIOL, V9, P2050, DOI 10.1111/j.1462-2920.2007.01321.x; Bouvier T, 2011, MICROB ECOL, V62, P669, DOI 10.1007/s00248-011-9862-3; Caporaso JG, 2012, ISME J, V6, P1621, DOI 10.1038/ismej.2012.8; Caporaso JG, 2011, P NATL ACAD SCI USA, V108, P4516, DOI 10.1073/pnas.1000080107; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Davey Hazel M., 2003, Current Issues in Molecular Biology, V5, P9; del Giorgio P.A., 2008, MICROBIAL ECOLOGY OC, V2, P243; Dethlefsen L, 2011, P NATL ACAD SCI USA, V108, P4554, DOI 10.1073/pnas.1000087107; Gasol JM, 1999, APPL ENVIRON MICROB, V65, P4475; Guillebault D, 2010, APPL ENVIRON MICROB, V76, P7352, DOI 10.1128/AEM.00621-10; Haiser HJ, 2012, SCIENCE, V336, P1253, DOI 10.1126/science.1224396; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Jellett JF, 1996, MAR ECOL PROG SER, V136, P213, DOI 10.3354/meps136213; Jernberg C, 2010, MICROBIOL-SGM, V156, P3216, DOI 10.1099/mic.0.040618-0; Jochem FJ, 2004, MAR BIOL, V145, P1213, DOI 10.1007/s00227-004-1406-7; Gosalbes MJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017447; Joux F, 2000, MICROBES INFECT, V2, P1523, DOI 10.1016/S1286-4579(00)01307-1; Kristiansson E, 2009, BIOINFORMATICS, V25, P2737, DOI 10.1093/bioinformatics/btp508; Le Blay G, 2007, LETT APPL MICROBIOL, V45, P252, DOI 10.1111/j.1472-765X.2007.02178.x; Lee HH, 2012, NAT CHEM BIOL, V8, P6, DOI 10.1038/nchembio.740; Levin BR, 2006, NAT REV MICROBIOL, V4, P556, DOI 10.1038/nrmicro1445; LINDENBAUM J, 1981, NEW ENGL J MED, V305, P789, DOI 10.1056/NEJM198110013051403; MAGNUSSON JO, 1982, BRIT J CLIN PHARMACO, V14, P284, DOI 10.1111/j.1365-2125.1982.tb01976.x; Martinez JL, 2011, FEMS MICROBIOL REV, V35, P768, DOI 10.1111/j.1574-6976.2011.00282.x; McNulty NP, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002701; Mortimer FC, 2000, ANTIMICROB AGENTS CH, V44, P676, DOI 10.1128/AAC.44.3.676-681.2000; Novo DJ, 2000, ANTIMICROB AGENTS CH, V44, P827, DOI 10.1128/AAC.44.4.827-834.2000; Peris-Bondia F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022448; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; RAAFLAUB J, 1975, EUR J CLIN PHARMACOL, V8, P261, DOI 10.1007/BF00567125; Reshef DN, 2011, SCIENCE, V334, P1518, DOI 10.1126/science.1205438; Rey FE, 2010, J BIOL CHEM, V285, P22082, DOI 10.1074/jbc.M110.117713; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Shapiro HH, 2000, J MICROBIOL METH, V42, P3, DOI 10.1016/S0167-7012(00)00167-6; SMITH GE, 1974, XENOBIOTICA, V4, P477, DOI 10.3109/00498257409052100; SOMOGYI AA, 1995, PHARMACEUT RES, V12, P149, DOI 10.1023/A:1016215510223; Sousa T, 2008, INT J PHARMACEUT, V363, P1, DOI 10.1016/j.ijpharm.2008.07.009; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; Turnbaugh PJ, 2010, P NATL ACAD SCI USA, V107, P7503, DOI 10.1073/pnas.1002355107; Turnbaugh PJ, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000322; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Wang YY, 2009, ISME J, V3, P889, DOI 10.1038/ismej.2009.46; Wickens HJ, 2000, ANTIMICROB AGENTS CH, V44, P682, DOI 10.1128/AAC.44.3.682-687.2000; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Zubkov MV, 2004, J MAR BIOL ASSOC UK, V84, P519, DOI 10.1017/S002531540400952Xh	48	526	550	9	280	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 17	2013	152	1-2					39	50		10.1016/j.cell.2012.10.052	http://dx.doi.org/10.1016/j.cell.2012.10.052			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	073CA	23332745	Bronze, Green Accepted			2023-01-03	WOS:000313719800005
J	Wang, F; Shi, Y; Lu, L; Liu, L; Cai, YL; Zheng, HR; Liu, X; Yan, F; Zou, C; Sun, CY; Shi, J; Lu, SK; Chen, Y				Wang, Feng; Shi, Yu; Lu, Lin; Liu, Li; Cai, Youli; Zheng, Hairong; Liu, Xin; Yan, Fei; Zou, Chao; Sun, Chengyu; Shi, Jie; Lu, Shukun; Chen, Yun			Targeted Delivery of GDNF through the Blood-Brain Barrier by MRI-Guided Focused Ultrasound	PLOS ONE			English	Article							NEUROTROPHIC FACTOR; PARKINSONS-DISEASE; P-SELECTIN; RAT-BRAIN; DRUG; MICROBUBBLES; DISRUPTION; ADDICTION; MOUSE	Neurotrophic factors, such as glial cell line-derived neurotrophic factor (GDNF), are promising therapeutic agents for neurodegenerative diseases. However, the application of GDNF to treat these diseases effectively is limited because the blood-brain barrier (BBB) prevents the local delivery of macromolecular therapeutic agents from entering the central nervous system (CNS). Focused ultrasound combined with microbubbles (MBs) using appropriate parameters has been previously demonstrated to be able to open the BBB locally and noninvasively. This study investigated the targeted delivery of GDNF MBs through the BBB by magnetic resonance imaging (MRI)-guided focused ultrasound. Evans Blue extravasation and histological examination were used to determine the optimum focused ultrasound parameters. Enzyme-linked immunosorbent assay was performed to verify the effects of GDNF bound on MBs using a biotin-avidin bridging chemistry method to promote GDNF delivery into the brain. The results showed that GDNF can be delivered locally and noninvasively into the CNS through the BBB using MRI-guided focused ultrasound combined with MBs under optimum parameters. MBs that bind GDNF combined with MRI-guided focused ultrasound may be an effective way of delivering neurotrophic factors directly into the CNS. The method described herein provides a potential means of treating patients with CNS diseases.	[Wang, Feng; Shi, Yu; Liu, Li; Cai, Youli; Lu, Shukun; Chen, Yun] Peking Univ, Dept Ultrasound, Shenzhen Hosp, Biomed Res Inst,Shenzhen PKU HKUST Med Ctr, Shenzhen, Peoples R China; [Lu, Lin; Sun, Chengyu; Shi, Jie] Peking Univ, Natl Inst Drug Dependence, Shenzhen, Peoples R China; [Zheng, Hairong; Liu, Xin; Yan, Fei; Zou, Chao] Chinese Acad Sci, Paul C Lauterbur Res Ctr Biomed Imaging, Inst Biomed & Hlth Engn, Shenzhen Inst Adv Technol, Shenzhen, Peoples R China; [Wang, Feng] Xinxiang Med Univ, Dept Physiol & Neurobiol, Xinxiang, Peoples R China; [Liu, Xin; Zou, Chao] Shenzhen Key Lab MRI, Shenzhen, Peoples R China	Hong Kong University of Science & Technology; Peking University; Shenzhen PKU-HKUST Medical Center; Peking University; Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology, CAS; Xinxiang Medical University	Chen, Y (corresponding author), Peking Univ, Dept Ultrasound, Shenzhen Hosp, Biomed Res Inst,Shenzhen PKU HKUST Med Ctr, Shenzhen, Peoples R China.	cyun126@126.com	SHI, JIE/GXG-3394-2022		National Natural Science Foundation [30970833, 81101048, U1204810]; National 973 basic research program [2011CB707903]; National Postdoctoral Science Foundation [2011M501111]; Shenzhen Basic Research Program [JC201005280495A]	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); National 973 basic research program(National Basic Research Program of China); National Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Shenzhen Basic Research Program	This work was supported by grants from the National Natural Science Foundation (No. 30970833), National 973 basic research program (No. 2011CB707903), the National Natural Science Foundation (No. 81101048 and No. U1204810), National Postdoctoral Science Foundation (No. 2011M501111), and Shenzhen Basic Research Program (No. JC201005280495A). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Camicella S, 2009, ALCOHOL, V43, P35, DOI 10.1016/j.alcohol.2008.12.001; Carnicella S, 2009, PHARMACOL THERAPEUT, V122, P9, DOI 10.1016/j.pharmthera.2008.12.001; Chopra R, 2010, ACS CHEM NEUROSCI, V1, P391, DOI 10.1021/cn9000445; Deng CX, 2010, THER DELIV, V1, P819, DOI 10.4155/TDE.10.66; Doolittle ND, 2000, CANCER, V88, P637, DOI 10.1002/(SICI)1097-0142(20000201)88:3<637::AID-CNCR22>3.0.CO;2-Y; Eisch AJ, 2003, BIOL PSYCHIAT, V54, P994, DOI 10.1016/j.biopsych.2003.08.003; Garbayo E, 2007, INT J PHARMACEUT, V344, P9, DOI 10.1016/j.ijpharm.2007.04.003; Gearhart DA, 2006, J NEUROSCI METH, V150, P159, DOI 10.1016/j.jneumeth.2005.06.009; Grondin R, 1998, J NEUROL, V245, pP35, DOI 10.1007/PL00007744; He DY, 2006, FASEB J, V20, P2420, DOI 10.1096/fj.06-6394fje; Hernot S, 2008, ADV DRUG DELIVER REV, V60, P1153, DOI 10.1016/j.addr.2008.03.005; Hynynen K, 2005, NEUROIMAGE, V24, P12, DOI 10.1016/j.neuroimage.2004.06.046; Jordao JF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010549; Kaufmann BA, 2007, EUR HEART J, V28, P2011, DOI 10.1093/eurheartj/ehm176; Kinoshita M, 2006, BIOCHEM BIOPH RES CO, V340, P1085, DOI 10.1016/j.bbrc.2005.12.112; Kinoshita M, 2006, P NATL ACAD SCI USA, V103, P11719, DOI 10.1073/pnas.0604318103; Lum AFH, 2006, J CONTROL RELEASE, V111, P128, DOI 10.1016/j.jconrel.2005.11.006; Mcdannold N, 2008, ULTRASOUND MED BIOL, V34, P930, DOI 10.1016/j.ultrasmedbio.2007.11.009; Murer MG, 2001, PROG NEUROBIOL, V63, P71, DOI 10.1016/S0301-0082(00)00014-9; Nevalainen N, 2010, NEUROSCIENCE, V171, P1357, DOI 10.1016/j.neuroscience.2010.10.010; Pardridge WM, 2007, DRUG DISCOV TODAY, V12, P54, DOI 10.1016/j.drudis.2006.10.013; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Takalkar AM, 2004, J CONTROL RELEASE, V96, P473, DOI 10.1016/j.jconrel.2004.03.002; Tempany CMC, 2003, RADIOLOGY, V226, P897, DOI 10.1148/radiol.2271020395; Treat LH, 2007, INT J CANCER, V121, P901, DOI 10.1002/ijc.22732; Volkow ND, 2007, ARCH NEUROL-CHICAGO, V64, P1575, DOI 10.1001/archneur.64.11.1575; Wang F, 2009, J ULTRAS MED, V28, P1501, DOI 10.7863/jum.2009.28.11.1501; Yang FY, 2008, ULTRASON SONOCHEM, V15, P636, DOI 10.1016/j.ultsonch.2007.08.003; Yang FY, 2011, J CONTROL RELEASE, V150, P111, DOI 10.1016/j.jconrel.2010.10.038	30	41	48	1	51	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2012	7	12							e52925	10.1371/journal.pone.0052925	http://dx.doi.org/10.1371/journal.pone.0052925			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	061EA	23300823	Green Submitted, Green Published, gold			2023-01-03	WOS:000312829100100
J	Leger, PL; Bonnin, P; Nguyen, T; Renolleau, S; Baud, O; Charriaut-Marlangue, C				Leger, Pierre-Louis; Bonnin, Philippe; Thao Nguyen; Renolleau, Sylvain; Baud, Olivier; Charriaut-Marlangue, Christiane			Ischemic Postconditioning Fails to Protect against Neonatal Cerebral Stroke	PLOS ONE			English	Article							BLOOD-FLOW; ARTERY OCCLUSION; FOCAL ISCHEMIA; COLLATERAL CIRCULATION; CASPASE INHIBITOR; HYPOXIA-ISCHEMIA; BRAIN-DAMAGE; NITRIC-OXIDE; RATS; REPERFUSION	The lack of efficient neuroprotective strategies for neonatal stroke could be ascribed to pathogenic ischemic processes differentiating adults and neonates. We explored this hypothesis using a rat model of neonatal ischemia induced by permanent occlusion of the left distal middle cerebral artery combined with 50 min of occlusion of both common carotid arteries (CCA). Postconditioning was performed by repetitive brief release and occlusion (30 s, 1 and/or 5 min) of CCA after 50 min of CCA occlusion. Alternative reperfusion was generated by controlled release of the bilateral CCA occlusion. Blood-flow velocities in the left internal carotid artery were measured using color-coded pulsed Doppler ultrasound imaging. Cortical perfusion was measured using laser Doppler. Cerebrovascular vasoreactivity was evaluated after inhalation with the hypercapnic gas or inhaled nitric oxide (NO). Whatever the type of serial mechanical interruptions of blood flow at reperfusion, postconditioning did not reduce infarct volume after 72 hours. A gradual perfusion was found during early re-flow both in the left internal carotid artery and in the cortical penumbra. The absence of acute hyperemia during early CCA re-flow, and the lack of NO-dependent vasoreactivity in P7 rat brain could in part explain the inefficiency of ischemic postconditioning after ischemia-reperfusion.	[Leger, Pierre-Louis; Thao Nguyen; Baud, Olivier; Charriaut-Marlangue, Christiane] Univ Paris Diderot, Sorbonne Paris Cite, INSERM, U676, Paris, France; [Bonnin, Philippe] Univ Paris Diderot, Hop Lariboisiere, AP HP, Sorbonne Paris Cite,Physiol Clin, Paris, France; [Bonnin, Philippe] Univ Paris Diderot, Sorbonne Paris Cite, INSERM, U965, Paris, France; [Leger, Pierre-Louis; Renolleau, Sylvain] UPMC Paris6, Hop Armand Trousseau, AP HP, Serv Reanimat Pediat, Paris, France; [Baud, Olivier] Univ Paris Diderot, Hop Robert Debre, AP HP, Sorbonne Paris Cite,Serv Reanimat Neonatale & Ped, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite	Charriaut-Marlangue, C (corresponding author), Univ Paris Diderot, Sorbonne Paris Cite, INSERM, U676, Paris, France.	christiane.marlangue@gmail.com	, CHARRIAUT-MARLANGUE/H-3249-2019; Bonnin, Philippe/Y-5872-2019	Bonnin, Philippe/0000-0003-3184-3740	Fondation pour la Recherche Medicale	Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	The "Fondation pour la Recherche Medicale" supported PL Leger. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aronowski J, 1997, J CEREBR BLOOD F MET, V17, P1048, DOI 10.1097/00004647-199710000-00006; Bonnin P, 2012, EXP NEUROL, V236, P50, DOI 10.1016/j.expneurol.2012.04.001; Bonnin P, 2011, J NEUROSCI METH, V198, P103, DOI 10.1016/j.jneumeth.2011.02.030; BONVENTO G, 1994, J CEREBR BLOOD F MET, V14, P699, DOI 10.1038/jcbfm.1994.90; Charriaut-Marlangue C, 2012, STROKE; Chauvier D, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.87; Choy M, 2006, J CEREBR BLOOD F MET, V26, P1066, DOI 10.1038/sj.jcbfm.9600259; Ducrocq S, 2000, J NEUROCHEM, V74, P2504, DOI 10.1046/j.1471-4159.2000.0742504.x; Fabian RH, 2008, AM J PHYSIOL-HEART C, V295, pH1809, DOI 10.1152/ajpheart.00301.2007; Fisher M, 2008, CURR OPIN DRUG DISC, V11, P626; Gao XW, 2008, J NEUROSCI RES, V86, P2505, DOI 10.1002/jnr.21703; Golomb MR, 2008, J CHILD NEUROL, V23, P279, DOI 10.1177/0883073807309246; KIRSCH JR, 1990, AM J PHYSIOL, V259, pH1551; Liebeskind DS, 2009, NAT REV NEUROL, V5, P645, DOI 10.1038/nrneurol.2009.193; Liebeskind DS, 2003, STROKE, V34, P2279, DOI 10.1161/01.STR.0000086465.41263.06; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MENZIES SA, 1992, NEUROSURGERY, V31, P100, DOI 10.1227/00006123-199207000-00014; Northington FJ, 2006, ILAR J, V47, P32, DOI 10.1093/ilar.47.1.32; Qiao M, 2004, MAGN RESON MATER PHY, V17, P117, DOI 10.1007/s10334-004-0058-4; Renolleau S, 1998, STROKE, V29, P1454, DOI 10.1161/01.STR.29.7.1454; Renolleau S, 2008, NEUROSCIENTIST, V14, P46, DOI 10.1177/1073858407308889; Renolleau S, 2007, J NEUROCHEM, V100, P1062, DOI 10.1111/j.1471-4159.2006.04269.x; Sutherland BA, 2011, J PHYSIOL-LONDON, V589, P4105, DOI 10.1113/jphysiol.2011.209601; van Laar PJ, 2007, RADIOLOGY, V242, P526, DOI 10.1148/radiol.2422060179; VANNUCCI RC, 1994, J CEREBR BLOOD F MET, V14, P279, DOI 10.1038/jcbfm.1994.35; Vannucci SJ, 2004, J EXP BIOL, V207, P3149, DOI 10.1242/jeb.01064; Wang JY, 2008, STROKE, V39, P983, DOI 10.1161/STROKEAHA.107.499079; Willis AP, 2001, AM J PHYSIOL-HEART C, V281, pH2366, DOI 10.1152/ajpheart.2001.281.6.H2366; Zhao H, 2006, J CEREBR BLOOD F MET, V26, P1114, DOI 10.1038/sj.jcbfm.9600348	29	7	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2012	7	12							e49695	10.1371/journal.pone.0049695	http://dx.doi.org/10.1371/journal.pone.0049695			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	066QV	23251348	Green Published, gold, Green Submitted			2023-01-03	WOS:000313236200019
J	Goto-Koshino, Y; Fukuchi, Y; Shibata, F; Abe, D; Kuroda, K; Okamoto, S; Kitamura, T; Nakajima, H				Goto-Koshino, Yuko; Fukuchi, Yumi; Shibata, Fumi; Abe, Daichi; Kuroda, Kana; Okamoto, Shinichiro; Kitamura, Toshio; Nakajima, Hideaki			Robo4 Plays a Role in Bone Marrow Homing and Mobilization, but Is Not Essential in the Long-Term Repopulating Capacity of Hematopoietic Stem Cells	PLOS ONE			English	Article							SLIT PROTEINS; NICHE; ANGIOGENESIS; RECEPTORS; GUIDANCE	Roundabout (Robo) family proteins are immunoglobulin-type surface receptors critical for cellular migration and pathway finding of neuronal axons. We have previously shown that Robo4 was specifically expressed in hematopoietic stem and progenitor cells and its high expression correlated with long-term repopulating (LTR) capacity. To reveal the physiological role of Robo4 in hematopoiesis, we examined the effects of Robo4 disruption on the function of hematopoietic stem cells (HSCs) and progenitors. In Robo4-deficient mice, basic hematological parameters including complete blood cell count and differentiation profile were not affected. In contrast to the previous report, HSC/hematopoietic progenitor (HPC) frequencies in the bone marrow (BM) were perfectly normal in Robo4(-/-) mice. Moreover, Robo4(-/-) HSCs were equally competitive as wild-type HSCs in transplantation assays and had normal long-term repopulating (LTR) capacity. Of note, the initial engraftment at 4-weeks after transplantation was slightly impaired by Robo4 ablation, suggesting a marginal defect in BM homing of Robo4(-/-) HSCs. In fact, homing efficiencies of HSCs/HPCs to the BM was significantly impaired in Robo4-deficient mice. On the other hand, granulocyte-colony stimulating factor-induced peripheral mobilization of HSCs was also impaired by Robo4 disruption. Lastly, marrow recovery from myelosuppressive stress was equally efficient in WT- and Robo4-mutant mice. These results clearly indicate that Robo4 plays a role in HSC trafficking such as BM homing and peripheral mobilization, but is not essential in the LTR and self-renewal capacity of HSCs.	[Fukuchi, Yumi; Abe, Daichi; Kuroda, Kana; Okamoto, Shinichiro; Nakajima, Hideaki] Keio Univ, Sch Med, Dept Internal Med, Div Hematol, Tokyo, Japan; [Goto-Koshino, Yuko; Shibata, Fumi; Kitamura, Toshio] Univ Tokyo, Inst Med Sci, Div Cellular Therapy, Adv Clin Res Ctr, Tokyo, Japan	Keio University; University of Tokyo	Nakajima, H (corresponding author), Keio Univ, Sch Med, Dept Internal Med, Div Hematol, Tokyo, Japan.	hnakajim@z2.keio.jp	Kitamura, Toshio/AAA-2071-2021	Goto-Koshino, Yuko/0000-0002-5228-7125	Ministry of Education, Culture, Sports, Science and Technology of Japan [18659278]	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported in part by a grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan (# 18659278). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Ema H, 2006, NAT PROTOC, V1, P2979, DOI 10.1038/nprot.2006.447; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Jones CA, 2008, NAT MED, V14, P448, DOI 10.1038/nm1742; Jones CA, 2009, NAT CELL BIOL, V11, P1325, DOI 10.1038/ncb1976; Nakajima H, 2006, BIOCHEM BIOPH RES CO, V340, P35, DOI 10.1016/j.bbrc.2005.11.146; Nakajima H, 2010, BLOOD, V116, P4474, DOI 10.1182/blood-2010-01-266528; Rajagopalan S, 2000, NEURON, V28, P767, DOI 10.1016/S0896-6273(00)00152-5; Rhee J, 2002, NAT CELL BIOL, V4, P798, DOI 10.1038/ncb858; Shibata F, 2009, STEM CELLS, V27, P183, DOI 10.1634/stemcells.2008-0292; Smith-Berdan S, 2011, CELL STEM CELL, V8, P72, DOI 10.1016/j.stem.2010.11.030; Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8; Wong K, 2002, CURR OPIN GENET DEV, V12, P583, DOI 10.1016/S0959-437X(02)00343-X; Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	18	11	12	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2012	7	11							e50849	10.1371/journal.pone.0050849	http://dx.doi.org/10.1371/journal.pone.0050849			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	054WM	23226403	Green Submitted, Green Published, gold			2023-01-03	WOS:000312376100214
J	Tsou, YA; Chen, KC; Lin, HC; Chang, SS; Chen, CYC				Tsou, Yung-An; Chen, Kuan-Chung; Lin, Hung-Che; Chang, Su-Sen; Chen, Calvin Yu-Chian			Uroporphyrinogen Decarboxylase as a Potential Target for Specific Components of Traditional Chinese Medicine: A Virtual Screening and Molecular Dynamics Study	PLOS ONE			English	Article							CRYSTAL-STRUCTURE; MINIMIZATION; ASSIGNMENT; PROGRAM; HEAD	Uroporphyrinogen decarboxylase (UROD) has been suggested as a protectant against radiation for head and neck cancer (HNC). In this study, we employed traditional Chinese medicine (TCM) compounds from TCM Database@Taiwan (http://tcm.cmu.edu.tw/) to screen for drug-like candidates with potential UROD inhibition characteristics using virtual screening techniques. Isopraeroside IV, scopolin, and nodakenin exhibited the highest Dock Scores, and were predicted to have good Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties. Two common moieties, 2H-chromen-2-one and glucoside, were observed among the top TCM candidates. Cross comparison of the docking poses indicated that candidates formed stable interactions with key binding and catalytic residues of UROD through these two moieties. The 2Hchromen-2- one moiety enabled pi-cation interactions with Arg37 and H-bonds with Tyr164. The glucoside moiety was involved in forming H-bonds with Arg37 and Asp86. From our computational results, we propose isopraeroside IV, scopolin, and nodakenin as ligands that might exhibit drug-like inhibitory effects on UROD. The glucoside and 2H-chromen-2-one moieties may potentially be used for designing inhibitors of UROD. Citation: Tsou Y-A, Chen K-C, Lin H-C, Chang S-S, Chen CY-C (2012) Uroporphyrinogen Decarboxylase as a Potential Target for Specific Components of Traditional Chinese Medicine: A Virtual Screening and Molecular Dynamics Study. PLoS ONE 7(11): e50087. doi:10.1371/journal.pone.0050087	[Chang, Su-Sen; Chen, Calvin Yu-Chian] China Med Univ Hosp, Dept Med Res, Taichung, Taiwan; [Tsou, Yung-An] China Med Univ Hosp, Dept Otolaryngol, Taichung, Taiwan; [Tsou, Yung-An] China Med Univ, Sch Med, Coll Med, Taichung, Taiwan; [Chen, Kuan-Chung] China Med Univ, Grad Inst Pharmaceut Chem, Taichung, Taiwan; [Lin, Hung-Che] China Med Univ, Sch Pharm, Taichung, Taiwan; [Chen, Calvin Yu-Chian] China Med Univ, Lab Computat & Syst Biol, Taichung, Taiwan; [Chen, Calvin Yu-Chian] Asia Univ, Dept Biotechnol, Taichung, Taiwan; [Chen, Calvin Yu-Chian] Asia Univ, Dept Biomed Informat, Taichung, Taiwan; [Chen, Calvin Yu-Chian] China Med Univ, Beigang Hosp, Yunlin, Taiwan	China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; Asia University Taiwan; Asia University Taiwan; China Medical University Taiwan	Chen, CYC (corresponding author), China Med Univ Hosp, Dept Med Res, Taichung, Taiwan.	ycc929@MIT.EDU	Chen, Kuan-Chung/G-2737-2011; Chen, Calvin Yu-Chian/E-9402-2010	Chen, Kuan-Chung/0000-0003-0223-1577; Chen, Calvin Yu-Chian/0000-0003-3306-250X; Chen, Calvin Yu-Chian/0000-0001-9213-9832	National Science Council of Taiwan [NSC101-2325-B-039-001]; Asia University [100-asia-56]; China Medical University and Asia University [DMR-101-094]; Taiwan Department of Health Clinical Trial and Research Center of Excellence [DOH101-TD-B-111-004]; Taiwan Department of Health Cancer Research Center of Excellence [DOH101-TD-C-111-005]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Asia University; China Medical University and Asia University; Taiwan Department of Health Clinical Trial and Research Center of Excellence; Taiwan Department of Health Cancer Research Center of Excellence	The research was supported by grants from the National Science Council of Taiwan (NSC101-2325-B-039-001), Asia University (100-asia-56), and China Medical University and Asia University (DMR-101-094). This study was also supported in part by Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH101-TD-B-111-004) and Taiwan Department of Health Cancer Research Center of Excellence (DOH101-TD-C-111-005). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Chang SS, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002315; Chen CYC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015939; Chen KC, 2011, SOFT MATTER, V7, P4001, DOI 10.1039/c0sm01548b; DUBART A, 1986, HUM GENET, V73, P277, DOI 10.1007/BF00401245; Fan J, 2007, J BACTERIOL, V189, P3573, DOI 10.1128/JB.01083-06; FLETCHER R, 1964, COMPUT J, V7, P149, DOI 10.1093/comjnl/7.2.149; Fletcher R, 1969, OPTIMIZATION; Gil Z, 2009, ISR MED ASSOC J, V11, P296; Heinemann IU, 2008, ARCH BIOCHEM BIOPHYS, V474, P238, DOI 10.1016/j.abb.2008.02.015; Ito E, 2011, FUTURE ONCOL, V7, P595, DOI [10.2217/fon.11.27, 10.2217/FON.11.27]; Ito E, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001922; JACKSON AH, 1976, PHILOS T ROY SOC B, V273, P191, DOI 10.1098/rstb.1976.0009; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kappas A, 1995, METABOLIC MOL BASES, P2103; Lambrecht RW, 2007, SEMIN LIVER DIS, V27, P99, DOI 10.1055/s-2006-960173; Lin TL, 2011, PROTEINS, V79, P2475, DOI 10.1002/prot.23071; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; LUO J, 1993, BIOCHEM J, V289, P529, DOI 10.1042/bj2890529; MCLELLAN T, 1985, CYTOGENET CELL GENET, V39, P224, DOI 10.1159/000132139; MUKERJI SK, 1987, BIOCHEM BIOPH RES CO, V146, P1196, DOI 10.1016/0006-291X(87)90775-3; Phillips JD, 2003, EMBO J, V22, P6225, DOI 10.1093/emboj/cdg606; Phillips JD, 1997, PROTEIN SCI, V6, P1343, DOI 10.1002/pro.5560060624; Phillips JD, 2001, P NATL ACAD SCI USA, V98, P259, DOI 10.1073/pnas.011481398; Phillips JD, 2009, J MOL BIOL, V389, P306, DOI 10.1016/j.jmb.2009.04.013; Ridge JA, 2011, CANC MANAGEMENT MULT; SMITH AG, 1979, BIOCHEM J, V183, P455, DOI 10.1042/bj1830455; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Venkatachalam CM, 2003, J MOL GRAPH MODEL, V21, P289, DOI 10.1016/S1093-3263(02)00164-X; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Whitby FG, 1998, EMBO J, V17, P2463, DOI 10.1093/emboj/17.9.2463; Yang SC, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002189	32	28	28	3	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2012	7	11							e50087	10.1371/journal.pone.0050087	http://dx.doi.org/10.1371/journal.pone.0050087			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	051DI	23209648	Green Published, gold, Green Submitted			2023-01-03	WOS:000312104900023
J	Wu, XL; Xiong, EH; An, SF; Gong, FP; Wang, W				Wu, XiaoLin; Xiong, ErHui; An, SuFang; Gong, FangPing; Wang, Wei			Sequential Extraction Results in Improved Proteome Profiling of Medicinal Plant Pinellia ternata Tubers, Which Contain Large Amounts of High-Abundance Proteins	PLOS ONE			English	Article							ELECTROPHORESIS; IDENTIFICATION; EXPRESSION; PREFRACTIONATION; PRINCIPLE; BACTERIAL; BINDING; CLONING; LECTIN; TISSUE	Pinellia ternata tuber is one of the well-known Chinese traditional medicines. In order to understand the pharmacological properties of tuber proteins, it is necessary to perform proteome analysis of P. ternata tubers. However, a few high-abundance proteins (HAPs), mainly mannose-binding lectin (agglutinin), exist in aggregates of various sizes in the tubers and seriously interfere with proteome profiling by two-dimensional electrophoresis (2-DE). Therefore, selective depletion of these HAPs is a prerequisite for enhanced proteome analysis of P. ternata tubers. Based on differential protein solubility, we developed a novel protocol involving two sequential extractions for depletion of some HAPs and prefractionation of tuber proteins prior to 2-DE. The first extraction using 10% acetic acid selectively extracted acid-soluble HAPs and the second extraction using the SDS-containing buffer extracted remaining acid-insoluble proteins. After application of the protocol, 2-DE profiles of P. ternata tuber proteins were greatly improved and more protein spots were detected, especially low-abundance proteins. Moreover, the subunit composition of P. ternata lectin was analyzed by electrophoresis. Native lectin consists of two hydrogen-bonded subunits (11 kDa and 25 kDa) and the 11 kDa subunit was a glycoprotein. Subsequently, major HAPs in the tubers were analyzed by mass spectrometry, with nine protein spots being identified as lectin isoforms. The methodology was easy to perform and required no specialized apparatus. It would be useful for proteome analysis of other tuber plants of Araceae.	[Wu, XiaoLin; Xiong, ErHui; An, SuFang; Gong, FangPing; Wang, Wei] Henan Agr Univ, Coll Life Sci, Key Lab Physiol Ecol & Genet Improvement Food Cro, Zhengzhou, Peoples R China	Henan Agricultural University	Wang, W (corresponding author), Henan Agr Univ, Coll Life Sci, Key Lab Physiol Ecol & Genet Improvement Food Cro, Zhengzhou, Peoples R China.	proteome@163.com						Bachner D, 1999, FEBS LETT, V457, P522, DOI 10.1016/S0014-5793(99)01092-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen JH, 2003, PHYTOCHEMISTRY, V64, P903, DOI 10.1016/S0031-9422(03)00421-7; Cordwell Stuart J., 2008, V424, P139, DOI 10.1007/978-1-60327-064-9_12; Cravatt BF, 2007, NATURE, V450, P991, DOI 10.1038/nature06525; Doud MK, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-25; Fountoulakis M, 2002, METHOD ENZYMOL, V358, P288; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Han MH, 2006, CHROMATOGRAPHIA, V64, P647, DOI 10.1365/s10337-006-0103-8; Horth P, 2006, MOL CELL PROTEOMICS, V5, P1968, DOI 10.1074/mcp.T600037-MCP200; Jin SX, 2012, PLANT BIOTECHNOL J, V10, P313, DOI 10.1111/j.1467-7652.2011.00663.x; Kim YJ, 2006, BIOL PHARM BULL, V29, P1278, DOI 10.1248/bpb.29.1278; Kurata K, 1998, PLANTA MED, V64, P645, DOI 10.1055/s-2006-957539; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lenkei Z, 2000, J HISTOCHEM CYTOCHEM, V48, P1553, DOI 10.1177/002215540004801112; Lin J, 2003, MOL BIOTECHNOL, V25, P215, DOI 10.1385/MB:25:3:215; MARKI T, 1987, PLANTA MED, V53, P410; Ohtaki T, 1999, J BIOL CHEM, V274, P37041, DOI 10.1074/jbc.274.52.37041; Pan YH, 1998, NAT SCI PROG, V8, P502; Righetti PG, 2005, ELECTROPHORESIS, V26, P297, DOI 10.1002/elps.200406189; Schagger H, 2006, NAT PROTOC, V1, P16, DOI 10.1038/nprot.2006.4; Wang KY, 1993, CHINESE BIOCH J, V9, P545; Wang W, 2004, SEX PLANT REPROD, V17, P41, DOI 10.1007/s00497-004-0207-y; Wang W, 2003, ELECTROPHORESIS, V24, P2369, DOI 10.1002/elps.200305500; WARDI AH, 1972, ANAL BIOCHEM, V49, P607, DOI 10.1016/0003-2697(72)90472-1; WEN TN, 1985, PLANT PHYSIOL, V78, P172, DOI 10.1104/pp.78.1.172; Wu XL, 2011, ACTA PHYSIOL PLANT, V33, P181, DOI 10.1007/s11738-010-0536-4; Yao JH, 2003, CELL RES, V13, P301, DOI 10.1038/sj.cr.7290175	28	7	9	1	39	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 20	2012	7	11							e50497	10.1371/journal.pone.0050497	http://dx.doi.org/10.1371/journal.pone.0050497			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	043II	23185632	gold, Green Published, Green Submitted			2023-01-03	WOS:000311535700087
J	Qiu, YF; Davis, MJ; Dayrit, JK; Hadd, Z; Meister, DL; Osterholzer, JJ; Williamson, PR; Olszewski, MA				Qiu, Yafeng; Davis, Michael J.; Dayrit, Jeremy K.; Hadd, Zachary; Meister, Daniel L.; Osterholzer, John J.; Williamson, Peter R.; Olszewski, Michal A.			Immune Modulation Mediated by Cryptococcal Laccase Promotes Pulmonary Growth and Brain Dissemination of Virulent Cryptococcus neoformans in Mice	PLOS ONE			English	Article							INTERFERON-GAMMA; MACROPHAGE ACTIVATION; HOST-RESISTANCE; AFFERENT PHASE; T-CELLS; INFECTION; INTERLEUKIN-4; INFLAMMATION; EXPRESSION; CD4(+)	C. neoformans is a leading cause of fatal mycosis linked to CNS dissemination. Laccase, encoded by the LAC1 gene, is an important virulence factor implicated in brain dissemination yet little is known about the mechanism(s) accounting for this observation. Here, we investigated whether the presence or absence of laccase altered the local immune response in the lungs by comparing infections with the highly virulent strain, H99 (which expresses laccase) and mutant strain of H99 deficient in laccase (lac1 Delta) in a mouse model of pulmonary infection. We found that LAC1 gene deletion decreased the pulmonary fungal burden and abolished CNS dissemination at weeks 2 and 3. Furthermore, LAC1 deletion lead to: 1) diminished pulmonary eosinophilia; 2) increased accumulation of CD4+ and CD8+ T cells; 3) increased Th1 and Th17 cytokines yet decreased Th2 cytokines; and 4) lung macrophage shifting of the lung macrophage phenotype from M2-towards M1-type activation. Next, we used adoptively transferred CD4+ T cells isolated from pulmonary lymph nodes of mice infected with either lac1 Delta or H99 to evaluate the role of laccase-induced immunomodulation on CNS dissemination. We found that in comparison to PBS treated mice, adoptively transferred CD4+ T cells isolated from lac1 Delta-infected mice decreased CNS dissemination, while those isolated from H99-infected mice increased CNS dissemination. Collectively, our findings reveal that immune modulation away from Th1/Th17 responses and towards Th2 responses represents a novel mechanism through which laccase can contribute to cryptococcal virulence. Furthermore, our data support the hypothesis that laccase-induced changes in polarization of CD4+ T cells contribute to CNS dissemination.	[Qiu, Yafeng; Davis, Michael J.; Dayrit, Jeremy K.; Osterholzer, John J.; Olszewski, Michal A.] Vet Adm Ann Arbor Hlth Syst, Res Serv, Ann Arbor, MI USA; [Qiu, Yafeng; Davis, Michael J.; Dayrit, Jeremy K.; Hadd, Zachary; Meister, Daniel L.; Osterholzer, John J.; Olszewski, Michal A.] Univ Michigan, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI USA; [Williamson, Peter R.] NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA; [Williamson, Peter R.] Univ Illinois, Coll Med, Sect Infect Dis Immunol & Int Med, Chicago, IL USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Olszewski, MA (corresponding author), Vet Adm Ann Arbor Hlth Syst, Res Serv, Ann Arbor, MI USA.	olszewsm@umich.edu		OLSZEWSKI, MICHAL/0000-0001-7474-0843; Davis, Michael/0000-0002-3970-2208	VA [1I01BX000656-01A1]; VA CDA-2; Multidisciplinary Training Program in Pulmonary Diseases [PHS T32-HL07749-19]; Intramural Research Program of the NIH, NIAID; Undergraduate Research Opportunity Program at the University of Michigan; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007749] Funding Source: NIH RePORTER	VA(US Department of Veterans Affairs); VA CDA-2; Multidisciplinary Training Program in Pulmonary Diseases; Intramural Research Program of the NIH, NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Undergraduate Research Opportunity Program at the University of Michigan(University of Michigan System); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This Research has been supported by VA Merit Review funding (1I01BX000656-01A1, MAO), VA CDA-2 funding (JJO), and the Multidisciplinary Training Program in Pulmonary Diseases (MJD, PHS T32-HL07749-19). This research was also supported, in part, by the Intramural Research Program of the NIH, NIAID (PRW). Undergraduate Research Opportunity Program at the University of Michigan supported undergraduate students (DLM, ZH) during their work in the authors' laboratory. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alanio A, 2011, MBIO, V2, DOI 10.1128/mBio.00158-11; Arora S, 2005, J IMMUNOL, V174, P6346, DOI 10.4049/jimmunol.174.10.6346; Arora S, 2011, INFECT IMMUN, V79, P1915, DOI 10.1128/IAI.01270-10; Blackstock R, 2004, AM J RESP CELL MOL, V30, P109, DOI 10.1165/rcmb.2003-0156OC; Blackstock R, 1999, MYCOPATHOLOGIA, V147, P1, DOI 10.1023/A:1007041401743; Buchanan KL, 2000, INFECT IMMUN, V68, P456, DOI 10.1128/IAI.68.2.456-462.2000; Chen GH, 2008, INFECT IMMUN, V76, P2379, DOI 10.1128/IAI.01143-07; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; Classen Andrea, 2009, V531, P29, DOI 10.1007/978-1-59745-396-7_3; Eisenman HC, 2007, MICROBIOL-SGM, V153, P3954, DOI 10.1099/mic.0.2007/011049-0; Erb-Downward JR, 2008, MOL MICROBIOL, V68, P1428, DOI 10.1111/j.1365-2958.2008.06245.x; Erb-Downward JR, 2007, EUKARYOT CELL, V6, P346, DOI 10.1128/EC.00336-06; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Hardison SE, 2010, AM J PATHOL, V176, P774, DOI 10.2353/ajpath.2010.090634; Hofford JM, 1996, J LAB CLIN MED, V128, P545, DOI 10.1016/S0022-2143(96)90126-2; Huffnagle GB, 1996, J IMMUNOL, V157, P4529; HUFFNAGLE GB, 1995, J IMMUNOL, V155, P3507; HUFFNAGLE GB, 1994, J LEUKOCYTE BIOL, V55, P35, DOI 10.1002/jlb.55.1.35; HUFFNAGLE GB, 1991, INFECT IMMUN, V59, P1423, DOI 10.1128/IAI.59.4.1423-1433.1991; HUFFNAGLE GB, 1991, J EXP MED, V173, P793, DOI 10.1084/jem.173.4.793; Jain AV, 2009, INFECT IMMUN, V77, P5389, DOI 10.1128/IAI.00809-09; Jarvis JN, 2007, AIDS, V21, P2119, DOI 10.1097/QAD.0b013e3282a4a64d; Kawakami K, 1996, FEMS IMMUNOL MED MIC, V13, P123, DOI 10.1111/j.1574-695X.1996.tb00225.x; Kawakami K, 1999, CELL IMMUNOL, V197, P55, DOI 10.1006/cimm.1999.1557; Kleinschek MA, 2006, J IMMUNOL, V176, P1098, DOI 10.4049/jimmunol.176.2.1098; Kronstad JW, 2011, NAT REV MICROBIOL, V9, P193, DOI 10.1038/nrmicro2522; Liu L, 1999, INFECT IMMUN, V67, P6034, DOI 10.1128/IAI.67.11.6034-6039.1999; MODY CH, 1993, J LAB CLIN MED, V121, P765; Muller U, 2007, J IMMUNOL, V179, P5367, DOI 10.4049/jimmunol.179.8.5367; Noverr MC, 2004, INFECT IMMUN, V72, P1693, DOI 10.1128/IAI.72.3.1693-1699.2004; Noverr MC, 2003, INFECT IMMUN, V71, P1538, DOI 10.1128/IAI.71.3.1538-1547.2003; Olszewski MA, 2000, J IMMUNOL, V165, P6429, DOI 10.4049/jimmunol.165.11.6429; Olszewski MA, 2001, INFECT IMMUN, V69, P6256, DOI 10.1128/IAI.69.10.6256-6263.2001; Olszewski MA, 2010, FUTURE MICROBIOL, V5, P1269, DOI [10.2217/fmb.10.93, 10.2217/FMB.10.93]; Osterholzer JJ, 2009, AM J PATHOL, V174, P932, DOI 10.2353/ajpath.2009.080673; Panepinto JC, 2006, FEMS YEAST RES, V6, P489, DOI 10.1111/j.1567-1364.2006.00078.x; Pappas PG, 2001, CLIN INFECT DIS, V33, P690, DOI 10.1086/322597; Pukkila-Worley R, 2005, EUKARYOT CELL, V4, P190, DOI 10.1128/EC.4.1.190-201.2005; Salas SD, 1996, J EXP MED, V184, P377, DOI 10.1084/jem.184.2.377; Shreiner AB, 2012, INFECT IMMUN, V80, P388, DOI 10.1128/IAI.05530-11; Traynor TR, 2000, J IMMUNOL, V164, P2021, DOI 10.4049/jimmunol.164.4.2021; Valdez PA, 2012, IMMUNITY, V36, P668, DOI 10.1016/j.immuni.2012.02.013; Wormley FL, 2007, INFECT IMMUN, V75, P1453, DOI 10.1128/IAI.00274-06; Wozniak KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017204; Zhang YM, 2009, AM J PATHOL, V175, P2489, DOI 10.2353/ajpath.2009.090530	45	53	55	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 22	2012	7	10							e47853	10.1371/journal.pone.0047853	http://dx.doi.org/10.1371/journal.pone.0047853			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	025MM	23110112	Green Published, gold, Green Submitted			2023-01-03	WOS:000310193400020
J	Arie, S				Arie, Sophie			Ending the French love affair with drugs	BRITISH MEDICAL JOURNAL			English	Editorial Material												mail@sophiearie.com						Benkimoun P, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c6882; Debre B, 2012, GUIDE 4000 MED UTILE; OECD, 2012, HLTH KEY TABL PHARM; OECD, 2011, HLTH GLANC 2011 PHAR	4	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	OCT 17	2012	345								e6996	10.1136/bmj.e6996	http://dx.doi.org/10.1136/bmj.e6996			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	024WR	23077372				2023-01-03	WOS:000310141900016
J	Heo, J; Reid, T; Ruo, L; Breitbach, CJ; Rose, S; Bloomston, M; Cho, M; Lim, HY; Chung, HC; Kim, CW; Burke, J; Lencioni, R; Hickman, T; Moon, A; Lee, YS; Kim, MK; Daneshmand, M; Dubois, K; Longpre, L; Ngo, M; Rooney, C; Bell, JC; Rhee, BG; Patt, R; Hwang, TH; Kirn, DH				Heo, Jeong; Reid, Tony; Ruo, Leyo; Breitbach, Caroline J.; Rose, Steven; Bloomston, Mark; Cho, Mong; Lim, Ho Yeong; Chung, Hyun Cheol; Kim, Chang Won; Burke, James; Lencioni, Riccardo; Hickman, Theresa; Moon, Anne; Lee, Yeon Sook; Kim, Mi Kyeong; Daneshmand, Manijeh; Dubois, Kara; Longpre, Lara; Ngo, Minhtran; Rooney, Cliona; Bell, John C.; Rhee, Byung-Geon; Patt, Richard; Hwang, Tae-Ho; Kirn, David H.			Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer	NATURE MEDICINE			English	Article							ADVANCED HEPATOCELLULAR-CARCINOMA; MODIFIED RECIST; POXVIRUS; SORAFENIB; VIROTHERAPY; DELIVERY; CRITERIA; THERAPY	Oncolytic viruses and active immunotherapeutics have complementary mechanisms of action (MOA) that are both self amplifying in tumors, yet the impact of dose on subject outcome is unclear. JX-594 (Pexa-Vec) is an oncolytic and immunotherapeutic vaccinia virus. To determine the optimal JX-594 dose in subjects with advanced hepatocellular carcinoma (HCC), we conducted a randomized phase 2 dose-finding trial (n = 30). Radiologists infused low- or high-dose JX-594 into liver tumors (days 1, 15 and 29); infusions resulted in acute detectable intravascular JX-594 genomes. Objective intrahepatic Modified Response Evaluation Criteria in Solid Tumors (mRECIST) (15%) and Choi (62%) response rates and intrahepatic disease control (50%) were equivalent in injected and distant noninjected tumors at both doses. JX-594 replication and granulocyte-macrophage colony-stimulating factor (GM-CSF) expression preceded the induction of anticancer immunity. In contrast to tumor response rate and immune endpoints, subject survival duration was significantly related to dose (median survival of 14.1 months compared to 6.7 months on the high and low dose, respectively; hazard ratio 0.39; P = 0.020). JX-594 demonstrated oncolytic and immunotherapy MOA, tumor responses and dose-related survival in individuals with HCC.	[Heo, Jeong; Cho, Mong; Kim, Chang Won] Pusan Natl Univ, Dept Internal Med, Pusan, South Korea; [Heo, Jeong; Cho, Mong; Kim, Chang Won] Pusan Natl Univ Hosp, Med Res Inst, Pusan, South Korea; [Reid, Tony; Rose, Steven] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Ruo, Leyo] McMaster Univ, Dept Surg, Med Ctr, Hamilton, ON L8S 4L8, Canada; [Breitbach, Caroline J.; Burke, James; Hickman, Theresa; Moon, Anne; Dubois, Kara; Longpre, Lara; Bell, John C.; Kirn, David H.] Jennerex Inc, San Francisco, CA USA; [Bloomston, Mark] Ohio State Univ, Dept Surg, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Lim, Ho Yeong] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea; [Chung, Hyun Cheol] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Yongdong Severance Hosp, Seoul, South Korea; [Lencioni, Riccardo] Univ Pisa, Sch Med, Div Diagnost Imaging & Intervent, I-56100 Pisa, Italy; [Lee, Yeon Sook; Kim, Mi Kyeong; Hwang, Tae-Ho] SillaJen Inc, Pusan, South Korea; [Daneshmand, Manijeh; Bell, John C.] Ottawa Hosp Res Inst, Ctr Innovat Canc Therapeut, Ottawa, ON, Canada; [Ngo, Minhtran; Rooney, Cliona] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; [Ngo, Minhtran; Rooney, Cliona] Baylor Coll Med, Houston, TX 77030 USA; [Rooney, Cliona] Texas Childrens Hosp, Houston, TX 77030 USA; [Rhee, Byung-Geon] Green Cross Co, Yongin, South Korea; [Patt, Richard] RadMD, Doylestown, PA USA; [Hwang, Tae-Ho] Pusan Natl Univ, Dept Pharmacol, Pusan, South Korea	Pusan National University; Pusan National University; Pusan National University Hospital; University of California System; University of California San Diego; McMaster University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Sungkyunkwan University (SKKU); Samsung Medical Center; Yonsei University; Yonsei University Health System; University of Pisa; University of Ottawa; Ottawa Hospital Research Institute; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Green Cross Corporation; Pusan National University	Kirn, DH (corresponding author), Jennerex Inc, San Francisco, CA USA.	thhwang@pusan.ac.kr; dkirn@jennerex.com	Rooney, Cliona/ABD-5475-2021; Lencioni, Riccardo/AAC-4723-2022; Bloomston, Mark/E-2767-2011	Chung, Hyun/0000-0002-0920-9471; LENCIONI, RICCARDO ANTONIO/0000-0002-8535-6449	Korea Healthcare technology Research and Development Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea [A091047]; Dan Duncan Cancer Center; Robert and Janice McNair Foundation; Baylor Research Advocates for Student Scientists Fund; Ontario Institute for Cancer Research; Terry Fox Foundation; Jennerex, Transgene SA (Illkirch, France); Green Cross Corporation; Korea Healthcare technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea; Canadian Institute for Health Research (CIHR); NATIONAL CANCER INSTITUTE [P30CA023100, P30CA016058] Funding Source: NIH RePORTER	Korea Healthcare technology Research and Development Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea; Dan Duncan Cancer Center; Robert and Janice McNair Foundation; Baylor Research Advocates for Student Scientists Fund; Ontario Institute for Cancer Research; Terry Fox Foundation; Jennerex, Transgene SA (Illkirch, France); Green Cross Corporation; Korea Healthcare technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea; Canadian Institute for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	J.-M. Limacher, M. Homerin, B.M. Bastien and M. Lusky (all from Transgene SA) gave insightful comments On the manuscript. T.-H.H. and M.K.K. were supported by a grant of the Korea Healthcare technology Research and Development Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (A091047). C.R. was supported by a pilot grant from the Dan Duncan Cancer Center. M.N. was supported by the Robert and Janice McNair Foundation and Baylor Research Advocates for Student Scientists Fund. J.C.B. is supported by the Ontario Institute for Cancer Research and the Terry Fox Foundation. Funding was provided by Jennerex, Transgene SA (Illkirch, France) and the Green Cross Corporation; grants to T.-H.H. from Korea Healthcare technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea; to J.C.B. from the Terry Fox Foundation and the Canadian Institute for Health Research (CIHR); and a pilot grant to C.R. from the Dan Duncan Cancer Center. This trial was registered with ClinicalTrials.gov, number NCT00554372.	Breitbach CJ, 2011, NATURE, V477, P99, DOI 10.1038/nature10358; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Chiocca EA, 2002, NAT REV CANCER, V2, P938, DOI 10.1038/nrc948; Choi H, 2007, J CLIN ONCOL, V25, P1753, DOI 10.1200/JCO.2006.07.3049; Edeline J, 2012, CANCER-AM CANCER SOC, V118, P147, DOI 10.1002/cncr.26255; Faivre S, 2011, CLIN CANCER RES, V17, P4504, DOI 10.1158/1078-0432.CCR-10-1708; Heise C, 2000, J CLIN INVEST, V105, P847, DOI 10.1172/JCI9762; Heo J, 2011, MOL THER, V19, P1170, DOI 10.1038/mt.2011.39; Hwang TH, 2011, MOL THER, V19, P1913, DOI 10.1038/mt.2011.132; Kaufman HL, 2010, ANN SURG ONCOL, V17, P718, DOI 10.1245/s10434-009-0809-6; Kim JH, 2006, MOL THER, V14, P361, DOI 10.1016/j.ymthe.2006.05.008; Kirn D, 2001, NAT MED, V7, P781, DOI 10.1038/89901; Kirn DH, 2009, NAT REV CANCER, V9, P64, DOI 10.1038/nrc2545; Lencioni R, 2010, SEMIN LIVER DIS, V30, P52, DOI 10.1055/s-0030-1247132; Liu TC, 2008, MOL THER, V16, P1637, DOI 10.1038/mt.2008.143; Liu TC, 2007, NAT CLIN PRACT ONCOL, V4, P101, DOI 10.1038/ncponc0736; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Parato KA, 2012, MOL THER, V20, P749, DOI 10.1038/mt.2011.276; Park BH, 2008, LANCET ONCOL, V9, P533, DOI 10.1016/S1470-2045(08)70107-4; Senzer NN, 2009, J CLIN ONCOL, V27, P5763, DOI 10.1200/JCO.2009.24.3675; Thorne SH, 2007, J CLIN INVEST, V117, P3350, DOI 10.1172/JCI32727; Wein LM, 2003, CANCER RES, V63, P1317	22	512	555	2	144	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2013	19	3					329	336		10.1038/nm.3089	http://dx.doi.org/10.1038/nm.3089			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	105BN	23396206	Green Accepted			2023-01-03	WOS:000316040700026
J	Lim, TC; Rokkappanavar, S; Toh, WS; Wang, LS; Kurisawa, M; Spector, M				Lim, Teck Chuan; Rokkappanavar, Swetha; Toh, Wei Seong; Wang, Li-Shan; Kurisawa, Motoichi; Spector, Myron			Chemotactic recruitment of adult neural progenitor cells into multifunctional hydrogels providing sustained SDF-1 alpha release and compatible structural support	FASEB JOURNAL			English	Article						tissue engineering; cavitary brain lesion; injectable biomaterials; nanoparticles; matrix metalloproteinases	GROWTH-FACTOR; STEM-CELLS; NEUROBLAST MIGRATION; FACTOR-I; NEUROGENESIS; REGENERATION; NEURONS; STROKE; BRAIN; RAT	Without chemotactic cues and structural support, cavitary brain lesions typically fail to recruit endogenous neural progenitor cells (NPCs). Toward resolving this, we engineered multifunctional biomaterials comprising injectable gelatin-hydroxyphenylpropionic acid (Gtn-HPA) hydrogels and dextran sulfate/chitosan polyelectrolyte complex nanoparticles (PCNs) that delivered stromal cell-derived factor-1 alpha (SDF-1 alpha). Over 7 d of interface with in vitro tissue simulant containing adult rat hippocampal NPCs (aNPCs) and their neuronal progeny, Gtn-HPA/SDF-1 alpha-PCN hydrogels promoted chemotactic recruitment to enhance infiltration of aNPCs by 3- to 45-fold relative to hydrogels that lacked SDF-1 alpha or vehicles to sustain SDF-1 alpha release. When cross-linked with 0.85-0.95mM H2O2, Gtn-HPA/SDF-1 alpha-PCN hydrogels provided optimally permissive structural support for migration of aNPCs. Specific matrix metalloproteinase (MMP) inhibitors revealed that 42, 30, and 55% of cell migration into Gtn-HPA/SDF-1 alpha-PCN hydrogels involved MMP-2, 3, and 9, respectively, demonstrating the hydrogels to be compatible toward homing endogenous NPCs, given their expression of similar MMPs. Interestingly, PCNs utilized FGF-2 found in situ to induce chemokinesis, potentiate SDF-1 alpha chemotactic recruitment, and increase proliferation of recruited cells, which collectively orchestrated a higher number of migrated aNPCs. Overall, Gtn-HPA/SDF-1 alpha-PCN hydrogels prove to be promising biomaterials for injection into cavitary brain lesions to recruit endogenous NPCs and enhance neural tissue repair/regeneration.-Lim, T. C., Rokkappanavar, S., Toh, W. S., Wang, L.-S., Kurisawa, M., Spector, M. Chemotactic recruitment of adult neural progenitor cells into multifunctional hydrogels providing sustained SDF-1 alpha release and compatible structural support. FASEB J. 27, 1023-1033 (2013). www.fasebj.org	[Lim, Teck Chuan; Spector, Myron] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Lim, Teck Chuan; Rokkappanavar, Swetha; Toh, Wei Seong; Spector, Myron] VA Boston Healthcare Syst, Tissue Engn Labs, Boston, MA 02130 USA; [Rokkappanavar, Swetha; Toh, Wei Seong; Spector, Myron] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Orthoped Surg, Boston, MA 02115 USA; [Wang, Li-Shan; Kurisawa, Motoichi] Inst Bioengn & Nanotechnol, Singapore, Singapore	Harvard University; Massachusetts Institute of Technology (MIT); US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Bioengineering & Bioimaging (IBB); A*STAR - Institute of Bioengineering & Nanotechnology (IBN)	Spector, M (corresponding author), VA Boston Healthcare Syst, Tissue Engn Labs, Mail Stop 151 Res,150 S Huntington Ave, Boston, MA 02130 USA.	mspector@rics.bwh.harvard.edu	KURISAWA, MOTOICHI/C-1325-2014; Wang, Li Shan/F-9460-2013; Toh, Wei Seong/K-7720-2013	KURISAWA, MOTOICHI/0000-0003-2413-6933; Toh, Wei Seong/0000-0001-9147-6423; Spector, Myron/0000-0003-3328-4858; Lim, Teck Chuan/0000-0002-4062-6046	U.S. Department of Veterans Affairs and Agency for Science, Technology and Research, Singapore	U.S. Department of Veterans Affairs and Agency for Science, Technology and Research, Singapore	The authors thank Marsha Doudna Guy for technical assistance and Chyan Ying Ke for critical reading of the manuscript. This work was supported by the Rehabilitation Research and Development Service of the U.S. Department of Veterans Affairs and Agency for Science, Technology and Research, Singapore ( to T.C.L., W.S.T., L.W., and M.K.).	Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Barkho BZ, 2008, STEM CELLS, V26, P3139, DOI 10.1634/stemcells.2008-0519; Bible E, 2009, BIOMATERIALS, V30, P2985, DOI 10.1016/j.biomaterials.2009.02.012; Borselli C, 2010, P NATL ACAD SCI USA, V107, P3287, DOI 10.1073/pnas.0903875106; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Guerra-Crespo M, 2009, NEUROSCIENCE, V160, P470, DOI 10.1016/j.neuroscience.2009.02.029; Haider HK, 2008, J MOL CELL CARDIOL, V45, P554, DOI 10.1016/j.yjmcc.2008.05.004; Hou SW, 2008, STROKE, V39, P2837, DOI 10.1161/STROKEAHA.107.510982; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Jo DY, 2000, J CLIN INVEST, V105, P101, DOI 10.1172/JCI7954; Khorana AA, 2003, ARTERIOSCL THROM VAS, V23, P2110, DOI 10.1161/01.ATV.0000090671.56682.D7; Lauten EH, 2010, BIOMACROMOLECULES, V11, P1863, DOI 10.1021/bm100384z; Lee CH, 2010, LANCET, V376, P440, DOI 10.1016/S0140-6736(10)60668-X; Lim TC, 2012, BIOMATERIALS, V33, P3446, DOI 10.1016/j.biomaterials.2012.01.037; Maeda N, 2011, NEUROCHEM RES, V36, P1228, DOI 10.1007/s11064-010-0324-y; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Masuda T, 2007, NEUROSCI LETT, V425, P114, DOI 10.1016/j.neulet.2007.08.039; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Padera R, 1999, FASEB J, V13, P1677, DOI 10.1096/fasebj.13.13.1677; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Pickering JG, 1997, CIRC RES, V80, P627, DOI 10.1161/01.RES.80.5.627; Salcedo R, 2003, MICROCIRCULATION, V10, P359, DOI 10.1038/sj.mn.7800200; Sasisekharan R, 1997, Angiogenesis, V1, P45, DOI 10.1023/A:1018318914258; Shah RN, 2010, P NATL ACAD SCI USA, V107, P3293, DOI 10.1073/pnas.0906501107; Speliotes EK, 1996, MOL BRAIN RES, V39, P31, DOI 10.1016/0169-328X(95)00351-R; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Wang LS, 2010, BIOMATERIALS, V31, P8608, DOI 10.1016/j.biomaterials.2010.07.075; Yamashita T, 2006, J NEUROSCI, V26, P6627, DOI 10.1523/JNEUROSCI.0149-06.2006; Yu T, 2010, J NEUROSCI RES, V88, P2775, DOI 10.1002/jnr.22454; Zhang HX, 2003, J CELL BIOL, V163, P1375, DOI 10.1083/jcb.200308040; Zhang RL, 2009, J CEREBR BLOOD F MET, V29, P1240, DOI 10.1038/jcbfm.2009.55; Zhang RL, 2011, J CEREBR BLOOD F MET, V31, P614, DOI 10.1038/jcbfm.2010.134	33	47	48	1	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2013	27	3					1023	1033		10.1096/fj.12-221515	http://dx.doi.org/10.1096/fj.12-221515			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23193174				2023-01-03	WOS:000315585200017
J	Elliott, JA; Abdulhadi, NN; Al-Maniri, AA; Al-Shafaee, MA; Wahlstrom, R				Elliott, James A.; Abdulhadi, Nadia Noor; Al-Maniri, Abdullah A.; Al-Shafaee, Mohammed A.; Wahlstrom, Rolf			Diabetes Self-Management and Education of People Living with Diabetes: A Survey in Primary Health Care in Muscat Oman	PLOS ONE			English	Article							DISEASE; PREVALENCE; KNOWLEDGE; MELLITUS; ILLNESS	Background: Although the prevalence of type 2 diabetes in Oman is high and rising, information on how people were self-managing their disease has been lacking. The objective of this study was therefore to assess diabetes self-management and education (DSME) among people living with type 2 diabetes in Oman. Methods: A questionnaire survey was conducted in public primary health care centres in Muscat. Diabetes self-management and education was assessed by asking how patients recognized and responded to hypo- and hyperglycaemia, and if they had developed strategies to maintain stable blood glucose levels. Patients' demographic information, self-treatment behaviours, awareness of potential long-term complications, and attitudes concerning diabetes management were also recorded. Associations between these factors and diabetes self-management and education were analysed. Results: In total, 309 patients were surveyed. A quarter (26%, n = 83) were unaware how to recognize hypoglycaemia or respond to it (26%, n = 81). Around half (49%, n = 151), could not recognize hyperglycaemia and more than half could not respond to it (60%, n = 184). Twelve percent (n = 37) of the patients did not have any strategies to stabilize their blood glucose levels. Patients with formal education generally had more diabetes self-management and education than those without (p<0.001), as had patients with longer durations of diabetes (p<0.01). Self-monitoring of blood glucose was practiced by 38% (n = 117) of the patients, and insulin was used by 22% (n = 67), of which about one third independently adjusted dosages. Patients were most often aware of complications concerning loss of vision, renal failure and cardiac problems. Many patients desired further health education. Conclusions: Many patients displayed dangerous diabetes self-management and education knowledge gaps. The findings suggest a need for improving knowledge transfer to people living with diabetes in the Omani clinical setting.	[Elliott, James A.; Abdulhadi, Nadia Noor; Wahlstrom, Rolf] Karolinska Inst, Div Global Hlth, Dept Publ Hlth Sci, Stockholm, Sweden; [Abdulhadi, Nadia Noor] Minist Hlth, Dept Hlth Affairs, Muscat, Oman; [Al-Maniri, Abdullah A.; Al-Shafaee, Mohammed A.] Sultan Qaboos Univ, Coll Med & Hlth Sci, Dept Family Med & Publ Hlth, Muscat, Oman; [Wahlstrom, Rolf] Uppsala Univ, Dept Publ Hlth & Caring Sci Family Med & Clin Epi, Uppsala, Sweden	Karolinska Institutet; Sultan Qaboos University; Uppsala University	Abdulhadi, NN (corresponding author), Karolinska Inst, Div Global Hlth, Dept Publ Hlth Sci, Stockholm, Sweden.	nadia.abdulhadi@ki.se		Elliott, James/0000-0001-7150-6074; Al Shafaee, Mohammed/0000-0002-4816-1706	Ministry of Health, Oman; Karolinska Institutet, Sweden; Sultan Qaboos University in Oman	Ministry of Health, Oman; Karolinska Institutet, Sweden(Karolinska Institutet); Sultan Qaboos University in Oman	Funding provided by Ministry of Health, Oman; Karolinska Institutet, Sweden (www.ki.se) and Sultan Qaboos University in Oman. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdulhadi N., 2006, BMC Family Practice, V7; Al Shafaee MA, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-249; Al-Lawati JA, 2002, DIABETIC MED, V19, P954, DOI 10.1046/j.1464-5491.2002.00818.x; Al-Lawati Jawad A, 2008, Prev Chronic Dis, V5, pA99; Al-Moosa Siba, 2006, Popul Health Metr, V4, P5, DOI 10.1186/1478-7954-4-5; Al-Shafaee Mohammed Ali, 2008, Metabolic Syndrome and Related Disorders, V6, P275, DOI 10.1089/met.2008.0019; Al-Shahib W, 2003, INT J FOOD SCI NUTR, V54, P247, DOI [10.1080/09637480120091982, 10.1080/096374803766666120]; Assal J P, 1995, Pharmacoeconomics, V8 Suppl 1, P68; Boutayeb A, 2006, T ROY SOC TROP MED H, V100, P191, DOI 10.1016/j.trstmh.2005.07.021; Fitzner K, 2008, POPUL HEALTH MANAG, V11, P329, DOI 10.1089/pop.2008.0012; Funnell Martha M, 2004, Crit Care Nurs Q, V27, P201; Funnell MM, 2002, AM J PREV MED, V22, P3, DOI 10.1016/S0749-3797(02)00431-2; Ganguly S S, 2009, East Mediterr Health J, V15, P209; Hjelm K, 2003, INT J NURS STUD, V40, P627, DOI 10.1016/S0020-7489(03)00020-8; Holmstrom IM, 2005, J ADV NURS, V49, P146, DOI 10.1111/j.1365-2648.2004.03274.x; Insight Guides, 2009, OMAN UAE; Kendall DM, 2001, AM J MANAG CARE, V7, pS327; Krosnick JA, 2010, HANDBOOK OF SURVEY RESEARCH, 2ND EDITION, P263; Lawrence P, 2001, J Transcult Nurs, V12, P228, DOI 10.1177/104365960101200307; Marrero David G, 2007, Clin Cornerstone, V8, P33; Ministry of Health Sultanate of Oman, 2003, DIAB MELL MAN GUID P; Ministry of Health Sultanate of Oman, 2008, WORLD HLTH SURV; Ministry of Information Sultanate of Oman, 2002, TRAD MOD; National Diabetes Information Clearinghouse, 2011, NAT DIAB STAT 2011; National Diabetes Information Clearinghouse, 2008, HYP; Norris SL, 2001, DIABETES CARE, V24, P561, DOI 10.2337/diacare.24.3.561; Otero LM, 2008, REV LAT-AM ENFERM, V16, P231, DOI 10.1590/S0104-11692008000200010; Peyrot M, 2005, DIABETES CARE, V28, P2673, DOI 10.2337/diacare.28.11.2673; Rothman RL, 2005, DIABETES EDUCATOR, V31, P215, DOI 10.1177/0145721705275002; Shaw JE, 2010, DIABETES RES CLIN PR, V87, P4, DOI 10.1016/j.diabres.2009.10.007; Sidorov J, 2002, DIABETES CARE, V25, P684, DOI 10.2337/diacare.25.4.684; Thompson DM, 1999, CAN MED ASSOC J, V161, P959; Travaline JM, 2005, J AM OSTEOPATH ASSOC, V105, P13; United Nations Development Program, 2010, 40 YEAR TRENDS AN SH; Urbanski P, 2008, J AM DIET ASSOC, V108, pS6, DOI 10.1016/j.jada.2008.01.019; Veg A, 2006, J ADV NURS, V56, P44, DOI 10.1111/j.1365-2648.2006.03978.x; Weiss BD, 2009, HLTH LIT PATIENT SAF, P1; Westphal SA, 2010, ENDOCR PRACT, V16, P506, DOI 10.4158/EP09344.RA; White J.R., 2003, CLIN DIABETES, V21, P14; WHO, 2010, COUNTR COOP STRAT WH	40	21	21	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2013	8	2							e57400	10.1371/journal.pone.0057400	http://dx.doi.org/10.1371/journal.pone.0057400			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	113IC	23451219	gold, Green Published, Green Submitted			2023-01-03	WOS:000316658800104
J	Manyando, C; Njunju, EM; D'Alessandro, U; Van Geertruyden, JP				Manyando, Christine; Njunju, Eric M.; D'Alessandro, Umberto; Van Geertruyden, Jean-Pierre			Safety and Efficacy of Co-Trimoxazole for Treatment and Prevention of Plasmodium falciparum Malaria: A Systematic Review	PLOS ONE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; TRIMETHOPRIM-SULFAMETHOXAZOLE PROPHYLAXIS; SUB-SAHARAN AFRICA; INSECTICIDE-TREATED BEDNETS; INFECTED UGANDAN CHILDREN; FOLIC-ACID ANTAGONISTS; SULFADOXINE-PYRIMETHAMINE; PREGNANT-WOMEN; PLACENTAL MALARIA; WESTERN KENYA	Introduction: Cotrimoxazole (CTX) has been used for half a century. It is inexpensive hence the reason for its almost universal availability and wide clinical spectrum of use. In the last decade, CTX was used for prophylaxis of opportunistic infections in HIV infected people. It also had an impact on the malaria risk in this specific group. Objective: We performed a systematic review to explore the efficacy and safety of CTX used for P. falciparum malaria treatment and prophylaxis. Result: CTX is safe and efficacious against malaria. Up to 75% of the safety concerns relate to skin reactions and this increases in HIV/AIDs patients. In different study areas, in HIV negative individuals, CTX used as malaria treatment cleared 56%-97% of the malaria infections, reduced fever and improved anaemia. CTX prophylaxis reduces the incidence of clinical malaria in HIV-1 infected individuals from 46%-97%. In HIV negative non pregnant participants, CTX prophylaxis had 39.5%-99.5% protective efficacy against clinical malaria. The lowest figures were observed in zones of high sulfadoxine-pyrimethamine resistance. There were no data reported on CTX prophylaxis in HIV negative pregnant women. Conclusion: CTX is safe and still efficacious for the treatment of P.falciparum malaria in non-pregnant adults and children irrespective of HIV status and antifolate resistance profiles. There is need to explore its effect in pregnant women, irrespective of HIV status. CTX prophylaxis in HIV infected individuals protects against malaria and CTX may have a role for malaria prophylaxis in specific HIV negative target groups.	[Manyando, Christine] Trop Dis Res Ctr, Dept Publ Hlth, Ndola, Zambia; [D'Alessandro, Umberto] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium; [D'Alessandro, Umberto] MRC Unit, Fajara, Gambia; [Van Geertruyden, Jean-Pierre] Univ Antwerp, Antwerp, Belgium; [Njunju, Eric M.] Trop Dis Res Ctr, Dept Biomed Sci, Ndola, Zambia	Institute of Tropical Medicine (ITM); University of London; London School of Hygiene & Tropical Medicine; University of Antwerp	Manyando, C (corresponding author), Trop Dis Res Ctr, Dept Publ Hlth, Ndola, Zambia.	cmanyando@yahoo.com	Van geertruyden, Jean-Pierre/K-6425-2014	Van geertruyden, Jean-Pierre/0000-0001-5006-6364	Belgian Development Co-operation	Belgian Development Co-operation	Belgian Development Co-operation funded the process through an institutional collaboration between the Tropical Disease Research Center, Ndola, Zambia, and the Institute of Tropical Medicine, Antwerp, Belgium. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akim NIJ, 2000, AM J TROP MED HYG, V63, P199, DOI 10.4269/ajtmh.2000.63.199; Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; Anglaret X, 2010, LANCET, V375, P1231, DOI 10.1016/S0140-6736(10)60200-0; [Anonymous], 2008, FOOD NUTR BULL, V29, pS3; [Anonymous], 2012, INT PREV TREATM MAL; Ayisi JG, 2003, AIDS, V17, P585, DOI 10.1097/00002030-200303070-00014; Badri M, 1999, LANCET, V354, P334, DOI 10.1016/S0140-6736(05)75237-5; Badri M, 2001, AIDS, V15, P1143, DOI 10.1097/00002030-200106150-00009; Brahmbhatt H, 2006, JAIDS-J ACQ IMM DEF, V41, P504, DOI 10.1097/01.qai.0000188122.15493.0a; Briand V, 2009, ANN TROP PAEDIATR, V29, P71, DOI 10.1179/146532809X440699; BUSHBY SRM, 1968, BRIT J PHARMACOL, V33, P72, DOI 10.1111/j.1476-5381.1968.tb00475.x; Byakika-Kibwika Pauline, 2007, Afr Health Sci, V7, P86; Corbett EL, 2002, CLIN INFECT DIS, V34, P1251, DOI 10.1086/339540; Crampin AC, 2003, AIDS, V17, P389, DOI 10.1097/00002030-200302140-00013; Czeizel AE, 2001, REPROD TOXICOL, V15, P637, DOI 10.1016/S0890-6238(01)00178-2; DARAMOLA OO, 1991, T ROY SOC TROP MED H, V85, P345, DOI 10.1016/0035-9203(91)90285-7; DARRELL JH, 1968, J CLIN PATHOL, V21, P202, DOI 10.1136/jcp.21.2.202; Dorsey G, 2004, AM J TROP MED HYG, V71, P758, DOI 10.4269/ajtmh.2004.71.758; Farrell J, 2003, J PHARMACOL EXP THER, V306, P229, DOI 10.1124/jpet.103.050112; FASAN PO, 1971, ANN TROP MED PARASIT, V65, P117, DOI 10.1080/00034983.1971.11686737; Fehintola F A, 2010, Afr J Med Med Sci, V39, P63; Feikin DR, 2000, J INFECT DIS, V181, P1501, DOI 10.1086/315382; Filler SJ, 2006, J INFECT DIS, V194, P286, DOI 10.1086/505080; Flateau C, 2011, LANCET INFECT DIS, V11, P541, DOI 10.1016/S1473-3099(11)70031-7; Forna F, 2006, AIDS REV, V8, P24; Gallagher M, 2005, AIDS, V19, P1849, DOI 10.1097/01.aids.0000189846.90946.5d; Gasasira AF, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-177; Gilks CF, 1996, LANCET, V347, P718, DOI 10.1016/S0140-6736(96)90076-8; Gill CJ, 2004, B WORLD HEALTH ORGAN, V82, P290; Hamel MJ, 2008, AM J TROP MED HYG, V79, P320, DOI 10.4269/ajtmh.2008.79.320; Hamel MJ, 2005, AM J TROP MED HYG, V73, P609, DOI 10.4269/ajtmh.2005.73.609; HANSFORD CF, 1982, S AFR MED J, V61, P512; Heimpel H, 1987, Infection, V15 Suppl 5, pS248, DOI 10.1007/BF01643198; Hernandez-Diaz S, 2001, AM J EPIDEMIOL, V153, P961, DOI 10.1093/aje/153.10.961; Hernandez-Diaz S, 2000, NEW ENGL J MED, V343, P1608, DOI 10.1056/NEJM200011303432204; HIRSCHTICK RE, 1995, NEW ENGL J MED, V333, P845, DOI 10.1056/NEJM199509283331305; Ho JMW, 2011, CAN MED ASSOC J, V183, P1851, DOI 10.1503/cmaj.111152; Inion I, 2003, J INFECT DIS, V188, P1675, DOI 10.1086/379737; Iyer JK, 2001, LANCET, V358, P1066, DOI 10.1016/S0140-6736(01)06201-8; JOOS B, 1995, ANTIMICROB AGENTS CH, V39, P2661, DOI 10.1128/AAC.39.12.2661; Kamya MR, 2007, AIDS, V21, P2059, DOI 10.1097/QAD.0b013e3282ef6da1; Kapito-Tembo A, 2011, J INFECT DIS, V203, P464, DOI 10.1093/infdis/jiq072; Kilian AHD, 1998, T ROY SOC TROP MED H, V92, P197, DOI 10.1016/S0035-9203(98)90748-9; Kone A, 2010, INT J PARASITOL, V40, P1221, DOI 10.1016/j.ijpara.2010.05.004; Korenromp EL, 2005, EMERG INFECT DIS, V11, P1410, DOI 10.3201/eid1109.050337; Kublin JG, 2002, J INFECT DIS, V185, P380, DOI 10.1086/338566; Kuhn L, 2005, CLIN INFECT DIS, V41, P1654, DOI 10.1086/498029; Kyabayinze D, 2003, AM J TROP MED HYG, V69, P247, DOI 10.4269/ajtmh.2003.69.247; Ladner J, 2003, AIDS, V17, P275, DOI 10.1097/00002030-200301240-00025; Lynen L, 2007, T ROY SOC TROP MED H, V101, P1059, DOI 10.1016/j.trstmh.2007.07.001; Malamba S, 2010, AM J TROP MED HYG, V82, P766, DOI 10.4269/ajtmh.2010.08-0408; Malamba SS, 2006, AM J TROP MED HYG, V75, P375, DOI 10.4269/ajtmh.2006.75.375; Mendez F, 2002, AM J EPIDEMIOL, V156, P230, DOI 10.1093/aje/kwf030; Mermin J, 2006, LANCET, V367, P1256, DOI 10.1016/S0140-6736(06)68541-3; Mermin J, 2006, JAIDS-J ACQ IMM DEF, V41, P129, DOI 10.1097/01.qai.0000179427.11789.a7; Mermin J, 2004, LANCET, V364, P1428, DOI 10.1016/S0140-6736(04)17225-5; Mermin J, 2005, AIDS, V19, P1035, DOI 10.1097/01.aids.0000174449.32756.c7; Mutabingwa TK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005138; Mutabingwa TK, 1996, T R SOC TROP MED HYG, V90, P476; Nakanjako D, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-66; Newell ML, 2004, LANCET, V364, P1236, DOI 10.1016/S0140-6736(04)17140-7; Newman PM, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-254; Njama-Meya D, 2004, TROP MED INT HEALTH, V9, P862, DOI 10.1111/j.1365-3156.2004.01277.x; Omar SA, 2001, T ROY SOC TROP MED H, V95, P657, DOI 10.1016/S0035-9203(01)90107-5; Parise ME, 1998, AM J TROP MED HYG, V59, P813, DOI 10.4269/ajtmh.1998.59.813; Peters PJ, 2007, DRUG SAFETY, V30, P481, DOI 10.2165/00002018-200730060-00003; PETERSEN E, 1987, T ROY SOC TROP MED H, V81, P238, DOI 10.1016/0035-9203(87)90226-4; Petri WA, 2012, GILMAN GOODMANS PHAR; REEVES DS, 1969, BRIT MED J, V1, P541, DOI 10.1136/bmj.1.5643.541; Robert V, 2000, AM J TROP MED HYG, V62, P210, DOI 10.4269/ajtmh.2000.62.210; Sandison TG, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1617; Santos F, 2011, BJOG-INT J OBSTET GY, V118, P1374, DOI 10.1111/j.1471-0528.2011.03041.x; Schellenberg D, 2002, AM J TROP MED HYG, V67, P17, DOI 10.4269/ajtmh.2002.67.17; Siega-Riz AM, 2004, AM J OBSTET GYNECOL, V191, P1851, DOI 10.1016/j.ajog.2004.07.076; Sowunmi A, 2006, ANN TROP MED PARASIT, V100, P205, DOI 10.1179/136485906X91503; Sowunmi A, 2005, MEM I OSWALDO CRUZ, V100, P451, DOI 10.1590/S0074-02762005000400019; Steketee RW, 2001, AM J TROP MED HYG, V64, P28, DOI 10.4269/ajtmh.2001.64.28; ter Kuile FO, 2007, JAMA-J AM MED ASSOC, V297, P2603, DOI 10.1001/jama.297.23.2603; Ter Kuile FO, 2004, AM J TROP MED HYG, V71, P41, DOI 10.4269/ajtmh.2004.71.41; ter Kuile FO, 2003, AM J TROP MED HYG, V68, P100, DOI 10.4269/ajtmh.2003.68.100; ter Kuile FO, 2003, AM J TROP MED HYG, V68, P68, DOI 10.4269/ajtmh.2003.68.68; Thera MA, 2005, J INFECT DIS, V192, P1823, DOI 10.1086/498249; Ticconi C, 2003, JAIDS-J ACQ IMM DEF, V34, P289, DOI 10.1097/00126334-200311010-00005; Tomasulo Patricia, 2007, Medical Reference Services Quarterly, V26, P51, DOI 10.1300/J115v26n01_05; Triglia T, 1997, P NATL ACAD SCI USA, V94, P13944, DOI 10.1073/pnas.94.25.13944; Uneke Chigozie J, 2007, Yale J Biol Med, V80, P95; van Eijk AM, 2003, AIDS, V17, P595, DOI 10.1097/00002030-200303070-00015; Van Eijk AM, 2001, AM J TROP MED HYG, V65, P623, DOI 10.4269/ajtmh.2001.65.623; Van Geertruyden JP, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-134; Van Geertruyden JP, 2004, AM J TROP MED HYG, V71, P35, DOI 10.4269/ajtmh.2004.71.35; Villalpando S, 2008, FOOD NUTR BULL, V29, pS112, DOI 10.1177/15648265080292S115; von Seidlein L, 2001, TROP MED INT HEALTH, V6, P92, DOI 10.1046/j.1365-3156.2001.00683.x; Walker AS, 2010, LANCET, V375, P1278, DOI 10.1016/S0140-6736(10)60057-8; Walter J, 2006, J INFECT DIS, V194, P1510, DOI 10.1086/508996; Whitworth J, 2000, LANCET, V356, P1051, DOI 10.1016/S0140-6736(00)02727-6; WHO, 2012, WORLD MALARIA REPORT 2012, P1; WHO, 2010, WORLD MALARIA REPORT 2010, P1; WHO, 2010, WHO POL REC IPTI; WHO, 2010, GUID TREATM MAL, V2nd; Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0; WILKINSON RN, 1973, T ROY SOC TROP MED H, V67, P148, DOI 10.1016/0035-9203(73)90340-4; World Health Organization (WHO), 2006, GUID COTR PROPH HIV; Yoshimine H, 2001, AM J TROP MED HYG, V64, P172; Zachariah R, 2003, AIDS, V17, P1053, DOI 10.1097/00002030-200305020-00015	104	53	53	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2013	8	2							e56916	10.1371/journal.pone.0056916	http://dx.doi.org/10.1371/journal.pone.0056916			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113IC	23451110	Green Submitted, Green Published, gold			2023-01-03	WOS:000316658800048
J	Balmford, A				Balmford, Andrew			Pollution, Politics, and Vultures	SCIENCE			English	Editorial Material							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; DICLOFENAC RESIDUES; GYPS VULTURES; THREAT; INDIA; DECLINE; POPULATION; PAKISTAN		Dept Zool, Conservat Sci Grp, Cambridge CB2 3EJ, England	University of Cambridge	Balmford, A (corresponding author), Dept Zool, Conservat Sci Grp, Downing St, Cambridge CB2 3EJ, England.	a.balmford@zoo.cam.ac.uk		Balmford, Andrew/0000-0002-0144-3589				[Anonymous], 2007, J BOMBAY NAT HIST SO; Chaudhry MJI, 2012, BIRD CONSERV INT, V22, P389, DOI 10.1017/S0959270912000445; Cuthbert R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019069; Cuthbert RJ, 2011, ORYX, V45, P420, DOI 10.1017/S0030605311000135; Gilbert N, 2012, NATURE, V491, P503, DOI 10.1038/491503a; Green RE, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000686; Markandya A, 2008, ECOL ECON, V67, P194, DOI 10.1016/j.ecolecon.2008.04.020; Naidoo V, 2010, BIOL LETTERS, V6, P339, DOI 10.1098/rsbl.2009.0818; Oaks JL, 2004, NATURE, V427, P630, DOI 10.1038/nature02317; Prakash V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049118; Sharma P, 2012, J RAPTOR RES, V46, P314, DOI 10.3356/JRR-11-66.1; Swan G, 2006, PLOS BIOL, V4, P395, DOI 10.1371/journal.pbio.0040066	12	15	17	0	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 8	2013	339	6120					653	654		10.1126/science.1234193	http://dx.doi.org/10.1126/science.1234193			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	085BM	23393251				2023-01-03	WOS:000314585600026
J	Unick, GJ; Rosenblum, D; Mars, S; Ciccarone, D				Unick, George Jay; Rosenblum, Daniel; Mars, Sarah; Ciccarone, Daniel			Intertwined Epidemics: National Demographic Trends in Hospitalizations for Heroin- and Opioid-Related Overdoses, 1993-2009	PLOS ONE			English	Article							INJECTION-DRUG USERS; NALOXONE DISTRIBUTION; UNITED-STATES; MORTALITY; PREVENTION; DEATHS; ABUSE; HIV	The historical patterns of opiate use show that sources and methods of access greatly influence who is at risk. Today, there is evidence that an enormous increase in the availability of prescription opiates is fuelling a rise in addiction nationally, drawing in new initiates to these drugs and changing the geography of opiate overdoses. Recent efforts at supply-based reductions in prescription opiates may reduce harm, but addicted individuals may switch to other opiates such as heroin. In this analysis, we test the hypothesis that changes in the rates of Prescription Opiate Overdoses (POD) are correlated with changes in the rate of heroin overdoses (HOD). ICD9 codes from the Nationwide Inpatient Sample and population data from the Census were used to estimate overall and demographic specific rates of POD and HOD hospital admissions between 1993 and 2009. Regression models were used to test for linear trends and lagged negative binomial regression models were used to model the interrelationship between POD and HOD hospital admissions. Findings show that whites, women, and middle-aged individuals had the largest increase in POD and HOD rates over the study period and that HOD rates have increased in since 2007. The lagged models show that increases in a hospitals POD predict an increase in the subsequent years HOD admissions by a factor of 1.26 (p < 0.001) and that each increase in HOD admissions increase the subsequent years POD by a factor of 1.57 (p < 0.001). Our hypothesis of fungibility between prescription opiates and heroin was supported by these analyses. These findings suggest that focusing on supply-based interventions may simply lead to a shift in use to heroin rather minimizing the reduction in harm. The alternative approach of using drug abuse prevention resources on treatment and demand-side reduction is likely to be more productive at reducing opiate abuse related harm.	[Unick, George Jay] Univ Maryland, Sch Social Work, Baltimore, MD 21201 USA; [Rosenblum, Daniel] Dalhousie Univ, Dept Econ, Halifax, NS, Canada; [Mars, Sarah; Ciccarone, Daniel] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA	University System of Maryland; University of Maryland Baltimore; Dalhousie University; University of California System; University of California San Francisco	Unick, GJ (corresponding author), Univ Maryland, Sch Social Work, 525 W Redwood St, Baltimore, MD 21201 USA.	junick@ssw.umaryland.edu	Ciccarone, Daniel/I-5404-2013	Ciccarone, Daniel/0000-0002-2355-5477; Rosenblum, Daniel/0000-0003-0056-9734	National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA) [RO1DA2759]; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA027599, R01DA010164] Funding Source: NIH RePORTER	National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was support by The National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA), grant number RO1DA2759 to Daniel Ciccarone. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albert S, 2011, PAIN MED, V12, pS77, DOI 10.1111/j.1526-4637.2011.01128.x; Barrett M, 2012, POPULATION DENOMINAT; Broz D, 2008, DRUG ALCOHOL DEPEN, V94, P221, DOI 10.1016/j.drugalcdep.2007.11.020; Cai R., 2010, Morbidity and Mortality Weekly Report, V59, P705; Centers for Disease Control, 2010, UN DRUG POIS US; Ciccarone D, 2009, INT J DRUG POLICY, V20, P392, DOI 10.1016/j.drugpo.2008.12.001; Cicero TJ, 2012, NEW ENGL J MED, V367, P187, DOI 10.1056/NEJMc1204141; Coben JH, 2010, AM J PREV MED, V38, P517, DOI 10.1016/j.amepre.2010.01.022; Colson J, 2012, PAIN PHYSICIAN, V15, pES231; Courtwright DT., 2001, DARK PARADISE HIST O, VEnl. ed., pxiii, 326; Daly EM, 2012, RISE YOUNG PAINKILLE; Darke S., 2007, MORTALITY ILLICIT DR; Denton JS, 2008, J FORENSIC SCI, V53, P452, DOI 10.1111/j.1556-4029.2008.00669.x; Doe-Simkins M, 2009, AM J PUBLIC HEALTH, V99, P788, DOI 10.2105/AJPH.2008.146647; Evans JL, 2012, AM J EPIDEMIOL, V175, P302, DOI 10.1093/aje/kwr318; FDA, 2009, JOINT M AN LIF SUPP; Frosch Dan, 2012, NY TIMES, P22; Galea S, 2006, ADDICT BEHAV, V31, P907, DOI 10.1016/j.addbeh.2005.07.020; Green TC, 2008, ADDICTION, V103, P979, DOI 10.1111/j.1360-0443.2008.02182.x; Hansen RN, 2011, CLIN J PAIN, V27, P194, DOI 10.1097/AJP.0b013e3181ff04ca; Havens JR, 2009, AM J DRUG ALCOHOL AB, V35, P18, DOI 10.1080/00952990802326298; HCUP, 1993, NAT INP SAMPL NIS; HCUP, 1993, NAT INP SAMPL TRENDS; Hickman T. A., 2004, ALTERING AM CONSCIOU, P182; IMS Institute for Healthcare Informatics, 2011, US MED US REV 2010; Kerlikowske R., 2012, COMMUNICATION; Khosla N, 2011, ADDICT BEHAV, V36, P1282, DOI 10.1016/j.addbeh.2011.07.046; Lankenau SE, 2012, INT J DRUG POLICY, V23, P37, DOI 10.1016/j.drugpo.2011.05.014; Manchikanti Laxmaiah, 2007, Pain Physician, V10, P399; Manchikanti Laxmaiah, 2006, Pain Physician, V9, P287; Manchikanti Laxmaiah, 2006, Pain Physician, V9, P215; Mars S, 2012, HARM RED C PORTL OR; Masson CL, 2002, DRUG ALCOHOL DEPEN, V66, P45, DOI 10.1016/S0376-8716(01)00182-X; Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512; Paulozzi L., 2007, Morbidity and Mortality Weekly Report, V56, P93; Paulozzi LJ, 2008, PHARMACOEPIDEM DR S, V17, P997, DOI 10.1002/pds.1626; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Peavy KM, 2012, J PSYCHOACTIVE DRUGS, V44, P259, DOI 10.1080/02791072.2012.704591; Piper Tinka Markham, 2007, Harm Reduct J, V4, P3, DOI 10.1186/1477-7517-4-3; Pletcher MJ, 2008, JAMA-J AM MED ASSOC, V299, P70, DOI 10.1001/jama.2007.64; Roy E, 2011, SUBST USE MISUSE, V46, P1142, DOI 10.3109/10826084.2011.552932; Schneider EC, 2008, POLIT CULT MOD AM, P1; Scott G, 2007, J URBAN HEALTH, V84, P292, DOI 10.1007/s11524-007-9157-7; Seal KH, 2005, J URBAN HEALTH, V82, P303, DOI 10.1093/jurban/jti053; Semaan S, 2011, DRUG ALCOHOL DEPEN, V118, P100, DOI 10.1016/j.drugalcdep.2011.03.006; Shah NG, 2008, ADDICTION, V103, P126, DOI 10.1111/j.1360-0443.2007.02054.x; Tobin KE, 2009, INT J DRUG POLICY, V20, P131, DOI 10.1016/j.drugpo.2008.03.002; U.S. General Accounting Office, 2003, PRESCR DRUGS OXYCONT; Volkow ND, 2011, JAMA-J AM MED ASSOC, V305, P1346, DOI 10.1001/jama.2011.369; Walley A, 2012, FDA PUBL WORKSH SEP; Walley AY, 2013, J SUBST ABUSE TREAT, V44, P241, DOI 10.1016/j.jsat.2012.07.004; Wang CL, 2005, AIDS, V19, P935, DOI 10.1097/01.aids.0000171407.30866.22; Warner M, 2009, INCREASE FATAL POISO; Webster PC, 2012, CAN MED ASSOC J, V184, pE345, DOI 10.1503/cmaj.109-4158; Wheeler Eliza, 2012, Morbidity and Mortality Weekly Report, V61, P101	55	208	208	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2013	8	2							e54496	10.1371/journal.pone.0054496	http://dx.doi.org/10.1371/journal.pone.0054496			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	092WJ	23405084	Green Published, gold			2023-01-03	WOS:000315153400028
J	Heidegger, CP; Berger, MM; Graf, S; Zingg, W; Darmon, P; Costanza, MC; Thibault, R; Pichard, C				Heidegger, Claudia Paula; Berger, Mette M.; Graf, Severine; Zingg, Walter; Darmon, Patrice; Costanza, Michael C.; Thibault, Ronan; Pichard, Claude			Optimisation of energy provision with supplemental parenteral nutrition in critically ill patients: a randomised controlled clinical trial	LANCET			English	Article							INTENSIVE INSULIN THERAPY; EARLY ENTERAL NUTRITION; CARE; METAANALYSIS; INFECTIONS; GUIDELINES; SUPPORT; BALANCE; IMPACT; INJURY	Background Enteral nutrition (EN) is recommended for patients in the intensive-care unit (ICU), but it does not consistently achieve nutritional goals. We assessed whether delivery of 100% of the energy target from days 4 to 8 in the ICU with EN plus supplemental parenteral nutrition (SPN) could optimise clinical outcome. Methods This randomised controlled trial was undertaken in two centres in Switzerland. We enrolled patients on day 3 of admission to the ICU who had received less than 60% of their energy target from EN, were expected to stay for longer than 5 days, and to survive for longer than 7 days. We calculated energy targets with indirect calorimetry on day 3, or if not possible, set targets as 25 and 30 kcal per kg of ideal bodyweight a day for women and men, respectively. Patients were randomly assigned (1: 1) by a computer-generated randomisation sequence to receive EN or SPN. The primary outcome was occurrence of nosocomial infection after cessation of intervention (day 8), measured until end of follow-up (day 28), analysed by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00802503. Findings We randomly assigned 153 patients to SPN and 152 to EN. 30 patients discontinued before the study end. Mean energy delivery between day 4 and 8 was 28 kcal/kg per day (SD 5) for the SPN group (103% [SD 18%] of energy target), compared with 20 kcal/kg per day (7) for the EN group (77% [27%]). Between days 9 and 28, 41 (27%) of 153 patients in the SPN group had a nosocomial infection compared with 58 (38%) of 152 patients in the EN group (hazard ratio 0.65, 95% CI 0.43-0.97; p=0.0338), and the SPN group had a lower mean number of nosocomial infections per patient (-0.42 [-0.79 to -0.05]; p=0.0248). Interpretation Individually optimised energy supplementation with SPN starting 4 days after ICU admission could reduce nosocomial infections and should be considered as a strategy to improve clinical outcome in patients in the ICU for whom EN is insufficient.	[Heidegger, Claudia Paula; Graf, Severine] Univ Hosp Geneva, Serv Intens Care, CH-1211 Geneva 14, Switzerland; [Graf, Severine; Darmon, Patrice; Thibault, Ronan; Pichard, Claude] Univ Hosp Geneva, Nutr Unit, CH-1211 Geneva 14, Switzerland; [Zingg, Walter] Univ Hosp Geneva, Infect Control Programme, CH-1211 Geneva 14, Switzerland; [Berger, Mette M.] Univ Lausanne Hosp, Serv Adult Intens Care, Lausanne, Switzerland; [Costanza, Michael C.] Univ Vermont, Dept Math & Stat, Burlington, VT 05405 USA	University of Geneva; University of Geneva; University of Geneva; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Vermont	Pichard, C (corresponding author), Univ Hosp Geneva, Nutr Unit, CH-1211 Geneva 14, Switzerland.	claude.pichard@unige.ch		Thibault, Ronan/0000-0002-6038-5649; Darmon, Patrice/0000-0003-1726-2296	Foundation Nutrition 2000Plus; ICU Quality Funds; Baxter; Fresenius Kabi; Laboratoire Aguettant; B Braun; Nestle Medical Nutrition; Novartis; Novo Nordisk France; Nutricia; Abbott; Cosmed; Nutricia-Numico; Pfizer; Solvay; APSI-ICU quality funds of the Geneva University Hospital; Internal Service Resources of the Lausanne University Hospital; academic Societe Nationale Francaise de Gastroenterologie	Foundation Nutrition 2000Plus; ICU Quality Funds; Baxter; Fresenius Kabi; Laboratoire Aguettant; B Braun; Nestle Medical Nutrition(Nestle SA); Novartis(Novartis); Novo Nordisk France(Novo Nordisk); Nutricia(Danone Nutricia); Abbott(Abbott Laboratories); Cosmed; Nutricia-Numico(Danone Nutricia); Pfizer(Pfizer); Solvay(Solvay SA); APSI-ICU quality funds of the Geneva University Hospital; Internal Service Resources of the Lausanne University Hospital; academic Societe Nationale Francaise de Gastroenterologie	Funding Foundation Nutrition 2000Plus, ICU Quality Funds, Baxter, and Fresenius Kabi.; MMB has received research grants and consulting fees from Laboratoire Aguettant, Baxter, B Braun, Fresenius Kabi, Nestle Medical Nutrition, and Novartis. PD was supported by an unrestricted academic research fellowship from Novo Nordisk France. RT has received consultancy fees from Baxter, B Braun, Nestle Medical Nutrition, and Nutricia. CP has received research grants and consulting fees from Abbott, Baxter, B Braun, Cosmed, Fresenius Kabi, Nestle Medical Nutrition, Novartis, Nutricia-Numico, Pfizer, and Solvay. CPH, SG, WZ, and MCC declare that they have no conflicts of interest.; The trial was investigator driven. Financial support came from the public Foundation Nutrition 2000Plus, APSI-ICU quality funds of the Geneva University Hospital, Internal Service Resources of the Lausanne University Hospital, and from unconditional and non-restrictive research grants from Baxter and Fresenius Kabi, representing less than 25% of the global expenses. RT has received a research award from the academic Societe Nationale Francaise de Gastroenterologie. The sponsors did not place any restrictions on the study design. We thank the entire team (physicians, nurses, physiotherapists, laboratory technicians) of both intensive care units; Aurelie Clerc, statistician, for her data processing work; and Vanessa Brancato and Marcos Coronado Lujan for helping to obtain the data.	Alberda C, 2009, INTENS CARE MED, V35, P1728, DOI 10.1007/s00134-009-1567-4; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bregeon F, 2008, CRIT CARE MED, V36, P3205, DOI 10.1097/CCM.0b013e31818f0e20; Cameron A. Colin, 2013, REGRESSION ANAL COUN; Casaer MP, 2011, NEW ENGL J MED, V365, P506, DOI 10.1056/NEJMoa1102662; Desachy A, 2008, INTENS CARE MED, V34, P1054, DOI 10.1007/s00134-007-0983-6; Dhaliwal R, 2004, INTENS CARE MED, V30, P1666, DOI 10.1007/s00134-004-2345-y; Doig GS, 2009, INTENS CARE MED, V35, P2018, DOI 10.1007/s00134-009-1664-4; Dvir D, 2006, CLIN NUTR, V25, P37, DOI 10.1016/j.clnu.2005.10.010; Genton L, 2004, CLIN NUTR, V23, P307, DOI 10.1016/j.clnu.2003.07.006; Gramlich L, 2004, NUTRITION, V20, P843, DOI 10.1016/j.nut.2004.06.003; Heidegger CP, 2007, INTENS CARE MED, V33, P963, DOI 10.1007/s00134-007-0654-7; Heyland DK, 2003, JPEN-PARENTER ENTER, V27, P355, DOI 10.1177/0148607103027005355; Hilbe J.M., 2011, NEGATIVE BINOMIAL RE; Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002; Krinsley J, 2010, CRIT CARE, V14, DOI 10.1186/cc9275; LARCA L, 1982, CRIT CARE MED, V10, P297, DOI 10.1097/00003246-198205000-00001; Levine S, 2008, NEW ENGL J MED, V358, P1327, DOI 10.1056/NEJMoa070447; Martin CM, 2004, CAN MED ASSOC J, V170, P197, DOI 10.1503/cmaj.1040621; Martindale RG, 2009, CRIT CARE MED, V37, P1757, DOI 10.1097/CCM.0b013e3181a40116; Peter JV, 2005, CRIT CARE MED, V33, P213, DOI 10.1097/01.CCM.0000150960.36228.C0; Rubinson L, 2004, CRIT CARE MED, V32, P350, DOI 10.1097/01.CCM.0000089641.06306.68; Simpson F, 2005, INTENS CARE MED, V31, P12, DOI 10.1007/s00134-004-2511-2; Singer P, 2011, INTENS CARE MED, V37, P601, DOI 10.1007/s00134-011-2146-z; Singer P, 2009, CLIN NUTR, V28, P387, DOI 10.1016/j.clnu.2009.04.024; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Villet S, 2005, CLIN NUTR, V24, P502, DOI 10.1016/j.clnu.2005.03.006; WILLIFORD WO, 1991, NEW ENGL J MED, V325, P525; Zingg W, 2011, J HOSP INFECT, V77, P304, DOI 10.1016/j.jhin.2010.11.011; Zingg W, 2009, CRIT CARE MED, V37, P2167, DOI 10.1097/CCM.0b013e3181a02d8f	30	478	501	0	59	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 2	2013	381	9864					385	393		10.1016/S0140-6736(12)61351-8	http://dx.doi.org/10.1016/S0140-6736(12)61351-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	084ZA	23218813				2023-01-03	WOS:000314578900035
J	Tantivess, S; Werayingyong, P; Chuengsaman, P; Teerawattananon, Y				Tantivess, Sripen; Werayingyong, Pitsaphun; Chuengsaman, Piyatida; Teerawattananon, Yot			Universal coverage of renal dialysis in Thailand: promise, progress, and prospects	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PERITONEAL-DIALYSIS; SIMILAR OUTCOMES; HEMODIALYSIS; DISEASE; PACKAGE	Thailand's experience in introducing renal replacement therapy as part of its universal health coverage scheme shows the importance of evidence and stakeholders' active participation in all phases of policy development, say Sripen Tantivess and colleagues	[Tantivess, Sripen; Werayingyong, Pitsaphun; Teerawattananon, Yot] Minist Publ Hlth, HITAP, Nonthaburi, Thailand; [Chuengsaman, Piyatida] Banphaeo Hosp Publ Org, CAPD Serv, Bangkok, Thailand; [Chuengsaman, Piyatida] Training Ctr, Bangkok, Thailand	Ministry of Public Health - Thailand	Teerawattananon, Y (corresponding author), Minist Publ Hlth, HITAP, Nonthaburi, Thailand.	yot.t@hitap.net		Teerawattananon, Yot/0000-0003-2217-2930				[Anonymous], 2010, B WORLD HEALTH ORGAN, V88, P84, DOI 10.2471/BLT.10.010210; [Anonymous], STAK M 2012 SEPT 28; Anothayanon K, 2002, J HEALTH SCI, V11, P826; Dhanakijcharoen Prateep, 2011, J Med Assoc Thai, V94 Suppl 4, pS153; Evans T. G., 2012, INDEPENDENT ASSESSME, V10, P2001; Kearkiat P, 2012, REPORT THAILAND RENA; Limwattananon S, 2007, B WORLD HEALTH ORGAN, V85, P600, DOI 10.2471/BLT.06.033720; Mehrotra R, 2011, ARCH INTERN MED, V171, P110, DOI 10.1001/archinternmed.2010.352; National Health Security Office, 2007, FUND MAN MAN NAT HLT; Patcharanarumol W, 2011, GOOD HLTH LOW COST 2; Praditpornsilp K, 2008, THAILAND RENAL REPLA; Praditpornsilpa Kearkiat, 2011, J Med Assoc Thai, V94 Suppl 4, pS1; Prakongsai P, 2006, J HEALTH SCI, V15, P617; Prakongsai P, 2009, J INT DEV, V21, P291, DOI 10.1002/jid.1553; Teerawattananon Y, 2004, HEALTH POLICY PLANN, V19, pI31, DOI 10.1093/heapol/czh043; Teerawattananon Y, 2007, VALUE HEALTH, V10, P61, DOI 10.1111/j.1524-4733.2006.00145.x; Thai Renal Replacement Therayp (TRT) Committee, 2005, TRT REG ANN REP; Tungsiripat R, 2003, 0403 HEFP LOND SCH H; United States Renal Data System, 2004, ANN DAT REP 2001 INC; WHO, 2010, WOR HEALT REP, P1; Yeates K, 2012, NEPHROL DIAL TRANSPL, V27, P3568, DOI 10.1093/ndt/gfr674	21	49	51	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 31	2013	346								f462	10.1136/bmj.f462	http://dx.doi.org/10.1136/bmj.f462			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	084BQ	23369775	Bronze			2023-01-03	WOS:000314511500007
J	Furuhashi, T; Saito, C; Torii, K; Nishida, E; Yamazaki, S; Morita, A				Furuhashi, Takuya; Saito, Chiyo; Torii, Kan; Nishida, Emi; Yamazaki, Sayuri; Morita, Akimichi			Photo(chemo)therapy Reduces Circulating Th17 Cells and Restores Circulating Regulatory T Cells in Psoriasis	PLOS ONE			English	Article							UVB INDUCES APOPTOSIS; INDUCED IMMUNOSUPPRESSION; CONTACT HYPERSENSITIVITY; SUPPRESSIVE FUNCTION; RECEPTOR EXPRESSION; DENDRITIC CELLS; ULTRAVIOLET; PHOTOTHERAPY; KERATINOCYTES; PATHOGENESIS	Background: Photo(chemo)therapy is widely used to treat psoriasis, the pathogenesis of which might be caused by an imbalance of Th17 cells/regulatory T cells (Treg). In the present study, we evaluated the effects of photo(chemo)therapy on the Th17/Treg balance and Treg function. Methods: Peripheral blood was obtained from psoriasis patients treated with bath-psoralen ultraviolet A (UVA, n = 50) or narrowband ultraviolet B (UVB, n = 18), and age-matched healthy volunteers (n = 20). CD3(+)CD4(+)IL-17A(+) or CD4(+)CD25(+)Foxp3(+)cells were analyzed to estimate Th17 or Treg number by fluorescence-activated cell sorting. Moreover, CD4(+) CD25(-) T cells from patients treated with PUVA(n = 14) were incubated in CFSE and activated with or without CD4(+)CD25(+)T cells, and the suppressive function of CD4(+) CD25(+)T cells were analyzed. Results: Photo(chemo)therapy significantly reduced Th17 levels from 5.66 +/- 3.15% to 2.96 +/- 2.89% in patients with increased Th17 (Th17/CD4>3.01% [mean+SD of controls]). In contrast, photo(chemo)therapy significantly increased Treg levels from 2.77 +/- 0.75 to 3.40 +/- 1.88% in patients with less than 4.07% Treg level, defined as the mean of controls. Furthermore, while Treg suppressed the CD4(+)CD25(-) T cell proliferation to a greater extent in controls (Treg Functional Ratio 94.4 +/- 4.28%) than in patients (70.3 +/- 25.1%), PUVA significantly increased Treg Functional Ratio to 88.1 +/- 6.47%. Th17 levels in severe patients (>30 PASI) were significantly higher as compared to controls. Th17 levels that were left after treatment in the patients not achieving PASI 50 (3.78 +/- 4.18%) were significantly higher than those in the patients achieving PASI 75 (1.83 +/- 1.87%). Treg levels in patients achieving PASI 90 (4.89 +/- 1.70%) were significantly higher than those in the patients not achieving PASI 90 (3.90 +/- 1.66%). Treg levels prior to treatment with Th17 high decreased group (5.16 +/- 2.20%) was significantly higher than that with Th17 high increased group (3.33 +/- 1.39%). Conclusion: These findings indicate that Treg is dysfunctional in psoriasis patients, and photochemotherapy restores those dysfunctional Treg. Photo(chemo)therapy resolved the Th17/Treg imbalance in patients with psoriasis.	[Furuhashi, Takuya; Saito, Chiyo; Torii, Kan; Nishida, Emi; Yamazaki, Sayuri; Morita, Akimichi] Nagoya City Univ, Grad Sch Med Sci, Dept Geriatr & Environm Dermatol, Nagoya, Aichi, Japan	Nagoya City University	Furuhashi, T (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Geriatr & Environm Dermatol, Nagoya, Aichi, Japan.	tmail@med.nagoya-cu.ac.jp		Nishida, Emi/0000-0001-6563-1274; Torii, Kan/0000-0003-1964-0529	Ministry of Education, Culture, Sports, Science, and Technology, Japan; Grants-in-Aid for Scientific Research [23390088] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science, and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by grant from the Ministry of Education, Culture, Sports, Science, and Technology, Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Annunziato F, 2012, TRENDS IMMUNOL, V33, P505, DOI 10.1016/j.it.2012.05.004; Aufiero BM, 2006, J PHOTOCH PHOTOBIO B, V82, P132, DOI 10.1016/j.jphotobiol.2005.08.011; Banham AH, 2006, TRENDS IMMUNOL, V27, P541, DOI 10.1016/j.it.2006.10.002; Brazzelli V, 2008, INT J IMMUNOPATH PH, V21, P481, DOI 10.1177/039463200802100232; Di Cesare A, 2009, J INVEST DERMATOL, V129, P1339, DOI 10.1038/jid.2009.59; Furuhashi T, 2011, EXP DERMATOL, V20, P768, DOI 10.1111/j.1600-0625.2011.01316.x; Inzinger M, 2011, BRIT J DERMATOL, V165, P640, DOI 10.1111/j.1365-2133.2011.10396.x; Johnson-Huang LM, 2010, J INVEST DERMATOL, V130, P2654, DOI 10.1038/jid.2010.166; Kagami S, 2010, J INVEST DERMATOL, V130, P1373, DOI 10.1038/jid.2009.399; Krutmann J, 1999, J INVEST DERM SYMP P, V4, P70, DOI 10.1038/sj.jidsp.5640185; Krutmann J., 2007, FITZPATRICKS DERMATO, P2243; Lande R, 2007, NATURE, V449, P564, DOI 10.1038/nature06116; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Lo YH, 2010, J DERMATOL SCI, V58, P225, DOI 10.1016/j.jdermsci.2010.03.018; Long SA, 2011, J IMMUNOL, V187, P2061, DOI 10.4049/jimmunol.1003224; Maddur MS, 2012, AM J PATHOL, V181, P8, DOI 10.1016/j.ajpath.2012.03.044; Meyer T, 2007, BRIT J DERMATOL, V157, P1, DOI 10.1111/j.1365-2133.2007.08264.x; Ozawa M, 1999, J EXP MED, V189, P711, DOI 10.1084/jem.189.4.711; Racz E, 2011, J INVEST DERMATOL, V131, P1547, DOI 10.1038/jid.2011.53; Saito C, 2009, J DERMATOL SCI, V53, P231, DOI 10.1016/j.jdermsci.2008.09.011; Sakaguchi S, 2006, IMMUNOL REV, V212, P8, DOI 10.1111/j.0105-2896.2006.00427.x; Schwarz A, 2005, J EXP MED, V201, P173, DOI 10.1084/jem.20041212; Schwarz A, 2007, J IMMUNOL, V178, P877, DOI 10.4049/jimmunol.178.2.877; Schwarz A, 2011, J ALLERGY CLIN IMMUN, V128, P826, DOI 10.1016/j.jaci.2011.06.005; Schwarz A, 2010, J INVEST DERMATOL, V130, P1419, DOI 10.1038/jid.2009.429; Schwarz T, 2008, PHOTOCHEM PHOTOBIOL, V84, P10, DOI 10.1111/j.1751-1097.2007.00223.x; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010; Shintani Y, 2008, PHOTODERMATOL PHOTO, V24, P32, DOI 10.1111/j.1600-0781.2008.00333.x; Smolders J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006635; Soyland E, 2011, BRIT J DERMATOL, V164, P344, DOI 10.1111/j.1365-2133.2010.10149.x; Sugiyama H, 2005, J IMMUNOL, V174, P164, DOI 10.4049/jimmunol.174.1.164; Sweeney CM, 2011, ARCH DERMATOL RES, V303, P691, DOI 10.1007/s00403-011-1169-1; Tan ZY, 2009, INT J BIOCHEM CELL B, V41, P733, DOI 10.1016/j.biocel.2008.04.027; Tohyama M, 2009, EUR J IMMUNOL, V39, P2779, DOI 10.1002/eji.200939473; Wang HL, 2008, J CLIN INVEST, V118, P2629, DOI 10.1172/JCI34916; Wilke CM, 2011, TRENDS IMMUNOL, V32, P603, DOI 10.1016/j.it.2011.08.003; Zhang L, 2010, CLIN IMMUNOL, V135, P108, DOI 10.1016/j.clim.2009.11.008	38	77	83	2	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2013	8	1							e54895	10.1371/journal.pone.0054895	http://dx.doi.org/10.1371/journal.pone.0054895			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	077JK	23365685	gold, Green Published, Green Submitted			2023-01-03	WOS:000314023600132
J	Dzierma, Y; Nuesken, FG; Fleckenstein, J; Kremp, S; Licht, NP; Ruebe, C				Dzierma, Yvonne; Nuesken, Frank G.; Fleckenstein, Jochen; Kremp, Stephanie; Licht, Norbert P.; Ruebe, Christian			Visualisation of Respiratory Tumour Motion and Co-Moving Isodose Lines in the Context of Respiratory Gating, IMRT and Flattening-Filter-Free Beams	PLOS ONE			English	Article							BREATHING ADAPTED RADIOTHERAPY; STEREOTACTIC BODY RADIOTHERAPY; MODULATED RADIATION-THERAPY; INTERNAL TARGET VOLUME; 4-DIMENSIONAL CT SCANS; I LUNG-CANCER; ORGAN MOTION; MULTILEAF COLLIMATOR; DOSIMETRIC IMPACT; MONTE-CARLO	Respiratory motion during percutaneous radiotherapy can be considered based on respiration-correlated computed tomography (4DCT). However, most treatment planning systems perform the dose calculation based on a single primary CT data set, even though cine mode displays may allow for a visualisation of the complete breathing cycle. This might create the mistaken impression that the dose distribution were independent of tumour motion. We present a movie visualisation technique with the aim to direct attention to the fact that the dose distribution migrates to some degree with the tumour and discuss consequences for gated treatment, IMRT plans and flattening-filter-free beams. This is a feasibility test for a visualisation of tumour and isodose motion. Ten respiratory phases are distinguished on the CT, and the dose distribution from a stationary IMRT plan is calculated on each phase, to be integrated into a movie of tumour and dose motion during breathing. For one example patient out of the sample of five lesions, the plan is compared with a gated treatment plan with respect to tumour coverage and lung sparing. The interplay-effect for small segments in the IMRT plan is estimated. While the high dose rate, together with the cone-shaped beam profile, makes the use of flattening-filter-free beams more problematic for conformal and IMRT treatment, it can be the option of choice if gated treatment is preferred. The different effects of respiratory motion, dose build-up and beam properties (segments and flatness) for gated vs. un-gated treatment can best be considered if planning is performed on the full 4DCT data set, which may be an incentive for future developments of treatment planning systems.	[Dzierma, Yvonne; Nuesken, Frank G.; Fleckenstein, Jochen; Kremp, Stephanie; Licht, Norbert P.; Ruebe, Christian] Univ Saarland, Med Ctr, Dept Radiat Oncol, Homburg, Germany	Saarland University	Dzierma, Y (corresponding author), Univ Saarland, Med Ctr, Dept Radiat Oncol, Homburg, Germany.	yvonne.dzierma@uks.eu						Alasti H, 2006, PHYS MED BIOL, V51, P3251, DOI 10.1088/0031-9155/51/12/017; Allen AM, 2004, INT J RADIAT ONCOL, V58, P1251, DOI 10.1016/j.ijrobp.2003.09.081; Balter JM, 1996, INT J RADIAT ONCOL, V36, P167, DOI 10.1016/S0360-3016(96)00275-1; Boda-Heggemann J, 2011, STRAHLENTHERAPIE UND, V5, P284; Bortfeld T, 2002, PHYS MED BIOL, V47, P2203, DOI 10.1088/0031-9155/47/13/302; Brock J, 2011, INT J RADIAT ONCOL, V81, P369, DOI 10.1016/j.ijrobp.2010.05.038; Chen HC, 2009, MED PHYS, V36, P893, DOI 10.1118/1.3070542; Chui CS, 2003, MED PHYS, V30, P1736, DOI 10.1118/1.1578771; Court L, 2011, J APPL CLIN MED PHYS, V12, P28, DOI 10.1120/jacmp.v12i1.3276; Ding CX, 2007, MED PHYS, V34, P3500, DOI 10.1118/1.2760308; Dzierma Y, 2012, MED PHYS, V39, P2595, DOI 10.1118/1.3703835; Flampouri S, 2006, PHYS MED BIOL, V51, P2763, DOI 10.1088/0031-9155/51/11/006; Frazier RC, 2004, INT J RADIAT ONCOL, V58, P1041, DOI 10.1016/j.ijrobp.2003.07.005; Gabrys D, 2011, RADIOTHER ONCOL, V100, P360, DOI 10.1016/j.radonc.2011.09.006; Guckenberger M, 2007, INT J RADIAT ONCOL, V69, P276, DOI 10.1016/j.ijrobp.2007.04.074; Jiang SB, 2003, PHYS MED BIOL, V48, P1773, DOI 10.1088/0031-9155/48/12/307; Keall PJ, 2005, MED PHYS, V32, P942, DOI 10.1118/1.1879152; Korreman SS, 2005, RADIOTHER ONCOL, V76, P311, DOI 10.1016/j.radonc.2005.07.009; Langen KM, 2001, INT J RADIAT ONCOL, V50, P265, DOI 10.1016/S0360-3016(01)01453-5; Liu HH, 2007, INT J RADIAT ONCOL, V68, P531, DOI 10.1016/j.ijrobp.2006.12.066; Liu J, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-11; Mancosu P, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-16; McQuaid D, 2011, PHYS MED BIOL, V56, P6935, DOI 10.1088/0031-9155/56/21/011; Muirhead R, 2010, RADIOTHER ONCOL, V95, P172, DOI 10.1016/j.radonc.2010.02.002; Nohadani O, 2010, PHYS MED BIOL, V55, P5189, DOI 10.1088/0031-9155/55/17/019; Peguret N, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-78; Rietzel E, 2006, INT J RADIAT ONCOL, V66, P287, DOI 10.1016/j.ijrobp.2006.05.024; Roland T, 2009, PHYS MED BIOL, V54, P5509, DOI 10.1088/0031-9155/54/18/011; ROSS CS, 1990, INT J RADIAT ONCOL, V18, P671, DOI 10.1016/0360-3016(90)90076-V; Saw C B, 2007, Biomed Imaging Interv J, V3, pe40, DOI 10.2349/biij.3.1.e40; Seco J, 2008, MED PHYS, V35, P356, DOI 10.1118/1.2821704; Sonke JJ, 2005, MED PHYS, V32, P1176, DOI 10.1118/1.1869074; Stromberg JS, 2000, INT J RADIAT ONCOL, V48, P797, DOI 10.1016/S0360-3016(00)00681-7; Underberg RWM, 2005, INT J RADIAT ONCOL, V62, P554, DOI 10.1016/j.ijrobp.2005.01.032; Underberg RWM, 2004, INT J RADIAT ONCOL, V60, P1283, DOI 10.1016/j.ijrobp.2004.07.665; Vedam S, 2005, MED PHYS, V32, P1607, DOI 10.1118/1.1915017; Webb S, 2008, PHYS MED BIOL, V53, P5177, DOI 10.1088/0031-9155/53/18/022; Webb S, 2006, PHYS MED BIOL, V51, pR403, DOI 10.1088/0031-9155/51/13/R23; Wu JZ, 2008, RADIOTHER ONCOL, V87, P35, DOI 10.1016/j.radonc.2008.02.010; Zhao B, 2009, MED PHYS, V36, P2248, DOI 10.1118/1.3129161	41	8	10	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 10	2013	8	1							e53799	10.1371/journal.pone.0053799	http://dx.doi.org/10.1371/journal.pone.0053799			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	070YV	23326510	Green Published, gold, Green Submitted			2023-01-03	WOS:000313552400048
J	Farrell, L				Farrell, Liam			THE BEST MEDICINE Conversation with a pill	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 2	2013	346								e8664	10.1136/bmj.e8664	http://dx.doi.org/10.1136/bmj.e8664			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	066QW	23284160				2023-01-03	WOS:000313236300002
J	Gao, N; Zou, D; Qiao, HL				Gao, Na; Zou, Dan; Qiao, Hai-Ling			Concentration-Dependent Inhibitory Effect of Baicalin on the Plasma Protein Binding and Metabolism of Chlorzoxazone, a CYP2E1 Probe Substrate, in Rats In Vitro and In Vivo	PLOS ONE			English	Article							PHARMACOKINETICS; LIVER; 6-HYDROXYCHLORZOXAZONE; CYTOCHROME-P-450; EXPRESSION; INDUCTION; INJURY; RADIX	Some of the components found in herbs may be inhibitors or inducers of cytochrome P450 enzymes, which may therefore result in undesired herb- drug interactions. As a component extracted from Radix Scutellariae, the direct effect of baicalin on cytochrome P450 has not been investigated sufficiently. In this study, we investigated concentration-dependent inhibitory effect of baicalin on the plasma protein binding and metabolism of chlorzoxazone (CZN), a model CYP2E1 probe substrate, in rats in vitro and in vivo. Animal experiment was a randomized, three-period crossover design. Significant changes in pharmacokinetic parameters of CZN such as C-max, t(1/2) and V-d were observed after treatment with baicalin in vivo (P < 0.05). C-max decreased by 25% and 33%, whereas t(1/2) increased by 34% and 53%, V-d increased by 37% and 50% in 225 mg/kg and 450 mg/kg baicalin-treated rats, respectively. The AUC and CL of CZN were not affected (P > 0.05). Correlation analysis showed that the changes in CZN concentrations and baicalin concentrations were in good correlation (r > 0.99). In vitro experiments, baicalin decreased the formation of 6-OH-chlorzoxazone in a concentration-dependent manner and exhibited a competitive inhibition in rat liver microsomes, with a Ki value of 145.8 mu M. The values of C-max/Ki were 20 and 39 after treatment with baicalin (225 and 450 mg/kg), respectively. Protein binding experiments in vivo showed that the plasma free-fraction (fu) of CZN increased 2.6-fold immediately after baicalin treatment (450 mg/kg) and in vitro showed that baicalin (125-2500 mg/L) increased the unbound CZN from 1.63% to 3.58%. The results indicate that pharmacokinetic changes in CZN are induced by inhibitory effect of baicalin on the plasma protein binding of CZN and CYP2E1 activity.	[Gao, Na; Qiao, Hai-Ling] Zhengzhou Univ, Sch Med, Dept Clin Pharmacol, Zhengzhou, Peoples R China; [Zou, Dan] Henan Med Coll Staff & Workers, Dept Histol & Embryol, Zhengzhou, Peoples R China	Zhengzhou University	Qiao, HL (corresponding author), Zhengzhou Univ, Sch Med, Dept Clin Pharmacol, Zhengzhou, Peoples R China.	qiaohl@zzu.edu.cn			National Natural Science Foundation of China [81041113]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (No. 81041113). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baek HW, 2006, J PHARM SCI-US, V95, P2452, DOI 10.1002/jps.20698; Chittur SV, 1997, J CHROMATOGR B, V693, P479, DOI 10.1016/S0378-4347(97)00024-8; Christensen H, 2006, J PHARM SCI-US, V95, P2778, DOI 10.1002/jps.20733; Fan L, 2009, EUR J CLIN PHARMACOL, V65, P403, DOI 10.1007/s00228-008-0594-3; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; Hou Yan-ning, 2000, Yaoxue Xuebao, V35, P890; Jang SI, 2003, IMMUNOPHARM IMMUNOT, V25, P585, DOI 10.1081/IPH-120026443; Lai MY, 2003, J PHARM PHARMACOL, V55, P205, DOI 10.1211/002235702522; Lai MY, 2004, PLANTA MED, V70, P132, DOI 10.1055/s-2004-815489; Lee KS, 2011, J APPL TOXI IN PRESS; Li CR, 2011, BIOPHARM DRUG DISPOS, V32, P427, DOI 10.1002/bdd.771; Li J, 2012, MED CHEM, V8, P208, DOI 10.2174/157340612800493692; Li Y, 2010, EUR J PHARMACOL, V640, P46, DOI 10.1016/j.ejphar.2010.05.017; Lininger SW, 2000, NATURAL PHARM; McGuffin M., 1997, AM HERBAL PRODUCTS A; Rockich K, 1999, DRUG METAB DISPOS, V27, P1074; Shaik IH, 2011, J PHARM SCI-US, V100, P5281, DOI 10.1002/jps.22708; Srinivas NR, 2010, XENOBIOTICA, V40, P357, DOI 10.3109/00498251003663724; Tang YH, 2006, BIOMED CHROMATOGR, V20, P1116, DOI 10.1002/bmc.655; Tortorici MA, 2006, CRIT CARE MED, V34, P785, DOI 10.1097/01.CCM.0000201899.52739.4F; WAXMAN DJ, 1985, BIOCHEMISTRY-US, V24, P4409, DOI 10.1021/bi00337a023; Zeng MF, 2010, FITOTERAPIA, V81, P490, DOI 10.1016/j.fitote.2010.01.004	22	20	25	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 2	2013	8	1							e53038	10.1371/journal.pone.0053038	http://dx.doi.org/10.1371/journal.pone.0053038			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	067UP	23301016	Green Published, Green Submitted, gold			2023-01-03	WOS:000313320900054
J	Yasuda, T; Loenneke, JP; Thiebaud, RS; Abe, T				Yasuda, Tomohiro; Loenneke, Jeremy P.; Thiebaud, Robert S.; Abe, Takashi			Effects of Blood Flow Restricted Low-Intensity Concentric or Eccentric Training on Muscle Size and Strength	PLOS ONE			English	Article							PROTEIN-SYNTHESIS; HORMONAL RESPONSES; CONTRACTIONS; EXERCISE; ACTIVATION; HYDRATION; HYPERTROPHY; GLUCOSE	We investigated the acute and chronic effects of low-intensity concentric or eccentric resistance training with blood flow restriction (BFR) on muscle size and strength. Ten young men performed 30% of concentric one repetition maximal dumbbell curl exercise (four sets, total 75 reps) 3 days/week for 6 weeks. One arm was randomly chosen for concentric BFR (CON-BFR) exercise only and the other arm performed eccentric BFR (ECC-BFR) exercise only at the same exercise load. During the exercise session, iEMG for biceps brachii muscles increased progressively during CON-BFR, which was greater (p<0.05) than that of the ECC-BFR. Immediately after the exercise, muscle thickness (MTH) of the elbow flexors acutely increased (p<0.01) with both CON-BFR and ECC-BFR, but was greater with CON-BFR (11.7%) (p<0.01) than ECC-BFR (3.9%) at 10-cm above the elbow joint. Following 6-weeks of training, MRI-measured muscle cross-sectional area (CSA) at 10-cm position and mid-upper arm (12.0% and 10.6%, respectively) as well as muscle volume (12.5%) of the elbow flexors were increased (p<0.01) with CON-BFR. Increases in muscle CSA and volume were lower in ECC-BFR (5.1%, 0.8% and 2.9%, respectively) than in the CON-BFR and only muscle CSA at 10-cm position increased significantly (p<0.05) after the training. Maximal voluntary isometric strength of elbow flexors was increased (p<0.05) in CON-BFR (8.6%), but not in ECC (3.8%). These results suggest that CON-BFR training leads to pronounced acute changes in muscle size, an index of muscle cell swelling, the response to which may be an important factor for promoting muscle hypertrophy with BFR resistance training.	[Yasuda, Tomohiro] Univ Tokyo, Dept Ischem Circulatory Physiol, Tokyo, Japan; [Loenneke, Jeremy P.; Thiebaud, Robert S.] Univ Oklahoma, Dept Hlth & Exercise Sci, Norman, OK 73019 USA; [Abe, Takashi] Univ Mississippi, Dept Hlth Exercise Sci & Recreat Management, Oxford, MS USA	University of Tokyo; University of Oklahoma System; University of Oklahoma - Norman; University of Mississippi	Yasuda, T (corresponding author), Univ Tokyo, Dept Ischem Circulatory Physiol, Tokyo, Japan.	yasuda-tomohiro@umin.ac.jp			Japan Ministry of Education, Culture, Sports, Science, and Technology [23700713]	Japan Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was supported, in part, by Grant-in-aid (#23700713 to TY) from the Japan Ministry of Education, Culture, Sports, Science, and Technology. No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe T., 2005, INT J KAATSU TRAIN R, V1, P6, DOI DOI 10.3806/IJKTR.1.6; Abe T, 2012, CLIN PHYSIOL FUNCT I, V32, P247, DOI 10.1111/j.1475-097X.2012.01126.x; Berneis K, 1999, AM J PHYSIOL-ENDOC M, V276, pE188, DOI 10.1152/ajpendo.1999.276.1.E188; BIGLANDRITCHIE B, 1986, ACTA PHYSIOL SCAND, V128, P137; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Cohen J., 2013, STAT POWER ANAL BEHA; DALTON PA, 1991, EUR J APPL PHYSIOL O, V63, P412, DOI 10.1007/BF00868071; Durand RJ, 2003, MED SCI SPORT EXER, V35, P937, DOI 10.1249/01.MSS.0000069522.38141.0B; Enoka RM, 1996, J APPL PHYSIOL, V81, P2339, DOI 10.1152/jappl.1996.81.6.2339; Farthing JP, 2003, EUR J APPL PHYSIOL, V89, P578, DOI 10.1007/s00421-003-0842-2; Fry CS, 2010, J APPL PHYSIOL, V108, P1199, DOI 10.1152/japplphysiol.01266.2009; Fujita S, 2007, J APPL PHYSIOL, V103, P903, DOI 10.1152/japplphysiol.00195.2007; Grant ACG, 2000, BBA-GEN SUBJECTS, V1475, P39, DOI 10.1016/S0304-4165(00)00045-3; Gundermann DM, 2012, J APPL PHYSIOL, V112, P1520, DOI 10.1152/japplphysiol.01267.2011; HAUSSINGER D, 1993, LANCET, V341, P1330, DOI 10.1016/0140-6736(93)90828-5; Higbie EJ, 1996, J APPL PHYSIOL, V81, P2173, DOI 10.1152/jappl.1996.81.5.2173; Karabulut M, 2010, EUR J APPL PHYSIOL, V108, P147, DOI 10.1007/s00421-009-1204-5; Keller U, 2003, EUR J CLIN NUTR, V57, pS69, DOI 10.1038/sj.ejcn.1601904; Kraemer RR, 2006, EUR J APPL PHYSIOL, V96, P551, DOI 10.1007/s00421-005-0094-4; Loenneke JP, 2012, MED HYPOTHESES, V78, P151, DOI 10.1016/j.mehy.2011.10.014; Loenneke JP, 2010, INT J SPORTS MED, V31, P1, DOI 10.1055/s-0029-1239499; Loenneke JP, 2012, EUR J APPL PHYSIOL, V112, P2903, DOI 10.1007/s00421-011-2266-8; Manini TM, 2011, ACTA PHYSIOL, V201, P255, DOI 10.1111/j.1748-1716.2010.02172.x; Manini TM, 2009, EXERC SPORT SCI REV, V37, P78, DOI 10.1097/JES.0b013e31819c2e5c; Millar ID, 1997, BIOCHEM BIOPH RES CO, V230, P351, DOI 10.1006/bbrc.1996.5959; MORITANI T, 1986, J APPL PHYSIOL, V60, P1179, DOI 10.1152/jappl.1986.60.4.1179; Nosaka K, 2001, MED SCI SPORT EXER, V33, P22; Ogawa M., 2012, J PHYS ED SPORTS MAN, V3, P14; Roig M, 2009, BRIT J SPORT MED, V43, P556, DOI 10.1136/bjsm.2008.051417; Seger JY, 1988, EUR J APPL PHYSL OCC, V79, P49; Takarada Y, 2000, J APPL PHYSIOL, V88, P2097, DOI 10.1152/jappl.2000.88.6.2097; Umbel JD, 2009, EUR J APPL PHYSIOL, V107, P687, DOI 10.1007/s00421-009-1175-6; Yasuda T, 2012, SCAND J MED IN PRESS; Yasuda T, 2011, EUR J APPL PHYSIOL, V111, P2525, DOI 10.1007/s00421-011-1873-8; Yasuda T, 2010, METABOLISM, V59, P1510, DOI 10.1016/j.metabol.2010.01.016; Yasuda T, 2010, CLIN PHYSIOL FUNCT I, V30, P338, DOI 10.1111/j.1475-097X.2010.00949.x; Yasuda T, 2008, J SPORT SCI MED, V7, P467; Yasuda T, 2009, J SPORT SCI, V27, P479, DOI 10.1080/02640410802626567	38	110	112	4	49	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2012	7	12							e52843	10.1371/journal.pone.0052843	http://dx.doi.org/10.1371/journal.pone.0052843			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	075GO	23300795	Green Published, gold, Green Submitted			2023-01-03	WOS:000313872600029
J	Mangin, I; Leveque, C; Magne, F; Suau, A; Pochart, P				Mangin, Irene; Leveque, Christophe; Magne, Fabien; Suau, Antonia; Pochart, Philippe			Long-Term Changes in Human Colonic Bifidobacterium Populations Induced by a 5-Day Oral Amoxicillin-Clavulanic Acid Treatment	PLOS ONE			English	Article							GRADIENT GEL-ELECTROPHORESIS; HUMAN FECAL FLORA; ANTIMICROBIAL SUSCEPTIBILITY; GUT MICROBIOTA; HUMAN FECES; PCR; DIVERSITY; HYBRIDIZATION; RESISTANCE; CYTOKINES	The objective of this study was to assess the possible modifications due to amoxicillin-clavulanic acid (AMC) treatment on total bacteria and on Bifidobacterium species balance in human colonic microbiota. Eighteen healthy volunteers (19 to 36 years old) were given a 875/125 mg dose of AMC twice a day for 5 days. Fecal samples were obtained before and after antibiotic exposure. After total DNA extraction, total bacteria and bifidobacteria were specifically quantified using real-time PCR. Dominant species were monitored over time using bacterial and bifidobacterial Temporal Temperature Gradient gel Electrophoresis (TTGE). At the end of AMC exposure, total bacterial concentrations as well as bifidobacteria concentrations were significantly reduced compared to before AMC exposure: 10.7 +/- 0.1 log(10) 16S rRNA gene copies/g vs 11.1 +/- 0.1 log(10) (p = 0.003) and 8.1 +/- 0.5 log(10) 16S rRNA gene copies/g vs 9.4 +/- 0.3 log(10) (p = 0.003), respectively. At the same time, the mean similarity percentages of TTGE bacteria and TTGE bifidobacteria profiles were significantly reduced compared to before AMC exposure: 51.6%+/- 3.5% vs 81.4%+/- 2.1% and 55.8%+/- 7.6% vs 84.5%+/- 4.1%, respectively. Occurrence of B. adolescentis, B. bifidum and B. pseudocatenulatum/B. catenulatum species significantly decreased. Occurrence of B. longum remained stable. Moreover, the number of distinct Bifidobacterium species per sample significantly decreased (1.5 +/- 0.3 vs 2.3 +/- 0.3; p = 0.01). Two months after AMC exposure, the mean similarity percentage of TTGE profiles was 55.6% for bacteria and 62.3% for bifidobacteria. These results clearly demonstrated that a common antibiotic treatment may qualitatively alter the colonic microbiota. Such modifications may have potential long-term physiological consequences.	[Mangin, Irene; Leveque, Christophe; Magne, Fabien; Suau, Antonia; Pochart, Philippe] Conservatoire Natl Arts & Metiers, Biol Lab, Paris, France; [Mangin, Irene; Leveque, Christophe; Pochart, Philippe] Univ Paris 05, Fac Sci Pharmaceut & Biol, EA 4065, Paris, France; [Suau, Antonia] Univ Grenoble 1, Lab Adaptat & Pathogenie Microorganisme, Grenoble, France	heSam Universite; Conservatoire National Arts & Metiers (CNAM); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Mangin, I (corresponding author), Conservatoire Natl Arts & Metiers, Biol Lab, Paris, France.	irene.mangin@cnam.fr	Suau, antonia/M-6587-2014; Magne, Fabien/F-1393-2014	Magne, Fabien/0000-0002-8210-4561	French Ministry of Health	French Ministry of Health	This work was supported by a grant from the French Ministry of Health (regional hospital project of clinical research). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antonopoulos DA, 2009, INFECT IMMUN, V77, P2367, DOI 10.1128/IAI.01520-08; Barc MC, 2004, ANTIMICROB AGENTS CH, V48, P1365, DOI 10.1128/AAC.48.4.1365-1368.2004; Bergogne-Berezin E, 2000, INT J ANTIMICROB AG, V16, P521, DOI 10.1016/S0924-8579(00)00293-4; Bertrand X, 2007, J APPL MICROBIOL, V102, P1052, DOI 10.1111/j.1365-2672.2006.03148.x; CHACHATY E, 1993, ANTIMICROB AGENTS CH, V37, P1432, DOI 10.1128/AAC.37.7.1432; De La Cochetiere MF, 2005, J CLIN MICROBIOL, V43, P5588, DOI 10.1128/JCM.43.11.5588-5592.2005; Delgado S, 2005, CURR MICROBIOL, V50, P202, DOI 10.1007/s00284-004-4431-3; Dethlefsen L, 2007, NATURE, V449, P811, DOI 10.1038/nature06245; Dethlefsen L, 2011, P NATL ACAD SCI USA, V108, P4554, DOI 10.1073/pnas.1000087107; Dethlefsen L, 2008, PLOS BIOL, V6, P2383, DOI 10.1371/journal.pbio.0060280; Donskey CJ, 2003, J MICROBIOL METH, V54, P249, DOI 10.1016/S0167-7012(03)00059-9; Finegold S.M., 1983, HUMAN INTESTINAL MIC, P3, DOI DOI 10.1016/B978-0-12-341280-5.50007-0; Fukuda S, 2011, NATURE, V469, P543, DOI 10.1038/nature09646; Godon JJ, 1997, APPL ENVIRON MICROB, V63, P2802, DOI 10.1128/AEM.63.7.2802-2813.1997; Gronvold AMR, 2010, FEMS MICROBIOL ECOL, V71, P313, DOI 10.1111/j.1574-6941.2009.00808.x; Guarner F, 2003, LANCET, V361, P512, DOI 10.1016/S0140-6736(03)12489-0; He F, 2002, MICROBIOL IMMUNOL, V46, P781, DOI 10.1111/j.1348-0421.2002.tb02765.x; Hurley BW, 2002, ARCH INTERN MED, V162, P2177, DOI 10.1001/archinte.162.19.2177; Jakobsson HE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009836; Jernberg C, 2007, ISME J, V1, P56, DOI 10.1038/ismej.2007.3; LANGENDIJK PS, 1995, APPL ENVIRON MICROB, V61, P3069, DOI 10.1128/AEM.61.8.3069-3075.1995; Lee JH, 2011, APPL ENVIRON MICROB, V77, P5879, DOI 10.1128/AEM.00571-11; LEONARD F, 1989, J INFECT DIS, V160, P274, DOI 10.1093/infdis/160.2.274; LIM KS, 1993, J DAIRY SCI, V76, P2168, DOI 10.3168/jds.S0022-0302(93)77553-0; Lode H, 2001, SCAND J INFECT DIS, V33, P899, DOI 10.1080/00365540110076714; Magne F, 2006, FEMS MICROBIOL ECOL, V58, P563, DOI 10.1111/j.1574-6941.2006.00182.x; Magne F, 2006, FEMS MICROBIOL ECOL, V57, P128, DOI 10.1111/j.1574-6941.2006.00097.x; Mangin I, 2006, FEMS MICROBIOL ECOL, V55, P28, DOI 10.1111/j.1574-6941.2005.00005.x; Mangin I, 2010, ANAEROBE, V16, P433, DOI 10.1016/j.anaerobe.2010.06.005; Mangin I, 1999, RES MICROBIOL, V150, P343, DOI 10.1016/S0923-2508(99)80060-6; Masco L, 2006, J ANTIMICROB CHEMOTH, V58, P85, DOI 10.1093/jac/dkl197; Matsuki T, 1999, APPL ENVIRON MICROB, V65, P4506; Matsuki T, 2004, APPL ENVIRON MICROB, V70, P167, DOI 10.1128/AEM.70.1.167-173.2004; Menard O, 2008, APPL ENVIRON MICROB, V74, P660, DOI 10.1128/AEM.01261-07; MOORE WEC, 1995, APPL ENVIRON MICROB, V61, P3202, DOI 10.1128/AEM.61.9.3202-3207.1995; MOORE WEC, 1974, APPL MICROBIOL, V27, P961, DOI 10.1128/AEM.27.5.961-979.1974; Moubareck C, 2005, J ANTIMICROB CHEMOTH, V55, P38, DOI 10.1093/jac/dkh495; Picard C, 2005, ALIMENT PHARM THER, V22, P495, DOI 10.1111/j.1365-2036.2005.02615.x; Satokari RM, 2001, APPL ENVIRON MICROB, V67, P504, DOI 10.1128/AEM.67.2.504-513.2001; SNEATH PHA, 1962, NATURE, V193, P855, DOI 10.1038/193855a0; Sullivan A, 2001, Lancet Infect Dis, V1, P101, DOI 10.1016/S1473-3099(01)00066-4; Vanhoutte T, 2004, FEMS MICROBIOL ECOL, V48, P437, DOI 10.1016/j.femsec.2004.03.001; Vasquez N, 2009, APPL ENVIRON MICROB, V75, P381, DOI 10.1128/AEM.01731-08; Wlodarska M, 2010, MUCOSAL IMMUNOL, V3, P100, DOI 10.1038/mi.2009.135; Yoshimura K, 2010, ANTON LEEUW INT J G, V97, P107, DOI 10.1007/s10482-009-9391-y; Young SL, 2004, CLIN DIAGN LAB IMMUN, V11, P686, DOI 10.1128/CDLI.11.4.686-690.2004; Young VB, 2004, J CLIN MICROBIOL, V42, P1203, DOI 10.1128/JCM.42.3.1203-1206.2004	47	22	22	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 27	2012	7	11							e50257	10.1371/journal.pone.0050257	http://dx.doi.org/10.1371/journal.pone.0050257			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	048BS	23209691	Green Published, Green Submitted, gold			2023-01-03	WOS:000311885800059
J	van Lettow, M; Akesson, A; Martiniuk, ALC; Ramsay, A; Chan, AK; Anderson, ST; Harries, AD; Corbett, E; Heyderman, RS; Zachariah, R; Bedell, RA				van Lettow, Monique; Akesson, Ann; Martiniuk, Alexandra L. C.; Ramsay, Andrew; Chan, Adrienne K.; Anderson, Suzanne T.; Harries, Anthony D.; Corbett, Elizabeth; Heyderman, Robert S.; Zachariah, Rony; Bedell, Richard A.			Six-Month Mortality among HIV-Infected Adults Presenting for Antiretroviral Therapy with Unexplained Weight Loss, Chronic Fever or Chronic Diarrhea in Malawi	PLOS ONE			English	Article							BLOOD-STREAM INFECTIONS; SOUTH-AFRICA; CRYPTOCOCCAL ANTIGENEMIA; PULMONARY TUBERCULOSIS; PROGRAM; BACTEREMIA; OUTCOMES; START; ETIOLOGY; SERVICE	Background: In sub-Saharan Africa, early mortality is high following initiation of antiretroviral therapy (ART). We investigated 6-month outcomes and factors associated with mortality in HIV-infected adults being assessed for ART initiation and presenting with weight loss, chronic fever or diarrhea, and with negative TB sputum microscopy. Methods: A prospective cohort study was conducted in Malawi, investigating mortality in relation to ART uptake, microbiological findings and treatment of opportunistic infection (OIs), 6 months after meeting ART eligibility criteria. Results: Of 469 consecutive adults eligible for ART, 74(16%) died within 6 months of enrolment, at a median of 41 days (IQR 20-81). 370(79%) started ART at a median time of 18 days (IQR 7-40) after enrolment. Six-month case-fatality rates were higher in patients with OIs; 25/121(21%) in confirmed/clinical TB and 10/50(20%) with blood stream infection (BSI) compared to 41/308(13%) in patients with no infection identified. Median TB treatment start was 27 days (IQR 17-65) after enrolment and mortality [8 deaths (44%)] was significantly higher among 18 culture-positive patients with delayed TB diagnosis compared to patients diagnosed clinically and treated promptly with subsequent culture confirmation [6/34 (18%); p = 0.04]. Adjusted multivariable analysis, excluding deaths in the first 21 days, showed weight loss >10%, low CD4 count, severe anemia, laboratory-only TB diagnosis, and not initiating ART to be independently associated with increased risk of death. Conclusions: Mortality remains high among chronically ill patients eligible for ART. Prompt initiation of ART is vital: more than half of deaths were among patients who never started ART. Diagnostic and treatment delay for TB was strongly associated with risk of death. More than half of deaths occurred without identification of a specific infection. ART programmes need access to rapid point-of-care-diagnostic tools for OIs. The role of early empiric OI treatment in this population requires further evaluation in clinical trials.	[van Lettow, Monique; Martiniuk, Alexandra L. C.; Chan, Adrienne K.; Bedell, Richard A.] Dignitas Int, Zomba, Malawi; [van Lettow, Monique; Martiniuk, Alexandra L. C.; Chan, Adrienne K.] Univ Toronto, Toronto, ON, Canada; [Akesson, Ann] Medecins Sans Frontieres, Thyolo, Malawi; [Martiniuk, Alexandra L. C.] George Inst Global Hlth, Sydney, NSW, Australia; [Martiniuk, Alexandra L. C.] Univ Sydney, Sydney, NSW 2006, Australia; [Ramsay, Andrew] WHO, Trop Dis Res Programme, CH-1211 Geneva, Switzerland; [Ramsay, Andrew] Univ St Andrews, Sch Med, St Andrews KY16 9AJ, Fife, Scotland; [Anderson, Suzanne T.; Corbett, Elizabeth; Heyderman, Robert S.] Univ Malawi, Malawi Liverpool Wellcome Trust Clin Res Programm, Coll Med, Blantyre, Malawi; [Harries, Anthony D.] Int Union TB & Lung Dis, Paris, France; [Harries, Anthony D.; Corbett, Elizabeth] London Sch Hyg & Trop Med, London WC1, England; [Zachariah, Rony] Brussels Operat Ctr, Operat Res Unit, Medecins Sans Frontieres, Luxembourg, Luxembourg; [Bedell, Richard A.] Univ British Columbia, Div Global Hlth, Vancouver, BC V5Z 1M9, Canada	University of Toronto; George Institute for Global Health; University of Sydney; University of Sydney; World Health Organization; University of St Andrews; University of Malawi; University of London; London School of Hygiene & Tropical Medicine; Doctors Without Borders; University of British Columbia	van Lettow, M (corresponding author), Dignitas Int, Zomba, Malawi.	m.vanlettow@dignitasinternational.org	Bedell, Richard/AAC-2595-2020; Martiniuk, Alexandra/K-2600-2019	Bedell, Richard/0000-0002-5687-8053; Martiniuk, Alexandra/0000-0003-1368-8206; Corbett, Elizabeth/0000-0002-3552-3181; zachariah, rony/0000-0002-2915-9328; Heyderman, Robert/0000-0003-4573-449X	TREAT TB; USAID Cooperative Agreement; University of Sydney Fellowship	TREAT TB; USAID Cooperative Agreement(United States Agency for International Development (USAID)); University of Sydney Fellowship	This study was funded through TREAT TB - An initiative led by the International Union Against Tuberculosis and Lung Disease (the Union) and supported by a USAID Cooperative Agreement. Medecins Sans Frontieres self-funded their involvement in this study and did not receive funds from USAID. AM is funded by a University of Sydney Fellowship (2012-2014 inclusive). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Archibald LK, 2000, J INFECT DIS, V181, P1414, DOI 10.1086/315367; Archibald LK, 1998, CLIN INFECT DIS, V26, P290, DOI 10.1086/516297; Arthur G, 2001, CLIN INFECT DIS, V33, P248, DOI 10.1086/321820; Bedell RA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039347; Bell M, 2001, Int J Infect Dis, V5, P63, DOI 10.1016/S1201-9712(01)90027-X; Bizuwork T., 2007, Journal of Infection in Developing Countries, V1, P118; Blanc FX, 2011, NEW ENGL J MED, V365, P1471, DOI 10.1056/NEJMoa1013911; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Cox JA, 2010, AIDS REV, V12, P183; Etard JF, 2006, AIDS, V20, P1181, DOI 10.1097/01.aids.0000226959.87471.01; Everett DB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017765; Fairall LR, 2008, ARCH INTERN MED, V168, P86, DOI 10.1001/archinternmed.2007.10; Gordon MA, 2002, AIDS, V16, P1633, DOI 10.1097/00002030-200208160-00009; Government of Malawi Ministry of Health with technical support from SACEMA and WHO, 2012, IMP ASS ART TB TREAT; Hill PC, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-2; Holtz TH, 2011, LANCET INFECT DIS, V11, P533, DOI 10.1016/S1473-3099(11)70057-3; Jarvis JN, 2009, CLIN INFECT DIS, V48, P856, DOI 10.1086/597262; Kerkhoff AD, 2011, AIDS, V25, P1003, DOI 10.1097/QAD.0b013e328345ee32; Kobayashi T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004736; Komati S, 2010, AIDS, V24, P1849, DOI 10.1097/QAD.0b013e32833a2507; Kumwenda M, 2011, INT J TUBERC LUNG D, V15, P1663, DOI 10.5588/ijtld.10.0741; Lawn SD, 2011, INT J TUBERC LUNG D, V15, P571, DOI 10.5588/ijtld.10.0483; Lawn SD, 2005, AIDS, V19, P2141, DOI 10.1097/01.aids.0000194802.89540.e1; Lawn SD, 2008, AIDS, V22, P1897, DOI 10.1097/QAD.0b013e32830007cd; Lawn SD, 2006, CLIN INFECT DIS, V43, P770, DOI 10.1086/507095; Lawn SD, 2011, JAIDS-J ACQ IMM DEF, V57, P136, DOI 10.1097/QAI.0b013e3182199ee9; Lawn SD, 2011, CURR OPIN INFECT DIS, V24, P34, DOI 10.1097/QCO.0b013e3283420f76; Lessells RJ, 2011, SAMJ S AFR MED J, V101, P251, DOI 10.7196/SAMJ.4378; Levesque LE, 2010, BMJ-BRIT MED J, V340, P907; Lewis DK, 2002, INT J TUBERC LUNG D, V6, P1067; Liechty CA, 2007, TROP MED INT HEALTH, V12, P929, DOI 10.1111/j.1365-3156.2007.01874.x; Malawi Ministry of Health, 2007, HIV SYPH SER NAT HIV; Mayanja BN, 2010, TROP MED INT HEALTH, V15, P697, DOI 10.1111/j.1365-3156.2010.02528.x; McDonald LC, 1999, LANCET, V354, P1159, DOI 10.1016/S0140-6736(98)12325-5; Muyanja SZ, 2011, TROP MED INT HEALTH, V16, P756, DOI 10.1111/j.1365-3156.2011.02754.x; Ngoma D, 2008, TROP DOCT, V38, P159, DOI 10.1258/td.2007.070244; Peters RPH, 2004, TROP MED INT HEALTH, V9, P928, DOI 10.1111/j.1365-3156.2004.01288.x; Reddy EA, 2010, LANCET INFECT DIS, V10, P417, DOI 10.1016/S1473-3099(10)70072-4; Ssali FN, 1998, J ACQ IMMUN DEF SYND, V19, P484, DOI 10.1097/00042560-199812150-00007; Stall N, 2011, INT J TUBERC LUNG D, V15, P641, DOI 10.5588/ijtld.10.0195; Vittinghoff E, 2007, AM J EPIDEMIOL, V165, P710, DOI 10.1093/aje/kwk052; Westreich D, 2009, AIDS, V23, P707, DOI 10.1097/QAD.0b013e328325d115; Yu JKL, 2007, B WORLD HEALTH ORGAN, V85, P550, DOI 10.2471/BLT.06.037739	43	10	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 19	2012	7	11							e48856	10.1371/journal.pone.0048856	http://dx.doi.org/10.1371/journal.pone.0048856			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	040PB	23185278	Green Accepted, Green Published, gold			2023-01-03	WOS:000311333800011
J	Ledizet, M; Murray, TS; Puttagunta, S; Slade, MD; Quagliarello, VJ; Kazmierczak, BI				Ledizet, Michel; Murray, Thomas S.; Puttagunta, Sailaja; Slade, Martin D.; Quagliarello, Vincent J.; Kazmierczak, Barbara I.			The Ability of Virulence Factor Expression by Pseudomonas aeruginosa to Predict Clinical Disease in Hospitalized Patients	PLOS ONE			English	Article							III SECRETION SYSTEM; VENTILATOR-ASSOCIATED PNEUMONIA; NOSOCOMIAL INFECTIONS; PROTEIN SECRETION; URINARY-TRACT; IN-VITRO; MOTILITY; IMMUNIZATION; PATHOGENESIS; PHENOTYPES	Background: Pseudomonas aeruginosa is an opportunistic pathogen that frequently causes hospital acquired colonization and infection. Accurate identification of host and bacterial factors associated with infection could aid treatment decisions for patients with P. aeruginosa cultured from clinical sites. Methods: We identified a prospective cohort of 248 hospitalized patients with positive P. aeruginosa cultures. Clinical data were analyzed to determine whether an individual met predefined criteria for infection versus colonization. P. aeruginosa isolates were tested for the expression of multiple phenotypes previously associated with virulence in animal models and humans. Logistic regression models were constructed to determine the degree of association between host and bacterial factors with P. aeruginosa infection of the bloodstream, lung, soft tissue and urinary tract. Results: One host factor (i.e. diabetes mellitus), and one bacterial factor, a Type 3 secretion system positive phenotype, were significantly associated with P. aeruginosa infection in our cohort. Subgroup analysis of patients with P. aeruginosa isolated from the urinary tract revealed that the presence of a urinary tract catheter or stent was an additional factor for P. aeruginosa infection. Conclusions: Among hospitalized patients with culture-documented P. aeruginosa, infection is more likely to be present in those with diabetes mellitus and those harboring a Type 3 secretion positive bacterial strain.	[Puttagunta, Sailaja; Quagliarello, Vincent J.; Kazmierczak, Barbara I.] Yale Univ, Sch Med, Dept Med, Infect Dis Sect, New Haven, CT 06510 USA; [Murray, Thomas S.] Yale Univ, Sch Med, Dept Pediat Infect Dis, New Haven, CT USA; [Ledizet, Michel] L2 Diagnost, New Haven, CT USA; [Slade, Martin D.] Yale Univ, Sch Med, Dept Occupat & Environm Med, New Haven, CT USA; [Kazmierczak, Barbara I.] Yale Univ, Sch Med, Dept Microbial Pathogenesis, New Haven, CT USA	Yale University; Yale University; Yale University; Yale University	Kazmierczak, BI (corresponding author), Yale Univ, Sch Med, Dept Med, Infect Dis Sect, New Haven, CT 06510 USA.	barbara.kazmierczak@yale.edu		Kazmierczak, Barbara/0000-0002-8162-803X	National Institutes of Health (NIH) [T32 AI007517, T32 AI07210, R42 AI058659]; Patrick and Catherine Weldon Donaghue Medical Research Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI081825, T32AI007517, R41AI058659, R42AI058659, T32AI007210] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Patrick and Catherine Weldon Donaghue Medical Research Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by National Institutes of Health (NIH) grants T32 AI007517 (to SP), T32 AI07210 (to TSM), R42 AI058659 (to BIK) and the Patrick and Catherine Weldon Donaghue Medical Research Foundation (to BIK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2010, MANDELL DOUGLAS BENN; Arnoldo A, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000005; Arora SK, 2005, INFECT IMMUN, V73, P4395, DOI 10.1128/IAI.73.7.4395-4398.2005; Balloy V, 2007, J INFECT DIS, V196, P289, DOI 10.1086/518610; Battle SE, 2008, J BACTERIOL, V190, P7130, DOI 10.1128/JB.00785-08; Caballero AR, 2001, ANAL BIOCHEM, V290, P330, DOI 10.1006/abio.2001.4999; Cardo D, 2004, AM J INFECT CONTROL, V32, P470, DOI 10.1016/j.ajic.2004.10.001; Carter MQ, 2010, J BACTERIOL, V192, P3249, DOI 10.1128/JB.00041-10; Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/ajrccm.165.7.2105078; Cortes P, 2001, INFECT CONT HOSP EP, V22, P720, DOI 10.1086/501853; El Solh AA, 2008, AM J RESP CRIT CARE, V178, P513, DOI 10.1164/rccm.200802-239OC; El-Solh AA, 2012, CRIT CARE MED, V40, P1157, DOI 10.1097/CCM.0b013e3182377906; Feldman M, 1998, INFECT IMMUN, V66, P43, DOI 10.1128/IAI.66.1.43-51.1998; Francois B, 2012, CRIT CARE MED, V40, P2320, DOI 10.1097/CCM.0b013e31825334f6; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Gaynes R, 2005, CLIN INFECT DIS, V41, P848, DOI 10.1086/432803; Hamood AN, 1996, J SURG RES, V61, P425, DOI 10.1006/jsre.1996.0140; Harrison EM, 2010, INFECT IMMUN, V78, P1437, DOI 10.1128/IAI.00621-09; Hauser AR, 2009, NAT REV MICROBIOL, V7, P654, DOI 10.1038/nrmicro2199; Hauser AR, 2002, CRIT CARE MED, V30, P521, DOI 10.1097/00003246-200203000-00005; He JX, 2004, P NATL ACAD SCI USA, V101, P2530, DOI 10.1073/pnas.0304622101; Holder IA, 2001, INFECT IMMUN, V69, P5908, DOI 10.1128/IAI.69.9.5908-5910.2001; Hu H, 2012, CLIN MICROBIOL INFEC; Jain M, 2004, J CLIN MICROBIOL, V42, P5229, DOI 10.1128/JCM.42.11.5229-5237.2004; Kulasekara BR, 2006, J BACTERIOL, V188, P4037, DOI 10.1128/JB.02000-05; Kumar R, 2009, KIDNEY INT, V76, P286, DOI 10.1038/ki.2009.183; Lambert PA, 2002, J ROY SOC MED, V95, P22; Lee DG, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r90; Lee VT, 2007, INFECT IMMUN, V75, P1089, DOI 10.1128/IAI.01184-06; Lee VT, 2005, INFECT IMMUN, V73, P1695, DOI 10.1128/IAI.73.3.1695-1705.2005; Li Li, 2005, Ann Clin Microbiol Antimicrob, V4, P22, DOI 10.1186/1476-0711-4-22; MAHENTHIRALINGAM E, 1994, INFECT IMMUN, V62, P596, DOI 10.1128/IAI.62.2.596-605.1994; Merritt Judith H, 2005, Curr Protoc Microbiol, VChapter 1, DOI 10.1002/9780471729259.mc01b01s00; Mikkelsen H, 2011, ENVIRON MICROBIOL, V13, P1666, DOI 10.1111/j.1462-2920.2011.02495.x; Mittal Rahul, 2009, J Infect Public Health, V2, P101, DOI 10.1016/j.jiph.2009.08.003; Miyata S, 2003, INFECT IMMUN, V71, P2404, DOI 10.1128/IAI.71.5.2404-2413.2003; Mun JJ, 2009, INFECT IMMUN, V77, P2392, DOI 10.1128/IAI.00173-09; Murray TS, 2010, J MED MICROBIOL, V59, P511, DOI 10.1099/jmm.0.017715-0; Nguyen D, 2007, PEDIATR PULM, V42, P533, DOI 10.1002/ppul.20620; O'Rourke N., 2013, STEP BY STEP APPROAC; Parsek MR, 2003, ANNU REV MICROBIOL, V57, P677, DOI 10.1146/annurev.micro.57.030502.090720; Preston MJ, 1997, INFECT IMMUN, V65, P3086, DOI 10.1128/IAI.65.8.3086-3090.1997; Roy-Burman A, 2001, J INFECT DIS, V183, P1767, DOI 10.1086/320737; Sawa T, 1999, NAT MED, V5, P392, DOI 10.1038/7391; Shaver CM, 2004, INFECT IMMUN, V72, P6969, DOI 10.1128/IAI.72.12.6969-6977.2004; Talon D, 1998, AM J RESP CRIT CARE, V157, P978, DOI 10.1164/ajrccm.157.3.9702096; TANG H, 1995, INFECT IMMUN, V63, P1278, DOI 10.1128/IAI.63.4.1278-1285.1995; Vance RE, 2005, INFECT IMMUN, V73, P1706, DOI 10.1128/IAI.73.3.1706-1713.2005; Wenzel RP, 2001, EMERG INFECT DIS, V7, P174, DOI 10.3201/eid0702.010203; Wiehlmann L, 2007, P NATL ACAD SCI USA, V104, P8101, DOI 10.1073/pnas.0609213104; Wolfgang MC, 2003, DEV CELL, V4, P253, DOI 10.1016/S1534-5807(03)00019-4; WOODS DE, 1986, J CLIN MICROBIOL, V24, P260, DOI 10.1128/JCM.24.2.260-264.1986	52	21	23	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2012	7	11							e49578	10.1371/journal.pone.0049578	http://dx.doi.org/10.1371/journal.pone.0049578			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	039HA	23152923	Green Submitted, Green Published, gold			2023-01-03	WOS:000311234000074
J	Cao, Y; Marks, JW; Liu, Z; Cheung, LH; Hittelman, WN; Rosenblum, MG				Cao, Y.; Marks, J. W.; Liu, Z.; Cheung, L. H.; Hittelman, W. N.; Rosenblum, M. G.			Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies	ONCOGENE			English	Article						immunotoxin; Her2/neu; gelonin; valency; design optimization	DISULFIDE-STABILIZED FV; SINGLE-CHAIN FV; HER2-POSITIVE BREAST-CANCER; IMPROVED ANTIGEN-BINDING; RECOMBINANT IMMUNOTOXINS; MONOCLONAL-ANTIBODY; ANTITUMOR-ACTIVITY; ONCOGENE PRODUCT; ERBB-2 RECEPTOR; CARCINOMA-CELLS	Targeted therapeutics are potential therapeutic agents because of their selectivity and efficacy against tumors resistant to conventional therapy. The goal of this study was to determine the comparative activity of monovalent, engineered anti-Her2/neu immunotoxins fused to recombinant gelonin (rGel) to the activity of bivalent IgG-containing immunoconjugates. Utilizing Herceptin and its derived humanized single-chain antibody (single-chain fragment variable, designated 4D5), we generated bivalent chemical Herceptin/rGel conjugate, and the corresponding monovalent recombinant immunotoxins in two orientations, 4D5/rGel and rGel/4D5. All the constructs showed similar affinity to Her2/neu-overexpressing cancer cells, but significantly different antitumor activities. The rGel/4D5 orientation construct and Herceptin/rGel conjugate were superior to 4D5/rGel construct in in vitro and in vivo efficacy. The enhanced activity was attributed to improved intracellular toxin uptake into target cells and efficient downregulation of Her2/neu-related signaling pathways. The Her2/neu-targeted immunotoxins effectively targeted cells with Her2/neu expression level > 1.5 x 10(5) sites per cell. Cells resistant to Herceptin or chemotherapeutic agents were not cross-resistant to rGel-based immunotoxins. Against SK-OV-3 tumor xenografts, the rGel/4D5 construct with excellent tumor penetration showed impressive tumor inhibition. Although Herceptin/rGel conjugate demonstrated comparatively longer serum half-life, the in vivo efficacy of the conjugate was similar to the rGel/4D5 fusion. These comparative studies demonstrate that the monovalent, engineered rGel/4D5 construct displayed comparable in vitro and in vivo antitumor efficacy as bivalent Herceptin/rGel conjugate. Immunotoxin orientation can significantly impact the overall functionality and performance of these agents. The recombinant rGel/4D5 construct with excellent tumor penetration and rapid blood clearance may reduce the unwanted toxicity when administrating to patients, and warrants consideration for further clinical evaluation.	[Cao, Y.; Marks, J. W.; Liu, Z.; Cheung, L. H.; Hittelman, W. N.; Rosenblum, M. G.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Immunopharmacol & Targeted Therapy Lab, Houston, TX 77054 USA	University of Texas System; UTMD Anderson Cancer Center	Rosenblum, MG (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77054 USA.	mrosenbl@mdanderson.org	Liu, Zhiming/GXG-6785-2022; Cao, Yu/L-6743-2014		NCI NIH HHS [P30 CA016672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams GP, 2006, CLIN CANCER RES, V12, P1599, DOI 10.1158/1078-0432.CCR-05-2217; Adams GP, 1998, BRIT J CANCER, V77, P1405, DOI 10.1038/bjc.1998.233; Azemar M, 2003, BREAST CANCER RES TR, V82, P155, DOI 10.1023/B:BREA.0000004371.48757.19; Beckman RA, 2007, CANCER-AM CANCER SOC, V109, P170, DOI 10.1002/cncr.22402; Benhar I, 1995, CLIN CANCER RES, V1, P1023; Bera TK, 1999, CANCER RES, V59, P4018; Bera TK, 1998, J MOL BIOL, V281, P475, DOI 10.1006/jmbi.1998.1948; Brand FX, 2006, ANTICANCER RES, V26, P715; Brinkmann U, 2000, IN VIVO, V14, P21; Cao Y, 2012, MOL CANCER THER, V11, P143, DOI 10.1158/1535-7163.MCT-11-0519; Cao Y, 2009, CANCER RES, V69, P8987, DOI 10.1158/0008-5472.CAN-09-2693; Cardinale D, 2010, J CLIN ONCOL, V28, P3910, DOI 10.1200/JCO.2009.27.3615; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Daniele L, 2009, RECENT PAT ANTI-CANC, V4, P9, DOI 10.2174/157489209787002489; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Hermanto U, 2001, ONCOGENE, V20, P7551, DOI 10.1038/sj.onc.1204964; Hossann M, 2006, PROTEIN EXPRES PURIF, V46, P73, DOI 10.1016/j.pep.2005.08.029; Jain KK, 2001, EXPERT OPIN BIOL TH, V1, P291, DOI 10.1517/14712598.1.2.291; Jain M, 2007, CLIN CANCER RES, V13, P1374, DOI 10.1158/1078-0432.CCR-06-2436; JAIN RK, 1988, CANCER RES, V48, P7022; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Krauss W C, 2000, Breast Dis, V11, P113; Kreitman RJ, 2003, CURR OPIN MOL THER, V5, P44; MAIER LA, 1991, CANCER RES, V51, P5361; Maurer-Gebhard M, 1998, CANCER RES, V58, P2661; Mazor Y, 2007, CANCER LETT, V257, P124, DOI 10.1016/j.canlet.2007.07.009; McLarty K, 2009, EUR J NUCL MED MOL I, V36, P81, DOI 10.1007/s00259-008-0923-x; Murphy CG, 2010, ONCOLOGY-NY, V24, P410; Nordstrom JL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3069; Pai-Scherf LH, 1999, CLIN CANCER RES, V5, P2311; Pennell CA, 2002, IMMUNOL RES, V25, P177, DOI 10.1385/IR:25:2:177; Phillips GDL, 2008, CANCER RES, V68, P9280, DOI 10.1158/0008-5472.CAN-08-1776; Pohlmann PR, 2009, CLIN CANCER RES, V15, P7479, DOI 10.1158/1078-0432.CCR-09-0636; Reiter Y, 2001, ADV CANCER RES, V81, P93, DOI 10.1016/S0065-230X(01)81003-4; RODRIGUEZ GC, 1993, AM J OBSTET GYNECOL, V168, P228, DOI 10.1016/S0002-9378(12)90918-7; Rosenblum MG, 1999, CLIN CANCER RES, V5, P865; Rosenblum MG, 2003, CANCER RES, V63, P3995; Scholl S, 2001, ANN ONCOL, V12, P81, DOI 10.1023/A:1011192622688; WELS W, 1992, CANCER RES, V52, P6310; Yee S, 1997, MICROBIOL IMMUNOL, V41, P563, DOI 10.1111/j.1348-0421.1997.tb01892.x; YOKOTA T, 1992, CANCER RES, V52, P3402	41	35	38	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					429	439		10.1038/onc.2012.612	http://dx.doi.org/10.1038/onc.2012.612			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23376850	Green Accepted, Bronze			2023-01-03	WOS:000330214600004
J	Jacobson, CA; Freedman, AS				Jacobson, Caron A.; Freedman, Arnold S.			First-line treatment of indolent lymphoma: axing CHOP?	LANCET			English	Editorial Material							NON-HODGKINS-LYMPHOMA; LARGE-CELL LYMPHOMA; FOLLICULAR LYMPHOMA; PLUS RITUXIMAB; LOW-GRADE; CHEMOTHERAPY; CYCLOPHOSPHAMIDE; MAINTENANCE; VINCRISTINE; SURVIVAL		[Jacobson, Caron A.; Freedman, Arnold S.] Dana Farber Canc Inst, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute	Freedman, AS (corresponding author), Dana Farber Canc Inst, Boston, MA 02215 USA.	arnold_freedman@dfci.harvard.edu						BARTLETT NL, 1994, J CLIN ONCOL, V12, P1349, DOI 10.1200/JCO.1994.12.7.1349; Friedberg JW, 2009, J CLIN ONCOL, V27, P1202, DOI 10.1200/JCO.2008.18.1495; Hiddemann W, 2005, BLOOD, V106, P3725, DOI 10.1182/blood-2005-01-0016; Hochster H, 2009, J CLIN ONCOL, V27, P1607, DOI 10.1200/JCO.2008.17.1561; JONES SE, 1983, CANCER, V51, P1083, DOI 10.1002/1097-0142(19830315)51:6<1083::AID-CNCR2820510619>3.0.CO;2-M; Leoni LM, 2008, CLIN CANCER RES, V14, P309, DOI 10.1158/1078-0432.CCR-07-1061; LISTER TA, 1978, BRIT MED J, V1, P533, DOI 10.1136/bmj.1.6112.533; Marcus R, 2005, BLOOD, V105, P1417, DOI 10.1182/blood-2004-08-3175; Martinelli G, 2010, J CLIN ONCOL, V28, P4480, DOI 10.1200/JCO.2010.28.4786; Robinson KS, 2008, J CLIN ONCOL, V26, P4473, DOI 10.1200/JCO.2008.17.0001; Rummel MJ, 2013, LANCET; Salles G, 2011, LANCET, V377, P42, DOI 10.1016/S0140-6736(10)62175-7	12	9	9	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 6	2013	381	9873					1163	1165		10.1016/S0140-6736(12)61965-5	http://dx.doi.org/10.1016/S0140-6736(12)61965-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122WU	23433738				2023-01-03	WOS:000317350100006
J	Nagpaul, C				Nagpaul, Chaand			Should GPs be fined for rises in avoidable emergency admissions to hospital? No	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CONTROLLED-TRIAL					chaand.nagpaul@gmail.com						[Anonymous], 2012, FIT FUTURE FOSTER HO; Blunt I, 2010, TRENDS EMERGENCY ADM; Curry N, 2010, CLIN SERVICE INTEGRA; Fan VS, 2012, ANN INTERN MED, V156, P673, DOI 10.7326/0003-4819-156-10-201205150-00003; Ham C., 2011, NEXT NHS REFORMS CAS; NHS Commissioning Board, QUAL PREM 2013 14 DR; Purdy S., 2012, AVOIDING HOSP ADMISS; Roland M, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e6017; Royal College of Physicians, 2012, HOSP EDG; Takahashi PY, 2012, ARCH INTERN MED, V172, P773, DOI 10.1001/archinternmed.2012.256	10	3	3	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 5	2013	346								f1391	10.1136/bmj.f1391	http://dx.doi.org/10.1136/bmj.f1391			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	104MN	23463140				2023-01-03	WOS:000315997600018
J	Zhang, JY; Li, P; Wang, YP; Liu, JX; Zhang, ZJ; Cheng, WD; Wang, YY				Zhang, Junying; Li, Peng; Wang, Yanping; Liu, Jianxun; Zhang, Zhanjun; Cheng, Weidong; Wang, Yongyan			Ameliorative Effects of a Combination of Baicalin, Jasminoidin and Cholic Acid on Ibotenic Acid-Induced Dementia Model in Rats	PLOS ONE			English	Article							EPIDERMAL-GROWTH-FACTOR; THYROTROPIN-RELEASING-HORMONE; NEURAL STEM-CELLS; IMPAIRED RECOGNITION MEMORY; TRANSGENIC MOUSE MODEL; RETINOIC ACID; ALZHEIMERS-DISEASE; IN-VITRO; CARBONYL REDUCTASE; AMYLOID DEPOSITION	Aims: To investigate the therapeutic effects and acting mechanism of a combination of Chinese herb active components, i.e., a combination of baicalin, jasminoidin and cholic acid (CBJC) on Alzheimer's disease (AD). Methods: Male rats were intracerebroventricularly injected with ibotenic acid (IBO), and CBJC was orally administered. Therapeutic effect was evaluated with the Morris water maze test, FDG-PET examination, and histological examination, and the acting mechanism was studied with DNA microarrays and western blotting. Results: CBJC treatment significantly attenuated IBO-induced abnormalities in cognition, brain functional images, and brain histological morphology. Additionally, the expression levels of 19 genes in the forebrain were significantly influenced by CBJC; approximately 60% of these genes were related to neuroprotection and neurogenesis, whereas others were related to anti-oxidation, protein degradation, cholesterol metabolism, stress response, angiogenesis, and apoptosis. Expression of these genes was increased, except for the gene related to apoptosis. Changes in expression for 5 of these genes were confirmed by western blotting. Conclusion: CBJC can ameliorate the IBO-induced dementia in rats and may be significant in the treatment of AD. The therapeutic mechanism may be related to CBJC's modulation of a number of processes, mainly through promotion of neuroprotection and neurogenesis, with additional promotion of anti-oxidation, protein degradation, etc.	[Zhang, Junying; Cheng, Weidong] Lanzhou Univ, Sch Basic Med Sci, Lanzhou 730000, Peoples R China; [Zhang, Junying; Zhang, Zhanjun] Beijing Normal Univ, State Key Lab Cognit Neurosci & Learning, Beijing 100875, Peoples R China; [Li, Peng; Liu, Jianxun] China Acad Chinese Med Sci, Lab Res Ctr, Xiyuan Hosp, Beijing, Peoples R China; [Wang, Yanping; Wang, Yongyan] China Acad Chinese Med Sci, Inst Basic Clin Med, Beijing, Peoples R China	Lanzhou University; Beijing Normal University; China Academy of Chinese Medical Sciences; Xiyuan Hospital, CACMS; China Academy of Chinese Medical Sciences; Institute of Basic Research In Clinical Medicine, CACMS	Zhang, ZJ (corresponding author), Beijing Normal Univ, State Key Lab Cognit Neurosci & Learning, Beijing 100875, Peoples R China.	zhang_rzs@bnu.edu; weidong_c@yahoo.cn			Fundamental Research Funds for the Central Universities [248-105102]; Program for New Century Excellent Talents in University [NCET-10]; Project of Institute of Basic Clinical Medicine, China Academy of Chinese Medical Sciences [Z0175]	Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); Project of Institute of Basic Clinical Medicine, China Academy of Chinese Medical Sciences	This study was supported by the Fundamental Research Funds for the Central Universities (248-105102), Program for New Century Excellent Talents in University (NCET-10) and Project of Institute of Basic Clinical Medicine, China Academy of Chinese Medical Sciences (Z0175). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABE K, 1992, NEUROSCI RES, V14, P117, DOI 10.1016/0168-0102(92)90087-S; Akama K, 2011, BBA-PROTEINS PROTEOM, V1814, P265, DOI 10.1016/j.bbapap.2010.10.009; Arai Y, 2005, J NEUROSCI, V25, P9752, DOI 10.1523/JNEUROSCI.2512-05.2005; Beattie J, 2006, BIOCHEM J, V395, P1, DOI 10.1042/BJ20060086; Bennett GW, 1997, EXP GERONTOL, V32, P451, DOI 10.1016/S0531-5565(96)00159-3; Benoit BO, 2001, J NEUROBIOL, V46, P265, DOI 10.1002/1097-4695(200103)46:4<265::AID-NEU1007>3.0.CO;2-B; Bergink S, 2006, NEUROBIOL DIS, V23, P708, DOI 10.1016/j.nbd.2006.06.005; Bi WM, 2007, HUM MOL GENET, V16, P1802, DOI 10.1093/hmg/ddm128; Boneva NB, 2011, HIPPOCAMPUS, V21, P162, DOI 10.1002/hipo.20732; Botella JA, 2004, CURR BIOL, V14, P782, DOI 10.1016/j.cub.2004.04.036; Calza L, 2003, P NATL ACAD SCI USA, V100, P7325, DOI 10.1073/pnas.1132092100; Chen-Plotkin AS, 2011, ANN NEUROL, V69, P655, DOI 10.1002/ana.22271; Christie VB, 2010, J NEUROSCI METH, V193, P239, DOI 10.1016/j.jneumeth.2010.08.022; Clark RE, 2000, J NEUROSCI, V20, P8853; Corcoran JPT, 2004, EUR J NEUROSCI, V20, P896, DOI 10.1111/j.1460-9568.2004.03563.x; Cui J, 2003, ZHONG GUO ZU ZHI HUA, V12, P81; Cunha-Reis D, 2006, ANN NY ACAD SCI, V1070, P210, DOI 10.1196/annals.1317.016; Ding Y, 2008, J NEUROSCI, V28, P11622, DOI 10.1523/JNEUROSCI.3153-08.2008; Encinas M, 2000, J NEUROCHEM, V75, P991, DOI 10.1046/j.1471-4159.2000.0750991.x; Etchamendy N, 2001, J NEUROSCI, V21, P6423, DOI 10.1523/JNEUROSCI.21-16-06423.2001; Farias EF, 2005, J NATL CANCER I, V97, P21, DOI 10.1093/jnci/dji004; Flore M, 2002, PHYSIOL BEHAV, V77, P437; Fujita Jun, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P243; Guo XF, 2000, GUANG ZHOU ZHONG YI, V17, P9; Hauck SM, 2008, MOL CELL PROTEOMICS, V7, P1349, DOI 10.1074/mcp.M700456-MCP200; Heo H, 2009, J ETHNOPHARMACOL, V122, P20, DOI 10.1016/j.jep.2008.11.026; Hicks D, 1998, GEN PHARMACOL, V30, P265, DOI 10.1016/S0306-3623(97)00356-X; Hoffrogge R, 2006, PROTEOMICS, V6, P1833, DOI 10.1002/pmic.200500556; Hu JG, 2001, J BIOL CHEM, V276, P47863, DOI 10.1074/jbc.M104068200; Ishikawa E, 2009, J NEUROL SCI, V285, P78, DOI 10.1016/j.jns.2009.05.026; Ji C, 2009, J ALZHEIMERS DIS, V16, P331, DOI 10.3233/JAD-2009-0979; Johansson K, 2010, FREE RADICAL BIO MED, V49, P1638, DOI 10.1016/j.freeradbiomed.2010.08.013; Kehoe PG, 1999, NAT GENET, V21, P71, DOI 10.1038/5009; Kim DH, 2006, MECH AGEING DEV, V127, P719, DOI 10.1016/j.mad.2006.05.002; Kim YB, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-42; Klafki HW, 2006, BRAIN, V129, P2840, DOI 10.1093/brain/awl280; Koriyama Y, 2010, J NEUROCHEM, V115, P79, DOI 10.1111/j.1471-4159.2010.06903.x; Kovacs T, 2001, NEUROREPORT, V12, P285, DOI 10.1097/00001756-200102120-00021; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Laskowski A, 2005, BRAIN RES, V1037, P78, DOI 10.1016/j.brainres.2004.12.035; Lee JW, 2009, COOPERATION INTEGRIN; Lee KH, 2000, J FOOD DRUG ANAL, V8, P219; Li M, 2011, CHEMBIOCHEM, V12, P449, DOI 10.1002/cbic.201000570; Luo GA, 2006, SCI TECHNOL MOD TRAD, V8, P6; Luo LG, 2002, J ALZHEIMERS DIS, V4, P97, DOI 10.3233/JAD-2002-4204; Marchal-Victorion S, 2003, MOL CELL NEUROSCI, V24, P198, DOI 10.1016/S1044-7431(03)00161-1; Maser E, 2006, BIOCHEM BIOPH RES CO, V340, P1019, DOI 10.1016/j.bbrc.2005.12.113; Matt N, 2005, DEV DYNAM, V233, P167, DOI 10.1002/dvdy.20313; MELLOW AM, 1989, PSYCHOPHARMACOLOGY, V98, P403, DOI 10.1007/BF00451695; MIYAMOTO M, 1994, EUR J PHARMACOL, V271, P357; MORRISON RS, 1988, J NEUROSCI RES, V21, P71, DOI 10.1002/jnr.490210111; Nordberg A, 2001, ALZHEIMER'S DISEASE, P153, DOI 10.1002/0470846453.ch15; Ono K, 2004, EXP NEUROL, V189, P380, DOI 10.1016/j.expneurol.2004.05.035; Paspalas CD, 2009, CEREB CORTEX, V19, P1666, DOI 10.1093/cercor/bhn203; Pattnaik BR, 2009, AM J PHYSIOL-CELL PH, V297, pC1001, DOI 10.1152/ajpcell.00250.2009; Rangon CM, 2005, J PHARMACOL EXP THER, V314, P745, DOI 10.1124/jpet.105.086405; Rashid MA, 2010, FREE RADICAL BIO MED, V49, P1522, DOI 10.1016/j.freeradbiomed.2010.08.015; Reilly JF, 2003, P NATL ACAD SCI USA, V100, P4837, DOI 10.1073/pnas.0330745100; Sakurai T, 2006, BBA-MOL CELL RES, V1763, P290, DOI 10.1016/j.bbamcr.2006.02.007; Salama RHM, 2006, CANCER LETT, V233, P16, DOI 10.1016/j.canlet.2005.02.047; Sarang SS, 2002, PHYSIOL GENOMICS, V11, P45, DOI 10.1152/physiolgenomics.00064.2002; Sultana R, 2007, NEUROCHEM RES, V32, P655, DOI 10.1007/s11064-006-9123-x; Tak E, 2011, J HEPATOL, V54, P328, DOI 10.1016/j.jhep.2010.06.045; Takahashi J, 1999, J NEUROBIOL, V38, P65, DOI 10.1002/(SICI)1097-4695(199901)38:1<65::AID-NEU5>3.3.CO;2-H; Tanaka M, 2009, BIOL PHARM BULL, V32, P1220, DOI 10.1248/bpb.32.1220; Wang TW, 2005, DEVELOPMENT, V132, P2721, DOI 10.1242/dev.01867; Wellmann S, 2004, J CELL SCI, V117, P1785, DOI 10.1242/jcs.01026; Xiao Lin, 2005, Shengli Xuebao, V57, P705; Yamada M, 2003, THYROID, V13, P1111, DOI 10.1089/10507250360731505; Yamazaki M, 2009, BIOL PHARM BULL, V32, P1043, DOI 10.1248/bpb.32.1043; Yu J, 2009, CLIN EXP PHARMACOL P, V36, P539, DOI 10.1111/j.1440-1681.2008.05105.x; Zaben M, 2009, STEM CELLS, V27, P2539, DOI 10.1002/stem.184; Zannis VI, 2008, ANN MED, V40, P14, DOI 10.1080/07853890701687219; Zhang Zhan-jun, 2006, Chinese Pharmacological Bulletin, V22, P964; Zhang ZJ, 2006, THESIS BEIJING U TRA, P31; Zhao BQ, 2011, INT J PHARMACEUT, V405, P1, DOI 10.1016/j.ijpharm.2010.11.018; Zhong XG, 2004, BEI JING ZHONG YI YA, V27, P21; Zola SM, 2000, J NEUROSCI, V20, P451, DOI 10.1523/JNEUROSCI.20-01-00451.2000; Zou K, 2007, J NEUROSCI, V27, P8628, DOI 10.1523/JNEUROSCI.1549-07.2007	79	19	25	0	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2013	8	2							e56658	10.1371/journal.pone.0056658	http://dx.doi.org/10.1371/journal.pone.0056658			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	093IE	23437202	gold, Green Published			2023-01-03	WOS:000315184200132
J	Yamakawa, K; Matsumoto, N; Imamura, Y; Muroya, T; Yamada, T; Nakagawa, J; Shimazaki, J; Ogura, H; Kuwagata, Y; Shimazu, T				Yamakawa, Kazuma; Matsumoto, Naoya; Imamura, Yukio; Muroya, Takashi; Yamada, Tomoki; Nakagawa, Junichiro; Shimazaki, Junya; Ogura, Hiroshi; Kuwagata, Yasuyuki; Shimazu, Takeshi			Electrical Vagus Nerve Stimulation Attenuates Systemic Inflammation and Improves Survival in a Rat Heatstroke Model	PLOS ONE			English	Article							CHOLINERGIC ANTIINFLAMMATORY PATHWAY; TUMOR-NECROSIS-FACTOR; KAPPA-B ACTIVATION; HEAT-STRESS; RELEASE; INJURY; SHOCK; RESUSCITATION; ACETYLCHOLINE; ENDOTOXEMIA	This study was performed to gain insights into novel therapeutic approaches for the treatment of heatstroke. The central nervous system regulates peripheral immune responses via the vagus nerve, the primary neural component of the cholinergic anti-inflammatory pathway. Electrical vagus nerve stimulation (VNS) reportedly suppresses pro-inflammatory cytokine release in several models of inflammatory disease. Here, we evaluated whether electrical VNS attenuates severe heatstroke, which induces a systemic inflammatory response. Anesthetized rats were subjected to heat stress (41.5 degrees C for 30 minutes) with/without electrical VNS. In the VNS-treated group, the cervical vagus nerve was stimulated with constant voltage (10 V, 2 ms, 5 Hz) for 20 minutes immediately after completion of heat stress. Sham-operated animals underwent the same procedure without stimulation under a normothermic condition. Seven-day mortality improved significantly in the VNS-treated group versus control group. Electrical VNS significantly suppressed induction of pro-inflammatory cytokines such as tumor necrosis factor-alpha and interleukin-6 in the serum 6 hours after heat stress. Simultaneously, the increase of soluble thrombomodulin and E-selectin following heat stress was also suppressed by VNS treatment, suggesting its protective effect on endothelium. Immunohistochemical analysis using tissue preparations obtained 6 hours after heat stress revealed that VNS treatment attenuated infiltration of inflammatory (CD11b-positive) cells in lung and spleen. Interestingly, most cells with increased CD11b positivity in response to heat stress did not express alpha 7 nicotinic acetylcholine receptor in the spleen. These data indicate that electrical VNS modulated cholinergic anti-inflammatory pathway abnormalities induced by heat stress, and this protective effect was associated with improved mortality. These findings may provide a novel therapeutic strategy to combat severe heatstroke in the critical care setting.	[Yamakawa, Kazuma; Matsumoto, Naoya; Muroya, Takashi; Yamada, Tomoki; Nakagawa, Junichiro; Shimazaki, Junya; Ogura, Hiroshi; Kuwagata, Yasuyuki; Shimazu, Takeshi] Osaka Univ, Grad Sch Med, Dept Traumatol & Acute Crit Med, Osaka, Japan; [Imamura, Yukio] Kyoto Univ, Grad Sch Med, Unit Liveable Cities, Kyoto, Japan	Osaka University; Kyoto University	Yamakawa, K (corresponding author), Osaka Univ, Grad Sch Med, Dept Traumatol & Acute Crit Med, Osaka, Japan.	k.yamakawa0911@gmail.com	Yamakawa, Kazuma/AAD-3436-2022	Yamakawa, Kazuma/0000-0003-2999-4021	Ministry of Education, Culture, Sports, Science, and Technology in Japan [24791938]; Grants-in-Aid for Scientific Research [24592734, 24791938] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science, and Technology in Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported by a Grant-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science, and Technology in Japan (No. 24791938). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altavilla D, 2006, SHOCK, V25, P500, DOI 10.1097/01.shk.0000209539.91553.82; Bansal V, 2010, J TRAUMA, V68, P1059, DOI 10.1097/TA.0b013e3181d87373; Bernik TR, 2002, J VASC SURG, V36, P1231, DOI 10.1067/mva.2002.129643; Bernik TR, 2002, J EXP MED, V195, P781, DOI 10.1084/jem.20011714; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; BOUCHAMA A, 1991, J APPL PHYSIOL, V70, P2640, DOI 10.1152/jappl.1991.70.6.2640; Bouchama A, 2002, NEW ENGL J MED, V346, P1978, DOI 10.1056/NEJMra011089; BOUCHAMA A, 1995, INTENS CARE MED, V21, P623, DOI 10.1007/BF01711537; Bouchama A, 2008, ARTERIOSCL THROM VAS, V28, P1318, DOI 10.1161/ATVBAHA.107.161737; Cai BL, 2009, J CELL MOL MED, V13, P3774, DOI 10.1111/j.1582-4934.2008.00550.x; Chang CK, 2006, CURR MED CHEM, V13, P3145, DOI 10.2174/092986706778742945; Chen CC, 2009, AM J MED SCI, V338, P382, DOI 10.1097/MAJ.0b013e3181b272ae; Guarini S, 2003, CIRCULATION, V107, P1189, DOI 10.1161/01.CIR.0000050627.90734.ED; Hagiwara S, 2011, J SURG RES, V171, P762, DOI 10.1016/j.jss.2010.05.008; Hagiwara S, 2010, INFLAMM RES, V59, P511, DOI 10.1007/s00011-009-0155-y; Hagiwara S, 2010, SHOCK, V33, P282, DOI 10.1097/SHK.0b013e3181b0ef7b; Hsiao SH, 2007, RESUSCITATION, V73, P437, DOI 10.1016/j.resuscitation.2006.11.003; Huang H, 2009, VET IMMUNOL IMMUNOP, V132, P116, DOI 10.1016/j.vetimm.2009.05.003; Huston JM, 2006, J EXP MED, V203, P1623, DOI 10.1084/jem.20052362; Kondo Masahide, 2011, Environ Health Prev Med, V16, P279, DOI 10.1007/s12199-011-0228-8; Leon LR, 2010, J APPL PHYSIOL, V109, P1980, DOI 10.1152/japplphysiol.00301.2010; Niederbichler AD, 2009, BURNS, V35, P783, DOI 10.1016/j.burns.2008.08.023; Nybo L, 2007, PROG BRAIN RES, V162, P29, DOI 10.1016/S0079-6123(06)62003-7; Pohanka M, 2011, CURR MED CHEM, V18, P539, DOI 10.2174/092986711794480140; Roberts GT, 2008, ARTERIOSCL THROM VAS, V28, P1130, DOI 10.1161/ATVBAHA.107.158709; Saeed RW, 2005, J EXP MED, V201, P1113, DOI 10.1084/jem.20040463; Sharma HS, 2005, INDIAN J MED RES, V121, P621; Shen KH, 2008, SHOCK, V30, P668, DOI 10.1097/SHK.0b013e31817538cb; Song XM, 2010, BURNS, V36, P75, DOI 10.1016/j.burns.2009.02.002; Swirski FK, 2009, SCIENCE, V325, P612, DOI 10.1126/science.1175202; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; van Westerloo DJ, 2005, J INFECT DIS, V191, P2138, DOI 10.1086/430323; Wang H, 2004, NAT MED, V10, P1216, DOI 10.1038/nm1124; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Wessler I, 2008, BRIT J PHARMACOL, V154, P1558, DOI 10.1038/bjp.2008.185	35	26	36	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2013	8	2							e56728	10.1371/journal.pone.0056728	http://dx.doi.org/10.1371/journal.pone.0056728			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104BU	23424673	Green Submitted, Green Published, gold			2023-01-03	WOS:000315965100061
J	Vaneckova, P; Bambrick, H				Vaneckova, Pavla; Bambrick, Hilary			Cause-Specific Hospital Admissions on Hot Days in Sydney, Australia	PLOS ONE			English	Article							HEAT-RELATED MORTALITY; CASE-CROSSOVER; CARDIOVASCULAR-DISEASES; HIGH-TEMPERATURES; SOUTH-AUSTRALIA; AIR-POLLUTION; WAVE; RISK; DEATHS; PEOPLE	Background: While morbidity outcomes for major disease categories during extreme heat have received increasing research attention, there has been very limited investigation at the level of specific disease subcategories. Methodology/Principal Findings: We analyzed daily hospital admissions for cardiovascular (CVD), respiratory (RD), genitourinary (GU) and mental diseases (MD), diabetes (DIA), dehydration (DEH) and 'the effects of heat and light' (HEAT) in Sydney between 1991 and 2009. We further investigated the sensitivity to heat of subcategories within the major disease groups. We defined hot days as those with temperatures in the 95th and 99th percentiles within the study period. We applied time-stratified case-crossover analysis to compare the hospital admissions on hot days with those on non-hot days matched by day of the week. We calculated the odds ratios (OR) of admissions between the two types of days, accounting for other environmental variables (relative humidity, ozone and particulate matter) and non-environmental trends (public and school holidays). On hot days, hospital admissions increased for all major categories except GU. This increase was not shared homogeneously across all diseases within a major category: within RD, only 'other diseases of the respiratory system' (includes pleurisy or empyema) increased significantly, while admissions for asthma decreased. Within MD, hospital admissions increased only for psychoses. Admissions due to some major categories increased one to three days after a hot day (e.g., DIA, RD and CVD) and on two and three consecutive days (e.g., HEAT and RD). Conclusions/Significance: High ambient temperatures were associated with increased hospital admissions for several disease categories, with some within-category variation. Future analyses should focus on subgroups within broad disease categories to pinpoint medical conditions most affected by ambient heat.	[Vaneckova, Pavla; Bambrick, Hilary] Univ Western Sydney, Sch Med, Sydney, NSW, Australia	Western Sydney University	Vaneckova, P (corresponding author), Univ Western Sydney, Sch Med, Sydney, NSW, Australia.	p.vaneckova@uws.edu.au		Bambrick, Hilary/0000-0001-5361-950X; Vaneckova, Pavla/0000-0001-9213-8733	'Flagship: Urbanism, Climate Adaptation and Health Collaboration Cluster'; CSIRO Climate Adaptation	'Flagship: Urbanism, Climate Adaptation and Health Collaboration Cluster'; CSIRO Climate Adaptation	The CSIRO Climate Adaptation. This study was funded by the 'Flagship: Urbanism, Climate Adaptation and Health Collaboration Cluster' grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABS, 2012, 2001 CENS QUICKSTATS; Bark N, 1998, PSYCHIATR SERV, V49, P1088, DOI 10.1176/ps.49.8.1088; Barnett, 2010, ANAL SEASONAL HLTH D; Barnett AG, 2010, ENVIRON RES, V110, P604, DOI 10.1016/j.envres.2010.05.006; Batscha C L, 1997, J Psychosoc Nurs Ment Health Serv, V35, P12; Bayentin L, 2010, INT J HEALTH GEOGR, V9, DOI 10.1186/1476-072X-9-5; Bell ML, 2008, INT J EPIDEMIOL, V37, P796, DOI 10.1093/ije/dyn094; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Benton D, 2009, APPETITE, V53, P143, DOI 10.1016/j.appet.2009.05.006; Bouchama A, 2007, ARCH INTERN MED, V167, P2170, DOI 10.1001/archinte.167.20.ira70009; Bureau of Meteorology (BoM), 2012, CLIM DAT ONL; Carracedo-Martinez E, 2010, ENVIRON HEALTH PERSP, V118, P1173, DOI 10.1289/ehp.0901485; CSIRO, 2007, CLIM CHANG SYDN METR; Dematte JE, 1998, ANN INTERN MED, V129, P173, DOI 10.7326/0003-4819-129-3-199808010-00001; Ebi KL, 2004, INT J BIOMETEOROL, V49, P48, DOI 10.1007/s00484-004-0207-5; FAUNT JD, 1995, AUST NZ J MED, V25, P117, DOI 10.1111/j.1445-5994.1995.tb02822.x; Gasparrini A, 2012, OCCUP ENVIRON MED, V69, P56, DOI 10.1136/oem.2010.059782; Green RS, 2010, INT J PUBLIC HEALTH, V55, P113, DOI 10.1007/s00038-009-0076-0; Hansen A, 2008, ENVIRON HEALTH PERSP, V116, P1369, DOI 10.1289/ehp.11339; Hansen AL, 2008, INT J EPIDEMIOL, V37, P1359, DOI 10.1093/ije/dyn165; Johnson Helen, 2005, Health Stat Q, P6; Khalaj B, 2010, INT ARCH OCC ENV HEA, V83, P833, DOI 10.1007/s00420-010-0534-2; Knowlton K, 2009, ENVIRON HEALTH PERSP, V117, P61, DOI 10.1289/ehp.11594; Koken PJM, 2003, ENVIRON HEALTH PERSP, V111, P1312, DOI 10.1289/ehp.5957; Kovats RS, 2004, OCCUP ENVIRON MED, V61, P893, DOI 10.1136/oem.2003.012047; LAVIZZOMOUREY RJ, 1987, J NATL MED ASSOC, V79, P1033; Lin S, 2009, EPIDEMIOLOGY, V20, P738, DOI 10.1097/EDE.0b013e3181ad5522; Linares C, 2008, EUR J PUBLIC HEALTH, V18, P317, DOI 10.1093/eurpub/ckm108; Loughnan ME, 2008, INT J HEALTH GEOGR, V7, DOI 10.1186/1476-072X-7-42; Lu Y, 2008, EPIDEMIOLOGY, V19, P169, DOI 10.1097/EDE.0b013e3181632c24; Lu Y, 2007, BIOSTATISTICS, V8, P337, DOI 10.1093/biostatistics/kxl013; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; Martin-Latry K, 2007, EUR PSYCHIAT, V22, P335, DOI 10.1016/j.eurpsy.2007.03.007; Mastrangelo G, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-200; Michelozzi P, 2009, AM J RESP CRIT CARE, V179, P383, DOI 10.1164/rccm.200802-217OC; Naughton MP, 2002, AM J PREV MED, V22, P221, DOI 10.1016/S0749-3797(02)00421-X; Nitschke M, 2007, MED J AUSTRALIA, V187, P662, DOI 10.5694/j.1326-5377.2007.tb01466.x; Nitschke M, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-42; Nordon C, 2009, AM J GERIAT PSYCHIAT, V17, P1059, DOI 10.1097/JGP.0b013e3181b7ef6e; Page LA, 2012, BRIT J PSYCHIAT, V200, P485, DOI 10.1192/bjp.bp.111.100404; Panagiotakos DB, 2004, INT J CARDIOL, V94, P229, DOI 10.1016/j.ijcard.2003.04.050; Pudpong N, 2011, SCI TOTAL ENVIRON, V409, P5260, DOI 10.1016/j.scitotenv.2011.09.005; Ren CZ, 2006, ENVIRON HEALTH PERSP, V114, P1690, DOI 10.1289/ehp.9266; Rydman R J, 1999, J Med Syst, V23, P41, DOI 10.1023/A:1020871528086; Schwartz J, 2005, EPIDEMIOLOGY, V16, P67, DOI 10.1097/01.ede.0000147114.25957.71; Schwartz J, 2004, EPIDEMIOLOGY, V15, P755, DOI 10.1097/01.ede.0000134875.15919.0f; Semenza JC, 1999, AM J PREV MED, V16, P269, DOI 10.1016/S0749-3797(99)00025-2; Vaneckova P, 2011, J APPL METEOROL CLIM, V50, P1165, DOI 10.1175/2011JAMC2632.1; Wichmann J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022904; Williams S, 2012, SCI TOTAL ENVIRON, V414, P126, DOI 10.1016/j.scitotenv.2011.11.038; Ye XF, 2012, ENVIRON HEALTH PERSP, V120, P19, DOI [10.1289/ehp.1003198, 10.1289/ehp.120-a19]	51	67	68	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2013	8	2							e55459	10.1371/journal.pone.0055459	http://dx.doi.org/10.1371/journal.pone.0055459			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	092XV	23408986	gold, Green Submitted, Green Published			2023-01-03	WOS:000315157200032
J	Demichelis, VT; Vilcaes, AA; Iglesias-Bartolome, R; Ruggiero, FM; Daniotti, JL				Demichelis, Vanina Torres; Vilcaes, Aldo A.; Iglesias-Bartolome, Ramiro; Ruggiero, Fernando M.; Daniotti, Jose L.			Targeted Delivery of Immunotoxin by Antibody to Ganglioside GD3: A Novel Drug Delivery Route for Tumor Cells	PLOS ONE			English	Article							MONOCLONAL-ANTIBODY; INTRACELLULAR TRAFFICKING; PLASMA-MEMBRANE; CHO-K1 CELLS; EXPRESSION; MELANOMA; CYTOTOXICITY; SELECTIVITY; SYNTHASE; PROTEIN	Gangliosides are sialic acid-containing glycolipids expressed on plasma membranes from nearly all vertebrate cells. The expression of ganglioside GD3, which plays essential roles in normal brain development, decreases in adults but is up regulated in neuroectodermal and epithelial derived cancers. R24 antibody, directed against ganglioside GD3, is a validated tumor target which is specifically endocytosed and accumulated in endosomes. Here, we exploit the internalization feature of the R24 antibody for the selective delivery of saporin, a ribosome-inactivating protein, to GD3-expressing cells [human (SK-Mel-28) and mouse (B16) melanoma cells and Chinese hamster ovary (CHO)-K1 cells]. This immunotoxin showed a specific cytotoxicity on tumor cells grew on 2D monolayers, which was further evident by the lack of any effect on GD3-negative cells. To estimate the potential antitumor activity of R24-saporin complex, we also evaluated the effect of the immunotoxin on the clonogenic growth of SK-Mel-28 and CHO-K1(GD3+) cells cultured in attachment-free conditions. A drastic growth inhibition (>80-90%) of the cell colonies was reached after 3 days of immunotoxin treatment. By the contrary, colonies continue to growth at the same concentration of the immuntoxin, but in the absence of R24 antibody, or in the absence of both immunotoxin and R24, undoubtedly indicating the specificity of the effect observed. Thus, the ganglioside GD3 emerge as a novel and attractive class of cell surface molecule for targeted delivery of cytotoxic agents and, therefore, provides a rationale for future therapeutic intervention in cancer.	[Demichelis, Vanina Torres; Vilcaes, Aldo A.; Iglesias-Bartolome, Ramiro; Ruggiero, Fernando M.; Daniotti, Jose L.] Univ Nacl Cordoba, Ctr Invest Quim Biol Cordoba CIQUIBIC, UNC CONICET, Dept Quim Biol,Fac Ciencias Quim, RA-5000 Cordoba, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Cordoba	Daniotti, JL (corresponding author), Univ Nacl Cordoba, Ctr Invest Quim Biol Cordoba CIQUIBIC, UNC CONICET, Dept Quim Biol,Fac Ciencias Quim, RA-5000 Cordoba, Argentina.	daniotti@dqb.fcq.unc.edu.ar	Iglesias-Bartolome, Ramiro/H-4460-2014	Iglesias-Bartolome, Ramiro/0000-0002-0792-1254	Secretaria de Ciencia y Tecnologia (SECyT)-Universidad Nacional de Cordoba (UNC); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET, Argentina); Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT, Argentina)	Secretaria de Ciencia y Tecnologia (SECyT)-Universidad Nacional de Cordoba (UNC)(Secretaria de Ciencia y Tecnologia (SECYT)); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT)(ANPCyT); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET, Argentina)(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT, Argentina)(ANPCyT)	This work was supported in part by Grants from Secretaria de Ciencia y Tecnologia (SECyT)-Universidad Nacional de Cordoba (UNC) (www.secyt.unc.edu.ar), Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) (www.conicet.gov.ar) and Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT) (www.agencia.gov.ar). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors thank the technical assistance of G. Schachner, S. Deza, C. Sampedro and C. Mas. Rab5-GFP and Lamp1-GFP were generously supplied by J. Bonifacino (NICHD, National Institute of Health, Bethesda, MD, USA). V.T.D. and A.A.V. are recipients of Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET, Argentina) Fellowships. F.M.R. is recipient of Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT, Argentina) Fellowship. J.L.D. is Career Investigator of CONICET.	Allen TM, 2002, NAT REV CANCER, V2, P750, DOI 10.1038/nrc903; Alley SC, 2010, CURR OPIN CHEM BIOL, V14, P529, DOI 10.1016/j.cbpa.2010.06.170; Crespo PM, 2002, J BIOL CHEM, V277, P44731, DOI 10.1074/jbc.M204604200; Daniotti JL, 2000, J NEUROCHEM, V74, P1711, DOI 10.1046/j.1471-4159.2000.0741711.x; Daniotti JL, 2002, NEUROCHEM RES, V27, P1421, DOI 10.1023/A:1021684018665; Daniotti JL, 1997, INT J DEV NEUROSCI, V15, P767, DOI 10.1016/S0736-5748(97)00027-0; GRAVOTTA D, 1989, J NEUROCHEM, V52, P768, DOI 10.1111/j.1471-4159.1989.tb02521.x; Guillemard V, 2004, ONCOGENE, V23, P3613, DOI 10.1038/sj.onc.1207463; Guillemard V, 2001, CANCER RES, V61, P694; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; Iglesias-Bartolome R, 2006, FEBS J, V273, P1744, DOI 10.1111/j.1742-4658.2006.05194.x; Lee FT, 2001, CANCER RES, V61, P4474; Lo ASY, 2010, CLIN CANCER RES, V16, P2769, DOI 10.1158/1078-0432.CCR-10-0043; Daniotti JL, 2011, IUBMB LIFE, V63, P513, DOI 10.1002/iub.477; Nasi ML, 1997, MELANOMA RES, V7, pS155; Polito I, 2004, LEUKEMIA, V18, P1215, DOI 10.1038/sj.leu.2403378; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; RAVINDRANATH M H, 1991, International Reviews of Immunology, V7, P303, DOI 10.3109/08830189109114877; SCHENGRUND CL, 1988, NEUROCHEM PATHOL, V8, P189; STIRPE F, 1992, BIO-TECHNOL, V10, P405, DOI 10.1038/nbt0492-405; Thomas PB, 2002, J PEDIATR SURG, V37, P539, DOI 10.1053/jpsu.2002.30856	21	12	12	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2013	8	1							e55304	10.1371/journal.pone.0055304	http://dx.doi.org/10.1371/journal.pone.0055304			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	085JH	23383146	Green Published, gold			2023-01-03	WOS:000314610600085
J	Bidwell, GL; Perkins, E; Hughes, J; Khan, M; James, JR; Raucher, D				Bidwell, Gene L., III; Perkins, Eddie; Hughes, Joshua; Khan, Majid; James, Judy R.; Raucher, Drazen			Thermally Targeted Delivery of a c-Myc Inhibitory Polypeptide Inhibits Tumor Progression and Extends Survival in a Rat Glioma Model	PLOS ONE			English	Article							INTENSITY FOCUSED ULTRASOUND; ELASTIN-LIKE POLYPEPTIDE; CANCER-CELL-PROLIFERATION; DRUG-DELIVERY; GLIOBLASTOMA-MULTIFORME; GENETIC ALTERATIONS; SOLID TUMORS; PEPTIDE; DIFFERENTIATION; ACCUMULATION	Treatment of glioblastoma is complicated by the tumors' high resistance to chemotherapy, poor penetration of drugs across the blood brain barrier, and damaging effects of chemotherapy and radiation to normal neural tissue. To overcome these limitations, a thermally responsive polypeptide was developed for targeted delivery of therapeutic peptides to brain tumors using focused hyperthermia. The peptide carrier is based on elastin-like polypeptide (ELP), which is a thermally responsive biopolymer that forms aggregates above a characteristic transition temperature. ELP was modified with cell penetrating peptides (CPPs) to enhance delivery to brain tumors and mediate uptake across the tumor cells' plasma membranes and with a peptide inhibitor of c-Myc (H1). In rats with intracerebral gliomas, brain tumor targeting of ELP following systemic administration was enhanced up to 5-fold by the use of CPPs. When the lead CPP-ELP-fused c-Myc inhibitor was combined with focused hyperthermia of the tumors, an additional 3 fold increase in tumor polypeptide levels was observed, and 80% reduction in tumor volume, delayed onset of tumor-associated neurological deficits, and at least doubled median survival time including complete regression in 80% of animals was achieved. This work demonstrates that a c-Myc inhibitory peptide can be effectively delivered to brain tumors.	[Bidwell, Gene L., III; Khan, Majid] Univ Mississippi, Med Ctr, Dept Neurol, Jackson, MS 39216 USA; [Bidwell, Gene L., III; Perkins, Eddie; Raucher, Drazen] Univ Mississippi, Med Ctr, Inst Canc, Jackson, MS 39216 USA; [Perkins, Eddie; Hughes, Joshua] Univ Mississippi, Med Ctr, Dept Neurosurg, Jackson, MS 39216 USA; [Perkins, Eddie] Univ Mississippi, Med Ctr, Dept Neurobiol & Anat Sci, Jackson, MS 39216 USA; [Khan, Majid; James, Judy R.] Univ Mississippi, Med Ctr, Dept Radiol, Jackson, MS 39216 USA; [Raucher, Drazen] Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center	Raucher, D (corresponding author), Univ Mississippi, Med Ctr, Inst Canc, Jackson, MS 39216 USA.	draucher@umc.edu	Raucher, Drazen/AAE-4540-2022	Khan, Majid/0000-0002-3807-1387; Hughes, Joshua/0000-0003-0362-302X; Bidwell, Gene/0000-0001-9104-150X	Department of Defense Breast Cancer Research Program fellowship [W81XWH-08-1-0647]; National Science Foundation [CBET-0931041]; National Institutes of Health (NIH) National Cancer Institute [R21 CA139589-01]; NIH from the MFGN INBRE Program of the National Center for Research Resources [RR016476]; NATIONAL CANCER INSTITUTE [R21CA139589] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016476] Funding Source: NIH RePORTER	Department of Defense Breast Cancer Research Program fellowship(United States Department of Defense); National Science Foundation(National Science Foundation (NSF)); National Institutes of Health (NIH) National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH from the MFGN INBRE Program of the National Center for Research Resources; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Funding for these studies was provided by a Department of Defense Breast Cancer Research Program fellowship [W81XWH-08-1-0647] to GLB, National Science Foundation grant [CBET-0931041] to DR, and National Institutes of Health (NIH) National Cancer Institute grant [R21 CA139589-01] to DR. The authors thank the Mississippi Functional Genomics Network (MFGN) Genomics Facility, which is supported by NIH Grant # RR016476 from the MFGN INBRE Program of the National Center for Research Resources, for access to and assistance with slide scanning. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barth RF, 2009, J NEURO-ONCOL, V94, P299, DOI 10.1007/s11060-009-9875-7; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Bidwell GL, 2012, CANCER LETT, V319, P136, DOI 10.1016/j.canlet.2011.12.042; Bidwell GL, 2010, ADV DRUG DELIVER REV, V62, P1486, DOI 10.1016/j.addr.2010.05.003; Bidwell GL, 2010, PEPTIDES, V31, P834, DOI 10.1016/j.peptides.2010.02.007; Bidwell GL, 2009, EXPERT OPIN DRUG DEL, V6, P1033, DOI 10.1517/17425240903143745; Bidwell GL, 2009, J CONTROL RELEASE, V135, P2, DOI 10.1016/j.jconrel.2008.11.015; Bidwell GL, 2006, BIOCHEM PHARMACOL, V71, P248, DOI 10.1016/j.bcp.2005.10.041; Bidwell GL, 2005, MOL CANCER THER, V4, P1076, DOI 10.1158/1535-7163.MCT-04-0253; Chilkoti A, 2002, ADV DRUG DELIVER REV, V54, P1093, DOI 10.1016/S0169-409X(02)00060-1; DRAEGER LJ, 1994, J BIOL CHEM, V269, P1785; Dreher MR, 2007, CANCER RES, V67, P4418, DOI 10.1158/0008-5472.CAN-06-4444; Gorin F, 2004, ACTA NEUROPATHOL, V107, P235, DOI 10.1007/s00401-003-0803-1; Grobben B, 2002, CELL TISSUE RES, V310, P257, DOI 10.1007/s00441-002-0651-7; Herms JW, 1999, SURG NEUROL, V51, P536, DOI 10.1016/S0090-3019(98)00028-7; Hou Lewis C, 2006, Neurosurg Focus, V20, pE5; Jolesz FA, 2008, J MAGN RESON IMAGING, V27, P391, DOI 10.1002/jmri.21261; Jolesz FA, 2009, ANNU REV MED, V60, P417, DOI 10.1146/annurev.med.60.041707.170303; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; Lefranc F, 2006, EXPERT REV ANTICANC, V6, P719, DOI 10.1586/14737140.6.5.719; Lipka E, 1996, J CONTROL RELEASE, V39, P121, DOI 10.1016/0168-3659(95)00145-X; Liu WE, 2006, J CONTROL RELEASE, V116, P170, DOI 10.1016/j.jconrel.2006.06.026; Maeda H, 2001, ADV ENZYME REGUL, V41, P189, DOI 10.1016/S0065-2571(00)00013-3; Marquet F, 2009, PHYS MED BIOL, V54, P2597, DOI 10.1088/0031-9155/54/9/001; Massodi I, 2005, J CONTROL RELEASE, V108, P396, DOI 10.1016/j.jconrel.2005.08.007; Massodi I, 2010, INT J CANCER, V126, P533, DOI 10.1002/ijc.24725; Massodi I, 2009, MOLECULES, V14, P1999, DOI 10.3390/molecules14061999; Meyer DE, 2001, CANCER RES, V61, P1548; ORIAN JM, 1992, BRIT J CANCER, V66, P106, DOI 10.1038/bjc.1992.225; Panicker SP, 2010, ONCOTARGET, V1, P289; Partanen A, 2012, INT J HYPERTHER, V28, P320, DOI 10.3109/02656736.2012.680173; Paul I, 2012, ONCOGENE; Pourquier P, 1998, BIOCHEM PHARMACOL, V55, P1963, DOI 10.1016/S0006-2952(98)00006-9; Raucher D, 2009, EXPERT OPIN DRUG DEL, V6, P1049, DOI 10.1517/17425240903158909; Rousselle C, 2000, MOL PHARMACOL, V57, P679, DOI 10.1124/mol.57.4.679; Sadler K, 2002, BIOCHEMISTRY-US, V41, P14150, DOI 10.1021/bi026661l; Smith JS, 2000, FRONT BIOSCI-LANDMRK, V5, pD213, DOI 10.2741/Smith; Talmadge JE, 1998, ADV DRUG DELIVER REV, V33, P241, DOI 10.1016/S0169-409X(98)00032-5; Thuroff S, 2003, J ENDOUROL, V17, P673, DOI 10.1089/089277903322518699; Wang JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003769; Wang X, 2002, CHINESE MED J-PEKING, V115, P1332; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443	42	80	83	2	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2013	8	1							e55104	10.1371/journal.pone.0055104	http://dx.doi.org/10.1371/journal.pone.0055104			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	093RV	23372821	Green Published, Green Submitted, gold			2023-01-03	WOS:000315210400063
J	Gao, Y; Zhu, J; Zhang, XH; Wu, QQ; Jiang, SN; Liu, YQ; Hu, ZB; Liu, BR; Chen, XF				Gao, Yong; Zhu, Jing; Zhang, Xiaohui; Wu, Qingquan; Jiang, Shaoning; Liu, Yangqing; Hu, Zhibin; Liu, Baorui; Chen, Xiaofei			BRCA1 mRNA Expression as a Predictive and Prognostic Marker in Advanced Esophageal Squamous Cell Carcinoma Treated with Cisplatin- or Docetaxel-Based Chemotherapy/Chemoradiotherapy	PLOS ONE			English	Article							DNA-REPAIR; TRIMODALITY THERAPY; LUNG-CANCER; PHASE-II; CHEMOTHERAPY; ERCC1; SURVIVAL; CHEMOSENSITIVITY; CHEMORESISTANCE; INACTIVATION	Background: The molecular backgrounds that determine therapeutic effectiveness in esophageal cancer remain largely unknown. Breast cancer susceptibility gene 1 (BRCA1) expression has been found to switch the response to cisplatin- or paclitaxel-based chemotherapy. It remains unclear how variations in BRCA1 expression influence clinical outcomes in esophageal cancer. Patients and Methods: Quantitative real-time polymerase chain reaction (qPCR) was performed to examine BRCA1 mRNA expressions in paraffin-embedded specimens from 144 patients with advanced or metastatic esophageal squamous cell carcinoma who received cisplatin- or docetaxel-based first-line treatments. Results: Low BRCA1 mRNA expression correlated with increased response rate (RR; P = 0.025 and 0.017, respectively) and median overall survival (mOS; P = 0.002 and P<0.001, respectively) in cisplatin-based chemotherapy or chemoradiotherapy group and also correlated with decreased RR (P = 0.017 and 0.024, respectively) and mOS (both P<0.001) in docetaxel-based chemotherapy or chemoradiotherapy group. Multivariate analysis revealed that low BRCA1 expression was an independent prognostic factor in cisplatin-based chemotherapy (HR 0.29; 95%CI 0.12-0.71; P = 0.007) or chemoradiotherapy (HR 0.12; 95%CI 0.04-0.37; P<0.001) group and higher risk for mortality in docetaxel-based chemotherapy (HR 5.02; 95%CI 2.05-12.28; P<0.001) or chemoradiotherapy (HR 7.02; 95%CI 2.37-27.77; P<0.001) group. Conclusions: BRCA1 mRNA expression could be used as a predictive and prognostic marker in esophageal cancer who underwent first-line cisplatin- or docetaxel-based treatments.	[Gao, Yong; Zhu, Jing; Zhang, Xiaohui; Liu, Yangqing; Chen, Xiaofei] Nanjing Med Univ, Huaian Peoples Hosp 1, Dept Med Oncol, Huaian, Peoples R China; [Wu, Qingquan] Nanjing Med Univ, Huaian Peoples Hosp 1, Dept Thorac Surg, Huaian, Peoples R China; [Jiang, Shaoning] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Hu, Zhibin] Nanjing Med Univ, Dept Epidemiol & Biostat, Nanjing, Jiangsu, Peoples R China; [Liu, Baorui] Nanjing Med Univ, Gulou Sch Clin Med, Ctr Comprehens Canc, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University; University of Alabama System; University of Alabama Birmingham; Nanjing Medical University; Nanjing Medical University	Liu, BR (corresponding author), Nanjing Med Univ, Gulou Sch Clin Med, Ctr Comprehens Canc, Nanjing, Jiangsu, Peoples R China.	baoruiliu@hotmail.com; hayycxf@163.com			Science Developing Foundation of Nanjing Medical University [09NJMUM063]; Science Developing Foundation of Huaian Government [HAS2011028]	Science Developing Foundation of Nanjing Medical University; Science Developing Foundation of Huaian Government	This work was supported in part by Science Developing Foundation of Nanjing Medical University (09NJMUM063 to Y.G.) and Science Developing Foundation of Huaian Government (HAS2011028 to X.F.C.). The funders had no role in study design, data collection and analysis.	AJANI JA, 1994, J NATL CANCER I, V86, P1086, DOI 10.1093/jnci/86.14.1086; Alexander BM, 2012, INT J RADIAT ONCOL, V83, P164, DOI 10.1016/j.ijrobp.2011.05.033; Byrski T, 2009, BREAST CANCER RES TR, V115, P359, DOI 10.1007/s10549-008-0128-9; Byrski T, 2010, J CLIN ONCOL, V28, P375, DOI 10.1200/JCO.2008.20.7019; Carser JE, 2011, GYNECOL ONCOL, V123, P492, DOI 10.1016/j.ygyno.2011.08.017; Chabalier C, 2006, CELL CYCLE, V5, P1001, DOI 10.4161/cc.5.9.2726; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; EZDINLI EZ, 1980, CANCER, V46, P2149, DOI 10.1002/1097-0142(19801115)46:10<2149::AID-CNCR2820461006>3.0.CO;2-W; Furuta T, 2002, CANCER RES, V62, P4899; Harpole DH, 2001, CLIN CANCER RES, V7, P562; Huen MSY, 2010, NAT REV MOL CELL BIO, V11, P138, DOI 10.1038/nrm2831; Husain A, 1998, CANCER RES, V58, P1120; Ilson DH, 1998, J CLIN ONCOL, V16, P1826, DOI 10.1200/JCO.1998.16.5.1826; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Joshi MBM, 2005, CLIN CANCER RES, V11, P2215; Kennedy RD, 2002, LANCET, V360, P1007, DOI 10.1016/S0140-6736(02)11087-7; Lafarge S, 2001, ONCOGENE, V20, P6597, DOI 10.1038/sj.onc.1204812; LEICHMAN L, 1991, SEMIN ONCOL, V18, P64; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Mullan PB, 2001, ONCOGENE, V20, P6123, DOI 10.1038/sj.onc.1204712; Muro K, 2004, ANN ONCOL, V15, P955, DOI 10.1093/annonc/mdh231; Olaussen KA, 2006, NEW ENGL J MED, V355, P983, DOI 10.1056/NEJMoa060570; PANETTIERE FJ, 1984, CANCER TREAT REP, V68, P1023; Papadaki C, 2011, BRIT J CANCER, V104, P316, DOI 10.1038/sj.bjc.6606027; Quinn JE, 2003, CANCER RES, V63, P6221; Rosell R, 2003, ONCOGENE, V22, P3548, DOI 10.1038/sj.onc.1206419; Rosell R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005133; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Santarosa M, 2009, MOL CANCER THER, V8, P844, DOI 10.1158/1535-7163.MCT-08-0951; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Shibata T, 2011, NEOPLASIA, V13, P864, DOI 10.1593/neo.11750; Shim HJ, 2010, CANCER SCI, V101, P1247, DOI 10.1111/j.1349-7006.2010.01514.x; Taron M, 2004, HUM MOL GENET, V13, P2443, DOI 10.1093/hmg/ddh260; Tassone P, 2003, BRIT J CANCER, V88, P1285, DOI 10.1038/sj.bjc.6600859; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Wang LF, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-97; Weberpals JI, 2011, ANN ONCOL, V22, P2403, DOI 10.1093/annonc/mdq770; Weberpals J, 2009, INT J CANCER, V124, P806, DOI 10.1002/ijc.23987; Wei J, 2011, J NATL CANCER I, V103, P1552, DOI 10.1093/jnci/djr326; Yun MH, 2009, NATURE, V459, P460, DOI 10.1038/nature07955	40	40	42	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2013	8	1							e52589	10.1371/journal.pone.0052589	http://dx.doi.org/10.1371/journal.pone.0052589			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	070YR	23326344	Green Published, Green Submitted, gold			2023-01-03	WOS:000313551500022
J	Firth, P; Ttendo, S				Firth, Paul; Ttendo, Stephen			Intensive Care in Low-Income Countries - A Critical Need	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							AFRICA		[Firth, Paul] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA; [Ttendo, Stephen] Mbarara Reg Referral Hosp, Dept Anaesthesia & Crit Care, Mbarara, Uganda	Harvard University; Massachusetts General Hospital	Firth, P (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.			Firth, Paul/0000-0003-1909-5225				[Anonymous], 2011, BMJ-BRIT MED J, DOI DOI 10.1136/bmj.d7031; Central Intelligence Agency, WORLD FACTB; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Riviello ED, 2011, CRIT CARE MED, V39, P860, DOI 10.1097/CCM.0b013e318206d6d5; Towey RM, 2008, AFR HEALTH SCI, V8, P61	5	47	47	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 22	2012	367	21					1974	1976		10.1056/NEJMp1204957	http://dx.doi.org/10.1056/NEJMp1204957			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	040RI	23171093				2023-01-03	WOS:000311340200003
J	Neto, AS; Cardoso, SO; Manetta, JA; Pereira, VGM; Esposito, DC; Pasqualucci, MDP; Damasceno, MCT; Schultz, MJ				Neto, Ary Serpa; Cardoso, Sergio Oliveira; Manetta, Jose Antonio; Moura Pereira, Victor Galvao; Esposito, Daniel Crepaldi; Prado Pasqualucci, Manoela de Oliveira; Toledo Damasceno, Maria Cecilia; Schultz, Marcus J.			Association Between Use of Lung-Protective Ventilation With Lower Tidal Volumes and Clinical Outcomes Among Patients Without Acute Respiratory Distress Syndrome A Meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED-TRIAL; MECHANICAL VENTILATION; CARDIOPULMONARY BYPASS; CARDIAC-SURGERY; INFLAMMATORY RESPONSES; GENERAL-ANESTHESIA; CANCER SURGERY; RISK-FACTOR; INJURY; PULMONARY	Context Lung-protective mechanical ventilation with the use of lower tidal volumes has been found to improve outcomes of patients with acute respiratory distress syndrome (ARDS). It has been suggested that use of lower tidal volumes also benefits patients who do not have ARDS. Objective To determine whether use of lower tidal volumes is associated with improved outcomes of patients receiving ventilation who do not have ARDS. Data Sources MEDLINE, CINAHL, Web of Science, and Cochrane Central Register of Controlled Trials up to August 2012. Study Selection Eligible studies evaluated use of lower vs higher tidal volumes in patients without ARDS at onset of mechanical ventilation and reported lung injury development, overall mortality, pulmonary infection, atelectasis, and biochemical alterations. Data Extraction Three reviewers extracted data on study characteristics, methods, and outcomes. Disagreement was resolved by consensus. Data Synthesis Twenty articles (2822 participants) were included. Meta-analysis using a fixed-effects model showed a decrease in lung injury development (risk ratio [RR], 0.33; 95% CI, 0.23 to 0.47; I-2, 0%; number needed to treat [NNT], 11), and mortality (RR, 0.64; 95% CI, 0.46 to 0.89; I-2, 0%; NNT, 23) in patients receiving ventilation with lower tidal volumes. The results of lung injury development were similar when stratified by the type of study (randomized vs nonrandomized) and were significant only in randomized trials for pulmonary infection and only in nonrandomized trials for mortality. Meta-analysis using a random-effects model showed, in protective ventilation groups, a lower incidence of pulmonary infection (RR, 0.45; 95% CI, 0.22 to 0.92; I-2, 32%; NNT, 26), lower mean (SD) hospital length of stay (6.91 [2.36] vs 8.87 [2.93] days, respectively; standardized mean difference [SMD], 0.51; 95% CI, 0.20 to 0.82; I-2, 75%), higher mean (SD) PaCO2 levels (41.05 [3.79] vs 37.90 [4.19] mm Hg, respectively; SMD, -0.51; 95% CI, -0.70 to -0.32; I-2, 54%), and lower mean (SD) pH values (7.37 [0.03] vs 7.40 [0.04], respectively; SMD, 1.16; 95% CI, 0.31 to 2.02; I-2, 96%) but similar mean (SD) ratios of PaO2 to fraction of inspired oxygen (304.40 [65.7] vs 312.97 [68.13], respectively; SMD, 0.11; 95% CI, -0.06 to 0.27; I-2, 60%). Tidal volume gradients between the 2 groups did not influence significantly the final results. Conclusions Among patients without ARDS, protective ventilation with lower tidal volumes was associated with better clinical outcomes. Some of the limitations of the meta-analysis were the mixed setting of mechanical ventilation (intensive care unit or operating room) and the duration of mechanical ventilation. JAMA. 2012;308(16):1651-1659 www.jama.com	[Neto, Ary Serpa; Cardoso, Sergio Oliveira; Manetta, Jose Antonio; Moura Pereira, Victor Galvao; Esposito, Daniel Crepaldi; Toledo Damasceno, Maria Cecilia] ABC Med Sch, Dept Crit Care Med, Sao Paulo, Brazil; [Schultz, Marcus J.] Univ Amsterdam, Acad Med Ctr, Dept Intens Care Med, NL-1105 AZ Amsterdam, Netherlands; [Toledo Damasceno, Maria Cecilia] Univ Sao Paulo, Dept Internal Med, Hosp Clin, Sao Paulo, Brazil; [Schultz, Marcus J.] Univ Amsterdam, Acad Med Ctr, Lab Expt Intens Care & Anesthesiol, NL-1105 AZ Amsterdam, Netherlands	Faculdade de Medicina do ABC; University of Amsterdam; Academic Medical Center Amsterdam; Universidade de Sao Paulo; University of Amsterdam; Academic Medical Center Amsterdam	Neto, AS (corresponding author), Av Lauro Gomes, BR-2000 Sao Paulo, Brazil.	aryserpa@terra.com.br	Schultz, Marcus J/K-6147-2012; Schultz, Marcus/AAB-6379-2021; Serpa Neto, Ary/D-1927-2012	Schultz, Marcus/0000-0003-3969-7792; Serpa Neto, Ary/0000-0003-1520-9387				Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Baudouin SV, 2001, THORAX, V56, P50; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Brun-Buisson C, 2004, INTENS CARE MED, V30, P51, DOI 10.1007/s00134-003-2022-6; Cai HW, 2007, J CLIN ANESTH, V19, P125, DOI 10.1016/j.jclinane.2006.08.008; Carney David, 2005, Crit Care Med, V33, pS122, DOI 10.1097/01.CCM.0000155928.95341.BC; Chaney MA, 2000, J CARDIOTHOR VASC AN, V14, P514, DOI 10.1053/jcan.2000.9487; Checkley W, 2008, AM J RESP CRIT CARE, V177, P1215, DOI 10.1164/rccm.200709-1424OC; de Oliveira RP, 2010, CRIT CARE, V14, DOI 10.1186/cc8919; de Prost N, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-28; Determann RM, 2008, AM J PHYSIOL-LUNG C, V294, pL344, DOI 10.1152/ajplung.00268.2007; Determann RM, 2010, CRIT CARE, V14, DOI 10.1186/cc8230; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Fernandez-Bustamante A, 2011, BMC ANESTHESIOL, V11, DOI 10.1186/1471-2253-11-22; Fernandez-Perez ER, 2006, ANESTHESIOLOGY, V105, P14, DOI 10.1097/00000542-200607000-00007; Gajic O, 2005, INTENS CARE MED, V31, P922, DOI 10.1007/s00134-005-2625-1; Gajic O, 2004, CRIT CARE MED, V32, P1817, DOI 10.1097/01.CCM.0000133019.52531.30; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE; Hager DN, 2005, AM J RESP CRIT CARE, V172, P1241, DOI 10.1164/rccm.200501-048CP; Koner O, 2004, INTENS CARE MED, V30, P620, DOI 10.1007/s00134-003-2104-5; LEE PC, 1990, CHEST, V97, P430, DOI 10.1378/chest.97.2.430; Lellouche F, 2012, ANESTHESIOLOGY, V116, P1072, DOI 10.1097/ALN.0b013e3182522df5; Licker M, 2009, CRIT CARE, V13, DOI 10.1186/cc7762; Lin Wen-Qian, 2008, Ai Zheng, V27, P870; Michelet P, 2006, ANESTHESIOLOGY, V105, P911, DOI 10.1097/00000542-200611000-00011; Mikkelsen ME, 2008, RESP CARE, V53, P455; Plotz FB, 2004, INTENS CARE MED, V30, P1865, DOI 10.1007/s00134-004-2363-9; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Schultz MJ, 2007, ANESTHESIOLOGY, V106, P1226, DOI 10.1097/01.anes.0000267607.25011.e8; Sundar S, 2011, ANESTHESIOLOGY, V114, P1102, DOI 10.1097/ALN.0b013e318215e254; Weingarten TN, 2010, BRIT J ANAESTH, V104, P16, DOI 10.1093/bja/aep319; Wolthuis EK, 2007, CRIT CARE, V11, DOI 10.1186/cc5969; Wrigge H, 2004, ANESTH ANALG, V98, P775; Wrigge H, 2005, INTENS CARE MED, V31, P1379, DOI 10.1007/s00134-005-2767-1; Yang M, 2011, CHEST, V139, P530, DOI 10.1378/chest.09-2293; Yilmaz M, 2007, CRIT CARE MED, V35, P1660, DOI 10.1097/01.CCM.0000269037.66955.F0; Zupancich E, 2005, J THORAC CARDIOV SUR, V130, P378, DOI 10.1016/j.jtcvs.2004.11.061	38	521	536	4	47	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 24	2012	308	16					1651	1659		10.1001/jama.2012.13730	http://dx.doi.org/10.1001/jama.2012.13730			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	028PI	23093163	Bronze			2023-01-03	WOS:000310434100019
J	McKenney, ES; Sargent, M; Khan, H; Uh, E; Jackson, ER; San Jose, G; Couch, RD; Dowd, CS; van Hoek, ML				McKenney, Elizabeth S.; Sargent, Michelle; Khan, Hameed; Uh, Eugene; Jackson, Emily R.; San Jose, Geraldine; Couch, Robin D.; Dowd, Cynthia S.; van Hoek, Monique L.			Lipophilic Prodrugs of FR900098 Are Antimicrobial against Francisella novicida In Vivo and In Vitro and Show GlpT Independent Efficacy	PLOS ONE			English	Article							PHOSPHONIC ACID ANTIBIOTICS; ESCHERICHIA-COLI; ISOPRENOID BIOSYNTHESIS; GLYCEROL-3-PHOSPHATE TRANSPORTER; MYCOBACTERIUM-TUBERCULOSIS; FOSMIDOMYCIN RESISTANCE; PLASMODIUM-FALCIPARUM; ANTIMALARIAL ACTIVITY; DRUG-RESISTANCE; ESTER PRODRUGS	Bacteria, plants, and algae produce isoprenoids through the methylerythritol phosphate (MEP) pathway, an attractive pathway for antimicrobial drug development as it is present in prokaryotes and some lower eukaryotes but absent from human cells. The first committed step of the MEP pathway is catalyzed by 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR/MEP synthase). MEP pathway genes have been identified in many biothreat agents, including Francisella, Brucella, Bacillus, Burkholderia, and Yersinia. The importance of the MEP pathway to Francisella is demonstrated by the fact that MEP pathway mutations are lethal. We have previously established that fosmidomycin inhibits purified MEP synthase (DXR) from F. tularensis LVS. FR900098, the acetyl derivative of fosmidomycin, was found to inhibit the activity of purified DXR from F. tularensis LVS (IC50 = 230 nM). Fosmidomycin and FR900098 are effective against purified DXR from Mycobacterium tuberculosis as well, but have no effect on whole cells because the compounds are too polar to penetrate the thick cell wall. Fosmidomycin requires the GlpT transporter to enter cells, and this is absent in some pathogens, including M. tuberculosis. In this study, we have identified the GlpT homologs in F. novicida and tested transposon insertion mutants of glpT. We showed that FR900098 also requires GlpT for full activity against F. novicida. Thus, we synthesized several FR900098 prodrugs that have lipophilic groups to facilitate their passage through the bacterial cell wall and bypass the requirement for the GlpT transporter. One compound, that we termed "compound 1", was found to have GlpT-independent antimicrobial activity. We tested the ability of this best performing prodrug to inhibit F. novicida intracellular infection of eukaryotic cell lines and the caterpillar Galleria mellonella as an in vivo infection model. As a lipophilic GlpT-independent DXR inhibitor, compound 1 has the potential to be a broad-spectrum antibiotic, and should be effective against most MEP-dependent organisms.	[McKenney, Elizabeth S.; van Hoek, Monique L.] George Mason Univ, Sch Syst Biol, Manassas, VA USA; [Sargent, Michelle; Khan, Hameed; Couch, Robin D.] George Mason Univ, Dept Chem & Biochem, Manassas, VA USA; [Uh, Eugene; Jackson, Emily R.; San Jose, Geraldine; Dowd, Cynthia S.] George Washington Univ, Dept Chem, Washington, DC 20052 USA; [Couch, Robin D.; van Hoek, Monique L.] George Mason Univ, Natl Ctr Biodefense & Infect Dis, Manassas, VA USA	George Mason University; George Mason University; George Washington University; George Mason University	van Hoek, ML (corresponding author), George Mason Univ, Sch Syst Biol, Manassas, VA USA.	mvanhoek@gmu.edu	van Hoek, Monique/E-1629-2011	van Hoek, Monique/0000-0003-1679-4899	Defense Threat Reduction Agency [HDTRA1-11-1-054]; National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) [RC1AI086453]; GWU Department of Chemistry; U.S. Army Medical Research and Materiel Command [W23RYX1291N601]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [RC1AI086453] Funding Source: NIH RePORTER	Defense Threat Reduction Agency(United States Department of DefenseDefense Threat Reduction Agency); National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); GWU Department of Chemistry; U.S. Army Medical Research and Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	MVH was supported by the Defense Threat Reduction Agency HDTRA1-11-1-054. CSD was funded by National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) grant RC1AI086453 and the GWU Department of Chemistry. RDC was supported by U.S. Army Medical Research and Materiel Command W23RYX1291N601. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad S, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-123; Andaloussi M, 2011, J MED CHEM, V54, P4964, DOI 10.1021/jm2000085; Aperis G, 2007, MICROBES INFECT, V9, P729, DOI 10.1016/j.micinf.2007.02.016; Arias CA, 2009, NEW ENGL J MED, V360, P439, DOI 10.1056/NEJMp0804651; BIEGELEISEN JZ, 1960, J BACTERIOL, V79, P155, DOI 10.1128/JB.79.1.155-156.1960; Blazewska K, 2003, TETRAHEDRON, V59, P10249, DOI 10.1016/j.tet.2003.10.056; Borrmann S, 2004, J INFECT DIS, V190, P1534, DOI 10.1086/424603; Brown AC, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-78; Cirz RT, 2005, PLOS BIOL, V3, P1024, DOI 10.1371/journal.pbio.0030176; D'Costa VM, 2006, SCIENCE, V311, P374, DOI 10.1126/science.1120800; Dennis DT, 2001, JAMA-J AM MED ASSOC, V285, P2763, DOI 10.1001/jama.285.21.2763; Dharia NV, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-2-r21; Dhiman RK, 2005, J BACTERIOL, V187, P8395, DOI 10.1128/JB.187.24.8395-8402.2005; Fokin AA, 2007, ORG LETT, V9, P4379, DOI 10.1021/ol702082k; Freshney R.I., 2005, CULTURE ANIMAL CELLS, DOI [10.1002/0471747599.CAC022, DOI 10.1002/0471747599.CAC022]; Fujisaki S, 1996, GENE, V175, P83, DOI 10.1016/0378-1119(96)00128-X; Gallagher LA, 2007, P NATL ACAD SCI USA, V104, P1009, DOI 10.1073/pnas.0606713104; Haemers T, 2008, BIOORGAN MED CHEM, V16, P3361, DOI 10.1016/j.bmc.2007.12.001; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Jawaid S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008288; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Kavanagh K, 2004, FEMS MICROBIOL REV, V28, P101, DOI 10.1016/j.femsre.2003.09.002; Koppisch AT, 2002, BIOCHEMISTRY-US, V41, P236, DOI 10.1021/bi0118207; Kurz T, 2007, ARCH PHARM, V340, P339, DOI 10.1002/ardp.200700013; Lemieux MJ, 2004, RES MICROBIOL, V155, P623, DOI 10.1016/j.resmic.2004.05.016; Li XZ, 2009, DRUGS, V69, P1555, DOI 10.2165/11317030-000000000-00000; Liu JR, 2007, BIOTECHNIQUES, V43, P487, DOI 10.2144/000112574; Mackie Ryan S, 2012, Front Microbiol, V3, P226, DOI 10.3389/fmicb.2012.00226; McLendon MK, 2006, ANNU REV MICROBIOL, V60, P167, DOI 10.1146/annurev.micro.60.080805.142126; Meibom KL, 2009, FUTURE MICROBIOL, V4, P713, DOI 10.2217/FMB.09.37; Nano FE, 2004, J BACTERIOL, V186, P6430, DOI 10.1128/JB.186.19.6430-6436.2004; OKUHARA M, 1980, J ANTIBIOT, V33, P24, DOI 10.7164/antibiotics.33.24; OKUHARA M, 1980, J ANTIBIOT, V33, P13, DOI 10.7164/antibiotics.33.13; OLSUFJEV NG, 1982, J HYG EPID MICROB IM, V26, P291; Ortmann R, 2005, ARCH PHARM, V338, P305, DOI 10.1002/ardp.200500976; Ortmann R, 2003, BIOORG MED CHEM LETT, V13, P2163, DOI 10.1016/S0960-894X(03)00354-8; Pechous RD, 2009, MICROBIOL MOL BIOL R, V73, P684, DOI 10.1128/MMBR.00028-09; Sakamoto Y, 2003, BIOSCI BIOTECH BIOCH, V67, P2030, DOI 10.1271/bbb.67.2030; Sangari FJ, 2010, P NATL ACAD SCI USA, V107, P14081, DOI 10.1073/pnas.1001962107; Santic M, 2010, CELL MICROBIOL, V12, P129, DOI 10.1111/j.1462-5822.2009.01400.x; Silver LL, 2011, CLIN MICROBIOL REV, V24, P71, DOI 10.1128/CMR.00030-10; Singh N, 2007, CURR PHARM DESIGN, V13, P1161, DOI 10.2174/138161207780618939; TSUCHIYA T, 1982, EUR J DRUG METAB PH, V7, P59, DOI 10.1007/BF03189544; Uh E, 2011, BIOORG MED CHEM LETT, V21, P6973, DOI 10.1016/j.bmcl.2011.09.123; Walsh C, 2003, NAT REV MICROBIOL, V1, P65, DOI 10.1038/nrmicro727; Weiss DS, 2007, P NATL ACAD SCI USA, V104, P6037, DOI 10.1073/pnas.0609675104; Zhang BC, 2011, BIOCHEMISTRY-US, V50, P3570, DOI 10.1021/bi200113y; Zingle C, 2010, J ORG CHEM, V75, P3203, DOI 10.1021/jo9024732; ZWIERZAK A, 1984, SYNTHESIS-STUTTGART, P223	49	35	35	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2012	7	10							e38167	10.1371/journal.pone.0038167	http://dx.doi.org/10.1371/journal.pone.0038167			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022WO	23077474	Green Published, Green Submitted, gold			2023-01-03	WOS:000309995100002
J	Teixeira, JJV; Crozatti, MTL; dos Santos, CA; Romano-Lieber, NS				Vieira Teixeira, Jorge Juarez; Lonardoni Crozatti, Marcia Terezinha; dos Santos, Carlos Aparecido; Romano-Lieber, Nicolina Silvana			Potential Drug-Drug Interactions in Prescriptions to Patients over 45 Years of Age in Primary Care, Southern Brazil	PLOS ONE			English	Article							MEDICAL PRESCRIPTIONS; RISK-FACTORS; ANTIDEPRESSANTS; POLYPHARMACY; POPULATION; ALERTS; UNITS	Background: Few cross-sectional studies involving adults and elderly patients with major DDIs have been conducted in the primary care setting. The study aimed to investigate the prevalence of potential drug-drug interactions (DDIs) in patients treated in primary care. Methodology/Principal Findings: A cross-sectional study involving patients aged 45 years or older was conducted at 25 Basic Health Units in the city of Maringa (southern Brazil) from May to December 2010. The data were collected from prescriptions at the pharmacy of the health unit at the time of the delivery of medication to the patient. After delivery, the researcher checked the electronic medical records of the patient. A total of 827 patients were investigated (mean age: 64.1; mean number of medications: 4.4). DDIs were identified in the Micromedex (R) database. The prevalence of potential DDIs and major DDIs was 63.0% and 12.1%, respectively. In both the univariate and multivariate analyses, the number of drugs prescribed was significantly associated with potential DDIs, with an increasing risk from three to five drugs (OR = 4.74; 95% CI: 2.90-7.73) to six or more drugs (OR = 23.03; 95% CI: 10.42-50.91). Forty drugs accounted for 122 pairs of major DDIs, the most frequent of which involved simvastatin (23.8%), captopril/enalapril (16.4%) and fluoxetine (16.4%). Conclusions/Significance: This is the first large-scale study on primary care carried out in Latin America. Based on the findings, the estimated prevalence of potential DDIs was high, whereas clinically significant DDIs occurred in a smaller proportion. Exposing patients to a greater number of prescription drugs, especially three or more, proved to be a significant predictor of DDIs. Prescribers should be more aware of potential DDIs. Future studies should assess potential DDIs in primary care over a longer period of time.	[Vieira Teixeira, Jorge Juarez] Univ Estadual Maringa, Ctr Ciencias Saude, Dept Anal Clin & Biomed, Maringa, Parana, Brazil; [Lonardoni Crozatti, Marcia Terezinha] Univ Fed Sao Paulo, Dept Ciencias Biol, Diadema, SP, Brazil; [dos Santos, Carlos Aparecido] Univ Estadual Maringa, Ctr Ciencias Exatas, Dept Estat, Maringa, Parana, Brazil; [Vieira Teixeira, Jorge Juarez; Romano-Lieber, Nicolina Silvana] Univ Sao Paulo, Fac Saude Publ, Dept Prat Saude Publ, Sao Paulo, Brazil	Universidade Estadual de Maringa; Universidade Federal de Sao Paulo (UNIFESP); Universidade Estadual de Maringa; Universidade de Sao Paulo	Teixeira, JJV (corresponding author), Univ Estadual Maringa, Ctr Ciencias Saude, Dept Anal Clin & Biomed, Maringa, Parana, Brazil.	jjvteixeira@uem.br			Brazilian fostering agency Conselho Nacional de Pesquisa, (CNPq) [476374/2010-3]; Brazilian fostering agency Fundacao Araucaria (state of Parana) [093/2010]	Brazilian fostering agency Conselho Nacional de Pesquisa, (CNPq)(Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Brazilian fostering agency Fundacao Araucaria (state of Parana)	This study received financial and logistical support from the Brazilian fostering agencies Conselho Nacional de Pesquisa, (CNPq; Brasilia; process number 476374/2010-3) and Fundacao Araucaria (state of Parana; announcement 18/2009 - agreement 093/2010), which provided a scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abarca Jacob, 2004, J Am Pharm Assoc (2003), V44, P136, DOI 10.1331/154434504773062582; Astrand B, 2006, EUR J CLIN PHARMACOL, V62, P749, DOI 10.1007/s00228-006-0143-x; Avery AJ, 2002, BRIT J GEN PRACT, V52, pS17; Becker ML, 2005, DRUG SAFETY, V28, P371, DOI 10.2165/00002018-200528050-00001; Becquemont L, 2007, CLIN PHARMACOL THER, V81, P679, DOI 10.1038/sj.clpt.6100098; Bergk V, 2004, CLIN PHARMACOL THER, V76, P85, DOI 10.1016/j.clpt.2004.02.009; Bjerrum L, 2003, SCAND J PRIM HEALTH, V21, P153, DOI 10.1080/02813430310001806; Bjorkman IK, 2002, ANN PHARMACOTHER, V36, P1675, DOI 10.1345/aph.1A484; Bleich GW, 2009, SAO PAULO MED J, V127, P206, DOI 10.1590/S1516-31802009000400005; Brvar Miran, 2009, BMC Clin Pharmacol, V9, P8, DOI 10.1186/1472-6904-9-8; Chatsisvili A, 2010, PHARM WORLD SCI, V32, P187, DOI 10.1007/s11096-010-9365-1; Neto VC, 2010, BRAZ J PHARM SCI, V46, P795, DOI 10.1590/S1984-82502010000400022; Cruciol-Souza Joice Mara, 2006, Clinics, V61, P515, DOI 10.1590/S1807-59322006000600005; de Abajo FJ, 2006, BASIC CLIN PHARMACOL, V98, P304, DOI 10.1111/j.1742-7843.2006.pto_303.x; Doubova SV, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-147; Egger SS, 2003, EUR J CLIN PHARMACOL, V58, P773, DOI 10.1007/s00228-002-0557-z; Fokter N, 2010, WIEN KLIN WOCHENSCHR, V122, P81, DOI 10.1007/s00508-009-1251-2; Guedon-Moreau L, 2003, EUR J CLIN PHARMACOL, V59, P689, DOI 10.1007/s00228-003-0684-1; Halkin H, 2001, CLIN PHARMACOL THER, V69, P260, DOI 10.1067/mcp.2001.114228; Haueis P, 2011, CLIN PHARMACOL THER, V90, P588, DOI 10.1038/clpt.2011.150; Indermitte J, 2007, DRUG SAFETY, V30, P71, DOI 10.2165/00002018-200730010-00007; JANKEL CA, 1990, DICP ANN PHARMAC, V24, P982, DOI 10.1177/106002809002401014; Juurlink DN, 2009, CAN MED ASSOC J, V180, P713, DOI 10.1503/cmaj.082001; Kravitz RL, 2008, AM J MED, V121, P1, DOI 10.1016/j.amjmed.2008.09.007; Lapi F, 2010, PHARM WORLD SCI, V32, P200, DOI 10.1007/s11096-010-9370-4; Lin CF, 2011, DRUG AGING, V28, P219, DOI 10.2165/11586870-000000000-00000; Linnarsson Rolf, 1993, Scandinavian Journal of Primary Health Care, V11, P181, DOI 10.3109/02813439308994827; Lopez-Picazo JJ, 2010, EUR J GEN PRACT, V16, P92, DOI 10.3109/13814788.2010.481709; Magnus D, 2002, J CLIN PHARM THER, V27, P377, DOI 10.1046/j.1365-2710.2002.00434.x; Mallet L, 2007, LANCET, V370, P185, DOI 10.1016/S0140-6736(07)61092-7; Mannheimer B, 2006, EUR J CLIN PHARMACOL, V62, P1075, DOI 10.1007/s00228-006-0214-z; Miyasaka LS, 2003, REV SAUDE PUBL, V37, P212, DOI 10.1590/S0034-89102003000200008; Morera T, 2005, BASIC CLIN PHARMACOL, V96, P289, DOI 10.1111/j.1742-7843.2005.pto960403.x; Nobili A, 2009, J CLIN PHARM THER, V34, P377, DOI 10.1111/j.1365-2710.2009.01021.x; Oshima Y, 2011, INTERNAL MED, V50, P845, DOI 10.2169/internalmedicine.50.4484; Paige NM, 2009, MAYO CLIN PROC, V84, P180, DOI 10.1016/S0025-6196(11)60826-4; Passarelli MCG, 2005, DRUG AGING, V22, P767, DOI 10.2165/00002512-200522090-00005; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; Pivatto Junior F, 2009, REV AMRIGS, V53, P251; Putnam Wayne, 2006, Can Fam Physician, V52, P340; Schech S, 2007, PHARMACOEPIDEM DR S, V16, P352, DOI 10.1002/pds.1287; Schuler J, 2008, WIEN KLIN WOCHENSCHR, V120, P733, DOI 10.1007/s00508-008-1089-z; Secoli SR, 2010, DRUG AGING, V27, P759, DOI 10.2165/11538460-000000000-00000; Seymour RM, 1998, DRUG AGING, V12, P485, DOI 10.2165/00002512-199812060-00006; Silva N. M. O., 2010, Revista de Ciencias Farmaceuticas Basica e Aplicada, V31, P171; Smithburger PL, 2010, DRUG SAFETY, V33, P879, DOI 10.2165/11532340-000000000-00000; Steinman MA, 2010, JAMA-J AM MED ASSOC, V304, P1592, DOI 10.1001/jama.2010.1482; Tatonetti NP, 2011, CLIN PHARMACOL THER, V90, P133, DOI 10.1038/clpt.2011.83; Viktil KK, 2007, BRIT J CLIN PHARMACO, V63, P187, DOI 10.1111/j.1365-2125.2006.02744.x; Weingart SN, 2003, ARCH INTERN MED, V163, P2625, DOI 10.1001/archinte.163.21.2625; Yang HJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016641; Zurakowski T, 2009, NURSE PRACT, V34, P36, DOI 10.1097/01.NPR.0000348320.38365.59	52	22	24	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2012	7	10							e47062	10.1371/journal.pone.0047062	http://dx.doi.org/10.1371/journal.pone.0047062			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	054ZU	23071711	Green Submitted, Green Published, gold			2023-01-03	WOS:000312385200073
J	Long, AR; O'Brien, CC; Alder, NN				Long, Ashley R.; O'Brien, Catherine C.; Alder, Nathan N.			The Cell-Free Integration of a Polytopic Mitochondrial Membrane Protein into Liposomes Occurs Cotranslationally and in a Lipid-Dependent Manner	PLOS ONE			English	Article							NASCENT POLYPEPTIDE-CHAINS; FREE EXPRESSION SYSTEMS; RIBOSOMAL EXIT TUNNEL; ADP/ATP CARRIER; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; FREE TRANSLATION; NUCLEOTIDE-BINDING; LACTOSE PERMEASE	The ADP/ATP Carrier (AAC) is the most abundant transporter of the mitochondrial inner membrane. The central role that this transporter plays in cellular energy production highlights the importance of understanding its structure, function, and the basis of its pathologies. As a means of preparing proteoliposomes for the study of membrane proteins, several groups have explored the use of cell-free translation systems to facilitate membrane protein integration directly into preformed unilamellar vesicles without the use of surfactants. Using AAC as a model, we report for the first time the detergent-free reconstitution of a mitochondrial inner membrane protein into liposomes using a wheat germ-based in vitro translation system. Using a host of independent approaches, we demonstrate the efficient integration of AAC into vesicles with an inner membrane-mimetic lipid composition and, more importantly, that the integrated AAC is functionally active in transport. By adding liposomes at different stages of the translation reaction, we show that this direct integration is obligatorily cotranslational, and by synthesizing stable ribosome-bound nascent chain intermediates, we show that the nascent AAC polypeptide interacts with lipid vesicles while ribosome-bound. Finally, we show that the presence of the phospholipid cardiolipin in the liposomes specifically enhances AAC translation rate as well as the efficiency of vesicle association and integration. In light of these results, the possible mechanisms of liposome-assisted membrane protein integration during cell-free translation are discussed with respect to the mode of integration and the role of specific lipids.	[Long, Ashley R.; O'Brien, Catherine C.; Alder, Nathan N.] Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT USA	University of Connecticut	Alder, NN (corresponding author), Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT USA.	nathan.alder@uconn.edu		Alder, Nathan/0000-0003-4474-7803	Scientist Development Grant from the American Heart Association [09SDG2380019]	Scientist Development Grant from the American Heart Association(American Heart Association)	This work was funded by a Scientist Development Grant from the American Heart Association to NA (Grant #: 09SDG2380019) (http://www.heart.org). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alder NN, 2008, CELL, V134, P439, DOI 10.1016/j.cell.2008.06.007; Alder NN, 2008, MOL BIOL CELL, V19, P159, DOI 10.1091/mbc.E07-07-0669; Alder NN, 2011, STRUCTURE BIOL MEMBR, P315; Babot M, 2012, J BIOL CHEM, V287, P10368, DOI 10.1074/jbc.M111.320697; Berrier C, 2004, BIOCHEMISTRY-US, V43, P12585, DOI 10.1021/bi049049y; Berrier C, 2011, BBA-BIOMEMBRANES, V1808, P41, DOI 10.1016/j.bbamem.2010.09.018; Bhushan S, 2010, NAT STRUCT MOL BIOL, V17, P313, DOI 10.1038/nsmb.1756; Bogdanov M, 1998, EMBO J, V17, P5255, DOI 10.1093/emboj/17.18.5255; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; Bogdanov M, 2010, P NATL ACAD SCI USA, V107, P15057, DOI 10.1073/pnas.1006286107; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; Cabrita LD, 2010, CURR OPIN STRUC BIOL, V20, P33, DOI 10.1016/j.sbi.2010.01.005; Cappuccio JA, 2009, METHODS MOL BIOL HIG; Chacinska A, 2009, CELL, V138, P628, DOI 10.1016/j.cell.2009.08.005; Claypool SM, 2008, J CELL BIOL, V182, P937, DOI 10.1083/jcb.200801152; Claypool SM, 2009, BBA-BIOMEMBRANES, V1788, P2059, DOI 10.1016/j.bbamem.2009.04.020; Clemencon B, 2008, J BIOL CHEM, V283, P11218, DOI 10.1074/jbc.M709565200; COLBEAU A, 1971, BIOCHIM BIOPHYS ACTA, V249, P462, DOI 10.1016/0005-2736(71)90123-4; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; Dahout-Gonzalez C, 2006, PHYSIOLOGY, V21, P242, DOI 10.1152/physiol.00005.2006; de Marcos-Lousa C, 2006, TRENDS BIOCHEM SCI, V31, P259, DOI 10.1016/j.tibs.2006.03.006; Dowhan W, 2012, BBA-BIOMEMBRANES, V1818, P1097, DOI 10.1016/j.bbamem.2011.09.013; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; Flanagan JJ, 2003, J BIOL CHEM, V278, P18628, DOI 10.1074/jbc.M300173200; Goren MA, 2008, PROTEIN EXPRES PURIF, V62, P171, DOI 10.1016/j.pep.2008.08.002; Gropp T, 1999, BIOPHYS J, V77, P714, DOI 10.1016/S0006-3495(99)76926-2; HOFFMANN B, 1994, J BIOL CHEM, V269, P1940; Hovijitra NT, 2009, BIOTECHNOL BIOENG, V104, P40, DOI 10.1002/bit.22385; Ishihara G, 2005, PROTEIN EXPRES PURIF, V41, P27, DOI 10.1016/j.pep.2005.01.013; Jha S, 2011, BIOTECHNOL J, V6, P623, DOI 10.1002/biot.201000327; Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199; Johnson AE, 2005, FEBS LETT, V579, P916, DOI 10.1016/j.febslet.2004.11.046; Junge F, 2011, NEW BIOTECHNOL, V28, P262, DOI 10.1016/j.nbt.2010.07.002; Kalmbach R, 2007, J MOL BIOL, V371, P639, DOI 10.1016/j.jmb.2007.05.087; Katzen F, 2005, TRENDS BIOTECHNOL, V23, P150, DOI 10.1016/j.tibtech.2005.01.003; Katzen F, 2008, J PROTEOME RES, V7, P3535, DOI 10.1021/pr800265f; Katzen F, 2009, TRENDS BIOTECHNOL, V27, P455, DOI 10.1016/j.tibtech.2009.05.005; Kawashima Y, 2008, J BIOL CHEM, V283, P24489, DOI 10.1074/jbc.M801812200; Kemper C, 2008, J CELL SCI, V121, P1990, DOI 10.1242/jcs.024034; Klammt C, 2005, FEBS J, V272, P6024, DOI 10.1111/j.1742-4658.2005.05002.x; Klingenberg M, 2008, BBA-BIOMEMBRANES, V1778, P1978, DOI 10.1016/j.bbamem.2008.04.011; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; Krishna AG, 2002, BIOCHEMISTRY-US, V41, P8298, DOI 10.1021/bi025534m; Kuruma Y, 2010, METHODS MOL BIOL, V607, P161, DOI 10.1007/978-1-60327-331-2_14; Liguori L, 2010, PROTEIN EXPRES PURIF, V69, P106, DOI 10.1016/j.pep.2009.07.004; Lionaki E, 2008, J BIOL CHEM, V283, P15747, DOI 10.1074/jbc.M800350200; Lobau S, 1998, BIOCHEMISTRY-US, V37, P10846, DOI 10.1021/bi9807153; Lousa CD, 2002, BIOCHEMISTRY-US, V41, P14412, DOI 10.1021/bi02641490; Lu JL, 2005, NAT STRUCT MOL BIOL, V12, P1123, DOI 10.1038/nsmb1021; Matthies D, 2011, J MOL BIOL, V413, P593, DOI 10.1016/j.jmb.2011.08.055; Merklinger E, 2012, BIOCHEM J, V442, P381, DOI 10.1042/BJ20111363; Moritani Y, 2010, FEBS J, V277, P3343, DOI 10.1111/j.1742-4658.2010.07736.x; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; Neupert W, 2007, ANNU REV BIOCHEM, V76, P723, DOI 10.1146/annurev.biochem.76.052705.163409; Nishiyama KI, 2006, J BIOL CHEM, V281, P35667, DOI 10.1074/jbc.M608228200; Nomura SIM, 2008, J BIOTECHNOL, V133, P190, DOI 10.1016/j.jbiotec.2007.08.023; Nozawa A, 2007, PLANT CELL PHYSIOL, V48, P1815, DOI 10.1093/pcp/pcm150; Nury H, 2006, ANNU REV BIOCHEM, V75, P713, DOI 10.1146/annurev.biochem.75.103004.142747; Nury H, 2005, FEBS LETT, V579, P6031, DOI 10.1016/j.febslet.2005.09.061; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Rajesh S, 2011, NEW BIOTECHNOL, V28, P250, DOI 10.1016/j.nbt.2010.07.011; Rehling P, 2004, NAT REV MOL CELL BIO, V5, P519, DOI 10.1038/nrm1426; Ridder ANJA, 2001, EMBO REP, V2, P403; Savage DF, 2007, PROTEIN SCI, V16, P966, DOI 10.1110/ps.062696307; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; Schlame M, 2009, BBA-BIOMEMBRANES, V1788, P2080, DOI 10.1016/j.bbamem.2009.04.019; Schmidt O, 2010, NAT REV MOL CELL BIO, V11, P655, DOI 10.1038/nrm2959; Schwarz D, 2008, PROTEOMICS, V8, P3933, DOI 10.1002/pmic.200800171; Schwarz D, 2007, METHODS, V41, P355, DOI 10.1016/j.ymeth.2006.07.001; Sevova ES, 2010, J BIOL CHEM, V285, P20580, DOI 10.1074/jbc.M110.127662; SHI LB, 1995, BIOCHEMISTRY-US, V34, P8250, DOI 10.1021/bi00026a006; STANLOTTER H, 1986, EUR J BIOCHEM, V154, P321, DOI 10.1111/j.1432-1033.1986.tb09400.x; Tu LW, 2010, J MOL BIOL, V396, P1346, DOI 10.1016/j.jmb.2009.12.059; van der Laan M, 2007, NAT CELL BIOL, V9, P1152, DOI 10.1038/ncb1635; Vasiljev A, 2004, MOL BIOL CELL, V15, P1445, DOI 10.1091/mbc.E03-05-0272; Voss NR, 2006, J MOL BIOL, V360, P893, DOI 10.1016/j.jmb.2006.05.023; Walther DM, 2009, BBA-MOL CELL RES, V1793, P42, DOI 10.1016/j.bbamcr.2008.04.013; Wilson DN, 2011, CURR OPIN STRUC BIOL, V21, P274, DOI 10.1016/j.sbi.2011.01.007; Woolhead CA, 2004, CELL, V116, P725, DOI 10.1016/S0092-8674(04)00169-2; YONATH A, 1987, SCIENCE, V236, P813, DOI 10.1126/science.3576200; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3; Zara V, 2009, BIOCHEM J, V419, P369, DOI 10.1042/BJ20082270; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602; Ziv G, 2005, P NATL ACAD SCI USA, V102, P18956, DOI 10.1073/pnas.0508234102	85	34	35	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2012	7	9							e46332	10.1371/journal.pone.0046332	http://dx.doi.org/10.1371/journal.pone.0046332			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	016YP	23050015	gold, Green Published, Green Submitted			2023-01-03	WOS:000309556100179
J	McShane, M				McShane, Martin			Should GPs be fined for rises in avoidable emergency admissions to hospital? Yes	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Natl Commissioning Board, Leeds LS2 7UE, W Yorkshire, England		McShane, M (corresponding author), Natl Commissioning Board, Leeds LS2 7UE, W Yorkshire, England.	martin.mcshane@btinternet.com						Bardsley M, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002007; Department of Health, 2012, BAS SPEND EST NEW NH; Francis R., 2013, FINAL REPORT MIDSTAF; Imison C, 2012, OLDER PEOPLE EMERGEN	4	2	2	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 5	2013	346								f1389	10.1136/bmj.f1389	http://dx.doi.org/10.1136/bmj.f1389			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	104MN	23463139				2023-01-03	WOS:000315997600017
J	Miao, Y; Sun, YB; Wang, WJ; Du, BJ; Xiao, SE; Hu, YJ; Hu, ZQ				Miao, Yong; Sun, Yabin; Wang, Wenjun; Du, Benjun; Xiao, Shun-e; Hu, Yijue; Hu, Zhiqi			6-Gingerol Inhibits Hair Shaft Growth in Cultured Human Hair Follicles and Modulates Hair Growth in Mice	PLOS ONE			English	Article							DERMAL PAPILLA CELLS; IN-VITRO; APOPTOSIS; BCL-2; PROLIFERATION; MITOCHONDRIA; PROTEINS; ALOPECIA; SURVIVAL; EXTRACT	Ginger (Zingiber officinale) has been traditionally used to check hair loss and stimulate hair growth in East Asia. Several companies produce shampoo containing an extract of ginger claimed to have anti-hair loss and hair growth promotion properties. However, there is no scientific evidence to back up these claims. This study was undertaken to measure 6-gingerol, the main active component of ginger, on hair shaft elongation in vitro and hair growth in vivo, and to investigate its effect on human dermal papilla cells (DPCs) in vivo and in vitro. 6-Gingerol suppressed hair growth in hair follicles in culture and the proliferation of cultured DPCs. The growth inhibition of DPCs by 6-gingerol in vitro may reflect a decrease in the Bcl-2/Bax ratio. Similar results were obtained in vivo. The results of this study showed that 6-gingerol does not have the ability to promote hair growth, on the contrary, can suppress human hair growth via its inhibitory and pro-apoptotic effects on DPCs in vitro, and can cause prolongation of telogen phase in vivo. Thus, 6-gingerol rather than being a hair growth stimulating drug, it is a potential hair growth suppressive drug; i.e. for hair removal.	[Miao, Yong; Du, Benjun; Xiao, Shun-e; Hu, Yijue; Hu, Zhiqi] So Med Univ, Nanfang Hosp, Dept Plast & Aesthet Surg, Guangzhou, Guangdong, Peoples R China; [Sun, Yabin] So Med Univ, Nanfang Hosp, GCP Off, Guangzhou, Guangdong, Peoples R China; [Wang, Wenjun] So Med Univ, Canc Res Inst, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China	Hu, ZQ (corresponding author), So Med Univ, Nanfang Hosp, Dept Plast & Aesthet Surg, Guangzhou, Guangdong, Peoples R China.	doctorhzq@hotmail.com	Hu, Zhi/AAD-1479-2020		Natural Science Foundation of China [31170949]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the Natural Science Foundation of China (Grant No. 31170949). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ali BH, 2008, FOOD CHEM TOXICOL, V46, P409, DOI 10.1016/j.fct.2007.09.085; Baliga MS, 2011, CRIT REV FOOD SCI, V51, P499, DOI 10.1080/10408391003698669; Blume-Peytavi U, 2011, BRIT J DERMATOL, V165, P19, DOI 10.1111/j.1365-2133.2011.10632.x; Botchkareva NV, 2006, J INVEST DERMATOL, V126, P258, DOI 10.1038/sj.jid.5700007; Cash TF, 1999, BRIT J DERMATOL, V141, P398; Datta K, 2009, J ETHNOPHARMACOL, V124, P450, DOI 10.1016/j.jep.2009.05.023; Han JH, 2004, J DERMATOL SCI, V34, P91, DOI 10.1016/j.jdermsci.2004.01.002; Kawano M, 2009, J NAT MED-TOKYO, V63, P335, DOI 10.1007/s11418-009-0324-x; Kim SC, 2010, EUR J DERMATOL, V20, P42, DOI 10.1684/ejd.2010.0807; Kwon OS, 2007, PHYTOMEDICINE, V14, P551, DOI 10.1016/j.phymed.2006.09.009; Lee C, 2011, FOOD CHEM TOXICOL, V49, P1261, DOI 10.1016/j.fct.2011.03.005; Lindner G, 1997, AM J PATHOL, V151, P1601; Luanpitpong S, 2011, APOPTOSIS, V16, P769, DOI 10.1007/s10495-011-0609-x; Magerl M, 2002, EXP DERMATOL, V11, P381, DOI 10.1034/j.1600-0625.2002.110414.x; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Muller-Rover S, 1999, J INVEST DERM SYMP P, V4, P272, DOI 10.1038/sj.jidsp.5640228; Muller-Rover S, 2001, J INVEST DERMATOL, V117, P3, DOI 10.1046/j.0022-202x.2001.01377.x; Nigam N, 2010, CANCER CHEMOTH PHARM, V65, P687, DOI 10.1007/s00280-009-1074-x; Park HJ, 2011, J ETHNOPHARMACOL, V135, P369, DOI 10.1016/j.jep.2011.03.028; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; Philpott MP, 1990, CELL SCI, V97, P471; Price VH, 1999, NEW ENGL J MED, V341, P964, DOI 10.1056/NEJM199909233411307; Schmidt S, 2001, BRIT J DERMATOL, V144, P1038, DOI 10.1046/j.1365-2133.2001.04195.x; Shukla Y, 2007, MOL NUTR FOOD RES, V51, P1492, DOI 10.1002/mnfr.200700197; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; Zoumaras J, 2008, BURNS, V34, P254, DOI 10.1016/j.burns.2007.03.018	28	16	16	6	45	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2013	8	2							e57226	10.1371/journal.pone.0057226	http://dx.doi.org/10.1371/journal.pone.0057226			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	093IT	23437345	Green Submitted, Green Published, gold			2023-01-03	WOS:000315186000086
J	Nguyen, DB; Do, NT; Shiraishi, RW; Le, YN; Tran, QH; Nguyen, HH; Medland, N; Nguyen, LT; Struminger, BB				Duc Bui Nguyen; Nhan Thi Do; Shiraishi, Ray W.; Yen Ngoc Le; Quang Hong Tran; Hai Huu Nguyen; Medland, Nicholas; Long Thanh Nguyen; Struminger, Bruce Baird			Outcomes of Antiretroviral Therapy in Vietnam: Results from a National Evaluation	PLOS ONE			English	Article							INJECTION-DRUG USERS; FOLLOW-UP; TREATMENT PROGRAM; PATIENTS LOST; SCALE-UP; MULTIPLE IMPUTATION; MISSING VALUES; SOUTH-AFRICA; RISK-FACTORS; HIV	Objectives: Vietnam has significantly scaled up its national antiretroviral therapy (ART) program since 2005. With the aim of improving Vietnam's national ART program, we conducted an outcome evaluation of the first five years of the program in this concentrated HIV epidemic where the majority of persons enrolled in HIV care and treatment services are people who inject drugs (PWID). The results of this evaluation may have relevance for other national ART programs with significant PWID populations. Design: Retrospective cohort analysis of patients at 30 clinics randomly selected with probability proportional to size among 120 clinics with at least 50 patients on ART. Methods: Charts of patients whose ART initiation was at least 6 months prior to the study date were abstracted. Depending on clinic size, either all charts or a random sample of 300 charts were selected. Analyses were limited to treatment-naive patients. Multiple imputations were used for missing data. Results: Of 7,587 patient charts sampled, 6,875 were those of treatment-naive patients (74.4% male, 95% confidence interval [CI]: 72.4-76.5, median age 30, interquartile range [IQR]: 26-34, 62.0% reported a history of intravenous drug use, CI: 58.6-65.3). Median baseline CD4 cell count was 78 cells/mm 3 (IQR: 30-162) and 30.4% (CI: 25.8-35.1) of patients were at WHO stage IV. The majority of patients started d4T/3TC/NVP (74.3%) or d4T/3TC/EFV (18.6%). Retention rates after 6, 12, 24, and 36 months were 88.4% (CI: 86.8-89.9), 84.0% (CI: 81.8-86.0), 78.8% (CI: 75.7-81.6), and 74.6% (CI: 69.6-79.0). Median CD4 cell count gains after 6, 12, 24, and 36 months were 94 (IQR: 45-153), 142 (IQR: 78-217), 213 (IQR: 120-329), and 254 (IQR: 135-391) cells/mm(3). Patients who were PWID showed significantly poorer retention. Conclusions: The study showed good retention and immunological response to ART among a predominantly PWID group of patients despite advanced HIV infections at baseline.	[Duc Bui Nguyen; Yen Ngoc Le; Medland, Nicholas; Struminger, Bruce Baird] US Ctr Dis Control & Prevent, Hanoi, Vietnam; [Nhan Thi Do; Hai Huu Nguyen; Long Thanh Nguyen] Vietnam Adm HIV AIDS Control, Minist Hlth, Hanoi, Vietnam; [Shiraishi, Ray W.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA; [Quang Hong Tran] Hanoi Sch Publ Hlth, Hanoi, Vietnam	Centers for Disease Control & Prevention - USA; Hanoi University of Public Health	Nguyen, DB (corresponding author), US Ctr Dis Control & Prevent, Hanoi, Vietnam.	vif8@cdc.gov		Medland, Nicholas Andrew/0000-0003-0403-8930; Shiraishi, Ray/0000-0001-7640-0666	Emory AIDS International Training and Research Program [NIH/FIC D43 TW01042]; United States's President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention [1U2GPS000747]; FOGARTY INTERNATIONAL CENTER [D43TW001042] Funding Source: NIH RePORTER	Emory AIDS International Training and Research Program; United States's President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention; FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	This evaluation was supported by the United States's President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention under the terms of 1U2GPS000747. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors would like to thank the data collection and entry team, as well as the clinic staff whose generous assistance made this survey possible. We would also like to thank the staff from the provincial Departments of Health and AIDS Control Centers where we collected data. We thank Dr. Mitchell Wolfe and Mr. Raymond Ransom from U.S. CDC for their contributions to the protocol development, and we thank Dr. Michelle McConnell, Dr. Anh Van Ho and Patrick Nadol from CDC Vietnam office for their valuable contributions to the study and the manuscript. We thank Dr. Stefan Wiktor and Dr. Andrew Baughman of CDC's Division of Global HIV/AIDS, and Timothy Dondero of CDC's National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention for their scientific reviews. We thank Dr. Michael Iademarco from U.S. CDC for his review of the manuscript. The team also acknowledges general support from the VAAC and U.S. CDC Vietnam office. Dr. Duc Bui Nguyen received training support from the Emory AIDS International Training and Research Program (NIH/FIC D43 TW01042).	Auld AF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018453; Boulle A, 2010, AIDS, V24, P563, DOI 10.1097/QAD.0b013e328333bfb7; Brinkhof MWG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005790; Chasombat S, 2009, JAIDS-J ACQ IMM DEF, V50, P506, DOI 10.1097/QAI.0b013e3181967602; Dalal RP, 2008, JAIDS-J ACQ IMM DEF, V47, P101, DOI 10.1097/QAI.0b013e31815b833a; Dronda F, 2004, AIDS, V18, P2210, DOI 10.1097/00002030-200411050-00018; Etard JF, 2006, AIDS, V20, P1181, DOI 10.1097/01.aids.0000226959.87471.01; Geng EH, 2010, JAIDS-J ACQ IMM DEF, V53, P405, DOI 10.1097/QAI.0b013e3181b843f0; Grigoryan A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004445; Lowrance DW, 2009, JAIDS-J ACQ IMM DEF, V52, P49, DOI 10.1097/QAI.0b013e3181b03316; Malta M, 2009, JAIDS-J ACQ IMM DEF, V52, P629, DOI 10.1097/QAI.0b013e3181b31b8a; May M, 2010, LANCET, V376, P449, DOI 10.1016/S0140-6736(10)60666-6; Ministry of Health, 2009, NAT GUID DIAGN TREAT; Ministry of Health, 2008, HIV SENT SURV; Moh R, 2007, AIDS, V21, P2483, DOI 10.1097/QAD.0b013e3282f09876; Mojumdar K, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-416; Moore RD, 2004, JAIDS-J ACQ IMM DEF, V35, P46, DOI 10.1097/00126334-200401010-00006; Morris John D, 2007, AIDS Res Ther, V4, P12, DOI 10.1186/1742-6405-4-12; Muga R, 2007, AIDS, V21, P2521, DOI 10.1097/QAD.0b013e3282f1c933; National Committee for Aids Drugs Control and Prostitution Prevention UNAIDS, 2012, VIET NAM AIDS RESP P; Nguyen Duc, 2011, 10 INT C AIDS AS PAC; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Royston P, 2005, STATA J, V5, P188, DOI 10.1177/1536867X0500500204; Royston P, 2005, STATA J, V5, P527, DOI 10.1177/1536867X0500500404; Royston P, 2004, STATA J, V4, P227, DOI 10.1177/1536867X0400400301; Royston P, 2009, STATA J, V9, P252, DOI 10.1177/1536867X0900900205; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Severe P, 2005, NEW ENGL J MED, V353, P2325, DOI 10.1056/NEJMoa051908; Solomon SS, 2008, INDIAN J MED RES, V127, P447; Solomon SS, 2008, JAIDS-J ACQ IMM DEF, V49, P327, DOI 10.1097/QAI.0b013e3181831e85; Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782; Vietnam Administration of HIV/AIDS Control, 2012, VIETN HIV AIDS EST P; White IR, 2009, STAT MED, V28, P1982, DOI 10.1002/sim.3618; Wolfe D, 2010, LANCET, V376, P355, DOI 10.1016/S0140-6736(10)60832-X; Wood E, 2008, HIV MED, V9, P503, DOI 10.1111/j.1468-1293.2008.00582.x; Yu JKL, 2007, B WORLD HEALTH ORGAN, V85, P550, DOI 10.2471/BLT.06.037739; Zachariah R, 2006, AIDS, V20, P2355, DOI 10.1097/QAD.0b013e32801086b0; Zhang FJ, 2009, ANN INTERN MED, V151, P241, DOI 10.7326/0003-4819-151-4-200908180-00006	38	57	57	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 15	2013	8	2							e55750	10.1371/journal.pone.0055750	http://dx.doi.org/10.1371/journal.pone.0055750			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	099EQ	23457477	Green Published, gold, Green Submitted			2023-01-03	WOS:000315603700017
J	Thompson, KA; Pappachan, JV; Bennett, AM; Mittal, H; Macken, S; Dove, BK; Nguyen-Van-Tam, JS; Copley, VR; O'Brien, S; Hoffman, P; Parks, S; Bentley, A; Isalska, B; Thomson, G				Thompson, Katy-Anne; Pappachan, John V.; Bennett, Allan M.; Mittal, Himanshu; Macken, Susan; Dove, Brian K.; Nguyen-Van-Tam, Jonathan S.; Copley, Vicky R.; O'Brien, Sarah; Hoffman, Peter; Parks, Simon; Bentley, Andrew; Isalska, Barbara; Thomson, Gail		EASE Study Consortium	Influenza Aerosols in UK Hospitals during the H1N1 (2009) Pandemic - The Risk of Aerosol Generation during Medical Procedures	PLOS ONE			English	Article							VIRAL LOAD; VIRUS; INFECTION; TRANSMISSION; TORONTO; SARS	Background: Nosocomial infection of health-care workers (HCWs) during outbreaks of respiratory infections (e. g. Influenza A H1N1 (2009)) is a significant concern for public health policy makers. World Health Organization (WHO)-defined 'aerosol generating procedures' (AGPs) are thought to increase the risk of aerosol transmission to HCWs, but there are presently insufficient data to quantify risk accurately or establish a hierarchy of risk-prone procedures. Methodology/Principal Findings: This study measured the amount of H1N1 (2009) RNA in aerosols in the vicinity of H1N1 positive patients undergoing AGPs to help quantify the potential risk of transmission to HCWs. There were 99 sampling occasions (windows) producing a total of 198 May stages for analysis in the size ranges 0.86-7.3 mu m. Considering stages 2 (4-7.3 mu m) and 3 (0.86-4 mu m) as comprising one sample, viral RNA was detected in 14 (14.1%) air samples from 10 (25.6%) patients. Twenty three air samples were collected while potential AGPs were being performed of which 6 (26.1%) contained viral RNA; in contrast, 76 May samples were collected when no WHO 2009 defined AGP was being performed of which 8 (10.5%) contained viral RNA (unadjusted OR = 2.84 (95% CI 1.11-7.24) adjusted OR = 4.31 (0.83-22.5)). Conclusions/Significance: With our small sample size we found that AGPs do not significantly increase the probability of sampling an H1N1 (2009) positive aerosol (OR (95% CI) = 4.31 (0.83-22.5). Although the probability of detecting positive H1N1 (2009) positive aerosols when performing various AGPs on intensive care patients above the baseline rate (i.e. in the absence of AGPs) did not reach significance, there was a trend towards hierarchy of AGPs, placing bronchoscopy and respiratory and airway suctioning above baseline (background) values. Further, larger studies are required but these preliminary findings may be of benefit to infection control teams.	[Thompson, Katy-Anne; Bennett, Allan M.; Macken, Susan; Parks, Simon] Hlth Protect Agcy, Biosafety Invest Unit, Porton Down, Wilts, England; [Pappachan, John V.] Univ Hosp Southampton NHS Fdn Trust, Paediat Intens Care Unit, Southampton, Hants, England; [Mittal, Himanshu] Hlth Protect Agcy, Biosafety Invest Unit, London, England; [Dove, Brian K.] Hlth Protect Agcy, Influenza Grp, Porton Down, Wilts, England; [Nguyen-Van-Tam, Jonathan S.] Univ Nottingham, Hlth Protect & Influenza Res Grp, Nottingham NG7 2RD, England; [Copley, Vicky R.] Hlth Protect Agcy, Microbial Risk Assessment Grp, Porton Down, Wilts, England; [O'Brien, Sarah] Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England; [Hoffman, Peter] Hlth Protect Agcy, Antimicrobial Resistance & Healthcare Associated, London, England; [Bentley, Andrew] Univ S Manchester Hosp, Acute Intens Care Unit, Manchester M20 8LR, Lancs, England; [Isalska, Barbara] Univ S Manchester Hosp, Dept Microbiol, Manchester M20 8LR, Lancs, England; [Thomson, Gail] Hlth Protect Agcy, Porton Down, Wilts, England	Health Protection Agency; University of Southampton; University Hospital Southampton NHS Foundation Trust; Health Protection Agency; Health Protection Agency; University of Nottingham; Health Protection Agency; University of Liverpool; Health Protection Agency; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Health Protection Agency	Thompson, KA (corresponding author), Hlth Protect Agcy, Biosafety Invest Unit, Porton Down, Wilts, England.	Katy-Anne.Thompson@hpa.org.uk	Nguyen-Van-Tam, Jonathan/I-2162-2019	Nguyen-Van-Tam, Jonathan/0000-0003-2579-4655; Bentley, Andrew/0000-0002-6883-9246; O'Brien, Sarah Jane/0000-0003-2896-8999; Pappachan, John/0000-0002-3559-0595; Bennett, Allan/0000-0001-7448-8182	Health Protection Agency; GlaxoSmithKline plc (GSK)	Health Protection Agency; GlaxoSmithKline plc (GSK)	This study was funded by the Health Protection Agency. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; KAT, BD, SM, SP, JP, GT, VC, HM, SO, PH, AB and BI have no conflict of interest. JVT: The University of Nottingham Health Protection Research Group is currently in receipt of research funds from GlaxoSmithKline plc (GSK), who are manufacturers/distributors of a virucidal respirator; this research funding is entirely unrelated to the performance or use of the virucidal respirator. Furthermore the research funding from GSK did not support any aspect of the work described in this manuscript. JVT has also received consultancy fees from GSK; but all forms of personal remuneration ceased in September, 2010. JVT is a former employee of SmithKline Beecham plc. (now GSK) prior to 2002, with no outstanding pecuniary interests in GSK by way of shareholdings, share options or accrued pension rights. This does not alter the authors' adherence to all PLOS ONE policies on sharing data and materials.	ALFORD RH, 1967, AM J EPIDEMIOL, V86, P185, DOI 10.1093/oxfordjournals.aje.a120723; Almstrand AC, 2010, J APPL PHYSIOL, V108, P584, DOI 10.1152/japplphysiol.00873.2009; [Anonymous], 2008, PANDEMIC INFLUENZA G; [Anonymous], 2007, INFECT PREVENTION CO; [Anonymous], 2007, ISOTS169761; [Anonymous], 2009, NAT PLAN INFL PAND N; [Anonymous], 2009, INTERIM GUIDANCE INF; [Anonymous], 2009, PANDEMIC H1N1 2009 I; [Anonymous], 2009, INFECT PREVENTION CO; Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885; Brankston G, 2007, LANCET INFECT DIS, V7, P257, DOI 10.1016/S1473-3099(07)70029-4; Carrat F, 2008, AM J EPIDEMIOL, V167, P775, DOI 10.1093/aje/kwm375; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P461; Cox CS., 1987, AEROBIOLOGICAL PATHW; Davies A., 2009, Journal of Infection Prevention, V10, P122, DOI 10.1177/1757177409106456; Edwards DA, 2004, P NATL ACAD SCI USA, V101, P17383, DOI 10.1073/pnas.0408159101; Fabian P, 2011, J AEROSOL MED PULM D, V24, P137, DOI 10.1089/jamp.2010.0815; Fabian P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002691; HALL CB, 1979, J INFECT DIS, V140, P610, DOI 10.1093/infdis/140.4.610; Hoffmann E, 2001, ARCH VIROL, V146, P2275, DOI 10.1007/s007050170002; Johnson GR, 2011, J AEROSOL SCI, V42, P839, DOI 10.1016/j.jaerosci.2011.07.009; Tran K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035797; Killingley B, 2010, HEALTH TECHNOL ASSES, V14, P237, DOI 10.3310/hta14460-04; Li IW, 2010, CHEST, V137, P759, DOI 10.1378/chest.09-3072; Lindsley WG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015100; Lindsley WG, 2010, CLIN INFECT DIS, V50, P693, DOI 10.1086/650457; MAY KR, 1966, BACTERIOL REV, V30, P559, DOI 10.1128/MMBR.30.3.559-570.1966; McDonald LC, 2004, EMERG INFECT DIS, V10, P777, DOI 10.3201/eid1005.030791; Milton DK, 2010, AM J RESP CRIT CARE, V181; Nicas M, 2006, RISK ANAL, V26, P1085, DOI 10.1111/j.1539-6924.2006.00802.x; SCHAFFER FL, 1976, ARCH VIROL, V51, P263, DOI 10.1007/BF01317930; SODERHOLM SC, 1989, ANN OCCUP HYG, V33, P301, DOI 10.1093/annhyg/33.3.301; Spackman E, 2002, J CLIN MICROBIOL, V40, P3256, DOI 10.1128/JCM.40.9.3256-3260.2002; Tellier R, 2006, EMERG INFECT DIS, V12, P1657, DOI 10.3201/eid1211.060426; Tellier R, 2009, J R SOC INTERFACE, V6, pS783, DOI 10.1098/rsif.2009.0302.focus; Teunis PFM, 2010, EPIDEMICS-NETH, V2, P215, DOI 10.1016/j.epidem.2010.10.001; The Influenza Pandemic Preparedness Team, 2011, ROUT TRANSM INFL VIR; To KKW, 2010, J MED VIROL, V82, P1, DOI 10.1002/jmv.21664	38	90	94	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2013	8	2							e56278	10.1371/journal.pone.0056278	http://dx.doi.org/10.1371/journal.pone.0056278			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104DM	23418548	Green Published, Green Accepted, gold, Green Submitted			2023-01-03	WOS:000315970300141
J	Uchida, S; Itaka, K; Uchida, H; Hayakawa, K; Ogata, T; Ishii, T; Fukushima, S; Osada, K; Kataoka, K				Uchida, Satoshi; Itaka, Keiji; Uchida, Hirokuni; Hayakawa, Kentaro; Ogata, Toru; Ishii, Takehiko; Fukushima, Shigeto; Osada, Kensuke; Kataoka, Kazunori			In Vivo Messenger RNA Introduction into the Central Nervous System Using Polyplex Nanomicelle	PLOS ONE			English	Article							TOLL-LIKE RECEPTORS; GENE DELIVERY; VACCINATION TRIAL; DIRECT-INJECTION; LINKING INNATE; CELLS; PSEUDOURIDINE; TRANSFECTION; EXPRESSION; EFFICIENT	Messenger RNA (mRNA) introduction is a promising approach to produce therapeutic proteins and peptides without any risk of insertion mutagenesis into the host genome. However, it is difficult to introduce mRNA in vivo mainly because of the instability of mRNA under physiological conditions and its strong immunogenicity through the recognition by Toll-like receptors (TLRs). We used a novel carrier based on self-assembly of a polyethylene glycol (PEG)-polyamino acid block copolymer, polyplex nanomicelle, to administer mRNA into the central nervous system (CNS). The nanomicelle with 50 nm in diameter has a core-shell structure with mRNA-containing inner core surrounded by PEG layer, providing the high stability and stealth property to the nanomicelle. The functional polyamino acids possessing the capacity of pH-responsive membrane destabilization allows smooth endosomal escape of the nanomicelle into the cytoplasm. After introduction into CNS, the nanomicelle successfully provided the sustained protein expression in the cerebrospinal fluid for almost a week. Immune responses after mRNA administration into CNS were effectively suppressed by the use of the nanomicelle compared with naked mRNA introduction. In vitro analyses using specific TLR expressing HEK293 cells confirmed that the nanomicelle inclusion prevented mRNA from the recognition by TLRs. Thus, the polyplex nanomicelle is a promising system that simultaneously resolved the two major problems of in vivo mRNA introduction, the instability and immunogenicity, opening the door to various new therapeutic strategies using mRNA.	[Uchida, Satoshi; Itaka, Keiji; Kataoka, Kazunori] Univ Tokyo, Grad Sch Med, Ctr Dis Biol & Integrat Med, Div Clin Biotechnol,Bunkyo Ku, Tokyo, Japan; [Uchida, Hirokuni; Ishii, Takehiko; Kataoka, Kazunori] Univ Tokyo, Grad Sch Engn, Dept Bioengn, Bunkyo Ku, Tokyo, Japan; [Hayakawa, Kentaro; Ogata, Toru] Natl Rehabil Ctr Persons Disabil, Res Inst, Dept Rehabil Movement Funct, Tokorozawa, Saitama, Japan; [Fukushima, Shigeto; Osada, Kensuke; Kataoka, Kazunori] Univ Tokyo, Grad Sch Engn, Dept Mat Engn, Bunkyo Ku, Tokyo, Japan	University of Tokyo; University of Tokyo; University of Tokyo	Itaka, K (corresponding author), Univ Tokyo, Grad Sch Med, Ctr Dis Biol & Integrat Med, Div Clin Biotechnol,Bunkyo Ku, Tokyo, Japan.	itaka-ort@umin.net; kataoka@bmw.t.u-tokyo.ac.jp	Kataoka, Kazunori/K-7108-2012; Ogata, Toru/ADC-3560-2022; UCHIDA, SATOSHI/H-6112-2018; Osada, Kensuke/V-3322-2017	Kataoka, Kazunori/0000-0002-8591-413X; Ogata, Toru/0000-0001-9011-8640; UCHIDA, SATOSHI/0000-0001-8726-0478; Osada, Kensuke/0000-0001-9557-6851	Core Research Program for Evolutional Science and Technology (CREST) from Japan Science and Technology Corporation (JST); Japanese Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT); Global COE Program 'Medical System Innovation through Multidisciplinary Integration' from MEXT, Japan; Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program) from the Japan Society for the Promotion of Science (JSPS)	Core Research Program for Evolutional Science and Technology (CREST) from Japan Science and Technology Corporation (JST)(Japan Science & Technology Agency (JST)Core Research for Evolutional Science and Technology (CREST)); Japanese Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Global COE Program 'Medical System Innovation through Multidisciplinary Integration' from MEXT, Japan; Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program) from the Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was financially supported in part by the Core Research Program for Evolutional Science and Technology (CREST) from Japan Science and Technology Corporation (JST) (K.K., http://www.jst.go.jp/kisoken/crest/en/index.html), Grants-in-Aid for Scientific Research form the Japanese Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT) (K.I., http://www.jsps.go.jp/english/e-grants/index.html), Global COE Program 'Medical System Innovation through Multidisciplinary Integration' from MEXT, Japan(http://park.itc.u-tokyo.ac.jp/CMSI/e/index.html) and Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program) from the Japan Society for the Promotion of Science (JSPS) (http://www.jsps.go.jp/english/index.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbott NJ, 2004, NEUROCHEM INT, V45, P545, DOI 10.1016/j.neuint.2003.11.006; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Anderson BR, 2010, NUCLEIC ACIDS RES, V38, P5884, DOI 10.1093/nar/gkq347; Bettinger T, 2001, NUCLEIC ACIDS RES, V29, P3882, DOI 10.1093/nar/29.18.3882; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; CALLIS J, 1987, NUCLEIC ACIDS RES, V15, P5823; Charette M, 2000, IUBMB LIFE, V49, P341; Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Itaka K, 2011, CURR GENE THER, V11, P457, DOI 10.2174/156652311798192879; Itaka K, 2010, BIOMATERIALS, V31, P3707, DOI 10.1016/j.biomaterials.2009.11.072; Itaka K, 2009, EUR J PHARM BIOPHARM, V71, P475, DOI 10.1016/j.ejpb.2008.09.019; Kanayama N, 2006, CHEMMEDCHEM, V1, P439, DOI 10.1002/cmdc.200600008; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200; Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200; Kariko K, 2012, MOL THER, V20, P948, DOI 10.1038/mt.2012.7; Kataoka K, 2001, ADV DRUG DELIVER REV, V47, P113, DOI 10.1016/S0169-409X(00)00124-1; Kawamoto T, 2003, ARCH HISTOL CYTOL, V66, P123, DOI 10.1679/aohc.66.123; Kormann MSD, 2011, NAT BIOTECHNOL, V29, P154, DOI 10.1038/nbt.1733; Krieg AM, 2007, IMMUNOL REV, V220, P251, DOI 10.1111/j.1600-065X.2007.00572.x; Listvanova S, 2003, J IMMUNOL METHODS, V281, P27, DOI 10.1016/S0022-1759(03)00267-9; Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; Masago K, 2007, BIOMATERIALS, V28, P5169, DOI 10.1016/j.biomaterials.2007.07.019; Mitchell DA, 2000, J CLIN INVEST, V106, P1065, DOI 10.1172/JCI11405; Miyata K, 2012, CHEM SOC REV, V41, P2562, DOI 10.1039/c1cs15258k; Miyata K, 2008, J AM CHEM SOC, V130, P16287, DOI 10.1021/ja804561g; Plews JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014397; Probst J, 2007, GENE THER, V14, P1175, DOI 10.1038/sj.gt.3302964; Qiu P, 1996, GENE THER, V3, P262; Reijneveld JC, 1999, J NEURO-ONCOL, V42, P137, DOI 10.1023/A:1006237917632; Rejman J, 2010, J CONTROL RELEASE, V147, P385, DOI 10.1016/j.jconrel.2010.07.124; Scheel B, 2005, EUR J IMMUNOL, V35, P1557, DOI 10.1002/eji.200425656; Su XF, 2011, MOL PHARMACEUT, V8, P774, DOI 10.1021/mp100390w; Tannous BA, 2009, NAT PROTOC, V4, P582, DOI 10.1038/nprot.2009.28; Tavernier G, 2011, BIOMATERIALS; Tavernier G, 2011, J CONTROL RELEASE, V150, P238, DOI 10.1016/j.jconrel.2010.10.020; Van Tendeloo VF, 2007, CURR OPIN MOL THER, V9, P423; Veening JG, 2010, FLUIDS BARRIERS CNS, V7, DOI 10.1186/1743-8454-7-1; Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012; Weide B, 2008, J IMMUNOTHER, V31, P180, DOI 10.1097/CJI.0b013e31815ce501; Weide B, 2009, J IMMUNOTHER, V32, P498, DOI 10.1097/CJI.0b013e3181a00068; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Zou S, 2010, INT J PHARMACEUT, V389, P232, DOI 10.1016/j.ijpharm.2010.01.019	45	69	79	0	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2013	8	2							e56220	10.1371/journal.pone.0056220	http://dx.doi.org/10.1371/journal.pone.0056220			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104DM	23418537	Green Submitted, Green Published, gold			2023-01-03	WOS:000315970300129
J	Ueda, K; Kawabata, R; Irie, T; Nakai, Y; Tohya, Y; Sakaguchi, T				Ueda, Kyoko; Kawabata, Ryoko; Irie, Takashi; Nakai, Yoshiaki; Tohya, Yukinobu; Sakaguchi, Takemasa			Inactivation of Pathogenic Viruses by Plant-Derived Tannins: Strong Effects of Extracts from Persimmon (Diospyros kaki) on a Broad Range of Viruses	PLOS ONE			English	Article							EPIGALLOCATECHIN GALLATE; GREEN TEA; INHIBITION; FRUITS; REPLICATION; POLYPHENOL; MEMBRANE; PROTEIN; BINDS; CD4	Tannins, plant-derived polyphenols and other related compounds, have been utilized for a long time in many fields such as the food industry and manufacturing. In this study, we investigated the anti-viral effects of tannins on 12 different viruses including both enveloped viruses (influenza virus H3N2, H5N3, herpes simplex virus-1, vesicular stomatitis virus, Sendai virus and Newcastle disease virus) and non-enveloped viruses (poliovirus, coxsachievirus, adenovirus, rotavirus, feline calicivirus and mouse norovirus). We found that extracts from persimmon (Diospyros kaki), which contains ca. 22% of persimmon tannin, reduced viral infectivity in more than 4-log scale against all of the viruses tested, showing strong anti-viral effects against a broad range of viruses. Other tannins derived from green tea, acacia and gallnuts were effective for some of the viruses, while the coffee extracts were not effective for any of the virus. We then investigated the mechanism of the antiviral effects of persimmon extracts by using mainly influenza virus. Persimmon extracts were effective within 30 seconds at a concentration of 0.25% and inhibited attachment of the virus to cells. Pretreatment of cells with the persimmon extracts before virus infection or post-treatment after virus infection did not inhibit virus replication. Protein aggregation seems to be a fundamental mechanism underlying the anti-viral effect of persimmon tannin, since viral proteins formed aggregates when purified virions were treated with the persimmon extracts and since the anti-viral effect was competitively inhibited by a non-specific protein, bovine serum albumin. Considering that persimmon tannin is a food supplement, it has a potential to be utilized as a safe and highly effective anti-viral reagent against pathogenic viruses.	[Ueda, Kyoko; Kawabata, Ryoko; Irie, Takashi; Sakaguchi, Takemasa] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Virol, Hiroshima, Japan; [Nakai, Yoshiaki] Altan Corp, Tokyo, Japan; [Tohya, Yukinobu] Nihon Univ, Coll Biosource Sci, Dept Vet Med, Kanagawa, Japan	Hiroshima University; Nihon University	Sakaguchi, T (corresponding author), Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Virol, Hiroshima, Japan.	tsaka@hiroshima-u.ac.jp	Sakaguchi, Takemasa/H-1488-2019	Sakaguchi, Takemasa/0000-0002-3754-1252	Hiroshima University; Altan Corporation	Hiroshima University; Altan Corporation	This work was supported by the basic research fund from Hiroshima University. It was also supported by the Altan Corporation as joint research to evaluate anti-viral activity of various reagents. However, the Altan Corporation was involved in the initial study design alone and not involved in any of the study design thereafter; collection, analysis, or interpretations presented in the paper.	Flint SJ, 2009, PRINCIPLES VIROLOGY, P82; Friedman M, 2007, MOL NUTR FOOD RES, V51, P116, DOI 10.1002/mnfr.200600173; FUKUCHI K, 1989, ANTIVIR RES, V11, P285, DOI 10.1016/0166-3542(89)90038-7; Green KY, 2006, FIELDS VIROLOGY, P949; Harrison SC, 2007, FIELDS VIROLOGY, P59; International Conference on Harmonization (ICH) for Registration of Pharmaceuticals for Human Use, 2003, INT C HARMONIZATION; Irie T, 2008, VIROLOGY, V371, P108, DOI 10.1016/j.virol.2007.09.020; Isaacs CE, 2008, ANTIMICROB AGENTS CH, V52, P962, DOI 10.1128/AAC.00825-07; ITO S, 1964, NATURE, V204, P475, DOI 10.1038/204475a0; Kawai K, 2003, J ALLERGY CLIN IMMUN, V112, P951, DOI 10.1016/S0091-6749(03)02007-4; KIYOTANI K, 1990, VIROLOGY, V177, P65, DOI 10.1016/0042-6822(90)90460-9; KUZUYA M, 1993, J CLIN MICROBIOL, V31, P1308, DOI 10.1128/JCM.31.5.1308-1311.1993; Matsumoto K, 2011, PHYTOTHER RES, V25, P624, DOI 10.1002/ptr.3306; MATSUO T, 1978, AGR BIOL CHEM TOKYO, V42, P1637, DOI 10.1080/00021369.1978.10863225; Mukhtar H, 2000, AM J CLIN NUTR, V71, p1698S, DOI 10.1093/ajcn/71.6.1698S; NAKASHIMA H, 1992, ANTIVIR RES, V18, P91, DOI 10.1016/0166-3542(92)90008-S; Nakatsubo F, 2002, J WOOD SCI, V48, P414, DOI 10.1007/BF00770702; NAKAYAMA M, 1993, ANTIVIR RES, V21, P289, DOI 10.1016/0166-3542(93)90008-7; Noma K, 1998, ARCH VIROL, V143, P1893, DOI 10.1007/s007050050428; Pourcel L, 2007, TRENDS PLANT SCI, V12, P29, DOI 10.1016/j.tplants.2006.11.006; Sakaguchi T, 1999, VIROLOGY, V263, P230, DOI 10.1006/viro.1999.9960; Sakaguchi T, 2002, J VIROL, V76, P1682, DOI 10.1128/JVI.76.4.1682-1690.2002; Serrano J, 2009, MOL NUTR FOOD RES, V53, pS310, DOI 10.1002/mnfr.200900039; Song JM, 2005, ANTIVIR RES, V68, P66, DOI 10.1016/j.antiviral.2005.06.010; WHITE T., 1957, Journal of the Science of Food and Agriculture, V8, P377, DOI 10.1002/jsfa.2740080702; Williamson MP, 2006, J ALLERGY CLIN IMMUN, V118, P1369, DOI 10.1016/j.jaci.2006.08.016; WRIGHT PF, 2006, FIELDS VIROLOGY, P1692; Yamaguchi K, 2002, ANTIVIR RES, V53, P19, DOI 10.1016/S0166-3542(01)00189-9	28	84	93	4	51	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2013	8	1							e55343	10.1371/journal.pone.0055343	http://dx.doi.org/10.1371/journal.pone.0055343			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	093RV	23372851	Green Submitted, Green Published, gold			2023-01-03	WOS:000315210400091
J	Dharmarajan, K; Hsieh, AF; Lin, ZQ; Bueno, H; Ross, JS; Horwitz, LI; Barreto, JA; Kim, N; Bernheim, SM; Suter, LG; Drye, EE; Krumholz, HM				Dharmarajan, Kumar; Hsieh, Angela F.; Lin, Zhenqiu; Bueno, Hector; Ross, Joseph S.; Horwitz, Leora I.; Barreto-Filho, Jose Augusto; Kim, Nancy; Bernheim, Susannah M.; Suter, Lisa G.; Drye, Elizabeth E.; Krumholz, Harlan M.			Diagnoses and Timing of 30-Day Readmissions After Hospitalization for Heart Failure, Acute Myocardial Infarction, or Pneumonia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESTRICTED ACTIVITY; INPATIENT CARE; RISK-FACTORS; REHOSPITALIZATION; QUALITY; MANAGEMENT; RATES; INTERVENTION; ASSOCIATION; PERFORMANCE	Importance To better guide strategies intended to reduce high rates of 30-day readmission after hospitalization for heart failure (HF), acute myocardial infarction (MI), or pneumonia, further information is needed about readmission diagnoses, readmission timing, and the relationship of both to patient age, sex, and race. Objective To examine readmission diagnoses and timing among Medicare beneficiaries readmitted within 30 days after hospitalization for HF, acute MI, or pneumonia. Design, Setting, and Patients We analyzed 2007-2009 Medicare fee-for-service claims data to identify patterns of 30-day readmission by patient demographic characteristics and time after hospitalization for HF, acute MI, or pneumonia. Readmission diagnoses were categorized using an aggregated version of the Centers for Medicare & Medicaid Services' Condition Categories. Readmission timing was determined by day after discharge. Main Outcome Measures We examined the percentage of 30-day readmissions occurring on each day (0-30) after discharge; the most common readmission diagnoses occurring during cumulative periods (days 0-3, 0-7, 0-15, and 0-30) and consecutive periods (days 0-3, 4-7, 8-15, and 16-30) after hospitalization; median time to readmission for common readmission diagnoses; and the relationship between patient demographic characteristics and readmission diagnoses and timing. Results From 2007 through 2009, we identified 329 308 30-day readmissions after 1 330 157 HF hospitalizations (24.8% readmitted), 108 992 30-day readmissions after 548 834 acute MI hospitalizations (19.9% readmitted), and 214 239 30-day readmissions after 1 168 624 pneumonia hospitalizations (18.3% readmitted). The proportion of patients readmitted for the same condition was 35.2% after the index HF hospitalization, 10.0% after the index acute MI hospitalization, and 22.4% after the index pneumonia hospitalization. Of all readmissions within 30 days of hospitalization, the majority occurred within 15 days of hospitalization: 61.0%, HF cohort; 67.6%, acute MI cohort; and 62.6%, pneumonia cohort. The diverse spectrum of readmission diagnoses was largely similar in both cumulative and consecutive periods after discharge. Median time to 30-day readmission was 12 days for patients initially hospitalized for HF, 10 days for patients initially hospitalized for acute MI, and 12 days for patients initially hospitalized for pneumonia and was comparable across common readmission diagnoses. Neither readmission diagnoses nor timing substantively varied by age, sex, or race. Conclusion and Relevance Among Medicare fee-for-service beneficiaries hospitalized for HF, acute MI, or pneumonia, 30-day readmissions were frequent throughout the month after hospitalization and resulted from a similar spectrum of readmission diagnoses regardless of age, sex, race, or time after discharge. JAMA. 2013;309(4):355-363 www.jama.com	[Dharmarajan, Kumar] Columbia Univ, Med Ctr, Dept Internal Med, Div Cardiol, New York, NY USA; [Dharmarajan, Kumar; Hsieh, Angela F.; Lin, Zhenqiu; Ross, Joseph S.; Horwitz, Leora I.; Barreto-Filho, Jose Augusto; Kim, Nancy; Bernheim, Susannah M.; Drye, Elizabeth E.; Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA; [Bueno, Hector] Hosp Gen Univ Gregorio Maranon, Dept Cardiol, Madrid, Spain; [Ross, Joseph S.; Horwitz, Leora I.; Kim, Nancy] Yale Univ, Sch Med, Dept Internal Med, Gen Internal Med Sect, New Haven, CT 06510 USA; [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT 06510 USA; [Ross, Joseph S.; Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Internal Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA; [Krumholz, Harlan M.] Sch Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT USA	Columbia University; Yale University; General University Gregorio Maranon Hospital; Yale University; Yale University; Yale University	Krumholz, HM (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, 1 Church St,Ste 200, New Haven, CT 06510 USA.	harlan.krumholz@yale.edu	Horwitz, Leora/ABD-1292-2020; Bueno, Hector/I-3910-2015; , Harlan/AAI-2875-2020; Horwitz, Leora/A-6959-2009	Bueno, Hector/0000-0003-0277-7596; Horwitz, Leora/0000-0003-1800-6040; Ross, Joseph/0000-0002-9218-3320	AstraZeneca; Bayer; DaiichiSankyo; Eli Lilly; Novartis; Roche; Medtronic through Yale University; (Center for Cardiovascular Outcomes Research at Yale University) from the National Heart, Lung, and Blood Institute [1U01HL105270-03]; National Heart, Lung, and Blood Institute [T32 HL007854]; National Institute on Aging and by the American Federation for Aging Research through the Paul B. Beeson Career Development Award Program [K08 AG032886, K08 AG038336]; CAPES (Coordenacao de Aperfeic, oamento de Pessoal de Nivel Superior, Ministry of Education, Brazil) [3436-10-1]; Federal University of Sergipe, Brazil; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL105270, T32HL007854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG038336, K08AG032886] Funding Source: NIH RePORTER	AstraZeneca(AstraZeneca); Bayer(Bayer AG); DaiichiSankyo(Daiichi Sankyo Company Limited); Eli Lilly(Eli Lilly); Novartis(Novartis); Roche(Roche Holding); Medtronic through Yale University; (Center for Cardiovascular Outcomes Research at Yale University) from the National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute on Aging and by the American Federation for Aging Research through the Paul B. Beeson Career Development Award Program; CAPES (Coordenacao de Aperfeic, oamento de Pessoal de Nivel Superior, Ministry of Education, Brazil); Federal University of Sergipe, Brazil; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Bernheim, Drye, Horwitz, Kim, Krumholz, Lin, Ross, and Suter work under contract with the Centers for Medicare & Medicaid Services to develop and maintain performance measures. Dr Bueno reported that he has received speaking or advisory fees from AstraZeneca, Bayer, DaiichiSankyo, Eli Lilly, Novartis, and Roche. Dr Krumholz reported that he is chair of a cardiac scientific advisory board for UnitedHealth. Dr Ross reported that he is a member of a scientific advisory board for FAIR Health. Drs Krumholz and Ross are the recipients of a research grant from Medtronic through Yale University.; This study was funded by grant 1U01HL105270-03 (Center for Cardiovascular Outcomes Research at Yale University) from the National Heart, Lung, and Blood Institute. Dr Dharmarajan is supported by grant T32 HL007854 from the National Heart, Lung, and Blood Institute; he is also supported as a Centers of Excellence Scholar in Geriatric Medicine at Yale by the John A. Hartford Foundation and the American Federation for Aging Research. Drs Ross and Horwitz are supported by grants K08 AG032886 and K08 AG038336 from the National Institute on Aging and by the American Federation for Aging Research through the Paul B. Beeson Career Development Award Program, respectively. Dr Barreto-Filho is supported by grant 3436-10-1 from CAPES (Coordenacao de Aperfeic, oamento de Pessoal de Nivel Superior, Ministry of Education, Brazil) and the Federal University of Sergipe, Brazil.	Ashton CM, 1996, SOC SCI MED, V43, P1533, DOI 10.1016/S0277-9536(96)00049-4; ASHTON CM, 1995, ANN INTERN MED, V122, P415, DOI 10.7326/0003-4819-122-6-199503150-00003; Ashton CM, 1997, MED CARE, V35, P1044, DOI 10.1097/00005650-199710000-00006; Bernheim SM, 2010, CIRC-CARDIOVASC QUAL, V3, P459, DOI 10.1161/CIRCOUTCOMES.110.957613; Birman-Deych E, 2005, MED CARE, V43, P480, DOI 10.1097/01.mlr.0000160417.39497.a9; Calvillo-King L, 2013, J GEN INTERN MED, V28, P269, DOI 10.1007/s11606-012-2235-x; Centers for Medicare & Medicaid Services, 2011, MED HOSP QUAL CHARTB; Centers for Medicare & Medicaid Services Hospital Pay-for-Performance Workgroup, 2007, 1 PUBL SESS WASH DC; Chaudhry SI, 2010, NEW ENGL J MED, V363, P2301, DOI 10.1056/NEJMoa1010029; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Covinsky KE, 2003, J AM GERIATR SOC, V51, P451, DOI 10.1046/j.1532-5415.2003.51152.x; Dunlay SM, 2012, ANN INTERN MED, V157, P11, DOI 10.7326/0003-4819-157-1-201207030-00004; Felker GM, 2011, NEW ENGL J MED, V364, P797, DOI 10.1056/NEJMoa1005419; Friedman MM, 1997, HEART LUNG, V26, P169, DOI 10.1016/S0147-9563(97)90053-4; Gill TM, 2010, JAMA-J AM MED ASSOC, V304, P1919, DOI 10.1001/jama.2010.1568; Gill TM, 2004, JAMA-J AM MED ASSOC, V292, P2115, DOI 10.1001/jama.292.17.2115; Hansen LO, 2011, ANN INTERN MED, V155, P520, DOI 10.7326/0003-4819-155-8-201110180-00008; Hernandez AF, 2010, JAMA-J AM MED ASSOC, V303, P1716, DOI 10.1001/jama.2010.533; Jack BW, 2009, ANN INTERN MED, V150, P178, DOI 10.7326/0003-4819-150-3-200902030-00007; Jasti H, 2008, CLIN INFECT DIS, V46, P550, DOI 10.1086/526526; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Keenan PS, 2008, CIRC-CARDIOVASC QUAL, V1, P29, DOI 10.1161/CIRCOUTCOMES.108.802686; Kiely DK, 2003, J GERONTOL A-BIOL, V58, P441, DOI 10.1093/gerona/58.5.M441; Kiyota Y, 2004, AM HEART J, V148, P99, DOI 10.1016/j.ahj.2004.02.013; Kocher RP, 2011, JAMA-J AM MED ASSOC, V306, P1794, DOI 10.1001/jama.2011.1561; Koehler F, 2011, CIRCULATION, V123, P1873, DOI 10.1161/CIRCULATIONAHA.111.018473; Kortebein P, 2007, JAMA-J AM MED ASSOC, V297, P1772, DOI 10.1001/jama.297.16.1772-b; Krumholz HM, 2013, NEW ENGL J MED, V368, P100, DOI 10.1056/NEJMp1212324; Krumholz HM, 2011, CIRC-CARDIOVASC QUAL, V4, P243, DOI 10.1161/CIRCOUTCOMES.110.957498; Lindenauer PK, 2011, J HOSP MED, V6, P142, DOI 10.1002/jhm.890; Lindenauer Peter K, 2010, J Hosp Med, V5, pE12, DOI 10.1002/jhm.822; Loo VG, 2011, NEW ENGL J MED, V365, P1693, DOI 10.1056/NEJMoa1012413; McBean A Marshall, 2006, Medicare Brief, P1; Medicare Payment Advisory Commission, 2007, PROM GREAT EFF MED; National Quality Forum, 2008, NAT VOL CONS STAND H; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; O'Connor CM, 2010, AM HEART J, V159, P841, DOI 10.1016/j.ahj.2010.02.023; Poch DS, 2009, SEMIN RESP CRIT CARE, V30, P26, DOI 10.1055/s-0028-1119806; Pope GC, 2004, HEALTH CARE FINANC R, V25, P119; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Riegel B, 2006, J CARD FAIL, V12, P211, DOI 10.1016/j.cardfail.2006.01.005; Ross JS, 2010, CIRC-HEART FAIL, V3, P97, DOI 10.1161/CIRCHEARTFAILURE.109.885210; SEARLE SR, 1980, AM STAT, V34, P216, DOI 10.2307/2684063; Skull SA, 2008, EPIDEMIOL INFECT, V136, P232, DOI 10.1017/S0950268807008564; Sochalski J, 2009, HEALTH AFFAIR, V28, P179, DOI 10.1377/hlthaff.28.1.179; Sullivan DH, 1999, JAMA-J AM MED ASSOC, V281, P2013, DOI 10.1001/jama.281.21.2013; Witte KKA, 2006, HEART, V92, P481, DOI 10.1136/hrt.2004.058073; Wong FKY, 2008, J ADV NURS, V62, P585, DOI 10.1111/j.1365-2648.2008.04631.x; Yoder JC, 2012, ARCH INTERN MED, V172, P68, DOI 10.1001/archinternmed.2011.603	49	701	711	4	59	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 23	2013	309	4					355	363		10.1001/jama.2012.216476	http://dx.doi.org/10.1001/jama.2012.216476			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074FT	23340637	Green Accepted, Bronze			2023-01-03	WOS:000313799000023
J	Reid, IC				Reid, Ian C.			Are antidepressants overprescribed? No	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							EFFICACY		Univ Aberdeen, Div Appl Med, Aberdeen, Scotland	University of Aberdeen	Reid, IC (corresponding author), Univ Aberdeen, Div Appl Med, Aberdeen, Scotland.	i.reid@abdn.ac.uk						Anderson IM, 2008, J PSYCHOPHARMACOL, V22, P343, DOI 10.1177/0269881107088441; Cameron IM, 2009, BRIT J GEN PRACT, V59, P644, DOI 10.3399/bjgp09X454061; Cuijpers P, 2010, PSYCHOL MED, V40, P211, DOI 10.1017/S0033291709006114; Fountoulakis KN, 2011, INT J NEUROPSYCHOPH, V14, P405, DOI 10.1017/S1461145710000957; Gibbons RD, 2012, ARCH GEN PSYCHIAT, V69, P572, DOI 10.1001/archgenpsychiatry.2011.2044; Kirsch I, 2008, PLOS MED, V5, P260, DOI 10.1371/journal.pmed.0050045; Leucht S, 2012, BRIT J PSYCHIAT, V200, P97, DOI 10.1192/bjp.bp.111.096594; Lockhart P, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X593848; Mitchell AJ, 2009, LANCET, V374, P609, DOI 10.1016/S0140-6736(09)60879-5; Moore M, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3999; Munoz-Arroyo R, 2006, BRIT J GEN PRACT, V56, P423; NHS Scotland, 2012, PRESCR MED MED US ME; Penn E, 2012, THER ADV PSYCHOPHARM, V2, P179, DOI 10.1177/2045125312445469; Robinson P, 2009, HLTH SERV J     0209; Scottish Parliament, 2010, 3 SCOTT PARL PUBL AU	15	15	15	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 22	2013	346								f190	10.1136/bmj.f190	http://dx.doi.org/10.1136/bmj.f190			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	080BG	23341567				2023-01-03	WOS:000314215600010
J	Ryan, CJ; Smith, MR; de Bono, JS; Molina, A; Logothetis, CJ; de Souza, P; Fizazi, K; Mainwaring, P; Piulats, JM; Ng, S; Carles, J; Mulders, PFA; Basch, E; Small, EJ; Saad, F; Schrijvers, D; Van Poppel, H; Mukherjee, SD; Suttmann, H; Gerritsen, WR; Flaig, TW; George, DJ; Yu, EY; Efstathiou, E; Pantuck, A; Winquist, E; Higano, CS; Taplin, ME; Park, Y; Kheoh, T; Griffin, T; Scher, HI; Rathkopf, DE				Ryan, Charles J.; Smith, Matthew R.; de Bono, Johann S.; Molina, Arturo; Logothetis, Christopher J.; de Souza, Paul; Fizazi, Karim; Mainwaring, Paul; Piulats, Josep M.; Ng, Siobhan; Carles, Joan; Mulders, Peter F. A.; Basch, Ethan; Small, Eric J.; Saad, Fred; Schrijvers, Dirk; Van Poppel, Hendrik; Mukherjee, Som D.; Suttmann, Henrik; Gerritsen, Winald R.; Flaig, Thomas W.; George, Daniel J.; Yu, Evan Y.; Efstathiou, Eleni; Pantuck, Allan; Winquist, Eric; Higano, Celestia S.; Taplin, Mary-Ellen; Park, Youn; Kheoh, Thian; Griffin, Thomas; Scher, Howard I.; Rathkopf, Dana E.		COU-AA-302 Investigators	Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN CYTOCHROME P450(17-ALPHA); HORMONAL-THERAPY; CONTROLLED-TRIAL; END-POINTS; ACETATE; MITOXANTRONE; INHIBITION; PREDNISONE; DOCETAXEL; CYP17	BACKGROUND Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated this agent in patients who had not received previous chemotherapy. METHODS In this double-blind study, we randomly assigned 1088 patients to receive abiraterone acetate (1000 mg) plus prednisone (5 mg twice daily) or placebo plus prednisone. The coprimary end points were radiographic progression-free survival and overall survival. RESULTS The study was unblinded after a planned interim analysis that was performed after 43% of the expected deaths had occurred. The median radiographic progression-free survival was 16.5 months with abiraterone-prednisone and 8.3 months with prednisone alone (hazard ratio for abiraterone-prednisone vs. prednisone alone, 0.53; 95% confidence interval [CI], 0.45 to 0.62; P<0.001). Over a median follow-up period of 22.2 months, overall survival was improved with abiraterone-prednisone (median not reached, vs. 27.2 months for prednisone alone; hazard ratio, 0.75; 95% CI, 0.61 to 0.93; P = 0.01) but did not cross the efficacy boundary. Abiraterone-prednisone showed superiority over prednisone alone with respect to time to initiation of cytotoxic chemotherapy, opiate use for cancer-related pain, prostate-specific antigen progression, and decline in performance status. Grade 3 or 4 mineralocorticoid- related adverse events and abnormalities on liver-function testing were more common with abiraterone-prednisone. CONCLUSIONS Abiraterone improved radiographic progression-free survival, showed a trend toward improved overall survival, and significantly delayed clinical decline and initiation of chemotherapy in patients with metastatic castration-resistant prostate cancer. (Funded by Janssen Research and Development, formerly Cougar Biotechnology; ClinicalTrials.gov number, NCT00887198.)	[Ryan, Charles J.; Small, Eric J.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Smith, Matthew R.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA; [Taplin, Mary-Ellen] Dana Farber Canc Inst, Boston, MA 02115 USA; [de Bono, Johann S.] Inst Canc Res, Sutton, Surrey, England; [de Bono, Johann S.] Royal Marsden Hosp, Sutton, Surrey, England; [Molina, Arturo; Park, Youn; Kheoh, Thian; Griffin, Thomas] Janssen Res & Dev, Los Angeles, CA USA; [Pantuck, Allan] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Logothetis, Christopher J.; Efstathiou, Eleni] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [de Souza, Paul] St George Private Hosp, Kogarah, NSW, Australia; [Mainwaring, Paul] Haematol & Oncol Clin Australia, Brisbane, Qld, Australia; [Ng, Siobhan] St John God Hosp, Subiaco, WA, Australia; [Fizazi, Karim] Univ Paris 11, Inst Gustave Roussy, Villejuif, France; [Piulats, Josep M.] Inst Catala Oncol Hosp, Barcelona, Spain; [Carles, Joan] Univ Vall dHebron, Barcelona, Spain; [Mulders, Peter F. A.] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Gerritsen, Winald R.] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; [Basch, Ethan; Scher, Howard I.; Rathkopf, Dana E.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Saad, Fred] Univ Montreal, Montreal, PQ, Canada; [Mukherjee, Som D.] Juravinski Canc Ctr, Hamilton Hlth Serv, Hamilton, ON, Canada; [Winquist, Eric] London Hlth Sci Ctr, London, ON, Canada; [Schrijvers, Dirk] Hosp Network Antwerp ZNA Middelheim, Antwerp, Belgium; [Van Poppel, Hendrik] Katholieke Univ Leuven Hosp, Louvain, Belgium; [Suttmann, Henrik] Urologikum Hamburg, Hamburg, Germany; [Flaig, Thomas W.] Univ Colorado, Ctr Canc, Aurora, CO USA; [George, Daniel J.] Duke Univ Hosp, Med Ctr, Durham, NC USA; [Yu, Evan Y.; Higano, Celestia S.] Univ Washington, Seattle, WA 98195 USA; [Efstathiou, Eleni] Univ Athens, Sch Med, Alexandra Hosp, Dept Clin Therapeut, GR-10679 Athens, Greece	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Harvard University; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Johnson & Johnson; Janssen Pharmaceuticals; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Texas System; UTMD Anderson Cancer Center; St John of God Health Care; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Radboud University Nijmegen; Vrije Universiteit Amsterdam; Memorial Sloan Kettering Cancer Center; Universite de Montreal; McMaster University; London Health Sciences Centre; ZNA Middelheim Hospital; Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven; University of Colorado System; University of Colorado Anschutz Medical Campus; Duke University; University of Washington; University of Washington Seattle; Alexandra Hospital; Athens Medical School; National & Kapodistrian University of Athens	Ryan, CJ (corresponding author), UCSF Helen Diller Family Comprehens Canc Ctr, Genitourinary Med Oncol Program, 1600 Divisadero St, San Francisco, CA 94115 USA.	ryanc@medicine.ucsf.edu	de Souza, Paul/P-5069-2019; gerritsen, Winald/H-8031-2014; Piulats, Josep M/F-2862-2019; Mulders, Peter F.A./H-8076-2014	Piulats, Josep M/0000-0002-3606-1724; Carles, Joan/0000-0002-9983-5934; de Bono, Johann S/0000-0002-2034-595X; OUDARD, Stephane/0000-0003-0893-285X; joly, florence/0000-0001-6168-4942; colombel, marc/0000-0002-0152-8021; Horvath, Lisa/0000-0001-6842-9223; Fradet, Yves/0000-0002-7581-2500; Rathkopf, Dana/0000-0002-4503-7582; Joshua, Anthony/0000-0001-5159-4580	Janssen Research and Development; NATIONAL CANCER INSTITUTE [P30CA008748, K24CA121990, P30CA016672] Funding Source: NIH RePORTER	Janssen Research and Development; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by Ortho Biotech Oncology Research and Development, a unit of Cougar Biotechnology (now Janssen Research and Development).	Attard G, 2005, BJU INT, V96, P1241, DOI 10.1111/j.1464-410X.2005.05821.x; Attard G, 2009, J CLIN ONCOL, V27, P3742, DOI 10.1200/JCO.2008.20.0642; Barrie SE, 1997, J STEROID BIOCHEM, V60, P347, DOI 10.1016/S0960-0760(96)00225-7; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Efstathiou E, 2012, J CLIN ONCOL, V30, P637, DOI 10.1200/JCO.2010.33.7675; Engel-Nitz Nicole M, 2011, Cancer Manag Res, V3, P233, DOI 10.2147/CMR.S21033; Garcia JA, 2012, CANCER-AM CANCER SOC, V118, P2583, DOI 10.1002/cncr.26582; Harris V, 2011, CLIN ONCOL-UK, V23, P706, DOI 10.1016/j.clon.2011.04.014; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; Holzbeierlein J, 2004, AM J PATHOL, V164, P217, DOI 10.1016/S0002-9440(10)63112-4; Jarman M, 1998, J MED CHEM, V41, P5375, DOI 10.1021/jm981017j; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Molenberghs G, 2004, STAT METHODS MED RES, V13, P177, DOI 10.1191/0962280204sm362ra; Molina A, 2011, J UROLOGY, V185, P787, DOI 10.1016/j.juro.2010.10.042; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; POTTER GA, 1995, J MED CHEM, V38, P2463, DOI 10.1021/jm00013a022; Ryan CJ, 2011, CLIN CANCER RES, V17, P4854, DOI 10.1158/1078-0432.CCR-11-0815; Ryan CJ, 2010, J CLIN ONCOL, V28, P1481, DOI 10.1200/JCO.2009.24.1281; Saad F, 2002, JNCI-J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458; Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487; Small EJ, 1997, J CLIN ONCOL, V15, P382, DOI 10.1200/JCO.1997.15.1.382; Sternberg CN, 2009, J CLIN ONCOL, V27, P5431, DOI 10.1200/JCO.2008.20.1228; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720	26	2010	2074	3	178	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 10	2013	368	2					138	148		10.1056/NEJMoa1209096	http://dx.doi.org/10.1056/NEJMoa1209096			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	066RO	23228172	Green Accepted, Green Published			2023-01-03	WOS:000313238100004
J	Sinha, SK; Detsky, AS				Sinha, Samir K.; Detsky, Allan S.			Measure, Promote, and Reward Mobility to Prevent Falls in Older Patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HOSPITALIZATION		[Detsky, Allan S.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON M5S 1A1, Canada; [Sinha, Samir K.; Detsky, Allan S.] Univ Toronto, Dept Med, Toronto, ON M5S 1A1, Canada; [Sinha, Samir K.; Detsky, Allan S.] Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; [Sinha, Samir K.; Detsky, Allan S.] Univ Hlth Network, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Detsky, AS (corresponding author), 600 Univ Ave,Room 429, Toronto, ON M5G 1X5, Canada.	adetsky@mtsinai.on.ca						ASHER RAJ, 1947, BRIT MED J, V2, P967, DOI 10.1136/bmj.2.4536.967; Brown R, 2009, POLYM TEST, V28, P1, DOI 10.1016/j.polymertesting.2008.12.001; Covinsky KE, 2011, JAMA-J AM MED ASSOC, V306, P1782, DOI 10.1001/jama.2011.1556; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; Inouye SK, 2009, NEW ENGL J MED, V360, P2390, DOI 10.1056/NEJMp0900963; Oliver D, 2010, CLIN GERIATR MED, V26, P645, DOI 10.1016/j.cger.2010.06.005; Rizzuto D, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e5568; Valkenet K, 2011, CLIN REHABIL, V25, P99, DOI 10.1177/0269215510380830	8	12	12	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 26	2012	308	24					2573	2574		10.1001/jama.2012.68313	http://dx.doi.org/10.1001/jama.2012.68313			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	062JR	23268514				2023-01-03	WOS:000312916600021
J	Chao, CT; Hou, CC; Wu, VC; Lu, HM; Wang, CY; Chen, L; Kao, TW				Chao, Chia-Ter; Hou, Chun-Cheng; Wu, Vin-Cent; Lu, Hsin-Ming; Wang, Cheng-Yi; Chen, Likwang; Kao, Tze-Wah			The Impact of Dialysis-Requiring Acute Kidney Injury on Long-Term Prognosis of Patients Requiring Prolonged Mechanical Ventilation: Nationwide Population-Based Study	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; ACUTE-RENAL-FAILURE; CRITICALLY-ILL PATIENTS; REPLACEMENT THERAPY; RESOURCE UTILIZATION; RISK-FACTORS; MORTALITY; OUTCOMES; DEATH; DISEASE	Background: Prolonged mechanical ventilation (PMV) is increasingly common worldwide, consuming enormous healthcare resources. Factors that modify PMV outcome are still obscure. Methods: We selected patients without preceding mechanical ventilation within the one past year and who developed PMV during index admission in Taiwan's National Health Insurance (NHI) system during 1998-2007 for comparison of mortality and resource use. They were divided into three groups: (1) patients with end-stage renal diseases (ESRD) before the index admission for PMV onset; (2) patients with dialysis-requiring acute kidney injury (AKI-dialysis) during the hospitalization course; and (3) patients without AKI or with non dialysis-requiring AKI during the hospitalization course (non-AKI). We used a random-effects logistic regression model to identify factors associated with mortality. Results: Compared with the other two groups, patients with AKI-dialysis had significantly longer mechanical ventilation, more frequent use of vasopressors, longer intensive care unit/hospital stay and higher inpatient expenditures during the index admission. Relative to non-AKI patients, patients with AKI-dialysis had an elevated mortality hazard; the adjusted relative risk ratios were 1.51 (95% confidence interval [CI]:1.46-1.56), 1.27 (95% CI: 1.23-1.32), and 1.10 (95% CI: 1.08-1.12) for mortality rates at discharge, 3 months, and 4 years after PMV, respectively. Patients with AKI-dialysis also consumed significantly higher total in-patient expenditure than the other two patient groups (p < 0.001). Conclusions: Among patients that need PMV care during an admission, the presence of de novo AKI requiring dialysis significantly increased short and long term mortality, and demand for health care resources.	[Chao, Chia-Ter; Wu, Vin-Cent; Kao, Tze-Wah] Natl Taiwan Univ Hosp, Dept Internal Med, Div Nephrol, Taipei 100, Taiwan; [Hou, Chun-Cheng] Min Sheng Gen Hosp, Dept Internal Med, Tao Yuan, Taiwan; [Lu, Hsin-Ming; Chen, Likwang] Natl Hlth Res Inst, Inst Populat Hlth Sci, Zhunan, Taiwan; [Wang, Cheng-Yi] Cardinal Tien Hosp, Dept Internal Med, Xindian, Taiwan; [Hou, Chun-Cheng] Taipei Med Univ, Sch Med, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Health Research Institutes - Taiwan; Taipei Medical University	Chen, L (corresponding author), Natl Hlth Res Inst, Inst Populat Hlth Sci, Zhunan, Taiwan.	likwang@nhri.org.tw; twkao2@ntuh.gov.tw	Chao, Chia-Ter/H-7994-2019; Chen, Li-Kwang/E-3934-2010	Chao, Chia-Ter/0000-0003-2892-7986; WU, VIN-CENT/0000-0001-7935-0991	Taiwan's National Health Research Institutes [PH-100-PP-19, PH-101-PP-16]; National Taiwan University Hospital	Taiwan's National Health Research Institutes; National Taiwan University Hospital(National Taiwan University)	This study was financially supported by Taiwan's National Health Research Institutes, through grants PH-100-PP-19 and PH-101-PP-16; and by intramural funding from National Taiwan University Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aksu U, 2011, CONTRIB NEPHROL, V174, P119, DOI 10.1159/000329249; Alkandari O, 2011, CRIT CARE, V15, DOI 10.1186/cc10269; Bruetto RG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035496; Bucaloiu ID, 2012, KIDNEY INT, V81, P477, DOI 10.1038/ki.2011.405; Carson SS, 2008, CRIT CARE MED, V36, P2061, DOI 10.1097/CCM.0b013e31817b8925; Carson SS, 2006, CURR OPIN CRIT CARE, V12, P405, DOI 10.1097/01.ccx.0000244118.08753.dc; Carson SS, 2012, CRIT CARE MED, V40, P1171, DOI 10.1097/CCM.0b013e3182387d43; Carson SS, 2001, CHEST, V120, P928, DOI 10.1378/chest.120.3.928; Chelluri L, 2004, CRIT CARE MED, V32, P61, DOI 10.1097/01.CCM.0000098029.65347.F9; Clermont G, 2002, KIDNEY INT, V62, P986, DOI 10.1046/j.1523-1755.2002.00509.x; Cox CE, 2007, CRIT CARE MED, V35, P1918, DOI 10.1097/01.CCM.0000275391.35834.10; Cox CE, 2007, CRIT CARE, V11, DOI 10.1186/cc5667; Flori HR, 2011, CRIT CARE RES PRACT, V2011, DOI 10.1155/2011/854142; Ho J, 2012, AM J KIDNEY DIS, V59, P196, DOI 10.1053/j.ajkd.2011.08.023; Hsu CY, 2009, CLIN J AM SOC NEPHRO, V4, P891, DOI 10.2215/CJN.05571008; Hung MC, 2011, CRIT CARE, V15, DOI 10.1186/cc10128; Hutchison CA, 2007, CRIT CARE, V11, DOI 10.1186/cc5785; Jassal SV, 2011, NEPHRON CLIN PRACT, V119, pC5, DOI 10.1159/000328017; Kao KC, 2011, J CRIT CARE, V26, P600, DOI 10.1016/j.jcrc.2011.03.005; Kojicic M, 2011, RESP CARE, V56, P1765, DOI 10.4187/respcare.01096; Kong WY, 2012, NEPHROLOGY, V17, P445, DOI 10.1111/j.1440-1797.2012.01593.x; Liano F, 1998, KIDNEY INT, V53, pS16; Lien YC, 2009, ANN THORAC SURG, V88, P1124, DOI 10.1016/j.athoracsur.2009.06.002; Lo LJ, 2009, KIDNEY INT, V76, P893, DOI 10.1038/ki.2009.289; Lone NI, 2011, CRIT CARE, V15, DOI 10.1186/cc10117; Lu HM, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-100; MacIntyre NR, 2005, CHEST, V128, P3937, DOI 10.1378/chest.128.6.3937; Mehta RL, 2004, KIDNEY INT, V66, P1613, DOI 10.1111/j.1523-1755.2004.00927.x; Metnitz PGH, 2002, CRIT CARE MED, V30, P2051, DOI 10.1097/00003246-200209000-00016; Needham DM, 2004, CRIT CARE MED, V32, P1504, DOI 10.1097/01.CCM.0000129972.31533.37; Nelson JE, 2010, AM J RESP CRIT CARE, V182, P446, DOI 10.1164/rccm.201002-0210CI; Nierman DM, 2002, CRIT CARE CLIN, V18, P477, DOI 10.1016/S0749-0704(02)00010-6; Nin N, 2010, SHOCK, V34, P109, DOI 10.1097/SHK.0b013e3181d671a6; Ostermann M, 2008, CRIT CARE, V12, DOI 10.1186/cc7085; Pan SW, 2011, J CRIT CARE, V26, P586, DOI 10.1016/j.jcrc.2011.04.009; Ricci Z, 2011, NAT REV NEPHROL, V7, P201, DOI 10.1038/nrneph.2011.14; Rocha E, 2009, NEPHROL DIAL TRANSPL, V24, P1925, DOI 10.1093/ndt/gfn750; Scheinhorn DJ, 1998, CRIT CARE CLIN, V14, P819, DOI 10.1016/S0749-0704(05)70032-4; Seferian EG, 2008, CRIT CARE MED, V36, P2779, DOI 10.1097/CCM.0b013e318186ab1b; Sood MM, 2011, NEPHROL DIAL TRANSPL, V26, P2965, DOI 10.1093/ndt/gfq835; Strijack B, 2009, J AM SOC NEPHROL, V20, P2441, DOI 10.1681/ASN.2009040366; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; Uchino S, 2003, BLOOD PURIFICAT, V21, P170, DOI 10.1159/000069156; Unroe M, 2010, ANN INTERN MED, V153, P167, DOI 10.7326/0003-4819-153-3-201008030-00007; Vieira JM, 2007, CRIT CARE MED, V35, P184, DOI 10.1097/01.CCM.0000249828.81705.65; Wald R, 2012, AM J MED, V125, P585, DOI 10.1016/j.amjmed.2012.01.016; Wald R, 2009, JAMA-J AM MED ASSOC, V302, P1179, DOI 10.1001/jama.2009.1322; Wi J, 2011, HEART, V97, P1753, DOI 10.1136/hrt.2010.218677; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	49	37	39	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2012	7	12							e50675	10.1371/journal.pone.0050675	http://dx.doi.org/10.1371/journal.pone.0050675			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	066QV	23251377	Green Published, gold, Green Submitted			2023-01-03	WOS:000313236200034
J	McCartney, M				McCartney, Margaret			Calorie restriction and longevity: fast and loose?	BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				YouTube, BBC HOR 2012 EAT FAS	1	1	1	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	OCT 24	2012	345								e6872	10.1136/bmj.e6872	http://dx.doi.org/10.1136/bmj.e6872			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	028MY	23097550				2023-01-03	WOS:000310427600014
J	Wang, H; Yang, YP; Wang, GJ; Wang, SM; Yeap, BY; Sykes, M; Yang, YG				Wang, Hui; Yang, Yanping; Wang, Guanjun; Wang, Shumei; Yeap, Beow Yong; Sykes, Megan; Yang, Yong-Guang			Donor Bone Marrow-Derived T Cells Inhibit GVHD Induced by Donor Lymphocyte Infusion in Established Mixed Allogeneic Hematopoietic Chimeras	PLOS ONE			English	Article							VERSUS-HOST-DISEASE; REFRACTORY HEMATOLOGIC MALIGNANCIES; REGULATORY-CELLS; TRANSPLANTATION; INDUCTION; THERAPY; SUPPRESSION; ENVIRONMENT; TOLERANCE; REJECTION	Delayed administration of donor lymphocyte infusion (DLI) to established mixed chimeras has been shown to achieve antitumor responses without graft-vs.-host disease (GVHD). Herein we show that de novo donor BM-derived T cells that are tolerant of the recipients are important in preventing GVHD in mixed chimeras receiving delayed DLI. Mixed chimeras lacking donor BM-derived T cells developed significantly more severe GVHD than those with donor BM-derived T cells after DLI, even though both groups had comparable levels of total T cells at the time of DLI. Post-DLI depletion of donor BM-derived T cells in mixed chimeras, as late as 20 days after DLI, also provoked severe GVHD. Although both CD4 and CD8 T cells contributed to the protection, the latter were significantly more effective, suggesting that inhibition of GVHD was not mainly mediated by CD4 regulatory T cells. The lack of donor BM-derived T cells was associated with markedly increased accumulation of DLI-derived alloreactive T cells in parenchymal GVHD target tissues. Thus, donor BM-derived T cells are an important factor in determining the risk of GVHD and therefore, offer a potential therapeutic target for preventing and ameliorating GVHD in the setting of delayed DLI in established mixed chimeras.	[Wang, Hui; Sykes, Megan; Yang, Yong-Guang] Columbia Univ Coll Phys & Surg, Columbia Ctr Translat Immunol, New York, NY 10032 USA; [Wang, Hui; Yang, Yanping; Wang, Shumei] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA USA; [Yang, Yanping; Wang, Guanjun; Yang, Yong-Guang] Jilin Univ, Bethune Hosp 1, Changchun 130023, Jilin, Peoples R China; [Yeap, Beow Yong] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA	Columbia University; Harvard University; Harvard Medical School; Massachusetts General Hospital; Jilin University; Harvard University; Harvard Medical School; Massachusetts General Hospital	Yang, YG (corresponding author), Columbia Univ Coll Phys & Surg, Columbia Ctr Translat Immunol, 630 W 168th St, New York, NY 10032 USA.	yy2324@columbia.edu		Yang, Yong-Guang/0000-0003-4985-1247	NIH [PO1 CA111519, RC1 HL100117, R01 AI064569]; NATIONAL CANCER INSTITUTE [P01CA111519] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [RC1HL100117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064569] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by grants from NIH (PO1 CA111519, RC1 HL100117 and R01 AI064569). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antony PA, 2005, J IMMUNOL, V174, P2591, DOI 10.4049/jimmunol.174.5.2591; Chakraverty R, 2008, J IMMUNOL, V181, P6820, DOI 10.4049/jimmunol.181.10.6820; Chakraverty R, 2006, J EXP MED, V203, P2021, DOI 10.1084/jem.20060376; Chen X, 2009, BLOOD, V114, P891, DOI 10.1182/blood-2009-01-197178; Dulude G, 1999, J EXP MED, V189, P1329, DOI 10.1084/jem.189.8.1329; Gattinoni L, 2005, J EXP MED, V202, P907, DOI 10.1084/jem.20050732; Gorski J, 2007, BLOOD, V109, P5502, DOI 10.1182/blood-2006-12-061713; Joetham A, 2011, J IMMUNOL, V186, P113, DOI 10.4049/jimmunol.1001663; Johnson BD, 1999, J IMMUNOL, V163, P6479; Johnson BD, 2002, BIOL BLOOD MARROW TR, V8, P525, DOI 10.1053/bbmt.2002.v8.pm12434947; Kapp JA, 2006, INT IMMUNOL, V18, P1549, DOI 10.1093/intimm/dxl088; Karlsson I, 2007, J VIROL, V81, P13444, DOI 10.1128/JVI.01466-07; Lu LR, 2006, IMMUNOL REV, V212, P51, DOI 10.1111/j.0105-2896.2006.00418.x; Mapara MY, 2002, BLOOD, V100, P1903, DOI 10.1182/blood-2002-01-0023; Miller JS, 2007, BLOOD, V110, P2761, DOI 10.1182/blood-2007-05-090340; Nakagawa T, 2010, INT IMMUNOL, V22, P129, DOI 10.1093/intimm/dxp119; Nguyen VH, 2008, BLOOD, V111, P945, DOI 10.1182/blood-2007-07-103895; Paulos CM, 2007, J CLIN INVEST, V117, P2197, DOI 10.1172/JCI32205; Pelot M R, 1999, Biol Blood Marrow Transplant, V5, P133, DOI 10.1053/bbmt.1999.v5.pm10392959; Quezada SA, 2010, J EXP MED, V207, P637, DOI 10.1084/jem.20091918; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Sho M, 2005, P NATL ACAD SCI USA, V102, P13230, DOI 10.1073/pnas.0505070102; Spitzer TR, 2000, BIOL BLOOD MARROW TR, V6, P309, DOI 10.1016/S1083-8791(00)70056-5; Spitzer TR, 2003, TRANSPLANTATION, V75, P1748, DOI 10.1097/01.TP.0000064211.23536.AD; Sugita S, 2007, EXP EYE RES, V85, P626, DOI 10.1016/j.exer.2007.07.015; Sykes M, 1999, LANCET, V353, P1755, DOI 10.1016/S0140-6736(98)11135-2; Taylor PA, 2004, BLOOD, V104, P3804, DOI 10.1182/blood-2004-05-1850; Wang H, 2009, BLOOD, V113, P3612, DOI 10.1182/blood-2008-07-168419; Yang YG, 1998, J EXP MED, V187, P1335, DOI 10.1084/jem.187.8.1335	29	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2012	7	10							e47120	10.1371/journal.pone.0047120	http://dx.doi.org/10.1371/journal.pone.0047120			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022WO	23077554	Green Published, Green Submitted, gold			2023-01-03	WOS:000309995100064
J	Del Ry, S; Cabiati, M; Lionetti, V; Aquaro, GD; Martino, A; Mattii, L; Morales, MA				Del Ry, Silvia; Cabiati, Manuela; Lionetti, Vincenzo; Aquaro, Giovanni D.; Martino, Alessandro; Mattii, Letizia; Morales, Maria-Aurora			Pacing-Induced Regional Differences in Adenosine Receptors mRNA Expression in a Swine Model of Dilated Cardiomyopathy	PLOS ONE			English	Article							VENTRICULAR PUMP FUNCTION; HEART-FAILURE; NPR-B; ACTIVATION; DESENSITIZATION; CONTRACTILITY; TRANSPORT; GENES	The adenosinergic system is essential in the mediation of intrinsic protection and myocardial resistance to insult; it may be considered a cardioprotective molecule and adenosine receptors (ARs) represent potential therapeutic targets in the setting of heart failure (HF). The aim of the study was to test whether differences exist between mRNA expression of ARs in the anterior left ventricle (LV) wall (pacing site: PS) compared to the infero septal wall (opposite region: OS) in an experimental model of dilated cardiomyopathy. Cardiac tissue was collected from LV PS and OS of adult male minipigs with pacing-induced HF (n = 10) and from a control group (C, n = 4). ARs and TNF-alpha mRNA expression was measured by Real Time-PCR and the results were normalized with the three most stably expressed genes (GAPDH, HPRT1, TBP). Immunohistochemistry analysis was also performed. After 3 weeks of pacing higher levels of expression for each analyzed AR were observed in PS except for A(1)R (A(1)R: C = 0.6 +/- 0.2, PS = 0.1 +/- 0.04, OS = 0.04 +/- 0.01, p<0.0001 C vs. PS and OS respectively; A(2A)R: C = 1.04 +/- 0.59, PS = 2.62 +/- 0.79, OS = 2.99 +/- 0.79; A(2B)R: C = 1.2 +/- 0.1, PS = 5.59 +/- 2.3, OS = 1.59 +/- 0.46; A(3)R: C = 0.76 +/- 0.18, PS = 8.40 +/- 3.38, OS = 4.40 +/- 0.83). Significant contractile impairment and myocardial hypoperfusion were observed at PS after three weeks of pacing as compared to OS. TNF-alpha mRNA expression resulted similar in PS (6.3 +/- 2.4) and in OS (5.9 +/- 2.7) although higher than in control group (3.4 +/- 1.5). ARs expression was mainly detected in cardiomyocytes. This study provided new information on ARs local changes in the setting of LV dysfunction and on the role of these receptors in relation to pacing-induced abnormalities of myocardial perfusion and contraction. These results suggest a possible therapeutic role of adenosine in patients with HF and dyssynchronous LV contraction.	[Del Ry, Silvia; Cabiati, Manuela; Morales, Maria-Aurora] CNR, Inst Clin Physiol, I-56100 Pisa, Italy; [Lionetti, Vincenzo] Scuola Super Sant Anna, Lab Med Sci, Inst Life Sci, Pisa, Italy; [Aquaro, Giovanni D.] Fdn CNR Reg Toscana G Monasterio, MRI Lab, Pisa, Italy; [Martino, Alessandro] Univ Pisa, Dept Biol, Div Genet, Pisa, Italy; [Mattii, Letizia] Univ Pisa, Med Histol & Embryol Sect, Dept Human Morphol & Appl Biol, Pisa, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); Scuola Superiore Sant'Anna; University of Pisa; University of Pisa	Del Ry, S (corresponding author), CNR, Inst Clin Physiol, Via Savi 8, I-56100 Pisa, Italy.	delry@ifc.cnr.it	Lionetti, Vincenzo/G-9528-2014; Cabiati, Manuela/K-1306-2014; MATTII, LETIZIA/B-6123-2018; mattii, letizia/K-3023-2019; Del Ry, Silvia/C-1149-2015; Mattii, Letizia/AAZ-4735-2021; Lionetti, Vincenzo/AAN-1994-2020; Lionetti, Vincenzo/AAH-9503-2020; aquaro, giovanni donato/AAB-8978-2019	Cabiati, Manuela/0000-0002-0811-6257; MATTII, LETIZIA/0000-0001-6835-7987; Del Ry, Silvia/0000-0001-7163-245X; Lionetti, Vincenzo/0000-0002-0640-8651; aquaro, giovanni donato/0000-0003-0915-915X				Baker CM, 2002, PACE, V25, P1166, DOI 10.1046/j.1460-9592.2002.01166.x; Ciruela F, 1997, MOL PHARMACOL, V52, P788, DOI 10.1124/mol.52.5.788; Del Ry S, 2011, PEPTIDES, V32, P1713, DOI 10.1016/j.peptides.2011.06.014; Del Ry S, 2007, PEPTIDES, V28, P1390, DOI 10.1016/j.peptides.2007.05.003; Del Ry S, 2011, J CARDIOVASC PHARM, V58, P149, DOI 10.1097/FJC.0b013e31821dcc0b; Del Ry S, 2009, PEPTIDES, V30, P1710, DOI 10.1016/j.peptides.2009.06.013; Del Ry S, 2008, PEPTIDES, V29, P2208, DOI 10.1016/j.peptides.2008.09.005; Fredholm BB, 2007, CELL DEATH DIFFER, V14, P1315, DOI 10.1038/sj.cdd.4402132; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Gemignani V, 2010, PACE, V33, P795, DOI 10.1111/j.1540-8159.2009.02684.x; Gorlach A, 2005, CIRC RES, V97, P1, DOI 10.1161/01.RES.0000174112.36064.77; GRINES CL, 1989, CIRCULATION, V79, P845, DOI 10.1161/01.CIR.79.4.845; Iuliano S, 2002, AM HEART J, V143, P1085, DOI 10.1067/mhj.2002.122516; Karsai D, 2006, J CARDIOVASC PHARM, V47, P103, DOI 10.1097/01.fjc.0000196239.51018.a0; KITAKAZE M, 1993, CARDIOVASC RES, V27, P18, DOI 10.1093/cvr/27.1.18; Klaasse EC, 2008, PURINERG SIGNAL, V4, P21, DOI 10.1007/s11302-007-9086-7; Lionetti V, 2007, AM J PHYSIOL-HEART C, V293, pH2747, DOI 10.1152/ajpheart.00592.2007; Lionetti Vincenzo, 2009, J Card Fail, V15, P920, DOI 10.1016/j.cardfail.2009.06.436; Martino A, 2011, J BIOTECHNOL, V153, P92, DOI 10.1016/j.jbiotec.2011.04.002; Monahan TS, 2000, AM J PHYSIOL-HEART C, V279, pH1472, DOI 10.1152/ajpheart.2000.279.4.H1472; Ojaimi C, 2007, PHYSIOL GENOMICS, V29, P76, DOI 10.1152/physiolgenomics.00159.2006; Prescimone T, 2011, PHARMACOL RES, V63, P207, DOI 10.1016/j.phrs.2010.09.006; Prinzen FW, 1999, J AM COLL CARDIOL, V33, P1735, DOI 10.1016/S0735-1097(99)00068-6; Prinzen FW, 2002, PACE, V25, P484, DOI 10.1046/j.1460-9592.2002.00484.x; Ralevic V, 1998, PHARMACOL REV, V50, P413; Robin E, 2011, J MOL CELL CARDIOL, V51, P945, DOI 10.1016/j.yjmcc.2011.08.023; Shryock JC, 1997, AM J CARDIOL, V79, P2, DOI 10.1016/S0002-9149(97)00256-7; Sweeney MO, 2008, CIRC-ARRHYTHMIA ELEC, V1, P127, DOI 10.1161/CIRCEP.108.777904; Talukder MAH, 2003, J CARDIOVASC PHARM, V41, P562, DOI 10.1097/00005344-200304000-00008	29	11	11	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2012	7	10							e47011	10.1371/journal.pone.0047011	http://dx.doi.org/10.1371/journal.pone.0047011			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	020LH	23071699	gold, Green Published			2023-01-03	WOS:000309809500029
J	Nowsheen, S; Cooper, T; Stanley, JA; Yang, ES				Nowsheen, Somaira; Cooper, Tiffiny; Stanley, Jennifer A.; Yang, Eddy S.			Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells	PLOS ONE			English	Article							FACTOR RECEPTOR EGFR; POLY(ADP-RIBOSE) POLYMERASE; DNA-REPAIR; GROWTH; BRCA1; HEAD; CETUXIMAB; CARCINOMAS; EXPRESSION; PATHWAYS	Few therapeutic options exist for the highly aggressive triple negative breast cancers (TNBCs). In this study, we report that a contextual synthetic lethality can be achieved both in vitro and in vivo with combined EGFR and PARP inhibition with lapatinib and ABT-888, respectively. The mechanism involves a transient DNA double strand break repair deficit induced by lapatinib and subsequent activation of the intrinsic pathway of apoptosis. Further dissection of the mechanism reveals that EGFR and BRCA1 can be found in the same protein complex, which is reduced by lapatinib. Interestingly, lapatinib also increases cytosolic BRCA1 and EGFR, away from their nuclear DNA repair substrates. Taken together, these results reveal a novel regulation of homologous recombination repair involving EGFR and BRCA1 interaction and alteration of subcellular localization. Additionally, a contextual synthetic lethality may exist between combined EGFR and PARP inhibitors.	[Nowsheen, Somaira; Cooper, Tiffiny; Stanley, Jennifer A.; Yang, Eddy S.] Univ Alabama Birmingham, Sch Med, Ctr Comprehens Canc, Dept Radiat Oncol, Birmingham, AL USA; [Yang, Eddy S.] Univ Alabama Birmingham, Sch Med, Dept Cell Dev & Integrat Biol, Birmingham, AL USA; [Yang, Eddy S.] Univ Alabama Birmingham, Sch Med, Ctr Comprehens Canc, Dept Pharmacol & Toxicol, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Yang, ES (corresponding author), Univ Alabama Birmingham, Sch Med, Ctr Comprehens Canc, Dept Radiat Oncol, Birmingham, AL USA.	eyang@uab.edu			UAB Specialized Programs of Research Excellence (SPORE) in breast cancer [5P50CA089019-10]; Translational Scholar Award from Sidney Kimmel Foundation; Breast Cancer Research Foundation of Alabama; State of Alabama Investment Pool for Action (IMPACT) Award from the University of Alabama at Birmingham School of Medicine; Comprehensive Cancer Center and Department of Radiation Oncology at the University of Alabama at Birmingham School of Medicine; NATIONAL CANCER INSTITUTE [P50CA089019] Funding Source: NIH RePORTER	UAB Specialized Programs of Research Excellence (SPORE) in breast cancer; Translational Scholar Award from Sidney Kimmel Foundation; Breast Cancer Research Foundation of Alabama; State of Alabama Investment Pool for Action (IMPACT) Award from the University of Alabama at Birmingham School of Medicine; Comprehensive Cancer Center and Department of Radiation Oncology at the University of Alabama at Birmingham School of Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a career development award from the UAB Specialized Programs of Research Excellence (SPORE) in breast cancer (5P50CA089019-10), a Translational Scholar Award from Sidney Kimmel Foundation, pilot funding from the Breast Cancer Research Foundation of Alabama, the State of Alabama Investment Pool for Action (IMPACT) Award from the University of Alabama at Birmingham School of Medicine, and developmental support from the Comprehensive Cancer Center and Department of Radiation Oncology at the University of Alabama at Birmingham School of Medicine (to ESY). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ang KK, 2002, CANCER RES, V62, P7350; Anido J, 2003, CLIN CANCER RES, V9, P1274; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Boyle F, 2012, J CLIN ONCOL, V30; Carey L, 2010, NAT REV CLIN ONCOL, V7, P683, DOI 10.1038/nrclinonc.2010.154; Chacon RD, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2574; Chung CH, 2006, J CLIN ONCOL, V24, P4170, DOI 10.1200/JCO.2006.07.2587; Dittmann K, 2005, RADIOTHER ONCOL, V76, P157, DOI 10.1016/j.radonc.2005.06.022; Esteva FJ, 2010, NAT REV CLIN ONCOL, V7, P98, DOI 10.1038/nrclinonc.2009.216; Feng ZH, 2004, J BIOL CHEM, V279, P28574, DOI 10.1074/jbc.M404137200; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Huang SM, 2000, CLIN CANCER RES, V6, P2166; Javle M, 2011, BRIT J CANCER, V105, P1114, DOI 10.1038/bjc.2011.382; Jiang JH, 2011, CANCER RES, V71, P5546, DOI 10.1158/0008-5472.CAN-10-3423; Laulier C, 2011, CANCER RES, V71, P3590, DOI 10.1158/0008-5472.CAN-10-3119; Lehmann Bd Fau - Bauer JA, 2011, IDENTIFICATION HUMAN; Li LP, 2008, CANCER RES, V68, P9141, DOI 10.1158/0008-5472.CAN-08-1127; Liu D, 2011, MED ONCOL; Martin V, 2012, HISTOL HISTOPATHOL, V27, P785, DOI 10.14670/HH-27.785; Myllynen L, 2011, RADIOTHER ONCOL, V101, P147, DOI 10.1016/j.radonc.2011.05.046; Nakajima H, 2012, BREAST CANC; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nowsheen S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024148; Nowsheen S, 2011, RADIOTHER ONCOL, V99, P331, DOI 10.1016/j.radonc.2011.05.084; Oliveras-Ferraros C, 2008, INT J ONCOL, V33, P1165, DOI 10.3892/ijo_00000106; Peddi PF, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/217185; Roberti MP, 2011, BREAST CANCER RES TR, V130, P465, DOI 10.1007/s10549-011-1360-2; Rodemann HP, 2007, INT J RADIAT BIOL, V83, P781, DOI 10.1080/09553000701769970; Subik K, 2010, BREAST CANCER-BASIC, V4, P35; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; Voldborg BR, 1997, ANN ONCOL, V8, P1197, DOI 10.1023/A:1008209720526; Vranic S, 2011, ONCOL LETT, V2, P1131, DOI 10.3892/ol.2011.375; Wang H, 2010, CANCER RES, V70, P6258, DOI 10.1158/0008-5472.CAN-09-4713; Yang ES, 2010, FEBS J, V277, P3079, DOI 10.1111/j.1742-4658.2010.07734.x; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004	37	86	92	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2012	7	10							e46614	10.1371/journal.pone.0046614	http://dx.doi.org/10.1371/journal.pone.0046614			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	020KP	23071597	Green Submitted, Green Published, gold			2023-01-03	WOS:000309807700023
J	Lee, U; Lee, H; Muller, M; Noh, GJ; Mashour, GA				Lee, UnCheol; Lee, HeonSoo; Mueller, Markus; Noh, Gyu-Jeong; Mashour, George A.			Genuine and Spurious Phase Synchronization Strengths during Consciousness and General Anesthesia	PLOS ONE			English	Article							FUNCTIONAL CONNECTIVITY; VOLUME-CONDUCTION; EEG; COHERENCE; BINDING; HUMANS; MODELS; INDEX; NOISE; MEG	Spectral content in a physiological dataset of finite size has the potential to produce spurious measures of coherence. This is especially true for electroencephalography (EEG) during general anesthesia because of the significant alteration of the power spectrum. In this study we quantitatively evaluated the genuine and spurious phase synchronization strength (PSS) of EEG during consciousness, general anesthesia, and recovery. A computational approach based on the randomized data method was used for evaluating genuine and spurious PSS. The validity of the method was tested with a simulated dataset. We applied this method to the EEG of normal subjects undergoing general anesthesia and investigated the finite size effects of EEG references, data length and spectral content on phase synchronization. The most influential factor for genuine PSS was the type of EEG reference; the most influential factor for spurious PSS was the spectral content. Genuine and spurious PSS showed characteristic temporal patterns for each frequency band across consciousness and anesthesia. Simultaneous measurement of both genuine and spurious PSS during general anesthesia is necessary in order to avoid incorrect interpretations regarding states of consciousness.	[Lee, UnCheol; Lee, HeonSoo; Mashour, George A.] Univ Michigan, Dept Anesthesiol, Sch Med, Div Neuroanesthesiol, Ann Arbor, MI 48109 USA; [Lee, HeonSoo] POSTECH, Dept Phys, Pohang, South Korea; [Mueller, Markus] Univ Nacl Autonoma Mexico, Fac Ciencias, Univ Autonoma Estado Morelos, Centro Int Ciencias, Cuernavaca 62191, Morelos, Mexico; [Noh, Gyu-Jeong] Univ Ulsan, Coll Med, Dept Clin Pharmacol & Therapeut, Dept Anesthesiol & Pain Med,Asan Med Ctr, Seoul, South Korea; [Mashour, George A.] Univ Michigan, Grad Program Neurosci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Pohang University of Science & Technology (POSTECH); Universidad Autonoma del Estado de Morelos; Universidad Nacional Autonoma de Mexico; University of Ulsan; University of Michigan System; University of Michigan	Lee, U (corresponding author), Univ Michigan, Dept Anesthesiol, Sch Med, Div Neuroanesthesiol, Ann Arbor, MI 48109 USA.	uclee@med.umich.edu		Muller, Markus Franziskus/0000-0002-2653-6204	Department of Anesthesiology, University of Michigan, Ann Arbor; National Institutes of Health [RR024987-01]; Consejo Nacional de Ciencia y Tecnologia, Mexico; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024987] Funding Source: NIH RePORTER	Department of Anesthesiology, University of Michigan, Ann Arbor(University of Michigan System); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Consejo Nacional de Ciencia y Tecnologia, Mexico(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This study was supported by the Department of Anesthesiology, University of Michigan, Ann Arbor; National Institutes of Health KL2 grant (RR024987-01) (GAM, UL); Consejo Nacional de Ciencia y Tecnologia, Mexico (MM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allefeld C, 2007, INT J BIFURCAT CHAOS, V17, P3493, DOI 10.1142/S0218127407019251; American Clinical Neurophysiology Society, 2006, J Clin Neurophysiol, V23, P111; Aviyente S, 2011, HUM BRAIN MAPP, V32, P80, DOI 10.1002/hbm.21000; Boveroux P, 2010, ANESTHESIOLOGY, V113, P1038, DOI 10.1097/ALN.0b013e3181f697f5; Cui D, 2010, NEURAL NETWORKS, V23, P698, DOI 10.1016/j.neunet.2010.04.003; Ferrarelli F, 2010, P NATL ACAD SCI USA, V107, P2681, DOI 10.1073/pnas.0913008107; Foster BL, 2008, COGN NEURODYNAMICS, V2, P283, DOI 10.1007/s11571-008-9063-z; Galka A, 2003, INT J BIFURCAT CHAOS, V13, P723, DOI 10.1142/S0218127403006881; Gencer NG, 2004, PHYS MED BIOL, V49, P701, DOI 10.1088/0031-9155/49/5/004; Guevara R, 2005, NEUROINFORMATICS, V3, P301, DOI 10.1385/NI:3:4:301; Kugiumtzis D, 2000, PHYS REV E, V62, pR25, DOI 10.1103/PhysRevE.62.R25; Laloux L, 1999, PHYS REV LETT, V83, P1467, DOI 10.1103/PhysRevLett.83.1467; Lee U, 2011, ANESTHESIOLOGY, V114, P872, DOI 10.1097/ALN.0b013e31821102c9; Lee U, 2009, CONSCIOUS COGN, V18, P1069, DOI 10.1016/j.concog.2009.04.004; Lee U, 2009, CONSCIOUS COGN, V18, P56, DOI 10.1016/j.concog.2008.10.005; Martuzzi R, 2010, NEUROIMAGE, V49, P823, DOI 10.1016/j.neuroimage.2009.07.028; Mhuircheartaigh RN, 2010, J NEUROSCI, V30, P9095, DOI 10.1523/JNEUROSCI.5516-09.2010; Mormann F, 2000, PHYSICA D, V144, P358, DOI 10.1016/S0167-2789(00)00087-7; Muller M, 2008, EPL-EUROPHYS LETT, V84, DOI 10.1209/0295-5075/84/10009; Muller MF, 2011, J CLIN NEUROPHYSIOL, V28, P450, DOI 10.1097/WNP.0b013e318231c894; Muller M, 2005, PHYS REV E, V71, P1; Nunez PL, 1997, ELECTROEN CLIN NEURO, V103, P499, DOI 10.1016/S0013-4694(97)00066-7; Peltier SJ, 2005, NEUROREPORT, V16, P285, DOI 10.1097/00001756-200502280-00017; Plerou V, 1999, PHYS REV LETT, V83, P1471, DOI 10.1103/PhysRevLett.83.1471; Rummel C, 2007, J NEUROSCI METH, V166, P138, DOI 10.1016/j.jneumeth.2007.06.023; Rummel C, 2010, J NEUROSCI METH, V191, P94, DOI 10.1016/j.jneumeth.2010.05.022; Salinas E, 2001, NAT REV NEUROSCI, V2, P539, DOI 10.1038/35086012; Schiff SJ, 2005, NEUROINFORMATICS, V3, P315, DOI 10.1385/NI:3:4:315; Schrouff J, 2011, NEUROIMAGE, V57, P198, DOI 10.1016/j.neuroimage.2011.04.020; Seba P, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.198104; Sheeba JH, 2008, BIOPHYS J, V95, P2722, DOI 10.1529/biophysj.108.134635; Stam CJ, 2007, HUM BRAIN MAPP, V28, P1178, DOI 10.1002/hbm.20346; Treisman A, 1996, CURR OPIN NEUROBIOL, V6, P171, DOI 10.1016/S0959-4388(96)80070-5; Vinck M, 2011, NEUROIMAGE, V55, P1548, DOI 10.1016/j.neuroimage.2011.01.055; VONDERMALSBURG C, 1995, CURR OPIN NEUROBIOL, V5, P520, DOI 10.1016/0959-4388(95)80014-X; White NS, 2003, NEUROIMAGE, V19, P402, DOI 10.1016/S1053-8119(03)00103-4; Zaveri HP, 2000, CLIN NEUROPHYSIOL, V111, P1293, DOI 10.1016/S1388-2457(00)00321-7	37	13	14	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2012	7	10							e46313	10.1371/journal.pone.0046313	http://dx.doi.org/10.1371/journal.pone.0046313			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	015NG	23056281	Green Submitted, Green Published, gold			2023-01-03	WOS:000309452600033
J	Leoncini, E; Prata, C; Malaguti, M; Marotti, I; Segura-Carretero, A; Catizone, P; Dinelli, G; Hrelia, S				Leoncini, Emanuela; Prata, Cecilia; Malaguti, Marco; Marotti, Ilaria; Segura-Carretero, Antonio; Catizone, Pietro; Dinelli, Giovanni; Hrelia, Silvana			Phytochemical Profile and Nutraceutical Value of Old and Modern Common Wheat Cultivars	PLOS ONE			English	Article							CORONARY-HEART-DISEASE; TRITICUM-AESTIVUM L.; PHASE-II ENZYMES; ANTIOXIDANT ACTIVITY; PHENOLIC-COMPOUNDS; OXIDATIVE STRESS; HEALTH-BENEFITS; NEURODEGENERATIVE DISEASES; CEREAL-GRAINS; WHOLE GRAINS	Among health-promoting phytochemicals in whole grains, phenolic compounds have gained attention as they have strong antioxidant properties and can protect against many degenerative diseases. Aim of this study was to profile grain phenolic extracts of one modern and five old common wheat (Triticum aestivum L.) varieties and to evaluate their potential antiproliferative or cytoprotective effect in different cell culture systems. Wheat extracts were characterized in terms of antioxidant activity and phenolic composition (HPLC/ESI-TOF-MS profile, polyphenol and flavonoid contents). Results showed that antioxidant activity (FRAP and DPPH) is mostly influenced by flavonoid (both bound and free) content and by the ratio flavonoids/polyphenols. Using a leukemic cell line, HL60, and primary cultures of neonatal rat cardiomyocytes, the potential antiproliferative or cytoprotective effects of different wheat genotypes were evaluated in terms of intracellular reactive oxygen species levels and cell viability. All tested wheat phenolic extracts exerted dose-dependent cytoprotective and antiproliferative effects on cardiomyocytes and HL60 cells, respectively. Due to the peculiar phenolic pattern of each wheat variety, a significant genotype effect was highlighted. On the whole, the most relevant scavenging effect was found for the old variety Verna. No significant differences in terms of anti-proliferative activities among wheat genotypes was observed. Results reported in this study evidenced a correspondence between the in vitro antioxidant activity and potential healthy properties of different extracts. This suggests that an increased intake of wheat grain derived products could represent an effective strategy to achieve both chemoprevention and protection against oxidative stress related diseases.	[Leoncini, Emanuela; Prata, Cecilia; Malaguti, Marco; Hrelia, Silvana] Univ Bologna, Dept Biochem, I-40126 Bologna, Italy; [Marotti, Ilaria; Catizone, Pietro; Dinelli, Giovanni] Univ Bologna, Dept Agroenvironm Sci & Technol, Bologna, Italy; [Segura-Carretero, Antonio] Univ Granada, Dept Analyt Chem, E-18071 Granada, Spain	University of Bologna; University of Bologna; University of Granada	Hrelia, S (corresponding author), Univ Bologna, Dept Biochem, I-40126 Bologna, Italy.	silvana.hrelia@unibo.it	Carretero, Antonio Segura/B-6867-2014; Hrelia, Silvana/P-2864-2015; Malaguti, Marco/K-5994-2015	Carretero, Antonio Segura/0000-0002-5564-5338; Hrelia, Silvana/0000-0001-7857-4512; Malaguti, Marco/0000-0003-0349-7772; Dinelli, Giovanni/0000-0003-1740-3511	Italian Ministry of Economic Development, Emilia Romagna region, Italy [CUP J31J09000430002]; Italian Ministry of Agriculture [CUP 31J09000370001]; Fondazione del Monte di Bologna e Ravenna (Italy)	Italian Ministry of Economic Development, Emilia Romagna region, Italy; Italian Ministry of Agriculture; Fondazione del Monte di Bologna e Ravenna (Italy)(Fondazione del Monte di Bologna e Ravenna)	This work was supported by grants from the Italian Ministry of Economic Development (Project "Made in Italy-over 50"), Emilia Romagna region, Italy (Project "BioPane", CUP J31J09000430002) and the Italian Ministry of Agriculture (Project "Pane della salute" MiPAF-OIGA, CUP 31J09000370001) and by Fondazione del Monte di Bologna e Ravenna (Italy). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adom KK, 2003, J AGR FOOD CHEM, V51, P7825, DOI 10.1021/jf030404l; Adom KK, 2002, J AGR FOOD CHEM, V50, P6182, DOI 10.1021/jf0205099; Angeloni C, 2008, AM J PHYSIOL-HEART C, V294, pH1233, DOI 10.1152/ajpheart.01091.2007; Angeloni C, 2007, BIOCHIMIE, V89, P73, DOI 10.1016/j.biochi.2006.09.006; Angeloni C, 2011, AM J PHYSIOL-HEART C, V300, pH2196, DOI 10.1152/ajpheart.00934.2010; Angeloni C, 2009, J AGR FOOD CHEM, V57, P5615, DOI 10.1021/jf900549c; Bach-Faig A, 2011, PUBLIC HEALTH NUTR, V14, P2274, DOI 10.1017/S1368980011002515; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; Bilodeau M, 2002, J MULTIVARIATE ANAL, V82, P457, DOI 10.1006/jmva.2001.2027; BLOIS MS, 1958, NATURE, V181, P1199, DOI 10.1038/1811199a0; Bonfili L, 2009, BIOCHIMIE, V91, P1131, DOI 10.1016/j.biochi.2009.06.001; Chen CM, 2008, J NEUROSCI RES, V86, P2696, DOI 10.1002/jnr.21706; Chen LJ, 2003, CHEM RES TOXICOL, V16, P1155, DOI 10.1021/tx0340605; Chlopicka J, 2012, LWT-FOOD SCI TECHNOL, V46, P548, DOI 10.1016/j.lwt.2011.11.009; Clerkin JS, 2008, CANCER LETT, V266, P30, DOI 10.1016/j.canlet.2008.02.029; Danielson SR, 2008, FREE RADICAL BIO MED, V44, P1787, DOI 10.1016/j.freeradbiomed.2008.03.005; de Munter JSL, 2007, PLOS MED, V4, P1385, DOI 10.1371/journal.pmed.0040261; Di Silvestro R, 2012, J SCI FOOD AGR, V92, P2800, DOI 10.1002/jsfa.5590; Dinelli G, 2007, ELECTROPHORESIS, V28, P4212, DOI 10.1002/elps.200700301; Dinelli G, 2011, J CHROMATOGR A, V1218, P7670, DOI 10.1016/j.chroma.2011.05.065; Dinelli G, 2009, J CHROMATOGR A, V1216, P7229, DOI 10.1016/j.chroma.2009.08.041; Diplock AT, 1999, BRIT J NUTR, V81, pS1, DOI 10.1017/S0007114599000471; Dykes L, 2007, CEREAL FOOD WORLD, V52, P105, DOI 10.1094/CFW-52-3-0105; Eilat-Adar S, 2010, NUTR METAB CARDIOVAS, V20, P459, DOI 10.1016/j.numecd.2010.01.011; Fardet A, 2010, NUTR RES REV, V23, P65, DOI 10.1017/S0954422410000041; Felice F, 2012, EUR J PHARM BIOPHARM, V80, P176, DOI 10.1016/j.ejpb.2011.09.002; FENG Y, 1988, CEREAL CHEM, V65, P452; Flight I, 2006, EUR J CLIN NUTR, V60, P1145, DOI 10.1038/sj.ejcn.1602435; Fraga CG, 2010, MOL ASPECTS MED, V31, P435, DOI 10.1016/j.mam.2010.09.006; Halliwell B., 2007, FREE RADICAL BIOL ME; Harris KA, 2010, CURR ATHEROSCLER REP, V12, P368, DOI 10.1007/s11883-010-0136-1; Heimler D, 2010, J AGR FOOD CHEM, V58, P7329, DOI 10.1021/jf1010534; Jambu M, 1991, STAT MODELING DECISI; Jonnalagadda SS, 2011, J NUTR, V141, p1011S, DOI 10.3945/jn.110.132944; KAISER HF, 1960, EDUC PSYCHOL MEAS, V20, P141, DOI 10.1177/001316446002000116; Kutala VK, 2007, ANTIOXID REDOX SIGN, V9, P1193, DOI 10.1089/ars.2007.1636; Lacikova L, 2009, MOLECULES, V14, P3259, DOI 10.3390/molecules14093259; LAM TBT, 1990, PHYTOCHEMISTRY, V29, P429, DOI 10.1016/0031-9422(90)85091-S; Leifert WR, 2008, NUTR RES, V28, P729, DOI [10.1016/j.nutres.2008.08.007, 10.1016/j.nutres.2008.09.001]; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; Mattila P, 2005, J AGR FOOD CHEM, V53, P8290, DOI 10.1021/jf051437z; Matus-Cadiz MA, 2008, J AGR FOOD CHEM, V56, P1644, DOI 10.1021/jf072970c; MCCALLUM JA, 1990, CEREAL CHEM, V67, P282; Middleton E, 2000, PHARMACOL REV, V52, P673; Okarter N, 2010, CRIT REV FOOD SCI, V50, P193, DOI 10.1080/10408390802248734; Olenichenko NA, 2006, RUSS J PLANT PHYSL+, V53, P495, DOI 10.1134/S1021443706040108; Pauwels EKJ, 2010, MED PRIN PRACT, V20, P103, DOI 10.1159/000321197; Prata C, 2010, LEUKEMIA RES, V34, P1630, DOI 10.1016/j.leukres.2010.02.032; Price RK, 2012, BR J NUTR, P1; Ramassamy C, 2006, EUR J PHARMACOL, V545, P51, DOI 10.1016/j.ejphar.2006.06.025; Scalbert A, 2005, CRIT REV FOOD SCI, V45, P287, DOI 10.1080/1040869059096; Serpen A, 2008, J AGR FOOD CHEM, V56, P7285, DOI 10.1021/jf8010855; Singleton VL, 1999, METHOD ENZYMOL, V299, P152; Tabachnick BG, 2001, USING MULTIVARIATE S, V4th; Tsutsui H, 2011, AM J PHYSIOL-HEART C, V301, pH2181, DOI 10.1152/ajpheart.00554.2011; van den Broeck HC, 2010, THEOR APPL GENET, V121, P1527, DOI 10.1007/s00122-010-1408-4; Yu LL, 2002, J AGR FOOD CHEM, V50, P1619, DOI 10.1021/jf010964p	58	56	58	0	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2012	7	9							e45997	10.1371/journal.pone.0045997	http://dx.doi.org/10.1371/journal.pone.0045997			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	016KP	23049918	Green Published, Green Submitted, gold			2023-01-03	WOS:000309517300073
J	Chen, MB; Wu, XY; Yu, R; Li, C; Wang, LQ; Shen, W; Lu, PH				Chen, Min-Bin; Wu, Xiao-Yang; Yu, Rong; Li, Chen; Wang, Li-Qiang; Shen, Wei; Lu, Pei-Hua			P53 Status as a Predictive Biomarker for Patients Receiving Neoadjuvant Radiation-Based Treatment: A Meta-Analysis in Rectal Cancer	PLOS ONE			English	Article							PREOPERATIVE RADIOTHERAPY; TUMOR-REGRESSION; HISTOPATHOLOGIC RESPONSE; CHEMORADIATION THERAPY; THYMIDYLATE SYNTHASE; IONIZING-RADIATION; INDUCED APOPTOSIS; CHEMORADIOTHERAPY; EXPRESSION; CARCINOMA	Background: Numerous studies have yielded inconsistent results regarding the relationship between p53 status and the response to neoadjuvant radiation-based therapy in patients with rectal cancer. We conducted a meta-analysis to clarify the relationship between p53 status and response to radiation-based therapy in rectal cancer. Methods/Findings: A total of 30 previously published eligible studies including 1,830 cases were identified and included in this meta-analysis. Wild-type form of p53 status (low expression of p53 protein and/or wild-type p53 gene) was associated with pathologic response in rectal cancer patients who received neoadjuvant radiation-based therapy (good response: risk ratio [RR] = 1.30; 95% confidence intervals [CI] = 1.14-1.49; p<0.001; complete response RR = 1.65; 95% CI = 1.19-2.30; p = 0.003; poor response RR = 0.85; 95% CI = 0.75-0.96; p = 0.007). In further stratified analyses, this association remained for sub-groups of good and poor response in neoadjuvant radiotherapy (RT) setting, good and complete response in chemoradiotherapy (CRT) setting. And the association between response and the presence of p53 gene mutations was stronger than that between response and protein positivity. Conclusion: The results of the present meta-analysis indicate that P53 status is a predictive factor for response in rectal cancer patient undergoing neoadjuvant radiation-based therapy.	[Shen, Wei; Lu, Pei-Hua] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Gen Surg, Wuxi City, Jiangsu, Peoples R China; [Chen, Min-Bin; Wang, Li-Qiang] Jiangsu Univ, Kunshan Peoples Hosp 1, Dept Med Oncol, Kunshan, Jiangsu, Peoples R China; [Wu, Xiao-Yang] Jiangsu Univ, Kunshan Peoples Hosp 1, Dept Surg Oncol, Kunshan, Jiangsu, Peoples R China; [Yu, Rong] Nanjing Med Univ, Affiliated Suzhou Hosp, Suzhou Municipal Hosp, Dept Oncol, Suzhou, Jiangsu, Peoples R China; [Li, Chen] Nanjing Univ Chinese Med, Xuzhou Chinese Med Hosp, Dept Gastroenterol, Xuzhou, Jiangsu, Peoples R China	Jiangnan University; Nanjing Medical University; Jiangsu University; Jiangsu University; Nanjing Medical University; Nanjing University of Chinese Medicine	Lu, PH (corresponding author), Nanjing Med Univ, Wuxi Peoples Hosp, Dept Gen Surg, Wuxi City, Jiangsu, Peoples R China.	lphty1_1@yahoo.com.cn		Lu, Peihua/0000-0002-4622-3061	Natural Science Foundation of Jiangsu Province [BK2010160, BK2011374]; National Natural Science Foundation [81108676, 81101801]	Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); National Natural Science Foundation(National Natural Science Foundation of China (NSFC))	This work was supported by the Natural Science Foundation of Jiangsu Province (BK2010160, BK2011374) and the National Natural Science Foundation (81108676, 81101801). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Brophy S, 2009, INT J CANCER, V125, P2778, DOI 10.1002/ijc.24693; Charara M, 2004, ANTICANCER RES, V24, P3161; Chen MF, 2010, INT J RADIAT ONCOL, V78, P868, DOI 10.1016/j.ijrobp.2010.05.025; Chen ZB, 2011, J AM COLL SURGEONS, V212, P1008, DOI 10.1016/j.jamcollsurg.2011.02.024; Cuddihy AR, 2004, CANCER METAST REV, V23, P237, DOI 10.1023/B:CANC.0000031764.81141.e4; Diez M, 2003, ONCOLOGY-BASEL, V64, P213, DOI 10.1159/000069307; Dworak O, 1997, INT J COLORECTAL DIS, V12, P19, DOI 10.1007/s003840050072; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Elsaleh H, 2000, RADIOTHER ONCOL, V56, P239, DOI 10.1016/S0167-8140(00)00184-5; Fu CG, 1998, DIS COLON RECTUM, V41, P68, DOI 10.1007/BF02236898; Huerta S, 2009, EXPERT REV MOL DIAGN, V9, P469, DOI 10.1586/ERM.09.26; Jakob C, 2008, WORLD J GASTROENTERO, V14, P1060, DOI 10.3748/wjg.14.1060; JapaneseSocietyforCanceroftheColonandRectum, 1994, GEN ROL CLIN PATH ST, P42; Kandioler D, 2002, ANN SURG, V235, P493, DOI 10.1097/00000658-200204000-00006; Kapiteijn E, 2001, NEW ENGL J MED, V345, P638, DOI 10.1056/NEJMoa010580; Kelley Scott T, 2005, Clin Colorectal Cancer, V5, P114, DOI 10.3816/CCC.2005.n.023; Kobayashi H, 2007, DIS COLON RECTUM, V50, P1354, DOI 10.1007/s10350-006-0881-y; Komuro Y, 2005, HEPATO-GASTROENTEROL, V52, P666; Komuro Y, 2003, J EXP CLIN CANC RES, V22, P223; Lopez-Crapez E, 2005, BRIT J CANCER, V92, P2114, DOI 10.1038/sj.bjc.6602622; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Luna-Perez P, 1998, ANN SURG ONCOL, V5, P203, DOI 10.1007/BF02303772; MANDARD AM, 1994, CANCER, V73, P2680, DOI 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C; MERRITT AJ, 1994, CANCER RES, V54, P614; Moral M, 2009, PATHOL RES PRACT, V205, P695, DOI 10.1016/j.prp.2009.04.006; Garcia VM, 2011, COLORECTAL DIS, V13, P989, DOI 10.1111/j.1463-1318.2010.02386.x; Nasierowska-Guttmejer Anna, 2001, Polish Journal of Pathology, V52, P53; Negri FV, 2008, BRIT J CANCER, V98, P143, DOI 10.1038/sj.bjc.6604131; Rebischung C, 2002, INT J CANCER, V100, P131, DOI 10.1002/ijc.10480; Rodel C, 2005, J CLIN ONCOL, V23, P8688, DOI 10.1200/JCO.2005.02.1329; Rodel C, 2002, INT J RADIAT ONCOL, V52, P294, DOI 10.1016/S0360-3016(01)02643-8; Sadahiro S, 2007, HEPATO-GASTROENTEROL, V54, P1107; Sakakura C, 1998, BRIT J CANCER, V77, P159, DOI 10.1038/bjc.1998.25; Sauer R, 2004, NEW ENGL J MED, V351, P1731, DOI 10.1056/NEJMoa040694; Saw RPM, 2003, DIS COLON RECTUM, V46, P192, DOI 10.1007/s10350-004-6524-2; Scott N, 1998, EUR J SURG ONCOL, V24, P169, DOI 10.1016/S0748-7983(98)92861-X; Shinto E, 2011, DIS COLON RECTUM, V54, P1098, DOI 10.1097/DCR.0b013e3182218155; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Smith FM, 2006, EJSO-EUR J SURG ONC, V32, P55, DOI 10.1016/j.ejso.2005.09.010; Spitz FR, 1997, CLIN CANCER RES, V3, P1685; Spitz FR, 1996, CLIN CANCER RES, V2, P1665; Suzuki T, 2004, JPN J CLIN ONCOL, V34, P740, DOI 10.1093/jjco/hyh140; Takeuchi K, 2007, HEPATO-GASTROENTEROL, V54, P367; Terzi C, 2008, INT J COLORECTAL DIS, V23, P37, DOI 10.1007/s00384-007-0376-x; Tewari M, 2008, SURG ONCOL, V17, P301, DOI 10.1016/j.suronc.2008.03.003; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wheeler JMD, 2002, DIS COLON RECTUM, V45, P1051, DOI 10.1007/s10350-004-6359-x; Wong RKS, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002102.pub2; Zlobec I, 2008, BRIT J CANCER, V98, P450, DOI 10.1038/sj.bjc.6604172	50	51	56	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2012	7	9							e45388	10.1371/journal.pone.0045388	http://dx.doi.org/10.1371/journal.pone.0045388			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	016YP	23049793	Green Published, gold, Green Submitted			2023-01-03	WOS:000309556100043
J	Bindman, AB; Blum, JD; Kronick, R				Bindman, Andrew B.; Blum, Jonathan D.; Kronick, Richard			Medicare's Transitional Care Payment - A Step toward the Medical Home	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Bindman, Andrew B.; Kronick, Richard] US Dept HHS, Off Assistant Secretary Planning & Evaluat, Washington, DC 20201 USA; [Blum, Jonathan D.] US Dept HHS, Ctr Medicare & Medicaid Serv, Washington, DC 20201 USA; [Bindman, Andrew B.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA	Centers for Medicare & Medicaid Services; University of California System; University of California San Francisco	Bindman, AB (corresponding author), US Dept HHS, Off Assistant Secretary Planning & Evaluat, Washington, DC 20201 USA.							[Anonymous], 2012, GAO REPORT THE OBAMA; Centers for Medicare & Medicaid Services (CMS) HHS, 2012, Fed Regist, V77, P68891; Grumbach K, 2010, OUTCOMES OF IMPLEMEN; Hesselink G, 2012, ANN INTERN MED, V157, P417, DOI 10.7326/0003-4819-157-6-201209180-00006; The Commonwealth Fund Commission on a High Performance Health System, 2009, THE PATH TO A HIGH P	5	34	36	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 21	2013	368	8					692	694		10.1056/NEJMp1214122	http://dx.doi.org/10.1056/NEJMp1214122			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	092CG	23425161	Green Published			2023-01-03	WOS:000315095800002
J	Molyneux, S; Njue, M; Boga, M; Akello, L; Olupot-Olupot, P; Engoru, C; Kiguli, S; Maitland, K				Molyneux, Sassy; Njue, Maureen; Boga, Mwanamvua; Akello, Lilian; Olupot-Olupot, Peter; Engoru, Charles; Kiguli, Sarah; Maitland, Kathryn			'The Words Will Pass with the Blowing Wind': Staff and Parent Views of the Deferred Consent Process, with Prior Assent, Used in an Emergency Fluids Trial in Two African Hospitals	PLOS ONE			English	Article							CLINICAL-RESEARCH; INFORMED-CONSENT; DEVELOPING-COUNTRIES; COMMUNITY; CHILDREN; CARE; ILLNESS; IF	Objective: To document and explore the views and experiences of key stakeholders regarding the consent procedures of an emergency research clinical trial examining immediate fluid resuscitation strategies, and to discuss the implications for similar trials in future. Methods: A social science sub-study of the FEAST (Fluid Expansion As Supportive Therapy) trial. Interviews were held with trial team members (n = 30), health workers (n = 15) and parents (n = 51) from two purposively selected hospitals in Soroti, Uganda, and Kilifi, Kenya. Findings: Overall, deferred consent with prior assent was seen by staff and parents as having the potential to protect the interests of both patients and researchers, and to avoid delays in starting treatment. An important challenge is that the validity of verbal assent is undermined when inadequate initial information is poorly understood. This concern needs to be balanced against the possibility that full prior consent on admission potentially causes harm through introducing delays. Full prior consent also potentially imposes worries on parents that clinicians are uncertain about how to proceed and that clinicians want to absolve themselves of any responsibility for the child's outcome (some parents' interpretation of the need for signed consent). Voluntariness is clearly compromised for both verbal assent and full prior consent in a context of such vulnerability and stress. Further challenges in obtaining verbal assent were: what to do in the absence of the household decision-maker (often the father); and how medical staff handle parents not giving a clear agreement or refusal. Conclusion: While the challenges identified are faced in all research in low-income settings, they are magnified for emergency trials by the urgency of decision making and treatment needs. Consent options will need to be tailored to particular studies and settings, and might best be informed by consultation with staff members and community representatives using a deliberative approach.	[Molyneux, Sassy; Njue, Maureen] Kenya Govt Med Res Ctr, Wellcome Trust Res Programme, Hlth Syst & Social Sci Res Grp, Kilifi, Kenya; [Molyneux, Sassy] Univ Oxford, Ctr Trop Med, Oxford, England; [Molyneux, Sassy] Univ Oxford, Dept Publ Hlth & Primary Hlth Care, Ethox Ctr, Oxford, England; [Boga, Mwanamvua; Maitland, Kathryn] Kenya Govt Med Res Ctr, Wellcome Trust Res Programme, Kilifi Clin Trials Facil, Kilifi, Kenya; [Maitland, Kathryn] Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Paediat, Wellcome Trust Ctr Clin Trop Med, London, England; [Kiguli, Sarah] Makerere Univ, Mulago Natl Referral Hosp, Dept Paediat, Kampala, Uganda; [Olupot-Olupot, Peter] Mbale Reg Referral Hosp, Mbale, Uganda; [Engoru, Charles] Soroti Reg Referral Hosp, Soroti, Uganda; [Akello, Lilian] Malaria Consortium, Kampala, Uganda	Kenya Medical Research Institute; University of Oxford; University of Oxford; Kenya Medical Research Institute; Imperial College London; University of London; London School of Hygiene & Tropical Medicine; Makerere University; Mulago National Referral Hospital	Molyneux, S (corresponding author), Kenya Govt Med Res Ctr, Wellcome Trust Res Programme, Hlth Syst & Social Sci Res Grp, Kilifi, Kenya.	SMolyneux@kemri-wellcome.org	Molyneux, Catherine/HGB-8464-2022	Molyneux, Catherine/0000-0001-9522-416X; Maitland, Kathryn/0000-0002-0007-0645	Wellcome Trust, United Kingdom [WT085418]; Medical Research Council, United Kingdom [G0801439]; MRC [G0801439, G0601027] Funding Source: UKRI; Medical Research Council [G0801439, G0601027] Funding Source: researchfish	Wellcome Trust, United Kingdom(Wellcome Trust); Medical Research Council, United Kingdom(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the Wellcome Trust, United Kingdom (WT085418 to S.M.) (http://www.wellcome.ac.uk), and Medical Research Council, United Kingdom (G0801439 to K.M.) (http://www.mrc.ac.uk). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allmark P, 2006, J MED ETHICS, V32, P439, DOI 10.1136/jme.2005.013722; Boga M, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001089; Brierley J, 2011, J MED ETHICS, V37, P429, DOI 10.1136/jme.2010.040667; Brierley J, 2009, CRIT CARE MED, V37, P666, DOI 10.1097/CCM.0b013e31819323c6; Chuma J, 2009, INT J EQUITY HEALTH, V8, DOI 10.1186/1475-9276-8-15; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; Emanuel EJ, 2005, LANCET, V366, P336, DOI 10.1016/S0140-6736(05)66992-9; Emanuel EJ, 2004, J INFECT DIS, V189, P930, DOI 10.1086/381709; Gamble C, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0039429, 10.1371/journal.pone.0035982]; Green J, 2009, QUALITATIVE METHODS; Jansen TC, 2007, INTENS CARE MED, V33, P894, DOI 10.1007/s00134-007-0580-8; Jansen TC, 2010, INTENS CARE MED, V36, P1962, DOI 10.1007/s00134-010-1988-0; Kamuya D, 2013, DEV WORLD B IN PRESS, V13; Lairumbi Geoffrey M, 2012, Philos Ethics Humanit Med, V7, P7, DOI 10.1186/1747-5341-7-7; Largent EA, 2010, ARCH INTERN MED, V170, P668, DOI 10.1001/archinternmed.2010.80; Lindegger G, 2000, S AFR J SCI, V96, P313; Luce JM, 2003, CRIT CARE MED, V31, pS153, DOI 10.1097/01.CCM.0000054901.80339.01; Maitland K, 2011, NEW ENGL J MED, V364, P2483, DOI 10.1056/NEJMoa1101549; Maitland K, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-90; Manning DJ, 2000, J MED ETHICS, V26, P249, DOI 10.1136/jme.26.4.249; Marsh VM, 2011, PUBLIC HEALTH ETH-UK, V4, P26, DOI 10.1093/phe/phr007; Molyneux CS, 2005, SOC SCI MED, V61, P1463, DOI 10.1016/j.socscimed.2004.11.073; Molyneux CS, 2005, SOC SCI MED, V61, P443, DOI 10.1016/j.socscimed.2004.12.003; Molyneux CS, 2004, SOC SCI MED, V59, P2547, DOI 10.1016/j.socscimed.2004.03.037; Molyneux CS, 2002, J BIOSOC SCI, V34, P109, DOI 10.1017/S0021932002001098; Molyneux S, 2012, BMC MED ETHICS, V13, DOI 10.1186/1472-6939-13-13; Myburgh JA, 2011, NEW ENGL J MED, V364, P2543, DOI 10.1056/NEJMe1105490; Pariyo GW, 2009, INT J EQUITY HEALTH, V8, DOI 10.1186/1475-9276-8-39; Van Loon K, 2009, INFORM CONSENT CLIN, P14; World Health Organization, 2005, EM TRIAG ASS TREATM	30	38	38	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 11	2013	8	2							e54894	10.1371/journal.pone.0054894	http://dx.doi.org/10.1371/journal.pone.0054894			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	092DU	23408950	Green Published, gold, Green Submitted			2023-01-03	WOS:000315100000009
J	Climo, MW; Yokoe, DS; Warren, DK; Perl, TM; Bolon, M; Herwaldt, LA; Weinstein, RA; Sepkowitz, KA; Jernigan, JA; Sanogo, K; Wong, ES				Climo, Michael W.; Yokoe, Deborah S.; Warren, David K.; Perl, Trish M.; Bolon, Maureen; Herwaldt, Loreen A.; Weinstein, Robert A.; Sepkowitz, Kent A.; Jernigan, John A.; Sanogo, Kakotan; Wong, Edward S.			Effect of Daily Chlorhexidine Bathing on Hospital-Acquired Infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; BLOOD-STREAM INFECTIONS; INTENSIVE-CARE-UNIT; GENES QACA; SUSCEPTIBILITIES; INTERVENTION; ENTEROCOCCUS; NETWORK; REDUCE	BACKGROUND Results of previous single-center, observational studies suggest that daily bathing of patients with chlorhexidine may prevent hospital-acquired bloodstream infections and the acquisition of multidrug-resistant organisms (MDROs). METHODS We conducted a multicenter, cluster-randomized, nonblinded crossover trial to evaluate the effect of daily bathing with chlorhexidine-impregnated washcloths on the acquisition of MDROs and the incidence of hospital-acquired bloodstream infections. Nine intensive care and bone marrow transplantation units in six hospitals were randomly assigned to bathe patients either with no-rinse 2% chlorhexidine-impregnated washcloths or with nonantimicrobial washcloths for a 6-month period, exchanged for the alternate product during the subsequent 6 months. The incidence rates of acquisition of MDROs and the rates of hospital-acquired bloodstream infections were compared between the two periods by means of Poisson regression analysis. RESULTS A total of 7727 patients were enrolled during the study. The overall rate of MDRO acquisition was 5.10 cases per 1000 patient-days with chlorhexidine bathing versus 6.60 cases per 1000 patient-days with nonantimicrobial washcloths (P = 0.03), the equivalent of a 23% lower rate with chlorhexidine bathing. The overall rate of hospital-acquired bloodstream infections was 4.78 cases per 1000 patient-days with chlorhexidine bathing versus 6.60 cases per 1000 patient-days with nonantimicrobial washcloths (P = 0.007), a 28% lower rate with chlorhexidine-impregnated washcloths. No serious skin reactions were noted during either study period. CONCLUSIONS Daily bathing with chlorhexidine-impregnated washcloths significantly reduced the risks of acquisition of MDROs and development of hospital-acquired bloodstream infections. (Funded by the Centers for Disease Control and Prevention and Sage Products; ClinicalTrials.gov number, NCT00502476.)	[Climo, Michael W.; Wong, Edward S.] Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA USA; [Climo, Michael W.; Sanogo, Kakotan; Wong, Edward S.] Virginia Commonwealth Univ, Med Ctr, Richmond, VA 23284 USA; [Yokoe, Deborah S.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Yokoe, Deborah S.] Harvard Univ, Sch Med, Boston, MA USA; [Warren, David K.] Washington Univ, Sch Med, St Louis, MO 63130 USA; [Perl, Trish M.] Johns Hopkins Univ, Baltimore, MD USA; [Bolon, Maureen] Northwestern Univ, Chicago, IL 60611 USA; [Weinstein, Robert A.] Cook Cty Hlth & Hosp Syst, Chicago, IL USA; [Herwaldt, Loreen A.] Iowa Univ Hosp, Iowa City, IA USA; [Sepkowitz, Kent A.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Jernigan, John A.] Ctr Dis Control & Prevent, Prevent Epictr Program, Atlanta, GA USA	Hunter Holmes McGuire Veterinary Affairs Medical Center; Virginia Commonwealth University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Washington University (WUSTL); Johns Hopkins University; Northwestern University; John H Stroger Junior Hospital Cook County; Memorial Sloan Kettering Cancer Center; Centers for Disease Control & Prevention - USA	Climo, MW (corresponding author), McGuire Vet Affairs Med Ctr, 1201 Broad Rock Blvd,Sect 111-C, Richmond, VA 23249 USA.	michael.climo@va.gov	卢, 悄佳/Z-5223-2019	Jernigan, John/0000-0001-8163-925X; Warren, David/0000-0001-8679-8241; Herwaldt, Loreen/0000-0002-9530-6859	Centers for Disease Control and Prevention [5UO1C1000395-02]; Sage Products; Centene; C.R. Bard; Cardinal Health; Sagentia; 3M Health Care; Cubist Pharmaceuticals; bioMerieux; Merck; Foglia Family Foundation; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INFECTIOUS DISEASES (NCID) [U01CI000395] Funding Source: NIH RePORTER	Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Sage Products(General Electric); Centene; C.R. Bard; Cardinal Health; Sagentia; 3M Health Care(3M); Cubist Pharmaceuticals; bioMerieux; Merck(Merck & Company); Foglia Family Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR INFECTIOUS DISEASES (NCID)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	Supported by a cooperative program award from the Centers for Disease Control and Prevention (5UO1C1000395-02) and Sage Products.; Dr. Climo reports receiving grant support from Sage Products. Dr. Warren reports receiving consulting fees from Centene, C.R. Bard, Cardinal Health, and Sagentia; lecture fees from 3M Health Care; and grant support through his institution from Cubist Pharmaceuticals and bioMerieux. Dr. Perl reports holding board memberships for Hospira and Pfizer and receiving grant support from Merck. Dr. Weinstein reports serving as an unpaid consultant for Sage Products and receiving grant support from the Foglia Family Foundation. No other potential conflict of interest relevant to this article was reported.	Alam MM, 2003, MICROB DRUG RESIST, V9, P109, DOI 10.1089/107662903765826697; Bleasdale SC, 2007, ARCH INTERN MED, V167, P2073, DOI 10.1001/archinte.167.19.2073; Bouchillon SK, 2004, INT J ANTIMICROB AG, V24, P119, DOI 10.1016/j.ijantimicag.2004.01.010; Espuny XB, 2010, PEDIATR DERMATOL, V27, P676, DOI 10.1111/j.1525-1470.2010.01178.x; Cheng CE, 2011, CLIN DERMATOL, V29, P622, DOI 10.1016/j.clindermatol.2011.08.006; Climo MW, 2009, CRIT CARE MED, V37, P1858, DOI 10.1097/CCM.0b013e31819ffe6d; Funuro JP, 2008, AM J INFECT CONTROL, V36, P468, DOI [10.1016/j.ajic:2008.01.003, 10.1016/j.ajic.2008.01.003]; Grundmann H, 2006, LANCET, V368, P874, DOI 10.1016/S0140-6736(06)68853-3; Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002; Kreman T, 2005, INFECT CONT HOSP EP, V26, P811, DOI 10.1086/502498; Lee AS, 2011, CLIN INFECT DIS, V52, P1422, DOI 10.1093/cid/cir233; Liippo J, 2011, CONTACT DERMATITIS, V64, P229, DOI 10.1111/j.1600-0536.2010.01851.x; Lockhart SR, 2011, J CLIN MICROBIOL, V49, P2404, DOI 10.1128/JCM.02474-10; Longtin J, 2011, ANTIMICROB AGENTS CH, V55, P2999, DOI 10.1128/AAC.01707-10; McDonnell G, 2001, CLIN MICROBIOL REV, V14, P227; McGann P, 2011, INFECT CONT HOSP EP, V32, P1116, DOI 10.1086/662380; Munoz-Price LS, 2009, INFECT CONT HOSP EP, V30, P1031, DOI 10.1086/644751; National Committee for Clinical Laboratory Standards, 2004, M100S14 NAT COMM CLI; Noguchi N, 2006, J CLIN MICROBIOL, V44, P2119, DOI 10.1128/JCM.02690-05; Popovich KJ, 2009, INFECT CONT HOSP EP, V30, P959, DOI 10.1086/605925; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; Pronovost PJ, 2007, NEW ENGL J MED, V356, P1268; Pronovost PJ, 2010, BMJ-BRIT MED J, V340, pc309; Roberts RR, 2010, MED CARE, V48, P1026, DOI 10.1097/MLR.0b013e3181ef60a2; Sheng WH, 2009, DIAGN MICR INFEC DIS, V63, P309, DOI 10.1016/j.diagmicrobio.2008.11.014; Siegel JD, 2007, AM J INFECT CONTROL, V35, pS65, DOI 10.1016/j.ajic.2007.10.007; Sijbesma T, 2011, HIP INT, V21, P630, DOI 10.5301/HIP.2011.8644; Sipkoff Martin, 2007, Manag Care, V16, P35; Smith K, 2008, J ANTIMICROB CHEMOTH, V61, P78, DOI 10.1093/jac/dkm395; Stone PW, 2010, MED CARE, V48, P433, DOI 10.1097/MLR.0b013e3181d5fb3f; Streit JM, 2004, INT J ANTIMICROB AG, V24, P111, DOI 10.1016/j.ijantimicag.2003.12.019; Vali L, 2008, J ANTIMICROB CHEMOTH, V61, P524, DOI 10.1093/jac/dkm520; Vernon MO, 2006, ARCH INTERN MED, V166, P306, DOI 10.1001/archinte.166.3.306; Warren DK, 2006, INFECT CONT HOSP EP, V27, P662, DOI 10.1086/506184; Warren DK, 2006, CRIT CARE MED, V34, P2084, DOI 10.1097/01.CCM.0000227648.15804.2D; Weber DJ, 2007, ANTIMICROB AGENTS CH, V51, P4217, DOI 10.1128/AAC.00138-07	36	398	414	4	104	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 7	2013	368	6					533	542		10.1056/NEJMoa1113849	http://dx.doi.org/10.1056/NEJMoa1113849			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	083VU	23388005	Green Accepted, Green Published			2023-01-03	WOS:000314494100004
J	Salisbury, C; Montgomery, AA; Hollinghurst, S; Hopper, C; Bishop, A; Franchini, A; Kaur, S; Coast, J; Hall, J; Grove, S; Foster, NE				Salisbury, Chris; Montgomery, Alan A.; Hollinghurst, Sandra; Hopper, Cherida; Bishop, Annette; Franchini, Angelo; Kaur, Surinder; Coast, Joanna; Hall, Jeanette; Grove, Sean; Foster, Nadine E.			Effectiveness of PhysioDirect telephone assessment and advice services for patients with musculoskeletal problems: pragmatic randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS; PRIMARY-CARE; HEALTH; OSTEOARTHRITIS; SF-36; RESPONSIVENESS; CONSULTATION; INDEX	Objectives To assess the clinical effectiveness, effect on waiting times, and patient acceptability of PhysioDirect services in patients with musculoskeletal problems, compared with usual care. Design Pragmatic randomised controlled trial to assess equivalence in clinical effectiveness. Patients were individually randomised in a 2:1 ratio to PhysioDirect or usual care. Setting Four physiotherapy services in England. Participants Adults (aged >= 18 years) referred by general practitioners or self referred for musculoskeletal physiotherapy. Interventions PhysioDirect services invited patients to telephone a physiotherapist for initial assessment and advice, followed by face-to-face physiotherapy if necessary. Usual care involved patients joining a waiting list for face-to-face treatment. Main outcome measures Numbers of appointments, waiting time for treatment, and non-attendance rates. Primary outcome was physical health (SF-36v2 physical component score) at six months. Secondary outcomes included four other measures of health outcome, mental component score and scales from the SF-36v2, time lost from work, and patient satisfaction and preference. Participants were not blind to allocation, but outcome data were collected blind to allocation. Results Of 1506 patients allocated to PhysioDirect and 743 to usual care, 85% provided primary outcome data at six months (1283 and 629 patients, respectively). PhysioDirect patients had fewer face-to-face appointments than usual care patients (mean 1.91 v 3.11; incidence rate ratio 0.59 (95% confidence interval 0.53 to 0.65)), a shorter waiting time (median 7 days v 34 days; arm time ratio 0.32 (0.29 to 0.35)), and lower rates of non-attendance (incidence rate ratio 0.55 (0.41 to 0.73)). After six months' follow-up, the SF-36v2 physical component score was equivalent between groups (adjusted difference in means -0.01 (-0.80 to 0.79)). Health outcome measures suggested a trend towards slightly greater improvement in the PhysioDirect arm at six week follow-up and no difference at six months. There was no difference in time lost from work. PhysioDirect patients were no more satisfied with access to physiotherapy than usual care patients, but had slightly lower satisfaction overall at six months (difference in satisfaction -3.8% (-7.3% to -0.3%); P=0.031). PhysioDirect patients were more likely than usual care patients to prefer PhysioDirect in future. No adverse events were detected. Conclusions PhysioDirect is equally clinically effective compared with usual care, provides faster access to physiotherapy, and seems to be safe. However, it could be associated with slightly lower patient satisfaction.	[Salisbury, Chris; Hollinghurst, Sandra; Hopper, Cherida; Kaur, Surinder] Univ Bristol, Sch Social & Community Med, Ctr Acad Primary Care, Bristol BS8 2PS, Avon, England; [Montgomery, Alan A.; Franchini, Angelo] Univ Bristol, Bristol Randomised Controlled Trials Collaborat, Bristol BS8 2PS, Avon, England; [Bishop, Annette; Foster, Nadine E.] Keele Univ, Arthrit Res UK Primary Care Ctr, Keele ST5 5BG, Staffs, England; [Coast, Joanna] Univ Birmingham, Sch Hlth & Populat Sci, Hlth Econ Unit, Birmingham, W Midlands, England; [Hall, Jeanette; Grove, Sean] Bristol Community Hlth, Musculoskeletal Outpatient Dept, Bristol, Avon, England	University of Bristol; University of Bristol; Keele University; University of Birmingham	Salisbury, C (corresponding author), Univ Bristol, Sch Social & Community Med, Ctr Acad Primary Care, Bristol BS8 2PS, Avon, England.	c.salisbury@bristol.ac.uk	Salisbury, Chris/C-6724-2008	Salisbury, Chris/0000-0002-4378-3960; Coast, Joanna/0000-0002-3537-5166; Foster, Nadine/0000-0003-4429-9756; Montgomery, Alan/0000-0003-0450-1606; Franchini, Angelo/0000-0002-7340-5266	Medical Research Council (MRC); Medical Research Council [G0800800, G0701575] Funding Source: researchfish; MRC [G0800800, G0701575] Funding Source: UKRI	Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The research was funded by the Medical Research Council (MRC) and managed by the National Institute for Health Research (NIHR) on behalf of the MRC-NIHR partnership. The funder had no role in the study design; the collection, analysis, or interpretation of data; the writing of the report; or the decision to submit the paper for publication. The researchers are all independent of the funders. All researchers had access to all the data.	Angst F, 2001, ANN RHEUM DIS, V60, P834; [Anonymous], 2012, STAND INSTR US MEAS; Bishop A, 2013, PHYSIOTHERAPY, V99, P113, DOI 10.1016/j.physio.2012.08.002; Black N, 1996, BRIT MED J, V312, P1215; Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; Bunn F, 2004, COCHRANE DB SYST REV, V4, DOI [DOI 10.1002/14651858.CD004180.PUB2, 10.1002/14651858.CD004180.pub2]; Conaghan PG, 2008, BRIT MED J, V336, P502, DOI 10.1136/bmj.39490.608009.AD; Consulting J, 2011, SURVEY NHS PHYS WAIT; Department of Health, 2008, SELF REF PIL MUSC PH; Foster NE, 2011, PHYSIOTHERAPY, V97, P78, DOI 10.1016/j.physio.2010.05.003; Gamlin J, 2005, DIRECT ACCESS PHYSIO; Green S, 2003, Cochrane Database Syst Rev, pCD004258; Health and Social Care Information Centre, 2005, NHS PSYS SERV SUMM I; Holdsworth LK, 2009, INT MULTICENTRED INV; Jordan KP, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-144; Kvien TK, 1998, J CLIN EPIDEMIOL, V51, P1077, DOI 10.1016/S0895-4356(98)00099-7; Lurie J, 2000, SPINE, V25, P3125, DOI 10.1097/00007632-200012150-00007; Maniadakis N, 2000, PAIN, V84, P95, DOI 10.1016/S0304-3959(99)00187-6; Miller J, 2010, MANUAL THER, V15, P334, DOI 10.1016/j.math.2010.02.007; Paterson C, 1996, BRIT MED J, V312, P1016; Pham T, 2003, J RHEUMATOL, V30, P1648; Salisbury C, 2013, HLTH TECHNOL ASSESS, P17; Salisbury C, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-136; Schulz KF, 2005, LANCET, V365, P1591, DOI 10.1016/S0140-6736(05)66461-6; Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393; Taylor S., 2002, PHYSIOTHERAPY, V88, P645; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; Walsh TL, 2003, SPINE, V28, P607, DOI 10.1097/00007632-200303150-00017; Ware J, 2007, USERS MANUAL SF36V2	29	40	40	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 29	2013	346								f43	10.1136/bmj.f43	http://dx.doi.org/10.1136/bmj.f43			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	084BH	23360891	Green Accepted, hybrid, Green Published			2023-01-03	WOS:000314510400002
J	Fontanarosa, PB; McNutt, RA				Fontanarosa, Phil B.; McNutt, Robert A.			Revisiting Hospital Readmissions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[McNutt, Robert A.] Rush Univ, Sch Med, Dept Med, Chicago, IL 60612 USA	Rush University		phil.fontanarosa@jamanetwork.org						[Anonymous], NY TIMES; Berry JG, 2013, JAMA-J AM MED ASSOC, V309, P372, DOI 10.1001/jama.2012.188351; Brock J, 2013, JAMA-J AM MED ASSOC, V309, P381, DOI 10.1001/jama.2012.216607; Dharmarajan K, 2013, JAMA-J AM MED ASSOC, V309, P355, DOI 10.1001/jama.2012.216476; Farmer SA, 2013, JAMA-J AM MED ASSOC, V309, P349, DOI 10.1001/jama.2012.191276; Jha AK, 2013, JAMA-J AM MED ASSOC, V309, P347, DOI 10.1001/jama.2012.196646; Kocher RP, 2011, JAMA-J AM MED ASSOC, V306, P1794, DOI 10.1001/jama.2011.1561; McCarthy D, 2013, JAMA-J AM MED ASSOC, V309, P351, DOI 10.1001/jama.2013.1; Medicare, MED; Srivastava R, 2013, JAMA-J AM MED ASSOC, V309, P396, DOI 10.1001/jama.2012.217006; Vaduganathan M, 2013, JAMA-J AM MED ASSOC, V309, P345, DOI 10.1001/jama.2012.205110; Vashi AA, 2013, JAMA-J AM MED ASSOC, V309, P364, DOI 10.1001/jama.2012.216219; Williams MV, 2013, JAMA-J AM MED ASSOC, V309, P394, DOI 10.1001/jama.2012.233964	13	88	88	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 23	2013	309	4					398	400		10.1001/jama.2013.42	http://dx.doi.org/10.1001/jama.2013.42			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074FT	23340644				2023-01-03	WOS:000313799000030
J	Vashi, AA; Fox, JP; Carr, BG; D'Onofrio, G; Pines, JM; Ross, JS; Gross, CP				Vashi, Anita A.; Fox, Justin P.; Carr, Brendan G.; D'Onofrio, Gail; Pines, Jesse M.; Ross, Joseph S.; Gross, Cary P.			Use of Hospital-Based Acute Care Among Patients Recently Discharged From the Hospital	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EMERGENCY; REHOSPITALIZATIONS; READMISSIONS; QUALITY; INTERVENTION; VISITS	Importance Current efforts to improve health care focus on hospital readmission rates as a marker of quality and on the effectiveness of transitions in care during the period after acute care is received. Emergency department (ED) visits are also a marker of hospital-based acute care following discharge but little is known about ED use during this period. Objectives To determine the degree to which ED visits and hospital readmissions contribute to overall use of acute care services within 30 days of discharge from acute care hospitals, to describe the reasons patients return for ED visits, and to describe these patterns among Medicare beneficiaries and those not covered by Medicare insurance. Design, Setting, and Participants Prospective study of patients aged 18 years or older (mean age: 53.4 years) who were discharged between July 1, 2008, and September 31, 2009, from acute care hospitals in 3 large, geographically diverse states (California, Florida, and Nebraska) with data recorded in the Healthcare Cost and Utilization Project state inpatient and ED databases. Main Outcome Measures The 3 primary outcomes during the 30-day period after hospital discharge were ED visits not resulting in admission (treat-and-release encounters), hospital readmissions from any source, and a combined measure of ED visits and hospital readmissions termed hospital-based acute care. Results The final cohort included 5 032 254 index hospitalizations among 4 028 555 unique patients. In the 30 days following discharge, 17.9% (95% CI, 17.9%-18.0%) of hospitalizations resulted in at least 1 acute care encounter. Of these 1 233 402 postdischarge acute care encounters, ED visits comprised 39.8% (95% CI, 39.7%-39.9%). For every 1000 discharges, there were 97.5 (95% CI, 97.2-97.8) ED treat-and-release visits and 147.6 (95% CI, 147.3-147.9) hospital readmissions in the 30 days following discharge. The number of ED treat-and-release visits ranged from a low of 22.4 (95% CI, 4.6-65.4) encounters per 1000 discharges for breast malignancy to a high of 282.5 (95% CI, 209.7-372.4) encounters per 1000 discharges for uncomplicated benign prostatic hypertrophy. Among the highest volume discharges, the most common reason patients returned to the ED was always related to their index hospitalization. Conclusions and Relevance After discharge from acute care hospitals in 3 states, ED visits within 30 days were common among adults and accounted for 39.8% of postdischarge hospital-based acute care visits. Improving care transitions should focus not only on decreasing readmissions but also on ED visits. JAMA. 2013;309(4):364-371 www.jama.com	[Vashi, Anita A.; Ross, Joseph S.; Gross, Cary P.] Yale Univ, Sch Med, Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT 06520 USA; [Vashi, Anita A.; D'Onofrio, Gail] Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT 06520 USA; [Ross, Joseph S.; Gross, Cary P.] Yale Univ, Sch Med, Gen Internal Med Sect, New Haven, CT 06520 USA; [Gross, Cary P.] Yale Univ, Sch Med, Canc Outcomes Policy & Effectiveness Res Ctr, New Haven, CT 06520 USA; [Gross, Cary P.] Yale Comprehens Canc Ctr, New Haven, CT USA; [Vashi, Anita A.] VA Connecticut Healthcare Syst, Dept Vet Affairs, West Haven, CT USA; [Fox, Justin P.] Wright State Univ, Boonshoft Sch Med, Dept Surg, Dayton, OH 45435 USA; [Carr, Brendan G.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA; [Carr, Brendan G.] Univ Penn, Dept Biostat, Philadelphia, PA 19104 USA; [Carr, Brendan G.] Univ Penn, Dept Epidemiol, Philadelphia, PA 19104 USA; [Pines, Jesse M.] George Washington Univ, Dept Emergency Med, Washington, DC USA; [Pines, Jesse M.] George Washington Univ, Dept Hlth Policy, Washington, DC USA; [Ross, Joseph S.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA	Robert Wood Johnson Foundation (RWJF); Yale University; Yale University; Yale University; Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; University System of Ohio; Wright State University Dayton; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; George Washington University; George Washington University; Yale University	Vashi, AA (corresponding author), Yale Univ, Sch Med, Robert Wood Johnson Fdn Clin Scholars Program, 333 Cedar St,SHM 1E-61, New Haven, CT 06520 USA.	anita.vashi@yale.edu		Ross, Joseph/0000-0002-9218-3320; D'Onofrio, Gail/0000-0002-3833-1871	Pew Charitable Trusts; Agency for Healthcare Research and Quality [K08 AG032886]; National Institute on Aging; American Federation for Aging Research through the Paul B. Beeson Career Development Award Program; NATIONAL INSTITUTE ON AGING [K08AG032886] Funding Source: NIH RePORTER	Pew Charitable Trusts; Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); American Federation for Aging Research through the Paul B. Beeson Career Development Award Program; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Carr reported being a senior policy advisor for the Office of the Assistant Secretary for Preparedness and Response. Dr Pines reported working as a senior advisor for the Centers for Medicare & Medicaid Services Innovation Center during the writing of this article. Dr Ross reported receiving funding from the Centers for Medicare & Medicaid Services to develop and maintain performance measures that are used for public reporting; and receiving funding from the Pew Charitable Trusts to examine regulatory issues at the US Food and Drug Administration. Drs Ross and Gross reported receiving funding as collaborators on the Yale University Open Access project, which is facilitating the objective analysis of Medtronic clinical trial data. Drs Ross and Gross are members of a scientific advisory board for FAIR Health Inc. No other disclosures were reported.; Dr Carr is supported by career development award K08 AG032886 from the Agency for Healthcare Research and Quality. Dr Ross is supported by the National Institute on Aging and by the American Federation for Aging Research through the Paul B. Beeson Career Development Award Program.	Abarca F, 2011, AM SURGEON, V77, P65; Baer RB, 2001, ACAD EMERG MED, V8, P1091, DOI 10.1111/j.1553-2712.2001.tb01121.x; Brousseau DC, 2010, JAMA-J AM MED ASSOC, V303, P1288, DOI 10.1001/jama.2010.378; Brown R, RES DESIGN EVALUATIO; Bundled Payments for Care Improvement (BPCI) Initiative: General Information, BUNDL PAYM CAR IMPR; Burt Catharine W, 2008, Natl Health Stat Report, P1; Clark SL, 2010, AM J OBSTET GYNECOL, V203, pe1, DOI DOI 10.1155/2012/252676.5.K0REN; Clark SL, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.02.033; Coleman E A, 2001, Eff Clin Pract, V4, P49; Coleman EA, 2003, J AM GERIATR SOC, V51, P549, DOI 10.1046/j.1532-5415.2003.51185.x; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Coleman Eric A, 2007, Home Health Care Serv Q, V26, P93, DOI 10.1300/J027v26n04_07; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Friedman B, 2009, MED CARE, V47, P583, DOI 10.1097/MLR.0b013e31819434da; Goodman DC, 2011, HOSPITALIZATION DART; Harrison PL, 2011, POPUL HEALTH MANAG, V14, P27, DOI 10.1089/pop.2009.0076; Healthcare Cost and Utilization Project, STAT PAT DAT; Healthcare Cost and Utilization Project, STAT EM DEP DAT; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Kocher RP, 2011, JAMA-J AM MED ASSOC, V306, P1794, DOI 10.1001/jama.2011.1561; Lautz TB, 2011, J PEDIATR SURG, V46, P1918, DOI 10.1016/j.jpedsurg.2011.04.012; Legrain S, 2011, J AM GERIATR SOC, V59, P2017, DOI 10.1111/j.1532-5415.2011.03628.x; Martin RCG, 2011, ANN SURG, V254, P591, DOI 10.1097/SLA.0b013e3182300a38; McCall N, 2010, EVALUATION MEDICARE; Morse RB, 2011, JAMA-J AM MED ASSOC, V306, P1454, DOI 10.1001/jama.2011.1385; Naylor MD, 2012, HEALTH AFFAIR, V31, P1623, DOI 10.1377/hlthaff.2012.0110; Peikes D, C EV MED COORD CAR D; Practice Management Information Corporation, 2005, INT CLASS DIS; Sharma G, 2010, ARCH INTERN MED, V170, P1664, DOI 10.1001/archinternmed.2010.345; Sommers A, 2011, PHYS VISITS HOSP DIS; Stone J, 2010, C MED HOSP READM ISS; US Department of Health and Human Services, PARTN PAT BETT CAR L	32	140	140	0	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 23	2013	309	4					364	371		10.1001/jama.2012.216219	http://dx.doi.org/10.1001/jama.2012.216219			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074FT	23340638	Green Accepted, Bronze			2023-01-03	WOS:000313799000024
J	Wang, D; Wise, ML; Li, F; Dey, M				Wang, Dan; Wise, Mitchell L.; Li, Feng; Dey, Moul			Phytochemicals Attenuating Aberrant Activation of beta-Catenin in Cancer Cells	PLOS ONE			English	Article							OXIDATIVE STRESS; WNT/BETA-CATENIN; SIGNALING PATHWAY; LITHIUM-CHLORIDE; IN-VITRO; AVENANTHRAMIDES; WNT; TRIPTOLIDE; OATS; PROLIFERATION	Phytochemicals are a rich source of chemoprevention agents but their effects on modulating the Wnt/beta-catenin signaling pathway have remained largely uninvestigated. Aberrantly activated Wnt signaling can result in the abnormal stabilization of beta-catenin, a key causative step in a broad spectrum of cancers. Here we report the modulation of lithium chloride-activated canonical Wnt/beta-catenin signaling by phytochemicals that have antioxidant, anti-inflammatory or chemopreventive properties. The compounds were first screened with a cervical cancer-derived stable Wnt signaling reporter HeLa cell line. Positive hits were subsequently evaluated for beta-catenin degradation, suppression of beta-catenin nuclear localization and down-regulation of downstream oncogenic targets of Wnt/beta-catenin pathway. Our study shows a novel degradation path of beta-catenin protein in HeLa cells by Avenanthramide 2p (a polyphenol) and Triptolide (a diterpene triepoxide), respectively from oats and a Chinese medicinal plant. The findings present Avenanthramide 2p as a potential chemopreventive dietary compound that merits further study using in vivo models of cancers; they also provide a new perspective on the mechanism of action of Triptolide. Citation: Wang D, Wise ML, Li F, Dey M (2012) Phytochemicals Attenuating Aberrant Activation of beta-Catenin in Cancer Cells. PLoS ONE 7(12): e50508. doi:10.1371/journal.pone.0050508	[Wang, Dan; Dey, Moul] S Dakota State Univ, Dept Hlth & Nutr Sci, Brookings, SD 57007 USA; [Wise, Mitchell L.] USDA, Madison, WI USA; [Li, Feng] S Dakota State Univ, Dept Biol & Microbiol, Brookings, SD 57007 USA; [Li, Feng] S Dakota State Univ, Dept Vet & Biomed Sci, Brookings, SD 57007 USA	South Dakota State University; United States Department of Agriculture (USDA); South Dakota State University; South Dakota State University	Dey, M (corresponding author), S Dakota State Univ, Dept Hlth & Nutr Sci, Brookings, SD 57007 USA.	moul.dey@sdstate.edu		Wang, Dan/0000-0002-7263-8420; DEY, MOUL/0000-0002-6423-9593; Li, Feng/0000-0002-8904-2893	National Institutes of Health [R00AT4245]; USDA/SD-AES grant [328100/318000]; SDSU AES Fund [3AH203]; NIH grant [AI076125]; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [R00AT004245] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [K99AT004245] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K02AI076125] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); USDA/SD-AES grant; SDSU AES Fund; NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The work is supported by the National Institutes of Health grant R00AT4245 (to MD), USDA/SD-AES grant 328100/318000 (to MD), SDSU AES Fund 3AH203 (to FL) and NIH grant AI076125 (to FL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1996, J Cell Biochem Suppl, V26, P149; Antonoff MB, 2009, SURGERY, V146, P282, DOI 10.1016/j.surg.2009.04.023; Arcidiacono B, 2012, EXP DIABETES RES, DOI 10.1155/2012/789174; Bulut G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027243; Cairo S, 2008, CANCER CELL, V14, P471, DOI 10.1016/j.ccr.2008.11.002; Chen CYO, 2007, J NUTR, V137, P1375, DOI 10.1093/jn/137.6.1375; Chen CY, 2004, J NUTR, V134, P1459, DOI 10.1093/jn/134.6.1459; Clement-Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Dey M, 2006, J PHARMACOL EXP THER, V317, P326, DOI 10.1124/jpet.105.096511; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Fuerer C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009370; Gao XF, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000708; Gregory CA, 2005, J BIOL CHEM, V280, P2309, DOI 10.1074/jbc.M406275200; Guo WM, 2010, NUTR CANCER, V62, P1007, DOI 10.1080/01635581.2010.492090; Guo W, 2008, FREE RADICAL BIO MED, V44, P415, DOI 10.1016/j.freeradbiomed.2007.10.036; Handeli S, 2008, MOL CANCER THER, V7, P521, DOI 10.1158/1535-7163.MCT-07-2063; He MF, 2009, J ETHNOPHARMACOL, V121, P61, DOI 10.1016/j.jep.2008.09.033; Hiyama A, 2011, J CELL BIOCHEM, V112, P2974, DOI 10.1002/jcb.23217; Jin TR, 2008, CELL SIGNAL, V20, P1697, DOI 10.1016/j.cellsig.2008.04.014; Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; Kim MJ, 2010, INT J ONCOL, V37, P1177, DOI 10.3892/ijo_00000769; Kitzen JJEM, 2009, EUR J CANCER, V45, P1764, DOI 10.1016/j.ejca.2009.01.026; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Koenig RT, 2011, J AGR FOOD CHEM, V59, P6438, DOI 10.1021/jf2002427; Krejci P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035826; Liu QY, 2011, INT IMMUNOPHARMACOL, V11, P377, DOI 10.1016/j.intimp.2011.01.012; Ma J, 2007, PHYTOCHEMISTRY, V68, P1172, DOI 10.1016/j.phytochem.2007.02.021; Macville M, 1999, CANCER RES, V59, P141; Meydani M, 2009, NUTR REV, V67, P731, DOI 10.1111/j.1753-4887.2009.00256.x; Nie L, 2006, ATHEROSCLEROSIS, V186, P260, DOI 10.1016/j.atherosclerosis.2005.07.027; Nishikawa A, 2004, CURR CANCER DRUG TAR, V4, P373, DOI 10.2174/1568009043332970; Okazaki Y, 2004, PLANT J, V39, P560, DOI 10.1111/j.1365-313X.2004.02163.x; Peterson CW, 2011, FRONT BIOSCI-LANDMRK, V16, P2206, DOI 10.2741/3848; Polk WW, 2012, INT J TOXICOL; Premkumar Vummidigiridhar, 2010, BMC Chemical Biology, V10, P3, DOI 10.1186/1472-6769-10-3; Rahmani M, 2005, J BIOL CHEM, V280, P13019, DOI 10.1074/jbc.M411766200; Ren Y, 2011, J AGR FOOD CHEM, V59, P206, DOI 10.1021/jf103938e; Shao F, 2007, BIOL PHARM BULL, V30, P702, DOI 10.1248/bpb.30.702; Sokol SY, 2011, CELL RES, V21, P1002, DOI 10.1038/cr.2011.86; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Sur R, 2008, ARCH DERMATOL RES, V300, P569, DOI 10.1007/s00403-008-0858-x; Tarapore RS, 2012, CARCINOGENESIS, V33, P483, DOI 10.1093/carcin/bgr305; Wang D, 2010, J VIROL, V84, P4673, DOI 10.1128/JVI.02306-09; Wise ML, 2011, J AGR FOOD CHEM, V59, P7028, DOI 10.1021/jf2008869; Wu XA, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-269	49	26	27	1	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 3	2012	7	12							e50508	10.1371/journal.pone.0050508	http://dx.doi.org/10.1371/journal.pone.0050508			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	051DH	23226522	gold, Green Published, Green Submitted			2023-01-03	WOS:000312104700019
J	Beletsky, L; Rich, JD; Walley, AY				Beletsky, Leo; Rich, Josiah D.; Walley, Alexander Y.			Prevention of Fatal Opioid Overdose	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							NALOXONE		[Beletsky, Leo] Northeastern Univ, Sch Law, Boston, MA 02115 USA; [Beletsky, Leo] Bouve Coll Hlth Sci, Boston, MA 02115 USA; [Beletsky, Leo] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA; [Rich, Josiah D.] Brown Med Sch, Providence, RI USA; [Rich, Josiah D.] Miriam Hosp, Providence, RI 02906 USA; [Walley, Alexander Y.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Walley, Alexander Y.] Boston Med Ctr, Boston, MA USA	Northeastern University; Northeastern University; University of California System; University of California San Diego; Brown University; Lifespan Health Rhode Island; Miriam Hospital; Boston University; Boston Medical Center	Beletsky, L (corresponding author), Northeastern Univ, Sch Law, 400 Huntington Ave, Boston, MA 02115 USA.	l.beletsky@neu.edu		Walley, Alexander/0000-0002-8158-4882; Beletsky, Leo/0000-0003-0726-0676	NATIONAL INSTITUTE ON DRUG ABUSE [R21DA029201, R37DA019829, K24DA022112, R01DA032082, R25DA013582] Funding Source: NIH RePORTER; NIAAA NIH HHS [U01AA11003] Funding Source: Medline; NIAID NIH HHS [P30 AI042853] Funding Source: Medline; NIDA NIH HHS [1R21DA029201, R25-DA13582, R25 DA013582, R01DA032082, R01 DA032082, R21 DA029201, 5K24DA022112, R37DA019829, R37 DA019829, K24 DA022112] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Albert S, 2011, PAIN MED, V12, pS77, DOI 10.1111/j.1526-4637.2011.01128.x; American Medical Association, AMA AD NEW POL ANN M; Beletsky L, 2007, J URBAN HEALTH, V84, P126, DOI 10.1007/s11524-006-9120-z; Burris S., 2009, DREXEL LAW REV, V1, P273; Doe-Simkins M, 2009, AM J PUBLIC HEALTH, V99, P788, DOI 10.2105/AJPH.2008.146647; Paulozzi Leonard, 2012, Morbidity and Mortality Weekly Report, V61, P10; Wheeler Eliza, 2012, Morbidity and Mortality Weekly Report, V61, P101	7	75	76	1	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 14	2012	308	18					1863	1864		10.1001/jama.2012.14205	http://dx.doi.org/10.1001/jama.2012.14205			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	035NA	23150005	Green Accepted			2023-01-03	WOS:000310952700019
J	Landsberg, J; Kohlmeyer, J; Renn, M; Bald, T; Rogava, M; Cron, M; Fatho, M; Lennerz, V; Wolfel, T; Holzel, M; Tuting, T				Landsberg, Jennifer; Kohlmeyer, Judith; Renn, Marcel; Bald, Tobias; Rogava, Meri; Cron, Mira; Fatho, Martina; Lennerz, Volker; Woelfel, Thomas; Hoelzel, Michael; Tueting, Thomas			Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation	NATURE			English	Article							METASTATIC MELANOMA; CANCER REGRESSION; IN-VIVO; IMMUNOTHERAPY; ANTIGEN; LYMPHOCYTES; MICE; GROWTH; AUTOIMMUNITY; RESPONSES	Adoptive cell transfer therapies (ACTs) with cytotoxic T cells that target melanocytic antigens can achieve remissions in patients with metastatic melanomas, but tumours frequently relapse(1,2). Hypotheses explaining the acquired resistance to ACTs include the selection of antigen-deficient tumour cell variants(3-5) and the induction of T-cell tolerance(6). However, the lack of appropriate experimental melanoma models has so far impeded clear insights into the underlying mechanisms. Here we establish an effective ACT protocol in a genetically engineered mouse melanoma model that recapitulates tumour regression, remission and relapse as seen in patients. We report the unexpected observation that melanomas acquire ACT resistance through an inflammation-induced reversible loss of melanocytic antigens. In serial transplantation experiments, melanoma cells switch between a differentiated and a dedifferentiated phenotype in response to T-cell-driven inflammatory stimuli. We identified the proinflammatory cytokine tumour necrosis factor (TNF)-alpha as a crucial factor that directly caused reversible dedifferentiation of mouse and human melanoma cells. Tumour cells exposed to TNF-alpha were poorly recognized by T cells specific for melanocytic antigens, whereas recognition by T cells specific for non-melanocytic antigens was unaffected or even increased. Our results demonstrate that the phenotypic plasticity of melanoma cells in an inflammatory microenvironment contributes to tumour relapse after initially successful T-cell immunotherapy. On the basis of our work, we propose that future ACT protocols should simultaneously target melanocytic and non-melanocytic antigens to ensure broad recognition of both differentiated and dedifferentiated melanoma cells, and include strategies to sustain T-cell effector functions by blocking immune-inhibitory mechanisms in the tumour microenvironment.	[Landsberg, Jennifer; Kohlmeyer, Judith; Renn, Marcel; Bald, Tobias; Rogava, Meri; Cron, Mira; Tueting, Thomas] Univ Bonn, Dept Dermatol & Allergy, Lab Expt Dermatol, D-53105 Bonn, Germany; [Fatho, Martina; Lennerz, Volker; Woelfel, Thomas] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med 3, D-55101 Mainz, Germany; [Hoelzel, Michael] Univ Bonn, Unit RNA Biol, Dept Clin Chem & Clin Pharmacol, D-53105 Bonn, Germany	University of Bonn; Johannes Gutenberg University of Mainz; University of Bonn	Tuting, T (corresponding author), Univ Bonn, Dept Dermatol & Allergy, Lab Expt Dermatol, D-53105 Bonn, Germany.	thomas.tueting@ukb.uni-bonn.de	Landsberg, Jennifer/AAF-5113-2019; Landsberg, Jenny/AGI-0216-2022; Tüting, Thomas/AAJ-3610-2021; Bald, Tobias/H-9525-2018; Wölfel, Thomas/G-6519-2012	Landsberg, Jenny/0000-0001-8029-3883; Tüting, Thomas/0000-0001-7146-0934; Bald, Tobias/0000-0003-0061-235X; Sirokay, Judith/0000-0003-3945-845X; Renn, Marcel/0000-0002-0120-4035; Rogava, Meri/0000-0002-0314-5323	DFG [SFB832, SFB704, SFB 432]; Deutsche Krebshilfe (P9 in the Melanoma Research Network); BONFOR	DFG(German Research Foundation (DFG)); Deutsche Krebshilfe (P9 in the Melanoma Research Network); BONFOR	We would like to thank G. Merlino and M. Barbacid for providing genetically engineered mice; E. Endl for help with FACS sorting; S. Herms and P. Hoffmann for the cDNA microarrays; S. Mikus, A. Sporleder and C. Lemke for managing the mouse colony and performing histopathology, immunohistopatholgoy, immunoblotting and real-time PCR. This research was supported in part by grants from the DFG (A12 in the SFB832 and A22 in the SFB704) and the Deutsche Krebshilfe (P9 in the Melanoma Research Network) to T. T., by grants from BONFOR to J.L. and J.K., and by a DFG grant (A1 in the SFB 432) to T. W. T. T. and M. H. are members of the Excellence Cluster ImmunoSensation.	[Anonymous], 2010, R LANG ENV STAT COMP; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Boon T, 2006, ANNU REV IMMUNOL, V24, P175, DOI 10.1146/annurev.immunol.24.021605.090733; Bourgon R, 2010, P NATL ACAD SCI USA, V107, P9546, DOI 10.1073/pnas.0914005107; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Britten CM, 2002, J IMMUNOL METHODS, V259, P95, DOI 10.1016/S0022-1759(01)00499-9; Corbiere V, 2011, CANCER RES, V71, P1253, DOI 10.1158/0008-5472.CAN-10-2693; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Dunning MJ, 2007, BIOINFORMATICS, V23, P2183, DOI 10.1093/bioinformatics/btm311; DuPage M, 2012, NATURE, V482, P405, DOI 10.1038/nature10803; Falcon S, 2007, BIOINFORMATICS, V23, P257, DOI 10.1093/bioinformatics/btl567; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Johnson LA, 2009, BLOOD, V114, P535, DOI 10.1182/blood-2009-03-211714; Kanik AB, 1996, J CUTAN PATHOL, V23, P205, DOI 10.1111/j.1600-0560.1996.tb01468.x; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; Kohlmeyer J, 2009, CANCER RES, V69, P6265, DOI 10.1158/0008-5472.CAN-09-0579; Landsberg J, 2010, PIGM CELL MELANOMA R, V23, P649, DOI 10.1111/j.1755-148X.2010.00744.x; Lennerz V, 2005, P NATL ACAD SCI USA, V102, P16013, DOI 10.1073/pnas.0500090102; Matsushita H, 2012, NATURE, V482, P400, DOI 10.1038/nature10755; Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; O'Rourke MGE, 2007, MELANOMA RES, V17, P316, DOI 10.1097/CMR.0b013e3282c3a73b; Overwijk WW, 2003, J EXP MED, V198, P569, DOI 10.1084/jem.20030590; Pilon-Thomas S, 2010, J IMMUNOL, V184, P3442, DOI 10.4049/jimmunol.0904114; Restifo NP, 2012, NAT REV IMMUNOL, V12, P269, DOI 10.1038/nri3191; Robbins PF, 2011, J CLIN ONCOL, V29, P917, DOI 10.1200/JCO.2010.32.2537; Rosenberg SA, 2011, CLIN CANCER RES, V17, P4550, DOI 10.1158/1078-0432.CCR-11-0116; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Steitz J, 2000, INT J CANCER, V86, P89, DOI 10.1002/(SICI)1097-0215(20000401)86:1<89::AID-IJC14>3.0.CO;2-I; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tormo D, 2006, AM J PATHOL, V169, P665, DOI 10.2353/ajpath.2006.060017; Tormo D, 2006, CANCER RES, V66, P5427, DOI 10.1158/0008-5472.CAN-06-0399; van der Laan M. J., 2009, U C BERKELEY DIV BIO; Vatakis DN, 2011, P NATL ACAD SCI USA, V108, pE1408, DOI 10.1073/pnas.1115050108; Willimsky G, 2005, NATURE, V437, P141, DOI 10.1038/nature03954; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Yee C, 2002, P NATL ACAD SCI USA, V99, P16168, DOI 10.1073/pnas.242600099	43	378	388	4	76	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 18	2012	490	7420					412	+		10.1038/nature11538	http://dx.doi.org/10.1038/nature11538			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	021XI	23051752				2023-01-03	WOS:000309918500048
J	Zhou, XM; Xie, GL; Wang, SB; Wang, YG; Zhang, KJ; Zheng, S; Chu, L; Xiao, LL; Yu, YM; Zhang, Y; Liu, XY				Zhou, Xiumei; Xie, Guoliang; Wang, Shibing; Wang, Yigang; Zhang, Kangjian; Zheng, Shu; Chu, Liang; Xiao, Lianli; Yu, Yuemei; Zhang, Yue; Liu, Xinyuan			Potent and Specific Antitumor Effect for Colorectal Cancer by CEA and Rb Double Regulated Oncolytic Adenovirus Harboring ST13 Gene	PLOS ONE			English	Article							APOPTOSIS-INDUCING LIGAND; CARCINOEMBRYONIC ANTIGEN; VIRO-THERAPY; TRAIL; VIROTHERAPY; CARCINOMA; SURVIVAL; PROTEIN; VECTOR	Cancer Targeting Gene-Viro-Therapy (CTGVT) is constructed by inserting an antitumor gene into an oncolytic virus (OV). It is actually an OV-gene therapy, which has much better antitumor effect than either gene therapy alone or virotherapy alone in our previously published papers. This study is a modification of CTGVT by inserting a colorectal cancer (CRC) specific suppressor gene, ST13, into a CRC specific oncolytic virus, the Ad.CEA.E1A(Delta 24), to construct the Ad.(ST13).CEA.E1A(Delta 24) for increasing the targeting tropism to colorectal cancer and it was briefly named as CTGVT-CRC. Although many studies on CEA promoter and ST13 gene were reported but no construct has been performed to combine both of them as a new strategy for colorectal cancer (CRC) specific therapy. In addition to the CRC specificity, the antitumor effect of Ad.(ST13).CEA.E1A(Delta 24) was also excellent and got nearly complete inhibition (not eradication) of CRC xenograft since ST13 was an effective antitumor gene with less toxicity, and a Chinese patent (No. 201110319434.4) was available for this study. Ad.(ST13).CEA.E1A(Delta 24) caused cell apoptosis through P38 MAPK (i.e. P38) which upregulated CHOP and ATF2 expression. The mitochondrial medicated apoptosis pathway was activated by the increase of caspase 9 and caspase 3 expression.	[Zhou, Xiumei; Wang, Shibing; Wang, Yigang; Xiao, Lianli; Yu, Yuemei; Zhang, Yue; Liu, Xinyuan] Zhejiang Sci Tech Univ, Coll Life Sci, Xinyuan Inst Med & Biotechnol, Hangzhou, Zhejiang, Peoples R China; [Zhang, Kangjian; Chu, Liang; Liu, Xinyuan] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Cell Biol, Shanghai, Peoples R China; [Xie, Guoliang] Zhejiang Univ, Affiliated Hosp 1, Dept Lab Med, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China; [Zheng, Shu] Zhejiang Univ, Affiliated Hosp 2, Inst Canc, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China	Zhejiang Sci-Tech University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Zhejiang University; Zhejiang University	Liu, XY (corresponding author), Zhejiang Sci Tech Univ, Coll Life Sci, Xinyuan Inst Med & Biotechnol, Hangzhou, Zhejiang, Peoples R China.	xyliu@sibs.ac.cn	Liu, Xinyuan/HDM-5505-2022; xie, guoliang/T-3191-2017		Science Foundation of Zhejiang Sci-Tech University (ZSTU) [1016834-Y]; National Basic Research Program of China (973 Program) [2010CB529901, 2011CB510104]; National Natural Science Foundation of China [81172449]; Important National Science AMP; Technology Specific Project of Hepatitis and Hepatoma Related Program [2008ZX10002-023]; New Innovation Program [2009-ZX-09102-246]	Science Foundation of Zhejiang Sci-Tech University (ZSTU)(Zhejiang Sci-Tech University); National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Important National Science AMP; Technology Specific Project of Hepatitis and Hepatoma Related Program; New Innovation Program	This work was supported by the Science Foundation of Zhejiang Sci-Tech University (ZSTU) under Grant No. 1016834-Y, the National Basic Research Program of China (973 Program) (No. 2010CB529901, No. 2011CB510104), the National Natural Science Foundation of China (81172449), the Important National Science & Technology Specific Project of Hepatitis and Hepatoma Related Program (2008ZX10002-023), and the New Innovation Program (2009-ZX-09102-246). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; Breitbach CJ, 2011, NATURE, V477, P99, DOI 10.1038/nature10358; Cao X, 2011, GENE THER, V18, P765, DOI 10.1038/gt.2011.16; Center MM, 2009, CA-CANCER J CLIN, V59, P366, DOI 10.3322/caac.20038; Chu L, 2006, CANCER BIOL THER, V5, P615, DOI 10.4161/cbt.5.6.2662; Chung-Faye GA, 2000, MOL MED TODAY, V6, P82, DOI 10.1016/S1357-4310(99)01598-1; DIMAIO JM, 1994, SURGERY, V116, P205; Ding M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035153; Evans J, 2011, NAT MED, V17, P268, DOI 10.1038/nm0311-268b; Horndasch M, 2006, ONCOGENE, V25, P3397, DOI 10.1038/sj.onc.1209380; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Liu XY, 2006, CELL RES, V16, P879, DOI 10.1038/sj.cr.7310108; Liu XY, 2005, MOL THER, V11, P531, DOI 10.1016/j.ymthe.2004.12.003; Liu XY, 2001, CHIN J CANC BIOTHER, V8, P1; Liu XY, 2012, RECENT ADV IN PRESS; Liu XY, 2012, CURR PHARM BIOTECHNO; Mo Y, 1996, Zhonghua Zhong Liu Za Zhi, V18, P241; Mo YQ, 1997, AIZHENG, V16, P12; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pei ZF, 2004, HEPATOLOGY, V39, P1371, DOI 10.1002/hep.20203; Sagawa T, 2004, MOL THER, V10, P1043, DOI 10.1016/j.ymthe.2004.08.023; SCHREWE H, 1990, MOL CELL BIOL, V10, P2738, DOI 10.1128/MCB.10.6.2738; Shi Zheng-Zheng, 2007, Journal of Zhejiang University-Science B, V8, P170, DOI 10.1631/jzus.2007.B0170; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wei RC, 2011, HUM GENE THER, V22, P1109, DOI 10.1089/hum.2010.219; Xu HN, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-133; Yang M, 2008, HUM GENE THER, V19, P343, DOI 10.1089/hum.2007.0137; Yu DB, 2009, CANCER SCI, V100, P678, DOI 10.1111/j.1349-7006.2009.01110.x; Zhang Q, 2004, CANCER RES, V64, P5390, DOI 10.1158/0008-5472.CAN-04-1229; Zhang YH, 2006, CANCER RES, V66, P4291, DOI 10.1158/0008-5472.CAN-05-1834; Zhang ZW, 2009, CLIN CANCER RES, V15, P5154, DOI 10.1158/1078-0432.CCR-09-0025; Zhang ZL, 2003, CELL RES, V13, P481, DOI 10.1038/sj.cr.7290191; Zhao L, 2006, CANCER GENE THER, V13, P1011, DOI 10.1038/sj.cgt.7700969; Zheng S, 1997, CHINESE MED J-PEKING, V110, P543; Zheng S, 1997, Zhonghua Yi Xue Za Zhi, V77, P256; Zheng S, 2005, CHIN GERMAN J CLIN O, V4, P2; Zheng S, 1998, INT J MODERN CANC TH, V1, P3; Zheng S, 2001, B CHINESE CANC, V10, P136	38	15	18	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2012	7	10							e47566	10.1371/journal.pone.0047566	http://dx.doi.org/10.1371/journal.pone.0047566			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022WO	23077639	gold, Green Published, Green Submitted			2023-01-03	WOS:000309995100134
J	Toltzis, P; Goldmann, D				Toltzis, Philip; Goldmann, Don			Rethinking infection prevention research	LANCET			English	Editorial Material							BLOOD-STREAM INFECTIONS; RANDOMIZED TRIAL; POVIDONE-IODINE; CARE; CHLORHEXIDINE; CATHETERS; RATES		[Toltzis, Philip] Rainbow Babies & Childrens Hosp, Cleveland, OH 44122 USA; [Goldmann, Don] Inst Healthcare Improvement, Cambridge, MA USA; [Goldmann, Don] Boston Childrens Hosp, Div Infect Dis, Boston, MA USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Institute for Healthcare Improvement; Harvard University; Boston Children's Hospital	Toltzis, P (corresponding author), Rainbow Babies & Childrens Hosp, Cleveland, OH 44122 USA.	philip.toltzis@UHHospitals.org						Berwick DM, 1998, ANN INTERN MED, V128, P651, DOI 10.7326/0003-4819-128-8-199804150-00009; Bleasdale SC, 2007, ARCH INTERN MED, V167, P2073, DOI 10.1001/archinte.167.19.2073; Brook RH, 2012, J GEN INTERN MED, DOI 10.1007/s11606-012-2242-y; Casey AL, 2008, LANCET INFECT DIS, V8, P763, DOI 10.1016/S1473-3099(08)70280-9; Dixon-Woods M, 2011, MILBANK Q, V89, P167, DOI 10.1111/j.1468-0009.2011.00625.x; Dudeck MA, 2011, AM J INFECT CONTROL, V39, P349, DOI 10.1016/j.ajic.2011.04.011; Garland JS, 2001, PEDIATRICS, V107, P1431, DOI 10.1542/peds.107.6.1431; Institute for Healthcare Improvement, 2012, BREAKTHR SER IHIS CO; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869, DOI DOI 10.1001/JAMA.1989.03430200113036; Landrigan CP, 2010, NEW ENGL J MED, V363, P2124, DOI 10.1056/NEJMsa1004404; Luce BR, 2009, ANN INTERN MED, V151, P206, DOI 10.7326/0003-4819-151-3-200908040-00126; MAKI DG, 1991, LANCET, V338, P339, DOI 10.1016/0140-6736(91)90479-9; Miller MR, 2010, PEDIATRICS, V125, P206, DOI 10.1542/peds.2009-1382; Milstone AM, 2013, LANCET; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; Schulman J, 2011, PEDIATRICS, V127, P436, DOI 10.1542/peds.2010-2873	16	3	2	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 30	2013	381	9872					1078	1079		10.1016/S0140-6736(12)61996-5	http://dx.doi.org/10.1016/S0140-6736(12)61996-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	122WL	23363665				2023-01-03	WOS:000317348900007
J	Friedman, SR; West, BS; Pouget, ER; Hall, HI; Cantrell, J; Tempalski, B; Chatterjee, S; Hu, XH; Cooper, HLF; Galea, S; Jarlais, DCD				Friedman, Samuel R.; West, Brooke S.; Pouget, Enrique R.; Hall, H. Irene; Cantrell, Jennifer; Tempalski, Barbara; Chatterjee, Sudip; Hu, Xiaohong; Cooper, Hannah L. F.; Galea, Sandro; Des Jarlais, Don C.			Metropolitan Social Environments and Pre-HAART/HAART Era Changes in Mortality Rates (per 10,000 Adult Residents) among Injection Drug Users Living with AIDS	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; INCOME INEQUALITY; TREATMENT COVERAGE; HIV PREVALENCE; UNITED-STATES; US; AREAS; INCARCERATION; HEALTH; IMPACT	Background: Among the largest US metropolitan areas, trends in mortality rates for injection drug users (IDUs) with AIDS vary substantially. Ecosocial, risk environment and dialectical theories suggest many metropolitan areas characteristics that might drive this variation. We assess metropolitan area characteristics associated with decline in mortality rates among IDUs living with AIDS (per 10,000 adult MSA residents) after highly active antiretroviral therapy (HAART) was developed. Methods: This is an ecological cohort study of 86 large US metropolitan areas from 1993-2006. The proportional rate of decline in mortality among IDUs diagnosed with AIDS (as a proportion of adult residents) from 1993-1995 to 2004-2006 was the outcome of interest. This rate of decline was modeled as a function of MSA-level variables suggested by ecosocial, risk environment and dialectical theories. In multiple regression analyses, we used 1993-1995 mortality rates to (partially) control for pre-HAART epidemic history and study how other independent variables affected the outcomes. Results: In multivariable models, pre-HAART to HAART era increases in 'hard drug' arrest rates and higher pre-HAART income inequality were associated with lower relative declines in mortality rates. Pre-HAART per capita health expenditure and drug abuse treatment rates, and pre- to HAART-era increases in HIV counseling and testing rates, were weakly associated with greater decline in AIDS mortality. Conclusions: Mortality among IDUs living with AIDS might be decreased by reducing metropolitan income inequality, increasing public health expenditures, and perhaps increasing drug abuse treatment and HIV testing services. Given prior evidence that drug-related arrest rates are associated with higher HIV prevalence rates among IDUs and do not seem to decrease IDU population prevalence, changes in laws and policing practices to reduce such arrests while still protecting public order should be considered.	[Friedman, Samuel R.; West, Brooke S.; Pouget, Enrique R.; Tempalski, Barbara; Des Jarlais, Don C.] Natl Dev & Res Inst Inc, Inst Infect Dis Res, New York, NY USA; [Hall, H. Irene; Hu, Xiaohong] Ctr Dis Control, Atlanta, GA 30333 USA; [Cantrell, Jennifer] Legacy Fdn, Washington, DC USA; [Cooper, Hannah L. F.] Emory Univ, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA; [Galea, Sandro] Columbia Univ, Dept Epidemiol, New York, NY USA; [Des Jarlais, Don C.] Beth Israel Deaconess Med Ctr, Baron Edmond de Rothschild Chem Dependency Inst, New York, NY 10003 USA	National Development & Research Institutes, Inc; Centers for Disease Control & Prevention - USA; Emory University; Columbia University; Harvard University; Beth Israel Deaconess Medical Center	Friedman, SR (corresponding author), Natl Dev & Res Inst Inc, Inst Infect Dis Res, New York, NY USA.	friedman@ndri.org	Pouget, Enrique Rodriguez/AAJ-5786-2020; Galea, Sandro/GLR-6066-2022	Pouget, Enrique Rodriguez/0000-0002-5907-1909; Galea, Sandro/0000-0002-7534-0945; West, Brooke S./0000-0003-0496-5769; Friedman, Sam/0000-0003-2083-1226; Tempalski, Barbara/0000-0002-6128-2510	National Institute of Drug Abuse [R01 DA013336, R01 DA 003574, 5T32 DA007233]; Public Health Solutions; National Development and Research Institutes; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA013336, T32DA007233, R01DA003574] Funding Source: NIH RePORTER	National Institute of Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Public Health Solutions; National Development and Research Institutes; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by National Institute of Drug Abuse grants # R01 DA013336 (Community Vulnerability and Responses to Drug-User-Related HIV/AIDS), R01 DA 003574 (Risk Factors for AIDS among Intravenous Drug Users), and 5T32 DA007233 (Behavioral Sciences Training in Drug Abuse Research program sponsored by Public Health Solutions and National Development and Research Institutes). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; [Anonymous], 2002, INT J DRUG POLICY, DOI [DOI 10.1016/S0955-3959(02)00075-0, DOI 10.1016/S0955-3959]; Backlund E, 2007, INT J EPIDEMIOL, V36, P590, DOI 10.1093/ije/dym012; Beal D. J., 2005, SAS CODE SELECT BEST; Bluthenthal R. N., 1999, International Journal of Drug Policy, V10, P25, DOI 10.1016/S0955-3959(98)00076-0; Bluthenthal R N, 1997, Med Anthropol, V18, P61, DOI 10.1080/01459740.1997.9966150; Bluthenthal RN, 1999, J DRUG ISSUES, V29, P1; Brady JE, 2008, J URBAN HEALTH, V85, P323, DOI 10.1007/s11524-007-9248-5; Brown B. S., 1993, HDB RISK AIDS INJECT; [Bureau UC US Census Bureau], 1990, HOUS HOUS EC STAT DI; Burnham KP, 2004, SOCIOL METHOD RES, V33, P261, DOI 10.1177/0049124104268644; Chaix B, 2010, EPIDEMIOLOGY, V21, P124, DOI 10.1097/EDE.0b013e3181c04e70; Cohen Stacy M., 2011, Morbidity and Mortality Weekly Report, V60, P1618; Cooper H, 2005, SOC SCI MED, V61, P673, DOI 10.1016/j.socscimed.2004.12.030; Cooper H, 2005, ANN EPIDEMIOL, V15, P326, DOI 10.1016/j.annepidem.2004.10.008; Cooper HLF, 2007, AM J PUBLIC HEALTH, V97, P344, DOI 10.2105/AJPH.2005.074542; Cooper HLF, 2009, J URBAN HEALTH, V86, P929, DOI 10.1007/s11524-009-9399-7; Cooper HLF, 2008, J URBAN HEALTH, V85, P826, DOI 10.1007/s11524-008-9304-9; Cooper RS, 2001, PUBLIC HEALTH REP, V116, P464, DOI 10.1016/S0033-3549(04)50074-2; Crum NF, 2006, JAIDS-J ACQ IMM DEF, V41, P194, DOI 10.1097/01.qai.0000179459.31562.16; Federal Bureau of Investigation, 2009, CRIM US; Friedman S, 2008, GEOGRAPHY DRUG ADDIC; Friedman SR, 2011, DIALECT ANTHROPOL, V35, P453, DOI 10.1007/s10624-011-9257-3; Friedman SR, 2011, DIALECT ANTHROPOL, V35, P403, DOI 10.1007/s10624-011-9222-1; Friedman SR, 2007, INT J DRUG POLICY, V18, P475, DOI 10.1016/j.drugpo.2006.10.004; Friedman SR, 2011, AM J PUBLIC HEALTH, V101, P344, DOI 10.2105/AJPH.2010.191759; Friedman SR, 2006, AIDS, V20, P93, DOI 10.1097/01.aids.0000196176.65551.a3; Friedman SR, 2004, J URBAN HEALTH, V81, P377, DOI 10.1093/jurban/jth125; Friedman SR, 2001, AM J PUBLIC HEALTH, V91, P791, DOI 10.2105/AJPH.91.5.791; Friedman SR, 2001, 2000 GLOB RES NETW M, P147; Galea S, 2005, J EPIDEMIOL COMMUN H, V59, P822, DOI 10.1136/jech.2005.033084; Galea S, 2011, AM J PUBLIC HEALTH, V101, P1456, DOI 10.2105/AJPH.2010.300086; Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243; Gill J, 2010, CLIN INFECT DIS, V50, P1387, DOI 10.1086/652283; Harper S, 2005, ESTIMATES GINI COEFF; Harrison KM, 2010, JAIDS-J ACQ IMM DEF, V53, P124, DOI 10.1097/QAI.0b013e3181b563e7; Kerr T, 2005, AIDS CARE, V17, P539, DOI 10.1080/09540120412331319778; Khan MR, 2008, ANN EPIDEMIOL, V18, P403, DOI 10.1016/j.annepidem.2007.12.003; Kondo N, 2009, BMJ, V10; Krieger N, 2001, INT J EPIDEMIOL, V30, P668, DOI 10.1093/ije/30.4.668; Krusi A, 2010, INT J DRUG POLICY, V21, P4, DOI 10.1016/j.drugpo.2009.08.003; Kuha J, 2004, SOCIOL METHOD RES, V33, P188, DOI 10.1177/0049124103262065; LAUS, 2009, LOC AR UN STAT; Link BG, 2005, POLICY CHALLENGES MO, P71; Lucas GM, 2006, CLIN INFECT DIS, V42, P1628, DOI 10.1086/503905; Lynch J, 2004, MILBANK Q, V82, P5, DOI 10.1111/j.0887-378X.2004.00302.x; Marmot M, 2004, STATUS SYNDROME; Marmot M., 2005, PUBLIC HEALTH; Meditz AL, 2011, J INFECT DIS, V203, P442, DOI 10.1093/infdis/jiq085; Milloy MJ, 2011, J INFECT DIS, V203, P1215, DOI 10.1093/infdis/jir032; Montaner JSG, 2010, JAIDS-J ACQ IMM DEF, V55, pS5, DOI 10.1097/QAI.0b013e3181f9c1f0; Nandi A, 2006, SOC SCI MED, V63, P662, DOI 10.1016/j.socscimed.2006.02.001; Office of Management and Budget, 2000, FED REG, V65, P8228; Rhodes T, 2009, INT J DRUG POLICY, V20, P193, DOI 10.1016/j.drugpo.2008.10.003; Roberts ET, 2010, DRUG ALCOHOL DEPEN, V106, P142, DOI 10.1016/j.drugalcdep.2009.08.007; Roux P, 2008, ADDICTION, V103, P1828, DOI 10.1111/j.1360-0443.2008.02323.x; Rubin MS, 2010, AM J PUBLIC HEALTH, V100, P1053, DOI 10.2105/AJPH.2009.170241; SAS, 2002, SAS 9 2; Schneider MF, 2005, AIDS, V19, P2009, DOI 10.1097/01.aids.0000189864.90053.22; Small W, 2007, INT J DRUG POLICY, V18, P27, DOI 10.1016/j.drugpo.2006.11.019; Small W, 2009, AIDS CARE, V21, P708, DOI 10.1080/09540120802511869; Song RG, 2011, PUBLIC HEALTH REP, V126, P70, DOI 10.1177/00333549111260S312; Springer KW, 1999, SUBST USE MISUSE, V34, P1917, DOI 10.3109/10826089909039432; Subramanian SV, 2004, EPIDEMIOL REV, V26, P78, DOI 10.1093/epirev/mxh003; Substance Abuse and Mental Health Services Administration, 1998, NAT HOUS SURV DRUG A; Substance Abuse and Mental Health Services Administration Office of Applied Studies, 1992, TREATMENT EPISODE DA; Syme S, 2005, EPIDEMIOL PERSPECT I, V2; Tempalski B, 2009, J URBAN HEALTH, V86, P132, DOI 10.1007/s11524-008-9328-1; Tempalski B, 2009, INT J DRUG POLICY, V20, P4, DOI 10.1016/j.drugpo.2008.02.002; Tempalski B, 2010, SUBST ABUSE TREAT PR, V5, DOI 10.1186/1747-597X-5-23; Thomas JC, 2005, J INFECT DIS, V191, pS55, DOI 10.1086/425278; Uhlmann S, 2010, ADDICTION, V105, P907, DOI 10.1111/j.1360-0443.2010.02905.x; United States Census Bureau, 2002, CENS GOV; *US BUR CENS, 1990, POP EST; US Census Bureau, 1992, CENS GOV; US Census Bureau, 2000, POP EST; [US Census Bureau Bureau UC], 2000, HOUS HOUS EC STAT DI; Wilkinson R, 1999, SOCIAL DETERMINANTS, pp256; Wood E, 2004, CAN MED ASSOC J, V170, P1551, DOI 10.1503/cmaj.1031928	79	19	19	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2013	8	2							e57201	10.1371/journal.pone.0057201	http://dx.doi.org/10.1371/journal.pone.0057201			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	093IT	23437341	Green Submitted, gold, Green Published			2023-01-03	WOS:000315186000084
J	Krumholz, HM				Krumholz, Harlan M.			Post-Hospital Syndrome - An Acquired, Transient Condition of Generalized Risk	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							READMISSION		[Krumholz, Harlan M.] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT 06520 USA; [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA; [Krumholz, Harlan M.] Yale Univ, Sch Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT USA; [Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA	Yale University; Yale University; Yale University; Yale University	Krumholz, HM (corresponding author), Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT 06520 USA.		Martin, Carmel Mary/B-6358-2011; , Harlan/AAI-2875-2020	Martin, Carmel Mary/0000-0001-8174-7859; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL105270] Funding Source: NIH RePORTER; NHLBI NIH HHS [U01 HL105270] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Friedmann JM, 1997, AM J CLIN NUTR, V65, P1714, DOI 10.1093/ajcn/65.6.1714; Jencks SF, 2009, NEW ENGL J MED, V360, P1418; Kansagara D, 2011, JAMA-J AM MED ASSOC, V306, P1688, DOI 10.1001/jama.2011.1515	3	755	762	3	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 10	2013	368	2					100	102		10.1056/NEJMp1212324	http://dx.doi.org/10.1056/NEJMp1212324			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	066RO	23301730	Green Accepted			2023-01-03	WOS:000313238100013
J	Bi, CWC; Xu, L; Tian, XY; Liu, J; Zheng, KYZ; Lau, CW; Lau, DTW; Choi, RCY; Dong, TTX; Huang, Y; Tsim, KWK				Bi, Cathy W. C.; Xu, Li; Tian, Xiao Yu; Liu, Jian; Zheng, Ken Y. Z.; Lau, Chi Wai; Lau, David T. W.; Choi, Roy C. Y.; Dong, Tina T. X.; Huang, Yu; Tsim, Karl W. K.			Fo Shou San, an Ancient Chinese Herbal Decoction, Protects Endothelial Function through Increasing Endothelial Nitric Oxide Synthase Activity	PLOS ONE			English	Article							SPONTANEOUSLY HYPERTENSIVE-RATS; FERULIC ACID; ANGELICAE SINENSIS; GINSENOSIDE RB1; REACTIVE OXYGEN; NADPH OXIDASE; CELLS; DYSFUNCTION; HOMOCYSTEINE; ACTIVATION	Fo Shou San (FSS) is an ancient herbal decoction comprised of Chuanxiong Rhizoma (CR; Chuanxiong) and Angelicae Sinensis Radix (ASR; Danggui) in a ratio of 2:3. Previous studies indicate that FSS promotes blood circulation and dissipates blood stasis, thus which is being used widely to treat vascular diseases. Here, we aim to determine the cellular mechanism for the vascular benefit of FSS. The treatment of FSS reversed homocysteine-induced impairment of acetylcholine (ACh)-evoked endothelium-dependent relaxation in aortic rings, isolated from rats. Like radical oxygen species (ROS) scavenger tempol, FSS attenuated homocysteine-stimulated ROS generation in cultured human umbilical vein endothelial cells (HUVECs), and it also stimulated the production of nitric oxide (NO) as measured by fluorescence dye and biochemical assay. In addition, the phosphorylation levels of both Akt kinase and endothelial NO synthases (eNOS) were markedly increased by FSS treatment, which was abolished by an Akt inhibitor triciribine. Likewise, triciribine reversed FSS-induced NO production in HUVECs. Finally, FSS elevated intracellular Ca2+ levels in HUVECs, and the Ca2+ chelator BAPTA-AM inhibited the FSS-stimulated eNOS phosphorylation. The present results show that this ancient herbal decoction benefits endothelial function through increased activity of Akt kinase and eNOS; this effect is causally via a rise of intracellular Ca2+ and a reduction of ROS.	[Bi, Cathy W. C.; Xu, Li; Zheng, Ken Y. Z.; Lau, David T. W.; Choi, Roy C. Y.; Dong, Tina T. X.; Tsim, Karl W. K.] Hong Kong Univ Sci & Technol, Div Life Sci, Hong Kong, Hong Kong, Peoples R China; [Bi, Cathy W. C.; Xu, Li; Zheng, Ken Y. Z.; Lau, David T. W.; Choi, Roy C. Y.; Dong, Tina T. X.; Tsim, Karl W. K.] Hong Kong Univ Sci & Technol, Ctr Chinese Med, Hong Kong, Hong Kong, Peoples R China; [Tian, Xiao Yu; Liu, Jian; Lau, Chi Wai; Huang, Yu] Chinese Univ Hong Kong, Sch Biomed Sci, Li Ka Shing Inst Hlth Sci, Inst Vasc Med, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; Chinese University of Hong Kong	Tsim, KWK (corresponding author), Hong Kong Univ Sci & Technol, Div Life Sci, Hong Kong, Hong Kong, Peoples R China.	botsim@ust.hk	Huang, Yu/K-2866-2017; Tian, Xiao Yu/P-1092-2016	Huang, Yu/0000-0002-1277-6784; Tian, Xiao Yu/0000-0003-3472-9898; Tsim, Karl/0000-0003-4808-1674; Liu, Jian/0000-0001-9719-2923; Lau, Tai Wai David/0000-0002-3443-1808	Research Grants Council of Hong Kong [N_HKUST629/07, 662608, 662911, 661110]; Croucher Foundation [CAS-CF07/08.SC03]	Research Grants Council of Hong Kong(Hong Kong Research Grants Council); Croucher Foundation	This research was supported by grants from Research Grants Council of Hong Kong (N_HKUST629/07, 662608, 662911 to KWKT; 661110 to DTWL), Croucher Foundation (CAS-CF07/08.SC03) to KWKT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Berndt N, 2010, CELL DEATH DIFFER, V17, P1795, DOI 10.1038/cdd.2010.63; Bi CWC, 2012, PLANTA MED, V78, P122, DOI 10.1055/s-0031-1280356; Bi CWC, 2010, PLANTA MED, V76, P1525, DOI 10.1055/s-0029-1241003; Cai H, 2008, CARDIOVASC RES, V77, P30, DOI 10.1093/cvr/cvm010; Chan WK, 2000, CARDIOVASC RES, V46, P180, DOI 10.1016/S0008-6363(99)00423-X; Chen ZY, 1998, LIFE SCI, V63, P1983, DOI 10.1016/S0024-3205(98)00476-7; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Hasin T, 2011, BASIC RES CARDIOL, V106, P175, DOI 10.1007/s00395-010-0145-9; Hemmens B, 2000, J BIOL CHEM, V275, P35786, DOI 10.1074/jbc.M005976200; Higashi Y, 2002, AM J HYPERTENS, V15, P326, DOI 10.1016/S0895-7061(01)02317-2; Hink U, 2001, CIRC RES, V88, pE14; Hu QH, 2000, J BIOL CHEM, V275, P15749, DOI 10.1074/jbc.M000381200; Huang Y, 1999, BBA-GEN SUBJECTS, V1427, P322, DOI 10.1016/S0304-4165(99)00034-3; Ignarro LJ, 2002, J PHYSIOL PHARMACOL, V53, P503; Kietadisorn R, 2012, AM J PHYSIOL-ENDOC M, V302, pE481, DOI 10.1152/ajpendo.00540.2011; Lan TH, 2011, BIOCHEM PHARMACOL, V82, P148, DOI 10.1016/j.bcp.2011.04.001; Landmesser U, 2003, J CLIN INVEST, V111, P1201, DOI 10.1172/JCI200314172; Leber A, 1999, J BIOL CHEM, V274, P37658, DOI 10.1074/jbc.274.53.37658; Lee JH, 2003, J BIOL CHEM, V278, P51360, DOI 10.1074/jbc.M302332200; Leung KW, 2007, FEBS LETT, V581, P2423, DOI 10.1016/j.febslet.2007.04.055; Li JM, 2001, CARDIOVASC RES, V52, P477, DOI 10.1016/S0008-6363(01)00407-2; Li YB, 1998, J BIOL CHEM, V273, P2015, DOI 10.1074/jbc.273.4.2015; Ma ZC, 2010, BIOL PHARM BULL, V33, P29, DOI 10.1248/bpb.33.29; Michel T, 2010, PFLUG ARCH EUR J PHY, V459, P807, DOI 10.1007/s00424-009-0765-9; Mikkelsen RB, 2003, ONCOGENE, V22, P5734, DOI 10.1038/sj.onc.1206663; Moens AL, 2008, CIRCULATION, V117, P1810, DOI 10.1161/CIRCULATIONAHA.107.725481; Mollnau H, 2002, CIRC RES, V90, pE58, DOI 10.1161/01.RES.0000012569.55432.02; Ohashi R, 2006, J SURG RES, V133, P89, DOI 10.1016/j.jss.2005.09.016; Shao M.L., 2010, PHARMACOPOEIA PEOP 1, P144; Stanger O, 2003, CLIN CHEM LAB MED, V41, P1444, DOI 10.1515/CCLM.2003.222; Stuhlinger MC, 2001, CIRCULATION, V104, P2569, DOI 10.1161/hc4601.098514; Suzuki A, 2002, AM J HYPERTENS, V15, P351, DOI 10.1016/S0895-7061(01)02337-8; Suzuki A, 2007, AM J HYPERTENS, V20, P508, DOI 10.1016/j.amjhyper.2006.11.008; Takimoto E, 2005, J CLIN INVEST, V115, P1221, DOI 10.1172/JCI200521968; Tang EHC, 2007, BRIT J PHARMACOL, V151, P15, DOI 10.1038/sj.bjp.0707190; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wang BH, 2004, J CARDIOVASC PHARM, V43, P549, DOI 10.1097/00005344-200404000-00010; Wong WT, 2011, CELL METAB, V14, P104, DOI 10.1016/j.cmet.2011.05.009; Wong WT, 2010, J CARDIOVASC PHARM, V55, P300, DOI 10.1097/FJC.0b013e3181d7671c; Zou MH, 2002, J CLIN INVEST, V109, P817, DOI 10.1172/JCI200214442	41	30	33	1	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 21	2012	7	12							e51670	10.1371/journal.pone.0051670	http://dx.doi.org/10.1371/journal.pone.0051670			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	065OW	23284736	Green Submitted, gold, Green Published			2023-01-03	WOS:000313158800013
J	Haeseker, MB; Dukers-Muijrers, NHTM; Hoebe, CJPA; Bruggeman, CA; Cals, JWL; Verbon, A				Haeseker, Michiel B.; Dukers-Muijrers, Nicole H. T. M.; Hoebe, Christian J. P. A.; Bruggeman, Cathrien A.; Cals, Jochen W. L.; Verbon, Annelies			Trends in Antibiotic Prescribing in Adults in Dutch General Practice	PLOS ONE			English	Article							ADVERSE DRUG-REACTIONS; ANTIMICROBIAL CONSUMPTION ESAC; INAPPROPRIATE MEDICATION USE; PRIMARY-CARE; EUROPEAN SURVEILLANCE; UNITED-STATES; OLDER-ADULTS; INFECTIONS; EVENTS; POPULATION	Background: Antibiotic consumption is associated with adverse drug events (ADE) and increasing antibiotic resistance. Detailed information of antibiotic prescribing in different age categories is scarce, but necessary to develop strategies for prudent antibiotic use. The aim of this study was to determine the antibiotic prescriptions of different antibiotic classes in general practice in relation to age. Methodology: Retrospective study of 22 rural and urban general practices from the Dutch Registration Network Family Practices (RNH). Antibiotic prescribing data were extracted from the RNH database from 2000-2009. Trends over time in antibiotic prescriptions were assessed with multivariate logistic regression including interaction terms with age. Registered ADEs as a result of antibiotic prescriptions were also analyzed. Principal Findings: In total 658,940 patients years were analyzed. In 11.5% (n = 75,796) of the patient years at least one antibiotic was prescribed. Antibiotic prescriptions increased for all age categories during 2000-2009, but the increase in elderly patients (>80 years) was most prominent. In 2000 9% of the patients >80 years was prescribed at least one antibiotic to 22% in 2009 (P<0.001). Elderly patients had more ADEs with antibiotics and co-medication was identified as the only independent determinant for ADEs. Conclusion/Discussion: The rate of antibiotic prescribing for patients who made a visit to the GP is increasing in the Netherlands with the most evident increase in the elderly patients. This may lead to more ADEs, which might lead to higher consumption of health care and more antibiotic resistance.	[Haeseker, Michiel B.; Dukers-Muijrers, Nicole H. T. M.; Hoebe, Christian J. P. A.; Bruggeman, Cathrien A.; Verbon, Annelies] Maastricht Univ, Dept Med Microbiol, Med Ctr, Maastricht, Netherlands; [Dukers-Muijrers, Nicole H. T. M.; Hoebe, Christian J. P. A.] Publ Hlth Serv S Limburg, Dept Sexual Hlth Infect Dis & Environm Hlth, Geleen, Netherlands; [Cals, Jochen W. L.] Maastricht Univ, Dept Gen Practice, Maastricht, Netherlands; [Haeseker, Michiel B.; Dukers-Muijrers, Nicole H. T. M.; Hoebe, Christian J. P. A.; Bruggeman, Cathrien A.; Cals, Jochen W. L.] Sch Publ Hlth & Primary Care CAPHRI, Maastricht, Netherlands; [Verbon, Annelies] Erasmus MC, Dept Internal Med Sect, Rotterdam, Netherlands	Maastricht University; Maastricht University; Maastricht University; Erasmus University Rotterdam; Erasmus MC	Haeseker, MB (corresponding author), Maastricht Univ, Dept Med Microbiol, Med Ctr, Maastricht, Netherlands.	m.haeseker@mumc.nl	Cals, Jochen WL/A-1262-2007; Dukers-Muijrers, Nicole/M-7178-2014	Cals, Jochen WL/0000-0001-9550-5674; Hoebe, Christian/0000-0003-1815-0974; Dukers-Muijrers, Nicole/0000-0003-4896-758X				Adriaenssens N, 2011, J ANTIMICROB CHEMOTH, V66, P3, DOI 10.1093/jac/dkr453; BEARD K, 1992, DRUG AGING, V2, P356, DOI 10.2165/00002512-199202040-00008; Beers MH, 1997, ARCH INTERN MED, V157, P1531, DOI 10.1001/archinte.157.14.1531; Cosby JL, 2007, LANCET INFECT DIS, V7, P749, DOI 10.1016/S1473-3099(07)70263-3; Eurostat, 2010, POP PROJ 2010 2060; Faulkner CM, 2005, CLIN INFECT DIS, V40, P997, DOI 10.1086/428125; Feldman C, 2001, MED CLIN N AM, V85, P1441, DOI 10.1016/S0025-7125(05)70390-4; Ferech M, 2006, J ANTIMICROB CHEMOTH, V58, P401, DOI 10.1093/jac/dkl188; Finkelstein JA, 2000, ARCH PEDIAT ADOL MED, V154, P395, DOI 10.1001/archpedi.154.4.395; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Goossens H, 2007, CLIN INFECT DIS, V44, P1091, DOI 10.1086/512810; Gulliford M, 2009, J PUBLIC HEALTH-UK, V31, P512, DOI 10.1093/pubmed/fdp081; Hanlon JT, 1997, J AM GERIATR SOC, V45, P945, DOI 10.1111/j.1532-5415.1997.tb02964.x; Herring AR, 2007, CLIN GERIATR MED, V23, P481, DOI 10.1016/j.cger.2007.03.009; HofmansOkkes IM, 1996, FAM PRACT, V13, P294, DOI 10.1093/fampra/13.3.294; HUTCHINSON TA, 1986, J CHRON DIS, V39, P533, DOI 10.1016/0021-9681(86)90198-0; KNOTTNERUS JA, 1992, FAM PRACT, V9, P15, DOI 10.1093/fampra/9.1.15; Kuyvenhoven MM, 2003, J ANTIMICROB CHEMOTH, V52, P675, DOI 10.1093/jac/dkg412; Laroche ML, 2007, BRIT J CLIN PHARMACO, V63, P177, DOI 10.1111/j.1365-2125.2006.02831.x; Laube S, 2004, AGEING RES REV, V3, P69, DOI 10.1016/j.arr.2003.08.003; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Linder JA, 2005, AM J MED, V118, P259, DOI 10.1016/j.amjmed.2004.09.015; Majeed A, 1999, BRIT J GEN PRACT, V49, P735; Metsemakers JFM, 1996, INT J BIOMED COMPUT, V42, P43, DOI 10.1016/0020-7101(96)01180-4; Norris P, 2011, J ANTIMICROB CHEMOTH, V66, P1921, DOI 10.1093/jac/dkr194; O'Mahony D, 2008, AGE AGEING, V37, P138, DOI 10.1093/ageing/Afm189; Otters HBM, 2004, J ANTIMICROB CHEMOTH, V53, P361, DOI 10.1093/jac/dkh062; Pan A, 2011, CLIN MICROBIOL INFEC, V17, P1698, DOI 10.1111/j.1469-0691.2011.03500.x; Richards Chesley L., 2004, International Urology and Nephrology, V36, P457, DOI 10.1007/s11255-004-4870-6; SFK, 2010, ANT GROEIT GEST; Shehab N, 2008, CLIN INFECT DIS, V47, P735, DOI 10.1086/591126; VANDENAKKER M, 2004, GEN PRACTICE GOLD MI	32	28	28	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2012	7	12							e51860	10.1371/journal.pone.0051860	http://dx.doi.org/10.1371/journal.pone.0051860			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	066QV	23251643	Green Published, Green Submitted, gold			2023-01-03	WOS:000313236200170
J	Mologni, L; Brussolo, S; Ceccon, M; Gambacorti-Passerini, C				Mologni, Luca; Brussolo, Stefania; Ceccon, Monica; Gambacorti-Passerini, Carlo			Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells	PLOS ONE			English	Article							PANCREATIC TUMOR-GROWTH; BETA-CATENIN; K-RAS; COLON-CANCER; PYRVINIUM PAMOATE; CARCINOMA-CELLS; IN-VITRO; FARNESYLTHIOSALICYLIC ACID; PROMOTES APOPTOSIS; THYROID CARCINOMAS	Activation of Wnt signalling due to inability to degrade beta-catenin is found in >85% of colorectal cancers. Approximately half of colon cancers express a constitutively active KRAS protein. A significant fraction of patients show both abnormalities. We previously reported that simultaneous down-regulation of both beta-catenin and KRAS was necessary to induce significant cell death and tumor growth inhibition of colorectal cancer cells. Although attractive, an RNAi-based therapeutic approach is still far from being employed in the clinical setting. Therefore, we sought to recapitulate our previous findings by the use of small-molecule inhibitors of beta-catenin and KRAS. We show here that the beta-catenin inhibitors PKF115-584 and pyrvinium pamoate block beta-catenin-dependent transcriptional activity and synergize with the KRAS inhibitor S-trans, transfarnesylthiosalicylic acid (FTS, salirasib) in colon cancer cells driven by Wnt and KRAS oncogenic signals, but not in cells carrying BRAF mutations. The combined use of these compounds was superior to the use of any drug alone in inducing cell growth arrest, cell death, MYC and survivin down-modulation, and inhibition of anchorage-independent growth. Expression analysis of selected cancer-relevant genes revealed down-regulation of CD44 as a common response to the combined treatments. These data provide a proof of principle for a combination therapeutic strategy in colorectal cancer.	[Mologni, Luca; Ceccon, Monica; Gambacorti-Passerini, Carlo] Univ Milano Bicocca, Dept Hlth Sci, Monza, Italy; [Brussolo, Stefania] Univ Ca Foscari, Dept Environm Sci, Venice, Italy	University of Milano-Bicocca; Universita Ca Foscari Venezia	Mologni, L (corresponding author), Univ Milano Bicocca, Dept Hlth Sci, Monza, Italy.	luca.mologni@unimib.it	Mologni, Luca/AAC-1065-2022	Mologni, Luca/0000-0002-6365-5149; GAMBACORTI PASSERINI, CARLO/0000-0001-6058-515X	Italian Association for Cancer Research (AIRC), Cariplo Foundation; Italian Ministry of Health and Lombardy Regional Government	Italian Association for Cancer Research (AIRC), Cariplo Foundation(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health and Lombardy Regional Government	This work was supported by the Italian Association for Cancer Research (AIRC), Cariplo Foundation, the Italian Ministry of Health and Lombardy Regional Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahlquist T, 2008, NEOPLASIA, V10, P680, DOI 10.1593/neo.08312; Balmanno K, 2009, INT J CANCER, V125, P2332, DOI 10.1002/ijc.24604; Biankin AV, 2011, HUM GENET, V130, P79, DOI 10.1007/s00439-011-1010-0; Bozic I, 2010, P NATL ACAD SCI USA, V107, P18545, DOI 10.1073/pnas.1010978107; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Doghman M, 2008, J CLIN ENDOCR METAB, V93, P3222, DOI 10.1210/jc.2008-0247; Downey AS, 2008, ANTIMICROB AGENTS CH, V52, P3106, DOI 10.1128/AAC.00207-08; Ebi H, 2011, J CLIN INVEST, V121, P4311, DOI 10.1172/JCI57909; Elad G, 1999, BBA-MOL CELL RES, V1452, P228, DOI 10.1016/S0167-4889(99)00144-5; Esumi H, 2004, CANCER SCI, V95, P685, DOI 10.1111/j.1349-7006.2004.tb03330.x; FABIEN N, 1992, BRIT J CANCER, V66, P1094, DOI 10.1038/bjc.1992.416; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; Frattini M, 2004, CLIN CANCER RES, V10, P4015, DOI 10.1158/1078-0432.CCR-04-0031; Friday BB, 2005, BBA-REV CANCER, V1756, P127, DOI 10.1016/j.bbcan.2005.08.001; Gandhirajan RK, 2010, NEOPLASIA, V12, P326, DOI 10.1593/neo.91972; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Gerstung M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027136; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Haklai R, 2008, CANCER CHEMOTH PHARM, V61, P89, DOI 10.1007/s00280-007-0451-6; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Janakiraman M, 2010, CANCER RES, V70, P5901, DOI 10.1158/0008-5472.CAN-10-0192; Janssen KP, 2006, GASTROENTEROLOGY, V131, P1096, DOI 10.1053/j.gastro.2006.08.011; Kaneko R, 2007, J BIOL CHEM, V282, P19273, DOI 10.1074/jbc.M610350200; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Kohler EM, 2009, HUM MOL GENET, V18, P213, DOI 10.1093/hmg/ddn338; Kucherlapati R, 2012, AACR ANN M; Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9; Levy R, 2010, MOL CANCER THER, V9, P2208, DOI 10.1158/1535-7163.MCT-10-0262; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; MARCIANO D, 1995, J MED CHEM, V38, P1267, DOI 10.1021/jm00008a004; Mariadason JM, 2001, CANCER RES, V61, P3465; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Migliardi G, 2012, CLIN CANCER RES, V2012, P12; Misra S, 1944, FEBS J, V278, P1429; Misra S, 2008, J BIOL CHEM, V283, P14335, DOI 10.1074/jbc.M703811200; Mologni L, 2010, CANCER RES, V70, P7253, DOI 10.1158/0008-5472.CAN-10-1108; Mologni L, 2009, INT J CANCER, V124, P1990, DOI 10.1002/ijc.24158; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Oxnard GR, 2010, ONCOLOGY-NY, V24, P392; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Rotblat B, 2008, METHOD ENZYMOL, V439, P467, DOI 10.1016/S0076-6879(07)00432-6; Sansom OJ, 2006, P NATL ACAD SCI USA, V103, P14122, DOI 10.1073/pnas.0604130103; Sarthy AV, 2007, MOL CANCER THER, V6, P269, DOI 10.1158/1535-7163.MCT-06-0560; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Sharma SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907; Singh A, 2012, CELL, V148, P639, DOI 10.1016/j.cell.2011.12.033; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Smakman N, 2006, CANCER RES, V66, P5403, DOI 10.1158/0008-5472.CAN-05-4108; SMITH TC, 1976, CLIN PHARMACOL THER, V19, P802; Sukhdeo K, 2007, P NATL ACAD SCI USA, V104, P7516, DOI 10.1073/pnas.0610299104; Tan YH, 2008, PATHOLOGY, V40, P295, DOI 10.1080/00313020801911512; Thorne CA, 2010, NAT CHEM BIOL, V6, P829, DOI 10.1038/NCHEMBIO.453; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vasovcak P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024114; Verma UN, 2003, CLIN CANCER RES, V9, P1291; Weis B, 1999, ONCOGENE, V18, P2579, DOI 10.1038/sj.onc.1202602; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Yang M, 2005, P NATL ACAD SCI USA, V102, P6027, DOI 10.1073/pnas.0501535102; Yu DH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003951; Zhang T, 2001, CANCER RES, V61, P8664; Zundelevich A, 2007, MOL CANCER THER, V6, P1765, DOI 10.1158/1535-7163.MCT-06-0706	63	35	40	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2012	7	12							e51449	10.1371/journal.pone.0051449	http://dx.doi.org/10.1371/journal.pone.0051449			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	057TZ	23227266	gold, Green Published, Green Submitted			2023-01-03	WOS:000312588200125
J	Kwak, DH; Lee, JH; Kim, T; Ahn, HS; Cho, WK; Ha, H; Hwang, YH; Ma, JY				Kwak, Dong Hoon; Lee, Ji-Hye; Kim, Taesoo; Ahn, Hyo Sun; Cho, Won-Kyung; Ha, Hyunil; Hwang, Youn-Hwan; Ma, Jin Yeul			Aristolochia Manshuriensis Kom Inhibits Adipocyte Differentiation by Regulation of ERK1/2 and Akt Pathway	PLOS ONE			English	Article							MITOTIC CLONAL EXPANSION; ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR-I; PPAR-GAMMA; 3T3-L1 ADIPOCYTES; SIGNALING PATHWAYS; METABOLIC SYNDROME; MAP KINASE; ADIPOGENESIS; CELLS	Aristolochia manshuriensis Kom (AMK) is a traditional medicinal herb used for the treatment of arthritis, rheumatism, hepatitis, and anti-obesity. Because of nephrotoxicity and carcinogenicity of AMK, there are no pharmacological reports on anti-obesity potential of AMK. Here, we showed AMK has an inhibitory effect on adipocyte differentiation of 3T3-L1 cells along with significantly decrease in the lipid accumulation by downregulating several adipocyte-specific transcription factors including peroxisome proliferation-activity receptor gamma (PPAR-gamma), CCAAT/enhancer binding protein alpha (C/EBP-alpha) and C/EBP-beta, which are critical for adipogenesis in vitro. AMK also markedly activated the extracellular signal-regulated protein kinase 1/2 (ERK1/2) pathway including Ras, Raf1, and mitogen-activated protein kinase kinase 1 (MEK1), and significantly suppressed Akt pathway by inhibition of phosphoinositide-dependent kinase 1 (PDK1). Aristolochic acid (AA) and ethyl acetate (EtOAc) fraction of AMK with AA were significantly inhibited TG accumulation, and regulated two pathway (ERK1/2 and Akt) during adipocyte differentiation, and was not due to its cytotoxicity. These two pathways were upstream of PPAR-gamma and C/EBP alpha in the adipogenesis. In addition, gene expressions of secreting factors such as fatty acid synthase (FAS), adiponectin, lipopreotein lipase (LPL), and aP2 were significantly inhibited by treatment of AMK during adipogenesis. We used the high-fat diet (HFD)-induced obesity mouse model to determine the inhibitory effects of AMK on obesity. Oral administration of AMK (62.5 mg/kg/day) significantly decreased the fat tissue weight, total cholesterol (TC), and low density lipoprotein-cholesterol (LDL-C) concentration in the blood. The results of this study suggested that AMK inhibited lipid accumulation by the down-regulation of the major transcription factors of the adipogensis pathway including PPAR-gamma and C/EBP-alpha through regulation of Akt pathway and ERK 1/2 pathway in 3T3-L1 adipocytes and HFD-induced obesity mice, and AA may be main act in inhibitory effects of AMK during adipocyte differentiation.	[Kwak, Dong Hoon; Lee, Ji-Hye; Kim, Taesoo; Ahn, Hyo Sun; Cho, Won-Kyung; Ha, Hyunil; Hwang, Youn-Hwan; Ma, Jin Yeul] Korea Inst Oriental Med, Herbal Med Res Div, Taejon, South Korea	Korea Institute of Oriental Medicine (KIOM)	Kwak, DH (corresponding author), Korea Inst Oriental Med, Herbal Med Res Div, Taejon, South Korea.	jyma@kiom.re.kr	Hwang, Youn-Hwan/AAU-9373-2021	Ha, Hyunil/0000-0001-5947-9982; Kwak, Dong Hoon/0000-0001-9820-3137				Abate N, 2000, J DIABETES COMPLICAT, V14, P154, DOI 10.1016/S1056-8727(00)00067-2; Arnott CH, 1997, FEBS LETT, V406, P179, DOI 10.1016/S0014-5793(97)00266-4; Aubert J, 1999, J BIOL CHEM, V274, P24965, DOI 10.1074/jbc.274.35.24965; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; Duvnjak L, 2009, J PHYSIOL PHARMACOL, V60, P19; Farmer S R, 2004, Obes Rev, V5, P189, DOI 10.1111/j.1467-789X.2004.00157.x; Farmer SR, 2006, CELL METAB, V4, P263, DOI 10.1016/j.cmet.2006.07.001; Farnsworth NR, 1998, NAPRALERT DATABASE; Fu J, 2005, NEUROPHARMACOLOGY, V48, P1147, DOI 10.1016/j.neuropharm.2005.02.013; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; Hiuge-Shimizu A, 2011, ARTERIOSCL THROM VAS, V31, P792, DOI 10.1161/ATVBAHA.110.221747; Hou YY, 2012, FREE RADICAL BIO MED, V52, P462, DOI 10.1016/j.freeradbiomed.2011.10.453; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Huang C, 2006, BIOCHEM BIOPH RES CO, V348, P571, DOI 10.1016/j.bbrc.2006.07.095; Hung PF, 2005, AM J PHYSIOL-CELL PH, V288, pC1094, DOI 10.1152/ajpcell.00569.2004; Hwang JT, 2005, BIOCHEM BIOPH RES CO, V338, P694, DOI 10.1016/j.bbrc.2005.09.195; Jessen BA, 2002, GENE, V299, P95, DOI 10.1016/S0378-1119(02)01017-X; Kim YK, 2007, BIOCHEM BIOPH RES CO, V358, P553, DOI 10.1016/j.bbrc.2007.04.165; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Liao QC, 2008, J CELL BIOCHEM, V104, P1853, DOI 10.1002/jcb.21753; Liu LH, 2004, ACTA PHARMACOL SIN, V25, P1052; Liu YB, 2012, BIOCHEM BIOPH RES CO, V417, P570, DOI 10.1016/j.bbrc.2011.12.007; Magun R, 1996, ENDOCRINOLOGY, V137, P3590, DOI 10.1210/en.137.8.3590; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Pozdzik AA, 2008, NEPHROL DIAL TRANSPL, V23, P2480, DOI 10.1093/ndt/gfn140; Prusty D, 2002, J BIOL CHEM, V277, P46226, DOI 10.1074/jbc.M207776200; Rayalam S, 2008, J NUTR BIOCHEM, V19, P717, DOI 10.1016/j.jnutbio.2007.12.007; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Seo JB, 2012, BIOCHEM BIOPH RES CO, V417, P800, DOI 10.1016/j.bbrc.2011.12.039; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; Soukas A, 2001, J BIOL CHEM, V276, P34167, DOI 10.1074/jbc.M104421200; Su Zhen, 2002, Zhonghua Yufang Yixue Zazhi, V36, P301; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P44, DOI 10.1073/pnas.0137044100; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Unger RH, 2001, DIABETES, V50, pS118, DOI 10.2337/diabetes.50.2007.S118; Uto-Kondo H, 2009, J NUTR, V139, P51, DOI 10.3945/jn.108.096131; Xing YF, 2010, BIOCHEM BIOPH RES CO, V396, P691, DOI 10.1016/j.bbrc.2010.04.163; Xu JF, 2004, J BIOL CHEM, V279, P35914, DOI 10.1074/jbc.M402297200; Yang L, 2007, NEPHROL DIAL TRANSPL, V22, P445, DOI 10.1093/ndt/gfl556; Yang X C, 1986, Zhong Yao Tong Bao, V11, P19; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zhu XL, 2011, J MOL BIOL, V410, P1035, DOI 10.1016/j.jmb.2011.03.055	47	27	27	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2012	7	11							e49530	10.1371/journal.pone.0049530	http://dx.doi.org/10.1371/journal.pone.0049530			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	038CD	23166699	Green Published, Green Submitted, gold			2023-01-03	WOS:000311151900156
J	Pande, S; Sengupta, A; Srivastava, A; Gude, RP; Ingle, A				Pande, Sneha; Sengupta, Amit; Srivastava, Anurag; Gude, Rajiv P.; Ingle, Arvind			Re-Evaluate the Effect of Hyperbaric Oxygen Therapy in Cancer - A Preclinical Therapeutic Small Animal Model Study	PLOS ONE			English	Article							OXIDATIVE DNA-DAMAGE; MOUSE MODELS; TUMOR-GROWTH; BLOOD-FLOW; APOPTOSIS; ANEUPLOIDY; INDUCTION; HEAD	Tumor hypoxia is a known driver of angiogenesis that also facilitates tumor growth. Moreover, poorly oxygenated central tumor area remains relatively radio or chemo resistant. HBO therapy is known to elevate the levels of dissolved oxygen and eliminates tumor hypoxia. It has been one of the modalities in cancer treatment; therefore its optimization is important. In this experimental study, no cancer enhancing effect was seen during the course of HBO therapy; however, post therapy there was an accelerated growth and progression of tumor. HBO treated mice lived shorter and the response to therapy was dose & tumor volume dependent. HBO therapy probably exert its effect on the cancer proliferating cells through multiple pathways such as increased DNA damage, apoptosis & geno-toxicity leading to slow cancer progression while post therapy tumorigenic effect could be due to impaired DNA repair mechanism, mutagenic effect & aneuploidy as well as altered blood supply & nutrients. Tumor growth reached plateau with time and this finding validated theoretical model predicting tumor reaching an asymptotic limit. While, marked asymmetry observed in tumor volume progression or cancer cell proliferation rate in each of the experimental C3H mouse suggested a need for an alternate small animal pre-clinical cancer therapeutic model.	[Pande, Sneha; Sengupta, Amit] Tata Mem Hosp, Adv Ctr Treatment Res & Educ Canc, Bioengn Lab, New Mumbai, Maharashtra, India; [Srivastava, Anurag] All India Inst Med Sci, Dept Canc Surg, New Delhi, India; [Gude, Rajiv P.] Tata Mem Hosp, Adv Ctr Treatment Res & Educ Canc, Gude Lab, New Mumbai, Maharashtra, India; [Ingle, Arvind] Tata Mem Hosp, Adv Ctr Treatment Res & Educ Canc, Lab Anim Facil, New Mumbai, Maharashtra, India	Tata Memorial Centre (TMC); Advance Centre for Treatment, Research & Education in Cancer (ACTREC); Tata Memorial Hospital; All India Institute of Medical Sciences (AIIMS) New Delhi; Tata Memorial Centre (TMC); Advance Centre for Treatment, Research & Education in Cancer (ACTREC); Tata Memorial Hospital; Tata Memorial Centre (TMC); Advance Centre for Treatment, Research & Education in Cancer (ACTREC); Tata Memorial Hospital	Sengupta, A (corresponding author), Tata Mem Hosp, Adv Ctr Treatment Res & Educ Canc, Bioengn Lab, New Mumbai, Maharashtra, India.	asengupta@actrec.gov.in		SENGUPTA, AMIT/0000-0002-9674-552X				Becher OJ, 2006, CANCER RES, V66, P3355, DOI 10.1158/0008-5472.CAN-05-3827; Bennett M, 2006, COCHRANE LIB; Borowsky AD, 2003, COMPARATIVE MED, V53, P248; Bradfield JJ, 1996, OTOLARYNG HEAD NECK, V114, P793, DOI 10.1016/S0194-5998(96)70103-1; Daruwalla J, 2006, WORLD J SURG, V30, P2112, DOI 10.1007/s00268-006-0190-6; DECOSSE JJ, 1966, CANCER RES, V26, P287; Fang X, 2011, SEMIN CELL DEV BIOL, V22, P595, DOI 10.1016/j.semcdb.2011.03.002; Feldmeier JJ, 2002, UNDERSEA HYPERBAR M, V29, P4; FELDMEIER JJ, 1994, UNDERSEA HYPERBAR M, V21, P467; Francia G, 2011, NAT REV CANCER, V11, P135, DOI 10.1038/nrc3001; Ganguly BJ, 2002, APOPTOSIS, V7, P499, DOI 10.1023/A:1020686908831; Granowitz EV, 2005, ANTICANCER RES, V25, P3833; Groger M, 2009, J APPL PHYSIOL, V106, P311, DOI 10.1152/japplphysiol.90737.2008; Guiot C, 2003, J THEOR BIOL, V225, P147, DOI 10.1016/S0022-5193(03)00221-2; Hansen K, 2004, EUR J CANCER, V40, P858, DOI 10.1016/j.ejca.2003.11.031; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; HENK JM, 1986, INT J RADIAT ONCOL, V12, P1339, DOI 10.1016/0360-3016(86)90167-7; Hironaka K, 2003, LAB INVEST, V83, P643, DOI 10.1097/01.LAB.0000067483.89649.11; JAMIESON D, 1963, BRIT J CANCER, V17, P70, DOI 10.1038/bjc.1963.11; Kim IS, 2010, BIOCHEM BIOPH RES CO, V394, P443, DOI 10.1016/j.bbrc.2010.03.070; Kuffler Damien P, 2010, OPEN CIRCULATION VAS, V3, P72; Kulikovsky M, 2009, ISR MED ASSOC J, V11, P480; Laufer J, 2012, J BIOMEDICAL OPTICS, V17; Liu Rui-Duan, 2010, Zhongguo Gu Shang, V23, P860; Macklin P, 2009, J MATH BIOL, V58, P765, DOI 10.1007/s00285-008-0216-9; Matsunami T, 2011, INT J CLIN EXP PATHO, V4, P255; Meirovithz E, 2007, BRAIN RES REV, V54, P294, DOI 10.1016/j.brainresrev.2007.04.004; Milovanova TN, 2009, J APPL PHYSIOL, V106, P711, DOI 10.1152/japplphysiol.91054.2008; Nasu R, 1999, BRIT J CANCER, V79, P780, DOI 10.1038/sj.bjc.6690125; Navarro A, 2004, AM J PHYSIOL-REG I, V286, pR505, DOI 10.1152/ajpregu.00208.2003; Obst B, 2000, CARCINOGENESIS, V21, P1111, DOI 10.1093/carcin/21.6.1111; Ong M, 2008, SINGAP MED J, V49, P105; Rothfuss A, 2000, MUTAT RES-GEN TOX EN, V471, P87, DOI 10.1016/S1383-5718(00)00123-6; Sengupta, 1998, Blood Press Monit, V3, P241; Sengupta A, 1997, MED BIOL ENG COMPUT, V35, P223, DOI 10.1007/BF02530042; SENGUPTA A, 1994, MED HYPOTHESES, V43, P322, DOI 10.1016/0306-9877(94)90111-2; Singh M, 2006, CLIN CANCER RES, V12, P5312, DOI 10.1158/1078-0432.CCR-06-0437; Speit G, 2002, MUTAT RES-REV MUTAT, V512, P111, DOI 10.1016/S1383-5742(02)00045-5; Tang H, 2009, UROLOGY, V73, P205, DOI 10.1016/j.urology.2008.04.057; Thom SR, 2006, AM J PHYSIOL-HEART C, V290, pH1378, DOI 10.1152/ajpheart.00888.2005; Tsai AG, 2003, PHYSIOL REV, V83, P933, DOI 10.1152/physrev.00034.2002; Williams L, 2009, MUTAT RES-FUND MOL M, V669, P104, DOI 10.1016/j.mrfmmm.2009.05.009; Zhang QX, 2008, J INVEST DERMATOL, V128, P2102, DOI 10.1038/jid.2008.53; Zimanova J, 2011, BRATISL MED J, V112, P447	44	4	4	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2012	7	11							e48432	10.1371/journal.pone.0048432	http://dx.doi.org/10.1371/journal.pone.0048432			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	048TK	23144880	Green Published, Green Submitted, gold			2023-01-03	WOS:000311935800060
J	Raheel, H; Karim, MS; Saleem, S; Bharwani, S				Raheel, Hina; Karim, Mehtab S.; Saleem, Sarah; Bharwani, Sulaiman			Knowledge, Attitudes and Practices of Contraception among Afghan Refugee Women in Pakistan: A Cross-Sectional Study	PLOS ONE			English	Article							REPRODUCTIVE HEALTH; RESETTLEMENT; ACCESS; CARE	Background: During the 1980s, approximately three million people migrated from Afghanistan to Pakistan and sought refuge in several cities including the city of Karachi. After the initial settlement of the refugees, the international organizations transitioned the health care of these refugees to the two local non-profit service agencies in Karachi. One of these agencies subsidized health care to the refugees under their care and the other agency encouraged the refugees under their care to utilize governmental and non-governmental private health resources at the disposal of general public. Our objective was to measure the effect of health subsidy on the uptake of contraception among Afghan refugee women and compare them to the group of Afghan women without such a subsidy. Methodology/Principal Findings: A randomly selected group of 650 married Afghan women-325 women in each group-participated in a detailed survey regarding the knowledge, attitude and practices of family planning and contraceptive use. 90 percent of the women in the health subsidy group had had heard of family planning, compared to the 45 percent in the non-subsidized group. The use of contraceptives was greater than two-fold in the former versus the latter. Results of logistic regression analysis revealed that the refugee women who had had access to subsidized healthcare were significantly more likely to use the contraceptive methods with advancing age as compared to the women in the non-health subsidy group. The difference remained significant after adjusting for other variables. Conclusions/Significance: Refugee women who are provided subsidized healthcare are more inclined to use contraceptives. It is therefore important that Afghan refugee women living elsewhere in Pakistan be provided healthcare subsidy, whereby their reproductive health indicators could improve with reduced fertility. We strongly encourage facilities introducing such subsidies to refugees in resource poor settings to assess the impact through similar inquiry.	[Bharwani, Sulaiman] UAE Univ, Dept Pediat, Fac Med & Hlth Sci, Al Ain, U Arab Emirates; [Raheel, Hina] UAE Univ, Fac Med & Hlth Sci, Dept Obstet & Gynecol, Al Ain, U Arab Emirates; [Karim, Mehtab S.] George Mason Univ, Sch Publ Policy, Arlington, VA USA; [Saleem, Sarah] Aga Khan Univ, Dept Community Hlth Sci, Karachi, Pakistan	United Arab Emirates University; United Arab Emirates University; George Mason University; Aga Khan University	Bharwani, S (corresponding author), UAE Univ, Dept Pediat, Fac Med & Hlth Sci, Al Ain, U Arab Emirates.	sulaiman_bharwani@uaeu.ac.ae		Bharwani, Sulaiman/0000-0002-2651-2640				Afghanistan Research and Evaluation Unit, 2005, AFGH KAR MIGR SETTL; [Anonymous], 2007, REPR HLTH ASS TOOLK; [Anonymous], 1997, POPUL TODAY, V25, P5; [Anonymous], 2011, POP COUNC ANN REP; Badshah S, 2011, J PAK MED ASSOC, V61, P161; Balsara ZP, 2010, J HEALTH POPUL NUTR, V28, P501; Barnes DM, 2004, JOGNN-J OBST GYN NEO, V33, P723, DOI 10.1177/0884217504270668; Dennis A, 2012, CONTRACEPTION, V85, P166, DOI 10.1016/j.contraception.2011.06.003; Haider S, 2009, HEALTH CARE WOMEN IN, V30, P935, DOI 10.1080/07399330903052129; Howard Natasha, 2008, Confl Health, V2, P12, DOI 10.1186/1752-1505-2-12; Hynes M, 2002, JAMA-J AM MED ASSOC, V288, P595, DOI 10.1001/jama.288.5.595; Institute of Policy Studies, 2008, AFGH PAK PROTR REF S; Khanani MR, 2010, J INFECTION, V61, P434, DOI 10.1016/j.jinf.2010.08.009; Kottegoda S, 2008, REPROD HEALTH MATTER, V16, P75, DOI 10.1016/S0968-8080(08)31359-7; Lagarde M, 2007, JAMA-J AM MED ASSOC, V298, P1900, DOI 10.1001/jama.298.16.1900; Leete R, 1991, Popul Res Leads, P1; Marie Stopes International, 2009, KEY STAT AFGH AFGH; Morris K, 2009, LANCET INFECT DIS, V9, P212, DOI 10.1016/S1473-3099(09)70096-9; Otsea K, 1999, Initiat Reprod Health Policy, V3, P1; PAKISTAN BUREAU OF STATISTICS, 2007, PAK DEM SURV; Ponsar F, 2011, HLTH POLICY PLANN S2, V26, pii72; ROSS J, 1995, STUD FAMILY PLANN, V26, P241, DOI 10.2307/2137849; Shaikh BT, 2005, J PUBLIC HEALTH-UK, V27, P49, DOI 10.1093/pubmed/fdh207; Sulaiman-Hill CMR, 2012, AUST NZ J PUBL HEAL, V36, P126, DOI 10.1111/j.1753-6405.2011.00778.x; Todd CS, 2008, CONTRACEPTION, V78, P249, DOI 10.1016/j.contraception.2008.05.005; UNHCR, 2005, PAK CENS AFGH PROV 1; van der Gaag J, 2012, HEALTH ECON, V21, P55, DOI 10.1002/hec.1811; Wali S, 1994, Migr World Mag, V22, P26	28	15	15	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2012	7	11							e48760	10.1371/journal.pone.0048760	http://dx.doi.org/10.1371/journal.pone.0048760			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	032GO	23133658	Green Published, Green Submitted, gold			2023-01-03	WOS:000310702400047
J	Kraus, EJH				Kraus, Erica J. Hemphill			A Shift on "Pay for Delay" - Reopening Doors for Pharmaceutical Competition?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Patton Boggs, Washington, DC USA		Kraus, EJH (corresponding author), Patton Boggs, Washington, DC USA.								0	3	3	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 1	2012	367	18					1681	1683		10.1056/NEJMp1209693	http://dx.doi.org/10.1056/NEJMp1209693			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	028RS	23113478				2023-01-03	WOS:000310440800003
J	Qian, GQ; Xue, K; Tang, LL; Wang, F; Song, X; Chyu, MC; Pence, BC; Shen, CL; Wang, JS				Qian, Guoqing; Xue, Kathy; Tang, Lili; Wang, Franklin; Song, Xiao; Chyu, Ming-Chien; Pence, Barbara C.; Shen, Chwan-Li; Wang, Jia-Sheng			Mitigation of Oxidative Damage by Green Tea Polyphenols and Tai Chi Exercise in Postmenopausal Women with Osteopenia	PLOS ONE			English	Article							BONE-MINERAL DENSITY; CONTROLLED-TRIAL; DNA-DAMAGE; STRESS; OSTEOPOROSIS; HEALTH; PREVENTION; CANCER; CHEMOPREVENTION; ANTIOXIDANTS	Background: Osteoporosis is a degenerative bone disease predominantly in postmenopausal women. Green tea polyphenols (GTP) and Tai Chi (TC) have been shown to be beneficial on human bone health. This study examined the efficacy of GTP and TC on mitigation of oxidative damage in postmenopausal women with osteopenia. Methods: A 6-month randomized and placebo-controlled clinical trial was conducted in 171 postmenopausal women with osteopenia, who were recruited from Lubbock County, Texas. These participants were treated with placebo, GTP (500 mg daily), placebo + TC (60-minute group exercise, 3 times/week), or GTP (500 mg daily) + TC (60-minute group exercise, 3 times/week), respectively. Their blood and urine samples were collected at the baseline, 1-, 3- and 6-months during intervention for assessing levels of 8-hydroxy-2'-deoxyguanosine (8-OHdG), an oxidative DNA damage biomarker, and concentrations of serum and urine GTP components. Results: The elevated concentrations of serum and urinary GTP components demonstrated a good adherence for the trial. A significant reduction of urinary 8-OHdG concentrations was found in all three treated groups during 3-month (P<0.001) and 6-month (P<0.001) intervention, as compared to the placebo group. The significant time- and dose-effects on mitigation of the oxidative damage biomarker were also found for GTP, TC, and GTP+TC intervened groups. Conclusion: Our study demonstrated that GTP and TC interventions were effective strategies of reducing the levels of oxidative stress, a putative mechanism for osteoporosis in postmenopausal women, and more importantly, working in an additive manner, which holds the potential as alternative tools to improve bone health in this population.	[Qian, Guoqing; Xue, Kathy; Tang, Lili; Wang, Franklin; Wang, Jia-Sheng] Univ Georgia, Dept Environm Hlth Sci, Athens, GA 30602 USA; [Song, Xiao] Univ Georgia, Dept Epidemiol & Biostat, Athens, GA 30602 USA; [Chyu, Ming-Chien] Texas Tech Univ, Dept Mech Engn, Lubbock, TX 79409 USA; [Pence, Barbara C.; Shen, Chwan-Li] Texas Tech Univ, Hlth Sci Ctr, Lab Sci & Primary Care, Lubbock, TX 79430 USA; [Shen, Chwan-Li] Texas Tech Univ, Hlth Sci Ctr, Dept Pathol, Lubbock, TX 79430 USA; [Shen, Chwan-Li] Texas Tech Univ, Hlth Sci Ctr, Laura W Bush Inst Womens Hlth, Lubbock, TX 79430 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Texas Tech University System; Texas Tech University; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Wang, JS (corresponding author), Univ Georgia, Dept Environm Hlth Sci, Athens, GA 30602 USA.	jswang@uga.edu	Qian, Guoqing/ABH-1307-2021	Qian, Guoqing/0000-0003-1804-7993	National Center for Complementary and Alternative Medicine [R21AT003735]; National Cancer Institute, National Institutes of Health [RO1CA90997]; NATIONAL CANCER INSTITUTE [R01CA090997] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT003735] Funding Source: NIH RePORTER	National Center for Complementary and Alternative Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	This work was supported by the National Center for Complementary and Alternative Medicine (R21AT003735)(nccam.nih.gov/) and National Cancer Institute, National Institutes of Health (RO1CA90997)(www.cancer.gov). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almeida M, 2010, J BONE MINER RES, V25, P769, DOI 10.1359/jbmr.091017; Basu S, 2001, BIOCHEM BIOPH RES CO, V288, P275, DOI 10.1006/bbrc.2001.5747; Boonen S, 2008, BEST PRACT RES CL EN, V22, P765, DOI 10.1016/j.beem.2008.07.002; Brunner E., 2002, NONPARAMETRIC ANAL L; Chan KM, 2004, ARCH PHYS MED REHAB, V85, P717, DOI 10.1016/j.apmr.2003.08.091; Clarke BL, 2010, ARCH BIOCHEM BIOPHYS, V503, P118, DOI 10.1016/j.abb.2010.07.006; Finaud J, 2006, SPORTS MED, V36, P327, DOI 10.2165/00007256-200636040-00004; Goon JA, 2009, J PHYS ACT HEALTH, V6, P43, DOI 10.1123/jpah.6.1.43; Goto C, 2003, CIRCULATION, V108, P530, DOI 10.1161/01.CIR.0000080893.55729.28; Hedeker D, 1999, J EDUC BEHAV STAT, V24, P70, DOI 10.3102/10769986024001070; Inada Masaki, 2010, Clin Calcium, V20, P1467, DOI CliCa101014671472; Isomura H, 2004, TOXICOLOGY, V197, P93, DOI 10.1016/j.tox.2003.12.006; Jochmann N, 2008, CURR OPIN CLIN NUTR, V11, P758, DOI 10.1097/MCO.0b013e328314b68b; Klibanski A, 2001, JAMA-J AM MED ASSOC, V285, P785; Lan C, 2004, AM J CHINESE MED, V32, P151, DOI 10.1142/S0192415X04001746; Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047; Lee MS, 2008, OSTEOPOROSIS INT, V19, P139, DOI 10.1007/s00198-007-0486-x; Li Qiong, 2010, Wei Sheng Yan Jiu, V39, P123; LOOKER AC, 1995, J BONE MINER RES, V10, P796; Lui PPY, 2008, CLIN SPORT MED, V27, P75, DOI 10.1016/j.csm.2007.09.002; Luo HT, 2006, CARCINOGENESIS, V27, P262, DOI 10.1093/carcin/bgi147; Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009-0024; Pilger A, 2006, INT ARCH OCC ENV HEA, V80, P1, DOI 10.1007/s00420-006-0106-7; Qin L, 2005, J BONE MINER METAB, V23, P186, DOI 10.1007/s00774-004-0559-2; Rice-Evans C, 1999, P SOC EXP BIOL MED, V220, P262, DOI 10.1046/j.1525-1373.1999.d01-45.x; SALAH N, 1995, ARCH BIOCHEM BIOPHYS, V322, P339, DOI 10.1006/abbi.1995.1473; Shen CL, 2011, OSTEOPOROSIS INT, V22, P327, DOI 10.1007/s00198-010-1209-2; Shen CL, 2012, OSTEOPOROSIS INT, V23, P1541, DOI 10.1007/s00198-011-1731-x; Shen CL, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-76; Shen CL, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-110; Shen CL, 2009, NUTR RES, V29, P437, DOI 10.1016/j.nutres.2009.06.008; Syed Farhan A, 2010, Curr Osteoporos Rep, V8, P235, DOI 10.1007/s11914-010-0035-y; Valavanidis A, 2009, J ENVIRON SCI HEAL C, V27, P120, DOI 10.1080/10590500902885684; Wang JS, 2008, FOOD CHEM TOXICOL, V46, P232, DOI 10.1016/j.fct.2007.08.007; Woo J, 2007, AGE AGEING, V36, P262, DOI 10.1093/ageing/afm005; Wu LL, 2004, CLIN CHIM ACTA, V339, P1, DOI 10.1016/j.cccn.2003.09.010; Yamamoto N, 2003, J CLIN INVEST, V112, P181, DOI 10.1172/JCI200317778; Yang CS, 2007, TOXICOL APPL PHARM, V224, P265, DOI 10.1016/j.taap.2006.11.024	38	31	33	0	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2012	7	10							e48090	10.1371/journal.pone.0048090	http://dx.doi.org/10.1371/journal.pone.0048090			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	030WJ	23118932	Green Published, gold, Green Submitted			2023-01-03	WOS:000310600500066
J	Moore, W				Moore, Wendy			Marie Stopes: botany and birth control	BRITISH MEDICAL JOURNAL			English	Editorial Material												wendymoore@ntlworld.com						Hall LA, 1880, OXFORD DICT NATL BIO; STOPES M, 1918, MARRIED LOVE; Stopes Marie C., 1918, WISE PARENTHOOD	3	0	0	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	OCT 29	2012	345								e7208	10.1136/bmj.e7208	http://dx.doi.org/10.1136/bmj.e7208			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	033EW	23109327				2023-01-03	WOS:000310778000002
J	Rennke, S; Nguyen, OK; Shoeb, MH; Magan, Y; Wachter, RM; Ranji, SR				Rennke, Stephanie; Nguyen, Oanh K.; Shoeb, Marwa H.; Magan, Yimdriuska; Wachter, Robert M.; Ranji, Sumant R.			Hospital-Initiated Transitional Care Interventions as a Patient Safety Strategy A Systematic Review	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED-CONTROLLED-TRIAL; INTEGRATED MEDICINES MANAGEMENT; PATIENTS AFTER-DISCHARGE; ADVERSE DRUG EVENTS; ELDERLY-PATIENTS; MEDICATION RECONCILIATION; GERIATRIC ASSESSMENT; READMISSION RATES; FOLLOW-UP; OLDER-ADULTS	Hospitals now have the responsibility to implement strategies to prevent adverse outcomes after discharge. This systematic review addressed the effectiveness of hospital-initiated care transition strategies aimed at preventing clinical adverse events (AEs), emergency department (ED) visits, and readmissions after discharge in general medical patients. MEDLINE, CINAHL, EMBASE, and Cochrane Database of Clinical Trials (January 1990 to September 2012) were searched, and 47 controlled studies of fair methodological quality were identified. Forty-six studies reported readmission rates, 26 reported ED visit rates, and 9 reported AE rates. A "bridging" strategy (incorporating both predischarge and postdischarge interventions) with a dedicated transition provider reduced readmission or ED visit rates in 10 studies, but the overall strength of evidence for this strategy was low. Because of scant evidence, no conclusions could be reached on methods to prevent postdischarge AEs. Most studies did not report intervention context, implementation, or cost. The strategies hospitals should implement to improve patient safety at hospital discharge remain unclear. Ann Intern Med. 2013;158:433-440. www.annals.org	[Rennke, Stephanie; Nguyen, Oanh K.; Shoeb, Marwa H.; Magan, Yimdriuska; Wachter, Robert M.; Ranji, Sumant R.] Univ Calif San Francisco, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	Rennke, S (corresponding author), Univ Calif San Francisco, UCSF Mt Zion Med Ctr, 1600 Divisadero St, San Francisco, CA 94115 USA.	srennke@medicine.ucsf.edu			Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services [HHSA-290-2007-10062I]; AHRQ; QuantiaMD; IPC-The Hospitalist Company; US-UK Fulbright Commission	Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); QuantiaMD; IPC-The Hospitalist Company; US-UK Fulbright Commission	Financial Support: From the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services (contract HHSA-290-2007-10062I).; Potential Conflicts of Interest: Dr. Rennke: Grant (money to self and to institution): AHRQ; Support for travel to meetings for the study or other purposes: AHRQ; Payment for writing or reviewing the manuscript (money to self and to institution): AHRQ; Provision of writing assistance, medicines, equipment, or administrative support (money to institution): AHRQ; Consultancy: Society Hospital of Medicine. Dr. Ranji: Grant (money to institution): AHRQ. Dr. Magan: Grant (money to institution): AHRQ. Dr. Wachter: Grant (money to institution): AHRQ; Support for travel to meetings for the study or other purposes (money to institution): AHRQ; Board membership: Chair of the American Board of Internal Medicine; Grants/grants pending (money to institution): AHRQ; Payment for lectures including service on speakers' bureaus: honorarium for lectures from more than 100 health care organizations, mostly on patient safety, health care quality, and hospitalists; Royalties: Lippincott Williams & Wilkins, McGraw-Hill; Payment for development of educational presentations: QuantiaMD; Payment for development of educational presentations (money to institution): IPC-The Hospitalist Company; Stock/stock options: PatientSafe Solutions, CRISI, EarlySense; Other: Compensation from John Wiley & Sons for writing "Wachter's World" blog, Benioff endowed chair in hospital medicine, funded by the US-UK Fulbright Commission for a sabbatical at Imperial College London from July to December 2011, unpaid member of the Board of Directors, Quality Committee of Salem Hospital. All other authors have no dislosures. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M12-2573.	Adler Alan, 2009, Manag Care, V18, P50; Al-Ghamdi SA, 2012, ANN SAUDI MED, V32, P492, DOI 10.5144/0256-4947.2012.492; Al-Rashed SA, 2002, BRIT J CLIN PHARMACO, V54, P657, DOI 10.1046/j.1365-2125.2002.01707.x; Balaban RB, 2008, J GEN INTERN MED, V23, P1228, DOI 10.1007/s11606-008-0618-9; Bettger JP, 2012, ANN INTERN MED, V157, P407, DOI 10.7326/0003-4819-157-6-201209180-00004; Bolas H, 2004, PHARM WORLD SCI, V26, P114, DOI 10.1023/B:PHAR.0000018601.11248.89; Brand Caroline A, 2004, Aust Health Rev, V28, P275; Bray-Hall ST, 2012, ANN INTERN MED, V157, P448, DOI 10.7326/0003-4819-157-6-201209180-00010; Chiu WK, 2007, PROF CASE MANAG, V12, P330; Coleman EA, 2004, J AM GERIATR SOC, V52, P1817, DOI 10.1111/j.1532-5415.2004.52504.x; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Courtney M, 2009, J AM GERIATR SOC, V57, P395, DOI 10.1111/j.1532-5415.2009.02138.x; Cowan MJ, 2006, J NURS ADMIN, V36, P79, DOI 10.1097/00005110-200602000-00006; Dellasega C A, 2000, Clin Excell Nurse Pract, V4, P286; Einstadter D, 1996, J GEN INTERN MED, V11, P684, DOI 10.1007/BF02600160; Epstein AM, 2011, NEW ENGL J MED, V365, P2287, DOI 10.1056/NEJMsa1101942; Finn KM, 2011, J HOSP MED, V6, P494, DOI 10.1002/jhm.924; FISHER ES, 1994, NEW ENGL J MED, V331, P989, DOI 10.1056/NEJM199410133311506; Forster AJ, 2005, AM J MED, V118, P1148, DOI 10.1016/j.amjmed.2005.04.019; Forster AJ, 2004, CAN MED ASSOC J, V170, P345; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; Gallagher PF, 2011, CLIN PHARMACOL THER, V89, P845, DOI 10.1038/clpt.2011.44; Gillespie U, 2009, ARCH INTERN MED, V169, P894, DOI 10.1001/archinternmed.2009.71; Gleason KM, 2010, J GEN INTERN MED, V25, P441, DOI 10.1007/s11606-010-1256-6; Gow P, 1999, J Qual Clin Pract, V19, P107, DOI 10.1046/j.1440-1762.1999.00312.x; Graumlich JF, 2009, J HOSP MED, V4, P356, DOI [10.1002/jhm.469, 10.1002/jhm.565]; Hansen LO, 2011, ANN INTERN MED, V155, P520, DOI 10.7326/0003-4819-155-8-201110180-00008; Hasan O, 2010, J GEN INTERN MED, V25, P211, DOI 10.1007/s11606-009-1196-1; HealthCare.gov, 2012, PARTN PAT BETT CAR L; Hellstrom LM, 2011, EUR J CLIN PHARMACOL, V67, P741, DOI 10.1007/s00228-010-0982-3; Hesselink G, 2012, ANN INTERN MED, V157, P417, DOI 10.7326/0003-4819-157-6-201209180-00006; HOGAN DB, 1990, AGE AGEING, V19, P107, DOI 10.1093/ageing/19.2.107; Jack BW, 2009, ANN INTERN MED, V150, P178, DOI 10.7326/0003-4819-150-3-200902030-00007; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Jha AK, 2012, NEW ENGL J MED, V366, P1606, DOI 10.1056/NEJMsa1112351; Joynt KE, 2011, JAMA-J AM MED ASSOC, V305, P675, DOI 10.1001/jama.2011.123; Kansagara D, 2011, JAMA-J AM MED ASSOC, V306, P1688, DOI 10.1001/jama.2011.1515; Karapinar-Carkit F, 2009, ANN PHARMACOTHER, V43, P1001, DOI 10.1345/aph.1L597; Kirby SE, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-216; Koehler BE, 2009, J HOSP MED, V4, P211, DOI 10.1002/jhm.427; Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831; Legrain S, 2011, J AM GERIATR SOC, V59, P2017, DOI 10.1111/j.1532-5415.2011.03628.x; Lim WK, 2003, MED J AUSTRALIA, V178, P262, DOI 10.5694/j.1326-5377.2003.tb05191.x; LIPTON HL, 1994, GERONTOLOGIST, V34, P307, DOI 10.1093/geront/34.3.307; Makaryus AN, 2005, MAYO CLIN PROC, V80, P991, DOI 10.4065/80.8.991; Makowsky Mark J, 2009, Med Care, V47, P642, DOI 10.1097/MLR.0b013e3181926032; MARTIN F, 1994, AGE AGEING, V23, P228, DOI 10.1093/ageing/23.3.228; Marusic S, 2012, INT J CLIN PHARM; Maynard GA, 2012, JT COMM J QUAL PATIE, V38, P301, DOI 10.1016/S1553-7250(12)38040-9; Mistiaen P, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-47; Moore C, 2007, ARCH INTERN MED, V167, P1305, DOI 10.1001/archinte.167.12.1305; Mudge A, 2006, INTERN MED J, V36, P558, DOI 10.1111/j.1445-5994.2006.01135.x; Naylor MD, 2011, HEALTH AFFAIR, V30, P746, DOI 10.1377/hlthaff.2011.0041; NAYLOR MD, 1990, NURS RES, V39, P156; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; Nazareth I, 2001, AGE AGEING, V30, P33, DOI 10.1093/ageing/30.1.33; Nikolaus T, 1999, AGE AGEING, V28, P543, DOI 10.1093/ageing/28.6.543; Palmer HC, 2002, SOUTHERN MED J, V95, P1318, DOI 10.1097/00007611-200211000-00016; Parker S G, 2002, Health Technol Assess, V6, P1; Parry Carla, 2009, Home Health Care Serv Q, V28, P84, DOI 10.1080/01621420903155924; Philbin EF, 2001, AM J CARDIOL, V87, P1367, DOI 10.1016/S0002-9149(01)01554-5; Rau J., 2012, KAISER HLTH NEW 0813; Richards Suzanne, 2003, J Health Serv Res Policy, V8, P171, DOI 10.1258/135581903322029539; Robinson S, 2012, POPUL HEALTH MANAG, V15, P338, DOI 10.1089/pop.2011.0095; Schnipper JL, 2009, ARCH INTERN MED, V169, P771, DOI 10.1001/archinternmed.2009.51; Schnipper JL, 2006, ARCH INTERN MED, V166, P565, DOI 10.1001/archinte.166.5.565; Scullin C, 2007, J EVAL CLIN PRACT, V13, P781, DOI 10.1111/j.1365-2753.2006.00753.x; Scullin C, 2012, J EVAL CLIN PRACT, V18, P807, DOI 10.1111/j.1365-2753.2011.01682.x; Shekelle PG, MAKING HLTH CARE SAF; Shepperd S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000313.pub3; Siu AL, 1996, ARCH INTERN MED, V156, P76, DOI 10.1001/archinte.156.1.76; Steeman E, 2006, INT J QUAL HEALTH C, V18, P352, DOI 10.1093/intqhc/mzl026; Stewart S, 1998, J AM GERIATR SOC, V46, P174, DOI 10.1111/j.1532-5415.1998.tb02535.x; Styrborn K, 1995, SCAND J SOC MED, V23, P273, DOI 10.1177/140349489502300409; Takeda A, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002752.pub3; THOMAS DR, 1993, J AM GERIATR SOC, V41, P101, DOI 10.1111/j.1532-5415.1993.tb02040.x; U. S. Department of Health and Human Services, 2012, HOSP COMP; van Walraven C, 2011, CAN MED ASSOC J, V183, pE1067, DOI 10.1503/cmaj.110400; Voss R, 2011, ARCH INTERN MED, V171, P1232, DOI 10.1001/archinternmed.2011.278; Walker PC, 2009, ARCH INTERN MED, V169, P2003, DOI 10.1001/archinternmed.2009.398; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; WILKINSON ST, 2011, HOSP PHARM, V46, P876, DOI DOI 10.1310/hpj4611-876	82	159	160	1	46	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 5	2013	158	5	2				433	+		10.7326/0003-4819-158-5-201303051-00011	http://dx.doi.org/10.7326/0003-4819-158-5-201303051-00011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105HX	23460101	Green Submitted			2023-01-03	WOS:000316058600011
J	Brinkhaus, B; Ortiz, M; Witt, CM; Roll, S; Linde, K; Pfab, F; Niggemann, B; Hummelsberger, J; Treszl, A; Ring, J; Zuberbier, T; Wegscheider, K; Willich, SN				Brinkhaus, Benno; Ortiz, Miriam; Witt, Claudia M.; Roll, Stephanie; Linde, Klaus; Pfab, Florian; Niggemann, Bodo; Hummelsberger, Josef; Treszl, Andras; Ring, Johannes; Zuberbier, Torsten; Wegscheider, Karl; Willich, Stefan N.			Acupuncture in Patients With Seasonal Allergic Rhinitis A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							CONTROLLED CLINICAL-TRIAL; EXPERIMENTALLY INDUCED ITCH; I HYPERSENSITIVITY ITCH; QUALITY-OF-LIFE; CROSSOVER TRIAL; ATOPIC ECZEMA; ALTERNATIVE MEDICINE; RHINOCONJUNCTIVITIS; COMPLEMENTARY; QUESTIONNAIRE	Background: Acupuncture is frequently used to treat seasonal allergic rhinitis (SAR) despite limited scientific evidence. Objective: To evaluate the effects of acupuncture in patients with SAR. Design: Randomized, controlled multicenter trial. (ClinicalTrials.gov:NCT00610584) Setting: 46 specialized physicians in 6 hospital clinics and 32 private outpatient clinics. Patients: 422 persons with SAR and IgE sensitization to birch and grass pollen. Intervention: Acupuncture plus rescue medication (RM) (cetirizine) (n = 212), sham acupuncture plus RM (n = 102), or RM alone (n = 108). Twelve treatments were provided over 8 weeks in the first year. Measurements: Changes in the Rhinitis Quality of Life Questionnaire (RQLQ) overall score and the RM score (RMS) from baseline to weeks 7 and 8 and week 16 in the first year and week 8 in the second year after randomization, with predefined noninferiority margins of -0.5 point (RQLQ) and -1.5 points (RMS). Results: Compared with sham acupuncture and with RM, acupuncture was associated with improvement in RQLQ score (sham vs. acupuncture mean difference, 0.5 point [97.5% CI, 0.2 to 0.8 point; P < 0.001]; RM vs. acupuncture mean difference, 0.7 point [97.5% CI, 0.4 to 1.0 point; P < 0.001]) and RMS (sham vs. acupuncture mean difference, 1.1 points [97.5% CI, 0.4 to 1.9 points; P < 0.001]; RM vs. acupuncture mean difference, 1.5 points [97.5% CI, 0.8 to 2.2 points; P < 0.001]). There were no differences after 16 weeks in the first year. After the 8-week follow-up phase in the second year, small improvements favoring real acupuncture over the sham procedure were noted (RQLQ mean difference, 0.3 point [95% CI, 0.03 to 0.6 point; P = 0.032]; RMS mean difference, 1.0 point [95% CI, 0.2 to 1.9 points; P = 0.018]). Limitation: The study was not powered to detect rare adverse events, and the RQLQ and RMS values were low at baseline. Conclusion: Acupuncture led to statistically significant improvements in disease-specific quality of life and antihistamine use measures after 8 weeks of treatment compared with sham acupuncture and with RM alone, but the improvements may not be clinically significant.	[Brinkhaus, Benno; Ortiz, Miriam; Witt, Claudia M.; Roll, Stephanie; Zuberbier, Torsten; Willich, Stefan N.] Charite Univ Med Ctr, D-10098 Berlin, Germany; [Niggemann, Bodo] German Red Cross Hosp Westend, D-14050 Berlin, Germany; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; Tech Univ Munich, Helmholtz Ctr Munich, D-80290 Munich, Germany; Int Soc Chinese Med, Munich, Germany; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA; Univ Med Ctr Eppendorf, Hamburg, Germany; [Linde, Klaus] Tech Univ Munich, Klinikum Rechts Isar, Inst Gen Practice, D-81667 Munich, Germany; [Pfab, Florian; Ring, Johannes] Christine Kuhne Ctr Allergy Res & Educ, D-80797 Munich, Germany; [Treszl, Andras; Wegscheider, Karl] Univ Med Ctr Eppendorf, Dept Med Biometry & Epidemiol, D-20246 Hamburg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University System of Maryland; University of Maryland Baltimore; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; Technical University of Munich; University of Hamburg; University Medical Center Hamburg-Eppendorf	Brinkhaus, B (corresponding author), Charite Univ Med Ctr, Inst Social Med Epidemiol & Hlth Econ, D-10098 Berlin, Germany.	stephanie.roll@charite.de	Witt, Claudia M./AAX-2370-2021; Ring, Johannes/GLN-4341-2022; Brinkhaus, Benno/AAU-2428-2021	Witt, Claudia M./0000-0002-5440-7805; Ring, Johannes/0000-0001-8236-3152; Brinkhaus, Benno/0000-0001-6290-744X; Linde, Klaus/0000-0002-2902-970X; Zuberbier, Torsten/0000-0002-1466-8875; Roll, Stephanie/0000-0003-1191-3289; Ortiz, Miriam/0000-0002-0889-7890	German Research Foundation [WI 957/16-1]	German Research Foundation(German Research Foundation (DFG))	By grant WI 957/16-1 from the German Research Foundation.	Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BELGRADE MJ, 1984, ACTA DERM-VENEREOL, V64, P129; Birch S., 2003, CLIN ACUPUNCT ORIENT, V4, P59, DOI DOI 10.1016/S1461-1449(03)00025-2; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; Brinkhaus B, 2006, ARCH INTERN MED, V166, P450; Brinkhaus B, 2004, ALLERGY, V59, P953, DOI 10.1111/j.1398-9995.2004.00540.x; Brinkhaus B, 2008, ANN ALLERG ASTHMA IM, V101, P535, DOI 10.1016/S1081-1206(10)60294-3; Brinkhaus B, 2010, FORSCH KOMPLEMENTMED, V17, P95, DOI 10.1159/000303012; Bullinger M, 1998, SF 36 FRAGEBOGEN ZUM; Carlsson CP, 2010, J EUR ACAD DERMATOL, V24, P1013, DOI 10.1111/j.1468-3083.2010.03585.x; Dincer F, 2003, COMPLEMENT THER MED, V11, P235, DOI 10.1016/S0965-2299(03)00124-9; Dmitrienko A, 2007, STAT MED, V26, P2465, DOI 10.1002/sim.2716; Elashoff JD, 2000, NQUERY ADVISOR VERSI; Hou W, 2011, TREATING AUTOIMMUNE; Juniper EF, 1996, J ALLERGY CLIN IMMUN, V98, P843, DOI 10.1016/S0091-6749(96)70135-5; Kenward MG, 2008, PUBLICATION NATL I H; Krouse JH, 1999, LARYNGOSCOPE, V109, P1223, DOI 10.1097/00005537-199908000-00007; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; Lee MS, 2009, ANN ALLERG ASTHMA IM, V102, P269, DOI 10.1016/S1081-1206(10)60330-4; Liang K-Y, 2000, SANKHYA INDIAN J STA, V62, P134; Linde K, 2005, JAMA-J AM MED ASSOC, V293, P2118, DOI 10.1001/jama.293.17.2118; Linde K, 2004, J ALTERN COMPLEM MED, V10, P379, DOI 10.1089/107555304323062374; Linde K, 2007, PAIN, V128, P264, DOI 10.1016/j.pain.2006.12.006; Liu GHF, 2009, STAT MED, V28, P2509, DOI 10.1002/sim.3639; Lund Irene, 2009, Chin Med, V4, P1, DOI 10.1186/1749-8546-4-1; LUNDEBERG T, 1987, BRIT J DERMATOL, V117, P771, DOI 10.1111/j.1365-2133.1987.tb07359.x; Magnusson AL, 2004, AM J CHINESE MED, V32, P105, DOI 10.1142/S0192415X04001813; Maurer W, 1995, BIOMETRIE CHEM PHARM, V6, P13; Melchart D, 2005, BMJ-BRIT MED J, V331, P376, DOI 10.1136/bmj.38512.405440.8F; Melchart D, 2004, ARCH INTERN MED, V164, P104, DOI 10.1001/archinte.164.1.104; Niggemann B, 2003, ALLERGY, V58, P707, DOI 10.1034/j.1398-9995.2003.00219.x; Pfab F, 2005, J ALLERGY CLIN IMMUN, V116, P1386, DOI 10.1016/j.jaci.2005.08.055; Pfab F, 2012, ALLERGY, V67, P566, DOI 10.1111/j.1398-9995.2012.02789.x; Pfab F, 2010, ALLERGY, V65, P903, DOI 10.1111/j.1398-9995.2009.02284.x; Pfab F, 2011, J ALTERN COMPLEM MED, V17, P309, DOI 10.1089/acm.2009.0684; Roberts J, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-13; Schafer T, 2002, ALLERGY, V57, P694, DOI 10.1034/j.1398-9995.2002.23469.x; van Cauwenberge P, 2000, ALLERGY, V55, P116, DOI 10.1034/j.1398-9995.2000.00526.x; Vincent C, 1990, COMPLEMENT MED RES, V4, P8; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; Williamson L, 1996, ACUPUNCT MED, V14, P6; Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7; Witt CM, 2009, FORSCH KOMPLEMENTMED, V16, P91, DOI 10.1159/000209315; Witt CM, 2009, AM J EPIDEMIOL, V169, P562, DOI 10.1093/aje/kwn370; Xue CCL, 2002, AM J CHINESE MED, V30, P1, DOI 10.1142/S0192415X0200020X	46	80	85	1	38	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 19	2013	158	4					225	234		10.7326/0003-4819-158-4-201302190-00002	http://dx.doi.org/10.7326/0003-4819-158-4-201302190-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	098WR	23420231				2023-01-03	WOS:000315580300013
J	Muller, N; Lorenz, I; Langguth, B; Weisz, N				Mueller, Nadia; Lorenz, Isabel; Langguth, Berthold; Weisz, Nathan			rTMS Induced Tinnitus Relief Is Related to an Increase in Auditory Cortical Alpha Activity	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; THETA-BURST STIMULATION; DORSAL COCHLEAR NUCLEUS; REPETITIVE TMS; GAMMA-OSCILLATIONS; CORTEX; EXCITABILITY; RESPONSES; ATTENTION; SCHIZOPHRENIA	Chronic tinnitus, the continuous perception of a phantom sound, is a highly prevalent audiological symptom. A promising approach for the treatment of tinnitus is repetitive transcranial magnetic stimulation (rTMS) as this directly affects tinnitus-related brain activity. Several studies indeed show tinnitus relief after rTMS, however effects are moderate and vary strongly across patients. This may be due to a lack of knowledge regarding how rTMS affects oscillatory activity in tinnitus sufferers and which modulations are associated with tinnitus relief. In the present study we examined the effects of five different stimulation protocols (including sham) by measuring tinnitus loudness and tinnitus-related brain activity with Magnetoencephalography before and after rTMS. Changes in oscillatory activity were analysed for the stimulated auditory cortex as well as for the entire brain regarding certain frequency bands of interest (delta, theta, alpha, gamma). In line with the literature the effects of rTMS on tinnitus loudness varied strongly across patients. This variability was also reflected in the rTMS effects on oscillatory activity. Importantly, strong reductions in tinnitus loudness were associated with increases in alpha power in the stimulated auditory cortex, while an unspecific decrease in gamma and alpha power, particularly in left frontal regions, was linked to an increase in tinnitus loudness. The identification of alpha power increase as main correlate for tinnitus reduction sheds further light on the pathophysiology of tinnitus. This will hopefully stimulate the development of more effective therapy approaches.	[Mueller, Nadia; Weisz, Nathan] Univ Trento, Ctr Mind Brain Sci, Mattarello, Italy; [Lorenz, Isabel] Univ Konstanz, Dept Psychol, Constance, Germany; [Langguth, Berthold] Univ Hosp Regensburg, Dept Psychiat & Psychotherapy, Regensburg, Germany; [Weisz, Nathan] Univ Konstanz, Constance, Germany	University of Trento; University of Konstanz; University of Regensburg; University of Konstanz	Muller, N (corresponding author), Univ Trento, Ctr Mind Brain Sci, Mattarello, Italy.	nadia.muller@unitn.it	Müller-Voggel, Nadia/ABB-6603-2020; Langguth, Berthold/AAP-2638-2021; Weisz, Nathan/K-3325-2015	Müller-Voggel, Nadia/0000-0002-6414-5669; Weisz, Nathan/0000-0001-7816-0037	Deutsche Forschungsgemeinschaft [4156/2-1]; Tinnitus Research Initiative	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Tinnitus Research Initiative	This work was supported by a grant from the Deutsche Forschungsgemeinschaft (grant number: 4156/2-1) and the Tinnitus Research Initiative. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ashton H, 2007, NEUROSCI LETT, V426, P23, DOI 10.1016/j.neulet.2007.08.034; Baguley DM, 2002, CLIN OTOLARYNGOL, V27, P219, DOI 10.1046/j.1365-2273.2002.00566.x; Benali A, 2011, J NEUROSCI, V31, P1193, DOI 10.1523/JNEUROSCI.1379-10.2011; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; Davidson RJ, 2002, ANNU REV PSYCHOL, V53, P545, DOI 10.1146/annurev.psych.53.100901.135148; De Ridder D, 2005, OTOL NEUROTOL, V26, P616, DOI 10.1097/01.mao.0000178146.91139.3c; Di Lazzaro V, 2011, J NEUROPHYSIOL, V105, P2150, DOI 10.1152/jn.00781.2010; Dietrich V, 2001, HEARING RES, V158, P95, DOI 10.1016/S0378-5955(01)00282-9; Dohrmann K, 2007, PROG BRAIN RES, V166, P473, DOI 10.1016/S0079-6123(07)66046-4; Eggermont JJ, 2004, TRENDS NEUROSCI, V27, P676, DOI 10.1016/j.tins.2004.08.010; Ferrarelli F, 2008, AM J PSYCHIAT, V165, P996, DOI 10.1176/appi.ajp.2008.07111733; Finlayson PG, 2009, HEARING RES, V256, P104, DOI 10.1016/j.heares.2009.07.006; Fitzgerald PB, 2006, CLIN NEUROPHYSIOL, V117, P2584, DOI 10.1016/j.clinph.2006.06.712; Folmer RL, 2006, ACTA OTO-LARYNGOL, V126, P96, DOI 10.1080/03655230600895465; Foxe JJ, 1998, NEUROREPORT, V9, P3929, DOI 10.1097/00001756-199812010-00030; Foxe JJ, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00154; Franca M, 2006, CLIN NEUROPHYSIOL, V117, P1808, DOI 10.1016/j.clinph.2006.03.019; Fregni F, 2006, EUR J NEUROL, V13, P996, DOI 10.1111/j.1468-1331.2006.01414.x; Fuggetta G, 2012, EXPT NEUROLOGY; Gamboa OL, 2010, EXP BRAIN RES, V204, P181, DOI 10.1007/s00221-010-2293-4; GOEBEL G, 1994, HNO, V42, P166; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; Gross J, 2001, P NATL ACAD SCI USA, V98, P694, DOI 10.1073/pnas.98.2.694; HALLAM RS, 1988, BRIT J CLIN PSYCHOL, V27, P213, DOI 10.1111/j.2044-8260.1988.tb00778.x; Huang MX, 1999, PHYS MED BIOL, V44, P423, DOI 10.1088/0031-9155/44/2/010; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Jardri R, 2011, AM J PSYCHIAT, V168, P73, DOI 10.1176/appi.ajp.2010.09101522; JASTREBOFF PJ, 1990, NEUROSCI RES, V8, P221, DOI 10.1016/0168-0102(90)90031-9; Jensen O, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00186; Kaltenbach JA, 2006, ACTA OTO-LARYNGOL, V126, P20, DOI 10.1080/03655230600895309; Khedr EM, 2009, EUR J NEUROL, V16, P404, DOI 10.1111/j.1468-1331.2008.02522.x; Kleinjung T, 2007, PROG BRAIN RES, V166, P359, DOI 10.1016/S0079-6123(07)66034-8; Kleinjung T, 2008, OTOLARYNG HEAD NECK, V138, P497, DOI 10.1016/j.otohns.2007.12.022; Kleinjung Tobias, 2009, Int Tinnitus J, V15, P154; Kleinjung Tobias, 2008, Int Tinnitus J, V14, P112; Klimesch W, 2007, BRAIN RES REV, V53, P63, DOI 10.1016/j.brainresrev.2006.06.003; Kringelbach ML, 2005, NAT REV NEUROSCI, V6, P691, DOI 10.1038/nrn1747; Langguth B, 2006, BRAIN TOPOGR, V18, P241, DOI 10.1007/s10548-006-0002-1; Langguth B, 2008, BRAIN STIMUL, V1, P192, DOI 10.1016/j.brs.2008.06.003; Lanting CP, 2009, HEARING RES, V255, P1, DOI 10.1016/j.heares.2009.06.009; Llinas RR, 1999, P NATL ACAD SCI USA, V96, P15222, DOI 10.1073/pnas.96.26.15222; Londero A, 2006, NEUROPHYSIOL CLIN, V36, P145, DOI 10.1016/j.neucli.2006.08.001; Lorenz I, 2010, J NEUROPHYSIOL, V104, P1497, DOI 10.1152/jn.00370.2010; Marcondes RA, 2010, EUR J NEUROL, V17, P38, DOI 10.1111/j.1468-1331.2009.02730.x; Mirz F, 2000, ACTA OTO-LARYNGOL, P241; Moazami-Goudarzi M, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-40; Moont R, 2011, PAIN, V60, P709; Mulders WHAM, 2009, NEUROSCIENCE, V164, P733, DOI 10.1016/j.neuroscience.2009.08.036; Norena AJ, 2003, HEARING RES, V183, P137, DOI 10.1016/S0378-5955(03)00225-9; Oostenveld R, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/156869; Ortmann M, 2011, EUR J NEUROSCI, V33, P568, DOI 10.1111/j.1460-9568.2010.07542.x; PASCUALLEONE A, 1994, BRAIN, V117, P847, DOI 10.1093/brain/117.4.847; Peinemann A, 2004, CLIN NEUROPHYSIOL, V115, P1519, DOI 10.1016/j.clinph.2004.02.005; Percival D.B., 1993, SPECTRAL ANAL PHYS A; Plewnia C, 2007, J NEUROL NEUROSUR PS, V78, P152, DOI 10.1136/jnnp.2006.095612; Plewnia C, 2003, ANN NEUROL, V53, P263, DOI 10.1002/ana.10468; Plewnia C, 2011, CNS NEUROSCI THER, V17, P449, DOI 10.1111/j.1755-5949.2010.00169.x; Poreisz C, 2008, EXP BRAIN RES, V185, P611, DOI 10.1007/s00221-007-1188-5; Poreisz C, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-54; Pridmore S, 1998, J ECT, V14, P25; Quartarone A, 2005, EXP BRAIN RES, V161, P114, DOI 10.1007/s00221-004-2052-5; Rajan R, 1998, AUDIOL NEURO-OTOL, V3, P123, DOI 10.1159/000013786; Ramirez RR, 2009, IEEE ENG MED BIO, P1940, DOI 10.1109/IEMBS.2009.5333457; Rihs TA, 2007, EUR J NEUROSCI, V25, P603, DOI 10.1111/j.1460-9568.2007.05278.x; Roberts LE, 2010, J NEUROSCI, V30, P14972, DOI 10.1523/JNEUROSCI.4028-10.2010; Romei V, 2008, NEUROREPORT, V19, P203, DOI 10.1097/WNR.0b013e3282f454c4; Salvi RJ, 2000, HEARING RES, V147, P261, DOI 10.1016/S0378-5955(00)00136-2; Schlee W, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-80; Sedley W, 2012, BRAIN, V135, P3089, DOI 10.1093/brain/aws220; Seki S, 2003, HEARING RES, V180, P28, DOI 10.1016/S0378-5955(03)00074-1; Shargorodsky J, 2010, AM J MED, V123, P711, DOI 10.1016/j.amjmed.2010.02.015; Singer W, 1999, NEURON, V24, P49, DOI 10.1016/S0896-6273(00)80821-1; Soekadar SR, 2009, CNS SPECTRUMS, V14, P208, DOI 10.1017/S1092852900020228; Takano B, 2004, NEUROIMAGE, V23, P849, DOI 10.1016/j.neuroimage.2004.06.032; Thut G, 2009, TRENDS COGN SCI, V13, P182, DOI 10.1016/j.tics.2009.01.004; Trippe J, 2009, EXPT BRAIN RES, V31, P1193; van der Loo E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007396; Vanneste S, 2010, EXP BRAIN RES, V202, P779, DOI 10.1007/s00221-010-2183-9; VanVeen BD, 1997, IEEE T BIO-MED ENG, V44, P867, DOI 10.1109/10.623056; Weiler Elmar W, 2002, Int Tinnitus J, V8, P87; Weisz N, 2005, PLOS MED, V2, P546, DOI 10.1371/journal.pmed.0020153; Weisz N, 2007, J NEUROSCI, V27, P1479, DOI 10.1523/JNEUROSCI.3711-06.2007; Weisz N, 2007, PROG BRAIN RES, V166, P61, DOI 10.1016/S0079-6123(07)66006-3; Westerhausen R, 2010, NEUROPSYCHOLOGIA, V48, P2075, DOI 10.1016/j.neuropsychologia.2010.03.028; Worden MS, 2000, J NEUROSCI, V20; Wunderlich AP, 2010, AUDIOL NEURO-OTOL, V15, P137, DOI 10.1159/000241094; Zacharek MA, 2002, HEARING RES, V172, P137, DOI 10.1016/S0378-5955(02)00575-0	87	35	35	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 4	2013	8	2							e55557	10.1371/journal.pone.0055557	http://dx.doi.org/10.1371/journal.pone.0055557			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	086NH	23390539	Green Published, gold, Green Submitted			2023-01-03	WOS:000314691100055
J	Silverman, E				Silverman, Ed			DRUG MARKETING Off-label marketing: free speech or illegal promotion?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Pharmalot, Millburn, NJ USA		Silverman, E (corresponding author), Pharmalot, Millburn, NJ USA.	pharmalot@gmail.com							0	1	1	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 22	2013	346								f320	10.1136/bmj.f320	http://dx.doi.org/10.1136/bmj.f320			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	080BG	23341546				2023-01-03	WOS:000314215600015
J	Parekh, AK; Galloway, JM; Hong, YL; Wright, JS				Parekh, Anand K.; Galloway, James M.; Hong, Yuling; Wright, Janet S.			Aspirin in the Secondary Prevention of Cardiovascular Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Parekh, Anand K.] US Dept Hlth & Human Serv, Off Assistant Secretary Hlth, Washington, DC USA; [Galloway, James M.] US Dept Hlth & Human Serv, Off Assistant Secretary Hlth, Chicago, IL USA; [Hong, Yuling; Wright, Janet S.] Ctr Dis Control & Prevent, Atlanta, GA USA; [Wright, Janet S.] Ctr Medicare & Medicaid Innovat, Baltimore, MD USA	Centers for Disease Control & Prevention - USA	Parekh, AK (corresponding author), US Dept Hlth & Human Serv, Off Assistant Secretary Hlth, Washington, DC USA.							Ademi Z, 2011, CARDIOVASC THER; [Anonymous], 2012, MMWR MORB MORTAL WKL, V61, P11; Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1; Heidenreich PA, 2011, CIRCULATION, V123, P933, DOI 10.1161/CIR.0b013e31820a55f5; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046	5	16	17	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 17	2013	368	3					204	205		10.1056/NEJMp1213380	http://dx.doi.org/10.1056/NEJMp1213380			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	070YG	23323896				2023-01-03	WOS:000313549900004
J	Fasano, A; Catassi, C				Fasano, Alessio; Catassi, Carlo			Celiac Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PEDIATRIC GASTROENTEROLOGY; TISSUE TRANSGLUTAMINASE; NATURAL-HISTORY; UNITED-STATES; AT-RISK; DIAGNOSIS; PREVALENCE; ANTIBODIES; CHILDREN; POPULATION	A 22-year-old woman fractures her wrist while playing volleyball. She reports a history of fatigue and intermittent oral ulcerations but no other symptoms. Radiography of her wrist shows osteopenia. Laboratory testing is notable for a hematocrit of 32% and low levels of ferritin and 25-hydroxyvitamin D. Although she reports no gastrointestinal symptoms, celiac disease is suspected. How should she be further evaluated and, if testing indicates celiac disease, how should her case be managed?	[Fasano, Alessio] Univ Maryland, Sch Med, Ctr Celiac Res, Hlth Sci Facil 2, Baltimore, MD 21201 USA; [Fasano, Alessio; Catassi, Carlo] Univ Maryland, Sch Med, Mucosal Biol Res Ctr, Baltimore, MD 21201 USA; [Catassi, Carlo] Univ Politecn Marche, Dept Pediat, Ancona, Italy	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Marche Polytechnic University	Fasano, A (corresponding author), Univ Maryland, Sch Med, Ctr Celiac Res, Hlth Sci Facil 2, Rm S345,20 Penn St, Baltimore, MD 21201 USA.	afasano@mbrc.umaryland.edu	Fasano, Alessio/K-5486-2016	Fasano, Alessio/0000-0002-2134-0261	Glaxo-SmithKline; Menarini Diagnostics; Dr. Schar, Inc.; Heinz	Glaxo-SmithKline(GlaxoSmithKline); Menarini Diagnostics(Menarini Group); Dr. Schar, Inc.; Heinz	Dr. Fasano reports receiving consulting fees from Glaxo-SmithKline and owning stock in Alba Therapeutics. Dr. Catassi reports receiving consulting fees from Menarini Diagnostics, Dr. Schar, Inc., and Heinz. No other potential conflict of interest relevant to this article was reported. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.	Alarida K, 2011, DIGEST LIVER DIS, V43, P688, DOI 10.1016/j.dld.2011.01.002; [Anonymous], 2001, Gastroenterology, V120, P1522; [Anonymous], 2004, NIH Consens State Sci Statements, V21, P1; Biagi F, 2010, ANN MED, V42, P557, DOI 10.3109/07853890.2010.523229; Canavan C, 2011, ALIMENT PHARM THER, V34, P1012, DOI 10.1111/j.1365-2036.2011.04811.x; Caproni M, 2009, J EUR ACAD DERMATOL, V23, P633, DOI 10.1111/j.1468-3083.2009.03188.x; Catassi C, 2007, AM J CLIN NUTR, V85, P160, DOI 10.1093/ajcn/85.1.160; Catassi C, 2007, AM J GASTROENTEROL, V102, P1454, DOI 10.1111/j.1572-0241.2007.01173.x; Catassi C, 2010, ANN MED, V42, P530, DOI 10.3109/07853890.2010.514285; Codex Alimentarius IFS, 2008, 1181979 COD COMM NUT, P118; Dalgic B, 2011, AM J GASTROENTEROL, V106, P1512, DOI 10.1038/ajg.2011.183; Daum S, 2005, BEST PRACT RES CL GA, V19, P413, DOI 10.1016/j.bpg.2005.02.001; Fasano A, 2003, ARCH INTERN MED, V163, P286, DOI 10.1001/archinte.163.3.286; Fasano A, 2001, GASTROENTEROLOGY, V120, P636, DOI 10.1053/gast.2001.22123; Frost AR, 2009, EUR J ENDOCRINOL, V160, P675, DOI 10.1530/EJE-08-0846; Giersiepen K, 2012, J PEDIATR GASTR NUTR, V54, P229, DOI 10.1097/MPG.0b013e318216f2e5; Green PHR, 2007, NEW ENGL J MED, V357, P1731, DOI 10.1056/NEJMra071600; Gupta R, 2009, WORLD J GASTROENTERO, V15, P6028, DOI 10.3748/wjg.15.6028; Hadjivassiliou M, 2008, CEREBELLUM, V7, P494, DOI 10.1007/s12311-008-0052-x; Hill ID, 2005, J PEDIATR GASTR NUTR, V40, P1, DOI 10.1097/00005176-200501000-00001; Husby S, 2012, J PEDIATR GASTR NUTR, V54, P136, DOI 10.1097/MPG.0b013e31821a23d0; Jabri B, 2009, NAT REV IMMUNOL, V9, P858, DOI 10.1038/nri2670; Karell K, 2003, HUM IMMUNOL, V64, P469, DOI 10.1016/S0198-8859(03)00027-2; Lanzini A, 2009, ALIMENT PHARM THER, V29, P1299, DOI 10.1111/j.1365-2036.2009.03992.x; Lenhardt A, 2004, DIGEST LIVER DIS, V36, P730, DOI 10.1016/j.dld.2004.06.017; Matysiak-Budnik T, 2007, GUT, V56, P1379, DOI 10.1136/gut.2006.100511; Mustalahti K, 2010, ANN MED, V42, P587, DOI 10.3109/07853890.2010.505931; Raivio T, 2006, ALIMENT PHARM THER, V24, P147, DOI 10.1111/j.1365-2036.2006.02957.x; Rashid M, 2007, CAN J GASTROENTEROL, V21, P649, DOI 10.1155/2007/340591; Rubio-Tapia A, 2008, CLIN GASTROENTEROL H, V6, P983, DOI 10.1016/j.cgh.2008.04.008; Salmi TT, 2006, GUT, V55, P1746, DOI 10.1136/gut.2005.071514; Sapone A, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-13; Sapone A, 2010, INT ARCH ALLERGY IMM, V152, P75, DOI 10.1159/000260087; Sattar N, 2011, J PEDIATR-US, V158, P272, DOI 10.1016/j.jpeds.2010.08.050; Schuppan D, 2009, GASTROENTEROLOGY, V137, P1912, DOI 10.1053/j.gastro.2009.09.008; Sellitto M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033387; Sharaiha RZ, 2012, CANCER-AM CANCER SOC, V118, P3786, DOI 10.1002/cncr.26700; Simell S, 2007, AM J GASTROENTEROL, V102, P2026, DOI 10.1111/j.1572-0241.2007.01360.x; Sverker A, 2005, J HUM NUTR DIET, V18, P171, DOI 10.1111/j.1365-277X.2005.00591.x; Szajewska H, 2012, ALIMENT PHARM THER, V36, P607, DOI 10.1111/apt.12023; Tonutti E, 2009, J CLIN LAB ANAL, V23, P165, DOI 10.1002/jcla.20313; Tosco A, 2011, CLIN GASTROENTEROL H, V9, P320, DOI 10.1016/j.cgh.2010.09.006; Trynka G, 2011, NAT GENET, V43, P1193, DOI 10.1038/ng.998; Volta U, 2011, EXPERT REV GASTROENT, V5, P479, DOI [10.1586/EGH.11.38, 10.1586/egh.11.38]; Wang XQ, 2011, J PEDIATR GASTR NUTR, V53, P368, DOI 10.1097/MPG.0b013e31822a0128; Wouters J, 2009, J PEDIATR-US, V154, P239, DOI 10.1016/j.jpeds.2008.08.007; Zanoni G, 2006, PLOS MED, V3, P1637, DOI 10.1371/journal.pmed.0030358; Zintzaras E, 2006, CLIN VACCINE IMMUNOL, V13, P187, DOI 10.1128/CVI.13.2.187-192.2006	48	413	431	3	124	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 20	2012	367	25					2419	2426		10.1056/NEJMcp1113994	http://dx.doi.org/10.1056/NEJMcp1113994			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	056ZP	23252527				2023-01-03	WOS:000312531600009
J	Bhatia, S; Moon, J; Margolin, KA; Weber, JS; Lao, CD; Othus, M; Aparicio, AM; Ribas, A; Sondak, VK				Bhatia, Shailender; Moon, James; Margolin, Kim A.; Weber, Jeffrey S.; Lao, Christopher D.; Othus, Megan; Aparicio, Ana M.; Ribas, Antoni; Sondak, Vernon K.			Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512	PLOS ONE			English	Article							EX-VIVO CHEMOSENSITIVITY; RAF/MEK/ERK PATHWAY; CHOROIDAL MELANOMA; PROGRESSION-FREE; SURVIVAL; MUTATIONS; BRAF; GEMCITABINE; BAY-43-9006; ACTIVATION	Background: Sorafenib, a multikinase inhibitor of cell proliferation and angiogenesis, inhibits the mitogen-activated protein kinase pathway that is activated in most uveal melanoma tumors. This phase II study was conducted by the SWOG cooperative group to evaluate the efficacy of sorafenib in combination with carboplatin and paclitaxel (CP) in metastatic uveal melanoma. Methods: Twenty-five patients with stage IV uveal melanoma who had received 0-1 prior systemic therapy were enrolled. Treatment included up to 6 cycles of carboplatin (AUC = 6) and paclitaxel (225 mg/m(2)) administered IV on day 1 plus sorafenib (400 mg PO twice daily), followed by sorafenib monotherapy until disease progression. The primary endpoint was objective response rate (ORR); a two-stage design was used with the study to be terminated if no confirmed responses were observed in the first 20 evaluable patients. Secondary efficacy endpoints included progression-free survival (PFS) and overall survival (OS). Results: No confirmed objective responses occurred among the 24 evaluable patients (ORR = 0% [95% CI: 0-14%]) and the study was terminated at the first stage. Minor responses (tumor regression less than 30%) were seen in eleven of 24 (45%) patients. The median PFS was 4 months [95% CI: 1-6 months] and the 6-month PFS was 29% [95% CI: 13%-48%]. The median OS was 11 months [95% CI: 7-14 months]. Conclusion: In this study, the overall efficacy of CP plus sorafenib in metastatic uveal melanoma did not warrant further clinical testing when assessed by ORR, although minor tumor responses and stable disease were observed in some patients.	[Bhatia, Shailender; Margolin, Kim A.] Univ Washington, Seattle, WA 98195 USA; [Moon, James; Othus, Megan] SWOG Stat Ctr, Seattle, WA USA; [Weber, Jeffrey S.; Sondak, Vernon K.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA; [Lao, Christopher D.] Univ Michigan, Ann Arbor, MI 48109 USA; [Aparicio, Ana M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Ribas, Antoni] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA	University of Washington; University of Washington Seattle; Southwest Oncology Group; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Michigan System; University of Michigan; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Bhatia, S (corresponding author), Univ Washington, Seattle, WA 98195 USA.	sbhatia@uw.edu		Margolin, Kim/0000-0002-5248-4356	National Cancer Institute, National Institutes of Health, Department of Health and Human Services [CA32102, CA38926, CA27057, CA42777, CA35178, CA20319, CA58861, CA04919, CA76429]; NATIONAL CANCER INSTITUTE [U10CA035178, U10CA032102, U10CA020319, U10CA076429, U10CA027057, U10CA038926, U10CA042777, P30CA015704, U10CA004919, U10CA058861] Funding Source: NIH RePORTER	National Cancer Institute, National Institutes of Health, Department of Health and Human Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This investigation was supported in part by the following PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute, National Institutes of Health, Department of Health and Human Services: CA32102, CA38926, CA27057, CA42777, CA35178, CA20319, CA58861, CA04919, and CA76429. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.	Amaravadi RK, 2009, CLIN CANCER RES, V15, P7711, DOI 10.1158/1078-0432.CCR-09-2074; Augsburger JJ, 2009, AM J OPHTHALMOL, V148, P119, DOI 10.1016/j.ajo.2009.01.023; Bedikian Agop Y., 2006, International Ophthalmology Clinics, V46, P151, DOI 10.1097/01.iio.0000195852.08453.de; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; Carter CA, 2007, CANCER CHEMOTH PHARM, V59, P183, DOI 10.1007/s00280-006-0257-y; Chang AE, 1998, CANCER, V83, P1664, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Diener-West M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1639; EINHORN LH, 1974, CANCER, V34, P1001, DOI 10.1002/1097-0142(197410)34:4<1001::AID-CNCR2820340406>3.0.CO;2-Z; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Flaherty KT, 2006, ANN ONCOL, V17, P33; GREEN SJ, 1992, STAT MED, V11, P853, DOI 10.1002/sim.4780110703; Guenterberg KD, 2011, AM J CLIN ONCOL-CANC, V34, P87, DOI 10.1097/COC.0b013e3181d2ed67; Hauschild A, 2009, J CLIN ONCOL, V27, P2823, DOI 10.1200/JCO.2007.15.7636; Heim M., 2003, International Journal of Clinical Pharmacology and Therapeutics, V41, P616; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Korn EL, 2008, J CLIN ONCOL, V26, P527, DOI 10.1200/JCO.2007.12.7837; Kujala E, 2003, INVEST OPHTH VIS SCI, V44, P4651, DOI 10.1167/iovs.03-0538; Kupsch Petra, 2005, Clin Colorectal Cancer, V5, P188, DOI 10.3816/CCC.2005.n.030; McLaughlin CC, 2005, CANCER-AM CANCER SOC, V103, P1000, DOI 10.1002/cncr.20866; Missotten GSO, 2006, ARCH OPHTHALMOL-CHIC, V124, P1428, DOI 10.1001/archopht.124.10.1428; Myatt N, 1997, ANTI-CANCER DRUG, V8, P756, DOI 10.1097/00001813-199709000-00004; Neale MH, 1999, BRIT J CANCER, V79, P1487, DOI 10.1038/sj.bjc.6690237; Neale MH, 2001, MELANOMA RES, V11, P601, DOI 10.1097/00008390-200112000-00006; Patel M, 2011, CLIN CANCER RES, V17, P2087, DOI 10.1158/1078-0432.CCR-10-3169; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pingpank JF, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.18_suppl.lba8512; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; RAJPAL S, 1983, CANCER, V52, P334, DOI 10.1002/1097-0142(19830715)52:2<334::AID-CNCR2820520225>3.0.CO;2-E; Richly H, 2006, ANN ONCOL, V17, P866, DOI 10.1093/annonc/mdl017; Richly H, 2004, Int J Clin Pharmacol Ther, V42, P650; Sato T, 2010, SEMIN ONCOL, V37, P127, DOI 10.1053/j.seminoncol.2010.03.014; Singh AD, 2011, OPHTHALMOLOGY, V118, P1881, DOI 10.1016/j.ophtha.2011.01.040; Siu LL, 2006, CLIN CANCER RES, V12, P144, DOI 10.1158/1078-0432.CCR-05-1571; Stitt AW, 1998, J PATHOL, V186, P306, DOI 10.1002/(SICI)1096-9896(1998110)186:3<306::AID-PATH183>3.0.CO;2-B; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Weber A, 2003, LAB INVEST, V83, P1771, DOI 10.1097/01.LAB.0000101732.89463.29; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Yang H, 2010, INVEST OPHTH VIS SCI, V51, P2835, DOI 10.1167/iovs.09-4755; Zuidervaart W, 2005, BRIT J CANCER, V92, P2032, DOI 10.1038/sj.bjc.6602598	43	50	51	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2012	7	11							e48787	10.1371/journal.pone.0048787	http://dx.doi.org/10.1371/journal.pone.0048787			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	054WM	23226204	gold, Green Published, Green Submitted			2023-01-03	WOS:000312376100013
J	Togtema, M; Pichardo, S; Jackson, R; Lambert, PF; Curiel, L; Zehbe, I				Togtema, Melissa; Pichardo, Samuel; Jackson, Robert; Lambert, Paul F.; Curiel, Laura; Zehbe, Ingeborg			Sonoporation Delivery of Monoclonal Antibodies against Human Papillomavirus 16 E6 Restores p53 Expression in Transformed Cervical Keratinocytes	PLOS ONE			English	Article							SMALL INTERFERING RNA; FOCUSED ULTRASOUND; CARCINOMA CELLS; IN-VITRO; INTRACELLULAR DELIVERY; GENE-PRODUCT; CANCER-CELLS; APOPTOSIS; PROTEIN; TYPE-16	High-risk types of human papillomavirus (HPV), such as HPV16, have been found in nearly all cases of cervical cancer. Therapies targeted at blocking the HPV16 E6 protein and its deleterious effects on the tumour suppressor pathways of the cell can reverse the malignant phenotype of affected keratinocytes while sparing uninfected cells. Through a strong interdisciplinary collaboration between engineering and biology, a novel, non-invasive intracellular delivery method for the HPV16 E6 antibody, F127-6G6, was developed. The method employs high intensity focused ultrasound (HIFU) in combination with microbubbles, in a process known as sonoporation. In this proof of principle study, it was first demonstrated that sonoporation antibody delivery into the HPV16 positive cervical carcinoma derived cell lines CaSki and SiHa was possible, using chemical transfection as a baseline for comparison. Delivery of the E6 antibody using sonoporation significantly restored p53 expression in these cells, indicating the antibody is able to enter the cells and remains active. This delivery method is targeted, non-cytotoxic, and non-invasive, making it more easily translatable for in vivo experiments than other transfection methods.	[Togtema, Melissa; Pichardo, Samuel; Jackson, Robert; Curiel, Laura; Zehbe, Ingeborg] Thunder Bay Reg Res Inst, Thunder Bay, ON, Canada; [Togtema, Melissa; Jackson, Robert] Lakehead Univ, Dept Biol, Thunder Bay, ON P7B 5E1, Canada; [Lambert, Paul F.] Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA	Northern Ontario School of Medicine; Lakehead University; University of Wisconsin System; University of Wisconsin Madison	Zehbe, I (corresponding author), Thunder Bay Reg Res Inst, Thunder Bay, ON, Canada.	zehbei@tbh.net	Jackson, Robert/AAP-7870-2021	Jackson, Robert/0000-0001-9898-5546	Natural Sciences and Engineering Research Council of Canada (NSERC) [355858-2008]; Philips Medical Healthcare	Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Philips Medical Healthcare	This work was mainly funded by a Natural Sciences and Engineering Research Council of Canada (NSERC) grant to IZ (#355858-2008) and partially funded by Philips Medical Healthcare. E6 antibodies were kindly provided by Arbor Vita Corporation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed HU, 2011, J UROLOGY, V185, P1246, DOI 10.1016/j.juro.2010.11.079; Allen-Hoffmann BL, 2000, J INVEST DERMATOL, V114, P444, DOI 10.1046/j.1523-1747.2000.00869.x; ANDROPHY EJ, 1985, SCIENCE, V230, P442, DOI 10.1126/science.2996134; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; Baleja JD, 2006, ANTIVIR RES, V72, P49, DOI 10.1016/j.antiviral.2006.03.014; Bao SP, 1997, ULTRASOUND MED BIOL, V23, P953, DOI 10.1016/S0301-5629(97)00025-2; Beerheide W, 1999, J NATL CANCER I, V91, P1211, DOI 10.1093/jnci/91.14.1211; Butz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894; Carpenter AE, 2007, NAT METHODS, V4, P120, DOI 10.1038/nmeth0207-120; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Choi JJ, 2007, ULTRASOUND MED BIOL, V33, P95, DOI 10.1016/j.ultrasmedbio.2006.07.018; Courtete J, 2007, MOL CANCER THER, V6, P1728, DOI 10.1158/1535-7163.MCT-06-0808; Crawford L, 1997, CLIN DERMATOL, V15, P207, DOI 10.1016/S0738-081X(96)00163-0; Curiel L, 2009, AIP C P, V1215, P119; Daling JR, 2004, CANCER-AM CANCER SOC, V101, P270, DOI 10.1002/cncr.20365; DeFilippis RA, 2003, J VIROL, V77, P1551, DOI 10.1128/JVI.77.2.1551-1563.2003; Endo-Takahashi Y, 2012, INT J PHARMACEUT, V422, P504, DOI 10.1016/j.ijpharm.2011.11.023; Forbes MM, 2008, ULTRASOUND MED BIOL, V34, P2009, DOI 10.1016/j.ultrasmedbio.2008.05.003; FRIEDL F, 1970, P SOC EXP BIOL MED, V135, P543; Hamilton N, 2009, TRAFFIC, V10, P951, DOI 10.1111/j.1600-0854.2009.00938.x; Horner SM, 2004, J VIROL, V78, P4063, DOI 10.1128/JVI.78.8.4063-4073.2004; Jackson R, 2012, VIROLOGY IN PRESS; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Karshafian R, 2010, ULTRASONICS, V50, P691, DOI 10.1016/j.ultras.2010.01.009; Kinoshita M, 2005, BIOCHEM BIOPH RES CO, V335, P393, DOI 10.1016/j.bbrc.2005.07.101; Kinoshita M, 2005, PHARM RES-DORDR, V22, P716, DOI 10.1007/s11095-005-2586-7; Kinoshita M, 2007, BIOCHEM BIOPH RES CO, V359, P860, DOI 10.1016/j.bbrc.2007.05.153; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kudo N, 2009, BIOPHYS J, V96, P4866, DOI 10.1016/j.bpj.2009.02.072; Lagrange M, 2005, J GEN VIROL, V86, P1001, DOI 10.1099/vir.0.80607-0; Liu YQ, 2004, BIOCHEMISTRY-US, V43, P7421, DOI 10.1021/bi049552a; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Maxwell AD, 2011, J VASC INTERV RADIOL, V22, P369, DOI 10.1016/j.jvir.2010.10.007; Mehier-Humbert S, 2005, J CONTROL RELEASE, V104, P213, DOI 10.1016/j.jconrel.2005.01.007; Meijering BDM, 2009, CIRC RES, V104, P679, DOI 10.1161/CIRCRESAHA.108.183806; Newman CMH, 2007, GENE THER, V14, P465, DOI 10.1038/sj.gt.3302925; Nygren PA, 2008, FEBS J, V275, P2668, DOI 10.1111/j.1742-4658.2008.06438.x; PATTILLO R A, 1977, Science (Washington D C), V196, P1456, DOI 10.1126/science.867042; Richard C, 2010, ONCOGENE, V29, P3435, DOI 10.1038/onc.2010.93; Rui M, 2002, LIFE SCI, V71, P1771, DOI 10.1016/S0024-3205(02)01943-4; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sezgin M, 2004, J ELECTRON IMAGING, V13, P146, DOI 10.1117/1.1631315; Siddiqui K, 2010, UROLOGY, V76, P1506, DOI 10.1016/j.urology.2010.04.046; Staruch R, 2011, IEEE PULSE, V2, P39, DOI 10.1109/MPUL.2011.942604; Staruch R, 2011, INT J HYPERTHER, V27, P156, DOI 10.3109/02656736.2010.518198; Strebhardt K, 2008, NAT REV CANCER, V8, P473, DOI 10.1038/nrc2394; Tran MA, 2008, CANCER RES, V68, P7638, DOI 10.1158/0008-5472.CAN-07-6614; Tran TA, 2008, IEEE T ULTRASON FERR, V55, P44, DOI 10.1109/TUFFC.2008.615; Walker CL, 2005, SCIENCE, V308, P1589, DOI 10.1126/science.1112063; WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre), 2010, HUM PAP REL CANC WOR; Wu J, 2006, ULTRASONICS, V44, pE21, DOI 10.1016/j.ultras.2006.06.033; YAMAIZUMI M, 1979, CELL, V18, P1009, DOI 10.1016/0092-8674(79)90213-7; Yamato K, 2008, CANCER GENE THER, V15, P140, DOI 10.1038/sj.cgt.7701118; Yang FY, 2011, IEEE T ULTRASON FERR, V58, P964, DOI 10.1109/TUFFC.2011.1897; Yudina A, 2011, MOL IMAGING BIOL, V13, P239, DOI 10.1007/s11307-010-0346-5; Zehbe I, 2009, VIROLOGY, V383, P69, DOI 10.1016/j.virol.2008.09.036; Zhao Y, 2003, APOPTOSIS, V8, P631, DOI 10.1023/A:1026139627930; Zhao YZ, 2008, J DRUG TARGET, V16, P18, DOI [10.1080/10611860701637792, 10.1080/10611860701637792 ]; Zheng YF, 2004, CANCER BIOL THER, V3, P1129, DOI 10.4161/cbt.3.11.1215; Zhou Y, 2009, ULTRASOUND MED BIOL, V35, P1756, DOI 10.1016/j.ultrasmedbio.2009.05.012; Zhou ZY, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-159; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	63	27	29	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2012	7	11							e50730	10.1371/journal.pone.0050730	http://dx.doi.org/10.1371/journal.pone.0050730			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	054WM	23226365	Green Published, gold, Green Submitted			2023-01-03	WOS:000312376100176
J	Tao, XJ; Zhang, QF; Ling, K; Chen, YC; Yang, WZ; Gao, FF; Shi, GG				Tao, Xiaojun; Zhang, Qiufang; Ling, Kai; Chen, Yicun; Yang, Wenzhi; Gao, Fenfei; Shi, Ganggang			Effect of Pullulan Nanoparticle Surface Charges on HSA Complexation and Drug Release Behavior of HSA-Bound Nanoparticles	PLOS ONE			English	Article							CHOLESTEROL-BEARING PULLULAN; ASSEMBLED HYDROGEL NANOPARTICLE; SELF-AGGREGATED NANOPARTICLES; BOVINE SERUM-ALBUMIN; PHYSICOCHEMICAL CHARACTERISTICS; POLYMERIC NANOPARTICLES; PROTEIN ADSORPTION; GLYCOL CHITOSAN; PLASMA-PROTEINS; NANOGELS	Nanoparticle (NP) compositions such as hydrophobicity and surface charge are vital to determine the presence and amount of human serum albumin (HSA) binding. The HSA binding influences drug release, biocompatibility, biodistribution, and intercellular trafficking of nanoparticles (NPs). Here, we prepared 2 kinds of nanomaterials to investigate HSA binding and evaluated drug release of HSA-bound NPs. Polysaccharides (pullulan) carboxyethylated to provide ionic derivatives were then conjugated to cholesterol groups to obtain cholesterol-modified carboxyethyl pullulan (CHCP). Cholesterol-modified pullulan (CHP) conjugate was synthesized with a similar degree of substitution of cholesterol moiety to CHCP. CHCP formed self-aggregated NPs in aqueous solution with a spherical structure and zeta potential of -19.9 +/- 0.23 mV, in contrast to -1.21 +/- 0.12 mV of CHP NPs. NPs could quench albumin fluorescence intensity with maximum emission intensity gradually decreasing up to a plateau at 9 to 12 h. Binding constants were 1.12x10(5) M-1 and 0.70x10(5) M-1 to CHP and CHCP, respectively, as determined by Stern-Volmer analysis. The complexation between HSA and NPs was a gradual process driven by hydrophobic force and inhibited by NP surface charge and shell-core structure. HSA conformation was altered by NPs with reduction of alpha-helical content, depending on interaction time and particle surface charges. These NPs could represent a sustained release carrier for mitoxantrone in vitro, and the bound HSA assisted in enhancing sustained drug release.	[Tao, Xiaojun; Shi, Ganggang] Shantou Univ, Coll Med, Dept Cardiovasc Dis, Affiliated Hosp 1, Shantou, Guangdong, Peoples R China	Shantou University	Tao, XJ (corresponding author), Shantou Univ, Coll Med, Dept Cardiovasc Dis, Affiliated Hosp 1, Shantou, Guangdong, Peoples R China.	ggshi@stu.edu.cn	Gao, Fenfei/S-5331-2019	Gao, Fenfei/0000-0003-4144-8891				Aggarwal P, 2009, ADV DRUG DELIVER REV, V61, P428, DOI 10.1016/j.addr.2009.03.009; Ahmad B, 2006, BIOMACROMOLECULES, V7, P1350, DOI 10.1021/bm050996b; Ahmad E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038372; Ahmad E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026186; Akiyama E, 2007, BIOMACROMOLECULES, V8, P2366, DOI 10.1021/bm070136q; Akiyoshi K, 1996, COLLOID SURFACE A, V112, P91, DOI 10.1016/0927-7757(96)03560-1; Akiyoshi K, 1997, MACROMOLECULES, V30, P857, DOI 10.1021/ma960786e; Akiyoshi K, 1998, J CONTROL RELEASE, V54, P313, DOI 10.1016/S0168-3659(98)00017-0; Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m; Ayame H, 2008, BIOCONJUGATE CHEM, V19, P882, DOI 10.1021/bc700422s; Beduneau A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004343; Belatik A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036723; Boridy S, 2009, BIOMATERIALS, V30, P5583, DOI 10.1016/j.biomaterials.2009.06.010; Cedervall T, 2007, ANGEW CHEM INT EDIT, V46, P5754, DOI 10.1002/anie.200700465; Cedervall T, 2007, P NATL ACAD SCI USA, V104, P2050, DOI 10.1073/pnas.0608582104; Deguchi S, 1999, COLLOID SURFACE A, V147, P203, DOI 10.1016/S0927-7757(98)00754-7; Dobrovolskaia MA, 2008, MOL PHARMACEUT, V5, P487, DOI 10.1021/mp800032f; Duan YR, 2006, J MATER SCI-MATER M, V17, P509, DOI 10.1007/s10856-006-8933-3; Dulong V, 2006, COLLOID SURFACE A, V274, P163, DOI 10.1016/j.colsurfa.2005.08.045; Froehlich E, 2009, J PHYS CHEM B, V113, P6986, DOI 10.1021/jp9011119; Fundueanu G, 2008, BIOMATERIALS, V29, P2767, DOI 10.1016/j.biomaterials.2008.03.025; Gessner A, 2002, EUR J PHARM BIOPHARM, V54, P165, DOI 10.1016/S0939-6411(02)00081-4; Ghaghada KB, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007628; Gokara M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008834; Grund S, 2012, J COLLOID INTERF SCI, V365, P33, DOI 10.1016/j.jcis.2011.09.003; Guven A, 2012, BIOMATERIALS, V33, P1455, DOI 10.1016/j.biomaterials.2011.10.060; Huang MH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012279; Jeong YI, 2006, J PHARM SCI-US, V95, P2348, DOI 10.1002/jps.20586; Karmali PP, 2011, EXPERT OPIN DRUG DEL, V8, P343, DOI 10.1517/17425247.2011.554818; Khan SN, 2008, EUR J PHARM SCI, V35, P371, DOI 10.1016/j.ejps.2008.07.010; Kwon S, 2003, LANGMUIR, V19, P10188, DOI 10.1021/la0350608; Lee ALZ, 2009, BIOMATERIALS, V30, P919, DOI 10.1016/j.biomaterials.2008.10.062; Lee I, 2004, BIOMATERIALS, V25, P2911, DOI 10.1016/j.biomaterials.2003.09.065; Lee KY, 1998, LANGMUIR, V14, P2329, DOI 10.1021/la970928d; Lindman S, 2007, NANO LETT, V7, P914, DOI 10.1021/nI062743+; Liu ZH, 2008, ADV DRUG DELIVER REV, V60, P1650, DOI 10.1016/j.addr.2008.09.001; Lundqvist M, 2004, LANGMUIR, V20, P10639, DOI 10.1021/la0484725; Lundqvist M, 2005, LANGMUIR, V21, P5974, DOI 10.1021/la050569j; Lundqvist M, 2008, P NATL ACAD SCI USA, V105, P14265, DOI 10.1073/pnas.0805135105; Lynch I, 2008, NANO TODAY, V3, P40, DOI 10.1016/S1748-0132(08)70014-8; Lynch I, 2007, ADV COLLOID INTERFAC, V134-35, P167, DOI 10.1016/j.cis.2007.04.021; MAIA MBS, 1994, FUNDAM CLIN PHARM, V8, P178, DOI 10.1111/j.1472-8206.1994.tb00795.x; Moghimi SM, 2001, PHARMACOL REV, V53, P283; Morimoto N, 2005, BIOMACROMOLECULES, V6, P1829, DOI 10.1021/bm050156x; Morimoto N, 2007, LANGMUIR, V23, P217, DOI 10.1021/la0616045; Nel AE, 2009, NAT MATER, V8, P543, DOI [10.1038/NMAT2442, 10.1038/nmat2442]; NISHIKAWA T, 1994, MACROMOLECULES, V27, P7654, DOI 10.1021/ma00104a021; Nishikawa T, 1996, J AM CHEM SOC, V118, P6110, DOI 10.1021/ja953843c; Roach P, 2006, J AM CHEM SOC, V128, P3939, DOI 10.1021/ja056278e; Sasaki Yoshihiro, 2011, Curr Drug Discov Technol, V8, P308; Shaikh VAE, 1998, J APPL POLYM SCI, V70, P195, DOI 10.1002/(SICI)1097-4628(19981003)70:1<195::AID-APP19>3.0.CO;2-6; Slomkowski S, 2011, CURR PHARM BIOTECHNO, V12, P1823, DOI 10.2174/138920111798377003; Tenzer S, 2011, ACS NANO, V5, P7155, DOI 10.1021/nn201950e; Vannoy CH, 2010, J PHYS CHEM B, V114, P10881, DOI 10.1021/jp1045904; Verma A, 2010, SMALL, V6, P12, DOI 10.1002/smll.200901158; Wang YS, 2007, CARBOHYD POLYM, V69, P597, DOI 10.1016/j.carbpol.2007.01.016; Wohlfart S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019121; Yang WZ, 2010, CURR NANOSCI, V6, P298, DOI 10.2174/157341310791171153; Yu JM, 2009, J PHARM PHARMACOL, V61, P713, DOI [10.1211/jpp/61.06.0003, 10.1211/jpp.61.06.0003]; Zhang XF, 2007, J PHYS CHEM C, V111, P14327, DOI 10.1021/jp073267u	60	19	19	5	50	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2012	7	11							e49304	10.1371/journal.pone.0049304	http://dx.doi.org/10.1371/journal.pone.0049304			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	038CD	23166632	Green Published, gold, Green Submitted			2023-01-03	WOS:000311151900118
J	Jagdeo, JR; Adams, LE; Brody, NI; Siegel, DM				Jagdeo, Jared R.; Adams, Lauren E.; Brody, Neil I.; Siegel, Daniel M.			Transcranial Red and Near Infrared Light Transmission in a Cadaveric Model	PLOS ONE			English	Article							LASER THERAPY; IRRADIATION; RADIATION; STROKE; SAFETY	Background and Objective: Low level light therapy has garnered significant interest within the past decade. The exact molecular mechanisms of how red and near infrared light result in physiologic modulation are not fully understood. Heme moieties and copper within cells are red and near infrared light photoreceptors that induce the mitochondrial respiratory chain component cytochrome C oxidase, resulting in a cascade linked to cytoprotection and cellular metabolism. The copper centers in cytochrome C oxidase have a broad absorption range that peaks around 830 nm. Several in vitro and in vivo animal and human models exist that have demonstrated the benefits of red light and near infrared light for various conditions. Clinical applications for low level light therapy are varied. One study in particular demonstrated improved durable functional outcomes status post-stroke in patients treated with near infrared low level light therapy compared to sham treatment [1]. Despite previous data suggesting the beneficial effect in treating multiple conditions, including stroke, with low level light therapy, limited data exists that measures transmission in a human model. Study Design/Materials and Methods: To investigate this idea, we measured the transmission of near infrared light energy, using red light for purposes of comparison, through intact cadaver soft tissue, skull bones, and brain using a commercially available LED device at 830 nm and 633 nm. Results: Our results demonstrate that near infrared measurably penetrates soft tissue, bone and brain parenchyma in the formalin preserved cadaveric model, in comparison to negligible red light transmission in the same conditions. Conclusion: These findings indicate that near infrared light can penetrate formalin fixed soft tissue, bone and brain and implicate that benefits observed in clinical studies are potentially related to direct action of near infrared light on neural tissue.	[Jagdeo, Jared R.; Adams, Lauren E.; Brody, Neil I.; Siegel, Daniel M.] Suny Downstate Med Ctr, Dept Dermatol, Brooklyn, NY 11203 USA; [Jagdeo, Jared R.] Sacramento Vet Affairs Med Ctr, Dermatol Serv, Mather, CA USA; [Jagdeo, Jared R.] Univ Calif Davis, Dept Dermatol, Sacramento, CA 95817 USA; [Siegel, Daniel M.] Brooklyn Vet Affairs Med Ctr, Dermatol Serv, Brooklyn, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of California System; University of California Davis	Jagdeo, JR (corresponding author), Suny Downstate Med Ctr, Dept Dermatol, Brooklyn, NY 11203 USA.	jrjagdeo@gmail.com						Bachelard HS, 1975, BRAIN WORK, P79; BEAUVOIT B, 1994, BIOPHYS J, V67, P2501, DOI 10.1016/S0006-3495(94)80740-4; Berrocal E, 2009, OPT EXPRESS, V17, P13792, DOI 10.1364/OE.17.013792; Chiappelli J, 2008, J ENVIRON HEALTH, V71, P24; Danno K, 2001, PHOTODERMATOL PHOTO, V17, P261, DOI 10.1034/j.1600-0781.2001.170603.x; GARN SM, 1954, AMA ARCH DERM SYPH, V70, P601, DOI 10.1001/archderm.1954.01540230051006; Giuliani A, 2009, BMC COMPLEM ALTERN M, V9, DOI 10.1186/1472-6882-9-8; Goldberg David J, 2006, J Drugs Dermatol, V5, P748; Hashmi JT, 2010, PM&R, V2, pS292, DOI 10.1016/j.pmrj.2010.10.013; Hirsch R, 2007, DERMATOLOGY, P2145; James Byrnes, 2009, NATO SCI PEACE SECUR, P21; Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lapchak PA, 2007, NEUROSCIENCE, V148, P907, DOI 10.1016/j.neuroscience.2007.07.002; Leonard DR, 2004, DIABETES CARE, V27, P168, DOI 10.2337/diacare.27.1.168; Levy M, 2004, PHYSIOLOGY, P265; Minatel DG, 2009, LASER SURG MED, V41, P433, DOI 10.1002/lsm.20789; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Pandian PS, 2009, MED BIOL ENG COMPUT, V47, P1197, DOI 10.1007/s11517-009-0531-3; Rojas JC, 2008, J NEUROSCI, V28, P13511, DOI 10.1523/JNEUROSCI.3457-08.2008; Samoilova K I, 2003, Tsitologiia, V45, P596; Samoilova KA, 2004, PHOTOCH PHOTOBIO SCI, V3, P96, DOI 10.1039/b305738k; Schubert V, 2001, PHOTODERMATOL PHOTO, V17, P32, DOI 10.1034/j.1600-0781.2001.017001032.x; Waiz Makram, 2006, J Cosmet Laser Ther, V8, P27, DOI 10.1080/14764170600607368; WAN S, 1981, PHOTOCHEM PHOTOBIOL, V34, P679, DOI 10.1111/j.1751-1097.1981.tb09424.x; Whelan HT, 2001, J CLIN LASER MED SUR, V19, P305, DOI 10.1089/104454701753342758; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Yamazaki M, 2003, INT J DERMATOL, V42, P738, DOI 10.1046/j.1365-4362.2003.01968.x; Yokoyama K, RHEUMATOID ARTHRITIS; Zhang R, 2009, J MOL CELL CARDIOL, V46, P4, DOI 10.1016/j.yjmcc.2008.09.707; Zhang YO, 2003, J INVEST DERMATOL, V120, P849, DOI 10.1046/j.1523-1747.2003.12133.x; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	32	92	97	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2012	7	10							e47460	10.1371/journal.pone.0047460	http://dx.doi.org/10.1371/journal.pone.0047460			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022WO	23077622	Green Published, gold, Green Submitted			2023-01-03	WOS:000309995100118
J	Looi, CY; Arya, A; Cheah, FK; Muharram, B; Leong, KH; Mohamad, K; Wong, WF; Rai, N; Mustafa, MR				Looi, Chung Yeng; Arya, Aditya; Cheah, Foo Kit; Muharram, Bushra; Leong, Kok Hoong; Mohamad, Khalit; Wong, Won Fen; Rai, Nitika; Mustafa, Mohd Rais			Induction of Apoptosis in Human Breast Cancer Cells via Caspase Pathway by Vernodalin Isolated from Centratherum anthelminticum (L.) Seeds	PLOS ONE			English	Article							CHROMATOGRAPHY MASS-SPECTROMETRY; DEPENDENT KINASE INHIBITOR; L KUNTZE SEED; SESQUITERPENE LACTONES; LIQUID-CHROMATOGRAPHY; TRADITIONAL MEDICINE; VERNONIA-AMYGDALINA; VERNOLIC ACID; MCF-7 CELLS; T-CELLS	Background: Centratherum anthelminticum (L.) seeds (CA) is a well known medicinal herb in Indian sub-continent. We recently reported anti-oxidant property of chloroform fraction of Centratherum anthelminticum (L.) seeds (CACF) by inhibiting tumor necrosis factor-alpha (TNF-alpha)-induced growth of human breast cancer cells. However, the active compounds in CACF have not been investigated previously. Methodology/Principal Findings: In this study, we showed that CACF inhibited growth of MCF-7 human breast cancer cells. CACF induced apoptosis in MCF-7 cells as marked by cell size shrinkage, deformed cytoskeletal structure and DNA fragmentation. To identify the cytotoxic compound, CACF was subjected to bioassay-guided fractionation which yielded 6 fractions. CACF fraction A and B (CACF-A, -B) demonstrated highest activity among all the fractions. Further HPLC isolation, NMR and LC-MS analysis of CACF-A led to identification of vernodalin as the cytotoxic agent in CACF-A, and -B. 12,13-dihydroxyoleic acid, another major compound in CACF-C fraction was isolated for the first time from Centratherum anthelminticum (L.) seeds but showed no cytotoxic effect against MCF-7 cells. Vernodalin inhibited cell growth of human breast cancer cells MCF-7 and MDA-MB-231 by induction of cell cycle arrest and apoptosis. Increased of reactive oxygen species (ROS) production, coupled with downregulation of anti-apoptotic molecules (Bcl-2, Bcl-xL) led to reduction of mitochondrial membrane potential (MMP) and release of cytochrome c in both human breast cancer cells treated with vernodalin. Release of cytochrome c from mitochondria to cytosol triggered activation of caspase cascade, PARP cleavage, DNA damage and eventually cell death. Conclusions/Significance: To the best of our knowledge, this is the first comprehensive study on cytotoxic and apoptotic mechanism of vernodalin isolated from the Centratherum anthelminticum (L.) seeds in human breast cancer cells. Overall, our data suggest a potential therapeutic value of vernodalin to be further developed as new anti-cancer drug.	[Looi, Chung Yeng; Arya, Aditya; Cheah, Foo Kit; Muharram, Bushra; Mustafa, Mohd Rais] Univ Malaya, Fac Med, Dept Pharmacol, Kuala Lumpur 50603, Malaysia; [Arya, Aditya; Leong, Kok Hoong; Mohamad, Khalit] Univ Malaya, Fac Med, Dept Pharm, Kuala Lumpur, Malaysia; [Wong, Won Fen] Univ Malaya, Fac Med, Dept Med Microbiol, Kuala Lumpur, Malaysia; [Rai, Nitika] Amritum Biobot Herbs Res Lab Pvt Ltd, Jogli, India	Universiti Malaya; Universiti Malaya; Universiti Malaya	Looi, CY (corresponding author), Univ Malaya, Fac Med, Dept Pharmacol, Kuala Lumpur 50603, Malaysia.	looicy@um.edu.my	Looi, Chung Yeng/A-2623-2013; Mustafa, Mohamed R/B-1647-2009; Mohd, Mustafa b Ali/B-9184-2010; Leong, Kok Hoong/D-9505-2012; Leong, Kok Hoong/J-1956-2015; Wong, Won Fen/D-3087-2012	Looi, Chung Yeng/0000-0002-4830-3495; Mustafa, Mohamed R/0000-0002-7864-5189; Mohd, Mustafa b Ali/0000-0002-4220-5384; Leong, Kok Hoong/0000-0002-7317-6117; Leong, Kok Hoong/0000-0002-7317-6117; Wong, Won Fen/0000-0003-1082-1956; Arya, Aditya/0000-0002-8747-3462	University Malaya [RP001-2012B]; University Malaya High Impact research grant from Ministry of Higher Education (MOHE), Malaysia [H-20001-E00002]	University Malaya(Universiti Malaya); University Malaya High Impact research grant from Ministry of Higher Education (MOHE), Malaysia	This study was supported by University Malaya research grant (RP001-2012B) and University Malaya High Impact research grant (H-20001-E00002) from Ministry of Higher Education (MOHE), Malaysia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allwood JW, 2010, PHYTOCHEM ANALYSIS, V21, P33, DOI 10.1002/pca.1187; Ani V, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-40; Arya A, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/627256; Ashok P, 2010, INDIAN J PHARM SCI, V72, P697, DOI 10.4103/0250-474X.84577; Azaizeh H, 2006, EVID-BASED COMPL ALT, V3, P229, DOI 10.1093/ecam/nel034; Ballot C, 2009, MOL CANCER THER, V8, P3307, DOI 10.1158/1535-7163.MCT-09-0639; BHAKUNI DS, 1969, INDIAN J EXP BIOL, V7, P250; Cheng JT, 2000, J CLIN PHARMACOL, V40, P445, DOI 10.1177/00912700022009198; Chinnaiyan Arul M., 1999, Neoplasia (New York), V1, P5; Chukwujekwu JC, 2009, S AFR J BOT, V75, P176, DOI 10.1016/j.sajb.2008.10.001; Crawford AD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014694; DEKOK TMCM, 1994, CARCINOGENESIS, V15, P1399, DOI 10.1093/carcin/15.7.1399; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Engel RH, 2006, FRONT BIOSCI-LANDMRK, V11, P300, DOI 10.2741/1798; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Forouzanfar MH, 2011, LANCET, V378, P1461, DOI 10.1016/S0140-6736(11)61351-2; Gogvadze V, 2008, TRENDS CELL BIOL, V18, P165, DOI 10.1016/j.tcb.2008.01.006; Gourlay CW, 2005, NAT REV MOL CELL BIO, V6, P583, DOI 10.1038/nrm1682; Hedenfalk IA, 2002, ADV CANCER RES, V84, P1, DOI 10.1016/S0065-230X(02)84001-5; HENION JD, 1980, BIOMED MASS SPECTROM, V7, P115, DOI 10.1002/bms.1200070306; Hosamani KM, 2000, IND CROP PROD, V12, P93, DOI 10.1016/S0926-6690(00)00041-8; Hosamani KM, 2003, IND CROP PROD, V18, P111, DOI 10.1016/S0926-6690(03)00031-1; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Indran IR, 2011, BBA-BIOENERGETICS, V1807, P735, DOI 10.1016/j.bbabio.2011.03.010; Kasim LS, 2011, PAK J PHARM SCI, V24, P475; KOSHIMIZU K, 1994, PHYSIOL BEHAV, V56, P1209, DOI 10.1016/0031-9384(94)90368-9; Kottke TJ, 2002, J BIOL CHEM, V277, P804, DOI 10.1074/jbc.M108419200; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kumar S, 1999, CLIN EXP PHARMACOL P, V26, P295, DOI 10.1046/j.1440-1681.1999.03031.x; KUPCHAN SM, 1969, J ORG CHEM, V34, P3908, DOI 10.1021/jo01264a035; Lambertini E, 2004, INT J ONCOL, V24, P419; Lev E, 2006, J ETHNOBIOL ETHNOMED, V2, DOI 10.1186/1746-4269-2-4; Liu Wen-Zhe, 2004, Zhiwu Shengli yu Fenzi Shengwuxue Xuebao, V30, P405; Liu YQ, 2010, TETRAHEDRON LETT, V51, P6584, DOI 10.1016/j.tetlet.2010.10.031; Looi CY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023640; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Mc Gee MM, 2002, FEBS LETT, V515, P66, DOI 10.1016/S0014-5793(02)02440-7; MORRIS LJ, 1969, LIPIDS, V4, P50, DOI 10.1007/BF02531794; Niessen WMA, 1998, J CHROMATOGR A, V794, P407, DOI 10.1016/S0021-9673(97)01112-6; Oh SY, 2007, MOL CANCER THER, V6, P2178, DOI 10.1158/1535-7163.MCT-07-0111; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; Pan MH, 2010, J AGR FOOD CHEM, V58, P226, DOI 10.1021/jf903067g; Paris F, 2002, MOL CELL ENDOCRINOL, V193, P43, DOI 10.1016/S0303-7207(02)00094-1; Pedersen MM, 2009, PHYTOCHEMISTRY, V70, P601, DOI 10.1016/j.phytochem.2009.02.005; Purnima A, 2009, INDIAN J PHARM SCI, V71, P461, DOI 10.4103/0250-474X.57302; Rabe T, 2002, J ETHNOPHARMACOL, V80, P91, DOI 10.1016/S0378-8741(02)00010-7; Sarkar FH, 2007, ACTA PHARMACOL SIN, V28, P1305, DOI 10.1111/j.1745-7254.2007.00689.x; Scartezzini P, 2000, J ETHNOPHARMACOL, V71, P23, DOI 10.1016/S0378-8741(00)00213-0; Sharma S, 1991, J Hyg Epidemiol Microbiol Immunol, V35, P157; Shimizu S, 1996, ONCOGENE, V13, P21; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Sims AH, 2007, NAT CLIN PRACT ONCOL, V4, P516, DOI 10.1038/ncponc0908; SINGHAL K C, 1992, Indian Journal of Experimental Biology, V30, P546; Tan AR, 2002, SEMIN ONCOL, V29, P77, DOI 10.1053/sonc.2002.34059; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VOLKOV SK, 1994, J CHROMATOGR B, V660, P405, DOI 10.1016/0378-4347(94)00290-8; Wang Q, 2011, CURR MED CHEM, V18, P2025, DOI 10.2174/092986711795590110; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; Weir NM, 2007, CANCER BIOL THER, V6, P178, DOI 10.4161/cbt.6.2.3577; Wohlbold L, 2006, CELL CYCLE, V5, P546, DOI 10.4161/cc.5.5.2541; Wong WF, 2012, J IMMUNOL, V188, P5408, DOI 10.4049/jimmunol.1102991; Wong YH, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/164689; Woo HJ, 2011, J ETHNOPHARMACOL, V135, P626, DOI 10.1016/j.jep.2011.03.067; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yesilada E, 2004, J ETHNOPHARMACOL, V95, P213, DOI 10.1016/j.jep.2004.07.021; Yu R, 2006, J INT MED RES, V34, P231, DOI 10.1177/147323000603400301	67	100	101	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2013	8	2							e56643	10.1371/journal.pone.0056643	http://dx.doi.org/10.1371/journal.pone.0056643			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	093IE	23437193	gold, Green Published, Green Accepted			2023-01-03	WOS:000315184200125
J	Guasch, L; Sala, E; Mulero, M; Valls, C; Salvado, MJ; Pujadas, G; Garcia-Vallve, S				Guasch, Laura; Sala, Esther; Mulero, Miquel; Valls, Cristina; Josepa Salvado, Maria; Pujadas, Gerard; Garcia-Vallve, Santiago			Identification of PPARgamma Partial Agonists of Natural Origin (II): In Silico Prediction in Natural Extracts with Known Antidiabetic Activity	PLOS ONE			English	Article							INDUCED-DIABETIC-RATS; HYPOGLYCEMIC ACTIVITY; CRYPTOLEPIS-SANGUINOLENTA; ANGELICA-KEISKEI; PPAR-GAMMA; SCUTELLARIA-BAICALENSIS; SALVIA-MILTIORRHIZA; MEDICINAL-PLANTS; DRUG DISCOVERY; GLUCOSE-UPTAKE	Background: Natural extracts have played an important role in the prevention and treatment of diseases and are important sources for drug discovery. However, to be effectively used in these processes, natural extracts must be characterized through the identification of their active compounds and their modes of action. Methodology/Principal Findings: From an initial set of 29,779 natural products that are annotated with their natural source and using a previously developed virtual screening procedure (carefully validated experimentally), we have predicted as potential peroxisome proliferators-activated receptor gamma (PPAR gamma) partial agonists 12 molecules from 11 extracts known to have antidiabetic activity. Six of these molecules are similar to molecules with described antidiabetic activity but whose mechanism of action is unknown. Therefore, it is plausible that these 12 molecules could be the bioactive molecules responsible, at least in part, for the antidiabetic activity of the extracts containing them. In addition, we have also identified as potential PPAR gamma partial agonists 10 molecules from 16 plants with undescribed antidiabetic activity but that are related (i.e., they are from the same genus) to plants with known antidiabetic properties. None of the 22 molecules that we predict as PPAR gamma partial agonists show chemical similarity with a group of 211 known PPAR gamma partial agonists obtained from the literature. Conclusions/Significance: Our results provide a new hypothesis about the active molecules of natural extracts with antidiabetic properties and their mode of action. We also suggest plants with undescribed antidiabetic activity that may contain PPAR gamma partial agonists. These plants represent a new source of potential antidiabetic extracts. Consequently, our work opens the door to the discovery of new antidiabetic extracts and molecules that can be of use, for instance, in the design of new antidiabetic drugs or functional foods focused towards the prevention/treatment of type 2 Diabetes Mellitus.	[Guasch, Laura; Sala, Esther; Mulero, Miquel; Valls, Cristina; Josepa Salvado, Maria; Pujadas, Gerard; Garcia-Vallve, Santiago] Univ Rovira & Virgili, Dept Bioquim & Biotecnol, Grp Recerca Nutrigenom, Tarragona, Catalonia, Spain; [Pujadas, Gerard; Garcia-Vallve, Santiago] CEICS, TECNIO, CTNS, Reus, Catalonia, Spain	Universitat Rovira i Virgili	Garcia-Vallve, S (corresponding author), Univ Rovira & Virgili, Dept Bioquim & Biotecnol, Grp Recerca Nutrigenom, Tarragona, Catalonia, Spain.	santi.garcia-vallve@urv.cat	PUJADAS, GERARD/W-9348-2019; Valls-Bautista, Cristina/K-8769-2014; Garcia-Vallve, Santi/A-4226-2008; Pujadas, Gerard/B-1457-2010; Mulero, Miquel/L-4672-2014; Salvado, M. Josepa/B-6062-2015; Sala, Esther/AAB-4997-2022	PUJADAS, GERARD/0000-0003-2598-8089; Valls-Bautista, Cristina/0000-0001-5583-5695; Garcia-Vallve, Santi/0000-0002-0348-7497; Pujadas, Gerard/0000-0003-2598-8089; Mulero, Miquel/0000-0003-2545-2065; Salvado, M. Josepa/0000-0003-3883-3326; Guasch, Laura/0000-0003-4990-7765; Sala, Esther/0000-0002-5149-1992	"Ministerio de Educacion y Ciencia'' of the Spanish Government [AGL2008-00387/ALI, AGL2011-25831/ALI]; Generalitat de Catalunya [ACC1O (TECCT11-1-0012)]; XRQTC grant from the "Generalitat de Catalunya''	"Ministerio de Educacion y Ciencia'' of the Spanish Government(Spanish Government); Generalitat de Catalunya(Generalitat de Catalunya); XRQTC grant from the "Generalitat de Catalunya''	This study was supported by grants AGL2008-00387/ALI and AGL2011-25831/ALI from the "Ministerio de Educacion y Ciencia'' of the Spanish Government and the ACC1O (TECCT11-1-0012) program and XRQTC grant from the "Generalitat de Catalunya''. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agbor Gabriel A, 2007, Pak J Biol Sci, V10, P537, DOI 10.3923/pjbs.2007.537.544; ARAI K, 1981, CHEM PHARM BULL, V29, P1005; Arredondo MF, 2004, J ETHNOPHARMACOL, V91, P13, DOI 10.1016/j.jep.2003.11.012; Aslan M, 2007, J ETHNOPHARMACOL, V109, P54, DOI 10.1016/j.jep.2006.07.001; BASNET P, 1995, PLANTA MED, V61, P402, DOI 10.1055/s-2006-958124; BASNET P, 1994, PLANTA MED, V60, P507, DOI 10.1055/s-2006-959560; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Bierer DE, 1998, J MED CHEM, V41, P2754, DOI 10.1021/jm970735n; BLASKO G, 1988, J ORG CHEM, V53, P6113, DOI 10.1021/jo00261a026; Bnouham M, 2006, INT J DIABETES METAB, V14, P1; BRIGGS LH, 1950, J CHEM SOC, P2376, DOI 10.1039/jr9500002376; Budantsev, 1993, CHEM NAT COMPD, V29, P133, DOI [DOI 10.1007/BF00631041, 10.1007/BF00631041]; CHANDRASEKAR B, 1990, INDIAN J EXP BIOL, V28, P616; Chang FR, 1998, PHYTOCHEMISTRY, V49, P2015, DOI 10.1016/S0031-9422(98)00376-8; Choi JH, 2011, NATURE, V477, P477, DOI 10.1038/nature10383; Choi JH, 2010, NATURE, V466, P451, DOI 10.1038/nature09291; Christensen KB, 2009, PHYTOTHER RES, V23, P1316, DOI 10.1002/ptr.2782; Cousins KR, 2011, J AM CHEM SOC, V133, P8388, DOI 10.1021/ja204075s; Dewi Rizna T, 2007, Pak J Biol Sci, V10, P3131, DOI 10.3923/pjbs.2007.3131.3135; Dey D, 2003, METABOLISM, V52, P1012, DOI 10.1016/S0026-0495(03)00152-5; Dixon SL, 2006, J COMPUT AID MOL DES, V20, P647, DOI 10.1007/s10822-006-9087-6; Duan JX, 2010, J MOL GRAPH MODEL, V29, P157, DOI 10.1016/j.jmgm.2010.05.008; Eidi M, 2005, J ETHNOPHARMACOL, V100, P310, DOI 10.1016/j.jep.2005.03.008; El-Lakany AM, 2003, PHARMAZIE, V58, P75; Enoki T, 2007, J AGR FOOD CHEM, V55, P6013, DOI 10.1021/jf070720q; Fakhrudin N, 2010, MOL PHARMACOL, V77, P559, DOI 10.1124/mol.109.062141; Feldman PL, 2008, CURR TOP MED CHEM, V8, P728, DOI 10.2174/156802608784535084; FERNANDO MR, 1990, GEN PHARMACOL, V21, P779, DOI 10.1016/0306-3623(90)91033-N; GHOSAL S, 1980, PHYTOCHEMISTRY, V19, P123, DOI 10.1016/0031-9422(80)85027-8; GLOMBITZA KW, 1981, TETRAHEDRON, V37, P3861, DOI 10.1016/S0040-4020(01)98884-2; GOMEZ F, 1985, PHYTOCHEMISTRY, V24, P1057, DOI 10.1016/S0031-9422(00)83182-9; Grover JK, 2002, J ETHNOPHARMACOL, V81, P81, DOI 10.1016/S0378-8741(02)00059-4; Guasch L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050816; Guasch L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044971; Guasch L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044972; Guasch L, 2012, J MOL GRAPH MODEL, V36, P1, DOI 10.1016/j.jmgm.2012.03.001; Guasch L, 2011, J COMPUT AID MOL DES, V25, P717, DOI 10.1007/s10822-011-9446-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HANSEL R, 1980, PHYTOCHEMISTRY, V19, P639, DOI 10.1016/0031-9422(80)87030-0; Huang N, 2006, J MED CHEM, V49, P6789, DOI 10.1021/jm0608356; IKESHIRO Y, 1991, PHYTOCHEMISTRY, V30, P2791, DOI 10.1016/0031-9422(91)85147-R; IKESHIRO Y, 1989, PHYTOCHEMISTRY, V28, P3139, DOI 10.1016/0031-9422(89)80294-8; Jahan N, 2001, HETEROCYCLES, V55, P1951; JAKUPOVIC J, 1986, PHYTOCHEMISTRY, V25, P1133, DOI 10.1016/S0031-9422(00)81569-1; JIMENEZ J, 1986, PLANTA MED, P260, DOI 10.1055/s-2007-969146; Jung SH, 2009, PHYTOMEDICINE, V16, P327, DOI 10.1016/j.phymed.2008.12.017; Kamperdick C, 1997, PHYTOCHEMISTRY, V45, P1049, DOI 10.1016/S0031-9422(97)00059-9; Kelley LA, 1996, PROTEIN ENG, V9, P1063, DOI 10.1093/protein/9.11.1063; KIMURA Y, 1991, AGR BIOL CHEM TOKYO, V55, P2673, DOI 10.1080/00021369.1991.10870996; Kinoshita T, 1996, CHEM PHARM BULL, V44, P1208, DOI 10.1248/cpb.44.1208; Lagorce D, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-396; LAMELA M, 1989, J ETHNOPHARMACOL, V27, P35, DOI 10.1016/0378-8741(89)90075-5; Lenta BN, 2007, CHEM PHARM BULL, V55, P464, DOI 10.1248/cpb.55.464; Li M, 2001, J NAT PROD, V64, P971, DOI 10.1021/np000350z; Likhitwitayawuid K, 2000, PLANTA MED, V66, P275, DOI 10.1055/s-2000-8656; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; Luo J, 1998, DIABETIC MED, V15, P367, DOI 10.1002/(SICI)1096-9136(199805)15:5<367::AID-DIA576>3.0.CO;2-G; Matsuura M, 2001, PLANTA MED, V67, P230, DOI 10.1055/s-2001-12011; MESQUITA AAL, 1986, PHYTOCHEMISTRY, V25, P1255, DOI 10.1016/S0031-9422(00)81599-X; Michihiro F, 2006, FOODS FOOD INGRED J, V211, P141; Modak M, 2007, J CLIN BIOCHEM NUTR, V40, P163, DOI 10.3164/jcbn.40.163; Negi JS, 2010, NAT PROD COMMUN, V5, P907; Nishimura R, 2007, BIOL PHARM BULL, V30, P1878, DOI 10.1248/bpb.30.1878; Nishioka T, 1998, J NAT PROD, V61, P1413, DOI 10.1021/np980163p; Pavana P, 2007, J ENVIRON BIOL, V28, P833; PERFUMI M, 1991, J ETHNOPHARMACOL, V34, P135, DOI 10.1016/0378-8741(91)90030-H; Petersen RK, 2011, J COMPUT AID MOL DES, V25, P107, DOI 10.1007/s10822-010-9398-5; Pourcet Benoit, 2006, Expert Opin Emerg Drugs, V11, P379, DOI 10.1517/14728214.11.3.379; Prabhakar PK, 2011, CHIN J INTEGR MED, V17, P563, DOI 10.1007/s11655-011-0810-3; Puhl AC, 2012, MOL PHARMACOL, V81, P788, DOI 10.1124/mol.111.076216; Rao YK, 2004, PHYTOCHEMISTRY, V65, P2317, DOI 10.1016/j.phytochem.2004.05.008; Sala E, 2011, EUR J MED CHEM, V46, P6098, DOI 10.1016/j.ejmech.2011.09.022; Sala E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016903; Schuster D, 2010, CURR PHARM DESIGN, V16, P1666, DOI 10.2174/138161210791164072; Sharaf MHM, 1996, J HETEROCYCLIC CHEM, V33, P789, DOI 10.1002/jhet.5570330343; SHARAF MHM, 1995, MAGN RESON CHEM, V33, P767, DOI 10.1002/mrc.1260331003; Shirwaikar A, 2004, J ETHNOPHARMACOL, V91, P171, DOI 10.1016/j.jep.2003.12.017; Simmonds MSJ, 2005, TRADITIONAL MED MODE, P19; Stewart M, 1997, AUST J CHEM, V50, P341, DOI 10.1071/C96120; Tan Y, 2011, CLIN SCI, V120, P297, DOI 10.1042/CS20100441; Tian LY, 2010, PHYTOMEDICINE, V17, P533, DOI 10.1016/j.phymed.2009.10.007; Ulubelen A, 2002, PLANTA MED, V68, P818, DOI 10.1055/s-2002-34408; Waisundara VY, 2008, AM J CHINESE MED, V36, P517, DOI 10.1142/S0192415X08005953; Weidner C, 2012, P NATL ACAD SCI USA, V109, P7257, DOI 10.1073/pnas.1116971109; Wibudi Aris, 2008, Acta Med Indones, V40, P63; Yeo J, 2011, CHIN MED-UK, V6, DOI 10.1186/1749-8546-6-10; Zhang Y, 2009, ACTA PHARMACOL SIN, V30, P333, DOI 10.1038/aps.2009.5; Zsoldos Z, 2007, J MOL GRAPH MODEL, V26, P198, DOI 10.1016/j.jmgm.2006.06.002	88	22	25	0	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2013	8	2							e55889	10.1371/journal.pone.0055889	http://dx.doi.org/10.1371/journal.pone.0055889			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	092WJ	23405231	Green Submitted, Green Published, gold			2023-01-03	WOS:000315153400176
J	Fishbane, S; Schiller, B; Locatelli, F; Covic, AC; Provenzano, R; Wiecek, A; Levin, NW; Kaplan, M; Macdougall, IC; Francisco, C; Mayo, MR; Polu, KR; Duliege, AM; Besarab, A				Fishbane, Steven; Schiller, Brigitte; Locatelli, Francesco; Covic, Adrian C.; Provenzano, Robert; Wiecek, Andrzej; Levin, Nathan W.; Kaplan, Mark; Macdougall, Iain C.; Francisco, Carol; Mayo, Martha R.; Polu, Krishna R.; Duliege, Anne-Marie; Besarab, Anatole		EMERALD Study Grp	Peginesatide in Patients with Anemia Undergoing Hemodialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC KIDNEY-DISEASE; RECOMBINANT-HUMAN-ERYTHROPOIETIN; STAGE RENAL-DISEASE; RED-CELL APLASIA; RECEIVING HEMODIALYSIS; ASSOCIATION; HEMATIDE; EPOETIN; TRIAL; AGENT	Background Peginesatide, a synthetic peptide-based erythropoiesis-stimulating agent (ESA), is a potential therapy for anemia in patients with advanced chronic kidney disease. Methods We conducted two randomized, controlled, open-label studies (EMERALD 1 and EMERALD 2) involving patients undergoing hemodialysis. Cardiovascular safety was evaluated by analysis of an adjudicated composite safety end point - death from any cause, stroke, myocardial infarction, or serious adverse events of congestive heart failure, unstable angina, or arrhythmia - with the use of pooled data from the two EMERALD studies and two studies involving patients not undergoing dialysis. In the EMERALD studies, 1608 patients received peginesatide once monthly or continued to receive epoetin one to three times a week, with the doses adjusted as necessary to maintain a hemoglobin level between 10.0 and 12.0 g per deciliter for 52 weeks or more. The primary efficacy end point was the mean change from the baseline hemoglobin level to the mean level during the evaluation period; noninferiority was established if the lower limit of the two-sided 95% confidence interval was -1.0 g per deciliter or higher in the comparison of peginesatide with epoetin. The aim of evaluating the composite safety end point in the pooled cohort was to exclude a hazard ratio with peginesatide relative to the comparator ESA of more than 1.3. Results In an analysis involving 693 patients from EMERALD 1 and 725 from EMERALD 2, peginesatide was noninferior to epoetin in maintaining hemoglobin levels (mean between-group difference, -0.15 g per deciliter; 95% confidence interval [CI], -0.30 to -0.01 in EMERALD 1; and 0.10 g per deciliter; 95% CI, -0.05 to 0.26 in EMERALD 2). The hazard ratio for the composite safety end point was 1.06 (95% CI, 0.89 to 1.26) with peginesatide relative to the comparator ESA in the four pooled studies (2591 patients) and 0.95 (95% CI, 0.77 to 1.17) in the EMERALD studies. The proportions of patients with adverse and serious adverse events were similar in the treatment groups in the EMERALD studies. The cardiovascular safety of peg-in-es-a-tide was similar to that of the comparator ESA in the pooled cohort. Conclusions Peginesatide, administered monthly, was as effective as epoetin, administered one to three times per week, in maintaining hemoglobin levels in patients undergoing hemodialysis. (Funded by Affymax and Takeda Pharmaceutical; ClinicalTrials.gov numbers, NCT00597753 [EMERALD 1], NCT00597584 [EMERALD 2], NCT00598273 [PEARL 1], and NCT00598442 [PEARL 2].)	[Fishbane, Steven] Hofstra N Shore LIJ Sch Med, Great Neck, NY 11021 USA; [Schiller, Brigitte] Satellite Healthcare, San Jose, CA USA; [Francisco, Carol; Mayo, Martha R.; Polu, Krishna R.; Duliege, Anne-Marie] Affymax, Palo Alto, CA USA; [Locatelli, Francesco] A Manzoni Hosp, Dept Nephrol Dialysis & Renal Transplant, Lecce, Italy; [Covic, Adrian C.] Dr CI Parhon, Spitalul Clin, Iasi, Romania; [Provenzano, Robert] Henry Ford Hosp, St Clair Specialty Phys, Detroit, MI 48202 USA; [Besarab, Anatole] Henry Ford Hosp, Henry Ford Hlth Syst, Detroit, MI 48202 USA; [Besarab, Anatole] Wayne State Univ, Sch Med, Detroit, MI USA; [Wiecek, Andrzej] Med Univ Silesia, Katowice, Poland; [Levin, Nathan W.] Renal Res Inst, New York, NY USA; [Kaplan, Mark] Nephrol Associates, Nashville, TN USA; [Macdougall, Iain C.] Kings Coll Hosp, Renal Unit, London, England	Hofstra University; Northwell Health; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Wayne State University; Medical University Silesia; Renal Research Institute; King's College Hospital NHS Foundation Trust; King's College Hospital	Fishbane, S (corresponding author), Hofstra N Shore LIJ Sch Med, 100 Community Dr,2nd Fl, Great Neck, NY 11021 USA.	sfishbane@nshs.edu	Besarab, Anatole/AAP-2569-2020; Covic, Adrian/G-5017-2016; Schiller, Brigitte/AAW-3230-2021; Portoles, Jose/C-3337-2013	Covic, Adrian/0000-0002-9985-2486; Portoles, Jose/0000-0002-2114-1385; phanish, mysore/0000-0001-8402-8286; MacPhee, Iain/0000-0003-2322-7622	Affymax and Takeda Pharmaceutical; Rockwell Medical; Akebia Therapeutics; Amgen; Roche; Janssen; Pharmacosmos; Fresenius Medical Care; Abbott; Boehringer Ingelheim; RoFAR; Aethlon Medical; FibroGen	Affymax and Takeda Pharmaceutical; Rockwell Medical; Akebia Therapeutics; Amgen(Amgen); Roche(Roche Holding); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Pharmacosmos; Fresenius Medical Care; Abbott(Abbott Laboratories); Boehringer Ingelheim(Boehringer Ingelheim); RoFAR; Aethlon Medical; FibroGen	Supported by Affymax and Takeda Pharmaceutical.; Dr. Fishbane reports receiving consulting fees from Affymax, Rockwell Medical, and Akebia Therapeutics and receiving grant support on behalf of his institution from Affymax and Rockwell Medical; Dr. Schiller, receiving consulting and lecture fees from Affymax and owning stock in Affymax; Dr. Locatelli, receiving payment for board membership from Affymax, Amgen, Roche, Takeda Pharmaceutical, Janssen, and Sandoz and lecture fees from Amgen, Roche, Janssen, Takeda Pharmaceutical, Pharmacosmos, and Fresenius Medical Care; Dr. Provenzano, owning stock in DaVita; Dr. Wiecek, receiving payment for board membership from Affymax, Sandoz, Boehringer Ingelheim, and Abbott, consulting fees from Affymax, Abbott, and Boehringer Ingelheim, and lecture fees from Amgen, Abbott, Boehringer Ingelheim, and Roche; Dr. Levin, receiving consulting fees from RoFAR, Roche, Aethlon Medical, FibroGen, and Affymax, being an employee of the Renal Research Institute, and owning stock in Fresenius Medical Care North America; Dr. Kaplan, being a former employee of Fresenius Medical Care North America and DSI Renal and a current employee of DaVita and Nephrology Associates and receiving payment on behalf of his employer, Nephrology Associates, for his participation in studies with Amgen, Abbott, Otsuka, Reata Pharmaceuticals, Mitsubishi, Keryx Biopharmaceuticals, Rockwell Medical, Celgene, Dynavax Technologies, Roche, and Merck; Dr. Macdougall, receiving payment for board membership from Affymax; Drs. Francisco, Mayo, Polu and Duliege, being employees of and owning stock in Affymax; and Dr. Besarab, receiving consulting fees, reimbursement for travel expenses, and payment for the development of educational presentations from Affymax and Takeda Pharmaceutical and grant support on behalf of his institution from Affymax and serving as an expert witness at the Food and Drug Administration on behalf of Affymax regarding anemia and kidney diseases. No other potential conflict of interest relevant to this article was reported.	[Anonymous], 2010, 2010 ANN REP DIAL OU; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Besarab A, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-95; Drueke TB, 2006, NEW ENGL J MED, V355, P2071, DOI 10.1056/NEJMoa062276; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; LAUPACIS A, 1990, BMJ-BRIT MED J, V300, P573; Macdougall Iain C, 2005, Curr Hematol Rep, V4, P436; Macdougall IC, 2013, NEW ENGL J MED, V368, P320, DOI 10.1056/NEJMoa1203166; Macdougall IC, 2011, CLIN J AM SOC NEPHRO, V6, P2579, DOI 10.2215/CJN.10831210; Macdougall IC, 2009, NEW ENGL J MED, V361, P1848, DOI 10.1056/NEJMoa074037; Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845; Postorino M, 2007, NEPHROL DIAL TRANSPL, V22, P1377, DOI 10.1093/ndt/gfl813; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Stead RB, 2006, BLOOD, V108, P1830, DOI 10.1182/blood-2006-04-015818; WINEARLS CG, 1995, NEPHROL DIAL TRANSPL, V10, P3, DOI 10.1093/ndt/10.supp2.3; Woodburn KW, 2007, EXP HEMATOL, V35, P1201, DOI 10.1016/j.exphem.2007.05.007; Woodburn KW, 2012, XENOBIOTICA, V42, P660, DOI 10.3109/00498254.2011.649310	17	60	61	0	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 24	2013	368	4					307	319		10.1056/NEJMoa1203165	http://dx.doi.org/10.1056/NEJMoa1203165			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	075KX	23343061	Green Published			2023-01-03	WOS:000313885900004
J	Zhou, QC; Sheng, GH				Zhou, Quancheng; Sheng, Guihua			Pyrolytic and Kinetic Characteristics of the Thermal Decomposition of Perilla frutescens Polysaccharide	PLOS ONE			English	Article							TG-FTIR; CAKE	The thermal decomposition of Perilla frutescens polysaccharide was examined by thermogravimetry, differential thermogravimetry, and differential thermal analysis. The results showed that the mass loss of the substance proceeded in three steps. The first stage can be attributed to the expulsion of the water from ambient temperature to 182 degrees C. The second stage corresponded to devolatilization from 182 degrees C to 439 degrees C. The residue slowly degraded in the third stage. The weight loss in air is faster than that in nitrogen, because the oxygen in air accelerated the pyrolytic reaction speed reaction. The heating rate significantly affected the pyrolysis of the sample. Similar activation energies of the degradation process (210-211 kJ mol(-1)) were obtained by the FWO, KAS, and Popescu techniques. According to Popescu mechanism functions, the possible kinetic model was estimated to be Avrami-Erofeev 20 g(alpha) = [-ln(1-alpha)](4).	[Zhou, Quancheng] Shandong Univ Technol, Sch Agr Engn & Food Sci, Zibo, Peoples R China; [Sheng, Guihua] Shandong Univ Technol, Sch Life Sci, Zibo, Peoples R China	Shandong University of Technology; Shandong University of Technology	Zhou, QC (corresponding author), Shandong Univ Technol, Sch Agr Engn & Food Sci, Zibo, Peoples R China.	zhouquancheng@126.com		Sheng, Guihua/0000-0003-3933-7930				Adriana V.M., 2011, BIOMA BIOEN, V35, P1121; Beis SH, 2002, RENEW ENERG, V26, P21, DOI 10.1016/S0960-1481(01)00109-4; Brebu M, 2011, CELL CHEM TECHNOL, V45, P43; Cabrales L, 2010, J THERM ANAL CALORIM, V102, P485, DOI 10.1007/s10973-010-0911-9; Feng XB, 2011, J MICROBIOL METH, V84, P359, DOI 10.1016/j.mimet.2010.12.012; Hirose S, 2002, J THERM ANAL CALORIM, V70, P853, DOI 10.1023/A:1022212421525; Karaosmanoglu F, 2001, ENERG SOURCE, V23, P377; KISSINGER HE, 1957, ANAL CHEM, V29, P1702, DOI 10.1021/ac60131a045; Lerdkanchanaporn S, 1998, THERMOCHIM ACTA, V324, P25, DOI 10.1016/S0040-6031(98)00520-6; Li DM, 2011, BIOMASS BIOENERG, V35, P1765, DOI 10.1016/j.biombioe.2011.01.011; Li DM, 2010, CHEM ENG RES DES, V88, P647, DOI 10.1016/j.cherd.2009.10.011; Liang J, 2008, THERMOSETTING RESIN, V23, P11; Liu Q, 2008, J ANAL APPL PYROL, V82, P170, DOI 10.1016/j.jaap.2008.03.007; Liu Y., 2008, J CHANGSHA U TECH NA, V5, P1; Lopez FA, 2008, J THERM ANAL CALORIM, V91, P633, DOI 10.1007/s10973-007-8321-3; Orfao JJM, 1999, FUEL, V78, P349, DOI 10.1016/S0016-2361(98)00156-2; OZAWA T, 1965, B CHEM SOC JPN, V38, P1881, DOI 10.1246/bcsj.38.1881; Pappa A, 2003, J ANAL APPL PYROL, V67, P221, DOI 10.1016/S0165-2370(02)00063-3; Park HY, 2010, FOOD CHEM, V119, P724, DOI 10.1016/j.foodchem.2009.07.020; Peiretti PG, 2011, LIVEST SCI, V138, P118, DOI 10.1016/j.livsci.2010.12.007; [彭云云 PENG Yunyun], 2009, [化工进展, Chemical Industry and Engineering Progress], V28, P1478; Popescu C, 1996, THERMOCHIM ACTA, V285, P309, DOI 10.1016/0040-6031(96)02916-4; Putun AE, 2002, ENERGY, V27, P703, DOI 10.1016/S0360-5442(02)00015-4; Putun E, 2006, BIORESOURCE TECHNOL, V97, P701, DOI 10.1016/j.biortech.2005.04.005; Rao TR, 1998, ENERGY, V23, P973, DOI 10.1016/S0360-5442(98)00037-1; Rychly J, 2002, POLYM DEGRAD STABIL, V78, P357, DOI 10.1016/S0141-3910(02)00187-8; Sensoz S, 2008, BIORESOURCE TECHNOL, V99, P5492, DOI 10.1016/j.biortech.2007.10.046; She ZG, 2003, CHINESE J ORG CHEM, V23, P1149; Shen DK, 2010, J ANAL APPL PYROL, V87, P199, DOI 10.1016/j.jaap.2009.12.001; Wang X., 2009, FOOD SCI, V44, P44; Xiujuan Guo, 2011, Recent Researches in Energy & Environment. 6th IASME - WSEAS International Conference on Energy and Environment (EE '11), P137; Ye NH, 2010, PLOS ONE, P126; Zhao G, 2010, NEUROCHEM INT, V56, P168, DOI 10.1016/j.neuint.2009.09.015; Zhou QC, 2012, ADV MAT RES, V518-523, P3904; Zhu JF, 2011, J ANHUI AGR SCI, V39, P266	35	2	3	0	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 26	2012	7	12							e52597	10.1371/journal.pone.0052597	http://dx.doi.org/10.1371/journal.pone.0052597			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	071TV	23300715	Green Published, gold, Green Submitted			2023-01-03	WOS:000313618800108
J	Diguisto, C; Le Ray, C; Maillard, F; Khoshnood, B; Verspyck, E; Perrotin, F; Goffinet, F				Diguisto, Caroline; Le Ray, Camille; Maillard, Francoise; Khoshnood, Babak; Verspyck, Eric; Perrotin, Franck; Goffinet, Francois		EVAPRIMA Grp	Individual and Organisational Determinants Associated with Maintenance Tocolysis in the Management of Preterm Labour: A Multilevel Analysis	PLOS ONE			English	Article							ORAL TERBUTALINE; CONTROLLED-TRIAL; CLINICAL-TRIAL; NIFEDIPINE; EFFICACY; DELIVERY; PLACEBO; BIRTH	Background: Clinical guidelines do not recommend maintenance tocolysis for the management of preterm labour. The French national survey EVAPRIMA revealed it was administered to more than 50% of women hospitalised for preterm labour. Our aim was to identify the individual and organisational determinants associated with maintenance tocolysis. Methods: The study was a secondary analysis of the prospective population-based EVAPRIMA study database. Population study included every women hospitalised for preterm labour and at risk of receiving maintenance tocolysis, over a one month period, in 99 randomly selected French maternity units. Main outcome was the prescription of maintenance tocolysis. The association between maintenance tocolysis and individual (maternal or obstetrical) and organisational determinants were evaluated with multilevel analysis. Results: Of the 531 women included, 68.9% (95% CI 0.65-0.73) received maintenance tocolysis. The only individual factor associated with maintenance tocolysis was gestational age at admission; the rate of maintenance tocolysis was higher among women hospitalised before 32 weeks of gestation. The significantly different rates between maternity units demonstrated the existence of a maternity unit effect. Maintenance tocolysis was also associated with organisational determinants and was more frequent in level 1 (ORa = 6.54[2.21-19.40]) and level 2 maternity units (ORa = 3.68[1.28-10.59]), in units with less than 1500 deliveries/year (ORa = 5.27[4.43-19.44]), and in specific areas of France. Conclusion: A maternity unit effect, explained partly by the organisational characteristics of the units, plays a major role in the practice of maintenance tocolysis. Widespread dissemination of these results might improve adherence to clinical guidelines.	[Diguisto, Caroline; Le Ray, Camille; Maillard, Francoise; Khoshnood, Babak; Goffinet, Francois] Univ Paris 06, Epidemiol Res Unit Perinatal Hlth & Womens & Chil, INSERM, UMR S953, Paris, France; [Le Ray, Camille; Goffinet, Francois] Univ Paris 05, Assistance Publ Hop Paris, Cochin St Vincent de Paul Hosp, Dept Obstet & Gynaecol, Paris, France; [Verspyck, Eric] Univ Hosp Rouen, Dept Obstet & Gynaecol, Rouen, France; [Diguisto, Caroline; Perrotin, Franck] Univ Tours, Univ Hosp Tours, Dept Obstet & Gynaecol, Tours, France; [Le Ray, Camille; Goffinet, Francois] Premup Fdn, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; CHU de Rouen; CHU Tours; Universite de Tours; UDICE-French Research Universities; Universite Paris Cite	Diguisto, C (corresponding author), Univ Paris 06, Epidemiol Res Unit Perinatal Hlth & Womens & Chil, INSERM, UMR S953, Paris, France.	carolinediguisto@gmail.com	Perrotin, Franck/AAL-8833-2021; Khoshnood, Babak/N-9096-2017	Perrotin, Franck/0000-0001-9694-6658; GOFFINET, Francois/0000-0001-9643-0299; Le Ray, Camille/0000-0003-0891-1063; Khoshnood, Babak/0000-0002-4031-4915	Ferring Company	Ferring Company(Ferring Pharmaceuticals)	The EVAPRIMA survey was supported by the Ferring Company. The funders had no role in the study design, data collection, data interpretation or the writing of the report.	Blondel B, 2006, J Gynecol Obstet Biol Reprod (Paris), V35, P373; Carr DB, 1999, AM J OBSTET GYNECOL, V181, P822, DOI 10.1016/S0002-9378(99)70308-X; D'Ercole C, 2002, J GYNECOL OBST BIO R, V31, pS84; Dodd JM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003927.pub2; Gaunekar NN, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004071; Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4; Grol R, 2003, LANCET, V362, P1225, DOI 10.1016/S0140-6736(03)14546-1; Gyetvai K, 1999, OBSTET GYNECOL, V94, P869, DOI 10.1016/S0029-7844(99)00329-4; HOW HY, 1995, AM J OBSTET GYNECOL, V173, P1518, DOI 10.1016/0002-9378(95)90642-8; Iams JD, 2008, LANCET, V371, P164, DOI 10.1016/S0140-6736(08)60108-7; Larroque B, 2004, ARCH DIS CHILD-FETAL, V89, P139, DOI 10.1136/adc.2002.020396; Lewis R, 1996, AM J OBSTET GYNECOL, V175, P834, DOI 10.1016/S0002-9378(96)80008-1; Lyell DJ, 2008, OBSTET GYNECOL, V112, P1221, DOI 10.1097/AOG.0b013e31818d8386; Nanda K, 2002, COCHRANE DB SYST REV; Papatsonis D, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005938.pub2; Parant O, 2008, BJOG-INT J OBSTET GY, V115, P1538, DOI 10.1111/j.1471-0528.2008.01929.x; PARILLA BV, 1993, AM J OBSTET GYNECOL, V169, P965, DOI 10.1016/0002-9378(93)90036-I; RCOG, 2002, CLIN GUID B; RICCI JM, 1991, AM J OBSTET GYNECOL, V165, P603, DOI 10.1016/0002-9378(91)90293-Z; Roos C, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-42; Saillour-Glenisson F, 2008, REV EPIDEMIOL SANTE, V56, pS207, DOI 10.1016/j.respe.2008.04.006; Sanchez-Ramos L, 1999, AM J OBSTET GYNECOL, V181, P484, DOI 10.1016/S0002-9378(99)70582-X; Slattery MM, 2002, LANCET, V360, P1489, DOI 10.1016/S0140-6736(02)11476-0; Valenzuela GJ, 2000, AM J OBSTET GYNECOL, V182, P1184, DOI 10.1067/mob.2000.105816; Veatch RM, 2000, JAMA-J AM MED ASSOC, V283, P1685, DOI 10.1001/jama.283.13.1685	25	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 13	2012	7	12							e50788	10.1371/journal.pone.0050788	http://dx.doi.org/10.1371/journal.pone.0050788			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	055AH	23272071	gold, Green Published, Green Submitted			2023-01-03	WOS:000312386600014
J	Preissner, S; Dunkel, M; Hoffmann, MF; Preissner, SC; Genov, N; Rong, WW; Preissner, R; Seeger, K				Preissner, Saskia; Dunkel, Mathias; Hoffmann, Michael F.; Preissner, Sarah C.; Genov, Nikolai; Rong, Wen Wei; Preissner, Robert; Seeger, Karlheinz			Drug Cocktail Optimization in Chemotherapy of Cancer	PLOS ONE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN LIVER-MICROSOMES; HUMAN HEPATOCYTES; IFOSFAMIDE ACTIVATION; METABOLIZING-ENZYMES; HEPG2 CELLS; IN-VITRO; CYTOCHROME-P450; DEXAMETHASONE; CYCLOPHOSPHAMIDE	Background: In general, drug metabolism has to be considered to avoid adverse effects and ineffective therapy. In particular, chemotherapeutic drug cocktails strain drug metabolizing enzymes especially the cytochrome P450 family (CYP). Furthermore, a number of important chemotherapeutic drugs such as cyclophosphamide, ifosfamide, tamoxifen or procarbazine are administered as prodrugs and have to be activated by CYP. Therefore, the genetic variability of these enzymes should be taken into account to design appropriate therapeutic regimens to avoid inadequate drug administration, toxicity and inefficiency. Objective: The aim of this work was to find drug interactions and to avoid side effects or ineffective therapy in chemotherapy. Data sources and methods: Information on drug administration in the therapy of leukemia and their drug metabolism was collected from scientific literature and various web resources. We carried out an automated textmining approach. Abstracts of PubMed were filtered for relevant articles using specific keywords. Abstracts were automatically screened for antineoplastic drugs and their synonyms in combination with a set of human CYPs in title or abstract. Results: We present a comprehensive analysis of over 100 common cancer treatment regimens regarding drug-drug interactions and present alternatives avoiding CYP overload. Typical concomitant medication, e. g. antiemetics or antibiotics is a preferred subject to improvement. A webtool, which allows drug cocktail optimization was developed and is publicly available on http://bioinformatics.charite.de/chemotherapy.	[Seeger, Karlheinz] Charite Univ Med Berlin, Dept Pediat, Div Hematol & Oncol, CC17, Berlin, Germany; [Preissner, Saskia] Charite Univ Med Berlin, Dept Operat & Prevent Dent, CC3, Berlin, Germany; [Dunkel, Mathias; Hoffmann, Michael F.; Preissner, Sarah C.; Genov, Nikolai; Rong, Wen Wei; Preissner, Robert] Charite Univ Med Berlin, Inst Physiol, CC2, Struct Bioinformat Grp, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Seeger, K (corresponding author), Charite Univ Med Berlin, Dept Pediat, Div Hematol & Oncol, CC17, Berlin, Germany.	karl.seeger@charite.de	Genov, Nikolai/F-1197-2017	Genov, Nikolai/0000-0002-0443-9841; Dunkel, Mathias/0000-0002-6642-483X; preissner, robert/0000-0002-2407-1087	Berliner Krebsgeselleschaft; DFG Graduate School 1776; BMBF MedSys; EU SynSys	Berliner Krebsgeselleschaft; DFG Graduate School 1776; BMBF MedSys(Federal Ministry of Education & Research (BMBF)); EU SynSys	This work was supported by Berliner Krebsgeselleschaft, DFG Graduate School 1776, BMBF MedSys, EU SynSys. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angalakuditi M, 2011, CLINICOECONOMIC OUTC, V3, P105, DOI 10.2147/CEOR.S21789; Araya Z, 2003, BIOCHEM J, V372, P529, DOI 10.1042/BJ20021651; Bates S, 2010, DRUG DISCOV TODAY, V15, P115, DOI 10.1016/j.drudis.2009.11.001; Baumhakel M, 2001, INT J CLIN PHARM TH, V39, P517; Bazargan A, 2012, EXPERT REV ANTICANC, V12, P393, DOI [10.1586/ERA.12.2, 10.1586/era.12.2]; Bell EC, 2007, ANN PHARMACOTHER, V41, P1819, DOI 10.1345/aph.1K316; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Berners-Lee T, 2001, NATURE, V410, P1023, DOI 10.1038/35074206; Berners-Lee T, 2006, SCIENCE, V313, P769, DOI 10.1126/science.1126902; Bosch TM, 2006, CLIN PHARMACOKINET, V45, P253, DOI 10.2165/00003088-200645030-00003; CHANG TKH, 1993, CANCER RES, V53, P5629; Chang TKH, 1997, CANCER RES, V57, P1946; Colburn Dawn E, 2004, Hematology, V9, P217, DOI 10.1080/10245330410001701585; Davidsen ML, 2008, J PEDIAT HEMATOL ONC, V30, P831, DOI 10.1097/MPH.0b013e3181868570; Dennison JB, 2006, DRUG METAB DISPOS, V34, P1317, DOI 10.1124/dmd.106.009902; Egbelakin A, 2011, PEDIATR BLOOD CANCER, V56, P361, DOI 10.1002/pbc.22845; Engelhardt MB, 2008, BLAUE BUCH; Ferron GM, 1999, J PHARMACOKINET BIOP, V27, P1, DOI 10.1023/A:1020626611479; Flockhart DA., 2007, DRUG INTERACTIONS CY; Gardiner SJ, 2006, PHARMACOL REV, V58, P521, DOI 10.1124/pr.58.3.6; Geer LY, 2010, NUCLEIC ACIDS RES, V38, pD492, DOI 10.1093/nar/gkp858; Gentile DM, 1996, J PHARMACOL EXP THER, V277, P105; Gerbal-Chaloin S, 2001, DRUG METAB DISPOS, V29, P242; Gor PP, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2570; Grishanova A. Y., 2003, Biomeditsinskaya Khimiya, V49, P27; Hukkanen J, 2000, AM J RESP CELL MOL, V22, P360, DOI 10.1165/ajrcmb.22.3.3845; Ingelman-Sundberg Magnus, 2005, Toxicol Appl Pharmacol, V207, P52; Kanou M, 2004, MOL BIOL REP, V31, P151, DOI 10.1023/B:MOLE.0000043582.35335.ff; Krusekopf S, 2003, EUR J PHARMACOL, V466, P7, DOI 10.1016/S0014-2999(03)01481-X; Lampen A, 1995, DRUG METAB DISPOS, V23, P1315; Lindley C, 2002, DRUG METAB DISPOS, V30, P814, DOI 10.1124/dmd.30.7.814; Lund B, 2011, PEDIATR BLOOD CANCER, V56, P551, DOI 10.1002/pbc.22719; May-Manke A, 1999, CANCER CHEMOTH PHARM, V44, P327, DOI 10.1007/s002800050985; Mehta PA, 2004, CURR OPIN HEMATOL, V11, P434, DOI 10.1097/01.moh.0000145671.04385.4f; Miranda SR, 2007, FOOD CHEM TOXICOL, V45, P871, DOI 10.1016/j.fct.2006.11.011; Morrow PK, 2011, CANCER; Nelson David R, 2006, Methods Mol Biol, V320, P1; Niwa T, 2011, CURR DRUG METAB, V12, P549; OERTLE M, 1993, MOL CELL ENDOCRINOL, V91, P201, DOI 10.1016/0303-7207(93)90273-M; Patterson LH, 2002, CURR PHARM DESIGN, V8, P1335, DOI 10.2174/1381612023394502; Potter GA, 2002, BRIT J CANCER, V86, P774, DOI 10.1038/sj.bjc.6600197; Roy P, 1999, DRUG METAB DISPOS, V27, P655; Savas U, 2003, ARCH BIOCHEM BIOPHYS, V409, P212, DOI 10.1016/S0003-9861(02)00499-X; TRZECIAK WH, 1993, MOL ENDOCRINOL, V7, P206, DOI 10.1210/me.7.2.206; Usui T, 2003, BIOL PHARM BULL, V26, P510; Villikka K, 1999, CLIN PHARMACOL THER, V66, P589, DOI 10.1016/S0009-9236(99)90067-X; Vrzal R, 2009, CHEM-BIOL INTERACT, V179, P288, DOI 10.1016/j.cbi.2008.10.035; Xia XY, 2002, ACTA PHARMACOL SIN, V23, P471; ZHOU XJ, 1993, BIOCHEM PHARMACOL, V45, P853, DOI 10.1016/0006-2952(93)90169-W; ZHOUPAN XR, 1993, CANCER RES, V53, P5121	50	10	10	0	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 7	2012	7	12							e51020	10.1371/journal.pone.0051020	http://dx.doi.org/10.1371/journal.pone.0051020			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	050OT	23236419	Green Published, Green Submitted, gold			2023-01-03	WOS:000312064100051
J	Koban, L; Brass, M; Lynn, MT; Pourtois, G				Koban, Leonie; Brass, Marcel; Lynn, Margaret T.; Pourtois, Gilles			Placebo Analgesia Affects Brain Correlates of Error Processing	PLOS ONE			English	Article							ANTERIOR CINGULATE CORTEX; FUNCTIONAL-SIGNIFICANCE; COGNITIVE CONTROL; ERP COMPONENTS; NEURAL SYSTEM; TIME-COURSE; PAIN; ANTICIPATION; POTENTIALS; MECHANISMS	Placebo analgesia (PA) is accompanied by decreased activity in pain-related brain regions, but also by greater prefrontal cortex (PFC) activation, which has been suggested to reflect increases in top-down cognitive control and regulation of pain. Here we test whether PA is associated with altered prefrontal monitoring functions that could adjust nociceptive processing to a mismatch between expected and experienced pain. We recorded event-related potentials to response errors in a go/nogo task during placebo vs. a matched control condition. Error commission was associated with two well-described components, the error-related negativity (ERN) and the error positivity (Pe). Results show that the Pe, but not the ERN, was amplified during placebo analgesia compared to the control condition, with neural sources in the lateral and medial PFC. This Pe increase was driven by participants showing a placebo-induced change in pain tolerance, but was absent in the group of non-responders. Our results shed new light on the possible functional mechanisms underlying PA, suggesting a placebo-induced transient change in prefrontal error monitoring and control functions.	[Koban, Leonie] Univ Geneva, Dept Neurosci, Lab Neurol & Imaging Cognit, CH-1211 Geneva 4, Switzerland; [Koban, Leonie] Univ Geneva, Swiss Ctr Affect Sci, CH-1211 Geneva 4, Switzerland; [Brass, Marcel; Lynn, Margaret T.] Univ Ghent, Dept Expt Psychol, B-9000 Ghent, Belgium; [Pourtois, Gilles] Univ Ghent, Dept Expt Clin & Hlth Psychol, B-9000 Ghent, Belgium	University of Geneva; University of Geneva; Ghent University; Ghent University	Koban, L (corresponding author), Univ Geneva, Dept Neurosci, Lab Neurol & Imaging Cognit, CH-1211 Geneva 4, Switzerland.	leonie.koban@unige.ch	Lynn, Margaret T/O-8723-2016; Koban, Leonie/AAG-5783-2019; Brass, Marcel/J-7082-2012	Lynn, Margaret T/0000-0003-2741-2067; Brass, Marcel/0000-0002-3364-4019; KOBAN, LEONIE/0000-0002-3121-6491; Pourtois, Gilles/0000-0002-5109-2801	Swiss National Science Foundation [51NF40-104897]; Network of European Neuroscience Schools (NENS); European Research Council [200758]; Ghent University (BOF) [05Z01708]; NCCR Affective Sciences	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Network of European Neuroscience Schools (NENS); European Research Council(European Research Council (ERC)European Commission); Ghent University (BOF)(Ghent University); NCCR Affective Sciences	LK was supported by the NCCR Affective Sciences financed by the Swiss National Science Foundation (no 51NF40-104897) and hosted by the University of Geneva, as well as a travel stipend from the Network of European Neuroscience Schools (NENS). GP is supported by grants from the European Research Council (Starting Grant #200758) and Ghent University (BOF Grant #05Z01708). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aarts K, 2010, COGN AFFECT BEHAV NE, V10, P479, DOI 10.3758/CABN.10.4.479; Allan LG, 2002, EVAL HEALTH PROF, V25, P410, DOI 10.1177/0163278702238054; Amanzio M, 2012, HUMAN BRAIN MAPPING; Benedetti F, 2006, PAIN, V121, P133, DOI 10.1016/j.pain.2005.12.016; Bingel U, 2006, PAIN, V120, P8, DOI 10.1016/j.pain.2005.08.027; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Buhle JT, 2012, PSYCHOL SCI; Carter CS, 2007, COGN AFFECT BEHAV NE, V7, P367, DOI 10.3758/CABN.7.4.367; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; Chang LJ, SOCIAL COGN IN PRESS; Cohen JD, 2004, SYSTEMS LEVEL PERSPE; Colloca L, 2005, NAT REV NEUROSCI, V6, P545, DOI 10.1038/nrn1705; DEHAENE S, 1994, PSYCHOL SCI, V5, P303, DOI 10.1111/j.1467-9280.1994.tb00630.x; Dhar M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019578; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; Falkenstein M, 2000, BIOL PSYCHOL, V51, P87, DOI 10.1016/S0301-0511(99)00031-9; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; Hajcak G, 2003, BIOL PSYCHOL, V64, P77, DOI 10.1016/S0301-0511(03)00103-0; Hayden BY, 2011, J NEUROSCI, V31, P4178, DOI 10.1523/JNEUROSCI.4652-10.2011; Herrmann MJ, 2004, COGNITIVE BRAIN RES, V20, P294, DOI 10.1016/j.cogbrainres.2004.02.013; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI [10.1037//0033-295X.109.4.679, 10.1037/0033-295X.109.4.679]; Klein TA, 2007, NEUROIMAGE, V34, P1774, DOI 10.1016/j.neuroimage.2006.11.014; Klucharev V, 2009, NEURON, V61, P140, DOI 10.1016/j.neuron.2008.11.027; Koban L, J COGNITIVE IN PRESS; Koban L, 2012, COGN AFFECT BEHAV NE, V12, P460, DOI 10.3758/s13415-012-0091-0; Koban L, 2010, SOC NEUROSCI-UK, V5, P360, DOI 10.1080/17470911003651547; Krummenacher P, 2010, PAIN, V148, P368, DOI 10.1016/j.pain.2009.09.033; LEHMANN D, 1980, ELECTROEN CLIN NEURO, V48, P609, DOI 10.1016/0013-4694(80)90419-8; Meissner K, 2011, J NEUROSCI, V31, P16117, DOI 10.1523/JNEUROSCI.4099-11.2011; Montague PR, 2007, NEURON, V56, P14, DOI 10.1016/j.neuron.2007.09.020; Morton DL, 2010, BRAIN RES, V1359, P137, DOI 10.1016/j.brainres.2010.08.046; Murray MM, 2008, BRAIN TOPOGR, V20, P249, DOI 10.1007/s10548-008-0054-5; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1111/1469-8986.3850752; Overbeek TJM, 2005, J PSYCHOPHYSIOL, V19, P319, DOI 10.1027/0269-8803.19.4.319; Pascual-Marqui RD, 2002, METHOD FIND EXP CLIN, V24, P5; PASCUALMARQUI RD, 1995, IEEE T BIO-MED ENG, V42, P658, DOI 10.1109/10.391164; Petrovic P, 2002, SCIENCE, V295, P1737, DOI 10.1126/science.1067176; Petrovic P, 2010, PAIN, V150, P59, DOI 10.1016/j.pain.2010.03.011; Pourtois G, 2008, BRAIN TOPOGR, V20, P265, DOI 10.1007/s10548-008-0053-6; Price DD, 2008, ANNU REV PSYCHOL, V59, P565, DOI 10.1146/annurev.psych.59.113006.095941; Price DD, 2007, PAIN, V127, P63, DOI 10.1016/j.pain.2006.08.001; Ridderinkhof KR, 2009, PSYCHOPHYSIOLOGY, V46, P531, DOI 10.1111/j.1469-8986.2009.00790.x; Ridderinkhof KR, 2004, SCIENCE, V306, P443, DOI 10.1126/science.1100301; Ridderinkhof KR, 2004, BRAIN COGNITION, V56, P129, DOI 10.1016/j.bandc.2004.09.016; Shackman AJ, 2011, NAT REV NEUROSCI, V12, P154, DOI 10.1038/nrn2994; Shackman AJ, 2011, J NEUROSCI, V31, P1156, DOI 10.1523/JNEUROSCI.3384-10.2011; Spielberger C.D., 1970, MANUAL STATE TRAIT A, DOI 10.2307/1831273; Ullsperger M, 2010, BRAIN STRUCT FUNCT, V214, P629, DOI 10.1007/s00429-010-0261-1; van Veen V, 2002, J COGNITIVE NEUROSCI, V14, P593, DOI 10.1162/08989290260045837; van Veen V, 2002, PHYSIOL BEHAV, V77, P477, DOI 10.1016/S0031-9384(02)00930-7; Vocat R, 2008, NEUROPSYCHOLOGIA, V46, P2545, DOI 10.1016/j.neuropsychologia.2008.04.006; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; Wager TD, 2011, J NEUROSCI, V31, P439, DOI 10.1523/JNEUROSCI.3420-10.2011; Watson A, 2009, PAIN, V145, P24, DOI 10.1016/j.pain.2009.04.003; Zhang WC, 2009, PSYCHOPHYSIOLOGY, V46, P626, DOI 10.1111/j.1469-8986.2009.00786.x	55	18	18	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2012	7	11							e49784	10.1371/journal.pone.0049784	http://dx.doi.org/10.1371/journal.pone.0049784			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	047ER	23185436	Green Submitted, Green Published, gold			2023-01-03	WOS:000311821000108
J	Allen, AS; Sequist, TD				Allen, Adrienne S.; Sequist, Thomas D.			Pharmacy Dispensing of Electronically Discontinued Medications	ANNALS OF INTERNAL MEDICINE			English	Article							ADVERSE DRUG EVENTS; HEALTH INFORMATION-TECHNOLOGY; CARE; PERFORMANCE; SAFETY	Background: Most physician offices do not transmit orders for medication discontinuation to the pharmacy, creating the potential for errors in dispensing of previously prescribed medications. Electronic health records offer the potential to assess this patient safety concern. Objective: To assess the frequency of and potential patient harm associated with pharmacy dispensing of discontinued medications in the ambulatory setting. Design: Retrospective cohort study. Setting: Multispecialty group practice in eastern Massachusetts using an electronic health record. Patients: 30 406 adult patients with an electronic discontinuation order for antihypertensive, antiplatelet, anticoagulant, oral hypoglycemic, and statin medications between November 2008 and October 2009. Measurements: Dispensing of discontinued medications within 12 months and associated potential patient harm. Results: Among 83 902 targeted medications that were electronically discontinued, 1218 (1.5% [95% CI, 1.4% to 1.5%]) were subsequently dispensed by the pharmacy a mean of 1.0 (SD, 0.3) time during the 12-month follow-up. Among the top 10 most frequently electronically discontinued medications, the rate of subsequent dispensing by a pharmacy ranged from 0.9% for metformin to 2.5% for metoprolol. Manual chart review of 416 medication-dispensing events that were predefined as high risk according to an automated algorithm identified potential harm in 50 (12%) cases, including clinical reactions (n = 18), laboratory abnormalities (n = 17), duplicated medication classes dispensed (n = 8), and potential allergic reactions (n = 7). Limitation: Information on pharmacy dispensing was available for only 52% of medication orders. Conclusion: The dispensing of discontinued medications represents an important ambulatory patient safety concern. Electronic health records should be used to facilitate better communication between providers and pharmacies and improve medication safety. Primary Funding Source: National Institutes of Health.	[Allen, Adrienne S.] N Shore Phys Grp, Danvers, MA 01923 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Harvard Vanguard Med Associates, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard Vanguard Medical Associates	Allen, AS (corresponding author), N Shore Phys Grp, 104 Endicott St,Suite 104, Danvers, MA 01923 USA.	aallen0@partners.org			National Institutes of Health [T32HP10251-02]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Dr. Allen was funded by a National Institutes of Health Institutional National Research Service Award (T32HP10251-02).	Allen AS, 2011, J PATIENT SAF, V7, P122, DOI 10.1097/PTS.0b013e318223cb41; Ammenwerth E, 2008, J AM MED INFORM ASSN, V15, P585, DOI 10.1197/jamia.M2667; Bates DW, 2003, NEW ENGL J MED, V348, P2526, DOI 10.1056/NEJMsa020847; Blumenthal D, 2010, NEW ENGL J MED, V363, P501, DOI 10.1056/NEJMp1006114; Daniel SB, 2011, NEW ENGL J MED, V365, P2002, DOI 10.1056/NEJMsa1103053; Buntin MB, 2011, HEALTH AFFAIR, V30, P464, DOI 10.1377/hlthaff.2011.0178; Chaudhry B, 2006, ANN INTERN MED, V144, P742, DOI 10.7326/0003-4819-144-10-200605160-00125; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; Kaushal R, 2010, J GEN INTERN MED, V25, P530, DOI 10.1007/s11606-009-1238-8; Metzger J, 2010, HEALTH AFFAIR, V29, P655, DOI 10.1377/hlthaff.2010.0160; Nemeth Lynne S, 2010, J Patient Saf, V6, P238, DOI 10.1097/PTS.0b013e3181fe401f; Sequist TD, 2006, ARCH INTERN MED, V166, P2237, DOI 10.1001/archinte.166.20.2237; Sequist TD, 2011, MED CARE, V49, P126, DOI 10.1097/MLR.0b013e3181d5690f; Sequist TD, 2010, ANN INTERN MED, V152, P40, DOI 10.7326/0003-4819-152-1-201001050-00009	15	27	27	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 20	2012	157	10					700	+		10.7326/0003-4819-157-10-201211200-00006	http://dx.doi.org/10.7326/0003-4819-157-10-201211200-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	043VZ	23165661				2023-01-03	WOS:000311580000015
J	Dorlo, TPC; Ravinetto, RM; Beijnen, JH; Boelaert, M				Dorlo, Thomas P. C.; Ravinetto, Raffaella M.; Beijnen, Jos H.; Boelaert, Marleen			Commentary: Substandard medicines are the priority for neglected tropical diseases	BRITISH MEDICAL JOURNAL			English	Editorial Material							CARDIOTOXICITY		[Dorlo, Thomas P. C.; Beijnen, Jos H.] Slotervaart Hosp, Netherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands; [Dorlo, Thomas P. C.; Beijnen, Jos H.] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands; [Ravinetto, Raffaella M.] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [Boelaert, Marleen] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium	Netherlands Cancer Institute; Slotervaart Hospital; Utrecht University; Institute of Tropical Medicine (ITM); Institute of Tropical Medicine (ITM)	Dorlo, TPC (corresponding author), Slotervaart Hosp, Netherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands.	thomas.dorlo@slz.nl	Dorlo, Thomas/F-1339-2011; Boelaert, Marleen/E-2698-2012	Dorlo, Thomas/0000-0003-3076-8435; Boelaert, Marleen/0000-0001-8051-6776				Attaran A, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e7381; Boelaert M, 2002, TROP MED INT HEALTH, V7, P955, DOI 10.1046/j.1365-3156.2002.00959.x; Caudron JM, 2008, TROP MED INT HEALTH, V13, P1062, DOI 10.1111/j.1365-3156.2008.02106.x; Dorlo TPC, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001544; Dorlo TPC, 2012, ANALYST, V137, P1265, DOI 10.1039/c2an15641e; Katsnelson A, 2010, NAT MED, V16, P364, DOI 10.1038/nm0410-364b; Ravinetto RM, 2012, TROP MED INT HEALTH, V17, P1412, DOI 10.1111/j.1365-3156.2012.03076.x; Rijal S, 2003, T ROY SOC TROP MED H, V97, P597, DOI 10.1016/S0035-9203(03)80043-3; Sundar S, 1998, AM J TROP MED HYG, V59, P139, DOI 10.4269/ajtmh.1998.59.139	9	7	7	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	NOV 14	2012	345								e7518	10.1136/bmj.e7518	http://dx.doi.org/10.1136/bmj.e7518			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	040PZ	23152570	Green Accepted			2023-01-03	WOS:000311336400007
J	Markowitz, N; Lopardo, G; Wentworth, D; Gey, D; Babiker, A; Fox, L; Tavel, J				Markowitz, Norman; Lopardo, Gustavo; Wentworth, Deborah; Gey, Daniela; Babiker, Abdel; Fox, Lawrence; Tavel, Jorge		STALWART Study Grp	Long-Term Effects of Intermittent IL-2 in HIV Infection: Extended Follow-Up of the INSIGHT STALWART Study	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; INTERLEUKIN-2 THERAPY; RANDOMIZED-TRIAL; CELL COUNT; CD4(+); EXPANSION; SURVIVAL; PLASMA; IMPACT	Background: The Study of Aldesleukin with and without Antiretroviral Therapy (STALWART) was designed to evaluate whether intermittent IL-2 alone or with peri-cycle ART increased CD4+ cell counts (and so delayed initiation of ART) in HIV infected individuals having >= 300 CD4+ cells/mm(3) compared to untreated controls. When the results of two large clinical trials, ESPRIT and SILCAAT, showed no clinical benefit from IL-2 therapy, IL-2 administration was halted in STALWART. Because IL-2 recipients in STALWART experienced a greater number of opportunistic disease (OD) or death and adverse events (AEs), participants were asked to consent to an extended follow-up phase in order to assess persistence of IL-2 effects. Methodology: Participants in this study were followed for clinical events and AEs every 4 months for 24 months. Unadjusted Cox proportional hazards models were used to summarize death, death or first OD event, and first grade 3 or 4 AE. Principal Findings: A total of 267 persons were enrolled in STALWART (176 randomized to the IL-2 arms and 91 to the no therapy arm); 142 individuals in the IL-2 group and 80 controls agreed to enter the extended follow-up study. Initiation of continuous ART was delayed in the IL-2 groups, but once started, resulted in similar CD4+ cell and viral load responses compared to controls. The hazard ratios (95% CI) for IL-2 versus control during the extension phase for death or OD, grade 3 or 4 AE, and grade 4 AE were 1.45 (0.38, 5.45), 0.43 (0.24, 1.63) and 0.20 (0.04, 1.03), respectively. The hazard ratios for the AE outcomes were significantly lower during the extension than during the main study. Conclusions: Adverse events associated with IL-2 cycling did not persist upon discontinuation of IL-2. The use of IL-2 did not impact the subsequent response to initiation of cART.	[Markowitz, Norman] Henry Ford Hosp, Detroit, MI 48202 USA; [Lopardo, Gustavo] Fdn Ctr Estudios Infectol, Buenos Aires, DF, Argentina; [Wentworth, Deborah] Univ Minnesota, Div Biostat, Minneapolis, MN USA; [Gey, Daniela] Univ Copenhagen, Copenhagen HIV Programme, Copenhagen, Denmark; [Babiker, Abdel] MRC, London, England; [Fox, Lawrence; Tavel, Jorge] NIAID, Bethesda, MD 20892 USA	Henry Ford Health System; Henry Ford Hospital; University of Minnesota System; University of Minnesota Twin Cities; University of Copenhagen; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Markowitz, N (corresponding author), Henry Ford Hosp, Detroit, MI 48202 USA.	nmarkow1@hfhs.org			National Institutes of Health (NIH) [U01-AI068641, U01-AI46957]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI068641, U01AI046957] Funding Source: NIH RePORTER; Medical Research Council [MC_U122886352] Funding Source: researchfish; MRC [MC_U122886352] Funding Source: UKRI	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The work was supported by National Institutes of Health (NIH) grants U01-AI068641 and U01-AI46957. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrams D, 2009, NEW ENGL J MED, V361, P1548, DOI 10.1056/NEJMoa0903175; Barbai VH, 2010, CLIN EXP IMMUNOL, V161, P134, DOI 10.1111/j.1365-2249.2010.04145.x; Beq S, 2004, EUR CYTOKINE NETW, V15, P279; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Fontas E, 2010, J ANTIMICROB CHEMOTH, V65, P2215, DOI 10.1093/jac/dkq296; Herzmann C, 2008, J ANTIMICROB CHEMOTH, V62, P583, DOI 10.1093/jac/dkn238; Kovacs JA, 2005, J CLIN INVEST, V115, P2139, DOI 10.1172/JCI23196; Kovacs JA, 2000, J INFECT DIS, V182, P1063, DOI 10.1086/315821; Lafeuillade A, 2001, HIV Med, V2, P189, DOI 10.1046/j.1468-1293.2001.00065.x; Lempicki RA, 2000, P NATL ACAD SCI USA, V97, P13778, DOI 10.1073/pnas.250472097; Molina JM, 2009, J INFECT DIS, V200, P206, DOI 10.1086/599989; Musselwhite LW, 2011, AIDS, V25, P787, DOI 10.1097/QAD.0b013e3283453fcb; Porter BO, 2009, AIDS, V23, P2015, DOI 10.1097/QAD.0b013e32832d72c6; Read SW, 2008, J INFECT DIS, V198, P843, DOI 10.1086/591250; Read SW, 2011, JAIDS-J ACQ IMM DEF, V56, P340, DOI 10.1097/QAI.0b013e31820bf84c; Sabbatini F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014119; Sereti I, 2004, BLOOD, V104, P775, DOI 10.1182/blood-2003-12-4355; Sereti I, 2005, J CLIN INVEST, V115, P1839, DOI 10.1172/JCI24307; Sereti I, 2002, BLOOD, V100, P2159, DOI 10.1182/blood.V100.6.2159.h81802002159_2159_2167; Sereti I, 2007, J INFECT DIS, V196, P677, DOI 10.1086/520087; Stellbrink HJ, 2002, AIDS, V16, P1479, DOI 10.1097/00002030-200207260-00004; Tavel JA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009334; Youle M, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010003; Zeng M, 2011, J CLIN INVEST, V121, P998, DOI 10.1172/JCI45157	24	9	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2012	7	10							e47506	10.1371/journal.pone.0047506	http://dx.doi.org/10.1371/journal.pone.0047506			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	038AF	23082173	gold, Green Published, Green Submitted, Green Accepted			2023-01-03	WOS:000311146900069
J	Wong, EB; Omar, T; Setlhako, GJ; Osih, R; Feldman, C; Murdoch, DM; Martinson, NA; Bangsberg, DR; Venter, WDF				Wong, Emily B.; Omar, Tanvier; Setlhako, Gosetsemang J.; Osih, Regina; Feldman, Charles; Murdoch, David M.; Martinson, Neil A.; Bangsberg, David R.; Venter, W. D. F.			Causes of Death on Antiretroviral Therapy: A Post-Mortem Study from South Africa	PLOS ONE			English	Article							RECONSTITUTION INFLAMMATORY SYNDROME; HIV-POSITIVE PATIENTS; SUB-SAHARAN AFRICA; EARLY MORTALITY; AUTOPSY; TUBERCULOSIS; DISEASE; ADULTS; PATHOLOGY; COHORT	Background: Mortality in the first months of antiretroviral therapy (ART) is a significant clinical problem in sub-Saharan Africa. To date, no post-mortem study has investigated the causes of mortality in these patients. Methods: HIV-positive adults who died as in-patients at a Johannesburg academic hospital underwent chart-review and ultrasound-guided needle autopsy for histological and microbiological examination of lung, liver, spleen, kidney, bone marrow, lymph node, skin and cerebrospinal fluid. A clinico-pathologic committee considered all available data and adjudicated immediate and contributing causes of death. Results: Thirty-nine adults were enrolled: 1 14 pre-ART, 15 early-ART (7-90 days), and 10 late-ART (>90 days). Needle sampling yielded adequate specimen in 100% of kidney, skin, heart and cerebrospinal fluid samples, 97% of livers and lungs, 92% of bone marrows, 87% of spleens and 68% of lymph nodes. Mycobacterial infections were implicated in 69% of deaths (26 of 27 of these due to M. tuberculosis), bacterial infections in 33%, fungal infections in 21%, neoplasm in 26%, and non-infectious organ failure in 26%. Immune reconstitution inflammatory syndrome (IRIS) was implicated in 73% of early-ART deaths. Post-mortem investigations revealed previously undiagnosed causes of death in 49% of cases. Multiple pathologies were common with 62% of subjects with mycobacterial infection also having at least one other infectious or neoplastic cause of death. Conclusions: Needle biopsy was efficient and yielded excellent pathology. The large majority of deaths in all three groups were caused by M. tuberculosis suggesting an urgent need for improved diagnosis and expedited treatment prior to and throughout the course of antiretroviral therapy. Complex, unrecognized co-morbidities pose an additional challenge.	[Wong, Emily B.; Setlhako, Gosetsemang J.; Osih, Regina; Venter, W. D. F.] Univ Witwatersrand, Wits Reprod Hlth & HIV Inst, Johannesburg, South Africa; [Wong, Emily B.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA; [Wong, Emily B.] Univ KwaZulu Natal, KwaZulu Natal Res Inst TB & HIV, Durban, South Africa; [Omar, Tanvier] Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Johannesburg, South Africa; [Setlhako, Gosetsemang J.; Feldman, Charles] Univ Witwatersrand, Charlotte Maxeke Johannesburg Acad Hosp, Dept Internal Med, Johannesburg, South Africa; [Murdoch, David M.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Martinson, Neil A.] Univ Witwatersrand, Perinatal HIV Res Unit, Johannesburg, South Africa; [Martinson, Neil A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Bangsberg, David R.] Harvard Univ, Sch Med, Ragon Inst MGH MIT & Harvard, Massachusetts Gen Hosp,Ctr Global Hlth, Boston, MA 02115 USA	University of Witwatersrand; Harvard University; Massachusetts General Hospital; University of Kwazulu Natal; University of Witwatersrand; University of Witwatersrand; Duke University; University of Witwatersrand; Johns Hopkins University; Harvard University; Harvard Medical School; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute	Wong, EB (corresponding author), Univ Witwatersrand, Wits Reprod Hlth & HIV Inst, Johannesburg, South Africa.	emily.wong@k-rith.org	Feldman, Charles/ABF-3315-2020	Feldman, Charles/0000-0002-6881-8314; Venter, Willem/0000-0002-4157-732X	Fogarty International Center at the National Institutes of Health [R24TW007988, RTW007373/0, D43TW000010-21S1]; President's Emergency Plan for AIDS Relief [674-A-00-08-00005-00]; National Research Foundation of South Africa; FOGARTY INTERNATIONAL CENTER [D43TW000010, K01TW008005, U2RTW007373, R24TW007988] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI060354, T32AI007387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K24MH087227] Funding Source: NIH RePORTER	Fogarty International Center at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); President's Emergency Plan for AIDS Relief(United States Agency for International Development (USAID)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Research Foundation of South Africa(National Research Foundation - South Africa); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported by the Fogarty International Center at the National Institutes of Health (www.fic.nih.gov, R24TW007988 supported and provided research training to E. B. W. and G.J.S.; RTW007373/0 supported N.M. and provided research training to W. D. F. V.; and D43TW000010-21S1 provided research training to T.O.), the President's Emergency Plan for AIDS Relief (www.pepfar.gov, 674-A-00-08-00005-00 supported R.O., G.J.S, W. D. F. V.), and the National Research Foundation of South Africa (www.nrf.ac.za, supported C. F.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ansari NA, 2002, INT J TUBERC LUNG D, V6, P55; BAUMGART KW, 1994, PATHOLOGY, V26, P141, DOI 10.1080/00313029400169381; Bisson GP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001725; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Castelnuovo B, 2009, CLIN INFECT DIS, V49, P965, DOI 10.1086/605500; Chakraborty R, 2002, ANN TROP PAEDIATR, V22, P125, DOI 10.1179/027249302125000841; Cohen T, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000296; Cox JA, 2010, AIDS REV, V12, P183; Cury PM, 2003, PATHOL RES PRACT, V199, P811, DOI 10.1078/0344-0338-00500; de Cherif TKS, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-205; Domoua K, 1995, Med Trop (Mars), V55, P252; Etard JF, 2006, AIDS, V20, P1181, DOI 10.1097/01.aids.0000226959.87471.01; Gous N, 2012, J CLIN MICROBIOL, V50, P2100, DOI 10.1128/JCM.00252-12; GREENBERG AE, 1995, AIDS, V9, P1251, DOI 10.1097/00002030-199511000-00006; Guerra I, 2001, PATHOL RES PRACT, V197, P165, DOI 10.1078/0344-0338-00028; Gupta A, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0022730, 10.1371/journal.pone.0028691]; Hanzlick R, 1996, ARCH INTERN MED, V156, P25, DOI 10.1001/archinte.156.1.25; Huston BM, 1996, MODERN PATHOL, V9, P1101; Karstaedt A, 2009, CAUSES DEATH PATIENT; Kyeyune R, 2010, JAIDS-J ACQ IMM DEF, V55, P446, DOI 10.1097/QAI.0b013e3181eb611a; Lanjewar DN, 2011, PATHOLOG RES INT, V2011; Lawn SD, 2005, AIDS, V19, P2050, DOI 10.1097/01.aids.0000191232.16111.f9; Lawn SD, 2008, AIDS, V22, P1897, DOI 10.1097/QAD.0b013e32830007cd; Lawn SD, 2008, CURR OPIN HIV AIDS, V3, P425, DOI 10.1097/COH.0b013e3282fe99dc; Lawn SD, 2009, AIDS, V23, P143, DOI 10.1097/QAD.0b013e32831d2a98; Leng K, 2008, INT J STD AIDS, V19, P642, DOI 10.1258/ijsa.2008.008062; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; Lucas S, 2012, CURR OPIN INFECT DIS, V25, P36, DOI 10.1097/QCO.0b013e32834ef5c4; MacPherson P, 2009, T ROY SOC TROP MED H, V103, P588, DOI 10.1016/j.trstmh.2008.10.001; Makadzange AT, 2010, CLIN INFECT DIS, V50, P1532, DOI 10.1086/652652; Martinson NA, 2007, AIDS, V21, P2043, DOI 10.1097/QAD.0b013e3282eea47f; Meintjes G, 2009, CLIN INFECT DIS, V48, P667, DOI 10.1086/596764; Meintjes G, 2008, LANCET INFECT DIS, V8, P516, DOI 10.1016/S1473-3099(08)70184-1; MOHAR A, 1992, AIDS, V6, P467, DOI 10.1097/00002030-199205000-00005; Murdoch DA, 2008, AIDS, V22, P601, DOI 10.1097/QAD.0b013e3282f4a607; Murray J, 2007, AIDS, V21, pS97, DOI 10.1097/01.aids.0000299416.61808.24; Nojilana B, 2009, SAMJ S AFR MED J, V99, P648; Rana FS, 2000, J ACQ IMMUN DEF SYND, V24, P23; Satyanarayana S, 2003, Indian J Pathol Microbiol, V46, P416; Severe P, 2005, NEW ENGL J MED, V353, P2325, DOI 10.1056/NEJMoa051908; Soeiro AD, 2008, CLINICS, V63, P497, DOI 10.1590/S1807-59322008000400014; Wester CW, 2007, JAIDS-J ACQ IMM DEF, V46, P318, DOI 10.1097/QAI.0b013e3181568e3f	42	104	105	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2012	7	10							e47542	10.1371/journal.pone.0047542	http://dx.doi.org/10.1371/journal.pone.0047542			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	024UX	23094059	Green Published, gold			2023-01-03	WOS:000310135800054
J	Sunyer, R; Jin, AJ; Nossal, R; Sackett, DL				Sunyer, Raimon; Jin, Albert J.; Nossal, Ralph; Sackett, Dan L.			Fabrication of Hydrogels with Steep Stiffness Gradients for Studying Cell Mechanical Response	PLOS ONE			English	Article							ATOMIC-FORCE MICROSCOPY; SUBSTRATE STIFFNESS; RIGIDITY; MOVEMENT; TIPS	Many fundamental cell processes, such as angiogenesis, neurogenesis and cancer metastasis, are thought to be modulated by extracellular matrix stiffness. Thus, the availability of matrix substrates having well-defined stiffness profiles can be of great importance in biophysical studies of cell-substrate interaction. Here, we present a method to fabricate biocompatible hydrogels with a well defined and linear stiffness gradient. This method, involving the photopolymerization of films by progressively uncovering an acrylamide/bis-acrylamide solution initially covered with an opaque mask, can be easily implemented with common lab equipment. It produces linear stiffness gradients of at least 115 kPa/mm, extending from similar to 1 kPa to 240 kPa (in units of Young's modulus). Hydrogels with less steep gradients and narrower stiffness ranges can easily be produced. The hydrogels can be covalently functionalized with uniform coatings of proteins that promote cell adhesion. Cell spreading on these hydrogels linearly correlates with hydrogel stiffness, indicating that this technique effectively modifies the mechanical environment of living cells. This technique provides a simple approach that produces steeper gradients, wider rigidity ranges, and more accurate profiles than current methods.	[Sunyer, Raimon; Nossal, Ralph; Sackett, Dan L.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Phys Biol, NIH, Bethesda, MD USA; [Jin, Albert J.] Natl Inst Biomed Imaging & Bioengn, Lab Cellular Imaging & Macromol Biophys, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)	Sunyer, R (corresponding author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Phys Biol, NIH, Bethesda, MD USA.	raimon.sunyer@nih.gov	Sunyer, Raimon/G-8605-2013	Sunyer, Raimon/0000-0003-0777-3973; Jin, Albert/0000-0003-3826-1081	Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health; Agency of Research and Universities (Ministry of Economy and Knowledge, Catalan Government); Cofund program (Marie Curie Actions, Seventh Framework Programme of the European Union); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008841] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [ZIAEB000015] Funding Source: NIH RePORTER	Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); Agency of Research and Universities (Ministry of Economy and Knowledge, Catalan Government); Cofund program (Marie Curie Actions, Seventh Framework Programme of the European Union); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	This work was supported by funds from the Intramural Research Programs of the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health. R Sunyer was supported by a postdoctoral fellowship from the Agency of Research and Universities (Ministry of Economy and Knowledge, Catalan Government) and the Cofund program (Marie Curie Actions, Seventh Framework Programme of the European Union). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alcaraz J, 2003, BIOPHYS J, V84, P2071, DOI 10.1016/S0006-3495(03)75014-0; Aratyn-Schaus Yvonne, 2010, J Vis Exp, DOI 10.3791/2173; BUTT HJ, 1995, NANOTECHNOLOGY, V6, P1, DOI 10.1088/0957-4484/6/1/001; Byfield FJ, 2009, BIOPHYS J, V96, P5095, DOI 10.1016/j.bpj.2009.03.046; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Fairbanks BD, 2009, BIOMATERIALS, V30, P6702, DOI 10.1016/j.biomaterials.2009.08.055; HUTTER JL, 1993, REV SCI INSTRUM, V64, P1868, DOI 10.1063/1.1143970; Isenberg BC, 2009, BIOPHYS J, V97, P1313, DOI 10.1016/j.bpj.2009.06.021; Jiang GY, 2006, BIOPHYS J, V90, P1804, DOI 10.1529/biophysj.105.072462; Johnson PM, 2005, POLYMER, V46, P3300, DOI 10.1016/j.polymer.2005.02.085; Kandow CE, 2007, METHOD CELL BIOL, V83, P29, DOI 10.1016/S0091-679X(07)83002-0; Kawano T, 2011, BIOMATERIALS, V32, P2725, DOI 10.1016/j.biomaterials.2011.01.009; Kloxin AM, 2010, BIOMATERIALS, V31, P1, DOI 10.1016/j.biomaterials.2009.09.025; Kumar S, 2009, CANCER METAST REV, V28, P113, DOI 10.1007/s10555-008-9173-4; Levental I, 2007, SOFT MATTER, V3, P299, DOI 10.1039/b610522j; Lo CM, 2000, BIOPHYS J, V79, P144, DOI 10.1016/S0006-3495(00)76279-5; Marklein RA, 2010, SOFT MATTER, V6, P136, DOI 10.1039/b916933d; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; Ramachandra M, 1996, MOL BIOL CELL, V7, P1485, DOI 10.1091/mbc.7.10.1485; Rico F, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.021914; ROSS RA, 1983, J NATL CANCER I, V71, P741; Seidi A, 2011, ACTA BIOMATER, V7, P1441, DOI 10.1016/j.actbio.2011.01.011; Tse J. R., 2009, CURR PROT CELL BIO; Tse JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015978; Ulrich TA, 2009, CANCER RES, V69, P4167, DOI 10.1158/0008-5472.CAN-08-4859; Venkatesh SK, 2008, AM J ROENTGENOL, V190, P1534, DOI 10.2214/AJR.07.3123; Wong JY, 2003, LANGMUIR, V19, P1908, DOI 10.1021/la026403p; Yeung T, 2005, CELL MOTIL CYTOSKEL, V60, P24, DOI 10.1002/cm.20041; Zaari N, 2004, ADV MATER, V16, P2133, DOI 10.1002/adma.200400883	30	147	148	0	79	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2012	7	10							e46107	10.1371/journal.pone.0046107	http://dx.doi.org/10.1371/journal.pone.0046107			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017HM	23056241	gold, Green Submitted, Green Published			2023-01-03	WOS:000309580800010
J	Sia, D; Tovar, V; Moeini, A; Llovet, JM				Sia, D.; Tovar, V.; Moeini, A.; Llovet, J. M.			Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies	ONCOGENE			English	Review						cholangiocarcinoma; molecular pathogenesis; targeted therapies	GROWTH-FACTOR-RECEPTOR; BILIARY-TRACT CANCER; PRIMARY LIVER CANCERS; GENOME-WIDE ANALYSIS; C VIRUS-INFECTION; PHASE-II; HEPATOCELLULAR-CARCINOMA; GENE-EXPRESSION; UNITED-STATES; BILE-DUCT	Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy with very poor prognosis. Genome-wide, high-throughput technologies have made major advances in understanding the molecular basis of this disease, although important mechanisms are still unclear. Recent data have revealed specific genetic mutations (for example, KRAS, IDH1 and IDH2), epigenetic silencing, aberrant signaling pathway activation (for example, interleukin (IL)-6/signal transducer and activator of transcription 3 (STAT3), tyrosine kinase receptor-related pathways) and molecular subclasses with unique alterations (for example, proliferation and inflammation subclasses). In addition, some ICCs share common genomic traits with hepatocellular carcinoma. All this information provides the basis to explore novel targeted therapies. Currently, surgery at early stage is the only effective therapy. At more advanced stages, chemotherapy regimens are emerging (that is, cisplatin plus gemcitabine), along with molecular targeted agents tested in several ongoing clinical trials. Nonetheless, a first-line conclusive treatment remains an unmet need. Similarly, there are no studies assessing tumor response related with genetic alterations. This review explores the recent advancements in the knowledge of the molecular alterations underlying ICC and the future prospects in terms of therapeutic strategies leading towards a more personalized treatment of this neoplasm.	[Sia, D.; Tovar, V.; Moeini, A.; Llovet, J. M.] Hosp Clin Barcelona, Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona Clin Liver Canc Grp, HCC Translat Res Lab,Liver Unit, E-08036 Barcelona, Catalonia, Spain; [Sia, D.] Natl Canc Inst, Gastrointestinal Surg & Liver Transplantat Unit, I-20133 Milan, Italy; [Llovet, J. M.] Mt Sinai Sch Med, Tisch Canc Inst, Dept Med, Div Liver Dis,Mt Sinai Liver Canc Program, New York, NY USA; [Llovet, J. M.] Inst Catalana Recerca & Estudis Avancats, Barcelona, Catalonia, Spain; [Llovet, J. M.] Univ Barcelona, Barcelona, Catalonia, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Fondazione IRCCS Istituto Nazionale Tumori Milan; Icahn School of Medicine at Mount Sinai; ICREA; University of Barcelona	Llovet, JM (corresponding author), Hosp Clin Barcelona, Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona Clin Liver Canc Grp, HCC Translat Res Lab,Liver Unit, Villarroel 170, E-08036 Barcelona, Catalonia, Spain.	jmllovet@clinic.ub.es	Llovet, Josep M/D-4340-2014; Llovet, Josep M/ABB-6264-2021	Llovet, Josep M/0000-0003-0547-2667; Llovet, Josep M/0000-0003-0547-2667; Sia, Daniela/0000-0002-9000-611X	US National Institutes of Diabetes and Digestive and Kidney Diseases [1R01DK076986]; European Commission [259744]; Asociacion Espanola Contra el Cancer; Spanish National Health Institute [SAF-2010-16055]; Samuel Waxman Cancer Research Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076986] Funding Source: NIH RePORTER; ICREA Funding Source: Custom	US National Institutes of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); European Commission(European CommissionEuropean Commission Joint Research Centre); Asociacion Espanola Contra el Cancer; Spanish National Health Institute(Spanish Government); Samuel Waxman Cancer Research Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); ICREA(ICREA)	Josep M Llovet is supported by grants from the US National Institutes of Diabetes and Digestive and Kidney Diseases (1R01DK076986), the European Commission's Framework Programme 7 (HEPTROMIC; 259744), the Asociacion Espanola Contra el Cancer, the Spanish National Health Institute (SAF-2010-16055) and the Samuel Waxman Cancer Research Foundation.	Aishima S, 2007, AM J SURG PATHOL, V31, P1059, DOI 10.1097/PAS.0b013e31802b34b6; Andersen JB, 2012, GASTROENTEROLOGY, V142, P1021, DOI 10.1053/j.gastro.2011.12.005; Bekaii-Saab T, 2011, J CLIN ONCOL, V29, P2357, DOI 10.1200/JCO.2010.33.9473; Bengala C, 2010, BRIT J CANCER, V102, P68, DOI 10.1038/sj.bjc.6605458; Berthiaume EP, 2004, SEMIN LIVER DIS, V24, P127, DOI 10.1055/s-2004-828890; Blechacz B, 2008, HEPATOLOGY, V48, P308, DOI 10.1002/hep.22310; Borbath C, 6 ILCA ANN C 2012; Borger DR, 2012, ONCOLOGIST, V17, P72, DOI 10.1634/theoncologist.2011-0386; Bragazzi MC., 2012, TRANSL GASTROINTEST, V1, P21, DOI [10.3978/j.issn.2224-4778.2011.11.04, DOI 10.3978/J.ISSN.2224-4778.2011.11.04]; Chen L, 2009, J HEPATOL, V50, P358, DOI 10.1016/j.jhep.2008.09.015; Chen TC, 2012, ANN SURG ONCOL, V19, pS675, DOI [10.1245/s10434-012-2224-7, 10.1245/s10434-012-2451-y]; Chiang DY, 2008, CANCER RES, V68, P6779, DOI 10.1158/0008-5472.CAN-08-0742; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Dachrut S, 2009, ASIAN PAC J CANCER P, V10, P575; de Jong MC, 2011, J CLIN ONCOL, V29, P3140, DOI 10.1200/JCO.2011.35.6519; Deshpande V, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-60; Edge S., 2010, AJCC CANC STAGING MA; El-Khoueiry AB, 2012, INVEST NEW DRUG, V30, P1646, DOI 10.1007/s10637-011-9719-0; El-Serag HB, 2009, HEPATOLOGY, V49, P116, DOI 10.1002/hep.22606; Endo K, 2002, HEPATOLOGY, V36, P439, DOI 10.1053/jhep.2002.34435; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Farazi PA, 2006, CANCER RES, V66, P6622, DOI 10.1158/0008-5472.CAN-05-4609; Fingas CD, 2011, HEPATOLOGY, V54, P2076, DOI 10.1002/hep.24588; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Furubo S, 1999, HISTOPATHOLOGY, V35, P230; Gruenberger B, 2010, LANCET ONCOL, V11, P1142, DOI 10.1016/S1470-2045(10)70247-3; Guedj N, 2009, J HEPATOL, V51, P93, DOI 10.1016/j.jhep.2009.03.017; Hammill CW, 2008, J AM COLL SURGEONS, V207, P594, DOI 10.1016/j.jamcollsurg.2008.04.031; Han C, 2004, CANCER RES, V64, P1369, DOI 10.1158/0008-5472.CAN-03-1086; Hasita H, 2010, CANCER SCI, V101, P1913, DOI 10.1111/j.1349-7006.2010.01614.x; Hedvat M, 2009, CANCER CELL, V16, P487, DOI 10.1016/j.ccr.2009.10.015; Hezel AF, 2010, J CLIN ONCOL, V28, P3531, DOI 10.1200/JCO.2009.27.4787; Hodge DR, 2001, J BIOL CHEM, V276, P39508, DOI 10.1074/jbc.C100343200; Homayounfar K, 2009, HUM PATHOL, V40, P834, DOI 10.1016/j.humpath.2008.11.005; Hoshida Y, 2009, CANCER RES, V69, P7385, DOI 10.1158/0008-5472.CAN-09-1089; Isa T, 2002, HEPATO-GASTROENTEROL, V49, P604; Isomoto H, 2007, GASTROENTEROLOGY, V132, P384, DOI 10.1053/j.gastro.2006.10.037; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jensen LH, 2012, ANN ONCOL, V23, P2341, DOI 10.1093/annonc/mds008; Jimeno A, 2005, CANCER RES, V65, P3003, DOI 10.1158/0008-5472.CAN-04-3586; Jinawath N, 2006, HEPATOLOGY, V44, P1025, DOI 10.1002/hep.21330; Karamitopoulou E, 2008, AM J CLIN PATHOL, V130, P780, DOI 10.1309/AJCP35FDCAVANWMM; Khan SA, 2005, LANCET, V366, P1303, DOI 10.1016/S0140-6736(05)67530-7; Kiguchi K, 2001, CANCER RES, V61, P6971; Kipp BR, 2012, HUM PATHOL, V43, P1552, DOI 10.1016/j.humpath.2011.12.007; Kobayashi M, 2000, CANCER, V88, P2471, DOI 10.1002/1097-0142(20000601)88:11<2471::AID-CNCR7>3.0.CO;2-T; Kobayashi S, 2005, GASTROENTEROLOGY, V128, P2054, DOI 10.1053/j.gastro.2005.03.010; Koo SH, 2001, CANCER GENET CYTOGEN, V130, P22, DOI 10.1016/S0165-4608(01)00460-5; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Lee J, 2012, LANCET ONCOL, V13, P181, DOI 10.1016/S1470-2045(11)70301-1; Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377; Lee S, 2002, AM J PATHOL, V161, P1015, DOI 10.1016/S0002-9440(10)64262-9; Leelawat K, 2006, J SURG RES, V136, P78, DOI 10.1016/j.jss.2006.05.031; Leelawat K, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-30; Leone F, 2006, CLIN CANCER RES, V12, P1680, DOI 10.1158/1078-0432.CCR-05-1692; Li B, 2012, FEBS J, V279, P2393, DOI 10.1111/j.1742-4658.2012.08618.x; Li H, 2012, LIVER INT, V32, P38, DOI 10.1111/j.1478-3231.2011.02646.x; Lubner SJ, 2010, J CLIN ONCOL, V28, P3491, DOI 10.1200/JCO.2010.28.4075; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Malhi H, 2006, J HEPATOL, V45, P856, DOI 10.1016/j.jhep.2006.09.001; Meng F, 2008, ONCOGENE, V27, P378, DOI 10.1038/sj.onc.1210648; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; Meng F, 2006, J HEPATOL, V44, P1055, DOI 10.1016/j.jhep.2005.10.030; Mesa RA, 2012, NAT REV DRUG DISCOV, V11, P103, DOI 10.1038/nrd3652; Miller G, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-62; Miyamoto M, 2011, BRIT J CANCER, V105, P131, DOI 10.1038/bjc.2011.199; Momoi H, 2001, J HEPATOL, V35, P235, DOI 10.1016/S0168-8278(01)00106-4; Nakazawa K, 2005, J PATHOL, V206, P356, DOI 10.1002/path.1779; Nathan H, 2010, CURR OPIN GASTROEN, V26, P269, DOI 10.1097/MOG.0b013e328337c899; O'Dell MR, 2012, CANCER RES, V72, P1557, DOI 10.1158/0008-5472.CAN-11-3596; Obama K, 2005, HEPATOLOGY, V41, P1339, DOI 10.1002/hep.20718; Oishi N, 2012, HEPATOLOGY, V56, P1792, DOI 10.1002/hep.25890; Okabe H, 2009, ANN SURG ONCOL, V16, P2555, DOI 10.1245/s10434-009-0568-4; Okuda K, 2002, J GASTROEN HEPATOL, V17, P1049, DOI 10.1046/j.1440-1746.2002.02781.x; Ong CK, 2012, NAT GENET, V44, P690, DOI 10.1038/ng.2273; Palmer WC, 2012, J HEPATOL, V57, P69, DOI 10.1016/j.jhep.2012.02.022; Pardanani A, 2011, J CLIN ONCOL, V29, P789, DOI 10.1200/JCO.2010.32.8021; Park BK, 2006, AM J CLIN ONCOL-CANC, V29, P138, DOI 10.1097/01.coc.0000204402.29830.08; Park J, 1999, HEPATOLOGY, V30, P1128, DOI 10.1002/hep.510300522; Parkin DM, 2002, CANC INCIDENCE 5 CON, VVIII; Pascher Andreas, 2003, J Hepatobiliary Pancreat Surg, V10, P282, DOI 10.1007/s00534-002-0731-9; Patel T, 2001, HEPATOLOGY, V33, P1353, DOI 10.1053/jhep.2001.25087; Philip PA, 2006, J CLIN ONCOL, V24, P3069, DOI 10.1200/JCO.2005.05.3579; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Radaeva S, 1999, HEPATOLOGY, V29, P1453, DOI 10.1002/hep.510290524; Ramanathan RK, 2009, CANCER CHEMOTH PHARM, V64, P777, DOI 10.1007/s00280-009-0927-7; Roskams T, 2006, ONCOGENE, V25, P3818, DOI 10.1038/sj.onc.1209558; Sandhu DS, 2008, LIVER INT, V28, P12, DOI 10.1111/j.1478-3231.2007.01624.x; Selaru FM, 2009, HEPATOLOGY, V49, P1595, DOI 10.1002/hep.22838; Sempoux C, 2011, SEMIN LIVER DIS, V31, P49, DOI 10.1055/s-0031-1272839; Settakorn J, 2005, J CLIN PATHOL, V58, P1249, DOI 10.1136/jcp.2005.026575; Shaib Y, 2004, SEMIN LIVER DIS, V24, P115, DOI 10.1055/s-2004-828889; Shaib YH, 2005, GASTROENTEROLOGY, V128, P620, DOI 10.1053/j.gastro.2004.12.048; Shaib YH, 2004, J HEPATOL, V40, P472, DOI 10.1016/j.jhep.2003.11.030; Shibahara H, 2004, HEPATOLOGY, V39, P220, DOI 10.1002/hep.20031; Shin HR, 2010, CANCER SCI, V101, P579, DOI 10.1111/j.1349-7006.2009.01458.x; Sia D, 2013, GASTROENTER IN PRESS; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; Sirica AE, 2002, SEMIN LIVER DIS, V22, P303, DOI 10.1055/s-2002-34507; Sirica AE, 2008, HEPATOLOGY, V47, P1178, DOI 10.1002/hep.22088; Sirica AE, 2012, NAT REV GASTRO HEPAT, V9, P44, DOI 10.1038/nrgastro.2011.222; Sirica AE, 2011, CURR OPIN GASTROEN, V27, P276, DOI 10.1097/MOG.0b013e32834405c3; Sirica AE, 2009, CLIN GASTROENTEROL H, V7, pS68, DOI 10.1016/j.cgh.2009.08.023; Sirica AE, 2008, WORLD J GASTROENTERO, V14, P7033, DOI 10.3748/wjg.14.7033; Sirica AE, 2008, HEPATOLOGY, V48, P2040, DOI 10.1002/hep.22623; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sugimachi K, 2001, MODERN PATHOL, V14, P900, DOI 10.1038/modpathol.3880409; Sugiyama H, 2011, J GASTROENTEROL, V46, P779, DOI 10.1007/s00535-011-0380-3; Tabernero J, 2007, MOL CANCER RES, V5, P203, DOI 10.1158/1541-7786.MCR-06-0404; Tannapfel A, 2000, DIGEST DIS SCI, V45, P317, DOI 10.1023/A:1005412626515; Tannapfel A, 2000, GUT, V47, P721, DOI 10.1136/gut.47.5.721; Tannapfel A, 2003, GUT, V52, P706, DOI 10.1136/gut.52.5.706; Tannapfel A, 2002, J PATHOL, V197, P624, DOI 10.1002/path.1139; Terada T, 1998, HUM PATHOL, V29, P175, DOI 10.1016/S0046-8177(98)90229-5; Tischoff I, 2005, INT J CANCER, V115, P684, DOI 10.1002/ijc.20944; Tokumoto N, 2005, INT J ONCOL, V27, P973; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736; Uhm KO, 2005, CANCER GENET CYTOGEN, V157, P37, DOI 10.1016/j.cancergencyto.2004.05.007; Valle Juan, 2010, N Engl J Med, V362, P1273, DOI 10.1056/NEJMoa0908721; Verstovsek S, 2010, NEW ENGL J MED, V363, P1117, DOI 10.1056/NEJMoa1002028; Wang P, 2012, CANC RES; Wehbe H, 2006, CANCER RES, V66, P10517, DOI 10.1158/0008-5472.CAN-06-2130; Welzel TM, 2011, HEPATOLOGY, V54, P463, DOI 10.1002/hep.24397; Wong N, 2002, J HEPATOL, V37, P633, DOI 10.1016/S0168-8278(02)00269-6; Woo HG, 2010, CANCER RES, V70, P3034, DOI 10.1158/0008-5472.CAN-09-2823; Wu GS, 2003, WORLD J GASTROENTERO, V9, P1302, DOI 10.3748/wjg.v9.i6.1302; Wu T, 2004, MOL CANCER THER, V3, P299; Xin H, 2011, CANCER RES, V71, P6601, DOI 10.1158/0008-5472.CAN-11-1217; Yamagiwa Y, 2006, LIFE SCI, V78, P2494, DOI 10.1016/j.lfs.2005.10.015; Yamamoto S, 2004, CANCER SCI, V95, P592, DOI 10.1111/j.1349-7006.2004.tb02492.x; Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004; Yang B, 2005, MODERN PATHOL, V18, P412, DOI 10.1038/modpathol.3800287; Yi JH, 2012, EUR J CANCER, V48, P196, DOI 10.1016/j.ejca.2011.11.017; Yoon JH, 2004, J HEPATOL, V41, P808, DOI 10.1016/j.jhep.2004.07.016; Yoshikawa D, 2008, BRIT J CANCER, V98, P418, DOI 10.1038/sj.bjc.6604129; Yoshikawa D, 2009, BRIT J CANCER, V100, P1257, DOI 10.1038/sj.bjc.6604988; Zhang ZC, 2010, HEPATOLOGY, V52, P975, DOI 10.1002/hep.23773; Zhu AX, 2011, HEPATOLOGY, V53, P695, DOI 10.1002/hep.24145; Zhu AX, 2010, LANCET ONCOL, V11, P48, DOI 10.1016/S1470-2045(09)70333-X	139	162	172	0	28	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4861	4870		10.1038/onc.2012.617	http://dx.doi.org/10.1038/onc.2012.617			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23318457	Green Accepted			2023-01-03	WOS:000325717800001
J	Ullrich, S; Bremer, P; Neumann-Grutzeck, C; Otto, H; Ruther, C; von Seydewitz, CU; Meyer, GP; Ahmadi-Simab, K; Rother, J; Hogan, B; Schwenk, W; Fischbach, R; Caselitz, J; Puttfarcken, J; Huggett, S; Tiedeken, P; Pober, J; Kirkiles-Smith, NC; Hagenmuller, F				Ullrich, Sebastian; Bremer, Phillip; Neumann-Grutzeck, Christine; Otto, Helge; Ruether, Christoph; von Seydewitz, Cay Uwe; Meyer, Gerd Peter; Ahmadi-Simab, Keihan; Roether, Joachim; Hogan, Barbara; Schwenk, Wolfgang; Fischbach, Roman; Caselitz, Joerg; Puttfarcken, Jochen; Huggett, Susanne; Tiedeken, Petra; Pober, Jordan; Kirkiles-Smith, Nancy C.; Hagenmueller, Friedrich			Symptoms and Clinical Course of EHEC O104 Infection in Hospitalized Patients: A Prospective Single Center Study	PLOS ONE			English	Article							HEMOLYTIC-UREMIC SYNDROME; THROMBOTIC THROMBOCYTOPENIC PURPURA; ESCHERICHIA-COLI; NEUROLOGICAL INVOLVEMENT; ANTIBIOTIC-TREATMENT; OUTBREAK; VEROTOXIN; RISK; HUS; ASSOCIATION	Objectives: Shiga-toxin producing O157:H7 Entero Haemorrhagic E. coli (STEC/EHEC) is one of the most common causes of Haemolytic Uraemic Syndrome (HUS) related to infectious haemorrhagic colitis. Nearly all recommendations on clinical management of EHEC infections refer to this strain. The 2011 outbreak in Northern Europe was the first to be caused by the serotype O104:H4. This EHEC strain was found to carry genetic features of Entero Aggregative E. coli (EAEC) and extended spectrum beta lactamase (ESBL). We report symptoms and complications in patients at one of the most affected centres of the 2011 EHEC O104 outbreak in Northern Germany. Methods: The courses of patients admitted to our hospital due to bloody diarrhoea with suspected EHEC O104 infection were recorded prospectively. These data include the patients' histories, clinical findings, and complications. Results: EHEC O104 infection was confirmed in 61 patients (female = 37; mean age: 44+/-2 years). The frequency of HUS was 59% (36/61) in our cohort. An enteric colonisation with co-pathogens was found in 57%. Thirty-one (51%) patients were treated with plasma-separation/plasmapheresis, 16 (26%) with haemodialysis, and 7 (11%) with Eculizumab. Patients receiving antibiotic treatment (n = 37; 61%) experienced no apparent change in their clinical course. Twenty-six (43%) patients suffered from neurological symptoms. One 83-year-old patient died due to comorbidities after HUS was successfully treated. Conclusions: EHEC O104: H4 infections differ markedly from earlier reports on O157: H7 induced enterocolitis in regard to epidemiology, symptomatology, and frequency of complications. We recommend a standard of practice for clinical monitoring and support the renaming of EHEC O104: H4 syndrome as "EAHEC disease".	[Ullrich, Sebastian; Bremer, Phillip; Neumann-Grutzeck, Christine; Otto, Helge; Ruether, Christoph; Hagenmueller, Friedrich] Asklepios Klin Altona, Dept Med Gastroenterol 1, Hamburg, Germany; [von Seydewitz, Cay Uwe] Asklepios Klin Altona, Dept Med Oncol & Haematol 2, Hamburg, Germany; [Meyer, Gerd Peter] Asklepios Klin Altona, Dept Med Cardiol Angiol & Pulmonol Intens Care 3, Hamburg, Germany; [Ahmadi-Simab, Keihan] Asklepios Klin Altona, Dept Med Rheumatol Immunol & Nephrol 4, Hamburg, Germany; [Roether, Joachim] Asklepios Klin Altona, Dept Neurol, Hamburg, Germany; [Hogan, Barbara] Asklepios Klin Altona, Emergency Dept, Hamburg, Germany; [Schwenk, Wolfgang] Asklepios Klin Altona, Dept Surg Gen & Visceral Surg 1, Hamburg, Germany; [Fischbach, Roman] Asklepios Klin Altona, Dept Radiol Neuroradiol & Nucl Med, Hamburg, Germany; [Caselitz, Joerg] Asklepios Klin Altona, Dept Pathol, Hamburg, Germany; [Puttfarcken, Jochen; Huggett, Susanne] Lab Gesell mbh, MEDILYS, Hamburg, Germany; [Tiedeken, Petra] Dialysezentrum Hamburg West, Hamburg, Germany; [Pober, Jordan] Yale Univ, Sch Med, Dept Immunobiol Pathol & Dermatol, New Haven, CT USA; [Kirkiles-Smith, Nancy C.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA	Asklepios Klinik Altona; Asklepios Klinik Altona; Asklepios Klinik Altona; Asklepios Klinik Altona; Asklepios Klinik Altona; Asklepios Klinik Altona; Asklepios Klinik Altona; Asklepios Klinik Altona; Asklepios Klinik Altona; Yale University; Yale University	Ullrich, S (corresponding author), Asklepios Klin Altona, Dept Med Gastroenterol 1, Hamburg, Germany.	mi.ullrich@asklepios.com	Bremer, Phillip/AAE-7842-2020; Schwenk, Wolfgamg/AAB-8515-2021	Fischbach, Roman/0000-0002-2125-6748				Ake JA, 2005, PEDIATRICS, V115, pE673, DOI 10.1542/peds.2004-2236; Aurass P, 2011, ENVIRON MICROBIOL, V13, P3139, DOI 10.1111/j.1462-2920.2011.02604.x; Bae WK, 2006, YONSEI MED J, V47, P437, DOI 10.3349/ymj.2006.47.3.437; Bettelheim KA, 1999, J DIARRHOEAL DIS RES, V17, P34; Bielaszewska M, 2012, ANTIMICROB AGENTS CH, V56, P3277, DOI 10.1128/AAC.06315-11; Bielaszewska M, 2011, LANCET INFECT DIS, V11, P671, DOI 10.1016/S1473-3099(11)70165-7; Bitzan M, 2010, SEMIN THROMB HEMOST, V36, P594, DOI 10.1055/s-0030-1262881; Bitzan M, 2009, KIDNEY INT, V75, pS62, DOI 10.1038/ki.2008.624; Brzuszkiewicz E, 2011, ARCH MICROBIOL, V193, P883, DOI 10.1007/s00203-011-0725-6; Chattaway MA, 2011, J INFECT DEV COUNTR, V5, P425, DOI 10.3855/jidc.2166; CIMOLAI N, 1992, PEDIATRICS, V90, P616; Deutsche Gesellschaft fur Infektiologie, 2011, EHEC ANT; Deutsche Gesellschaft fur Nephrologie, 2011, THER APH BEI EHEC AS; Dolgikh T. I., 2010, Klinicheskaya Laboratornaya Diagnostika, P52; Ducker C, 2011, DEUT MED WOCHENSCHR, V136, P1770, DOI 10.1055/s-0031-1286099; European Food Safety Authority, 2011, TRAC SEEDS PART FEN; Frank C, 2011, NEW ENGL J MED, V365, P1771, DOI 10.1056/NEJMoa1106483; GALLO GE, 1995, PEDIATR NEPHROL, V9, P117, DOI 10.1007/BF00858990; GASSER C, 1955, Schweiz Med Wochenschr, V85, P905; HAHN JS, 1989, J CHILD NEUROL, V4, P108, DOI 10.1177/088307388900400206; HUGHES DA, 1991, SCOT MED J, V36, P9, DOI 10.1177/003693309103600105; Iizuka S, 2005, JPN J INFECT DIS, V58, P329; Karpac CA, 2008, BRIT J HAEMATOL, V141, P696, DOI 10.1111/j.1365-2141.2008.07116.x; Lapeyraque AL, 2011, NEW ENGL J MED, V364, P2561, DOI 10.1056/NEJMc1100859; McGannon CM, 2010, ANTIMICROB AGENTS CH, V54, P3790, DOI 10.1128/AAC.01783-09; Mellmann A, 2008, EMERG INFECT DIS, V14, P1287, DOI 10.3201/eid1408.071082; Michael M, 2009, AM J KIDNEY DIS, V53, P259, DOI 10.1053/j.ajkd.2008.07.038; Michino H, 1999, AM J EPIDEMIOL, V150, P787, DOI 10.1093/oxfordjournals.aje.a010082; Nathanson S, 2010, CLIN J AM SOC NEPHRO, V5, P1218, DOI 10.2215/CJN.08921209; Nayar Deepa M, 2006, J Infect, V52, pe103, DOI 10.1016/j.jinf.2005.07.029; Nitschke M, 2012, JAMA-J AM MED ASSOC, V307, P1046, DOI 10.1001/jama.2012.264; Ochoa TJ, 2007, ANTIMICROB AGENTS CH, V51, P2837, DOI 10.1128/AAC.01397-06; Panos GZ, 2006, ALIMENT PHARM THER, V24, P731, DOI 10.1111/j.1365-2036.2006.03036.x; Pennington H, 2010, LANCET, V376, P1428, DOI 10.1016/S0140-6736(10)60963-4; PROULX F, 1992, J PEDIATR-US, V121, P299, DOI 10.1016/S0022-3476(05)81209-0; Robert Koch Institut, 2011, ABSCHL DARST BEW EP; Robert Koch-Institut, 2011, PRAV ENT EINZ WERN; Safdar N, 2002, JAMA-J AM MED ASSOC, V288, P996, DOI 10.1001/jama.288.8.996; SHETH KJ, 1986, ANN NEUROL, V19, P90, DOI 10.1002/ana.410190120; Steinborn M, 2004, PEDIATR RADIOL, V34, P805, DOI 10.1007/s00247-004-1289-2; Tarr PI, 2005, LANCET, V365, P1073, DOI 10.1016/S0140-6736(05)71144-2; TAYLOR CM, 1986, BRIT MED J, V292, P1513, DOI 10.1136/bmj.292.6534.1513; Wong CS, 2000, NEW ENGL J MED, V342, P1930, DOI 10.1056/NEJM200006293422601; Yoh M, 1999, CAN J MICROBIOL, V45, P732, DOI 10.1139/cjm-45-9-732	44	18	19	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2013	8	2							e55278	10.1371/journal.pone.0055278	http://dx.doi.org/10.1371/journal.pone.0055278			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	098BN	23460784	gold, Green Published, Green Submitted			2023-01-03	WOS:000315519000007
J	Masse, V; Valiquette, L; Boukhoudmi, S; Bonenfant, F; Talab, Y; Carvalho, JC; Alarie, I; Carrier, N; Farand, P				Masse, Vincent; Valiquette, Louis; Boukhoudmi, Soraya; Bonenfant, Francis; Talab, Yasmine; Carvalho, Jean-Christophe; Alarie, Isabelle; Carrier, Nathalie; Farand, Paul			Impact of Methicillin Resistant Staphylococcus aureus Contact Isolation Units on Medical Care	PLOS ONE			English	Article							OF-THE-LITERATURE; PRECAUTIONS	Background: Patient isolation using contact precautions has gained widespread use to halt MRSA transmission, however supportive data is scarce and concerns regarding patient safety and satisfaction have been raised. At our institution, MRSA patients are isolated on a dedicated ward (cohort isolation), rather than in separate rooms. Our objectives were (1) to determine the proportion of bedside medical visits to patients on an isolation ward, (2) to quantify complications in those patients and (3) to determine if those complications are related to isolation and if they can be prevented. Methods: This retrospective case-control study was performed on the two sites of a tertiary teaching hospital in Sherbrooke, QC, Canada. We matched MRSA patients with an admission diagnosis of heart failure or chronic obstructive pulmonary disease to similar non-isolated controls. The proportion of bedside visits was ascertained through the number of progress notes with subjective elements or with a physical examination. Complications were sought through an extensive file review, and events were analysed according to Baker's CAES causality and preventability scales. Results: Overall, 111 patient pairs were analysed (35 with heart failure and 76 with COPD). Isolated patients received less bedside visits (subjective notes/1,000 patient-days: 849.6 vs. 983.3, p = 0,001). Attending physicians (454.5 vs. 451.4, p = 0,02) and residents (347.0 vs. 416.9, p = 0.01) are responsible for this discrepancy, while medical students appear to visit isolated and non-isolated patients equally (116.5 vs. 114.9, p = 0.90). Isolated patients showed a tendency towards longer stay and more preventable complications, although no difference in the total number of complications was observed. Conclusion: Isolated patients have less documented care that suggests less bedside visits from the medical staff, which could hamper the therapeutical relationship. Further studies are needed to explain this finding.	[Masse, Vincent; Valiquette, Louis; Boukhoudmi, Soraya; Alarie, Isabelle] Ctr Hosp Univ Sherbrooke, Div Infect Dis, Sherbrooke, PQ, Canada; [Bonenfant, Francis; Talab, Yasmine; Carvalho, Jean-Christophe; Farand, Paul] Ctr Hosp Univ Sherbrooke, Div Internal Med, Sherbrooke, PQ, Canada; [Valiquette, Louis; Farand, Paul] Ctr Hosp Univ Sherbrooke, Etienne Lessel Res Ctr, Sherbrooke, PQ, Canada	University of Sherbrooke; University of Sherbrooke; University of Sherbrooke	Farand, P (corresponding author), Ctr Hosp Univ Sherbrooke, Div Internal Med, Sherbrooke, PQ, Canada.	Paul.Farand@USherbrooke.ca			University of Sherbrooke	University of Sherbrooke	Funding for the chart review process came from institutional scholarships grants from the University of Sherbrooke. Y.T. received salary support from these grants. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abad C, 2010, J HOSP INFECT, V76, P97, DOI 10.1016/j.jhin.2010.04.027; Baker GR, 2004, CAN MED ASSOC J, V170, P1678, DOI 10.1503/cmaj.1040498; Charlson ME, 2008, J CLIN EPIDEMIOL, V61, P1234, DOI 10.1016/j.jclinepi.2008.01.006; Cooper BS, 2004, BMJ-BRIT MED J, V329, P533, DOI 10.1136/bmj.329.7465.533; Edmond M, 2008, PUBLIC HEALTH ETH-UK, V1, P235, DOI 10.1093/phe/phn014; Evans HL, 2003, SURGERY, V134, P180, DOI 10.1067/msy.2003.222; Kirkland KB, 2009, CLIN INFECT DIS, V48, P766, DOI 10.1086/597090; Marshall C, 2004, J HOSP INFECT, V56, P253, DOI 10.1016/j.jhin.2004.02.001; Morgan DJ, 2009, AM J INFECT CONTROL, V37, P85, DOI 10.1016/j.ajic.2008.04.257; Muto CA, 2003, INFECT CONT HOSP EP, V24, P362, DOI 10.1086/502213; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Saint S, 2003, AM J INFECT CONTROL, V31, P354, DOI 10.1016/S0196-6553(02)48250-8; Stelfox HT, 2003, JAMA-J AM MED ASSOC, V290, P1899, DOI 10.1001/jama.290.14.1899	13	23	23	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2013	8	2							e57057	10.1371/journal.pone.0057057	http://dx.doi.org/10.1371/journal.pone.0057057			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115ZB	23451144	Green Submitted, gold, Green Published			2023-01-03	WOS:000316849500057
J	Kirk-Ballard, H; Wang, ZQ; Acharya, P; Zhang, XH; Yu, YM; Kilroy, G; Ribnicky, D; Cefalu, WT; Floyd, ZE				Kirk-Ballard, Heather; Wang, Zhong Q.; Acharya, Priyanka; Zhang, Xian H.; Yu, Yongmei; Kilroy, Gail; Ribnicky, David; Cefalu, William T.; Floyd, Z. Elizabeth			An Extract of Artemisia dracunculus L. Inhibits Ubiquitin-Proteasome Activity and Preserves Skeletal Muscle Mass in a Murine Model of Diabetes	PLOS ONE			English	Article							FOXO TRANSCRIPTION FACTORS; INSULIN-RESISTANCE; GENE-EXPRESSION; ATROPHY; PATHWAYS; PROTEOLYSIS; MECHANISMS; ATROGIN-1; LIGASES; MURF1	Impaired insulin signaling is a key feature of type 2 diabetes and is associated with increased ubiquitin-proteasome-dependent protein degradation in skeletal muscle. An extract of Artemisia dracunculus L. (termed PMI5011) improves insulin action by increasing insulin signaling in skeletal muscle. We sought to determine if the effect of PMI5011 on insulin signaling extends to regulation of the ubiquitin-proteasome system. C2C12 myotubes and the KK-A(y) murine model of type 2 diabetes were used to evaluate the effect of PMI5011 on steady-state levels of ubiquitylation, proteasome activity and expression of Atrogin-1 and MuRF-1, muscle-specific ubiquitin ligases that are upregulated with impaired insulin signaling. Our results show that PMI5011 inhibits proteasome activity and steady-state ubiquitylation levels in vitro and in vivo. The effect of PMI5011 is mediated by PI3K/Akt signaling and correlates with decreased expression of Atrogin-1 and MuRF-1. Under in vitro conditions of hormonal or fatty acid-induced insulin resistance, PMI5011 improves insulin signaling and reduces Atrogin-1 and MuRF-1 protein levels. In the KK-A(y) murine model of type 2 diabetes, skeletal muscle ubiquitylation and proteasome activity is inhibited and Atrogin-1 and MuRF-1 expression is decreased by PMI5011. PMI5011-mediated changes in the ubiquitin-proteasome system in vivo correlate with increased phosphorylation of Akt and FoxO3a and increased myofiber size. The changes in Atrogin-1 and MuRF-1 expression, ubiquitin-proteasome activity and myofiber size modulated by PMI5011 in the presence of insulin resistance indicate the botanical extract PMI5011 may have therapeutic potential in the preservation of muscle mass in type 2 diabetes.	[Kirk-Ballard, Heather; Acharya, Priyanka; Kilroy, Gail; Floyd, Z. Elizabeth] Pennington Biomed Res Ctr, Ubiquitin Biol Lab, Baton Rouge, LA USA; [Wang, Zhong Q.; Acharya, Priyanka; Zhang, Xian H.; Yu, Yongmei; Cefalu, William T.] Pennington Biomed Res Ctr, Diabet & Nutr Lab, Baton Rouge, LA USA; [Ribnicky, David] Rutgers State Univ, Dept Plant Biol & Pathol, New Brunswick, NJ 08903 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Rutgers State University New Brunswick	Floyd, ZE (corresponding author), Pennington Biomed Res Ctr, Ubiquitin Biol Lab, Baton Rouge, LA USA.	elizabeth.floyd@pbrc.edu	Floyd, Elizabeth/N-1962-2017; Floyd, Elizabeth/W-2758-2019	Floyd, Elizabeth/0000-0002-3002-6186; Floyd, Elizabeth/0000-0002-3002-6186	Botanical Research Center of Pennington Biomedical Research Center; The Biotech Center of Rutgers University; National Center for Complementary and Alternative Medicine; Office of Dietary Supplements [P50AT002776-01]; American Diabetes Association [1-10-BS-55]; Centers of Biomedical Research Excellence [NIH P20-RR021945]; Nutrition Obesity Research Centers [NIH P30-DK072476]; National Institutes of Health; National Center for Complementary & Integrative Health [P50AT002776] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR021945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072476] Funding Source: NIH RePORTER	Botanical Research Center of Pennington Biomedical Research Center; The Biotech Center of Rutgers University; National Center for Complementary and Alternative Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); Office of Dietary Supplements(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Diabetes Association(American Diabetes Association); Centers of Biomedical Research Excellence(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Nutrition Obesity Research Centers; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was supported by pilot funding (ZEF and ZQW) from the Botanical Research Center of Pennington Biomedical Research Center and The Biotech Center of Rutgers University, which is funded by the National Center for Complementary and Alternative Medicine and the Office of Dietary Supplements P50AT002776-01, and the American Diabetes Association (grant 1-10-BS-55, awarded to ZEF). This project used Genomics Core and Cell Biology and Imaging Core facilities that are supported in part by Centers of Biomedical Research Excellence (NIH P20-RR021945) and Nutrition Obesity Research Centers (NIH P30-DK072476) center grants from the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbatecola AM, 2011, J NUTR HEALTH AGING, V15, P890, DOI 10.1007/s12603-011-0366-0; Altun M, 2010, J BIOL CHEM, V285, P39597, DOI 10.1074/jbc.M110.129718; Bassel-Duby R, 2006, ANNU REV BIOCHEM, V75, P19, DOI 10.1146/annurev.biochem.75.103004.142622; Bennett RG, 2000, ENDOCRINOLOGY, V141, P2508, DOI 10.1210/en.141.7.2508; Boden G, 2011, CURR OPIN ENDOCRINOL, V18, P139, DOI 10.1097/MED.0b013e3283444b09; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Carballo-Jane E, 2004, J STEROID BIOCHEM, V88, P191, DOI 10.1016/j.jsbmb.2003.11.012; Chavez JA, 2005, J BIOL CHEM, V280, P20148, DOI 10.1074/jbc.M412769200; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Cohen S, 2009, J CELL BIOL, V185, P1083, DOI 10.1083/jcb.200901052; Du J, 2004, J CLIN INVEST, V113, P115, DOI 10.1172/JCI200418330; Edstrom E, 2006, J GERONTOL A-BIOL, V61, P663, DOI 10.1093/gerona/61.7.663; Fielding RA, 2011, J AM MED DIR ASSOC, V12, P249, DOI 10.1016/j.jamda.2011.01.003; Glass DJ, 2010, CURR TOP MICROBIOL, V346, P267, DOI 10.1007/82_2010_78; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Hasselgren PO, 2001, ANN SURG, V233, P9, DOI 10.1097/00000658-200101000-00003; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Ibrahim RM, 2008, J ANIM SCI, V86, P1426, DOI 10.2527/jas.2007-0618; IKEDA H, 1994, DIABETES RES CLIN PR, V24, pS313, DOI 10.1016/0168-8227(94)90268-2; KETTELHUT IC, 1994, BRAZ J MED BIOL RES, V27, P981; Kim TN, 2012, CLIN ENDOCRINOLOGY; Kisselev AF, 2006, J BIOL CHEM, V281, P8582, DOI 10.1074/jbc.M509043200; Koyama S, 2008, J MOL BIOL, V376, P1224, DOI 10.1016/j.jmb.2007.11.049; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lee CG, 2011, J AM GERIATR SOC, V59, P1217, DOI 10.1111/j.1532-5415.2011.03472.x; Levine ME, 2012, IMPACT INSULIN RESIS; Logendra S, 2006, PHYTOCHEMISTRY, V67, P1539, DOI 10.1016/j.phytochem.2006.05.015; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; MUNOZ KA, 1993, METABOLISM, V42, P1006, DOI 10.1016/0026-0495(93)90014-F; Park SW, 2009, DIABETES CARE, V32, P1993, DOI 10.2337/dc09-0264; Ribnicky DM, 2006, PHYTOMEDICINE, V13, P550, DOI 10.1016/j.phymed.2005.09.007; Ribnicky DM, 2009, INT J PHARMACEUT, V370, P87, DOI 10.1016/j.ijpharm.2008.11.012; Rosenzweig R, 2008, NAT STRUCT MOL BIOL, V15, P573, DOI 10.1038/nsmb.1427; Sacheck JM, 2004, AM J PHYSIOL-ENDOC M, V287, pE591, DOI 10.1152/ajpendo.00073.2004; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Schmidt B, 2008, METABOLISM, V57, pS3, DOI 10.1016/j.metabol.2008.03.001; Sishi B, 2010, EXP PHYSL; Srikanthan P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010805; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Sultan KR, 2006, AM J PHYSIOL-CELL PH, V290, pC650, DOI 10.1152/ajpcell.00163.2005; Wang XN, 2006, ENDOCRINOLOGY, V147, P4160, DOI 10.1210/en.2006-0251; Wang ZQ, 2008, METABOLISM, V57, pS58, DOI 10.1016/j.metabol.2008.04.003; Wang ZQ, 2011, J NUTR BIOCHEM, V22, P71, DOI 10.1016/j.jnutbio.2009.11.015; Wang ZQ, 2009, DIABETES, V58, P1488, DOI 10.2337/db08-0977; Wing SS, 2011, CRIT REV CL LAB SCI, V48, P49, DOI 10.3109/10408363.2011.586171; Winzell MS, 2004, DIABETES, V53, pS215, DOI 10.2337/diabetes.53.suppl_3.S215; Witters LA, 2001, J CLIN INVEST, V108, P1105, DOI 10.1172/JCI14178; Zuberi AR, 2008, METABOLISM, V57, pS10, DOI 10.1016/j.metabol.2008.03.002	49	16	16	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2013	8	2							e57112	10.1371/journal.pone.0057112	http://dx.doi.org/10.1371/journal.pone.0057112			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	093IE	23437325	Green Submitted, Green Published, gold			2023-01-03	WOS:000315184200218
J	Ji, XM; Xie, CH; Hu, DS; Fan, X; Zhou, YJ; Zheng, YJ				Ji, Xuemei; Xie, Conghua; Hu, Desheng; Fan, Xia; Zhou, Yajuan; Zheng, Yingjie			Survival Benefit of Adding Chemotherapy to Intensity Modulated Radiation in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma	PLOS ONE			English	Article							ADJUVANT CHEMOTHERAPY; RANDOMIZED-TRIAL; IN-VIVO; RADIOTHERAPY; CANCER; EXPERIENCE; RADIOSENSITIZATION; CHEMORADIOTHERAPY; GEMCITABINE; POPULATION	Background: To evaluate the contribution of chemotherapy for patients with locoregionally advanced nasopharyngeal carcinoma (NPC) treated by intensity modulated radiotherapy (IMRT) and to identify the optimal combination treatment strategy. Patients and Methods: Between 2006 and 2010, 276 patients with stage II-IVb NPC were treated by IMRT alone or IMRT plus chemotherapy. Cisplatin-based chemotherapy included neoadjuvant or concurrent, or neoadjuvant plus concurrent protocols. The IMRT alone and chemoradiotherapy groups were well-matched for prognostic factors, except N stage, with more advanced NPC in the chemoradiotherapy arm. Results: With a mean follow-up of 33.8 months, the 3-year actuarial rates of overall survival (OS), metastasis-free survival (MFS), relapse-free survival (RFS), and disease-free survival (DFS) were 90.3%, 84.2%, 80.3%, and 69.2% for all of the patients, respectively. Compared with the IMRT alone arm, patients treated by concurrent chemoradiotherapy had a significantly better DFS (HR = 2.64; 95% CI, 1.12-6.22; P = 0.03), patients with neoadjuvant-concurrent chemoradiotherapy had a significant improvement in RFS and DFS (HR = 4.03; 95% CI, 1.35-12.05; P = 0.01 and HR = 2.43; 95% CI, 1.09-5.44; P = 0.03), neoadjuvant chemoradiotherapy provided no significant benefit in OS, MFS, RFS, and DFS. Stage group and alcohol consumption were prognostic factors for OS and N stage was a significant predictor for DFS. Conclusions: Addition of concurrent or neoadjuvant-concurrent chemotherapy to IMRT is available to prolong RFS or DFS for locoregionally advanced NPC. Such work could be helpful to guide effective individualized therapy.	[Ji, Xuemei; Zheng, Yingjie] Capital Med Univ, Beijing Chaoyang Hosp, Dept Radiat Oncol, Beijing, Peoples R China; [Ji, Xuemei; Xie, Conghua; Fan, Xia] Wuhan Univ, Dept Radiat & Med Oncol, Zhongnan Hosp, Wuhan 430072, Peoples R China; [Hu, Desheng; Zhou, Yajuan] Tumor Hosptal Hubei Prov, Dept Radiat Oncol, Wuhan, Peoples R China	Capital Medical University; Wuhan University	Ji, XM (corresponding author), Capital Med Univ, Beijing Chaoyang Hosp, Dept Radiat Oncol, Beijing, Peoples R China.	xuemei.ji@yahoo.com; chxie65@hotmail.com	Ji, Xuemei/B-9774-2015	Ji, Xuemei/0000-0001-7416-9122	National Natural Science Foundation of China [81101561]; UICC American Cancer Society Beginning Investigators Fellowship; American Cancer Society; Scientific Research Foundation	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); UICC American Cancer Society Beginning Investigators Fellowship; American Cancer Society(American Cancer Society); Scientific Research Foundation	This work was supported by National Natural Science Foundation of China (81101561); a UICC American Cancer Society Beginning Investigators Fellowship funded by the American Cancer Society; the Scientific Research Foundation for the Returned Overseas Chinese Scholars from State Education Ministry, China to Xuemei Ji. URL of National Natural Science Foundation of China: http://www.nsfc.gov.cn/Portal0/default152.htm, URL of the American Cancer Society: http://www.cancer.org/, and URL of State Education Ministry, China: http://www.moe.edu.cn/. There are no grant numbers for a UICC American Cancer Society Beginning Investigators Fellowship funded by the American Cancer Society, whose certification is available if needed or can be found in URL: http://www.uicc.org/fellowships/beginning-investigators. There are also no grant numbers for the Scientific Research Foundation for the Returned Overseas Chinese Scholars from State Education Ministry to Xuemei Ji, which is available if needed. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Sarraf M, 1998, J CLIN ONCOL, V16, P1310, DOI 10.1200/JCO.1998.16.4.1310; BEGG AC, 1986, INT J RADIAT BIOL, V50, P871, DOI 10.1080/09553008614551291; Chinese Center for Disease Control and Prevention, 2010, 2008 CAUS DEATH DAT, P57; Fang FM, 2008, INT J RADIAT ONCOL, V72, P356, DOI 10.1016/j.ijrobp.2007.12.054; FERLITO A, 1993, ANN OTO RHINOL LARYN, V102, P666, DOI 10.1177/000348949310200903; Fields MT, 2000, INT J RADIAT ONCOL, V47, P785, DOI 10.1016/S0360-3016(00)00447-8; Ji XM, 2011, INT J CANCER, V129, P724, DOI 10.1002/ijc.25696; Kam MKM, 2007, J CLIN ONCOL, V25, P4873, DOI 10.1200/JCO.2007.11.5501; Kam MKM, 2004, INT J RADIAT ONCOL, V60, P1440, DOI 10.1016/j.ijrobp.2004.05.022; Lai SZ, 2011, INT J RADIAT ONCOL, V80, P661, DOI 10.1016/j.ijrobp.2010.03.024; Langendijk JA, 2004, J CLIN ONCOL, V22, P4604, DOI 10.1200/JCO.2004.10.074; Laskar S, 2008, INT J RADIAT ONCOL, V72, P728, DOI 10.1016/j.ijrobp.2008.01.032; Lee AWM, 2012, SEMIN RADIAT ONCOL, V22, P233, DOI 10.1016/j.semradonc.2012.03.008; Lee AWM, 2010, JNCI-J NATL CANCER I, V102, P1188, DOI 10.1093/jnci/djq258; Lee N, 2002, INT J RADIAT ONCOL, V53, P12, DOI 10.1016/S0360-3016(02)02724-4; LEVINE PH, 1992, CANCER, V70, P1024, DOI 10.1002/1097-0142(19920901)70:5<1024::AID-CNCR2820700503>3.0.CO;2-4; Lin SJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-39; Lu HM, 2008, CANCER TREAT REV, V34, P27, DOI 10.1016/j.ctrv.2007.08.004; Miles EA, 2005, RADIOTHER ONCOL, V77, P241, DOI 10.1016/j.radonc.2005.10.011; National Marine Fisheries Service Southeast Fisheries Center, 2008, NOAA TECHNICAL MEMOR, P92; Ng WT, 2011, INT J RADIAT ONCOL, V79, P420, DOI 10.1016/j.ijrobp.2009.11.024; Nordsmark M, 1996, RADIOTHER ONCOL, V41, P31, DOI 10.1016/S0167-8140(96)91811-3; Rosier JF, 1999, INT J RADIAT BIOL, V75, P245, DOI 10.1080/095530099140708; Su Sheng-Fa, 2011, Chin J Cancer, V30, P565, DOI 10.5732/cjc.010.10547; Teicher BA, 1998, INT J ONCOL, V13, P437; Tham IWK, 2010, AM J CLIN ONCOL-CANC, V33, P294, DOI 10.1097/COC.0b013e3181d2edab; Tham IWK, 2009, INT J RADIAT ONCOL, V75, P1481, DOI 10.1016/j.ijrobp.2009.01.018; Vaughan TL, 1996, CANCER EPIDEM BIOMAR, V5, P587; Wee J, 2005, J CLIN ONCOL, V23, P6730, DOI 10.1200/JCO.2005.16.790; YU MC, 1988, CANCER RES, V48, P1954; Zhou GQ, 2012, INT J RADIAT ONCOL, V82, pE359, DOI 10.1016/j.ijrobp.2011.06.1967; ZHU KM, 1995, CANCER CAUSE CONTROL, V6, P507, DOI 10.1007/BF00054158	32	19	23	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2013	8	2							e56208	10.1371/journal.pone.0056208	http://dx.doi.org/10.1371/journal.pone.0056208			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	092YP	23441169	gold, Green Published, Green Submitted			2023-01-03	WOS:000315159200026
J	Haase, N; Perner, A; Inkeri, L; Siegemund, M; Lauridsen, B; Wetterslev, M; Wetterslev, J				Haase, Nicolai; Perner, Anders; Inkeri, Louise; Siegemund, Martin; Lauridsen, Bo; Wetterslev, Mik; Wetterslev, Jorn			Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CRITICALLY-ILL PATIENTS; ACUTE-RENAL-FAILURE; ACUTE KIDNEY INJURY; VOLUME REPLACEMENT; 6-PERCENT HYDROXYETHYLSTARCH; PULMONARY PERMEABILITY; LIVER-TRANSPLANTATION; FLUID RESUSCITATION; INFORMATION SIZE; MOLECULAR-WEIGHT	Objective To assess the effects of fluid therapy with hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin on mortality, kidney injury, bleeding, and serious adverse events in patients with sepsis. Design Systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. Data sources Cochrane Library, Medline, Embase, Biosis Previews, Science Citation Index Expanded, CINAHL, Current Controlled Trials, Clinicaltrials.gov, and Centerwatch to September 2012; hand search of reference lists and other systematic reviews; contact with authors and relevant pharmaceutical companies. Study selection Eligible trials were randomised clinical trials comparing hydroxyethyl starch 130/0.38-0.45 with either crystalloid or human albumin in patients with sepsis. Published and unpublished trials were included irrespective of language and predefined outcomes. Data extraction Two reviewers independently assessed studies for inclusion and extracted data on methods, interventions, outcomes, and risk of bias. Risk ratios and mean differences with 95% confidence intervals were estimated with fixed and random effects models. Results Nine trials that randomised 3456 patients with sepsis were included. Overall, hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin did not affect the relative risk of death (1.04, 95% confidence interval 0.89 to 1.22, 3414 patients, eight trials), but in the predefined analysis of trials with low risk of bias the relative risk of death was 1.11 (1.00 to 1.23, trial sequential analysis (TSA) adjusted 95% confidence interval 0.95 to 1.29, 3016 patients, four trials). In the hydroxyethyl starch group, renal replacement therapy was used more (1.36, 1.08 to 1.72, TSA adjusted 1.03 to 1.80, 1311 patients, five trials), and the relative risk of acute kidney injury was 1.18 (0.99 to 1.40, TSA adjusted 0.90 to 1.54, 994 patients, four trials). More patients in the hydroxyethyl starch group were transfused with red blood cells (1.29, 1.13 to 1.48, TSA adjusted 1.10 to 1.51, 973 patients, three trials), and more patients had serious adverse events (1.30, 1.02 to 1.67, TSA adjusted 0.93 to 1.83, 1069 patients, four trials). The transfused volume of red blood cells did not differ between the groups (mean difference 65 mL, 95% confidence interval -20 to 149 mL, three trials). Conclusion In conventional meta-analyses including recent trial data, hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin increased the use of renal replacement therapy and transfusion with red blood cells, and resulted in more serious adverse events in patients with sepsis. It seems unlikely that hydroxyethyl starch 130/0.38-0.45 provides overall clinical benefit for patients with sepsis.	[Haase, Nicolai; Perner, Anders; Inkeri, Louise; Lauridsen, Bo; Wetterslev, Mik] Rigshosp, Dept Intens Care, Copenhagen Univ Hosp, DK-2100 Copenhagen, Denmark; [Siegemund, Martin] Baden State Hosp AG, Dept Anaesthesia Intens Care & Rescue Med, Baden, Switzerland; [Wetterslev, Jorn] Rigshosp, Copenhagen Trial Unit, Ctr Clin Intervent Res, Copenhagen Univ Hosp, DK-2200 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Haase, N (corresponding author), Rigshosp, Dept Intens Care, Copenhagen Univ Hosp, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	nicolai.haase@rh.regionh.dk	Wetterslev, Jørn/ABF-1251-2020; Siegemund, Martin/AAM-8929-2020	Wetterslev, Jørn/0000-0001-7778-1771; Siegemund, Martin/0000-0002-2013-4140; Perner, Anders/0000-0002-4668-0123; Hennings, Louise/0000-0001-8383-776X	Danish Research Council; Rigshospitalet Research Council; Scandinavian Society of Anaesthesiology and Intensive Care Medicine (the ACTA foundation); Fresenius Kabi; BioPorto; Department of Anaesthesia and Intensive Care of the University Hospital Basel	Danish Research Council(Det Frie Forskningsrad (DFF)); Rigshospitalet Research Council; Scandinavian Society of Anaesthesiology and Intensive Care Medicine (the ACTA foundation); Fresenius Kabi; BioPorto; Department of Anaesthesia and Intensive Care of the University Hospital Basel	All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: AP was principal investigator for the Scandinavian Starch for Severe Sepsis/Septic Shock (6S) trial and NH and JW were members of the steering committee. The 6S trial was funded by the Danish Research Council, the Rigshospitalet Research Council, and the Scandinavian Society of Anaesthesiology and Intensive Care Medicine (the ACTA foundation). B Braun Melsungen delivered trial fluid to all sites free of charge. Neither the funders nor B Braun Melsungen had an influence on the protocol, trial conduct, data analyses, or reporting of the 6S trial. AP is head of research in his intensive care unit, which receives research funds from Fresenius Kabi and BioPorto. B Braun Melsungen has covered his travel expenses for presenting 6S data at the German Anaesthetic Congress 2012. MS was principal investigator for the Basel starch evaluation in sepsis (BaSES) trial. The BaSES trial was funded by the Department of Anaesthesia and Intensive Care of the University Hospital Basel. Fresenius Kabi delivered study fluids for free and paid for the packaging and blinding process. A signed contract between Fresenius Kabi and MS stated that MS was free to publish all data without influence from Fresenius Kabi. Fresenius Kabi covered travel expenses for MS's participation in meetings about fluid resuscitation.	Ando Y, 2008, J ANESTH, V22, P391, DOI 10.1007/s00540-008-0659-6; [Anonymous], 2012, BASEL STARCH EVALUAT; Asfar P, 2000, INTENS CARE MED, V26, P1282, DOI 10.1007/s001340000606; Bagshaw SM, 2007, CLIN J AM SOC NEPHRO, V2, P431, DOI 10.2215/CJN.03681106; Bellmann R, 2012, CLIN PHARMACOKINET, V51, P225, DOI 10.2165/11594700-000000000-00000; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Boldt J, 1998, INTENS CARE MED, V24, P28, DOI 10.1007/s001340050511; BOLDT J, 1995, BRIT J ANAESTH, V75, P740, DOI 10.1093/bja/75.6.740; Boldt J, 1996, CRIT CARE MED, V24, P385, DOI 10.1097/00003246-199603000-00005; Boldt J, 2004, INTENS CARE MED, V30, P416, DOI 10.1007/s00134-003-2110-7; Boldt J, 1996, BRIT J ANAESTH, V77, P480, DOI 10.1093/bja/77.4.480; Boldt J, 2002, BRIT J ANAESTH, V89, P722, DOI 10.1093/bja/aef242; Boldt J, 2001, INFUS THER TRANSFUS, V28, P144; Boldt J, 2006, ANESTH ANALG, V103, P191, DOI 10.1213/01.ane.0000221179.07006.06; Brok J, 2008, J CLIN EPIDEMIOL, V61, P763, DOI 10.1016/j.jclinepi.2007.10.007; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Bulanov A Iu, 2004, Anesteziol Reanimatol, P25; Bunn F, 2012, COCHRANE DATABASE SY; Chen Feng, 2006, Wuhan Daxue Xuebao (Yixue Ban), V27, P520; Christidis C, 2001, J HEPATOL, V35, P726, DOI 10.1016/S0168-8278(01)00200-8; Clermont G, 2002, KIDNEY INT, V62, P986, DOI 10.1046/j.1523-1755.2002.00509.x; Dart AB, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007594.pub2; Dolecek M, 2009, HEPATO-GASTROENTEROL, V56, P1622; Du XJ, 2011, PANCREAS, V40, P1220, DOI 10.1097/MPA.0b013e3182217f17; Dubin Arnaldo, 2010, J Crit Care, V25, DOI 10.1016/j.jcrc.2010.04.007; Expert Working Group International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2009, ICH HARMONIZATION TR, V51; Finfer S, 2011, INTENS CARE MED, V37, P86, DOI 10.1007/s00134-010-2039-6; Finfer S, 2010, CRIT CARE, V14, DOI 10.1186/cc9293; Franz A, 2001, ANESTH ANALG, V92, P1402, DOI 10.1097/00000539-200106000-00008; Gattas DJ, 2012, ANESTH ANALG, V114, P159, DOI 10.1213/ANE.0b013e318236b4d6; Gondos T, 2010, EUR J ANAESTH, V27, P794, DOI 10.1097/EJA.0b013e32833b3504; Guidet B, 2012, CRIT CARE, V16, DOI 10.1186/cc11358; Haas T, 2007, ANAESTHESIA, V62, P1000, DOI 10.1111/j.1365-2044.2007.05186.x; Harten J, 2008, Int J Surg, V6, P197, DOI 10.1016/j.ijsu.2008.03.002; Hartog CS, 2011, ANESTH ANALG, V112, P635, DOI 10.1213/ANE.0b013e31820ad607; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Higgins JPT, 2011, STAT MED, V30, P903, DOI 10.1002/sim.4088; Jones SB, 2003, ANESTH ANALG, V96, P363, DOI 10.1097/00000539-200302000-00012; Jover JL, 2009, REV ESP ANEST REANIM, V56, P27, DOI 10.1016/S0034-9356(09)70317-2; Kim DH, 2005, TRANSFUS ALTERN TRAN, V7, P79; Kumle B, 1999, ANESTH ANALG, V89, P1124, DOI 10.1213/00000539-199911000-00009; Li Feng, 2008, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V20, P472; Lv Jie, 2012, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V24, P38; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Mukhtar A, 2009, ANESTH ANALG, V109, P924, DOI 10.1213/ane.0b013e3181aed54f; Myburgh JA, 2012, NEW ENGL J MED, V367, P1901, DOI 10.1056/NEJMoa1209759; Palumbo D, 2006, MINERVA ANESTESIOL, V72, P655; Pape L, 2008, PEDIATR NEPHROL, V23, P1630; Perel P, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000567.pub4; Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242; Pillebout E, 2005, AM J TRANSPLANT, V5, P1120, DOI 10.1111/j.1600-6143.2005.00852.x; Protsenko D. N., 2009, Anesteziologiya i Reanimatologiya, P9; Reine PA, 2008, ACTA ANAESTH SCAND, V52, P406, DOI 10.1111/j.1399-6576.2007.01555.x; Schmidt-Hieber M, 2006, EUR J HAEMATOL, V77, P83, DOI 10.1111/j.1600-0609.2006.00657.x; Schortgen F, 2001, LANCET, V357, P911, DOI 10.1016/S0140-6736(00)04211-2; Schramko AA, 2010, PERFUSION-UK, V25, P283, DOI 10.1177/0267659110377819; Sweeting MJ, 2004, STAT MED, V23, P1351, DOI 10.1002/sim.1761; Thomas-Rueddel DO, 2012, INTENS CARE MED, V38, P1134, DOI 10.1007/s00134-012-2560-x; Thorlund K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025491; Trof RJ, 2010, INTENS CARE MED, V36, P697, DOI 10.1007/s00134-010-1776-x; van der Heijden M, 2009, CRIT CARE MED, V37, P1275, DOI 10.1097/CCM.0b013e31819cedfd; Veneman TF, 2004, WIEN KLIN WOCHENSCHR, V116, P305, DOI 10.1007/BF03040900; Verheij J, 2006, BRIT J ANAESTH, V96, P21, DOI 10.1093/bja/aei286; Wetterslev J, 2008, J CLIN EPIDEMIOL, V61, P64, DOI 10.1016/j.jclinepi.2007.03.013; Wetterslev J, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-86; Wills BA, 2005, NEW ENGL J MED, V353, P877, DOI 10.1056/NEJMoa044057; Zhu Guo-chao, 2011, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V23, P150	67	204	217	1	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 15	2013	346								f839	10.1136/bmj.f839	http://dx.doi.org/10.1136/bmj.f839			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	091ZW	23418281	Green Published, hybrid			2023-01-03	WOS:000315089600008
J	Schilling, B; Harasymczuk, M; Schuler, P; Egan, J; Ferrone, S; Whiteside, TL				Schilling, Bastian; Harasymczuk, Malgorzata; Schuler, Patrick; Egan, James; Ferrone, Soldano; Whiteside, Theresa L.			IRX-2, a Novel Immunotherapeutic, Enhances Functions of Human Dendritic Cells	PLOS ONE			English	Article							COLONY-STIMULATING FACTOR; MONOCLONAL-ANTIBODIES; T-CELLS; EFFECTOR-CELLS; FLOW-CYTOMETRY; TUMOR-CELLS; IN-VIVO; CANCER; ANTIGEN; MATURATION	Background: In a recent phase II clinical trial for HNSCC patients, IRX-2, a cell-derived biologic, promoted T-cell infiltration into the tumor and prolonged overall survival. Mechanisms responsible for these IRX-2-mediated effects are unknown. We hypothesized that IRX-2 enhanced tumor antigen-(TA)-specific immunity by up-regulating functions of dendritic cells (DC). Methodology/Principal Findings: Monocyte-derived DC obtained from 18 HNSCC patients and 12 healthy donors were matured using IRX-2 or a mix of TNF-alpha, IL-1 beta and IL-6 ("conv. mix''). Multicolor flow cytometry was used to study the DC phenotype and antigen processing machinery (APM) component expression. ELISPOT and cytotoxicity assays were used to evaluate tumor-reactive cytotoxic T lymphocytes (CTL). IL-12p70 and IL-10 production by DC was measured by Luminex (R) and DC migration toward CCL21 was tested in transwell migration assays. IRX-2-matured DC functions were compared with those of conv. mix-matured DC. IRX-2-matured DC expressed higher levels (p<0.05) of CD11c, CD40, CCR7 as well as LMP2, TAP1, TAP2 and tapasin than conv. mix-matured DC. IRX-2-matured DC migrated significantly better towards CCL21, produced more IL-12p70 and had a higher IL12p70/IL-10 ratio than conv. mix-matured DC (p<0.05 for all). IRX-2-matured DC carried a higher density of tumor antigen-derived peptides, and CTL primed with these DC mediated higher cytotoxicity against tumor targets (p<0.05) compared to the conv. mix-matured DC. Conclusion: Excellent ability of IRX-2 to induce ex vivo DC maturation in HNSCC patients explains, in part, its clinical benefits and emphasizes its utility in ex vivo maturation of DC generated for therapy.	[Schilling, Bastian; Harasymczuk, Malgorzata; Schuler, Patrick; Ferrone, Soldano; Whiteside, Theresa L.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA; [Schilling, Bastian; Harasymczuk, Malgorzata; Schuler, Patrick; Ferrone, Soldano; Whiteside, Theresa L.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA; [Egan, James] IRX Therapeut Inc, Farmingdale, NY USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Whiteside, TL (corresponding author), Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA.	whitesidetl@upmc.edu	Schilling, Bastian/AAY-8646-2020	Schilling, Bastian/0000-0001-8859-4103	National Institutes of Health [PO-1 CA 109688]; NATIONAL CANCER INSTITUTE [P01CA109688] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Research described in this article was supported in part by National Institutes of Health grant PO-1 CA 109688 to TLW. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agnello D, 2003, J CLIN IMMUNOL, V23, P147, DOI 10.1023/A:1023381027062; Ahmadi M, 2008, CANCER RES, V68, P7520, DOI 10.1158/0008-5472.CAN-08-1060; Almand B, 2000, CLIN CANCER RES, V6, P1755; Amigorena S, 2010, CURR OPIN IMMUNOL, V22, P109, DOI 10.1016/j.coi.2010.01.022; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bandoh N, 2005, TISSUE ANTIGENS, V66, P185, DOI 10.1111/j.1399-0039.2005.00462.x; Berinstein NL, 2012, CANCER IMMUNOL IMMUN, V61, P771, DOI 10.1007/s00262-011-1134-z; Butterfield LH, 2008, J IMMUNOTHER, V31, P89, DOI 10.1097/CJI.0b013e318158fce0; Chaux P, 1996, LAB INVEST, V74, P975; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Egan JE, 2007, J IMMUNOTHER, V30, P624, DOI 10.1097/CJI.0b013e3180691593; Frasca L, 2008, J IMMUNOL, V180, P1471, DOI 10.4049/jimmunol.180.3.1471; Gabrilovich DI, 1997, CLIN CANCER RES, V3, P483; HEO DS, 1989, CANCER RES, V49, P5167; Hoffmann TK, 2000, J IMMUNOL, V165, P5938, DOI 10.4049/jimmunol.165.10.5938; Hoffmann TK, 2001, J IMMUNOTHER, V24, P162, DOI 10.1097/00002371-200103000-00011; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Jonuleit H, 1997, EUR J IMMUNOL, V27, P3135, DOI 10.1002/eji.1830271209; Kalinski P, 2009, CURR OPIN INVEST DR, V10, P526; Kim GG, 2007, J IMMUNOL METHODS, V325, P51, DOI 10.1016/j.jim.2007.05.013; Kirkwood JM, 2009, CLIN CANCER RES, V15, P1443, DOI 10.1158/1078-0432.CCR-08-1231; LANGLADEDEMOYEN P, 1994, INT IMMUNOL, V6, P1759, DOI 10.1093/intimm/6.11.1759; Lopez-Abaitero A, 2009, J IMMUNOTHER, V32, P465, DOI 10.1097/CJI.0b013e3181a1c24e; Ma DY, 2009, SEMIN IMMUNOL, V21, P265, DOI 10.1016/j.smim.2009.05.010; Muthuswamy R, 2010, BLOOD, V116, P1454, DOI 10.1182/blood-2009-12-258038; Ogino T, 2003, TISSUE ANTIGENS, V62, P385, DOI 10.1034/j.1399-0039.2003.00114.x; Okada H, 2011, J CLIN ONCOL, V29, P330, DOI 10.1200/JCO.2010.30.7744; Pinzon-Charry A, 2005, IMMUNOL CELL BIOL, V83, P451, DOI 10.1111/j.1440-1711.2005.01371.x; Poon IKH, 2010, J LEUKOCYTE BIOL, V88, P559, DOI 10.1189/jlb.0210087; Procko E, 2009, CURR OPIN IMMUNOL, V21, P84, DOI 10.1016/j.coi.2009.02.003; Rapidis AD, 2009, J ONCOL, V2009, DOI 10.1155/2009/346345; Sousa CR, 2006, NAT REV IMMUNOL, V6, P476, DOI 10.1038/nri1845; Sadhu C, 2007, J LEUKOCYTE BIOL, V81, P1395, DOI 10.1189/jlb.1106680; Schilling B, 2012, J MOL MED, V90, P139, DOI 10.1007/s00109-011-0813-8; TEMPONI M, 1989, HYBRIDOMA, V8, P85, DOI 10.1089/hyb.1989.8.85; Visus C, 2007, CANCER RES, V67, P10538, DOI 10.1158/0008-5472.CAN-07-1346; Wang XH, 2005, J IMMUNOL METHODS, V299, P139, DOI 10.1016/j.jim.2005.02.006; Whiteside TL, 2012, CANCER IMMUNOL IMMUN, V61, P783, DOI 10.1007/s00262-011-1136-x; Whiteside TL, 2004, J IMMUNOL, V173, P1526, DOI 10.4049/jimmunol.173.3.1526; Wolf GT, 2011, HEAD NECK-J SCI SPEC, V33, P1666, DOI 10.1002/hed.21660; Young MRI, 1997, INT J CANCER, V74, P69, DOI 10.1002/(SICI)1097-0215(19970220)74:1<69::AID-IJC12>3.0.CO;2-D	41	14	14	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2013	8	2							e47234	10.1371/journal.pone.0047234	http://dx.doi.org/10.1371/journal.pone.0047234			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	092XV	23408925	gold, Green Accepted, Green Published			2023-01-03	WOS:000315157200002
J	Stoneman, P; Sturgis, P; Allum, N; Sibley, E				Stoneman, Paul; Sturgis, Patrick; Allum, Nick; Sibley, Elissa			Incommensurable Worldviews? Is Public Use of Complementary and Alternative Medicines Incompatible with Support for Science and Conventional Medicine?	PLOS ONE			English	Article							CONTROLLED-TRIALS; HOMEOPATHY; ATTITUDES; POPULATION; THERAPIES; CARE	Proponents of controversial Complementary and Alternative Medicines, such as homeopathy, argue that these treatments can be used with great effect in addition to, and sometimes instead of, 'conventional' medicine. In doing so, they accept the idea that the scientific approach to the evaluation of treatment does not undermine use of and support for some of the more controversial CAM treatments. For those adhering to the scientific canon, however, such efficacy claims lack the requisite evidential basis from randomised controlled trials. It is not clear, however, whether such opposition characterises the views of the general public. In this paper we use data from the 2009 Wellcome Monitor survey to investigate public use of and beliefs about the efficacy of a prominent and controversial CAM within the United Kingdom, homeopathy. We proceed by using Latent Class Analysis to assess whether it is possible to identify a sub-group of the population who are at ease in combining support for science and conventional medicine with use of CAM treatments, and belief in the efficacy of homeopathy. Our results suggest that over 40% of the British public maintain positive evaluations of both homeopathy and conventional medicine simultaneously. Explanatory analyses reveal that simultaneous support for a controversial CAM treatment and conventional medicine is, in part, explained by a lack of scientific knowledge as well as concerns about the regulation of medical research.	[Stoneman, Paul] Univ Surrey, Dept Sociol, Guildford GU2 5XH, Surrey, England; [Sturgis, Patrick] Univ Southampton, Natl Ctr Res Methods, Southampton, Hants, England; [Allum, Nick; Sibley, Elissa] Univ Essex, Dept Sociol, Colchester CO4 3SQ, Essex, England	University of Surrey; University of Southampton; University of Essex	Stoneman, P (corresponding author), Univ Surrey, Dept Sociol, Guildford GU2 5XH, Surrey, England.	p.stoneman@surrey.ac.uk			Wellcome Trust [EDU/28/4/20/SotonUni/DO18-1299]	Wellcome Trust(Wellcome TrustEuropean Commission)	This research was funded by the Wellcome Trust, as part of the 'Developing a novel segmentation of adults and young people in relation to biomedical science' project, grant reference number: EDU/28/4/20/SotonUni/DO18-1299. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AAPOR, 2016, STAND DEF FIN DISP C; [Anonymous], 1987, SAGE U PAPER SERIES; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; Bains SS, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-138; Barry CA, 2006, SOC SCI MED, V62, P2646, DOI 10.1016/j.socscimed.2005.11.025; Berman BM, 2000, ALTERN THER HEALTH M, V6, P98; Beyerstein BL, 2001, ACAD MED, V76, P230, DOI 10.1097/00001888-200103000-00009; Blais R, 1997, CAN J PUBLIC HEALTH, V88, P159, DOI 10.1007/BF03403880; Boissel JP, 1996, CRITICAL LIT REV EFF, V1996, P195; Braun LA, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-38; Butt S., 2009, WELLCOME TRUST MONIT; Callahan D., 2002, HAST CENT S; Caulfield Timothy, 2005, BMC Complement Altern Med, V5, P12, DOI 10.1186/1472-6882-5-12; Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65; Conboy Lisa, 2007, Complement Ther Clin Pract, V13, P146, DOI 10.1016/j.ctcp.2006.12.003; Cucherat M, 2000, EUR J CLIN PHARMACOL, V56, P27, DOI 10.1007/s002280050716; Easthope G, 2000, SOC SCI MED, V51, P1555, DOI 10.1016/S0277-9536(00)00048-4; Ernst E, 2008, BRIT J CLIN PHARMACO, V65, P163, DOI 10.1111/j.1365-2125.2007.03007.x; Ernst E, 2002, BRIT J CLIN PHARMACO, V54, P577, DOI 10.1046/j.1365-2125.2002.01699.x; Ernst E, 1999, J MANIP PHYSIOL THER, V22, P87, DOI 10.1016/S0161-4754(99)70112-0; Ernst E, 2012, GUARDIAN NEWSPA 0403; Ernst E, 2007, J HEALTH PSYCHOL, V12, P868, DOI 10.1177/1359105307082448; Goldacre B, 2007, LANCET, V370, P1672, DOI 10.1016/S0140-6736(07)61706-1; Grossinger R, 1998, HOMEOPATHY GREAT RID; Hameen-Anttila KP, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-107; Hori S, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-14; House of Commons (HoC) Report, 2010, 4 HOC; Hyland ME, 2003, COMPLEMENT THER MED, V11, P33, DOI 10.1016/S0965-2299(02)00113-9; KISH L, 1962, J AM STAT ASSOC, V57, P92, DOI 10.2307/2282442; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; Kuha J, 2004, SOCIOL METHOD RES, V33, P188, DOI 10.1177/0049124103262065; Linde K, 1998, J ALTERN COMPLEM MED, V4, P371, DOI 10.1089/acm.1998.4.371; MacLennan AH, 2002, PREV MED, V35, P166, DOI 10.1006/pmed.2002.1057; Metcalfe A, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-58; Miller JD, 1998, PUBLIC UNDERST SCI, V7, P203, DOI 10.1088/0963-6625/7/3/001; Muth?n B., 2001, NEW DEV TECHNIQUES S, V2, P1, DOI DOI 10.4324/9781410601858-6; Nagin DS, 1999, PSYCHOL METHODS, V4, P139, DOI 10.1037/1082-989X.4.2.139; Nguyen LT, 2011, J GEN INTERN MED, V26, P399, DOI 10.1007/s11606-010-1542-3; O'Mathuna DP, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002766.pub2; Pawluch D, 2000, SOC SCI MED, V51, P251, DOI 10.1016/S0277-9536(99)00450-5; Sehon S, 2010, J EVAL CLIN PRACT, V16, P276, DOI 10.1111/j.1365-2753.2010.01384.x; Shang AJ, 2005, LANCET, V366, P726, DOI 10.1016/S0140-6736(05)67177-2; Testerman J, 2004, COMPLEMENT HLTH PRAC, V9, P81, DOI [10.1177/1076167503261254, DOI 10.1177/1076167503261254]; Vermunt J. K., 1997, ADV QUANTITATIVE TEC, V8; Vincent C, 1997, COMPLEMENTARY MED RE; Walach H, 2009, J ALTERN COMPLEM MED, V15, P1139, DOI 10.1089/acm.2009.0423; YATES PM, 1993, SOCIOL HEALTH ILL, V15, P199, DOI 10.1111/1467-9566.ep11346886	47	7	7	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2013	8	1							e53174	10.1371/journal.pone.0053174	http://dx.doi.org/10.1371/journal.pone.0053174			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	098QM	23382836	Green Accepted, Green Submitted, Green Published, gold			2023-01-03	WOS:000315563800019
J	Liu, Y; Whelan, RJ; Pattnaik, BR; Ludwig, K; Subudhi, E; Rowland, H; Claussen, N; Zucker, N; Uppal, S; Kushner, DM; Felder, M; Patankar, MS; Kapur, A				Liu, Yang; Whelan, Rebecca J.; Pattnaik, Bikash R.; Ludwig, Kai; Subudhi, Enkateswar; Rowland, Helen; Claussen, Nick; Zucker, Noah; Uppal, Shitanshu; Kushner, David M.; Felder, Mildred; Patankar, Manish S.; Kapur, Arvinder			Terpenoids from Zingiber officinale (Ginger) Induce Apoptosis in Endometrial Cancer Cells through the Activation of p53	PLOS ONE			English	Article							PHASE-III TRIAL; DOXORUBICIN PLUS CISPLATIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; MOUSE SKIN; CARCINOMA; PACLITAXEL; GROWTH; FILGRASTIM; INHIBITION	Novel strategies are necessary to improve chemotherapy response in advanced and recurrent endometrial cancer. Here, we demonstrate that terpenoids present in the Steam Distilled Extract of Ginger (SDGE) are potent inhibitors of proliferation of endometrial cancer cells. SDGE, isolated from six different batches of ginger rhizomes, consistently inhibited proliferation of the endometrial cancer cell lines Ishikawa and ECC-1 at IC50 of 1.25 mu g/ml. SDGE also enhanced the anti-proliferative effect of radiation and cisplatin. Decreased proliferation of Ishikawa and ECC-1 cells was a direct result of SDGE-induced apoptosis as demonstrated by FITC-Annexin V staining and expression of cleaved caspase 3. GC/MS analysis identified a total of 22 different terpenoid compounds in SDGE, with the isomers neral and geranial constituting 30-40%. Citral, a mixture of neral and geranial inhibited the proliferation of Ishikawa and ECC-1 cells at an IC50 10 mu M (2.3 mu g/ml). Phenolic compounds such as gingerol and shogaol were not detected in SDGE and 6-gingerol was a weaker inhibitor of the proliferation of the endometrial cancer cells. SDGE was more effective in inducing cancer cell death than citral, suggesting that other terpenes present in SDGE were also contributing to endometrial cancer cell death. SDGE treatment resulted in a rapid and strong increase in intracellular calcium and a 20-40% decrease in the mitochondrial membrane potential. Ser-15 of p53 was phosphorylated after 15 min treatment of the cancer cells with SDGE. This increase in p53 was associated with 90% decrease in Bcl2 whereas no effect was observed on Bax. Inhibitor of p53, pifithrin-alpha, attenuated the anti-cancer effects of SDGE and apoptosis was also not observed in the p53(neg) SKOV-3 cells. Our studies demonstrate that terpenoids from SDGE mediate apoptosis by activating p53 and should be therefore be investigated as agents for the treatment of endometrial cancer.	[Liu, Yang] Shandong Univ, Dept Obstet & Gynecol, Qi Lu Hosp, Jinan, Peoples R China; [Liu, Yang; Ludwig, Kai; Rowland, Helen; Claussen, Nick; Zucker, Noah; Uppal, Shitanshu; Kushner, David M.; Felder, Mildred; Patankar, Manish S.; Kapur, Arvinder] Univ Wisconsin, Dept Obstet & Gynecol, Madison, WI 53706 USA; [Whelan, Rebecca J.] Oberlin Coll, Dept Chem & Biochem, Oberlin, OH 44074 USA; [Pattnaik, Bikash R.] Univ Wisconsin, Dept Pediat, Madison, WI USA; [Subudhi, Enkateswar] Siksha O Anusandhan Univ, Ctr Biotechnol, Bhubaneswar, Orissa, India	Shandong University; University of Wisconsin System; University of Wisconsin Madison; Oberlin College; University of Wisconsin System; University of Wisconsin Madison; Siksha 'O' Anusandhan University	Patankar, MS (corresponding author), Univ Wisconsin, Dept Obstet & Gynecol, Madison, WI 53706 USA.	patankar@wisc.edu; akaur@wisc.edu	Uppal, Shitanshu/D-9374-2015; Whelan, Rebecca/J-7861-2019; Subudhi, Enketeswara/B-6206-2016	Uppal, Shitanshu/0000-0002-8329-6948; Whelan, Rebecca/0000-0002-9293-1528; Subudhi, Enketeswara/0000-0003-0571-6940; Ludwig, Kai/0000-0001-9867-9346; Pattnaik, Bikash/0000-0002-5385-358X	Department of Obstetrics and Gynecology; Wisconsin Ovarian Cancer Alliance; Rebecca Meyer Brown Professorship of the UW-Eye Research Institute (Retina Research Foundation); University of Wisconsin Comprehensive Cancer Centers; National Institutes of Health [CA14520]; NATIONAL CANCER INSTITUTE [P30CA014520] Funding Source: NIH RePORTER	Department of Obstetrics and Gynecology; Wisconsin Ovarian Cancer Alliance; Rebecca Meyer Brown Professorship of the UW-Eye Research Institute (Retina Research Foundation); University of Wisconsin Comprehensive Cancer Centers; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funding for this research was provided by grants from the Department of Obstetrics and Gynecology to AK and MSP, a charitable donation from Jean McKenzie and research grants from the Wisconsin Ovarian Cancer Alliance to MSP and the Rebecca Meyer Brown Professorship of the UW-Eye Research Institute (Retina Research Foundation) to BRP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We are deeply grateful to Dagna Sheerar and Karen Erslund (University of Wisconsin-Madison Paul P. Carbone Comprehensive Cancer Center, Flow Cytometry Facility) for their advice and help with the flow cytometry assays, to Rob McClain (Department of Chemistry) for his help with the GC-MS analysis, Dr. Randy Kimple and Molly Smith for their assistance with the irradiation of cells, and Jennifer Gubbels (Augustana College, Sioux Falls, ND) for critical reading of the manuscript. We also acknowledge the support provided by the University of Wisconsin Comprehensive Cancer Centers Flow Cytometry facility which is supported by a core grant (CA14520) from the National Institutes of Health.	Adams R.P., 2007, IDENTIFICATION ESSEN, V4th; Bagci EZ, 2006, BIOPHYS J, V90, P1546, DOI 10.1529/biophysj.105.068122; Brown AC, 2009, PHYTOTHER RES, V23, P640, DOI 10.1002/ptr.2677; Chen CY, 2008, J NAT PROD, V71, P137, DOI 10.1021/np070279y; Choudhury D, 2010, FOOD CHEM TOXICOL, V48, P2872, DOI 10.1016/j.fct.2010.07.020; COHEN CJ, 1984, OBSTET GYNECOL, V63, P719; Creasman WT, 2006, INT J GYNECOL OBSTET, V95, pS105, DOI 10.1016/S0020-7292(06)60031-3; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Fleming GF, 2004, J CLIN ONCOL, V22, P2159, DOI 10.1200/JCO.2004.07.184; Fleming GF, 2004, ANN ONCOL, V15, P1173, DOI 10.1093/annonc/mdh316; Gallion HH, 2003, J CLIN ONCOL, V21, P3808, DOI 10.1200/JCO.2003.10.083; Gehrig PA, 2010, GYNECOL ONCOL, V116, P187, DOI 10.1016/j.ygyno.2009.10.041; Hemann MT, 2006, CELL DEATH DIFFER, V13, P1256, DOI 10.1038/sj.cdd.4401962; Homesley HD, 2009, GYNECOL ONCOL, V112, P543, DOI 10.1016/j.ygyno.2008.11.014; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Huang HC, 2011, BIOSCI BIOTECH BIOCH, V75, P1067, DOI 10.1271/bbb.100851; Ishiguro K, 2007, BIOCHEM BIOPH RES CO, V362, P218, DOI 10.1016/j.bbrc.2007.08.012; Jeong CH, 2009, CANCER RES, V69, P5584, DOI 10.1158/0008-5472.CAN-09-0491; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Ju SA, 2012, INT J CANCER, V130, P2618, DOI 10.1002/ijc.26316; Katiyar SK, 1996, CANCER RES, V56, P1023; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Krell J, 2012, LANCET ONCOL, V13, P235, DOI 10.1016/S1470-2045(12)70097-9; Lee C, 2011, FOOD CHEM TOXICOL, V49, P1261, DOI 10.1016/j.fct.2011.03.005; Lee HS, 2008, J NUTR BIOCHEM, V19, P313, DOI 10.1016/j.jnutbio.2007.05.008; Lee SH, 2008, MOL CARCINOGEN, V47, P197, DOI 10.1002/mc.20374; LUNA RMD, 1995, NATURE, V378, P203; Mo B, 2006, BIOL REPROD, V75, P387, DOI 10.1095/biolreprod.106.051870; Nigam N, 2010, CANCER CHEMOTH PHARM, V65, P687, DOI 10.1007/s00280-009-1074-x; Nishida M, 1985, Nihon Sanka Fujinka Gakkai Zasshi, V37, P1103; Pan MH, 2008, MOL NUTR FOOD RES, V52, P527, DOI 10.1002/mnfr.200700157; Park EJ, 2002, CANCER METAST REV, V21, P231, DOI 10.1023/A:1021254725842; Randall ME, 2006, J CLIN ONCOL, V24, P36, DOI 10.1200/JCO.2004.00.7617; Rhode Jennifer, 2007, BMC Complement Altern Med, V7, P44, DOI 10.1186/1472-6882-7-44; Riyazi A, 2007, PLANTA MED, V73, P355, DOI 10.1055/s-2007-967171; SATYASWAROOP PG, 1991, CANCER RES, V51, P5661; Shahzad MMK, 2011, NEOPLASIA, V13, P309, DOI 10.1593/neo.101372; Shukla Y, 2007, MOL NUTR FOOD RES, V51, P1492, DOI 10.1002/mnfr.200700197; Shukla Y, 2007, FOOD CHEM TOXICOL, V45, P683, DOI 10.1016/j.fct.2006.11.002; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Spinner DM, 2000, METH MOLEC MED, V39, P175; Sullivan KD, 2012, BBA-REV CANCER, V1825, P229, DOI 10.1016/j.bbcan.2012.01.004; Thigpen JT, 2004, J CLIN ONCOL, V22, P3902, DOI 10.1200/JCO.2004.02.088; Weng CJ, 2010, MOL NUTR FOOD RES, V54, P1618, DOI 10.1002/mnfr.201000108; Wohlmuth H, 2006, J AGR FOOD CHEM, V54, P1414, DOI 10.1021/jf0521799; YAGINUMA Y, 1992, CANCER RES, V52, P4196; Yodkeeree S, 2009, CANCER RES, V69, P6581, DOI 10.1158/0008-5472.CAN-09-1161; Zhang SY, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/936030	48	64	68	0	63	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2012	7	12							e53178	10.1371/journal.pone.0053178	http://dx.doi.org/10.1371/journal.pone.0053178			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	075GO	23300887	Green Published, gold, Green Submitted			2023-01-03	WOS:000313872600067
J	Ju, JM; Qi, ZC; Cai, XT; Cao, P; Huang, Y; Wang, SZ; Liu, N; Chen, YJ				Ju, Jianming; Qi, Zhichao; Cai, Xueting; Cao, Peng; Huang, Yan; Wang, Shuzhen; Liu, Nan; Chen, Yijun			The Apoptotic Effects of Toosendanin Are Partially Mediated by Activation of Deoxycytidine Kinase in HL-60 Cells	PLOS ONE			English	Article							CHINESE TRADITIONAL MEDICINE; HUMAN CANCER-CELLS; HUMAN-LYMPHOCYTES; NUCLEOSIDE ANALOGS; DNA-SYNTHESIS; PHOSPHORYLATION; INHIBITION; CYTOTOXICITY; IRRADIATION; BINDING	Triterpenoid toosendanin (TSN) exhibits potent cytotoxic activity through inducing apoptosis in a variety of cancer cell lines. However, the target and mechanism of the apoptotic effects by TSN remain unknown. In this study, we captured a specific binding protein of TSN in HL-60 cells by serial affinity chromatography and further identified it as deoxycytidine kinase (dCK). Combination of direct activation of dCK and inhibition of TSN-induced apoptosis by a dCK inhibitor confirmed that dCK is a target for TSN partially responsible for the apoptosis in HL-60 cells. Moreover, the activation of dCK by TSN was a result of conformational change, rather than auto-phosphorylation. Our results further imply that, in addition to the dATP increase by dCK activation in tumor cells, dCK may also involve in the apoptotic regulation.	[Ju, Jianming; Qi, Zhichao; Huang, Yan; Wang, Shuzhen; Liu, Nan; Chen, Yijun] China Pharmaceut Univ, State Key Lab Nat Med, Nanjing, Jiangsu, Peoples R China; [Ju, Jianming; Qi, Zhichao; Huang, Yan; Wang, Shuzhen; Liu, Nan; Chen, Yijun] China Pharmaceut Univ, Biol Chem Lab, Nanjing, Jiangsu, Peoples R China; [Ju, Jianming; Cai, Xueting; Cao, Peng] Jiangsu Prov Acad Tradit Chinese Med, Dept Pharmaceut Anal & Metabol, Nanjing, Jiangsu, Peoples R China	China Pharmaceutical University; China Pharmaceutical University; Nanjing University of Chinese Medicine	Liu, N (corresponding author), China Pharmaceut Univ, State Key Lab Nat Med, Nanjing, Jiangsu, Peoples R China.	liunan0428@yahoo.com.cn; yjchen@cpu.edu.cn	Chen, Yijun/H-3209-2019; Wang, Shuzhen/L-2895-2016	Chen, Yijun/0000-0002-4920-152X; Wang, Shuzhen/0000-0003-3869-2463; , Peng/0000-0002-2044-3074	Ministry of Education of China; State Administration of Foreign Export Affairs of China [111-2-07]; National Natural Science Foundation of China [81001378, 81102467]; State Key Laboratory of Natural Medicines, China Pharmaceutical University [SKLNMKF201208]	Ministry of Education of China(Ministry of Education, China); State Administration of Foreign Export Affairs of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Key Laboratory of Natural Medicines, China Pharmaceutical University	This work was supported by the grants from the "111'' Project from the Ministry of Education of China and the State Administration of Foreign Export Affairs of China (No. 111-2-07), the National Natural Science Foundation of China (No. 81001378 and No. 81102467) and the Open Project Program of State Key Laboratory of Natural Medicines, China Pharmaceutical University (No. SKLNMKF201208). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; Bierau J, 2006, CANCER CHEMOTH PHARM, V57, P105, DOI 10.1007/s00280-005-0005-8; Carpinella MC, 2003, J AGR FOOD CHEM, V51, P369, DOI 10.1021/jf025811w; Chung C.-C., 1975, ACTA CHIM SINICA, V33, P35; Csapo Z, 2003, BIOCHEM PHARMACOL, V65, P2031, DOI 10.1016/S0006-2952(03)00182-5; Csapo Z, 2001, BIOCHEM PHARMACOL, V61, P191, DOI 10.1016/S0006-2952(00)00534-7; Guo Y, 2012, J AGR FOOD CHEM, V60, P7016, DOI 10.1021/jf301734h; He YJ, 2010, PLANTA MED, V76, P1447, DOI 10.1055/s-0029-1240902; Ju JM, 2012, TOXICOL IN VITRO; Keszler G, 2005, ARCH BIOCHEM BIOPHYS, V436, P69, DOI 10.1016/j.abb.2005.01.009; Keszler G, 2004, NUCLEOS NUCLEOT NUCL, V23, P1335, DOI 10.1081/NCN-200027586; Keszler G, 2004, BIOCHEM PHARMACOL, V67, P947, DOI 10.1016/j.bcp.2003.10.019; Kotake Y, 2007, NAT CHEM BIOL, V3, P570, DOI 10.1038/nchembio.2007.16; LI PZ, 1982, CHIN TRADIT HERB DRU, V13, P28; Liu Qian, 2010, Journal of China Pharmaceutical University, V41, P451; McSorley T, 2008, FEBS LETT, V582, P720, DOI 10.1016/j.febslet.2008.01.048; Paintsil E, 2011, ANTIMICROB AGENTS CH, V55, P895, DOI 10.1128/AAC.01303-10; PLAGEMANN PGW, 1978, CANCER RES, V38, P978; Raynal NJM, 2011, LEUKEMIA RES, V35, P110, DOI 10.1016/j.leukres.2010.04.014; Sabini E, 2003, NAT STRUCT BIOL, V10, P513, DOI 10.1038/nsb942; Sabini E, 2007, NUCLEIC ACIDS RES, V35, P186, DOI 10.1093/nar/gkl1038; Saiki Y, 2012, BIOCHEM BIOPH RES CO, V421, P98, DOI 10.1016/j.bbrc.2012.03.122; Sasvari-Szekely M, 1998, BIOCHEM PHARMACOL, V56, P1175, DOI 10.1016/S0006-2952(98)00108-7; Sato S, 2011, CHEM BIOL, V18, P131, DOI 10.1016/j.chembiol.2010.10.017; Shi YL, 2007, PROG NEUROBIOL, V82, P1, DOI 10.1016/j.pneurobio.2007.02.002; Shu G.X., 1980, ACTA CHIM SINICA, V38, P196; Smal C, 2006, J BIOL CHEM, V281, P4887, DOI 10.1074/jbc.M512129200; Smal C, 2010, NUCLEOS NUCLEOT NUCL, V29, P404, DOI 10.1080/15257771003741216; Spasokoukotskaja T, 1999, EUR J CANCER, V35, P1862, DOI 10.1016/S0959-8049(99)00223-3; Tang MZ, 2004, TOXICOLOGY, V201, P31, DOI 10.1016/j.tox.2004.03.023; Titov DV, 2011, NAT CHEM BIOL, V7, P182, DOI 10.1038/NCHEMBIO.522; Toy G, 2010, P NATL ACAD SCI USA, V107, P5551, DOI 10.1073/pnas.0913900107; Van den Neste E, 2003, BIOCHEM PHARMACOL, V65, P573, DOI 10.1016/S0006-2952(02)01559-9; Wu GS, 2003, J COMPUT CHEM, V24, P1549, DOI 10.1002/jcc.10306; Yamamoto K, 2006, ANAL BIOCHEM, V352, P15, DOI 10.1016/j.ab.2006.02.008; Yu JCH, 2004, NEUROSIGNALS, V13, P248, DOI 10.1159/000079339; Yu XC, 2010, J BIOMOL SCREEN, V15, P72, DOI 10.1177/1087057109353604; Zhang B, 2005, INVEST NEW DRUG, V23, P547, DOI 10.1007/s10637-005-0909-5; Zhang J, 2008, ANAL CHIM ACTA, V622, P182, DOI 10.1016/j.aca.2008.05.046; Zhou JY, 2003, FEBS LETT, V555, P375, DOI 10.1016/S0014-5793(03)01291-2; ZOU J, 1985, Journal of Traditional Chinese Medicine, V5, P29	41	14	18	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2012	7	12							e52536	10.1371/journal.pone.0052536	http://dx.doi.org/10.1371/journal.pone.0052536			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	061EA	23300702	Green Published, gold, Green Submitted			2023-01-03	WOS:000312829100061
J	Balducci, S; Zanuso, S; Cardelli, P; Salvi, L; Bazuro, A; Pugliese, L; Maccora, C; Iacobini, C; Conti, FG; Nicolucci, A; Pugliese, G				Balducci, Stefano; Zanuso, Silvano; Cardelli, Patrizia; Salvi, Laura; Bazuro, Alessandra; Pugliese, Luca; Maccora, Carla; Iacobini, Carla; Conti, Francesco G.; Nicolucci, Antonio; Pugliese, Giuseppe		IDES Investigators	Effect of High- versus Low- Intensity Supervised Aerobic and Resistance Training on Modifiable Cardiovascular Risk Factors in Type 2 Diabetes; The Italian Diabetes and Exercise Study (IDES)	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; CORONARY-HEART-DISEASE; TIME PHYSICAL-ACTIVITY; QUALITY-OF-LIFE; CARDIORESPIRATORY FITNESS; MODERATE-INTENSITY; GLYCEMIC CONTROL; WEIGHT-LOSS; IMPROVEMENTS; METAANALYSIS	Background: While current recommendations on exercise type and volume have strong experimental bases, there is no clear evidence from large-sized studies indicating whether increasing training intensity provides additional benefits to subjects with type 2 diabetes. Objective: To compare the effects of moderate-to-high intensity (HI) versus low-to-moderate intensity (LI) training of equal energy cost, i.e. exercise volume, on modifiable cardiovascular risk factors. Design: Pre-specified sub-analysis of the Italian Diabetes and Exercise Study (IDES), a randomized multicenter prospective trial comparing a supervised exercise intervention with standard care for 12 months (2005-2006). Setting: Twenty-two outpatient diabetes clinics across Italy. Patients: Sedentary patients with type 2 diabetes assigned to twice-a-week supervised progressive aerobic and resistance training plus exercise counseling (n = 303). Interventions: Subjects were randomized by center to LI (n = 142, 136 completed) or HI (n = 161, 152 completed) progressive aerobic and resistance training, i.e. at 55% or 70% of predicted maximal oxygen consumption and at 60% or 80% of predicted 1-Repetition Maximum, respectively, of equal volume. Main Outcome Measure(s): Hemoglobin (Hb) A(1c) and other cardiovascular risk factors; 10-year coronary heart disease (CHD) risk scores. Results: Volume of physical activity, both supervised and non-supervised, was similar in LI and HI participants. Compared with LI training, HI training produced only clinically marginal, though statistically significant, improvements in HbA(1c) (mean difference -0.17% [95% confidence interval -0.44,0.10], P = 0.03), triglycerides (-0.12 mmol/l [-0.34,0.10], P = 0.02) and total cholesterol (-0.24 mmol/l [-0.46, -0.01], P = 0.04), but not in other risk factors and CHD risk scores. However, intensity was not an independent predictor of reduction of any of these parameters. Adverse event rate was similar in HI and LI subjects. Conclusions: Data from the large IDES cohort indicate that, in low-fitness individuals such as sedentary subjects with type 2 diabetes, increasing exercise intensity is not harmful, but does not provide additional benefits on cardiovascular risk factors.	[Balducci, Stefano; Cardelli, Patrizia; Salvi, Laura; Bazuro, Alessandra; Pugliese, Luca; Maccora, Carla; Iacobini, Carla; Conti, Francesco G.; Pugliese, Giuseppe] Univ Roma La Sapienza, Dept Clin & Mol Med, Rome, Italy; [Balducci, Stefano; Salvi, Laura; Bazuro, Alessandra; Pugliese, Luca; Maccora, Carla; Conti, Francesco G.; Pugliese, Giuseppe] St Andrea Hosp, Diabet Unit, Rome, Italy; [Balducci, Stefano; Iacobini, Carla] Metab Fitness Assoc, Rome, Italy; [Zanuso, Silvano] Univ Greenwich, Sch Sci, London SE18 6PF, England; [Cardelli, Patrizia] St Andrea Hosp, Clin Chem Lab, Rome, Italy; [Nicolucci, Antonio] Consorzio Mario Negri Sud, Dept Clin Pharmacol & Epidemiol, Chieti, Italy	Sapienza University Rome; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; University of Greenwich; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; Consorzio Mario Negri Sud	Pugliese, G (corresponding author), Univ Roma La Sapienza, Dept Clin & Mol Med, Rome, Italy.	giuseppe.pugliese@uniroma1.it	Pugliese, Giuseppe/G-8776-2012; Menini, Stefano/G-1130-2010	Menini, Stefano/0000-0001-7328-2385; Pugliese, Giuseppe/0000-0003-1574-0397; Maccora, Carla/0000-0002-3384-6606; Pugliese, Luca/0000-0001-9061-7247	Lifescan SrL; Novo Nordisk Ltd; Bristol Myers Squibb Italy; Technogym SpA; Cosmed SrL	Lifescan SrL; Novo Nordisk Ltd(Novo Nordisk); Bristol Myers Squibb Italy(Bristol-Myers Squibb); Technogym SpA; Cosmed SrL	This work was supported by Lifescan SrL, Novo Nordisk Ltd, Bristol Myers Squibb Italy, Technogym SpA and Cosmed SrL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; Alberti KGMM, 2005, LANCET, V366, P1059, DOI 10.1016/S0140-6736(05)67402-8; *AM COLL SPORTS ME, 2005, ACSMS GUID EX TEST P; Balducci S, 2012, DIABETES CARE, V35, P1347, DOI 10.2337/dc11-1859; Balducci S, 2010, ARCH INTERN MED, V170, P1794, DOI 10.1001/archinternmed.2010.380; Balducci S, 2008, NUTR METAB CARDIOVAS, V18, P585, DOI 10.1016/j.numecd.2007.07.006; BALKE B, 1959, U S Armed Forces Med J, V10, P675; Blair SN, 2004, AM J CLIN NUTR, V79, P913; Boule NG, 2001, JAMA-J AM MED ASSOC, V286, P1218, DOI 10.1001/jama.286.10.1218; Boule NG, 2003, DIABETOLOGIA, V46, P1071, DOI 10.1007/s00125-003-1160-2; Brzycki M., 1993, J PHYS EDUC RECREAT, V64, P88, DOI [DOI 10.1080/07303084.1993.10606684, 10.1080/07303084.1993.10606684]; Church TS, 2010, JAMA-J AM MED ASSOC, V304, P2253, DOI 10.1001/jama.2010.1710; Clinical Guidelines Task Force, 2005, GLOB GUID TYP 2 DIAB, P56; Di Loreto C, 2003, DIABETES CARE, V26, P404, DOI 10.2337/diacare.26.2.404; DiPietro L, 2006, J APPL PHYSIOL, V100, P142, DOI 10.1152/japplphysiol.00474.2005; FOLSOM AR, 1986, J CHRON DIS, V39, P505, DOI 10.1016/0021-9681(86)90195-5; Gavin JR, 1997, DIABETES CARE, V20, P1183; Gregg EW, 2003, ARCH INTERN MED, V163, P1440, DOI 10.1001/archinte.163.12.1440; Hansen D, 2009, DIABETOLOGIA, V52, P1789, DOI 10.1007/s00125-009-1354-3; Houmard JA, 2004, J APPL PHYSIOL, V96, P101, DOI 10.1152/japplphysiol.00707.2003; Hu G, 2004, CIRCULATION, V110, P666, DOI 10.1161/01.CIR.0000138102.23783.94; HUGHES VA, 1993, AM J PHYSIOL, V264, pE855, DOI 10.1152/ajpendo.1993.264.6.E855; Jakicic JM, 2003, JAMA-J AM MED ASSOC, V290, P1323, DOI 10.1001/jama.290.10.1323; Larose J, 2011, DIABETOLOGIA, V54, P93, DOI 10.1007/s00125-010-1941-3; Manson JE, 2002, NEW ENGL J MED, V347, P716, DOI 10.1056/NEJMoa021067; Nicolucci A, 2012, DIABETOLOGIA, V55, P579, DOI 10.1007/s00125-011-2425-9; Nicolucci A, 2011, ARCH INTERN MED, V171, P1951, DOI 10.1001/archinternmed.2011.561; O'Donovan G, 2005, EUR J APPL PHYSIOL, V95, P522, DOI 10.1007/s00421-005-0040-5; O'Donovan G, 2005, J APPL PHYSIOL, V98, P1619, DOI 10.1152/japplphysiol.01310.2004; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; Ruiz JR, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a439; Sigal RJ, 2010, DIABETES CARE, V33, P147, DOI DOI 10.2337/DC10-9990; Sigal RJ, 2007, ANN INTERN MED, V147, P357, DOI 10.7326/0003-4819-147-6-200709180-00005; Sigal RJ, 2006, DIABETES CARE, V29, P1433, DOI 10.2337/dc06-9910; Snowling NJ, 2006, DIABETES CARE, V29, P2518, DOI 10.2337/dc06-1317; Stevens RJ, 2001, CLIN SCI, V101, P671, DOI 10.1042/CS20000335; Umpierre D, 2011, JAMA-J AM MED ASSOC, V305, P1790, DOI 10.1001/jama.2011.576; Zanuso S, 2009, DIABETES RES CLIN PR, V85, pE40, DOI 10.1016/j.diabres.2009.05.003; Zanuso S, 2010, ACTA DIABETOL, V47, P15, DOI 10.1007/s00592-009-0126-3	39	62	64	2	62	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2012	7	11							e49297	10.1371/journal.pone.0049297	http://dx.doi.org/10.1371/journal.pone.0049297			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	047ER	23185314	Green Published, Green Submitted, gold			2023-01-03	WOS:000311821000039
J	Murray, B				Murray, Barbara			Liverpool care pathway: doctors have always aimed to ease distress in dying	BRITISH MEDICAL JOURNAL			English	Editorial Material									Manor Med Practice, Stockport SK1 3PZ, Lancs, England		Murray, B (corresponding author), Manor Med Practice, Stockport SK1 3PZ, Lancs, England.	barby@doctors.org.uk						European Federation of National Associations of Orthopaedics and Traumatology, 2012, CONSENSUS STATEMENT; General Medical Council, 2010, TREATM CAR END LIFE; Marie Curie Palliative Care Institute Liverpool, 2010, WHAT IS LIV CAR PATH; Morrow A., 2009, WHAT IS HOSPICE COMF; National Institute for Health and Clinical Excellence, 2010, PALL CAR NEEDS	5	1	1	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	NOV 14	2012	345								e7606	10.1136/bmj.e7606	http://dx.doi.org/10.1136/bmj.e7606			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	040PZ	23152571				2023-01-03	WOS:000311336400008
J	Baggett, HC; Chittaganpitch, M; Thamthitiwat, S; Prapasiri, P; Naorat, S; Sawatwong, P; Ditsungnoen, D; Olsen, SJ; Simmerman, JM; Srisaengchai, P; Chantra, S; Peruski, LF; Sawanpanyalert, P; Maloney, SA; Akarasewi, P				Baggett, Henry C.; Chittaganpitch, Malinee; Thamthitiwat, Somsak; Prapasiri, Prabda; Naorat, Sathapana; Sawatwong, Pongpun; Ditsungnoen, Darunee; Olsen, Sonja J.; Simmerman, James M.; Srisaengchai, Prasong; Chantra, Somrak; Peruski, Leonard F.; Sawanpanyalert, Pathom; Maloney, Susan A.; Akarasewi, Pasakorn			Incidence and Epidemiology of Hospitalized Influenza Cases in Rural Thailand during the Influenza A (H1N1) pdm09 Pandemic, 2009-2010	PLOS ONE			English	Article							UNITED-STATES; VIRUS-INFECTION; PNEUMONIA; BURDEN; SURVEILLANCE; IMPACT	Background: Data on the burden of the 2009 influenza pandemic in Asia are limited. Influenza A(H1N1)pdm09 was first reported in Thailand in May 2009. We assessed incidence and epidemiology of influenza-associated hospitalizations during 2009-2010. Methods: We conducted active, population-based surveillance for hospitalized cases of acute lower respiratory infection (ALRI) in all 20 hospitals in two rural provinces. ALRI patients were sampled 1: 2 for participation in an etiology study in which nasopharyngeal swabs were collected for influenza virus testing by PCR. Results: Of 7,207 patients tested, 902 (12.5%) were influenza-positive, including 190 (7.8%) of 2,436 children aged,5 years; 86% were influenza A virus (46% A(H1N1) pdm09, 30% H3N2, 6.5% H1N1, 3.5% not subtyped) and 13% were influenza B virus. Cases of influenza A(H1N1) pdm09 first peaked in August 2009 when 17% of tested patients were positive. Subsequent peaks during 2009 and 2010 represented a mix of influenza A(H1N1) pdm09, H3N2, and influenza B viruses. The estimated annual incidence of hospitalized influenza cases was 136 per 100,000, highest in ages <5 years (477 per 100,000) and >75 years (407 per 100,000). The incidence of influenza A(H1N1) pdm09 was 62 per 100,000 (214 per 100,000 in children <5 years). Eleven influenza-infected patients required mechanical ventilation, and four patients died, all adults with influenza A(H1N1) pdm09 (1) or H3N2 (3). Conclusions: Influenza-associated hospitalization rates in Thailand during 2009-10 were substantial and exceeded rates described in western countries. Influenza A(H1N1) pdm09 predominated, but H3N2 also caused notable morbidity. Expanded influenza vaccination coverage could have considerable public health impact, especially in young children.	[Baggett, Henry C.; Thamthitiwat, Somsak; Prapasiri, Prabda; Naorat, Sathapana; Sawatwong, Pongpun; Olsen, Sonja J.; Simmerman, James M.; Srisaengchai, Prasong; Peruski, Leonard F.; Maloney, Susan A.] US Ctr Dis Control & Prevent Collaborat, Thailand Minist Publ Hlth MOPH, Int Emerging Infect Program, Nonthaburi, Thailand; [Baggett, Henry C.; Peruski, Leonard F.; Maloney, Susan A.] Ctr Dis Control & Prevent, Global Dis Detect Branch, Global Dis Detect & Emergency Response Div, Atlanta, GA USA; [Chittaganpitch, Malinee; Sawanpanyalert, Pathom] MOPH, Natl Inst Hlth, Nonthaburi, Thailand; [Ditsungnoen, Darunee] Nakhon Phanom Prov Hlth Off, Nakhon Phanom, Thailand; [Olsen, Sonja J.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA; [Chantra, Somrak] MOPH, Sa Kaeo Prov Hlth Off, Sa Kaeo, Thailand; [Akarasewi, Pasakorn] MOPH, Bur Epidemiol, Nonthaburi, Thailand	Ministry of Public Health - Thailand; Centers for Disease Control & Prevention - USA; Ministry of Public Health - Thailand; Centers for Disease Control & Prevention - USA	Baggett, HC (corresponding author), US Ctr Dis Control & Prevent Collaborat, Thailand Minist Publ Hlth MOPH, Int Emerging Infect Program, Nonthaburi, Thailand.	hbaggett@cdc.gov			U.S. Centers for Disease Control and Prevention	U.S. Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This research was funded by the U.S. Centers for Disease Control and Prevention. The funders had a role in study design, data collection and analysis, decision to publish, and preparation of the manuscript.	Baggett HC, 2009, CLIN INFECT DIS, V48, pS65, DOI 10.1086/596484; Brammer L, 2011, CLIN INFECT DIS, V52, pS27, DOI 10.1093/cid/ciq009; Brooks WA, 2010, PEDIATR INFECT DIS J, V29, P216, DOI 10.1097/INF.0b013e3181bc23fd; Cao B, 2009, NEW ENGL J MED, V361, P2507, DOI 10.1056/NEJMoa0906612; Champunot R, 2010, JPN J INFECT DIS, V63, P251; Feikin DR, 2012, B WORLD HEALTH ORGAN, V90, P256, DOI 10.2471/BLT.11.094326; Nuorti J. Pekka, 2010, Morbidity and Mortality Weekly Report, V59, P1; Grijalva CG, 2007, EPIDEMIOL INFECT, V135, P951, DOI 10.1017/S095026880600762X; Hancock K, 2009, NEW ENGL J MED, V361, P1945, DOI 10.1056/NEJMoa0906453; Ismail HIM, 2011, EMERG INFECT DIS, V17, P708, DOI 10.3201/eid1704.101212; Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695; Javadi M, 2006, INT J INFECT DIS, V10, P129, DOI 10.1016/j.ijid.2005.01.007; Koon K, 2010, EMERG INFECT DIS, V16, P1976, DOI 10.3201/eid1612.091697; Lindblade KA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015826; Morens DM, 2010, MBIO, V1, DOI 10.1128/mBio.00211-10; Mustaquim D., 2010, Morbidity and Mortality Weekly Report, V59, P901; Olsen SJ, 2010, EPIDEMIOL INFECT, V138, P1811, DOI 10.1017/S0950268810000646; Olsen SJ, 2006, INT J INFECT DIS, V10, P439, DOI 10.1016/j.ijid.2006.06.004; Reyes L, 2010, INFLUENZA OTHER RESP, V4, P129, DOI 10.1111/j.1750-2659.2010.00138.x; Rhodes J, 2010, AM J TROP MED HYG, V83, P301, DOI 10.4269/ajtmh.2010.09-0584; Rudan I, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001099; Shrestha SS, 2011, CLIN INFECT DIS, V52, pS75, DOI 10.1093/cid/ciq012; Simmerman JM, 2008, INFLUENZA OTHER RESP, V2, P81, DOI 10.1111/j.1750-2659.2008.00045.x; Simmerman JM, 2009, PLOS ONE, V4, pA107, DOI 10.1371/journal.pone.0007776; Skarbinski J, 2011, CLIN INFECT DIS, V52, pS50, DOI 10.1093/cid/ciq021; Thailand National Economic and Social Development Board, 2006, POP PROJ THAIL 2000; Thailand National Statistics Office, 2011, PER CAP INC POP REG; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; Vongphrachanh P, 2010, INFLUENZA OTHER RESP, V4, P47, DOI 10.1111/j.1750-2659.2009.00120.x; WHO CDC, 2009, CDC PROT REALT RTPCR	30	18	19	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2012	7	11							e48609	10.1371/journal.pone.0048609	http://dx.doi.org/10.1371/journal.pone.0048609			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	040IE	23139802	gold, Green Submitted, Green Published			2023-01-03	WOS:000311315300044
J	Baxi, SM; Tan, W; Murphy, ST; Smeal, T; Yin, MJ				Baxi, Sangita M.; Tan, Wei; Murphy, Sean T.; Smeal, Tod; Yin, Min-Jean			RETRACTED: Targeting 3-Phosphoinoside-Dependent Kinase-1 to Inhibit Insulin-Like Growth Factor-I Induced AKT and p70 S6 Kinase Activation in Breast Cancer Cells (Retracted article. See vol. 12, art no e0175772, 2017)	PLOS ONE			English	Article; Retracted Publication							RECEPTOR; METASTASIS; PDK1; PHOSPHORYLATION; RESISTANCE; DISCOVERY; INVASION; AKT/PKB; PATHWAY	Binding of IGF to IGF-IR activates PI3K to generate PIP3 which in turn recruits and activates proteins that contain a pleckstrin homology (PH) domain, including AKT and PDK1. PDK1 is highly expressed in breast tumor samples and breast cancer cell lines. Here we demonstrate that targeting PDK1 with the potent and selective PDK1 inhibitor PF-5177624 in the IGF-PI3K pathway blocks breast cancer cell proliferation and transformation. Breast cancer cell lines MCF7 and T47D, representing the luminal ER positive subtype and harboring PIK3CA mutations, were most responsive to IGF-I induction resulting in upregulated AKT and p70S6K phosphorylation via PDK1 activation. PF-5177624 downregulated AKT and p70S6K phosphorylation, blocked cell cycle progression, and decreased cell proliferation and transformation to block IGFR-I induced activation in breast cancer cells. These results may provide insight into clinical strategies for developing an IGFR-I inhibitor and/or a PDK1 inhibitor in luminal breast cancer patients.	[Baxi, Sangita M.; Tan, Wei; Smeal, Tod; Yin, Min-Jean] Pfizer Worldwide Res & Dev, Oncol Res, San Diego, CA USA; [Murphy, Sean T.] Pfizer Worldwide Res & Dev, Med Chem, San Diego, CA USA	Pfizer; Pfizer	Yin, MJ (corresponding author), Pfizer Worldwide Res & Dev, Oncol Res, San Diego, CA USA.	min-jean.yin@pfizer.com	Baxi, Sangita M/K-6865-2016	Baxi, Sangita M/0000-0001-9476-3831				Alberobello AT, 2010, J BIOL CHEM, V285, P6563, DOI 10.1074/jbc.M109.097410; Bayascas JR, 2005, CURR BIOL, V15, P1839, DOI 10.1016/j.cub.2005.08.066; Becker MA, 2011, MOL ENDOCRINOL, V25, P516, DOI 10.1210/me.2010-0373; Bobkova EV, 2010, J BIOL CHEM, V285, P18838, DOI 10.1074/jbc.M109.089946; Camirand A, 2005, BREAST CANCER RES, V7, pR570, DOI 10.1186/bcr1028; Dunn SE, 1998, CANCER RES, V58, P3353; Ellwood-Yen K, 2011, CANCER RES, V71, P3052, DOI 10.1158/0008-5472.CAN-10-2282; Feldman RI, 2005, J BIOL CHEM, V280, P19867, DOI 10.1074/jbc.M501367200; Flynn P, 2000, CURR BIOL, V10, P1439, DOI 10.1016/S0960-9822(00)00801-0; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Huang XP, 2010, CANCER RES, V70, P1204, DOI 10.1158/0008-5472.CAN-09-3321; Jackson JG, 2001, ONCOGENE, V20, P7318, DOI 10.1038/sj.onc.1204920; Jin Q, 2008, J MAMMARY GLAND BIOL, V13, P485, DOI 10.1007/s10911-008-9107-3; Lann D, 2008, J MAMMARY GLAND BIOL, V13, P371, DOI 10.1007/s10911-008-9100-x; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lin HJ, 2005, BRIT J CANCER, V93, P1372, DOI 10.1038/sj.bjc.6602862; Liu Y, 2009, MOL CANCER RES, V7, P944, DOI 10.1158/1541-7786.MCR-08-0368; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Maurer M, 2009, CANCER RES, V69, P6299, DOI 10.1158/0008-5472.CAN-09-0820; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Murphy ST, 2011, J MED CHEM, V54, P8490, DOI 10.1021/jm201019k; Nagashima K, 2011, J BIOL CHEM, V286, P6433, DOI 10.1074/jbc.M110.156463; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Sachdev D, 2004, J BIOL CHEM, V279, P5017, DOI 10.1074/jbc.M305403200; Sachdev D, 2010, ONCOGENE, V29, P251, DOI 10.1038/onc.2009.316; Sachdev D, 2008, J MAMMARY GLAND BIOL, V13, P431, DOI 10.1007/s10911-008-9105-5; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Werner Haim, 2009, Archives of Physiology and Biochemistry, V115, P58, DOI 10.1080/13813450902783106; Wu JH, 2011, CANCER RES, V71, P2622, DOI 10.1158/0008-5472.CAN-10-3837; Yee D, 2006, BRIT J CANCER, V94, P465, DOI 10.1038/sj.bjc.6602963; Zeng X, 2002, CANCER RES, V62, P3538	34	14	16	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2012	7	10							e48402	10.1371/journal.pone.0048402	http://dx.doi.org/10.1371/journal.pone.0048402			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	030WJ	23119004	Green Published, Green Submitted, gold			2023-01-03	WOS:000310600500124
J	Nurmatov, U; Buckingham, S; Kendall, M; Murray, SA; White, P; Sheikh, A; Pinnock, H				Nurmatov, Ulugbek; Buckingham, Susan; Kendall, Marilyn; Murray, Scott A.; White, Patrick; Sheikh, Aziz; Pinnock, Hilary			Effectiveness of Holistic Interventions for People with Severe Chronic Obstructive Pulmonary Disease: Systematic Review of Controlled Clinical Trials	PLOS ONE			English	Article							QUALITY-OF-LIFE; END-STAGE COPD; PALLIATIVE CARE; CASE-MANAGEMENT; ACUTE EXACERBATION; CHRONIC ILLNESS; OLDER-PEOPLE; RISK-FACTORS; PROGRAM; PREVALENCE	Background: Despite a well-recognised burden of disabling physical symptoms compounded by co-morbidities, psychological distress and social isolation, the needs of people with severe chronic obstructive pulmonary disease (COPD) are typically poorly addressed. Aim: To assess the effectiveness of interventions designed to deliver holistic care for people with severe COPD. Methods: We searched 11 biomedical databases, three trial repositories (January 1990-March 2012; no language restrictions) and contacted international experts to locate published, unpublished and in-progress randomised controlled trials (RCTs), quasi-RCTs and controlled clinical trials (CCTs) that investigated holistic interventions to support patients with severe COPD in any healthcare context. The primary outcome was health-related quality of life (HRQoL). Quality assessment and data extraction followed Cochrane Collaboration methodology. We used a piloted data extraction sheet and undertook narrative synthesis. Results: From 2,866 potentially relevant papers, we identified three trials: two RCTs (from United States and Australia), and one CCT (from Thailand): total 216 patients. Risk of bias was assessed as moderate in two studies and high in the third. All the interventions were led by nurses acting in a co-ordinating role (e.g. facilitating community support in Thailand, providing case-management in the USA, or co-ordinating inpatient care in Australia). HRQoL improved significantly in the Thai CCT compared to the (very limited) usual care (p < 0.001), in two sub-domains in the American trial, but showed no significant changes in the Australian trial. Exercise tolerance, dyspnoea, and satisfaction with care also improved in the Thai trial. Conclusions: Some 15 years after reports first highlighted the unmet needs of people with severe COPD, we have been unable to find robust trial evidence about interventions that can address those needs. There is an urgent need to develop and evaluate holistic care interventions designed improve HRQoL for people with severe COPD.	[Nurmatov, Ulugbek; Buckingham, Susan; Sheikh, Aziz; Pinnock, Hilary] Univ Edinburgh, Ctr Populat Hlth Sci, Allergy & Resp Res Grp, Edinburgh, Midlothian, Scotland; [Kendall, Marilyn; Murray, Scott A.] Univ Edinburgh, Ctr Populat Hlth Sci, Primary Palliat Care Res Grp, Edinburgh, Midlothian, Scotland; [White, Patrick] Kings Coll London, Dept Primary Care & Publ Hlth Sci, London WC2R 2LS, England	University of Edinburgh; University of Edinburgh; University of London; King's College London	Pinnock, H (corresponding author), Univ Edinburgh, Ctr Populat Hlth Sci, Allergy & Resp Res Grp, Edinburgh, Midlothian, Scotland.	hilary.pinnock@ed.ac.uk	Sheikh, Aziz/D-2818-2009; White, Patrick/AAN-7799-2020	Sheikh, Aziz/0000-0001-7022-3056; White, Patrick/0000-0002-2047-8787	Dunhill Medical Trust Grant [R210 071]; Primary Care Research Career Award from the Chief Scientist Office of the Scottish Government; The Dunhill Medical Trust [R210/0711] Funding Source: researchfish; Chief Scientist Office [CZH/4/320, PCRCA/08/01] Funding Source: researchfish	Dunhill Medical Trust Grant(Dunhill Medical Trust); Primary Care Research Career Award from the Chief Scientist Office of the Scottish Government; The Dunhill Medical Trust(Dunhill Medical Trust); Chief Scientist Office	This work was supported by Dunhill Medical Trust Grant R210 071 (http://www.dunhillmedical.org.uk). HP is supported by a Primary Care Research Career Award from the Chief Scientist Office of the Scottish Government (http://www.cso.scot.nhs.uk). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aiken LS, 2006, J PALLIAT MED, V9, P111, DOI 10.1089/jpm.2006.9.111; Almagro P, 2002, CHEST, V121, P1441, DOI 10.1378/chest.121.5.1441; BELMAN MJ, 1993, THORAX, V48, P936, DOI 10.1136/thx.48.9.936; BJELLAND I, 2002, J PSYCHOSOM RES, V0052; Bourbeau J, 2003, ARCH INTERN MED, V163, P585, DOI 10.1001/archinte.163.5.585; British Lung Foundation, 2012, BREATH EAS; Brumley Richard D, 2003, J Palliat Med, V6, P715, DOI 10.1089/109662103322515220; Casas A, 2006, EUR RESPIR J, V28, P123, DOI 10.1183/09031936.06.00063205; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; Clavarino AM, 1997, DYING FROM EXPERIENC; Cochrane Eff ective Practice and Organisation of Care Group, RISK BIAS EPOC SPEC; Communities and local government, 2012, BUILD BIG SOC; Connors AF, 1996, AM J RESP CRIT CARE, V154, P959, DOI 10.1164/ajrccm.154.4.8887592; Coventry PA, 2005, AGE AGEING, V34, P218, DOI 10.1093/ageing/afi054; Craig P., 2008, DEV EVALUATING COMPL; Davies E, 2004, SOLID FACTS PALLIATI; Department of Health, 2004, PALL CAR; Dewan NA, 2011, COPD, V8, P153, DOI 10.3109/15412555.2011.560129; Egan Elizabeth, 2002, Lippincotts Case Manag, V7, P170, DOI 10.1097/00129234-200209000-00002; Elofsson LC, 2004, PALLIATIVE MED, V18, P611, DOI 10.1191/0269216304pm922oa; Exley C, 2005, PALLIATIVE MED, V19, P76, DOI 10.1191/0269216305pm973oa; Garcia-Ayrnerich J, 2007, RESP MED, V101, P1462, DOI 10.1016/j.rmed.2007.01.012; Gore JM, 2000, THORAX, V55, P1000, DOI 10.1136/thorax.55.12.1000; Gravelle H, 2007, BMJ-BRIT MED J, V334, P31, DOI 10.1136/bmj.39020.413310.55; Habraken JM, 2007, PATIENT EDUC COUNS, V68, P121, DOI 10.1016/j.pec.2007.05.011; Habraken JM, 2008, BRIT J GEN PRACT, V58, P844, DOI 10.3399/bjgp08X376186; JONES PW, 1991, RESP MED, V85, P25, DOI 10.1016/S0954-6111(06)80166-6; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lockhart Carol A, 2003, J Palliat Med, V6, P1001, DOI 10.1089/109662103322654929; Lynn J, 2000, J AM GERIATR SOC, V48, pS91, DOI 10.1111/j.1532-5415.2000.tb03147.x; Lynn J, 2003, LIVING WELL END LIFE; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; Mannino DM, 2007, LANCET, V370, P765, DOI 10.1016/S0140-6736(07)61380-4; Markle-Reid M, 2013, J EVAL CLIN PRACT, V19, P118, DOI 10.1111/j.1365-2753.2011.01782.x; Meier Diane E, 2004, J Palliat Med, V7, P119, DOI 10.1089/109662104322737395; Melis RJF, 2008, J GERONTOL A-BIOL, V63, P283, DOI 10.1093/gerona/63.3.283; Murray SA, 2005, BRIT MED J, V330, P611, DOI 10.1136/bmj.330.7492.611; Neuman B., 1995, NEUMAN SYSTEMS MODEL; NHS End of Life Care Programme, 2012, GOLD STAND FRAM; Noonill NSS., 2007, THAI J NURSING RES, V11, P118; Oeseburg B, 2009, NURS RES, V58, P201, DOI 10.1097/NNR.0b013e3181a30941; Parshall MB, 2012, AM J RESP CRIT CARE, V185, P435, DOI 10.1164/rccm.201111-2042ST; Pinnock H, 2012, HELPING OLDER PEOPLE; Pinnock H, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d142; PORTENOY RK, 1994, EUR J CANCER, V30A, P1326, DOI 10.1016/0959-8049(94)90182-1; Rocker GM, 2007, J PALLIAT MED, V10, P783, DOI 10.1089/jpm.2007.9951; Seamark DA, 2007, J ROY SOC MED, V100, P225, DOI 10.1258/jrsm.100.5.225; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; Sindhu SAR, 2004, THAI J NURSING COUNC, V19, P1; Sprangers MAG, 1999, SOC SCI MED, V48, P1507, DOI 10.1016/S0277-9536(99)00045-3; Sridhar M, 2008, THORAX, V63, P194, DOI 10.1136/thx.2007.077578; US Department of Health and Human Services, 2008, US DEP HLTH HUM SERV; Ware J.E., 1993, SF 36 HLTH SURVEY MA; White P, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X578043	54	0	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2012	7	10							e46433	10.1371/journal.pone.0046433	http://dx.doi.org/10.1371/journal.pone.0046433			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	025MO	23110052	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000310193600004
J	Artunc, F; Mueller, C; Breidthardt, T; Twerenbold, R; Peter, A; Thamer, C; Weyrich, P; Haering, HU; Friedrich, B				Artunc, Ferruh; Mueller, Christian; Breidthardt, Tobias; Twerenbold, Raphael; Peter, Andreas; Thamer, Claus; Weyrich, Peter; Haering, Hans-Ulrich; Friedrich, Bjoern			Sensitive Troponins - Which Suits Better for Hemodialysis Patients? Associated Factors and Prediction of Mortality	PLOS ONE			English	Article							STAGE RENAL-DISEASE; CHRONIC KIDNEY-DISEASE; LEFT-VENTRICULAR MASS; CARDIAC TROPONIN; MYOCARDIAL-INFARCTION; ASYMPTOMATIC PATIENTS; HEART-FAILURE; I ASSAYS; RELEASE; DEATH	Background: In hemodialysis patients, elevated plasma troponin concentrations are a common finding that has even increased with the advent of newly developed sensitive assays. However, the interpretation and relevance of this is still under debate. Methods: In this cross-sectional study, we analyzed plasma concentrations of sensitive troponin I (TnI) and troponin T (TnT) in stable ambulatory hemodialysis patients (n = 239) and investigated their associations with clinical factors and mortality. Results: In all of the enrolled patients, plasma TnI or TnT was detectable at a median concentration of 14 pg/ml (interquartile range: 7-29) using the Siemens TnI ultra assay and 49 pg/ml (31-74) using the Roche Elecsys high sensitive TnT assay. Markedly more patients exceeded the 99th percentile for TnT than for TnI (95% vs. 14%, p<0.0001). In a multivariate linear regression model, TnT was independently associated with age, gender, systolic dysfunction, time on dialysis, residual diuresis and systolic blood pressure, whereas TnI was independently associated with age, systolic dysfunction, pulse pressure, time on dialysis and duration of a HD session. During a follow-up period of nearly two years, TnT concentration above 38 pg/mL was associated with a 5-fold risk of death, whereas elevation of TnI had a gradual association to mortality. Conclusion: In hemodialysis patients, elevations of plasma troponin concentrations are explained by cardiac function and dialysis-related parameters, which contribute to cardiac strain. Both are highly predictive of increased risk of death.	[Artunc, Ferruh; Peter, Andreas; Thamer, Claus; Weyrich, Peter; Haering, Hans-Ulrich; Friedrich, Bjoern] Univ Tubingen, Dept Internal Med, Div Endocrinol Diabetol Vasc Dis Nephrol & Clin C, D-72074 Tubingen, Germany; [Mueller, Christian; Breidthardt, Tobias; Twerenbold, Raphael] Univ Basel, Div Cardiol, Dept Internal Med, Basel, Switzerland; [Friedrich, Bjoern] Dialysis Ctr, Leonberg, Germany	Eberhard Karls University of Tubingen; University of Basel	Artunc, F (corresponding author), Univ Tubingen, Dept Internal Med, Div Endocrinol Diabetol Vasc Dis Nephrol & Clin C, D-72074 Tubingen, Germany.	ferruh.artunc@med.uni-tuebingen.de	Müller, Christian/AAB-4783-2022; Twerenbold, Raphael/H-3533-2018	Müller, Christian/0000-0002-1120-6405; Breidthardt, Tobias/0000-0003-2671-6456; Twerenbold, Raphael/0000-0003-3814-6542				Apple FS, 2009, CLIN CHEM, V55, P1303, DOI 10.1373/clinchem.2009.128363; Apple FS, 2002, CIRCULATION, V106, P2941, DOI 10.1161/01.CIR.0000041254.30637.34; Artunc Ferruh, 2010, Dtsch Med Wochenschr, V135, P240, DOI 10.1055/s-0030-1247609; Bodor GS, 1997, CLIN CHEM, V43, P476; Breidthardt T, 2011, REV CARDIOVASC MED, V12, P13, DOI 10.3909/ricm0585; deFilippi C, 2003, JAMA-J AM MED ASSOC, V290, P353, DOI 10.1001/jama.290.3.353; Dierkes J, 2000, CIRCULATION, V102, P1964, DOI 10.1161/01.CIR.102.16.1964; Diris JHC, 2004, CIRCULATION, V109, P23, DOI 10.1161/01.CIR.0000109483.45211.8F; Ellis K, 2001, SOUTHERN MED J, V94, P993; EVRIN PE, 1972, SCAND J CLIN LAB INV, V29, P69, DOI 10.3109/00365517209081057; Fernandez-Reyes MJ, 2004, J NEPHROL, V17, P721; Freda BJ, 2002, J AM COLL CARDIOL, V40, P2065, DOI 10.1016/S0735-1097(02)02608-6; Giannitsis E, 2004, CIRCULATION, V110, pE25, DOI 10.1161/01.CIR.0000135543.93270.D2; Hayashi T, 2008, NEPHROL DIAL TRANSPL, V23, P2936, DOI 10.1093/ndt/gfn181; Hickman PE, 2007, ANN CLIN BIOCHEM, V44, P285, DOI 10.1258/000456307780480855; Horwich TB, 2003, CIRCULATION, V108, P833, DOI 10.1161/01.CIR.0000084543.79097.34; Jacobs LH, 2009, ANN CLIN BIOCHEM, V46, P283, DOI 10.1258/acb.2009.008197; Jung HH, 2004, NEPHROL DIAL TRANSPL, V19, P3117, DOI 10.1093/ndt/gfh488; Kalantar-Zadeh K, 2009, CIRCULATION, V119, P671, DOI 10.1161/CIRCULATIONAHA.108.807362; Kanderian AS, 2006, KIDNEY INT, V69, P1112, DOI 10.1038/sj.ki.5000174; KATUS HA, 1995, CLIN CHEM, V41, P1201; Keller T, 2011, CIRCULATION, V123, P1361, DOI 10.1161/CIRCULATIONAHA.111.023200; Khan NA, 2005, CIRCULATION, V112, P3088, DOI 10.1161/CIRCULATIONAHA.105.560128; Kumar N, 2011, NEPHROL DIAL TRANSPL, V26, P665, DOI 10.1093/ndt/gfq442; London GM, 2002, NEPHROL DIAL TRANSPL, V17, P29, DOI 10.1093/ndt/17.suppl_1.29; Mallamaci F, 2002, AM J KIDNEY DIS, V40, P68, DOI 10.1053/ajkd.2002.33914; Mallamaci F, 2002, KIDNEY INT, V62, P1884, DOI 10.1046/j.1523-1755.2002.00641.x; McGill D, 2010, CLIN CHIM ACTA, V411, P936, DOI 10.1016/j.cca.2010.03.004; Noordzij M, 2011, NEPHROL DIAL TRANSPL; Peacock WF, 2008, NEW ENGL J MED, V358, P2117, DOI 10.1056/NEJMoa0706824; Porter GA, 1998, EUR HEART J, V19, pN34; Reichlin T, 2009, NEW ENGL J MED, V361, P858, DOI 10.1056/NEJMoa0900428; Stolear JC, 1999, NEPHROL DIAL TRANSPL, V14, P1961, DOI 10.1093/ndt/14.8.1961; Termorshuizen F, 2004, J AM SOC NEPHROL, V15, P1061, DOI 10.1097/01.ASN.0000117976.29592.93; Thygesen K, 2007, EUR HEART J, V28, P2525; Wang AYM, 2008, J AM SOC NEPHROL, V19, P1643, DOI 10.1681/ASN.2008010012; Wu AHB, 1999, CLIN CHIM ACTA, V284, P161, DOI 10.1016/S0009-8981(99)00078-9; Zumrutdal AO, 2000, NEPHRON, V86, P522, DOI 10.1159/000045852	38	49	49	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2012	7	10							e47610	10.1371/journal.pone.0047610	http://dx.doi.org/10.1371/journal.pone.0047610			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022WO	23077650	Green Submitted, Green Published, gold			2023-01-03	WOS:000309995100145
J	Diaz-Rubio, E; Gomez-Espana, A; Massuti, B; Sastre, J; Reboredo, M; Manzano, JL; Rivera, F; Safont, MJ; Montagut, C; Gonzalez, E; Benavides, M; Marcuello, E; Cervantes, A; de Prado, PM; Fernandez-Martos, C; Arrivi, A; Bando, I; Aranda, E				Diaz-Rubio, Eduardo; Gomez-Espana, Auxiliadora; Massuti, Bartomeu; Sastre, Javier; Reboredo, Margarita; Luis Manzano, Jose; Rivera, Fernando; Jose Safont, Ma; Montagut, Clara; Gonzalez, Encarnacion; Benavides, Manuel; Marcuello, Eugenio; Cervantes, Andres; Martinez de Prado, Purificacion; Fernandez-Martos, Carlos; Arrivi, Antonio; Bando, Inmaculada; Aranda, Enrique		Spanish Cooperative Grp Treatment	Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study	PLOS ONE			English	Article							KIRSTEN RAS MUTATIONS; K-RAS; PHASE-III; POOR-PROGNOSIS; CETUXIMAB; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; PANITUMUMAB; COMBINATION	Background: In the MACRO study, patients with metastatic colorectal cancer (mCRC) were randomised to first-line treatment with 6 cycles of capecitabine and oxaliplatin (XELOX) plus bevacizumab followed by either single-agent bevacizumab or XELOX plus bevacizumab until disease progression. An additional retrospective analysis was performed to define the prognostic value of tumour KRAS status on progression-free survival (PFS), overall survival (OS) and response rates. Methodology/Principal Findings: KRAS data (tumour KRAS status and type of mutation) were collected by questionnaire from participating centres that performed KRAS analyses. These data were then cross-referenced with efficacy data for relevant patients in the MACRO study database. KRAS status was analysed in 394 of the 480 patients (82.1%) in the MACRO study. Wild-type (WT) KRAS tumours were found in 219 patients (56%) and mutant (MT) KRAS in 175 patients (44%). Median PFS was 10.9 months for patients with WT KRAS and 9.4 months for patients with MT KRAS tumours (p = 0.0038; HR: 1.40; 95% CI: 1.12-1.77). The difference in OS was also significant: 26.7 months versus 18.0 months for WT versus MT KRAS, respectively (p = 0.0002; HR: 1.55; 95% CI: 1.23-1.96). Univariate and multivariate analyses showed that KRAS was an independent variable for both PFS and OS. Responses were observed in 126 patients (57.5%) with WT KRAS tumours and 76 patients (43.4%) with MT KRAS tumours (p = 0.0054; OR: 1.77; 95% CI: 1.18-2.64). Conclusions/Significance: This analysis of the MACRO study suggests a prognostic role for tumour KRAS status in patients with mCRC treated with XELOX plus bevacizumab. For both PFS and OS, KRAS status was an independent factor in univariate and multivariate analyses.	[Diaz-Rubio, Eduardo; Sastre, Javier; Bando, Inmaculada] Univ Complutense, Inst Invest Sanitaria HCSC IdISSC, Hosp Clin San Carlos HCSC,Dept Med Oncol, Fac Med,Red Temat Invest Cooperat Canc RD06 0020, E-28040 Madrid, Spain; [Gomez-Espana, Auxiliadora; Aranda, Enrique] Hosp Reina Sofia, Dept Med Oncol, Cordoba, Spain; [Massuti, Bartomeu] Gen Hosp, Dept Med Oncol, Alicante, Spain; [Reboredo, Margarita] Complejo Hosp Univ A Coruna, Dept Med Oncol, La Coruna, Spain; [Luis Manzano, Jose] Hosp Badalona Germans Trias & Pujol, Inst Catalan Oncol, Dept Med Oncol, Badalona, Spain; [Rivera, Fernando] Hosp Marques de Valdecilla, Dept Med Oncol, Santander, Spain; [Jose Safont, Ma] Hosp Gen Valencia, Dept Med Oncol, Valencia, Spain; [Montagut, Clara] Hosp del Mar, Dept Med Oncol, Barcelona, Spain; [Gonzalez, Encarnacion] Hosp Virgen de las Nieves, Dept Med Oncol, Granada, Spain; [Benavides, Manuel] Hosp Univ Carlos Haya, Dept Med Oncol, Malaga, Spain; [Marcuello, Eugenio] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain; [Cervantes, Andres] Univ Valencia, Inst Hlth Res INCLIVA, Dept Med Oncol, Valencia, Spain; [Martinez de Prado, Purificacion] Hosp Basurto, Dept Med Oncol, Vizcaya, Spain; [Fernandez-Martos, Carlos] Inst Valenciano Oncol, Dept Med Oncol, Valencia, Spain; [Arrivi, Antonio] Fdn Hosp Son Llatzer, Dept Med Oncol, Palma De Mallorca, Spain	Complutense University of Madrid; Hospital Universitario Reina Sofia - Cordoba; General University Hospital of Alicante; Complejo Hospitalario Universitario A Coruna; Universidade da Coruna; Catalan Institute of Oncology; Hospital Germans Trias i Pujol; Hospital Universitario Marques de Valdecilla (HUMV); Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Hospital Universitario Virgen de las Nieves; Hospital Carlos Haya; Hospital of Santa Creu i Sant Pau; University of Valencia; Basurto Hospital; Instituto Valenciano De Oncologia; Hospital Universitari Son Llatzer	Diaz-Rubio, E (corresponding author), Univ Complutense, Inst Invest Sanitaria HCSC IdISSC, Hosp Clin San Carlos HCSC,Dept Med Oncol, Fac Med,Red Temat Invest Cooperat Canc RD06 0020, E-28040 Madrid, Spain.	ediazrubio.hcsc@salud.madrid.org	Aranda, Enrique/AAA-4147-2019; Valladares-Ayerbes, Manuel/K-8986-2014; Cervantes, Andres/J-8713-2013	Valladares-Ayerbes, Manuel/0000-0002-7950-9584; Cervantes, Andres/0000-0003-3806-3691; Ruiz, Alvaro J/0000-0001-6528-4268; La Casta, Adelaida/0000-0002-7235-6378; CARRATO, ALFREDO/0000-0001-7749-8140; J, Garcia-Foncillas/0000-0002-7591-8006; Diaz-Rubio, Eduardo/0000-0003-2792-5348; Massuti, Bartomeu/0000-0002-6247-4493; Tabernero, Josep/0000-0002-2495-8139	Roche	Roche(Roche Holding)	This work was supported by Roche (www.roche.es) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahnen DJ, 1998, CANCER RES, V58, P1149; Allegra CJ, 2009, J CLIN ONCOL, V27, P2091, DOI 10.1200/JCO.2009.21.9170; Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Andersen SN, 1997, SCAND J GASTROENTERO, V32, P62, DOI 10.3109/00365529709025065; Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964; Andreyev HJN, 1998, J NATL CANCER I, V90, P675, DOI 10.1093/jnci/90.9.675; Benvenuti S, 2007, CANCER RES, V67, P2643, DOI 10.1158/0008-5472.CAN-06-4158; Bokemeyer C, 2011, ANN ONCOL, V22, P1535, DOI 10.1093/annonc/mdq632; Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397; Bouzourene H, 2000, EUR J CANCER, V36, P1008, DOI 10.1016/S0959-8049(00)00036-8; De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6; Diaz-Rubio E, 2012, ONCOLOGIST, V17, P15, DOI 10.1634/theoncologist.2011-0249; Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860; Esteller M, 2001, J CLIN ONCOL, V19, P299, DOI 10.1200/JCO.2001.19.2.299; *EUR MED AG, ERB EUR PUBL ASS REP; Food and Drug Administration, FULL PRESCR INF ERB; Garcia-Foncillas J, 2010, EUR SOC MED ONC 2010; Gonzalez-Aguilera JJ, 2004, AM J CLIN ONCOL-CANC, V27, P39, DOI 10.1097/01.coc.0000045920.49210.7A; Hecht JR, 2009, J CLIN ONCOL, V27, P672, DOI 10.1200/JCO.2008.19.8135; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Hurwitz HI, 2009, ONCOLOGIST, V14, P22, DOI 10.1634/theoncologist.2008-0213; Ince WL, 2005, JNCI-J NATL CANCER I, V97, P981, DOI 10.1093/jnci/dji174; Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3706, DOI 10.1200/JCO.2005.00.232; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906; Masi G, 2010, LANCET ONCOL, V11, P845, DOI 10.1016/S1470-2045(10)70175-3; Maughan TS, 2011, LANCET, V377, P2103, DOI 10.1016/S0140-6736(11)60613-2; Mizukami Y, 2007, CLIN CANCER RES, V13, P5670, DOI 10.1158/1078-0432.CCR-07-0111; Price TJ, 2011, J CLIN ONCOL, V29, P2675, DOI 10.1200/JCO.2010.34.5520; Rak J, 2002, CANCER RES, V62, P1931; Richman SD, 2009, J CLIN ONCOL, V27, P5931, DOI 10.1200/JCO.2009.22.4295; Roth AD, 2010, J CLIN ONCOL, V28, P466, DOI 10.1200/JCO.2009.23.3452; Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930; Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268; Van Cutsem E, 2010, ANN ONCOL, V21, pv93, DOI 10.1093/annonc/mdq222; Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Westra JL, 2005, J CLIN ONCOL, V23, P5635, DOI 10.1200/JCO.2005.04.096	38	33	33	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2012	7	10							e47345	10.1371/journal.pone.0047345	http://dx.doi.org/10.1371/journal.pone.0047345			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	020LH	23174912	gold, Green Submitted, Green Published			2023-01-03	WOS:000309809500043
J	Bodner, M; Turner, RP; Schwacke, J; Bowers, C; Norment, C				Bodner, Mark; Turner, Robert P.; Schwacke, John; Bowers, Christopher; Norment, Caroline			Reduction of Seizure Occurrence from Exposure to Auditory Stimulation in Individuals with Neurological Handicaps: A Randomized Controlled Trial	PLOS ONE			English	Article							MUSIC; EPILEPSY; CHILDREN; FMRI	Background: The purpose of this work was to determine in a clinical trial the efficacy of reducing or preventing seizures in patients with neurological handicaps through sustained cortical activation evoked by passive exposure to a specific auditory stimulus (particular music). The specific type of stimulation had been determined in previous studies to evoke anti-epileptiform/ anti-seizure brain activity. Methods: The study was conducted at the Thad E. Saleeby Center in Harstville, South Carolina, which is a permanent residence for individuals with heterogeneous neurological impairments, many with epilepsy. We investigated the ability to reduce or prevent seizures in subjects through cortical stimulation from sustained passive nightly exposure to a specific auditory stimulus (music) in a three-year randomized controlled study. In year 1, baseline seizure rates were established. In year 2, subjects were randomly assigned to treatment and control groups. Treatment group subjects were exposed during sleeping hours to specific music at regular intervals. Control subjects received no music exposure and were maintained on regular anti-seizure medication. In year 3, music treatment was terminated and seizure rates followed. We found a significant treatment effect (p = 0.024) during the treatment phase persisting through the follow-up phase (p = 0.002). Subjects exposed to treatment exhibited a significant 24% decrease in seizures during the treatment phase, and a 33% decrease persisting through the follow-up phase. Twenty-four percent of treatment subjects exhibited a complete absence of seizures during treatment. Conclusion/ Significance: Exposure to specific auditory stimuli (i.e. music) can significantly reduce seizures in subjects with a range of epilepsy and seizure types, in some cases achieving a complete cessation of seizures. These results are consistent with previous work showing reductions in epileptiform activity from particular music exposure and offers potential for achieving a non-invasive, non-pharmacologic treatment of epilepsy.	[Bodner, Mark] MIND Res Inst, Santa Ana, CA USA; [Bodner, Mark] Johns Hopkins Univ, Dept Neurosurg, Baltimore, MD USA; [Turner, Robert P.] Med Univ S Carolina, Dept Neurosci Pediat Epidemiol & Biostat, Charleston, SC 29425 USA; [Schwacke, John] Med Univ S Carolina, Dept Epidemiol & Biostat, Charleston, SC 29425 USA; [Bowers, Christopher; Norment, Caroline] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA	Johns Hopkins University; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Bodner, M (corresponding author), MIND Res Inst, Santa Ana, CA USA.	mbodner@mindresearch.net; turnerrp@musc.edu	Khayyam Manesh, Matin/HGB-7432-2022		Ralph and Leona Gerard Family Trust	Ralph and Leona Gerard Family Trust	This work was supported in part by the Ralph and Leona Gerard Family Trust. No other external funding sources for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson WS, 2009, EPILEPSY RES, V84, P42, DOI 10.1016/j.eplepsyres.2008.12.005; ARSENI C, 1967, EPILEPSIA, V8, P162, DOI 10.1111/j.1528-1157.1967.tb04433.x; Auon P, 2004, NEUROL RES, V27, P787; Bodner M, 2001, NEUROL RES, V23, P683, DOI 10.1179/016164101101199108; Chakravarthy N, 2009, J COMB OPTIM, V17, P98, DOI 10.1007/s10878-008-9182-9; CRITCHLEY M, 1962, EPILEPSIA, V3, P402, DOI 10.1111/j.1528-1157.1962.tb06178.x; D'Souza WJ, 2007, NEUROLOGY, V68, P769, DOI 10.1212/01.wnl.0000256375.39476.be; Ferlazzo E, 2005, BRAIN, V128, P700, DOI 10.1093/brain/awh446; FISHER RS, 1992, EPILEPSIA, V33, P841, DOI 10.1111/j.1528-1157.1992.tb02192.x; Franaszczuk PJ, 2003, EPILEPSY RES, V53, P65, DOI 10.1016/S0920-1211(02)00248-6; Fuster J.M., 1989, PREFRONTAL CORTEX; George MS, 2000, BIOL PSYCHIAT, V47, P287, DOI 10.1016/S0006-3223(99)00308-X; GREEN JB, 1971, EPILEPSIA, V12, P225, DOI 10.1111/j.1528-1157.1971.tb04930.x; Harding G, 2005, EPILEPSIA, V46, P1423, DOI 10.1111/j.1528-1167.2005.31305.x; Hetland L, 2000, J AESTHET EDUC, V34, P105, DOI 10.2307/3333640; Hsu D, 2008, EPILEPSY BEHAV, V13, P511, DOI 10.1016/j.yebeh.2008.05.007; Hsu D, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.041909; Hughes JR, 2001, EPILEPSY BEHAV, V2, P396, DOI 10.1006/ebeh.2001.0250; Hughes JR, 1999, CLIN ELECTROENCEPHAL, V30, P44, DOI 10.1177/155005949903000204; Hughes JR, 2000, CLIN ELECTROENCEPHAL, V31, P94, DOI 10.1177/155005940003100208; Hughes JR, 1998, CLIN ELECTROENCEPHAL, V29, P109, DOI 10.1177/155005949802900301; Hunter JD, 2002, BIO MED PHY, P115; Jacobs MP, 2009, EPILEPSY BEHAV, V14, P438, DOI 10.1016/j.yebeh.2009.02.036; Jenkins JS, 2001, J ROY SOC MED, V94, P170, DOI 10.1177/014107680109400404; JOYNT RJ, 1962, JAMA-J AM MED ASSOC, V179, P501, DOI 10.1001/jama.1962.03050070023005; Kaplan PW, 2003, EPILEPSY BEHAV, V4, P464, DOI 10.1016/S1525-5050(03)00172-0; Kudela P, 2002, NEUROCOMPUTING, V44, P897, DOI 10.1016/S0925-2312(02)00489-7; Kudela Pawel, 2001, Epilepsia, V42, P121; Lado FA, 2002, J NEUROL NEUROSUR PS, V72, P812, DOI 10.1136/jnnp.72.6.812; Lahir N, 2007, EPILEPSY BEHAV, V11, P152, DOI 10.1016/j.yebeh.2007.04.017; Lin LC, 2011, EPILEPSY BEHAV, V21, P420, DOI 10.1016/j.yebeh.2011.05.015; Lin LC, 2011, EPILEPSY BEHAV, V20, P490, DOI 10.1016/j.yebeh.2010.12.044; Lin LC, 2010, EPILEPSY RES, V89, P238, DOI 10.1016/j.eplepsyres.2010.01.007; Lulic D, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.6.FOCUS09126; Martin da Silva A, 1989, REFLEX SEIZURES REFL, P323; McCormick DA, 2001, ANNU REV PHYSIOL, V63, P815, DOI 10.1146/annurev.physiol.63.1.815; Mikati MA, 2005, EPILEPSIA, V46, P48, DOI 10.1111/j.1528-1167.2005.00351.x; Milton JG, 2004, BIOCOMP-DORDRECH, V2, P117; Plummer M, 2010, RJAGS BAYESIAN GRAPH; Portas CM, 2000, NEURON, V28, P991, DOI 10.1016/S0896-6273(00)00169-0; R Core Team, 2021, R LANG ENV STAT COMP; RAUSCHER FH, 1993, NATURE, V365, P611, DOI 10.1038/365611a0; Rauscher FH, 1998, NEUROL RES, V20, P427; Sarnthein J, 1997, NEUROL RES, V19, P107; SCHWARTZKROIN PA, 1994, EPILEPSY RES, V17, P185, DOI 10.1016/0920-1211(94)90049-3; Shaw GL, 2005, NEOCORTICAL MODULARITY AND THE CELL MINICOLUMN, P187; Shaw GL, 1999, CLIN ELECTROENCEPHAL, V30, P151, DOI 10.1177/155005949903000407; Theodore William H., 2003, Epilepsy Curr, V3, P191, DOI 10.1046/j.1535-7597.2003.03607.x; Timofeev I, 2005, NEURON, V661, P1; Turner RP, 2004, EPILEPSY BEHAV, V5, P662, DOI 10.1016/j.yebeh.2004.07.003; Turner RP, 2004, NEUROLOGY REV, V12, P13; Verduzco-Flores S, 2012, NEURAL NETWORKS, V27, P21, DOI 10.1016/j.neunet.2011.09.007; Verduzco-Flores S, 2009, CHAOS, V19, DOI 10.1063/1.3080663; Zifkin B G, 1998, Adv Neurol, V75, P273	54	27	28	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2012	7	10							e45303	10.1371/journal.pone.0045303	http://dx.doi.org/10.1371/journal.pone.0045303			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	020KP	23071510	gold, Green Submitted, Green Published			2023-01-03	WOS:000309807700007
J	Ma, JM; Xu, JQ; Anderson, RN; Jemal, A				Ma, Jiemin; Xu, Jiaquan; Anderson, Robert N.; Jemal, Ahmedin			Widening Educational Disparities in Premature Death Rates in Twenty Six States in the United States, 1993-2007	PLOS ONE			English	Article							CAUSE-SPECIFIC MORTALITY; SOCIOECONOMIC-STATUS; ALL-CAUSE; INEQUALITIES; ADULTS; TRENDS; NORWAY; GAP	Background: Eliminating socioeconomic disparities in health is an overarching goal of the U.S. Healthy People decennial initiatives. We present recent trends in mortality by education among working-aged populations. Methods and Findings: Age-standardized death rates and their average annual percent change for all-cause and five major causes (cancer, heart disease, stroke, diabetes, and accidents) were calculated from 1993 through 2007 for individuals aged 25-64 years by educational attainment as a marker of socioeconomic status, using national vital registration data for 26 states with consistent educational information on the death certificates. Rate ratios and rate differences were used to assess disparities (<= 12 versus >= 16 years of education) for 1993 through 2007. From 1993 through 2007, relative educational disparities in all-cause mortality continued to increase among working-aged men and women in the U. S., due to larger decreases of mortality rates among the most educated coupled with smaller decreases or even worsening trends in the less educated. For example, the rate ratios of all-cause mortality increased from 2.5 (95% confidence interval (CI), 2.4-2.6) in 1993 to 3.6 (95% CI, 3.5-3.7) in 2007 in men and from 1.9 (95% CI, 1.8-2.0) to 3.0 (95% CI, 2.9-3.1) in women. Generally, the rate differences (per 100,000 persons) of all-cause mortality increased from 415.5 (95% CI, 399.1-431.9) in 1993 to 472.7 (95% CI, 460.2-485.2) in 2007 in men and from 165.4 (95% CI, 154.5-176.2) to 256.2 (95% CI, 248.3-264.2) in women. Disparity patterns varied largely across the five specific causes considered in this study, with the largest increases of relative disparities for accidents, especially in women. Conclusions: Relative educational differentials in mortality continued to widen among men and women despite emphasis on reducing disparities in the U. S. Healthy People decennial initiatives.	[Ma, Jiemin; Jemal, Ahmedin] Amer Canc Soc, Surveillance Res Program, Atlanta, GA 30329 USA; [Xu, Jiaquan; Anderson, Robert N.] Ctr Dis Control & Prevent, Mortal Stat Branch, Natl Ctr Hlth Stat, Hyattsville, MD USA	American Cancer Society; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Ma, JM (corresponding author), Amer Canc Soc, Surveillance Res Program, Atlanta, GA 30329 USA.	jiemin.ma@cancer.org	shen, Guanxin/F-7441-2011	Liu, Hongbo/0000-0002-7187-8115	American Cancer Society and the Centers for Disease Control and Prevention	American Cancer Society and the Centers for Disease Control and Prevention	The American Cancer Society and the Centers for Disease Control and Prevention funded the analysis, interpretation, and compilation of surveillance data. No staff at either agency, other than the authors, was involved in the conduct of the study; collection, management, analysis, and interpretation of the data; or preparation of the manuscript.	Agency for Healthcare Research and Quality, 2010, 2010 NAT HEALTHC DIS; Ahluwalia IB, 2008, J COMMUN HEALTH, V33, P293, DOI 10.1007/s10900-008-9106-8; Albano JD, 2007, JNCI-J NATL CANCER I, V99, P1384, DOI 10.1093/jnci/djm127; Anderson R N, 2001, Natl Vital Stat Rep, V49, P1; [Anonymous], 1992, INT STAT CLASS DIS R; Berkman L F, 1997, IARC Sci Publ, P51; Braveman PA, 2005, JAMA-J AM MED ASSOC, V294, P2879, DOI 10.1001/jama.294.22.2879; FELDMAN JJ, 1989, AM J EPIDEMIOL, V129, P919, DOI 10.1093/oxfordjournals.aje.a115225; Hadden WC, 2008, INT J HEALTH SERV, V38, P47, DOI 10.2190/HS.38.1.c; Jemal A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009584; Jemal A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002181; Kanjilal S, 2006, ARCH INTERN MED, V166, P2348, DOI 10.1001/archinte.166.21.2348; Kim HJ, 2000, STAT MED, V19, P335, DOI 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.3.CO;2-Q; Kominski R., 1994, ED ATTAINMENT US MAR, P20; Korhonen N, 2011, INJURY, V42, P885, DOI 10.1016/j.injury.2010.08.033; Krieger N, 2008, PLOS MED, V5, P227, DOI 10.1371/journal.pmed.0050046; Mackenbach JP, 2010, SOC SCI MED, V71, P1249, DOI 10.1016/j.socscimed.2010.07.014; Mackenbach JP, 2003, INT J EPIDEMIOL, V32, P830, DOI 10.1093/ije/dyg209; Meara ER, 2008, HEALTH AFFAIR, V27, P350, DOI 10.1377/hlthaff.27.2.350; Minino A., 2007, NATL VITAL STAT REP, V55, P1; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; Paulozzi L., 2007, Morbidity and Mortality Weekly Report, V56, P93; Rim Sun Hee, 2011, Morbidity and Mortality Weekly Report, V60, P42; Roger Veronique L, 2011, Circulation, V123, pe18, DOI 10.1161/CIR.0b013e3182009701; Rostron BL, 2010, ED REP CLASS DEATH C, Viii; Rothman K.J., 2008, MODERN EPIDEMIOLOGY, V3rd; Schalick LM, 2000, INT J HEALTH SERV, V30, P13, DOI 10.2190/8QMH-4FAB-XAWP-VU95; Schwartz CR, 2005, DEMOGRAPHY, V42, P621, DOI 10.1353/dem.2005.0036; Shkolnikov VM, 2012, J EPIDEMIOL COMMUN H, V66, P372, DOI 10.1136/jech.2009.104786; Sorlie PD, 1996, EPIDEMIOLOGY, V7, P437, DOI 10.1097/00001648-199607000-00017; Steenland K, 2004, AM J PUBLIC HEALTH, V94, P1037, DOI 10.2105/AJPH.94.6.1037; Steenland K, 2002, AM J EPIDEMIOL, V156, P11, DOI 10.1093/aje/kwf001; Strand BH, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c654; U.S. Department of Health and Human Services, 2000, HLTH PEOPL 2010 UND; U.S. Department of Health and Human Services, 2010, HLTH PEOPL 2020; U.S. Department of Health and Human Services, 2007, HLTH PEOPL 2010 MIDC; World Health Organization, 1977, INT STAT CLASS DIS R	37	76	81	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2012	7	7							e41560	10.1371/journal.pone.0041560	http://dx.doi.org/10.1371/journal.pone.0041560			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	977GL	23094023	Green Published, gold, Green Submitted			2023-01-03	WOS:000306644600087
J	Jiang, JQ; Zhou, ZW				Jiang, JiaQian; Zhou, Zhengwei			Removal of Pharmaceutical Residues by Ferrate(VI)	PLOS ONE			English	Article							WASTE-WATER TREATMENT; PERSONAL CARE PRODUCTS; DISRUPTING CHEMICALS EDCS; SEWAGE-TREATMENT PLANTS; POTASSIUM FERRATE(VI); ENDOCRINE DISRUPTORS; ACTIVE COMPOUNDS; RISK-ASSESSMENT; OXIDATION; CARBAMAZEPINE	Background: Pharmaceuticals and their metabolites are inevitably emitted into the waters. The adverse environmental and human health effects of pharmaceutical residues in water could take place under a very low concentration range; from several mu g/L to ng/L. These are challenges to the global water industries as there is no unit process specifically designed to remove these pollutants. An efficient technology is thus sought to treat these pollutants in water and waste water. Methodology/Major Results: A novel chemical, ferrate, was assessed using a standard jar test procedure for the removal of pharmaceuticals. The analytical protocols of pharmaceuticals were standard solid phase extraction together with various instrumentation methods including LC-MS, HPLC-UV and UV/Vis spectroscopy. Ferrate can remove more than 80% of ciprofloxacin (CIP) at ferrate dose of 1 mg Fe/L and 30% of ibuprofen (IBU) at ferrate dose of 2 mg Fe/L. Removal of pharmaceuticals by ferrate was pH dependant and this was in coordinate to the chemical/physical properties of pharmaceuticals. Ferrate has shown higher capability in the degradation of CIP than IBU; this is because CIP has electron-rich organic moieties (EOM) which can be readily degraded by ferrate oxidation and IBU has electron-withdrawing groups which has slow reaction rate with ferrate. Promising performance of ferrate in the treatment of real waste water effluent at both pH 6 and 8 and dose range of 1-5 mg Fe/L was observed. Removal efficiency of ciprofloxacin was the highest among the target compounds (63%), followed by naproxen (43%). On the other hand, n-acetyl sulphamethoxazole was the hardest to be removed by ferrate (8% only). Conclusions: Ferrate is a promising chemical to be used to treat pharmaceuticals in waste water. Adjusting operating conditions in terms of the properties of target pharmaceuticals can maximise the pharmaceutical removal efficiency.	[Jiang, JiaQian; Zhou, Zhengwei] Glasgow Caledonian Univ, Sch Engn & Built Environm, Glasgow G4 0BA, Lanark, Scotland	Glasgow Caledonian University	Jiang, JQ (corresponding author), Glasgow Caledonian Univ, Sch Engn & Built Environm, Glasgow G4 0BA, Lanark, Scotland.	jiaqian.jiang@gcu.ac.uk	Zhou, Zhengwei/M-9957-2015; Jiang, Jia-Qian/O-9493-2014	Zhou, Zhengwei/0000-0001-9014-5139; Jiang, Jia-Qian/0000-0003-3607-8910; Bines, Julie/0000-0002-5452-6601	Glasgow Caledonian University Research Committee	Glasgow Caledonian University Research Committee	The authors thank the Glasgow Caledonian University Research Committee for offering a research studentship to ZZ for his PhD study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anquandah GAK, 2011, ENVIRON SCI TECHNOL, V45, P10575, DOI 10.1021/es202237g; Castiglioni S, 2006, ENVIRON SCI TECHNOL, V40, P357, DOI 10.1021/es050991m; Comeau F, 2008, SCI TOTAL ENVIRON, V396, P132, DOI 10.1016/j.scitotenv.2008.02.031; Comerton AM, 2008, J MEMBRANE SCI, V313, P323, DOI 10.1016/j.memsci.2008.01.021; Daughton CG, 1999, ENVIRON HEALTH PERSP, V107, P907, DOI 10.2307/3434573; Ferrari B, 2003, ECOTOX ENVIRON SAFE, V55, P359, DOI 10.1016/S0147-6513(02)00082-9; Filip J, 2011, CHEM-EUR J, V17, P10097, DOI 10.1002/chem.201100711; Grung M, 2008, ECOTOX ENVIRON SAFE, V71, P328, DOI 10.1016/j.ecoenv.2007.10.015; Hu L, 2009, ENVIRON SCI TECHNOL, V43, P509, DOI 10.1021/es8023513; Jiang JQ, 2007, J HAZARD MATER, V146, P617, DOI 10.1016/j.jhazmat.2007.04.075; Jiang JQ, 2012, GLOBAL NEST J, V14, P93; Jiang JQ, 2007, DESALINATION, V210, P266, DOI 10.1016/j.desal.2006.05.051; Jiang JQ, 2012, SEP PURIF TECHNOL, V88, P95, DOI 10.1016/j.seppur.2011.12.021; Jiang JQ, 2009, SEP PURIF TECHNOL, V68, P227, DOI 10.1016/j.seppur.2009.05.007; Jiang JQ, 2002, WATER RES, V36, P1397, DOI 10.1016/S0043-1354(01)00358-X; Jiang JQ, 2006, J ENVIRON MANAGE, V79, P215, DOI 10.1016/j.jenvman.2005.06.009; Jiang JQ, 2005, CHEMOSPHERE, V61, P544, DOI 10.1016/j.chemosphere.2005.02.029; Jiang JQ, 2001, ENVIRON ENG SCI, V18, P323, DOI 10.1089/10928750152726041; Jiang JQ, 2001, SEPAR PURIF METHOD, V30, P127, DOI 10.1081/SPM-100102986; Jjemba PK, 2006, ECOTOX ENVIRON SAFE, V63, P113, DOI 10.1016/j.ecoenv.2004.11.011; Lee HB, 2007, J CHROMATOGR A, V1139, P45, DOI 10.1016/j.chroma.2006.11.068; Lee Y, 2009, ENVIRON SCI TECHNOL, V43, P3831, DOI 10.1021/es803588k; Lishman L, 2006, SCI TOTAL ENVIRON, V367, P544, DOI 10.1016/j.scitotenv.2006.03.021; Nakada N, 2006, WATER RES, V40, P3297, DOI 10.1016/j.watres.2006.06.039; Okuda T, 2008, WATER SCI TECHNOL, V57, P65, DOI 10.2166/wst.2008.822; Paxeus N, 2004, WATER SCI TECHNOL, V50, P253, DOI 10.2166/wst.2004.0335; Santos JL, 2007, ENVIRON INT, V33, P596, DOI 10.1016/j.envint.2006.09.014; Seitz W, 2008, CHEMOSPHERE, V70, P1238, DOI 10.1016/j.chemosphere.2007.07.081; Sharma VK, 2008, J WATER SUPPLY RES T, V57, P419, DOI 10.2166/aqua.2008.077; Sharma VK, 2006, ENVIRON CHEM LETT, V3, P182, DOI 10.1007/s10311-005-0002-5; Sharma VK, 2012, CHEMOSPHERE, V87, P644, DOI 10.1016/j.chemosphere.2012.01.019; Sharma VK, 2011, CHEMOSPHERE, V82, P1083, DOI 10.1016/j.chemosphere.2010.12.053; Sharma VK, 2010, J ENVIRON SCI HEAL A, V45, P645, DOI 10.1080/10934521003648784; Sharma VK, 2002, ADV ENVIRON RES, V6, P143, DOI 10.1016/S1093-0191(01)00119-8; Sharma VK, 2001, PHYS CHEM CHEM PHYS, V3, P2059, DOI 10.1039/b101432n; Snyder SA, 2007, DESALINATION, V202, P156, DOI 10.1016/j.desal.2005.12.052; Stanford C, 2010, WATER AIR SOIL POLL, V209, P483, DOI 10.1007/s11270-009-0216-4; Ternes TA, 1998, WATER RES, V32, P3245, DOI 10.1016/S0043-1354(98)00099-2; Wang L, 2010, SCI TOTAL ENVIRON, V408, P3139, DOI 10.1016/j.scitotenv.2010.04.047; Westerhoff P, 2005, ENVIRON SCI TECHNOL, V39, P6649, DOI 10.1021/es0484799; Yang B, 2012, WATER RES, V46, P2194, DOI 10.1016/j.watres.2012.01.047; Zhou ZW, 2012, J APPL SPECTROSC+, V79, P459, DOI 10.1007/s10812-012-9623-1	42	183	187	14	143	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2013	8	2							e55729	10.1371/journal.pone.0055729	http://dx.doi.org/10.1371/journal.pone.0055729			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	092XV	23894308	gold, Green Submitted, Green Published			2023-01-03	WOS:000315157200054
J	Ma, JW; Huang, CM; Yao, XX; Shi, C; Sun, LF; Yuan, L; Lei, P; Zhu, HF; Liu, HB; Wu, XW; Ning, Q; Zhou, C; Shen, GX				Ma, Jingwei; Huang, Chunmei; Yao, Xinxin; Shi, Chuan; Sun, Lifang; Yuan, Lu; Lei, Ping; Zhu, Huifen; Liu, Hongbo; Wu, Xiongwen; Ning, Qin; Zhou, Chun; Shen, Guanxin			Inhibition of Hepatitis B Virus and Induction of Hepatoma Cell Apoptosis by ASGPR-Directed Delivery of shRNAs	PLOS ONE			English	Article							SMALL INTERFERING RNAS; ASIALOGLYCOPROTEIN RECEPTOR; INCREASES MIGRATION; NATURAL-HISTORY; PROTEIN-X; SURVIVIN; GENE; EXPRESSION; LIVER; SIRNA	Hepatitis B virus (HBV) infection is a worldwide liver disease and nearly 25% of chronic HBV infections terminate in hepatocellular carcinoma (HCC). Currently, there is no effective therapy to inhibit HBV replication and to eliminate hepatoma cells, making it highly desired to develop novel therapies for these two stages of the HBV-caused detrimental disease. Recently, short hairpin RNA (shRNA) has emerged as a potential therapy for virus-infected disease and cancer. Here, we have generated a shRNA, pGenesil-siHBV4, which effectively inhibits HBV replication in the human hepatoma cell line HepG2.2.15. The inhibitory effects of pGenesil-siHBV4 are manifested by the decrease of both the HBV mRNA level and the protein levels of the secreted HBV surface antigen (HBsAg) and HBV e antigen (HBeAg), and by the reduction of secreted HBV DNA. Using mouse hydrodynamic tail vein injection, we demonstrate that pGenesil-siHBV4 is effective in inhibiting HBV replication in vivo. Because survivin plays a key role in cancer cell escape from apoptosis, we further generated pGenesil-siSurvivin, a survivin-silencing shRNA, and showed its effect of triggering apoptosis of HBV-containing hepatoma cells. To develop targeted shRNA therapy, we have identified that as a specific binder of the asialoglycoprotein receptor (ASGPR), jetPEI-Hepatocyte delivers pGenesil-siHBV4 and pGenesil-siSurvivin specifically to hepatocytes, not other types of cells. Finally, co-transfection of pGenesil-siHBV4 and pGenesil-siSurvivin exerts synergistic effects in inducing hepatoma cell apoptosis, a novel approach to eliminate hepatoma by downregulating survivin via multiple mechanisms. The application of these novel shRNAs with the jetPEI-Hepatocyte targeting strategy demonstrates the proof-of-principle for a promising approach to inhibit HBV replication and eliminate hepatoma cells with high specificity.	[Zhou, Chun] Columbia Univ, Dept Environm Hlth Sci, New York, NY 10027 USA; [Ma, Jingwei; Huang, Chunmei; Yao, Xinxin; Shi, Chuan; Sun, Lifang; Yuan, Lu; Lei, Ping; Zhu, Huifen; Liu, Hongbo; Wu, Xiongwen; Shen, Guanxin] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Immunol, Wuhan 430074, Peoples R China; [Ning, Qin] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Infect Dis, Wuhan 430074, Peoples R China	Columbia University; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Zhou, C (corresponding author), Columbia Univ, Dept Environm Hlth Sci, New York, NY 10027 USA.	cz2132@columbia.edu; guanxin_shen@yahoo.com.cn	shen, Guanxin/F-7441-2011	Liu, Hongbo/0000-0002-7187-8115	Program for Changjiang Scholars and Innovative Research Team in University [IRT1131]; State Project on Major Infectious Diseases Prevention [2012ZX10002006-003]; International Science & Technology Cooperation Program of China [2011DFA31030]	Program for Changjiang Scholars and Innovative Research Team in University(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT)); State Project on Major Infectious Diseases Prevention; International Science & Technology Cooperation Program of China	This research work was supported by Program for Changjiang Scholars and Innovative Research Team in University (Grant, No: IRT1131), State Project on Major Infectious Diseases Prevention (Grant 2012ZX10002006-003), and the International Science & Technology Cooperation Program of China (2011DFA31030). The funding organizations had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akinc A, 2005, J GENE MED, V7, P657, DOI 10.1002/jgm.696; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Budker VG, 2006, J GENE MED, V8, P874, DOI 10.1002/jgm.920; But DYK, 2008, WORLD J GASTROENTERO, V14, P1652, DOI 10.3748/wjg.14.1652; Chen Y, 2004, WORLD J GASTROENTERO, V10, P82; De Paula D, 2007, RNA, V13, P431, DOI 10.1261/rna.459807; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Giladi H, 2003, MOL THER, V8, P769, DOI 10.1016/S1525-0016(03)00244-2; Gong Q, 2011, DNA CELL BIOL, V30, P347, DOI 10.1089/dna.2010.1172; Guan SH, 2007, WORLD J GASTROENTERO, V13, P228, DOI 10.3748/wjg.v13.i2.228; Guo PX, 2010, NAT NANOTECHNOL, V5, P833, DOI 10.1038/NNANO.2010.231; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Ikeguchi M, 2002, DIAGN MOL PATHOL, V11, P33, DOI 10.1097/00019606-200203000-00007; KANEKO S, 1988, J VIROL, V62, P3979, DOI 10.1128/JVI.62.11.3979-3984.1988; Kew MC, 2010, PATHOL BIOL, V58, P273, DOI 10.1016/j.patbio.2010.01.005; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim EM, 2005, J CONTROL RELEASE, V108, P557, DOI 10.1016/j.jconrel.2005.09.001; Kim SI, 2007, MOL THER, V15, P1145, DOI 10.1038/sj.mt.6300168; Kumar R, 2003, GENOME RES, V13, P2333, DOI 10.1101/gr.1575003; Kuo TC, 2010, BIOCHEM PHARMACOL, V80, P1093, DOI 10.1016/j.bcp.2010.06.003; Li Donghua, 2003, J Huazhong Univ Sci Technolog Med Sci, V23, P383; Li L, 2009, MOL BIOSYST, V5, P1361, DOI 10.1039/b903428e; Liu FJ, 2007, WORLD J GASTROENTERO, V13, P5324, DOI 10.3748/wjg.v13.i40.5324; Liu HY, 2007, CANCER BIOL THER, V6, P697; Liu YQ, 2009, MOL THER, V17, P269, DOI 10.1038/mt.2008.266; Lupberger J, 2007, WORLD J GASTROENTERO, V13, P74, DOI 10.3748/wjg.v13.i1.74; Marusawa H, 2003, EMBO J, V22, P2729, DOI 10.1093/emboj/cdg263; Masiero M, 2007, MOL ASPECTS MED, V28, P143, DOI 10.1016/j.mam.2006.12.004; McCaffrey AP, 2003, NAT BIOTECHNOL, V21, P639, DOI 10.1038/nbt824; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223; Mello CC, 2004, NATURE, V431, P338, DOI 10.1038/nature02872; Nguyen DH, 2008, J CELL PHYSIOL, V216, P289, DOI 10.1002/jcp.21416; NISHIKAWA M, 1995, AM J PHYSIOL-GASTR L, V268, pG849, DOI 10.1152/ajpgi.1995.268.5.G849; O'Driscoll L, 2003, CURR CANCER DRUG TAR, V3, P131, DOI 10.2174/1568009033482038; Pan XF, 2011, MOL IMMUNOL, V48, P1573, DOI 10.1016/j.molimm.2011.03.012; SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005; Shu Y, 2011, MOL THER, V19, P1304, DOI 10.1038/mt.2011.23; Shu Y, 2011, METHODS, V54, P204, DOI 10.1016/j.ymeth.2011.01.008; Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101; STOCKERT RJ, 1995, PHYSIOL REV, V75, P591, DOI 10.1152/physrev.1995.75.3.591; Ui-Tei K, 2004, NUCLEIC ACIDS RES, V32, P936, DOI 10.1093/nar/gkh247; Uprichard SL, 2005, P NATL ACAD SCI USA, V102, P773, DOI 10.1073/pnas.0409028102; Werle-Lapostolle B, 2004, GASTROENTEROLOGY, V126, P1750, DOI 10.1053/j.gastro.2004.03.018; Wieland SF, 2004, P NATL ACAD SCI USA, V101, P2129, DOI 10.1073/pnas.0308478100; Xia LM, 2009, VIROLOGY, V385, P335, DOI 10.1016/j.virol.2008.11.042; Zhang R, 2010, CANCER GENE THER, V17, P275, DOI 10.1038/cgt.2009.68; Zhang XD, 2005, J MED VIROL, V77, P374, DOI 10.1002/jmv.20466; Zhang X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031458; Zhou Y, 2010, J BIOL CHEM, V285, P12159, DOI 10.1074/jbc.M109.067629	50	76	81	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 19	2012	7	10							e46096	10.1371/journal.pone.0046096	http://dx.doi.org/10.1371/journal.pone.0046096			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	023QT	23094023	gold, Green Published, Green Submitted			2023-01-03	WOS:000310050200007
J	Wu, JY; Chen, CH; Wang, CZ; Ho, ML; Yeh, ML; Wang, YH				Wu, Jyun-Yi; Chen, Chia-Hsin; Wang, Chau-Zen; Ho, Mei-Ling; Yeh, Ming-Long; Wang, Yan-Hsiung			Low-Power Laser Irradiation Suppresses Inflammatory Response of Human Adipose-Derived Stem Cells by Modulating Intracellular Cyclic AMP Level and NF-kappa B Activity	PLOS ONE			English	Article							MESSENGER-RNA EXPRESSION; TOLL-LIKE RECEPTORS; THERAPY LLLT; SIGNALING PATHWAY; RAT; NM; FIBROBLASTS; MECHANISMS; PROTEIN; MUSCLE	Mesenchymal stem cell (MSC)-based tissue regeneration is a promising therapeutic strategy for treating damaged tissues. However, the inflammatory microenvironment that exists at a local injury site might restrict reconstruction. Low-power laser irradiation (LPLI) has been widely applied to retard the inflammatory reaction. The purpose of this study was to investigate the anti-inflammatory effect of LPLI on human adipose-derived stem cells (hADSCs) in an inflammatory environment. We showed that the hADSCs expressed Toll-like Receptors (TLR) 1, TLR2, TLR3, TLR4, and TLR6 and that lipopolysaccharide (LPS) significantly induced the production of pro-inflammatory cytokines (Cyclooxygenase-2 (Cox-2), Interleukin-1b (IL-1b), Interleukin-6 (IL-6), and Interleukin-8 (IL-8)). LPLI markedly inhibited LPS-induced, pro-inflammatory cytokine expression at an optimal dose of 8 J/cm(2). The inhibitory effect triggered by LPLI might occur through an increase in the intracellular level of cyclic AMP (cAMP), which acts to down-regulate nuclear factor kappa B (NF-kappa B) transcriptional activity. These data collectively provide insight for further investigations of the potential application of anti-inflammatory treatment followed by stem cell therapy.	[Wu, Jyun-Yi; Yeh, Ming-Long] Natl Cheng Kung Univ, Inst Biomed Engn, Tainan 70101, Taiwan; [Chen, Chia-Hsin] Kaohsiung Med Univ Hosp, Dept Phys Med & Rehabil, Kaohsiung, Taiwan; [Chen, Chia-Hsin] Kaohsiung Med Univ, Coll Med, Fac Med, Dept Phys Med & Rehabil, Kaohsiung, Taiwan; [Chen, Chia-Hsin] Kaohsiung Municipal Tatung Hosp, Dept Phys Med & Rehabil, Kaohsiung, Taiwan; [Wang, Chau-Zen; Ho, Mei-Ling; Wang, Yan-Hsiung] Kaohsiung Med Univ, Coll Med, Orthopaed Res Ctr, Kaohsiung, Taiwan; [Wang, Chau-Zen; Ho, Mei-Ling] Kaohsiung Med Univ, Dept Physiol, Coll Med, Kaohsiung, Taiwan; [Wang, Chau-Zen; Ho, Mei-Ling] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan; [Wang, Yan-Hsiung] Kaohsiung Med Univ, Sch Dent, Coll Dent Med, Kaohsiung, Taiwan	National Cheng Kung University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Municipal Ta-Tung Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University	Yeh, ML (corresponding author), Natl Cheng Kung Univ, Inst Biomed Engn, Tainan 70101, Taiwan.	mlyeh@mail.ncku.edu.tw; yhwang@kmu.edu.tw	Wang, Yan-Hsiung/ABD-4004-2020	Wang, Yan-Hsiung/0000-0001-8161-7472; Ho, Mei-Ling/0000-0001-8064-8488; Chen, Chia-Hsin/0000-0002-6557-9848	National Health Research Institutes [NHRI-EX101-9914EC]; Kaohsiung Municipal Ta-Tung Hospital [KMTTH-99-013]; Kaohsiung Medical University of Taiwan [KMU-Q099018]	National Health Research Institutes(National Health Research Institutes, Japan); Kaohsiung Municipal Ta-Tung Hospital; Kaohsiung Medical University of Taiwan	This study was supported by a grant from the National Health Research Institutes (NHRI-EX101-9914EC), a grant from the Kaohsiung Municipal Ta-Tung Hospital (KMTTH-99-013), and a grant from the Kaohsiung Medical University (KMU-Q099018) of Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aimbire F, 2008, INFLAMMATION, V31, P189, DOI 10.1007/s10753-008-9064-4; Aimbire F, 2008, INT IMMUNOPHARMACOL, V8, P603, DOI 10.1016/j.intimp.2007.12.007; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004; Behfar A, 2007, J EXP MED, V204, P405, DOI 10.1084/jem.20061916; Bortone F, 2008, INT IMMUNOPHARMACOL, V8, P206, DOI 10.1016/j.intimp.2007.09.004; Boschi ES, 2008, LASER SURG MED, V40, P500, DOI 10.1002/lsm.20658; Bunnell BA, 2008, METHODS, V45, P115, DOI 10.1016/j.ymeth.2008.03.006; Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200; Cho HH, 2006, STEM CELLS, V24, P2744, DOI 10.1634/stemcells.2006-0189; Correa F, 2007, PHOTOMED LASER SURG, V25, P245, DOI 10.1089/pho.2007.2079; Crisostomo PR, 2007, SHOCK, V28, P375, DOI 10.1097/shk.0b013e318058a817; de Lima FM, 2011, LASER MED SCI, V26, P389, DOI 10.1007/s10103-010-0874-x; Doyle SL, 2006, BIOCHEM PHARMACOL, V72, P1102, DOI 10.1016/j.bcp.2006.07.010; Garcia-Gomez I, 2010, EXPERT OPIN BIOL TH, V10, P1453, DOI 10.1517/14712598.2010.519333; Gerlo S, 2011, CELL MOL LIFE SCI, V68, P3823, DOI 10.1007/s00018-011-0757-8; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; KARU TI, 1985, DOKL AKAD NAUK SSSR+, V281, P1242; Lombardo E, 2009, TISSUE ENG PT A, V15, P1579, DOI 10.1089/ten.tea.2008.0340; Martin P, 2003, CURR BIOL, V13, P1122, DOI 10.1016/S0960-9822(03)00396-8; O'Neill LAJ, 2007, NAT REV IMMUNOL, V7, P353, DOI 10.1038/nri2079; Parry GCN, 1997, J IMMUNOL, V159, P5450; Pires D, 2011, LASER MED SCI, V26, P85, DOI 10.1007/s10103-010-0811-z; Rizzi CF, 2006, LASER SURG MED, V38, P704, DOI 10.1002/lsm.20371; Sakurai Y, 2000, EUR J ORAL SCI, V108, P29, DOI 10.1034/j.1600-0722.2000.00783.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Uemura R, 2006, CIRC RES, V98, P1414, DOI 10.1161/01.RES.0000225952.61196.39; Wu JY, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0046393, 10.1371/journal.pone.0044027]; Xiong Fang, 2007, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V15, P449; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhu YX, 2008, CELL BIOCHEM FUNCT, V26, P664, DOI 10.1002/cbf.1488; Zungu IL, 2009, PHOTOCHEM PHOTOBIOL, V85, P987, DOI 10.1111/j.1751-1097.2008.00523.x	33	54	59	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2013	8	1							e54067	10.1371/journal.pone.0054067	http://dx.doi.org/10.1371/journal.pone.0054067			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072OV	23825677	Green Published, gold			2023-01-03	WOS:000313682700083
J	Chen, WF; Chang, KP; Chen, CH; Shyu, VBH; Kao, HK				Chen, Wei F.; Chang, Kai-Ping; Chen, Chih-Hao; Shyu, Victor Bong-Hang; Kao, Huang-Kai			Outcomes of Anterolateral Thigh Flap Reconstruction for Salvage Laryngopharyngectomy for Hypopharyngeal Cancer after Concurrent Chemoradiotherapy	PLOS ONE			English	Article							FUNCTIONAL OUTCOMES; PHARYNGOESOPHAGEAL RECONSTRUCTION; CARCINOMA; HEAD; RESECTION	Objective: To evaluate the functional and oncological outcomes of anterolateral thigh flap reconstruction for salvage laryngopharyngectomy after concurrent chemoradiotherapy for patients with hypopharyngeal carcinoma. Materials/Methods: A retrospective review was conducted on patients who underwent pharyngoesophageal reconstruction using anterolateral thigh flap after salvage laryngopharyngectomy for recurrent hypopharyngeal carcinoma between June 2003 and May 2010 at Chang Gung Memorial Hospital. The perioperative morbidity, mortality, functional outcomes, and oncological outcomes were evaluated. Results: 33 patients were entered into the study. The mean follow-up time was 19.5 +/- 12.3 months. Recurrent pathological TNM stages included 3 (9.1%), 2 (6.1%), and 28 (84.8%) patients with stage II, III, and IV disease, respectively. Mean ICU stay was 10.3 days and the mean hospital stay was 39.9 days. Peri-operative mortality occurred in one patient (3%). 16 patients (48.5%) developed recipient site complications. Among them, 14 patients (42.4%) developed fistulas and 9 patients (27.3%) developed strictures. Except for 4 patients (12.1%), all achieved varying degree of oral intake with 29 patients (60.6%) being completely independent from tube feeding. The mean interval to start oral intake was 15.1 days. The 5-year overall survival and disease-free survival rates were 51.8% and 53.7%, respectively. The pN status is an independent predictor of overall survival and disease-free survival (P = 0.027 and 0.038, respectively). Conclusion: Pharyngoesophageal reconstruction after salvage laryngopharyngectomy remains challenging even in the experienced hands. Reconstructive microsurgeons who are prepared to take on these cases should be equally well prepared to manage the potential postoperative complications.	[Chen, Wei F.] Univ Iowa Hosp & Clin, Dept Surg, Div Plast & Reconstruct Surg, Iowa City, IA 52242 USA; [Chang, Kai-Ping] Chang Gung Mem Hosp, Dept Otolaryngol Head & Neck Surg, Tao Yuan, Taiwan; [Chang, Kai-Ping; Chen, Chih-Hao; Shyu, Victor Bong-Hang; Kao, Huang-Kai] Chang Gung Univ, Coll Med, Tao Yuan, Taiwan; [Chen, Chih-Hao; Shyu, Victor Bong-Hang; Kao, Huang-Kai] Chang Gung Mem Hosp, Dept Plast & Reconstruct Surg, Tao Yuan, Taiwan	University of Iowa; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital	Kao, HK (corresponding author), Chang Gung Mem Hosp, Dept Plast & Reconstruct Surg, Tao Yuan, Taiwan.	kai3488@gmail.com		Yang, Guoyan (Emily)/0000-0002-8012-2379; Liu, Bo/0000-0003-3101-650X; Chen, Wei/0000-0002-4163-6641; Liu, Jianping/0000-0002-0320-061X	NCCIH NIH HHS [R24 AT001293] Funding Source: Medline	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Ali Rozina S, 2009, Plast Reconstr Surg, V124, pe395, DOI 10.1097/PRS.0b013e3181bcf05c; Chan YW, 2011, J PLAST RECONSTR AES, V64, P1022, DOI 10.1016/j.bjps.2011.03.021; Chang MFT, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-91; Chen KT, 2007, PLAST RECONSTR SURG, V120, P187, DOI 10.1097/01.prs.0000264077.07779.50; Chu PY, 2005, HEAD NECK-J SCI SPEC, V27, P901, DOI 10.1002/hed.20262; Guibert M, 2011, EUR ANN OTORHINOLARY, V128, P218, DOI 10.1016/j.anorl.2011.02.010; Kadota H, 2010, LARYNGOSCOPE, V120, P1103, DOI 10.1002/lary.20887; Kao HK, 2009, ORAL ONCOL, V45, P1058, DOI 10.1016/j.oraloncology.2009.07.010; Lewin JS, 2005, LARYNGOSCOPE, V115, P1266, DOI 10.1097/01.MLG.0000165456.01648.B8; Lutz BS, 2005, CLIN PLAST SURG, V32, P421, DOI 10.1016/j.cps.2005.02.006; Murray DJ, 2007, HEAD NECK-J SCI SPEC, V29, P147, DOI 10.1002/hed.20489; Paximadis P, 2012, INT J RADIAT ONCOL, V82, P1515, DOI 10.1016/j.ijrobp.2011.04.064; Relic A, 2009, EUR ARCH OTO-RHINO-L, V266, P1799, DOI 10.1007/s00405-009-0946-3; Sagar B, 2010, J PLAST RECONSTR AES, V63, P970, DOI 10.1016/j.bjps.2009.04.019; Shellenberger TD, 2011, ARCH OTOLARYNGOL, V137, P1086, DOI 10.1001/archoto.2011.177; Takes RP, 2012, HEAD NECK-J SCI SPEC, V34, P270, DOI 10.1002/hed.21613; Tsou YA, 2010, HEAD NECK-J SCI SPEC, V32, P1494, DOI 10.1002/hed.21352; Wang HM, 2002, CANCER, V94, P2989, DOI 10.1002/cncr.10570; Wong CH, 2010, HEAD NECK-J SCI SPEC, V32, P1236, DOI 10.1002/hed.21284; Yu PR, 2006, PLAST RECONSTR SURG, V117, P968, DOI 10.1097/01.prs.0000200622.13312.d3	20	205	209	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2013	8	1							e53985	10.1371/journal.pone.0053985	http://dx.doi.org/10.1371/journal.pone.0053985			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	069IY	24069229	gold, Green Submitted, Green Published			2023-01-03	WOS:000313429800078
J	Chen, WK; Miao, CH				Chen, Wan-Kun; Miao, Chang-Hong			The Effect of Anesthetic Technique on Survival in Human Cancers: A Meta-Analysis of Retrospective and Prospective Studies	PLOS ONE			English	Article							EPIDURAL-ANESTHESIA; COLORECTAL-CANCER; NEURAXIAL ANESTHESIA; SPINAL-ANESTHESIA; SURGERY; RECURRENCE; ANALGESIA; REDUCTION; ASSOCIATION; MORTALITY	Animal models have shown that regional anesthesia (combined with or without general anesthesia) would attenuate the surgical stress response by preserving immune function and result in better long-term outcome. In order to test the hypothesis that cancer patients who had surgery with epidural anesthesia (EA) would have better outcome (either overall survival [OS] or recurrence-free survival [RFS]) than those who were general anesthesia (GA), we performed this meta-analysis. By searching relevant literature, a total of 14 studies containing 18 sub-studies (seven in OS analysis and eleven in RFS analysis) were identified and meta-analyzed. Adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) were used to assess the strength of association. For OS, the random-effects model was used to analyze the data and demonstrated an OS benefit in favor of EA compared with GA alone (HR = 0.84, 95% CI 0.74-0.96, P = 0.013). The influence analysis showed the robustness of the results. Specifically, a significantly positive association between EA and improved OS was observed in colorectal cancer (HR = 0.65, 95% CI 0.43-0.99, P = 0.045). For RFS, the random-effects model was used to analyze the data and no significant relationship between RFS benefit and EA (HR = 0.88, 95% CI 0.64-1.22, P = 0.457) was detected. In conclusion, our meta-analysis suggests that epidural anesthesia and/or analgesia might be associated with improved overall survival in patients with operable cancer undergoing surgery (especially in colorectal cancer), but it does not support an association between epidural anesthesia and cancer control. Prospective studies are needed to determine whether the association between epidural use and survival is causative.	[Chen, Wan-Kun] Fudan Univ, Dept Anesthesiol, Shanghai Canc Ctr, Shanghai 200433, Peoples R China; Fudan Univ, Inst Canc, Shanghai Med Coll, Shanghai 200433, Peoples R China	Fudan University; Fudan University	Chen, WK (corresponding author), Fudan Univ, Dept Anesthesiol, Shanghai Canc Ctr, Shanghai 200433, Peoples R China.	wkchen1981@hotmail.com; miaochh@yahoo.com.cn		Yang, Guoyan (Emily)/0000-0002-8012-2379; Liu, Bo/0000-0003-3101-650X; Chen, Wei/0000-0002-4163-6641; Liu, Jianping/0000-0002-0320-061X	Shanghai Committee of Science and Technology [114119a4400]; NCCIH NIH HHS [R24 AT001293] Funding Source: Medline	Shanghai Committee of Science and Technology(Shanghai Science & Technology Committee); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	This research is supported by grants from Guide Project of Shanghai Committee of Science and Technology (2011-2013, 114119a4400). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bar-Yosef S, 2001, ANESTHESIOLOGY, V94, P1066, DOI 10.1097/00000542-200106000-00022; BEILIN B, 1989, Brain Behavior and Immunity, V3, P129, DOI 10.1016/0889-1591(89)90013-5; Biagi JJ, 2011, JAMA-J AM MED ASSOC, V305, P2335, DOI 10.1001/jama.2011.749; Biki B, 2008, ANESTHESIOLOGY, V109, P180, DOI 10.1097/ALN.0b013e31817f5b73; Christopherson R, 2008, ANESTH ANALG, V107, P325, DOI 10.1213/ane.0b013e3181770f55; Cummings KC, 2012, ANESTHESIOLOGY, V116, P797, DOI 10.1097/ALN.0b013e31824674f6; de Oliveira GS, 2011, REGION ANESTH PAIN M, V36, P271, DOI 10.1097/AAP.0b013e318217aada; ERSKINE R, 1992, CAN J ANAESTH, V39, P905, DOI 10.1007/BF03008337; Exadaktylos AK, 2006, ANESTHESIOLOGY, V105, P660, DOI 10.1097/00000542-200610000-00008; Gottschalk A, 2010, ANESTHESIOLOGY, V113, P27, DOI 10.1097/ALN.0b013e3181de6d0d; Gupta A, 2011, BRIT J ANAESTH, V107, P164, DOI 10.1093/bja/aer100; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Ismail H, 2010, BRIT J ANAESTH, V105, P145, DOI 10.1093/bja/aeq156; Koodie L, 2010, AM J PATHOL, V177, P984, DOI 10.2353/ajpath.2010.090621; Lai RC, 2012, ANESTH ANALG, V114, P290, DOI 10.1213/ANE.0b013e318239c2e3; Landoni G, 2012, J CARDIOTHOR VASC AN, V26, P764, DOI 10.1053/j.jvca.2012.04.018; Larsson SC, 2010, JAMA-J AM MED ASSOC, V303, P1077, DOI 10.1001/jama.2010.263; LEWIS J W, 1983, Natural Immunity and Cell Growth Regulation, V3, P43; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lin L, 2011, BRIT J ANAESTH, V106, P814, DOI 10.1093/bja/aer055; Luo CF, 2010, EUR J ANAESTH, V27, P212, DOI 10.1097/00003643-201006121-00682; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; MARKOVIC SN, 1993, ANESTHESIOLOGY, V78, P700, DOI 10.1097/00000542-199304000-00013; Myles PS, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1491; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; Snyder GL, 2010, BRIT J ANAESTH, V105, P106, DOI 10.1093/bja/aeq164; Tsui BCH, 2010, CAN J ANAESTH, V57, P107, DOI 10.1007/s12630-009-9214-7; Urwin SC, 2000, BRIT J ANAESTH, V84, P450, DOI 10.1093/oxfordjournals.bja.a013468; Wijeysundera DN, 2008, LANCET, V372, P562, DOI 10.1016/S0140-6736(08)61121-6; Wuethrich PY, 2010, ANESTHESIOLOGY, V113, P570, DOI 10.1097/ALN.0b013e3181e4f6ec; Zhou D, 2012, WORLD J GASTROENTERO, V18, P3089, DOI 10.3748/wjg.v18.i24.3089	31	205	209	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2013	8	2							e56540	10.1371/journal.pone.0056540	http://dx.doi.org/10.1371/journal.pone.0056540			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	093IE	24069229	Green Published, Green Submitted, gold			2023-01-03	WOS:000315184200100
J	Wang, XM; Mao, XO; Xie, L; Sun, F; Greenberg, DA; Jin, KL				Wang, Xiaomei; Mao, XiaoOu; Xie, Lin; Sun, Fen; Greenberg, David A.; Jin, Kunlin			Conditional Depletion of Neurogenesis Inhibits Long-Term Recovery after Experimental Stroke in Mice	PLOS ONE			English	Article							FOCAL CEREBRAL-ISCHEMIA; SUBVENTRICULAR ZONE; FOREBRAIN NEUROGENESIS; BRAIN; CELLS; REPLACEMENT; PRECURSORS; MIGRATION; NEURONS	We reported previously that ablation of doublecortin (DCX)-immunopositive newborn neurons in mice worsens anatomical and functional outcome measured 1 day after experimental stroke, but whether this effect persists is unknown. We generated transgenic mice that express herpes simplex virus thymidine kinase under control of the DCX promoter (DCX-TK transgenic mice). DCX-expressing and recently divided cells in the rostral subventricular zone (SVZ) and hippocampus of DCX-TK transgenic mice, but not wild-type mice, were specifically depleted after ganciclovir (GCV) treatment for 14 days. Focal cerebral ischemia was induced by permanent distal middle cerebral artery occlusion (MCAO) on day 14 of vehicle or GCV treatment, and mice were killed 12 weeks after MCAO. Infarct volume was significantly increased and neurologic deficits were more severe in GCV- compared to vehicle-treated DCX-TK transgenic mice at first 8 weeks, after depletion of DCX- and bromodeoxyuridine-immunoreactive cells in the SVZ and dentate gyrus following focal ischemia. Our results indicate that endogenous neurogenesis in a critical period following experimental stroke influences the course of long-term recovery.	[Wang, Xiaomei; Mao, XiaoOu; Xie, Lin; Sun, Fen; Greenberg, David A.; Jin, Kunlin] Buck Inst Res Aging, Novato, CA USA; [Jin, Kunlin] Univ N Texas Hlth Sci Ctr Ft Worth, Dept Pharmacol & Neurosci, Ft Worth, TX USA; [Jin, Kunlin] Univ N Texas Hlth Sci Ctr Ft Worth, Inst Aging & Alzheimers Dis Res, Ft Worth, TX USA	Buck Institute for Research on Aging; University of North Texas System; University of North Texas Health Science Center; University of North Texas System; University of North Texas Health Science Center	Wang, XM (corresponding author), Buck Inst Res Aging, Novato, CA USA.	kunlin.jin@unthsc.edu	Sun, Fen/I-8516-2016; Pausch, Hubert/U-5934-2019; Prokopenko, Mikhail/A-3995-2008; Zeng, Maomao/M-1422-2013; Wang, Xuelong/GQB-3574-2022; Lizier, Joseph/B-8093-2008; Wang, X. Rosalind/B-7097-2008	Pausch, Hubert/0000-0002-0501-6760; Prokopenko, Mikhail/0000-0002-4215-0344; Wurmser, Christine/0000-0003-0649-6206; SUN, FEN/0000-0003-2094-9494; Zeng, Maomao/0000-0001-9259-1992; Wang, Xuelong/0000-0003-4616-1531; Yu, Zhuowei/0000-0002-9152-6491; Lizier, Joseph/0000-0002-9910-8972; Kou, Xiaoxing/0000-0001-9680-0077; Wang, X. Rosalind/0000-0001-5454-6197; Fries, Ruedi/0000-0002-4657-1787; Tang, Hailiang/0000-0003-1852-3128; Mao, Ying/0000-0001-8055-115X; Yan, Jizhou/0000-0001-7482-7842; Tetens, Jens/0000-0001-5352-464X; Miller, Jennifer/0000-0003-2110-3693	United States Public Health Service Grant [NS57186, AG21980, NS44921, NS62414]	United States Public Health Service Grant(United States Department of Health & Human ServicesUnited States Public Health Service)	This work was supported by United States Public Health Service Grants NS57186 and AG21980 (to KJ) and NS44921 and NS62414 (to DAG). The URL of any funder's website is www.nih.gov/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ameh EA, 2009, SURG INFECT, V10, P105, DOI 10.1089/sur.2007.082; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Encarnacion A, 2011, J NEUROSCI METH, V196, P247, DOI 10.1016/j.jneumeth.2011.01.010; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Gu WG, 2000, J CEREBR BLOOD F MET, V20, P1166, DOI 10.1097/00004647-200008000-00002; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Jin KL, 2010, AGING CELL, V9, P1076, DOI 10.1111/j.1474-9726.2010.00638.x; Jin KL, 2010, P NATL ACAD SCI USA, V107, P7993, DOI 10.1073/pnas.1000154107; Jorgensen H S, 1999, Phys Med Rehabil Clin N Am, V10, P887; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Lai B, 2008, NEUROSCI LETT, V442, P305, DOI 10.1016/j.neulet.2008.07.032; Liu JL, 1998, J NEUROSCI, V18, P7768; Mayo NE, 1999, DISABIL REHABIL, V21, P258; MCDERMOTT KW, 1991, J ANAT, V178, P45; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; OHLSSON AL, 1995, STROKE, V26, P644, DOI 10.1161/01.STR.26.4.644; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Raber J, 2004, ANN NEUROL, V55, P381, DOI 10.1002/ana.10853; REARDON JE, 1989, J BIOL CHEM, V264, P19039; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Yamashita T, 2006, J NEUROSCI, V26, P6627, DOI 10.1523/JNEUROSCI.0149-06.2006; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhu CL, 2009, J NEUROCHEM, V111, P1447, DOI 10.1111/j.1471-4159.2009.06413.x	26	657	679	34	86	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2012	7	6							e38932	10.1371/journal.pone.0038932	http://dx.doi.org/10.1371/journal.pone.0038932			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	963VI	23071805	Green Submitted, gold, Green Published			2023-01-03	WOS:000305652700041
J	Wang, XJ; Wei, DL; Song, ZG; Jiao, HC; Lin, H				Wang, Xiao Juan; Wei, Dai Lin; Song, Zhi Gang; Jiao, Hong Chao; Lin, Hai			Effects of Fatty Acid Treatments on the Dexamethasone-Induced Intramuscular Lipid Accumulation in Chickens	PLOS ONE			English	Article							ACTIVATED PROTEIN-KINASE; SKELETAL-MUSCLE CELLS; INDUCED INSULIN-RESISTANCE; MAMMALIAN TARGET; GENE-EXPRESSION; DOWN-REGULATION; PPAR-ALPHA; RAT; RECEPTOR; LIVER	Background: Glucocorticoid has an important effect on lipid metabolism in muscles, and the type of fatty acid likely affects mitochondrial utilization. Therefore, we hypothesize that the different fatty acid types treatment may affect the glucocorticoid induction of intramuscular lipid accumulation. Methodology/Principal Findings: The effect of dexamethasone (DEX) on fatty acid metabolism and storage in skeletal muscle of broiler chickens (Gallus gallus domesticus) was investigated with and without fatty acid treatments. Male Arbor Acres chickens (31 d old) were treated with either palmitic acid (PA) or oleic acid (OA) for 7 days, followed by DEX administration for 3 days (35-37 d old). The DEX-induced lipid uptake and oxidation imbalance, which was estimated by increased fatty acid transport protein 1 (FATP1) expression and decreased carnitine palmitoyl transferase 1 activity, contributed to skeletal muscle lipid accumulation. More sensitive than glycolytic muscle, the oxidative muscle in DEX-treated chickens showed a decrease in the AMP to ATP ratio, a decrease in AMP-activated protein kinase (AMPK) alpha phosphorylation and its activity, as well as an increase in the phosphorylation of mammalian target of rapamycin (mTOR) and ribosomal p70S6 kinase, without Akt activation. DEX-stimulated lipid deposition was augmented by PA, but alleviated by OA, in response to pathways that were regulated differently, including AMPK, mTOR and FATP1. Conclusions: DEX-induced intramuscular lipid accumulation was aggravated by SFA but alleviated by unsaturated fatty acid. The suppressed AMPK and augmented mTOR signaling pathways were involved in glucocortcoid-mediated enhanced intramuscular fat accumulation.	[Wang, Xiao Juan; Song, Zhi Gang; Jiao, Hong Chao; Lin, Hai] Shandong Agr Univ, Dept Anim Sci, Tai An, Shandong, Peoples R China; [Wei, Dai Lin] Taian Cent Hosp, Dept Endocrine, Tai An, Shandong, Peoples R China	Shandong Agricultural University	Wang, XJ (corresponding author), Shandong Agr Univ, Dept Anim Sci, Tai An, Shandong, Peoples R China.	hailin@sdau.edu.cn	Sun, Fen/I-8516-2016; Pausch, Hubert/U-5934-2019; Prokopenko, Mikhail/A-3995-2008; Zeng, Maomao/M-1422-2013; Wang, Xuelong/GQB-3574-2022; Lizier, Joseph/B-8093-2008; Wang, X. Rosalind/B-7097-2008	Pausch, Hubert/0000-0002-0501-6760; Prokopenko, Mikhail/0000-0002-4215-0344; Wurmser, Christine/0000-0003-0649-6206; SUN, FEN/0000-0003-2094-9494; Zeng, Maomao/0000-0001-9259-1992; Wang, Xuelong/0000-0003-4616-1531; Yu, Zhuowei/0000-0002-9152-6491; Lizier, Joseph/0000-0002-9910-8972; Kou, Xiaoxing/0000-0001-9680-0077; Wang, X. Rosalind/0000-0001-5454-6197; Fries, Ruedi/0000-0002-4657-1787; Tang, Hailiang/0000-0003-1852-3128; Mao, Ying/0000-0001-8055-115X; Yan, Jizhou/0000-0001-7482-7842; Tetens, Jens/0000-0001-5352-464X; Miller, Jennifer/0000-0003-2110-3693	Shandong Science Fund for Distinguished Youth Scholars; National Basic Research Program of China [2004CB117507]; National Natural Science Foundation of China [30771573]; Research Fund for the Doctoral Program of Higher Education of China	Shandong Science Fund for Distinguished Youth Scholars; National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Fund for the Doctoral Program of Higher Education of China(Research Fund for the Doctoral Program of Higher Education of China (RFDP)Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP))	This work was supported by grants from the Shandong Science Fund for Distinguished Youth Scholars, the National Basic Research Program of China (2004CB117507), the National Natural Science Foundation of China (No.30771573), and Research Fund for the Doctoral Program of Higher Education of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the sponsoring agencies.	Andrews RC, 1999, CLIN SCI, V96, P513, DOI 10.1042/cs0960513; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Berthiaume M, 2007, AM J PHYSIOL-ENDOC M, V293, pE1045, DOI 10.1152/ajpendo.00276.2007; BIEBER LL, 1972, ANAL BIOCHEM, V50, P509, DOI 10.1016/0003-2697(72)90061-9; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Bowes SB, 1996, J ENDOCRINOL, V148, P501, DOI 10.1677/joe.0.1480501; Braun EJ, 2008, COMP BIOCHEM PHYS B, V151, P1, DOI 10.1016/j.cbpb.2008.05.007; Cai YL, 2009, COMP BIOCHEM PHYS C, V150, P164, DOI 10.1016/j.cbpc.2009.04.005; Caton PW, 2011, BIOCHEM J, V437, P521, DOI 10.1042/BJ20110702; Christ-Crain M, 2008, FASEB J, V22, P1672, DOI 10.1096/fj.07-094144; Chuang JC, 2010, J LIPID RES, V51, P1344, DOI 10.1194/jlr.M002196; Clark H, 2004, EUR J BIOCHEM, V271, P2215, DOI 10.1111/j.1432-1033.2004.04151.x; Close B, 1997, LAB ANIM-UK, V31, P1, DOI 10.1258/002367797780600297; Coll T, 2006, DIABETES, V55, P2779, DOI 10.2337/db05-1494; Cota D, 2009, OBESITY, V17, P1641, DOI 10.1038/oby.2009.84; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; de Oliveira C, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-11; Duchene S, 2008, DOMEST ANIM ENDOCRIN, V34, P1, DOI 10.1016/j.domaniend.2006.09.002; Dupont J, 1999, J ENDOCRINOL, V162, P67, DOI 10.1677/joe.0.1620067; Dupont JL, 2004, DOMEST ANIM ENDOCRIN, V26, P127, DOI 10.1016/j.domaniend.2003.09.004; Dupont J, 2008, J ENDOCRINOL, V197, P531, DOI 10.1677/JOE-08-0055; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Foucaud L, 1998, BBA-LIPID LIPID MET, V1391, P204, DOI 10.1016/S0005-2760(97)00213-0; Gao D, 2009, BRIT J NUTR, V102, P1557, DOI 10.1017/S0007114509990948; Gaster M, 2005, DIABETES, V54, P648, DOI 10.2337/diabetes.54.3.648; GRIFFIN HD, 1982, BRIT POULTRY SCI, V23, P307, DOI 10.1080/00071688208447962; Halevy O, 2000, J NUTR, V130, P858, DOI 10.1093/jn/130.4.858; Hardie DG, 2007, ANNU REV PHARMACOL, V47, P185, DOI 10.1146/annurev.pharmtox.47.120505.105304; Hayat MA, 1973, PRINCIPLES TECHNIQUE, V3, P237; Hickson-Bick DLM, 2000, J MOL CELL CARDIOL, V32, P511, DOI 10.1006/jmcc.1999.1098; Holland WL, 2007, CELL METAB, V5, P167, DOI 10.1016/j.cmet.2007.01.002; Hu ZY, 2009, J CLIN INVEST, V119, P3059, DOI 10.1172/JCI38770; HUNNICUTT JW, 1994, DIABETES, V43, P540, DOI 10.2337/diabetes.43.4.540; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Kamara K, 1998, PHYSIOL BEHAV, V64, P1, DOI 10.1016/S0031-9384(97)00534-9; Khamzina L, 2005, ENDOCRINOLOGY, V146, P1473, DOI 10.1210/en.2004-0921; Koh EH, 2003, DIABETES, V52, P2331, DOI 10.2337/diabetes.52.9.2331; Korach-Andre M, 2005, AM J PHYSIOL-ENDOC M, V288, pE106, DOI 10.1152/ajpendo.00089.2004; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee WJ, 2006, BIOCHEM BIOPH RES CO, V340, P291, DOI 10.1016/j.bbrc.2005.12.011; Lillie RD, 1976, HISTOPATHOLOGIC TECH, Vfourth, P559; Lin H, 2004, COMP BIOCHEM PHYS B, V139, P737, DOI 10.1016/j.cbpc.2004.09.013; Liu ZQ, 2004, AM J PHYSIOL-ENDOC M, V287, pE275, DOI 10.1152/ajpendo.00457.2003; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mordier S, 2007, BIOCHEM BIOPH RES CO, V362, P206, DOI 10.1016/j.bbrc.2007.08.004; Nader N, 2010, MOL ENDOCRINOL, V24, P1748, DOI 10.1210/me.2010-0192; Nakken GN, 2010, J APPL PHYSIOL, V108, P298, DOI 10.1152/japplphysiol.00906.2009; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Prasad SSSV, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-111; Proszkowiec-Weglarz M, 2006, COMP BIOCHEM PHYS B, V143, P92, DOI 10.1016/j.cbpb.2005.10.009; Qi D, 2004, DIABETES, V53, P1790, DOI 10.2337/diabetes.53.7.1790; Qi D, 2006, AM J PHYSIOL-ENDOC M, V291, P420; Rivas DA, 2009, J ENDOCRINOL, V202, P441, DOI 10.1677/JOE-09-0202; Ruddock MW, 2008, J BIOCHEM, V144, P599, DOI 10.1093/jb/mvn105; Ruderman NB, 2006, OBESITY, V14, p25S, DOI 10.1038/oby.2006.279; Rutter GA, 2003, BIOCHEM J, V375, P1, DOI 10.1042/BJ20030048; RYDER JM, 1985, J AGR FOOD CHEM, V33, P678, DOI 10.1021/jf00064a027; Saha AK, 2003, MOL CELL BIOCHEM, V253, P65, DOI 10.1023/A:1026053302036; Schwartz GJ, 2008, CELL METAB, V8, P281, DOI 10.1016/j.cmet.2008.08.005; Sekulic A, 2000, CANCER RES, V60, P3504; Shah OJ, 2000, AM J PHYSIOL, V279, P74; SIMON J, 1974, ENDOCRINOLOGY, V95, P1439, DOI 10.1210/endo-95-5-1439; Sipula IJ, 2006, METABOLISM, V55, P1637, DOI 10.1016/j.metabol.2006.08.002; SMOLENSKI RT, 1993, BIOMED CHROMATOGR, V7, P189, DOI 10.1002/bmc.1130070404; Staiger H, 2005, DIABETOLOGIA, V48, P2115, DOI 10.1007/s00125-005-1895-z; Stuart M, 2010, END ABSTR, V21, P180; Tremblay F, 2007, P NATL ACAD SCI USA, V104, P14056, DOI 10.1073/pnas.0706517104; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Wang XJ, 2012, STRESS, V15, P443, DOI 10.3109/10253890.2011.639413; Wang XJ, 2010, COMP BIOCHEM PHYS C, V151, P447, DOI 10.1016/j.cbpc.2010.01.010; Watt MJ, 2006, J PHYSIOL-LONDON, V574, P139, DOI 10.1113/jphysiol.2006.107318; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; Wu QW, 2006, MOL CELL BIOL, V26, P3455, DOI 10.1128/MCB.26.9.3455-3467.2006; Zhang JL, 2004, AM J PHYSIOL-ENDOC M, V286, pE168, DOI 10.1152/ajpendo.00232.2003; Zhao JP, 2009, COMP BIOCHEM PHYS C, V149, P448, DOI 10.1016/j.cbpc.2008.10.106	75	657	679	34	86	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2012	7	5							e36663	10.1371/journal.pone.0036663	http://dx.doi.org/10.1371/journal.pone.0036663			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959VG	23071805	Green Published, Green Submitted, gold			2023-01-03	WOS:000305343500022
J	Wang, XL; Wurmser, C; Pausch, H; Jung, S; Reinhardt, F; Tetens, J; Thaller, G; Fries, R				Wang, Xiaolong; Wurmser, Christine; Pausch, Hubert; Jung, Simone; Reinhardt, Friedrich; Tetens, Jens; Thaller, Georg; Fries, Ruedi			Identification and Dissection of Four Major QTL Affecting Milk Fat Content in the German Holstein-Friesian Population	PLOS ONE			English	Article							QUANTITATIVE TRAIT LOCUS; GROWTH-HORMONE RECEPTOR; MISSENSE MUTATION; GENE; DGAT1; AGPAT6; YIELD; TRANSCRIPTION; EXPRESSION; TISSUE	Milk composition traits exhibit a complex genetic architecture with a small number of major quantitative trait loci (QTL) explaining a large fraction of the genetic variation and numerous QTL with minor effects. In order to identify QTL for milk fat percentage (FP) in the German Holstein-Friesian (HF) population, a genome-wide association study (GWAS) was performed. The study population consisted of 2327 progeny-tested bulls. Genotypes were available for 44,280 SNPs. Phenotypes in the form of estimated breeding values (EBVs) for FP were used as highly heritable traits. A variance components-based approach was used to account for population stratification. The GWAS identified four major QTL regions explaining 46.18% of the FP EBV variance. Besides two previously known FP QTL on BTA14 (P = 8.91x10-(198)) and BTA20 (P = 7.03x10(-12)) within DGAT1 and GHR, respectively, we uncovered two additional QTL regions on BTA5 (P = 2.00x10(-13)) and BTA27 (P = 9.83x10(-5)) encompassing EPS8 and GPAT4, respectively. EPS8 and GPAT4 are involved in lipid metabolism in mammals. Re-sequencing of EPS8 and GPAT4 revealed 50 polymorphisms. Genotypes for five of them were inferred for the entire study population. Two polymorphisms affecting potential transcription factor binding sites of EPS8 (P = 1.40x10(-12)) and GPAT4 (P = 5.18x10(-5)), respectively, were highly significantly associated with the FP EBV. Our results provide evidence that alteration of regulatory sites is an important aspect of genetic variation of complex traits in cattle.	[Wang, Xiaolong; Wurmser, Christine; Pausch, Hubert; Jung, Simone; Fries, Ruedi] Tech Univ Muenchen, Chair Anim Breeding, Freising Weihenstephan, Germany; [Reinhardt, Friedrich] Vereinigte Informat Syst Tierhaltung wV, Verden, Germany; [Tetens, Jens; Thaller, Georg] Univ Kiel, Inst Anim Breeding & Husb, Kiel, Germany	Technical University of Munich; University of Kiel	Wang, XL (corresponding author), Tech Univ Muenchen, Chair Anim Breeding, Freising Weihenstephan, Germany.	xiaolong.wang@tierzucht.tum.de	Sun, Fen/I-8516-2016; Pausch, Hubert/U-5934-2019; Prokopenko, Mikhail/A-3995-2008; Zeng, Maomao/M-1422-2013; Wang, Xuelong/GQB-3574-2022; Lizier, Joseph/B-8093-2008; Wang, X. Rosalind/B-7097-2008	Pausch, Hubert/0000-0002-0501-6760; Prokopenko, Mikhail/0000-0002-4215-0344; Wurmser, Christine/0000-0003-0649-6206; SUN, FEN/0000-0003-2094-9494; Zeng, Maomao/0000-0001-9259-1992; Wang, Xuelong/0000-0003-4616-1531; Yu, Zhuowei/0000-0002-9152-6491; Lizier, Joseph/0000-0002-9910-8972; Kou, Xiaoxing/0000-0001-9680-0077; Wang, X. Rosalind/0000-0001-5454-6197; Fries, Ruedi/0000-0002-4657-1787; Tang, Hailiang/0000-0003-1852-3128; Mao, Ying/0000-0001-8055-115X; Yan, Jizhou/0000-0001-7482-7842; Tetens, Jens/0000-0001-5352-464X; Miller, Jennifer/0000-0003-2110-3693	German Ministry of Education and Research, BMBF [0315134A, 0315134D, 0315131A]; Forderverein Biotechnologieforschung e.V. (FBF), Bonn; Lohmann Tierzucht GmbH, Cuxhaven; China Scholarship Council (CSC)	German Ministry of Education and Research, BMBF(Federal Ministry of Education & Research (BMBF)); Forderverein Biotechnologieforschung e.V. (FBF), Bonn; Lohmann Tierzucht GmbH, Cuxhaven; China Scholarship Council (CSC)(China Scholarship Council)	This study is part of the projects FUGATO-plus GenoTrack and FUGATO-plus MeGA-M and was financially supported by the German Ministry of Education and Research, BMBF (grants 0315134A, 0315134D and 0315131A), the Forderverein Biotechnologieforschung e.V. (FBF), Bonn, and Lohmann Tierzucht GmbH, Cuxhaven. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors acknowledge the vit w.V. Verden for providing phenotype data and the China Scholarship Council (CSC) for supporting X. Wang by a grant.	Beigneux AP, 2006, J LIPID RES, V47, P734, DOI 10.1194/jlr.M500556-JLR200; Bionaz M, 2008, J NUTR, V138, P1019, DOI 10.1093/jn/138.6.1019; Blott S, 2003, GENETICS, V163, P253; Bouwman AC, 2011, BMC GENET, V12, DOI 10.1186/1471-2156-12-43; Browning BL, 2009, AM J HUM GENET, V84, P210, DOI 10.1016/j.ajhg.2009.01.005; Buttchereit N, 2010, J DAIRY SCI, V93, P1702, DOI 10.3168/jds.2009-2198; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chakravarty K, 2005, CRIT REV BIOCHEM MOL, V40, P129, DOI 10.1080/10409230590935479; Chatterjee S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005197; Cohen-Zinder M, 2005, GENOME RES, V15, P936, DOI 10.1101/gr.3806705; Ed L, 2009, BIOINFORMATICS, V25, P1836, DOI 10.1093/bioinformatics/btp314; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Gremme G, 2005, INFORM SOFTWARE TECH, V47, P965, DOI 10.1016/j.infsof.2005.09.005; Grisart B, 2002, GENOME RES, V12, P222, DOI 10.1101/gr.224202; Guo DL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000446; Hamza MS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004907; Hayes BJ, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001139; Jiang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013661; Kang HM, 2010, NAT GENET, V42, P348, DOI 10.1038/ng.548; Loor JJ, 2005, PHYSIOL GENOMICS, V23, P217, DOI 10.1152/physiolgenomics.00132.2005; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; Portales-Casamar E, 2009, JASPAR 2010 GREATLY; Quackenbush J, 2001, NUCLEIC ACIDS RES, V29, P159, DOI 10.1093/nar/29.1.159; Schennink A, 2007, ANIM GENET, V38, P467, DOI 10.1111/j.1365-2052.2007.01635.x; Schennink A, 2009, ANIM GENET, V40, P909, DOI 10.1111/j.1365-2052.2009.01940.x; Schug Jonathan, 2008, Curr Protoc Bioinformatics, VChapter 2, DOI 10.1002/0471250953.bi0206s21; Signorelli F, 2009, LIVEST SCI, V125, P74, DOI 10.1016/j.livsci.2009.02.014; Thaller G, 2003, J ANIM SCI, V81, P1911; VanRaden PM, 2008, J DAIRY SCI, V91, P4414, DOI 10.3168/jds.2007-0980; Vergnes L, 2006, J LIPID RES, V47, P745, DOI 10.1194/jlr.M500553-JLR200; Viitala S, 2006, GENETICS, V173, P2151, DOI 10.1534/genetics.105.046730; Winter A, 2002, P NATL ACAD SCI USA, V99, P9300, DOI 10.1073/pnas.142293799; Yang JA, 2011, AM J HUM GENET, V88, P76, DOI 10.1016/j.ajhg.2010.11.011; Zimin AV, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-4-r42	35	657	679	34	86	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2012	7	7							e40711	10.1371/journal.pone.0040711	http://dx.doi.org/10.1371/journal.pone.0040711			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973LU	23071805	Green Published, gold, Green Submitted			2023-01-03	WOS:000306362400093
